<SEC-DOCUMENT>0001213900-24-017526.txt : 20240227
<SEC-HEADER>0001213900-24-017526.hdr.sgml : 20240227
<ACCEPTANCE-DATETIME>20240227161505
ACCESSION NUMBER:		0001213900-24-017526
CONFORMED SUBMISSION TYPE:	F-1
PUBLIC DOCUMENT COUNT:		128
FILED AS OF DATE:		20240227
DATE AS OF CHANGE:		20240227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SciSparc Ltd.
		CENTRAL INDEX KEY:			0001611746
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		F-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-277394
		FILM NUMBER:		24686910

	BUSINESS ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916
		BUSINESS PHONE:		972-3-6103100

	MAIL ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SciSparc Ltd./ADR
		DATE OF NAME CHANGE:	20210129

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Therapix Biosciences Ltd.
		DATE OF NAME CHANGE:	20140624
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1
<SEQUENCE>1
<FILENAME>ea0200391-f1_scisparcltd.htm
<DESCRIPTION>REGISTRATION STATEMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:sprcy="http://trpx.com/20230630" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As filed with the Securities and Exchange Commission on February 27,
2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Registration No. 333-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, DC 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Form&#160;<ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-37506">F-1</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-37507">SCISPARC LTD.</ix:nonNumeric> </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Exact name of registrant as specified in its
charter)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>State&#160;of&#160;<ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="ixv-37508">Israel</ix:nonNumeric></b></span></td> <td style="text-align: center; width: 2%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2834</b></span></td> <td style="text-align: center; width: 2%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Not&#160;Applicable</b></span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(State&#160;or&#160;other&#160;jurisdiction&#160;of<br/> incorporation&#160;or&#160;organization)</i></span></td> <td style="text-align: center">&#160;</td> <td style="padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Primary&#160;Standard&#160;Industrial<br/> Classification&#160;Code&#160;Number)</i></span></td> <td style="text-align: center">&#160;</td> <td style="padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(I.R.S. Employer<br/> Identification&#160;Number)</i></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 49%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine1" id="ixv-37509">20 Raul Wallenberg Street</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine2" id="ixv-37510">Tower A</ix:nonNumeric>,</b></span></td> <td style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td> <td style="width: 49%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-89"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Puglisi &amp; Associates</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressCityOrTown" id="ixv-37511">Tel Aviv</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:EntityAddressPostalZipCode" id="ixv-37512">6971916</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-37513">Israel</ix:nonNumeric></b></span></td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>850 Library Ave., <ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2" id="ixv-37514">Suite 204</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-37515">Newark</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressStateOrProvince" id="ixv-37516">DE</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-37517">19711</ix:nonNumeric></b></span></td></tr> <tr style="vertical-align: top"> <td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tel: <ix:nonNumeric contextRef="c1" name="dei:CityAreaCode" id="ixv-37518">(+972)</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:LocalPhoneNumber" id="ixv-37519">(3) 610-3100</ix:nonNumeric></b></span></td> <td style="padding-bottom: 1.5pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td> <td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tel: <ix:nonNumeric contextRef="c0" name="dei:CityAreaCode" id="ixv-37520">(302)</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber" id="ixv-37521">738-6680</ix:nonNumeric></b></span></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Address, including zip code, and telephone number,</i></span></td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Name,
address, including zip code, and telephone number,</i></span></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>including area code, of registrant&#8217;s principal executive offices)</i></span></td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><i>including area code, of agent for service)</i></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><i>Copies to:</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Oded Har-Even,
    Esq. </b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dr. Shachar
    Hadar, Adv.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Howard Berkenblit,
    Esq.<br/>
    Sullivan &amp; Worcester LLP</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>1633 Broadway </b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>New York, NY 10019</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Tel: 212.660.3000</b></p></td>
    <td style="text-align: center"/>
    <td style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Meitar | Law Offices</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>16 Abba Hillel Silver
    Rd.</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Ramat Gan 52506,
    Israel</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Tel: (+972) (3) 610-3100
    </b></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Approximate date of commencement of proposed sale to the public:
</b>As soon as practicable after the effective date hereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt; margin: 0pt"><span style="font-size: 10pt">If
any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under
the Securities Act, check the following box.&#160;</span>&#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt; margin: 0pt">If this form is filed to register
additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt; margin: 0pt">If this form is a post-effective
amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.&#160;&#9744;</p><div>

</div><p style="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">If this form is a post-effective
amendment filed pursuant to Rule&#160;462(d) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.&#160;&#9744;</p><div>

</div><p style="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.</p><div>

</div><p style="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Emerging growth company&#160;<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="ixv-37522">&#9744;</ix:nonNumeric></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p><div>

</div><p style="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">If an emerging growth company
that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use
the extended transition period for complying with any new or revised financial accounting standards &#8224; provided pursuant to Section
7(a)(2)(B) of the Securities Act. &#9744;</p><div>

</div><p style="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#8224; The term &#8220;new
or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting
Standards Codification after April 5, 2012.&#160;</p><div>

</div><p style="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>The registrant hereby amends
this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further
amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a)
of the Securities Act or until the registration statement shall become effective on such date as the Commission, acting pursuant to said
Section&#160;8(a), may determine.&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="color: Red"><b>The information in
this prospectus is not complete and may be changed. The Selling Shareholder may not sell these securities until the registration statement
filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting
an offer to buy these securities in any state where the offer or sale is not permitted.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-top: Black 1.5pt solid; width: 30%; border-bottom: Black 1.5pt solid; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>PRELIMINARY
    PROSPECTUS</b></span></td>
    <td style="border-top: Black 1.5pt solid; width: 40%; border-bottom: Black 1.5pt solid; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>SUBJECT
    TO COMPLETION</b></span></td>
    <td style="border-top: Black 1.5pt solid; width: 30%; border-bottom: Black 1.5pt solid; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>DATED
    FEBRUARY 27, 2024</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Up to 5,402,887 Ordinary Shares</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SciSparc Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus relates to
the offer and sale of up to 5,402,887 of our ordinary shares, no par value, or the Ordinary Shares, by YA II PN, LTD., a Cayman Islands
exempt limited partnership, or YA or the Selling Shareholder. The Selling Shareholder is a fund managed by Yorkville Advisors Global,
LP.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 21, 2024, we
entered into a Standby Equity Purchase Agreement, as amended on February 26, 2024, or the SEPA, with the Selling Shareholder, which
provided for the sale of up to $20.0 million of our Ordinary Shares. Of the $20.0 million eligible to be sold pursuant to the SEPA,
or the Commitment Amount, to date we have not sold any Ordinary Shares. In connection with the SEPA, we may request pre-paid
advances of the Commitment Amount, in an amount up to $5.0 million, each a Pre-Paid Advance. Each Pre-Paid Advance will be evidenced
by a promissory note, each, a Promissory Note. Each Promissory Note will fully mature 24-months following its issuance and shall
accrue interest on the outstanding principal balance thereon at a rate of 5% per annum, increasing to 18% per annum upon an Event of
Default (as defined in the Promissory Note). Beginning 150 days after the issuance of a Promissory Note, we shall pay to YA a
monthly installment payment of 10% of the original principal amount of the Promissory Note and accrued interest, payable in cash or
by submitting an Advance Notice, where YA will offset the amount due to be paid to us under such notice against an equal amount of
the monthly installment amount, at our option. If we elect to pay in cash, the installment amount shall also include a payment
premium in the amount of 5% of the principal amount of the installment payment. The Promissory Note contains our customary
representations and warranties and Events of Default.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Ordinary Shares being
offered by the Selling Shareholder may be issued pursuant to the SEPA. We are not selling any securities under this prospectus and will
not receive any of the proceeds from the sale of our Ordinary Shares by the Selling Shareholder. However, we may receive up to $20.0&#160;million
in aggregate gross proceeds from sales of our Ordinary Shares to the Selling Shareholder that we may make under the SEPA, from time to
time after the date of this prospectus. Pursuant to the SEPA, we have issued to the Selling Shareholder an aggregate of 55,293 of our
Ordinary Shares, or the Commitment Shares, in satisfaction of payment of the commitment fee of $200,000. The additional shares that may
be offered pursuant to this prospectus would be purchased by the Selling Shareholder pursuant to the SEPA at 97% of the market price,
which is defined as the lowest daily volume weighted average price of the Ordinary Shares during the three consecutive trading days commencing
on the trading day immediately following our delivery of an advance notice to the Selling Shareholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Shareholder may
sell the Ordinary Shares included in this prospectus in a number of different ways and at varying prices. We provide more information
about how the Selling Shareholder may sell the shares in the section entitled &#8220;<i>Plan of Distribution</i>.&#8221; The Selling
Shareholder is an &#8220;underwriter&#8221; within the meaning of Section&#160;2(a)(11) of the Securities Act of 1933, as amended, or
the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Shareholder will
pay all brokerage fees and commissions and similar expenses in connection with the offer and sale of the Ordinary Shares by the Selling
Shareholder pursuant to this prospectus. We will pay the expenses (except brokerage fees and commissions and similar expenses) incurred
to register under the Securities Act the offer and sale of the Ordinary Shares included in this prospectus by the Selling Shareholder.
See &#8220;<i>Plan of Distribution</i>.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Ordinary Shares are listed&#160;on
the Nasdaq Capital Market, or Nasdaq, under the symbol &#8220;SPRC&#8221;. On February 26, 2024, the last reported sale price of our Ordinary
Shares on Nasdaq was $3.74 per share.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Investing in our securities
involves a high degree of risk.&#160;See &#8220;Risk Factors&#8221; beginning on page 7 of this prospectus.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Neither the Securities
and Exchange Commission, or the SEC, nor any state or other foreign securities commission has approved nor disapproved these securities
or determined if this prospectus is truthful or complete.&#160;Any representation to the contrary is a criminal offense.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The date of this prospectus is&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 91%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus Summary</span></a></td>
    <td style="text-align: center">1</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="text-align: center">7</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cautionary Note Regarding Forward-Looking Statements</span></a></td>
    <td style="text-align: center">58</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</span></a></td>
    <td style="text-align: center">60</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend Policy</span></a></td>
    <td style="text-align: center">61</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalization</span></a></td>
    <td style="text-align: center">62</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial
    Condition and Results of Operations</span></a></td>
    <td style="text-align: center">63</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</span></a></td>
    <td style="text-align: center">73</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management</span></a></td>
    <td style="text-align: center">110</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial Ownership of Principal Shareholders and
    Management</span></a></td>
    <td style="text-align: center">132</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_021">Related Party Transactions</a></span></td>
    <td style="text-align: center">134</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Share Capital</span></a></td>
    <td style="text-align: center">135</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling Shareholder</span></a></td>
    <td style="text-align: center">152</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan of Distribution</span></a></td>
    <td style="text-align: center">153</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses</span></a></td>
    <td style="text-align: center">154</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Matters</span></a></td>
    <td style="text-align: center">154</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Experts</span></a></td>
    <td style="text-align: center">154</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enforceability of Civil Liabilities</span></a></td>
    <td style="text-align: center">155</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where You Can Find Additional Information</span></a></td>
    <td style="text-align: center">156</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_020">Index of Financial Statements</a></span></td>
    <td style="text-align: center">F-1</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><b>You should rely only
on the information contained in this prospectus and any free writing prospectus prepared by or on behalf of us or to which we have referred
you. Neither we nor the Selling Shareholder have authorized anyone to provide you with information that is different. The Selling Shareholder
is offering to sell the securities, and seeking offers to buy the securities, only in jurisdictions where offers and sales are permitted.
The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus
or any sale of the securities. </b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><b>For investors outside
of the United States: Neither we nor the Selling Shareholder have done anything that would permit this offering or possession or distribution
of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to
inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus.</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><b>In this prospectus,
&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;Company&#8221; and &#8220;SciSparc&#8221; refer to SciSparc Ltd. and
its consolidated subsidiaries. </b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><b>All trademarks or
trade names referred to in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade
names in this prospectus are referred to without the&#160;<sup>&#174;</sup>&#160;and&#160;<sup>&#8482;</sup>&#160;symbols, but such references
should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their
rights thereto. We do not intend the use or display of other companies&#8217; trademarks and trade names to imply a relationship with,
or endorsement or sponsorship of us by, any other companies.</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><b>&#160;</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><b>Our reporting currency
and functional currency is the U.S. dollar.&#160;Unless otherwise expressly stated or the context otherwise requires, references in this
prospectus to &#8220;NIS&#8221; are to New Israeli Shekels, and references to &#8220;dollars&#8221; or &#8220;$&#8221; mean U.S. dollars.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: white"><b>&#160;</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><b>On September 28, 2023,
we completed a reverse split of our share capital in the ratio of 26:1, or the Reverse Split. Unless the context expressly indicates
otherwise, all references to share and per share amounts referred to herein reflect the amounts after giving effect to the Reverse Split.</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><b>This prospectus includes
statistical, market and industry data and forecasts which we obtained from publicly available information and independent industry publications
and reports that we believe to be reliable sources. These publicly available industry publications and reports generally state that they
obtain their information from sources that they believe to be reliable, but they do not guarantee the accuracy or completeness of the
information.</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><b>We
report financial information under International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards
Board and none of the financial statements were prepared in accordance with generally accepted accounting principles in the United States.</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<a id="a_001"></a><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PROSPECTUS SUMMARY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>This
summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information you should
consider before investing in our securities. Before you decide to invest in our securities, you should read the entire prospectus carefully,
including the sections titled &#8220;Risk Factors.&#8221; &#8220;Business&#8221; and &#8220;Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations&#8221; and our financial statements and related notes included elsewhere in this prospectus.</i>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Company</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
are a specialty clinical-stage pharmaceutical company. Our focus is creating and enhancing a portfolio of technologies and assets based
on cannabinoid therapies. With this focus, we are currently engaged in developing and testing pharmaceutical compositions comprised of
N-acylethanolamines and cannabinoids such as Palmitoylethanolamide, or PEA, and/or &#916;9-tetrahydrocannabinol, or THC, and/or non-psychoactive
cannabidiol, or CBD, and/or other cannabinoid receptor agonists, from which we have derived three main proprietary combinations: SCI-110
for the treatment of Tourette syndrome and Alzheimer&#8217;s disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for
the treatment of Autism Spectrum Disorder, or ASD. We hold a 50.86% controlling stake in our subsidiary SciSparc Nutraceuticals Inc.,
which focuses on the sale of hemp-based products on Amazon Marketplace.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SCI-110
is a proprietary drug candidate based on two components: (1) THC, which is the major cannabinoid molecule in the cannabis plant, and
(2) CannAmide&#8482;, a proprietary Palmitoylethanolamide, or PEA, formulation. PEA is an endogenous fatty acid amide that belongs to
the class of nuclear factor agonists, which are molecules that regulate the expression of genes. We believe that the combination of THC
and PEA may induce a reaction known as the &#8220;sparing effect,&#8221; which has strong potential to treat various diseases such as
TS and Alzheimer&#8217;s disease&#160;and agitation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SCI-210
is a proprietary drug candidate based on two components: (1) CBD, and (2) CannAmide&#8482;. We believe that the combination of CBD and
PEA may also induce a sparing effect reaction, which has strong potential to treat various diseases such as ASD and SE.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SCI-160
is a novel pharmaceutical preparation containing a cannabinoid receptor type 2, or CB2 receptor, agonist for the treatment of pain. This
innovative CB2 receptor agonist was synthesized by Raphael Mechoulam, Ph.D., Professor of Medicinal Chemistry at the Hebrew University,
a member of the SciSparc Scientific Advisory Board. We believe that modulating CB2 receptor activity by selective CB2 receptor agonists
holds unique therapeutic potential for addressing pain conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
believe that modulating CB2 receptor activity by selective CB2 receptor agonists holds unique therapeutic potential for addressing pain
conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to the positive results obtained in a phase IIa TS study conducted at Yale School of Medicine, we developed a regulatory dossier that
was submitted to the German Federal Institute for Drugs and Medical Devices, or BfArM, and the Israeli Ministry of Health, or MoH, for
our SCI-110 program for TS. Both agencies approved the program. We plan to submit this regulatory dossier to the U.S. Food and Drug Administration,
or the FDA. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
June 2023, we announced positive topline results from our Phase IIa clinical trial of SCI-110 in patients with Alzheimer&#8217;s disease
and agitation at the Israeli Medical Center for Alzheimer&#8217;s, suggesting that SCI-110 is safe and tolerable while significantly
improving agitation symptoms over time in the elderly population with Alzheimer&#8217;s disease. This Phase IIa clinical trial was an
open label study, which included 18 patients diagnosed with Alzheimer&#8217;s disease and agitation, to evaluate the safety, tolerability
and efficacy trends of twice daily oral administration of SCI-110. Results showed that the clinical trial met its primary endpoints of
the number of drop-out subjects due to poor tolerability and the number of clinical trial treatment-related adverse events, with no SCI-110
related safety issues observed and no dropouts from the clinical trial due to clinical trial medication. Specifically, SCI-110 did not
cause delirium, oversedation, hypotension or falls. In addition, analysis of the clinical trial results showed that the clinical trial
also met its secondary end point of change from baseline to end of treatment in agitation measured by the Cohen Mansfield Agitation Inventory
where out of the fifteen patients treated with SCI-110 at least two consecutive times during the trial, thirteen of them at doses ranging
between 7.5mg-12.5mg/day showed amelioration in agitation with no need to use rescue medication to control agitation. Although not significant,
in the exploratory endpoints, eleven patients reduced food intake and showed feeding difficulties, as measured by the Edinburgh Feeding
Evaluation in Dementia scale. There was not an effect observed resulting from the treatment on cognition and sleep quality, as measured
by the Mini Mental State Examination and by the Sleep Order Inventory, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 8, 2022, we announced
that we have received approval from the MoH and Ethics Committee of Soroka Medical Center to conduct our clinical trial for SCI-210 in
patients suffering ASD. Our regulatory request to carry out this clinical trial was granted by the Israeli Medical Cannabis Agency, or
IMCA, on July 10, 2023. On January 9, 2023, we signed an agreement with Soroka Medical Center to conduct the clinical trial pediatric
patients suffering from ASD. This randomized, double blind placebo-controlled clinical trial to evaluate the potential efficacy, safety
and tolerability of SCI-210 in treating patients with ASD was initiated in July 2023. We initiated patient enrollment for the clinical
trial in January 2024. In February 2024, we announced that we had successfully completed the manufacturing of the SCI-210 treatment for
the clinical trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">For
our proprietary SCI-160, in August 2021, we announced positive top-line results for a controlled pre-clinical trial on neuropathic and
post-operative pain. The study &#8220;An evaluation of SCI-160 on neuropathic pain in the rat spared nerve injury (SNI) model and post-surgical
pain in the rat hind paw incision model,&#8221; was designed to help assess the potential of SCI-160. Key findings from the pre-clinical
trial are that SCI-160 significantly alleviates pain up to six hours after injection as compared with vehicle-treated animals. Daily
SCI-160 injections significantly alleviate subject pain from mechanical stimuli as compared with vehicle-treated animals, for up to seven
days after surgery. Daily injections of SCI-160 significantly alleviate pain in a hind paw incision model of post-surgical pain up to
four days post-surgery as compared with vehicle treated animals, and SCI-160 analgesic effects are prolonged in the presence of PEA.
Collectively, the results indicated that treatment with SCI-160 significantly alleviates both chronic and acute pain. Based on the positive
results, we have decided to continue the development of SCI-160 towards a first in-human clinical study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Standby Equity Purchase Agreement with YA</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 21, 2024, we entered
into the SEPA with YA, as amended on February 26, 2024. Pursuant to the SEPA, we will be able to sell up to $20.0 million of our Ordinary Shares, at our sole option,
any time during the three-year period following the execution date of the SEPA. Of the Commitment Amount, to date we have not sold any
Ordinary Shares. Pursuant to the terms of the SEPA, any Ordinary Shares sold to YA will be priced at 97% of the market price, which is
defined as the lowest daily volume weighted average price of the Ordinary Shares during the three consecutive trading days commencing
on the trading day immediately following our delivery of an advance notice to YA, or the Advance Price. Any sale of Ordinary Shares pursuant
to the SEPA is subject to certain limitations, including that YA is not permitted to purchase any Ordinary Shares that would result in
it owning more than 9.99% of our Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to certain conditions
precedent as described in the SEPA, we may request Pre-Paid Advances. Each Pre-Paid Advance will be evidenced by a Promissory Note. Each
Promissory Note will fully mature 24-months following its issuance and shall accrue interest on the outstanding principal balance thereon
at a rate of 5% per annum, increasing to 18% per annum upon an Event of Default (as defined in the Promissory Note). Beginning 150 days
after the issuance of a Promissory Note, we shall pay to YA a monthly installment payment of 10% of the original principal amount of
the Promissory Note and accrued interest, payable in cash or by submitting an Advance Notice, where YA will offset the amount due to
be paid to us under such notice against an equal amount of the monthly installment amount, at the our option. If we elect to pay in cash,
the installment amount shall also include a payment premium in the amount of 5% of the principal amount of the installment payment. The
Promissory Note contains our customary representations and warranties and Events of Default.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not obligated to utilize
any of the $20.0 million available under the SEPA and there are no minimum commitments or minimum use penalties. The total amount of
funds that ultimately can be raised under the SEPA over the three-year term will depend on the market price for the Ordinary Shares and
the number of Ordinary Shares actually sold. The SEPA does not impose any restrictions on our operating activities. During the term of
the SEPA, YA, and its affiliates, are prohibited from engaging in any short selling or hedging transactions related to the Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we also agreed
to pay YA a commitment fee equal to $200,000, or 1.0% of the aggregate amount available to be sold under the SEPA, as consideration for
its irrevocable commitment to purchase our Ordinary Shares under the SEPA, payable in an amount of our Ordinary Shares equal to $200,000
divided by the daily volume-weighted average price of the Ordinary Shares on the trading day immediately prior to the SEPA and also agreed
to pay to YA a structuring fee in the amount of $10,000. As satisfaction of the commitment fee, we issued 55,293 of our Ordinary Shares
as the Commitment Shares to YA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the SEPA, we
were required to register resales of the Ordinary Shares eligible to be sold pursuant to the SEPA and Commitment Shares, collectively
referred to as the Registrable Shares. We agreed to file a registration statement and shall not have the ability to request any advances
under the SEPA until the registration statement, of which this prospectus forms a part, is declared effective.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Corporate Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were incorporated under
the laws of the State of Israel on August 23, 2004. Our principal executive office is located at 20 Raul Wallenberg Street, Tower A,
Second Floor, Tel Aviv 6971916, Israel. Our telephone number in Israel is: +972 (3) 610-3100. Our website address is by http://www.scisparc.com.
The information contained on our website or available through our website is not incorporated by reference into and should not be considered
a part of this prospectus.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Summary Risk Factors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The risk factors described
below are a summary of the principal risk factors associated with an investment in us. These are not the only risks we face. You should
carefully consider these risk factors, together with the risk factors set forth in the section &#8220;Risk Factors&#8221; beginning on
page  7 of this prospectus and the other reports and documents filed by us with the SEC.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Risks Related to Our Financial Condition and Capital Requirements</i></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are a specialty clinical-stage pharmaceutical company and have a limited operating history on which to assess the prospects for our
    business, have incurred significant losses since the date of our inception, and anticipate that we will continue to incur significant
    losses until we are able to successfully commercialize our product candidates.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have not generated any revenue from the sale of our current product candidates and may never be profitable.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    expect that we will need to raise substantial additional funding before we can expect to become profitable from sales of our product
    candidates. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product candidate
    development efforts or other operations.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    report of our independent registered public accounting firm contains an explanatory paragraph regarding substantial doubt about our
    ability to continue as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Risks Related to the Discovery and Development of Our Pharmaceutical
Product Candidates</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are heavily dependent on the success of our pharmaceutical product candidates, which are in the late stages of pre-clinical development
    or early stages of clinical development. We cannot give any assurance that any of our product candidates will receive regulatory
    approval, which is necessary before they can be commercialized.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies may not be predictive
    of future study results. We may also find it difficult to enroll patients in our clinical studies. Difficulty in enrolling patients
    could delay or prevent clinical studies of our pharmaceutical product candidates.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the FDA does not conclude that our pharmaceutical product candidates satisfy the requirements for the Section 505(b)(2) regulatory
    approval pathway, or if the requirements for our pharmaceutical product candidates under Section 505(b)(2) are not as we expect,
    the approval pathway would likely take significantly longer, cost significantly more and entail significantly greater complications
    and risks than anticipated and in either case may not be successful.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    respect of our pharmaceutical product candidates targeting rare indications, orphan drug exclusivity may afford limited protection,
    and if another party obtains orphan drug exclusivity for the drugs and indications we are targeting, we may be precluded from commercializing
    our pharmaceutical product candidates in those indications during that period of exclusivity. </span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Risks Related to Our Reliance on Third Parties</i></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    rely on third parties to conduct our preclinical and clinical studies and perform other tasks for us. If these third parties do not
    successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able
    to obtain regulatory approval for or commercialize our pharmaceutical product candidates and our business could be substantially
    harmed.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will rely on third parties to manufacture our active pharmaceutical ingredient, or API, and formulations. Our business could be harmed
    if those third parties fail to provide us with sufficient quantities of our needed supplies or fail to do so at acceptable quality
    levels or prices.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Risks Related to Commercialization of Our Pharmaceutical Product
Candidates</i></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the market opportunities for our pharmaceutical product candidates are smaller than we believe they are, our revenue may be adversely
    affected, and our business may suffer.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    face intense competition and rapid technological change and the possibility that our competitors may discover, develop or commercialize
    therapies that are similar, more advanced or more effective than ours, which may adversely affect our financial condition and our
    ability to successfully commercialize our pharmaceutical product candidates.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Risks Related to Our Intellectual Property</i></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are unable to obtain and maintain effective patent rights for our product candidates, we may not be able to compete effectively
    in our markets. Further, if we are unable to protect the confidentiality of our trade secrets or know-how, such proprietary information
    may be used by others to compete against us.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not be able to identify infringements of our patents and accordingly the enforcement of our intellectual property rights may
    be difficult.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Risks Related to Our Pharmaceutical Business Operations</i></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
    time to time, we may sign letters of intent and/or enter into term sheets or other similar arrangements that are subject to negotiation
    of definitive agreements. There can be no assurance that we will enter into any such definitive agreements. Similarly, we may strategically
    invest in transactions from time to time, and there can be no assurance that the value of our investment will increase or that it
    will not fluctuate.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may strategically invest in transactions from time to time, and there can be no assurance that the value of our investment will increase
    or that it will not fluctuate or that we will be able to successfully integrate or operate any new business we acquire. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will need to expand our organization and we may experience difficulties in recruiting needed additional employees and consultants,
    which could disrupt our operations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Risks Related to our Intended Corporate Restructuring Plan</i></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    intended restructuring plan, or Restructuring Plan, which may involve transferring our pharmaceutical activities to NewCo may not
    be completed in accordance with the expected plans or anticipated timeline, or at all, and may not achieve the expected results.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Risks Related to Our Subsidiary&#8217;s eCommerce Operations</i></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be unable to successfully integrate or execute our new subsidiary&#8217;s eCommerce operations business.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    subsidiary&#8217;s eCommerce operations rely on the Amazon.com marketplace and fulfillment by Amazon.com and changes to the Amazon.com
    marketplace, Amazon&#8217;s services and their terms of use may harm our business.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.65pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b><i>Risks Related to the Ownership of Our Securities</i></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.65pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will need additional capital in the future. Raising additional capital by issuing securities may cause dilution to existing shareholders.
    </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    do not know whether a market for the Ordinary Shares will be sustained or what the trading price of the Ordinary Shares will be and
    as a result it may be difficult for you to sell your Ordinary Shares</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Risks Related to Israeli Law and Our Operations in Israel</i></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
    of Israeli law may make it easy for our shareholders to demand that we convene a shareholders meeting, and/or allow shareholders
    to convene a shareholder meeting without the consent of our management, which may disrupt our management&#8217;s ability to run our
    company.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    principal executive offices, most of our research and development activities and other significant operations are located in Israel,
    and, therefore, our results may be adversely affected by political, economic and military instability in Israel, including (i) the
    recent attack by Hamas and other terrorist organizations from the Gaza Strip and elsewhere in the region and Israel&#8217;s war against
    them as well as the war&#8217;s potential impact on our business and operations and (ii) military hostilities with Hezbollah on the
    northern border of Israel.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>THE OFFERING</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issuer</b></span></td>
    <td style="width: 2%; text-align: justify">&#160;</td>
    <td style="width: 78%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc Ltd.&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities offered by the Selling Shareholder</b></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up to 5,402,887 Ordinary Shares consisting of: (i) 55,293 Commitment Shares and (ii) up to 5,347,594 Ordinary Shares that we may sell to YA under the SEPA from time to time.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ordinary Shares issued and outstanding prior to the offering</b></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,095,784 Ordinary Shares.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ordinary Shares to be outstanding after this offering <sup>(1)</sup></b></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,443,378 Ordinary Shares, assuming the sale of a total 5,347,594 Ordinary Shares to YA pursuant to the SEPA (at an assumed price per share of $3.74, which is the last reported sales price of our Ordinary Shares on Nasdaq on February 26, 2024).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of proceeds</b></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will not receive any proceeds from the sale of the Ordinary Shares included in this prospectus by the Selling Shareholder. We may receive up to $20.0 million aggregate gross proceeds under the SEPA from sales of the Ordinary Shares that we elect to make to YA pursuant to the SEPA, if any, from time to time in our sole discretion, although the actual amount of proceeds that we may receive cannot be determined at this time and will depend on the number of shares we sell under the SEPA and market prices at the times of such sales. In connection with the SEPA, we may request Pre-Paid Advances of the Commitment Amount in an amount up to $5.0 million. Any proceeds that we receive from sales of our Ordinary Shares to YA or Pre-Paid Advances under the SEPA will be used for working capital and general corporate purposes. See &#8220;Use of Proceeds.&#8221;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk factors</b></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing in our securities involves a high degree of risk. You should read the &#8220;Risk Factors&#8221; section starting on page 7 of this prospectus, for a discussion of factors to consider carefully before deciding to invest in the Ordinary Shares.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nasdaq symbol:&#160;</b></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Ordinary Shares are listed on Nasdaq under the symbol &#8220;SPRC&#8221;. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The number of the Ordinary Shares to be outstanding immediately after this offering as shown above assumes that all of the Ordinary Shares offered hereby are sold and is based on 1,095,784 Ordinary Shares outstanding as of February 26, 2024. This number excludes:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,049 Ordinary Shares issuable upon the exercise of
    options outstanding under our 2015 Share Option Plan, at a weighted average exercise price of $6.38 per share;</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify; padding-right: 0.8pt">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,687 Ordinary Shares reserved for issuance and available
    for future grant under our 2015 Share Option Plan;</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify; padding-right: 0.8pt">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">364,694 Ordinary Shares issuable upon the exercise
    of outstanding warrants, with exercise prices ranging from $68.38 to $637.0 per Ordinary Share; and</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify; padding-right: 0.8pt">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    </tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,359,468 Ordinary Shares issuable upon the exercise
    of outstanding pre-funded warrants, with exercise prices ranging from $0.001 to $0.026 per Ordinary Share.</span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>RISK FACTORS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Investing
in our Ordinary Shares involves risks. Before making an investment decision, you should carefully consider the risk factors described
below. The risks and uncertainties described below are not the only risks facing us. We may face additional risks and uncertainties not
currently known to us or that we currently deem to be immaterial. Any of the risks described below, and any such additional risks, could
materially adversely affect our business, financial condition or results of operations. In such case, you may lose all or part of your
original investment. You should be able to bear a complete loss of your investment.<b>&#160;</b></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to the Offering&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>It is not possible to predict the actual
number of shares we will sell under the SEPA to the Selling Shareholder, or the actual gross proceeds resulting from those sales.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 21, 2024, we entered
into the SEPA with YA, pursuant to which YA has committed to purchase up to $20.0 million of our Ordinary Shares, subject to certain
limitations and conditions set forth in the SEPA. Of the Commitment Amount, to date we have not sold any Ordinary Shares (other than
the Commitment Shares). The Ordinary Shares that may be issued under the SEPA may be sold by us to YA at our discretion from time to
time over an approximately 36-month period commencing on the date of the SEPA.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We generally have the right
to control the timing and amount of any sales of our Ordinary Shares to YA under the SEPA. Sales of our Ordinary Shares, if any, to YA
under the SEPA will depend upon market conditions and other factors. We may ultimately decide to sell to YA all, some or none of the
Ordinary Shares that may be available for us to sell to YA pursuant to the SEPA.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because the purchase price
per share to be paid by YA for the Ordinary Shares that we may elect to sell to YA under the SEPA, if any, will fluctuate based on the
market prices of Ordinary Shares during the applicable purchase valuation period for each purchase made pursuant to the SEPA, if any,
it is not possible for us to predict, as of the date of this prospectus and prior to any such sales, the number of Ordinary Shares that
we will sell to YA under the SEPA, the purchase price per share that YA will pay for shares purchased from us under the SEPA, or the
aggregate gross proceeds that we will receive from those purchases by YA under the SEPA, if any.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, although the SEPA
provides that we may sell up to an aggregate of $20.0 million of our Ordinary Shares to YA, other than the Commitment Shares only 5,347,594
Ordinary Shares are being registered hereunder that we may elect to sell to YA, in our sole discretion, from time to time from and after
the date of, and pursuant to, the SEPA. Even if we elect to sell to YA all of the Ordinary Shares being registered for resale under this
prospectus, depending on the market prices of our Ordinary Shares at the time of such sales, the actual gross proceeds from the sale of
all such shares may be substantially less than the $20.0 million total commitment under the SEPA, which could materially adversely affect
our liquidity.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we desire to issue and
sell to YA under the SEPA more than the 5,347,594 Ordinary Shares being registered for resale under this prospectus, we would need to
file with the SEC one or more additional registration statements to register under the Securities Act the resale by YA of any such additional
Ordinary Shares and the SEC would have to declare such registration statement or statements effective before we could sell additional
shares.&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any issuance and sale by
us under the SEPA of a substantial number of Ordinary Shares in addition to the Ordinary Shares being registered for resale by YA under
this prospectus could cause additional substantial dilution to our shareholders. The number of Ordinary Shares ultimately offered for
sale by YA is dependent upon the number of Ordinary Shares, if any, we ultimately sell to YA under the SEPA.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, the resale by YA
of a significant number of shares registered for resale in this offering at any given time, or the perception that these sales may occur,
could cause the market price of our Ordinary Shares to decline and to be highly volatile.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Investors who buy shares at different times
will likely pay different prices.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the SEPA, we
will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold to YA. If and when we do elect
to sell Ordinary Shares to YA pursuant to the SEPA, YA may resell all, some or none of such shares at any time or from time to time in
its discretion and at different prices. As a result, investors who purchase shares from YA in this offering at different times will likely
pay different prices for those shares, and so may experience different levels of dilution and in some cases substantial dilution and
different outcomes in their investment results. Investors may experience a decline in the value of the shares they purchase from YA in
this offering as a result of future sales made by us to YA at prices lower than the prices such investors paid for their shares in this
offering.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may require additional financing to
sustain our operations and without it we will not be able to continue operations.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The extent to which we rely
on YA as a source of funding will depend on a number of factors, including the prevailing market price of our Ordinary Shares, our ability
to meet the conditions necessary to deliver advance notices under the SEPA and the extent to which we are able to secure funding from
other sources. Regardless of the amount of funds we ultimately raise under the SEPA, if any, we expect to continue to seek other sources
of funding. Even if we were to sell to YA the total commitment of $20.0 million, of which to date we have not sold any Ordinary Shares
(other than the Commitment Shares), under the SEPA we will still need additional capital to fully implement our business plan.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Future sales and issuances of our Ordinary
Shares or other securities might result in significant dilution and could cause the price of our Ordinary Shares to decline.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To raise capital, we may
sell Ordinary Shares, convertible securities or other equity securities in one or more transactions other than those contemplated by
the SEPA, at prices and in a manner we determine from time to time. We may sell shares or other securities in any other offering at a
price per share that is less than the price per share paid by investors in this offering, and investors purchasing shares or other securities
in the future could have rights superior to existing stockholders. The price per share at which we sell additional Ordinary Shares, or
securities convertible or exchangeable into Ordinary Shares, in future transactions may be higher or lower than the price per share paid
by investors in this offering. Any sales of additional shares will dilute our stockholders.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales of a substantial number
of Ordinary Shares in the public market or the perception that these sales might occur could depress the market price of our Ordinary
Shares and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect
that sales may have on the prevailing market price of our Ordinary Shares. In addition, the sale of substantial numbers of our Ordinary
Shares could adversely impact their price.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Management will have broad discretion as
to the use of the proceeds from the SEPA or any potential Pre-Paid Advance and uses may not improve our financial condition or market
value.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because we have not designated
the amount of net proceeds or potential Pre-Paid Advance from the SEPA to be used for any particular purpose, our management will have
broad discretion as to the application of such proceeds. Our management may use the proceeds for working capital and general corporate
purposes that may not improve our financial condition or advance our business objectives. <b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Financial Condition and
Capital Requirements</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are a specialty clinical</i></b>-<b><i>stage
pharmaceutical company and have incurred significant losses since the date of our inception, and anticipate that we will continue to
incur significant losses until we are able to successfully commercialize our product candidates.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have historically incurred
substantial net losses; including net losses of approximately $2.6 million for the year ended December 31, 2022, net losses of approximately
$5.8 million in 2021, and net losses of approximately $2.9 million for the six months ended June 30, 2023. As of the year ended December
31, 2022 and the six months ended June 30, 2023, we had accumulated deficits of approximately $63.6 million and $66 million, respectively.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have devoted substantially
all of our financial resources to develop our product candidates, and more recently, to a lesser degree, we have been searching for strategic
transactions. We have financed our operations primarily through the issuance of equity securities. The amount of our future net losses
will depend, in part, on completing the development of our product candidates, the demand for our product candidates, the rate of our
future expenditures and our ability to obtain funding through the issuance of our securities, strategic collaborations or grants. Pharmaceutical
product development is a highly speculative undertaking and involves a substantial degree of risk. We are in the late stages of preclinical
and at the early stages of clinical development for our product candidates, we have not yet commenced pivotal clinical studies for any
product candidate. Although we have begun early commercialization efforts for our proprietary PEA oral tablets formulation, CannAmide&#8482;,
which we expect will be marketed to pharmacies and other retail outlets across Canada following our entering into a distribution agreement(s),
it may be several years, if ever, before we complete pivotal clinical studies and have our lead product candidate approved for commercialization.
Even if we obtain regulatory approval to market a product candidate, our future revenue will depend upon the size of the markets for
which our product candidates may receive approval and our ability to achieve sufficient market acceptance, pricing, reimbursement from
third-party payors and adequate market share for our product candidates in those markets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to continue to
incur significant losses until we are able to commercialize our main pharmaceutical product candidates, which we may not be successful
in achieving. We anticipate that our expenses will increase substantially if and as we:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
    the research and development of our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand
    the scope of our current clinical studies for our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    regulatory and marketing approvals for our product candidates that successfully complete clinical studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    a sales, marketing and distribution infrastructure to commercialize our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    to identify, assess, acquire, license, and/or develop other product candidates and subsequent generations of our current product
    candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    to maintain, protect, and expand our intellectual property portfolio;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    to attract and retain skilled personnel; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">create
    additional infrastructure to support our operations as a public company and our product candidate development and planned future
    commercialization efforts.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have not generated any revenue from
the sale of our current pharmaceutical product candidates and may never be profitable.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not yet commercialized
any of our pharmaceutical product candidates and have not generated any revenue from sales of our pharmaceutical product candidates since
the date of our inception. Although we have begun early commercialization efforts for our proprietary PEA oral tablets formulation. CannAmide&#8482;,
we do not currently expect the sale of CannAmide to result in material revenues, nor is CannAmide&#8482; our lead pharmaceutical product
candidate. We do not know whether or when we will become profitable. Our ability to generate revenue and achieve profitability depends
on our ability to successfully complete the development of, and to commercialize, our pharmaceutical product candidates and on the demand
for our pharmaceutical product candidates. Our ability to generate revenue and achieve profitability depends on our ability, alone or
with strategic collaboration partners, to successfully complete the development of, and obtain the regulatory and marketing approvals
necessary to commercialize, one or more of our pharmaceutical product candidates. Our ability to generate future revenue from pharmaceutical
product candidate sales depends heavily on our success in many areas, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completing
    research and preclinical and clinical development of our pharmaceutical product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    regulatory and marketing approvals for pharmaceutical product candidates for which we complete clinical studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    and maintaining supply and manufacturing relationships with third parties that can provide adequate (in amount and quality) pharmaceutical
    products to support market demand for our pharmaceutical product candidates, if approved;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching
    and commercializing pharmaceutical product candidates if and when we obtain regulatory and marketing approval, either directly or
    with a collaborator or distributor;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    market acceptance of our pharmaceutical product candidates as viable treatment options;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">addressing
    any competing pharmaceutical or biotechnological and market developments;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying,
    assessing, acquiring and/or developing new pharmaceutical product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negotiating
    favorable terms in any collaboration, licensing or other arrangements into which we may enter;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining,
    protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attracting,
    hiring and retaining qualified personnel.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if one or more of the
pharmaceutical product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated
with commercializing any approved pharmaceutical product candidate. Our expenses could increase beyond expectations if we are required
by the FDA, the European Medicines Agency, or the EMA, or other regulatory agencies, domestic or foreign, to perform clinical, nonclinical
or other types of studies in addition to those that we currently anticipate. In cases where we are successful in obtaining regulatory
approvals to market one or more of our pharmaceutical product candidates, our revenue will be dependent, in part, upon the size of the
markets in the territories for which we gain regulatory approval, the accepted price for the pharmaceutical product candidate, the ability
to get reimbursement at an acceptable price and whether we own the commercial rights for that territory. If the number of our addressable
patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect, or the reasonably
expected population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant
revenue from sales of such pharmaceutical product candidates, even if approved. Additionally, if we are not able to generate revenue
from the sale of any approved pharmaceutical product candidates, we may be forced to cease operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We expect that we will need to raise substantial
additional funding before we can expect to become profitable from sales of our pharmaceutical product candidates. This additional financing
may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit
or terminate our pharmaceutical product candidate development efforts or other operations.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2022,
our cash was approximately $3.6 million, other accounts receivable was approximately $0.2 million, we had a negative working capital
of approximately $131 thousand and an accumulated deficit of approximately $63.6 million. As of the six months ended June 30, 2023, our
cash was approximately $2.1 million, other accounts receivable was approximately $815,000, we had working capital of approximately $529,000
and an accumulated deficit of approximately $66 million. Based upon our currently expected level of operating expenditures, we do not
expect that our existing cash will be sufficient to fund operations for at least the next 12 months. We expect that we will require substantial
additional capital to commercialize our pharmaceutical product candidates. In addition, our operating plans may change as a result of
many factors that may currently be unknown to us, and we may need to seek additional funds sooner than planned. Our future funding requirements
will depend on many factors, including but not limited to:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, rate of progress, results and cost of pharmaceutical product development, clinical studies, preclinical testing, and other
    related activities;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost, timing and outcomes of regulatory approvals;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost and timing of establishing sales, marketing, and distribution capabilities; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    terms and timing of any collaborative, licensing, and other arrangements that we may establish.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any additional fundraising
efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize
our pharmaceutical product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts
or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of holders
of our securities and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may
cause the market price of our Ordinary Shares to decline. The incurrence of indebtedness could result in increased fixed payment obligations,
and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations
on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact
our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise
at an earlier stage than otherwise would be desirable, and we may be required to relinquish rights to some of our technologies or pharmaceutical
product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating
results and prospects. Even if we believe that we have sufficient funds for our current or future operating plans, we may seek additional
capital if market conditions are favorable or if we have specific strategic considerations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable to obtain
funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development
programs or the commercialization of any pharmaceutical product candidates or be unable to expand our operations or otherwise capitalize
on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The report of our independent registered
public accounting firm contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern,
which could prevent us from obtaining new financing on reasonable terms or at all.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The report of our independent
registered public accounting firm on our audited consolidated financial statements for the period ended December 31, 2022 contains an
explanatory paragraph regarding substantial doubt about our ability to continue as a going concern. Our consolidated financial statements
do not include any adjustments that might result from the outcome of the uncertainty regarding our ability to continue as a going concern.
This going concern opinion could materially limit our ability to raise additional funds through the issuance of equity or debt securities
or otherwise. Further reports on our consolidated financial statements may include an explanatory paragraph with respect to our ability
to continue as a going concern. Until we can generate significant recurring revenues, we expect to satisfy our future cash needs through
debt or equity financing. We cannot be certain that additional funding will be available to us on acceptable terms, if at all. If funds
are not available, we may be required to delay, reduce the scope of, or eliminate research or development plans for, or commercialization
efforts with respect to our products. This may raise substantial doubts about our ability to continue as a going concern.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to the Discovery and Development
of Our Pharmaceutical Product Candidates </b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are heavily dependent on the success
of our pharmaceutical product candidates, which are in the late stages of pre-clinical development or early stages of clinical development.
We cannot give any assurance that any of our pharmaceutical product candidates will receive regulatory approval, which is necessary before
they can be commercialized.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have invested
substantially all of our efforts and financial resources to design and develop our pharmaceutical product candidates, including conducting
preclinical studies and providing general and administrative support for these operations. Our future success is dependent on our ability
to successfully develop, obtain regulatory approval for, and then successfully commercialize one or more pharmaceutical product candidates.
We currently generate no revenue from sales of any pharmaceutical product candidate, and we may never be able to develop or commercialize
a marketable pharmaceutical product candidate.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of our pharmaceutical
product candidates is in the late stages of pre-clinical development or early stages of development and will require additional clinical
development (and in some cases additional preclinical development), management of nonclinical, clinical and manufacturing activities,
regulatory approval, obtaining adequate manufacturing supply, building of a commercial organization and significant marketing efforts
before we generate any revenue from pharmaceutical product candidate sales. It may be years before a pivotal study is initiated, if at
all. Any clinical trials in the United States will require the approval of an Investigational New Drug, or IND, application by the FDA,
and we cannot assure that we will obtain such approval in a timely manner, or at all. We are not permitted to market or promote any of
our pharmaceutical product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities,
and we may never receive such regulatory approval for any of our pharmaceutical product candidates.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We as a company have never
submitted marketing applications to the FDA or comparable foreign regulatory authorities. We cannot be certain that any of our pharmaceutical
product candidates will be successful in clinical studies or receive regulatory approval or what regulatory pathway the regulatory authorities
shall designate for our pharmaceutical product candidates. Further, our pharmaceutical product candidates may not receive regulatory
approval even if they are successful in clinical studies. If we do not receive regulatory approvals for our pharmaceutical product candidates,
we may not be able to continue our operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We generally plan to seek
regulatory approval to commercialize our pharmaceutical product candidates in the United States, the European Union and in additional
foreign countries. To obtain regulatory approvals we must comply with the numerous and varying regulatory requirements of such countries
regarding safety, efficacy, chemistry, manufacturing and controls, clinical studies, commercial sales, pricing and distribution of our
product candidates. Even if we are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval
in any other jurisdictions. If we are unable to obtain approval for our pharmaceutical product candidates in multiple jurisdictions,
our revenue and results of operations would be negatively affected.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The regulatory approval processes of the
FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable. If we are ultimately unable to obtain
regulatory approval for our pharmaceutical product candidates, our business will be substantially harmed.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The time required to obtain
approval by the FDA and comparable foreign authorities is unpredictable, typically takes many years following the commencement of clinical
studies and depends upon numerous factors. In addition, approval policies, regulations or the type and amount of clinical data necessary
to gain approval may change during the course of a pharmaceutical product candidate&#8217;s clinical development and may vary among jurisdictions,
which may cause delays in the approval or the decision not to approve an application. We have not obtained regulatory approval for any
pharmaceutical product candidate, and it is possible that none of our existing pharmaceutical product candidates or any pharmaceutical
product candidates we may seek to develop in the future will ever obtain regulatory approval.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Applications for our pharmaceutical
product candidates could fail to receive regulatory approval for many reasons, including but not limited to the following:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to demonstrate to the FDA or comparable foreign regulatory authorities that a pharmaceutical product candidate&#8217;s
    safety-benefit ratio for its proposed indication is acceptable;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical
    studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    data collected from clinical studies of our pharmaceutical product candidates may not be sufficient to support the submission of
    a New Drug Application, or NDA, in the United States or elsewhere;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications
    or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering
    our clinical data insufficient for approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This lengthy approval process,
as well as the unpredictability of the results of clinical studies, may result in our failing to obtain regulatory approval to market
any of our pharmaceutical product candidates, which would significantly harm our business, results of operations and prospects.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical drug development involves a lengthy
and expensive process with an uncertain outcome, and results of earlier studies may not be predictive of future study results.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical testing is expensive
and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical study
process. The results of preclinical studies and early clinical studies of our product candidates may not be predictive of the results
of later-stage clinical studies. Product candidates that have shown promising results in early-stage clinical studies may still suffer
significant setbacks in subsequent advanced clinical studies. There is a high failure rate for drugs proceeding through clinical studies,
and product candidates in later stages of clinical studies may fail to show the desired safety and efficacy traits despite having progressed
satisfactorily through preclinical studies and initial clinical studies. A number of companies in the pharmaceutical industry have suffered
significant setbacks in advanced clinical studies due to lack of efficacy or adverse safety profiles, notwithstanding promising results
in earlier studies. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses. We do not
know whether any Phase I, Phase II, Phase III or other clinical studies we may conduct will demonstrate consistent or adequate efficacy
and safety sufficient to obtain regulatory approval to market our product candidates.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may find it difficult to enroll patients
in our clinical studies. Difficulty in enrolling patients could delay or prevent clinical studies of our pharmaceutical product candidates.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Identifying and qualifying
patients to participate in clinical studies of our pharmaceutical product candidates is critical to our success. The timing of our clinical
studies depends in part on the speed at which we can recruit patients to participate in testing our pharmaceutical product candidates,
and we may experience delays in our clinical studies if we encounter difficulties in enrollment.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some of the conditions for
which we plan to evaluate our current pharmaceutical product candidates are for rare diseases. Accordingly, there is a limited patient
pool from which to draw for clinical studies. Further, the eligibility criteria of our clinical studies will further limit the pool of
available study participants as we will require that patients have specific characteristics that we can measure or to assure their disease
is either severe enough or not too advanced to include them in a study.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, the process
of finding patients may prove costly. We also may not be able to identify, recruit and enroll a sufficient number of patients to complete
our clinical studies because of the perceived risks and benefits of the pharmaceutical product candidate under study, the availability
and efficacy of competing therapies and clinical studies, the proximity and availability of clinical study sites for prospective patients
and the patient referral practices of physicians. If patients are unwilling to participate in our studies for any reason, the timeline
for recruiting patients, conducting studies and obtaining regulatory approval of potential pharmaceutical product candidates will be
delayed.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we experience delays in
the completion or termination of any clinical study of our pharmaceutical product candidates, the commercial prospects of our pharmaceutical
product candidates will be harmed, and our ability to generate pharmaceutical product candidate revenue from any of these pharmaceutical
product candidates could be delayed or prevented. In addition, any delays in completing our clinical studies will increase our costs,
slow down our product candidate development and approval process and jeopardize our ability to commence pharmaceutical product candidate
sales and generate revenue. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition,
many of the factors that cause, or lead to, a delay in the commencement or completion of clinical studies may also ultimately lead to
the denial of regulatory approval of our pharmaceutical product candidates.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If the FDA does not conclude that our pharmaceutical
product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements for our </i></b>pharmaceutical
<b><i>product candidates under Section 505(b)(2) are not as we expect, the approval pathway would likely take significantly longer, cost
significantly more and entail significantly greater complications and risks than anticipated and in either case may not be successful.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to seek FDA approval
through the Section 505(b)(2) regulatory pathway for our pharmaceutical product candidate SCI-110 and potentially for our drug candidate
SCI-210. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Amendments, added Section
505(b)(2) to the Federal Food, Drug, and Cosmetic Act of 1938, as amended, or the FDC Act, or Section 505(b)(2). Section 505(b)(2) permits
the filing of an NDA where at least some of the information required for approval comes from studies not conducted by or for the applicant
and for which the applicant has not obtained a right of reference.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the FDA does not allow
us to pursue the Section 505(b)(2) regulatory pathway as anticipated, we may need to conduct additional clinical trials, provide additional
data and information and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required
to obtain FDA approval, and complications and risks associated with FDA approval, would substantially increase. We may need to obtain
additional funding, which could result in significant dilution to the ownership interests of our then existing shareholders to the extent
we issue equity securities or convertible debt. We cannot assure you that we would be able to obtain such additional financing on terms
acceptable to us, if at all. Moreover, inability to pursue the Section 505(b)(2) regulatory pathway could result in new competitive pharmaceutical
product candidates reaching the market faster than our pharmaceutical product candidates, which could materially adversely impact our
competitive position and prospects. Even if we are allowed to pursue the Section 505(b)(2) regulatory pathway, we cannot assure you that
our pharmaceutical product candidates will receive the requisite approvals for commercialization.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, notwithstanding
the approval of a number of pharmaceutical product candidates by the FDA under Section 505(b)(2) over the last few years, some pharmaceutical
companies and others have objected to the FDA&#8217;s interpretation of Section 505(b)(2). For example, several companies have previously
petitioned the FDA regarding the constitutionality of allowing others to rely upon FDA findings that are based on their proprietary data.
If the FDA&#8217;s interpretation of Section 505(b)(2) is successfully challenged, the FDA may be required to change its 505(b)(2) policies
and practices, which could require that we generate full data regarding safety and effectiveness for previously approved active ingredients
and delay or even prevent the FDA from approving any NDA that we submit under Section 505(b)(2). In addition, the pharmaceutical industry
is highly competitive, and Section 505(b)(2) NDAs are subject to special requirements designed to protect the patent rights of sponsors
of previously approved drugs that are referenced in a Section 505(b)(2) NDA. These requirements may give rise to patent litigation and
mandatory delays in approval of our potential future NDAs for up to 30 months depending on the outcome of any litigation. It is not uncommon
for a manufacturer of an approved pharmaceutical product to file a citizen petition with the FDA seeking to delay approval of, or impose
additional approval requirements for, pending competing pharmaceutical products. If successful, such petitions can significantly delay,
or even prevent, the approval of the new pharmaceutical product. However, even if the FDA ultimately denies such a petition, the FDA
may substantially delay approval while it considers and responds to the petition. In addition, even if we are able to utilize the Section
505(b)(2) regulatory pathway for our pharmaceutical product candidates, there is no guarantee this would ultimately lead to faster pharmaceutical
product development or earlier approval. Moreover, even if these pharmaceutical product candidates are approved under the Section 505(b)(2)
pathway, as the case may be, the approval may be subject to limitations on the indicated uses for which the pharmaceutical products may
be marketed or to other conditions of approval or may contain requirements for costly post-marketing testing and surveillance to monitor
the safety or efficacy of the pharmaceutical products. Our pharmaceutical product candidates are at early stages of development and are
subject to uncertainty over what we must do on our development program in order to secure approval under Section 505(b)(2).&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may encounter substantial delays in
our clinical studies, or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before obtaining marketing
approval from regulatory authorities for the sale of our pharmaceutical product candidates, we must conduct extensive clinical studies
to demonstrate the safety and efficacy of the pharmaceutical product candidates in humans. Clinical testing is expensive, time consuming
and uncertain as to outcome. We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if
at all. A failure of one or more clinical studies can occur at any stage of testing, and our future clinical studies may not be successful.
Events that may prevent successful or timely completion of clinical development include but are not limited to:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation of human clinical studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    occurrence of a pandemic or the spread of a virus that diverts the attention of regulatory agencies from reviewing our study design
    or results or which, as a result of such pandemic or widespread, requires us to materially modify our planned clinical studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in reaching a consensus with regulatory agencies on study design;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical study sites, the
    terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical study sites;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in obtaining required Institutional Review Board, or IRB, approval at each clinical study site;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition
    of a clinical hold by regulatory agencies, after review of an IND, application, or equivalent application, or an inspection of our
    clinical study operations or study sites;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in recruiting suitable patients to participate in our clinical studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    collaborating with patient groups and investigators;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    by our CROs, other third parties or us to adhere to clinical study requirements;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to perform in accordance with the FDA&#8217;s Good Clinical Practices, or GCP, requirements, or applicable regulatory guidelines
    in other countries;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in having patients complete participation in a study or return for post-treatment follow-up;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
    dropping out of a study;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">occurrence
    of serious adverse events associated with the pharmaceutical product candidate that are viewed to outweigh its potential benefits;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in regulatory requirements and guidance that require amending or submitting new clinical protocols;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of clinical studies of our pharmaceutical product candidates being greater than we anticipate;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    studies of our pharmaceutical product candidates producing negative or inconclusive results, which may result in us deciding, or
    regulators requiring us, to conduct additional clinical studies or abandon pharmaceutical product candidate development programs;
    and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of our pharmaceutical product
    candidates for use in clinical studies or the inability to do any of the foregoing.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any inability to successfully
complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue. We may
also be required to conduct additional safety, efficacy and comparability studies before we will be allowed to start clinical studies
with our repurposed drugs. Clinical study delays could also shorten any periods during which our pharmaceutical product candidates have
patent protection and may allow our competitors to bring pharmaceutical product candidates to market before we do, which could impair
our ability to obtain orphan exclusivity and successfully commercialize our pharmaceutical product candidates and may harm our business
and results of operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>In respect of our pharmaceutical product
candidates targeting rare indications, orphan drug exclusivity may afford limited protection, and if another party obtains orphan drug
exclusivity for the drugs and indications we are targeting, we may be precluded from commercializing our pharmaceutical product candidates
in those indications during that period of exclusivity</i>.</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are seeking to obtain
an orphan designation for some of our pharmaceutical product candidates in the United States. Under the Orphan Drug Act, the FDA may
designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, defined, in part, as a patient population
of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable
expectation that the cost of developing the drug will be recovered from sales in the United States. Additionally, designation is granted
for products intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic
condition and when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the
necessary investment in developing the drug.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, the
first NDA applicant with an orphan drug designation for a particular active moiety to treat a specific disease or condition that receives
FDA approval is entitled to a seven-year exclusive marketing period in the United States for that product candidate, for that indication.
In the European Union, orphan drug designation also entitles a party to financial incentives such as reduction of fees or fee waivers
and 10 years of market exclusivity is granted following drug approval. This period may be reduced to six years if the orphan drug designation
criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market
exclusivity.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2016, we submitted
a request for orphan drug designation to the FDA for SCI-110 for the treatment of TS. In a letter dated September 29, 2016, the FDA informed
us that our request could not be granted at such time, and is being held in abeyance until and subject to us providing additional information
pertaining to the overall prevalence of TS in both children and adults, and further clinical data to support our scientific rationale
for our request for orphan drug designation within 12 months. In September 2017, we responded to such FDA letter within the designated
time frame, and provided the FDA with our articulated and reasoned responses including documentation and clinical data that supports
it. On December 26, 2017, we received the FDA&#8217;s response to our response. The FDA accepted that there is adequate scientific rationale
for the treatment of TS with SCI-110 mainly through the preliminary results of ongoing clinical trials, suggesting that SCI-110 may provide
benefit in treating TS. However, the FDA stated that it was unable to grant our request and indicated that we did not provide adequate
prevalence estimates, and any evidence to support our statement that only moderate to severe TS patients would require pharmacological
treatment. We further responded in January 2018 by providing additional information. On January 23, 2020, following additional correspondence
with the FDA, the FDA still did not grant us our request due to the fact that we have not yet provided adequate prevalence estimates.
However, the FDA did agree with our position that we could potentially qualify for orphan drug designation with respect to the moderate-to-severe
TS sub-group population only rather than the entire population. After we had provided additional prevalence estimates, the FDA raised
a concern in its letter, dated December 7, 2020, about our ability to limit the use of the pharmaceutical product to the subset of patients
we are pursuing. Due to the fact that we disagree with this concern, we requested a clarification call. In the clarification call conducted
on February 2, 2021, we agreed with the FDA concern about our ability to limit the use of the pharmaceutical product to the subset of
patients in addition to a safety concern associated with THC treatment in pediatrics population so we suggested to amend our preliminary
request and asked to include only adults in the treated population. An amendment letter was discussed and the FDA described what it would
want to see in such an amendment. In March 2021, we sent our response to the FDA. In June 2021, we received a response from the FDA explaining
that they are unable to grant our request until new information becomes available to support our request for orphan drug designation.
We will re-visit the application after we obtain clinical results from our upcoming phase IIb clinical trial in TS.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no assurance that
we will successfully obtain orphan drug designation for TS, any future rare indications or orphan exclusivity upon approval of any of
our pharmaceutical product candidates that have already obtained designation.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we do obtain orphan
exclusivity for any pharmaceutical product candidate, the exclusive marketing rights may be lost if the FDA later determines that the
request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug. Moreover,
a drug product candidate with an active moiety that is a different cannabinoid from that in our drug candidate or, under limited circumstances,
the same drug product candidate, may be approved by the FDA for the same indication during the period of marketing exclusivity. The limited
circumstances include a showing that the second drug is clinically superior to the drug with marketing exclusivity through a demonstration
of superior safety or efficacy or that it makes a major contribution to patient care. In addition, if a competitor obtains approval and
marketing exclusivity for a drug product candidate with an active moiety that is the same as that in a pharmaceutical product candidate
we are pursuing for the same indication, approval of our pharmaceutical product candidate would be blocked during the period of marketing
exclusivity unless we could demonstrate that our product candidate is clinically superior to the approved pharmaceutical product candidate.
In addition, if a competitor obtains approval and marketing exclusivity for a drug product candidate with an active moiety that is the
same as that in a pharmaceutical product candidate we are pursuing for a different orphan indication, this may negatively impact the
market opportunity for our pharmaceutical product candidate.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There have been legal challenges
to aspects of the FDA&#8217;s regulations and policies concerning the exclusivity provisions of the Orphan Drug Act, and future challenges
could lead to changes that affect the protections afforded our pharmaceutical product candidates in ways that are difficult to predict.
In a recent successful legal challenge, a court invalidated the FDA&#8217;s denial of orphan exclusivity to a drug on the grounds that
the drug was not proven to be clinically superior to a previously approved pharmaceutical product candidate containing the same ingredient
for the same orphan use. In response to the decision, the FDA released a policy statement stating that the court&#8217;s decision is
limited just to the facts of that particular case and that the FDA will continue to require the sponsor of a designated drug that is
the &#8220;same&#8221; as a previously approved drug to demonstrate that its drug is clinically superior to that drug upon approval in
order to be eligible for orphan drug exclusivity, or in some cases, to even be eligible for marketing approval. In the future, there
is the potential for additional legal challenges to the FDA&#8217;s orphan drug regulations and policies, and it is uncertain how such
challenges might affect our business.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>While orphan drug product candidates are
typically sold at a high price relative to other medications, the market may not be receptive to high pricing of our product candidates.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We develop our product candidates
to treat rare diseases, a space where medications are usually sold at high prices compared with other medications. However, our product
candidates are repurposed drugs, which means, among other things, that they contain drug substances available in pharmacies for the purpose
of treating indications that are different from the indications for which we plan to use. Accordingly, even if regulatory authorities
approve our product candidates, the market may not be receptive to, and it may be difficult for us to achieve, a per-patient per-year
price high enough to allow us to realize a return on our investment.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our product candidates may cause undesirable
side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved
label or result in significant negative consequences following marketing approval, if any.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The use of dronabinol has
been associated with seizures, paranoia, rapid heart rate and unusual thoughts and behaviors. Undesirable side effects caused by our
product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical studies and could result in a more restrictive
marketing label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Potential side effects
of our cannabinoid-based treatments may include: asthenia, palpitations, tachycardia, vasodilation/facial flush, abdominal pain, nausea,
vomiting, amnesia, anxiety/nervousness, ataxia, confusion, depersonalization, dizziness, euphoria, hallucinations, paranoid reaction,
somnolence and abnormal thinking. Results of our studies may identify unacceptable severity and prevalence of these or other side effects.
In such an event, our studies could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order
us to cease further development of or deny or withdraw approval of our product candidates for any or all targeted indications.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Drug-related side effects
could affect patient recruitment, the ability of enrolled patients to complete the study or result in potential product candidate liability
claims.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, if one or more
of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such product
candidates, a number of potentially significant negative consequences could result, including but not limited to:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may withdraw approvals of such product candidate;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may require additional warnings on the label;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to create a Risk Evaluation and Mitigation Strategy, or REMS, plan, which could include a medication guide outlining
    the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other Elements
    To Assure Safe Use, or ETASU;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    could be sued and held liable for harm caused to patients; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reputation may suffer.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these events
could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly
harm our business, results of operations and prospects.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we obtain regulatory approval for
a product candidate, our product candidates will remain subject to regulatory scrutiny.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our product candidates
are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion,
sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including
both federal and state requirements in the United States. In addition, manufacturers and manufacturers&#8217; facilities are required
to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to current Good
Manufacturing Practices, or cGMP, regulations and Quality System Regulation, or QSR. As such, we and our contract manufacturers will
be subject to continual review and inspections to assess compliance with cGMP, QSR and adherence to commitments made in any NDA. Accordingly,
we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing,
production and quality control.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any regulatory approvals
that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product candidate
may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase
4 clinical trials and surveillance to monitor the safety and efficacy of the product candidate. We will also be required to report certain
adverse reactions and production problems, if any, to the FDA, and to comply with requirements concerning advertising and promotion for
our product candidates. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory
restrictions and must be consistent with the information in the product candidate&#8217;s approved label. As such, we may not promote
our product candidates for indications or uses for which they do not have FDA approval. The holder of an approved NDA must also submit
new or supplemental applications and obtain FDA approval for certain changes to the approved product candidate, product candidate labeling
or manufacturing process. We could also be asked to conduct post-marketing clinical studies to verify the safety and efficacy of our
product candidates in general or in specific patient subsets. If original marketing approval were obtained via the accelerated approval
pathway, we could be required to conduct a successful post-marketing clinical study to confirm clinical benefit for our product candidates.
An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval. Furthermore,
any new legislation addressing drug safety issues could result in delays in product candidate development or commercialization or increased
costs to assure compliance. Foreign regulatory authorities impose similar requirements.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a regulatory agency discovers
previously unknown problems with a product candidate, such as adverse events of unanticipated severity or frequency, or problems with
the facility where the product candidate is manufactured, or disagrees with the promotion, marketing or labeling of a product candidate,
such regulatory agency may impose restrictions on that product candidate or us, including requiring withdrawal of the product candidate
from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among
other things:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue
    warning letters;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impose
    civil or criminal penalties;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    or withdraw regulatory approval;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    any of our ongoing clinical studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to approve pending applications or supplements to approved applications submitted by us;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impose
    restrictions on our operations, including closing our contract manufacturers&#8217; facilities; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize
    or detain product candidates, or require a product candidate recall.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any government investigation
of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity.
Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate
revenue from our product candidates. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company
and our operating results will be adversely affected.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are subject to numerous complex regulations
and failure to comply with these regulations, or the cost of compliance with these regulations, may harm our business.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The research, testing, development,
manufacturing, quality control, approval, labeling, packaging, storage, recordkeeping, promotion, advertising, marketing, distribution,
possession and use of our product candidates, among other things, are subject to regulation by numerous governmental authorities in the
United States and elsewhere. The FDA regulates drugs under the FDC Act, and implementing regulations. Noncompliance with any applicable
regulatory requirements can result in refusal to approve product candidates for marketing, warning letters, product candidate recalls
or seizure of product candidates, total or partial suspension of production, prohibitions or limitations on the commercial sale of product
candidates or refusal to allow the entering into of federal and state supply contracts, fines, civil penalties and/or criminal prosecution.
Additionally, the FDA and comparable governmental authorities have the authority to withdraw product candidate approvals that have been
previously granted. Moreover, the regulatory requirements relating to our product candidates may change from time to time and it is impossible
to predict what the impact of any such changes may be.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing product
candidates that are controlled substances as defined in the Controlled Substances Act of 1970, or CSA, which establishes, among other
things, certain registration, production quotas, security, recordkeeping, reporting, import, export and other requirements administered
by the Drug Enforcement Administration, or the DEA. As a result, any product candidate that is a controlled substance (or includes a
controlled substance) cannot be marketed before such substance is rescheduled by the DEA as a Schedule II, III, IV or V substance. The
active ingredient in our product candidates is dronabinol, which is a Schedule III controlled substance. See &#8220;Business-Government
Regulation&#8221; for additional information.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The manufacture, shipment,
storage, sale and use, among other things, of controlled substances that are pharmaceutical product candidates are subject to a high
degree of regulation. The DEA also conducts periodic inspections of registered establishments that handle controlled substances. Facilities
that conduct research, manufacture, distribute, import or export controlled substances must be registered to perform these activities
and have the security, control and inventory mechanisms required by the DEA to prevent drug loss and diversion. Failure to maintain compliance,
particularly non-compliance resulting in loss or diversion, can result in regulatory action that could have a material adverse effect
on our business, results of operations, financial condition and prospects. The DEA may seek civil penalties, refuse to renew necessary
registrations, or initiate proceedings to suspend or revoke those registrations. In certain circumstances, violations could lead to criminal
proceedings.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Individual states also have
controlled substances laws. Though state controlled substances laws often mirror federal law, because the states are separate jurisdictions,
they may separately schedule our product candidates as well. While some states automatically schedule a drug when the DEA does so, other
states schedule drugs through rulemaking or a legislative action. State scheduling may delay commercial sale of any product candidate
for which we obtain federal regulatory approval and adverse scheduling could have a material adverse effect on the commercial attractiveness
of such product candidate. We or our partners must also obtain separate state registrations, permits or licenses in order to be able
to obtain, handle, and distribute controlled substances for clinical trials or commercial sale, and failure to meet applicable regulatory
requirements could lead to enforcement and sanctions from the states in addition to those from the DEA or otherwise arising under federal
law.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Reliance on Third Parties
</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely on third parties to conduct our
preclinical and clinical studies and perform other tasks for us. If these third parties do not successfully carry out their contractual
duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize
our product candidates and our business could be substantially harmed.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have relied upon and plan
to continue to rely upon third-party CROs to monitor and manage data for our ongoing preclinical and clinical programs, including Target
Health, Inc., FGK Clinical Research GmbH, or FGK, and others. We rely on these parties for execution of our preclinical and clinical
studies, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies
is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs does
not relieve us of our regulatory responsibilities. We and our CROs and other vendors are required to comply with current cGMP, GCP, QSR
and Good Laboratory Practices, or GLP, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member
States of the European Economic Area, and comparable foreign regulatory authorities for all of our product candidates in clinical development.
Regulatory authorities enforce these regulations through periodic inspections of study sponsors, principal investigators, study sites
and other contractors. If we or any of our CROs or vendors fail to comply with applicable regulations, the clinical data generated in
our clinical studies may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform
additional clinical studies before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory
authority, such regulatory authority will determine that any of our clinical studies comply with GCP regulations. In addition, our clinical
studies must be conducted with product candidates which are produced under cGMP regulations. Our failure to comply with these regulations
may require us to repeat clinical studies, which would delay the regulatory approval process.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of our relationships
with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable
terms. In addition, our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot
control whether or not they devote sufficient time and resources to our on-going clinical, nonclinical and preclinical programs. These
risks may be heightened in the event of new uncontrolled outbreaks of COVID-19. If CROs do not successfully carry out their contractual
duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they
obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical
studies may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize
our product candidates. CROs may also generate higher costs than anticipated. As a result, our results of operations and the commercial
prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Switching or adding additional
CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO
commences work. As a result, delays may occur, which could materially impact our ability to meet our desired clinical development timelines.
Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or
delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition
and prospects.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will rely on third parties to manufacture
our API and formulations. Our business could be harmed if those third parties fail to provide us with sufficient quantities of our needed
supplies, or fail to do so at acceptable quality levels or prices.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have the infrastructure
or capability internally to manufacture the API formulations, and we lack the resources and the capability to manufacture any of our
product candidates on a clinical or commercial scale. We plan to rely on third parties for such supplies. There are a limited number
of manufacturers who have the ability to produce our API and there may be a need to identify alternate manufacturers to prevent a possible
disruption of our clinical studies. Any significant delay or discontinuity in the supply of these components could considerably delay
completion of our clinical studies, product candidate testing and potential regulatory approval of our product candidates, which could
harm our business and results of operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We and our collaborators and contract manufacturers
are subject to significant regulation with respect to manufacturing our product candidates. The manufacturing facilities on which we
rely may not continue to meet regulatory requirements and have limited capacity.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All entities involved in
the preparation of therapeutics for clinical studies or commercial sale, including our existing contract manufacturers for our product
candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or a product
candidate used in late-stage clinical studies must be manufactured in accordance with cGMP. These regulations govern manufacturing processes
and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of
investigational product candidates and products approved for sale. Poor control of production processes can lead to the introduction
of contaminants or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final
product testing. We, our collaborators or our contract manufacturers must supply all necessary documentation in support of an NDA, or
Marketing Authorization Application, or MAA, on a timely basis and must adhere to GLP and cGMP QSR regulations enforced by the FDA and
other regulatory agencies through their facilities inspection program. Some of our contract manufacturers have never produced a commercially
approved pharmaceutical product and therefore have not obtained the requisite regulatory authority approvals to do so. The facilities
and quality systems of some or all of our collaborators and third-party contractors must pass a pre-approval inspection for compliance
with the applicable regulations as a condition of regulatory approval of our product candidates or any of our other potential product
candidates. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation
of our product candidates or our other potential product candidates or the associated quality systems for compliance with the regulations
applicable to the activities being conducted. We do not control the manufacturing process of, and are completely dependent on, our contract
manufacturing partners for compliance with the regulatory requirements. If these facilities do not pass a pre-approval plant inspection,
regulatory approval of the product candidates may not be granted or may be substantially delayed until any violations are corrected to
the satisfaction of the regulatory authority, if ever.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The regulatory authorities
also may, at any time following approval of a product candidate for sale, if ever, audit the manufacturing facilities of our collaborators
and third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation
of our product candidate specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant
regulatory authority may require remedial measures that may be costly and/or time consuming for us or a third party to implement, and
that may include the temporary or permanent suspension of a clinical study or commercial sales, or the temporary or permanent closure
of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we, our collaborators,
or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA or other applicable regulatory authority can
impose regulatory sanctions including, among other things, refusal to approve a pending application for a new drug product, withdrawal
of an approval or suspension of production. As a result, our business, financial condition and results of operations may be materially
harmed.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, if supply from
one approved manufacturer is interrupted, an alternative manufacturer would need to be qualified through an NDA or MAA amendment, or
equivalent foreign regulatory filing, which could result in further delay. The regulatory agencies may also require additional studies
if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to
result in a delay in our desired clinical and commercial timelines.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These factors could cause
us to incur higher costs and could cause the delay or termination of clinical studies, regulatory submissions, required approvals or
commercialization of our product candidates. Furthermore, if our suppliers fail to meet contractual requirements and we are unable to
secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical studies may be delayed
or we could lose potential revenue.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our reliance on third parties requires
us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be
misappropriated or disclosed.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because we rely on third
parties to develop and manufacture our product candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary
technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research
agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning
research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our
confidential information, such as trade secrets. Despite the contractual provisions employed when working with third parties, the need
to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors,
are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our
proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other
unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Commercialization of Our Pharmaceutical
Product Candidates</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If the market opportunities for our pharmaceutical
product candidates are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our projections of both the
number of people who have our target diseases, as well as the subset of people with these diseases who have the potential to benefit
from treatment with our pharmaceutical product candidates, are based on our beliefs and estimates. These estimates have been derived
from a variety of sources, including the scientific literature, surveys of clinics, patient foundations or market research and may prove
to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may
turn out to be lower than expected. The effort to identify patients with diseases we seek to treat is in early stages, and we cannot
accurately predict the number of patients for whom treatment might be possible. Additionally, the potentially addressable patient population
for each of our pharmaceutical product candidates may be limited or may not be amenable to treatment with our pharmaceutical product
candidates, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results
of operations and our business.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face intense competition and rapid technological
change and the possibility that our competitors may discover, develop or commercialize therapies that are similar, more advanced or more
effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our product candidates.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The biotechnology and pharmaceutical
industries are highly competitive. There are many pharmaceutical companies, biotechnology companies, public and private universities
and research organizations actively engaged in the research and development of products that may be similar to our product candidates.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The first THC-based
pharmaceutical, a pill sold under the commercial name of Marinol (scientific name: dronabinol), was developed by a company called
Unimed Pharmaceuticals, with funding provided by the National Cancer Institute. In 1985, Marinol received FDA approval as a
treatment for chemotherapy-related nausea and vomiting. Today, Marinol is marketed by AbbVie, Inc. Since the introduction of Marinol
into the market, other pharmaceuticals containing THC have also been developed. These include generic oral capsules of dronabinol,
such as those marketed by SVC Pharma LP and Akorn Inc., Meda AB&#8217;s Cesamet (nabilone), a synthetic derivative of THC, and
Sativex (nabiximols), a whole cannabis extract administered as an oral spray. Furthermore, to the best of our knowledge, multiple
companies that are working in the cannabis therapeutic area and are pursuing regulatory approval for their product candidates. For
example, GW Pharmaceuticals PLC, or GW, which markets Sativex, a botanical cannabinoid oral mucosal for the treatment of spasticity
due to multiple sclerosis, received FDA approval in the United States in June 2018 for Epidiolex, a liquid formulation of highly
purified cannabidiol extract, as a treatment for Dravet&#8217;s Syndrome, Lennox Gastaut Syndrome, and various childhood epilepsy
syndromes. In addition, GW is developing, among others, cannabidivarin, or CBDV, based therapy for ASD and therapy for neonatal
hypoxic-ischemic encephalopathy and schizophrenia. Zynerba Pharmaceuticals, Inc., or Zynerba, is developing a transdermal
formulation of cannabidiol for Fragile X and certain refractory epilepsies and ASD. Skye Bioscience, Inc., or Skye, is focused on
developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need.
Corbus Pharmaceuticals Holdings is seeking FDA approval for their synthetic cannabinoid for systemic sclerosis, cystic fibrosis,
dermatomyositis and systemic lupus erythematosus and metabolism and solid tumors. RespireRx Pharmaceutical Inc., or RespireRx,
developing dronabinol for OSA treatment. Synendos Therapeutics AG, or Synendos, is a developer of endocannabinoid modulators for the
treatment of central nervous system, or CNS, disorders. It has developed pharmaceutical products to restore the natural function of
the brain and treat neuropsychiatric disorders. Synendos is developing small molecules as selective endocannabinoid reuptake
inhibitors that increase the levels of endogenous cannabinoids to treat CNS disorders caused by cannabinoid deficiency. Inversago
Pharma (formerly GIcare Pharma) is focused on developing peripheral cannabinoid (CB1) receptor antagonist/inverse agonist for the
treatment of metabolic diseases such as obesity, insulin resistance, and liver fibrosis. Its drug INV-101 (Inverse agonist of
peripheral CB1) under phase-1.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">More established companies
may have a competitive advantage over us due to their greater size, cash flows and institutional experience. Compared to us, many of
our competitors may have significantly greater financial, technical and human resources. As a result of these factors, our competitors
may have an advantage in marketing their approved products and may obtain regulatory approval of their product candidates before we are
able to, which may limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs that
are safer, more effective, more widely used and less expensive than ours, and may also be more successful than us in manufacturing and
marketing their products. These advantages could materially impact our ability to develop and commercialize our product candidates successfully.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates may
also compete with medical and recreational marijuana, in markets where the recreational and/or medical use of marijuana is legal. There
is support in the United States for further legalization of marijuana. In markets where recreational and/or medical marijuana is not legal,
our product candidates may compete with marijuana purchased in the illegal drug market. We cannot assess the extent to which patients
may utilize marijuana obtained illegally for the treatment of the indications for which we are developing our product candidates.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we successfully develop
our product candidates, and obtain marketing approval for them, other treatments or therapeutics may be preferred and we may not be successful
in commercializing our product candidates or in bringing them to market.&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many of our competitors have
substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing
and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in
even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than
we are able to and may be more effective in selling and marketing their products as well. Smaller or early-stage companies may also prove
to be significant competitors, particularly through collaborative arrangements with large, established companies. Competition may increase
further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in
these industries. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective
or less costly than any product candidate that we may develop, or achieve earlier patent protection, regulatory approval, product commercialization
and market penetration than we do. Additionally, technologies developed by our competitors may render our potential product candidates
uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We currently have no marketing and sales
organization. If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and
sell our product candidates, we may be unable to generate any revenue.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although our employees may
have sold other similar products in the past while employed at other companies, we as a company have no experience selling and marketing
our product candidates and we currently have no marketing or sales organization. To successfully commercialize any products that may result
from our development programs, we will need to develop these capabilities, either on our own or with others. If our product candidates
receive regulatory approval, we intend to establish a sales and marketing organization with technical expertise and supporting distribution
capabilities to commercialize our product candidates in major markets, which will be expensive, difficult and time consuming. Any failure
or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization
of our products.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, given our lack of
prior experience in marketing and selling pharmaceutical products, our initial estimate of the size of the required sales force may be
materially more or less than the size of the sales force actually required to effectively commercialize our product candidates. As such,
we may be required to hire substantially more sales representatives to adequately support the commercialization of our product candidates
or we may incur excess costs as a result of hiring more sales representatives than necessary. With respect to certain geographical markets,
we may enter into collaborations with other entities to utilize their local marketing and distribution capabilities, but we may be unable
to enter into such agreements on favorable terms, if at all. If our future collaborators do not commit sufficient resources to commercialize
our future products, if any, and we are unable to develop the necessary marketing capabilities on our own, we will be unable to generate
sufficient product revenue to sustain our business. We may be competing with companies that currently have extensive and well-funded marketing
and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable
to compete successfully against these more established companies.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The commercial success of any current or
future product candidate will depend upon the degree of market acceptance by physicians, patients, third-party payors and others in the
medical community.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even with the requisite approvals
from the FDA and comparable foreign regulatory authorities, the commercial success of our product candidates will depend in part on the
medical community, patients and third-party payors accepting our product candidates as medically useful, cost-effective and safe. Any
product that we bring to the market may not gain market acceptance by physicians, patients, third-party payors and others in the medical
community. The degree of market acceptance of any of our product candidates, if approved for commercial sale, will depend on a number
of factors, including:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
safety and efficacy of the product as demonstrated in clinical studies and potential advantages over competing treatments;</span></td>
</tr></table><div>
</div><p style="margin-top: 0; margin-bottom: 0"></p><div>


</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
prevalence and severity of any side effects, including any limitations or warnings contained in a product&#8217;s approved labeling;&#160;</span></p></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
clinical indications for which approval is granted;&#160;</span></p></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">relative
convenience and ease of administration;&#160;</span></p></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
cost of treatment, particularly in relation to competing treatments;&#160;</span></p></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;&#160;</span></p></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
strength of marketing and distribution support and timing of market introduction of competitive products;</span></p></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">publicity
concerning our products or competing products and treatments; and</span></p></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sufficient third-party insurance coverage and reimbursement.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if a potential product
displays a favorable efficacy and safety profile in preclinical and clinical studies, market acceptance of the product will not be fully
known until after it is launched. Our efforts to educate the medical community and third-party payors on the benefits of the product candidates
may require significant resources and may never be successful. If our product candidates are approved but fail to achieve an adequate
level of acceptance by physicians, patients, third-party payors and others in the medical community, we will not be able to generate sufficient
revenue to become or remain profitable.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The insurance coverage and reimbursement
status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new or current products
could limit our ability to market those products and decrease our ability to generate revenue.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pricing, coverage and
reimbursement of our product candidates, if approved, must be adequate to support our commercial infrastructure. Our per-patient prices
must be sufficient to recover our development and manufacturing costs and potentially achieve profitability. Accordingly, the availability
and adequacy of coverage and reimbursement by governmental and private payors are essential for most patients to be able to afford expensive
treatments such as ours, assuming approval. Sales of our product candidates will depend substantially, both domestically and abroad, on
the extent to which the costs of our product candidates will be paid for by health maintenance, managed care, pharmacy benefit and similar
healthcare management organizations, or reimbursed by government authorities, private health insurers and other third-party payors. If
coverage and reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize
our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish
or maintain pricing sufficient to realize a return on our investment.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is significant uncertainty
related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions about coverage
and reimbursement for new drugs are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the U.S.
Department of Health and Human Services, or DHHS, as CMS decides whether and to what extent a new drug will be covered and reimbursed
under Medicare. Private payors tend to follow the coverage reimbursement policies established by CMS to a substantial degree. It is difficult
to predict what CMS will decide with respect to reimbursement for products such as ours.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Outside the United States,
international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the
increasing emphasis on cost-containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the
pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms
as part of national health systems. In general, the prices of medicines under such systems are substantially lower than in the United
States. Other countries allow companies to fix their own prices for medicinal products, but monitor and control company profits. Additional
foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates.
Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and
may be insufficient to generate commercially reasonable revenue and profits.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, increasing efforts
by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations
to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover or provide adequate
payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates
due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes.
The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has
become very intense. As a result, increasingly high barriers are being erected to the entry of new products.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Healthcare legislative reform measures may
have a material adverse effect on our business and results of operations.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, there
have been and continue to be a number of legislative initiatives to contain healthcare costs. The following are among the provisions established
by the Affordable Care Act, or ACA, of greatest importance to the pharmaceutical and biotechnology industry:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs;</span></td></tr>
  </table><div>


</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the Average Manufacturer Price, or AMP, for most branded and generic drugs, respectively, and capped the total rebate amount for innovator drugs at 100% of the AMP;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations, or MCOs;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (now 70%) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion of the entities eligible for discounts under federal 340B;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishment of a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending. This center is currently focused on the following priorities:</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">testing new payment and service delivery models;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating results and advancing best practices; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">engaging a broad range of stakeholders to develop additional models for testing.</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">implementation of the federal physician payment transparency requirements, or the Sunshine Act. The Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act, or the SUPPORT Act, signed into law on October 24, 2018, expanded Sunshine Act reporting to include data for physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and certified nurse midwifes. The amendment applies to reports submitted to CMS on or after January 1, 2022.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ACA may be modified, amended
or repealed at any time and may or may not be replaced with a different law or health care payment system. The ACA is expected to continue
to have a significant impact on the health care industry. With regard to pharmaceutical product candidates, among other things, the ACA
may expand and increase industry rebates for drugs covered under Medicaid programs and make changes to the coverage requirements under
the Medicare D program. Since the enactment of the ACA, numerous regulations have been issued providing further guidance on its requirements.
The ACA continues to be implemented through regulation and government activity but is subject to possible amendment, additional implementing
regulations and interpretive guidelines. Several states have decided not to expand their Medicaid programs and are seeking alternative
reimbursement models to provide care to the uninsured. The manner in which these issues are resolved could materially affect the extent
to which and the amount at which pharmaceuticals are reimbursed by government programs such as Medicare, Medicaid and Tricare.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2016, CMS issued a final
rule regarding the Medicaid Drug Rebate Program that, among other things, revised the manner in which the AMP is calculated by manufacturers
participating in the program and implemented certain amendments to the Medicaid rebate statute created under the ACA. In addition, on
December 21, 2020, CMS issued a final rule that made changes to the Medicaid Drug Rebate Program regulations in several areas, including
some changes to the treatment of value-based purchasing arrangements and price reporting for patient benefit programs sponsored by pharmaceutical
manufacturers.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Two bills affecting the implementation
of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or the TCJA, included a provision that repealed,
effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain
qualifying health coverage for all or part of a year, that is commonly referred to as the &#8220;individual mandate.&#8217;&#8217; Additionally,
on January 22, 2018, then President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation
of certain ACA-mandated fees. Further, the Bipartisan Budget Act of 2018, among other things, amended the ACA, effective January 1, 2019,
to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; In July 2018, CMS published
a final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under
the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine
this risk adjustment. On April 27, 2020, the U.S. Supreme Court reversed a Federal Circuit decision that previously upheld Congress&#8217;
denial of $12 billion in &#8220;risk corridor&#8221; funding. Congress may consider additional legislation to repeal, or repeal and replace,
other elements of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued that the ACA
is unconstitutional in its entirety because the individual mandate was repealed by Congress. Thus, the ACA will remain in effect in its
current form. Prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a
special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed
certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among
others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary
barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to
judicial or Congressional challenges in the future. It is unclear how such challenges and the healthcare reform measures of the Biden
administration will impact the ACA and our business. We continue to evaluate the ACA and its possible repeal and replacement, as the extent
to which any such changes may impact our business or financial condition remains uncertain.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, other legislative
changes have been proposed and adopted in the United States since the ACA was enacted. In 2011, the Budget Control Act of 2011 among other
things, created measures for spending reductions by Congress. This includes aggregate reductions of Medicare payments to providers of
2% per fiscal year. These reductions, known as Medicare sequestration adjustments, went into effect in 2013. However, under the Coronavirus
Aid, Relief, Economic Securities Act of 2020, and related legislation, Medicare sequestration adjustments from May 1, 2020 through March
31, 2021 have been suspended, though sequestration has been extended through 2030. Additionally, there has been heightened governmental
scrutiny recently over the manner in which manufacturers set prices for their marketed products. For example, there have been several
recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency
to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement
methodologies for drug products. At the federal level, including the former Administration&#8217;s budget for fiscal year 2020, there
were further drug price control measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part D,
to continue to allow some states to negotiate drug prices under Medicaid through supplemental rebate negotiations and other mechanisms,
and legislation was introduced to eliminate cost sharing for generic drugs for Part D low-income patients.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, in November 2020,
the U.S. DHHS, finalized a regulation aimed at lowering prescription drug prices and out-of-pocket spending for prescription drugs by
excluding rebates on prescription drugs paid by manufacturers to or purchased by Medicare Part D plan sponsors or pharmacy benefit managers,
or PBMs, acting under contract with Medicare Part D plan sponsors from the existing discount safe harbor under the federal Anti-Kickback
Statute, or the AKS. The regulation reflects the first change to the AKS Statute discount safe harbor since the Medicare Part D program
was established. In addition to the rebate exclusions, two new safe harbors were added. One of these new safe harbors protects point-of-sale
reductions in price from a manufacturer to a plan sponsor under Medicare Part D or a MCO, for a prescription drug payable, in whole or
in part, by a plan sponsor under Medicare Part D or a MCO, provided certain conditions are met. The other protects certain fixed-fee services
arrangements between manufacturers and PBMs.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Congress and the executive
branch have each indicated that it will continue to seek new legislative or administrative measures to control drug costs. At the state
level, legislatures have been increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological
product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing
cost disclosure and transparency measures, drug price increases, and, in some cases, designed to encourage importation from other countries
and bulk purchasing.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the European Union, similar
political, economic and regulatory developments may affect our ability to profitably commercialize any of our product candidates, if approved.
In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state
level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare
in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is
almost exclusively a matter for national, rather than European Union, law and policy. National governments and health service providers
have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context.
In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement
of medicines by relevant health service providers. Coupled with ever-increasing European Union and national regulatory burdens on those
wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate
post-approval activities and affect our ability to commercialize any products for which we obtain marketing approval. Political, economic
and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has
been obtained. Reference pricing used by various EU member states, and parallel trade, i.e., arbitrage between low-priced and high-priced
member states, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations
for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries.
In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted
price ceilings on specific products and therapies.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that these and other
healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and
in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or
other government-funded programs may result in a similar reduction in payments from private payors. The implementation of cost containment
measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs,
once marketing approval is obtained. We cannot predict what healthcare reform initiatives may be adopted in the future. However, it is
possible that there will be further legislation or regulation that could harm the business, financial condition and results of operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The COVID-19 pandemic has resulted in delays
to our product development and may adversely affect any potential future revenues, results of operations and financial condition.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">COVID-19 and the various precautionary
measures taken by many governmental authorities around the world to limit its spread had a severe effect on global markets and the global
economy. The extent to which the coronavirus impacts our business and operations will depend on future developments, which are highly
uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and the nature and extent
of governmental actions taken to contain or treat its impact and the availability, costs, effectiveness and public acceptance of any FDA-approved
vaccines, among others. COVID-19 and official actions taken in response to it caused a major slowdown in overall economic activity in
the U.S. and elsewhere, curtailed consumer spending and made it more challenging to adequately staff and manage our business and operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The COVID-19 pandemic impacted
our various vendors, including CROs, and caused delays in the development of our product candidates. We also experienced delays in the
preparation toward various clinical trials, including being unable to receive prioritization to conduct clinical trials, availability
of physicians and other staff members involved in our clinical trials. At this time, we do not anticipate that the COVID-19 pandemic and
official responses would cause a material adverse effect on our results of operations and financial condition but there can be no assurance
that this will be the case.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Intellectual Property </b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to obtain and maintain
effective patent rights for our product candidates, we may not be able to compete effectively in our markets. If we are unable to protect
the confidentiality of our trade secrets or know-how, such proprietary information may be used by others to compete against us.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Historically, we have relied
on trade secret protection and confidentiality agreements to protect the intellectual property related to our technologies and product
candidates. Since 2015, we have also sought patent protection for certain of our product candidates. Our success depends in large part
on our ability to obtain and maintain patent and other intellectual property protection in the United States and in other countries with
respect to our proprietary technology and new product candidates.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We seek to protect our proprietary
position by filing patent applications in the United States and in other countries, with respect to our novel technologies and product
candidates, which are important to our business. Patent prosecution is expensive and time consuming, and we may not be able to file and
prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will
fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not including patents and
applications which we are in the process of being assigned, we have a portfolio of seven granted patents with the U.S. Patent and Trademark
Office, or USPTO, nine patent families and two trademarks, of which four families include Patent Cooperation Treaty, or PCT, applications,
that have entered the national phase in various national entities. We cannot offer any assurances about which, if any, patent applications
will issue, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable or will be threatened
by third parties. Any successful opposition to our patents after issuance could deprive us of rights necessary for the successful commercialization
of any new product candidates that we may develop and would allow other third parties to compete with us.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have exclusively licensed:
(i) one U.S. patent from Dekel Pharmaceuticals Ltd., or Dekel, and (ii) one U.S. patent family from Yissum Research Development Company
of the Hebrew University of Jerusalem Ltd., or Yissum. We cannot assure you that we will ever enter into definitive license agreements
with any third-party licensor. See &#8220;Business - Intellectual Property - In-Licensed Patents and Patent Applications.&#8221; To the
extent the licensed or future licensed patents are found to be invalid or unenforceable, we may be limited in our ability to compete and
market our product candidates. Moreover, the terms of our licenses affect our ability to control the value of any of our product candidates.
If we or any of the parties that control the enforcement of licensed patents elect not to enforce any or all of the licensed patents it
could significantly undercut the value of any of our product candidates, which would materially adversely affect our future revenue, financial
condition and results of operations. Moreover, fluctuating currency rates may create inconsistencies in the royalty payments we are obligated
to make under our licenses.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Also, there is no guarantee
that the patent registration applications that were submitted by us with regard to our technologies will result in patent registration.
In the event of failure to complete patent registration, our developments will not be proprietary, which might allow other entities to
manufacture our product candidates and compete with them.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, there is no assurance
that all potentially relevant prior art relating to our patent applications has been found. Such prior art, to the extent it exists, may
invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, and even
if such patents cover our product candidates, third parties may challenge their validity, enforceability, or scope, which may result in
such patents being narrowed, found unenforceable or invalidated. Furthermore, even if they are unchallenged, our patent applications and
any future patents may not adequately protect our intellectual property, provide exclusivity for our new product candidates, or prevent
others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third parties, which
may have an adverse impact on our business.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Engagement in any type of
intellectual property collaboration agreement requires diligent management of intellectual property rights. Joint intellectual property
engagements may&#160;create additional administrative and financial burdens and may place us at heightened risk of disputes or litigation
regarding ownership, maintenance or enforcement of such joint intellectual property. For example, our collaboration with Clearmind Medicine
Inc., or Clearmind, has resulted in filings of provisional patent applications related to certain combinations of our respective proprietary
compounds. As a joint-owner of intellectual property, we are generally or would be unable to use or exploit the intellectual property
without the consent of the other joint owner. If we cannot obtain sole commercial use rights for such jointly-owned intellectual property
as a result of our collaboration, our future product development and commercialization plans may be adversely affected. Moreover, if we
cannot obtain and maintain effective patent rights for our product candidates, we may not be able to compete effectively, and our business
and results of operations may be harmed.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to identify infringements
of our patents and accordingly the enforcement of our intellectual property rights may be difficult.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The drug substance in some
of our product candidates is repurposed, which means that it is available in other pharmaceutical products for the purpose of treating
indications that are different from the indications for our product candidates. It is possible that if we receive regulatory approval
to market and sell our drug candidates, some patients that receive a prescription could be sold the same drug substance but not our product
candidate. It would be difficult, if not impossible, for us to identify such instances that may constitute an infringement of our patents.
In addition, because the drug substance of some of our product candidates is repurposed, such substance may not be eligible for patent
protection or data exclusivity. Even if we identify infringing parties, there is no guarantee that a court will agree with our arguments
and find that a third party is infringing our patents or that the court will issue an order for an adequate remedy for that infringement.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to maintain effective proprietary
rights for our product candidates, we may not be able to compete effectively in our markets.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the protection
afforded by any patents currently owned and that may be granted, historically, we have relied on trade secret protection and confidentiality
agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes that are not easily known,
knowable or easily ascertainable, and for which patent infringement is difficult to monitor and enforce and any other elements of our
product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered
by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part,
by entering into confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We also seek to preserve
the integrity and confidentiality of our data, trade secrets and intellectual property by maintaining physical security of our premises
and physical and electronic security of our information technology systems. Agreements or security measures may be breached, and we may
not have adequate remedies for any breach. In addition, our trade secrets and intellectual property may otherwise become known or be independently
discovered by competitors.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot provide any assurances
that our trade secrets and other confidential proprietary information will not be disclosed in violation of our confidentiality agreements
or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information
and techniques. Also, misappropriation or unauthorized and unavoidable disclosure of our trade secrets and intellectual property could
impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our
trade secrets and intellectual property are deemed inadequate, we may have insufficient recourse against third parties for misappropriating
any trade secret.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Intellectual property rights of third parties
could adversely affect our ability to commercialize our product candidates, and we might be required to litigate or obtain licenses from
third parties in order to develop or market our product candidates. Such litigation or licenses could be costly or not available on commercially
reasonable terms.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is inherently difficult
to conclusively assess our freedom to operate without infringing on third party rights. Our competitive position may be adversely affected
if existing patents or patents resulting from patent applications issued to third parties or other third party intellectual property rights
are held to cover our product candidates or elements thereof, or our manufacturing or uses relevant to our development plans. In such
cases, we may not be in a position to develop or commercialize product candidates or our product candidates unless we successfully pursue
litigation to nullify or invalidate the third party intellectual property right concerned, or enter into a license agreement with the
intellectual property right holder, if available on commercially reasonable terms. There may also be pending patent applications that
if they result in issued patents, could be alleged to be infringed by our new product candidates. If such an infringement claim should
be brought and be successful, we may be required to pay substantial damages, be forced to abandon our new product candidates or seek a
license from any patent holders. No assurances can be given that a license will be available on commercially reasonable terms, if at all.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is also possible that we
have failed to identify relevant third-party patents or applications. For example, certain U.S. patent applications that will not be filed
outside the United States remain confidential until patents issue. Patent applications in the United States and elsewhere are published
approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred
to as the priority date. Therefore, patent applications covering our new product candidates or platform technology could have been filed
by others without our knowledge. Additionally, pending patent applications which have been published can, subject to certain limitations,
be later amended in a manner that could cover our platform technologies, our new product candidates or the use of our new product candidates.
Third party intellectual property right holders may also actively bring infringement claims against us. We cannot guarantee that we will
be able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims on
terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation and may be prevented
from or experience substantial delays in pursuing the development of and/or marketing our new product candidates. If we fail in any such
dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing our new product
candidates that are held to be infringing. We might, if possible, also be forced to redesign our new product candidates so that we no
longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require
us to divert substantial financial and management resources that we would otherwise be able to devote to our business.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Third-party claims of intellectual property
infringement may prevent or delay our development and commercialization efforts.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success depends
in part on our avoiding infringement of the patents and proprietary rights of third parties. Numerous U.S. and foreign issued patents
and pending patent applications, which are owned by third parties, exist in the fields in which we are developing new product candidates.
As our industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement
of the patent rights of third parties.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Third parties may assert that
we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims
to materials, designs or methods of manufacture related to the use or manufacture of our product candidates. There may be currently pending
patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain
patents in the future and claim that use of our technologies infringes upon these patents.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any third-party patents
were held by a court of competent jurisdiction to cover aspects of our formulations, processes for designs, or methods of use, the holders
of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtain a
license or until such patent expires or is finally determined to be invalid or unenforceable. In either case, such a license may not be
available on commercially reasonable terms or at all.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Parties making claims against
us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one
or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and
would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us
in the U.S. or any other relevant jurisdiction, we may have to pay substantial damages, including treble damages and attorneys&#8217;
fees for willful infringement, pay royalties, redesign our infringing product candidates or obtain one or more licenses from third parties,
which may be impossible or require substantial time and monetary expenditure.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patent policy and rule changes could increase
the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any issued patents.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Changes in either the patent
laws or interpretation of the patent laws in the United States and other countries may diminish the value of any patents that may issue
from our patent applications, or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to
the same extent as the laws of the United States. Publications of discoveries in the scientific literature often lag behind the actual
discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing,
or in some cases not at all. We therefore cannot be certain that we were the first to file the invention claimed in our owned and licensed
patent or pending applications, or that we or our licensor were the first to file for patent protection of such inventions. Assuming all
other requirements for patentability are met, in the United States prior to 2013, the first to make the claimed invention without undue
delay in filing, is entitled to the patent, while outside the United States, the first to file a patent application is entitled to the
patent. After 2013, the United States moved to a first to file system. Changes in patent litigation could increase the uncertainties and
costs surrounding the prosecution of our patent applications and the enforcement or defense of any issued patents, all of which could
have a material adverse effect on our business and financial condition.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be involved in lawsuits to protect
or enforce our intellectual property, which could be expensive, time consuming, and unsuccessful.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competitors may infringe our
intellectual property. If we were to initiate legal proceedings against a third party to enforce a patent covering one of our new product
candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent
litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity
challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement.
Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant
information from the USPTO, or made a misleading statement, during prosecution. The validity of U.S. patents may also be challenged in
post-grant proceedings before the USPTO. The outcome following legal assertions of invalidity and unenforceability is unpredictable.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Derivation proceedings initiated
by third parties or brought by us may be necessary to determine the priority of inventions and/or their scope with respect to our patent
or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to
attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license
on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in
substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have
a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs,
license necessary technology from third parties, or enter into development partnerships that would help us bring our new product candidates
to market.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, because of the
substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential
information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results
of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative,
it could have a material adverse effect on the price of our Ordinary Shares.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to claims challenging
the inventorship of our intellectual property.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be subject to claims
that former employees, collaborators or other third parties have an interest in, or right to compensation, with respect to our current
patent and patent applications, future patents or other intellectual property as an inventor or co-inventor. For example, we may have
inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates.
Litigation may be necessary to defend against these and other claims challenging inventorship or claiming the right to compensation. If
we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such
as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our
business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management and other employees.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to protect our intellectual
property rights throughout the world.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Filing, prosecuting, and defending
patents on product candidates, as well as monitoring their infringement in all countries throughout the world would be prohibitively expensive,
and our intellectual property rights in some countries can be less extensive than those in the United States. In addition, the laws of
some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competitors may use our technologies
in jurisdictions where we have not obtained patent protection to develop their own products and may also export otherwise infringing products
to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete
with our product candidates. Future patents or other intellectual property rights may not be effective or sufficient to prevent them from
competing.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many companies have encountered
significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries,
particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection,
which could make it difficult for us to stop the marketing of competing products in violation of our proprietary rights generally. Proceedings
to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts
and attention from other aspects of our business, could put our future patents at risk of being invalidated or interpreted narrowly and
our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any
lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts
to monitor and enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage
from the intellectual property that we develop or license.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have received a termination notice for
a license agreement for certain intellectual property rights from an entity controlled by our former chairman and chief executive officer,
Dr. Ascher Shmulewitz. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2015, we entered into
a license agreement, which, following an amendment thereto in August 2015, became effective, with Dekel, an Israeli private company controlled
by Dr. Ascher Shmulewitz, our former chairman and chief executive officer, under which we were granted an irrevocable, worldwide, exclusive,
royalty-bearing license to certain of Dekel&#8217;s technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have any agreement
with Dr. Shmulewitz to notify us with business opportunities he may wish to pursue, subject only to his duties under Israeli law, and
we do not have proprietary rights to Dr. Shmulewitz&#8217; inventions that are not included under the consulting and services agreement
we previously had entered into with him (pertaining solely to the field of immunomodulators including cannabinoids to treat chronic pain
and inflammation).&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 17, 2017, we
entered into an amendment to the license agreement, which, if certain conditions precedent were met by June 30, 2018, would provide for
an amendment to the compensation terms of such license agreement. We did not meet the conditions precedent required under such amendment
to the license agreement with Dekel by June 30, 2018, and as a result thereof, the amendment never went into effect. On July 14, 2019,
we entered into an amendment to the license agreement, which encompasses our and Dekel&#8217;s original intention to exclude certain consumer
packaged goods (including, inter alia, food, beverage, cosmetics, pet products and hemp based products, which are sources of nutrients
or other substances which may have a nutritional effect) from the scope of the licensed products and the field of our activity, as described
in the license agreement, which intention was not reflected in the license agreement, and therefore, desired and agreed to amend the license
agreement to reflect the foregoing clarification, as well as certain additional less material matters as discussed in the amendment. The
amendment also prescribes a specific development plan under the license agreement requiring us to invest in the licensed technology (as
defined under the license agreement) formulation development and maintain a total annual investment cap of $350,000 and for a non-compete
and non-solicitation obligation by Dekel and Dr. Shmulewitz, towards our field of activity.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
August 2020, Dr. Shmulewitz was replaced by Mr. Amitay Weiss, who was later replaced by Mr. Oz Adler in January 2022, each of whom was
appointed as our Chief Executive Officer. In February 2021, we received a request from Dr. Shmulewitz to provide him with information
relating to our compliance with the Dekel license agreement. On February 5, 2024, we received a written notice from Dekel for the termination
of the license agreement, effective immediately, based on its allegation that we failed to provide Dekel with certain reports regarding
the licensed products under the license agreement. We reject all of Dekel&#8217;s allegations as set forth in the termination notice and
intend to defend ourselves vigorously, should it be necessary. We are assessing the effects, if any, on our business as a result of the
termination notice received from Dekel. If we are no longer able to license certain of Dekel&#8217;s technology under the Dekel license
agreement or if any potential dispute results in a determination adverse to us, our business may be impeded or materially harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Pharmaceutical Business
Operations</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>From time to time, we may sign letters of
intent and/or enter into term sheets or other similar arrangements that are subject to negotiation of definitive agreements. There can
be no assurance that we will enter into any such definitive agreements. Similarly, we may strategically invest in transactions from time
to time, and there can be no assurance that the value of our investment will increase or that it will not fluctuate.</i></b>&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
sign letters of intent and/or enter into term sheets or other similar arrangements that are subject to negotiation of definitive agreements.
We may never enter into definitive agreements after signing a letter of intent and/or entering into a term sheet or other similar arrangement
for a multitude of reasons, including, but not limited to, regulatory, operational, financial and other considerations. There may also
be forces outside of our control that have an effect on our ability or decision as to whether we enter into such definitive agreements.
As a result, there can be no assurance that upon signing a letter of intent and/or entering into a term sheet or similar arrangement,
that we will enter into definitive documents. This could have a material adverse effect on our reputation and could cause us to incur
expenses if any legal claims arise as a result thereof. For example, in November 2019, we entered into a memorandum of understanding with
Heavenly Rx, Ltd., or Heavenly Rx, pursuant to which we and Heavenly Rx agreed to pursue a business combination. In accordance with the
memorandum of understanding between the parties, any transaction between the parties remained subject to entry into definitive agreements,
and to shareholder and regulatory approvals. We never entered into definitive agreements and do not expect to do so.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Similarly, we may strategically
invest into various pharmaceutical companies. However, we can offer no assurance that the value of our investment will increase or that
it will not fluctuate because the value of our investments may be adversely affected by a number of factors, such as negative changes
in a company&#8217;s results of operations, cash flows, financial position and accounting impairment. For example, on March 31, 2022,
we entered into an agreement with and invested in MitoCareX Bio Ltd., or MitoCareX, a company focused on the discovery and development
of potential drugs for cancers and other life-threatening conditions. In addition, on November 17, 2022, we invested in Clearmind, a psychedelic
pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread
and underserved health problems. The potential benefits of the agreement with MitoCareX, the investment in Clearmind or other potential
investments may not be realized to the full extent, in a timely fashion, or at all, which may have a material adverse effect on our results
of operations, cash flows and financial position. The potential benefits of agreements with potential ventures may not materialize or
may not be realized to the full extent, in a timely fashion, or at all, which may have a material adverse effect on our results of operations,
cash flows and financial position.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will need to expand our organization
and we may experience difficulties in recruiting needed additional employees and consultants, which could disrupt our operations.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As our development and commercialization
plans and strategies develop and because we are so leanly staffed, we will need additional managerial, operational, sales, marketing,
financial, legal and other resources. The competition for qualified personnel in the pharmaceutical field is intense. Due to this intense
competition, we may be unable to attract and retain qualified personnel necessary for the development of our business or to recruit suitable
replacement personnel.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management may need to
divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing
these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our
infrastructure, operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees.
Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the
development of additional pharmaceutical product candidates. If our management is unable to effectively manage our growth, our expenses
may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our
business strategy. Our future financial performance and our ability to commercialize pharmaceutical product candidates and compete effectively
will depend, in part, on our ability to effectively manage any future growth.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be successful in our efforts
to identify, license or discover additional pharmaceutical product candidates.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although a substantial amount
of our effort will focus on the continued clinical testing, potential approval and commercialization of our existing pharmaceutical product
candidates, the success of our business also depends in part upon our ability to identify, license or discover additional pharmaceutical
product candidates. Our research programs or licensing efforts may fail to yield additional pharmaceutical product candidates for clinical
development for a number of reasons, including but not limited to the following:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our research or business development methodology or search criteria and process may be unsuccessful in identifying potential pharmaceutical product candidates;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able or willing to assemble sufficient resources to acquire or discover additional pharmaceutical product candidates;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our pharmaceutical product candidates may not succeed in preclinical or clinical testing;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our potential pharmaceutical product candidates may be shown to have harmful side effects or may have other characteristics that may make the pharmaceutical products unmarketable or unlikely to receive marketing approval;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competitors may develop alternatives that render our pharmaceutical product candidates obsolete or less attractive;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pharmaceutical product candidates we develop may be covered by third parties&#8217; patents or other exclusive rights;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the market for a pharmaceutical product candidate may change during our program so that such a pharmaceutical product may become unreasonable to continue to develop;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a pharmaceutical product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a pharmaceutical product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of these events occur,
we may be forced to abandon our development efforts for a program or programs, or we may not be able to identify, license or discover
additional pharmaceutical product candidates, which would have a material adverse effect on our business and could potentially cause us
to cease operations. Research programs to identify new pharmaceutical product candidates require substantial technical, financial and
human resources. We may focus our efforts and resources on potential programs or pharmaceutical product candidates that ultimately prove
to be unsuccessful.<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject, directly or indirectly,
to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy and security laws. If we are unable
to comply, or have not fully complied, with such laws, we could face substantial penalties.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we obtain FDA approval
for any of our pharmaceutical product candidates and begin commercializing those pharmaceutical products in the United States, our operations
may be directly or indirectly through our customers, subject to various federal and state fraud and abuse laws, including, without limitation,
the federal AKS, the federal False Claims Act and physician sunshine laws and regulations. These laws may impact, among other things,
our proposed sales, marketing and education programs. In addition, we may be subject to patient privacy regulation by both the federal
government and the states in which we conduct our business. The laws that may affect our ability to operate include:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal AKS, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other third-party payors that are false or fraudulent;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"/>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA, as amended by the Health Information Technology and Clinical Health Act, or HITECH and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal physician sunshine requirements under the ACA requires manufacturers of drugs, devices and medical supplies to report annually to the U.S. DHHS information related to payments and other transfers of value to physicians, other healthcare providers and teaching hospitals and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers, state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because of the breadth of
these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities
could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has strengthened these
laws. For example, the ACA, among other things, amends the intent requirement of the federal anti-kickback and criminal healthcare fraud
statutes. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. Moreover, the
ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal AKS constitutes
a false or fraudulent claim for purposes of the False Claims Act.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our operations are found
to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties,
including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare
and Medicaid, imprisonment and the curtailment or restructuring of our operations, any of which could adversely affect our ability to
operate our business and our results of operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Widespread public health pandemics could
have a material and adverse effect on our business, financial condition and results of operations.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any public health pandemic
or other disease outbreak in countries where we or our CROs operate could have a material and adverse effect on our business, financial
condition and results of operations. For example, we reduced our operating expenses at the onset of the COVID-19 pandemic and our Chief
Technologies Officer was on temporary unpaid leave between May 2020 and September 2020.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operating results and
financial condition may also be materially adversely affected by laws, regulations, orders or other governmental or regulatory actions
addressing widespread public health concerns that place restrictions on, or require us to make changes to, our operations. For example,
a significant reduction in our workforce and our compliance with instructions imposed by relevant authorities may harm our ability to
continue operating our business and materially and adversely affect our operations and financial condition. In addition, the impact of
a widespread public health crisis may cause delays to our future research and development operations, including but not limited to our
pharmaceutical products development, manufacturing, pre-clinical and clinical trials, and may make it difficult for us to recruit patients
to all of our clinical trials, and keep all of our research and development projects on time.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to our suppliers,
disruptions resulting from the COVID-19 pandemic resulted and in the event of a future widespread public health crisis may result in cancellations
or delays and increased transport times for delivery of materials to our facilities. If such difficulties arise, we may need to seek alternate
suppliers, which may be more expensive, may not be available or may result in delays in shipments to us.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Disruptions to our business
as a result of a widespread public health crisis, as well as any global recession resulting from the impact of such a crisis, could materially
adversely affect our business, financial condition and results of operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The use of any of our pharmaceutical product
candidates and marketed products could result in product liability or similar claims that could be expensive, damage our reputation and
harm our business.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business exposes us to
an inherent risk of potential pharmaceutical product liability or similar claims. The pharmaceutical and nutraceuticals industries have
historically been litigious, and we face financial exposure to pharmaceutical product liability or similar claims if the use of any of
our pharmaceutical products were to cause or contribute to injury or death. There is also the possibility that defects in the design or
manufacture of any of our pharmaceutical products might necessitate a pharmaceutical product recall. Although we plan to maintain pharmaceutical
product liability insurance, the coverage limits of these policies may not be adequate to cover future claims. In the future, we may be
unable to maintain pharmaceutical product liability insurance on acceptable terms or at reasonable costs and such insurance may not provide
us with adequate coverage against potential liabilities. A pharmaceutical product liability claim, regardless of merit or ultimate outcome,
or any pharmaceutical product recall could result in substantial costs to us, damage to our reputation, customer dissatisfaction and frustration
and a substantial diversion of management attention. A successful claim brought against us in excess of, or outside of, our insurance
coverage could have a material adverse effect on our business, financial condition and results of operations.<b>&#160;</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to comply with environmental,
health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse
effect on the success of our business.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
activities and our third-party manufacturers&#8217; and suppliers&#8217; activities involve the controlled storage, use and disposal of
hazardous materials, including the components of our pharmaceutical product candidates and other hazardous compounds. We and our manufacturers
and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials.
In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&#8217; facilities
pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization
efforts, research and development efforts, business operations and environmental damage resulting in costly clean-up and liabilities under
applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste pharmaceutical
products. Although we believe that the safety procedures utilized by our third-party manufacturers for handling and disposing of these
materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate
the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages
and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials
and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended
to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently
carry biological or hazardous waste insurance coverage.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to our Intended Corporate Restructuring
Plan&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The intended Restructuring Plan, which may
involve transferring our pharmaceutical activities to a new wholly-owned subsidiary, may not be completed in accordance with the expected
plans or anticipated timeline, or at all, and may not achieve the expected results.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 25, 2023, we announced
that our board of directors resolved to pursue a Restructuring Plan which may involve transferring our pharmaceutical activities to NewCo.
As part of or independent to the Restructuring Plan, we intend to examine the possibility of listing NewCo on a leading stock exchange,
while maintaining our controlling interest in NewCo such that we will continue to control our current business activities. We also intend
to explore other potential new opportunities, activities and investments in a variety of sectors.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Restructuring
Plan, on November 22, 2023, we announced the signing of a non-binding letter of intent, or LOI, to acquire a leading vehicle importer
company in Israel, or the Target Company, with certain new negotiated terms as announced on December 7, 2023. According to the new negotiated
terms, we will acquire 100% of the Target Company and establish a new wholly-owned Israeli subsidiary, which would in turn merge with
and into the Target Company, or the Acquisition. Following the Acquisition, if completed, it is contemplated that our shareholders will
hold approximately 50.01% of the share capital of the post-closing combined company.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Completion of the transactions
contemplated by this LOI, or any other potential restructuring plans or transactions, in addition to the possible listing of NewCo on
an exchange, may be subject to, among other things, market conditions, tax or other business analyses, regulatory approvals, receipt of
any necessary consents, final approvals from our board of directors and shareholders and satisfaction of any closing conditions to effectuate
such corporate restructuring. On January 19, 2024, we announced, that we had entered into a bridge loan agreement as lender, with the
Target Company, pursuant to which the Target Company received a bridge loan from us in the amount of $1.4 million. See also &#8212; <i>With
our extension of a bridge loan to the Target Company, we are subject to creditor risk.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unanticipated developments
or changes, including but not limited to, changes in the general or financial market conditions, possible delays in obtaining various
regulatory and tax approvals, changes in the law, and challenges in executing the Acquisition or any other restructuring plan could delay
or prevent the completion of the Restructuring Plan and listing of NewCo or cause the Restructuring Plan and listing of NewCo to occur
on terms or conditions that are different or less favorable than initially expected. These or other developments could cause us not to
realize some or all of the expected benefits of the Restructuring Plan and listing of NewCo or to realize them on a different timeline
than expected. If the Restructuring Plan and listing of NewCo do not occur, we could pursue other transactions involving our pharmaceutical
activities.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Restructuring Plan and listing of NewCo
may not achieve the anticipated benefits and may expose us to additional risks.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not realize the anticipated
strategic, financial, operational or other benefits of the Restructuring Plan and listing of NewCo. We cannot predict with certainty when
the benefits expected from these transactions will occur or the extent to which they will be achieved. There is no assurance that following
the Restructuring Plan and listing of NewCo that each separate company will be successful. Whether the Restructuring Plan and listing
of NewCo is completed, we may face material challenges in connection with the intended transactions, including but not limited to, the
diversion of management time on matters relating to the Restructuring Plan and listing of NewCo, the impact of having to operate under
the terms of any transition service agreements, the impact on our ability to retain talent and potential impacts on our relationships
with customers, suppliers, employees and other counterparties. In addition, we will incur one-time costs and ongoing costs in connection
with, or as a result of, the Restructuring Plan and listing of NewCo, including costs of operating as independent, publicly-traded companies
that the separate businesses will no longer be able to share. Those costs may exceed our estimates or could negate some of the benefits
we expect to realize. Further, we have not yet analyzed whether the Restructuring Plan and listing of NewCo will be tax-free to our shareholders
for U.S. federal income tax or Israeli tax purposes and there is no assurance that the Restructuring Plan and listing of NewCo will qualify
for this treatment. If the Restructuring Plan and listing of NewCo is ultimately determined to be taxable, any of NewCo, our shareholders
or us could incur income tax liabilities that could be significant. If we do not realize the anticipated benefits of the Restructuring
Plan and listing of NewCo it could adversely affect our business, results of operations, cash flows and financial condition.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Following any Restructuring Plan and listing
of NewCo, the trading price of our Ordinary Shares may fluctuate significantly.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot predict whether
the market value of our Ordinary Shares after any Restructuring Plan and listing of NewCo will be, in the aggregate, less than, equal
to or greater than the market value of our ordinary shares prior to such transactions. The trading price of our Ordinary Shares may be
more volatile around the time of the intended separation.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>With our extension of a bridge loan to the
Target Company, we are subject to creditor risk.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 19, 2024, we announced,
that we had entered into a bridge loan agreement as lender, with the Target Company, pursuant to which the Target Company received a bridge
loan from us in the amount of $1.4 million. The bridge loan is unsecured which means that we have limited recourse against the Target
Company in the case of missed payments, delayed payments, or a failure to repay the loan which might lead to a partial or total default.
Any potential partial or total default could lead to financial distress in our financial condition arising from reduced cash flow and
a significantly weakened balance sheet. Moreover, there can be no assurance about the timing or eventuality the Restructuring Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to the eCommerce Operations of
SciSparc Nutraceuticals&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be unable to successfully pursue,
integrate, or execute upon the eCommerce operations business of SciSparc Nutraceuticals.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2022, we purchased
Wellution&#8482;, a business and brand which sells hemp-based products on the Amazon.com marketplace.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management has limited
prior experience in eCommerce business operations. There can be no assurance that we will be able to successfully implement our new business
ventures or successfully operate within this industry. The successful integration of a new business also depends on our ability to manage
the new business, realize forecasted synergies and full value from the combined business. Our business, results of operations, financial
condition and cash flows could be materially adversely affected if we are unable to successfully integrate Wellution into our existing
operations and any inability to do so may also hinder our ability to grow, divert the attention of management and our key personnel, disrupt
our business and impair our financial results.<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operations of SciSparc Nutraceuticals
rely on the Amazon.com marketplace and fulfillment by Amazon.com and changes to the Amazon.com marketplace, Amazon&#8217;s services and
their terms of use may harm our business.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Wellution&#8217;s products
are sold predominantly on the Amazon.com marketplace and orders are fulfilled entirely by Amazon.com utilizing the fulfilled by Amazon,
or FBA, model. In order to continue to utilize the Amazon.com marketplace and FBA, we must comply with the applicable policies and terms
of use relating to these services. Such policies and terms of use may be altered or amended at Amazon&#8217;s sole discretion, including
changes regarding the cost of securing these services, and changes that increase the burden of compliance with its requirements, may cause
us to significantly alter our business model or incur additional costs in order to comply, which could negatively impact our results of
operations. Non-compliance with applicable terms of use and policies can result in the removal of one or more products from the marketplace
and suspension of fulfillment services either of which could have a material adverse effect on our business and results of our operations.
Although we exert efforts in order to ensure ongoing compliance and no notices of non-compliance have been received to date, we cannot
assure you that events of this kind will not occur in the future.<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operations of SciSparc Nutraceuticals
rely on other information technologies and systems to operate its business and to maintain its competitiveness, and any failure to invest
in and adapt to technological developments and industry trends could harm our business.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We depend on sophisticated
information technologies and systems, technology and systems used for Wellution&#8217;s websites and apps, customer service, logistics
and fulfillment, supplier connectivity, communications and administration. As our operations grow in size, scope and complexity, we will
need to continuously improve and upgrade our systems and infrastructure to offer an increasing number of consumer-enhanced services, features
and functionalities, while maintaining and improving the reliability and integrity of our systems and infrastructure.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future success also depends
on our ability to use A.I. tools and infrastructure, including logistics and fulfillment platform which leverages, to meet rapidly evolving
eCommerce trends and demands. The emergence of alternative platforms may require us to continue to invest in new and costly technology.
We may not be successful, or we may be less successful than our competitors, in adopting technologies that operate effectively across
multiple eCommerce platforms, which would negatively impact our business and financial performance. New developments in other areas, such
as cloud computing providers, could also make it easier for competitors to enter our markets due to lower up-front technology costs. In
addition, we may not be able to maintain our existing systems or replace our current systems or introduce new technologies and systems
as quickly or cost effectively as we would like. Failure to invest in and adapt to technological developments and industry trends may
have a material adverse effect on our business, results of operations, financial condition and prospects.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operations of SciSparc Nutraceuticals
rely on data provided by third parties, the loss of which could limit the functionality of our platforms, cause us to invest in the wrong
product or disrupt our business.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We use third party software
to determine market trends and what markets to enter into. Our ability to successfully use this software depends on our ability to analyze
and utilize data, including search engine results, provided by unaffiliated third parties, primarily, Google and Amazon. Some of this
data is provided to us pursuant to third-party data sharing policies and terms of use, under data sharing agreements by third-party providers
or by customer consent. The majority of this data is sourced for free or for de minimis amounts. These sources of data allow us, along
with A.I. tools, to determine trends, performance and consumer sentiment on products and searches within eCommerce platforms. This functionality
allows us to help determine which products to market, in some cases manufacture through contract manufacturers, import and sell on eCommerce
marketplaces. The connection to multiple eCommerce platforms through application programming interfaces allow us to develop the automation
of the purchase of marketing and automate the change of pricing of product listings on those eCommerce platforms.<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the future, any of these
third parties could change its data sharing policies, including making them more restrictive, charging fees or altering its algorithms
that determine the placement, display and accessibility of search results and social media updates, any of which could result in the loss
of, or significant impairment to, our ability to collect useful data. These third parties could also interpret our, or our service providers&#8217;,
data collection policies or practices as being inconsistent with their policies, which could result in the loss of our ability to collect
this data. Privacy concerns may cause end users to resist providing the personal data necessary to allow us to determine market trends
as well as our ability to effectively retain existing customers. Privacy advocacy groups and the technology and other industries are considering
various new, additional or different self-regulatory standards that may place additional burdens on us. Any such changes could impair
our ability to use data and could adversely impact select functionality of our proprietary software, impairing our ability to use this
data to anticipate customer demand and market trends, as well as adversely affecting our business and our ability to generate revenue.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operations of SciSparc Nutraceuticals
depend on our ability to build and maintain strong product listings on eCommerce platforms. We may not be able to maintain and enhance
our product listings if we receive a substantial number of customer complaints, negative publicity or otherwise fail to live up to customers&#8217;
expectations, any of which could materially adversely affect our business, results of operations and growth prospects.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Maintaining and enhancing
our product listings is critical in expanding and growing our business. However, a significant portion of our perceived performance to
the customer depends on third parties outside of our control, including suppliers and logistics providers such as FedEx, UPS, postal services
and other third-party delivery agents and online retailers, mainly Amazon. Because our agreements with our online retail partners are
generally terminable at will, we may be unable to maintain these relationships, and our results of operations could fluctuate significantly
from period to period. Because we rely on third party logistics companies to deliver our products, we are subject to shipping delays or
disruptions caused by inclement weather, natural disasters, labor activism, health epidemics or bioterrorism. In addition, because we
rely on national, regional and local transportation companies for the delivery of some of our other products, we are also subject to risks
of breakage or other damage during delivery by any of these third parties. If these third parties do not meet our or our customers&#8217;
expectations, our brands may suffer irreparable damage. In addition, maintaining and enhancing our current and future brands may require
us to make substantial investments, and these investments may not yield sufficient returns. If we fail to promote and maintain our brands,
or if we incur excessive expenses in this effort, our business, operating results and financial condition may be materially adversely
affected. We anticipate that, as our market becomes increasingly competitive, maintaining and enhancing our brands may become increasingly
difficult and expensive. Maintaining and enhancing our brands will depend largely on our ability to anticipate market trends and customer
demand and to provide high quality products to our customers and a reliable, trustworthy and profitable sales channel to our suppliers,
which we may not be able to do successfully.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A substantial number of customer
complaints or negative publicity about our sites, products, delivery times, customer data handling and security practices or customer
support, especially on blogs, social media websites or our sites, could rapidly and severely diminish consumer views of our products and
result in harm to our brands. Customers may also make safety-related claims regarding products sold through our online retail partners,
such as Amazon, which may result in an online retail partner removing the product from its marketplace. Such removal may materially impact
our financial results depending on the product that is removed and length of time that it is removed. We also use and rely on other services
from third parties, such as our telecommunications services, and those services may be subject to outages and interruptions that are not
within our control.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operations efforts of SciSparc
Nutraceuticals to acquire or retain customers, and our efforts to sell new products or increase sales of our existing products, may not
be successful, which could prevent us from maintaining or increasing our sales and achieving profitability.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we do not successfully
promote and sustain our new and/or existing product listings and brands through marketing and other tools, we may fail to maintain or
increase our sales and achieve profitability. Promoting and positioning our brands and product listings will depend largely on the success
of our marketing efforts, our ability to attract customers cost effectively and our ability to consistently provide a high-quality product
and maintain consumer satisfaction. We also use promotions to drive sales, which may not be effective and may adversely affect our gross
margins. Our investments in marketing may not effectively reach potential customers, potential customers may decide not to buy our products
or the spending of customers that purchase from us may not yield the intended return on investment, any of which could negatively affect
our financial results. The failure of our marketing activities could also adversely affect our ability to promote our product listings
and sell our products, and to develop and maintain relationships with our customers, retailers and brands, which may have a material adverse
effect on our business, results of operations, financial condition and prospects.<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If the eCommerce operations of SciSparc
Nutraceuticals fail to offer high-quality customer support, our business and reputation may suffer.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">High-quality education and
training of customer support personnel to deliver high-quality customer support are important for the successful retention of existing
customers. Providing this education, training and support requires that our support personnel have specific knowledge and expertise of
our products and markets, making it more difficult for us to hire experienced personnel and to scale up our support operations. The importance
of high-quality customer support will increase as we expand our business and pursue new customers. If we do not provide effective and
timely ongoing support, our ability to retain existing customers may suffer, and our reputation with existing or potential customers may
be harmed, which would have a material adverse effect on our business, results of operations, financial condition and prospects.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operations efforts of SciSparc
Nutraceuticals to expand our business into new brands, products, services, technologies and geographic regions will subject us to additional
business, legal, financial and competitive risks and may not be successful.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Wellution&#8217;s business
success depends to some extent on our ability to expand our consumer offerings by launching new brands, products and services and by expanding
our existing offerings into new geographic regions. Our strategy is to use our skills to determine which markets to enter and optimize
the mix of products and services that we offer.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Launching new brands, products
and services requires significant upfront investments, including investments in marketing (namely digital marketing and Pay Per Click
(PPC), information technology and additional personnel. We operate in highly competitive industries with relatively low barriers to entry
and must compete successfully in order to grow our business. We may not be able to generate satisfactory revenue from these efforts to
offset these costs. Any lack of market acceptance of our efforts to launch new brands, products or services or to expand our existing
offerings could have a material adverse effect on our business, prospects, financial condition and results of operations. Further, as
we continue to expand our fulfillment capability or add new businesses with different requirements, our logistics networks will become
increasingly complex and operating them will become more challenging. There can be no assurance that we will be able to operate our networks
effectively.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have also entered and may
continue to enter new markets and provide product offerings in which we have limited or no experience, which may not be successful or
appealing to our customers.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The eCommerce consumer products
goods industry is subject to evolving standards and practices, as well as changing consumer needs, requirements and preferences. Our ability
to attract new customers and increase revenue from existing customers depends, in part, on our ability to enhance and improve our existing
tools that enable us to pinpoint new markets and introduce new products. The success of any enhancements or new instruments depends on,
in part, market-accepted pricing levels and overall market acceptance. We may not be successful in these efforts, which could result in
significant expenditures that could impact our revenue or distract management&#8217;s attention from current offerings.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Increased emphasis on the
sale of new products could distract us from sales of our existing products in existing markets, negatively affecting our overall sales.
We have invested and expect to continue to invest in new businesses, products, features, services and technologies. Such endeavors may
involve significant risks and uncertainties, including insufficient revenue from such investments to offset any new liabilities assumed
and expenses associated with these new investments, inadequate return of capital on our investments, distraction of management from current
operations and unidentified issues not discovered in our due diligence of such investments that could cause us to fail to realize the
anticipated benefits of such investments and incur unanticipated liabilities. Because these new strategies and offerings are inherently
risky, no assurance can be given that they will be successful. Our new features or enhancements could fail to attain sufficient market
acceptance for many reasons, including:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in introducing products in new markets;</span></td></tr>
  </table><div>


</div><p style="margin: 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to accurately predict market demand or end consumer preferences;</span></td></tr>
</table><div>

</div><p style="margin: 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction of competing products;</span></td></tr>
</table><div>

</div><p style="margin: 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">poor financial conditions for our customers or poor general macroeconomic conditions;</span></td></tr>
</table><div>

</div><p style="margin: 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in legal or regulatory requirements, or increased legal or regulatory scrutiny, adversely affecting our products;</span></td></tr>
</table><div>

</div><p style="margin: 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure of our brands, and products, digital promotion activities or negative publicity about the performance or effectiveness of our existing brands and products; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruptions or delays in the online retailers and, or in addition to, logistics providers distributing our products.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no assurance that
we will successfully identify new opportunities or develop and bring new products to market on a timely basis, which could materially
and adversely affect our business and operating results and compromise our ability to generate revenue.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operations&#8217; use of social
media and email by SciSparc Nutraceuticals may adversely impact our reputation or subject us to fines or other penalties.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We use social media and email
as part of our digital marketing efforts. As laws and regulations rapidly evolve to govern the use of these channels, the failure by us,
our employees or third parties acting at on our behalf to abide by applicable laws and regulations in the use of these channels could
adversely affect our reputation or subject us to fines or other penalties. In addition, our employees or third parties acting on our behalf
may knowingly or inadvertently make use of social media in ways that could lead to the loss or infringement of intellectual property,
as well as the public disclosure of proprietary, confidential or sensitive personal information of our business, employees, customers
or others. Any such inappropriate use of social media or email could also cause reputational damage.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Customers value readily available
information concerning retailers and their goods and services and often act on such information without further investigation and with
no regard to its accuracy. Our customers may engage with us online through our social media platforms, including Facebook and Instagram,
by providing feedback and public commentary about all aspects of our business. Information concerning us or our retailers and brands,
whether accurate or not, may be posted on social media platforms at any time and may have a disproportionately adverse impact on our brand,
reputation or business. The harm may be immediate without affording us an opportunity for redress or correction and could have a material
adverse effect on our business, results of operations, financial condition and prospects.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>With respect to the eCommerce operations
of SciSparc Nutraceuticals, if our emails are not delivered and accepted or are routed by email providers less favorably than other emails,
or our sites or mobile applications are not accessible or are treated disadvantageously by Internet service providers, our business may
be substantially harmed.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If email providers or Internet
service providers, or ISPs, implement new restrictive email or content delivery or accessibility policies, including with respect to net
neutrality, or begin enforcement of existing policies, it may become more difficult to deliver emails to our customers or for customers
to access our sites, products and services. For example, certain email providers, including Google, categorize our emails as &#8220;promotional&#8221;,
and these emails are directed to an alternate, and less readily accessible, section of a customer&#8217;s inbox. If email providers materially
limit or halt the delivery of our emails, or if we fail to deliver emails to customers in a manner compatible with email providers&#8217;
email handling or authentication technologies, our ability to contact customers through email could be significantly restricted. In addition,
if we are placed on &#8220;spam&#8221; lists or lists of entities that have been involved in sending unwanted, unsolicited emails, our
operating results and financial condition could be substantially harmed. Further, if ISPs prioritize or provide superior access to our
competitors&#8217; content, our business and results of operations may be negatively impacted.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operations of SciSparc Nutraceuticals
are subject to risks related to online payment methods.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We accept payments using a
variety of methods, including credit card, debit card, PayPal, Payoneer, credit accounts (including promotional financing) and gift cards.
For certain payment methods, including credit and debit cards, we pay interchange and other fees, which may increase over time and raise
our operating costs and lower profitability. In addition, our credit card and other payment processors could impose receivable holdback
or reserve requirements in the future. We rely on third parties to provide payment processing services, including the processing of credit
cards and debit cards, and it could disrupt our business if these companies become unwilling or unable to provide these services to us.
We are also subject to payment card association operating rules, certification requirements and rules governing electronic funds transfers,
which could change or be reinterpreted to make it difficult or impossible for us to comply. If we fail to comply with the rules or requirements
of any provider of a payment method we accept, if the volume of fraud in our transactions limits or terminates our rights to use payment
methods we currently accept, or if a data breach occurs relating to our payment systems, we may, among other things, be subject to fines
or higher transaction fees and may lose, or face restrictions placed upon, our ability to accept credit card or debit card payments from
customers or to facilitate other types of online payments. If any of these events were to occur, our business, financial condition and
operating results could be materially adversely affected.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>With respect to the eCommerce operations
of SciSparc Nutraceuticals, if we are unable to manage our inventory effectively, our operating results could be adversely affected.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To ensure timely delivery
of products, we generally enter into purchase orders in advance with manufacturers. As a result, we are vulnerable to demand and pricing
shifts and to suboptimal selection and timing of product purchases. We rely on our procurement team to order products and we rely on our
data analytics to inform the levels of inventory we purchase, including when to reorder items that are selling well and when to write
off items that are not selling well. In these instances, we may be unable to always predict the appropriate demand for our products by
customers with accuracy, which may result in inventory shortages, inventory write offs and lower gross margins.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our sales and procurement
teams do not predict demand well or if our algorithms do not help us reorder the right products or write off the right products timely,
we may not effectively manage our inventory, which could result in inventory excess or shortages, and our operating results and financial
condition could be adversely affected.<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operations of SciSparc Nutraceuticals,
including the costs and supply chain, are subject to risks associated with sourcing, importing and warehousing.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We source the products we
offer from third-party vendors and, as a result, we may be subject to price fluctuations or demand disruptions. Our operating results
could be negatively impacted by increases in the prices of our products, and we have no guarantees that prices will not rise. In addition,
as we expand into new categories and types of products, we expect that we may not have strong purchasing power in these new areas, which
could lead to higher costs than we have historically seen in our current product categories and types. We may not be able to pass increased
costs on to customers, which could adversely affect our operating results.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we cannot guarantee
that products we receive from vendors will be of sufficient quality or free from damage or defects, or that such merchandise will not
be damaged during shipping or storage. While we take measures to ensure product quality and avoid damage, including evaluating vendor
facilities, operations and product samples, conducting inventory inspections and inspecting returned products, we cannot control merchandise
while it is out of our possession or prevent all damage while in our distribution centers. We may incur additional expenses and our reputation
could be harmed if or current or potential customers believe that our merchandise is not of high quality or may be damaged.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks associated with the suppliers from
whom our products are sourced could materially adversely affect our financial performance, as well as our reputation and brand.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We depend on our ability to
provide our customers with a wide range of products from high quality suppliers in a timely and efficient manner. Our agreements with
most of our suppliers do not provide for the long-term availability of merchandise or the continuation of particular pricing practices,
nor do they usually restrict such suppliers from selling products to other buyers or directly themselves. There can be no assurance that
our current suppliers will continue to seek to sell us products on current terms or that we will be able to establish new or otherwise
extend current supply relationships to ensure product acquisitions in a timely and efficient manner and on acceptable commercial terms.
Our ability to develop and maintain relationships with reputable suppliers and offer high quality products to our customers is critical
to our success. If we are unable to develop and maintain relationships with suppliers that would allow us to offer a sufficient amount
and variety of quality products on acceptable commercial terms, our ability to satisfy our customers&#8217; needs, and therefore our long-term
growth prospects, would be materially adversely affected.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also are unable to predict
whether any of the countries in which our suppliers&#8217; products are currently manufactured or may be manufactured in the future will
be subject to trade restrictions imposed by the U.S. or foreign governments or the likelihood, type or effect of any such restrictions.
Any event causing a disruption or delay of imports from suppliers with international manufacturing operations, including the imposition
of additional import restrictions, restrictions on the transfer of funds or increased tariffs or quotas, could increase the cost or reduce
the supply of merchandise available to our customers and materially adversely affect our financial performance as well as our reputation
and brand. Our competitors may have greater existing inventory positions and other advantages that may allow them to price more competitively
relative to our products. Furthermore, some or all of our suppliers&#8217; foreign operations may be adversely affected by political and
financial instability, resulting in the disruption of trade from exporting countries, restrictions on the transfer of funds or other trade
disruptions.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not accurately forecast revenues,
profitability and appropriately plan our expenses.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We base our current and future
expense levels on our operating forecasts and estimates of future income and operating results. Income and operating results are difficult
to forecast because they generally depend on the volume and timing of the orders we receive, which are uncertain. Additionally, our business
is affected by general economic and business conditions around the world. A softening in income, whether caused by changes in consumer
preferences, a weakening in global economies or inflation, may result in decreased net revenue levels, and we may be unable to adjust
our spending in a timely manner to compensate for any unexpected shortfall in income. This inability could cause our income (loss) from
operations after tax in a given quarter to be lower or higher than expected. We also make certain assumptions when forecasting the expenses
we expect related to our share-based payments, which includes the expected volatility of our share price, and the expected life of equity
awards granted. These assumptions are partly based on historical results. If actual results differ from our estimates, our operating results
in a given quarter may be lower than expected.<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operation&#8217;s operating
results of SciSparc Nutraceuticals are subject to seasonal fluctuations.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The eCommerce business is
seasonal in nature and the fourth quarter is a significant period for our operating results due to the holiday season. As a result, revenue
generally declines and loss from operations generally increases in the first quarter sequentially from the fourth quarter of the previous
year. Any disruption in our ability to process and fulfill customer orders during the fourth quarter could have a negative effect on our
quarterly and annual operating results. For example, if a large number of customers purchase our products in a short period of time due
to increased holiday demand, inefficient management of our inventory may prevent us from efficiently fulfilling orders, which may reduce
sales and harm our brands.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The inability to acquire, use or maintain
our marks and domain names for our sites could substantially harm our business and operating results.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have registered
trademarks for our brands in numerous jurisdictions and have registered the Internet domain names for our websites, as well as various
related domain names. However, we have not registered our trademarks or domain names in all major international jurisdictions. Domain
names generally are regulated by Internet regulatory bodies. If we do not have, or cannot obtain on reasonable terms, the ability to use
our marks in a particular country or to use or register any of our domain names, we could be forced either to incur significant additional
expenses to market our products within that country, including the development of a new brand and the creation of new promotional materials
and packaging, or to elect not to sell products in that country. Either result could materially adversely affect our business, financial
condition and operating results.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, the regulations
governing domain names and laws protecting marks and similar proprietary rights could change in ways that block or interfere with our
ability to use relevant domains or our current brand names. Furthermore, we might not be able to prevent third parties from registering,
using or retaining domain names that interfere with our consumer communications or infringe or otherwise decrease the value of our marks,
domain names and other proprietary rights. Regulatory bodies also may establish additional generic or country-code top-level domains or
may allow modifications of the requirements for registering, holding or using domain names. As a result, we may not be able to register,
use or maintain the domain names that utilize the Wellution name in all of the countries in which we currently or intend to conduct business.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Any significant disruption in service on
our websites or apps or in our computer systems, a number of which are currently hosted or provided by third-party providers, could materially
affect our ability to operate, damage our reputation and result in a loss of customers, which would harm our business and results of operations.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to sell and market
our products relies on FBA platform whose functionality relies upon a number of third-party related services, including those relating
to cloud infrastructure, technology services, servers, open-source libraries and vendor application programming interfaces. Any disruption
or loss of any of these third-party services could have a negative effect on our business, results of operations, financial condition
and prospects. We may experience interruptions in our systems, including server failures that temporarily slow down or interfere with
the performance of our platforms and the ability to sell on eCommerce marketplaces.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Interruptions in these systems,
whether due to system failures, human input errors, computer viruses or physical or electronic break-ins, and denial-of-service attacks
on us, third-party vendors or communications infrastructure, could affect the availability of our services on our platform and prevent
or inhibit the ability of selling our products. Volume of traffic and activity on eCommerce marketplaces spikes on certain days, such
as during a Black Friday promotion, and any such interruption would be particularly problematic if it were to occur at such a high-volume
time. Problems with the reliability of our systems or third-party marketplaces could prevent us from earning revenue and could harm our
reputation. Damage to our reputation, any resulting loss of customers, eCommerce confidence and the cost of remedying these problems could
negatively affect our business, results of operations, financial condition and prospects.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to maintain communications,
network and computer hardware in the countries in which they are used may in the future be subject to regulatory review and licensing,
and the failure to obtain any required licenses could negatively affect our business. Our systems and infrastructure are predominately
reliant on third parties. Problems faced by our third-party service providers with the telecommunications network providers with whom
they contract or with the systems by which they allocate capacity among their users, including us, could adversely affect the experience
of our customers. Our third-party service providers could decide to close their facilities without adequate notice. Any financial difficulties,
such as bankruptcy or reorganization, faced by our third-party service providers or any of the service providers with whom they contract
may have negative effects on our business, the nature and extent of which are difficult to predict. If our third-party service providers
are unable to keep up with our needs for capacity, this could have an adverse effect on our business. Any errors, defects, disruptions
or other performance problems with our services could harm our reputation and may have a material adverse effect on our business, results
of operations, financial condition and prospects.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to the Ownership of Our Securities</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will need additional capital in the future.
Raising additional capital by issuing securities may cause dilution to existing shareholders.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have incurred losses every
year since our inception. If we continue to use cash at our historical rates of use we will need significant additional financing, which
we may seek through a combination of private and public equity offerings, debt financings and collaborations and strategic and licensing
arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, an existing shareholder&#8217;s
ownership interest will be diluted, and the terms of any such offerings may include liquidation or other preferences that may adversely
affect the then existing shareholders rights. Debt financing, if available, would result in increased fixed payment obligations and may
involve agreements that include covenants limiting or restricting our ability to take specific actions such as incurring debt or making
capital expenditures. If we raise additional funds through collaboration, strategic alliance or licensing arrangements with third parties,
we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates, or grant licenses on terms
that are not favorable to us.<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We do not know whether a market for the
Ordinary Shares will be sustained or what the trading price of the Ordinary Shares will be and as a result it may be difficult for you
to sell your Ordinary Shares</i></b>.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although our Ordinary Shares
are listed on Nasdaq, an active trading market for the Ordinary Shares may not be sustained. It may be difficult for you to sell your
Ordinary Shares without depressing the market price for the Ordinary Shares or at all. Further, an inactive market may also impair our
ability to raise capital by selling Ordinary Shares and may impair our ability to enter into strategic partnerships or acquire companies,
products, or services by using our equity securities as consideration.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sales of a substantial number of our Ordinary
Shares in the public market by our existing shareholders could cause our share price to fall.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales of a substantial number
of our Ordinary Shares in the public market, including as a result of the SEPA, or the perception that these sales might occur, could
depress the market price of our Ordinary Shares and could impair our ability to raise capital through the sale of additional equity securities.
We are unable to predict the effect that sales may have on the prevailing market price of our Ordinary Shares.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The exercise of outstanding warrants will
cause significant dilution to holders of our equity securities and could adversely affect the price of our Ordinary Shares. </i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of February 26, 2024, holders
of warrants may exercise their warrants into up to 3,821,272&#160;Ordinary Shares. In the event that such warrants are exercised in full,
the ownership interest of existing holders of our equity securities will be diluted and may have a negative effect on the trading price
of our Ordinary Shares.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Upon a trigger event, we may be required
to make payments that could cause us financial hardship. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the SEPA,
we may request Pre-Paid Advances of the Commitment Amount in an amount up to $5.0 million. Each Pre-Paid Advance will be evidenced by
a Promissory Note. Each Promissory Note will fully mature 24-months following its issuance and shall accrue interest on the outstanding
principal balance thereon at a rate of 5% per annum, increasing to 18% per annum upon an Event of Default (as defined in the Promissory
Note). Beginning 150 days after the issuance of a Promissory Note, we shall pay to YA a monthly installment payment of 10% of the original
principal amount of the Promissory Note and accrued interest, payable in cash or by submitting an Advance Notice, where YA will offset
the amount due to be paid to us under such notice against an equal amount of the monthly installment amount, at our option. If we elect
to pay in cash, the installment amount shall also include a payment premium in the amount of 5% of the principal amount of the installment
payment. The Promissory Note contains our customary representations and warranties and Events of Default.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These financial obligations,
including to repay the Pre-Paid&#160;Advance, may be an undue and unsustainable burden to us and may cause a material adverse effect on
our operations and financial condition. Any debt we incur from the Selling Shareholder or other parties could make us more vulnerable
to a downturn in our operating results or a downturn in economic conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The market price of our securities may be
highly volatile, and you may not be able to resell your Ordinary Shares at or above the price you paid. </i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price of our Ordinary
Shares is volatile. Our Ordinary Share price is and will continue to be subject to wide fluctuations in response to a variety of factors,
including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
results or delays in preclinical studies or clinical trials;</span></td>
</tr></table><div>


</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reports of adverse events in our product candidates or clinical trial failures of our product candidates;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability to obtain additional funding;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any delay in filing a regulatory submission for any of our product or product candidates and any adverse development or perceived adverse development with respect to the review of that regulatory submission by the FDA or European or Asian authorities;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to successfully develop and commercialize our products or product candidates;&#160;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to enter into strategic collaborations or failure to successfully integrate acquisitions we have made;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure by us or strategic collaboration partners to prosecute, maintain or enforce our intellectual property rights;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in laws or regulations applicable to future products;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability to scale up our manufacturing capabilities through third-party manufacturers, inability to obtain adequate product supply for our products or the inability to do so at acceptable prices;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction of new products or technologies by our competitors;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to meet or exceed financial projections we may provide to the public;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failures or delays in our intended Restructuring Plan;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to meet or exceed the financial expectations of the investment community;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by our competitors;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our platform technologies, technologies, products or product candidates;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions or departures of key scientific or management personnel;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant lawsuits, including patent or shareholder litigation;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the market valuations of similar companies;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in general conditions in the economy and the financial markets in the countries in which we operate including those related to recent unrest and actual or potential armed conflict in Israel and other parts of the Middle East, such as the recent attack by Hamas and other terrorist organizations from the Gaza Strip and elsewhere in the region and Israel&#8217;s war against them and military hostilities with Hezbollah on the northern border of Israel;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales of our securities by us or our shareholders in the future; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trading volumes of our securities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, companies trading
in the stock market have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating
performance of these companies. Broad market and industry factors may negatively affect the market price of our Ordinary Shares, regardless
of our actual operating performance.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Outstanding warrants and pre-funded warrants
to acquire our Ordinary Shares are speculative in nature. Furthermore, holders of our warrants and pre-funded warrants will have no rights
as shareholders until such holders exercise their warrants and acquire our Ordinary Shares.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until holders of the warrants
and pre-funded warrants acquire our Ordinary Shares upon exercise of the warrants and pre-funded warrants, holders of the warrants and
pre-funded warrants will have no rights with respect to our Ordinary Shares underlying such warrants and pre-funded warrants. Upon exercise
of the warrants and pre-funded warrants, the holders thereof will be entitled to exercise the rights of a holder of Ordinary Shares only
as to matters for which the record date occurs after the exercise date.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our warrants and pre-funded
warrants only represent the right to acquire Ordinary Shares at a fixed price, and in the case of the warrants, for a limited period of
time. Specifically, holders of the warrants and pre-funded warrants that we issued in private placements in March 2019, March 2020, March
2021, June 2022 and October 2023 and in our November 2020 and August 2023 public offerings may exercise their right to acquire Ordinary
Shares and pay an exercise price per Ordinary Shares (in the case of the pre-funded warrants, $0.001 per Ordinary Share and in the case
of other warrants, ranging from $2.57 to $245.00 per Ordinary Share), subject to adjustment upon certain events, and in the case of warrants
only prior to five years from their respective issuance dates, after which date any unexercised warrants will expire and have no further
value.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We cannot assure you that our Ordinary Shares
will remain listed on Nasdaq or any other securities exchange.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ADSs, which previously
represented our Ordinary Shares, were listed on Nasdaq from March 2017 through July 2020. On September 21, 2020, our ADSs were delisted
from Nasdaq as a result of not meeting the shareholders equity requirements of Nasdaq. Between December 2020 and August 2021, our ADSs
were quoted on the OTCQB. In August 2021, our ADR program was terminated and our ADSs were converted to Ordinary Shares on a one-for-one
basis. In September 2021, our Ordinary Shares began to be quoted for trading on the OTCQB under the ticker &#8220;SPRCF&#8221;. In December
2021, our Ordinary Shares were re-listed on Nasdaq and began trading under the symbol &#8220;SPRC&#8221;.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, on March 10,
2023, we received a written notice, or the Notice, from Nasdaq indicating that we were not in compliance with the minimum bid price requirement
for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of
$1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), we were granted a period of 180 calendar days to regain compliance with the
minimum bid price requirement.&#160;Although we have since cured this deficiency and have regained compliance with Nasdaq Listing Rule
5550(a)(2), there is a risk that we could be subject to additional notices of delisting for failure to comply with Nasdaq Listing Rule
5550(a)(2) or other Nasdaq Listing Rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No assurance can be given
that we will remain eligible to be listed on Nasdaq. Further, because of the previous delisting of our ADSs from Nasdaq, if we fall out
of compliance with Nasdaq requirements in the future, our Ordinary Shares may be more likely to be subject to Nasdaq&#8217;s delisting
process and no assurance can be given that we will be able to regain compliance. Any delisting could adversely affect our ability to obtain
financing for the continuation of our operations and could result in the loss of confidence by investors, customers and employees.<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to achieve and maintain effective
internal controls in accordance with Section 404 of the Sarbanes-Oxley Act could have a material adverse effect on our business, results
of operation or financial condition. In addition, current and potential shareholders could lose confidence in our financial reporting,
which could have a material adverse effect on the price of our Ordinary Shares.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective internal controls
are necessary for us to provide reliable financial reports and effectively prevent fraud. We are required to document and test our internal
control procedures in order to satisfy the requirements of Section 404 of the Sarbanes-Oxley Act, which requires annual management assessments
of the effectiveness of our internal control over financial reporting. In addition, if we fail to maintain the adequacy of our internal
control, as such standards are modified, supplemented or amended from time to time, we may not be able to ensure that we can conclude
on an ongoing basis that we have effective internal control over financial reporting in accordance with Section 404. Disclosing deficiencies
or weaknesses in our internal control, failing to remediate these deficiencies or weaknesses in a timely fashion or failing to achieve
and maintain an effective internal control environment may cause investors to lose confidence in our reported financial information, which
could have a material adverse effect on the price of our Ordinary Shares. If we cannot provide reliable financial reports or prevent fraud,
our operating results could be harmed.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have not paid, and do not intend to pay,
dividends on our Ordinary Shares and, therefore, unless our traded securities appreciate in value, our investors may not benefit from
holding our securities.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not paid any cash
dividends on our Ordinary Shares since inception. We do not anticipate paying any cash dividends our Ordinary Shares in the foreseeable
future. Moreover, the Israeli Companies Law-1999, or the Companies Law, imposes certain restrictions on our ability to declare and pay
dividends. As a result, investors in our Ordinary Shares will not be able to benefit from owning these securities unless their market
price becomes greater than the price paid by such investors and they are able to sell such securities. We cannot assure you that you will
ever be able to resell our securities at a price in excess of the price paid.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Unfavorable outcomes
in legal proceedings may harm our business and results of operations. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regardless of whether or not
there is merit to the claims underlying any legal proceedings to which we are subject, and regardless of whether or not we are found as
a result of such proceedings to have violated any applicable laws, such proceedings can be expensive to defend or respond to, and could
result in substantial costs and diversion of management&#8217;s attention and resources, which could harm our business, and potentially
could cause substantial and irreparable harm to our public reputation. For example, on May 2, 2023, Capital Point Ltd., or Capital Point,
filed a lawsuit in the Tel Aviv-Jaffa District Court against us as the sole defendant in connection with the warrant we issued to Capital
Point pursuant to a joint venture transaction entered into on May 15, 2020 by and between us, Capital Point and Evero Health Ltd. one
of our subsidiaries. The lawsuit includes allegations of breaches of contract under the Israeli Contracts Law (General Part), 1973, unjust
enrichment under the Israeli Unjust Enrichment Law, 1979 and breaches under the Israeli Torts Ordinance (New Version), 1968. The lawsuit
claims damages in the amount of NIS 10,000,000 (approximately $2.75 million), which accounts for, as of the date of the filing of the
lawsuit, liquidated damages according to the provisions set forth in the warrant, and seeks as well for the court to order a mandatory
injunction order for us to issue a warrant to Capital Point to purchase $340,000 of our ordinary shares, the return of any unlawful profits
received by us and punitive damages. As of February 26, 2024, in connection with the aforementioned litigation, the shares of Evero Health
Ltd. held by Capital Point are dormant and were forfeited by Evero Health Ltd. As of the date of this prospectus, we cannot predict the
likelihood of our success in the lawsuit. If we do not prevail in such lawsuit, our results of operations and reputation could be adversely
affected.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be a &#8220;passive foreign investment
company,&#8221; or PFIC, for U.S. federal income tax purposes in the current taxable year or may become one in any subsequent taxable
year. There generally would be negative tax consequences for U.S. taxpayers that are holders of our Ordinary Shares if we are or were
to become a PFIC.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, we will be treated
as a PFIC for U.S. federal income tax purposes in any taxable year in which either (1) at least 75% of our gross income is &#8220;passive
income&#8221; or (2) on average at least 50% of our assets by value produce passive income or are held for the production of passive income.
Passive income for this purpose generally includes, among other things, certain dividends, interest, royalties, rents and gains from commodities
and securities transactions and from the sale or exchange of property that gives rise to passive income. Passive income also includes
amounts derived by reason of the temporary investment of funds, including those raised in a public offering. In determining whether a
non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in which it owns, directly or indirectly,
at least a 25% interest (by value) is taken into account. We do not believe that we would be deemed a PFIC for 2023. If we are a PFIC
in any taxable year during which a U.S. taxpayer holds the Ordinary Shares, such U.S. taxpayer would be subject to certain adverse U.S.
federal income tax rules. In particular, if the U.S. taxpayer did not make an election to treat us as a &#8220;qualified electing fund,&#8221;
or QEF, or make a &#8220;mark-to-market&#8221; election, then &#8220;excess distributions&#8221; to the U.S. taxpayer, and any gain realized
on the sale or other disposition of the Ordinary Shares by the U.S. taxpayer: (1) would be allocated ratably over the U.S. taxpayer&#8217;s
holding period for the Ordinary Shares; (2) the amount allocated to the current taxable year and any period prior to the first day of
the first taxable year in which we were a PFIC would be taxed as ordinary income; and (3) the amount allocated to each of the other taxable
years would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for that year, and an interest
charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each such other taxable year.
In addition, if the U.S. Internal Revenue Service, or the IRS, determines that we are a PFIC for a year with respect to which we have
determined that we were not a PFIC, it may be too late for a U.S. taxpayer to make a timely QEF or mark-to-market election. U.S. taxpayers
that have held the Ordinary Shares during a period when we were a PFIC will be subject to the foregoing rules, even if we cease to be
a PFIC in subsequent years, subject to exceptions for U.S. taxpayer who made a timely QEF or mark-to-market election. A U.S. taxpayer
can make a QEF election by completing the relevant portions of and filing IRS Form 8621 in accordance with the instructions thereto. U.S.
taxpayers that hold the Ordinary Shares are strongly urged to consult their tax advisors about the PFIC rules, including tax return filing
requirements and the eligibility, manner, and consequences to them of making a QEF or mark-to-market election with respect to the Ordinary
Shares in the event that we are a PFIC. See &#8220;Taxation-U.S. Federal Income Tax Considerations-Passive Foreign Investment Companies&#8221;
for additional information.&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Israeli Law and Our Operations
in Israel</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We conduct our operations
in Israel.&#160;Conditions in Israel, including the recent attack by&#160;Hamas&#160;and other terrorist organizations and Israel&#8217;s
war against them, may affect our operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are incorporated under
the laws of the State of Israel and our headquarters and principal offices and most of our operations are located in the State of Israel.
In addition, all of our key employees and officers are residents of Israel. Accordingly, political, economic and military conditions in
Israel and the surrounding region may directly affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any hostilities involving
Israel or the interruption or curtailment of trade between Israel and its present trading partners, or a significant downturn in the economic
or financial condition of Israel, could affect adversely our operations. Ongoing and revived hostilities or other Israeli political or
economic factors could harm our operations, product development and results of operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 7, 2023, an attack
was launched against Israel by terrorists from the Hamas&#160;terrorist organization that infiltrated Israel&#8217;s border with the Gaza
Strip, attacking civilians and military targets while simultaneously launching extensive rocket attacks on the Israeli population. These
attacks resulted in extensive deaths, injuries and kidnapping of civilians and soldiers. In response, the Security Cabinet of the State
of Israel declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued
rocket and terror attacks. To date, the State of Israel continues to be at war with Hamas. In the months since the initial attack by Hamas,
clashes with Hezbollah on Israel&#8217;s northern border with Lebanon and attacks on Israeli-controlled or owned ships in the Red Sea
by members of the Houthi Movement in Yemen have taken place. It is possible that other terrorist organizations, including Palestinian
military organizations in the West Bank, as well as other hostile countries, such as Iran, will join the hostilities and that such clashes
may escalate in the future into a greater regional conflict.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since the war broke out on
October 7, 2023, our operations have not been adversely affected, except with regards to our SCI-210 ASD clinical trial at Soroka Medical
Center which was delayed by three months. At this time, it is not possible to predict the intensity or duration of the war, nor can we
predict how this war will ultimately affect Israel&#8217;s economy in general, which may involve additional credit rating agencies downgrading
Israel&#8217;s credit rating score after Moody&#8217;s downgrading of Israel&#8217;s credit rating from A1 to A2 and outlook rating from
&#8220;stable&#8221; to &#8220;negative&#8221;, and we continue to monitor the situation closely and examine the potential disruptions
that could adversely affect our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the Israeli
security cabinet&#8217;s declaration of war against Hamas and possible hostilities with other organizations, several hundred thousand
Israeli military reservists were drafted to perform immediate military service. Although many such military reservists have been discharged,
they may be called up again depending on how events unfold. As of February 26, 2024, none of our 3 current employees in Israel have been
called to active military duty, though we rely on service providers located in Israel and have entered into certain agreements with Israeli
counterparties. Employees of such service providers or contractual counterparties may be called for service in the current or future wars
or other armed conflicts with Hamas, in addition to other prospective armed conflicts Israel may be engaged in, and such persons may be
absent from their positions for a period of time. As of February 26, 2024, we have not been impacted by any absences of personnel at our
service providers or counterparties located in Israel. However, military service call ups that result in absences of personnel from us,
our service providers or contractual counterparties in Israel may disrupt our operations and absences for an extended period of time may
materially and adversely affect our business, prospects, financial condition and results of operations.&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the months since the initial
attack by Hamas, other regional hostilities have become more pronounced. This includes clashes with Hezbollah on Israel&#8217;s northern
border with Lebanon and attacks on Israeli-controlled or owned ships in the Red Sea by members of the Houthi Movement in Yemen, resulting
in shipping companies rerouting their cargo ships or ceasing shipments to Israel in the case of the latter. Hostilities with Hamas, Hezbollah,
the Houthi Movement, and other terrorist organizations include and may include terror and missile and drone attacks. Any hostilities involving
Israel or the interruption or curtailment of trade between Israel and its trading partners could adversely affect our operations and results
of operations. Our insurance policies do not cover losses that may occur as a result of events associated with war and terrorism. Although
the Israeli government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war,
we cannot assure you that this government coverage will be maintained or that it will sufficiently cover our potential damages. Any losses
or damages incurred by us could have a material adverse effect on our business. Any armed conflicts or political instability in the region
would likely negatively affect business conditions and could harm our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Several countries, principally
in the Middle East, still restrict doing business with Israel and Israeli companies, and additional countries may impose restrictions
on doing business with Israel and Israeli companies, whether as a result of hostilities in the region or otherwise. In addition, there
have been increased efforts by certain countries, activists and organizations to cause companies, research institutions and consumers
to boycott Israeli goods and cooperation with Israeli-related entities based on Israeli government policies. In December 2023, the Republic
of South Africa brought a case to the International Court of Justice, or the ICJ, about which Israel as a member of the Convention on
the Prevention and Punishment of the Crime of Genocide, falls under its jurisdiction. The claim asserted that Israel had committed genocide
against Palestinians in the Gaza Strip. Prosecutorial proceedings took place in January 2024. The ICJ issued an interim ruling that prescribed
Israel to prevent genocidal acts, prevent and punish incitement to genocide, and take steps to provide basic services and humanitarian
aid to the people of Gaza. In light of this ruling, certain companies and business have terminated commercial relationships <span style="font-family: Times New Roman, Times, Serif">&#160;</span>with
Israeli companies and more may follow. If such international tribunal and ICJ rulings continue to issue rulings against Israel, this may
adversely impact our ability to cooperate with research institutions and collaborate with other third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Political instability in Israel,
originating before October 2023, could disrupt our operations. Having held five general elections between 2019 and 2022, government policy
is subject to regular disruptive changes. The current government of Israel has pursued extensive changes to Israel&#8217;s judicial system.
In response to the foregoing developments, individuals, organizations and institutions, both within and outside of Israel, have voiced
concerns that the proposed changes may negatively impact the business environment in Israel including due to reluctance of foreign investors
to invest or transact business in Israel as well as to increased currency fluctuations, downgrades in credit rating, increased interest
rates, increased volatility in securities markets, and other changes in macroeconomic conditions. Not only have the proposed judicial
reforms been put on hold due to the ongoing focus on the war, but also the Supreme Court of Israel ruled that the judicial reform passed
into legislation relating to reasonability is unconstitutional. If such changes to the judicial system resume, however, this may have
an adverse effect on our business, our results of operations and our ability to raise additional funds, if deemed necessary by our management
and board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Provisions of Israeli law may make it easy
for our shareholders to demand that we convene a shareholders meeting, and/or allow shareholders to convene a shareholder meeting without
the consent of our management, which may disrupt our management&#8217;s ability to run our company.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 63(b) of the Companies
Law may allow any one or more of our shareholders holding at least 5% of our voting rights to demand that we convene a special shareholders
meeting. Also, in the event that we choose not to convene a special shareholders meeting pursuant to such a request, Sections 64-65 of
the Companies Law provide, among others, that such shareholders may independently convene a special shareholders meeting within three
months (or under court&#8217;s ruling) and require us to cover the costs, within reason, and as a result thereof, our directors might
be required to repay us such costs. If our shareholders decide to exercise these rights in a way inconsistent with our management&#8217;s
strategic plans, our management&#8217;s ability to run our company may be disrupted, and this process may entail significant costs to
us.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our operations are subject to currency and
interest rate fluctuations.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We incur expenses in U.S.
dollars and NIS, but our financial statements are denominated in U.S. dollars. U.S. dollars is our functional currency and is the currency
that represents the principal economic environment in which we operate. As a result, we are affected by foreign currency exchange fluctuations
through both translation risk and transaction risk. As a result, we are exposed to the risk that the NIS may appreciate relative to the
dollar, or, if the NIS instead devalues relative to the dollar, that the inflation rate in Israel may exceed such rate of devaluation
of the NIS, or that the timing of such devaluation may lag behind inflation in Israel. In any such event, the dollar cost of our operations
in Israel would increase and our dollar-denominated results of operations would be adversely affected.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Provisions of Israeli law and our amended
and restated articles of association may delay, prevent or otherwise impede a merger with, or an acquisition of, our company, which could
prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders. </i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provisions of Israeli law
and our amended and restated articles of association could have the effect of delaying or preventing a change in control and may make
it more difficult for a third party to acquire us or our shareholders to elect different individuals to our board of directors, even if
doing so would be considered to be beneficial by some of our shareholders, and may limit the price that investors may be willing to pay
in the future for our Ordinary Shares. Among other things:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli corporate law regulates mergers and requires that a tender offer be effected when more than a specified percentage of shares in a company are purchased;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli corporate law does not provide for shareholder action by written consent, thereby requiring all shareholder actions to be taken at a general meeting of shareholders; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our amended and restated articles of association divide our directors into three classes, each of which is elected once every three years;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our amended and restated articles of association require a vote of the holders of a majority of our outstanding Ordinary Shares entitled to vote present and voting on the matter at a general meeting of shareholders (referred to as simple majority), and the amendment of a limited number of provisions, such as the provision stating that each year the term of office of only one class of directors will and dividing our directors into three classes, requires a vote of the holders of 65% of the voting power represented at a general meeting of our shareholders and voting thereon has been obtained, provided the majority constitutes more than 33.33% of the total issued and outstanding share capital as of the record date of such meeting. The affirmative vote of at least three-quarters (3/4) of the directors, in addition to the approval of our shareholders, is also required in order to amend our amended and restated articles of association;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our amended and restated articles of association provide that director vacancies may be filled by our board of directors;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to certain exceptions, our amended and restated articles of association restrict us from engaging in certain business combination transactions, with any shareholder who holds 15% or more of our voting power. The transactions subject to such restrictions include mergers, consolidations and dispositions of our assets with a market value of 10% or more of our assets or outstanding shares. Subject to certain exceptions, such restrictions will apply for a period of three years following each time a shareholder became the holder of 15% or more of our voting power; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to certain exceptions, our amended and restated articles of association restrict certain transactions which may have a significant effect on the Company&#8217;s structure, assets or business, including significant mergers and acquisitions, a disposition of all or substantially all of the assets of the Company, a voluntary dissolution and material changes to the principal business of the Company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, Israeli tax considerations
may make potential transactions undesirable to us or to some of our shareholders whose country of residence does not have a tax treaty
with Israel granting tax relief to such shareholders from Israeli tax. With respect to mergers, Israeli tax law allows for tax deferral
in certain circumstances but makes the deferral contingent on the fulfillment of numerous conditions, including a holding period of two
years from the date of the transaction during which certain sales and dispositions of shares of the participating companies are restricted.
<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>


</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>It may be difficult to enforce a judgment
of a United States court against us and our officers and directors and the Israeli experts named in this prospectus in Israel or the United
States, to assert United States securities laws claims in Israel or to serve process on our officers and directors and these experts.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were incorporated in Israel
and our corporate headquarters are located in Israel. All of our executive officers and directors and the Israeli experts named in this
prospectus are located in Israel. All of our assets and most of the assets of these persons are located in Israel. Service of process
upon us or our non-U.S. resident directors and officers and enforcement of judgments obtained in the United States against us or our non-U.S.
directors and executive officers may be difficult to obtain within the United States. We have been informed by our legal counsel in Israel
that it may be difficult to assert claims under U.S. securities laws in original actions instituted in Israel, or obtain a judgment based
on the civil liability provisions of U.S. federal securities laws. Israeli courts may refuse to hear a claim based on a violation of U.S.
securities laws against us or our non-U.S. officers and directors because Israel may not be the most appropriate forum to bring such a
claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable
to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact, which can be a time-consuming
and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel addressing
the matters described above. Israeli courts might not enforce judgments rendered outside Israel, which may make it difficult to collect
on judgments rendered against us or our non-U.S. officers and directors.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, an Israeli court
will not enforce a non-Israeli judgment if it was given in a state whose laws do not provide for the enforcement of judgments of Israeli
courts (subject to exceptional cases), if its enforcement is likely to prejudice the sovereignty or security of the State of Israel, if
it was obtained by fraud or in the absence of due process, if it is at variance with another valid judgment that was given in the same
matter between the same parties, or if a suit in the same matter between the same parties was pending before a court or tribunal in Israel
at the time the foreign action was brought.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our principal executive offices, most of
our research and development activities and other significant operations are located in Israel, and, therefore, our results may be adversely
affected by political, economic and military instability in Israel.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our executive offices, corporate
headquarters and principal research and development facilities are located in Israel. In addition, all of our officers and directors are
residents of Israel. Accordingly, political, economic and security conditions in Israel and the surrounding region may directly affect
our business. Any conflicts, political instability, terrorism, cyberattacks or any other hostilities involving Israel or the interruption
or curtailment of trade between Israel and its present trading partners could adversely affect our operations. Ongoing and revived hostilities
in the Middle East or other Israeli political or economic factors, could harm our operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial insurance does
not cover losses that may occur as a result of events associated with war and terrorism. Although the Israeli government currently covers
the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot assure you that this government
coverage will be maintained or that it will sufficiently cover our potential damages. Any losses or damages incurred by us could have
a material adverse effect on our business. Any armed conflicts or political instability in the region would likely negatively affect business
conditions and could harm our results of operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli government is
currently pursuing extensive changes to Israel&#8217;s judicial system. In response to the foregoing developments, individuals, organizations
and institutions, both within and outside of Israel, have voiced concerns that the proposed changes may negatively impact the business
environment in Israel including due to reluctance of foreign investors to invest or transact business in Israel as well as to increased
currency fluctuations, downgrades in credit rating, increased interest rates, increased volatility in securities markets, and other changes
in macroeconomic conditions. To the extent that any of these negative developments do occur, they may have an adverse effect on our business,
our results of operations and our ability to raise additional funds, if deemed necessary by our management and board of directors.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, in the past,
the State of Israel and Israeli companies have been subjected to economic boycotts. Several countries still restrict business with
the State of Israel and with Israeli companies. These restrictive laws and policies may have an adverse impact on our operating
results, financial condition or the expansion of our business. A campaign of boycotts, divestment and sanctions has been undertaken
against Israel, which could also adversely impact our business.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Finally, many Israeli citizens
are obligated to perform several days, and in some cases more, of annual military reserve duty each year until they reach the age of 40
(or older, for reservists who are military officers or who have certain occupations) and, in the event of a military conflict, may be
called to active duty. In response to increases in terrorist activity, there have been periods of significant call-ups of military reservists.
It is possible that there will be military reserve duty call-ups in the future. Our operations could be disrupted by such call-ups, which
may include the call-up of members of our management. Such disruption could materially adversely affect our business, prospects, financial
condition and results of operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Competition for skilled technical and other
personnel in Israel is intense, and as a result we may fail to attract, recruit, retain and develop qualified employees, which could materially
and adversely impact our business, financial condition and results of operations.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We compete in a market marked
by rapidly changing technologies and an evolving competitive landscape. In order for us to successfully compete and grow, we must attract,
recruit, retain and develop personnel with requisite qualifications to provide expertise across the entire spectrum of our intellectual
capital and business needs.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal research and
development as well as significant elements of our general and administrative activities are conducted at our headquarters in Israel,
and we face significant competition for suitably skilled employees in Israel. While there has been intense competition for qualified human
resources in the Israeli high-tech industry historically, the industry experienced record growth and activity in 2021, both at the earlier
stages of venture capital and growth equity financings, and at the exit stage of initial public offerings and mergers and acquisitions.
This flurry of growth and activity has caused a sharp increase in job openings in both Israeli high-tech companies and Israeli research
and development centers of foreign companies, and intensification of competition between these employers to attract qualified employees
in Israel. As a result, the high-tech and bio-tech industry in Israel has experienced significant levels of employee attrition and is
currently facing a severe shortage of skilled human capital, including engineering, research and development, sales and customer support
personnel. Many of the companies with which we compete for qualified personnel have greater resources than we do, and we may not succeed
in recruiting additional experienced or professional personnel, retaining personnel or effectively replacing current personnel who may
depart with qualified or effective successors. Failure to retain or attract qualified personnel could have a material adverse effect on
our business, financial condition and results of operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Your rights and responsibilities as a holder
of our securities will be governed by Israeli law, which differs in some material respects from the rights and responsibilities of shareholders
of U.S. companies. </i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are incorporated under
Israeli law. The rights and responsibilities of holders of our Ordinary Shares are governed by our amended and restated articles of association
and the Companies Law. These rights and responsibilities differ in some respects from the rights and responsibilities of shareholders
in typical U.S. corporations. In particular, pursuant to the Companies Law, each shareholder of an Israeli company has to act in good
faith and in a customary manner in exercising his or her rights and fulfilling his or her obligations toward the Company and other shareholders
and to refrain from abusing his or her power in the Company, including, among other things, in voting at the general meeting of shareholders,
on amendments to a company&#8217;s articles of association, increases in a company&#8217;s authorized share capital, mergers and certain
transactions requiring shareholders&#8217; approval under the Companies Law. In addition, a controlling shareholder of an Israeli company
or a shareholder who knows that it possesses the power to determine the outcome of a shareholder vote or who has the power to appoint
or prevent the appointment of a director or officer in the Company, or has other powers toward the Company has a duty of fairness toward
the Company. However, Israeli law does not define the substance of this duty of fairness. There is little case law available to assist
in understanding the implications of these provisions that govern shareholder behavior.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We received Israeli government grants for
certain of our past research and development activities and programs, some of which we sold or are in the process of selling. The terms
of such grants may require us, in the future, to pay royalties and to satisfy specific conditions if and to the extent we receive future
royalties or in order to complete the sale of such grant based technologies and programs. We may be required to pay penalties in addition
to payment of the royalties.</i></b>&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
efforts with respect to some of our past activities, which was focused on developing an immunotherapeutic monoclonal antibody for the
treatment of Alzheimer&#8217;s disease, which we sold in March 2015, and our Anti-CD3 technology directed toward the treatment of inflammatory
and autoimmune diseases, which in part was returned and re-assigned to Hadasit Medical Research Services &amp; Development Ltd., or Hadasit,
and in part is still in the process of being sold, were financed in part through royalty-bearing grants from the Israeli Innovation Authority,
or the IIA. As of December 31, 2023, we had received the aggregate amount of approximately $1.1 million from the IIA for the development
of our abovementioned technologies. As of December 31, 2021, our contingent liabilities regarding IIA grants received by us were in an
aggregate amount of $1.2 million including interest. With respect to such grants, we are committed to pay certain royalties up to $1.2
million relating only to technologies in our possession and excluding any royalties for technologies that we sold to third parties. We
are required to comply with the requirements of the Israeli Encouragement of Industrial Research, Development and Technological Innovation
Law, 5744-1984, as amended, or the Innovation Law, and related regulations, or the Research Law, with respect to those past grants. When
a company develops know-how, technology or products using IIA grants, the terms of these grants and the Research Law restrict the transfer
or license of such know-how, and the transfer of manufacturing or manufacturing rights of such products, technologies or know-how outside
of Israel, without the prior approval of the IIA. Therefore, the discretionary approval of an IIA committee would be required for any
transfer or license to third parties inside or outside of Israel of know how or for the transfer outside of Israel of manufacturing or
manufacturing rights related to those aspects of such technologies. We may not receive those approvals. Furthermore, the IIA may impose
certain conditions on any arrangement under which it permits us to transfer technology or development.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Innovation Law and
the regulations thereunder, a recipient of IIA grants is required to return the grants by the payment of royalties of 3% to 6% on the
revenues generated from the sale of products (and related services) developed (in whole or in part) under an IIA program up to the total
amount of the grants received from IIA plus the relevant interest rate, if any. Under IIA regulations, grants received before June 30,
2017, bear the annual interest rate that applied at the time of the approval of the applicable IIA file which will apply to all of the
funding received under such IIA approval. Grants received from the IIA after June 30, 2017, bear an annual interest rate based on the
12-month Secured Overnight Financing Rate, or SOFR, or at an alternative rate published by the Bank of Israel plus 0.71513%. Grants approved
after January 1, 2024, shall bear the higher interest rate of (i) 12 months SOFR, plus 1%, or (ii) a fixed annual interest rate of 4%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transfer or license of
IIA-supported technology or know-how outside of Israel and the transfer of manufacturing of IIA-supported products, technology or know-how
outside of Israel may involve the payment of significant amounts, depending upon the value of the transferred or licensed technology or
know-how, our research and development expenses, the amount of IIA support, the time of completion of the IIA-supported research project
and other factors. These restrictions and requirements for payment may impair our ability to sell, license or otherwise transfer our technology
assets outside of Israel or to outsource or transfer development or manufacturing activities with respect to any product or technology
outside of Israel. Furthermore, the consideration available to our shareholders in a transaction involving the transfer outside of Israel
of technology or know-how developed with IIA funding (such as a merger or similar transaction) may be reduced by any amounts that we are
required to pay to the IIA.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>General Risk Factors</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>As a &#8220;foreign private issuer&#8221;
we are permitted to and follow certain home country corporate governance practices instead of otherwise applicable SEC requirements, which
may result in less protection than is accorded to investors under rules applicable to domestic U.S. issuers. </i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our status as a foreign
private issuer also exempts us from compliance with certain SEC laws and regulations, including the proxy rules and the short-swing
profits recapture rules. In addition, we will not be required under the Exchange Act to file current reports and financial
statements with the SEC as frequently or as promptly as U.S. domestic companies whose securities are registered under the Exchange
Act and we will generally be exempt from filing quarterly reports with the SEC. Also, although the Companies Law requires us to
disclose the annual compensation of our five most highly compensated senior officers on an individual basis, this disclosure is not
as extensive as that required of a U.S. domestic issuer. Furthermore, as a foreign private issuer, we are also not subject to the
requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act. These exemptions and leniencies will reduce the
frequency and scope of information and protections to which you are entitled as an investor.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>International expansion of our business
exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the
United States or Israel.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than our headquarters
and other operations which are located in Israel (as further described below), we currently have limited international operations, but
our business strategy incorporates potentially significant international expansion, particularly in anticipation of approval of our product
candidates. We plan to maintain sales representatives and conduct physician and patient association outreach activities, as well as clinical
trials, outside of the United States and Israel. Doing business internationally involves a number of risks, including but not limited
to:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure by us to obtain regulatory approvals for the use of our products in various countries;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional potentially relevant third-party patent rights;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities and difficulties in obtaining protection and enforcing our intellectual property;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties in staffing and managing foreign operations;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limits in our ability to penetrate international markets;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an outbreak of a contagious disease, such as coronavirus, which may cause us, third party vendors and manufacturers and/or customers to temporarily suspend our or their respective operations in the affected city or country;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain expenses including, among others, expenses for travel, translation and insurance; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, or FCPA, its books and records provisions or its anti-bribery provisions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these factors could
significantly harm our future international expansion and operations and, consequently, our results of operations.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to comply with the FCPA could subject
us to penalties and other adverse consequences.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the FCPA,
which generally prohibits companies, such as us, whose securities are listed in the United States, from paying, offering or authorizing
payment or offering of anything of value, directly or indirectly, to any foreign government official, political party or candidate for
public office for the purpose of influencing any act or decision of such foreign person in order to assist companies like us in obtaining
or retaining business. The FCPA also obligates companies like us, whose securities are listed in the United States, to comply with accounting
provisions requiring the companies to maintain books and records that accurately and fairly reflect all transactions of the companies,
including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international
operations. The U.S. Department of Justice and the SEC, which have responsibility for enforcement of the FCPA, both consider employees
of government-operated health care systems to be &#8220;foreign officials&#8221; for FCPA purposes. In addition, the U.S. Department of
Justice and the SEC are both engaged in a long-running FCPA compliance review of pharmaceutical companies. If our employees or agents
are found to have engaged in conduct that violates the FCPA, we would be held responsible and could suffer severe penalties and other
consequences, including adverse publicity and damage to our reputation.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cybersecurity issues, security breaches
and other disruptions could compromise our information, expose us to liability and harm our reputation and business.</i></b>&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business relies upon information
technology systems operated by us and by our third-party service providers. These systems may fail or experience operational disruption,
experience cybersecurity attacks, or be damaged by computer viruses and unauthorized access. In the ordinary course of our business we
collect and store sensitive data, including intellectual property, personal information and our proprietary business information. The
secure maintenance and transmission of this information is critical to our operations and business strategy. We rely on commercially available
systems, software, tools and domestically available monitoring to provide security for processing, transmitting and storing this sensitive
data.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Hackers may attempt to penetrate
our computer systems, and, if successful, misappropriate personal or confidential business information. In addition, an associate, contractor
or other third-party with whom we do business may attempt to circumvent our security measures in order to obtain such information, and
may purposefully or inadvertently cause a breach involving such information. While we continue to implement additional protective measures
to reduce the risk of and detect cyber incidents, cyber-attacks are becoming more sophisticated and frequent, and the techniques used
in such attacks change rapidly. If our third-party vendors fail to protect their information technology systems and our confidential and
proprietary information, we may be vulnerable to disruptions in service and unauthorized access to our confidential or proprietary information
and we could incur liability and reputational damage and the further development and commercialization of our product candidates could
be delayed. While we have not, to our knowledge, experienced any material IT system failures or cybersecurity attacks to date, we cannot
assure you that our data protection efforts and our investment in information technology will prevent significant breakdowns, data leakages,
breaches in our systems or those of our third-party vendors and other contractors and consultants, or other cyber incidents that could
have a material adverse effect upon our reputation, business, operations or financial condition. If such an event were to occur and cause
interruptions in our operations, it could result in a material disruption of our development programs, business operations, a breach of
sensitive personal information or a loss or corruption of critical data assets including trade secrets or other proprietary information.
For example, the loss of clinical trial data from future clinical trials could result in delays in our regulatory approval efforts and
significantly increase our costs to recover or reproduce the data. Such IT system failures, cybersecurity attacks or vulnerabilities to
our or our third-party vendors&#8217; information security programs or defenses could result in legal liability, reputational damage,
business interruption, and our competitive position could be harmed and the further development and commercialization of our products
or any future products could be delayed or disrupted. Moreover, containing and remediating any IT system failure, cybersecurity attack
or vulnerability may require significant investment of resources.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our information technology
networks and infrastructure may still be vulnerable to damage, disruptions or shutdowns due to attack by hackers or breaches, employee
error or malfeasance, power outages, computer viruses, telecommunication or utility failures, systems failures, natural disasters or other
catastrophic events. Furthermore, significant security breaches or disruptions of our internal information technology systems or those
of our third-party vendors and other contractors and consultants could result in the loss, misappropriation and/or unauthorized access,
use, or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property,
proprietary business information and personal information), which could result in financial, legal, business and reputational harm to
us., Any such compromise could disrupt our operations, damage our reputation and subject us to additional costs and liabilities, any of
which could adversely affect our business.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to securities litigation,
which is expensive and could divert management attention.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the past, companies that
have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the
target of this type of litigation in the future. Litigation of this type could result in substantial costs and diversion of management&#8217;s
attention and resources, which could seriously hurt our business. Any adverse determination in litigation could also subject us to significant
liabilities.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If securities or industry analysts do not
publish or cease publishing research or reports about us, our business or our market, or if they adversely change their recommendations
or publish negative reports regarding our business or our shares, the share price and trading volume of our securities could decline.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading market for
our Ordinary Shares will be influenced by the research and reports that industry or securities analysts may publish about us, our
business, our market or our competitors. We do not have any control over these analysts and we cannot provide any assurance that
analysts will cover us or provide favorable coverage. If any of the analysts who may cover us adversely change their recommendation
regarding our securities, or provide more favorable relative recommendations about our competitors, the price of our securities
would likely decline. If any analyst who may cover us were to cease coverage of our company or fail to regularly publish reports on
us, we could lose visibility in the financial markets, which in turn could cause the price or trading volume of our securities to
decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus contains forward-looking
statements that involve substantial risks and uncertainties. Forward-looking statements are often characterized by the use of forward-looking
terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221;
&#8220;believe,&#8221; &#8220;should,&#8221; &#8220;intend,&#8221; &#8220;project&#8221; or other similar words, but are not the only
way these statements are identified.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">These
forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements
that contain projections of results of operations or of financial condition, expected capital needs and expenses, statements relating
to the research, development, completion and use of our product candidates, and all statements (other than statements of historical facts)
that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Forward-looking
statements are not guarantees of future performance and are subject to risks and uncertainties. We have based these forward-looking statements
on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current
conditions, expected future developments and other factors they believe to be appropriate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Important
factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking
statements include, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to raise capital through the issuance of additional securities and ability to continue as a going concern;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">our ability to advance the development our pharmaceutical product candidates, including the anticipated starting and ending dates of our anticipated clinical trials</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">our assessment of the potential of our pharmaceutical product candidates to treat certain indications</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">our ability to successfully receive approvals from the FDA or other regulatory bodies, including approval to conduct clinical trials, the scope of those trials and the prospects for regulatory approval of, or other regulatory action with respect to our product candidates, including the regulatory pathway to be designated to our product candidates</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">the regulatory environment and changes in the health policies and regimes in the countries in which we operate, including the impact of any changes in regulation and legislation that could affect the pharmaceutical industry</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">our ability to commercialize our existing product candidates and future sales of our existing product candidates or any other future potential product candidates</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">our ability to meet our expectations regarding the commercial supply of our product candidates</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">our ability to integrate our new eCommerce operations business, which focuses on the sale of hemp-based products on the Amazon.com marketplace</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">;</span></td></tr>
</table><div>

</div><p style="margin: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to pursue a restructuring plan which involves transferring our pharmaceutical activities to a new wholly-owned subsidiary and listing it on a leading stock exchange;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">the overall global economic environment</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general market, political and economic conditions in the countries in which we operate including those related to recent unrest and actual or potential armed conflict in Israel and other parts of the Middle East, such as the recent attack by Hamas and other terrorist organizations from the Gaza Strip and Israel&#8217;s war against them and hostilities with Hezbollah on the northern border of Israel;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">projected capital expenditures and liquidity;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in our strategy;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">litigation; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">those factors discussed in
    the section &#8220;Risk Factors&#8221; beginning on page 7 of this prospectus.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">These
statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause
our or our industry&#8217;s actual results, levels of activity, performance or achievements to be materially different from those
anticipated by the forward-looking statements. We discuss many of these risks in this prospectus in greater detail under the heading
&#8220;Risk Factors&#8221; on page 7 of this prospectus<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
You should not rely upon forward-looking statements as predictions of future events.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Although
we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels
of activity, performance, or achievements. Except as required by law, we are under no duty to update or revise any of the forward-looking
statements, whether as a result of new information, future events or otherwise, after the date of this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>USE OF PROCEEDS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus relates to
our Ordinary Shares that may be offered and sold from time to time by YA, the Selling Shareholder. All of the Ordinary Shares offered
by the Selling Shareholder pursuant to this prospectus will be sold by the Selling Shareholder for its own account. We will not receive
any of the proceeds from these sales.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may receive up to $20.0&#160;million
aggregate gross proceeds under the SEPA from any sales we make to YA pursuant to the SEPA. To date, we have not sold any Ordinary Shares
(other than the Commitment Shares), pursuant to the SEPA. However, we are unable to estimate the actual amount of proceeds that we may
receive, as it will depend on the number of shares that we choose to sell, our ability to meet the conditions to purchases set forth in
SEPA, market conditions and the price of our Ordinary Shares, among other factors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to use any proceeds
that we receive under the SEPA for working capital, which includes research and development to advance our technology, general corporate
purposes, and pursuing strategic opportunities which include expanding our pipeline and investments in other companies that may not necessarily
be aligned with our current business strategy. We cannot provide any assurance that we will be able to carry out any potential investments
we may identify. As of the date of this prospectus, we cannot specify with certainty all of the particular uses, and the respective amounts
we may allocate to those uses, for any net proceeds we receive. Accordingly, we will retain broad discretion over the use of these proceeds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DIVIDEND POLICY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
have never declared or paid any cash dividends on our Ordinary Shares and do not anticipate paying any cash dividends in the foreseeable
future. Payment of cash dividends, if any, in the future will be at the discretion of our board of directors and will depend on then-existing
conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and
other factors our board of directors may deem relevant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Under
the Israeli Companies Law 5759-2999, or the Companies Law, we may declare and pay dividends only if, upon the determination of our board
of directors, there is no reasonable concern that the distribution will prevent us from being able to meet the terms of our existing and
foreseeable obligations as they become due. Under the Companies Law, the distribution amount is further limited to the greater of retained
earnings or earnings generated over the two most recent years legally available for distribution according to our then last reviewed or
audited financial statements, provided that the end of the period to which the financial statements relate is not more than six months
prior to the date of distribution. In the event that we do not meet such earnings criteria, we may seek the approval of the court in order
to distribute a dividend. The court may approve our request if it is convinced that there is no reasonable concern that the payment of
a dividend will prevent us from satisfying our existing and foreseeable obligations as they become due.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally, under the Companies
Law, the decision to distribute dividends and the amount to be distributed is made by a company&#8217;s board of directors. Our amended
and restated articles of association, provide that the board of directors may from time to time declare, and cause us to pay, such dividends
as may appear to it to be justified by our profits and that the board of directors has the authority to determine the time for payment
of such dividends and the record date for determining the shareholders entitled to receive such dividends, provided the date is not before
the date of the resolution to distribute the dividend. Declaration of dividends does not require shareholder approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to our amended and
restated articles of association, subject to the rights of holders of shares with limited or preferred rights, Ordinary Shares shall confer
upon the holders thereof equal rights to receive dividends and to participate in the distribution of our assets upon its winding-up, in
proportion to the amount of the number of issued and outstanding Ordinary Shares held by each shareholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Payment of dividends may
be subject to Israeli withholding taxes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CAPITALIZATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth our cash and cash
equivalents and our capitalization as of June 30, 2023:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
an actual basis;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on a pro forma basis to give effect to (i) the issuance of 5,525,000
Ordinary Shares and 975,000 pre-funded warrants to purchase up to 975,000 Ordinary Shares at a purchase price of $0.20 per share in a
public offering which closed on August 14, 2023; (ii) the issuance of units, consisting of (x) 1,930,108 pre-funded warrants to purchase
up to 1,930,108 Ordinary Shares and (y) 1,930,108 pre-funded warrants to purchase up to 1,930,108 Ordinary Shares at a purchase price
of $3.72 per unit in a private placement which closed on October 13, 2023;  (iii) our extension of a $1.4 million bridge loan to the
Target Company; and (iv) the issuance of 55,293 Commitment Shares; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">on a pro forma as adjusted basis to give effect to the offerings and
bridge loan described above and the additional issuance of 5,347,594&#160;Ordinary Shares under the SEPA, at an assumed public offering
price of $3.74&#160;per Ordinary Share, which is the last reported sales price on Nasdaq of our Ordinary Shares on February 26, 2024,
and after deducting estimated offering expenses, as if the sale of the Ordinary Shares had occurred on June 30, 2023.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information in this table should be read in
conjunction with and is qualified by reference to the financial information thereto and other financial information incorporated by reference
into this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-style: italic; border-bottom: Black 1.5pt solid">USD in thousands</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Actual</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pro
Forma</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Pro Forma As<br/> Adjusted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,081</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,964</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25,866</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9,892</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">15,422</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">35,328</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,114</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,114</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,114</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Shareholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Share capital and premium</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">58,989</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">64,432</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">84,334</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; padding-left: 0pt; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: -0.25in">Ordinary shares, no par value: 75,000,000 ordinary shares authorized
(actual, pro forma and as adjusted); 282,782 ordinary shares issued and outstanding (actual); 1,095,784 ordinary shares outstanding (pro
forma); and 6,443,378 ordinary shares outstanding (as adjusted).</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Reserve for share-based payment transactions</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,248</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,248</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,248</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Warrants</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,190</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$$5,190</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,190</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Foreign currency translation reserve</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">497</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">497</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">497</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Transactions with non-controlling interests</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">712</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">712</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">712</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Accumulated loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(66,449</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(66,449</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(66,449</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Non-controlling interests</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,682</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,682</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,682</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt; text-align: left">Total equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,778</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">12,312</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">32,214</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table above is based on 282,782 Ordinary Shares outstanding as
of June 30, 2023. This number excludes:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,049 Ordinary Shares issuable upon the exercise of options outstanding under our 2015 Share Option Plan, at a weighted average exercise price of $6.38 per share;</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,687 Ordinary Shares reserved for issuance and available for future grant under our 2015 Share Option Plan;</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">364,694
Ordinary Shares issuable upon the exercise of outstanding warrants, with exercise prices ranging from $68.38 to $637.0 per Ordinary Share;
and</span></p></td>
    </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    </tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify">3,359,468 Ordinary Shares issuable upon the exercise of outstanding pre-funded warrants, with exercise prices ranging from $0.001 to $0.026 per Ordinary Share.</td>
    </tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS OF<br/>
FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The following discussion
and analysis of our financial condition and results of operations should be read in conjunction with both our audited consolidated financial
statements as of and for the&#160;years ended December&#160;31, 2022, and 2021 and our unaudited interim consolidated financial statements
as of and for the six&#160;months ended June&#160;30, 2023, and 2022, and the accompanying notes thereto included elsewhere in this prospectus.
The discussion below contains forward-looking statements that are based upon our current expectations and are subject to uncertainty and
changes in circumstances. Actual results may differ materially from these expectations due to inaccurate assumptions and known or unknown
risks and uncertainties, including those identified in &#8220;Cautionary Note&#160;Regarding Forward-Looking Statements&#8221; and under
&#8220;Risk Factors&#8221; elsewhere in this prospectus. </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a specialty clinical-stage
pharmaceutical company. Our focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid therapies. With
this focus, we are currently engaged in the development of the following pharmaceutical compositions comprised of N-acylethanolamines
and cannabinoids, such as PEA and/or THC and/or CBD and/or other cannabinoid receptor agonists: SCI-110 for the treatment of Tourette
syndrome, or TS and Alzheimer&#8217;s disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of Autism
Spectrum Disorder, or ASD. We also have a majority-owned subsidiary whose business focuses on the sale of hemp-based products on the Amazon.com
marketplace.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SCI-110 is a proprietary combination
therapy candidate based on two components: (1) THC, which is the major cannabinoid molecule in the cannabis plant, and (2) CannAmide&#8482;,
a proprietary PEA formulation. PEA is an endogenous fatty acid amide that belongs to the class of nuclear factor agonists, which are molecules
that regulate the expression of genes. We believe that the combination of THC and PEA may induce a synergistic effect, which has strong
potential to treat various indications, including TS and Alzheimer&#8217;s disease and agitation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SCI-160 is a novel pharmaceutical
preparation containing a CB2 receptor agonist for the treatment of pain. This innovative CB2 receptor agonist was synthesized by the late
Raphael Mechoulam, Ph.D., who was professor of medicinal chemistry at the Hebrew University and a member of the SciSparc Scientific Advisory
Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">SCI-210
is a proprietary drug candidate based on two components: (1) CBD, and (2) CannAmide&#8482;. We believe that the combination of CBD and
PEA may also induce a sparing effect reaction, which has strong potential to treat various diseases such as ASD and SE.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the positive results
obtained in the phase IIa TS study conducted at Yale School of Medicine, we developed a regulatory dossier that was submitted to <span style="background-color: white">the
BfArM and MoH for our SCI-110 program for TS. Both agencies approved the program. We plan to submit this regulatory dossier to the FDA.
</span>In February 2021, we announced an agreement with The Israeli Medical Center for Alzheimer&#8217;s, to conduct a phase IIa clinical
trial to evaluate the potential safety, tolerability and efficacy of SCI-110 in patients with Alzheimer&#8217;s disease and agitation
using our proprietary cannabinoid-based technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">In
June 2023, we announced positive topline results from our Phase IIa clinical trial of SCI-110 in patients with Alzheimer&#8217;s
disease and agitation at the Israeli Medical Center for Alzheimer&#8217;s, suggesting that SCI-110 is safe and tolerable while
significantly improving agitation symptoms over time in the elderly population with Alzheimer&#8217;s disease. This Phase IIa
clinical trial was an open label study, which included 18 patients diagnosed with Alzheimer&#8217;s disease and agitation, to
evaluate the safety, tolerability and efficacy trends of twice daily oral administration of SCI-110. </span>Results showed that the
clinical trial met its primary endpoints of the number of drop-out subjects due to poor tolerability and the number of clinical
trial treatment-related adverse events, with no SCI-110 related safety issues observed and no dropouts from the clinical trial due
to trial medication. Specifically, SCI-110 did not cause delirium, oversedation, hypotension or falls. In addition, analysis of the
clinical trial results showed that the clinical trial also met its secondary end point of change from baseline to end of treatment
in agitation measured by the Cohen Mansfield Agitation Inventory where out of the fifteen patients treated with SCI-110 at least two
consecutive times during the clinical trial, thirteen of them at doses ranging between 7.5mg-12.5mg/day showed amelioration in
agitation with no need to use rescue medication to control agitation. Although not significant, in the exploratory endpoints, eleven
patients reduced food intake and showed feeding difficulties, as measured by the Edinburgh Feeding Evaluation in Dementia scale.
There was not an effect observed resulting from the treatment on cognition and sleep quality, as measured by the Mini Mental State
Examination and by the Sleep Order Inventory, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Comparison of the six months ended June 30,
2023 to the six months ended June 30, 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Operating Results</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2022, we began generating revenues through our subsidiary SciSparc Nutraceuticals, which owns the Wellution&#8482; brand. Total revenues
recognized in the six months ended June 30, 2023, amounted to $1,972 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have not generated
revenue from our drug development segment from the sale of any pharmaceutical product candidates, and we do not expect to generate significant
revenue in this business within the next year at least. As of June 30, 2023, we had an accumulated deficit of approximately $66 million.
Our operating activities are described below under &#8220;Operating Expenses.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Revenues</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the six months ended
June 30, 2023, we generated revenues in the amount of $1,972 thousand, compared to $0 revenue recorded during the six months ended June
30, 2022. Revenue in the six months ended June 30, 2023, was primarily attributable to our subsidiary SciSparc Nutraceuticals, which owns
the Wellution&#8482; brand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cost of goods sold </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost of goods sold comprises
mainly purchases of Wellution&#8482; brand products, Amazon transaction fees, storage and transportation costs to our warehouse. The cost
of goods sold in the six months ended June 30, 2023 amounted to $1,267 thousand, compared to $0 cost of goods recorded during the six
months ended June 30, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Operating Expenses (in thousands of dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our
current operating expenses consist of two components &#8211; research and development expenses, and general and administrative expenses,
including sales and marketing expenses through our subsidiary SciSparc Nutraceuticals, which owns the Wellution&#8482; brand.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Expenses</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
research and development expenses consist primarily of salaries and related personnel expenses, regulatory and other expenses and clinical
studies expenses.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
following table discloses the breakdown of research and development expenses:&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six month period ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(in thousands of USD)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Wages and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">202</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">243</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Share-based payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">224</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Clinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">145</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">106</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Research and preclinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">410</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Chemistry and formulations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Regulatory and other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">366</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">373</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">781</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,474</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General and Administrative Expenses&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">General
and administrative expenses consist primarily of salaries, share-based compensation expense, professional service fees for accounting,
legal, bookkeeping, facilities and other general and administrative expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table discloses
the breakdown of general and administrative expenses:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six month period ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(in thousands of USD)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Wages and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">217</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">245</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">431</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Professional and directors&#8217; fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,366</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,292</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Investor relations and business expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">310</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,193</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Office maintenance, rent and other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Regulatory expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">113</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Wellution operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">366</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Business development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">38</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,494</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,339</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Expenses, net&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
expenses for the six months ended June 30, 2023, amounted to $781 thousand, representing a decrease of $693 thousand, or 47%, compared
to $1,474 thousand for the six months ended June 30, 2022. The decrease was primarily attributable to a decrease of $201 thousand in share-based
expenses, a decrease of $365 thousand in research and preclinical studies, and a decrease of $118 thousand in chemistry and formulations
expenses.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General and Administrative Expenses&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
general and administrative expenses totaled $2,494 thousand for the six months ended June 30, 2023, a decrease of $845 thousand, or 25%,
compared to $3,339 thousand for the six months ended June 30, 2022. The decrease was primarily attributable to a decrease of $883 thousand
in investor relations and business expenses, and a decrease of $386 thousand in share-based expenses, offset in part by an increase of
$366 thousand in operating expenses of the Wellution&#8482; brand consisting primarily of advertising expenses, promotional rebates, and
other fees charged by Amazon.&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sales and marketing&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The sales and marketing expenses
comprises mainly of advertising and promotional rebates on Amazon. The sales and marketing expenses in the six months ended June 30, 2023
amounted to $397 thousand, compared to $0 sales and marketing expenses recorded during the six months ended June 30, 2022. This increase
was primarily attributable to our subsidiary SciSparc Nutraceuticals, which owns the Wellution&#8482; brand, and its sales and marketing
expenses.<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operating Loss&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the foregoing,
our operating loss for the six months ended June 30, 2023, was $2,967 thousand, compared to an operating loss of $3,339 thousand for the
six months ended June 30, 2022, a decrease of $372 thousand, or 13%.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Finance Expense and Income</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Finance
expenses and income consist of revaluation of debt instruments presented at fair value, related issuance expenses of debt instruments
and bank fees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
recognized finance income, net for the six months ended June 30, 2023, of $147 thousand, representing a change of $1,052 thousand compared
to finance expenses of $905 thousand for the six months ended June 30, 2022. The increase was primarily due to a change in the fair value
of the warrants we issued in June 2022, offset by impairment of financial assets. Changes in the fair value of the June 2022 warrants
are mainly due &#8211; and correlate &#8211; to the changes in the market price of our shares.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Total Comprehensive Loss&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
total comprehensive loss for the six months ended June 30, 2023, was $2.93 million, representing a decrease of $2.83 million, or 49%,
compared to $5.76 million for the six months ended June 30, 2022.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Comparison of the
year ended December 31, 2022 to the year ended December 31, 2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Operating Results</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2022, we have started generating revenues through our subsidiary SciSparc Nutraceuticals, which owns the Wellution&#8482; brand. Total
revenues recognized in the year ended December 31, 2022, amounted to $1,347 thousand.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Operating Results</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have not generated
revenue from our drug development segment from the sale of any pharmaceutical product candidates, and we do not expect to generate significant
revenue in this business within the next year at least. As of December 31, 2022, we had an accumulated deficit of approximately $64 million.
Our operating activities are described below under &#8220;Operating Expenses.&#8221;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Revenues&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since the acquisition of the
Wellution&#8482; brand, we have generated revenues in the amount of $1,347 thousand.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cost of goods sold </b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost of goods sold comprises
mainly purchase of products and transportation costs to our warehouse. Since the acquisition of the Wellution&#8482; brand, the cost of
goods sold amounted to $322 thousand.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Operating Expenses (in thousands of dollars)</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current operating expenses
consist of two components - research and development expenses and general and administrative expenses.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Expenses, net</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
expenses consist primarily of salaries and related personnel expenses, research and preclinical studies, chemistry and formulations, regulatory,
professional and other related research and development expenses.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table discloses
the breakdown of research and development expenses:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><i>USD in thousands</i></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Wages and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">436</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">357</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Share-based payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">264</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Clinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">369</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">172</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and preclinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">703</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Chemistry and formulations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">281</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">335</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Regulatory, professional and other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">750</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">934</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,803</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,990</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that our research
and development expenses will materially increase as we plan to continue clinical trials and develop new products.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>General and Administrative Expenses</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses consist primarily of salaries, professional service fees for accounting, legal, bookkeeping, investor relations, Amazon transaction
fees, advertising and promotion on Amazon, regulatory and other general and administrative expenses.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table discloses
the breakdown of general and administrative expenses:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><i>USD in thousands</i></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Wages and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">437</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">256</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">633</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional and directors&#8217; fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,499</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,417</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investor relations and business expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,486</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">784</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office maintenance, rent and other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">224</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">135</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Wellution operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">907</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Regulatory expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">162</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Business development expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">161</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,509</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,778</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Results of Operations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><i>USD in thousands</i></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,347</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cost of goods sold</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">322</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,803</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,990</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,509</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,778</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,287</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,768</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Company&#8217;s share of losses of company accounted for at equity, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Financial expense (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,818</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,592</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,789</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss attributable to holders of Ordinary Shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,592</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,789</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Research and Development Expenses </i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
expenses for the year ended December 31, 2022, amounted to $2,803, representing an increase of $813, or 41%, compared to $1,990 for the
year ended December 31, 2021. The increase was primarily attributable to an increase of $972 in share-based compensation, clinical studies,
research and pre-clinical studies, reflecting the acceleration of clinical studies that were initiated in the previous year.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>General and Administrative Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;Our general and administrative expenses totaled $6,509 for the
year ended December 31, 2022, representing an increase of $2,731, or 72%, compared to $3,778 for the year ended December 31, 2021. The
increase resulted primarily from the inclusion of results of our new subsidiary Scisparc Nutraceuticals, which amounted to $907, and comprised
mainly by Amazon transaction fees, advertising, and promotion on Amazon. Another main reason for the increase is the increase of $703
in investor relations and business expenses, an increase of $617 in share-based compensation, and an increase of $181 in wages and related
expenses.<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Operating Loss</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operating loss for the
year ended December 31, 2022, was $8,287, representing an increase of $2,519, or 44%, as compared to an operating loss of $5,768 for the
year ended December 31, 2021.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Financial Expense and Income</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial expense and income
consist of revaluations of instruments measured at fair value, exchange rate differences, bank fees, loans interest and other transactional
costs.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognized financial income
in the amount of $7,832 for the year ended December 31, 2022, as compared to no financial income for the year ended December 31, 2021.
The financial income recognized in 2022 was primarily due to changes in the fair value of warrants.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognized financial expenses
for the year ended December 31, 2022, of $2,014, representing an increase of $41,993, as compared to financial expense of $21 for the
year ended December 31, 2021. The financial expenses recognized in 2022 are primarily due to issuance expenses of shares and warrants
in the amount of $1,204, and losses from the change in the fair value of our investment in securities in the amount of $770.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Total Comprehensive Loss</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our total comprehensive loss
for the year ended December 31, 2022, was $2,592, representing a decrease of $3,197, or 55%, as compared to $5,789 for the year ended
December 31, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity and Capital Resources</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Comparison of the six months ended June 30,
2023 to the six months ended June 30, 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of June 30, 2023, we had
$2,125,000 in cash, including short term restricted deposits.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below presents our
cash flows:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(in thousands of USD)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Net cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(3,201</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(2,188</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,071</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(708</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,779</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,966</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Comparison of the
year ended December 31, 2022 to the year ended December 31, 2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2022, we
had $3,634,000 in cash, including short term restricted deposits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below presents our
cash flows for the periods indicated:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><i>USD in thousands</i></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(7,917</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(5,061</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,084</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(70</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,060</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net increase in cash and cash equivalents<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,301</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,929</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022 and 2021, we did not have any cash equivalents.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operating Activities&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities was $3,233 thousand for the six months ended June 30, 2023, compared with net cash used in operating activities of $2,188 thousand
for the six months ended June 30, 2022. The increase is primarily due to decreases in adjustments to the profit or loss item of finance
expenses relating to the change in fair value of warrants of $1,023 thousand, offset in part by losses from remeasurement of investment
in financial assets of $855 thousand, and in adjustments to the working capital item of change in other accounts receivable of $684 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities was $7,917 during 2022 in comparison to $5,061 during 2021. The increase of $2,856 was primarily attributable to an increase
in research and development and general and administrative expenses.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Investing Activities&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in investing
activities was $1,071 thousand for the six months ended June 30, 2023, compared with $708 thousand cash used in investing activities
for the six months ended June 30, 2022. Net cash used in investing activities was due to our investment in MitoCareX Bio Ltd. in the
amount of $400 thousand, and our investment in financial assets of $687 thousand.<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in investing
activities was $7,084 during 2022 in comparison to $70 during 2021. The increase of $7,014 was primarily attributable to a purchase of
the Wellution brand in the amount of $4,861, and investment in MitoCareX in the amount of $700, and an investment in securities of Clearmind
in the amount to $1,500.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in investing
activities of $70 during the year ended December 31, 2021, primarily reflected the investment in restricted bank deposits and purchase
of fixed assets.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Financing Activities&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing
activities of $2,811 thousand in the six months ended June 30, 2023, primarily from the sale of a minority interest in a subsidiary pursuant
to the Wellution Sales Agreement in the amount of $2,886 thousand, offset by issuance expenses in respect of a shelf prospectus in the
amount of $50 thousand and by repayment of lease liability in the amount of $26 thousand. Net cash provided by financing activities of
$8.97 million in the six months ended June 30, 2022, consisted mainly of $9.0 million of net proceeds from the issuance of share capital
and warrants, offset by repayment of lease liability in the amount of $39 thousand.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in investing
activities was $7,084 during 2022 in comparison to $70 during 2021. The increase of $7,014 was primarily attributable to a purchase of
the Wellution brand in the amount of $4,861, and investment in MitoCareX in the amount of $700, and an investment in securities of Clearmind
in the amount to $1,500.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in investing
activities of $70 during the year ended December 31, 2021, primarily reflected the investment in restricted bank deposits and purchase
of fixed assets.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>March 2021 Securities Purchase Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 1, 2021, we entered into a definitive agreement with several
accredited and institutional investors providing for the issuance of an aggregate of 1,152,628 units, as follows: (a) 916,316 units, at
a price of $7.07 per unit, consisting of (i) one American Depositary Share, or ADS, and (ii) a Series A Warrant to purchase an equal number
of units purchased and a Series B Warrant to purchase half the number of units, and (b) 236,312 pre-funded units, at a price of $7.069
per unit, consisting of (i) one pre-funded warrant to purchase one ADS and (ii) a Series A Warrant to purchase an equal number of units
purchased and a Series B Warrant to purchase half the number of units. The pre-funded warrants have an exercise price of $0.001 per full
ADS and will be exercisable at any time after the date of issuance upon payment of the exercise price. The Series A Warrants have an exercise
price of $7.07, subject to adjustments therein. The Series B Warrants have an exercise price equal to $10.60, subject to adjustments therein.
The Series A Warrants and the Series B Warrants are exercisable six months from the date of issuance and have a term of exercise equal
to five years from the initial exercise date. Following the mandatory cancellation of our ADSs and exchange of ADSs for Ordinary Shares
in August 2021, the aforementioned Series A Warrants, Series B Warrants and pre-funded warrants became securities that could be exercised
for Ordinary Shares. As of February 26, 2024, there were 43,947 Series A Warrants, 22,166 Series B Warrants and 698 pre-funded warrants
outstanding. Aegis Capital Corp. acted as exclusive placement agent in connection with this offering and received a transaction fee equal
to $0.4949 per unit and $0.4949 per pre-funded unit sold at the closing. The offering closed on March 4, 2021, and resulted in gross proceeds
to us of approximately $8.15 million.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>June 2022 Securities Purchase Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 27, 2022, we
announced the entrance into a securities purchase agreement, which closed on June 1, 2022, with a single healthcare-focused
institutional investor for aggregate gross proceeds of approximately $10.0 million, before deducting fees to the placement agent and
other offering expenses payable by us, or the 2022 Private Placement. In connection with the 2022 Private Placement, we issued
3,546,100 units and pre-funded units at a purchase price of $2.82 per unit (or $0.001 less per pre-funded unit). Each unit and
pre-funded unit consisted of one Ordinary Share (or Ordinary Share equivalent) and two non-tradable warrants each exercisable for
one Ordinary Share for $2.57 (for a total of 7,092,200 shares underlying the warrants). The warrants have a term of five years from
the issuance date. No actual units were issued in the 2022 Private Placement. Aegis Capital Corp. was the exclusive placement agent
in connection with the 2022 Private Placement.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>June 2022 Letter Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 30, 2022, we and the
institutional investor entered into a letter agreement and agreed, among other things, to amend: (i) the warrants to: (a) extend the termination
date for exercising the warrants from June 1, 2027 to June 1, 2029; and (b) amend the exercise price from $2.57 per share to $2.63 per
share; and (ii) the securities purchase agreement to reflect a new purchase price of $2.88 per unit (or $0.001 less per pre-funded unit),
resulting in additional gross proceeds to us of $212,766. On August 19, 2022, 3,211,100 of the pre-funded warrants were fully exercised
at a nominal exercise price of $0.001 per share, which resulted in an issuance of 3,211,100 Ordinary Shares.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Wellution Acquisition Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 14, 2022, we
entered into the Wellution Acquisition Agreement, pursuant to which we acquired the Wellution&#8482; brand, or the Brand. We established
SciSparc Nutraceuticals, a wholly owned subsidiary, to hold the new assets, which is also a party to the Wellution Acquisition Agreement.&#160;On
September 30, 2022, we closed the acquisition of the Brand and paid $4.59 million for it. In addition, at the closing we issued the M.R.M
Warrant to M.R.M (each as defined below), to purchase up to 82,418 of our Ordinary Shares.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Wellution Sales Agreement</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
February 23, 2023, we entered into the Wellution Sales Agreement with Jeffs&#8217; Brands Holdings Inc., or Jeffs&#8217; Holdings and
Jeffs&#8217; Brands Ltd., or Jeffs&#8217; Brands. Pursuant to the Wellution Sales Agreement, closing, on March 28, 2023, Jeffs&#8217;
Brands acquired from us 57 shares of common stock of SciSparc Nutraceuticals, which is approximately a 49% interest in our wholly owned
subsidiary, SciSparc Nutraceuticals, which owns the Wellution<sup>TM</sup> brand, for a consideration of $2.5 million in cash, and additional
deferred cash payments of approximately $489 thousand.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
connection with the closing, we and Jeffs&#8217; Brands undertook a mutual share exchange in the amount of approximately $288 thousand
of ordinary shares from each of us and Jeffs&#8217; Brands. The number of shares in the share exchange was calculated based on the average
closing price of the relevant company&#8217;s shares for 30 consecutive trading days ending on the third trading day immediately prior
to the closing. Accordingly, we acquired 247,415 ordinary shares of Jeffs&#8217; Brands and Jeffs&#8217; Brands acquired 13,858 Ordinary
Shares from us having an aggregate value of $288 thousand.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Following
the closing of the transaction, which included an equity conversion of the financing amounts of approximately $700 thousand previously
provided by us to SciSparc Nutraceuticals for working capital, into shares of common stock at the price per share of the Wellution Sales
Agreement and the release of the Holdback Shares, we hold approximately 51% of SciSparc Nutraceuticals.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>At-The-Market Issuance
Sales Agreement </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in">On
May 16, 2023, we entered into an At-the-Market Issuance Sales Agreement with Aegis Capital Corp., or the ATM Agreement, pursuant to which
we may offer and sell up to $1,729,964 of our Ordinary Shares. Between May 16, 2023 and August, 9, 2023, we sold approximately $4,779
of Ordinary Shares. On August 9, 2023, the ATM Agreement was terminated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>AutoMax SPA</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
June 25, 2023, we entered into a securities purchase agreement with AutoMax Motors Ltd., or AutoMax, pursuant to which, at the closing
and upon the terms and conditions set forth in the securities purchase agreement with AutoMax, we invested NIS 2,500 thousand in cash,
in exchange for ordinary shares of AutoMax based on a price per share of NIS 0.5. Following the closing, we hold approximately 5.6% of
the issued and outstanding share capital of AutoMax.<i>&#160;</i></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Underwritten Public
Offering</i><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">On
August 14, 2023, we closed an underwritten public offering, or the Public Offering, of 212,500 Ordinary Shares, at a purchase price of
$5.20 per Ordinary Share and pre-funded warrants to purchase up to 37,500 Ordinary Shares at a purchase price of $5.174 per pre-funded
warrant, for aggregate gross proceeds of approximately $1.3 million, pursuant to an underwriting agreement between us and Aegis, or the
Underwriter, on August 10, 2023. Pursuant to the terms of the Underwriting Agreement, we also granted the Underwriter a 45-day option
to purchase up to an additional 37,500 Ordinary Shares solely to cover over-allotments, if any, at the Public Offering share price less
underwriting discounts and commissions.</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
pre-funded warrants were exercisable immediately upon issuance and have an exercise price of $0.026 per share. Following the Public Offering
and as of February 26, 2024, we issued 25,000 Ordinary Shares in respect of the exercise of 25,000 pre-funded warrants.</span>&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>October 2023 Private Placement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 12, 2023, we closed
a private placement transaction, or the 2023 Private Placement, pursuant to a securities purchase agreement and a registration rights
agreement with an institutional investor for aggregate gross proceeds of approximately $5 million (representing a 30% original issue discount
to the aggregate purchase price of $7,180,000), before deducting fees to Aegis, the placement agent and other expenses payable by us in
connection with the transaction. We sold units to the investors at a purchase price of $3.72 per unit, consisting of 1,930,108 pre-funded
Ordinary Share purchase warrants to purchase up to 1,930,108 Ordinary Shares, and an additional accompanying pre-funded warrant to purchase
up to 1,930,108 Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
pre-funded warrants were exercisable immediately upon issuance and have an exercise price of $0.001 per share. Following the transaction
and as of February 26, 2024, we have issued 466,218 Ordinary Shares in respect of the exercise of 466,218 pre-funded warrants.</span>&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>January 2024 Standby Equity Purchase Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 21, 2024, we entered
into the SEPA with YA. Pursuant to the SEPA, we will be able to sell up to $20.0 million of our Ordinary Shares, at our sole option, any
time during the three-year period following the execution date of the SEPA. Of the Commitment Amount, to date we have not sold any Ordinary
Shares (other than the Commitment Shares). Pursuant to the terms of the SEPA, any Ordinary Shares sold to YA will be priced at 97% of
the market price, which is defined as the lowest daily volume weighted average price of the Ordinary Shares during the three consecutive
trading days commencing on the trading day immediately following our delivery of an advance notice to YA. Any sale of Ordinary Shares
pursuant to the SEPA is subject to certain limitations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Share Buyback Program </b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 6, 2022, we announced
that our board of directors authorized a $1 million buyback program for our Ordinary Shares. However, as of the date of this prospectus
we have not proceeded with the buyback program and do not currently intend to do so. If we wish to trigger the buyback program in the
future, we would be required to file a motion seeking a court approval in Israel for the buyback program and the effectiveness of the
buyback plan, if formally approved, will be contingent upon such approval.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Current Outlook&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have financed our operations
to date primarily through proceeds from sales of our Ordinary Shares and ADSs, as well as exercises of warrants and options to purchase
Ordinary Shares or ADSs, as the case may be. We have incurred losses and generated negative cash flows from operations since August 2004.
Since August 2004, we have not generated any revenue from the sale of our pharmaceutical product candidates and we do not expect to generate
revenues from sale of our pharmaceutical product candidates in the next few years.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of June 30, 2023, our cash,
including short-term bank deposits, were $2,125 thousand.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
believe that our existing cash resources will not be sufficient to finance our operating activities in the foreseeable future, and we
expect that we will require substantial additional capital to complete the development of, and to commercialize, our product candidates.
If we do seek to raise additional capital, there can be no guarantee or assurance that we will be successful in raising such additional
capital or that the term of such capital raise will be on terms favorable to us.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2022, we purchased
Wellution&#8482;, a business and brand which sells hemp-based products on the Amazon.com marketplace.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 25, 2023, we announced
that our board of directors resolved to pursue a Restructuring Plan which may involve transferring our pharmaceutical activities to NewCo.
As part of or independent to the Restructuring Plan, we intend to examine the possibility of listing NewCo on a leading stock exchange,
while maintaining our controlling interest in NewCo such that we will continue to control our current business activities. We also intend
to explore other potential new opportunities, activities and investments in a variety of sectors.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Restructuring
Plan, on November 22, 2023, we announced the signing of a non-binding letter of intent, or LOI, to acquire a leading vehicle importer
company in Israel, or the Target Company, with certain new negotiated terms as announced on December 7, 2023. According to the new negotiated
terms, we will acquire 100% of the Target Company and establish a new wholly-owned Israeli subsidiary, which would in turn merge with
and into the Target Company, or the Acquisition. Following the Acquisition, if completed, it is contemplated that the our shareholders
will hold approximately 50.01% of the share capital of the post-closing combined company.&#160;On January 19, 2024, we announced, that
we had entered into a bridge loan agreement as lender, with the Target Company, pursuant to which the Target Company received a bridge
loan from us in the amount of $1.4 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any Restructuring Plan and
possible listing of NewCo on a stock exchange may be subject to, among other things, market conditions, tax or other business analyses,
regulatory approvals, receipt of any necessary consents, final approvals from our board of directors and shareholders and satisfaction
of any closing conditions to effectuate such corporate Restructuring Plan and listing of NewCo. There can be no assurance regarding the
ultimate timing of the Restructuring Plan and listing of NewCo or that they will be completed at all.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our operating
plans may change as a result of many factors that may currently be unknown to us, and we may need to seek additional financing sooner
than planned. Our efforts to commercialize our proprietary PEA oral tablets CannAmide&#8482; may not lead to any revenue or revenue at
the level at which we are expecting. Our future capital requirements will depend on many factors, including:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the progress and costs of our research and development activities;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of manufacturing our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential costs of contracting with third parties to provide marketing and distribution services for us or for building such capacities internally; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the magnitude of our general and administrative expenses.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until we can generate significant
recurring revenues, we expect to satisfy our future cash needs through debt and/or equity financings. We cannot be certain that additional
funding will be available to us on acceptable terms, if at all. This raises substantial doubts about our ability to continue as a going
concern. If funds are not available, we may be required to delay, reduce the scope of, or eliminate research or development plans for,
or commercialization efforts with respect to our product candidates.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and development, patents and licenses,
etc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A comprehensive discussion
of our research and development, patents and licenses, etc., is included in &#8220;Item 5. Operating and Financial Review and Prospects
- Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Trend information</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The COVID-19 pandemic has
impacted companies in Israel and around the world, and as its trajectory remains highly uncertain, and although the impact of COVID-19
has lessened in Israel recently, we cannot predict the duration and severity of the outbreak and its containment measures for our Company.
Further, we cannot predict impacts, trends and uncertainties involving the pandemic&#8217;s effects on economic activity, the size of
our labor force, and the extent to which our income, profitability, liquidity, or capital resources may be materially and adversely affected.
See also &#8220;Risk Factors-Risks Related to Our Pharmaceutical Business Operations-Widespread public health pandemics, including COVID-19,
could have a material and adverse effect on our business, financial condition and results of operations&#8221; in this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Critical Accounting Policies</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
preparation of financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, obligations
and expenses during the reporting periods. A comprehensive discussion of our critical accounting policies is included in &#8220;Item 5.
Operating and Financial Review and Prospects - Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;
in our Annual Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="background-color: white"><b>BUSINESS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>History and Development of the Company</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our legal and commercial name
is SciSparc Ltd. We were incorporated in the State of Israel on August 23, 2004, and are subject to the Companies Law. Our registered
office and principal place of business is located at 20 Raul Wallenberg St., Tower A, 2<sup>nd</sup> Floor, Tel Aviv 6971916, Israel.
Our telephone number in Israel is: +972-73-3447180.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our website address is http://www.scisparc.com.
The information contained on our website or available through our website is not incorporated by reference into and should not be considered
a part of this prospectus, and the reference to our website in this prospectus is an inactive textual reference only. The SEC also maintains
an Internet website that contains reports, proxy and information statements, and other information regarding issuers that file electronically
with the SEC. Our filings with the SEC will also be available to the public through the SEC&#8217;s website at www.sec.gov.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a foreign private issuer
as defined by the rules under the Securities Act and the Exchange Act. Our status as a foreign private issuer also exempts us from compliance
with certain laws and regulations of the SEC, including the proxy rules and the short-swing profits recapture rules. In addition, we will
not be required to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly as U.S.
domestic companies registered under the Exchange Act.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our capital expenditures for
2022, 2021, 2020 and the six months ended June 30, 2023 amounted to $9,200, $35,000, $0 and $0 respectively. These expenditures were primarily
for purchases of fixed assets. Our purchases of fixed assets primarily include, computers, and equipment used for the development of our
products, and we financed these expenditures primarily from cash on hand.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Business Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview </b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a specialty clinical-stage
pharmaceutical company. Our focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid therapies. With
this focus, we are currently engaged in the following development programs based on THC and/or CBD and/or other CBR agonists: SCI-110
for the treatment of TS and for the treatment of Alzheimer&#8217;s disease and agitation; SCI-160 for the treatment of pain; and SCI-210
for the treatment of ASD. We also have a majority-owned subsidiary whose business focuses on the sale of hemp seeds oil-based products
and others on the Amazon.com marketplace.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SCI-110 is a proprietary drug
candidate based on two components: (1) THC, which is the major cannabinoid molecule in the cannabis plant, and (2) CannAmide&#8482;, a
proprietary PEA, formulation. PEA is an endogenous fatty acid amide that belongs to the class of nuclear factor agonists, which are molecules
that regulate the expression of genes. We believe that the combination of THC and PEA may induce a reaction known as the &#8220;sparing
effect,&#8221; which has strong potential to treat various diseases of the central nervous system such as TS and Alzheimer&#8217;s disease
and agitation.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SCI-210 is a proprietary drug
candidate based on two components: (1) CBD, and (2) CannAmide&#8482;. We believe that the combination of CBD and PEA may also induce a
sparing effect reaction, which has strong potential to treat various diseases such as ASD and SE.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SCI-160 is a novel pharmaceutical
preparation containing a CB2 receptor, agonist for the treatment of pain. This innovative CB2 receptor agonist was synthesized by the
late Raphael Mechoulam,, who was professor of medicinal chemistry at the Hebrew University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that modulating
CB2 receptor activity by selective CB2 receptor agonists holds unique therapeutic potential for addressing pain conditions.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the positive results
obtained in a phase IIa TS study conducted at Yale School of Medicine, we developed a regulatory dossier that was submitted to <span style="background-color: white">BfArM,
and MoH for our SCI-110 program for TS. Both agencies approved the program. We plan to submit this regulatory dossier to the FDA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt; background-color: white">In
February 2021, we announced an agreement with The Israeli Medical Center for Alzheimer&#8217;s, to conduct a phase IIa clinical trial
to evaluate the safety, tolerability and efficacy of SCI-110 in patients with Alzheimer&#8217;s disease and agitation using our proprietary
cannabinoid-based technology. In December 2021, The Israeli Medical Center for Alzheimer&#8217;s recruited the first patient to participate
in the phase IIa clinical trial. <span style="background-color: white">In June 2023, we announced positive topline results from our Phase
IIa clinical trial of SCI-110 in patients with Alzheimer&#8217;s disease and agitation at the Israeli Medical Center for Alzheimer&#8217;s,
suggesting that SCI-110 is safe and tolerable while significantly improving agitation symptoms over time in the elderly population with
Alzheimer&#8217;s disease. This Phase IIa clinical trial was an open label study, which included 18 patients diagnosed with Alzheimer&#8217;s
disease and agitation, to evaluate the safety, tolerability and efficacy trends of twice daily oral administration of SCI-110. </span>Results
showed that the clinical trial met its primary endpoints of the number of drop-out subjects due to poor tolerability and the number of
clinical trial treatment-related adverse events, with no SCI-110 related safety issues observed and no dropouts from the clinical trial
due to clinical trial medication. Specifically, SCI-110 did not cause delirium, oversedation, hypotension or falls. In addition, analysis
of the clinical trial results showed that the clinical trial also met its secondary end point of change from baseline to end of treatment
in agitation measured by the Cohen Mansfield Agitation Inventory where out of the fifteen patients treated with SCI-110 at least two consecutive
times during the trial, thirteen of them at doses ranging between 7.5mg-12.5mg/day showed amelioration in agitation with no need to use
rescue medication to control agitation. Although not significant, in the exploratory endpoints, eleven patients reduced food intake and
showed feeding difficulties, as measured by the Edinburgh Feeding Evaluation in Dementia scale. There was not an effect observed resulting
from the treatment on cognition and sleep quality, as measured by the Mini Mental State Examination and by the Sleep Order Inventory,
respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 8, 2022, we announced
that we have received approval from the MoH and <span style="background-color: white">Ethics Committee of Soroka Medical Center </span>to
conduct our clinical trial for SCI-210 in patients suffering ASD. Our regulatory request to carry out this clinical trial was granted
by the IMCA on July 10, 2023. On January 9, 2023, we signed an agreement with Soroka Medical Center to conduct the clinical trial pediatric
patients suffering from ASD. This randomized, double blind placebo-controlled clinical trial to evaluate the potential efficacy, safety
and tolerability of SCI-210 in treating patients with ASD was initiated in July 2023. We initiated patient enrollment for the clinical
trial in January 2024. In February 2024, we announced that we had successfully completed the manufacturing of the SCI-210 treatment for
the clinical trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For our proprietary SCI-160,
in August 2021, we announced positive top-line results for a controlled pre-clinical trial on neuropathic and post-operative pain. The
study &#8220;An evaluation of SCI-160 on neuropathic pain in the rat spared nerve injury (SNI) model and post-surgical pain in the rat
hind paw incision model,&#8221; was designed to help assess the potential of SCI-160. Key findings from the pre-clinical trial are that
SCI-160 significantly alleviates pain up to six hours after injection as compared with vehicle-treated animals. Daily SCI-160 injections
significantly alleviate subject pain from mechanical stimuli as compared with vehicle-treated animals, for up to seven days after surgery.
Daily injections of SCI-160 significantly alleviate pain in a hind paw incision model of post-surgical pain up to four days post surgery
as compared with vehicle treated animals, and SCI-160 analgesic effects are prolonged in the presence of PEA. Collectively, the results
indicated that treatment with SCI-160 significantly alleviates both chronic and acute pain. Based on the positive results, we have decided
to continue the development of SCI-160 towards a first in-human clinical study.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Pharmaceutical Drug Development Programs</b>&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">SCI-110 - TS, Alzheimer&#8217;s
disease and agitation</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our pharmaceutical
product candidate, SCI-110, offers a safe and potentially effective solution for a variety of medical concerns. Despite being in its
early phases of clinical testing, the application of SCI-110 has extended into several treatments, including TS and Alzheimer&#8217;s
disease and agitation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>TS</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TS is a neuropsychiatric disorder,
characterized by physical (motor) tics and vocal (phonic) tics. Motor tics generally precede the development of phonic tics in TS, and
the onset of simple tics usually predates that of complex tics. TS ranges from mild symptoms to loud noises and forceful movements that
can result in self-injury (e.g. punching oneself in the face, repeating other people&#8217;s words or involuntary swearing). Many with
TS experience additional neurobehavioral problems and comorbidities including inattention, hyperactivity and impulsivity, anger control
problems, sleep difficulties, and obsessive-compulsive symptoms. Pharmacotherapy is used when symptoms are more severe and interfere with
the ability to function. Furthermore, according to the CDC, in most cases, the prevalence of tics decreases during adolescence and early
adulthood, and sometimes disappears entirely; therefore, there are a limited number of adults with TS and it is usually manifested mainly
through moderate to severe symptoms.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Market Size</span>&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The exact number of people
with TS is unknown. The prevalence of TS and TS symptoms is greater in children than in adults. The global TS drugs market size (revenues
of total drugs sold) was approximately $80 million in 2019 and is expected to reach $98.7 million by 2023. North America dominated the
TS market in 2018 and is estimated to hold the largest market size today and in the future owing to high incidences of TS, highly aware
population, advanced healthcare infrastructure, and favorable government initiatives. One out of 162 children in the U.S. have TS, and
it affects three out of every 1,000 children between the ages of 6 and 17.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Current Treatment</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pharmacological intervention
is considered the first line of therapy for TS, but is reserved for more severe symptoms that interfere with the individual&#8217;s ability
to function. Today, a full class of drugs that interact with dopamine and non-dopamine systems in the brain are used in the treatment
of TS symptoms. Although as of the date of this prospectus the FDA has approved only two pharmacological treatments for adult TS- haloperidol
and pimozide &#8211; these treatments have a &#8220;black box warning&#8221;. Many drugs approved or off-label to treat TS are limited
to the treatment of a narrow range of TS symptoms (mainly tics), and are associated with severe side effects, both of which limit their
utility. Furthermore, several of these drugs have a black box warning on their label due to their potentially lethal effect. A black box
warning is the strictest warning put in the labeling of prescription drugs or drug products by the FDA when there is reasonable evidence
of an association of a serious hazard with the drug.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The medications commonly used
to treat symptoms of TS can be divided into the following groups:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Antipsychotic medications: belong to a class of drugs primarily used to manage psychosis (including haloperidol, pimozide and fluphenazine), all of which are associated with severe side effects (including weight gain, sedation, akathisia (a state of agitation, distress, and restlessness), nausea and tardive dyskinesia (involuntary movements of the face and jaw), among others).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alpha2 Adrenergic Agonists: belong to a class of drugs primarily used to manage hypertension and migraine headaches prevention (including clonidine and guanfacine), which have limited utility despite common application to children with Attention Deficit Hyperactivity Disorder, or ADHD. Similar to antipsychotic medications, these also are associated with several side effects, and some of them, such as clonidine, might even be lethal.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benzodiazepines, an anticonvulsant or antiepileptic drug: belong to a class of drugs primarily used to manage seizures, panic disorder and movement disorders. Of these, Clonazepam is used off-label for the reduction of tics in TS patients, which also has associated negative side effects.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As the currently used medications
are managing only a small number of disease symptoms with limited efficacy and questionable safety, there is a clear unmet medical need
for the management of TS.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Our SCI-110 Solution for
TS</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our SCI-110 platform is a
drug candidate for the treatment of TS.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 4, 2018, we announced
topline results of our Phase IIa investigator-initiated study at Yale University of SCI-110 for the treatment of TS. The study was a single-arm,
open-label trial, in which each subject both received one daily treatment of SCI-110 via oral administration and was followed-up for a
period of 12 weeks. 16 subjects participated in the study and received SCI-110 at the Yale University Child Study Center at Yale University.
The primary endpoint of the study was to assess the performance of SCI-110 in the treatment of adult patients suffering from symptoms
of TS, as measured by the Yale Global Tic Severity Scale Total Tic Score, or YGTSS-TTS, the customary index for assessing symptom severity.
Treatment was given in a dose titration regimen with a maximum dose of SCI-110 consisting of 10mg dronabinol and 800mg CannAmide&#8482;.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The topline results of the
study showed that each of these 16 subjects with medication-refractory TS sustained a significant reduction of tic symptoms (paired t-test:
YGTSS-TTS mean difference (mean +/- SD) =7.9+/-8.4, t= 3.7, df=15, p=0.002) from baseline (YGTSS-TTS: 38.4 +/- 8.3) to endpoint YGTSS-TTS:
30.5 +/- 10.9). This resulted in an average tic reduction of 21% across the entire sample of 16 TS subjects. Six of the 16 medication-refractory
TS subjects experienced a response to treatment as defined by a reduction in YGTSS-TTS of greater than 25%. Improvement over time with
treatment was also observed when generalized linear models were used to analyze repeated measures data on the YGTSS-TTS. In the study,
SCI-110 demonstrated no significant effects on comorbid ADHD, anxiety, depression or obsessive-compulsive disorder, or OCD, symptoms.
The medication was generally well-tolerated by the subjects with only two subjects stopping treatment early (one due to sedation and another
due to lack of improvement in tic symptoms). 12 of the 16 subjects elected to proceed with a 24-week extension phase of the trial, which
was also completed.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the Phase IIa study,
we announced in June 2023 BfArM approval for a Phase IIb clinical trial for SCI-110 in subjects suffering from TS, with a view to such
clinical trial being carried out in Germany at the Hannover Medical School. In August 2022, we received MoH approval to conduct the clinical
trial in Israel at Sourasky Medical Center. We also received Ethics Committee approvals in 2022 from Hannover Medical School and Sourasky
Medical Center and Internal Review Board approval in 2023 at the Child Study Center at Yale School of Medicine.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2023, we initiated
the Phase IIb clinical trial at Sourasky Medical Center. The 86 patients in the clinical trial are randomized to either oral SCI-110 or
placebo at a 1:1 ratio. The overall estimated clinical trial duration is 18-24 months. We may also be required to conduct further preclinical
studies in parallel to our clinical plans as part of registration process with the FDA and EMA. Following these clinical trials, if successful,
we intend to conduct a Phase III, multinational, multicenter, randomized, double-blind, parallel-group, placebo controlled clinical trial
to evaluate the safety, tolerability and efficacy of up to twice daily oral SCI-110 in treating TS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2016, we submitted
a request for orphan drug designation to the FDA for SCI-110 for the treatment of TS. The request is still pending and we are in communication
with FDA. Our last communication was in December 2020 when we received a letter from FDA raising a concern that it will be hard to limit
the use of the pharmaceutical product to the subset of patients we are pursuing. There is no assurance that we will successfully obtain
orphan drug designation for TS. However, in light of the fact that we disagree with this concern expressed by the FDA, we requested a
clarification call. In the clarification call conducted on February 2, 2021, we agreed with the FDA concern about our ability to limit
the use of the pharmaceutical product to the subset of patients in addition to a safety concern associated with THC treatment in pediatrics
population so we suggested to amend our preliminary request and asked to include only adults in the treated population. An amendment letter
was discussed and the FDA described what it would want to see in such an amendment. In March we sent our response to the FDA. In June
2021, we received a response from the FDA, explaining that they are unable to grant our request until new information becomes available
to support our request for orphan drug designation. We will re-visit the application after we obtain clinical results from our phase IIb
clinical trial in TS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the FDA does not
allow us to pursue the Section 505(b)(2) regulatory pathway as anticipated, we may need to conduct additional clinical trials,
provide additional data and information and meet additional standards for regulatory approval. If this were to occur, the time and
financial resources required to obtain FDA approval, and complications and risks associated with FDA approval, would substantially
increase. In a pre-IND meeting we had with FDA in February 2018, the FDA did not oppose our plans to submit an NDA via the 505(b)(2)
pathway relying, in part, on clinical and nonclinical information from literature related to dronabinol and the FDA&#8217;s previous
finding of safety and efficacy for the reference listed drug (Marinol).&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Alzheimer&#8217;s disease and Agitation</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Alzheimer&#8217;s disease
is the most common type of dementia, accounting for over two-thirds of cases of dementia. Alzheimer&#8217;s disease is a neurodegenerative
disease that causes progressive and disabling impairment of cognitive functions including memory, comprehension, language, attention,
reasoning and judgment. Symptoms of Alzheimer&#8217;s disease depend on the stage of the disease. Neuropsychiatric symptoms like apathy,
social withdrawal, disinhibition, agitation, psychosis, insomnia, poor appetite and wandering are also common in the mid to late stages.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="text-decoration:underline">Market Size </span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is estimated that the global
Alzheimer&#8217;s therapeutics market is projected to reach $13.57 billion by 2027 from $7.42 billion in 2019 with a compounded annual
growth rate of 9.2% through 2027, which is primarily attributed to the increasing pipeline drug development and increasing investments
for drug development biomarkers.<i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="text-decoration:underline">Current Treatment</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The current pharmacological
treatment of agitation in Alzheimer&#8217;s disease has an unsatisfactory benefit/risk ratio and often involves using off-label drugs.
Antipsychotic drugs, which are the most frequently used drugs for this purpose, are only marginally better than placebo.<i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Our SCI-110 Solution for
Alzheimer&#8217;s disease and Agitation</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The drug product, SCI-110,
is a unique proprietary combination of dronabinol (synthetic delta-9-tetrahydrocannabinol (&#916;&#8313;-THC), and PEA.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2021, we signed
an agreement with The Israeli Medical Center for Alzheimer&#8217;s, to conduct a phase IIa clinical trial to evaluate the safety, tolerability
and efficacy of SCI-110 in patients with Alzheimer&#8217;s disease and agitation using our proprietary cannabinoid-based technology. The
study&#8217;s primary objective is the safety of SCI-110 and the secondary objective is the ability of the compound to ameliorate agitation
and other behavioral disturbances in patients with Alzheimer&#8217;s disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Phase IIa clinical trial
was an open label clinical trial, which included 18 patients diagnosed with AD and agitation, to evaluate the safety, tolerability, and
efficacy trends of twice daily oral administration of SCI-110. Results showed that the clinical trial met its primary endpoints of the
number of drop-out subjects due to poor tolerability and the number of clinical trial treatment-related adverse events, with no SCI-110
related safety issues observed and no dropouts from the clinical trial due to clinical trial medication. Specifically, SCI-110 did not
cause delirium, oversedation, hypotension or falls. In addition, analysis of the clinical trial results showed that the clinical trial
also met its secondary end point of change from baseline to end of treatment in agitation measured by the Cohen Mansfield Agitation Inventory,
or CMAI, where out of the fifteen patients treated with SCI-110 at least two consecutive times during the clinical trial, thirteen of
them at doses ranging between 7.5mg-12.5mg/day showed amelioration in agitation with no need to use rescue medication to control agitation.
CMAI is the gold standard measure for measuring agitation in people with dementia. The clinical trial showed that these subjects had amelioration
in agitation (paired t-test: CMAI mean difference (mean +/- SD) =10.6+/-14.88, t= 2.76, df=14, p=0.015) from baseline (CMAI: 45.87 +/-
15.17) to endpoint (CMAI: 35.27 +/- 11.09). This resulted in an average reduction of 23% across the entire sample.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the exploratory end points,
a decrease in eating and feeding difficulties was shown in 11 patients out of the 15 patients treated at least two consecutive times during
the trial as measured by the Edinburgh Feeding Evaluation in Dementia Scale, although the increase was not significant. No effect from
the treatment was observed on cognitive measurements and sleep quality, as measured by the Mini Mental State Exam and by the and the Sleep
Disorder Inventory, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">SCI-210 - ASD and SE</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our pharmaceutical
product candidate, SCI-210, offers a safe and potentially effective solution for a variety of medical concerns. Despite being in its early
phases of pre-clinical and clinical testing, the application of SCI-210 has extended into several treatments, including ASD and SE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>ASD</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASD is a neurodevelopmental
disorder. The specific etiologies and neural bases of autism remain largely unknown; it has been proposed that alterations in multiple
genes in combination with environmental factors constitute the cause for the development of the autism phenotype. ASD is characterized
by early dysfunction in communication and social interactions, presenting with repetitive, restrictive, stereotyped patterns of behavior
and loss of interest in diverse activities. Additionally, ASD is frequently accompanied by impairments in adaptive functioning, sensory
processing disorder, aggression, or self-injury.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Market Size</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is estimated that the global
ASD therapeutics market was approximately $3.3 billion in 2018 and is expected to reach approximately $4.6 billion by 2026 with a compounded
annual growth rate of 4.3% during such time period.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="text-decoration:underline">Current Treatment</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No cure exists for ASD. The
goal of treatment is to maximize patients&#8217; ability to function by reducing ASD symptoms and supporting development and learning.
Treatment options may include: (i) behavior and communication therapies - successful programs typically include a team of specialists
and a variety of activities to improve social skills, communication and behavior; and (ii) medications - to date, no medication can improve
the core signs of ASD, specific medications can help control comorbidity symptoms. The main symptoms to be treated in patients with ASD
are: epilepsy, aggression, hyperactivity, irritability, attention deficit, sleep problems, obsessions and anxiety. Antipsychotic drugs
are sometimes used to treat severe behavioral problems and antidepressants may be prescribed for anxiety. Among the main drugs used in
the treatment of ASD are typical antipsychotics such as Haloperidol, Thioridazine, Chlorpromazine and the atypical risperidone, Olanzapine
and Clozapine, whose use is more common. These are used with the objective to treat the child&#8217;s behavioral problems by blocking
the D2 dopaminergic channels, causing a diminished reaction to stimuli known as &#8220;neuroleptic syndrome,&#8221; observed as calm and
quiet behavior in the child. In turn, some atypical antipsychotics also exhibit an antagonism of type 2A receptors for serotonin, aside
from their effect on the D2 channels. It is important to individualize the patient when these drugs are administered, since there are
no pre-established criteria for dosing and such drugs could present extrapyramidal adverse effects such as tremors, sialorrhea, sedation,
impaired liver function, etc. Serotonin reuptake inhibitors such as Fluoxetine, Paroxetine and Sertraline are given to children with autism
because they have been found to increase 25% of serotonin levels in platelets and serum. This treatment is based on suppressing symptoms
such as anxiety, depression, OCDs, and self-injurious behavior.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unfortunately, about 40% of
children with ASD and disruptive behavior do not respond well to standard behavioral and medical treatment. Consequently, an exceptionally
high percentage of parents are seeking help through unproven methods, including the use of compounds made of the cannabis plant.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Our SCI-210 Solution for
ASD</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The drug product SCI-210 is
a proprietary drug candidate based on two components: (1) CBD, and (2) CannAmide&#8482;.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 8, 2022, we
announced that we have received approval from the MoH and <span style="background-color: white">Ethics Committee of Soroka Medical
Center </span>to conduct our clinical trial for SCI-210 in patients suffering ASD. Our regulatory request to carry out this clinical
trial was granted by the IMCA on July 10, 2023. On January 9, 2023, we signed an agreement with Soroka Medical Center to conduct the
clinical trial on pediatric patients suffering from ASD. This randomized, double-blind placebo-controlled clinical trial to evaluate
the potential efficacy, safety and tolerability of SCI-210 in treating patients with ASD was initiated in July 2023. We initiated
patient enrollment for the clinical trial in January 2024. In February 2024, we announced that we had successfully completed the
manufacturing of the SCI-210 treatment for the clinical trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>SE</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SE is a common life-threatening
medical emergency characterized by an acute, prolonged epileptic seizure. SE can represent either the exacerbation of a pre-existing seizure
or the initial manifestation of epilepsy. In order to avoid neurological sequelae, a timely treatment should be started. When the continuous
seizure does not respond to conventional drug treatment, SE can pose serious life-threatening risks.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2018, GW&#8217;s Epidiolex,
a plant-based, pharmaceutical grade CBD extract was approved by the FDA for the treatment of seizures associated with two rare and severe
forms of epilepsy. Our study for SCI-210 previously met its endpoint (efficacy) when comparing its effect to the effect of CBD alone in
an in-vitro hepatocytes model of fat accumulation; the effect of CBD was enhanced by the addition of PEA, lowering the required effective
concentration of CBD. In this study, we hope to meet the study endpoint (efficacy) when comparing treatment using our pharmaceutical product
candidate compared to the effect of CBD alone on SE and its neurological cognitive sequelae.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Market Size</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the World Health
Organization, or WHO, report on epilepsy in 2019, around 50 million people have epilepsy. In addition, it has been estimated that the
global epilepsy market size would grow from $10.6 billion in 2021 to $14.9 billion towards the end of 2031. North America accounted for
approximately 50% of the global epilepsy therapeutics market in 2021. The U.S. is the largest epilepsy drug market in North America.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2017, the Americas held
a 41% market share ($1.49 billion) and are projected to hold such position, estimated to be $1.6 billion in 2023.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="text-decoration:underline">Current Treatment</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The first-line treatment for
early SE mainly comprises the administration of benzodiazepines, the most frequently used of which include Diazepam, Lorazepam, and Midazolam.
Seizures continue and progress to established SE in about 40% of patients with Convulsive Status Epilepticus (CSE) despite benzodiazepine
administration as the first-line treatment. The second-line treatment for established SE consists of a loading dose of antiepileptic drugs.
Frequently used antiepileptic drugs include Phenytoin or Fosphenytoin, Valproate, Levetiracetam, Phenobarbital, and Lacosamide. There
is no clear evidence for the relative superiority of any of these drugs.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Our SCI-210 Solution for
SE</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The drug product SCI-210 is
a proprietary drug candidate based on two components: (1) CBD, and (2) CannAmide&#8482;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 7, 2022, we
announced positive results from our pre-clinical study of SCI-210 on SE, conducted at The Sheba Fund for Health Services and
Research at Chaim Sheba Medical Center, which reaffirms the potential of its proprietary combination products to have a positive
effect while minimizing adverse side effects. Our SCI-210 platform combines PEA with CBD. The non-clinical trial objective was to
study the potential therapeutic effects of SCI-210 on SE and on neuro-biochemical markers for neurological cognitive sequelae. A
pilocarpine SE-induced mice (C57BL/6 male) model to study SCI-210&#8217;s effects on seizure severity and mortality was used. After
calibration, four groups of animals were studied: an effective-high dose CBD group, a sub-effective dose CBD group, a SCI-210 group
(a combination of sub-effective CBD dose and PEA) and a non-treated control group. The results indicated differences in mortality
rate as well as seizure rates over time. In the low-CBD group, a higher mortality rate (although not significant) was found and
therefore it is reasonable to believe that no significant impact on neuronal protection was achieved. In the high-CBD group, higher,
although not significant, levels of neuronal protection were found together with a decreased mortality rate when compared to
control. The level of neuronal protection in the SCI-210 treatment was significantly higher compared to the control group and no
mortality was found in this group. It was concluded that SCI-210 treatment may potentially be more effective than a CBD monotherapy.
Moreover, since the concentrations used in the combo treatment are significantly lower than those recommended for CBD monotherapy,
this treatment also has the potential to be safer.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Our SCI-160 Pain Solution</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pain is the most common reason
for physician consultation in most developed countries. It is a major symptom in many medical conditions and can interfere with a person&#8217;s
quality of life and general functioning. Opioid medications can provide short, intermediate or long acting analgesia depending upon the
specific properties of the medication and whether it is formulated as an extended release drug. Opioids are efficacious analgesics in
chronic malignant pain and modestly effective in nonmalignant pain management. However, there are associated adverse effects, especially
during the commencement or change in dose. Prolonged opioid use may cause drug tolerance, chemical dependency, diversion and addiction.
The potency and availability of these substances, despite their high risk of addiction and overdose, have made them popular both as formal
medical treatments and as recreational drugs. Due to their sedative effects on the medulla oblongata, opioids in high doses present the
potential for respiratory depression, and may cause respiratory failure and death. In a 2013 review study published in Fundamental &amp;
Clinical Pharmacology, various studies were cited demonstrating that cannabinoids exhibit comparable effectiveness to opioids in models
of acute pain and even greater effectiveness in models of chronic pain. Cannabis produces several compounds with various known activities
known together as cannabinoids, such as THC and CBD. In general, cannabinoids bind and act through the two characterized CRP: CB1 and
CB2. However, activation of the CB1 receptor (as for example in the case of THC) leads to unwanted psychoactive &#8220;high&#8221; and
other adverse events, whereas activation of CB2 does not lead to any psychoactivity. In addition and unrelated to the above sentence,
the affinity of the cannabis derived cannabinoids to these receptors is limited and partial. Newly synthetic cannabinoid HU-433, a specific
CB2 agonist with high CB2 receptor affinity, was specifically synthesized by Prof. Raphael Mechoulam from Hebrew University of Jerusalem
and is our proprietary new chemical entity.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2018, we executed
a license agreement with Yissum, the technology transfer company of the Hebrew University of Jerusalem, for SCI-160, a synthetic cannabinoid
synthesized by Prof. Mechoulam. We completed two preliminary preclinical studies evaluating analgesic and opioid-sparing effects of this
compound in a rat model of acute and chronic pain. In the preclinical studies, SCI-160 was well tolerated and did not cause any significant
adverse clinical effects. In addition, efficacy studies demonstrated the analgesic superiority of SCI-160 over control and were comparable
to high-dose morphine analgesic effects and in some instances exerted greater potency. These preclinical studies in SCI-160 were able
to meet their endpoints - efficacy and safety - for both acute and chronic pain.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Market Size</span>&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The global pain management
drugs market size was estimated at $78.14 billion in 2022 and is projected to hit around $115 billion by 2032, growing at a CAGR of 3.94%
during the forecast period 2023 to 2032. On the basis of geography, North America dominated the market and captured more than 45% revenue
share in 2022.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the U.S. National
Center for Health Statistics, over 310 million major procedures are performed annually, of which approximately 40 to 50 million are in
the U.S. and 20 million in Europe. Moreover, there is a rise in the rate of surgeries worldwide which is the primary reason for the growing
consumption of pain management drugs. Subsequently, the increased cancer therapies associated with pain incidence and a rising geriatric
population having various therapies drive the market. Consumer preference for pain management therapies is influenced by their high availability,
ease of access, heightened awareness, cost-effectiveness, and rapid relief.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, rising road accidents
due to the increasing number of vehicles and traffic violations lead to related trauma injuries, which create demand for pain management
post surgeries. According to the WHO, 1.3 million people die yearly from road traffic crashes. Between 20 and 50 million people suffer
from non-fatal injuries, with many incurring a disability due to their injury.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Current Treatment</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently available
treatments are antidepressant and anticonvulsant analgesics, opioids and nonsteroidal anti-inflammatory drugs. These are inadequate
to control all pain or are associated with limiting side effects (e.g., most problematic being sedation with the antidepressant and
anticonvulsant group, constipation with the opioids and gastrointestinal and cardiovascular effects with the Non-steroidal
anti-inflammatory drugs, or NSAIDs).&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Our SCI-160 Solution for
pain</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SCI-160 is a newly synthetic
cannabinoid, a specific CB2 agonist with high CB2 receptor affinity.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For our proprietary SCI-160,
in August 2021, we announced positive top-line results for a controlled pre-clinical trial on neuropathic and post-operative pain. The
study &#8220;An evaluation of SCI-160 on neuropathic pain in the rat spared nerve injury (SNI) model and post-surgical pain in the rat
hind paw incision model,&#8221; was designed to help assess the potential of SCI-160. Key findings from the pre-clinical trial are that
SCI-160 significantly alleviates pain up to six hours after injection as compared with vehicle-treated animals. Daily SCI-160 injections
significantly alleviate subject pain from mechanical stimuli as compared with vehicle-treated animals, for up to seven days after surgery.
Daily injections of SCI-160 significantly alleviate pain in a hind paw incision model of post-surgical pain up to four days post surgery
as compared with vehicle treated animals and SCI-160 analgesic effects are prolonged in the presence of PEA. Collectively, the results
indicated that treatment with SCI-160 significantly alleviates both chronic and acute pain. Based on the positive results, we are continuing
the development of SCI-160 towards a first in-human clinical study.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Other Programs</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Our CannAmide&#8482; Anti-Inflammatory
and Chronic Pain Solution</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CannAmide&#8482; is a cannabimimetic
compound that regulates endocannabinoid levels by enhancing receptor sensitivity and inhibiting their metabolism, and is particularly
attractive therapeutically as it appears to have a very high safety profile with low or no abuse liability. Although numerous clinical
trials have shown the favorable effect of PEA as an analgesic agent it has low solubility.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2019, we announced
the issuance of a product license for our proprietary PEA oral tablet CannAmide&#8482; by Health Canada&#8217;s Natural and NNHPD, for
the recommended use as an anti-inflammatory and to help relieve chronic pain. This license was issued by the NNHPD under the authority
of the NHPR. Dosage form of the described natural health product is tablets composed of 400mg PEA with a recommended dose of one tablet
three times a day. Chronic pain is estimated to affect 38% of people worldwide, and according to an analysis by the World Health Organization,
half of the most prevalent conditions responsible for living with disability is characterized by the presence of different kinds of pain.
With the NNHPD license, we are able to offer safe and beneficial non-opiate pain management products. CannAmide&#8482;&#8217;s active
compound PEA is a cannabimimetic compound that regulates endocannabinoid levels by enhancing receptor sensitivity and inhibiting their
metabolism, and is particularly attractive therapeutically as it appears to have a very high safety profile with low or to no possibility
for abuse. On February 10, 2021, we announced that we had entered into an agreement with Procaps, a leader in contract development and
manufacturing services in softgel advanced technologies for the global pharmaceutical and nutraceutical industries, to develop and commercially
manufacture both of our drug candidates, SCI-110 and our proprietary PEA oral tablets CannAmide&#8482;, in softgel capsule form.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cannabinoids have great therapeutic
potential and have been used for years for medicinal purposes. For example, cannabis and cannabinoids are being used to improve the quality
of life of patients with numerous and diverse indications (oncological patients, chronic pain conditions, etc.). We believe that the novel
approaches and unique mechanism of action of our proprietary technology platforms, including our drug delivery systems and unique combination
and specific dosages, may be expanded to treat additional diseases and unmet medical needs.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the future, we may consider
expanding our pipeline to include these additional indications.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Collaboration with Clearmind&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 7, 2022, we
entered into a cooperation agreement, or the Cooperation Agreement, with Clearmind. The Cooperation Agreement includes, among
others, examination of the benefit of integrating the core technologies of each company to explore the development of
psychedelic-centric drug candidates and targeting mental health- related diseases. Pursuant to the terms of the Cooperation
Agreement, we conducted a joint pre-clinical study with Clearmind. Under the Cooperation Agreement, we aim to pursue, develop and
commercialize psychedelic-centric drug candidates. Our collaboration with Clearmind has resulted as of the date of this prospectus,
in the filing of nine patent applications. All patent applications refer to the combination of SciSparc&#8217;s CannAmide&#8482;
with Clearmind&#8217;s 5-Methoxy-2-aminoindane, or MEAI, an innovative proprietary psychedelic treatment for addictions and others.
&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2022, we announced
that our collaboration with Clearmind resulted in the filing of a provisional patent application related to a psychedelic combination
therapy treating numerous binge behaviors. The patent application referred to the combination of our CannAmide&#8482; with Clearmind&#8217;s
MEAI. The patent application followed successful pre-clinical studies that showed a significant dose dependent effect for MEAI treatment
in reducing alcohol consumption of treated animals, with additional significant effect for the CannAmide&#8482; treatment at the lower
sub-effective MEAI dose. Additionally, in May 2022, we announced positive safety profile results from our joint pre-trial with Clearmind.
The clinical trial tested the proprietary combination of our CannAmide&#8482; with Clearmind&#8217;s psychedelic molecule, MEAI, for alcohol
consumption. A histopathology assessment was conducted on several organs (heart, lungs, liver, kidneys, brain, pancreas, spleen, and thyroid
gland) from all experiment groups (n=3-5 per group) to determine the safety of the proprietary combination of MEAI and CannAmide&#8482;
versus control (mice) that were not exposed to alcohol). The severity of changes was scored by a 5-point scale by a qualified blinded
toxicologist (Schafer et al., Toxicol Pathol 2018, 46:256-265). The results indicated a high safety profile of the combination treatment
with no treatment-related changes observed.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2022, we announced
that our collaboration with Clearmind resulted in the filing of a provisional patent application related to treating cocaine addiction.
The patent application refers to the proprietary combination of our CannAmide&#8482; with Clearmind&#8217;s MEAI, for treating cocaine
addiction.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2022, we announced
additional positive pre-clinical results of our psychedelic-based pharma collaboration for treatment for cocaine addiction using MEAI.
These pre-clinical study results added to our announcements regarding our collaboration with Clearmind for their combination treatment
based on our CannAmide&#8482; compound and Clearmind&#8217;s MEAI for various addictions, including pre-clinical studies results, the
filing of two provisional patent applications related to compositions comprised of MEAI and n-acylethanolamines and uses thereof and treating
cocaine addiction. The pre-trial was led by Professor Gal Yadid and his team from the Gonda Multidisciplinary Brain Research Center located
at Bar Ilan University (Ramat Gan, Israel) and was designed to evaluate the possible reward-like effects of MEAI with connection to cocaine
and its ability to abolish cocaine-induced conditioned place preference. In the pre-trial, the self-administration paradigm was utilized,
which is the gold-standard model for examining drug addiction and is based on operant conditioning. Rats were catheterized and trained
to self-administer cocaine. The results identified a statistically significant sub-group within the study, in a non-biased manner and
high integrity, which dramatically responded to the treatment, significantly decreasing the craving for cocaine as compared to non-treated
control group. This sub-group, representing 60% of animals, showed a very high response within the group.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2022, we announced
that Clearmind filed a provisional patent application related to metabolic syndromes including obesity, regarding our collaboration with
Clearmind. The patent application is the third of the collaboration, each referring to the proprietary combination of our PEA and Clearmind&#8217;s
MEAI.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2023, we announced that announced that Clearmind filed
three provisional patent applications were filed by Clearmind with the USPTO as a part of our ongoing collaboration. The patent applications
refer to novel proprietary combinations of lysergic acid diethylamide, psilocybin, and N,N-dimethyltryptamine and our PEA. Additionally,
in February 2023, we announced that as part of our ongoing collaboration with Clearmind, Clearmind filed three provisional patent applications
with the USPTO, for unique combinations of future psychedelic-based compounds. The patent applications refer to novel proprietary combinations
of 3,4 Methylenedioxymethamphetamine, Ibogaine and Ketamine each with our PEA.&#160;In February 2024, Clearmind also filed patent applications
under the PCT for these combinations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2023, we announced
that we and Clearmind were to conduct a study evaluating our combination treatment for obesity and metabolic syndrome.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2023, Clearmind
filed a patent application for the treatment of dyskinesia, a combination of the pyschadelic molecule 3-Methylmethcathinone and PEA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2023, successful
results were announced from a pre-trial on rodents, testing the efficacy of the combination treatment of PEA and MEAI on obesity, performed
by Joseph Tam from the Hebrew University of Jerusalem. The results indicated that there was an increase in the metabolic process and fat
burn, a reduction in appetite and meal sizes, and reductions in ambulation with affecting voluntary activity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Collaboration with Polyrizon
&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 31, 2022, we entered
into a collaboration agreement with Polyrizon Ltd., or Polyrizon, a biotech company focused on the development of innovative medical device
hydrogels delivered in the form of nasal sprays, or the Polyrizon Collaboration Agreement. As part of this collaboration, we will work
together to develop a unique technology for the treatment of pain, based on our SCI-160 platform and Polyrizon&#8217;s Trap and Target<sup>TM</sup>
intranasal drug delivery technology to target the central nervous system. We have agreed to pay development fees to Polyrizon up to a
total of $2,550,000 upon the completion of certain milestones, as well as royalties in the low single digits upon sales of products under
the agreement and additional royalties for sales under any sublicense by us.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Acquisition of Wellution&#8482;&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 14, 2022, we
entered into the Wellution Acquisition Agreement with Merhavit M.R.M Holding and Management Ltd., or M.R.M, and the other parties named
therein, to acquire from M.R.M its rights to purchase, the Wellution&#8482; brand. In connection therewith, we incorporated a new wholly
owned subsidiary, SciSparc Nutraceuticals, to hold the new assets of the Brand. The Brand sells hemp-based products, including hemp gummies,
hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and
hair treatment products that are all manufactured in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with the closing
of the Wellution Acquisition Agreement for the Brand which took place on September 30, 2022, we paid $4.59 million for the Brand and issued
to M.R.M $15 million worth of warrants to purchase up to an aggregate amount of 82,418 of our Ordinary Shares, or the M.R.M Warrants.
The M.R.M Warrants have an exercise price of $182 per share and an exercise period of five years from the closing, until September 30,
2027. The M.R.M Warrants will become exercisable during the exercise period upon the earlier of (i) an achievement of $100 million of
gross sales by the Brand in the aggregate or (ii) if the price of our Ordinary Shares closes at $10.00 or above.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 23, 2023, we entered
into the Wellution Sale Agreement with Jeffs&#8217; Holdings and Jeffs&#8217; Brands, pursuant to which, at the closing on March 28, 2023,
Jeffs&#8217; Holdings acquired from us 57 of common stock of SciSparc Nutraceuticals, equal to approximately a 49% interest in our wholly
owned subsidiary, SciSparc Nutraceuticals, which owns the Wellution<sup>TM</sup> Brand, for a cash consideration of $2.5 million. In addition
to the cash consideration upon closing, we received from Jeffs&#8217; Brands an additional amount accounting for certain purchase price
adjustments related to inventory and working capital, which adjustments increased the purchase price by approximately $489,330.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the closing of the
Wellution Sale Agreement on March 28, 2023, including an equity conversion of the financing amounts we previously provided to SciSparc
Nutraceuticals for working capital, we hold approximately 51% of the outstanding capital stock of SciSparc Nutraceuticals.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the Wellution
Sale Agreement, at the closing, Jeffs&#8217; Brands and SciSparc Nutraceuticals entered into a consulting agreement, or the Wellution
Management Agreement for the provision of services by Jeffs&#8217; Brands for the management of the Brand for a monthly fee of $20,000.
Jeffs&#8217; Brands also received a one-time signing bonus at the closing in the amount of $51,000. The Wellution Management Agreement
is in effect for an undefined period of time and may be terminated by either party with 30 days&#8217; advance notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, pursuant to the
Wellution Sale Agreement, at the closing, we undertook a share exchange with Jeffs&#8217; Brands, in which we acquired 247,415 ordinary
shares of Jeffs&#8217; Brands and Jeffs&#8217; Brands acquired 360,297 of our Ordinary Shares, in each case having an aggregate value
of $288,238, or the Share Exchange. The number of shares exchanged was calculated based on the average closing price of the shares on
the Nasdaq for the 30 consecutive trading days ending on the third trading day immediately prior to the closing date.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Restructuring Plan&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 25, 2023, we announced
that our board of directors resolved to pursue a Restructuring Plan which may involve transferring our pharmaceutical activities to NewCo.
As part of or independent to the Restructuring Plan, we intend to examine the possibility of listing NewCo on a leading stock exchange,
while maintaining our controlling interest in NewCo such that we will continue to control our current business activities. We also intend
to explore other potential new opportunities, activities and investments in a variety of sectors.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any restructuring and possible
listing of NewCo on a stock exchange may be subject to, among other things, market conditions, tax or other business analyses, regulatory
approvals, receipt of any necessary consents, final approvals from our board of directors and satisfaction of any closing conditions to
effectuate such corporate restructuring and listing of NewCo. There can be no assurance regarding the ultimate timing of the intended
restructuring and listing of NewCo or that they will be completed at all. Other than the signing of the LOI with the Target Company on
November 22, 2023, as of the date of this prospectus, we have not initiated the Restructuring Plan.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Strategic Transaction Opportunity
Engagement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2023, we engaged
Rosario Capital Ltd. to identify potential opportunities for a strategic transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Non-Binding Letter of Intent
with Leading Vehicle Importer Company in Israel</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Restructuring
Plan, on November 22, 2023, we announced the signing of the LOI to acquire the Target Company, a leading vehicle importer company in Israel,
with certain new negotiated terms as announced on December 7, 2023. This Acquisition is expected to be consummated by means of a reverse
triangular merger, pursuant to which we will establish a new wholly-owned Israeli subsidiary, which would in turn merge with and into
the Target Company, leaving the Target Company as the surviving company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
a result of the Acquisition, all outstanding shares of the Target Company would be converted into the right to receive Ordinary Shares
of SciSparc and any warrants issued by the Target Company would be converted into the right to receive warrants of SciSparc. Following
the completion of the Acquisition, it is contemplated that SciSparc shareholders will hold approximately 50.01% of the share capital of
the post-closing combined company</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Bridge Loan with Leading
Vehicle Importer Company in Israel</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 19, 2024, we announced,
that we had entered into a bridge loan agreement, or the Loan Agreement, as lender, with the Target Company, pursuant to which the Target
Company received a bridge loan, or the Bridge Loan, in the amount of $1.4 million, further to the previously-announced LOI for us to acquire
the Target Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Loan Agreement, signed
on January 16, 2024, states that the principal amount of the Bridge Loan will bear interest at a rate of 7% per annum (or 9% per annum
if the Acquisition is not consummated prior to the repayment date), compounded annually. The Bridge Loan amount, together with any accrued
interest, or the Owed Amount, may be repaid in part or in whole at the discretion of the Target Company prior to the repayment date. The
repayment of the Owed Amount will be due at the earlier date of: (a) the closing of the Acquisition, in which the Owed Amount shall be
deemed a part of, and set-off against, the financing amount we will provide the Target Company with upon closing, or $4,250,000; (b) if
the definitive agreement for the Acquisition is terminated, in accordance with its terms, within three months from such termination date;
or (c) July 15, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual Property</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our intellectual property
portfolio comprises seven granted U.S. patents, pending patent applications in nine families, all of which are currently international
PCT applications or PCT applications that have entered the national phase. Of this portfolio, we have exclusively licensed one granted
U.S. patent from Dekel and one patent family from Yissum. Our intellectual property portfolio also includes two trademarks.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Internally Developed Patent Applications</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2013, we filed a
provisional application with the USPTO for the technology of proprietary sequences of anti-CD3 antibody and the utilization of the latter
in various autoimmune diseases, as well as in hepato-pathologies. The provisional application has been converted to a PCT and then entered
a National Status in December 2014 in the U.S., with the European Patent Office, or EPO, and in China, Canada and Japan. In the U.S. it
received a grant status in June 2018.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2015, we filed a
provisional application with the USPTO for combinations of cannabinoids, n-acylethanolamines, and inhibitors of n-acylethanolamine degradation,
which, in April 2016 was converted into an international PCT application that subsequently entered national phase in the following state
entities: U.S., EPO, Israel, Australia, Canada, China and Japan. The technology is directed to utilizing the potentiating effect of n-acylethanolamines
on cannabinoids for any cannabinoid amenable indication, including but not limited to analgesia and TS. The 20-year term of any patent
issuing from this application would expire in April 2036. In August and September 2021, the patent was granted in Australia and Japan,
respectively, and three patents have been issued in the U.S., two in December 2021 and one in February 2022. A patent was issued in Israel
in August 2022 and a patent was issued in Australia in November 2023. The EPO granted a patent in December 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2015, we filed a provisional
application with the USPTO for combinations of opioids, n-acylethanolamines, and inhibitors of n-acylethanolamines degradation, which,
in May 2016 was converted into an international PCT application that subsequently entered national phase in the following state entities:
U.S., EPO, Israel, Australia, Canada, China and Japan. The technology is directed to potentiating effect of N-acylethanolamines on opioids
for opioid amenable indications. The 20-year term of any patent issuing from this application would expire in May 2036. In July 2021,
the patent was granted in Australia, and a divisional patent was granted in November 2023.&#160;In November 2023, a patent was granted
by the EPO. A patent granted in Japan in March 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2016, we filed a provisional
application with the USPTO for the use of cannabinoids for potentiating the efficacy of antibiotics, which in July 2017 was converted
into an international PCT application that subsequently entered national phase in the following state entities: U.S., EPO, Canada and
China. The 20-year term of any patent issuing from this application would expire in July 2037. In November 2022, the USPTO issued this
patent called &#8220;Compositions and Methods of Potentiating Antimicrobials&#8221;.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2018, we filed
a provisional application with the USPTO directed to methods of treating OSA, which in January 2019 was converted into an international
PCT application that subsequently entered national phase in the following state entities: U.S., EPO, Canada and Australia. The 20-year
term of any patent issuing from this application would expire in January 2039.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2019, we filed a
provisional application with the USPTO directed to compositions and methods for potentiating derivatives of 4-aminophenols, which in April
2020 was converted into an international PCT application. The PCT application subsequently entered the national phase in Australia, Canada,
China, EPO, Israel, India, Japan, Mexico, Russia, and the U.S. The 20-year term of any patent issuing from this application would expire
in April 2040.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, we filed a
provisional application with the USPTO directed to methods for maintaining microvascular integrity, which in August 2021 was converted
into an international PCT application. The PCT application subsequently entered the national phase in Australia, Canada, China, EPO, Israel,
India, Japan, and the U.S. The 20-year term of any patent issuing from this application would expire in August 2041.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2022, we received
an Israeli patent for our core technology that treats central nervous systems disorders. The invention relates to &#8220;Pharmaceutical
compositions comprised of cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable
conditions.&#8221;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2022, the USPTO
granted us a new patent - U.S. Patent No. 11,491,172, title: COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS. This patent further
strengthens our intellectual property portfolio and protection of our core technologies, and in one of the most important markets in the
world. This is SciSparc&#8217;s seventh granted patent in the United States.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>In-Licensed Patents and Patent Applications</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2015, we entered into
an exclusive, irrevocable, worldwide license agreement with Dekel for certain technology and one granted U.S. patent related to compositions
and methods for treating inflammatory disorders. The agreement became effective in August 2015 immediately after we and Dekel entered
into an amendment to the license agreement. Pursuant to the license agreement, in May 2016 we issued Dekel 200,000 of our Ordinary Shares
at a price per share of NIS 0.5 on account of future royalty payments. Also, pursuant to the license agreement, we are obligated to pay
Dekel fees based on specific milestones and royalties upon commercialization. The milestone payments include: (i) $25,000 upon the successful
completion of preclinical trials (which milestone was met in November 2016, resulting in this payment becoming due, and which was paid
in March 2017); (ii) $75,000 upon the successful completion of a Phase I/IIa trial (which was paid in April 2018); and (iii) $75,000 upon
the earlier of generating net revenues of at least $200,000 from the commercialization of the technology or the approval of the FDA /
the EMA of a drug based on the licensed assets. In each case, and subject to our discretion, the respective milestone payments are payable
in cash or equity based on a price per Ordinary Share of NIS 0.5. The royalty payments are 8% for commercialization and 35% pursuant to
a sub-license of the licensed assets. The patent expiration dates of any patents maturing from this application would likely be 2029.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 14, 2019, we entered
into an amendment to the license agreement, to encompass our and Dekel&#8217;s original intention to exclude certain consumer packaged
goods (including, inter alia, food, beverage, cosmetics, pet products and hemp based products, which are sources of nutrients or other
substances which may have a nutritional effect) from the scope of the licensed products and the field of our activity, as described in
the license agreement, which intention was not reflected in the license agreement, and therefore, desired and agreed to amend the license
agreement to reflect the foregoing clarification, as well as certain additional less material matters as discussed in the amendment. The
amendment also prescribes a specific development plan under the license agreement requiring us to invest in the licensed technology (as
defined under the license agreement) formulation development and maintenance of a total annual investment cap of $350,000 and for a non-compete
and non-solicitation obligation by Dekel and Dr. Shmulewitz, our former chairman and chief executive officer, towards our field of activity.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
February 5, 2024, we received written notice from Dekel for the termination of the license agreement, effective immediately, based on
our allegedly breaching our material contractual obligations by allegedly failing to provide Dekel with certain reports regarding the
licensed products under the license agreement. We disagree and reject Dekel&#8217;s allegations as set forth in the notice and we are
assessing the effects, if any, on our business. For further information, see &#8220;<i>Risk Factors - Risks Related to Our Intellectual
Property &#8211; We have received a termination notice for a license agreement for certain intellectual property rights from an entity
controlled by our former chairman and chief executive officer, Dr. Ascher Shmulewitz.&#8221;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 29, 2018, we entered
into an exclusive, worldwide, sublicensable, royalty-bearing license agreement with Yissum for a license to make commercial use of the
licensed technology, in order to develop, obtain regulatory approvals, manufacture, market, distribute or sell products, or the Yissum
License Agreement. According to the Yissum License Agreement, we were required to pay Yissum an initial payment of $133,000, and shall
pay Yissum royalties at the rates of 3% of net sales, subject to the royalty reductions as described in the Yissum License Agreement.
All right, title and interest in and to the Yissum License Agreement shall vest solely in Yissum, and we shall hold and make use of the
rights granted. All rights in the development results shall be solely owned by us, except to the extent that an employee of the Yissum,
including the researcher, is considered an inventor of a patentable invention arising from the development results, in which case such
invention and all patent applications and/or patents claiming such invention shall be owned jointly by us and Yissum, as appropriate,
and Yissum&#8217;s share in such joint patents shall be automatically included in the Yissum License Agreements.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Other Intellectual Property Protection </i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to patent and
trademark protection, we intend to use other means to protect our proprietary rights, including pursuing marketing or data exclusivity
periods, orphan drug status, and similar rights that are available under regulatory provisions in certain countries, including but not
limited to the United States, Europe, Canada, Japan, and China.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also rely on trade secrets,
know-how, and continuing innovation to develop and maintain our competitive position. We cannot be certain that patents will be granted
with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we
be sure that any of our existing patents or any patents granted to us in the future will be commercially useful in protecting our technology.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also seek regulatory approval
for our products for indications with high unmet medical need, great market potential, and where we have a proprietary position through
patents covering various aspects of our products, including but not limited to: composition, dosage, formulation, use, and manufacturing
process. Our success depends, in part, on an intellectual property portfolio that supports future revenue streams and erects barriers
to our competitors. We are maintaining and building our patent portfolio through filing new patent applications, prosecuting existing
applications, and licensing and acquiring new patents and patent applications.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Despite these measures, any
of our intellectual property and proprietary rights could be challenged, invalidated, circumvented, infringed or misappropriated. Intellectual
property and proprietary rights may not be sufficient to permit us to take advantage of current market trends or otherwise to provide
competitive one. For more information, see. &#8220;Risk Factors-Risks Related to our Intellectual Property.&#8221;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
our portfolio of patents:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; border-bottom: Black 1.5pt solid; width: 12%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 12%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 12%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing
    Date</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 35%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 12%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
    Expiration Date</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 12%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product<br/>
    Covered</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2036</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    THX-210</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Jul-2021</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2036</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    THX-210</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-Oct-2023</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2036</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    THX-210</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allowed</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2036</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    THX-210</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2036</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    THX-210</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01-Oct-2019</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2036</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    THX-210</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Oct-2019</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2036</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    THX-210</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30-Aug-2019</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2036</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    THX-210</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27-Aug-2021</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2036</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    THX-210</span></td></tr>

<tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Nov-2021</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND<br/>
N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
THX-210</span></td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Nov-2021</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2036</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    THX-210</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2036</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    THX-210</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31-Mar-2022</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2036</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    THX-210</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China (People&#8217;s Republic)</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2036</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    THX-210</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08-Jun-2023</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2036</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    THX-210</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European
    Patent Convention<sup>(1)</sup></span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND <br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2036</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    THX-210</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European
    Patent Convention<sup>(1)</sup></span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2036</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    THX-210</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND <br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2036</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    THX-210</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30-Mar-2021</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2036</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    THX-210</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16-Jun-2023</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND <br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    20236</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    THX-210</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF OPIOIDS AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2036</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>

<tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30-Jun-2021</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF OPIOIDS AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Oct-2023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS
    AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>

<tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF OPIOIDS AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; border-bottom: black 1.5pt solid; text-align: left; vertical-align: bottom; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing
    Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
    Expiration Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product<br/>
    Covered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24-Aug-2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF OPIOIDS AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China (People&#8217;s Republic)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF OPIOIDS AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03-Apr-2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF OPIOIDS AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF OPIOIDS AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30-Apr-2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF OPIOIDS AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-Nov-2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF OPIOIDS AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European
    Patent Convention<sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF OPIOIDS AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF OPIOIDS AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27-Nov-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF OPIOIDS AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allowed</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF OPIOIDS AND<br/>
    N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29-Jul-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR<br/>
    TREATING OBSTRUCTIVE SLEEP APNEA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    2039</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European
    Patent Convention<sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28-Aug-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR<br/>
    TREATING OBSTRUCTIVE SLEEP APNEA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    2039</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24-Aug-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR<br/>
    TREATING OBSTRUCTIVE SLEEP APNEA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    2039</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24-Aug-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR<br/>
    TREATING OBSTRUCTIVE SLEEP APNEA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    2039</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25-Jan-2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR<br/>
    TREATING OBSTRUCTIVE SLEEP APNEA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    2039</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR<br/>
    POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2040</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR<br/>
    POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2040</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR<br/>
    POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2040</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European
    Patent Convention<sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR<br/>
    POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2040</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18-Mar-2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR<br/>
    POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2040</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR<br/>
    POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2040</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">India</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR<br/>
    POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2040</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR<br/>
    POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2040</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mexico</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR<br/>
    POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2040</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Russia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR<br/>
    POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2040</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-Mar-2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR<br/>
    POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2040</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr>
    <td style="border-bottom: black 1.5pt solid; text-align: left; vertical-align: bottom; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing
    Date</b></span></td>
    <td style="vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
    Expiration Date</b></span></td>
    <td style="vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product<br/>
    Covered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    FOR<br/>
    POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED ANTIBODIES TO<br/>
    CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2033</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED ANTIBODIES TO<br/>
    CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2033</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    Kingdom</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED ANTIBODIES TO<br/>
    CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2033</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Germany</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED ANTIBODIES TO<br/>
    CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2033</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">France</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED ANTIBODIES TO<br/>
    CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2033</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED ANTIBODIES TO<br/>
    CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2033</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">09-Jun-2020</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    OF<br/>
    POTENTIATING ANTIMICROBIALS</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2037</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11-Jan-2019</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    OF<br/>
    POTENTIATING ANTIMICROBIALS</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2037</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29-Sep-2022</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    OF<br/>
    POTENTIATING ANTIMICROBIALS</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2037</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European
    Patent Convention<sup>(1)</sup></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11-Jan-2019</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    OF<br/>
    POTENTIATING ANTIMICROBIALS</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2037</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11-Jan-2019</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    OF<br/>
    POTENTIATING ANTIMICROBIALS</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2037</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13-Jul-2017</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS
    OF<br/>
    POTENTIATING ANTIMICROBIALS</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2037</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* Compositions comprising
    CB receptor agonists, uses thereof and methods for their preparation</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2029</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-160</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    Kingdom</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* Composition comprising
    cb receptor agonists and uses thereof</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2029</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-160</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Germany</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* Composition comprising
    cb receptor agonists and uses thereof</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2029</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-160</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">France</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* Composition comprising
    cb receptor agonists and uses thereof</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2029</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-160</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29-Jul-2009</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* COMPOSITIONS AND METHODS
    FOR<br/>
    TREATING INFLAMMATORY DISORDERS</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2029</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-2021</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING<br/>
    MICROVASCULAR INTEGRITY</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16-Sep-2021</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING<br/>
    MICROVASCULAR INTEGRITY</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-2021</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING<br/>
    MICROVASCULAR INTEGRITY</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European
    Patent Convention<sup>(1)</sup></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-2021</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING<br/>
    MICROVASCULAR INTEGRITY</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-2021</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING<br/>
    MICROVASCULAR INTEGRITY</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">India</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-2021</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING<br/>
    MICROVASCULAR INTEGRITY</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-2021</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING<br/>
    MICROVASCULAR INTEGRITY</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-2021</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING<br/>
    MICROVASCULAR INTEGRITY</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7-Jun-2023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING<br/>
    MICROVASCULAR INTEGRITY</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have also been granted a trademark for CannAmide&#8482;
in the United States with registration pending.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.5pt; text-indent: -0.25in"><span style="font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Validation states are not listed separately.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Sales and Transfer of Intellectual Property
Assets</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Transaction with Former Subsidiary</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2016, we entered into
a share transfer agreement with our former subsidiary, Orimmune Bio Ltd., or Orimmune, and Karma Link Ltd., or Karma Link. According to
the agreement, we agreed to sell our interests in Orimmune to Karma Link, and also use our best efforts to transfer to and assign Orimmune
our rights in the Anti-CD3 technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 13, 2018, an additional
amendment to the transfer agreement was signed, or the Additional Amendment, between us, Karma Link and Orimmune, under which it was agreed
that Orimmune (and Karma Link) will be assigned certain rights in IP related to the licensed technology owned by us, subject to certain
conditions precedent. In 2021, we received the approval of the IIA to complete the assignment and we are now seeking to complete the transaction.
As of the date of this prospectus, the conditions precedent have not yet been completed and the assignment of the intellectual property
rights related to the licensed technology owned by us has not yet been transferred.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>MitoCareX Bio</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 10, 2022, we entered
into a Founders and Investment Agreement with Dr. Alon Silberman, or the MitoCareX Agreement. Pursuant to the MitoCareX Agreement, we
invested an initial amount of $700,000 in MitoCareX and agreed to invest over the next two years an additional $1,000,000, subject to
the achievement of certain pre-determined milestones as agreed upon in the MitoCareX Agreement, for up to a 50.01% ownership in MitoCareX.
MitoCareX is focused on the discovery and development of potential drugs for cancers and other life-threatening conditions. The MitoCareX
Agreement also contains customary representations, warranties, covenants and indemnification provisions and on March 31, 2022, the closing
conditions were met.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 17, 2023, we announced
that MitoCareX has achieved its first milestone pursuant to the MitoCareX Agreement. The first milestone refers to the establishment of
MitoCareX&#8217;s cloud-based computing infrastructure that is expected to allow its future expansion into machine learning system. The
system is harnessed to investigating mitochondrial carriers that are crucial for cell viability. As a result of MitoCareX meeting this
milestone, we invested an additional $400,000 in MitoCareX and increase our share ownership holdings in MitoCareX Bio from 31.48% to 41.92%.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 8, 2023, we announced
that MitoCareX successfully developed its core algorithm for allowing the generation of reliable 3D comparative models of human SLC25A
mitochondrial carrier proteins.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 27, 2023, we announced
that MitoCareX achieved positive results with the development of its laboratory capabilities by establishing a variety of small-molecule
screening platforms. With this development, MitoCareX achieved its second milestone pursuant to the MitoCareX Agreement. We are contractually
obligated to complete the $600,000 payment sum pursuant to the achievement of the second milestone by March 24, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Commercialization</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we started early
commercialization of our proprietary PEA oral tablets CannAmide&#8482;, we intend to build a global commercial infrastructure to effectively
support the commercialization of our main pharmaceutical product candidates, if and when we believe regulatory approval of a pharmaceutical
product candidate in a particular geographic market appears imminent.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To develop the appropriate
commercial infrastructure, we will likely have to invest significant amounts of financial and management resources, some of which we expect
to commit prior to completing the regulatory process for our pharmaceutical product candidates. Where appropriate, we may elect in the
future to utilize strategic partners, distributors, or contract sales forces to assist in the commercialization of our pharmaceutical
products. In certain instances we may consider building our own commercial infrastructure.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2023, we entered into
a license and distribution agreement with SciSparc Nutraceuticals pursuant to which we granted SciSparc Nutraceuticals an exclusive license
to sell and market its PEA oral tablets, CannAmide&#8482; on Amazon Marketplace in Canada.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Competition</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The biotechnology and pharmaceutical
industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While
we believe that our scientific knowledge, technology and development experience provide us with competitive advantages, we face potential
competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic
institutions, governmental agencies and public and private research institutions. Any product candidates that we successfully develop
and commercialize will compete with existing therapies and new therapies that may become available in the future.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The first THC-based pharmaceutical,
a pill sold under the commercial name of Marinol (scientific name: dronabinol), was developed by a company called Unimed Pharmaceuticals,
with funding provided by the National Cancer Institute. In 1985, Marinol received FDA approval as a treatment for chemotherapy-related
nausea and vomiting. Today, Marinol is marketed by AbbVie, Inc. Since the introduction of Marinol into the market, other pharmaceuticals
containing THC have also been developed. These include generic oral capsules of dronabinol, such as those marketed by SVC Pharma LP and
Akorn Inc., Meda AB&#8217;s Cesamet (nabilone), a synthetic derivative of THC, and Sativex (nabiximols), a whole cannabis extract administered
as an oral spray. Furthermore, to the best of our knowledge, there are multiple companies that are working in the cannabis therapeutic
area and are pursuing regulatory approval for their product candidates. For example, GW, which markets Sativex, a botanical cannabinoid
oral mucosal for the treatment of spasticity due to multiple sclerosis, received FDA approval in the United States in June 2018 for Epidiolex,
a liquid formulation of highly purified cannabidiol extract, as a treatment for Dravet&#8217;s Syndrome, Lennox Gastaut Syndrome, and
various childhood epilepsy syndromes. In addition, GW is developing, among others, CBDV based therapy for ASD and therapy for neonatal
hypoxic-ischemic encephalopathy and schizophrenia. Zynerba is developing a transdermal formulation of cannabidiol for Fragile X and certain
refractory epilepsies and ASD. Skye is focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and
other diseases with significant unmet need. Corbus Pharmaceuticals Holdings is seeking FDA approval for their synthetic cannabinoid for
systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus and metabolism and solid tumors. RespireRx is developing
dronabinol for OSA treatment. Synendos is a developer of endocannabinoid modulators for the treatment of CNS disorders. It has developed
pharmaceutical products to restore the natural function of the brain and treat neuropsychiatric disorders. Synendos is developing small
molecules as selective endocannabinoid reuptake inhibitors that increase the levels of endogenous cannabinoids to treat CNS disorders
caused by cannabinoid deficiency. Inversago Pharma (formerly GIcare Pharma) is focused on developing peripheral cannabinoid, or CB1, receptor
antagonist/inverse agonist for the treatment of metabolic diseases such as obesity, insulin resistance, and liver fibrosis. Its drug INV-101
(Inverse agonist of peripheral CB1) under phase-1.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our competitors, either alone
or through their strategic partners, might have substantially greater name recognition and financial, technical, manufacturing, marketing
and human resources than we do and significantly greater experience and infrastructure in researching and developing pharmaceutical products,
obtaining FDA and other regulatory approvals of those products and commercializing those products around the world. They may also have
intellectual property portfolios that provide them with significant competitive advantages or create substantial barriers in our target
markets.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Manufacturing</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently contract with
third parties for the manufacturing and testing of our product candidates for preclinical trials and clinical trials and also intend to
do so in the future. We do not own or operate manufacturing facilities for the production of clinical quantities of our product candidates.
The use of contracted manufacturing and reliance on collaboration partners is relatively cost-efficient and may eliminate the need to
directly invest in manufacturing facilities and additional staff.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, our third-party manufacturers
have met our manufacturing requirements. We expect third-party manufacturers to be capable of providing sufficient quantities of our product
candidates to meet anticipated full scale commercial demands. To meet our projected needs for commercial manufacturing, third parties
with whom we currently work might need to increase their scale of production, or we will need to secure alternate suppliers. We believe
that there are alternate sources of supply that can satisfy our clinical and commercial requirements, although we cannot be certain that
identifying and establishing relationships with such sources, if necessary, would not result in significant delay or material additional
costs.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Government Regulation </b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>FDA Approval Process</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, pharmaceutical
product candidates are subject to extensive regulation by the FDA. The FDC Act, and other federal and state statutes and regulations,
govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion, marketing,
distribution, post-approval monitoring, reporting, sampling, and import and export of pharmaceutical drug product candidates. Failure
to comply with applicable U.S. rules and regulations may subject a company to a variety of administrative or judicial sanctions, such
as FDA refusal to approve pending NDAs, warning letters, product candidate recalls, product candidate seizures, total or partial suspension
of production or distribution, injunctions, fines, civil penalties and criminal prosecution.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pharmaceutical drug product
candidate development in the United States typically involves pre-clinical laboratory and animal testing, the submission to the FDA of
an IND Application, which must become effective before clinical testing may commence, and adequate, well-controlled clinical trials to
establish the safety and effectiveness of the drug for each indication for which FDA approval is sought. Satisfaction of FDA pre-market
approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity and
novelty of the product candidate or disease.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nonclinical tests include
laboratory evaluation of an API or drug substance and drug product&#8217;s candidate chemistry, formulation and toxicity, as well as animal
trials to assess the characteristics and potential safety and efficacy of the product candidate. The conduct of the nonclinical toxicology
studies must comply with federal regulations and requirements, including GLP. The results of nonclinical testing are submitted to the
FDA as part of an IND along with other information, including information about product candidate chemistry, manufacturing and controls,
and a proposed clinical trial protocol. Long term nonclinical tests, such as animal tests of reproductive toxicity and carcinogenicity,
may continue after the IND is submitted.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A 30-day waiting period after
the submission of an original IND is required prior to the commencement of clinical testing in humans. If the FDA has not imposed a clinical
hold on the IND or otherwise commented or questioned the IND within this 30-day period, the clinical trial proposed in the IND may begin.
In practice, a submitting party should contact the division after this 30-day period to ensure that the FDA has reviewed the IND to the
extent that they can assure there will be no hold placed on the IND if the FDA has not responded to the Company within this period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials involve the
administration of the investigational product to healthy volunteers or patients under the supervision of a qualified investigator. Clinical
trials must be conducted: (i) in compliance with federal regulations, (ii) in compliance with GCP, an international standard meant to
protect the rights and health of patients to ensure the quality of the trial and to define the roles of clinical trial sponsors, administrators
and monitors. Clinical protocols and details of the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness
criteria to be evaluated. Each protocol and any amendment involving testing of U.S. study subjects within the United States and subsequent
protocol amendments must be submitted to the FDA as part of the IND.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may order the temporary
hold of a clinical trial at any time or impose other sanctions if the FDA believes that the clinical trial either is not being conducted
in accordance with FDA requirements, regulations or presents a potentially unacceptable risk to the clinical trial subjects. The trial
protocol and informed consent information for subjects in clinical trials must also be submitted to an IRB for approval. An IRB may impose
other conditions for the protocol and may also require the clinical trial at the site to be halted, either temporarily or permanently,
for failure to comply with the IRB&#8217;s requirements.<i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>505(b)(2) Regulatory Approval Process</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 505(b)(2) of the FDC
Act, or 505(b)(2), provides a regulatory pathway to FDA approval for new or improved formulations or new uses of previously approved drug
products. Specifically, 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from
studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference, or use from the person
by or for whom the investigations were conducted. The applicant may rely upon the FDA&#8217;s prior findings of safety and efficacy for
an approved product that acts as the reference listed drug for purposes of a 505(b)(2) NDA. The FDA may also require 505(b)(2) applicants
to perform additional studies or measurements to support any changes from the reference listed drug. The FDA may then approve the new
product candidate for all or some of the labeled indications for which the referenced product has been approved, as well as for any new
indication sought by the 505(b)(2) applicant.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Orange Book Listing</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 505 of the FDC Act
describes three types of marketing applications that may be submitted to the FDA to request marketing authorization for a new drug. A
Section 505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A Section 505(b)(2) NDA is
an application that contains full reports of investigations of safety and efficacy, but where at least some of the information required
for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a
right of reference or use from the person by or for whom the investigations were conducted. This regulatory pathway enables the applicant
to rely, in part, on the FDA&#8217;s prior findings of safety and efficacy for an existing product, or published literature, in support
of its application.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In seeking approval for a
drug through an NDA, including a 505(b)(2) NDA, applicants are required to list with the FDA patents whose claims cover the applicant&#8217;s
product. Upon approval of an NDA, each of the patents listed in the application for the drug is then published in Approved Drug Products
with Therapeutic Equivalence Evaluations, also known as the Orange Book. These products may be cited by potential competitors in support
of approval of a 505(b)(2) NDA.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any applicant who submits
a 505(b)(2) NDA referencing a drug listed in the Orange Book must certify to the FDA that (1) no patent information on the drug product
that is the subject of the application has been submitted to the FDA; (2) such patent has expired; (3) the date on which such patent expires;
or (4) such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application
is submitted. This last certification is known as a Paragraph IV certification. Generally, 505(b)(2) NDA cannot be approved until all
listed patents have expired, except where 505(b)(2) NDA applicant challenges a listed patent through a Paragraph IV certification. If
the applicant does not challenge the listed patents or does not indicate that it is not seeking approval of a patented method of use,
the 505(b)(2) NDA application will not be approved until all of the listed patents claiming the referenced product have expired.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although some of our product
candidates are based on repurposed drugs, there are at present no patents or other exclusivities listed in the Orange Book pertaining
to a product containing the active ingredient dronabinol.<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Exclusivity</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Three-year exclusivity is
available to the holder of an NDA, including a 505(b)(2) NDA, for a particular condition of approval, or change to a marketed product,
such as a new formulation for a previously approved product, if one or more new clinical trials, other than bioavailability or bioequivalence
trials, was essential to the approval of the application and was conducted or sponsored by the applicant. This three-year exclusivity
period protects against FDA approval of 505(b)(2) NDAs for the condition of the new drug&#8217;s approval. As a general matter, three-year
exclusivity does not prohibit the FDA from approving 505(b)(2) NDAs for generic versions of the original, unmodified drug product. Five-year
and three-year exclusivity will not delay the submission or approval of a full NDA; however, an applicant submitting a full NDA would
be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials
necessary to demonstrate safety and efficacy.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>NDA Submission and Review by the FDA</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Assuming successful completion
of the required clinical and nonclinical testing, among other items, the results of product development, including chemistry, manufacture
and controls, nonclinical studies and clinical trials are submitted to the FDA, along with proposed labeling, as part of an NDA. The submission
of an NDA requires payment of a substantial user fee to the FDA. These user fees must be paid at the time of the first submission of the
application, even if the application is being submitted on a rolling basis. Fee waivers or reductions are available in some circumstances.
One basis for a waiver of the application user fee is if the applicant employs fewer than 500 employees, including employees of affiliates,
the applicant does not have an approved marketing application for a product that has been introduced or delivered for introduction into
interstate commerce, and the applicant, including its affiliates, is submitting its first marketing application.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost of preparing and
submitting an NDA is substantial, mainly due to the non-clinical and clinical trial costs. Under federal law, the submission of most NDAs
is additionally subject to a substantial application user fee; the fee in the fiscal year 2020 is $2,942,965.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA has 60 or 74 days
from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency&#8217;s threshold determination
that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth
review. The FDA has agreed to certain performance goals in the review of NDAs. Most such applications for standard review drug product
candidates are reviewed within 10 to 12 months, while most applications for priority review drugs are reviewed within six months. Priority
review can be applied to drugs that the FDA determines offer major advances in treatment or provide a treatment where no adequate therapy
exists. The review process for both standard and priority review may be extended by FDA for three additional months to consider certain
late-submitted information, or information intended to clarify information already provided in the submission.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may also refer applications
for novel drug product candidates, or drug product candidates that present difficult questions of safety or efficacy, to an advisory committee,
which is typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application
should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations.
Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA
may inspect the facility or the facilities at which the drug substance and drug product are manufactured. The FDA will not approve the
drug product candidate unless compliance with or current GMP, or cGMP, is satisfactory and the NDA contains data that provide substantial
evidence that the drug is safe and effective in the indication studied.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After the FDA evaluates the
NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter generally
outlines the deficiencies in the submission and may require substantial additional testing, or information, in order for the FDA to reconsider
the application. If, or when, those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the
FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of
requested information.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An approval letter authorizes
commercial marketing of the drug with specific prescribing information for specific indications. As a condition of NDA approval, the FDA
may require a REMS plan to help ensure that the benefits of the drug outweigh the potential risks. REMS can include medication guides,
communication plans for health care professionals, and ETASU. An ETASU can include, but are not limited to, special training or certification
for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The
requirement for a REMS can materially affect the potential market and profitability of the drug. Moreover, product candidate approval
may require substantial post-approval testing and surveillance to monitor the drug&#8217;s safety or efficacy. Once granted, product candidate
approvals may be withdrawn if compliance with regulatory standards is not maintained- related to the manufacture, safety, or effectiveness
- or problems are identified following initial marketing.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Disclosure of Clinical Trial Information</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sponsors of clinical trials
of certain FDA-regulated product candidates, including prescription drugs, are required to register and disclose certain clinical trial
information on a public website (clinicaltrials.gov) which is maintained by the U.S. National Institutes of Health. Information related
to the product candidate, patient population, phase of investigation, study sites and investigator, and other aspects of the clinical
trial is made public as part of the registration. Sponsors are also obligated to disclose the results of these trials after completion.
Disclosure of the results of these trials can be delayed until the product candidate drug product or new indication being studied has
been approved. Competitors may use this publicly available information to gain knowledge regarding the design and progress of our development
programs.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fast Track Designation and Accelerated Approval</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA has programs to facilitate
the development, and thus expedite the review, of drugs that are intended for the treatment of a serious or life-threatening disease or
condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the condition.
These therapies for serious conditions are approved and available to patients as soon as it can be concluded that the therapies&#8217;
benefits outweigh their risk. Under the Fast Track Program, the sponsor of a new drug candidate may request that FDA designate the drug
candidate for a specific indication as a Fast Track drug concurrent with, or after, the filing of the IND for the drug candidate. FDA
must determine if the drug candidate qualifies for Fast Track designation within 60 days of receipt of the sponsor&#8217;s request.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the FDA&#8217;s accelerated
approval regulations, FDA may approve a drug for a serious or life-threatening illness that provides meaningful therapeutic benefit to
patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit. Accelerated approval
may also be based on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely
to predict an effect on irreversible morbidity or mortality or other clinical benefit, considering the severity, rarity or prevalence
of the condition and the availability or lack of alternative treatments.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In clinical trials, a surrogate
endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a
patient feels, functions or survives. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. A
drug product that is approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of
confirmatory or post-approval clinical trial(s) or registries to confirm the effect on the clinical endpoint. Failure to conduct required
post-approval studies, or confirm a clinical benefit during post-marketing studies, will allow FDA to withdraw the drug from the market
on an expedited basis. All promotional materials for drug candidates approved under accelerated approval regulations are subject to prior
review by FDA.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to other benefits
such as the ability to use surrogate endpoints and engage in more frequent interactions with FDA, FDA may initiate review of sections
of a Fast Track drug&#8217;s NDA before the application is complete. This rolling review is available if the applicant provides, and FDA
approves, a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, FDA&#8217;s
time period goal for reviewing an application does not begin until the last section of the NDA is submitted. Additionally, the Fast Track
designation may be withdrawn by FDA if FDA believes that the designation is no longer supported by data emerging in the clinical trial
process.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patent Term Extension</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After NDA approval, owners
of relevant drug patents may apply for up to a five-year patent extension. The allowable patent term extension is calculated as half of
the drug&#8217;s testing phase, the time between IND submission and NDA submission, and all of the review phase-the time between NDA submission
and approval up to a maximum of five years. The time can be shortened if FDA determines that the applicant did not pursue approval with
due diligence. The total patent term after the extension may not exceed 14 years.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For patents that might expire
during the application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent
term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval patent extension is
reduced by one year. The director of the USPTO must determine that approval of the drug covered by the patent for which a patent extension
is being sought is likely. Interim patent extensions are not available for a drug for which an NDA has not been submitted.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Advertising and Promotion</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once an NDA is approved, a
drug product will be subject to certain post-approval requirements. Products manufactured or distributed by us pursuant to FDA approvals
are subject to continuing regulation by the FDA, including manufacturing, periodic reporting, product sampling and distribution, advertising,
promotion, drug shortage reporting, compliance with any post-approval requirements imposed as a conditional of approval such as Phase
4 clinical trials, REMS and surveillance, recordkeeping and reporting requirements, including adverse experiences. For instance, FDA closely
regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer advertising,
off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Drugs may be marketed only
for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established
in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and
FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new indication typically requires
clinical data similar to that in the original application. The FDA uses the same procedures and actions in reviewing NDA supplements as
it does in reviewing NDAs.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Adverse Event Reporting and GMP Compliance</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Adverse event reporting and
submission of periodic reports are required following FDA approval of an NDA. The FDA also may require post-marketing testing, known as
Phase 4 testing, REMS and surveillance to monitor the effects of an approved product candidate, or the FDA may place conditions on an
approval that could restrict the distribution or use of the drug product. In addition, quality-control, drug manufacture, packaging, and
labeling procedures must continue to conform with cGMPs after approval. Drug manufacturers and certain of their subcontractors are required
to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced
inspections by the FDA, during which the FDA inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers
must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMPs. Regulatory
authorities may withdraw product candidate approvals or request product candidate recalls if a company fails to comply with regulatory
standards, if it encounters problems following initial marketing or if previously unrecognized problems are subsequently discovered.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Pediatric Exclusivity and Pediatric Use</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Best Pharmaceuticals for
Children Act, or BPCA, provides NDA holders a six-month extension of any exclusivity-patent or non-patent-for a drug if certain conditions
are met. Conditions for exclusivity include a determination by the FDA that information relating to the use of a new drug in the pediatric
population may produce health benefits in that population; a written request by the FDA for pediatric studies; and agreement by the applicant
to perform the requested studies and the submission to the FDA; and the acceptance by the FDA, of the reports of the requested studies
within the statutory timeframe. Applications under the BPCA are treated as priority applications.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, under the Pediatric
Research Equity Act, or PREA, NDAs or supplements to NDAs must contain data to assess the safety and effectiveness of the drug for the
claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation
for which the drug is safe and effective, unless the sponsor has received a deferral or waiver from the FDA. Unless otherwise required
by regulation, PREA does not apply to any drug for an indication for which orphan designation has been granted with the exception of certain
oncological indications. The required pediatric assessment must assess the safety and effectiveness of the product candidate for the claimed
indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which
the product candidate is safe and effective. The sponsor or FDA may request a deferral of pediatric studies for some or all of the pediatric
subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults
before pediatric studies are complete or that additional safety or effectiveness data need to be collected before the pediatric studies
begin. Under PREA, the FDA must send a non-compliance letter requesting a response with 45 days to any sponsor that fails to submit the
required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Orphan Drugs</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Orphan Drug Act,
the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition-generally a disease or condition with
a prevalence of fewer than 200,000 individuals in the United States. Orphan drug designation must be requested and granted before submitting
an NDA. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly
by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.
The first NDA applicant to receive FDA approval for a particular active ingredient to treat a particular disease with an FDA orphan drug
designation is entitled to a seven-year exclusive marketing period in the United States for that drug product candidate for that indication.
During the seven-year exclusivity period, the FDA may not approve any other applications to market the same drug for the same disease,
except in limited circumstances, such as a showing of clinical superiority to the product candidate with orphan drug exclusivity. Orphan
drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different
disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA
application user fee. In addition to the potential seven years of market exclusivity after approval, orphan drug designation status qualifies
sponsors for tax credits for qualified clinical trials and exemption from user fees.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Special Protocol Assessment</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A company may reach an agreement
with the FDA under the Special Protocol Assessment, or SPA, process as to the required design and size of clinical trials intended to
form the primary basis of an efficacy claim. According to its performance goals, the FDA is supposed to evaluate the protocol within 45
days of the request to assess whether the proposed trial is adequate, and that evaluation may result in discussions and a request for
additional information. An SPA request must be made, and all open issues must be resolved before the clinical trial begins. If a written
agreement is reached, it will be documented and made part of the administrative record. Under the FDC Act and FDA guidance implementing
the statutory requirement, an SPA is generally binding upon the FDA except in limited circumstances, such as if the FDA identifies a substantial
scientific issue essential to determining safety or efficacy after the study begins, public health concerns emerge that were unrecognized
at the time of the protocol assessment, the sponsor and FDA agree to the change in writing, or if the study sponsor fails to follow the
protocol that was agreed upon with the FDA.<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Controlled Substances</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The CSA and its implementing
regulations establish a &#8220;closed system&#8221; of regulations for controlled substances. The CSA imposes registration, security,
recordkeeping and reporting, storage, manufacturing, distribution, importation and other requirements under the oversight of the DEA.
The DEA is the federal agency responsible for regulating controlled substances, and requires those individuals or entities that manufacture,
import, export, distribute, research, or dispense controlled substances to comply with the regulatory requirements in order to prevent
the diversion of controlled substances to illicit channels of commerce.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The DEA categorizes controlled
substances into one of five schedules-Schedule I, II, III, IV or V-with varying qualifications for listing in each schedule. Schedule
I substances by definition have a high potential for abuse, have no currently accepted medical use in treatment in the United States and
lack accepted safety for use under medical supervision. Schedule I substances may be used only in federally approved research programs
and may not be marketed or sold for dispensing to patients in the United States. Pharmaceutical product candidates having a currently
accepted medical use that are otherwise approved for marketing may be listed as Schedule II, III, IV or V substances, with Schedule II
substances presenting the highest potential for abuse and physical or psychological dependence, and Schedule V substances presenting the
lowest relative potential for abuse and dependence. The regulatory requirements are more restrictive for Schedule II substances than Schedule
III substances. For example, all Schedule II drug prescriptions must be signed by a physician, physically presented to a pharmacist in
most situations and cannot be refilled.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following NDA approval of
a drug containing a Schedule I controlled substance, that substance must be rescheduled as a Schedule II, III, IV or V substance before
it can be marketed. In 2015, the Improving Regulatory Transparency for New Medical Therapies Act, removed uncertainty associated with
timing of the DEA rescheduling process after NDA approval. Specifically, it requires DEA to issue an &#8220;interim final rule,&#8221;
pursuant to which a manufacturer may market its product candidate within 90 days of FDA approval. The new law also preserves the period
of orphan marketing exclusivity for the full seven years such that this period only begins after DEA scheduling. This contrasts with the
previous situation whereby the orphan &#8220;clock&#8221; began to tick upon FDA approval, even though the product candidate could not
be marketed until DEA scheduling was complete.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Facilities that manufacture,
distribute, import or export any controlled substance must register annually with the DEA. The DEA registration is specific to the particular
location, activity(ies) and controlled substance schedule(s). For example, separate registrations are required for importation and manufacturing
activities, and each registration authorizes which schedules of controlled substances the registrant may handle. However, certain coincident
activities are permitted without obtaining a separate DEA registration, such as distribution of controlled substances by the manufacturer
that produces them.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The DEA inspects all manufacturing
facilities to review security, recordkeeping, reporting and handling prior to issuing a controlled substance registration. The specific
security requirements vary by the type of business activity and the schedule and quantity of controlled substances handled. The most stringent
requirements apply to manufacturers of Schedule I and Schedule II substances. Required security measures commonly include background checks
on all employees and physical control of controlled substances through storage in approved vaults, safes and cages, and through use of
alarm systems and surveillance cameras. An application for a manufacturing registration as a bulk manufacturer (not a dosage form manufacturer
or a repacker/relabeler) for a Schedule I or II substance must be published in the Federal Register, and the application is open for 30
days to permit interested persons to submit comments, objections or requests for a hearing. A copy of the notice of the Federal Register
publication is forwarded by DEA to all those registered, or applicants for registration, as bulk manufacturers of that substance. Once
registered, manufacturing facilities must maintain records documenting the manufacture, receipt and distribution of all controlled substances.
Manufacturers must submit periodic reports to the DEA of the distribution of Schedule I and II controlled substances, Schedule III narcotic
substances, and other designated substances. Registrants must also report any controlled substance thefts or significant losses, and must
obtain authorization to destroy or dispose of controlled substances. As with applications for registration as a bulk manufacturer, an
application for an importer registration for a Schedule I or II substance must also be published in the Federal Register, which remains
open for 30 days for comments. Imports of Schedule I and II controlled substances for commercial purposes are generally restricted to
substances not already available from domestic supplier or where there is not adequate competition among domestic suppliers. In addition
to an importer or exporter registration, importers and exporters must obtain a permit for every import or export of a Schedule I and II
substance or Schedule III, IV and V narcotic, and submit import or export declarations for Schedule III, IV and V non-narcotics. In some
cases, Schedule III non-narcotic substances may be subject to the import/export permit requirement, if it is necessary to ensure that
the United States complies with its obligations under international drug control treaties.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For drugs manufactured in
the United States, the DEA establishes annually an aggregate quota for the amount of substances within Schedules I and II that may be
manufactured or produced in the United States based on the DEA&#8217;s estimate of the quantity needed to meet legitimate medical, scientific,
research and industrial needs. This limited aggregate amount of cannabis that the DEA allows to be produced in the United States each
year is allocated among individual companies, which, in turn, must annually apply to the DEA for individual manufacturing and procurement
quotas. The quotas apply equally to the manufacturing of the API/drug substance and production of dosage forms. The DEA may adjust aggregate
production quotas a few times per year, and individual manufacturing or procurement quotas from time to time during the year, although
the DEA has substantial discretion in whether or not to make such adjustments for individual companies.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Individual states may also
maintain separate controlled substance laws and regulations, including licensing, recordkeeping, security, distribution, and dispensing
requirements. State Authorities, including Boards of Pharmacy, regulate use of controlled substances in each state. Failure to maintain
compliance with applicable requirements, particularly as manifested in the loss or diversion of controlled substances, can result in enforcement
action that could have a material adverse effect on our business, operations and financial condition. The DEA may seek civil penalties,
refuse to renew necessary registrations, or initiate proceedings to revoke those registrations. In certain circumstances, violations could
lead to criminal prosecution.<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Europe/Rest of World Government Regulation</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to regulations
in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution
of our products to the extent we choose to develop or sell any products outside of the United States. The approval process varies from
country to country and the time may be longer or shorter than that required to obtain FDA approval. The requirements governing the conduct
of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Whether or not we obtain FDA
approval for a product candidate, we must obtain the requisite approvals from regulatory authorities in non-U.S. countries prior to the
commencement of clinical trials or marketing of the product candidate in those countries. Certain countries outside of the United States
have a process that requires the submission of a Clinical Trial Application, or CTA, much like an IND prior to the commencement of human
clinical trials. In Europe, for example, a CTA must be submitted to the competent national health authority and to independent ethics
committees in each country in which a company intends to conduct clinical trials. Once the CTA is approved in accordance with a country&#8217;s
requirements, clinical trial development may proceed in that country.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The requirements and process
governing the conduct of clinical trials, product candidate licensing, pricing and reimbursement vary from country to country, even though
there is already some degree of legal harmonization in the European Union member states resulting from the national implementation of
underlying European Union legislation. In all cases, the clinical trials are conducted in accordance with GCP and other applicable regulatory
requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To obtain regulatory approval
of an investigational drug under the European Union. regulatory systems, we must submit a MAA. This application is similar to the NDA
in the United States, with the exception of, among other things, country-specific document requirements. Drugs can be authorized in the
European Union by using (i) the centralized authorization procedure, (ii) the Mutual Recognition Procedure, or MRP, (iii) the decentralized
procedure or (iv) national authorization procedures. The initial Sativex approvals were a consequence of an application under the De-Centralized
Procedure, or DCP, to the European Union member state of Spain.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The European Commission implemented
the centralized procedure for the approval of human drugs to facilitate marketing authorizations that are valid throughout the European
Economic Area, or EEA. This procedure results in a single marketing authorization granted by the European Commission that is valid across
the European Union, as well as in Iceland, Liechtenstein and Norway (forming together the EEA). The centralized procedure is compulsory
for human drugs that are: (i) derived from biotechnology processes, such as genetic engineering, (ii) contain a new active substance indicated
for the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative diseases, autoimmune and other immune dysfunctions
and viral diseases, (iii) officially designated &#8220;orphan drugs&#8221; (drugs used for rare human diseases) and (iv) advanced-therapy
medicines, such as gene- therapy, somatic cell-therapy or tissue-engineered medicines. The centralized procedure may at the request of
the applicant also be used for human drugs which do not fall within the above mentioned categories if the human drug (a) contains a new
active substance which, on the date of entry into force of this Regulation, was not authorized in the Community; or (b) the applicant
shows that the medicinal product candidate constitutes a significant therapeutic, scientific or technical innovation or that the granting
of authorization in the centralized procedure is in the interests of patients or animal health at the European Community level.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the centralized procedure
in the European Union, the maximum timeframe for the evaluation of a MAA by the EMA is 210 days (excluding clock stops, when additional
written or oral information is to be provided by the applicant in response to questions asked by the Committee for Medicinal Products
for Human Use, or CHMP, with adoption of the actual marketing authorization by the European Commission thereafter. Accelerated evaluation
might be granted by the CHMP in exceptional cases, when a medicinal product candidate is expected to be of a major public health interest
from the point of view of therapeutic innovation, defined by three cumulative criteria: (1) the seriousness of the disease to be treated;
(2) the absence of an appropriate alternative therapeutic approach, and (3) anticipation of exceptional high therapeutic benefit. In this
circumstance, EMA ensures that the evaluation for the opinion of the CHMP is completed within 150 days and the opinion issued thereafter.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Should any Member State refuse
to recognize the marketing authorization by the reference member state in a decentralized procedure, on the grounds of potential serious
risk to public health, the issue will be referred to the Committee for the Mutual Recognition and Decentralized Procedures human. Within
a timeframe of 60 days, member states shall, within the coordination group, make all efforts to reach a consensus. If this fails, the
procedure is submitted to the CHMP for arbitration. The opinion of the CHMP is then forwarded to the Commission, for the start of the
decision making process. As in the centralized procedure, this process entails consulting various European Commission Directorates General
and the Standing Committee on Human Medicinal Product candidates or Veterinary Medicinal Product candidates, as appropriate. Since the
initial approvals of Sativex in the United Kingdom and Spain, there have been three &#8220;waves&#8221; of additional approvals under
three separate MRPs. Each of these procedures have been completed without any referral, and therefore without any delay.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For other countries outside
of the European Union, the requirements governing the conduct of clinical trials, product candidate licensing, pricing and reimbursement
vary from country to country. In all cases, again, the clinical trials are conducted in accordance with GCP and the other applicable regulatory
requirements.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we fail to comply with
applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical trials, suspension
or withdrawal of regulatory approvals, product candidate recalls, seizure of product candidates, operating restrictions and criminal prosecution.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, most countries
are parties to the Single Convention on Narcotic Drugs 1961, which governs international trade and domestic control of narcotic substances,
including cannabis extracts. Countries may interpret and implement their treaty obligations in a way that creates a legal obstacle to
our obtaining marketing approval for Sativex and our other product candidates in those countries. These countries may not be willing or
able to amend or otherwise modify their laws and regulations to permit Sativex or our other product candidates to be marketed, or achieving
such amendments to the laws and regulations may take a prolonged period of time. In that case, we would be unable to market our product
candidates in those countries in the near future or perhaps at all.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Expanded Access to Investigational Drugs
in the U.S.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An investigational drug may
be eligible for clinical use outside the context of a manufacturer&#8217;s clinical trial of the drug. &#8220;Expanded access&#8221; refers
to the use of an investigational drug where the primary purpose is to diagnose, monitor, or treat a patient&#8217;s disease or condition
rather than to collect information about the safety or effectiveness of a drug. Expanded access INDs are typically sponsored by individual
physicians to treat patients who fall into one of three FDA-recognized categories of expanded access: expanded access for individual patients,
including for emergency use; expanded access for intermediate-size patient populations; and expanded access for large patient populations
under a treatment IND or treatment protocol. For all types of expanded access, the FDA must determine prior to authorizing expanded access
that: (1) the patient or patients to be treated have a serious or life threatening disease or condition and there is no comparable or
satisfactory alternative therapy; (2) the potential patient benefit justifies the potential risks of use and that the potential risks
are not unreasonable in the context of the disease or condition to be treated; and (3) granting the expanded access will not interfere
with the initiation, conduct, or completion of clinical studies in support of the drug&#8217;s approval. In addition, the sponsor of an
expanded access IND must submit IND safety reports and, in the cases of protocols continuing for one year or longer, annual reports to
the FDA. Expanded access programs are not intended to yield information relevant to evaluating a drug&#8217;s effectiveness for regulatory
purposes. If a patient enrolled in one of our clinical trials is not eligible or able to continue enrollment, we may be required to continue
to provide our product candidate to such patient through expanded access.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Pricing and Reimbursement in the U.S.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales of pharmaceutical product
candidates in the United States will depend, in part, on the extent to which the costs of the product candidates will be covered by third-party
payors, such as government health programs, commercial insurance and managed health care organizations. These third-party payors are increasingly
challenging the prices charged for medical product candidates and services. Additionally, the containment of health care costs has become
a priority of federal and state governments, and the prices of drugs have been a focus in this effort. The United States government, state
legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls,
restrictions on reimbursement and requirements for substitution of generic product candidates. Adoption of price controls and cost-containment
measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net
revenue and results. If these third-party payors do not consider our product candidates to be cost-effective compared to other available
therapies, they may not cover our product candidates after approval as a benefit under their plans or, if they do, the level of payment
may not be sufficient to allow us to sell our product candidates on a profitable basis.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Medicare Prescription
Drug, Improvement, and Modernization Act of 2003, or the MMA, imposed new requirements for the distribution and pricing of prescription
drugs for Medicare beneficiaries and included a major expansion of the prescription drug benefit under Medicare Part D. Under Part D,
Medicare beneficiaries may enroll in prescription drug plans offered by private entities which will provide coverage of outpatient prescription
drugs. Part D plans include both stand-alone prescription drug benefit plans and prescription drug coverage as a supplement to Medicare
Advantage plans. Unlike Medicare Part A and B, Part D coverage is not standardized. Part D prescription drug plan sponsors are not required
to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and
at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of
covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part D prescription drug
plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription
drugs may increase demand for product candidates for which we receive marketing approval. However, any negotiated prices for our product
candidates covered by a Part D prescription drug plan will likely be lower than the prices we might otherwise obtain. Moreover, while
the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations
in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from
non-governmental payors.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2010, the Patient
Protection and ACA was enacted. This sweeping law was intended to broaden access to health insurance, reduce or constrain the growth of
healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements (inclusive of price increases) for healthcare
and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. Effective
October 1, 2010, the ACA revised the definition of &#8220;average manufacturer price&#8221; for reporting purposes, which could increase
the amount of all Medicaid drug rebates. On January 21, 2016, the Centers for Medicare and Medicaid Services, or CMS, finalized a rule
detailing reforms to the rebate and reimbursement systems for Medicaid prescription drugs. This final rule was intended to save taxpayers
billions and ultimately improve beneficiary access to prescription drugs. The final rule allows manufacturers to recalculate the baseline
&#8220;average manufacturer price&#8221; and includes U.S. territories in the calculation of &#8220;average manufacturer price&#8221;
and &#8220;best price&#8221; effective April 1, 2017. Further, the new law imposes a significant annual fee on companies that manufacture
or import certain branded prescription drug products and biologic agents. On December 31, 2020, CMS issued a final rule to support state
flexibility to enter into value-based purchasing arrangements, or VBPs, with manufacturers for prescription drugs and to provide manufacturers
with regulatory support to enter into VBPs with payors, including Medicaid. This final rule is intended in part to further value-based
payment arrangements. Implementation of certain aspects of this final rule were delayed until July 1, 2022. Substantial new provisions
affecting compliance also have been enacted, which may require us to modify our business practices with healthcare practitioners and also
may increase our regulatory burdens and operating costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since its enactment, there
have been judicial and Congressional challenges to certain aspects of the law. The ACA may be modified, amended or repealed at any time
and may or may not be replaced with a different law or health care payment system. The ACA is expected to continue to have a significant
impact on the health care industry. With regard to pharmaceutical product candidates, among other things, the ACA may expand and increase
industry rebates for drugs covered under Medicaid programs and make changes to the coverage requirements under the Medicare Part D program.
Since the enactment of the ACA, numerous regulations have been issued providing further guidance on its requirements. The ACA continues
to be implemented through regulation and government activity but is subject to possible amendment, additional implementing regulations
and interpretive guidelines. Several states have decided not to expand their Medicaid programs and are seeking alternative reimbursement
models to provide care to the uninsured. The manner in which these issues are resolved could materially affect the extent to which and
the amount at which pharmaceuticals are reimbursed by government programs such as Medicare, Medicaid and Tricare. We are unable to predict
the full impact of any potential modification, amendment, or repeal of the ACA.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to commercialize
any products successfully also will depend in part on the extent to which coverage and adequate reimbursement for our products, once approved,
and related treatments will be available from third-party payors, such as government health administration authorities, private health
insurers and managed care organizations. Third-party payors determine which medications they will cover and separately establish reimbursement
levels. Even if we obtain coverage for a given product by a third-party payor, the third-party payor&#8217;s reimbursement rates may not
be adequate to make the product affordable to patients or profitable to us, or the third-party payors may require co-payments that patients
find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians,
generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely
to use our products unless coverage is provided, and reimbursement is adequate to cover all or a significant portion of the cost of our
products. Therefore, coverage and adequate reimbursement is critical to new product acceptance. Coverage decisions may depend upon clinical
and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available
or subsequently become available.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Government authorities and
other third-party payors are developing increasingly sophisticated methods of controlling healthcare costs, such as by limiting coverage
and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide
them with predetermined discounts from list prices as a condition of coverage, are using restrictive formularies and preferred drug lists
to leverage greater discounts in competitive classes and are challenging the prices charged for medical products. Further, no uniform
policy for determining coverage and reimbursement for drug products exists among third-party payors in the United States. Therefore, coverage
and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often
a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each
payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot be sure that coverage
and reimbursement will be available for any product that we commercialize and, if reimbursement is available, that the level of reimbursement
will be adequate. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing
approval. If coverage and reimbursement are not available, or if reimbursement is available only to limited levels, we may not successfully
commercialize any product candidate for which we obtain marketing approval.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a condition of receiving
Medicaid coverage for prescription drugs, the Medicaid Drug Rebate Program requires manufacturers to calculate and report to CMS their
AMP, which is used to determine rebate payments shared between the states and the federal government and, for some multiple source drugs,
Medicaid payment rates for the drug, and for drugs paid under Medicare Part B, to also calculate and report their average sales price,
which is used to determine the Medicare Part B payment rate for the drug. In January 2016, CMS issued a final rule regarding the Medicaid
Drug Rebate Program, effective April 1, 2016, that, among other things, revised the manner in which the AMP is calculated by manufacturers
participating in the program and implemented certain amendments to the Medicaid rebate statute created under the ACA. Drugs that are approved
under an NDA, including a 505(b)(2) NDA, are subject to an additional requirement to calculate and report the manufacturer&#8217;s best
price for the drug and inflation penalties which can substantially increase rebate payments. On December 21, 2020, CMS issued a final
rule that made changes to the Medicaid Drug Rebate Program regulations in several areas, including some changes to the treatment of value-based
purchasing arrangements and price reporting for patient benefit programs sponsored by pharmaceutical manufacturers.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For NDA drugs, the Veterans
Health Care Act of 1992 requires manufacturers to calculate and report to the Department of Veterans Affairs a different price called
the Non-Federal AMP, offer the drugs for sale on the Federal Supply Schedule, and charge the government no more than a statutory price
referred to as the Federal Ceiling Price, which includes an inflation penalty. A separate law requires manufacturers to pay rebates on
these drugs when paid by the Department of Defense under its TRICARE Retail Pharmacy Program. Knowingly submitting false pricing information
to the government creates potential federal False Claims Act liability.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, there has been increasing
legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been
several recent U.S. Congressional inquiries and proposed and enacted legislation at the federal and state levels designed to, among other
things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the
cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. We expect that the pharmaceutical industry
will continue to experience pricing pressures due to the trend toward managed healthcare, particularly towards specialty pharmacy, the
increasing influence of managed care organizations, and additional legislative proposals. For example, CMS issued an interim final rule
on November 27, 2020 designed to test whether a Most-Favored-Nation model will help control growth in spending for Medicare Part B drugs
without adversely affecting quality of care. This followed an Executive Order issued in September 2020 that directed the Secretary of
DHHS to implement new payment models under the Medicare Part B and Part D programs to curb &#8220;unfair&#8221; and high drug prices in
the United States. Implementation of this interim final rule was blocked by a temporary restraining order and preliminary injunctions
through various court actions and CMS published a final rule on December 27, 2021 that rescinded the interim final rule. Nonetheless,
we expect that there will continue to be a number of U.S. federal and state proposals to implement governmental pricing controls and limit
the growth of healthcare costs, including the cost of prescription drugs. It is unknown what form any such changes or any law would take,
and how or whether it may affect the biopharmaceutical industry as a whole or our business in the future. We expect that changes or additions
to the ACA, the Medicare and Medicaid programs, such as changes allowing the federal government to directly negotiate drug prices, and
changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing or other legislation in
individual states, could have a material adverse effect on the health care industry in the United States.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.6pt; text-align: justify; text-indent: 30.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.6pt; text-align: justify; text-indent: 30.4pt">At the state level,
legislatures have been increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological
product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing
cost disclosure and transparency measures, drug price increases, and, in some cases, designed to encourage importation from other countries
and bulk purchasing. On the federal level, the Trump Administration issued a final rule in 2020 for the safe importation of drugs from
Canada and other countries. Per this rule, the FDA authorized its first section 804 importation program, or SIP, a program allowing the
State of Florida to import certain prescription products from Canada. Section 804 (21 U.S.C. &#167; 384) of the Federal Food, Drug, and
Cosmetic Act provides a pathway for U.S. states and Indian tribes to allow importation of certain prescription drugs from Canada. Programs
under this pathway must significantly reduce the cost of these drugs to the American consumer without imposing additional risk to public
health and safety. As the first program of its kind, we have yet to see how this Program will be implemented and what specific products
will be imported. There is much opposition from the biopharmaceutical industry regarding this Program, but if Florida can execute it as
planned, it may signal a trend in the U.S. The practical implications of SIPs, and their implications for the biopharmaceutical industry
as a whole or our business in particular remain to be determined.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.6pt; text-align: justify; text-indent: 30.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.6pt; text-align: justify; text-indent: 30.4pt"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.6pt; text-align: justify; text-indent: 30.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2021, the Biden administration
issued an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at increasing competition
for prescription drugs. The DHHS has released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing
reform and potential legislative policies that Congress could pursue to advance these principles. While no legislation or administrative
actions have been finalized to implement these principles, Congress is considering legislation that, if passed, could have significant
impact on prices of prescription drugs covered by Medicare, including limitations on drug price increases and allowing Medicare to negotiate
pricing for certain covered drug products. The impact of these legislative, executive, and administrative actions and any future healthcare
measures and agency rules implemented by the Biden administration on us and the pharmaceutical industry as a whole is unclear. The implementation
of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or
commercialize any of the product candidates for which we receive approval.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt; text-align: justify; text-indent: 34.05pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt; text-align: justify; text-indent: 34.05pt">The passage of
the Inflation Reduction Act, or the IRA, of 2022 further affects Medicare reimbursement. The IRA has three key elements reforming Medicare
drug-pricing policy. The implementation of certain elements of the IRA are still forthcoming, as outlined below, so the specific implications
for biopharmaceutical pricing and reimbursement are yet to be determined. Likewise, we are unable to predict potential modification, amendment,
or repeal of the IRA, though some predict that challenges may be made as different provisions are enacted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt; text-align: justify; text-indent: 34.05pt">As the first
key element, the IRA created a program for Medicare drug-price negotiation, enabling the Secretary of DHHS to negotiate the prices of
certain costly, single-source drugs or biologics within the Medicare program. Certain drugs and biologics are excluded from this negotiation
process, such as drugs that are less than 9 years, and biologics less than 13 years, from their FDA-approval or licensure date, and drugs
with an orphan designation as their only FDA-approved indication. The first set of these negotiated prices will not take effect until
2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt; text-align: justify; text-indent: 34.05pt">Second, the IRA
requires drug manufacturers to pay rebates to the federal government for price increases above the rate of inflation for single-source
drugs or biologics covered under Medicare Part B and most drugs under Medicare Part D, which already occurs under the Medicaid program.
This inflation-rebate provision for Medicare Part B took effect at the start of 2023, and such provision for Medicare Part D took effect
in 2022 as the starting point for measuring drug-price increases, with rebate payments required as of the beginning of 2023. DHHS will
start to send rebate invoices to drug manufacturers in 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt; text-align: justify; text-indent: 34.05pt">Third, the IRA
restructures the Medicare Part D benefit to limit patients&#8217; out-of-pocket costs and rebalance the bearing of risk for Part D plans
and manufacturers. As of 2024, Medicare Part D plan buyers will no longer have to pay out-of-pocket costs for covered drugs once they
reach the catastrophic coverage level (when the policyholder&#8217;s out-of-pocket spending reaches $7,400). Other aspects of this provision
will take effect in 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The bipartisan <i>Drug-Price
Transparency for Consumers Act</i> was introduced to Senate on April 20, 2023, and the House of Representatives on October 13, 2023 (S.1250
and H.R.5958, respectively). The Act is currently in committee. This Act would require that direct-to-consumer advertisements for drugs
and biologics include a disclosure of pricing information. The Act would apply to drugs and biologicals reimbursable under Medicare or
Medicaid and for which direct-to-consumer advertisements are required to include information relating to side effects, contraindications,
and effectiveness in accordance with section 202.1(e)(1) of title 21, Code of Federal Regulations. If passed, this Act would amend the
Social Security Act to allow the Secretary of DHHS to require such advertisements to disclose the wholesale acquisition cost, or WAC,
for a 30-day supply or typical course of treatment and clearly and conspicuously present such price information. If enacted, the Act contemplates
that implementing regulations would include the visual and audio components required to communicate the WAC appropriately for the medium
of the advertisement, the reasonable amount of time to update the advertisement to reflect any changes to WAC, and the way the manufacturer
may include a statement explaining that certain consumers may pay a different amount depending on their insurance coverage. The Act would
also subject advertisers to a penalty of up to $100,000 per violation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt; text-align: justify; text-indent: 34.05pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt; text-align: justify; text-indent: 34.05pt"></p><div>

</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt; text-align: justify; text-indent: 34.05pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt; text-align: justify; text-indent: 34.05pt">The full implications
of changes such as those discussed above, and their practical impact on biopharmaceutical pricing and reimbursement, as well as advertising
requirements and related costs, on the biopharmaceutical industry as a whole and our business in particular cannot yet be determined.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt; text-align: justify; text-indent: 34.05pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As noted above, the marketability
of any products for which we receive regulatory approval for commercial sale may suffer if the government and other third-party payors
fail to provide adequate coverage and reimbursement. We expect that an increasing emphasis on cost containment measures in the U.S. will
continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time.
Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less
favorable coverage policies and reimbursement rates may be implemented in the future.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Pricing and Reimbursement in Foreign Countries</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, in some foreign
countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing
vary widely from country to country. For example, a member state of the European Union may approve a specific price for the medicinal
product candidate. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical
product candidates will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, product
candidates launched in the European Union do not follow price structures of the United States and generally tend to be significantly lower.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As another example, in Canada,
for patented drugs, the Patented Medicines Prices Review Board, or PMPRB, uses the median international publicly available ex-factory
list price (using prices in 11 pre-determined countries) as the maximum price the Company is allowed to charge. The PMPRB is a quasi-judicial
body with a regulatory mandate to prevent pharmaceutical patentees from charging consumers excessive prices during the market exclusivity
period. This agency then monitors the prices charged by patentees for patented drugs on an ongoing basis. Under the Canadian Patent Act,
patentees are required to file price and sales information about their patented drug products at introduction and twice a year thereafter
for each strength of each dosage form of each patented drug product sold in Canada.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other Health Care Laws and Compliance Requirements</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, our
activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including CMS,
other divisions of the DHHS (e.g., the Office of Inspector General), the U.S. Department of Justice and individual U.S. Attorney offices
within the Department of Justice, and state and local governments.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The federal AKS prohibits,
among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly
or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, the referral of an individual for, or purchasing,
leasing, ordering, or arranging for the purchase, lease or order of, any good, facility, item or service reimbursable, in whole or in
part, by Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything
of value, including unlawful financial inducements paid to prescribers and beneficiaries, as well as impermissible promotional practices.
There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but the exceptions
and safe harbors are drawn narrowly. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory
safe harbor does not make the conduct per se illegal under the federal AKS. Instead, the legality of the arrangement will be evaluated
on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Additionally, the ACA amended the intent requirement
of the federal AKS so that a person or entity no longer needs to have actual knowledge of the federal AKS, or specific intent to violate
it, to have violated the statute. The ACA also provided that a violation of the federal AKS is grounds for the government or whistleblower
to assert that a claim for payment of items or services resulting from such violation constitutes a false or fraudulent claim for purposes
of the civil False Claims Act.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, in November 2020,
DHHS finalized a regulation aimed at lowering prescription drug prices and out-of-pocket spending for prescription drugs by excluding
rebates on prescription drugs paid by manufacturers to or purchased by Medicare Part D plan sponsors or PBMs acting under contract with
Medicare Part D plan sponsors from the existing discount safe harbor under the federal AKS. The regulation reflects the first change to
the AKS discount safe harbor since the Medicare Part D program was established. In addition to the rebate exclusions, two new safe harbors
were added. One of these new safe harbors protects point-of-sale reductions in price from a manufacturer to a plan sponsor under Medicare
Part D or a MCO for a prescription drug payable, in whole or in part, by a plan sponsor under Medicare Part D or a MCO, provided certain
conditions are met. The other protects certain fixed-fee services arrangements between manufacturers and PBMs.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The federal civil and criminal
false claims laws, including the federal False Claims Act, prohibit, among other things, any person or entity from knowingly presenting,
or causing to be presented, a false claim for payment to, or for approval by, the federal government, including the Medicare and Medicaid
programs, or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim
to avoid, decrease or conceal an obligation to pay money to the federal government.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The civil monetary penalties
statute imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented
a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or
is false or fraudulent.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">HIPAA created additional federal
criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit
program, including public and private payors, or obtain, by means of false or fraudulent pretenses, representations or promises, any of
the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of whether the payor is
public or private, knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal
investigation of a health care offense and knowingly and willfully falsifying, concealing or covering up by any trick or device a material
fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services
relating to healthcare matters. The ACA amended the federal health care fraud criminal statute implemented under HIPAA so that a person
or entity no longer needs to have actual knowledge of the statute, or the specific intent to violate it, to have violated the statute.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, the federal
Open Payments program pursuant to the Physician Payments Sunshine Act, created under Section 6002 of the ACA and its implementing regulations,
require some manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid
or the Children&#8217;s Health Insurance Program (with specified exceptions) to report annually information related to specified payments
or other transfers of value provided to physicians and teaching hospitals, or to entities or individuals at the request of, or designated
on behalf of, the physicians and teaching hospitals and to report annually specified ownership and investment interests held by physicians
and their immediate family members. The SUPPORT Act, signed into law on October 24, 2018, expanded Sunshine Act reporting to include data
for physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and certified nurse
midwifes. The amendment applies to reports submitted to CMS on or after January 1, 2022.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we may be subject
to data privacy and security regulation by both the federal government and the states in which we conduct our business or target consumers.
The Health Insurance Portability and Accountability Act, as amended by the Health Information Technology for Economic and Clinical Health
Act, or HITECH, and their implementing regulations, collectively HIPAA, impose requirements relating to the privacy, security and transmission
of individually identifiable health information on HIPAA covered entities and their business associates, including mandatory contractual
terms and the implementation of certain safeguards of such information. Among other things, HITECH makes HIPAA&#8217;s security standards
directly applicable to business associates, independent contractors or agents of covered entities that receive or obtain protected health
information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary
penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general
new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217;
fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information
in some circumstances, many of which differ from each other in significant ways, may not have the same effect and may not be preempted
by HIPAA, thus complicating compliance efforts.&#160;Most recently, fourteen states including California have adopted laws that regulate
the privacy and security of consumer personal information, and apply in instances where HIPAA and clinical trial laws do not. In addition,
other states such as Washington, have adopted laws that regulate the privacy and security of consumer health data which, again, apply
in instances where HIPAA and clinical trial laws do not.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many states have also adopted
laws similar to each of the above federal laws, which may be broader in scope and apply to items or services reimbursed by any payor,
including commercial insurers. We may also be subject to state laws that require pharmaceutical companies to comply with the pharmaceutical
industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, and/or state
laws that require drug manufacturers to report information related to marketing expenditures or payments and other transfers of value
to physicians and other healthcare providers.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Enforcement actions can be
brought by federal or state governments or, in some cases, as &#8220;qui tam&#8221; actions brought by individual whistleblowers in the
name of the government. Depending on the circumstances, failure to comply with these laws can result in penalties, including criminal,
civil and/or administrative criminal penalties, damages, fines, disgorgement, debarment from government contracts, individual imprisonment,
additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve
allegations of non-compliance with these laws, exclusion from government programs, refusal to allow us to enter into supply contracts,
including government contracts, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our
operations, any of which could adversely affect our business.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to distribute product
candidates commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of pharmaceutical
product candidates in a state, including, in certain states, manufacturers and distributors who ship product candidates into the state,
even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers
and distributors to establish the pedigree of product candidate in the chain of distribution, including some states that require manufacturers
and others to adopt new technology capable of tracking and tracing product candidate as it moves through the distribution chain. Several
states have enacted legislation requiring pharmaceutical companies to establish marketing compliance programs, file periodic reports with
the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities or register their sales
representatives. Other legislation has been enacted in certain states prohibiting pharmacies and other health care entities from providing
certain physician prescribing data to pharmaceutical companies for use in sales and marketing, and prohibiting certain other sales and
marketing practices. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Foreign Corrupt Practices Act</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Foreign Corrupt Practices Act of 1977, or the
FCPA, Pub. L. 95-213, 91 Stat. 1494 (1977), 15 U.S.C. &#167;&#167;78dd-1, et seq., or the FCPA, regulates part of our business activities.
The FCPA has two main provisions applicable to us: (a) the antibribery provisions, which prohibit individuals and businesses from bribing
foreign government officials in order to obtain or retain business; and (b) the accounting provisions, which impose certain record keeping
and internal control requirements on issuers, and prohibit individuals and companies from knowingly falsifying an issuer&#8217;s books
and records or circumventing or failing to implement an issuer&#8217;s system of internal controls. Violations of the FCPA can lead to
civil and criminal penalties, sanctions, and remedies, including fines, disgorgement, and/or imprisonment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The antibribery provisions of the FCPA prohibits
the paying, offering, promising, or authorizing payment or offering money or of anything of value, directly or indirectly, to any foreign
official, political party, or candidate for the purpose of influencing any act or decision of such foreign official, political party,
or candidate in his or her official capacity or to secure any improper advantage in obtaining or retaining business. Under the statute,
a company is liable when its directors, officers, employees, or agents, acting within the scope of their employment, commit FCPA violations
intended, at least in part, to benefit the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The accounting provisions of the FCPA consist of
two primary components. First, under the &#8220;books and records&#8221; provision, issuers must make and keep books, records, and accounts
that, in reasonable detail, accurately and fairly reflect an issuer&#8217;s transactions and dispositions of an issuer&#8217;s assets.
Second, under the &#8220;internal controls&#8221; provision, issuers must devise and maintain a system of internal accounting controls
sufficient to assure management&#8217;s control, authority, and responsibility over the Company&#8217;s assets. The accounting provisions
do not apply only to bribery-related violations. Rather, the accounting provisions require that all public companies account for all of
their assets and liabilities accurately and in reasonable detail.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company, its affiliates, and its and their
operations around the world are subject to the FCPA because the Company is an &#8216;issuer&#8217; as defined in the statute. The U.S.
Department of Justice aggressively enforces the FCPA and has, at times, focused its enforcement attention to the pharmaceutical sector.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Grants from the IIA</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
efforts mainly with respect to our past activities (with respect to immunotherapy programs such as the Anti-CD3) were financed in part
through royalty-bearing grants from the IIA. As of June 30, 2023, we had received the aggregate amount of approximately $1.1 million from
the IIA for the development of our abovementioned technologies. With respect to such grants, we are committed to pay royalties of up to
an aggregate amount of approximately $1.2 million relating only to technologies in our possession and excluding any royalties for technologies
that we sold to third parties. We are further required to comply with the requirements of the Research Law, with respect to those past
grants. In addition, any change of control and any change of ownership of our Ordinary Shares that would make a non-Israel citizen or
resident an &#8220;interested party&#8221; as defined in the Research Law requires prior written notice to the IIA. Non-Israeli citizens
and residents are required to execute an undertaking in favor of the IIA, in the form prescribed by the IIA. When a company develops know-how,
technology or products using IIA grants, the terms of these grants and the Research Law restrict the transfer or licensing of such know-how
inside or outside of Israel, and the transfer or licensing outside of Israel of manufacturing or manufacturing rights of such products,
technologies or know-how, without the prior approval of the IIA. None of our current projects in the field of cannabinoid therapeutics
are supported by the IIA, yet if eligible, we might apply for such support in the future.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Current Regulatory Status of SciSparc&#8217;s
Pharmaceutical Products<i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>United States</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The active ingredient in our
pharmaceutical product candidate SCI-110 is a Schedule I controlled substance. Other drug candidates in our portfolio are either not controlled
or as yet to be scheduled.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our drug candidate SCI-110
is being developed, among others, for the treatment of TS. TS may be considered a serious condition with a potentially disabling nature.
Thus, it may be eligible for a fast-tracked submission. However, a request for eligibility may be filed by us later in the development
of this molecule. In June 2016, we submitted a request for orphan drug designation to the FDA for SCI-110 for the treatment of TS. In
a letter dated September 29, 2016, the FDA informed us that our request could not be granted at such time and is being held in abeyance
until and subject to us providing additional information pertaining to the overall prevalence of TS in both children and adults, and further
clinical data to support our scientific rationale for our request for orphan drug designation within 12 months. In September 2017, we
responded to such FDA letter within the designated time frame and provided the FDA with our articulated and reasoned responses including
documentation and clinical data that supports it. On December 26, 2017, we received the FDA&#8217;s response to our response. The FDA
accepted that there is adequate scientific rationale for the treatment of TS with SCI-110 mainly through the preliminary results of ongoing
clinical trials, suggesting that SCI-110 may provide benefit in treating TS. However, the FDA stated that it was unable to grant our request
and indicated that we did not provide adequate prevalence estimates, and any evidence to support our statement that only moderate to severe
TS patients would require pharmacological treatment. We further responded in January 2018 by providing the requested information. On January
23, 2020, following additional correspondence with the FDA, the FDA still did not grant us our request due to fact that we have not yet
provided adequate prevalence estimates. However, the FDA did agree with our position that we could potentially qualify for orphan drug
designation with respect to the moderate-to-severe TS sub-group population only rather than the entire population. After we had provided
additional prevalence estimates, the FDA raised a concern in its letter, dated December 7, 2020, about our ability to limit the use of
the pharmaceutical product to the subset of patients we are pursuing. Due to the fact that we disagree with this concern, we requested
a clarification call. In the clarification call conducted on February 2, 2021, we agreed with the FDA concern about our ability to limit
the use of the pharmaceutical product to the subset of patients in addition to a safety concern associated with THC treatment in pediatrics
population so we suggested to amend our preliminary request and asked to include only adults in the treated population. An amendment letter
was discussed and the FDA described what it would want to see in such an amendment. In March 2021, we sent our response to the FDA. In
June 2021, we received a response from the FDA explaining that they are unable to grant our request until new information becomes available
to support our request for orphan drug designation. We will re-visit the application after we obtain clinical results from our phase IIb
clinical study in TS.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Canada&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>NNHPD Approval</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to a non-traditional
class III Product License Application, CannAmide&#8482; (TheraPEA) received Health Canada approval (NPN 80093504) from the NNHPD on July
23, 2019. In the approval letter, the NNHPD confirmed that the application was in compliance with section 7 of the NHPR. The dosage of
1 x 400 mg tablet 3 times daily was approved for the following use: &#8220;Studies show that PEA may be used as an anti-inflammatory to
help relieve chronic pain&#8221;.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any labels used in the marketing
of CannAmide, or TheraPEA, must reflect the information outlined on the product license and must comply with the labelling requirements
as per Part 5 of the NHPR. In addition, natural health products, such as TheraPEA, must be manufactured, packaged, labelled, imported,
distributed and stored in accordance with GMP as required by NHPR or in accordance with equivalent requirements if the natural health
product is imported. Furthermore, in accordance with Section 44 of the NHPR, each product for sale in Canada must comply with the finished
product specifications submitted to Health Canada.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the NHPR, companies
are required to provide the NNHPD with the Canadian site information prior to commencing the importation and/or sale of the natural health
products in Canada.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Changes made in respect of
a licensed product require the submission of an amendment, notification or a new product license application as per sections 11, 12 and
13 of the NHPR.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Organizational Structure</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc Nutraceuticals Inc.
is our majority-owned subsidiary (approximately 51%), a company focused on e-commerce operations of Wellution&#8482;, a top- seller account
of Amazon, which sells hemp-based products. Brain Bright Ltd. is an inactive wholly-owned subsidiary. We also own 100% of the issued and
outstanding share capital of Evero Health Ltd., a company focused on the development and commercialization of SCI-110 sleep technology.&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 17, 2022, we invested
$1.5 million in Clearmind in connection with its initial public offering on the Nasdaq Capital Market, in exchange for 230,769 Ordinary
Shares of Clearmind, representing 9.33% of the outstanding share capital of Clearmind.<i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also hold approximately
31.48% of MitoCareX Bio Ltd., an Israeli private company<i>.</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We hold a minority interest
in AutoMax of approximately 4.82% and a minority interest of approximately 1.14% of Jeffs&#8217; Brands.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Property, Plants and Equipment </b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our offices are located at
20 Raul Wallenberg Street,&#8239;Tower A, 2nd Floor, Tel Aviv 6971916, Israel, where we currently occupy approximately 120 square meters,
under a joint lease with a third-party for a total of 240 square meters. The lease ends on June 30, 2025. Our current monthly rent payment
is NIS 10,200 (approximately $3,300).&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We consider that our current
office space is sufficient to meet our anticipated needs for the foreseeable future and is suitable for the conduct of our business. However,
we are currently assessing our future needs and have not renewed our lease as of the date hereof.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>Litigation</b></span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with a joint
venture transaction, entered on May 15, 2020, by and between us, Capital Point and Evero Health Ltd., one of our subsidiaries, we issued
a warrant to Capital Point to purchase $340,000 of our Ordinary Shares, or the Warrant Shares, with an exercise price per ordinary share
equal to the closing price of our Ordinary Shares on the trading day on which the notice of exercise is actually received by us. Such
warrant was exercisable for 12 months starting from May 15, 2021.&#160;On November 4, 2021, we received from Capital Point a notice of
exercise with respect to the Warrant Shares, which we rejected. On May 2, 2023, Capital Point filed a lawsuit in the Tel Aviv-Jaffa District
Court against us as the sole defendant in connection with the Warrant Shares. The lawsuit includes allegations of breaches of contract
under the Israeli Contracts Law (General Part), 1973, unjust enrichment under the Israeli Unjust Enrichment Law, 1979 and breaches under
the Israeli Torts Ordinance (New Version), 1968. The lawsuit claims damages in the amount of NIS 10,000,000 (approximately $2.75 million),
which accounts for, as of the date of the filing of the lawsuit, liquidated damages according to the provisions set forth in the warrant,
and seeks as well for the court to order a mandatory injunction order for us to issue a warrant to Capital Point to purchase $340,000
of our Ordinary Shares to Capital Point, the return of any unlawful profits received by us and punitive damages. As of February 26, 2024,
in connection with the aforementioned litigation, the shares of Every Health Ltd. held by Capital Point are dormant and were forfeited
by Evero Health Ltd. As of the date of this prospectus, we cannot predict the likelihood of our success in the lawsuit.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="background-color: white"><b>MANAGEMENT</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Directors and Senior Management </b>&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information regarding our executive officers, key employees and directors as of February 26, 2024:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 25%"><b>Name</b></td>
    <td style="text-align: justify; width: 1%"><b>&#160;</b></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 8%"><b>Age</b></td>
    <td style="text-align: justify; width: 1%"><b>&#160;</b></td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify; width: 65%"><b>Position</b></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; text-align: justify">Itschak Shrem</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center">76</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">President and Director</td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: justify">Amitay Weiss</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center">61</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">Chairman of the Board of Directors</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; text-align: justify">Oz Adler</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center">37</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">Chief Executive Officer and Chief Financial Officer</td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: justify">Dr. Adi Zuloff-Shani</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center">55</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">Chief Technologies Officer</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; text-align: justify">Amnon Ben Shay<sup>(1)(2)(3)</sup></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center">61</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">Director</td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: justify">Alon Dayan<sup>(1)(2)(3)</sup></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center">48</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">Director</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; text-align: justify">Moshe Revach<sup>(3)</sup></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center">48</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">Director</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; text-align: justify">Liat Sidi<sup>(3)</sup></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center">49</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">Director</td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: justify">Lior Vider<sup>(1)(2)(3)</sup></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center">47</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">Director</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
of the Compensation Committee</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>



</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
of the Audit Committee</span></td>
</tr></table><div>



</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
Director (as determined by our Board of Directors, pursuant to the definition prescribed to such term under Nasdaq Stock Market rules)</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Mr. Itschak Shrem </i>was appointed to
serve as our President in January 2022, prior to which he served as our Chairman from August 2020 to January 2022. Mr. Shrem has more
than 40 years of experience in financial markets and venture capital. In 1991, Mr. Shrem founded Dovrat Shrem Ltd., an investment banking,
management and technology company. Prior to that, he spent 15 years at Clal Israel Ltd., where he served in various capacities, including
chief operating officer, and was responsible for capital markets and insurance businesses. In 1993, Mr. Shrem founded Pitango Venture
Capital Fund (formerly, Polaris) and served as a partner of Pitango Funds I, II and III. He has been the Managing Director of Yaad Consulting
1995 Ltd. since 1995. Previously, Mr. Shrem served on the board of Tel-Aviv Sourasky Medical Center, the Weizman Institute Eden Spring
Ltd., Rail Vision Ltd., Nano Dimension Ltd., Ormat Industries Ltd., Retalix Ltd. and as chairman of Sphera Funds Management Ltd. Mr. Shrem
holds a B.A. in Economics and Accounting from Bar-Ilan University and an M.B.A. from Tel-Aviv University. <i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Amitay Weiss </i>has
served on our Board of Directors since August 2020 and as our Chairman since January 2022. Mr. Weiss served as our Chief Executive Officer
from August 2020 to January 2022. Mr. Weiss currently serves as chairman of the board of directors of Automax Motors Ltd. (TASE: AMX.TA),
as a director of Jeffs&#8217; Brands Ltd. (Nasdaq: JFBR) and as an external director of Cofix Group Ltd. (TASE: CFCS). Mr. Weiss also
chairs and serves as director on the board of director of several public and private companies, including, Clearmind, Maris Tech Ltd.
(Nasdaq: MTEK) and Save Foods Inc. (Nasdaq: SVFD). In 2016, Mr. Weiss founded Amitay Weiss Management Ltd. and now serves as its chief
executive officer. From 2001 until 2015, Mr. Weiss served as vice president of business marketing &amp; development and in various other
positions at Bank Poalei Agudat Israel Ltd. from the First International Bank of Israel group. Mr. Weiss holds a B.A. in economics from
New England College, an M.B.A. in business administration from Ono Academic College in Israel, an Israeli branch of University of Manchester
and an LL.B. from the Ono Academic College.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Oz Adler, CPA, </i>was
appointed to serve as our Chief Executive Officer in January 2022 and has served as our Chief Financial Officer since April 2018 and previously
held served as our VP Finance from March 2018 until April 2018 and as our Controller from September 2017 to March 2018. Mr. Adler has
experience in a wide variety of managerial, financial, tax and accounting roles. Mr. Adler currently serves on the board of directors
of numerous private, such as Polyrizon Ltd., and public companies, including Jeffs&#8217; Brands Ltd. (Nasdaq: JFBR), Rail Vision Ltd.
(Nasdaq: RVSN) and Clearmind (CSE: CMND), (OTC: CMNDF), (FSE: CWY), and previously served as the chief financial officer of Medigus Ltd.
(Nasdaq: MDGS) from December 2020 to April 2021. From 2012 until 2017, Mr. Adler was employed as a certified public accountant at Kost
Forer Gabbay &amp; Kasierer, a member of Ernst &amp; Young Global. Mr. Adler holds a B.A. in Accounting and Business management from The
College of Management, Israel.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Adi Zuloff-Shani </i>has
served as our Chief Technologies Officer since February 2016. Dr. Zuloff-Shani has more than 20 years of experience as a research and
development executive. Prior to joining us, and from 2012 to 2016, Dr. Zuloff-Shani served as a vice president development at Macrocure
Ltd. (Nasdaq: MCUR) where besides leading all research and development activities, she interacted and was involved with the activities
of all departments including clinical, operations, quality assurance, quality control, finance, and regulatory affairs. Dr. Zuloff-Shani
currently serves as the Chief Executive Officer of Clearmind. She has also served as the Chairman of Orsus Therapeutics, Inc. since November
2022. Dr. Zuloff-Shani holds a Ph.D. in human biology and immunology from Bar-Ilan University, Israel.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Amnon Ben Shay</i>
has served as a member of our Board of Directors since January 2021 and served as our external director under the Companies Law between
January 2021 and January 2022. Mr. Ben Shay has been serving as the chief financial officer of Hadar Hasharon Marketing and Distributions
Ltd. since 2019. Mr. Ben Shay previously served on the board of directors of Azorim Investments and Building Development Company Ltd.
(TASE: AZRM), Value Capital One Ltd. (TASE: VALU) and B.G.I. Investments (1961) Ltd. (TASE: BGI). From 2017 to 2019, Mr. Ben Shay served
as the chief financial officer of Fridenson Air &amp; Ocean Ltd. From 2014 to 2017, he served as the chief financial officer of Abetrans
Logistics Ltd. Prior to that, Mr. Ben Shay served as the chief financial officer of Isline Export and Import Services Ltd. from 2010 to
2013. Prior to the year 2009, Mr. Ben Shay served as the chief financial officer of several Israeli real estate investment groups. Mr.
Ben Shay holds a B.A. in economics and business and an M.B.A in business, both from The Hebrew University of Jerusalem, Israel, and an
accounting certificate from The College of Management Academic Studies, Israel.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Alon Dayan</i> has
served as a member of our Board of Directors since January 2021 and served as our external director under the Companies Law between January
2021 and January 2022. Mr. Dayan is the founder of L1-Systems Ltd. and has been serving as its chief executive officer since 2015. Since
2018, Mr. Dayan has served as the chief executive officer of Virtual Crypto Technologies Inc. (OTC: VBIX) from 2018 to 2019, which he
founded as well. Prior to that, he served as a business development manager at Elbit Systems Ltd. from 2006 to 2013. Mr. Dayan holds a
B.A. in electronical engineering from Ariel University, Israel.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Moshe Revach</i> has
served as a member of our board of directors since September 2022. Mr. Revach also previously served as our director since August 2020
until his resignation on March 13, 2022. Mr. Revach serves as deputy mayor of the city of Ramat Gan, Israel, has headed both the sports
and government relations departments in the Ramat Gan municipality since 2013, and has served in various other Ramat Gan municipality
positions since 2008. Mr. Revach serves as a director of L.L.N IT solutions, a wholly-owned subsidiary of the Jewish Agency for Israel,
of Jeffs&#8217; Brands Ltd. (Nasdaq: JFBR) and of Biomedico Hadarim Ltd. Mr. Revach previously served as a director of the RPG Economic
Society and Jewish Experience Company on behalf of the Jewish Agency. Mr. Revach holds an LL.B from the Ono Academic College, Israel,
and a B.A. in management and economics from the University of Derby.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Ms. Liat Sidi</i> has served
as our Director since August 2020. Ms. Sidi serves as the manager of the accounting department for Foresight Autonomous Holdings Ltd.
(Nasdaq and TASE: FRSX). Ms. Sidi previously served as an accountant for Panaxia Labs Israel Ltd. (TASE: PNAK) from 2015 to 2020 and as
an accountant for Soho Real Estate Ltd. from 2015 to 2016. Ms. Sidi also served as an accountant for Feldman-Felco Ltd. from 2006 to 2010
and as an accountant for Eli Abraham accounting firm from 2000 to 2006. Ms. Sidi completed tax, finance and accounting studies in Ramat
Gan College of Accounting.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Lior Vider</i> has
served as our Director since August 2020. Mr. Vider has served as a senior investment portfolio manager at Forte Investment House Ltd.
since 2021. Mr. Vider previously served as chief investment manager for Impact Investment Management Ltd., from the Union Bank group,
from 2007 to 2010 and as chairman of the board of directors and a member of the group&#8217;s investment committee of Rahkia Capital Markets
Ltd. from 2006 to 2007. Mr. Vider also served as a director at Endymed Medical Ltd. and Apollo Power Ltd. Mr. Vider founded and managed
sponser.co.il, a financial portal specializing in services for investors from 2005 to 2017. Mr. Vider holds a B.A. in industry and management
engineering from Shenkar College in Israel.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Scientific Advisory Board</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have a Scientific Advisory
Board of eleven award winning and active physicians and scientists in the field(s) of: psychiatry and child psychiatry, TS, neurology,
Alzheimer&#8217;s disease, hospice and palliative medicine neurobiology, pharmacology and neuropsychopharmacology, organic and medicinal
chemistry, cannabinoids and drug discovery. We consult with the members of our Scientific Advisory Board on a regular basis.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. Yossi Tam</i> received
his B.Med.Sc., M.Sc., Ph.D. and D.M.D. from the Hebrew University of Jerusalem. He did his postdoctoral training at the National Institutes
of Health (NIH), and in 2014 he moved to the Hebrew University to head the Obesity and Metabolism Laboratory at the Institute for Drug
Research, where he focuses on targeting the endocannabinoid system for Obesity, Diabetes and the metabolic syndrome. Prof. Tam won major
national and international grants. He authored over 80 peer-reviewed papers in leading journals (such as Science, Nature Medicine, Cell
Metabolism, JCI, PNAS, Hepatology, Gastroenterology, Molecular Metabolism, to name a few), and three book chapters, with 5,412 citations
yielding an H-index of 36. In addition, Prof. Tam co-invented 14 patents that were commercialized to different pharmaceutical companies
for further clinical development and testing. Prof. Tam also serves as the Director of the Hebrew University&#8217;s Multidisciplinary
Center for Cannabinoid Research and a Scientific Advisory Board Member of several biotech companies, which develop a portfolio of non-psychoactive
cannabinoid-modulating medicines for unmet market needs. Prof. Tam&#8217;s research projects over the past twenty years have crossed subjects,
disciplines and methodologies, yet the main research interests remain focused on the different pathophysiological aspects of the endocannabinoid
system. Having a clinical background with basic science training, he has always been interested in how science can directly improve people&#8217;s
everyday lives. Thus, he has strived unceasingly to integrate his clinical curiosity and experimental knowledge, in order to deepen the
understanding of clinically relevant research questions. <i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. Elon Eisenberg,</i>
is the Dean of the Faculty of Medicine at the Technion - Israel Institute of Technology. Prof. Eisenberg is a Professor of Neurology and
Pain Medicine at the Faculty of Medicine and holds the Otto Barth Family Academic Chair in Biomedical Science. Prof. Eisenberg graduated
from Sackler School of Medicine, Tel-Aviv University in Israel. Prof. Eisenberg completed a residency in Neurology, at Rambam Medical
Center, Haifa, Israel, and Neurology - Pain Fellowship at Massachusetts General Hospital, Harvard Medical School in Boston, USA. Prof.
Eisenberg has been the director of the Institute of Pain Medicine at Rambam Health Care Campus, Haifa, Israel, and the President of the
Israeli Pain Association. Prof. Eisenberg is currently the director of the Pain Research Unit at the Institute of Pain Medicine, Rambam
Health Care Campus. H Prof. Eisenberg&#8217;s main areas of research include mechanisms and treatment of pain with special emphasis on
neuropathic pain, CRPS, cancer pain, opioids and cannabinoids. Prof. Eisenberg has published about two-hundred articles, book chapters
and other manuscripts in various areas of pain.<i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. James Leckman, M.D.</i>
is the Neison Harris Professor of Child Psychiatry, Psychiatry, Psychology and Pediatrics at Yale University. Prof. Leckman is a well-known
child psychiatrist and patient-oriented clinical investigator. For more than 20, years he served as the Director of Research for the Yale
Child Study Center. His peers have regularly selected him as one of the Best Doctors in America. Dr. Leckman is the author or co-author
of over 430 original articles published in peer-reviewed journals, twelve books, and 140 book chapters. Dr. Leckman has a longstanding
interest in Tourette syndrome and Obsessive-Compulsive Disorder (OCD). His research on these disorders is multifaceted from phenomenology
and natural history, to neurobiology to genetics, to risk factor research and treatment studies. One area of active research interest
concerns the role of the immune system in the pathobiology of Tourette syndrome and other neuropsychiatric disorders.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. Michael Davidson
</i>currently serves, among other things, as Chairman of the Israeli Medical Centre for Alzheimer&#8217;s Disease Care and Research in
Ramat Gan and Chairman of the department of psychiatry at the Nicosia University Medical School. Prof. Davidson served as Chief Psychiatrist
at the Department of Psychiatry of the Sheba Medical Centre in Tel-Hashomer for six years. Prof. Davidson holds a secondary professorship
at the Sackler School of Medicine of Tel Aviv University and at the Mount Sinai School of Medicine in New York. Prof. Davidson is considered
an international expert on Alzheimer&#8217;s disease and schizophrenia is the author of approximately 350 publications in scientific literature.<i>&#160;&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. Daniele Piomelli</i>
serves as the Louise Turner Arnold Chair in Neurosciences and Professor of Anatomy and Neurobiology, Pharmacology, and Biological Chemistry
at University of California, Irvine. Prof. Piomelli is also the founding director of the drug discovery and development unit (D3) at the
Italian Institute of Technology in Genoa, Italy, as well as the Editor in Chief of Cannabis and Cannabinoid Research of Cannabis and Cannabinoid
Research. Prof. Piomelli&#8217;s research has resulted in several contributions to the pharmacology of lipid based signaling molecules
including endocannabinoid substances and lipid amides. Prof. Piomelli is the author of more than 400 peer reviewed articles and books
and has received several awards and honors. Prof. Piomelli studied Pharmacology and Neuroscience at Columbia University, and the Rockefeller
University, and earned his degree of Doctor of Pharmacy from University of Naples.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. Kirsten M&#252;ller-Vahl
</i>is a Professor of Psychiatry at the Department of Psychiatry, Socialpsychiatry and Psychotherapy at the Hannover Medical School, Germany.
Prof. M&#252;ller-Vahl is a specialist in both neurology and adult psychiatry. She serves as the head of the TS outpatient department
and over the past twenty-five years, Prof. M&#252;ller-Vahl has investigated more than 4000 patients with TS, both children and adults.
She serves on the scientific advisory board of the German Tourette Syndrome Association and is the current president of the European Society
of the study of Tourette syndrome (ESSTS), the national German Association for Cannabinoid Medicines (ACM) as well as the International
Alliance for Cannabinoid Medicines (IACM). Her scientific work related to TS includes a large number of clinical trials funded by the
EU (TS-EUROTRAIN: FP7-PEOPLE-2012-ITN, No. 316978; EMTICS: EU FP7-HEALTH-2011, 278367), by the NIMH (TIC-GENETICS (1R01MH115958-01), by
the German ministry of education and research (BMBF) (ONLINE-TICS: 01KG1421) and the German Research Foundation (DFG) (CANNA-TICS: NCT03087201).
At the 9th IACM Conference on Cannabinoids in Medicine in 2017 she received the &#8220;IACM Award 2017 for Clinical Research&#8221; for
her special achievements regarding the re-introduction of cannabis and cannabinoids as medicine.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. M&#252;ller-Vahl</i>
has published more than 180 scientific articles, is the author of several book chapters and the leading German textbook on TS, and co-editor
of the leading German textbook on cannabis-based medicine. She is author of several guidelines on TS including ESSTS guidelines and treatment
guidelines published by the American Academy of Neurology (AAN).<i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. Avi Weizman</i> is
a Professor of Child and Adult Psychiatry at the Sackler Faculty of Medicine of Tel Aviv University, a former Director of the Felsentein
Medical Research Center and the head of the Laboratory for Biological and Molecular Psychiatry and the head of the Research Unit at the
Geha Mental Health Center. Prof. Weizman&#8217;s research involves the investigation of brain mechanisms of mental disorders. Currently,
it focuses on neurodevelopmental disorders, the development of new strategies for treating psychotic disorders, and the psychopharmacology
of mental disorders. Prof. Weizman is the author of more than 760 original papers, five full books, 28 book chapters, and 60 review articles.
After completing his residency in Psychiatry, Prof. Weizman spent two years as a visiting scientist at the National Institute of Mental
Health in Bethesda, MD. <i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Michael H. Bloch, M.D.,
M.S.</i> graduated from Yale School of Medicine and completed his child and adult psychiatry training at Yale. His research interests
focus on studying TS, obsessive-compulsive disorder (OCD) and trichotillomania (TTM) across the lifespan and developing better pharmacological
treatments for children with depression, anxiety and ADHD. His research focuses on developing better treatments for children and adults
with these conditions particularly through clinical trials and meta-analysis. He has over 200 peer-reviewed publications and is currently
the Research Review Editor for the Journal of Child Psychology and Psychiatry. He also serves on the scientific advisory boards of the
Tourette Association of America and the TLC Foundation for Body-Focused Repetitive Behaviors. <i>Prof. Saoirse O&#8217;Sullivan, PhD</i>
received her doctorate from Trinity College Dublin in 2001 and moved to the University of Nottingham in 2002 as a Research fellow where
she began researching cannabinoid pharmacology through basic and clinical research. She was made Lecturer in 2007 and Associate Professor
in 2011 and Full Professor in 2019. Prof. O&#8217;Sullivan has over 40 peer reviewed articles, six reviews and three books chapters on
the topic of cannabinoid pharmacology, with specific interests on the cardiovascular and gastrointestinal effects of cannabinoids and
therapeutic potential of cannabis-based medicines. Prof. O&#8217;Sullivan&#8217;s research methodologies span from cellular and animal
models to human healthy volunteer studies and early phase clinical trials. In 2016, Prof. O&#8217;Sullivan was named the International
Cannabinoid Research Society Young Investigator of the year. Prof. O&#8217;Sullivan now runs an independent consulting company called
CanPharmaConsulting Ltd, and through this, acts as scientific advisor to Artelo Biosciences, Inc., CBD Science Group PLC, Scisparc, FSD
Pharma Inc., and Dragonfly Biosciences Ltd. She is the science lead for the Centre for Medicine Cannabis, working to shape the UK&#8217;s
new medicinal cannabis regime for patients. She is also secretary to the International Cannabinoid Research Society.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Mellar P. Davis, MD,
FCCP FAAHPM </i>is a Professor of Palliative Medicine, the Geisinger Commonwealth School of Medicine and a member of the Palliative Care
Department, and Section Head, Geisinger Medical System Danville, PA. He has been a member of the Geisinger Medical Staff since August
2016. In his role as Section Head, Dr. Davis is responsible for developing palliative care services throughout the Geisinger Medical System
including outpatient and inpatient services. In addition, Dr. Davis works with the Geisinger Hospice Services to develop and coordinate
care within the central region. Dr. Davis was a member of the Cleveland Clinic Palliative Care section, Taussig Cancer Institute and fellowship
director until joining the Geisinger Medical System. Dr. Davis was the co-chair of the Palliative Care Study Group of the Multinational
Association of Supportive Care (MASCC) and a past board member since 2010. Dr. Davis has been a Professor of Medicine in The Cleveland
Clinic Lerner College of Medicine, Case Western Reserve University, since 2009 and was elected as a Fellow to the American Academy of
Hospice and Palliative Medicine in 2010. Dr. Davis is Editor in Chief of Progress on Palliative Care. Dr. Davis&#8217; present duties
are as the Associate Editor in Chief of PC Fast Article Critical Summary for Clinicians in Palliative Care.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. Avi Schroeder</i>
is the head of the Targeted Drug Delivery and Personalized Medicine Group, at the Technion, Israel Institute of Technology, and has translational
research experience with the development of liposome-based clinical systems. He is the author of 60 scientific papers in the field of
nanotechnology and medicine and is the inventor on 17 patents, and a recipient of 30 national and international innovation awards. Prof.
Schroeder is a scientific entrepreneur, starting multiple successful Technion spin-outs. Prof. Schroeder received three degrees in Chemical
Engineering from the Ben-Gurion University of the Negev and his postdoctoral training took place at MIT. <b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Family Relationships</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no family relationships
between any members of our executive management and our directors.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Arrangements for Election of Directors and
Members of Management</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not a party to, and
there are no arrangements or voting agreements that we are aware of for the election of our directors and members of management.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Compensation</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compensation</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents
in the aggregate all compensation we paid to all of our directors and senior management, as a group for the year ended December 31, 2023.
The table does not include any amounts we paid to reimburse any of such persons for costs incurred in providing us with services during
this period.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All amounts reported in the
tables below reflect the cost to the Company, in thousands of U.S. Dollars, for the year ended December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><b><i>USD in thousands</i></b></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><b>Salary/Fee</b></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><b>Pension,<br/> Retirement<br/> and
    Other <br/> Similar<br/> Benefits(1)</b></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><b>Share-<br/> Based<br/> Compensation(2)</b></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">All directors and senior management as a group, consisting of 9 persons</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">1,114</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">90</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">84</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
the directors and senior management&#8217;s payment of mandatory social benefits made by the Company on behalf of such officer. Such
benefits may include, to the extent applicable to the executive, payments, contributions and/or allocations for savings funds, education
funds (referred to in Hebrew as &#8220;<i>Keren Hishtalmut</i>&#8221;), pension, severance, risk insurances (e.g., life or work disability
insurance) and payments for social security.</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computed
based on fair value for Ordinary Shares options granted and estimated using the Black-Scholes option pricing model.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with the Companies
Law, the table below reflects the compensation granted to our five most highly compensated officers or directors during or with respect
to the year ended December 31, 2023.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Annual Compensation </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Executive Officer</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Salary/Fee</b></span></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Pension, Retirement and Other Similar Benefits</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share-<br/>
    Based <br/>
    Compensation <sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Total</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">USD in thousands</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amitay Weiss<br/>
 <i>Chairman and Former Chief Executive Officer</i></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">219</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;16</td><td style="width: 1%; text-align: left"/><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">235</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Adi Zuloff-Shani <br/>
<i>Chief Technologies Officer</i></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">232</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">296</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oz Adler <br/>
<i>Chief Executive Officer and Chief Financial Officer</i></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">315</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">379</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Itschak Shrem<br/>
    <i>President and Former Chairman</i></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">219</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">235</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lior Vider<br/>
 <i>Director</i></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">26</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">29</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based
compensation includes the cost of our non-cash share-based compensation in 2023.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Employment and Services Agreements with
Executive Officers</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into written
employment agreements and/or consulting agreements with each of our executive officers. All of these agreements contain customary provisions
regarding noncompetition, confidentiality of information and assignment of inventions. However, the enforceability of the noncompetition
provisions may be limited under applicable law. Most of these agreements are terminable by either party upon 30 days&#8217; prior written
notice. However, a longer 90 day notice period is required with respect to each of our executive officers. In addition, we have entered
into agreements with each executive officer and director pursuant to which we have agreed to indemnify each of them up to a certain amount
and to the extent that these liabilities are not covered by directors&#8217; and officers&#8217; insurance. Members of our senior management
are eligible for bonuses each year, subject to a pre-determined target-based bonus plan, which is usually set during the first quarter
of each calendar year following the recommendation of our compensation committee and the approval of our Board of Directors. The annual
bonuses are payable upon meeting objectives and targets that are set by our Chief Executive Officer and compensation committee and approved
annually by our Board of Directors.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a description of the terms
of our options and option plans, see &#8220;Beneficial Ownership of Principal Shareholders and Management&#8221; below.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As required by the Companies
Law, our compensation committee and Board of Directors approved, and recommended to our shareholders to approve, amended terms of compensation
of our Chief Executive Officer, Mr. Oz Adler, our President, Mr. Itschak Shrem, and our and Chairperson of the Board of Directors, Mr.
Amitay Weiss, as set forth below. Such terms are in line with our Compensation Policy and were approved by our shareholders on February
10, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">President and Chairperson of the Board of Directors</span> - a monthly fee in the amount of NIS 52,500 (approximately $14,919) and an annual target bonus of up to six monthly salaries, or eight in the case of overachievement.</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Chief
Executive Officer </span>- a monthly fee in the amount of NIS 66,000 (approximately $18,755) and an annual target bonus of up to six monthly
salaries, or eight in the case of overachievement, plus applicable pension, retirement and other similar benefits.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Directors&#8217; Service Contracts</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have written agreements
with any director providing for benefits upon the termination of his/her employment with us.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board Practices </b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Corporate Governance Practices</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As an Israeli company, we
are subject to various corporate governance requirements under the Companies Law. However, pursuant to regulations promulgated under the
Companies Law, companies with shares traded on certain U.S. stock exchanges, including the Nasdaq, may, subject to certain conditions,
&#8220;opt out&#8221; from the requirements to appoint external directors and related rules concerning the composition of the audit committee
and compensation committee of the board of directors, other than the gender diversification rule, which requires the appointment of a
director from the other gender if, at the time a director is appointed, all members of the board of directors are of the same gender.
In accordance with these regulations, following our listing on the Nasdaq, in January 2022, we elected to &#8220;opt out&#8221; from these
requirements of the Companies Law. Under these regulations, the exemptions from such Companies Law requirements will continue to be available
to us so long as: (i) we do not have a &#8220;controlling shareholder&#8221;, as such term is defined under the Companies Law, (ii) our
shares are traded on certain U.S. stock exchanges, including the Nasdaq, and (iii) we comply with the director independence requirements
and the audit committee and compensation committee composition requirements under U.S. laws, including the rules of the applicable exchange,
that are applicable to U.S. domestic issuers.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a &#8220;foreign private
issuer&#8221;, as such term is defined in Rule 405 under the Securities Act. As a foreign private issuer we are permitted to comply with
Israeli corporate governance practices instead of the corporate governance rules of Nasdaq, provided that we disclose which requirements
we are not following and the equivalent Israeli requirement. As a foreign private issuer, we are exempt under the Exchange Act from, among
other things, the rules prescribing the furnishing and content of proxy statements, and our officers, directors and principal shareholders
are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we
are not required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as
U.S. companies whose securities are registered under the Exchange Act.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For more information regarding
our corporate governance practices and foreign private issuer status, see &#8220;Corporate Governance&#8221; below.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Board of Directors</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors presently
consists of seven members. Nasdaq listing standards require that a majority of our Board of Directors be independent. These standards
provide, among other things, that a person will be considered an independent director if he or she is not an officer of the Company and
is, in the view of the Company&#8217;s board of directors, free of any relationship that would interfere with the exercise of independent
judgment. We believe that Mr. Vider, Ms. Sidi, Mr. Ben Shay, Mr. Revach and Mr. Dayan are all currently considered &#8220;independent&#8221;
for purposes of the Nasdaq rules. As such, our Board of Directors is comprised of a majority of independent directors as such term is
defined in the Nasdaq rules. Our amended and restated articles of association provide that the number of directors shall be set by the
general meeting of the shareholders provided that it will consist of not less than three and not more than 12 directors. Pursuant to the
Companies Law, the overall planning and management of our business is vested in our Board of Directors. Our Board of Directors may exercise
all powers and may take all actions that are not specifically granted to our shareholders or to management. Our executive officers are
responsible for our day-to-day management and have individual responsibilities established by our Board of Directors. Our Chief Executive
Officer is appointed by, and serves at the discretion of, our Board of Directors. All other executive officers are appointed by the Board
of Directors or by our Chief Executive Officer, provided that he was authorized by the Board of Directors to do so. Their terms of employment
are subject to the approval of our Board of Directors&#8217; Compensation Committee (see &#8220;-Compensation Committee<span style="font-variant: small-caps">&#8221;</span>)
and of the Board of Directors (and in case the terms are not compatible with the provisions of the compensation policy, to our shareholders&#8217;
approval as well), and are subject to the terms of any applicable employment agreements that we may enter into with them.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our directors are divided
into three classes with staggered three-year terms. Each class of directors consists, as nearly as possible, of one third of the total
number of directors constituting the entire board of directors. At each annual general meeting of our shareholders, the election or re-election
of directors following the expiration of the term of office of the directors of that class of directors is for a term of office that expires
on the third annual general meeting following such election or re-election, such that at each annual general meeting the term of office
only one class of directors will expire. Each director holds office until the annual general meeting of our shareholders for the year
in which his or her term expires and until his or her successor is duly appointed, unless the tenure of such director expires earlier
pursuant to the Companies Law upon the occurrence of certain events or unless removed from office by a vote of the holders of at least
65% of the total voting power of our shareholders at a general meeting of our shareholders in accordance with our amended and restated
articles of association.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our directors are divided
among the three classes as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
Class I directors consist of Ms. Liat Sidi and Mr. Amnon Ben Shay, and their terms will expire at our annual general meeting of shareholders
to be held in 2024;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Class II directors consist of Mr. Alon Dayan, Mr. Moshe Revach and Mr. Lior Vider and their terms will expire at our annual general meeting of shareholders to be held in 2025; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Class III directors consist of Mr. Amitay Weiss and Mr. Itschak Shrem and their terms will expire at our annual general meeting of shareholders to be held in 2026.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our amended and
restated articles of association allow our Board of Directors to appoint directors to fill vacancies on our Board of Directors or in addition
to the acting directors (subject to the limitation on the number of directors and their qualifications), until the next general meeting
in which directors may be appointed or such appointment terminated.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, nominations
for directors may be made by any shareholder holding at least 1% of our outstanding voting power. However, any such shareholder may make
such a nomination only if a written notice of such shareholder&#8217;s intent to make such nomination has been given to our Board of Directors.
Any such notice must include certain information, a description of all arrangements between the nominating shareholder and the proposed
director nominee(s) and any other person pursuant to which the nomination(s) are to be made by the nominating shareholder, the consent
of the proposed director nominee(s) to serve as our director(s) if elected and a declaration signed by the nominee(s) declaring that there
is no limitation under the Companies Law preventing their election and that all of the information that is required to be provided to
us in connection with such election under the Companies Law has been provided.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, our
Board of Directors must determine the minimum number of directors who are required to have accounting and financial expertise. Our Board
of Directors has determined that the minimum number of directors of our company who are required to have accounting and financial expertise
is one.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors is
required to elect one director to serve as the Chairman of the Board of Directors to preside at the meetings of the Board of Directors
and may also remove that director as Chairman. Pursuant to the Companies Law, neither the chief executive officer nor any of his or her
relatives is permitted to serve as the Chairman of the Board of Directors, and a company may not (subject to a certain time-limited exemption,
as described below) vest the Chairman or any of his or her relatives with the chief executive officer&#8217;s authorities. In addition,
a person who reports, directly or indirectly, to the chief executive officer may not serve as the Chairman of the Board of Directors;
the Chairman may not be vested with authorities of a person who reports, directly or indirectly, to the chief executive officer; and the
Chairman may not serve in any other position in the Company or a controlled company, but he or she may serve as a director or chairman
of a controlled company. However, and notwithstanding the foregoing, the Companies Law permits the shareholders of a company to determine,
for periods not exceeding three years from each such determination, that the Chairman or his or her relative may serve as chief executive
officer or be vested with the chief executive officer&#8217;s authorities, and that the chief executive officer or his or her relative
may serve as Chairman or be vested with the Chairman&#8217;s authorities. Such determination of a company&#8217;s shareholders requires
either: (1) the approval of at least the majority of the shares of those shareholders present and voting on the matter (other than controlling
shareholders and those having a personal interest in the determination); or (2) that the total number of shares opposing such determination
does not exceed 2% of the total voting power in the Company.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors may,
subject to the provisions of the Companies Law, delegate any or all of its powers to committees of the Board of Directors, and it may,
from time to time, revoke such delegation or alter the composition of any such committees, subject to certain limitations. Unless otherwise
expressly provided by the Board of Directors, the committees shall not be empowered to further delegate such powers. The composition and
duties of our audit committee and compensation committee, are described below. See &#8220;-Committees of the Board of Directors&#8221;
below.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Role of Board of Directors in Risk Oversight
Process</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors oversees
how management monitors compliance with our risk management policies and procedures, and reviews the adequacy of the risk management framework
in relation to the risks faced by us. Our Board of Directors encourages management to promote a culture that incorporates risk management
into our corporate strategy and day-to-day business operations. Management discusses strategic and operational risks at regular management
meetings, and conducts specific strategic planning and review sessions that include a focused discussion and analysis of the risks we
face. Senior management reviews these risks with the Board of Directors focusing on particular business functions, operations or strategies,
and presents the steps taken by management to mitigate or eliminate such risks. The Board of Directors is assisted in its oversight role
by an internal auditor. The internal auditor undertakes both regular and ad hoc reviews of risk management controls and procedures, the
results of which are reported to our audit committee. See &#8220;-Committees of the Board of Directors-Internal Auditor&#8221; below.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Leadership Structure of the Board of Directors</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with the Companies
Law and our amended and restated articles of association, our Board of Directors is required to appoint one of its members to serve as
Chairman of the Board of Directors. Our Board of Directors has appointed Mr. Amitay Weiss to serve as Chairman of the Board of Directors,
effective January 10, 2022, and subsequently further named as our President, Mr. Itschak Shrem, the authorities of the Chairman of the
Board of Directors as well.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Alternate Directors</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated articles
of association provide, consistent with the Companies Law, that any director, and with respect to external directors (to the extent required
under applicable law - see the description of the External Directors Relief Resolution under &#8220;-External Directors&#8221; below)
- only subject to certain preconditions, may appoint another person to serve as his alternate director, provided such person has the qualifications
prescribed under the Companies Law to be appointed and to serve as a director and is not already serving as a director or an alternate
director of the Company. The term of an alternate director may be terminated at any time by the appointing director and automatically
terminates upon the termination of the term of the appointing director. An alternate director has the same rights and responsibilities
as a director. To date there are no alternate director appointments in effect.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>External Directors</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, companies
incorporated under the laws of the State of Israel that are &#8220;public companies&#8221; are required to appoint at least two external
directors who meet the qualification requirements under the Companies Law. Pursuant to regulations promulgated under the Companies Law,
companies with shares traded on certain U.S. stock exchanges, including Nasdaq, which do not have a &#8220;controlling shareholder,&#8221;
may, subject to certain conditions, &#8220;opt out&#8221; from the Companies Law requirements to appoint external directors and related
Companies Law rules concerning the composition of the audit committee and compensation committee of the board of directors (other than
the gender diversification rule under the Companies Law, which requires the appointment of a director from the other gender if at the
time a director is appointed all members of the board of directors are of the same gender). In accordance with these regulations, in January
2022, following our listing on Nasdaq, our Board of Directors elected to &#8220;opt out&#8221; from the Companies Law requirement to appoint
external directors and related Companies Law rules concerning the composition of the audit committee and compensation committee of our
board of directors.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fiduciary Duties of Office Holders</i></b><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law imposes
a duty of care and a duty of loyalty on all office holders of a company. &#8220;Office holders&#8221; includes the chief executive officer,
general manager, chief business manager, deputy general manager, vice general manager, any other person assuming the responsibilities
of any of the above positions regardless of that person&#8217;s title, and a director, or a manager directly subordinate to the chief
executive officer or general manager.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The duty of care requires
an office holder to act with the level of care with which a reasonable office holder in the same position would have acted under the same
circumstances. The duty of care of an office holder includes a duty to use reasonable means to obtain:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">information
on the advisability of a given action brought for his approval or performed by him by virtue of his position; and</span></td>
</tr></table><div>



</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
other important information pertaining to these actions.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The duty of loyalty of an
office holder requires an office holder to act in good faith and for the benefit of the Company, and includes a duty to:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain
from any conflict of interest between the performance of his duties in the Company and his performance of his other duties or personal
affairs;</span></td>
</tr></table><div>



</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from any action that constitutes competition with the Company&#8217;s business;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from exploiting any business opportunity of the Company to receive a personal gain for himself or others; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclose to the Company any information or documents relating to the Company&#8217;s affairs which the office holder has received due to his position as an office holder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Approval of Related Party Transactions under
Israeli Law</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>General</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, we
may approve an action by an office holder from which the office holder would otherwise have to refrain, as described above, if:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
office holder acts in good faith and the act or its approval does not cause harm to the Company; and</span></td>
</tr></table><div>



</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the office holder disclosed the nature of his or her interest in the transaction (including any significant fact or document) to the Company at a reasonable time before the Company&#8217;s approval of such matter.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Disclosure of Personal Interests of an Office
Holder</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law requires
that an office holder disclose to the Company, promptly, and, in any event, not later than the board meeting at which the transaction
is first discussed, any direct or indirect personal interest that he or she may have and all related material information known to him
or her relating to any existing or proposed transaction by the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A &#8220;personal interest&#8221;
includes the personal interest of a person for whom the office holder holds a voting proxy or the personal interest of the office holder
with respect to his or her vote on behalf of a person for whom he or she holds a proxy even if such shareholder has no personal interest
in the matter.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the transaction is an extraordinary
transaction, the office holder must also disclose any personal interest held by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
office holder&#8217;s relatives; or</span></td>
</tr></table><div>



</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
corporation in which the office holder or his or her relatives holds 5% or more of the shares or voting rights, serves as a director
or general manager or has the right to appoint at least one director or the general manager.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An office holder is not, however,
obliged to disclose a personal interest if it derives solely from the personal interest of his or her relative in a transaction that is
not considered an extraordinary transaction.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, an
extraordinary transaction is a transaction:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
in the ordinary course of business;</span></td>
</tr></table><div>



</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not on market terms; or</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that is likely to have a material effect on the Company&#8217;s profitability, assets or liabilities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law does not
specify neither to who within us nor the manner in which required disclosures are to be made. We require our office holders to make such
disclosures to our Board of Directors.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, once
an office holder complies with the above disclosure requirement, the board of directors may approve a transaction between the Company
and an office holder, or a third party in which an office holder has a personal interest, unless the articles of association provide otherwise
and provided that the transaction is in the Company&#8217;s interest and is performed by the office holder in good faith. If the transaction
is an extraordinary transaction, first the audit committee and then the board of directors, in that order, must approve the transaction.
Under specific circumstances, shareholder approval may also be required. Any director (and any person, in general) who has a personal
interest in an extraordinary transaction, which is considered at a meeting of the board of directors or the audit committee, may not be
present at this meeting or vote on this matter, unless the chairman of the relevant committee or board of directors determines that he
or she should be present in order to present the transaction that is subject to approval. If a majority of the board of directors or the
audit committee, as the case may be, has a personal interest in the approval of a transaction, then all directors may participate in discussions
of the audit committee or the board of directors (as applicable) on such transaction and the voting on approval thereof, but shareholder
approval is also required for such transaction.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, all
arrangements as to compensation and indemnification or insurance of office holders require approval of the compensation committee and
board of directors, and compensation of office holders who are directors must be also approved, subject to certain exceptions, by the
shareholders, in that order. If shareholders of a company do not approve the compensation terms of office holders, other than directors,
the compensation committee and board of directors may override the shareholders&#8217; decision, subject to certain conditions.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Disclosure of Personal Interests of a Controlling
Shareholder</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, the
disclosure requirements that apply to an office holder also apply to a &#8220;controlling shareholder&#8221; of a public company. Extraordinary
transactions with a controlling shareholder or in which a controlling shareholder has a personal interest, including a private placement
in which a controlling shareholder has a personal interest, as well as transactions for the provision of services whether directly or
indirectly by a controlling shareholder or his or her relative, or a company such controlling shareholder controls, and transactions concerning
the terms of engagement of a controlling shareholder or a controlling shareholder&#8217;s relative, whether as an office holder or an
employee, require the approval of the audit committee or the compensation committee, as the case may be, the board of directors and a
majority of the shares voted by the shareholders of the Company participating and voting on the matter in a shareholders&#8217; meeting.
In addition, the shareholder approval must fulfill one of the following requirements:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
least a majority of the shares held by shareholders who have no personal interest in the transaction and are voting at the meeting must
be voted in favor of approving the transaction, excluding abstentions; or</span></td>
</tr></table><div>



</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the shares voted by shareholders who have no personal interest in the transaction who vote against the transaction represent no more than 2% of the voting rights in the Company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, any extraordinary
transaction with a controlling shareholder or in which a controlling shareholder has a personal interest with a term of more than three
years requires the abovementioned approval every three years; however, such transactions not involving the receipt of services or compensation
can be approved for a longer term, provided that the audit committee determines that such longer term is reasonable under the circumstances.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to regulations promulgated
under the Companies Law, certain transactions with a controlling shareholder or his or her relative, or with directors, that would otherwise
require approval of a company&#8217;s shareholders may be exempt from shareholder approval upon certain determinations of the audit or
compensation committee and board of directors.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law requires
that every shareholder that participates, in person, by proxy or by voting instrument, in a vote regarding a transaction with a controlling
shareholder, must indicate in advance or in the ballot whether or not that shareholder has a personal interest in the vote in question.
Failure to so indicate will result in the invalidation of that shareholder&#8217;s vote.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term &#8220;controlling
shareholder&#8221; is defined in the Companies Law as a shareholder with the ability to direct the activities of the Company, other than
by virtue of being an office holder. A shareholder is presumed to be a controlling shareholder if the shareholder holds 50% or more of
the voting rights in a company or has the right to appoint the majority of the directors of the Company or its general manager. The definition
a &#8220;controlling shareholder&#8221; is deemed to include any shareholder that holds 25% or more of the voting rights in a company
if no other shareholder holds more than 50% of the voting rights in the Company. For the purpose of determining the holding percentage
stated above, two or more shareholders who have a personal interest in a transaction that is brought for the Company&#8217;s approval
are deemed as joint holders. According to the foregoing, the Companies Law recognizes a situation where there exists a &#8220;controlling
shareholder&#8221; regarding a particular matter or in relation to a particular transaction, although such shareholder would not be considered
to have a controlling interest on an ongoing basis or in any other case.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Duties of Shareholders</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, a
shareholder has a duty to refrain from abusing its power in the Company and to act in good faith and in an acceptable manner in exercising
its rights and performing its obligations to the Company and other shareholders, including, among other things, voting at general meetings
of shareholders on the following matters:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">amendment
of the articles of association;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase
in the Company&#8217;s authorized share capital;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">merger;
and</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
approval of &#8220;related party&#8221; transactions and acts of office holders that require shareholder approval.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A shareholder also has a general
duty to refrain from oppressing and discriminating against other shareholders.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The remedies generally available
upon a breach of contract will also apply to a breach of the above mentioned duties, and in the event of oppression of other shareholders,
additional remedies are available to the injured shareholder.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, any controlling
shareholder, any shareholder that knows that its vote can determine the outcome of a shareholder vote and any shareholder that, under
a company&#8217;s articles of association, has the power to appoint or prevent the appointment of an office holder, or has another power
with respect to a company, is under a duty to act with fairness towards the Company. The Companies Law does not describe the substance
of this duty except to state that the remedies generally available upon a breach of contract will also apply in the event of a breach
of the duty to act with fairness, taking the shareholder&#8217;s position in the Company into account.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Committees of the Board of Directors</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors has
established two standing committees, both of which (the audit committee and the compensation committee) are mandatory (and to date comprised
of the same members and combined into one functional committee which resides as a unified committee). In addition, occasionally our Board
of Directors may form sub-committees for certain matters on an ad hoc basis, such as a pricing committee or a nomination and corporate
governance committee, with advisory powers only, operating under a framework and guidelines as outlined and defined in advance by our
Board of Directors.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Audit Committee</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Companies Law Requirements</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, we
are required to appoint an audit committee.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Listing Requirements&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the corporate governance
rules of Nasdaq, we are required to maintain an audit committee consisting of at least three independent directors, each of whom is financially
literate and one of whom has accounting or related financial management expertise.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 125; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee, acting
pursuant to a written charter, consists of Mr. Vider, Mr. Ben Shay and Mr. Dayan. Mr. Ben Shay serves as chairperson of our audit committee.
All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC
and the corporate governance rules of Nasdaq. Our Board of Directors has determined that Amnon Ben Shay is an audit committee financial
expert as defined by the SEC rules and has the requisite financial experience as defined by the corporate governance rules of Nasdaq.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Audit Committee Role&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, our
audit committee is responsible for:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining
whether there are deficiencies in the business management practices of our company, and making recommendations to the Board of Directors
to improve such practices;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining
whether to approve certain related party transactions (including transactions in which an office holder has a personal interest and whether
such transaction is extraordinary or material under Companies Law) (see &#8220;-Approval of Related Party Transactions under Israeli
Law&#8221;);</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">examining
our internal controls and internal auditor&#8217;s performance, including whether the internal auditor has sufficient resources and tools
to dispose of its responsibilities;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">examining
the scope of our auditor&#8217;s work and compensation and submitting a recommendation with respect thereto to our Board of Directors
or shareholders, depending on which of them is considering the appointment of our auditor;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
procedures for the handling of employees&#8217; complaints as to the management of our business and the protection to be provided to
such employees;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining
whether certain acts of an office holder not in accordance with his or her fiduciary duty owed to the Company are extraordinary or material
and to approve such acts and certain related party transactions (including transactions in which an office holder has a personal interest)
and whether such transaction is extraordinary or material under the Companies Law (see &#8220;-Approval of Related Party Transactions
Under Israeli Law&#8221;);</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">deciding
whether to approve and to establish the approval process (including by tender or other competitive proceedings) for certain transactions
with a controlling shareholder or in which a controlling shareholder has a personal interest; and</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining
the process of approving of transactions that are not negligible, including determining the types of transactions that will be subject
to the approval of the audit committee.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted an audit committee
charter setting forth among others, the responsibilities of the audit committee consistent with the rules of the SEC and Nasdaq listing
rules, including, among others, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">considering
and making recommendations to the Board of Directors on our financial statements, reviewing and discussing the financial statements and
presenting its recommendations with respect to the financial statements to the Board of Directors prior to the approval of the financial
statements by our Board of Directors;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">oversight
of our independent registered public accounting firm and recommending the engagement, compensation or termination of engagement of our
independent registered public accounting firm to the Board of Directors in accordance with Israeli law;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
the engagement or termination of the person filling the office of our internal auditor, reviewing the services provided by our internal
auditor and reviewing effectiveness of our system of internal control over financial reporting;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
the terms of audit and non-audit services provided by the independent registered public accounting firm for pre-approval by our Board
of Directors; and</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
and monitoring, if applicable, legal matters with significant impact, reviewing regulatory authorities&#8217; findings, receiving reports
regarding irregularities and legal compliance, acting according to &#8220;whistleblower policy&#8221; and recommending to our Board of
Directors if so required, and overseeing our policies and procedures regarding compliance with applicable financial and accounting related
standards, rules and regulations.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compensation Committee</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Companies Law Requirements</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, the
board of directors of any public company must establish a compensation committee. The compensation committee must be comprised of at least
three directors.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Listing Requirements</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation committee
is acting pursuant to a written charter, and consists of Mr. Vider, Mr. Ben Shay and Mr. Dayan. Mr. Ben Shay is the Chairperson of the
compensation committee. Our Board of Directors has determined that each member of our compensation committee is independent under the
corporate governance rules of Nasdaq, including the additional independence requirements applicable to the members of a compensation committee.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Compensation Committee Role</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation committee
reviews and recommends to our Board of Directors: (1) the annual base compensation of our executive officers and directors; (2) annual
incentive bonus, including the specific goals and amount; (3) equity compensation; (4) employment agreements, severance arrangements,
and change in control agreements/provisions; (5) retirement grants and/or retirement bonuses; and (6) any other benefits, compensation,
compensation policies or arrangements.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The duties of the compensation
committee include the recommendation to the Company&#8217;s board of directors of a policy regarding the terms of engagement of office
holders, to which we refer as a Compensation Policy. The Compensation Policy must be adopted by the Company&#8217;s Board of Directors,
after considering the recommendations of the Compensation Committee. The Compensation Policy is then brought for approval by our shareholders
and is subject to special majority requirements. On February 10, 2022, our shareholders approved our new Compensation Policy, which unless
amended shall remain in effect until February 9, 2025.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Compensation Policy</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Policy must
serve as the basis for decisions concerning the financial terms of employment or engagement of executive officers and directors, including
exculpation, insurance, indemnification or any monetary payment or obligation of payment in respect of employment or engagement. The Compensation
Policy must be approved (or reapproved) not longer than every three years, and relate to certain factors, including advancement of the
Company&#8217;s objectives, the Company&#8217;s business and its long-term strategy, and creation of appropriate incentives for executives.
It must also consider, among other things, the Company&#8217;s risk management, size and the nature of its operations. The Compensation
Policy must furthermore consider the following additional factors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
knowledge, skills, expertise and accomplishments of the relevant office holder (director or executive);</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
director&#8217;s or executive&#8217;s roles and responsibilities and prior compensation agreements with him or her;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
relationship between the terms offered and the average and median compensation of the other employees of the Company, including those
employed through manpower companies;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
impact of disparities in salary upon work relationships in the Company;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
possibility of reducing variable compensation at the discretion of the board of directors; and the possibility of setting a limit on
the exercise value of non-cash variable compensation; and</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
to severance compensation, the period of service of the director or executive, the terms of his or her compensation during such service
period, the Company&#8217;s performance during that period of service, the person&#8217;s contribution towards the Company&#8217;s achievement
of its goals and the maximization of its profits, and the circumstances under which the person is leaving the Company.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Policy must
also include the following principles:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
link between variable compensation and long-term performance and measurable criteria;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
relationship between variable and fixed compensation, and the ceiling for the value of variable compensation;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
conditions under which a director or executive would be required to repay compensation paid to him or her if it was later shown that
the data upon which such compensation was based was inaccurate and was required to be restated in the Company&#8217;s financial statements;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
minimum holding or vesting period for variable, equity-based compensation; and</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maximum
limits for severance compensation.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Policy must
also consider appropriate incentives from a long-term perspective and maximum limits for severance compensation.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Committee
is responsible for (1) recommending the Compensation Policy to a company&#8217;s Board of Directors for its approval (and subsequent approval
by our shareholders) and (2) duties related to the compensation policy and to the compensation of a company&#8217;s office holders as
well as functions previously fulfilled by a Company&#8217;s Audit Committee with respect to matters related to approval of the terms of
engagement of office holders, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
whether a compensation policy should continue in effect, if the then-current policy has a term of greater than three years (approval
of either a new compensation policy or the continuation of an existing compensation policy must in any case occur every three years);</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
to the board of directors periodic updates to the compensation policy;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assessing
implementation of the compensation policy; and</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining
whether the compensation terms of the chief executive officer of the Company need not be brought to approval of the shareholders.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Internal Auditor</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, the
Board of Directors of an Israeli public company must also appoint an internal auditor nominated and supervised by the audit committee.
Our internal auditor is Mr. Daniel Shapira, who has been serving as our internal auditor since March 2006. Mr. Shapira is a Certified
Public Accountant and holds a B.A. degree in Economics and Accounting from Bar-Ilan University, Israel.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The role of the internal auditor
is to examine whether a company&#8217;s actions comply with the law and proper business procedure. Our Chairman acts as the internal auditor&#8217;s
organizational supervisor. The internal auditor will submit his internal auditor&#8217;s work plan for the approval of our audit committee.
The internal auditor may not be an &#8220;interested party&#8221; or office holder, or a relative of any interested party or office holder,
and may not be a member of the Company&#8217;s independent accounting firm or its representative. The Companies Law defines an interested
party as a holder of 5% or more of the shares or voting rights of a company, any person or entity that has the right to nominate or appoint
at least one director or the general manager of the Company or any person who serves as a director or as the general manager of a company.
Our internal auditor is not our employee, but the managing partner of a firm which specializes in internal auditing.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Remuneration of Directors</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, remuneration
of directors is subject to the approval of the compensation committee, thereafter by the board of directors and thereafter by the general
meeting of the shareholders. In case the remuneration of the directors is in accordance with regulation applicable to remuneration of
the external directors then such remuneration shall be exempt from the approval of the general meeting.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Insurance</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law and
our amended and restated articles of association, a company may obtain insurance for any of its office holders for:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
breach of his or her duty of care to the Company or to another person, including a breach arising out of the negligent conduct of the
office holder;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
breach of his or her duty of loyalty to the Company, provided that the office holder acted in good faith and had reasonable cause to
assume that his or her act would not prejudice the Company&#8217;s interests;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
financial liability imposed upon him or her in favor of another person concerning an act performed by such office holder in his or her
capacity as an officer holder;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
other insurable action in accordance with the Companies Law;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
incurred by an office holder relating to an administrative enforcement proceeding conducted with respect to such office holder including
reasonable litigation expenses and attorneys&#8217; fees; and</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payments
to the party injured by the violation, in accordance with the Securities Law.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have liability
insurance providing total coverage of $5 million per claim and in the aggregate for the benefit of all of our directors and officers and
company coverage for securities claims. We also have an excess Side A difference in conditions policy providing a total coverage of $2.5
million per claim and in the aggregate for the benefit of all of our directors and officers for claims against them, which may operate
as a primary coverage in certain cases, subject to policy terms and conditions.<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Indemnification</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law and our
amended and restated articles of association provide that we may indemnify an office holder against:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
financial liability imposed on him or her in favor of another person by any judgment concerning an act performed in his or her capacity
as an office holder, including a settlement or arbitrator&#8217;s award approved by a court; However, if an undertaking to indemnify
an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in
the opinion of the board of directors, can be foreseen based on a company&#8217;s activities when the undertaking to indemnify is given,
and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking
must detail the abovementioned foreseen events and amount or criteria;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable
litigation expenses, including attorneys&#8217; fees, incurred by the office holder: (i) as a result of an investigation or proceeding
instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (a) no indictment
(as defined in the Companies Law) was filed against such office holder as a result of such investigation or proceeding; and (b) no financial
liability as a substitute for the criminal proceeding (as defined in the Companies Law) was imposed upon him or her as a result of such
investigation or proceeding, or, if such financial liability was imposed, it was imposed with respect to an offense that does not require
proof of criminal intent; and (ii) in connection with a monetary sanction;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable
litigation expenses, including attorneys&#8217; fees, expended by the office holder or charged to him or her by a court relating to an
act performed in his or her capacity as an office holder, in connection with: (1) proceedings that the Company institutes, or that another
person institutes on the Company&#8217;s behalf, against him or her; (2) a criminal charge of which he or she was acquitted; or (3) a
criminal charge for which he or she was convicted for a criminal offense that does not require proof of criminal thought;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
incurred by an office holder relating to an administrative enforcement proceeding conducted with regard to such office holder, including
reasonable litigation expenses and including attorneys&#8217; fees;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment
to the party injured by the violation; and</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">liability
or expense otherwise permitted as an indemnification by the Companies Law.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated articles
of association allow us to indemnify our office holders up to a certain amount. The Companies Law also permits a company to undertake
in advance to indemnify an office holder, provided that if such indemnification relates to financial liability imposed on him or her,
as described above, then the undertaking should be limited:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
categories of events that the board of directors determines are likely to occur in light of the operations of the Company at the time
that the undertaking to indemnify is made; and</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
amount or criterion determined by the board of directors, at the time of the giving of such undertaking to indemnify, to be reasonable
under the circumstances.</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into indemnification
agreements, with each of our directors and with certain members of our senior management. Each such indemnification agreement provides
the office holder with indemnification to the fullest extent permitted under applicable law and up to a certain amount, and including
with respect to liabilities resulting from our initial public offering in the United States and any other subsequent public offerings,
and to the extent that the directors and officers insurance do not cover these liabilities.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Exculpation</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, an
Israeli company may not exculpate an office holder from liability for a breach of his or her duty of loyalty, but may exculpate in advance
an office holder from his or her liability to the Company, in whole or in part, and for damages caused to the Company as a result of a
breach of his or her duty of care (other than in relation to distributions), but only if a provision authorizing such exculpation is included
in its articles of association. A company may not exculpate a director from liability arising out of a prohibited dividend or distribution
to shareholders. Our amended and restated articles of association provide that we may exculpate any office holder from liability to us
to the fullest extent permitted by law.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into exculpation
agreements with each of our current directors and executive officers undertaking to exculpate and release our office holders from any
and all liability to us related to any breach by them of their duty of care to us to the fullest extent permitted by law and including
with respect to liabilities resulting from our initial public offering in the United States and any other subsequent public offerings.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Limitations</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law provides
that we may not exculpate or indemnify an office holder nor enter into an insurance contract that would provide coverage for any liability
incurred as a result of any of the following: (1) a breach by the office holder of his or her duty of loyalty unless (in the case of indemnity
or insurance only, but not exculpation) the office holder acted in good faith and had a reasonable basis to believe that the act would
not prejudice us; (2) a breach by the office holder of his or her duty of care if the breach was carried out intentionally or recklessly
(as opposed to merely negligently); (3) any action taken or omission committed with the intent to derive an illegal personal benefit;
or (4) any fine or forfeit levied against the office holder.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Incentive Plans</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Israeli Share Option Plan (2015); Israeli
Share Option Plan (2005) </i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2005, we adopted the
Israeli Share Option Plan (2005), or the 2005 Plan, which was in force for a period of 10 years. Upon the expiration of the 2005 Plan,
we adopted the Israeli Share Option Plan (2015), or the 2015 Plan. There are no options outstanding under our 2005 Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">We
no longer grant any awards under the 2015 Plan as it was superseded by the 2023 Share Incentive Plan, or the 2023 Plan, although previously
granted awards remain outstanding. Ordinary Shares subject to outstanding options granted under the 2015 Plan that expire or have ceased
to be eligible for exercise without having been exercised in full will become available again for future grant under the 2023 Plan. Our
board of directors, or a duly authorized committee of our board of directors administers the 2023 Plan.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2023 Share Incentive Plan</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2023 Plan was adopted
by our board of directors on December 28, 2023. The 2023 Plan provides for the grant of equity-based incentive awards to our employees,
directors, office holders, service providers and consultants in order to incentivize them to increase their efforts on our behalf and
to promote the success of our business. As of February 1, 2024, 1,013,787, Ordinary Shares were reserved for issuance under the 2023 Plan.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Shares
Available for Grants.&#160;</i>The maximum number Ordinary Shares available for issuance under the 2023 Plan is equal to the sum of (i)
1,000,0000 shares and (ii) any shares subject to awards under the 2015 Plan which have expired, or were cancelled, terminated, forfeited
or settled in cash in lieu of issuance of shares or became <span style="background-color: white">have ceased to be eligible for exercise</span>
without having been exercised, provided that no more than 1,013,787, Ordinary Shares may be issued upon the exercise of Incentive Stock
Options. If permitted by our board of directors, shares tendered to pay the exercise price or withholding tax obligations with respect
to an award granted under the 2023 Plan or the 2015 Plan may again be available for issuance under the 2023 Plan, unless determined otherwise
by the board of directors. Our board of directors may also reduce the number of Ordinary Shares reserved and available for issuance under
the 2023 Plan in its discretion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Administration.&#160;</i>Our
board of directors, or a duly authorized committee of our board of directors, or the administrator, will administer the 2023 Plan. Under
the 2023 Plan, the administrator has the authority, subject to applicable law, to interpret the terms of the 2023 Plan and any award agreements
or awards granted thereunder, designate recipients of awards, determine and amend the terms of awards, including the exercise price of
an option award, the fair market value of an ordinary share, the time and vesting schedule applicable to an award or the method of payment
for an award, accelerate or amend the vesting schedule applicable to an award, prescribe the forms of agreement for use under the 2023
Plan and take all other actions and make all other determinations necessary for the administration of the 2023 Plan in order to effectuate
the purposes of the 2023 Plan but without amending the 2023 Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Eligibility.&#160;</i>The
2023 Plan provides for granting awards under various tax regimes, including, without limitation, in compliance with Section 102 of the
Ordinance, and Section 3(i) of the Ordinance and for awards granted to our United States employees or service providers, including those
who are deemed to be residents of the United States for tax purposes, Section 422 of the Code and Section 409A of the Code.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Grants.&#160;</i>All
awards granted pursuant to the 2023 Plan will be evidenced by an award agreement, in a form approved, from time to time, by the administrator
in its sole discretion. The award agreement will set forth the terms and conditions of the award, including the type of award, number
of shares subject to such award, vesting schedule and conditions (including performance goals or measures) and the exercise price, if
applicable. Certain awards under the 2023 Plan may constitute or provide for a deferral of compensation, subject to Section 409A of the
Code, which may impose additional requirements on the terms and conditions of such awards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless
otherwise determined by the administrator and stated in the award agreement, and subject to the conditions of the 2023 Plan, awards vest
and become exercisable under the following schedule: 25% of the shares covered by the award on the first anniversary of the vesting commencement
date determined by the administrator (and in the absence of such determination, the date on which such award was granted) and 6.25% of
the shares covered by the award at the end of each subsequent three-month period thereafter over the course of the following three years;
provided that the grantee remains continuously as an employee or provides services to the Company throughout such vesting dates. Each
award will expire ten years from the date of the grant thereof, unless such shorter term of expiration is otherwise designated by the
administrator.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Awards.&#160;</i>The
2023 Plan provides for the grant of share options (including Incentive Stock Options and nonqualified stock options), Ordinary Shares,
restricted shares, RSUs, share appreciation rights and other share-based awards. Options granted under the 2023 Plan to the Company employees
who are U.S. residents may qualify as &#8220;Incentive Stock Options&#8221; within the meaning of Section 422 of the Code, or may be non-qualified
stock options. The exercise price of an Incentive Stock Option may not be less than 100% of the fair market value of the underlying share
on the date of grant or such other amount as may be required pursuant to the Code, and in the case of Incentive Stock Options granted
to ten percent stockholders, not less than 110%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Exercise.</i>&#160;An
option award under the 2023 Plan may be exercised by providing the Company with a written or electronic notice of exercise and full payment
of the exercise price for such shares underlying the award, if applicable, in such form and method as may be determined by the administrator
and permitted by applicable law. An option award may not be exercised for a fraction of a share. The administrator may, in its discretion,
accept cash or provide for net withholding of shares in a cashless exercise mechanism with respect to tax withholding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Transferability.&#160;</i>Other
than by will, the laws of descent and distribution or as otherwise provided under the 2023 Plan, neither the options nor any right in
connection with such options are assignable or transferable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Termination
of Employment.&#160;</i>In the event of termination of a grantee&#8217;s employment or service with the Company or any of its affiliates,
all vested and exercisable awards held by such grantee as of the date of termination may be exercised within three months after such date
of termination, unless otherwise determined by the administrator, but in no event later than the date of expiration of the award as set
forth in the award agreement. After such three-month period, all such unexercised awards will terminate and the shares covered by such
awards shall again be available for issuance under the 2023 Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In
the event of a grantee&#8217;s death or permanent disability, or in the event of the grantee&#8217;s death within the three month period
(or such longer period as determined by the administrator) following his or her termination of service, all vested and exercisable awards
held by such grantee as of the date of termination may be exercised by the grantee or the grantee&#8217;s legal guardian, estate or by
a person who acquired the right to exercise the award by bequest or inheritance, as applicable, within one year after such date of termination,
unless otherwise provided by the administrator, but in no event later than the date of expiration of the award as set forth in the award
agreement. Any unvested awards as of the date of such termination or which are vested but not exercised within the one-year period following
such date, will terminate and the shares covered by such awards shall again be available for issuance under the 2023 Plan. If a grantee&#8217;s
employment or services with the Company or any of its affiliates is terminated for &#8220;cause&#8221; (as defined in the 2023 Plan),
all outstanding awards held by such grantee (whether vested or unvested) will terminate on the date of such termination and the shares
covered by such awards shall again be available for issuance under the 2023 Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Voting
Rights.&#160;</i>Except with respect to restricted share awards, grantees will not have the rights as a shareholder of the Company with
respect to any shares covered by an award until the award has vested and/or the grantee has exercised such award, paid any exercise price
for such award and becomes the record holder of the shares. With respect to restricted share awards, grantees will possess all incidents
of ownership of the restricted shares, including the right to vote and receive dividends on such shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dividends.&#160;</i>Grantees
holding restricted share awards will be entitled to receive dividends and other distributions with respect to the shares underlying the
restricted share award. Any stock split, stock dividend, combination of shares or similar transaction will be subject to the restrictions
of the original restricted share award. Grantees holding RSUs will not be eligible to receive dividend but may be eligible to receive
dividend equivalents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Transactions.&#160;</i>In
the event of a share split, reverse share split, share dividend, recapitalization, combination or reclassification of the Company&#8217;s
shares, the administrator in its sole discretion may, and where required by applicable law shall, without the need for a consent of any
holder, make an appropriate adjustment in order to adjust (i) the number and class of shares reserved and available for the outstanding
awards, (ii) the number and class of shares covered by outstanding awards, (iii) the exercise price per share covered by any award, (iv)
the terms and conditions concerning vesting and exercisability and the term and duration of the outstanding awards, (v) the type or class
of security, asset or right underlying the award (which need not be only that of the Company, and may be that of the surviving corporation
or any affiliate thereof or such other entity party to any of the above transactions), and (vi) any other terms of the award that in the
opinion of the administrator should be adjusted; provided that any fractional shares resulting from such adjustment shall be rounded to
the nearest whole share unless otherwise determined by the administrator. In the event of a distribution of a cash dividend to all shareholders,
the administrator may determine, without the consent of any holder of an award, that the exercise price of an outstanding and unexercised
award shall be reduced by an amount equal to the per share gross dividend amount distributed by the Company, subject to applicable law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In
the event of a merger or consolidation of the Company or a sale of all, or substantially all, of the Company&#8217;s shares or assets
or other transaction having a similar effect on the Company, or change in the composition of the board of directors, or liquidation or
dissolution, or such other transaction or circumstances that our board of directors determines to be a relevant transaction, then without
the consent of the grantee, (i) unless otherwise determined by the administrator, any outstanding award will be assumed or substituted
by such successor corporation, or (ii) regardless of whether or not the successor corporation assumes or substitutes the award (a) provide
the grantee with the option to exercise the award as to all or part of the shares, and may provide for an acceleration of vesting of unvested
awards, (b) cancel the award and pay in cash, shares of the Company, the acquirer or other corporation which is a party to such transaction
or other property as determined by the administrator as fair in the circumstances, or (c) provide that the terms of any award shall be
otherwise amended, modified or terminated, as determined by the administrator to be fair in the circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employees.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 31, 2021, we had
4 full-time employees. On December 31, 2022, we had 3 full-time employees. On December 31, 2023 we had 3 full-time employees, 2 of whom
were members of senior management: our Chief Executive Officer who is also our Chief Financial Officer and Chief Technologies Officer.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of our current employees
and officeholders is represented by labor unions or covered by collective bargaining agreements. We believe that we maintain good relations
with all of our employees. However, in Israel, we are subject to certain Israeli labor laws, regulations and national labor court precedent
rulings, as well as certain provisions of collective bargaining agreements applicable to us by virtue of extension orders issued in accordance
with relevant labor laws by the Israeli and Industry of Economy and which apply such agreement provisions to our employees even though
they are not part of a union that has signed a collective bargaining agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>BENEFICIAL OWNERSHIP OF PRINCIPAL SHAREHOLDERS
AND MANAGEMENT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth information regarding beneficial ownership
of our Ordinary Shares as of February 26, 2024 by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>each person, or group of affiliated persons, known to us to be the beneficial owner of more than 5% of our outstanding ordinary shares; &#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each of our directors, and executive officers; and</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all of our directors, and
    executive officers as a group.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as indicated in footnotes
to this table, we believe that the shareholders named in this table have sole voting and investment power with respect to all shares shown
to be beneficially owned by them, based on information provided to us by such shareholders. Unless otherwise noted below, each beneficial
owner&#8217;s address is c/o SciSparc Ltd., 20 Raul Wallenberg Street, Tower A, Tel Aviv, 6971916 Israel.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><b>Holders of more than 5% of our Ordinary Shares:</b></td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">Number of<br/> Ordinary<br/> Shares<br/> Beneficially<br/> Owned (1)</td>
    <td style="padding-bottom: 4pt; font-weight: bold"><sup>&#160;</sup></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percent of<br/> Class (2)</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">YA II PN, LTD.<sup>(3)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">55,293</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">5.06</td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><b><span style="text-decoration:underline">Officers and Directors who are not 5% holders:</span></b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Itschak Shrem (President and Director)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,136 </span></td>
    <td style="padding-bottom: 4pt; width: 1%; text-align: left"><sup>(4)</sup></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left"><sup>&#160;</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amitay Weiss (Chairman of the Board of Directors)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">821 </span></td>
    <td style="padding-bottom: 4pt; text-align: left"><sup>(5)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left"><sup>&#160;</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Oz Adler (Chief Executive Officer and Chief Financial Officer)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">856 </span></td>
    <td style="padding-bottom: 4pt; text-align: left"><sup>(6)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left"><sup>&#160;</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. Adi Zuloff-Shani (Chief Technology Officer)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">840 </span></td>
    <td style="padding-bottom: 4pt; text-align: left"><sup>(7)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left"><sup>&#160;</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amnon Ben Shay (Director)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">141 </span></td>
    <td style="padding-bottom: 4pt; text-align: left"><sup>(8)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left"><sup>&#160;</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Alon Dayan (Director)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">141 </span></td>
    <td style="padding-bottom: 4pt; text-align: left"><sup>(8)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left"><sup>&#160;</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Moshe Revach (Director)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">141 </span></td>
    <td style="padding-bottom: 4pt; text-align: left"><sup>(8)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left"><sup>&#160;</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Liat Sidi (Director)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">141 </span></td>
    <td style="padding-bottom: 4pt; text-align: left"><sup>(8)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left"><sup>&#160;</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lior Vider (Director)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">141 </span></td>
    <td style="padding-bottom: 4pt; text-align: left"><sup>(8)</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left"><sup>&#160;</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">All directors and executive officers as a group (9 persons)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4,358</td>
    <td style="padding-bottom: 4pt; text-align: left"><sup>&#160;</sup></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td>
    <td style="text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
than 1%.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities.
Ordinary Shares relating to options currently exercisable or exercisable within 60 days of the date of this table are deemed outstanding
for computing the percentage of the person holding such securities but are not deemed outstanding for computing the percentage of any
other person. Except as indicated by footnote, and subject to community property laws where applicable, the persons named in the table
above have sole voting and investment power with respect to all shares shown as beneficially owned by them.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The percentages shown are based on 1,096,677 Ordinary Shares issued and
outstanding as of February 22, 2024, plus Ordinary Shares relating to options and warrants currently exercisable or exercisable within
60 days of the date of this table, which are deemed outstanding for computing the percentage of the person holding such securities but
are not deemed outstanding for computing the percentage of any other person.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">YA is a fund managed by Yorkville Advisors Global, LP, or Yorkville LP. Yorkville Advisors Global II, LLC, or Yorkville LLC, is the General Partner of Yorkville LP. All investment decisions for YA are made by Yorkville LLC&#8217;s President and Managing Member, Mr. Mark Angelo. The business address of YA is 1012 Springfield Avenue, Mountainside, NJ 07092.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(4)</td><td style="text-align: justify">Includes 340 Ordinary Shares and options to purchase 996
Ordinary Shares at an exercise price of $169 per share. In addition, Mr. Shrem holds options to purchase 200 Ordinary Shares that are
not exercisable within 60 days. Mr. Shrem&#8217;s options have an expiration date of January 3, 2028, and a weighted average exercise
price of $169.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
25 Ordinary Shares and options to purchase 996 Ordinary Shares at an exercise price of $169 per share. In addition, Mr. Weiss holds options
to purchase 200 Ordinary Shares that are not exercisable within 60 days. Mr. Weiss&#8217;s options have an expiration date of January
3, 2028, and a weighted average exercise price of $169.</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
options to purchase 996 Ordinary Shares at an exercise price of $169 per share, and options to purchase 60 Ordinary Shares at an exercise
price of $5,460 per share. In addition, Mr. Adler holds options to purchase 200 Ordinary Shares that are not exercisable within 60 days.
Mr. Adler&#8217;s options have an expiration date of January 3, 2028 to October 10, 2029, and a weighted average exercise price of $422.</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
options to purchase 6 Ordinary Shares at an exercise price of NIS 77,241 (approximately $20,876) per share, options to purchase 38 Ordinary
Shares at an exercise price of $5,640 per share, and options to purchase 996 Ordinary Shares at an exercise price of $169 per share.
In addition, Dr. Zuloff-Shani holds options to purchase 200 Ordinary Shares that are not exercisable within 60 days. Dr. Zuloff-Shani&#8217;s
options have an expiration date of February 16, 2026 to October 10, 2029, and a weighted average exercise price of $207.</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td><td style="text-align: justify">Includes options to purchase 176 Ordinary Shares at an exercise price
of $169 per share. Each of Amnon Ben Shay, Alon Dayan, Moshe Revach, Liat Sidi and Lior Vider holds options to purchase 35 Ordinary Shares
that are not exercisable within 60 days. The options have an expiration date of January 3, 2028, and a weighted average exercise price
of $169.</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Changes in Percentage
Ownership by Major Shareholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">To
our knowledge, other than as disclosed in the table above, our other filings with the SEC and the Annual Report, there has been no significant
change in the percentage ownership held by any major shareholder during the past three years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Voting Rights</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 30.6pt; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">No
major shareholders listed above had or have voting rights with respect to their Ordinary Shares that are different from the voting rights
of other holders of our Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Record Holders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
of February 7, 2024, there were 23 holders of record of our Ordinary Shares, 8 of which have a registered address in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">These
numbers are not representative of the number of beneficial holders of our shares nor is it representative of where such beneficial holders
reside, since many of these shares were held of record by brokers or other nominees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Change in Control
Arrangements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
are not controlled by another corporation, by any foreign government or by any natural or legal persons except as set forth herein, and
there are no arrangements known to us which would result in a change in control at a subsequent date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>RELATED PARTY TRANSACTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employment Agreements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into written
employment agreements with Mr. Oz Adler, our Chief Executive Officer and Chief Financial Officer, and Dr. Adi Zuloff-Shani, our Chief
Technologies Officer. Each of these agreements contains customary provisions regarding noncompetition, confidentiality of information
and assignment of inventions. However, the enforceability of the noncompetition provisions may be limited under applicable law. These
agreements are terminable by either party upon 30 days&#8217; prior written notice. In addition, we have entered into agreements with
each executive officer and director pursuant to which we have agreed to indemnify each of them up to a certain amount and to the extent
that these liabilities are not covered by directors and officers insurance. Members of our senior management are eligible for bonuses
each year. The bonuses are payable upon meeting objectives and targets that are set by our Chief Executive Officer and approved annually
by our Board of Directors that also set the bonus targets for our Chief Executive Officer. See &#8220;Compensation- Employment and Services
Agreements with Executive Officers&#8221; and see the descriptions of exculpation and indemnification agreements and directors and officers
insurance arrangements in Item 6. &#8220;Indemnification of Directors, Officers, and Employees&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Options </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our inception, we have
granted options to purchase our Ordinary Shares to our employees, officers, service providers and certain of our directors. Such option
agreements may contain acceleration provisions upon certain merger, acquisition, or change of control transactions. We describe our option
plans under the &#8220;2023 Share Ownership-Equity Incentive Plans.&#8221; If the relationship between us and an executive officer or
a director is terminated, except for cause (as defined in the various option plan agreements), options that are vested will generally
remain exercisable for 90 days after such termination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Commercial Agreements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Clearmind</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 7, 2022, we entered into the Cooperation Agreement with Clearmind,
a company in which Dr. Adi Zuloff-Shani, our Chief Technologies Officer, Mr. Weiss, our President, and Mr. Adler, our Chief Executive
Officer and Chief Financial Officer serve as officers and directors. See Item 4.B. &#8220;Business Overview- <i>Collaboration with Clearmind</i>&#8221;
for additional information. On November 17, 2022, we invested $1.5 million in Clearmind in connection with its initial public offering
on the Nasdaq Capital Market, in exchange for 230,769 common shares of Clearmind, representing 9.33% of the outstanding share capital
of Clearmind. In February 2023, we announced that Clearmind filed three provisional patent applications were filed by Clearmind with the
USPTO as a part of our ongoing collaboration. The patent applications refer to novel proprietary combinations of lysergic acid diethylamide,
psilocybin, and N,N-dimethyltryptamine and our PEA. Additionally, in February 2023, we announced as part of our ongoing collaboration
with Clearmind, Clearmind filed three provisional patent applications with the USPTO, for unique combinations of future psychedelic-based
compounds. The patent applications refer to novel proprietary combinations of 3,4 Methylenedioxymethamphetamine, Ibogaine and Ketamine
each with our PEA. In February 2024, Clearmind also filed patent applications under the PCT for these combinations.&#160;In June 2023,
we announced that we and Clearmind were to conduct a study evaluating our combination treatment for obesity and metabolic syndrome. In
August 2023, Clearmind filed a patent application for the treatment of dyskinesia, a combination of the psychedelic molecule 3-Methylmethcathinone
and PEA. In November 2023, successful results were announced from a pre-trial on rodents, testing the efficacy of the combination treatment
of PEA and MEAI on obesity, performed by Joseph Tam from the Hebrew University of Jerusalem. The results indicated that there was an increase
in the metabolic process and fat burn, a reduction in appetite and meal sizes, and reductions in ambulation with affecting voluntary activity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Polyrizon</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 31, 2022, we entered
into the Polyrizon Collaboration Agreement with Polyrizon. Mr. Adler, our Chief Executive Officer and Chief Financial Officer, serves
as a director in Polyrizon. See Item 4.B. &#8220;Business Overview - <i>Collaboration with Polyrizon</i>&#8221; for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Jeffs&#8217; Brands</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 15, 2022, we entered
into a letter of intent with Jeffs&#8217; Brands, to establish the Jeffs&#8217; Joint Venture. On February 23, 2023, we entered into the
Wellution Sale Agreement with Jeffs&#8217; Holdings and Jeffs&#8217; Brands, pursuant to which, at the closing on March 28, 2023, Jeffs&#8217;
Holdings acquired from us 57 of common stock of SciSparc Nutraceuticals, equal to approximately a 49% interest in our wholly owned subsidiary,
SciSparc Nutraceuticals, which owns the Wellution<sup>TM</sup> Brand, for a cash consideration of $2.5 million. In addition to the cash
consideration upon closing, we received from Jeffs&#8217; Brands an additional amount accounting for certain purchase price adjustments
related to inventory and working capital, which adjustments increased the purchase price by approximately $489,330.&#160;Following the
closing of the Wellution Sale Agreement on March 28, 2023, including an equity conversion of the financing amounts we previously provided
to SciSparc Nutraceuticals for working capital, we hold approximately 51% of the outstanding capital stock of SciSparc Nutraceuticals.&#160;In
connection with the Wellution Sale Agreement, at the closing, Jeffs&#8217; Brands and SciSparc Nutraceuticals entered into a consulting
agreement, or the Wellution Management Agreement for the provision of services by Jeffs&#8217; Brands for the management of the Brand
for a monthly fee of $20,000. Jeffs&#8217; Brands also received a one-time signing bonus at the closing in the amount of $51,000. The
Wellution Management Agreement is in effect for an undefined period of time and may be terminated by either party with 30 days&#8217;
advance notice. In addition, pursuant to the Wellution Sale Agreement, at the closing, we undertook a share exchange with Jeffs&#8217;
Brands, in which we acquired 247,415 ordinary shares of Jeffs&#8217; Brands and Jeffs&#8217; Brands acquired 360,297 of our Ordinary Shares,
in each case having an aggregate value of $288,238, or the Share Exchange. The number of shares exchanged was calculated based on the
average closing price of the shares on the Nasdaq for the 30 consecutive trading days ending on the third trading day immediately prior
to the closing date.&#160;Mr. Oz Adler, our Chief Executive Officer and Chief Financial Officer, is the chairman of the board of directors
of&#160;Jeffs&#8217;&#160;Brands, Mr. Amitay Weiss, our chairman of the board of directors and Mr. Moshe Revach, a member of our board
of directors, are both directors in&#160;Jeffs&#8217;&#160;Brands. We hold a minority interest of 1.14% in Jeffs&#8217; Brands.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DESCRIPTION OF SHARE CAPITAL</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description
of SciSparc Ltd.&#8217;s (the &#8220;Company&#8221;) share capital and provisions of the amended and restated articles of association
(the &#8220;Articles&#8221;) are summaries and do not purport to be complete.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Registration number and purposes of the Company</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our registration number with
the Israeli Registrar of Companies is 51-358165-2. Our purpose as set forth in our Articles is to engage in any lawful activity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Type and class of securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our authorized share capital
consists of 75,000,000 Ordinary shares. All of our outstanding Ordinary Shares have been validly issued, are fully paid and non-assessable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Preemptive rights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Ordinary Shares are not
redeemable and are not subject to any preemptive right.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Transfer of shares</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our fully paid Ordinary Shares
are issued in registered form and may be freely transferred under our Articles, unless the transfer is restricted or prohibited by another
instrument, applicable law or the rules of a stock exchange on which the shares are listed for trade. The ownership or voting of our
Ordinary Shares by non-residents of Israel is not restricted in any way by our Articles or the laws of the State of Israel, except for
ownership by nationals of certain countries that are, or have been, in a state of war with Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liability to further capital calls</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors may
make, from time to time, such calls as it may deem fit upon shareholders with respect to any sum unpaid with respect to shares held by
such shareholders which is not payable at a fixed time. Such shareholder has to pay the amount of every call so made upon him or her.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Election of directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our Articles, our board
of directors must consist of at least three (3) and not more than eight (8) directors, including, if applicable, two external directors
appointed as required under the Companies Law 5759-1999 (the &#8220;Companies Law&#8221;). Other than our external directors (if any),
our directors are divided into three classes with staggered three-year terms. Each class of directors consists, as nearly as possible,
of one third of the total number of directors constituting the entire board of directors. At each annual general meeting of our shareholders,
the election or re-election of directors following the expiration of the term of office of the directors of that class of directors is
for a term of office that expires on the third annual general meeting following such election or re-election, such that from 2020 and
after, at each annual general meeting the term of office only one class of directors will expire. Each director, holds office until the
annual general meeting of our shareholders for the year in which his or her term expires and until his or her successor is duly appointed,
unless the tenure of such director expires earlier pursuant to the Companies Law upon the occurrence of certain events or unless removed
from office by a vote of the holders of at least 65% of the total voting power of our shareholders at a general meeting of our shareholders
in accordance with our amended and restated Articles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further,&#160;our&#160;shareholders&#160;approved
an approval mechanism similar to a mechanism that exists in the Delaware Generate Corporate Law, which requires an affirmative vote of
the board of directors (by 75% of the members) in addition to the approval of our shareholders in order to amend such provisions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if a director&#8217;s
office becomes vacant, the remaining serving directors may continue to act in any manner, provided that the number of the serving directors
shall not be less than three (3). If the number of serving Directors is lower than their minimal one, the Board shall not be permitted
to act, other than for the purpose of convening a general meeting of the Company&#8217;s shareholders for the purpose of appointing additional
Directors. For further information on the election and removal of directors see &#8220;Item 6. Directors, Senior Management and Employees&#8212;C.
Board Practices&#8221; of the Company&#8217;s annual report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Contested election</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under our Articles, in the event of a contested election, our board
of directors in its discretion, will set the method of calculation of the votes and the manner in which the resolutions will be presented
to our shareholders at the general meeting. In the event that our board of directors does not or is unable to make a determination on
such matter, then the directors will be elected by a plurality of the voting power represented at the general meeting in person or by
proxy and voting on the election of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Dividend and liquidation rights</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may declare a dividend
to be paid to the holders of our Ordinary Shares in proportion to their respective shareholdings. Under the Companies Law, dividend distributions
are determined by the board of directors and do not require the approval of the shareholders of a company unless the Company&#8217;s
articles of association provide otherwise. Our Articles do not require shareholder approval of a dividend distribution and provide that
dividend distributions may be determined by our board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Companies
Law, the distribution amount is limited to the greater of retained earnings or earnings generated over the previous two years, according
to our then last reviewed or audited consolidated financial statements, provided that the date of the financial statements is not more
than six months prior to the date of the distribution, or we may distribute dividends that do not meet such criteria only with court
approval. In each case, we are only permitted to distribute a dividend if our board of directors and the court, if applicable, determines
that there is no reasonable concern that payment of the dividend will prevent us from satisfying our existing and foreseeable obligations
as they become due.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">In the event of our liquidation,
after satisfaction of liabilities to creditors, our assets will be distributed to the holders of our Ordinary Shares in proportion to
their shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential dividend or
distribution rights to the holders of a class of shares with preferential rights that may be authorized in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Exchange controls</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are currently no Israeli
currency control restrictions on remittances of dividends on our Ordinary Shares, proceeds from the sale of the shares or interest or
other payments to non-residents of Israel, except for shareholders who are subjects of certain countries that are, or have been, in a
state of war with Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Taxation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ISRAELI TAX CONSIDERATIONS AND GOVERNMENT
PROGRAMS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a description
of the material Israeli income tax consequences of the ownership of our Ordinary Shares. The following also contains a description of
material relevant provisions of the current Israeli income tax structure applicable to companies in Israel, with reference to its effect
on us. To the extent that the discussion is based on new tax legislation which has not been subject to judicial or administrative interpretation,
there can be no assurance that the tax authorities will accept the views expressed in the discussion in question. The discussion is not
intended, and should not be taken, as legal or professional tax advice and is not exhaustive of all possible tax considerations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description
is not intended to constitute a complete analysis of all tax consequences relating to the ownership or disposition of our Ordinary Shares.
Shareholders should consult their own tax advisors concerning the tax consequences of their particular situation, as well as any tax
consequences that may arise under the laws of any state, local, foreign or other taxing jurisdiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General Corporate Tax Structure in Israel</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli resident companies
are generally subject to corporate tax, currently at the rate of 23% of a company&#8217;s taxable income. Capital gains derived by an
Israeli resident company are subject to tax at the prevailing corporate tax rate. Under Israeli tax legislation, a corporation will be
considered as an &#8220;Israeli resident company&#8221; if it meets one of the following: (i) it was incorporated in Israel; or (ii)
the control and management of its business are exercised in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Encouragement of Research, Development
and Technological Innovations in the Industry Law, 5744-1984</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the Innovation Law, research and development programs which meet specified criteria and are approved by a committee of the IIA are eligible
for grants of up to 50% of the project&#8217;s expenditure, as determined by the research committee, and subject to the benefit track
under which the grant was awarded. A company that receives a grant from the IIA, or a grant recipient, is typically required to pay royalties
from the revenues generated from the sale of products and related services developed, in whole or in part pursuant to, or as a result
of, a research and development program funded by the IIA. Under the regular benefits tracks, the royalties are generally at a range of
3.0% to 5.0% of revenues until the entire IIA grant is repaid, together with the relevant annual interest rate. Under IIA regulations,
grants received before January 1, 1999, bear no interest.Grants received before June 30, 2017 bear an annual interest rate that
applied at the time of the approval of the applicable IIA file, and that interest rate will apply to all of the funding received under
that IIA approval. </span>&#160;<span style="font-family: Times New Roman, Times, Serif">Grants received from the IIA after June 30,
2017 bear an annual interest rate based on the 12-month Secured Overnight Financing Rate, or SOFR, or at an alternative rate published
by the Bank of Israel plus 0.71513%. Grants approved after January 1, 2024, shall bear the higher interest rate of (i) 12 months SOFR,
plus 1%, or (ii) a fixed annual interest rate of 4%.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The obligation to pay royalties
is contingent on actual income generated from such products and services. In the absence of such income, no payment of such royalties
is required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The terms of the Innovation
Law also require that the manufacture of products developed with government grants be performed in Israel. The transfer of manufacturing
activity outside Israel is subject to the prior approval of the IIA (such approval is not required for the transfer of a portion of the
manufacturing capacity which does not exceed, in the aggregate, 10% of the portion declared to be manufactured outside of Israel in the
applications for funding, in which case only notification is required). It should be noted that the terms of the Innovation Law do not
restrict the export of products that incorporate the funded technology. Under the regulations of the Innovation Law, assuming we receive
approval from the IIA to manufacture our IIA-funded products outside Israel, our liability to the IIA may be increased depending upon
the manufacturing volume that is performed outside of Israel as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Manufacturing Volume Outside of Israel</b></p></td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Royalties<br/> to the IIA as a
    Percentage<br/> of Grant</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Up to 50%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">120</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">between 50% and 90%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">90% and more</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the manufacturing is performed
outside of Israel by us, the rate of royalties payable by us on revenues from the sale of products manufactured outside of Israel will
increase by 1% over the regular rates. A company requesting funds from the IIA also has the option of declaring in its IIA grant application
its intention to perform part of its manufacturing outside Israel, thus avoiding the need to obtain additional approval under the same
manufacturing scope indicated at the application. On January 6, 2011, the Innovation Law was amended to clarify that the potential increased
royalties specified in the table above will apply even in those cases where the IIA approval for transfer of manufacturing outside of
Israel is not required, namely when the volume of the transferred manufacturing capacity is less than 10% of total capacity. For applications
to manufacture abroad, submitted to the IIA after October 25, 2023, the maximum increased liability is up to 150% of the IIA grants,
plus interest accrued thereon, instead of 300%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The know-how developed within
the framework of the IIA plan may not be transferred or licensed to third parties outside Israel without the prior approval of the IIA.
The approval, however, is not required for the export of any products developed using grants received from the IIA. The IIA approval
to transfer know-how created, in whole or in part, in connection with an IIA-funded project to a third party outside Israel is subject
to payment of a redemption fee to the IIA calculated according to a formula provided under the Innovation Law that is based, in general,
on the ratio between the aggregate IIA grants and our aggregate investments in the project that was funded by these IIA grants, multiplied
by the transaction consideration taking into account a depreciation mechanism, and less royalties already paid to the IIA. According
to regulations promulgated under the Innovation Law, the maximum amount payable to the IIA in case of transfer of know how outside Israel
shall not exceed six times the amount of the grants received plus interest, with a possibility to reduce such payment to up to three
times the amount of the grants received plus interest if the grant recipient undertakes to continue the research and development activity
in Israel for a period of at least three years after the transfer of knowhow, and maintain at least 75% of the research and development
employees the Company had for the six months before the know-how was transferred, subject to additional conditions specified in the regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Transfer or license of know-how
to an Israeli entity is subject to the IIA approval and to an undertaking of the recipient Israeli entity to undertake all the transferor&#8217;s
obligations to the IIA and to comply with the provisions of the Innovation Law and related regulations, including the restrictions on
the transfer and license of know-how and the obligation to pay royalties, as further described in the Innovation Law and related regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The restrictions under the
Innovation Law will continue to apply even after we repay the full amount of royalties payable pursuant to the grants. In addition, the
government of the State of Israel may from time to time audit sales of product candidates which it claims incorporate technology funded
via IIA programs and this may lead to additional royalties being payable on additional product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These restrictions may impair
our ability to outsource manufacturing or otherwise transfer or license our know-how outside Israel and may require us to obtain the
approval of the IIA for certain actions and transactions and pay additional royalties or other payments to the IIA. If we fail to comply
with certain restrictions under the Innovation Law, we may be subject to mandatory repayment of grants received by us (together with
interest and penalties), as well as be exposed to criminal charges.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
research and development efforts have been financed, partially, through grants that we have received from the IIA. We therefore must
comply with the requirements of the Innovation Law and related regulations. Our total outstanding obligation to the IIA,
respectively, including the interest accrued through December 31, 2023, amounts to approximately $1.2 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tax Benefits for Research and Development
under the Innovation Law</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli tax law allows, under
certain conditions, a tax deduction for expenditures, including capital expenditures, in scientific research in the fields of industry,
agriculture, transportation or energy, for the year in which they are incurred. Expenditures are deemed related to scientific research
and development projects, if:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expenditures are approved
    by the relevant Israeli government ministry, determined by the field of research;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The research and development
    must be for the promotion of the Company; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The research and development
    is carried out by or on behalf of the Company seeking such tax deduction.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of such deductible
expenses is reduced by the sum of any funds received through government grants for the finance of such scientific research and development
projects. No deduction under these research and development deduction rules is allowed if such deduction is related to an expense invested
in an asset depreciable under the general depreciation rules of the Israeli Income Tax Ordinance (New Version) 1961, or the Ordinance.
Expenditures not so approved are deductible in equal amounts over three years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time we may
apply the IIA for approval to allow a tax deduction for all research and development expenses during the year incurred. There can be
no assurance that such application will be accepted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration:underline">Law for the Encouragement of Capital Investments, 5719-1959</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Law for the Encouragement
of Capital Investments, 5719-1959, generally referred to as the Investment Law, provides certain incentives for capital investments in
production facilities (or other eligible assets) by &#8220;Industrial Enterprises&#8221; (as defined under the Investment Law).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Investment Law was significantly
amended effective April&#160;1, 2005 (which we refer to as the 2005 Amendment), further amended as of January&#160;1, 2011 (which we
refer to as the 2011 Amendment) and further amended as of January 1, 2017 (which we refer to as the 2017 Amendment). Pursuant to the
2005 Amendment, tax benefits granted in accordance with the provisions of the Investment Law prior to its revision by the 2005 Amendment
remain in force but any benefits granted subsequently are subject to the provisions of the 2005 Amendment. Similarly, the 2011 Amendment
introduced new benefits to replace those granted in accordance with the provisions of the Investment Law in effect prior to the 2011
Amendment. However, companies entitled to benefits under the Investment Law as in effect prior to January&#160;1, 2011 were entitled
to choose to continue to enjoy such benefits, provided that certain conditions are met, or elect instead irrevocably to forego such benefits
and have the benefits of the 2011 Amendment apply. The 2017 Amendment introduced new benefits for Technological Enterprises, alongside
the existing tax benefits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Taxation of our Shareholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Capital Gains</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Capital gain tax is imposed
on the disposal of capital assets by an Israeli resident, and on the disposal of such assets by a non-Israeli resident if those assets
are either (i) located in Israel; (ii) are shares or a right to a share in an Israeli resident corporation, or (iii) represent, directly
or indirectly, rights to assets located in Israel, unless a tax treaty between Israel and the seller&#8217;s country of residence provides
otherwise. The Ordinance, distinguishes between &#8220;Real Gain&#8221; and the &#8220;Inflationary Surplus.&#8221; Real Gain is the
excess of the total capital gain over Inflationary Surplus. Inflationary Surplus is computed generally on the basis of the increase in
the Israeli Consumer Price Index or, in certain circumstances, according to the change in the foreign currency exchange rate, between
the date of purchase and the date of disposal. Inflationary Surplus is not subject to tax in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 142; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Real Gain accrued by individuals
on the sale of our Ordinary Shares will be taxed at the rate of 25%. However, if the shareholder claims deduction of interest and linkage
differences expenses in connection with the purchase and holding of such shares or the individual shareholder is a &#8220;Controlling
Shareholder&#8221; (i.e., a person who holds, directly or indirectly, alone or together with such person&#8217;s relative or another
person who collaborates with such person on a permanent basis, based on a written contract, 10% or more of one of the Israeli resident
company&#8217;s &#8220;means of control&#8221; including, among other things, the right to company profits, voting rights, the right
to the Company&#8217;s liquidation proceeds and the right to appoint a company director) at the time of sale or at any time during the
preceding 12 months period, such gain will be taxed at the rate of 30%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Real Gain derived by corporations
will be generally subject to the regular corporate tax rate (23% in 2023).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Individual and corporate
shareholder dealing in securities in Israel for whom the income from the sale of securities is considered &#8220;business income&#8221;
as defined in Section 2(1) of the Ordinance are taxed at the tax rates applicable to business income- 23% for corporations in 2023 and
a marginal tax rate of up to 47% in 2023 for individuals, unless the benefiting provisions of an applicable tax treaty applies. Certain
Israeli institutions who are exempt from tax under Section 9(2) or Section 129(I)(a)(1) of the Ordinance (such as exempt trust fund,
pension fund) may be exempt from capital gains tax from the sale of shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Capital Gains Taxes is
Applicable also to Non-Israeli Resident Shareholders</i>. A non-Israeli resident (whether an individual or a corporation) who derives
capital gains from the sale of shares in an Israeli resident company may be exempt from Israeli capital gain tax so long as the following
cumulative conditions are met: (i) the shares were purchased upon or after the registration of the securities on a recognized stock exchange,
outside of Israel (such as Nasdaq) (ii) the seller does not have a permanent establishment in Israel to which the derived capital gain
is attributed, and (iii) with respect to securities listed on a recognized stock exchange outside of Israel, such shareholders are not
subject to the Israeli Income Tax Law (Inflationary Adjustments) 5745-1985. However, non-Israeli corporation will not be entitled to
the foregoing exemptions if Israeli residents (a) have a controlling interest of more than 25% in such non-Israeli corporation, or (b)
are the beneficiaries of or are entitled to 25% or more of the revenues or profits of such non-Israeli corporation, whether directly
and indirectly. In addition, such exemption would not be available to a person whose gains from selling or otherwise disposing of the
securities are deemed to be business income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If not exempt, a&#160;non-Israeli&#160;resident
would generally be subject to tax on capital gain at the ordinary corporate tax rate (23% in 2023) if generated by a company, or at the
rate of 25%, if generated by an individual, or 30%, if generated by an individual who is a &#8220;Controlling Shareholder&#8221;, at
the time of sale or at any time during the preceding&#160;12-month&#160;period (or if the shareholder claims a deduction for interest
and linkage differences expenses in connection with the purchase and holding of such shares).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, a sale of shares
by a non-Israeli resident may be exempt from Israeli capital gains tax under the provisions of an applicable tax treaty. For example,
under the Convention Between the Government of the United States of America and the Government of the State of Israel with respect to
Taxes on Income, as amended, or the United States-Israel Tax Treaty, the sale, exchange or other disposition of shares by a shareholder
who is a United States resident (for purposes of the United States-Israel Tax Treaty) holding the shares as a capital asset and is entitled
to claim the benefits afforded to such a resident by the United States.-Israel Tax Treaty, or a Treaty U.S. Resident, is generally exempt
from Israeli capital gains tax unless either: (i) the capital gain arising from such sale, exchange or disposition is attributed to real
estate located in Israel; (ii) the capital gain arising from such sale, exchange or disposition is attributed to royalties; (iii) the
capital gain arising from the such sale, exchange or disposition is attributed to a permanent establishment of the shareholder which
is maintained in Israel, under certain terms; (iv) such Treaty U.S. Resident holds, directly or indirectly, shares representing 10% or
more of the voting capital during any part of the 12-month period preceding the disposition, subject to certain conditions; or (v) such
Treaty U.S. Resident, if an individual, was present in Israel for a period or periods of 183 days or more in the aggregate during the
relevant taxable year. In any such case, the sale, exchange or disposition of such shares would be subject to Israeli tax, to the extent
applicable; however, under the United States-Israel Treaty, a U.S. resident would be permitted to claim a credit for the Israeli tax
against the U.S. federal income tax imposed with respect to the sale, exchange or disposition, subject to the limitations in U.S. laws
applicable to foreign tax credits. The United States-Israel Treaty does not provide such credit against any U.S. state or local taxes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In some instances where our
shareholders may be liable for Israeli tax on the sale of their Ordinary Shares, the payment of the consideration may be subject to the
withholding of Israeli tax at source. Shareholders may be required to demonstrate that they are exempt from tax on their capital gains
in order to avoid withholding at source at the time of sale. Specifically, in transactions involving a sale of all of the shares of an
Israeli resident company, in the form of a merger or otherwise, the Israel Tax Authority may require from shareholders who are not liable
for Israeli tax to sign declarations in forms specified by this authority or obtain a specific exemption from the Israel Tax Authority
to confirm their status as non-Israeli residents, and, in the absence of such declarations or exemptions, may require the purchaser of
the shares to withhold taxes at source.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 143; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Either the purchaser, the
Israeli stockbrokers or financial institution through which the shares are held is obliged, subject to the above mentioned exemptions,
to withhold tax on the amount of consideration paid upon the sale of securities from the Real Gain at the rate of 25% for individuals
or 23% for corporations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the sale of securities
traded on a stock exchange, a detailed return, including a computation of the tax due, must be filed and an advance payment must be made
on January 31 and July 31 of every calendar year in respect of sales of securities made within the previous six months. However, if all
tax due was withheld at source according to applicable provisions of the Ordinance and regulations promulgated thereunder, the aforementioned
return need not be filed and no advance payment must be paid. Capital gains are also reportable on the annual income tax return.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Dividends</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A distribution of dividends
from an Israeli Company to an Israeli resident individual, will generally be subject to income tax at a rate of 25%. However, a 30% tax
rate will apply if the dividend recipient is a Controlling Shareholder (as defined above in this section) at the time of distribution
or at any time during the preceding 12 months period. If the recipient of the dividend is an Israeli resident corporation, generally,
such dividend will be exempt from income tax provided the income from which such dividend is distributed was derived or accrued within
Israel (although, if such dividends are subsequently distributed to individuals, the aforesaid will apply).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Non-Israeli residents (whether individuals or a corporations) are generally
subject to Israeli income tax on the receipt of dividends paid on our Ordinary Shares at the rate of 25% or 30% with respect to a Controlling
Shareholder (as defined above) at the time of receiving the dividend or on any time during the preceding twelve months. Such dividends
are generally subject to Israeli withholding tax at a rate of 25% so long as the shares are registered with a Nominee Company (whether
the recipient is a Controlling Shareholder or not) unless relief is provided in a treaty between Israel and the shareholder&#8217;s country
of residence (subject to the receipt in advance of a valid certificate from the Israel Tax Authority allowing for a reduced tax rate).
For example, under the United States-Israel Tax Treaty, the rate of tax withheld at source in Israel on dividends paid to a holder of
our Ordinary Shares who is a Treaty U.S. Resident is 25%. However, generally, the maximum rate of withholding tax on dividends, not generated
by an Approval/Beneficial/Preferred Enterprise (as defined under the Investment Law), that are paid to a United States corporation holding
10% or more of the outstanding voting capital throughout the tax year in which the dividend is distributed as well as during the previous
tax year, is 12.5%, provided that not more than 25% of the gross income for such preceding year consists of certain types of dividends
and interest. The aforementioned rates will not apply if the dividend income was generated through a permanent establishment of U.S. residency
in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A non-Israeli resident who
receives dividends from which tax was withheld is generally exempt from the obligation to file tax returns in Israel with respect to
such income, provided that (i) such income was not generated from business conducted in Israel by the taxpayer, (ii) the taxpayer has
no other taxable sources of income in Israel with respect to which a tax return is required to be filed, and (iii) in the case of individuals,
the taxpayer is not obligated to pay excess tax in Israel (as further explained below).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Excess Tax</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Individuals who are subject
to tax in Israel (whether any such individual is an Israeli resident or non-Israeli resident) are also subject to an additional tax at
a rate of 3% on annual income exceeding a certain threshold (NIS 698,280 for 2023, which amount is linked to the annual changes to the
Israeli Consumer Price Index), including, but not limited to income derived from dividends, interest and capital gains.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Foreign Exchange Regulations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Non-residents of Israel who
hold our Ordinary Shares are able to receive any dividends, and any amounts payable upon the dissolution, liquidation and winding up
of our affairs, repayable in non-Israeli currency at the rate of exchange prevailing at the time of conversion. However, Israeli income
tax is generally required to have been paid or withheld on these amounts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Estate and Gift Tax</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli law presently does
not impose estate or gift taxes. if the Israeli Tax Authority is satisfied that the gift was made by an Israeli resident individual in
good faith and on condition that the recipient of the gift is not a non-Israeli resident. If the gift giver is a non-Israeli resident
individual, then he should be exempted under the aforementioned capital gains tax exemptions provided for a regular sale of shares.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 144; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>YOU SHOULD CONSULT YOUR OWN TAX ADVISOR REGARDING
THE PARTICULAR ISRAELI TAX CONSEQUENCES OF PURCHASING, HOLDING, AND DISPOSING OF OUR SHARES, INCLUDING THE CONSEQUENCES OF ANY PROPOSED
CHANGE IN APPLICABLE LAWS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>U.S. FEDERAL INCOME TAX CONSIDERATIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THE FOLLOWING SUMMARY IS INCLUDED HEREIN FOR
GENERAL INFORMATION AND IS NOT INTENDED TO BE, AND SHOULD NOT BE CONSIDERED TO BE, LEGAL OR TAX ADVICE. EACH U.S. HOLDER SHOULD CONSULT
WITH HIS OR HER OWN TAX ADVISOR AS TO THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND SALE OF ORDINARY
SHARES AND AMERICAN DEPOSITARY SHARES, INCLUDING THE EFFECTS OF APPLICABLE STATE, LOCAL, FOREIGN OR OTHER TAX LAWS AND POSSIBLE CHANGES
IN THE TAX LAWS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the limitations
described in the next paragraph, the following discussion summarizes the material U.S. federal income tax consequences to a &#8220;U.S.
Holder&#8221; arising from the purchase, ownership and sale of the Ordinary Shares. For this purpose, a &#8220;U.S. Holder&#8221; is
a holder of Ordinary Shares that is: (1) an individual citizen or resident of the United States, including an alien individual who is
a lawful permanent resident of the United States or meets the substantial presence residency test under U.S. federal income tax laws;
(2) a corporation (or entity treated as a corporation for U.S. federal income tax purposes) or a partnership (other than a partnership
that is not treated as a U.S. person under any applicable U.S. Treasury regulations) created or organized under the laws of the United
States or the District of Columbia or any political subdivision thereof; (3) an estate, the income of which is includable in gross income
for U.S. federal income tax purposes regardless of source; (4) a trust if a court within the United States is able to exercise primary
supervision over the administration of the trust and one or more U.S. persons have authority to control all substantial decisions of
the trust; or (5) a trust that has a valid election in effect to be treated as a U.S. person to the extent provided in U.S. Treasury
regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This summary is for general
information purposes only and does not purport to be a comprehensive description of all of the U.S. federal income tax considerations
that may be relevant to a decision to purchase our Ordinary Shares. This summary generally considers only U.S. Holders that will own
our Ordinary Shares as capital assets. Except to the limited extent discussed below, this summary does not consider the U.S. federal
tax consequences to a person that is not a U.S. Holder, nor does it describe the rules applicable to determine a taxpayer&#8217;s status
as a U.S. Holder. This summary is based on the provisions of the Internal Revenue Code of 1986, as amended, or the Code, final, temporary
and proposed U.S. Treasury regulations promulgated thereunder, administrative and judicial interpretations thereof, (including with respect
to the TCJA of 2017), and the U.S./Israel Income Tax Treaty, all as in effect as of the date hereof and all of which are subject to change,
possibly on a retroactive basis, and all of which are open to differing interpretations. We will not seek a ruling from the IRS with
regard to the U.S. federal income tax treatment of an investment in our Ordinary Shares by U.S. Holders and, therefore, can provide no
assurances that the IRS will agree with the conclusions set forth below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 145; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This discussion does not
address all of the aspects of U.S. federal income taxation that may be relevant to a particular U.S. holder based on such holder&#8217;s
particular circumstances and in particular does not discuss any estate, gift, generation-skipping, transfer, state, local, excise or
foreign tax considerations. In addition, this discussion does not address the U.S. federal income tax treatment of a U.S. Holder who
is: (1) a bank, life insurance company, regulated investment company, or other financial institution or &#8220;financial services entity;&#8221;
(2) a broker or dealer in securities or foreign currency; (3) a person who acquired our Ordinary Shares in connection with employment
or other performance of services; (4) a U.S. Holder that is subject to the U.S. alternative minimum tax; (5) a U.S. Holder that holds
our Ordinary Shares as a hedge or as part of a hedging, straddle, conversion or constructive sale transaction or other risk-reduction
transaction for U.S. federal income tax purposes; (6) a tax-exempt entity; (7) real estate investment trusts or grantor trusts; (8) a
U.S. Holder that expatriates out of the United States or a former long-term resident of the United States; or (9) a person having a functional
currency other than the U.S. dollar. This discussion does not address the U.S. federal income tax treatment of a U.S. Holder that owns,
directly or constructively, at any time, Ordinary Shares representing 10% or more of our voting power. Additionally, the U.S. federal
income tax treatment of partnerships (or other pass-through entities) or persons who hold Ordinary Shares through a partnership or other
pass-through entity are not addressed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each prospective investor
is advised to consult his or her own tax adviser for the specific tax consequences to that investor of purchasing, holding or disposing
of our Ordinary Shares, including the effects of applicable state, local, foreign or other tax laws and possible changes in the tax laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Taxation of Dividends Paid on our Ordinary
Shares </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not intend to pay dividends
in the foreseeable future. In the event that we do pay dividends, and subject to the discussion under the heading &#8220;Passive Foreign
Investment Companies&#8221; below and the discussion of &#8220;qualified dividend income&#8221; below, a U.S. Holder will be required
to include in gross income as ordinary income the amount of any distribution paid on our Ordinary Shares (including the amount of any
Israeli tax withheld on the date of the distribution), to the extent that such distribution does not exceed our current and accumulated
earnings and profits, as determined for U.S. federal income tax purposes. The amount of a distribution which exceeds our earnings and
profits will be treated first as a non-taxable return of capital, reducing the U.S. Holder&#8217;s tax basis for the Ordinary Shares
to the extent thereof, and then capital gain. We do not expect to maintain calculations of our earnings and profits under U.S. federal
income tax principles and, therefore, U.S. Holders should expect that the entire amount of any distribution generally will be reported
as dividend income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, preferential
tax rates for &#8220;qualified dividend income&#8221; and long-term capital gains are applicable for U.S. Holders that are individuals,
estates or trusts. For this purpose, &#8220;qualified dividend income&#8221; means, inter alia, dividends received from a &#8220;qualified
foreign corporation.&#8221; A &#8220;qualified foreign corporation&#8221; is a corporation that is entitled to the benefits of a comprehensive
tax treaty with the United States which includes an exchange of information program. The IRS has stated that the Israel/U.S. Tax Treaty
satisfies this requirement, and we believe we are eligible for the benefits of that treaty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dividends will not qualify
for the preferential rate if we are treated, in the year the dividend is paid or in the prior year, as a PFIC, as described below under
&#8220;Passive Foreign Investment Companies.&#8221; A U.S. Holder will not be entitled to the preferential rate: (1) if the U.S. Holder
has not held our Ordinary Shares for at least 61 days of the 121 day period beginning on the date which is 60 days before the ex-dividend
date, or (2) to the extent the U.S. Holder is under an obligation to make related payments on substantially similar property. Any days
during which the U.S. Holder has diminished its risk of loss on our Ordinary Shares are not counted towards meeting the 61-day holding
period. Finally, U.S. Holders who elect to treat the dividend income as &#8220;investment income&#8221; pursuant to Code section 163(d)(4)
will not be eligible for the preferential rate of taxation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of a distribution
with respect to our Ordinary Shares will be measured by the amount of the fair market value of any property distributed, and for U.S.
federal income tax purposes, the amount of any Israeli taxes withheld therefrom. Cash distributions paid by us in NIS will be included
in the income of U.S. Holders at a U.S. dollar amount based upon the spot rate of exchange in effect on the date the dividend is includible
in the income of the U.S. Holder, and U.S. Holders will have a tax basis in such NIS for U.S. federal income tax purposes equal to such
U.S. dollar value. If the U.S. Holder subsequently converts the NIS into U.S. dollars or otherwise disposes of it, any subsequent gain
or loss in respect of such NIS arising from exchange rate fluctuations will be U.S. source ordinary exchange gain or loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 146; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Taxation of the Disposition of our Ordinary
Shares </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as provided under
the PFIC rules described below under &#8220;Passive Foreign Investment Companies,&#8221; upon the sale, exchange or other disposition
of our Ordinary Shares, a U.S. Holder will recognize capital gain or loss in an amount equal to the difference between such U.S. Holder&#8217;s
tax basis for the Ordinary Shares in U.S. dollars and the amount realized on the disposition in U.S. dollar (or its U.S. dollar equivalent
determined by reference to the spot rate of exchange on the date of disposition, if the amount realized is denominated in a foreign currency).
The gain or loss realized on the sale, exchange or other disposition of Ordinary Shares will be long-term capital gain or loss if the
U.S. Holder has a holding period of more than one year at the time of the disposition. Individuals who recognize long-term capital gains
may be taxed on such gains at reduced rates of tax. The deduction of capital losses is subject to various limitations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Gain realized by a U.S. Holder
on a sale, exchange or other disposition of our Ordinary Shares will generally be treated as U.S. source income for U.S. foreign tax
credit purposes. A loss realized by a U.S. Holder on the sale, exchange or other disposition of our Ordinary Shares is generally allocated
to U.S. source income. The deductibility of a loss realized on the sale, exchange or other disposition of our Ordinary Shares is subject
to limitations. An additional 3.8% net investment income tax (described below) may apply to gains recognized upon the sale, exchange
or other taxable disposition of our Ordinary Shares by certain U.S. Holders who meet certain income thresholds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Passive Foreign Investment Companies</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Special U.S. federal income
tax laws apply to U.S. taxpayers who own shares of a corporation that is a PFIC. We will be treated as a PFIC for U.S. federal income
tax purposes for any taxable year that either:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75% or more of our gross
    income (including our pro rata share of gross income for any company, in which we are considered to own 25% or more of the shares
    by value), in a taxable year is passive; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At least 50% of our assets,
    averaged over the year and generally determined based upon fair market value (including our pro rata share of the assets of any company
    in which we are considered to own 25% or more of the shares by value) are held for the production of, or produce, passive income.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For this purpose, passive
income generally consists of dividends, interest, rents, royalties, annuities and income from certain commodities transactions and from
notional principal contracts. Cash is treated as generating passive income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not believe that we
would be deemed a PFIC for 2023. The tests for determining PFIC status are applied annually, and it is difficult to make accurate projections
of future income and assets which are relevant to this determination. In addition, our PFIC status may depend in part on the market value
of our Ordinary Shares. Accordingly, there can be no assurance that we currently are not or will not become a PFIC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we currently are or become
a PFIC, each U.S. Holder who has not elected to mark the shares to market (as discussed below), would, upon receipt of certain distributions
by us and upon disposition of our Ordinary Shares at a gain: (1) have such distribution or gain allocated ratably over the U.S. Holder&#8217;s
holding period for the Ordinary Shares, as the case may be; (2) the amount allocated to the current taxable year and any period prior
to the first day of the first taxable year in which we were a PFIC would be taxed as ordinary income; and (3) the amount allocated to
each of the other taxable years would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for
that year, and an interest charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to
each such other taxable year. In addition, when shares of a PFIC are acquired by reason of death from a decedent that was a U.S. Holder,
the tax basis of such shares would not receive a step-up to fair market value as of the date of the decedent&#8217;s death, but instead
would be equal to the decedent&#8217;s basis if lower, unless all gain were recognized by the decedent. Indirect investments in a PFIC
may also be subject to these special U.S. federal income tax rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 147; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The PFIC rules described
above would not apply to a U.S. Holder who makes a QEF election for all taxable years that such U.S. Holder has held our Ordinary Shares
while we are a PFIC, provided that we comply with specified reporting requirements. Instead, each U.S. Holder who has made such a QEF
election is required for each taxable year that we are a PFIC to include in income such U.S. Holder&#8217;s pro rata share of our ordinary
earnings as ordinary income and such U.S. Holder&#8217;s pro rata share of our net capital gains as long-term capital gain, regardless
of whether we make any distributions of such earnings or gain. In general, a QEF election is effective only if we make available certain
required information. The QEF election is made on a shareholder-by-shareholder basis and generally may be revoked only with the consent
of the IRS. We do not intend to furnish U.S. Holders annually with information needed in order to complete IRS Form 8621 and to make
and maintain a valid QEF election for any year in which we or any of our subsidiaries are a PFIC. Therefore, the QEF election will not
be available with respect to our Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. Holders who hold our
Ordinary Shares during a period when we are a PFIC will be subject to the foregoing rules, even if we cease to be a PFIC. U.S. Holders
are strongly urged to consult their tax advisors about the PFIC rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Tax on Net Investment Income</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to certain adjustments
under the PFIC rules, U.S. Holders who are individuals, estates or trusts will generally be required to pay a 3.8% Medicare tax on their
net investment income (including dividends on and gains from the sale or other disposition of our Ordinary Shares), or in the case of
estates and trusts on their net investment income that is not distributed. In each case, the 3.8% Medicare tax applies only to the extent
the U.S. Holder&#8217;s total adjusted income exceeds applicable thresholds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Tax Consequences for Non-U.S. Holders of Ordinary
Shares </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as provided below,
an individual, corporation, estate or trust that is not a U.S. Holder referred to below as a non-U.S. Holder, generally will not be subject
to U.S. federal income or withholding tax on the payment of dividends on, and the proceeds from the disposition of, our Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A non-U.S. Holder may be
subject to U.S. federal income tax on a dividend paid on our Ordinary Shares or gain from the disposition of our Ordinary Shares if:
(1) such item is effectively connected with the conduct by the non-U.S. Holder of a trade or business in the United States and, if required
by an applicable income tax treaty is attributable to a permanent establishment or fixed place of business in the United States; or (2)
in the case of a disposition of our Ordinary Shares, the individual non-U.S. Holder is present in the United States for 183 days or more
in the taxable year of the disposition and other specified conditions are met. Any dividend income or gain described in clause (1) above
will be subject to U.S. federal income tax on a net income tax basis in the same manner as a U.S. Holder and, with respect to corporate
holders, a branch profits tax imposed at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty) may
also apply to its effectively connected earnings and profits (subject to adjustments). Any dividend income or gain described in clause
(2) above that is not effectively connected with the conduct by a Non-U.S. Holder of a trade or business within the U.S. generally will
be subject to 30% withholding tax (or such lower rate as may be specified by an applicable income tax treaty) net of certain U.S. source
capital losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, non-U.S. Holders
will not be subject to backup withholding with respect to the payment of dividends on our Ordinary Shares if payment is made through
a paying agent, or office of a foreign broker outside the United States. However, if payment is made in the United States or by a U.S.
related person, non-U.S. Holders may be subject to backup withholding, unless the non-U.S. Holder provides an applicable IRS Form W-8
(or a substantially similar form) certifying its foreign status, or otherwise establishes an exemption.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of any backup
withholding from a payment to a non-U.S. Holder will be allowed as a credit against such holder&#8217;s U.S. federal income tax liability
and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 148; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Information Reporting and Withholding</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A U.S. Holder may be subject
to backup withholding at a rate of 24% with respect to cash dividends and proceeds from a disposition of Ordinary Shares. In general,
backup withholding will apply only if a U.S. Holder fails to comply with specified identification procedures. Backup withholding will
not apply with respect to payments made to designated exempt recipients, such as corporations and tax-exempt organizations. Backup withholding
is not an additional tax and may be claimed as a credit against the U.S. federal income tax liability of a U.S. Holder, provided that
the required information is timely furnished to the IRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Election of directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our Articles, our board
of directors must consist of at least three (3) and not more than eight (8) directors, including, if applicable, two external directors
appointed as required under the Companies Law. Other than our external directors (if any), our directors are divided into three classes
with staggered three-year terms. Each class of directors consists, as nearly as possible, of one third of the total number of directors
constituting the entire board of directors. At each annual general meeting of our shareholders, the election or re-election of directors
following the expiration of the term of office of the directors of that class of directors is for a term of office that expires on the
third annual general meeting following such election or re-election, such that at each annual general meeting the term of office of only
one class of directors will expire. Each director, holds office until the annual general meeting of our shareholders for the year in
which his or her term expires and until his or her successor is duly appointed, unless the tenure of such director expires earlier pursuant
to the Companies Law upon the occurrence of certain events or unless removed from office by a vote of the holders of at least 65% of
the total voting power of our shareholders at a general meeting of our shareholders in accordance with our Articles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Articles provide that
directors are appointed by a simple majority vote of holders of our Ordinary Shares, participating and voting at an annual general meeting
of our shareholders. In the event of a contested election, the board of directors may, in its discretion, set the method of calculation
of the votes and the manner in which the resolutions will be presented to our shareholders at the general meeting. In the event that
our board of directors does not or is unable to make a determination on such matter, then the directors will be elected by a plurality
of the voting power represented at the general meeting in person or by proxy and voting on the election of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if a director&#8217;s
office becomes vacant, the remaining serving directors may continue to act in any manner, provided, that the number of the serving directors
shall not be less than three (3). If the number of serving directors is lower than their minimal one, the board of directors shall not
be permitted to act, other than for the purpose of convening a general meeting of the Company&#8217;s shareholders for the purpose of
appointing additional directors.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Shareholder meetings</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law,
we are required to hold an annual general meeting of our shareholders once every calendar year that must be held no later than 15 months
after the date of the previous annual general meeting. All general meetings other than the annual meeting of shareholders are referred
to in our Articles as special general meetings. Our board of directors may call special general meetings whenever it sees fit, at such
time and place, within or outside of Israel, as it may determine. In addition, the Companies Law provides that our board of directors
is required to convene a special meeting upon the written request of (i) any two of our directors or one-quarter of the members of our
board of directors or (ii) one or more shareholders holding, in the aggregate, either (a) 5% or more of our outstanding issued shares
and 1% or more of our outstanding voting power or (b) 5% or more of our outstanding voting power.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law,
one or more shareholders holding at least 1% of the voting rights at the general meeting may request that the board of directors include
a matter in the agenda of a general meeting to be convened in the future, provided, that it is appropriate to discuss such a matter at
the general meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 149; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the provisions
of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are
the shareholders of record the date determined by the board of directors, which must be between 4 and 40 days prior to the date of the
meeting. Furthermore, the Companies Law requires that resolutions regarding the following matters must be passed at a general meeting
of our shareholders:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">amendments to our Articles;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointment or termination
    of our auditors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointment of external
    directors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval of certain related
    party transactions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increases or reductions
    of our authorized share capital;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">mergers; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the exercise
    of our board of directors&#8217; powers by a general meeting, if our board of directors is unable to exercise its powers and the
    exercise of any of its powers is required for our proper management.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, pursuant to
our Articles, in order to approve any amendment to our Articles, in addition and prior to the approval of a general meeting of shareholders,
the approval of the board of directors with the affirmative vote of at least three-quarters&#160;(3/4) of the directors then in office
and entitled to vote thereon is required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our Articles, we are
not required to give notice to our registered shareholders pursuant to the Companies Law, unless otherwise required by law. The Companies
Law requires that a notice of any annual general meeting or special general meeting be provided to shareholders at least 21 days prior
to the meeting and if the agenda of the meeting includes the appointment or removal of directors, the approval of transactions with office
holders or interested or related parties, or an approval of a merger, or as otherwise required under applicable law, notice must be provided
at least 35 days prior to the meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Access to corporate records</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law,
shareholders are provided access to minutes of our general meetings, our shareholders register and principal shareholders register, our
Articles, our financial statements and any document that we are required by law to file publicly with the Israeli Companies Registrar
or the Israel Securities Authority. In addition, shareholders may request to be provided with any document related to an action or transaction
requiring shareholder approval under the related party transaction provisions of the Companies Law. We may deny this request if we believe
it has not been made in good faith or if such denial is necessary to protect our interest or protect a trade secret or patent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Modification of class rights</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law and
our Articles, the rights attached to any class of shares, such as voting, liquidation and dividend rights, may be amended by adoption
of a resolution by the holders of a majority of the shares of that class present at a separate class meeting, or otherwise in accordance
with the rights attached to such class of shares, as set forth in our Articles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Acquisitions under Israeli law</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Full tender offer</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A person wishing to acquire
shares of an Israeli public company and who would as a result hold over 90% of the target company&#8217;s issued and outstanding share
capital is required by the Companies Law to make a tender offer to all of the Company&#8217;s shareholders for the purchase of all of
the issued and outstanding shares of the Company. A person wishing to acquire shares of a public Israeli company and who would as a result
hold over 90% of the issued and outstanding share capital of a certain class of shares is required to make a tender offer to all of the
shareholders who hold shares of the relevant class for the purchase of all of the issued and outstanding shares of that class. If the
shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of the Company or of the applicable
class, and more than half of the shareholders who do not have a personal interest in the offer accept the offer, all of the shares that
the acquirer offered to purchase will be transferred to the acquirer by operation of law. However, a tender offer will also be accepted
if the shareholders who do not accept the offer hold less than 2% of the issued and outstanding share capital of the Company or of the
applicable class of shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 150; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->147<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon a successful completion
of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder accepted the tender offer
or not, may, within six months from the date of acceptance of the tender offer, petition an Israeli court to determine whether the tender
offer was for less than fair value and that the fair value should be paid as determined by the court. However, under certain conditions,
the offeror may include in the terms of the tender offer that an offeree who accepted the offer will not be entitled to petition the
Israeli court as described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a tender offer is not
accepted in accordance with the requirements set forth above, the acquirer may not acquire shares of the Company that will increase its
holdings to more than 90% of the Company&#8217;s issued and outstanding share capital or of the applicable class from shareholders who
accepted the tender offer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Special tender offer</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law provides
that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if as a result of the acquisition
the purchaser would become a holder of 25% or more of the voting rights in the Company. This requirement does not apply if there is already
another holder of at least 25% of the voting rights in the Company. Alternatively, such an acquisition may be approved pursuant to a
private placement approved by the Company&#8217;s shareholders with the purpose of approving the acquisition of 25% or more, or 45% or
more of the Company&#8217;s voting rights. Similarly, the Companies Law provides that an acquisition of shares in a public company must
be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of more than 45% of
the voting rights in the Company, if there is no other shareholder of the Company who holds more than 45% of the voting rights in the
Company, subject to certain exceptions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Merger</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law permits
merger transactions if approved by each party&#8217;s board of directors and, unless certain requirements described under the Companies
Law are met, by a majority vote of each party&#8217;s shares, and, in the case of the target company, a majority vote of each class of
its shares voted on the proposed merger at a shareholders meeting. The board of directors of a merging company is required pursuant to
the Companies Law to discuss and determine whether in its opinion there exists a reasonable concern that as a result of a proposed merger,
the surviving company will not be able to satisfy its obligations towards its creditors, such determination taking into account the financial
status of the merging companies. If the board of directors has determined that such a concern exists, it may not approve a proposed merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of the shareholder
vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the votes of the shares represented at
the shareholders meeting that are held by parties other than the other party to the merger, or by any person (or group of persons acting
in concert) who holds (or hold, as the case may be) 25% or more of the voting rights or the right to appoint 25% or more of the directors
of the other party, vote against the merger. If, however, the merger involves a merger with a company&#8217;s own controlling shareholder
or if the controlling shareholder has a personal interest in the merger, then the merger is instead subject to the same special majority
approval that governs all extraordinary transactions with controlling shareholders&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the transaction would
have been approved by the shareholders of a merging company but for the separate approval of each class or the exclusion of the votes
of certain shareholders as provided above, a court may still approve the merger upon the request of holders of at least 25% of the voting
rights of a company, if the court holds that the merger is fair and reasonable, taking into account the value to&#160;the parties to
the merger and the consideration offered to the shareholders of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the request of a creditor
of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern
that, as a result of the merger, the surviving company will be unable to satisfy the obligations of the merging entities, and may further
give instructions to secure the rights of creditors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 151; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->148<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, a merger may
not be consummated unless at least 50 days have passed from the date on which a proposal for approval of the merger was filed by each
party with the Israeli Registrar of Companies and at least 30 days have passed from the date on which the merger was approved by the
shareholders of each party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Significant Transactions</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our Articles, the affirmative
vote of at least three-quarters&#160;(3/4) of the then serving directors is required in order to approve certain transactions which may
have a significant effect on the Company&#8217;s structure, assets or business, including mergers acquisitions, consolidations and issuance
of equity securities or debt securities convertible into equity in each case that would reasonably be expected to result in change of
beneficial ownership of above than fifteen percent (15%) in the Company, material changes to the principal business of the Company and
any resolution to transfer the headquarters of the Company outside of Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Business Combinations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Articles restrict certain
business transactions with any shareholder and/or its affiliates and/or investors for a period of three&#160;years following (i)&#160;with
respect to any shareholder of the Company holding fifteen percent (15%) or more of the voting power of the Ordinary Shares as of September
15, 2022 (the effective date of the amended and restated Articles), and (ii)&#160;with respect to all shareholders of the Company, each
time as such shareholder and/or any of its affiliates and/or investors become(s)&#160;(other than due to a buyback, redemption or cancellation
of shares by the Company) the holder(s)&#160;(beneficially or of record) of fifteen percent (15%) or more of the issued and outstanding
voting power of the Ordinary Shares. The restricted business transactions include mergers, consolidations and dispositions of assets
with an aggregate market value equal to 10% or more of the Company&#8217;s assets or outstanding shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Borrowing powers</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Companies
Law and our Articles, our board of directors may exercise all powers and take all actions that are not required under law or under our
Articles to be exercised or taken by a certain organ of the Company, including the power to borrow money for company purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Changes in capital</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Articles enable us to
increase or reduce our share capital. Any such changes are subject to the provisions of the Companies Law and must be approved by a resolution
duly adopted by our shareholders at a general meeting. In addition, transactions that have the effect of reducing capital, such as the
declaration and payment of dividends in the absence of sufficient retained earnings or profits, require the approval of both our board
of directors and an Israeli court.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Transfer agent and registrar</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our transfer agent is and
registrar is Vstock Transfer LLC. Its address is 18 Lafayette Place, Woodmere, New York 11598 and its telephone number is (212) 828-8436.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Description of Rights to Purchase&#160;SciSparc Ltd. Ordinary Shares</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Rights and Rights Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors authorized,
pursuant to the Rights Plan, (i) the issuance, on December 8, 2023, of one special purchase right , or a &#8220;Right for each Ordinary
Share outstanding at the Close of Business on December 8, 2023, or the &#8220;Record Date, as well as (ii) the issuance of one Right
for each Ordinary Share issued after the Record Date and prior to the earliest of the Issuance Date, the Redemption Date (as defined
below) and the Final Expiration Date (as defined below) (including Ordinary Shares issued pursuant to the exercise, conversion or settlement
of securities exercisable for, convertible into or that may be settled for, Ordinary Shares or rights, in each case, issued or granted
prior to, and outstanding as of, the Issuance Date). Each Right will represent the right to purchase one (1) Ordinary Share, at the price
of $0.001 per share upon the terms and subject to the conditions described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 152; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->149<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Rights were issued pursuant
to a Rights Agreement, dated as of November 28, 2023, or the Rights Agreement, between the Company and VStock Transfer LLC, as rights
agent, or the &#8220;Rights Agent. Each Right will allow its holder to purchase from the Company one (1) Ordinary Share, at a purchase
price of $0.001 per Ordinary Share, once the Rights become exercisable. Prior to exercise, each Right does not give its holder any dividend,
voting, liquidation or other rights as a shareholder of the Company</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Exercise Period; Rights Certificates</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Rights will not be exercisable
until the close of business on the tenth (10<sup>th</sup>) day after the public announcement or public disclosure that a person or group
has become an &#8220;Acquiring Person&#8221; by obtaining beneficial ownership of 10% or more of the Company&#8217;s outstanding Ordinary
Shares (subject to the parameters and exceptions described below and in the Rights Agreement, referred here as an &#8220;Acquiring Person&#8221;),
except if such person or group has become an Acquiring Person pursuant to an offer approved by the majority of the board of directors
(such date, upon which the Rights become exercisable, is referred to as the &#8220;Issuance Date&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a Person&#8217;s beneficial
ownership of the then-outstanding Ordinary Shares as of the time of the public announcement of the Rights Plan is at or above 10% (including
through entry into certain derivative positions), that person or group&#8217;s then-existing ownership percentage would be grandfathered
and would not trigger the exercisability of the Rights, as that Person will not be deemed to be an Acquiring Person. However, the Rights
would become exercisable (and such Person will be deemed to be an Acquiring Person) if at any time after such announcement, that shareholder
increases its beneficial ownership percentage of Ordinary Shares of the Company by 0.5% or if at any time after such announcement, such
shareholder&#8217;s beneficial ownership of Ordinary Shares is reduced to an amount that is less than 10% of the then-outstanding Ordinary
Shares and thereafter such shareholder becomes an Acquiring Person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until the Issuance Date,
the balances in the book-entry accounting system of the transfer agent for our Ordinary Shares or, in the case of certificated shares,
Ordinary Shares certificates, will also evidence the Rights, and any transfer of Ordinary Shares or, in the case of certificated shares,
certificates for Ordinary Shares, will constitute a transfer of Rights. After that date, the Rights will separate from the Ordinary Shares
and be evidenced solely by Rights Certificates that we will mail to all eligible holders of Ordinary Shares, or we may choose to use
book-entry in lieu of physical certificates. Under certain circumstances, any Rights held by an Acquiring Person or any Associate or
Affiliate thereof are void and may not be exercised. The Rights shall not be exercisable, and shall be void so long as held, by a holder
in any jurisdiction where the requisite qualification for the issuance to such holder, or the exercise by such holder of the Rights in
such jurisdiction, shall not have been obtained or be obtainable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, in connection
with the issuance or sale of Ordinary Shares following the Issuance Date and prior to the redemption, exchange, or expiration of the
Rights, the Company (a) shall, with respect to Ordinary Shares so issued or sold pursuant to the exercise of share options or pursuant
to any other award or right under any employee benefit plan or arrangement, granted or awarded as of the Issuance Date (including, for
example, upon the or purchase of Ordinary Shares under the Company&#8217;s share incentive plans), or upon the exercise, conversion or
exchange of securities hereinafter issued by the Company (except as may otherwise be provided in the instrument(s) governing such securities),
and (b) may, in any other case, if deemed necessary or appropriate by the board of directors, issue Rights Certificates representing
the appropriate number of Rights in connection with such issuance or sale; provided, however, that (i) no such Rights Certificate shall
be issued if, and to the extent that, the Company shall be advised by counsel that such issuance would create a significant risk of material
adverse tax consequences to the Company or the Person to whom such Rights Certificate would be issued, and (ii) no such Rights Certificate
shall be issued if, and to the extent that, appropriate adjustment shall otherwise have been made in lieu of the issuance thereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Flip-In/Flip-Over</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a person or group becomes
an Acquiring Person, then beginning on the Issuance Date, all holders of Rights except the Acquiring Person or any associate or affiliate
thereof may, for a purchase price of $0.001 per one Ordinary Share, purchase one (1) Ordinary Share for each Ordinary Share of the Company
then beneficially owned by such person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our Company is later acquired
in a merger or similar transaction after the Issuance Date, all holders of Rights except the Acquiring Person or any associate or affiliate
thereof may, for a purchase price of $0.001 per share (subject to adjustments as provided in the Rights Agreement, purchase one (1) times
the number of shares of the acquiring corporation, that each shareholder of the Company is entitled for each Ordinary Share held.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt"></p><div>

</div><!-- Field: Page; Sequence: 153; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->150<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Scope of &#8220;Acquiring Person&#8221; Definition</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An &#8220;Acquiring Person&#8221;
is any Person who or which, together with all affiliates and associates of such Person, shall be the Beneficial Owner of 10% or more
of the Ordinary Shares of the Company then outstanding, but shall not include the Company, any Subsidiary of the Company, any employee
benefit or share ownership plan of the Company or any Subsidiary of the Company, or any entity holding Ordinary Shares for or pursuant
to the terms of any such plan. Notwithstanding the foregoing, no Person shall become an &#8220;Acquiring Person&#8221; as the result
of an acquisition of Ordinary Shares by the Company which, by reducing the number of Ordinary Shares of the Company outstanding, increases
the proportionate number of Ordinary Shares of the Company beneficially owned by such Person to 10% or more of the Ordinary Shares of
the Company then outstanding;&#160;<span style="text-decoration:underline">provided</span>,&#160;<span style="text-decoration:underline">however</span>, that, if a Person shall become the Beneficial Owner of 10% or
more of the Ordinary Shares of the Company then outstanding by reason of share purchases by the Company and shall, after the public disclosure
of such share purchases by the Company, become the Beneficial Owner of any additional Ordinary Shares of the Company, then such Person
shall be deemed to be an &#8220;Acquiring Person.&#8221; Notwithstanding the foregoing, if the board of directors determines in good
faith that a Person who would otherwise be an &#8220;Acquiring Person&#8221; has become such inadvertently, and such Person divests or
undertakes to divest, as promptly as practicable a sufficient number of Ordinary Shares, so that such Person would no longer be an &#8220;Acquiring
Person,&#8221; as defined pursuant to the foregoing provisions of this paragraph, then such Person shall not be deemed to be an &#8220;Acquiring
Person&#8221; for any purposes of the Rights Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a bona fide swaps dealer
who would otherwise be an &#8220;Acquiring Person&#8221; has become so as a result of its actions in the ordinary course of its business
that the Board determines were taken without the intent or effect of evading or assisting any other Person to evade the purposes and
intent of the Rights Agreement, or otherwise seeking to control or influence the management or policies of the Company, then, and unless
and until the board of directors shall otherwise determine, such Person shall not be deemed to be an &#8220;Acquiring Person&#8221; for
purposes of the Rights Agreement. Furthermore, no Person who purchases securities of the Company either directly from the Company or
from any underwriters engaged by the Company, in each case in a securities offering transaction approved by the board of directors as
an offering intended to allow a Person or a group of Persons to beneficially own, upon the consummation of such offering, more than 10%
of the Ordinary Shares of the Company then outstanding, shall become an &#8220;Acquiring Person&#8221; unless such Person shall, after
the consummation of such offering, beneficially own additional Ordinary Shares of the Company in the amount equal to or greater than
the sum of (I) the lowest Ordinary Shares beneficially owned by such Person as a percentage of the outstanding Ordinary Shares as of
immediately after the consummation of such offering and (II) 0.5%. The definition of Acquiring Person is furthermore subject to the &#8220;grandfathering&#8221;
scenarios described under &#8220;<i>Exercise Period; Rights Certificates</i>&#8221; above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Exchange</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board may, at its option,
at any time after the Issuance Date, exchange all or part of the then outstanding and exercisable Rights (except for Rights that have
become void) for Ordinary Shares at an exchange ratio of one (1) Ordinary Share per Right, appropriately adjusted to reflect any adjustment
in the number of Rights, or the Exchange Ratio. However, the board of directors will not be empowered to effect such exchange at any
time after any Person (other than the Company, any Subsidiary of the Company, any employee benefit or share ownership plan of the Company
or any such Subsidiary, or any entity holding Ordinary Shares for or pursuant to the terms of any such plan), together with all affiliates
and associates of such Person, becomes the Beneficial Owner of 50% or more of the Ordinary Shares then outstanding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Immediately upon the action
of the board of directors ordering the foregoing exchange, the right to exercise the Rights that are to be exchanged will terminate and
the only right thereafter of a holder of such Rights shall be to receive that number of Ordinary Shares equal to the number of such Rights
held by such holder multiplied by the Exchange Ratio. In the event that there shall not be sufficient Ordinary Shares issued but not
outstanding or authorized but unissued to permit any exchange of Rights, the Company will take all such action as may be necessary to
authorize additional Ordinary Shares for issuance upon exchange of the Rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Anti-Dilution Provisions</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors may
adjust the purchase price of Ordinary Shares under each Right, the number of Ordinary Shares issuable under each Right, and the number
of outstanding Rights to prevent dilution that may occur from a share dividend, a share split, or a reclassification of the Ordinary
Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Amendments</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The terms of the Rights Agreement
may be amended by our board of directors without the consent of the holders of the Rights. After a person or group becomes an Acquiring
Person, our board of directors may not amend the Rights Agreement in a way that adversely affects holders of the Rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Redemption</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The board of directors may
at its option, at any time prior to the Issuance Date, redeem all but not less than all the then outstanding Rights. The redemption of
the Rights by the board of directors may be made effective at such time, on such basis and with such conditions as the board of directors,
in its sole discretion, may establish (the effective date of redemption, the is referred to as the &#8220;Redemption Date&#8221;). Immediately
upon the effectiveness of the action of the board of directors ordering the redemption of the Rights, and without any further action
and without any notice, the right to exercise the Rights will terminate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Expiration</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Rights will expire on November 27, 2024, or
the Final Expiration Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 154; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->151<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>SELLING SHAREHOLDER</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus relates to
the possible resale from time to time by YA of any or all of the Ordinary Shares that have been or may be issued by us to YA under the
SEPA. For additional information regarding the issuance of Ordinary Shares covered by this prospectus, see the section titled &#8220;<i>Prospectus
Summary &#8212;Standby Equity Purchase Agreement with YA</i>&#8221; above. Except for the transactions contemplated by the SEPA, YA does
not, and has not had, any material relationship with us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;The table below presents
information regarding the Selling Shareholder and the Ordinary Shares that it may offer from time to time under this prospectus. This
table is prepared based on information supplied to us by the Selling Shareholder. The number of shares in the column &#8220;Maximum Number
of Ordinary Shares to be Offered Pursuant to this Prospectus&#8221; represents all of the Ordinary Shares that the Selling Shareholder
may offer under this prospectus. The Selling Shareholder may sell some, all or none of its shares in this offering. We do not know how
long the Selling Shareholder will hold the shares before selling them, and we currently have no agreements, arrangements or understandings
with the Selling Shareholder regarding the sale of any of the shares.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Beneficial ownership is determined
in accordance with Rule 13d-3(d) promulgated by the SEC under the Exchange Act, and includes Ordinary Shares with respect to which the
Selling Shareholder has voting and investment power. The percentage of Ordinary Shares beneficially owned by the Selling Shareholder prior
to the offering shown in the table below is based on an aggregate of 1,095,784 of our Ordinary Shares outstanding on February 26, 2024.
The number of shares that may actually be sold by us under the SEPA may be fewer than the number of shares being offered by this prospectus.
The fourth column assumes the sale of all of the shares offered by the Selling Shareholder pursuant to this prospectus.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of Selling Shareholder</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Shares of<br/>
Ordinary Shares Owned<br/>
Prior to Offering</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum Number of <br/>
Ordinary Shares to be<br/>
Offered Pursuant<br/>
to this Prospectus</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Ordinary<br/>
Shares Owned After<br/>
Offering</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number(1)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percent</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number(2)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percent</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">YA II PN, LTD.(3) (4)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55,293</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.06</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">5,347,594</p></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have excluded from the number of shares beneficially owned prior to the offering all of the shares that YA may be required to purchase
under the SEPA, because the issuance of such shares is solely at our discretion and is subject to conditions contained in the SEPA, the
satisfaction of which are entirely outside of YA&#8217;s control, including the registration statement that includes this prospectus
becoming and remaining effective.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumes
the sale of all shares being offered pursuant to this prospectus. Depending on the price per share at which we sell our Ordinary Shares
to YA pursuant to the SEPA, we may need to sell to YA under the SEPA more shares of our Ordinary Shares than are offered under this prospectus
in order to receive aggregate gross proceeds equal to the $20.0 million total commitment under the SEPA. If we choose to do so and otherwise
satisfy the conditions in the SEPA, we must first register for resale under the Securities Act such additional shares. The number of
shares ultimately offered for resale by YA is dependent upon the number of shares we sell to YA under the SEPA.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">YA is a fund managed by Yorkville Advisors Global, LP, or Yorkville LP. Yorkville Advisors Global II, LLC, or Yorkville LLC, is the General Partner of Yorkville LP. All investment decisions for YA are made by Yorkville LLC&#8217;s President and Managing Member, Mr. Mark Angelo. The business address of YA is 1012 Springfield Avenue, Mountainside, NJ 07092.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">(4)</p></td><td style="text-align: justify">Pursuant to  the SEPA, YA is not permitted to purchase nor acquire Ordinary Shares
                                                                             of the Company under the SEPA that would result in it beneficially owning in excess of 9.99% of the outstanding voting power or
                                                                             number of Ordinary Shares outstanding.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 155; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->152<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PLAN OF DISTRIBUTION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 21, 2024, we entered
into the SEPA with YA. The SEPA provides that, upon the terms and subject to the conditions set forth therein, YA is committed to purchase
up to $20.0&#160;million of our Ordinary Shares over an approximately 36-month commitment period. Of the Commitment Amount, to date we
have not sold any Ordinary Shares (other than the Commitment Shares). From time to time, and at our sole discretion, we may present YA
with advance notices to purchase our Ordinary Shares. The shares would be purchased pursuant to the SEPA at 97% of the market price,
which is defined as the lowest daily volume weighted average price of the Shares during the three consecutive trading days commencing
on the trading day immediately following our delivery of an advance notice to YA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Ordinary Shares offered
by this prospectus are being offered by the Selling Shareholder, YA. The Selling Shareholder is an &#8220;underwriter&#8221; within the
meaning of Section&#160;2(a)(11) of the Securities Act. We have agreed in the SEPA to provide customary indemnification to YA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is possible that our shares
may be sold from time to time by YA in one or more of the following manners:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary
brokerage transactions and transactions in which the broker solicits purchasers;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a block trade in which
    the broker or dealer so engaged will attempt to sell the shares as agent, but may position and resell a portion of the block as principal
    to facilitate the transaction;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to a broker-dealer as principal
    and resale by the broker-dealer for its account; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a combination of any such
    methods of sale.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">YA has agreed that, during
the term of the SEPA, it shall not engage in any short sales or hedging transactions with respect to our Ordinary Shares, provided that
upon receipt of an advance notice, YA may sell shares that it is obligated to purchase under such advance notice prior to taking possession
of such shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">YA and any unaffiliated broker-dealer
will be subject to liability under the federal securities laws and must comply with the requirements of the Exchange Act, including without
limitation, Rule&#160;10b-5 and Regulation&#160;M under the Exchange Act. These rules and regulations may limit the timing of purchases
and sales of Ordinary Shares by YA or any unaffiliated broker-dealer. Under these rules and regulations, YA and any unaffiliated broker-dealer:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may not engage in any stabilization
    activity in connection with our securities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">must furnish each broker which offers
shares of our common stock covered by the prospectus and accompanying prospectus that are a part of our Registration Statement with the
number of copies of such prospectus and accompanying prospectus which are required by each broker; and</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">may not bid for or purchase any of our
        securities or attempt to induce any person to purchase any of our securities other than as permitted under the Exchange Act.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These restrictions may affect
the marketability of the Ordinary Shares by YA and any unaffiliated broker-dealer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will pay the expenses incident
to the registration under the Securities Act of the offer and sale of the Ordinary Shares covered by this prospectus by the Selling Shareholder.
We estimate that our total expenses for the offering will be approximately $98,000.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 156; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->153<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXPENSES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Set forth below is an itemization of the total
expenses expected to be incurred by us in connection with the offer and sale of the securities.&#160;With the exception of the SEC registration
fee, all amounts are estimates:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">SEC registration fee</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,854.93</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Printer fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Legal fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">80,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounting and professional fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Miscellaneous</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">97,854.93</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>LEGAL MATTERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain legal matters concerning the SEPA will
be passed upon for us by Sullivan &amp; Worcester LLP, New York, New York. Certain legal matters with respect to the validity of the
Ordinary Shares offered by this prospectus supplement will be passed upon for us by Meitar | Law Offices, Ramat Gan, Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXPERTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial statements of SciSparc
Ltd. appearing in this registration statement for the year ended December 31, 2022 have been audited by Kost Forer Gabbay &amp; Kasierer,
a member firm of Ernst &amp; Young Global, an independent registered public accounting firm, as set forth in their report thereon, included
therein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 157; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->154<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ENFORCEABILITY OF CIVIL LIABILITIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are incorporated under
the laws of the State of Israel. Service of process upon us and upon our directors and officers and the Israeli experts named in the
registration statements of which this prospectus forms a part, a substantial majority of whom reside outside of the United States, may
be difficult to obtain within the United States. Furthermore, because substantially all of our assets and a substantial of our directors
and officers are located outside of the United States, any judgment obtained in the United States against us or any of our directors
and officers may not be collectible within the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have been informed by
our legal counsel in Israel, Meitar | Law Offices, that it may be difficult to assert U.S. securities law claims in original actions
instituted in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning Israel
is not the most appropriate forum to bring such a claim. In Israeli courts, the content of applicable U.S. law must be proved as a fact
which can be a time-consuming and costly process and certain matters of procedure will also be governed by Israeli law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to specified time
limitations and legal procedures, Israeli courts may enforce a U.S. judgment in a civil matter which, subject to certain exceptions,
is non-appealable, including judgments based upon the civil liability provisions of the Securities Act and the Exchange Act and including
a monetary or compensatory judgment in a non-civil matter, provided that among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment was rendered
    by a court which was, according to the laws of the state of the court, competent to render the judgment;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the obligation imposed
    by the judgment is enforceable according to the rules relating to the enforceability of judgments in Israel and the substance of
    the judgment is not contrary to public policy; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment is executory
    in the state in which it was given.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if these conditions
are met, an Israeli court will not declare a foreign civil judgment enforceable if:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment was given
    in a state whose laws do not provide for the enforcement of judgments of Israeli courts (subject to exceptional cases);</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the enforcement of the
    judgment is likely to prejudice the sovereignty or security of the State of Israel;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment was obtained
    by fraud;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the opportunity given to
    the defendant to bring its arguments and evidence before the court was not reasonable in the opinion of the Israeli court;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment was rendered
    by a court not competent to render it according to the laws of private international law as they apply in Israel;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment is contradictory
    to another judgment that was given in the same matter between the same parties and that is still valid; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at the time the action
    was brought in the foreign court, a lawsuit in the same matter and between the same parties was pending before a court or tribunal
    in Israel.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a foreign judgment is
enforced by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into non-Israeli currency
and transferred out of Israel. The usual practice in an action before an Israeli court to recover an amount in a non-Israeli currency
is for the Israeli court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange in force on the date
of the judgment, but the judgment debtor may make payment in foreign currency. Pending collection, the amount of the judgment of an Israeli
court stated in Israeli currency ordinarily will be linked to the Israeli consumer price index plus interest at the annual statutory
rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 158; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->155<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WHERE YOU CAN FIND ADDITIONAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have filed with the SEC
a registration statement on Form&#160;F-1 under the Securities Act relating to this offering of our Ordinary Shares. This prospectus
does not contain all of the information contained in the registration statement. The rules and regulations of the SEC allow us to omit
certain information from this prospectus that is included in the registration statement. Statements made in this prospectus concerning
the contents of any contract, agreement or other document are summaries of all material information about the documents summarized, but
are not complete descriptions of all terms of these documents. If we filed any of these documents as an exhibit to the registration statement,
you may read the document itself for a complete description of its terms. The SEC maintains an Internet website that contains reports
and other information regarding issuers that file electronically with the SEC. Our filings with the SEC are also available to the public
through the SEC&#8217;s website at www.sec.gov.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the information
reporting requirements of the Exchange Act that are applicable to foreign private issuers, and under those requirements are filing reports
with the SEC. Those other reports or other information may be inspected without charge at the locations described above. As a foreign
private issuer, we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our
officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in
Section&#160;16 of the Exchange Act. In addition, we are not required under the Exchange Act to file annual, quarterly and current reports
and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange
Act. However, we are required to file with the SEC, within 120&#160;days after the end of each fiscal year, or such applicable time as
required by the SEC, an annual report on Form&#160;20-F containing financial statements audited by an independent registered public accounting
firm, and will submit to the SEC, on Form&#160;6-K, unaudited interim financial information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain a corporate website
at www.scisparc.com. Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus.
We have included our website address in this prospectus solely as an inactive textual reference. We will post on our website any materials
required to be so posted on such website under applicable corporate or securities laws and regulations, including, posting any XBRL interactive
financial data required to be filed with the SEC and any notices of general meetings of our shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 159; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->156<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>INDEX TO FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>SCISPARC
LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>INTERIM
CONSOLIDATED FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>AS
OF JUNE 30, 2023</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>UNAUDITED</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>INDEX&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_001"><b>Consolidated
    Statements of Financial Position</b></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-2 - F-3 </b></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_002"><b>Consolidated
    Statements of Profit or Loss and Other Comprehensive Loss </b></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-4</b></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_003"><b>Consolidated
    Statements of Changes in Equity (Deficit)</b></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-5
    - F-7 </b></span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_004"><b>Consolidated
    Statements of Cash Flows</b></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-8
    - F-10</b></span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_005"><b>Notes
    to Interim Consolidated Financial Statements </b></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-11
    - F-22</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 160; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>SCISPARC
LTD.</b></span></p><div>

</div><div><a id="f_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>CONSOLIDATED
STATEMENTS OF FINANCIAL POSITION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Unaudited</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Audited</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Note</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">USD
    in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">ASSETS</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">CURRENT ASSETS:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: justify; text-indent: -0.125in; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-37523">2,081</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-37524">12,945</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-37525">3,574</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Restricted
    deposit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" unitRef="usd" id="ixv-37526">44</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" unitRef="usd" id="ixv-37527">40</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" unitRef="usd" id="ixv-37528">60</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Trade
    receivables</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentTradeReceivables" scale="3" unitRef="usd" id="ixv-37529">43</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-0; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentTradeReceivables" scale="3" unitRef="usd" id="ixv-37530">77</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Other
    accounts receivable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentReceivables" scale="3" unitRef="usd" id="ixv-37531">815</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentReceivables" scale="3" unitRef="usd" id="ixv-37532">699</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentReceivables" scale="3" unitRef="usd" id="ixv-37533">131</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Inventory</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="3" unitRef="usd" id="ixv-37534">660</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-1; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="3" unitRef="usd" id="ixv-37535">668</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd" id="ixv-37536">3,643</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd" id="ixv-37537">13,684</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd" id="ixv-37538">4,510</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">NON-CURRENT
    ASSETS:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Intangible
    asset, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-37539">4,474</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-2; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-37540">4,717</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Investment
    in company account for at equity</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentsInAssociates" scale="3" unitRef="usd" id="ixv-37541">893</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentsInAssociates" scale="3" unitRef="usd" id="ixv-37542">659</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentsInAssociates" scale="3" unitRef="usd" id="ixv-37543">591</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Investments
    in financial assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentFinancialAssets" scale="3" unitRef="usd" id="ixv-37544">849</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-3; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentFinancialAssets" scale="3" unitRef="usd" id="ixv-37545">730</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Property
    and equipment, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-37546">33</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-37547">79</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-37548">57</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd" id="ixv-37549">6,249</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd" id="ixv-37550">738</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd" id="ixv-37551">6,095</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="3" unitRef="usd" id="ixv-37552">9,892</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="3" unitRef="usd" id="ixv-37553">14,422</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="3" unitRef="usd" id="ixv-37554">10,605</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of the interim consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 161; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>SCISPARC
LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>CONSOLIDATED
STATEMENTS OF FINANCIAL POSITION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30,</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Unaudited</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Audited</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Note</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD
    in thousands</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">LIABILITIES AND
    EQUITY</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">CURRENT LIABILITIES:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Trade
    payables</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-37555">1,247</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-37556">874</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,199</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other
    accounts payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" unitRef="usd" id="ixv-37557">153</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" unitRef="usd" id="ixv-37558">214</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">193</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentWarrantLiability" scale="3" unitRef="usd" id="ixv-37559">1,714</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentWarrantLiability" scale="3" unitRef="usd" id="ixv-37560">10,252</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,737</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease
    liability</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-4; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-37561">45</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-37562">3,114</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-37563">11,385</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,156</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">EQUITY
    ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">9</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share
    capital and premium</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SharePremium" scale="3" unitRef="usd" id="ixv-37564">58,898</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SharePremium" scale="3" unitRef="usd" id="ixv-37565">58,547</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">58,592</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Reserve
    from share-based payment transactions</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="3" unitRef="usd" id="ixv-37566">5,248</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="3" unitRef="usd" id="ixv-37567">4,980</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,180</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WarrantLiability" scale="3" unitRef="usd" id="ixv-37568">5,190</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WarrantLiability" scale="3" unitRef="usd" id="ixv-37569">5,190</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,190</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Foreign
    currency translation reserve</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" scale="3" unitRef="usd" id="ixv-37570">497</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" scale="3" unitRef="usd" id="ixv-37571">497</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">497</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Transactions
    with non-controlling interests</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherEquityInterest" scale="3" unitRef="usd" id="ixv-37572">712</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherEquityInterest" scale="3" unitRef="usd" id="ixv-37573">559</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">559</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="3" sign="-" unitRef="usd" id="ixv-37574">66,449</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="3" sign="-" unitRef="usd" id="ixv-37575">66,736</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(63,569</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="3" unitRef="usd" id="ixv-37576">4,096</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="3" unitRef="usd" id="ixv-37577">3,037</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,449</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-controlling
    interests</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncontrollingInterests" scale="3" unitRef="usd" id="ixv-37578">2,682</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-5; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    equity</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37579">6,778</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37580">3,037</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,449</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    liabilities and equity</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAndLiabilities" scale="3" unitRef="usd" id="ixv-37581">9,892</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAndLiabilities" scale="3" unitRef="usd" id="ixv-37582">14,422</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,605</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of the interim consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 162; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>SCISPARC
LTD.</b></span></p><div>

</div><div><a id="f_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>CONSOLIDATED
STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE LOSS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    months ended <br/>
    June 30,</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended<br/>
    December&#160;31,</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Unaudited</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Audited</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Note</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD
    in thousands, except per share amounts</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 56%"><span style="font-family: Times New Roman, Times, Serif">Revenues</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="3" unitRef="usd" id="ixv-37583">1,972</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-9; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="3" unitRef="usd" id="ixv-37584">1,347</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cost
    of goods sold</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-37585">1,267</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-10; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-37586">322</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gross
    profit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="3" unitRef="usd" id="ixv-37587">705</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-11; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="3" unitRef="usd" id="ixv-37588">1,025</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research
    and development expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">10a</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-37589">781</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-37590">1,474</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-37591">2,803</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Sales
    and marketing</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-37592">397</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-12; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-13; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">General
    and administrative expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">11b</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37593">2,494</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37594">3,339</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37595">6,509</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating
    loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-37596">2,967</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-37597">4,813</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-37598">8,287</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Company&#8217;s
    share of losses of companies accounted for at equity, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="3" sign="-" unitRef="usd" id="ixv-37599">99</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="3" sign="-" unitRef="usd" id="ixv-37600">41</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="3" sign="-" unitRef="usd" id="ixv-37601">109</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Finance
    income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-37602">1,024</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-14; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-37603">7,832</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Finance
    expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-37604">877</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-37605">905</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-37606">2,014</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss
    before income taxes</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-37607">2,919</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-37608">5,759</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-37609">2,578</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Taxes
    on income</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" unitRef="usd" id="ixv-37610">13</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-15; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" unitRef="usd" id="ixv-37611">14</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    comprehensive loss</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-37612">2,932</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-37613">5,759</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-37614">2,592</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Attributable
    to:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Equity
    holders of the Company</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" scale="3" unitRef="usd" id="ixv-37615">2,880</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" scale="3" unitRef="usd" id="ixv-37616">5,759</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" scale="3" unitRef="usd" id="ixv-37617">2,592</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-controlling
    interests</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-37618">52</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-16; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-17; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-37619">2,932</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-37620">5,759</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-37621">2,592</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basic
    loss per share attributable to equity holders of the Company:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss
    from operations</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c8" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-37622">10.85</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c9" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-37623">46.80</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c10" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-37624">14.82</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Diluted
    loss per share attributable to equity holders of the Company:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss
    from operations</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c8" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-37625">10.85</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c9" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-37626">46.80</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c10" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-37627">14.82</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of the interim consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 163; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>SCISPARC
LTD.</b></span></p><div>

</div><div><a id="f_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN EQUITY (DEFICIT)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>For the
six months ended June 30, 2023</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="26" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Attributable
    to equity holders of the Company</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Share<br/>
    capital<br/> and<br/> premium</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Reserve<br/>
    from<br/> share-based<br/> payment<br/> transactions</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Transactions<br/>
    with non-<br/> controlling<br/> interests</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Foreign<br/>
    currency<br/> translation<br/> reserve</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Accumulated<br/>
    deficit</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Non-<br/>
    controlling<br/> interests</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total<br/>
    equity</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="34" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">USD
    in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 19%"><span style="font-family: Times New Roman, Times, Serif">Balance
    at January 1, 2023</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37628">58,592</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37629">5,180</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37630">5,190</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37631">559</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37632">497</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-37633">63,569</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37634">6,449</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-28; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37635">6,449</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income
    (loss)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-29; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-30; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-32; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-33; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-37636">2,880</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-37637">2,880</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-37638">52</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-37639">2,932</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issue
    of share capital in respect of investment in affiliate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="3" unitRef="usd" id="ixv-37640">288</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-34; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-35; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-36; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-37; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-38; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="3" unitRef="usd" id="ixv-37641">288</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-39; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="3" unitRef="usd" id="ixv-37642">288</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Sale
    of minority interest in subsidiary</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-40; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-41; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-42; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" scale="3" unitRef="usd" id="ixv-37643">153</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-43; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-44; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" scale="3" unitRef="usd" id="ixv-37644">153</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" scale="3" unitRef="usd" id="ixv-37645">2,734</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" scale="3" unitRef="usd" id="ixv-37646">2,887</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Issue of shares,
    net of issue expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfSharesNetOfIssueExpenses" scale="3" sign="-" unitRef="usd" id="ixv-37647">45</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-45; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-46; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-47; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-48; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-49; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfSharesNetOfIssueExpenses" scale="3" sign="-" unitRef="usd" id="ixv-37648">45</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfSharesNetOfIssueExpenses" scale="3" sign="-" unitRef="usd" id="ixv-37649">45</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cost
    of share-based payment</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-37650">63</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-37651">68</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-51; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-54; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-37652">131</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-55; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-37653">131</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Balance at June
    30, 2023</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37654">58,898</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37655">5,248</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37656">5,190</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37657">712</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37658">497</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-37659">66,449</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37660">4,096</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37661">2,682</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37662">6,778</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b>&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of the interim consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p><div>

</div><!-- Field: Page; Sequence: 164; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>SCISPARC
LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN EQUITY (DEFICIT)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>For the
six months ended June 30, 2022</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="26" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Attributable
    to equity holders of the Company</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Share<br/>
    capital<br/> and<br/> premium</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Reserve<br/>
    from<br/> share-based<br/> payment<br/> transactions</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Transactions<br/>
    with non-<br/> controlling<br/> interests</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Foreign<br/>
    currency<br/> translation<br/> reserve</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated<br/>
    deficit</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Non-<br/>
    controlling<br/> interests</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total<br/>
    equity</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="34" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD
    in thousands</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 19%"><span style="font-family: Times New Roman, Times, Serif">Balance
    at January 1, 2022</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37663">58,541</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37664">4,331</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37665">5,190</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37666">559</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37667">497</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-37668">60,977</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37669">8,141</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-56; font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37670">8,141</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income
    (loss)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-57; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-58; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-59; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-60; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-61; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-37671">5,759</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-37672">5,759</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-62; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-37673">5,759</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Expiration of share
    options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" unitRef="usd" id="ixv-37674">6</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" sign="-" unitRef="usd" id="ixv-37675">6</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-63; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-64; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-67; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-68; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-69; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cost
    of share-based payment</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-70; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-37676">655</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-71; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-72; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-73; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-74; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-37677">655</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-75; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-37678">655</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Balance at June
    30, 2022</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37679">58,547</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37680">4,980</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37681">5,190</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37682">559</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37683">497</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-37684">66,736</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37685">3,037</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-76; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37686">3,037</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.4pt"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of the interim consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 165; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>SCISPARC
LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN EQUITY </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>For the
year ended December 31, 2022</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="26" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Attributable
    to equity holders of the Company</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Share<br/>
    capital<br/> and<br/> premium</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Reserve<br/>
    from<br/> share-based<br/> payment<br/> transactions</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Transactions<br/>
    with non-<br/> controlling<br/> interests</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Foreign<br/>
    currency<br/> translation<br/> reserve</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated<br/>
    deficit</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Non-<br/>
    controlling<br/> interests</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total<br/>
    equity</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="34" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD
    in thousands</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 19%"><span style="font-family: Times New Roman, Times, Serif">Balance
    at January 1, 2022</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37687">58,541</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37688">4,331</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37689">5,190</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37690">559</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37691">497</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-37692">60,977</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37693">8,141</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-77; font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37694">8,141</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income
    (loss)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-78; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-79; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c66" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-37695">2,592</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-37696">2,592</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-37697">2,592</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Exercise of warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-37698">3</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-88; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-37699">3</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-89; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-37700">3</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cost
    of share-based payment</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-37701">48</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-37702">849</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-90; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-91; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-92; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-93; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-37703">897</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-94; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-37704">897</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Balance at December
    31, 2021</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37705">58,592</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37706">5,180</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37707">5,190</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37708">559</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37709">497</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-37710">63,569</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37711">6,449</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-95; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-37712">6,449</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of the interim consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 166; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>SCISPARC
LTD.</b></span></p><div>

</div><div><a id="f_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    months ended<br/> June 30,</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended<br/> December&#160;31,</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Unaudited</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Audited</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD
    in thousands</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Cash
    flows from operating activities:</span></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Loss</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-37713">2,932</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-37714">5,759</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-37715">2,592</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Adjustments
    to reconcile net loss to net cash used&#160;in operating activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Adjustments
    to the profit or loss items:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Depreciation
    and amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" unitRef="usd" id="ixv-37716">267</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" unitRef="usd" id="ixv-37717">21</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" unitRef="usd" id="ixv-37718">187</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Cost
    of share-based payment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-37719">131</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-37720">655</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-37721">897</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Finance
    expenses, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" scale="3" unitRef="usd" id="ixv-37722">1,023</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" scale="3" sign="-" unitRef="usd" id="ixv-37723">913</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" scale="3" unitRef="usd" id="ixv-37724">6,585</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Group&#8217;s
    share of losses of company accounted for at equity, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" scale="3" unitRef="usd" id="ixv-37725">98</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" scale="3" unitRef="usd" id="ixv-37726">41</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" scale="3" unitRef="usd" id="ixv-37727">109</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Losses
    from remeasurement of investment in financial assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdjustmentsForImpairmentOfInvestmentInAssociate" scale="3" unitRef="usd" id="ixv-37728">855</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-180; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdjustmentsForImpairmentOfInvestmentInAssociate" scale="3" unitRef="usd" id="ixv-37729">770</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForReconcileProfitLoss" scale="3" unitRef="usd" id="ixv-37730">328</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForReconcileProfitLoss" scale="3" unitRef="usd" id="ixv-37731">1,630</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForReconcileProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-37732">4,622</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Working
    capital adjustments:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Decrease
    (increase) in other accounts receivable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="3" sign="-" unitRef="usd" id="ixv-37733">684</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="3" unitRef="usd" id="ixv-37734">2,205</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="3" unitRef="usd" id="ixv-37735">3</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Increase
    (decrease) in trade payables</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="3" unitRef="usd" id="ixv-37736">48</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="3" sign="-" unitRef="usd" id="ixv-37737">324</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-181; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Increase
    (decrease) in other accounts payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" sign="-" unitRef="usd" id="ixv-37738">40</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" unitRef="usd" id="ixv-37739">60</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" unitRef="usd" id="ixv-37740">39</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Decrease
    (increase) in trade receivables</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="3" unitRef="usd" id="ixv-37741">39</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-182; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="3" sign="-" unitRef="usd" id="ixv-37742">77</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Decrease
    (increase) in inventory</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="3" unitRef="usd" id="ixv-37743">8</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-183; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="3" sign="-" unitRef="usd" id="ixv-37744">668</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" scale="3" sign="-" unitRef="usd" id="ixv-37745">629</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" scale="3" unitRef="usd" id="ixv-37746">1,941</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" scale="3" sign="-" unitRef="usd" id="ixv-37747">703</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Net
    cash used in operating activities</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-37748">3,233</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-37749">2,188</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-37750">7,917</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of the interim consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 167; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>SCISPARC
LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    months ended<br/>
    June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended <br/> December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Unaudited</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Audited</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">USD
    in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Cash flows from investing
    activities:</span></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -0.125in; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Investment
    (withdrawal) in restricted bank deposits</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-37751">16</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-37752">8</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-37753">15</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Purchase
    of property and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-184; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-185; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-37754">8</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Investment
    in a company accounted for at equity</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" scale="3" sign="-" unitRef="usd" id="ixv-37755">400</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" scale="3" sign="-" unitRef="usd" id="ixv-37756">700</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" scale="3" sign="-" unitRef="usd" id="ixv-37757">700</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Purchase
    of financial assets at fair value through profit or loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" scale="3" sign="-" unitRef="usd" id="ixv-37758">687</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-186; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" scale="3" sign="-" unitRef="usd" id="ixv-37759">1,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Purchase
    of intangible asset</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-187; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-188; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-37760">4,861</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Net
    cash provided by investing activities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-37761">1,071</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-37762">708</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-37763">7,084</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Cash
    flows from financing activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Proceeds
    from issue of share capital and warrants (net of issuance expenses) (Note 8)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" scale="3" unitRef="usd" id="ixv-37764">50</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" scale="3" sign="-" unitRef="usd" id="ixv-37765">9,005</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" scale="3" sign="-" unitRef="usd" id="ixv-37766">9,005</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Repayment
    of lease liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RepaymentOfLeaseLiabilities" scale="3" unitRef="usd" id="ixv-37767">26</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RepaymentOfLeaseLiabilities" scale="3" unitRef="usd" id="ixv-37768">39</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RepaymentOfLeaseLiabilities" scale="3" unitRef="usd" id="ixv-37769">70</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Interest
    paid on lease liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-189; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-190; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InterestPaidOnLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-37770">8</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Proceeds
    from issuance of shares to minority interests in a subsidiary</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="3" unitRef="usd" id="ixv-37771">2,887</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-191; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-192; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Exercise of warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-193; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-194; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromExerciseOfOptions" scale="3" unitRef="usd" id="ixv-37772">2,770</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Payment
    of issuance expenses related to previous period</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-195; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-196; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod" scale="3" unitRef="usd" id="ixv-37773">3</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Net
    cash provided by financing activities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-37774">2,811</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-37775">8,966</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-37776">11,700</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Increase
    (decrease) in cash and cash equivalents</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-37777">1,493</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-37778">6,070</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-37779">3,301</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents at the beginning of the period</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-37780">3,574</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-37781">6,875</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-37782">6,875</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents at the end of the period</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-37783">2,081</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-37784">12,945</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-37785">3,574</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>






</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of the interim consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 168; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>SCISPARC
LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Six
    months ended<br/> June 30,</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended<br/> December 31,</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Unaudited</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Audited</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">USD
    in thousands</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
    <span style="text-decoration:underline">Significant non-cash transactions:</span></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Mutual
    share exchange of ordinary shares (see note 10)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:MutualShareExchangeOfOrdinarySharessee" scale="3" unitRef="usd" id="ixv-37786">288</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-197; font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;-</span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-198; font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of the interim consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 169; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>SCISPARC
LTD.</b></span></p><div>

</div><div><a id="f_005"></a></div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (USD in thousands, except per share and per unit amounts)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="sprcy_DisclosureOfGeneralExplanatoryTextBlock-c0_cont_1" escape="true" name="sprcy:DisclosureOfGeneralExplanatoryTextBlock" id="ixv-21871"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
1:- GENERAL</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">SciSparc
    Ltd. (formerly known as Therapix Biosciences Ltd.) (&#8220;SciSparc&#8221; or the &#8220;Company&#8221; or the &#8220;Group&#8221;),
    a pharmaceutical company, was incorporated in Israel and commenced its operations on August 23, 2004. Until March 2014, SciSparc
    and its subsidiaries at the time were mainly engaged in developing several innovative immunotherapy products and SciSparc&#8217;s
    own patents in the immunotherapy field. In August 2015, the Company decided to adopt a different business strategy and began focusing
    on developing a portfolio of approved drugs based on cannabinoid molecules. With this focus, the Company is currently engaged in
    development programs based on &#916;9-tetrahydrocannabinol (&#8220;THC&#8221;) and/or non-psychoactive cannabidiol for the treatment
    of Tourette syndrome, Alzheimer&#8217;s disease and agitation, pain, autism spectrum disorder and Status Epilepticus. The headquarters
    of the Company are located in Tel Aviv, Israel.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
    September 30, 2022, the Company announced the closing of the acquisition of Wellution<sup>TM</sup>, a top seller Amazon.com Marketplace
    account (the &#8220;Brand&#8221;), American food supplements and cosmetics brand and trademark (the &#8220;Acquisition&#8221;). In
    connection with the Acquisition, the Company incorporated a new wholly owned Delaware subsidiary, SciSparc Nutraceuticals Inc. (&#8220;SciSparc
    US&#8221;), to hold the new assets.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company&#8217;s ordinary shares are listed on Nasdaq and are trading under the symbol &#8220;SPRC&#8221;.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As of June 30, 2023, the Company had three private subsidiaries, including a company incorporated under the laws of Israel: Evero Health Ltd (&#8220;Evero&#8221;); an inactive company incorporated under the laws of Israel: Brain Bright Ltd (&#8220;Brain Bright&#8221;); and a company incorporated under the laws of the State of Delaware: Scisparc US (together with Evero and Brain Bright, the &#8220;Subsidiaries&#8221;).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On August 18, 2023, the Company convened a general meeting of its shareholders, whereby the shareholders approved, inter alia, a reverse split of the Company&#8217;s share capital up to a ratio of 30:1 (the &#8220;Reverse Split&#8221;). Following the implementation of the reverse split, the Company&#8217;s authorized share capital will not be adjusted under the Company&#8217;s articles of association, as currently in effect (the &#8220;Articles&#8221;), which as of the date hereof consists of <ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-37787">75,000,000</ix:nonFraction> Ordinary Shares, no par value.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
September 14, 2023, the Company&#8217;s Board resolved that the final ratio for the Reverse Split will be 26:1, which became effective
on September 28, 2023.&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Consequently,
all share numbers, share prices, and exercise prices have been retroactively adjusted in these interim consolidated financial statements
for all periods presented.</span>&#160;</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These interim consolidated
    financial statements should be read in conjunction with the Company&#8217;s annual financial statements for the year ended December
    31, 2022, and accompanying notes, that were approved on April 27, 2023, and signed on May 1, 2023 (the &#8220;2022 Annual Consolidated
    Financial Statements&#8221;).</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:nonNumeric><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 170; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>SCISPARC
LTD.</b></span></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (USD in thousands, except per share and per unit amounts)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
1:- GENERAL (cont.)</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="sprcy_DisclosureOfGeneralExplanatoryTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company incurred a net loss of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnNetMonetaryPosition" scale="3" unitRef="usd" id="ixv-37788">2,932</ix:nonFraction> and had negative cash flows from operating activities of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-37789">3,233</ix:nonFraction> for the six month period ended June 30, 2023. As of June 30, 2023, the Company had an accumulated deficit of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RetainedEarning" scale="3" unitRef="usd" id="ixv-37790">66,449</ix:nonFraction> as a result of recurring operating losses. At June 30, 2023, the Company&#8217;s cash and cash equivalents position is not sufficient to fund the Company&#8217;s planned operations for at least a year beyond the date of the filing date of the consolidated financial statements.. The Company&#8217;s pharmaceuticals operations are dependent on its ability to raise additional funds from existing and/or new investors. This dependency will continue until the Group will be able to completely finance its operations by generating revenue from its pharmaceutical products. These abovementioned factors raise substantial doubt about the Group&#8217;s ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529"><span style="font-family: Times New Roman, Times, Serif">The Company intends to finance operating costs over the next twelve months through a combination of actions that may include existing cash on hand, reducing operating expenses and issuing equity and/or debt securities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529"><span style="font-family: Times New Roman, Times, Serif">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The interim consolidated financial statements for the period ended June 30, 2023, do not include any adjustments to the carrying amounts and classifications of assets and liabilities that might result should the Group be unable to continue as a going concern.</span></p>
</td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The interim consolidated financial statements
    of the Company for the six-month period ended on June&#160;30, 2023, were approved for issuance on October 2, 2023 (the &#8220;Approval
    Date&#8221;). In connection with the preparation of the interim consolidated financial statements and in accordance with authoritative
    guidance for subsequent events, the Company evaluated subsequent events after the consolidated statements of financial position date
    of June 30, 2023, through September 27, 2023, the date on which the unaudited interim consolidated financial statements were available
    to be issued.</span></td></tr>
  </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory" id="ixv-22000"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
2:- SIGNIFICANT ACCOUNTING POLICIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="ixv-22006"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Unaudited
Interim Financial Information</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_2" id="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s unaudited condensed consolidated financial statements have been prepared in accordance with International Accounting
Standard (&#8220;IAS&#8221;) 34, &#8220;Interim Financial Reporting&#8221;. The significant accounting policies adopted in the preparation
of the interim consolidated financial statements are consistent with those followed in the preparation of the 2022 Annual Consolidated
Financial Statements. Accordingly, these condensed consolidated financial statements should be read in conjunction with the 2022 Annual
Consolidated Financial Statements. The results for any interim period are not necessarily indicative of results for any future period.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_3" id="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
unaudited condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the
opinion of the Company&#8217;s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments
that are necessary to present fairly the Company&#8217;s financial position and results of operations for the interim periods presented.
The results for the six month period ended June 30, 2023, are not necessarily indicative of the results for the year ending December&#160;31,
2023, or for any future period.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of June 30, 2023, there have been no material changes in the Company&#8217;s significant accounting policies from those that were disclosed
in the 2022 Annual Consolidated Financial Statements.<b>&#160;</b></span></p></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 171; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>SCISPARC
LTD.</b></span></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (USD in thousands, except per share and per unit amounts)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" id="ixv-22055"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
3:- INVESTMENT IN ASSOCIATE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
March 10, 2022, the Company entered into a Founders and Investment Agreement with Dr. Alon Silberman, or the MitoCareX Agreement. Pursuant
to the MitoCareX Agreement, the Company invested an initial amount of $<ix:nonFraction contextRef="c106" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestedInitialAmount" scale="3" unitRef="usd" id="ixv-37791">700</ix:nonFraction>, and agreed to invest over the next&#160;two years, an additional
$<ix:nonFraction contextRef="c106" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdditionalAgreedInvest" scale="3" unitRef="usd" id="ixv-37792">1,000</ix:nonFraction>, subject to the achievement of certain pre-determined milestones as agreed upon in the MitoCareX Agreement, for up to a&#160;<ix:nonFraction contextRef="c107" decimals="4" format="ixt:num-dot-decimal" name="sprcy:OwnershipAgreement" scale="-2" unitRef="pure" id="ixv-37793">50.01</ix:nonFraction>%
ownership in MitoCareX Bio Ltd. (&#8220;MitoCareX&#8221;). MitoCareX is focused on the discovery and development of potential drugs for
cancers and other life-threatening conditions. The MitoCareX Agreement also contains customary representations, warranties, covenants,
and indemnification provisions. On March 31, 2022, the closing conditions were met, and the Company paid the initial investment amount
of $<ix:nonFraction contextRef="c108" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InitialInvestment" scale="3" unitRef="usd" id="ixv-37794">700</ix:nonFraction>&#160;to MitoCareX. As of December 31, 2022, the Company owns&#160;<ix:nonFraction contextRef="c7" decimals="4" format="ixt:num-dot-decimal" name="sprcy:OutstandingSharesPercentage" scale="-2" unitRef="pure" id="ixv-37795">31.48</ix:nonFraction>% of the outstanding shares of MitoCareX.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
February 17, 2023, MitoCareX achieved its first milestone pursuant to the MitoCareX Agreement. The first milestone refers to the establishment
of MitoCareX&#8217;s cloud-based computing infrastructure that is expected to allow its future expansion into machine learning system.
The system is harnessed to investigating mitochondrial carriers that are crucial for cell viability. As a result of MitoCareX meeting
this milestone, the Company will invest an additional $<ix:nonFraction contextRef="c109" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionalProvisionsOtherProvisions" scale="3" unitRef="usd" id="ixv-37796">400</ix:nonFraction>&#160;in MitoCareX and increase its share ownership in MitoCareX Bio from&#160;<ix:nonFraction contextRef="c110" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" unitRef="pure" id="ixv-37797">31.48</ix:nonFraction>%
to&#160;<ix:nonFraction contextRef="c111" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" unitRef="pure" id="ixv-37798">41.92</ix:nonFraction>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory" id="ixv-22070"><span style="font-family: Times New Roman, Times, Serif">The
table below summarizes the fair value of the investment in MitoCareX:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance at January
    1, 2022</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-220; font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Investment
    date March 31, 2022</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentDate" scale="3" unitRef="usd" id="ixv-37799">700</ix:nonFraction></span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Equity
    losses from investment in MitoCareX</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:EquityLossesFromInvestmentInMitoCareX" scale="3" sign="-" unitRef="usd" id="ixv-37800">109</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance at December
    31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-37801">591</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Investment date March
    31, 2023</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentDate" scale="3" unitRef="usd" id="ixv-37802">400</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Equity
    losses from investment in MitoCareX</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:EquityLossesFromInvestmentInMitoCareX" scale="3" sign="-" unitRef="usd" id="ixv-37803">98</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    at June 30, 2023</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-37804">893</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During
the six months ended June 30, 2023, and 2022, the Company recorded equity losses from the investment in MitoCareX in the amount of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:EquityLossesInvestment" scale="3" unitRef="usd" id="ixv-37805">98</ix:nonFraction>
and $<ix:nonFraction contextRef="c112" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:EquityLossesInvestment" scale="3" unitRef="usd" id="ixv-37806">41</ix:nonFraction>, respectively.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 172; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>SCISPARC
LTD.</b></span></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (USD in thousands, except per share and per unit amounts)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfIntangibleAssetsExplanatory" id="ixv-22218"><p style="text-align: justify; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4:- INTANGIBLE ASSET</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
September 30, 2022, the Company announced the closing of the Acquisition. In connection with the Acquisition, the Company incorporated
a new wholly owned Delaware subsidiary, SciSparc US, to hold the new assets. The definitive agreement for the acquisition of the Brand
was entered into with Merhavit M.R.M Holding and Management Ltd (&#8220;M.R.M&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">At
the closing, the Company paid a base cash payment of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CashPayment" scale="3" unitRef="usd" id="ixv-37807">4,540</ix:nonFraction> and in 12 months following the closing agreed to pay an additional deferred
cash payment equal to a multiple of 3 times the amount by which the Brand&#8217;s EBITDA exceeds $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount" scale="3" unitRef="usd" id="ixv-37808">1,120</ix:nonFraction> during the 12-month period following
the closing of the Acquisition. The Company paid an additional $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PurchaseCosts" scale="3" unitRef="usd" id="ixv-37809">321</ix:nonFraction> as purchase costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
addition, the Company issued to M.R.M $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsToPurchase" scale="3" unitRef="usd" id="ixv-37810">15,000</ix:nonFraction> worth of warrants to purchase ordinary shares of the Company at an exercise price of $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-37811">7.00</ix:nonFraction>
per share (with a cashless exercise mechanism) and with an exercise period of <ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="sprcy:ExercisePeriod" id="ixv-37812">five years</ix:nonNumeric> from the closing of the Acquisition (the &#8220;September
2022 Warrants&#8221;). The September 2022 Warrants will become exercisable upon the earlier of (i) an achievement of $<ix:nonFraction contextRef="c113" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-37813">100,000</ix:nonFraction> of gross
sales by the Brand in the aggregate or (ii) if the price of our Ordinary Shares closes at $<ix:nonFraction contextRef="c113" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PricePerShare" scale="0" unitRef="usdPershares" id="ixv-37814">10.00</ix:nonFraction> or above.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company reviewed the transaction and deemed it to be the purchase of assets for accounting purposes under generally accepted accounting
principles and not as a business combination. The Company reviewed the guidance under IFRS 3 for the transaction and determined that
the fair value of the gross assets acquired was concentrated in a single identifiable asset, a brand. Accordingly, the Company treated
the transaction as an asset acquisition. On the closing date of the Acquisition, the Company fully recognized the acquisition amount
total of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AmountTotal" scale="3" unitRef="usd" id="ixv-37815">4,861</ix:nonFraction> as an intangible asset, to be amortized over a period of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" id="ixv-37816">10</ix:nonNumeric> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="sprcy_ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock-c0_cont_1" escape="true" name="sprcy:ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock" id="ixv-22241"><span style="font-family: Times New Roman, Times, Serif">The
table below summarizes the fair value of the intangible asset:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="sprcy_ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance at January
    1, 2022</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-221; font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Purchase
    date September 30, 2022</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PurchaseOfAssets" scale="3" unitRef="usd" id="ixv-37817">4,861</ix:nonFraction></span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Depreciation
    of intangible asset</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" unitRef="usd" id="ixv-37818">144</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance at December
    31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="3" unitRef="usd" id="ixv-37819">4,717</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Depreciation
    of intangible asset</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" unitRef="usd" id="ixv-37820">243</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    at June 30, 2023</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="3" unitRef="usd" id="ixv-37821">4,474</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During
the year ended December 31, 2022, the Company recognized depreciation expenses in respect to intangible asset in the amount of $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-37822">144</ix:nonFraction>.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
estimated fair values of the tangible and intangible assets in respect of the Acquisition of&#160;the Wellution&#8482; brand are provisional
and are based on information that was available as of the Acquisition date to estimate the fair value of these amounts. The Group&#8217;s
management believes the information provides a reasonable basis for estimating the fair values of these amounts but is waiting for additional
information necessary to finalize those fair values. Therefore, provisional measurements of fair value that appear are subject to change.
The Group expects to finalize the tangible and intangible assets valuation and complete the Acquisition accounting as soon as practicable
but no later than the measurement period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During
the six months ended June 30, 2023, and 2022, the Company recorded depreciation expenses with respect to intangible asset in the amount
of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-37823">243</ix:nonFraction> and $ <span style="-sec-ix-hidden: hidden-fact-222">nil</span>, respectively.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 173; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>SCISPARC
LTD.</b></span></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (USD in thousands, except per share and per unit amounts)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" id="ixv-22387"><p style="text-align: justify; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5:- INVESTMENT IN FINANCIAL ASSETS</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
June 25, 2023, the Company entered into a Share Purchase Agreement (the &#8220;Agreement&#8221;) with AutoMax Motors Ltd. (&#8220;AutoMax&#8221;),
an Israeli company traded on the Tel Aviv Stock Exchange (&#8220;TASE&#8221;) and the leading parallel importer and distributor of vehicles
in Israel, pursuant to which, at the closing and upon the terms and conditions set forth in the Agreement, the Company will invest NIS
<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="ils" id="ixv-37824">2,500,000</ix:nonFraction> in cash, in exchange for ordinary shares, NIS <ix:nonFraction contextRef="c114" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ParValuePerShare" scale="0" unitRef="ilsPershares" id="ixv-37825">0.05</ix:nonFraction> par value, of AutoMax (the &#8220;AutoMax Shares&#8221;) based on a price
per share of NIS <ix:nonFraction contextRef="c115" decimals="1" format="ixt:num-dot-decimal" name="ifrs-full:ParValuePerShare" scale="0" unitRef="ilsPershares" id="ixv-37826">0.5</ix:nonFraction>. As of June 30, 2023, the listed share price of AutoMax on the TASE was NIS <ix:nonFraction contextRef="c116" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ExerciseOfPricePerShare" scale="0" unitRef="ilsPershares" id="ixv-37827">0.41</ix:nonFraction>, and the Company has recorded a
loss in its statements of comprehensive loss of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-37828">133</ix:nonFraction> on its investment. &#160;</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" id="ixv-22399"><p style="text-align: justify; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6:- TRANSACTIONS AND BALANCES WITH RELATED PARTIES</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Mr. Oz Adler, the Company&#8217;s Chief Executive Officer and Chief Financial Officer, is the chairman of the board of directors of&#160;Jeffs&#8217;&#160;Brands Ltd. (&#8220;Jeffs&#8217; Brands&#8221;) (see Note 11).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On March 7, 2022, the Company entered into the Cooperation Agreement with Clearmind Medicine Inc. (&#8220;Clearmind&#8221;), a company in which Dr. Adi Zuloff-Shani, the Company&#8217;s Chief Technologies Officer, Mr. Weiss, the Company&#8217;s President, and Mr. Adler, the Company&#8217;s Chief Executive Officer and Chief Financial Officer, serve as officers and directors.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During
the year ended December 31, 2022, the Company recognized expenses in respect of the Cooperation Agreement with Clearmind in the amount
of $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CooperationAgreementWithClearmindAmount" scale="3" unitRef="usd" id="ixv-37829">208</ix:nonFraction>, and the balance owed to Clearmind as of December 31, 2022, was $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:BalanceOwedToClearmind" scale="3" unitRef="usd" id="ixv-37830">55</ix:nonFraction>.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
November 17, 2022, the Company invested $<ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestedAmount" scale="3" unitRef="usd" id="ixv-37831">1,500</ix:nonFraction> thousand in Clearmind in connection with its initial public offering on the Nasdaq Capital
Market, in exchange for <ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ExchangeCommonShares" scale="0" unitRef="shares" id="ixv-37832">230,769</ix:nonFraction> common shares of Clearmind, representing <ix:nonFraction contextRef="c117" decimals="4" format="ixt:num-dot-decimal" name="sprcy:ClearmindOutstandingShareCapitalPercentage" scale="-2" unitRef="pure" id="ixv-37833">9.33</ix:nonFraction>% of the outstanding share capital of Clearmind.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Mr. Amitai Weiss, our chairman of the board of directors, is the chairman of the board of directors of&#160;AutoMax (see Note 5).</span></td></tr> </table></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" id="ixv-22445"><p style="text-align: justify; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7:- FINANCIAL INSTRUMENTS</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Calibri, Helvetica, Sans-Serif; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification
of financial assets and financial liabilities:</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfFinancialLiabilitiesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory" id="ixv-22456"><span style="font-family: Times New Roman, Times, Serif">The
financial assets and financial liabilities in the consolidated statements of financial position are classified by groups of financial
instruments pursuant to IFRS 9, &#8220;<i>Financial Instruments</i>&#8221;:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DisclosureOfFinancialLiabilitiesExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Unaudited</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Audited</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Note</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD
    in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Financial assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 52%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-37834">2,081</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-37835">12,945</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-37836">3,574</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Trade receivables</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeReceivables" scale="3" unitRef="usd" id="ixv-37837">43</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-223; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeReceivables" scale="3" unitRef="usd" id="ixv-37838">60</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Government authorities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GovernmentAuthorities" scale="3" unitRef="usd" id="ixv-37839">100</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GovernmentAuthorities" scale="3" unitRef="usd" id="ixv-37840">77</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GovernmentAuthorities" scale="3" unitRef="usd" id="ixv-37841">45</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other
    receivables</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentReceivables" scale="3" unitRef="usd" id="ixv-37842">715</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentReceivables" scale="3" unitRef="usd" id="ixv-37843">622</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentReceivables" scale="3" unitRef="usd" id="ixv-37844">86</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Investments in financial
    assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="3" unitRef="usd" id="ixv-37845">849</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-224; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="3" unitRef="usd" id="ixv-37846">730</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilitiesAtAmortisedCost" scale="3" unitRef="usd" id="ixv-37847">3,778</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilitiesAtAmortisedCost" scale="3" unitRef="usd" id="ixv-37848">13,644</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilitiesAtAmortisedCost" scale="3" unitRef="usd" id="ixv-37849">4,495</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Financial liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Credit from others</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-225; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-226; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CreditFromOthers" scale="3" unitRef="usd" id="ixv-37850">102</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Warrants liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsLiability" scale="3" unitRef="usd" id="ixv-37851">1,714</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsLiability" scale="3" unitRef="usd" id="ixv-37852">10,252</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsLiability" scale="3" unitRef="usd" id="ixv-37853">2,737</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Lease
    liability</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-227; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-37854">45</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-37855">27</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total financial and
    lease liabilities</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd" id="ixv-37856">1,714</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd" id="ixv-37857">10,297</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd" id="ixv-37858">2,866</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 174; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>SCISPARC
LTD.</b></span></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (USD in thousands, except per share and per unit amounts)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="sprcy:WarrantTextBlock" id="ixv-23051"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
8:- WARRANTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
June 1, 2022, the Company completed a private offering with an investor for gross proceeds of $<ix:nonFraction contextRef="c118" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GrossProceed" scale="3" unitRef="usd" id="ixv-37859">10,210</ix:nonFraction> (the &#8220;June 2022 Private Placement&#8221;),
providing for the issuance of an aggregate of <ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="sprcy:IssuanceOfAggregateShares" scale="0" unitRef="shares" id="ixv-37860">136,388</ix:nonFraction> units and pre-funded units, as follows: <ix:nonNumeric contextRef="c118" name="sprcy:WarrantsDescription" id="ixv-37861">(a) 12,884 units at a price of $74.88 per
unit, each consisting of (i) one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#8220;June
2022 Warrants&#8221;), and (b) 123,504 pre-funded units at a price of $73.294 per unit, each consisting of (i) one pre-funded warrant
to purchase one ordinary share and (ii) two June 2022 Warrants.</ix:nonNumeric></span></p>

<p style="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
June 2022 Warrants have an exercise price of $<ix:nonFraction contextRef="c120" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ExerciseOfPricePerShare" scale="0" unitRef="usdPershares" id="ixv-37862">68.38</ix:nonFraction> per ordinary share. The June 2022 Warrants were exercisable upon issuance and will
expire <ix:nonNumeric contextRef="c7" format="ixt-sec:durwordsen" name="sprcy:WarrantExpiryPeriod" id="ixv-37863">seven years</ix:nonNumeric> from the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>General
Overview of Valuation Approaches used in the Valuation:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Fair
value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants
at the measurement date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Economic
methodology:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" id="ixv-23082"><span style="font-family: Times New Roman, Times, Serif">The
June 2022 Warrants&#8217; fair value was calculated using the Black&#8211;Scholes option pricing model, which takes into account the
parameters as disclosed below for each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting
date with the following assumptions:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,<br/>
    2022</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30,<br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend
    yield (%)</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c121" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-37864">0</ix:nonFraction></span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c122" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-37865">0</ix:nonFraction></span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected
    volatility (%)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c121" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-37866">72</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c122" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-37867">72</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free
    interest rate (%)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c121" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-37868">3.97</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c122" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-37869">3.97</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Underlying share
    price ($)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c121" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-37870">19.656</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c122" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-37871">14.274</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercise price ($)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c121" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-37872">68.38</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c122" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-37873">68.38</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Warrants fair value
    ($)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c121" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LossesOnChangeInFairValueOfDerivatives" scale="3" unitRef="usd" id="ixv-37874">2,396</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c122" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LossesOnChangeInFairValueOfDerivatives" scale="3" unitRef="usd" id="ixv-37875">1,373</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
June 2022 Warrants are classified as current warrant liability in the Company&#8217;s balance sheet, as they are exercisable at any given
time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During
the six months ended June 30, 2023, and 2022, the Company recorded finance income from the change in fair value of the June 2022 Warrants
in the amount of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WarrantReserve" scale="3" unitRef="usd" id="ixv-37876">1,023</ix:nonFraction> and $<span style="-sec-ix-hidden: hidden-fact-228">nil</span>, respectively.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 175; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>SCISPARC
LTD.</b></span></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (USD in thousands, except per share and per unit amounts)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="ixv-23256"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
9:- EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Reverse
Share Splits</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
August 18, 2023, the Company convened a general meeting of its shareholders, whereby the shareholders approved, inter alia, a reverse
split of the Company&#8217;s share capital up to a ratio of 30:1. Following the implementation of the Reverse Split, the Company&#8217;s
authorized share capital will not be adjusted under the Company&#8217;s Articles, which as of the date hereof consists of <ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="sprcy:StockIssuedDuringPeriodReverseStockSplits" scale="0" unitRef="shares" id="ixv-37877">75,000,000</ix:nonFraction>
Ordinary Shares, <span style="-sec-ix-hidden: hidden-fact-229">no</span> par value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
September 14, 2023, the Company&#8217;s Board resolved that the final ratio for the Reverse Split will be 26:1, which became effective
on September 28, 2023.&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="ixv-23284"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition of share capital as of June 30, 2023, June 30, 2022, and December 31, 2022:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2023</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2022</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2022</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Authorized</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Issued
    and<br/> outstanding</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Authorized</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Issued
    and<br/> outstanding</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Authorized</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Issued
    and<br/> outstanding</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of shares</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 28%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Ordinary
    Shares of no par value each</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c137" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" unitRef="shares" id="ixv-37878">75,000,000</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c137" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-37879">282,782</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c138" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" unitRef="shares" id="ixv-37880">75,000,000</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c138" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-37881">261,494</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c139" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" unitRef="shares" id="ixv-37882">25,714,286</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c139" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-37883">135,644</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in share capital:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="sprcy_DisclosureOfIssuedAndOutstandingShareCapital-c0_cont_1" escape="true" name="sprcy:DisclosureOfIssuedAndOutstandingShareCapital" id="ixv-23426"><span style="font-family: Times New Roman, Times, Serif"><i>Issued
and outstanding share capital:</i></span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="sprcy_DisclosureOfIssuedAndOutstandingShareCapital-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/> ordinary<br/> shares</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance
    at January 1, 2023</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="sprcy:NumberOfSharesIssued1" scale="0" unitRef="shares" id="ixv-37884">261,494</ix:nonFraction></span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of share capital &#8211; in respect of investment in affiliate (Note 6e)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="sprcy:IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" scale="0" unitRef="shares" id="ixv-37885">13,858</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares
    issued to consultants (Note 6e)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="sprcy:SharesIssuedToConsultants" scale="0" unitRef="shares" id="ixv-37886">7,134</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of share capital &#8211; in respect of shelf prospectus (Note 6e)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="sprcy:IssuanceOfShareCapitalInRespectOfShelfProspectus" scale="0" unitRef="shares" id="ixv-37887">296</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    at June 30, 2023</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="sprcy:NumberOfSharesIssued1" scale="0" unitRef="shares" id="ixv-37888">282,782</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 176; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>SCISPARC
LTD.</b></span></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (USD in thousands, except per share and per unit amounts)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
9:- EQUITY (cont.)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_2" id="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights attached to shares:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Voting
rights at shareholders meetings, right to dividends, rights upon liquidation of the Company and right to nominate the directors in the
Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital management in the
    Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s capital management objectives are to preserve the Company&#8217;s ability to ensure business continuity thereby creating
a return for the shareholders, investors and other interested parties. The Company is not under any minimal equity requirements nor is
it required to attain a certain level of capital return.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional issuance of
    ordinary shares:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
August 2, 2022, the Company issued a consultant <ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-37889">923</ix:nonFraction> ordinary shares in respect of services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
November 1, 2022, the Company issued a consultant <ix:nonFraction contextRef="c125" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-37890">1,423</ix:nonFraction> ordinary shares in respect of services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
March 22, 2023, the Company issued <ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-37891">13,858</ix:nonFraction> ordinary shares in respect of the stock purchase<span style="text-transform: uppercase"><b>&#160;</b></span>agreement
entered into by and among Jeffs&#8217; Brands and Jeffs&#8217; Brands Holdings Inc. (&#8220;NewCo&#8221;) (see also note 8a)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
May 31, 2023, the Company issued <ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-37892">7,134</ix:nonFraction> ordinary shares to consultants in respect of services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2021 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
March 4, 2021, <ix:nonNumeric contextRef="c128" name="sprcy:DescriptionOfPrivateOffering" id="ixv-37893">the Company completed a private offering with several accredited and institutional investors for gross proceeds of $8,150,
providing for the issuance of an aggregate of 44,331 units, as follows: (a) 35,242 units at a price of $183,82 per unit, consisting of
(i) one ordinary share of the Company, and (ii) a Series A Warrant to purchase an equal number of units purchased (the &#8220;2021 Series
A Warrants&#8221;) and a Series B Warrant (the &#8220;2021 Series B Warrants&#8221; and, collectively with the 2021 Series A Warrants,
the March 2021 Warrants) to purchase half the number of units, and (b) 9,089 pre-funded units at a price of $183.794 per unit, consisting
of (i) one pre-funded warrant to purchase one ordinary share and (ii) one 2021 Series A Warrant and one 2021 Series B Warrant.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Series A Warrants have an exercise price of&#160;$<ix:nonFraction contextRef="c129" decimals="-1" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="3" unitRef="usdPershares" id="ixv-37894">183.82</ix:nonFraction>&#160;per ordinary share and the Series B Warrants have an exercise price of&#160;$<ix:nonFraction contextRef="c130" decimals="-1" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="3" unitRef="usdPershares" id="ixv-37895">275.60</ix:nonFraction>&#160;per
ordinary share). Both were exercisable upon issuance and will expire <ix:nonNumeric contextRef="c2" format="ixt-sec:durwordsen" name="sprcy:DateOfIssuance" id="ixv-37896">five years</ix:nonNumeric> from the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
March 2021 Warrants are classified as issued warrants in the Company&#8217;s equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During
the year ended December 31, 2021, the Company issued <ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-37897">4,929</ix:nonFraction> ordinary shares in respect of the exercise of <ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="sprcy:WarrantsAndExercise" scale="0" unitRef="shares" id="ixv-37898">385</ix:nonFraction> 2021 Series A Warrants and
the exercise of <ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ExerciseOfPrefundedWarrants" scale="0" unitRef="shares" id="ixv-37899">4,544</ix:nonFraction> of pre-funded warrants.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 177; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>SCISPARC
LTD.</b></span></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (USD in thousands, except per share and per unit amounts)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
9:- EQUITY (cont.)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During
the year ended December 31, 2022, the Company issued <ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="sprcy:IssuanceOfShares" scale="0" unitRef="shares" id="ixv-37900">3,846</ix:nonFraction> ordinary shares in respect of the exercise of <ix:nonFraction contextRef="c133" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ExerciseOfPrefundedWarrants" scale="0" unitRef="shares" id="ixv-37901">3,846</ix:nonFraction> pre-funded warrants. During
the six months ended June 30, 2023, there were no exercises of 2021 Series A Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 2022 Financing Round
    (see also note 8)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
June 1, 2022, <ix:nonNumeric contextRef="c134" name="sprcy:DescriptionOfPrivateOffering" id="ixv-37902">the Company completed the June 2022 Private Placement with an investor for gross proceeds of $10,210, providing for the
issuance of an aggregate of 136,388 units and pre-funded units, as follows: (a) 12,884 units at a price of $74.88 per unit, each consisting
of (i) one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#8220;June 2022 Warrants&#8221;),
and (b) 123,504 pre-funded units at a price of $73.294 per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary
share and (ii) two June 2022 Warrants.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
June 2022 Warrants have an exercise price of&#160;$<ix:nonFraction contextRef="c135" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-37903">68.38</ix:nonFraction>&#160;per ordinary share. The June 2022 Warrants were exercisable upon issuance
and will expire <ix:nonNumeric contextRef="c136" format="ixt-sec:durwordsen" name="sprcy:DateOfIssuance" id="ixv-37904">seven years</ix:nonNumeric> from the date of issuance.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
June 2022 Warrants are classified as current warrant liability in the Company&#8217;s balance sheet, as they are exercisable at any given
time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During
the year ended December 31, 2022, the Company issued <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" scale="0" unitRef="shares" id="ixv-37905">123,504</ix:nonFraction> ordinary shares in respect of the exercise of <ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="sprcy:WarrantsAndExercise" scale="0" unitRef="shares" id="ixv-37906">123,504</ix:nonFraction> pre-funded warrants.
During the six months ended June 30, 2023, there were no exercises of June 2022 Warrants.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 178; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>SCISPARC
LTD.</b></span></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (USD in thousands, except per share and per unit amounts)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfAdditionalInformationExplanatory" id="ixv-23752"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
10:- ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosureOfInformationToTheItemsOfProfitOrLoss" id="ixv-23759"><table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    months ended<br/> June 30,</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended<br/> December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Unaudited</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Audited</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD
    in thousands</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; font-style: italic; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">a.
    Research and development expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Wages
    and related expenses</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c140" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-37907">202</ix:nonFraction></span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c141" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-37908">243</ix:nonFraction></span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c142" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-37909">436</ix:nonFraction></span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Share-based
    payment</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c143" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-37910">23</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c144" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-37911">224</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c145" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-37912">264</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Clinical
    studies</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c146" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-37913">145</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c147" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-37914">106</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c148" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-37915">369</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Regulatory,
    professional and other expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c149" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-37916">366</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c150" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-37917">373</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c151" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-37918">750</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Research
    and preclinical studies</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c152" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-37919">45</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c153" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-37920">410</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c154" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-37921">703</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Chemistry
    and formulations</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-230; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c156" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-37922">118</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c157" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-37923">281</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-37924">781</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-37925">1,474</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-37926">2,803</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; font-style: italic; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">b.
    General and administrative expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Wages
    and related expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c140" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37927">217</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c141" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37928">245</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c142" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37929">437</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Share-based
    payment</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c143" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37930">45</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c144" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37931">431</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c145" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37932">633</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Professional
    and directors&#8217; fees</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c158" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37933">1,366</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c159" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37934">1,292</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c160" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37935">2,499</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Business
    development expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c161" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37936">38</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c162" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37937">2</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c163" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37938">161</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Office
    maintenance, rent and other expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c164" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37939">48</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c165" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37940">63</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c166" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37941">224</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Investor
    relations and business expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c167" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37942">310</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c168" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37943">1,193</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c169" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37944">1,486</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Wellution
    operating expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c170" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37945">366</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-231; font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c172" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37946">907</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Regulatory
    expenses</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c173" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37947">104</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c174" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37948">113</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c175" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37949">162</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37950">2,494</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37951">3,339</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37952">6,509</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>

</div><!-- Field: Page; Sequence: 179; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>SCISPARC
LTD.</b></span></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (USD in thousands, except per share and per unit amounts)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" id="ixv-24462"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
11:- SIGNIFICANT EVENTS DURING THE REPORTING PERIOD </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 48px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">a.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On February 23, 2023, the Company entered into an agreement with Jeffs&#8217; Brands and NewCo, a newly-formed wholly owned subsidiary of Jeffs&#8217; Brands, pursuant to which, at the closing and upon the terms and conditions set forth in the Agreement, NewCo Inc. acquired from the Company a number of shares of stock equal to approximately a <ix:nonFraction contextRef="c176" decimals="2" format="ixt:num-dot-decimal" name="sprcy:InterestPercentgae" scale="-2" unitRef="pure" id="ixv-37953">49</ix:nonFraction>% interest in the Company&#8217;s wholly owned subsidiary, SciSparc US which owns Wellution<sup>TM</sup>&#160;, for $<ix:nonFraction contextRef="c177" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="3" unitRef="usd" id="ixv-37954">2,500</ix:nonFraction> in cash, and additional deferred cash payments of approximately $<ix:nonFraction contextRef="c176" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:DeferredCashPayments" scale="3" unitRef="usd" id="ixv-37955">489,330</ix:nonFraction> accounting for price adjustments related to inventory and working capital, which is to be paid in five equal monthly installments beginning in May 2023 (the &#8220;Price Adjustment&#8221;). As collateral for the payment in full of the Price Adjustment, SciSparc held back such number of shares of common stock of SciSparc US, equal to the outstanding due amount of the Price Adjustment (the &#8220;Holdback Shares&#8221;). Following the closing of the transaction on March 22, 2023, which included an equity conversion of financing amounts previously provided to SciSparc US. by the Company for working capital, and the release of the Holdback Shares upon the payment in full of the Price Adjustment the Company will hold approximately <ix:nonFraction contextRef="c178" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareCapitalPercentage" scale="-2" unitRef="pure" id="ixv-37956">51</ix:nonFraction>% of the share capital of SciSparc US.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Pursuant to the agreement, at the closing of the transaction, Jeffs&#8217; Brands and SciSparc US. entered into a consulting agreement, pursuant to which Jeffs&#8217; Brands will provide management services to SciSparc US for the WellutionTM brand for a monthly fee of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:FeeExpenses" scale="3" unitRef="usd" id="ixv-37957">20</ix:nonFraction> and Jeffs&#8217; Brands will receive a one-time signing bonus in the amount of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:BonusAmountReceived" scale="3" unitRef="usd" id="ixv-37958">51</ix:nonFraction>. The consulting agreement is for an undefined period of time and may be terminated by either party with 30 days advance notice.&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In addition, in connection with the closing of the transaction, the Company and Jeffs&#8217; Brands, engaged in a mutual share exchange in the amount of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:MutualShareExchangeAmount" scale="3" unitRef="usd" id="ixv-37959">288,238</ix:nonFraction> of ordinary shares from each of the Company and Jeffs&#8217; Brands. The number of shares in the share exchange was calculated based on the average closing price of the relevant company&#8217;s shares for 30 consecutive trading days ending on the third trading day immediately prior to the closing. Accordingly, the Company acquired <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="sprcy:OrdinarySharesAcquired" scale="0" unitRef="shares" id="ixv-37960">247,415</ix:nonFraction> ordinary shares of Jeffs&#8217; Brands and Jeffs&#8217; Brands acquired <ix:nonFraction contextRef="c179" decimals="0" format="ixt:num-dot-decimal" name="sprcy:OrdinarySharesAcquired" scale="0" unitRef="shares" id="ixv-37961">13,858</ix:nonFraction> ordinary shares of the Company having an aggregate value of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AggregateValue" scale="3" unitRef="usd" id="ixv-37962">288,238</ix:nonFraction>, which was adjusted from $<ix:nonFraction contextRef="c179" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdjustedAmountOfAggregateValue" scale="3" unitRef="usd" id="ixv-37963">300,000</ix:nonFraction> according to the <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="sprcy:OwnershipPercentage" scale="-2" unitRef="pure" id="ixv-37964">4.99</ix:nonFraction>% ownership limit included in the definitive agreements.</span></p></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">b.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On May 2, 2023, Capital Point Ltd. (&#8220;Capital Point&#8221;) filed with the Tel Aviv-Jaffa District Court (the &#8220;Court&#8221;) a suit against the Company, case number 2050-05-23 (the &#8220;Suit&#8221;). The Suit names the Company as the sole defendant and includes allegations of breaches of contract by the Company under the Israeli Contracts Law, 1973, unjust enrichment under the Israeli Unjust Enrichment Law, 1979 and breaches of the Company under the Israeli Torts Ordinance, 1968.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Suit challenges a certain warrant issued by the Company to Capital Point (the &#8220;Capital Point Warrant&#8221;) to purchase $<ix:nonFraction contextRef="c180" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsToPurchase" scale="3" unitRef="usd" id="ixv-37965">340,000</ix:nonFraction> of ordinary shares of the Company (the &#8220;Warrant Shares&#8221;). The Capital Point Warrant was exercisable for 12 months from May 15, 2021, to May 15, 2022 and was issued in connection with the joint venture transaction, entered on May 15, 2020, by and between the Company, Capital Point and Evero Health Ltd., a majority owned subsidiary of the Company, as further described in the Company&#8217;s Report on Form 6-K, filed on May 19, 2020. The Suit claims that the Company unlawfully refused to accept the Capital Point Warrant exercise notice as of November 4, 2021 and accordingly the Company did not issue to Capital Point the Warrant Shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Suit claims damages in the amount of NIS <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ClaimsOnDamages" scale="0" unitRef="ils" id="ixv-37966">10,000,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c0" decimals="-4" format="ixt:num-dot-decimal" name="sprcy:ClaimsOnDamages" scale="6" unitRef="usd" id="ixv-37967">2.75</ix:nonFraction> million), which accounts for, as of the date of the filing of the Suit, the agreed compensation according to Section 2(d)(i) of the Capital Point Warrant, an injunction order for the Company to issue the Warrant Shares to Capital Point, return of any unlawful profits received by the Company and punitive damages.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">As of the Approval Date, the Company cannot predict the likelihood of success of the Suit.</span></p></td></tr> </table></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>

</div><!-- Field: Page; Sequence: 180; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>SCISPARC
LTD.</b></span></p><div>

</div><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (USD in thousands, except per share and per unit amounts)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="ixv-24548"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
12:- EVENTS AFTER THE REPORTING PERIOD </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 48px"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">a.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On August 1, 2023, the Company issued a consultant 807 ordinary shares in respect of services rendered.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">b.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; background-color: white">On August 14, 2023, <ix:nonNumeric contextRef="c181" name="sprcy:DescriptionOfPublicOffering" id="ixv-37968">the Company closed an underwritten public offering (the &#8220;Public Offering&#8221;) of 212,500 ordinary shares, at a purchase price of $5.20 per ordinary share and pre-funded warrants to purchase up to 37,500 ordinary shares at a purchase price of $5.174 per pre-funded warrant, for aggregate gross proceeds of approximately $1.3 million, pursuant to an underwriting agreement between the Company and Aegis Capital Corp (&#8220;Aegis&#8221;), the underwriter in the Public Offering, dated August 10, 2023. Pursuant to the terms of the underwriting agreement, the Company also granted the underwriter a 45-day option to purchase up to an additional 37,500 ordinary shares solely to cover over-allotments, if any, at the share price of the Public Offering less underwriting discounts and commissions.</ix:nonNumeric></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; background-color: white">The pre-funded warrants were exercisable immediately upon issuance and have an exercise price of $<ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-37969">0.026</ix:nonFraction> per share. Following the offering and </span><span style="font-family: Times New Roman, Times, Serif">as of the Approval Date, the Company issued <ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-37970">25,000</ix:nonFraction> ordinary shares in respect of the exercise of <ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ExerciseOfPrefundedWarrants" scale="0" unitRef="shares" id="ixv-37971">25,000</ix:nonFraction> pre-funded warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On August 18, 2023, the Company convened a general meeting of its shareholders, whereby the shareholders approved, inter alia, a reverse split of the Company&#8217;s share capital up to a ratio of 30:1. Following the implementation of the Reverse Split, the Company&#8217;s authorized share capital will not be adjusted under the Company&#8217;s Articles, which as of the date hereof consists of <ix:nonFraction contextRef="c184" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-37972">75,000,000</ix:nonFraction> Ordinary Shares, <span style="-sec-ix-hidden: hidden-fact-232">no</span> par value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On September 14, 2023, the Company&#8217;s Board resolved that the final ratio for the Reverse Split will be 26:1, which became effective on September 28, 2023.&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
</td></tr>
<tr style="vertical-align: top"> <td style="font-size: 10pt; width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: justify; font-size: 10pt; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On October 11, 2023, the Company entered into a private placement transaction (the &#8220;Private Placement&#8221;), pursuant to a Securities Purchase Agreement (the &#8220;Agreement&#8221;) and a Registration Rights Agreement (the &#8220;Registration Rights Agreement&#8221;) with an institutional investor (the &#8220;Purchaser&#8221;) for aggregate gross proceeds of approximately $<ix:nonFraction contextRef="c186" decimals="-6" format="ixt:num-dot-decimal" name="sprcy:AggregateGrossProceeds" scale="6" unitRef="usd" id="ixv-37973">5</ix:nonFraction> million (representing a <ix:nonFraction contextRef="c186" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfAggregatePurchasePrice" scale="-2" unitRef="pure" id="ixv-37974">30</ix:nonFraction>% original issue discount to the aggregate purchase price of approximately $<ix:nonFraction contextRef="c186" decimals="-4" format="ixt:num-dot-decimal" name="sprcy:AggregatePurchasePrice" scale="6" unitRef="usd" id="ixv-37975">7.18</ix:nonFraction> million), before deducting fees to the placement agent and other expenses payable by the Company in connection with the Private Placement. The Company intends to use the net proceeds from the Private Placement for general corporate purposes, including working capital. Aegis, acted as the exclusive placement agent for the Private Placement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
part of the Private Placement, the Company issued units (the &#8220;Units&#8221;), at a purchase price of $<ix:nonFraction contextRef="c186" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-37976">3.72</ix:nonFraction> per Unit, consisting
of <ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="sprcy:PrefundedOrdinaryShare" scale="0" unitRef="shares" id="ixv-37977">1,930,108</ix:nonFraction> pre-funded ordinary share purchase warrants (the &#8220;Pre-Funded Warrant&#8221;) to purchase up to <ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="sprcy:OrdinarySharesAcquired" scale="0" unitRef="shares" id="ixv-37978">1,930,108</ix:nonFraction> ordinary
shares of the Company, no par value per share (the &#8220;Ordinary Shares&#8221;), and an additional accompanying Pre-Funded Warrant
to purchase up to <ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="sprcy:PurchaseOrdinaryShares" scale="0" unitRef="shares" id="ixv-37979">1,930,108</ix:nonFraction> Ordinary Shares. The Pre-Funded Warrants are immediately exercisable upon issuance and have a term of <ix:nonNumeric contextRef="c186" format="ixt-sec:durwordsen" name="sprcy:TermOfIssuance" id="ixv-37980">five
years</ix:nonNumeric> from issuance at an exercise price of $<ix:nonFraction contextRef="c186" decimals="3" format="ixt:num-dot-decimal" name="sprcy:ExercisePricePerShare" scale="0" unitRef="usdPershares" id="ixv-37981">0.001</ix:nonFraction> per Ordinary Share.</span></p></td></tr> </table></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>

</div><!-- Field: Page; Sequence: 181; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AS OF DECEMBER 31, 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>U.S. DOLLARS IN THOUSANDS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEX</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="vertical-align: top; width: 92%; padding-bottom: 1.5pt; text-align: justify">&#160;</td> <td style="vertical-align: top; width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: bottom; width: 7%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Page</b></span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: justify"><a href="#F_006"><span style="font-size: 10pt"><b>Report of Independent Registered Public Accounting Firm (PCAOB ID&#160;1281)</b></span></a></td> <td>&#160;</td> <td style="text-align: center"><span style="font-size: 10pt"><b>F-24 - F-25</b></span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td>&#160;</td> <td style="text-align: center"/></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: justify"><a href="#F_007"><span style="font-size: 10pt"><b>Consolidated Statements of Financial Position</b></span></a></td> <td>&#160;</td> <td style="text-align: center"><span style="font-size: 10pt"><b>F-26 - F-27</b></span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify"><a href="#F_008"><span style="font-size: 10pt"><b>Consolidated Statements of Comprehensive Loss</b></span></a></td> <td>&#160;</td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>F-28</b></span></td></tr> <tr> <td style="vertical-align: top; text-align: justify">&#160;</td> <td>&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify"><a href="#F_009"><span style="font-size: 10pt"><b>Consolidated Statements of Changes in Equity</b></span></a></td> <td>&#160;</td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>F-29</b></span></td></tr> <tr> <td style="vertical-align: top; text-align: justify">&#160;</td> <td>&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify"><a href="#F_010"><span style="font-size: 10pt"><b>Consolidated Statements of Cash Flows</b></span></a></td> <td>&#160;</td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>F-30- F-32</b></span></td></tr> <tr> <td style="vertical-align: top; text-align: justify">&#160;</td> <td>&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify"><a href="#F_011"><span style="font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></span></a></td> <td>&#160;</td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>F-33 - F-71</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 182; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="vertical-align: top; width: 34%"><img alt="" src="image_002.jpg"/></td> <td style="vertical-align: bottom; width: 33%"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b>Kost Forer Gabbay &amp; Kasierer</b></span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">144 Menachem
Begin Road,</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Tel-Aviv 6492102, Israel</span></p></td> <td style="vertical-align: bottom; width: 33%"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Tel: +972-3-6232525</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Fax: +972-3-5622555</span></p> <p style="text-align: left; margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">ey.com</span></p></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="F_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REPORT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>To the Shareholders and
the Board of Directors of</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SCISPARC LTD. (formerly
known as THERAPIX BIOSCIENCES LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Opinion on the Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have audited the accompanying
consolidated statements of financial position of SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) and its subsidiaries (the
&#8220;Company&#8221;) as of December 31, 2022, and 2021, and the related consolidated statements of comprehensive loss, changes in equity
and cash flows for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the
&#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material
respects, the consolidated financial position of the Company at December 31, 2022, and 2021, and the consolidated results of its operations
and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with International Financial Reporting
Standards (&#8220;IFRS&#8221;) as issued by the International Accounting Standards Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The Company&#8217;s Ability to Continue as
a Going Concern</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying consolidated
financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial
statements, the Company has suffered recurring losses from operations, negative cash flows from operating activities and has stated that
substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management&#8217;s evaluation of the events
and conditions and management&#8217;s plans regarding these matters are also described in Note 1. The consolidated financial statements
do not include any adjustments that might result from the outcome of this uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis for Opinion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These financial statements
are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We conducted our audits in
accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to
have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required
to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness
of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audits included performing
procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management,
as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for
our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 183; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical Audit Matters</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The critical audit matter communicated below is
a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the
audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially
challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on
the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a
separate opinion on the critical audit matter or on the account or disclosure to which it relates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-indent: -118.05pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 30%"><span style="font-size: 10pt; background-color: White"><i>Description of the Matter</i></span></td> <td style="width: 2%"><span style="background-color: White">&#160;</span></td> <td style="width: 68%; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As discussed in Note 1 to the consolidated financial
statements, the Company has incurred losses since inception, and expects to continue to incur losses for the foreseeable future. At December
31, 2022, the Company&#8217;s cash and cash equivalents position is not sufficient to fund the Company&#8217;s planned operations for
at least a year beyond the date of the issuance of the consolidated financial statements. Those factors raise substantial doubt about
the Company&#8217;s ability to continue as a going concern.</p></td></tr> <tr style="vertical-align: top"> <td><span style="background-color: White">&#160;</span></td> <td><span style="background-color: White">&#160;</span></td> <td style="text-align: justify"><span style="background-color: White">&#160;</span></td></tr> <tr style="vertical-align: top"> <td><span style="background-color: White">&#160;</span></td> <td><span style="background-color: White">&#160;</span></td> <td style="text-align: justify"><span style="font-size: 10pt; background-color: White">We determined the Company&#8217;s ability to continue as a going concern
is a critical audit matter due to the estimation and execution uncertainty regarding the Company&#8217;s future cash flows and the risk
of bias in management&#8217;s judgments and assumptions in estimating these cash flows to conclude the Company would have sufficient liquidity
to sustain itself for at least a year beyond the date of the issuance of the consolidated financial statements. This in turn led to a
high degree of auditor subjectivity and judgment to evaluate the audit evidence supporting the liquidity conclusions.</span></td></tr> <tr style="vertical-align: top"> <td><span style="background-color: White">&#160;</span></td> <td><span style="background-color: White">&#160;</span></td> <td style="text-align: justify"><span style="background-color: White">&#160;</span></td></tr> <tr style="vertical-align: top"> <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt; background-color: White"><i>How We Addressed the Matter in Our Audit</i></span></td> <td><span style="background-color: White">&#160;</span></td> <td style="text-align: justify"><span style="font-size: 10pt; background-color: White">Addressing the matter involved performing procedures and evaluating
audit evidence in connection with our overall opinion on the consolidated financial statements.&#160;Our audit procedures included, among
others, testing the reasonableness of the forecasted revenue, operating expenses, and uses and sources of cash used in management&#8217;s
assessment of whether the Company has sufficient liquidity to fund operations for at least one year from the consolidated financial statement
issuance date. This testing included inquiries with management, consideration of positive and negative evidence impacting management&#8217;s
forecasts, the Company&#8217;s financing arrangements in place as of the report date, market and industry factors, we evaluated management&#8217;s
analysis of their impact on the forecasted cash flows.</span>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We assessed the adequacy of the Company&#8217;s
going concern disclosures included in Note 1 to the consolidated financial statements.</p>
</td></tr> </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="border-bottom: Black 1.5pt solid; width: 40%"><span style="font-size: 10pt">/s/ KOST FORER GABBAY &amp; KASIERER</span></td> <td style="width: 20%"><span style="background-color: White">&#160;</span></td> <td style="width: 40%"><span style="font-size: 10pt; background-color: White">Tel Aviv, Israel</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt">KOST FORER GABBAY &amp; KASIERER</span></td> <td><span style="background-color: White">&#160;</span></td> <td><span style="font-size: 10pt; background-color: White"><span style="background-color: white">May 1</span>, 2023</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-indent: -118.05pt">A Member of Ernst &amp; Young Global</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&#8217;s auditor since 2009.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 184; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="F_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December&#160;31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Note</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">USD in thousands</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>CURRENT ASSETS:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 64%">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">4</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-37982">3,574</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-37983">6,875</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Restricted deposit</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" unitRef="usd" id="ixv-37984">60</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" unitRef="usd" id="ixv-37985">45</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Trade receivables</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentTradeReceivables" scale="3" unitRef="usd" id="ixv-37986">77</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Other accounts receivable</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentReceivables" scale="3" unitRef="usd" id="ixv-37987">131</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentReceivables" scale="3" unitRef="usd" id="ixv-37988">2,904</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Inventory</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="3" unitRef="usd" id="ixv-37989">668</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd" id="ixv-37990">4,510</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd" id="ixv-37991">9,824</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">NON-CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Intangible asset, net</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-37992">4,717</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Investments in company accounted for at equity</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentsInAssociates" scale="3" unitRef="usd" id="ixv-37993">591</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Investments in financial assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8, 24e</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentFinancialAssets" scale="3" unitRef="usd" id="ixv-37994">730</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Property and equipment, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">10</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-37995">57</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-37996">92</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd" id="ixv-37997">6,095</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd" id="ixv-37998">92</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="3" unitRef="usd" id="ixv-37999">10,605</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="3" unitRef="usd" id="ixv-38000">9,916</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 185; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Note</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>LIABILITIES AND EQUITY</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Trade payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">12</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-38001">1,199</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-38002">1,199</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other accounts payable</td><td>&#160;</td>
    <td style="text-align: center">13</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" unitRef="usd" id="ixv-38003">193</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" unitRef="usd" id="ixv-38004">154</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: center">18h</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentWarrantLiability" scale="3" unitRef="usd" id="ixv-38005">2,737</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentWarrantLiability" scale="3" unitRef="usd" id="ixv-38006">359</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">9</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-38007">27</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-38008">45</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-38009">4,156</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-38010">1,757</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">NON-CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-38011">18</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:</td><td>&#160;</td>
    <td style="text-align: center">18</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Share capital and premium</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SharePremium" scale="3" unitRef="usd" id="ixv-38012">58,592</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SharePremium" scale="3" unitRef="usd" id="ixv-38013">58,541</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Reserve from share-based payment transactions</td><td>&#160;</td>
    <td style="text-align: center">19</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="3" unitRef="usd" id="ixv-38014">5,180</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="3" unitRef="usd" id="ixv-38015">4,331</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: center">18</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WarrantLiability" scale="3" unitRef="usd" id="ixv-38016">5,190</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WarrantLiability" scale="3" unitRef="usd" id="ixv-38017">5,190</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign currency translation reserve</td><td>&#160;</td>
    <td style="text-align: center">2d</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" scale="3" unitRef="usd" id="ixv-38018">497</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" scale="3" unitRef="usd" id="ixv-38019">497</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Transactions with non-controlling interests</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherEquityInterest" scale="3" unitRef="usd" id="ixv-38020">559</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherEquityInterest" scale="3" unitRef="usd" id="ixv-38021">559</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="3" sign="-" unitRef="usd" id="ixv-38022">63,569</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="3" sign="-" unitRef="usd" id="ixv-38023">60,977</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38024">6,449</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38025">8,141</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total liabilities and equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAndLiabilities" scale="3" unitRef="usd" id="ixv-38026">10,605</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAndLiabilities" scale="3" unitRef="usd" id="ixv-38027">9,916</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 186; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="F_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands (except per share data)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 53%">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">20</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="3" unitRef="usd" id="ixv-38028">1,347</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Cost of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">20</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-38029">322</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="3" unitRef="usd" id="ixv-38030">1,025</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: center">21a</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-38031">2,803</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-38032">1,990</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-38033">649</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">21b</td><td style="padding-bottom: 1.5pt; text-align: left"/><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38034">6,509</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38035">3,778</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38036">1,902</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-38037">8,287</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-38038">5,768</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-38039">3,293</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Company&#8217;s share of losses of company accounted for at equity, net</td><td>&#160;</td>
    <td style="text-align: center">21c</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="3" sign="-" unitRef="usd" id="ixv-38040">109</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="3" sign="-" unitRef="usd" id="ixv-38041">742</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Finance income</td><td>&#160;</td>
    <td style="text-align: center">21d</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-38042">7,832</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-38043">630</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Finance expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">21e</td><td style="padding-bottom: 1.5pt; text-align: left"/><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-38044">2,014</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-38045">21</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-38046">872</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Loss before income taxes</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-38047">2,578</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-38048">5,789</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-38049">3,535</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Taxes on income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" unitRef="usd" id="ixv-38050">14</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total comprehensive loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-38051">2,592</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-38052">5,789</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-38053">3,535</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Attributable to:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Equity holders of the Company</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" scale="3" unitRef="usd" id="ixv-38054">2,592</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" scale="3" unitRef="usd" id="ixv-38055">5,789</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" scale="3" unitRef="usd" id="ixv-38056">3,482</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Non-controlling interests</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ComprehensiveIncomeAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-38057">53</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-38058">2,592</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-38059">5,789</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-38060">3,535</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Basic loss per ordinary share attributable to equity holders of the Company:</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">22</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-38061">0.57</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-38062">2.83</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c12" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-38063">0.10</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Diluted loss per ordinary share attributable to equity holders of the Company:</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">22</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-38064">0.57</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-38065">2.83</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c12" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-38066">0.11</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 187; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="F_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-size: 8pt; vertical-align: bottom">
    <td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="26" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Attributable to equity holders of the Company</td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; text-align: center">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; text-align: center">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font-size: 8pt; vertical-align: bottom">
    <td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Share capital and premium</td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Reserve from share-based payment transactions</td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrants</td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Transactions with non-<br/> controlling interests</td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Foreign currency translation reserve</td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated deficit</td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Non-<br/> controlling interests</td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total equity</td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="font-size: 8pt; vertical-align: bottom">
    <td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="34" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD in thousands</td><td style="font-size: 8pt; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 8pt; width: 32.5%; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2020</td><td style="font-size: 8pt; width: 0.5%; padding-bottom: 4pt">&#160;</td>
    <td style="font-size: 8pt; width: 0.5%; border-bottom: Black 4pt double; text-align: left">$</td><td style="font-size: 8pt; width: 6%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c70" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38067">45,636</ix:nonFraction></td><td style="font-size: 8pt; width: 0.5%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-size: 8pt; width: 0.5%; padding-bottom: 4pt">&#160;</td>
    <td style="font-size: 8pt; width: 0.5%; border-bottom: Black 4pt double; text-align: left">$</td><td style="font-size: 8pt; width: 6%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38068">4,862</ix:nonFraction></td><td style="font-size: 8pt; width: 0.5%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-size: 8pt; width: 0.5%; padding-bottom: 4pt">&#160;</td>
    <td style="font-size: 8pt; width: 0.5%; border-bottom: Black 4pt double; text-align: left">$</td><td style="font-size: 8pt; width: 6%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38069">464</ix:nonFraction></td><td style="font-size: 8pt; width: 0.5%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-size: 8pt; width: 0.5%; padding-bottom: 4pt">&#160;</td>
    <td style="font-size: 8pt; width: 0.5%; border-bottom: Black 4pt double; text-align: left">$</td><td style="font-size: 8pt; width: 6%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38070">261</ix:nonFraction></td><td style="font-size: 8pt; width: 0.5%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-size: 8pt; width: 0.5%; padding-bottom: 4pt">&#160;</td>
    <td style="font-size: 8pt; width: 0.5%; border-bottom: Black 4pt double; text-align: left">$</td><td style="font-size: 8pt; width: 6%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c74" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38071">497</ix:nonFraction></td><td style="font-size: 8pt; width: 0.5%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-size: 8pt; width: 0.5%; padding-bottom: 4pt">&#160;</td>
    <td style="font-size: 8pt; width: 0.5%; border-bottom: Black 4pt double; text-align: left">$</td><td style="font-size: 8pt; width: 6%; border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-38072">51,706</ix:nonFraction></td><td style="font-size: 8pt; width: 0.5%; padding-bottom: 4pt; text-align: left">)</td><td style="font-size: 8pt; width: 0.5%; padding-bottom: 4pt">&#160;</td>
    <td style="font-size: 8pt; width: 0.5%; border-bottom: Black 4pt double; text-align: left">$</td><td style="font-size: 8pt; width: 6%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38073">14</ix:nonFraction></td><td style="font-size: 8pt; width: 0.5%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-size: 8pt; width: 0.5%; padding-bottom: 4pt">&#160;</td>
    <td style="font-size: 8pt; width: 0.5%; border-bottom: Black 4pt double; text-align: left">$</td><td style="font-size: 8pt; width: 6%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="font-size: 8pt; width: 0.5%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-size: 8pt; width: 0.5%; padding-bottom: 4pt">&#160;</td>
    <td style="font-size: 8pt; width: 0.5%; border-bottom: Black 4pt double; text-align: left">$</td><td style="font-size: 8pt; width: 6%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c78" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38074">14</ix:nonFraction></td><td style="font-size: 8pt; width: 0.5%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="font-size: 8pt; vertical-align: bottom; background-color: White">
    <td style="font-size: 8pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 8pt; text-indent: -9pt; padding-left: 9pt">Loss</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">(<ix:nonFraction contextRef="c84" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-38075">3,482</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">(<ix:nonFraction contextRef="c85" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-38076">3,482</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">(<ix:nonFraction contextRef="c86" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-38077">53</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">(<ix:nonFraction contextRef="c87" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-38078">3,535</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">)</td></tr>
  <tr style="font-size: 8pt; vertical-align: bottom; background-color: White">
    <td style="font-size: 8pt; text-align: left; text-indent: -9pt; padding-left: 9pt">Warrants reclassification</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">(<ix:nonFraction contextRef="c81" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" sign="-" unitRef="usd" id="ixv-38079">464</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">(<ix:nonFraction contextRef="c85" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" sign="-" unitRef="usd" id="ixv-38080">464</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" sign="-" unitRef="usd" id="ixv-38081">464</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">)</td></tr>
  <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 8pt; text-align: left; text-indent: -9pt; padding-left: 9pt">Issue of share capital, net of issue expenses&#160;(1)</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction contextRef="c79" decimals="-3" format="ixt:num-dot-decimal" id="ix_0_fact" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd">2,763</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction contextRef="c81" decimals="-3" format="ixt:num-dot-decimal" id="ix_1_fact" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd">2,207</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction contextRef="c85" decimals="-3" format="ixt:num-dot-decimal" id="ix_2_fact" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd">4,970</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" id="ix_3_fact" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd">4,970</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr style="font-size: 8pt; vertical-align: bottom; background-color: White">
    <td style="font-size: 8pt; text-align: left; text-indent: -9pt; padding-left: 9pt">Conversion of convertible debentures (Note&#160;14b)</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction contextRef="c79" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" scale="3" unitRef="usd" id="ixv-38086">3</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction contextRef="c85" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" scale="3" unitRef="usd" id="ixv-38087">3</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" scale="3" unitRef="usd" id="ixv-38088">3</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 8pt; text-align: left; text-indent: -9pt; padding-left: 9pt">Non-controlling interests</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction contextRef="c82" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-38089">298</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction contextRef="c85" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-38090">298</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction contextRef="c86" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-38091">53</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-38092">351</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr style="font-size: 8pt; vertical-align: bottom; background-color: White">
    <td style="font-size: 8pt; text-indent: -9pt; padding-left: 9pt">Expiration of share options</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction contextRef="c79" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" unitRef="usd" id="ixv-38093">638</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">(<ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" sign="-" unitRef="usd" id="ixv-38094">638</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 8pt; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cost of share-based payment</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-38095">91</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c85" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-38096">91</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-38097">91</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font-size: 8pt; vertical-align: bottom; background-color: White">
    <td style="font-size: 8pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 8pt; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December&#160;31, 2020</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c88" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38098">49,040</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c89" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38099">4,315</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38100">2,207</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c91" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38101">559</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38102">497</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c93" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-38103">55,188</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c94" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38104">1,430</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c96" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38105">1,430</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font-size: 8pt; vertical-align: bottom; background-color: White">
    <td style="font-size: 8pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 8pt; text-indent: -9pt; padding-left: 9pt">Loss</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">(<ix:nonFraction contextRef="c102" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-38106">5,789</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">(<ix:nonFraction contextRef="c103" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-38107">5,789</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">(<ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-38108">5,789</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">)</td></tr>
  <tr style="font-size: 8pt; vertical-align: bottom; background-color: White">
    <td style="font-size: 8pt; text-indent: -9pt; padding-left: 9pt">Exercise of warrants&#160;(3)</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction contextRef="c97" decimals="-3" format="ixt:num-dot-decimal" id="ix_8_fact" name="sprcy:ExerciseOfWarrants" scale="3" unitRef="usd">6,110</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">(<ix:nonFraction contextRef="c99" decimals="-3" format="ixt:num-dot-decimal" id="ix_9_fact" name="sprcy:ExerciseOfWarrants" scale="3" sign="-" unitRef="usd">1,352</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction contextRef="c103" decimals="-3" format="ixt:num-dot-decimal" id="ix_10_fact" name="sprcy:ExerciseOfWarrants" scale="3" unitRef="usd">4,758</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" id="ix_11_fact" name="sprcy:ExerciseOfWarrants" scale="3" unitRef="usd">4,758</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 8pt; text-align: left; text-indent: -9pt; padding-left: 9pt">Issue of share capital, net of issue expenses&#160;(2)</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction contextRef="c97" decimals="-3" format="ixt:num-dot-decimal" id="ix_4_fact" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd">3,364</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction contextRef="c99" decimals="-3" format="ixt:num-dot-decimal" id="ix_5_fact" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd">4,335</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction contextRef="c103" decimals="-3" format="ixt:num-dot-decimal" id="ix_6_fact" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd">7,699</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" id="ix_7_fact" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd">7,699</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr style="font-size: 8pt; vertical-align: bottom; background-color: White">
    <td style="font-size: 8pt; text-indent: -9pt; padding-left: 9pt">Expiration of share options</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction contextRef="c97" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" unitRef="usd" id="ixv-38117">27</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">(<ix:nonFraction contextRef="c98" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" sign="-" unitRef="usd" id="ixv-38118">27</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 8pt; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cost of share-based payment</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">-</div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c98" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-38119">43</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">-</div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">-</div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">-</div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c103" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-38120">43</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-38121">43</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font-size: 8pt; vertical-align: bottom; background-color: White">
    <td style="font-size: 8pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 8pt; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December&#160;31, 2021</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38122">58,541</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38123">4,331</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38124">5,190</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38125">559</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38126">497</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-38127">60,977</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38128">8,141</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">-</div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38129">8,141</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font-size: 8pt; vertical-align: bottom; background-color: White">
    <td style="font-size: 8pt; padding-left: 9pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 8pt; text-indent: -9pt; padding-left: 9pt">Loss</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">(<ix:nonFraction contextRef="c66" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-38130">2,592</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">(<ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-38131">2,592</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-38132">2,592</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">)</td></tr>
  <tr style="font-size: 8pt; vertical-align: bottom; background-color: White">
    <td style="font-size: 8pt; text-indent: -9pt; padding-left: 9pt">Exercise of warrants</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-38133">3</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-38134">3</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-38135">3</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 8pt; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cost of share-based payment</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-38136">48</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-38137">849</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-38138">897</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">-</div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-38139">897</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font-size: 8pt; vertical-align: bottom; background-color: White">
    <td style="font-size: 8pt; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December&#160;31, 2022</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38140">58,592</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38141">5,180</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38142">5,190</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38143">559</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38144">497</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-38145">63,569</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38146">6,449</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">-</div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-38147">6,449</ix:nonFraction></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-size: 10pt">(1)</span></td> <td style="text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US"><span style="font-size: 10pt">Net of issue expenses of $784</span></ix:footnote></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-size: 10pt">(2)</span></td> <td style="text-align: justify"><ix:footnote id="ix_1_footnote" xml:lang="en-US"><span style="font-size: 10pt">Net of issue expenses of $449</span></ix:footnote></td></tr> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt">(3)</span></td> <td style="text-align: justify"><ix:footnote id="ix_2_footnote" xml:lang="en-US"><span style="font-size: 10pt">Net of issue expenses of $358</span></ix:footnote></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 188; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="F_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="text-decoration:underline">Cash flows from operating activities:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 64%; padding-bottom: 1.5pt">Loss</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-38148">2,592</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(<ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-38149">5,789</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-38150">3,535</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Adjustments to reconcile loss to net cash used&#160;in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Adjustments to the profit or loss items:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" unitRef="usd" id="ixv-38151">187</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" unitRef="usd" id="ixv-38152">33</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" unitRef="usd" id="ixv-38153">164</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left">Cost of share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-38154">897</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-38155">43</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-38156">91</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left">Finance expenses (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" scale="3" unitRef="usd" id="ixv-38157">6,585</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" scale="3" sign="-" unitRef="usd" id="ixv-38158">9</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" scale="3" unitRef="usd" id="ixv-38159">476</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left">Group&#8217;s share of losses of company accounted for at equity, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" scale="3" unitRef="usd" id="ixv-38160">109</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-199">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" scale="3" unitRef="usd" id="ixv-38161">795</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left">Losses from remeasurement of investment in financial assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdjustmentsForImpairmentOfInvestmentInAssociate" scale="3" unitRef="usd" id="ixv-38162">770</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-200">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-201">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForReconcileProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-38163">4,622</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForReconcileProfitLoss" scale="3" unitRef="usd" id="ixv-38164">85</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForReconcileProfitLoss" scale="3" unitRef="usd" id="ixv-38165">574</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Working capital adjustments:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left">Decrease (increase) in other accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="3" unitRef="usd" id="ixv-38166">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="3" unitRef="usd" id="ixv-38167">170</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="3" sign="-" unitRef="usd" id="ixv-38168">519</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left">Increase (decrease) in trade payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="3" unitRef="usd" id="ixv-38169">353</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="3" sign="-" unitRef="usd" id="ixv-38170">752</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left">Increase (decrease) in other accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" unitRef="usd" id="ixv-38171">39</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" unitRef="usd" id="ixv-38172">120</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" sign="-" unitRef="usd" id="ixv-38173">75</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left">Increase in trade receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="3" sign="-" unitRef="usd" id="ixv-38174">77</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Increase in inventory</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="3" sign="-" unitRef="usd" id="ixv-38175">668</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" scale="3" sign="-" unitRef="usd" id="ixv-38176">703</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" scale="3" unitRef="usd" id="ixv-38177">643</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" scale="3" sign="-" unitRef="usd" id="ixv-38178">1,346</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net cash used in operating activities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-38179">7,917</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-38180">5,061</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-38181">4,307</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 189; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="text-decoration:underline">Cash flows from investing activities:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 27pt">Investment (withdrawal) in restricted bank deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-38182">15</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-38183">35</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-38184">24</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Purchase of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-38185">8</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-38186">35</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-202">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Investment in a company accounted for at equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" scale="3" sign="-" unitRef="usd" id="ixv-38187">700</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-203">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-204">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Purchase of financial assets at fair value through profit or loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" scale="3" sign="-" unitRef="usd" id="ixv-38188">1,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-205">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-206">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Purchase of intangible asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-38189">4,861</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-208">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net cash provided by (used in) investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-38190">7,084</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-38191">70</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" unitRef="usd" id="ixv-38192">24</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Proceeds from issue of share capital (net of issuance expenses)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" scale="3" sign="-" unitRef="usd" id="ixv-38193">9,005</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" scale="3" sign="-" unitRef="usd" id="ixv-38194">7,699</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" scale="3" sign="-" unitRef="usd" id="ixv-38195">2,650</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 27pt">Exercise of warrants (a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromExerciseOfOptions" scale="3" unitRef="usd" id="ixv-38196">2,770</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromExerciseOfOptions" scale="3" unitRef="usd" id="ixv-38197">2,568</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromExerciseOfOptions" scale="3" unitRef="usd" id="ixv-38198">2,376</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Payment of issuance expenses related to previous period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod" scale="3" unitRef="usd" id="ixv-38199">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-209">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod" scale="3" unitRef="usd" id="ixv-38200">116</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Interest paid on lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InterestPaidOnLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-38201">8</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-210">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InterestPaidOnLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-38202">7</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Repayment of lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RepaymentOfLeaseLiabilities" scale="3" unitRef="usd" id="ixv-38203">70</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RepaymentOfLeaseLiabilities" scale="3" unitRef="usd" id="ixv-38204">19</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RepaymentOfLeaseLiabilities" scale="3" unitRef="usd" id="ixv-38205">26</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Repayment of short-term credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-211">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RepaymentOfShorttermCredit" scale="3" unitRef="usd" id="ixv-38206">188</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RepaymentOfShorttermCredit" scale="3" unitRef="usd" id="ixv-38207">1,410</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Receipt of short-term credit from others, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-212">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-213">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ReceiptofShortTermCreditFromOthers" scale="3" unitRef="usd" id="ixv-38208">1,660</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-38209">11,700</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-38210">10,060</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-38211">5,359</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Increase (decrease) in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-38212">3,301</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-38213">4,929</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-38214">1,076</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Cash at the beginning of the period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-38215">6,875</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c96" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-38216">1,946</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c78" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-38217">870</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Cash at the end of the period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-38218">3,574</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-38219">6,875</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c96" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-38220">1,946</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 190; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">(a) <span style="text-decoration:underline">Significant non-cash transactions</span>:</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt">Right-of-use asset recognized with corresponding lease liability</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability" scale="3" unitRef="usd" id="ixv-38221">78</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-215">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Registration of warrants</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-216">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RegistrationOfWarrants" scale="3" unitRef="usd" id="ixv-38222">2,480</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-217">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Unpaid issue expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-218">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:UnpaidIssueExpenses" scale="3" unitRef="usd" id="ixv-38223">290</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-219">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 191; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="F_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" continuedAt="sprcy_DisclosureOfGeneralExplanatoryTextBlock-c7_cont_1" escape="true" name="sprcy:DisclosureOfGeneralExplanatoryTextBlock" id="ixv-28399"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-size: 10pt"><b>NOTE 1:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>GENERAL</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) (&#8220;SciSparc&#8221;
or the &#8220;Company&#8221; or the &#8220;Group&#8221;), a pharmaceutical company, was incorporated in Israel and commenced its operations
on August 23, 2004. Until March 2014, SciSparc and its subsidiaries at the time (the &#8220;Group&#8221;) were mainly engaged in developing
several innovative immunotherapy products and SciSparc&#8217;s own patents in the immunotherapy field. In August 2015, the Company decided
to adopt a different business strategy and began focusing on developing a&#160;portfolio of approved drugs based on cannabinoid molecules.
With this focus, the Company is currently engaged in the following development programs based on &#916;9-tetrahydrocannabinol (&#8220;THC&#8221;)
and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer&#8217;s disease&#160;and agitation, pain, autism
spectrum disorder and Status Epilepticus. The headquarters of the Company are located in Tel Aviv, Israel.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company was previously a dual-listed
company, whereby it listed (a) its ordinary shares, no par value each (&#8220;ordinary shares&#8221;), on the Tel-Aviv Stock Exchange
(&#8220;TASE&#8221;) from December 26, 2005 until its delisting on August 7, 2018, and (b) its American Depository Shares (&#8220;ADSs&#8221;)
on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) following its initial public offering (&#8220;IPO&#8221;) on March 27, 2017, at which
time it raised $<ix:nonFraction contextRef="c187" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ProceedsFromIssuanceIPO" scale="3" unitRef="usd" id="ixv-38224">13,700</ix:nonFraction>, until its suspension from listing, and subsequent delisting, from Nasdaq on July 2, 2020 and September 21, 2020,
respectively. Following the delisting of the ADSs from Nasdaq, the Company&#8217;s ADSs were listed on the Pink Sheets and then subsequently
upgraded to the OTCQB on December 8, 2020. On August 26, 2021, the Company&#8217;s ADSs were mandatorily cancelled and were exchanged
for ordinary shares at a one-for-one ratio.&#160;On December 22, 2021, the Company&#8217;s ordinary shares were re-listed on Nasdaq and
began trading under the symbol &#8220;SPRC&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As of December 31, 2022, the Company
had three private subsidiaries, including a company incorporated under the laws of Israel: Evero Health Ltd (&#8220;Evero&#8221;); an
inactive company incorporated under the laws of Israel: Brain Bright Ltd (&#8220;Brain Bright&#8221;); and a company incorporated under
the laws of the State of Delaware: Scisparc Nutraceuticals Inc. (&#8220;Scisparc US&#8221; and together with Evero and Brain Bright, the
&#8220;Subsidiaries&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The consolidated financial statements
of the Company for the year ended December&#160;31, 2022, were approved on April 27, 2023, and signed on May 1, 2023 (the &#8220;Approval
Date&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 192; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-size: 10pt"><b>NOTE 1:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>GENERAL (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="sprcy_DisclosureOfGeneralExplanatoryTextBlock-c7_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">The Group incurred operating losses since its incorporation and expects
to continue to incur operating losses for the foreseeable future. As of December 31, 2022, the Group had an accumulated deficit of approximately
$<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RetainedEarning" scale="3" unitRef="usd" id="ixv-38225">64,009</ix:nonFraction> as a result of recurring operating losses.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A<span style="background-color: white">s
of the Approval Date, the Group has started recognizing revenues from sales. However, its pharmaceuticals operations are dependent on
its ability to raise additional funds from existing and/or new investors. This dependency will continue until the Group will be able to
completely finance its operations by generating revenue from its products. These abovementioned factors raise substantial doubt about
the Group&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments to the carrying amounts
and classifications of assets and liabilities that might result should the Group be unable to continue as a going concern.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Definitions and Meanings:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 10%; text-align: justify"><span style="font-size: 10pt">The Company</span></td>
    <td style="width: 2%; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Group</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">SciSparc Ltd. (formerly Therapix Biosciences Ltd.) and its Subsidiaries, as detailed in Note 1a.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Subsidiaries</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Companies that are controlled by the Company, as defined in IFRS 10, &#8220;<i>Consolidated Financial Statements</i>&#8221;, and whose accounts are consolidated with those of the Company (if active).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Associates</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">An entity over which the Company has significant influence, as defined in IAS 28, &#8220;<i>Investment in Associates and Joint Ventures</i>&#8221; and is not a Subsidiary.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Related Parties</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">As defined in IAS 24, &#8220;<i>Related Party Disclosures</i>&#8221;. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">IAS</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">International Accounting Standards issued by the International Accounting Standards Board (&#8220;IASB&#8221;).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">IFRS</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">International Financial Reporting Standards issued by the IASB.</span></td></tr>
  </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 193; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c7_cont_1" escape="true" name="ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory" id="ixv-28605"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td><span style="font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following accounting policies have
been applied consistently in the financial statements for all periods presented, unless otherwise stated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c7" continuedAt="sprcy_BasisOfPresentationOfFinancialStatements-c7_cont_1" escape="true" name="sprcy:BasisOfPresentationOfFinancialStatements" id="ixv-28617"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Basis of presentation of the financial statements:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_BasisOfPresentationOfFinancialStatements-c7_cont_2" id="sprcy_BasisOfPresentationOfFinancialStatements-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">These financial statements have been
prepared in accordance with IFRS, as issued by the IASB.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_BasisOfPresentationOfFinancialStatements-c7_cont_3" id="sprcy_BasisOfPresentationOfFinancialStatements-c7_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s financial statements
have been prepared on a cost basis, unless otherwise indicated.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_BasisOfPresentationOfFinancialStatements-c7_cont_4" id="sprcy_BasisOfPresentationOfFinancialStatements-c7_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has elected to present
the profit or loss items using the function of expense method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_BasisOfPresentationOfFinancialStatements-c7_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements are presented
in USD and all values are rounded to the nearest thousand (&#8217;000), except when otherwise indicated.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c7" continuedAt="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory-c7_cont_1" escape="true" name="sprcy:DescriptionOfAccountingPolicyForoperatingcycleExplanatory" id="ixv-28638"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">The operating cycle:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The operating cycle of the Company
is <ix:nonNumeric contextRef="c7" format="ixt-sec:durwordsen" name="sprcy:OperatingTerm" id="ixv-38226">one year</ix:nonNumeric>.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c7" continuedAt="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c7_cont_1" escape="true" name="sprcy:DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" id="ixv-28650"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Consolidated financial statements:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c7_cont_2" id="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The consolidated financial statements
comprise the financial statements of companies that are controlled by the Company (Subsidiaries). Control of a company is achieved when
the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those
returns through its power over the investee. Potential voting rights are considered when assessing whether an entity has control over
the other entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such
control ceases.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c7_cont_3" id="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c7_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements of the Company
and of the Subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform
accounting policies by all companies in the Group. Significant intra-Group balances and transactions and gains or losses resulting from
intra-Group transactions are eliminated in full in the consolidated financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c7_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Non-controlling interests in subsidiaries
represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in
equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive
income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they
result in a negative balance of non-controlling interests in the consolidated statement of financial position.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><!-- Field: Page; Sequence: 194; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c7_cont_2" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c7_cont_1"><ix:nonNumeric contextRef="c7" continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c7_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" id="ixv-28708"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 72px"/><td style="width: 48px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td><td style="text-align: justify">Functional currency and foreign currency:</td>
</tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The functional currency of the Company, which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions is the U.S. Dollar (&#8220;USD&#8221; or &#8220;$&#8221;), since it&#8217;s the primary currency of the economic environment in which the Company operates. The consolidated financial statements are also presented in USD since the Company believes that preparing the consolidated financial statements in USD provides more relevant information to the users of the consolidated financial statements.</p></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c7" continuedAt="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany-c7_cont_1" escape="true" name="sprcy:DescriptionOfAcquisitionOfASingleAssetCompany" id="ixv-28719"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Acquisition of a single asset company:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Upon the acquisition
of a single asset company, the Group evaluates whether it is the acquisition of a business or of an asset. To be considered a business,
the acquisition must include, at a minimum, an input and a substantive process that together can significantly contribute to the creation
of outputs. The acquisition is accounted for as a business combination if the single asset company is a business. If it is not a business,
the acquisition is accounted for as the acquisition of assets and liabilities. In such an acquisition, the cost of the acquisition includes
transaction costs which are allocated to the identifiable acquired assets and liabilities proportionally based on their fair value on
the acquisition date. In such case, goodwill and deferred taxes in respect of the temporary differences existing as of the acquisition
date are not recognized.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c7" continuedAt="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit-c7_cont_1" escape="true" name="sprcy:DescriptionOfAccountingPolicyForRestrictedDeposit" id="ixv-28731"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify; font-size: 10pt">&#160;</td> <td style="width: 48px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted deposits:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">A restricted deposit is cash invested
in a short-term deposit (between three months and one year) or in a long-term deposit (with a maturity of more than one year from the
date of investment). Restricted deposits are designated to secure the Company&#8217;s office facilities lease agreements and its credit
cards.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c7" continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c7_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" id="ixv-28743"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 72px"/><td style="width: 48px">g.</td><td style="text-align: justify">Investment in joint arrangements:</td></tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c7_cont_2" id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Joint arrangements
are arrangements in which the Company has joint control. Joint control is the contractually agreed sharing of control of an arrangement,
which exists only when decisions about the relevant activities require the unanimous consent of the parties sharing control.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c7_cont_3" id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c7_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 1.25in"/><td style="width: 0.5in">1.</td><td style="text-align: justify">Joint ventures:</td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c7_cont_4" id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c7_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in">In joint ventures
the parties that have joint control of the arrangement have rights to the net assets of the arrangement. A joint venture is accounted
for at equity</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c7_cont_5" id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c7_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 1.25in"/><td style="width: 0.5in">2.</td><td style="text-align: justify">Joint operations:</td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c7_cont_6" id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c7_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in">In joint operations
the parties that have joint control of the arrangement have rights to the assets and obligations for the liabilities relating to the arrangement.
The Company recognizes in relation to its interest its share of the assets, liabilities, revenues and expenses of the joint operation.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: -28.35pt">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c7_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in">The acquisition
of interests in a joint operation which represents a business, as defined in IFRS 3, is accounted for using the acquisition method, including
the measurement of the identifiable assets and liabilities at fair value, the recognition of deferred taxes arising from this measurement,
the accounting treatment of the related transaction costs and the recognition of goodwill or bargain purchase gains. This applies to the
acquisition of the initial interest and additional interests in a joint operation that represents a business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 195; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c7_cont_3" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c7_cont_2"><ix:nonNumeric contextRef="c7" continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociates-c7_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociates" id="ixv-28818"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 72px"/><td style="width: 48px">h.</td><td style="text-align: justify">Investments in associates:</td></tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"><span style="text-transform: uppercase">&#160;</span></p>

<ix:continuation id="_DescriptionOfAccountingPolicyForInvestmentInAssociates-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Associates are companies in which the Group has significant
influence over the financial and operating policies without having control. The investment in an associate is accounted for using the
equity method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt">&#160;</p>

<ix:nonNumeric contextRef="c7" continuedAt="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c7_cont_1" escape="true" name="sprcy:DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" id="ixv-28829"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 72px"/><td style="width: 48px">i.</td><td style="text-align: justify">Investments accounted for using the equity method:</td></tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"><span style="text-transform: uppercase">&#160;</span></p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c7_cont_2" id="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Group&#8217;s investments
in associates and joint ventures are accounted for using the equity method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c7_cont_3" id="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c7_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Under the equity
method, the investment in the associate or in the joint venture is presented at cost with the addition of post-acquisition changes in
the Group&#8217;s share of net assets, including other comprehensive income of the associate or the joint venture. Gains and losses resulting
from transactions between the Group and the associate or the joint venture are eliminated to the extent of the interest in the associate
or in the joint venture. The cost of the investment includes transaction costs.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c7_cont_4" id="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c7_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Goodwill relating
to the acquisition of an associate or a joint venture is presented as part of the investment in the associate or the joint venture, measured
at cost and not systematically amortized. Goodwill is evaluated for impairment as part of the investment in the associate or in the joint
venture as a whole.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c7_cont_5" id="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c7_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The financial statements
of the Company and of the associate or joint venture are prepared as of the same dates and periods. The accounting policies applied in
the financial statements of the associate or the joint venture are uniform and consistent with the policies applied in the financial statements
of the Group.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c7_cont_6" id="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c7_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Upon the acquisition
of an associate or a joint venture achieved in stages when the former investment in the acquiree was accounted for pursuant to the provisions
of IFRS 9, the Group applies the principles of IFRS 3 regarding business combinations achieved in stages. Consequently, equity interests
in the acquiree that had been held by the Group prior to achieving significant influence or joint control are measured at fair value on
the acquisition date and are included in the acquisition consideration while recognizing a gain or loss resulting from the fair value
measurement.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c7_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The equity method
is applied until the loss of significant influence in the associate or loss of joint control in the joint venture or classification as
investment held for sale.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 196; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c7_cont_4" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c7_cont_3"><ix:nonNumeric contextRef="c7" continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c7_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" id="ixv-28897"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">j.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Property and equipment, net:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c7_cont_2" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Property and equipment are measured
at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment
grants and excluding day-to-day servicing expenses.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c7_cont_3" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c7_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><ix:nonNumeric contextRef="c7" continuedAt="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory-c7_cont_1" escape="true" name="sprcy:DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" id="ixv-38227">Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:</ix:nonNumeric></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory-c7_cont_1"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c7_cont_4" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c7_cont_3"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>%</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Mainly %</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Lab equipment</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 9%"><ix:nonFraction contextRef="c188" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-38228">6</ix:nonFraction>-<ix:nonFraction contextRef="c189" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-38229">50</ix:nonFraction></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c190" decimals="2" format="ixt:num-dot-decimal" name="sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" scale="-2" unitRef="pure" id="ixv-38230">33</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Computers</td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonFraction contextRef="c191" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-38231">33</ix:nonFraction>-<ix:nonFraction contextRef="c192" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-38232">50</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c193" decimals="2" format="ixt:num-dot-decimal" name="sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" scale="-2" unitRef="pure" id="ixv-38233">33</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office furniture and equipment</td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonFraction contextRef="c194" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-38234">20</ix:nonFraction>-<ix:nonFraction contextRef="c195" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-38235">33</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c196" decimals="2" format="ixt:num-dot-decimal" name="sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" scale="-2" unitRef="pure" id="ixv-38236">25</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td>
    <td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c197" name="ifrs-full:DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" id="ixv-38237">see below</ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-233">-</div></td>
    <td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c7_cont_5" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c7_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including the extension option held by a company and intended to be exercised)
and the expected life of the improvement.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c7_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The useful life, depreciation method
and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting
estimate. Depreciation of an asset ceases at the earlier of: the date that the asset is classified as held for sale and the date that
the asset is derecognized.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<ix:nonNumeric contextRef="c7" continuedAt="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c7_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" id="ixv-28963"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">k.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Intangible assets:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c7_cont_2" id="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Separately acquired intangible assets
are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination
are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized
development costs, are recognized in profit or loss when incurred.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c7_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Intangible assets with a finite useful
life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired.
The amortization period and the amortization method for an intangible asset are reviewed at least at each year end.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c7" continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory-c7_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" id="ixv-28978"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">l.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Impairment of non-financial assets:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company evaluates the need to record
an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.
If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount. The
recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future cash
flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset that
does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses are
recognized in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 197; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c7_cont_5" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c7_cont_4"><ix:nonNumeric contextRef="c7" continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" id="ixv-29032"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">m.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Financial instruments:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_2" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial assets:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_3" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets are measured upon
initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except
for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_4" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company classifies and measures
debt instruments in the financial statements based on the following criteria:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_5" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Company&#8217;s business model for managing financial assets; and</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_6" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The contractual cash flow terms of the financial asset.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_7" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">a)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Debt instruments are measured at amortized cost when:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_8" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">The Company&#8217;s business model
is to hold the financial assets in order to collect their contractual cash flows, and the contractual terms of the financial assets give
rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial
recognition, the instruments in this category are measured according to their terms at amortized cost using the effective interest rate
method, less any provision for impairment.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_9" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">On the date of initial recognition,
the Company may irrevocably designate a debt instrument as measured at fair value through profit or loss if doing so eliminates or significantly
reduces a measurement or recognition inconsistency, such as when a related financial liability is also measured at fair value through
profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_10" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">b)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Debt instruments are measured at fair value through profit or loss when:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_11" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">A financial asset which is a debt instrument
does not meet the criteria for measurement at amortized cost or at fair value through other comprehensive income. After initial recognition,
the financial asset is measured at fair value and gains or losses from fair value adjustments are recognized in profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_12" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_11"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">c)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Equity instruments and other financial assets held for trading:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_13" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Investments in equity instruments do
not meet the above criteria and accordingly are measured at fair value through profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_14" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Other financial assets held for trading
such as derivatives, including embedded derivatives separated from the host contract, are measured at fair value through profit or loss
unless they are designated as effective hedging instruments.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_15" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Dividends from investments in equity
instruments are recognized in profit or loss when the right to receive the dividends is established.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 198; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">m.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial instruments: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c7_cont_6" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c7_cont_5"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_16" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_15"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Derecognition of financial assets:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_17" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial asset is derecognized only
when:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_18" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_17"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The contractual rights to the cash flows from the financial asset have expired;</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_19" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_18"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Company has transferred substantially all the risks and rewards deriving from the contractual rights to receive cash flows from the financial asset or has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset; or</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_20" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_19"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Company has retained its contractual rights to receive cash flows from the financial asset but has assumed a contractual obligation to pay the cash flows in full without material delay to a third party.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_21" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_20"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial liabilities:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_22" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_21"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">a)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial liabilities measured at amortized cost:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_23" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_22"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Financial liabilities are initially
recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_24" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_23"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, the Company
measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair
value through profit or loss such as derivatives.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_25" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_24"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">b)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial liabilities measured at fair value through profit or loss:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_26" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_25"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">At initial recognition, the Company
measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_27" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_26"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, changes
in fair value are recognized in profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_28" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_27"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Derecognition of financial liabilities:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_29" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_28"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial liability is derecognized
only when it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires. A financial
liability is extinguished when the debtor discharges the liability by paying in cash, other financial assets, goods or services, or is
legally released from the liability.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_30" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_29"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Offsetting financial instruments:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_31" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_30"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets and financial liabilities
are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off the
recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously.
The right of set-off must be legally enforceable not only during the ordinary course of business of the parties to the contract but also
in the event of bankruptcy or insolvency of one of the parties. In order for the right of set-off to be currently available, it must not
be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events that
will cause the right to expire.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 199; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">m.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial instruments: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c7_cont_7" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c7_cont_6"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_32" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_31"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Compound financial instruments:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_33" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_32"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Convertible debentures which contain
both an equity/derivative component and a liability component are separated into two components. This separation is performed by first
determining the liability component based on the fair value of an equivalent non-convertible liability. The value of the conversion component
is determined to be the residual amount. Directly attributable transaction costs are apportioned between the equity component and the
liability component based on the allocation of proceeds to the equity and liability components.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_34" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_33"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">7.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Issue of a unit of securities:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c7_cont_34"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The issue of a unit of securities involves
the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following order: financial
derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for financial liabilities
that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual amount. Issue costs
are allocated to each component pro rata to the amounts determined for each component in the unit.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c7" continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c7_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" id="ixv-29349"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">n.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Research and development expenditures:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c7_cont_2" id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Research expenditures are recognized
in profit or loss when incurred.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c7_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The conditions enabling capitalization
of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss when
incurred.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c7" continuedAt="_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory-c7_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" id="ixv-29364"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">o.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Finance income and expenses:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Finance income and expenses comprise
interest income on amounts invested and exchange rate gains and losses. Interest income is recognized as it accrues using the effective
interest method. Finance income and expenses derive also from changes in the fair value of financial liabilities measured at fair value
through profit or loss. Borrowing costs are recognized in profit or loss using the effective interest method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c7" continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c7_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" id="ixv-29376"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">p.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Fair value measurement:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c7_cont_2" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Fair value measurement is based on the assumption that the transaction will take place in the asset&#8217;s or the liability&#8217;s
principal market, or in the absence of a principal market, in the most advantageous market.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c7_cont_3" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c7_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The fair value of an asset or a liability
is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants
act in their economic best interest.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c7_cont_4" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c7_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value measurement of a non-financial
asset takes into account a market participant&#8217;s ability to generate economic benefits by using the asset in its highest and best
use or by selling it to another market participant that would use the asset in its highest and best use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><!-- Field: Page; Sequence: 200; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">p.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Fair value measurement: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c7_cont_8" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c7_cont_7"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c7_cont_5" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c7_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company uses valuation techniques
that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant
observable inputs and minimizing the use of unobservable inputs.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c7_cont_6" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c7_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">All assets and liabilities measured
at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level
input that is significant to the entire fair value measurement:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c7_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">Level 1</span></td>
    <td style="width: 2%; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 2</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Inputs other than quoted prices included within Level 1 that are observable directly or indirectly.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 3</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c7" continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c7_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" id="ixv-29487"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">q.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Taxes on income:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c7_cont_2" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Current or deferred taxes are recognized
in profit or loss, except to the extent that they relate to items which are recognized in other comprehensive income or equity.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c7_cont_3" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c7_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Current taxes:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c7_cont_4" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c7_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A current tax liability is measured
using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required
in connection with the tax liability in respect of previous years.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c7_cont_5" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c7_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Deferred taxes:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c7_cont_6" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c7_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are computed in respect
of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c7_cont_7" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c7_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are measured at the
tax rate that is expected to apply when the asset is realized, or the liability is settled, based on tax laws that have been enacted or
substantively enacted by the reporting date.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c7_cont_8" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c7_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred tax assets are reviewed at
each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and temporary
differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred tax asset
is recognized to the extent that their utilization is probable.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c7_cont_9" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c7_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes that would apply in the event
of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of the
investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution
of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends
does not involve an additional tax liability or since it is the Company&#8217;s policy not to initiate distribution of dividends from
a subsidiary that would trigger an additional tax liability.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c7_cont_10" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c7_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes on income that relate to distributions
of an equity instrument and to transaction costs of an equity transaction are accounted for pursuant to IAS 12, &#8220;<i>Income Taxes</i>&#8221;.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c7_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are offset if there
is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same
taxpayer and the same taxation authority.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 201; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c7_cont_9" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c7_cont_8"><ix:nonNumeric contextRef="c7" continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c7_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" id="ixv-29581"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">r.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Share-based payment transactions:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c7_cont_2" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s employees and other
service providers may receive remuneration in the form of share-based payments (&#8220;Equity-settled transactions&#8221;).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c7_cont_3" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c7_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Equity-settled transactions:</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c7_cont_4" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c7_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable
option pricing model (&#8220;OPM&#8221;). As for service providers, the cost of the transactions is measured at the fair value of the
goods or services received as consideration for equity instruments granted.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c7_cont_5" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c7_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
is recognized in profit or loss together with a corresponding increase in equity during the period in which the performance and/or service
conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award (the &#8220;Vesting Period&#8221;).
The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects
the extent to which the Vesting Period has expired and the Company&#8217;s best estimate of the number of equity instruments that will
ultimately vest.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c7_cont_6" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c7_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">No expense is recognized for awards
that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective
of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c7_cont_7" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c7_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If the Company modifies the conditions
on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value
of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c7_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If a grant of an equity instrument
is cancelled, it is accounted for as if it had vested on the cancellation date and any expense not yet recognized for the grant is recognized
immediately. However, if a new grant replaces the cancelled grant and is identified as a replacement grant on the grant date, the cancelled
and new grants are accounted for as a modification of the original grant, as described above.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;&#160;</p>

<ix:nonNumeric contextRef="c7" continuedAt="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c7_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" id="ixv-29612"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">s.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Earnings (loss) per share:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c7_cont_2" id="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Earnings (loss) per share are calculated
by dividing the income (loss) attributable to equity holders of the Company by the weighted number of ordinary shares outstanding during
the period.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c7_cont_3" id="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c7_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Basic loss per ordinary share includes
only ordinary shares that were outstanding during the period.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c7_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Potential ordinary shares are included
in the computation of diluted loss per ordinary share when their conversion increases loss per ordinary share from continuing operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 202; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; font-size: 10pt"><span style="font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c7_cont_10" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c7_cont_9"><ix:nonNumeric contextRef="c7" continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c7_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" id="ixv-29672"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt; text-align: justify">&#160;</td> <td style="width: 48px; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">t.</span></td> <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Employee benefit liabilities:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c7_cont_2" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The Company has several employee-benefit
plans:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c7_cont_3" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c7_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Short-term employee benefits:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c7_cont_4" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c7_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">Short-term employee benefits are benefits
that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render
the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions
and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and a
reliable estimate of the amount can be made.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c7_cont_5" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c7_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Post-employment benefits:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c7_cont_6" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c7_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">The plans are normally financed by contributions
to insurance companies and classified as defined contribution plans or as defined benefit plans.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c7_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">The Company has defined contribution
plans to its employees according to the specific laws per country.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c7" continuedAt="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c7_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory" id="ixv-29711"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">u.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Provisions:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c7_cont_2" id="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">A provision in accordance with IAS 37,
&#8220;<i>Provisions, Contingent Liabilities and Contingent Assets</i>&#8221;, is recognized when the Company has a present obligation
(legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required
to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects part or all of
the expense to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when
the reimbursement is virtually certain. The expense is recognized in the statement of profit or loss net of any reimbursement.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c7_cont_3" id="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c7_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">Following are the types of provisions
included in the financial statements:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c7_cont_4" id="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c7_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"><i>Legal claims:</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c7_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">A provision for claims is recognized
when the Company has a present legal or constructive obligation as a result of a past event, it is more likely than not that an outflow
of resources embodying economic benefits will be required by the Company to settle the obligation and a reliable estimate can be made
of the amount of the obligation.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c7" continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c7_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" id="ixv-29734"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">v.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Leases:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c7_cont_2" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The Company elected to apply the provisions
of IFRS 16, &#8220;<i>Leases</i>&#8221; (&#8220;IFRS 16&#8221;) using the modified retrospective method (without restatement of comparative
data).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c7_cont_3" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c7_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The accounting policy for leases applied
effective from January 1, 2019, is as follows:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c7_cont_4" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c7_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The Company accounts for a contract as
a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 203; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">v.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Leases: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c7_cont_11" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c7_cont_10"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c7_cont_5" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c7_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Company as a lessee:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c7_cont_6" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c7_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">For leases in which the Company is the
lessee, the Company recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases whose
term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Company has elected
to recognize lease payments as an expense in profit or loss on a straight-line basis over the lease term (see Note 9). In measuring the
lease liability, the Company has elected to apply the practical expedient in IFRS 16 and separates the lease components from the non-lease
components (such as management and maintenance services, etc.) included in a single contract.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c7_cont_7" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c7_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">On the commencement date, the lease
liability includes all unpaid lease payments discounted at the interest rate implicit in the lease, if that rate can be readily determined,
or otherwise using the Company&#8217;s incremental borrowing rate. After the commencement date, the Company measures the lease liability
using the effective interest rate method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c7_cont_8" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c7_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">On the commencement date, the right-of-use
asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and
initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful
life and the lease term.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c7_cont_9" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c7_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">The Company tests for impairment of
the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36, &#8220;<i>Impairment of Assets</i>&#8221;.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c7_cont_10" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c7_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Lease extension and termination options:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c7_cont_11" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c7_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">A non-cancelable lease term includes
both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised, and
the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c7_cont_12" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c7_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">In the event of any change in the expected
exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Company remeasures the lease
liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total change
is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized
in profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c7_cont_13" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c7_cont_12"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Lease modifications:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c7_cont_14" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c7_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">If a lease modification does not reduce
the scope of the lease and does not result in a separate lease, the Company remeasures the lease liability based on the modified lease
terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the
right-of-use asset.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c7_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">If a lease modification reduces the
scope of the lease, the Company recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use
asset and the lease liability. The Company subsequently remeasures the carrying amount of the lease liability according to the revised
lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment to
the right-of-use asset.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 204; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c7_cont_11"><ix:nonNumeric contextRef="c7" continuedAt="sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements-c7_cont_1" escape="true" name="sprcy:DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements" id="ixv-29901"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 72px"/><td style="width: 48px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">w.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
to IAS 1, &#8220;Presentation of Financial Statements&#8221;:</span></td>
</tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements-c7_cont_2" id="sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements-c7_cont_1"><p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">In January 2020, the IASB issued
an amendment to IAS 1, &#8220;Presentation of Financial Statements&#8221; regarding the criteria for determining the classification of liabilities
as current or non-current (&#8220;the Original Amendment&#8221;). In October 2022, the IASB issued a subsequent amendment (&#8220;the Subsequent
Amendment&#8221;).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-indent: 0pt">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements-c7_cont_3" id="sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements-c7_cont_2"><p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">According to the Subsequent Amendment:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-indent: 0pt">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements-c7_cont_4" id="sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements-c7_cont_3"><p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">Only covenants with which an entity
must comply on or before the reporting date will affect a liability&#8217;s classification as current or non-current.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-indent: 0pt">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements-c7_cont_5" id="sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements-c7_cont_4"><p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">An entity should provide disclosure
when a liability arising from a loan agreement is classified as non-current and the entity&#8217;s right to defer settlement is contingent on
compliance with future covenants within twelve months from the reporting date. This disclosure is required to include information about
the covenants and the related liabilities. The disclosures must include information about the nature of the future covenants and when
compliance is applicable, as well as the carrying amount of the related liabilities. The purpose of this information is to allow users
to understand the nature of the future covenants and to assess the risk that a liability classified as non-current could become repayable
within twelve months. Furthermore, if facts and circumstances indicate that an entity may have difficulty in complying with such covenants,
those facts and circumstances should be disclosed.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0pt">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements-c7_cont_6" id="sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements-c7_cont_5"><p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">According to the Original Amendment,
the conversion option of a liability affects the classification of the entire liability as current or non-current unless the conversion
component is an equity instrument.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-indent: 0pt">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements-c7_cont_7" id="sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements-c7_cont_6"><p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">The Original Amendment and Subsequent
Amendment are both effective for annual periods beginning on or after January 1, 2024, and must be applied retrospectively. Early application
is permitted.</p></ix:continuation>

<p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements-c7_cont_7"><p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">The Company is evaluating the
effects of the Amendments on its financial statements.</p></ix:continuation>

<p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c7" continuedAt="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors-c7_cont_1" escape="true" name="sprcy:DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" id="ixv-29931"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 72px"/><td style="width: 48px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">x.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
to IAS 8, &#8220;Accounting Policies, Changes to Accounting Estimates and Errors&#8221;:</span></td>
</tr></table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -10.1pt">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors-c7_cont_2" id="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors-c7_cont_1"><p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in">In February 2021, the IASB issued an amendment to IAS 8,
&#8220;Accounting Policies, Changes to Accounting Estimates and Errors&#8221; (&#8220;the Amendment&#8221;), in which it introduces a new
definition of &#8220;accounting estimates&#8221;.</p></ix:continuation>

<p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors-c7_cont_3" id="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors-c7_cont_2"><p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">Accounting estimates are defined as
&#8220;monetary amounts in financial statements that are subject to measurement uncertainty&#8221;. The Amendment clarifies the distinction
between changes in accounting estimates and changes in accounting policies and the correction of errors.</p></ix:continuation>

<p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors-c7_cont_3"><p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">The Amendment is to be applied prospectively
for annual reporting periods beginning on or after January 1, 2023 and is applicable to changes in accounting policies and changes in
accounting estimates that occur on or after the start of that period. Early application is permitted.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 205; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c7" continuedAt="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock-c7_cont_1" escape="true" name="sprcy:SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" id="ixv-29980"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 3:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">In the process of applying the significant
accounting policies, the Company has made the following judgments which have the most significant effect on the amounts recognized in
the financial statements:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Judgments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Discount rate for a lease liability:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">When a company in the Group is unable
to readily determine the discount rate implicit in a lease in order to measure the lease liability, such company uses an incremental borrowing
rate. That rate represents the rate of interest that the Company would have to pay to borrow over a similar term and with similar security,
the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment. When there are no
financing transactions that can serve as a basis, said company determines the incremental borrowing rate based on its credit risk, the
lease term and other economic variables deriving from the lease contract&#8217;s conditions and restrictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Effective control:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">The Company assesses whether it controls
a company in which it holds less than the majority of the voting rights by, among others, reference to the size of its holding of voting
rights relative to the size and dispersion of holdings of the other vote holders including voting patterns at previous shareholders&#8217;
meetings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Determining the fair value of share-based payment transactions:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">The fair value of share-based payment
transactions is determined upon initial recognition by an acceptable OPM. The inputs to the model include share price, exercise price
and assumptions regarding expected volatility, expected life of share option, risk-free interest and expected dividend yield.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Estimates and assumptions:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The preparation of the financial statements
requires management to make estimates and assumptions that have an effect on the application of the accounting policies and on the reported
amounts of assets, liabilities, revenues and expenses. Changes in accounting estimates are reported in the period of the change in estimate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The key assumptions made in the financial
statements concerning uncertainties at the reporting date and the critical estimates computed by the Company that may result in a material
adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Legal claims:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">In estimating the likelihood of outcome
of legal claims filed or threatened to commence against the Company and/or its Subsidiaries and/or affiliates, the Company relies on its
management&#8217;s best knowledge and estimations and where applicable, on the opinion of their legal counsels. These estimates are based,
among others, on management&#8217;s familiarity of and proximity to the circumstances, and also on the legal counsels&#8217; best professional
judgment, taking into account the stage of proceedings and legal precedents in respect of the different issues. Since the outcome of the
claims might be determined in courts and/or other quasi-judicial tribunals, the results could differ from these estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 206; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 3:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Estimates and assumptions: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock-c7_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Lease extension and/or termination options:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">In evaluating whether it is reasonably
certain that a company of the Group will exercise an option to extend a lease or not exercise an option to terminate a lease, the Company
considers all relevant facts and circumstances that create an economic incentive for the Company to exercise the option to extend or not
exercise the option to terminate such as: significant amounts invested in leasehold improvements, the significance of the underlying asset
to the Company&#8217;s operation and whether it is a specialized asset, the company&#8217;s past experience with similar leases, etc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">After the commencement date, the Company
reassesses the term of the lease upon the occurrence of a significant event or a significant change in circumstances that affects whether
the company is reasonably certain to exercise an option or not exercise an option previously included in the determination of the lease
term, such as significant leasehold improvements that had not been anticipated on the lease commencement date, sublease of the underlying
asset for a period that exceeds the end of the previously determined lease period, etc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Fair value of financial instruments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">When the fair values of financial assets
and financial liabilities recorded in the statement of financial position cannot be derived from active markets, their fair value is determined
using a variety of valuation techniques that include the use of valuation models. The inputs to these models are taken from observable
markets where possible, but where this is not feasible, estimation is required in establishing fair values. The models are tested for
validity by calibrating to prices from any observable current market transactions in the same instrument when available.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" escape="true" name="ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory" id="ixv-30128"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4:-</b></span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CASH</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p>

<ix:nonNumeric contextRef="c7" escape="true" name="sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock" id="ixv-30139"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash for immediate withdrawal - in USD</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CashForImmediateWithdrawal" scale="3" unitRef="usd" id="ixv-38238">3,443</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CashForImmediateWithdrawal" scale="3" unitRef="usd" id="ixv-38239">6,590</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash for immediate withdrawal - in NIS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CashForImmediateWithdrawalInNIS" scale="3" unitRef="usd" id="ixv-38240">131</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CashForImmediateWithdrawalInNIS" scale="3" unitRef="usd" id="ixv-38241">285</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashOnHand" scale="3" unitRef="usd" id="ixv-38242">3,574</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashOnHand" scale="3" unitRef="usd" id="ixv-38243">6,875</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 207; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" escape="true" name="ifrs-full:DisclosureOfInventoriesExplanatory" id="ixv-30225"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5:-</b></span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVENTORY</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c7" escape="true" name="ifrs-full:DisclosureOfInvestmentEntitiesExplanatory" id="ixv-30235"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Goods in transit</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentInventoriesInTransit" scale="3" unitRef="usd" id="ixv-38244">198</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-234">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinishedGoods" scale="3" unitRef="usd" id="ixv-38245">470</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-235">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InventoriesNet" scale="3" unitRef="usd" id="ixv-38246">668</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-236">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" escape="true" name="ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory" id="ixv-30296"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6:-</b></span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OTHER ACCOUNTS RECEIVABLE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p>

<ix:nonNumeric contextRef="c7" escape="true" name="sprcy:DisclourseOfAccountsReceivablesTableTextBlock" id="ixv-30307"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Government authorities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ValueAddedTaxReceivables" scale="3" unitRef="usd" id="ixv-38247">45</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ValueAddedTaxReceivables" scale="3" unitRef="usd" id="ixv-38248">52</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-38249">46</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-38250">2,504</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Prepaid expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentPrepaidExpenses" scale="3" unitRef="usd" id="ixv-38251">40</ix:nonFraction></p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentPrepaidExpenses" scale="3" unitRef="usd" id="ixv-38252">348</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentReceivables" scale="3" unitRef="usd" id="ixv-38253">131</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentReceivables" scale="3" unitRef="usd" id="ixv-38254">2,904</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" continuedAt="_DisclosureOfInvestmentPropertyExplanatory-c7_cont_1" escape="true" name="ifrs-full:DisclosureOfInvestmentPropertyExplanatory" id="ixv-30376"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7:-</b></span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVESTMENT IN ASSOCIATES AND INVESTMENTS IN INVESTEES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Sale of Orimmune Bio Ltd.:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On June 22, 2016, the Company entered
into a share transfer agreement (the &#8220;Transfer Agreement&#8221;) with its then wholly owned subsidiary, Orimmune Bio Ltd. (&#8220;Orimmune&#8221;)
and Karma Link Ltd. (the &#8220;Buyer&#8221;), whereby the Company would sell its interests in Orimmune to the Buyer, and also use its
best efforts to transfer to and assign Orimmune its rights in the Anti-CD3 technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On December 13, 2018, an additional amendment
to the Transfer Agreement was signed (the &#8220;Second Amendment&#8221;) between the parties, under which it was agreed that Orimmune
will be assigned certain rights in intellectual property (&#8220;IP&#8221;) related to the licensed technology owned by the Company subject
to certain conditions precedent which were still not met as of December 31, 2022. As of the Approval Date, the conditions precedent have
not yet been completed and the assignment of the IP related to the licensed technology owned by us has not yet been transferred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.5in; text-align: left"><span style="font-size: 10pt">b.</span></td><td style="text-align: justify"><span style="font-size: 10pt">Coeruleus - Joint Venture Transaction</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; margin-top: 0pt; margin-bottom: 0pt">On May 15, 2020, the Company entered into a series of transactions (together, the &#8220;Joint Venture Transaction&#8221;), including a definitive share transfer agreement with Capital Point Ltd. (&#8220;Capital Point&#8221;), an Israeli holding company traded on the TASE, and Evero, pursuant to which Capital Point sold to Evero <ix:nonFraction contextRef="c199" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ConversionOfOrdinaryShares" scale="0" unitRef="shares" id="ixv-38255">5,952,469</ix:nonFraction> ordinary shares, NIS <ix:nonFraction contextRef="c200" decimals="2" format="ixt:num-dot-decimal" name="sprcy:OrdinarySharesPerValue" scale="0" unitRef="ilsPershares" id="ixv-38256">0.01</ix:nonFraction> par value each, of Coeruleus Ltd. (the &#8220;Purchased Coeruleus Shares&#8221; and &#8220;Coeruleus,&#8221; respectively), an Israeli company and a subsidiary of Capital Point (owns approximately <ix:nonFraction contextRef="c201" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" unitRef="pure" id="ixv-38257">46</ix:nonFraction>%), engaged in, among others, developing innovative medications based on the active generic substance flumazenil, including a sublingual spray to reduce the side effects of hypnotic sleep medication, and a sublingual spray to improve function and quality of life in patients with hepatic encephalopathy. The Purchased Coeruleus Shares represented approximately <ix:nonFraction contextRef="c201" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfSharesIssuedAndOutstandingShareCapital" scale="-2" unitRef="pure" id="ixv-38258">35</ix:nonFraction>% of the issued and outstanding share capital of Coeruleus. In consideration thereof, Evero issued and sold to Capital Point <ix:nonFraction contextRef="c201" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ConversionOfOrdinaryShares" scale="0" unitRef="shares" id="ixv-38259">176,470</ix:nonFraction> ordinary shares, NIS <ix:nonFraction contextRef="c202" decimals="2" format="ixt:num-dot-decimal" name="sprcy:OrdinarySharesPerValue" scale="0" unitRef="ilsPershares" id="ixv-38260">1.00</ix:nonFraction> par value each, constituting <ix:nonFraction contextRef="c199" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfSharesIssuedAndOutstandingShareCapital" scale="-2" unitRef="pure" id="ixv-38261">15</ix:nonFraction>% of the issued and outstanding share capital of Evero, which was valued at $<ix:nonFraction contextRef="c201" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:FairMarketValue" scale="3" unitRef="usd" id="ixv-38262">351</ix:nonFraction>, based on apportionment of the fair market value of the Company as reflected on Nasdaq as of May 15, 2020. Following the transaction, Capital Point held approximately <ix:nonFraction contextRef="c203" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfSharesIssuedAndOutstandingShareCapital" scale="-2" unitRef="pure" id="ixv-38263">11</ix:nonFraction>% of Coeruleus&#8217; issued and outstanding share capital. The transaction costs of $<ix:nonFraction contextRef="c201" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" scale="3" unitRef="usd" id="ixv-38264">51</ix:nonFraction> were also capitalized as part of the investment in associate.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">As part of the Joint Venture Transaction,
the Company transferred to Evero its SCI-110 sleep technology, to be fully owned by Evero, under the terms and conditions of an asset
purchase agreement. In addition, the Company issued to Capital Point a warrant (the &#8220;Capital Point Warrant&#8221;) to purchase $<ix:nonFraction contextRef="c204" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PurchaseOfOrdinaryShares" scale="3" unitRef="usd" id="ixv-38265">340</ix:nonFraction>
of ordinary shares of the Company. Pursuant to the terms of the Capital Point Warrant, the exercise price per ordinary share is equal
to the closing price of the Company&#8217;s ordinary shares on the trading day on which the notice of exercise was actually received by
the Company and shall be paid by transferring to the Company a duly executed share transfer deed for <ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ConversionOfOrdinaryShares" scale="0" unitRef="shares" id="ixv-38266">9,577</ix:nonFraction> ordinary shares of Evero. The
Capital Point Warrant is exercisable for twelve months starting from May 15, 2021, until May 15, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>



</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 208; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 7:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>INVESTMENT IN ASSOCIATES AND INVESTMENTS IN INVESTEES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.5in; text-align: left"><span style="font-size: 10pt">b.</span></td><td style="text-align: justify"><span style="font-size: 10pt">Coeruleus - Joint Venture Transaction</span> (Cont.)</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfInvestmentPropertyExplanatory-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 29, 2020, the shareholders
of Coeruleus approved an investment from its shareholders of approximately $<ix:nonFraction contextRef="c206" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ShareholdersAmount" scale="3" unitRef="usd" id="ixv-38267">30</ix:nonFraction>. The Company did not participate in this investment in
Coeruleus and therefore, as of the completion of such financing, the Company held less than <ix:nonFraction contextRef="c207" decimals="2" format="ixt:num-dot-decimal" name="sprcy:IssuedAndOutstandingSharesPercentage" scale="-2" unitRef="pure" id="ixv-38268">1</ix:nonFraction>% of the issued and outstanding shares of
Coeruleus. As of December 31, 2022, the fair value of the Company&#8217;s investment in Coeruleus is $nil.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">MitocareX - Joint Venture Transaction</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">On March 10, 2022, the Company entered into a Founders and Investment Agreement with Dr. Alon Silberman, or the MitoCareX Agreement. Pursuant to the MitoCareX Agreement, the Company invested an initial amount of $<ix:nonFraction contextRef="c106" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForAmountsTransferredToInitialCarryingAmountOfHedgedItems" scale="3" unitRef="usd" id="ixv-38269">700</ix:nonFraction>, and agreed to invest over the next <ix:nonNumeric contextRef="c106" format="ixt-sec:durwordsen" name="sprcy:InvestedInitialAmounts" id="ixv-38270">two years</ix:nonNumeric>, an additional $<ix:nonFraction contextRef="c106" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PreDeterminedValue" scale="3" unitRef="usd" id="ixv-38271">1,000</ix:nonFraction>, subject to the achievement of certain pre-determined milestones as agreed upon in the MitoCareX Agreement, for up to a <ix:nonFraction contextRef="c106" decimals="4" format="ixt:num-dot-decimal" name="sprcy:OwnershipPercentage" scale="-2" unitRef="pure" id="ixv-38272">50.01</ix:nonFraction>% ownership in MitoCareX Bio Ltd. (&#8220;MitoCareX&#8221;). MitoCareX is focused on the discovery and development of potential drugs for cancers and other life-threatening conditions. The MitoCareX Agreement also contains customary representations, warranties, covenants, and indemnification provisions. On March 31, 2022, the closing conditions were met, and the Company paid the initial investment amount of $<ix:nonFraction contextRef="c108" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InitialInvestmentAmount" scale="3" unitRef="usd" id="ixv-38273">700</ix:nonFraction> to MitoCareX. As of December 31, 2022, the Company owns <ix:nonFraction contextRef="c7" decimals="4" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStocks" scale="-2" unitRef="pure" id="ixv-38274">31.48</ix:nonFraction>% of the outstanding shares of MitocareX.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">On February 17, 2023, MitoCareX achieved its first milestone pursuant to the MitoCare X Agreement. The first milestone refers to the establishment of MitoCareX&#8217;s cloud-based computing infrastructure that is expected to allow its future expansion into machine learning system. The system is harnessed to investigating mitochondrial carriers that are crucial for cell viability. As a result of MitoCareX meeting this milestone, the Company will invest an additional $<ix:nonFraction contextRef="c208" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InitialInvestmentAmount" scale="3" unitRef="usd" id="ixv-38275">400</ix:nonFraction> in MitoCareX and increase its share ownership in MitoCareX Bio from <ix:nonFraction contextRef="c209" decimals="4" format="ixt:num-dot-decimal" name="sprcy:OwnershipPercentage" scale="-2" unitRef="pure" id="ixv-38276">31.48</ix:nonFraction>% to <ix:nonFraction contextRef="c210" decimals="4" format="ixt:num-dot-decimal" name="sprcy:OwnershipPercentage" scale="-2" unitRef="pure" id="ixv-38277">41.92</ix:nonFraction>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">During the year ended December 31, 2022, the Company recorded equity losses from the investment in MitoCareX in the amount of $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InitialInvestmentAmount" scale="3" unitRef="usd" id="ixv-38278">109</ix:nonFraction>.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><ix:nonNumeric contextRef="c7" continuedAt="sprcy_DisclosureOfFairValueMeasurementOfAssetstable-c7_cont_1" escape="true" name="sprcy:DisclosureOfFairValueMeasurementOfAssetstable" id="ixv-38279">The table below summarizes the fair value of the
investment in MitoCareX:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DisclosureOfFairValueMeasurementOfAssetstable-c7_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-237">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%">Investment date March 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentDate" scale="3" unitRef="usd" id="ixv-38280">700</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:EquityLossesFromInvestment" scale="3" unitRef="usd" id="ixv-38281">109</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance at December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-38282">591</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" escape="true" name="ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" id="ixv-30518"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8:-</b></span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVESTMENT IN FINANCIAL ASSETS</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On November 17, 2022, the Company invested
$<ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentAmount" scale="3" unitRef="usd" id="ixv-38283">1,500</ix:nonFraction> in the initial public offering of Clearmind Medicine Inc. (&#8220;Clearmind&#8221;) and received <ix:nonFraction contextRef="c211" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssuedButNotFullyPaid" scale="0" unitRef="shares" id="ixv-38284">230,769</ix:nonFraction> common shares of Clearmind,
resulting in the Company holding <ix:nonFraction contextRef="c117" decimals="4" format="ixt:num-dot-decimal" name="sprcy:ShareCapitalPercentage" scale="-2" unitRef="pure" id="ixv-38285">9.33</ix:nonFraction>% of share capital of Clearmind. Clearmind is a psychedelic pharmaceutical biotech company focused
on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including
alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as
regulated medicines, foods or supplements. Shares of Clearmind are listed for trading on Nasdaq and the Canadian Securities Exchange under
the symbol &#8220;CMND&#8221; and the Frankfurt Stock Exchange under the symbol &#8220;CWY.&#8221; &#160; As of December 31, 2022, the
listed share price of Clearmind on Nasdaq was $<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="sprcy:SharePricePerShare" scale="0" unitRef="usdPershares" id="ixv-38286">3.16</ix:nonFraction>, and the Company has recorded a loss in its statements of comprehensive loss of $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ComprehensiveLoss" scale="3" unitRef="usd" id="ixv-38287">771</ix:nonFraction>
on its investment. &#160;</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" escape="true" name="ifrs-full:DisclosureOfLeasesExplanatory" id="ixv-30532"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 9:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>LEASES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">On September 1, 2020, the Company entered
into a one-year lease agreement (&#8220;the 2020 Lease&#8221;) with a third party for an area of approximately <ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="sprcy:SquareMeters" scale="0" unitRef="pure" id="ixv-38288">100</ix:nonFraction> square meters for the
Company&#8217;s offices in the district of Tel Aviv, Israel. The yearly lease fee was set at approximately $<ix:nonFraction contextRef="c212" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:LeaseFee" scale="3" unitRef="usd" id="ixv-38289">44</ix:nonFraction>, linked to the NIS. The
lease expired on <ix:nonNumeric contextRef="c213" format="ixt:date-monthname-day-year-en" name="sprcy:ExpireTerm" id="ixv-38290">August 31, 2021</ix:nonNumeric>. The Company did not exercise its option to extend the lease until August 31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">On July 1, 2021, the Company entered
into a two-year joint lease agreement (&#8220;the 2021 Lease&#8221;) with a third party and for a total area of approximately <ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="sprcy:SquareMeters" scale="0" unitRef="pure" id="ixv-38291">240</ix:nonFraction> square
meters, whereby the Company occupies approximately <ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="sprcy:SquareMeters" scale="0" unitRef="pure" id="ixv-38292">120</ix:nonFraction> square meters for the Company&#8217;s offices, in the district of Tel Aviv, Israel.
The Company and the third party have an option to extend for an additional three-year term. The yearly lease fee was set at approximately
$<ix:nonFraction contextRef="c214" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:LeaseFee" scale="3" unitRef="usd" id="ixv-38293">40</ix:nonFraction>, linked to the NIS.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 209; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" escape="true" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" id="ixv-30579"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 10:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>PROPERTY AND EQUIPMENT, NET</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c7" escape="true" name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" id="ixv-30589"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="11" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Assets owned and used by the Company</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Right-of-<br/> use assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Computers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Lab<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Office<br/> furniture<br/> and<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Leasehold<br/> office</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic">Cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c216" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:BeginningBalanceCost" scale="3" unitRef="usd" id="ixv-38294">7</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-238">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c218" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:BeginningBalanceCost" scale="3" unitRef="usd" id="ixv-38295">29</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c219" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:BeginningBalanceCost" scale="3" unitRef="usd" id="ixv-38296">78</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c220" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:BeginningBalanceCost" scale="3" unitRef="usd" id="ixv-38297">114</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Purchases</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c221" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PurchasesOfCost" scale="3" unitRef="usd" id="ixv-38298">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-239">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c223" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PurchasesOfCost" scale="3" unitRef="usd" id="ixv-38299">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-240">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c224" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PurchasesOfCost" scale="3" unitRef="usd" id="ixv-38300">8</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c221" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:BeginningBalanceCost" scale="3" unitRef="usd" id="ixv-38301">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-241">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c223" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:BeginningBalanceCost" scale="3" unitRef="usd" id="ixv-38302">33</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c198" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:BeginningBalanceCost" scale="3" unitRef="usd" id="ixv-38303">78</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c224" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:BeginningBalanceCost" scale="3" unitRef="usd" id="ixv-38304">122</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance at January&#160;1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c216" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentCost" scale="3" unitRef="usd" id="ixv-38305">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-242">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c218" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentCost" scale="3" unitRef="usd" id="ixv-38306">1</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c219" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentCost" scale="3" unitRef="usd" id="ixv-38307">20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c220" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentCost" scale="3" unitRef="usd" id="ixv-38308">22</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c193" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-38309">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-243">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c226" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-38310">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c197" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-38311">39</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c227" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-38312">43</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c221" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentCost" scale="3" unitRef="usd" id="ixv-38313">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-244">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c223" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentCost" scale="3" unitRef="usd" id="ixv-38314">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c198" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentCost" scale="3" unitRef="usd" id="ixv-38315">59</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c224" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentCost" scale="3" unitRef="usd" id="ixv-38316">65</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Depreciated cost at December 31, 2022</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c221" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" scale="3" unitRef="usd" id="ixv-38317">8</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-245">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c223" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" scale="3" unitRef="usd" id="ixv-38318">30</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c198" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" scale="3" unitRef="usd" id="ixv-38319">19</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c224" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" scale="3" unitRef="usd" id="ixv-38320">57</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2021</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c228" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:BeginningBalanceCost" scale="3" unitRef="usd" id="ixv-38321">20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c229" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:BeginningBalanceCost" scale="3" unitRef="usd" id="ixv-38322">12</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c230" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:BeginningBalanceCost" scale="3" unitRef="usd" id="ixv-38323">23</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-246">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c232" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:BeginningBalanceCost" scale="3" unitRef="usd" id="ixv-38324">55</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">New leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-247">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-248">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-249">-</div></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c219" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:NewLeases" scale="3" unitRef="usd" id="ixv-38325">78</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c220" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:NewLeases" scale="3" unitRef="usd" id="ixv-38326">78</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Purchases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c216" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PurchasesOfCost" scale="3" unitRef="usd" id="ixv-38327">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-250">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c218" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PurchasesOfCost" scale="3" unitRef="usd" id="ixv-38328">29</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-251">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c220" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PurchasesOfCost" scale="3" unitRef="usd" id="ixv-38329">35</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Disposals</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c233" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-38330">19</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c234" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-38331">12</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c235" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-38332">23</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-252">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c237" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-38333">54</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c216" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:BeginningBalanceCost" scale="3" unitRef="usd" id="ixv-38334">7</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-253">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c218" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:BeginningBalanceCost" scale="3" unitRef="usd" id="ixv-38335">29</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c219" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:BeginningBalanceCost" scale="3" unitRef="usd" id="ixv-38336">78</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c220" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:BeginningBalanceCost" scale="3" unitRef="usd" id="ixv-38337">114</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance at January&#160;1, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c228" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentCost" scale="3" unitRef="usd" id="ixv-38338">19</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c229" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentCost" scale="3" unitRef="usd" id="ixv-38339">12</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c230" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentCost" scale="3" unitRef="usd" id="ixv-38340">13</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-254">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c232" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentCost" scale="3" unitRef="usd" id="ixv-38341">44</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Depreciation of leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-255">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-256">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-257">-</div></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c236" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AccumulatedTerminationOfLeases" scale="3" unitRef="usd" id="ixv-38342">20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c237" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AccumulatedTerminationOfLeases" scale="3" unitRef="usd" id="ixv-38343">20</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c233" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-38344">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-258">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c235" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-38345">11</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-259">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c237" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-38346">12</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Disposals</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c233" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-38347">19</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c234" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-38348">12</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c235" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-38349">23</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-260">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c237" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-38350">54</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c216" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentCost" scale="3" unitRef="usd" id="ixv-38351">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-261">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c219" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentCost" scale="3" unitRef="usd" id="ixv-38352">20</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c220" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentCost" scale="3" unitRef="usd" id="ixv-38353">22</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Depreciated cost at December 31, 2021</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c216" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" scale="3" unitRef="usd" id="ixv-38354">6</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-262">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c218" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" scale="3" unitRef="usd" id="ixv-38355">28</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c219" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" scale="3" unitRef="usd" id="ixv-38356">58</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c220" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" scale="3" unitRef="usd" id="ixv-38357">92</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Depreciation expenses for the years
ended December 31, 2022, 2021 and 2020 amounted to $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="3" unitRef="usd" id="ixv-38358">43</ix:nonFraction>, $<ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="3" unitRef="usd" id="ixv-38359">32</ix:nonFraction> and $<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="3" unitRef="usd" id="ixv-38360">7</ix:nonFraction>, respectively.</p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" continuedAt="_DisclosureOfIntangibleAssetsExplanatory-c7_cont_1" escape="true" name="ifrs-full:DisclosureOfIntangibleAssetsExplanatory" id="ixv-31309"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 11:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>INTANGIBLE ASSET</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">On September 30, 2022, the Company announced
the closing of the acquisition of Wellution<sup>TM</sup>, a top seller Amazon.com Marketplace account (the &#8220;Brand&#8221;), American
food supplements and cosmetics brand and trademark (the &#8220;Acquisition&#8221;). In connection with the Acquisition, the Company incorporated
a new wholly owned Delaware subsidiary, SciSparc Nutraceuticals Inc., to hold the new assets. The definitive agreement for the acquisition
of the Brand was entered into with Merhavit M.R.M Holding and Management Ltd (&#8220;M.R.M&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">At the closing, the Company paid a
base cash payment of $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CashPayment" scale="3" unitRef="usd" id="ixv-38361">4,540</ix:nonFraction> and in 12 months following the closing agreed to pay an additional deferred cash payment equal to a multiple
of 3 times the amount by which the Brand&#8217;s EBITDA exceeds $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount" scale="3" unitRef="usd" id="ixv-38362">1,120</ix:nonFraction> during the 12-month period following the closing of the Acquisition.
The Company paid an additional $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PurchaseCosts" scale="3" unitRef="usd" id="ixv-38363">321</ix:nonFraction> as purchase costs.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In addition, the Company issued to
M.R.M $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsToPurchase" scale="3" unitRef="usd" id="ixv-38364">15,000</ix:nonFraction> worth of warrants to purchase ordinary shares of the Company at an exercise price of $<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-38365">7.00</ix:nonFraction> per share (with a cashless exercise
mechanism) and with an exercise period of <ix:nonNumeric contextRef="c7" format="ixt-sec:durwordsen" name="sprcy:ExercisePeriod" id="ixv-38366">five years</ix:nonNumeric> from the closing of the Acquisition (the &#8220;September 2022 Warrants&#8221;).
The September 2022 Warrants will become exercisable upon the earlier of (i) an achievement of $<ix:nonFraction contextRef="c7" decimals="-6" format="ixt:num-dot-decimal" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="6" unitRef="usd" id="ixv-38367">100</ix:nonFraction> million of gross sales by the Brand
in the aggregate or (ii) if the price of our Ordinary Shares closes at $<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="sprcy:pricePerShare" scale="0" unitRef="usdPershares" id="ixv-38368">10.00</ix:nonFraction> or above.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 210; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: justify; width: 72px"><span style="font-size: 10pt"><b>NOTE 11:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>INTANGIBLE ASSET (CONT.)</b></span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfIntangibleAssetsExplanatory-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company reviewed the transaction
and deemed it to be the purchase of assets for accounting purposes under generally accepted accounting principles and not as a business
combination. The Company reviewed the guidance under IFRS 3 for the transaction and determined that the fair value of the gross assets
acquired was concentrated in a single identifiable asset, a brand. Accordingly, the Company treated the transaction as an asset acquisition.
On the closing date of the acquisition, the Company fully recognized the acquisition amount total of $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AmountTotal" scale="3" unitRef="usd" id="ixv-38369">4,861</ix:nonFraction> as an intangible asset, to
be amortized over a period of <ix:nonNumeric contextRef="c7" format="ixt-sec:duryear" name="ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" id="ixv-38370">10</ix:nonNumeric> years.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c7" continuedAt="sprcy_ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock-c7_cont_1" escape="true" name="sprcy:ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock" id="ixv-38371">The table below
summarizes the fair value of the intangible asset:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock-c7_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-263">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%">Purchase date September 30, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PurchaseofAssets" scale="3" unitRef="usd" id="ixv-38372">4,861</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation of intangible asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetFairValueUsedAsDeemedCost" scale="3" unitRef="usd" id="ixv-38373">144</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance at December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="3" unitRef="usd" id="ixv-38374">4,717</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">During the year ended December 31,
2022, the Company recognized depreciation expenses in respect to intangible asset in the amount of $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-38375">144</ix:nonFraction>.&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The estimated fair values of the tangible
and intangible assets in respect of the acquisition of&#160;the Wellution&#8482; brand are provisional and are based on information that
was available as of the acquisition date to estimate the fair value of these amounts. The Group&#8217;s management believes the information
provides a reasonable basis for estimating the fair values of these amounts but is waiting for additional information necessary to finalize
those fair values. Therefore, provisional measurements of fair value that appear are subject to change. The Group expects to finalize
the tangible and intangible assets valuation and complete the acquisition accounting as soon as practicable but no later than the measurement
period.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" escape="true" name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory" id="ixv-31412"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 12:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>TRADE PAYABLES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c7" escape="true" name="sprcy:DisclosureOfTradePayables" id="ixv-31422"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 78%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AccruedExpenses" scale="3" unitRef="usd" id="ixv-38376">901</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AccruedExpenses" scale="3" unitRef="usd" id="ixv-38377">758</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Open debts</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-38378">298</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-38379">441</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-38380">1,199</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-38381">1,199</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 211; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" escape="true" name="sprcy:DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent" id="ixv-31526"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 13:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>OTHER ACCOUNTS PAYABLE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c7" escape="true" name="sprcy:ScheduleOfOtherAccountsPayable" id="ixv-31536"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Employees and payroll accruals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermEmployeeBenefitsAccruals" scale="3" unitRef="usd" id="ixv-38382">102</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermEmployeeBenefitsAccruals" scale="3" unitRef="usd" id="ixv-38383">45</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Accruals" scale="3" unitRef="usd" id="ixv-38384">77</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Accruals" scale="3" unitRef="usd" id="ixv-38385">38</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherPayables" scale="3" unitRef="usd" id="ixv-38386">14</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherPayables" scale="3" unitRef="usd" id="ixv-38387">71</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:TradeAndOtherPayable" scale="3" unitRef="usd" id="ixv-38388">193</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:TradeAndOtherPayable" scale="3" unitRef="usd" id="ixv-38389">154</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" continuedAt="_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory-c7_cont_1" escape="true" name="ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" id="ixv-31604"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 14:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>FINANCIAL INSTRUMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Classification of financial assets and financial liabilities:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"><ix:nonNumeric contextRef="c7" continuedAt="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities-c7_cont_1" escape="true" name="sprcy:DisclosureOfFinancialAssetsAndFinancialLiabilities" id="ixv-31623">The financial assets and financial liabilities
in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9, &#8220;<i>Financial
Instruments</i>&#8221; (&#8220;IFRS 9&#8221;):</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities-c7_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">Financial assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and restricted deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-38390">3,634</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-38391">6,920</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Government authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GovernmentAuthorities" scale="3" unitRef="usd" id="ixv-38392">45</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GovernmentAuthorities" scale="3" unitRef="usd" id="ixv-38393">52</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other receivables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-38394">46</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-38395">2,504</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Investments in financial assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentsInFinancialAssets" scale="3" unitRef="usd" id="ixv-38396">591</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-264">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total financial assets at amortized cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentFinancialAssetsAtAmortisedCost" scale="3" unitRef="usd" id="ixv-38397">4,316</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentFinancialAssetsAtAmortisedCost" scale="3" unitRef="usd" id="ixv-38398">9,476</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">Financial liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Credit from others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CreditsFromOthers" scale="3" unitRef="usd" id="ixv-38399">102</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CreditsFromOthers" scale="3" unitRef="usd" id="ixv-38400">45</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsLiability" scale="3" unitRef="usd" id="ixv-38401">2,737</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsLiability" scale="3" unitRef="usd" id="ixv-38402">359</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-38403">27</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-38404">18</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total financial and lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd" id="ixv-38405">2,866</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd" id="ixv-38406">422</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><!-- Field: Page; Sequence: 212; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><ix:continuation continuedAt="_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory-c7_cont_2" id="_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 14:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>FINANCIAL INSTRUMENTS (CONT.)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px">b<span style="font-size: 10pt">.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Bridge Loan</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On January 15, 2020, the Company entered
into a bridge loan agreement (the &#8220;Bridge Loan&#8221;) with a third party, in which the third party lent to the Company $<ix:nonFraction contextRef="c238" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:BridgeLoanAmount" scale="3" unitRef="usd" id="ixv-38407">50</ix:nonFraction> (the
&#8220;Bridge Loan Amount&#8221;). On April 17, 2020, the Bridge Loan Amount was fully repaid by the Company, including interest in the
amount of $<ix:nonFraction contextRef="c239" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestPayable" scale="3" unitRef="usd" id="ixv-38408">2</ix:nonFraction>. Accordingly, the Bridge Loan was terminated with no further effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px">c<span style="font-size: 10pt">.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Line of Credit</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On September 8, 2020, the Company entered
into a certain credit agreement (the &#8220;Credit Facility&#8221;), with M.R.M. Merchavit Holdings and Management Ltd. (the &#8220;Lender&#8221;),
whereby the Lender agreed to extend a line of credit to the Company in the aggregate amount of $<ix:nonFraction contextRef="c240" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AggregateAmountOrCreditAmount" scale="3" unitRef="usd" id="ixv-38409">200</ix:nonFraction>, or the Credit Amount. According to
the terms of the Credit Facility, $<ix:nonFraction contextRef="c240" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CreditFacilityAmount" scale="3" unitRef="usd" id="ixv-38410">100</ix:nonFraction> of the Credit Amount (the &#8220;Loan Amount&#8221;), was immediately drawn on the date of the
Credit Facility, and the remaining $<ix:nonFraction contextRef="c240" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CreditFacilityAndRemainingAvailableDrawnAmount" scale="3" unitRef="usd" id="ixv-38411">100</ix:nonFraction> was available be drawn on an as-needed basis. The Loan Amount was due upon the earlier of <ix:nonNumeric contextRef="c240" format="ixt-sec:durwordsen" name="sprcy:LoanAmountDueTerm" id="ixv-38412">one
year</ix:nonNumeric> from September 8, 2020 or at such time that the Company raised $<ix:nonFraction contextRef="c240" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:LoanAmountRaised" scale="3" unitRef="usd" id="ixv-38413">1,500</ix:nonFraction>. <ix:nonNumeric contextRef="c240" name="ifrs-full:DisclosureOfCompoundFinancialInstrumentsWithMultipleEmbeddedDerivativesExplanatory" id="ixv-38414">The Lender was entitled to a transaction and interest fee
of $5 (plus VAT) that was offset from the Credit Facility for the immediately drawn $100 and 5% from any additional withdrawal amount
from the Credit Facility. On November 24, 2020, the Loan Amount was fully repaid by the Company.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px">d<span style="font-size: 10pt">.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Dekel</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On March 19, 2020, the Company entered
into a securities purchase agreement with Dekel Pharmaceutical Ltd. (&#8220;Dekel&#8221;) pursuant to which Dekel agreed to invest in
the Company through a private placement transaction (the &#8220;Private Placement&#8221;). At the time of the Private Placement, Dekel
was considered as a related party to the Company; however, it is no longer a related party to the Company. In connection with the Private
Placement, Dekel received convertible promissory notes (the &#8220;Notes&#8221;), with an aggregate original principal amount of approximately
$<ix:nonFraction contextRef="c241" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashOutflowForLeases" scale="3" unitRef="usd" id="ixv-38415">350</ix:nonFraction>, at an aggregate purchase price of $<ix:nonFraction contextRef="c242" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash" scale="3" unitRef="usd" id="ixv-38416">315</ix:nonFraction> to be paid in several tranches spread across a twelve-month period. In addition, the Company
issued a warrant to purchase up to <ix:nonFraction contextRef="c242" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" scale="0" unitRef="shares" id="ixv-38417">314,285</ix:nonFraction> ordinary shares of the Company (the &#8220;Private Placement Warrant&#8221;) and <ix:nonFraction contextRef="c243" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" scale="0" unitRef="shares" id="ixv-38418">40,000</ix:nonFraction> ordinary
shares. The initial tranche of the Private Placement was for a principal amount of $<ix:nonFraction contextRef="c244" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashOutflowForLeases" scale="3" unitRef="usd" id="ixv-38419">220</ix:nonFraction> at a purchase price of $<ix:nonFraction contextRef="c244" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PurchasePrice" scale="3" unitRef="usd" id="ixv-38420">198</ix:nonFraction>. The Notes are unsecured,
have a maturity date of <ix:nonNumeric contextRef="c241" format="ixt:date-monthname-day-year-en" name="sprcy:MaturityDate" id="ixv-38421">March 23, 2021</ix:nonNumeric>, bear interest at a rate of <ix:nonFraction contextRef="c242" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" unitRef="pure" id="ixv-38422">12</ix:nonFraction>% per annum, and may be converted, at the election of the holder,
into ordinary shares at an initial conversion price of $<ix:nonFraction contextRef="c242" decimals="2" format="ixt:num-dot-decimal" name="sprcy:InitialConversionPrice" scale="0" unitRef="usdPershares" id="ixv-38423">0.35</ix:nonFraction> per ordinary share (the &#8220;Fixed Conversion Price&#8221;), subject to
adjustments. After the six-month anniversary of the issuance of the Notes, the conversion price shall be equal to the lower of the Fixed
Conversion Price or <ix:nonFraction contextRef="c241" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ConversionPrice" scale="-2" unitRef="pure" id="ixv-38424">70</ix:nonFraction>% of the lowest trading price of the ordinary shares as reported on Nasdaq or any exchange upon which the ordinary
shares of the Company are traded at such time, for the 20 prior trading days including the day upon which a notice of conversion is received
by the Company or its transfer agent. The Private Placement Warrant is exercisable at any time on or after the actual closing date and
on or prior to the close of business on the five-year anniversary of the date of issuance, at an initial exercise price of $<ix:nonFraction contextRef="c241" decimals="2" format="ixt:num-dot-decimal" name="sprcy:OrdinaryShareExercisePrice" scale="0" unitRef="usdPershares" id="ixv-38425">0.35</ix:nonFraction> per ordinary
share, subject to adjustment. On November 8, 2020, the Notes were terminated and the initial tranche was fully repaid by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"><i>General Overview of Valuation Approaches
used in the Valuation:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">Fair value is the price that would be
received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 213; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 14:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>FINANCIAL INSTRUMENTS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px">d<span style="font-size: 10pt">.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Dekel (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory-c7_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"><i>Economic methodology:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"><ix:nonNumeric contextRef="c7" continuedAt="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock-c7_cont_1" escape="true" name="sprcy:ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock" id="ixv-38426">The warrants&#8217; fair value was calculated
using the Black&#8211;Scholes OPM, which takes into account the parameters as disclosed below for each period valuated, in which a valuation
was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock-c7_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;23,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="sprcy:DividendYield" scale="-2" unitRef="pure" id="ixv-38427">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="sprcy:DividendYield" scale="-2" unitRef="pure" id="ixv-38428">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c245" decimals="2" format="ixt:num-dot-decimal" name="sprcy:DividendYield" scale="-2" unitRef="pure" id="ixv-38429">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ExpectedVolatility" scale="-2" unitRef="pure" id="ixv-38430">72</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ExpectedVolatility" scale="-2" unitRef="pure" id="ixv-38431">148</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c245" decimals="4" format="ixt:num-dot-decimal" name="sprcy:ExpectedVolatility" scale="-2" unitRef="pure" id="ixv-38432">122.01</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="4" format="ixt:num-dot-decimal" name="sprcy:RiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-38433">4.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="4" format="ixt:num-dot-decimal" name="sprcy:RiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-38434">0.87</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c245" decimals="4" format="ixt:num-dot-decimal" name="sprcy:RiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-38435">0.38</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Underlying Share Price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="sprcy:UnderlyingAdsPrice" scale="0" unitRef="usdPershares" id="ixv-38436">0.756</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="sprcy:UnderlyingAdsPrice" scale="0" unitRef="usdPershares" id="ixv-38437">6.23</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c245" decimals="2" format="ixt:num-dot-decimal" name="sprcy:UnderlyingAdsPrice" scale="0" unitRef="usdPershares" id="ixv-38438">0.43</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ExercisePricePerShare" scale="0" unitRef="usdPershares" id="ixv-38439">24.50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ExercisePricePerShare" scale="0" unitRef="usdPershares" id="ixv-38440">24.50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c245" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ExercisePricePerShare" scale="0" unitRef="usdPershares" id="ixv-38441">24.50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants fair value ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="sprcy:WarrantsFairValueinDollarsPerShares" scale="0" unitRef="usdPershares" id="ixv-38442">0</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="sprcy:WarrantsFairValueinDollarsPerShares" scale="0" unitRef="usdPershares" id="ixv-38443">4.15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c245" decimals="2" format="ixt:num-dot-decimal" name="sprcy:WarrantsFairValueinDollarsPerShares" scale="0" unitRef="usdPershares" id="ixv-38444">0.36</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify">e<span style="font-size: 10pt">.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial risk factors:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The Company&#8217;s activities expose
it to various financial risks such as market risks (foreign currency risk and interest risk), credit risk and liquidity risk. The Company&#8217;s
comprehensive risk management plan focuses on activities that reduce to a minimum any possible adverse effects on the Company&#8217;s
financial performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">Risk management is performed by management
in accordance with the policies approved by the Company&#8217;s board of directors (the &#8220;Board&#8221;). The Board establishes written
principles for the overall risk management activities as well as specific policies with respect to certain exposures to risks such as
exchange rate risk, credit risk and the investments of surplus funds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Market risks:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"><i>Foreign currency risk:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">The Company is exposed to exchange rate
risk resulting from the exposure to different currencies, mainly from transactions in NIS. Exchange rate risk arises from recognized liabilities
that are denominated in a foreign currency other than the functional currency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Credit risks:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">All cash and restricted deposits related
to the Company are held in two banks in Israel which are considered financially solid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Liquidity risk:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">The Company monitors the risk of a shortage
of funds on a regular basis and acts to raise funds to satisfy its liabilities. As of December 31, 2022, the Company expects to settle
all of its financial liabilities in less than one year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">The carrying amounts of cash and restricted
deposits, and all other financial assets and liabilities approximate their fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">Refer to Note 1c for more information.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 214; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" escape="true" name="ifrs-full:DisclosureOfEmployeeBenefitsExplanatory" id="ixv-32105"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 15:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>EMPLOYEE BENEFIT LIABILITIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">Employee benefits consist of short-term
benefits and post-employment benefits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify"><i>Post-employment benefits:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">According to the labor laws and the Israeli
Severance Pay Law, 1963 (the &#8220;Severance Pay Law&#8221;), the Company is required to pay compensation to an employee upon dismissal
or retirement or to make current contributions in defined contribution plans pursuant to Section 14 of the Severance Pay Law, as specified
below. The Company&#8217;s liability is accounted for as a post-employment benefit. The computation of the Company&#8217;s employee benefit
liability is made in accordance with a valid employment contract based on the employee&#8217;s salary and employment term which establish
the entitlement to receive the compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">The post-employment benefits are normally
financed by contributions classified as defined benefit plans or as defined contribution plans as detailed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify"><i>Defined contribution plans:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">Section 14 of the Severance Pay Law applies
to a substantial part of the compensation payments, pursuant to which the fixed contributions paid by the Company into pension funds and/or
policies of insurance companies release the Company from any additional liability to employees for whom said contributions were made.
<ix:nonNumeric contextRef="c7" continuedAt="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory-c7_cont_1" escape="true" name="sprcy:DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" id="ixv-38445">These contributions and contributions for compensation represent defined contribution plans.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory-c7_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Expenses in respect of defined contribution plans</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" unitRef="usd" id="ixv-38446">115</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" unitRef="usd" id="ixv-38447">98</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" unitRef="usd" id="ixv-38448">52</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" escape="true" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="ixv-32164"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 16:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>TAXES ON INCOME</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Tax rates applicable to the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The Israeli statutory corporate tax rate
and real capital gains tax rate were <ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ApplicableTaxRate" scale="-2" unitRef="pure" id="ixv-38449"><ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ApplicableTaxRate" scale="-2" unitRef="pure" id="ixv-38450"><ix:nonFraction contextRef="c12" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ApplicableTaxRate" scale="-2" unitRef="pure" id="ixv-38451">23</ix:nonFraction></ix:nonFraction></ix:nonFraction>% in 2022, 2021, and 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Tax assessments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The assessments of the Company are
deemed final through the 2016 tax year.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Carryforward tax losses and other temporary differences:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The Company has accumulated tax losses
since its inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">As of December 31, 2022, the Company&#8217;s
net carryforward tax losses are estimated to grow to approximately $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:OperatingLossCarryforwardsTaxAmount" scale="3" unitRef="usd" id="ixv-38452">58,000</ix:nonFraction>.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 215; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" continuedAt="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c7_cont_1" escape="true" name="ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" id="ixv-32234"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE 17:-</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; font-size: 10pt; text-align: justify">&#160;</td>
    <td style="width: 48px; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">a.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">License Agreement with Dekel Pharmaceuticals Ltd.:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">In May 2015, the Company entered into
an exclusive, irrevocable, worldwide license agreement with Dekel for certain technology and one granted U.S. patent related to compositions
and methods for treating inflammatory disorders (the &#8220;Dekel License Agreement&#8221;). The Dekel License Agreement became effective
in August 2015.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">Pursuant to the Dekel License Agreement,
the Company is obligated to pay Dekel fees based on specific milestones and royalties upon commercialization. The milestone payments include:
<ix:nonNumeric contextRef="c7" name="sprcy:DekelLicenseAgreementDescription" id="ixv-38453">(i) $25 upon the successful completion of preclinical trials (which milestone was met in November 2016; this milestone was paid in cash
in March 2017); (ii) $75 upon the successful completion of a Phase I/IIa trial; and (iii) $75 upon the earlier of generating net revenues
of at least $200 from the commercialization of the technology or the approval of the U.S. Food and Drug Administration or the European
Medicines Agency, of a drug based on the licensed assets. In each case, and subject to the Company&#8217;s discretion, the respective
milestone payments are payable in cash or equity based on a price per ordinary share of NIS 0.5. The royalty payments are 8% for commercialization
and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of any patents maturing from this application would
likely be 2029.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On July 14, 2019, an amendment to the
Dekel License Agreement was signed (the &#8220;Amendment&#8221;), which encompasses the Company and Dekel&#8217;s original intention to
exclude certain consumer packaged goods (meaning, inter alia, food, beverage, cosmetics, pet products and hemp based products, which are
sources of nutrients or other substances which may have a nutritional effect) from the scope of the licensed products and the field of
activity of the Company described in the Dekel License Agreement. The parties agreed to amend the Dekel License Agreement to reflect the
foregoing clarification, as well as certain additional less material matters as discussed in the Amendment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The Amendment also prescribes for a specific
development plan under the Dekel License Agreement requiring the Company to invest in the licensed technology (as defined under the License
Agreement) formulation development and maintenance a total annual investment to be capped at $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AnnualInvestment" scale="3" unitRef="usd" id="ixv-38454">350</ix:nonFraction>. The Amendment also included a non-compete
and non-solicitation obligation by Dekel and Dr. Ascher Shmulewitz, the Company&#8217;s former Executive Chairman of the Board and former
interim Chief Executive Officer, towards the Company&#8217;s field of activity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On November 13, 2019, an additional milestone
under the Dekel License Agreement, in the amount of $<ix:nonFraction contextRef="c246" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdditionalMilestoneAmount" scale="3" unitRef="usd" id="ixv-38455">75</ix:nonFraction>, was reached upon the successful completion of a Phase IIa clinical trial. The
Company paid the milestone amount on April 13, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 216; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE 17:-</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c7_cont_2" id="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c7_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">License Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (&#8220;Yissum&#8221;):</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On July 29, 2018, the Company entered
into an exclusive, worldwide, sublicensable, royalty-bearing license with Yissum for a license to make commercial use of the licensed
technology, in order to develop, obtain regulatory approvals, manufacture, market, distribute or sell products, all within the field and
the territory only, as determined in the agreement (the &#8220;Yissum License Agreement&#8221;). According to the Yissum License Agreement,
the Company shall pay Yissum royalties at the rates of future net sales, subject to the royalty reductions as described in the Yissum
License Agreement. The Company is also obligated to pay sublicense fees out of the sublicense consideration. All right, title and interest
in and to the Yissum License Agreement shall vest solely in Yissum, and the Company shall hold and make use of the rights granted. All
rights in the development results shall be solely owned by the Company, except to the extent that an employee of Yissum, including the
researcher, is considered an inventor of a patentable invention arising from the development results, in which case such invention and
all patent applications and/or patents claiming such invention shall be owned jointly by the Company and Yissum, as appropriate, and Yissum&#8217;s
share in such joint patents shall be automatically included in the Yissum License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Agreement with Hannover Medical School:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On April 11, 2017, the Company entered
into an investigator-initiated study contract with Hannover Medical School (&#8220;MHH&#8221;) to conduct during 2018 a phase IIb clinical
trial titled &#8220;A Randomized, Double-Blind, Placebo controlled study to Evaluate the Safety, Tolerability and Efficacy of Up to Twice
Daily Oral SCI-110 in Treating Adults with Tourette Syndrome&#8221; in treating approximately 20 Tourette syndrome subjects aged 18 to
65. Upon the execution of the agreement the Company paid the first installment in the amount of $<ix:nonFraction contextRef="c247" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InstallmentAmount" scale="3" unitRef="usd" id="ixv-38456">122</ix:nonFraction> out of a total estimated amount of
approximately $<ix:nonFraction contextRef="c247" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:TotalAgreementEstimatingAmount" scale="3" unitRef="usd" id="ixv-38457">776</ix:nonFraction>. Due to regulatory and strategic reasons, the Company decided to change the study design from investigator-initiated
to an industry sponsored trial. During October 2017, a discussion was carried out between the Company and MHH and the latter was informed
about this change and a termination letter stating the above was sent to MHH on November 19, 2017. MHH has acknowledged that part of the
first instalment that was paid by the Company, in accordance with the initial agreement, will be used to set-off amounts owed under a
new agreement or will be paid back to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On August 13, 2018, the Company entered
into an agreement with MHH to conduct a clinical investigation and laboratory services for a randomized, double-blind, placebo-controlled
proof of concept study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating adults with Tourette syndrome,
which agreement was subsequently updated on December 2, 2021, in an estimated amount of $<ix:nonFraction contextRef="c248" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:TotalAgreementEstimatingAmount" scale="3" unitRef="usd" id="ixv-38458">1,385</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-size: 10pt">d.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Agreement with Yale University:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 27, 2022, the Company entered into an agreement with Yale University to conduct a clinical investigation and laboratory services for a randomized, double-blind, placebo-controlled, cross over study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating adults with Tourette syndrome in treating approximately 10 Tourette syndrome subjects aged 18 to 65. The total estimated amount of the agreement is approximately $<ix:nonFraction contextRef="c249" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:TotalAgreementEstimatingAmount" scale="3" unitRef="usd" id="ixv-38459">370</ix:nonFraction>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 217; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 17:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c7_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify">e<span style="font-size: 10pt">.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 23, 2020, the Company submitted to the Tel Aviv-Jaffa District Court (the &#8220;Court&#8221;) a petition pursuant to the Israeli Insolvency and Economic Rehabilitation Law, 2018, to commence proceedings for the economic rehabilitation of the Company (the &#8220;Petition&#8221;). In the Petition submitted to the Court, the Company stated that it is insolvent (as determined by the cash flow test) and unable to pay its debts to the Company&#8217;s creditors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 6, 2020, L.I.A. Pure Capital Ltd. (&#8220;Pure Capital&#8221;) filed with the Court a demand, requesting an order to have the results of the Company&#8217;s annual general meeting held on August 4, 2020, declared invalid, mainly due to the Company&#8217;s reliance on discretionary voting of the depositary bank for the Company&#8217;s then outstanding ADSs. The Court asked for the Company and directors&#8217; response by no later than August 13, 2020, which was subsequently extended.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 11, 2020, Pure Capital proposed to deposit $<ix:nonFraction contextRef="c250" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CapitalProposedToDeposit" scale="3" unitRef="usd" id="ixv-38460">1,500</ix:nonFraction> with the Company&#8217;s temporary trustee nominated by the Court to cover and pay all of the Company&#8217;s debts, without derogating from any other creditor&#8217;s rights towards the Company (the &#8220;Pure Capital Proposal&#8221;). The Pure Capital Proposal was made subject to the replacement of the Company&#8217;s Board as of the date of the Pure Capital Proposal (the &#8220;Prior Board&#8221;) with Pure Capital&#8217;s designated nominees that were voted upon at the adjourned annual general meeting of the Company&#8217;s shareholders on August 4, 2020 (as discussed below). The Court&#160;issued an order on August 14, 2020 (the &#8220;Order&#8221;), approving the Pure Capital Proposal and settlement agreement submitted to the Court by the parties thereto.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the terms of the Order and following the deposit by Pure Capital, the Prior Board was replaced with: Itschak Shrem (chairman), Amity Weiss (also appointed to act as the Company&#8217;s Chief Executive Officer), Moshe Revach, Lior Amit, Lior Vider and Liat Sidi. Following the issuance of the Order, a related case that was filed by Pure Capital with the Court was withdrawn as well.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 15, 2020, Mr. Lior Amit tendered his resignation from the Board and on March 13, 2022, Mr. Moshe Revach tendered his resignation from the Board and then later re-joined the Board in September 2022.</p></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" continuedAt="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c7_cont_1" escape="true" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="ixv-32397"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 18:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>EQUITY</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">a.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c7" continuedAt="_DisclosureOfClassesOfShareCapitalExplanatory-c7_cont_1" escape="true" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="ixv-32413"><span style="font-size: 10pt">Composition of share capital:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DisclosureOfClassesOfShareCapitalExplanatory-c7_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and<br/>
outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and<br/>
outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 4pt">Ordinary shares</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" unitRef="shares" id="ixv-38461">75,000,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-38462">6,798,840</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" unitRef="shares" id="ixv-38463">25,714,285</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-38464">3,091,740</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 218; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 18:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>EQUITY (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Composition of share capital: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c7_cont_2" id="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c7_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"><i>Reverse Share Splits</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On September 17, 2020, <ix:nonNumeric contextRef="c251" name="sprcy:DescriptionOfReverseShareSplit" id="ixv-38465">the Company convened
a special general meeting of its shareholders, whereby the shareholders approved, inter alia, (i) an increase to the Company&#8217;s share
capital from <ix:nonFraction contextRef="c252" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-38466">500,000,000</ix:nonFraction> ordinary shares to <ix:nonFraction contextRef="c253" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-38467">750,000,000</ix:nonFraction> ordinary shares; and (ii) a reverse split of the Company&#8217;s share capital
up to a ratio of 20:1 (the &#8220;Reverse Split&#8221;).</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On October 16, 2020, the Company convened
a special general meeting of its shareholders, whereby the shareholders approved an increase to the Company&#8217;s share capital from
<ix:nonFraction contextRef="c254" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-38468">750,000,000</ix:nonFraction> ordinary shares to <ix:nonFraction contextRef="c255" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-38469">1,800,000,000</ix:nonFraction> ordinary shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On October 1, 2020, the Company&#8217;s
Board resolved that the final ratio for the Reverse Split will be 20:1, which went effective on October 16, 2020.&#160;Concurrently with
the Reverse Split, a change to the ratio of its ADSs to its ordinary shares was effective pursuant to which each ADS representing <ix:nonFraction contextRef="c256" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-38470">40</ix:nonFraction> ordinary
shares changed to each ADS representing <ix:nonFraction contextRef="c257" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-38471">140</ix:nonFraction> ordinary shares. This resulted in a reverse split on the Company&#8217;s American Depositary
Receipt program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On March 2, 2021, the Company convened
a special general meeting of its shareholders, whereby the shareholders approved to eliminate the par value of the ordinary shares and
an increase to the Company&#8217;s share capital from <ix:nonFraction contextRef="c258" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-38472">1,800,000,000</ix:nonFraction> ordinary shares to <ix:nonFraction contextRef="c259" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-38473">3,600,000,000</ix:nonFraction> ordinary shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;On July 19, 2021, the Company&#8217;s
Board resolved that the final ratio for the Second Reverse Split will be 140:1, which went effective on August 9, 2021.&#160;Concurrently
with the Second Reverse Split, a change to the ratio of its ADSs to its Ordinary Shares was effective pursuant to which each ADS representing
140 ordinary shares changed to each ADS representing 1 ordinary share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">Consequently, all share numbers, share
prices, and exercise prices have been retroactively adjusted in these consolidated financial statements for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On September 15, 2022, the Company convened
an annual general meeting of its shareholders, whereby the shareholders approved to increase to the Company&#8217;s share capital to <ix:nonFraction contextRef="c260" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-38474">75,000,000</ix:nonFraction>
ordinary shares with no par value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Changes in share capital:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"><ix:nonNumeric contextRef="c7" continuedAt="sprcy_DisclosureOfIssuedAndOutstandingShareCapital-c7_cont_1" escape="true" name="sprcy:DisclosureOfIssuedAndOutstandingShareCapital" id="ixv-32546"><i>Issued and outstanding share capital:</i></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DisclosureOfIssuedAndOutstandingShareCapital-c7_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of<br/> ordinary</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">shares</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-38475">3,091,740</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of share capital &#8211; June 2022 Financing Round (Note 18h)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-38476">335,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Exercise of pre-funded warrants (Note 18g)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="sprcy:ExerciseOfPrefundedWarrantsOne" scale="0" unitRef="shares" id="ixv-38477">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise of pre-funded warrants (Note 18h)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="sprcy:ExerciseOfPrefundedWarrants" scale="0" unitRef="shares" id="ixv-38478">3,211,100</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Share issued to a consultant (Note 18f)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="sprcy:ShareIssuedToAConsultant" scale="0" unitRef="shares" id="ixv-38479">61,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-38480">6,798,840</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 219; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 18:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>EQUITY (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c7_cont_3" id="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c7_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Rights attached to shares:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">Voting rights at the shareholders meeting,
right to dividends, rights upon liquidation of the Company and right to nominate the directors in the Company.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">d.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Capital management in the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The Company&#8217;s capital management
objectives are to preserve the Company&#8217;s ability to ensure business continuity thereby creating a return for the shareholders, investors
and other interested parties. The Company is not under any minimal equity requirements nor is it required to attain a certain level of
capital return.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">e.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financing Rounds: (Cont.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; font-size: 10pt">&#160;</td>
    <td style="width: 48px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2020 Financing Round</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">On April 1, 2020, <ix:nonNumeric contextRef="c261" name="sprcy:PurchaseAgreementsDescription" id="ixv-38481">the Company entered
into a definitive securities purchase agreement (the &#8220;April 2020 Purchase Agreement&#8221;) with institutional investors to purchase
of 4,166,168 units, each consisting of (i) one pre-funded warrant to purchase one ordinary share and (ii) one Series B warrant to purchase
one ordinary share, at a purchase price of $0.2999 per unit. The Series B warrants have an exercise price of $0.43 per ordinary share,
are exercisable upon issuance and expire five years from the date of issuance. The offering resulted in gross proceeds to the Company
of approximately $1,250. The closing of the sale of the securities took place on April 3, 2020. After the closing of the April 2020 Purchase
Agreement and until the Approval Date, all pre-funded warrants were exercised. In addition, 4,166,168 of the Series B warrants were exercised
pursuant to a cashless exercise mechanism as described in the April 2020 Purchase Agreement for no further consideration to the Company.
As of the Approval Date, all Series B warrants were exercised.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">The Series B warrants are classified
as a financial liability that will be measured at fair value, through profit or loss, as of the issuance date and on any following financial
reporting date (accordingly, issue expenses related to the Series B warrants will be recorded through profit or loss). No consideration
will be left to attribute to the pre-funded warrants, which is an equity instrument.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">The valuation of the conversion component
of the Series B warrants was set at fair value, as required in IFRS 9, and in accordance with IFRS 13, and was categorized as Level 3
by the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 220; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 18:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>EQUITY (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">e.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financing Rounds: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c7_cont_4" id="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c7_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">November 2020 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">On November 20, 2020, the Company completed
an offering for gross proceeds of $<ix:nonFraction contextRef="c262" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GrossProceeds" scale="3" unitRef="usd" id="ixv-38482">4,200</ix:nonFraction> by way of the issuance of an aggregate of <ix:nonFraction contextRef="c263" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-38483">835,447</ix:nonFraction> units, each consisting of <ix:nonNumeric contextRef="c262" name="sprcy:PurchaseAgreementsDescription" id="ixv-38484">(i) one ordinary
share and (ii) two warrants to purchase one ordinary share each, at a purchase price of&#160;$5.02&#160;per unit (&#8220;November 2020
Warrants&#8221;). The November 2020 Warrants have an exercise price of&#160;$5.02&#160;per ordinary share, will be exercisable upon issuance
and will expire five years from the date of issuance.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">The November 2020 Warrants are classified
as issued warrants in the Company&#8217;s equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">During the year ended December 31,
2021, the Company issued <ix:nonFraction contextRef="c264" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-38485">1,004,494</ix:nonFraction> ordinary shares in respect of the exercise of <ix:nonFraction contextRef="c265" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" scale="0" unitRef="shares" id="ixv-38486">1,004,494</ix:nonFraction> November 2020 Warrants. During the year ended
December 31, 2022, there were no exercises of November 2020 Warrants.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">f.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Additional issuance of ordinary shares:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On July 21, 2021, the Company issued
a consultant <ix:nonFraction contextRef="c266" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-38487">6,000</ix:nonFraction> ordinary shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 2, 2022, the Company issued
a consultant <ix:nonFraction contextRef="c267" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-38488">24,000</ix:nonFraction> ordinary shares in respect of services rendered.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 1, 2022, the Company issued
a consultant <ix:nonFraction contextRef="c268" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-38489">37,000</ix:nonFraction> ordinary shares in respect of services rendered.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">g.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">March 2021 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On March 4, 2021, <ix:nonNumeric contextRef="c269" name="sprcy:DescriptionOfPrivateOffering" id="ixv-38490">the Company completed
a private offering with several accredited and institutional investors for gross proceeds of $8,150, providing for the issuance of an
aggregate of 1,152,628 units, as follows: (a) 916,316 units at a price of $7.07 per unit, consisting of (i) one ordinary share of the
Company, and (ii) a Series A Warrant to purchase an equal number of units purchased (the &#8220;2021 Series A Warrants&#8221;) and a Series
B Warrant (the &#8220;2021 Series B Warrants&#8221; and, collectively with the 2021 Series A Warrants, the March 2021 Warrants) to purchase
half the number of units, and (b) 236,312 pre-funded units at a price of $7.069 per unit, consisting of (i) one pre-funded warrant to
purchase one ordinary share and (ii) one 2021 Series A Warrant and one 2021 Series B Warrant.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The Series A Warrants have an exercise
price of&#160;$<ix:nonFraction contextRef="c270" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-38491">7.07</ix:nonFraction>&#160;per ordinary share and the Series B Warrants have an exercise price of&#160;$<ix:nonFraction contextRef="c271" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-38492">10.60</ix:nonFraction>&#160;per ordinary share).
Both were exercisable upon issuance and will expire <ix:nonNumeric contextRef="c5" format="ixt-sec:durwordsen" name="sprcy:DateOfIssuance" id="ixv-38493">five years</ix:nonNumeric> from the date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The March 2021 Warrants are classified
as issued warrants in the Company&#8217;s equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">During the year ended December 31, 2021,
the Company issued <ix:nonFraction contextRef="c272" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-38494">128,156</ix:nonFraction> ordinary shares in respect of the exercise of <ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="sprcy:WarrantsAndExercise" scale="0" unitRef="shares" id="ixv-38495">10,000</ix:nonFraction> 2021 Series A Warrants and the exercise of <ix:nonFraction contextRef="c270" decimals="0" format="ixt:num-dot-decimal" name="sprcy:WarrantsAndExercise" scale="0" unitRef="shares" id="ixv-38496">118,156</ix:nonFraction> of
pre-funded warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">During the year ended December 31, 2022,
the Company issued <ix:nonFraction contextRef="c273" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-38497">100,000</ix:nonFraction> ordinary shares in respect of the exercise of <ix:nonFraction contextRef="c274" decimals="0" format="ixt:num-dot-decimal" name="sprcy:WarrantsAndExercise" scale="0" unitRef="shares" id="ixv-38498">100,000</ix:nonFraction> pre-funded warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">h.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">June 2022 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On June 1, 2022, <ix:nonNumeric contextRef="c118" name="sprcy:DescriptionOfPrivateOffering" id="ixv-38499">the Company completed
a private offering with an investor for gross proceeds of $<ix:nonFraction contextRef="c118" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GrossProceeds" scale="3" unitRef="usd" id="ixv-38500">10,210</ix:nonFraction> (the &#8220;June 2022 Private Placement&#8221;), providing for the issuance
of an aggregate of <ix:nonFraction contextRef="c275" decimals="0" format="ixt:num-dot-decimal" name="sprcy:IssuanceOfAggregateShares" scale="0" unitRef="shares" id="ixv-38501">3,546,100</ix:nonFraction> units and pre-funded units, as follows: (a) 335,000 units at a price of $2.88 per unit, each consisting of
(i) one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#8220;June 2022 Warrants&#8221;),
and (b) 3,211,100 pre-funded units at a price of $2.819 per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary
share and (ii) two June 2022 Warrants.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The June 2022 Warrants have an exercise
price of&#160;$<ix:nonFraction contextRef="c3" decimals="-1" format="ixt:num-dot-decimal" name="sprcy:WarrantsExercisePrice" scale="3" unitRef="pure" id="ixv-38502">2.63</ix:nonFraction>&#160;per ordinary share. The June 2022 Warrants were exercisable upon issuance and will expire seven years from the
date of issuance.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 221; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: justify; width: 72px"><span style="font-size: 10pt"><b>NOTE 18:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>EQUITY (CONT.)</b></span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">h.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">June 2022 Financing Round</span> (Cont.)</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c7_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"><i>General Overview of Valuation Approaches
used in the Valuation:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">Fair value is the price that would be
received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"><i>Economic methodology:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"><ix:nonNumeric contextRef="c7" continuedAt="_DisclosureOfFairValueOfFinancialInstrumentsExplanatory-c7_cont_1" escape="true" name="ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory" id="ixv-38503">The June 2022 Warrants&#8217; fair value
was calculated using the Black&#8211;Scholes option pricing model, which takes into account the parameters as disclosed below for each
period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DisclosureOfFairValueOfFinancialInstrumentsExplanatory-c7_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 1,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-38504">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c278" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-38505">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-38506">72</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c278" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-38507">72</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-38508">3.97</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c278" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-38509">2.74</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Underlying share price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="sprcy:UnderlyingOrdinarySharePrice" scale="0" unitRef="usdPershares" id="ixv-38510">0.756</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-265">2,87</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Exercise price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ExercisePrice" scale="0" unitRef="usdPershares" id="ixv-38511">2.63</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c278" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ExercisePrice" scale="0" unitRef="usdPershares" id="ixv-38512">2.63</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Warrants fair value ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="sprcy:WarrantsFairValueinDollarsPerShare" scale="0" unitRef="usdPershares" id="ixv-38513">2,396</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c278" decimals="0" format="ixt:num-dot-decimal" name="sprcy:WarrantsFairValueinDollarsPerShare" scale="0" unitRef="usdPershares" id="ixv-38514">10,209</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The June 2022 Warrants are classified
as current warrant liability in the Company&#8217;s balance sheet, as they are exercisable at any given time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">During the year ended December 31, 2022,
the Company issued <ix:nonFraction contextRef="c276" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-38515">3,211,100</ix:nonFraction> ordinary shares in respect of the exercise of <ix:nonFraction contextRef="c277" decimals="0" format="ixt:num-dot-decimal" name="sprcy:WarrantsAndExercise" scale="0" unitRef="shares" id="ixv-38516">3,211,100</ix:nonFraction> pre-funded warrants.</p></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c7_cont_1" escape="true" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="ixv-32963"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 19:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>SHARE-BASED PAYMENT TRANSACTIONS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The cost of share-based payment recognized in the financial statements:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"><ix:nonNumeric contextRef="c7" continuedAt="sprcy_DisclosureOfExpenseRecognizedExplanatoryTableTextBlock-c7_cont_1" escape="true" name="sprcy:DisclosureOfExpenseRecognizedExplanatoryTableTextBlock" id="ixv-38517">The expenses due to share-based compensation
for the years ended December 31, 2022, 2021 and 2020, recognized in the financial statements in respect of the share option plan of the
Company is shown in the following table, detailed by departments:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DisclosureOfExpenseRecognizedExplanatoryTableTextBlock-c7_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses01" scale="3" unitRef="usd" id="ixv-38518">264</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses01" scale="3" unitRef="usd" id="ixv-38519">27</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses01" scale="3" unitRef="usd" id="ixv-38520">69</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GeneralAndAdministrativeExpenses" scale="3" unitRef="usd" id="ixv-38521">633</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GeneralAndAdministrativeExpenses" scale="3" unitRef="usd" id="ixv-38522">16</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GeneralAndAdministrativeExpenses" scale="3" unitRef="usd" id="ixv-38523">22</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExpensesDueToSharebasedCompensation" scale="3" unitRef="usd" id="ixv-38524">897</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExpensesDueToSharebasedCompensation" scale="3" unitRef="usd" id="ixv-38525">43</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExpensesDueToSharebasedCompensation" scale="3" unitRef="usd" id="ixv-38526">91</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The 2005 and 2015 ESOP of the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify">During 2005, the Board adopted the 2005
Employees Share Option Plan (the &#8220;2005 ESOP&#8221;). Ten years later the Board adopted a new plan - the 2015 Employees Share Option
Plan (the &#8220;2015 ESOP&#8221;). Under both the 2005 ESOP and 2015 ESOP, the Company may grant its employees and other service providers
options to purchase the Company&#8217;s ordinary shares (&#8220;Share Options&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify">On November 13, 2019, the Board reserved
an additional number of <ix:nonFraction contextRef="c279" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" scale="0" unitRef="shares" id="ixv-38527">6,788</ix:nonFraction> Share Options for the purposes of the 2015 ESOP, bringing the amount of Share Options reserved under the
2015 ESOP to <ix:nonFraction contextRef="c279" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ShareOptionsReserved" scale="0" unitRef="shares" id="ixv-38528">15,714</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">On April 21, 2021, the Board reserved
an additional number of <ix:nonFraction contextRef="c280" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" scale="0" unitRef="shares" id="ixv-38529">338,929</ix:nonFraction>&#160;Share Options for the purposes of the 2015 ESOP, bringing the amount of Share Options reserved under
the 2015 ESOP to <ix:nonFraction contextRef="c280" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ShareOptionsReserved" scale="0" unitRef="shares" id="ixv-38530">357,143</ix:nonFraction>, out of which a total of <ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfSharesOptionGrantedInSharebasedPaymentArrangement" scale="0" unitRef="shares" id="ixv-38531">161,114</ix:nonFraction> were still available for grant as of December 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 222; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px"/>
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE&#160;19:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>SHARE-BASED PAYMENT TRANSACTIONS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The cost of share-based payment recognized in the financial statements: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c7_cont_2" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c7_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On March 12, 2019, the Board approved and granted <ix:nonFraction contextRef="c281" decimals="0" format="ixt:num-dot-decimal" name="sprcy:OrdinaryShares" scale="0" unitRef="shares" id="ixv-38532">1,171</ix:nonFraction> ordinary shares under the 2015 ESOP to a new consultant of the Company. The exercise price was set at $<ix:nonFraction contextRef="c282" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="usdPershares" id="ixv-38533">420.00</ix:nonFraction> per share Option.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"><ix:nonNumeric contextRef="c7" continuedAt="sprcy_DescriptionOfOptionPricingModelShareOptionGranted-c7_cont_1" escape="true" name="sprcy:DescriptionOfOptionPricingModelShareOptionGranted" id="ixv-33134"><i>The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:</i></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfOptionPricingModelShareOptionGranted-c7_cont_2" id="sprcy_DescriptionOfOptionPricingModelShareOptionGranted-c7_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" scale="-2" unitRef="pure" id="ixv-38534">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-38535">76</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="4" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-38536">2.61</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expected life of share options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c7" format="ixt-sec:duryear" name="sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" id="ixv-38537">10</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">The fair value of the Share Options
was set at $<ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:FairValueOption" scale="3" unitRef="usd" id="ixv-38538">224</ix:nonFraction> per Share Option.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On October 10, 2019 (the &#8220;2019 Grant Date&#8221;), <ix:nonNumeric contextRef="c283" name="sprcy:StockOptionDescription" id="ixv-38539">the Board approved the grant of 72 Share Options under the 2015 ESOP to directors, officers and employees, some of which required the approval of the general meeting of the Company&#8217;s shareholders (the &#8220;2019 General Meeting&#8221;), which occurred on January 15, 2020. Following the resignation of some directors and employees on December 31, 2019, 15 Share Options (were not granted. Out of the 57 Share Options that were granted, 10 Share Options didn&#8217;t require the General Meeting&#8217;s approval. The date of commencement for all Share Options granted, the date on which the vesting started, was the 2019 Grant Date. The exercise price was set at $210.00 per Share Option.</ix:nonNumeric></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">According to IFRS 2, &#8220;<i>Share-based
Payment</i>&#8221;, the fair value of the Share Options was estimated using the Black-Scholes OPM, in which the fair value estimation
for the Share Options which required the 2019 General Meeting&#8217;s approval was calculated based on parameters as of December 31, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"><ix:continuation continuedAt="sprcy_DescriptionOfOptionPricingModelShareOptionGranted-c7_cont_3" id="sprcy_DescriptionOfOptionPricingModelShareOptionGranted-c7_cont_2"><i>Based on the above-mentioned, hereinafter
are the parameters used in order to estimate the fair value of the Share Options using the Black-Scholes OPM:</i></ix:continuation></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfOptionPricingModelShareOptionGranted-c7_cont_4" id="sprcy_DescriptionOfOptionPricingModelShareOptionGranted-c7_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>
2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">October&#160;10,<br/>
2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Underlying ordinary share price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c292" decimals="2" format="ixt:num-dot-decimal" name="sprcy:UnderlyingOrdinarySharePrices" scale="0" unitRef="usdPershares" id="ixv-38540">78.12</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c293" decimals="0" format="ixt:num-dot-decimal" name="sprcy:UnderlyingOrdinarySharePrices" scale="0" unitRef="usdPershares" id="ixv-38541">154</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c292" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" scale="-2" unitRef="pure" id="ixv-38542">0</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c293" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" scale="-2" unitRef="pure" id="ixv-38543">0</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c292" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-38544">73</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c293" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-38545">70</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c292" decimals="4" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-38546">1.91</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c293" decimals="4" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-38547">1.67</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected life of Share Options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c292" format="ixt-sec:duryear" name="sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" id="ixv-38548">9.78</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c293" format="ixt-sec:duryear" name="sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" id="ixv-38549">10</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"><ix:nonNumeric contextRef="c284" name="sprcy:FairValueDescription" id="ixv-38550">The fair value of the Share Options
approved on October 10, 2019 by the Board, and on January 15, 2020 at the General Meeting (valuated as of December 31, 2019) was set at
$114.1 and $51.1, per Share Option, respectively.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 223; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px"/>
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE&#160;19:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>SHARE-BASED PAYMENT TRANSACTIONS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c7_cont_3" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c7_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On January 3, 2022 (the &#8220;2022 Grant Date&#8221;), the Board approved the grant of <ix:nonFraction contextRef="c285" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ShareOptionsReserved" scale="0" unitRef="shares" id="ixv-38551">178,140</ix:nonFraction> Share Options under the 2015 ESOP to directors, officers, employees and consultants, some of which required the approval of the general meeting of the Company&#8217;s shareholders (the &#8220;2022 General Meeting&#8221;), which occurred on February 10, 2022. The date of commencement for all Share Options granted, the date on which the vesting started, was the 2022 Grant Date. The exercise price was set at $<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="usdPershares" id="ixv-38552">6.50</ix:nonFraction> per Share Option.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"><ix:continuation continuedAt="sprcy_DescriptionOfOptionPricingModelShareOptionGranted-c7_cont_5" id="sprcy_DescriptionOfOptionPricingModelShareOptionGranted-c7_cont_4"><i>The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:</i></ix:continuation></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfOptionPricingModelShareOptionGranted-c7_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">February&#160;2,<br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 3,<br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Underlying ordinary share price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c294" decimals="2" format="ixt:num-dot-decimal" name="sprcy:UnderlyingOrdinarySharePrices" scale="0" unitRef="usdPershares" id="ixv-38553">4.99</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c295" decimals="2" format="ixt:num-dot-decimal" name="sprcy:UnderlyingOrdinarySharePrices" scale="0" unitRef="usdPershares" id="ixv-38554">6.73</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c294" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" scale="-2" unitRef="pure" id="ixv-38555">0</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c295" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" scale="-2" unitRef="pure" id="ixv-38556">0</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c294" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-38557">133</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c295" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-38558">134</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c294" decimals="4" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-38559">2.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c295" decimals="4" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-38560">1.46</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected life of Share Options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c294" format="ixt-sec:duryear" name="sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" id="ixv-38561">6</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c295" format="ixt-sec:duryear" name="sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" id="ixv-38562">6</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"><ix:nonNumeric contextRef="c286" name="sprcy:FairValueDescription" id="ixv-38563">The fair value of the Share Options
granted on January 3, 2022, was set at $6.09 per Share Option, and the fair value of the Share Options granted on February 10, 2022, was
set at $4.41 per Share Option</ix:nonNumeric>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 120px; font-size: 10pt">&#160;</td> <td style="width: 48px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company granted consultants Restricted Share Units (&#8220;RSUs&#8221;) in respect of services rendered. The RSU&#8217;s were granted at a discount rate of <ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="sprcy:RSUGrantedDiscountRate" scale="-2" unitRef="pure" id="ixv-38564">25</ix:nonFraction>% to share price quoted on the date of each grant. The total fair value of the RSU&#8217;s granted to consultants was $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:FairValueOfTheRSUsGranted" scale="3" unitRef="usd" id="ixv-38565">70</ix:nonFraction>. </span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 120px; font-size: 10pt">&#160;</td> <td style="width: 48px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company issued consultants <ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="sprcy:OrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-38566">61,000</ix:nonFraction> ordinary shares in respect of services rendered. The ordinary were granted at a discount rate of <ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="sprcy:OrdinaryGrantedDiscountRate" scale="-2" unitRef="pure" id="ixv-38567">25</ix:nonFraction>% to share price quoted on the date of each grant. The total fair value of the RSU&#8217;s granted to consultants was $<ix:nonFraction contextRef="c287" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:FairValueOfTheRSUsGranted" scale="3" unitRef="usd" id="ixv-38568">48</ix:nonFraction>. </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 224; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px"/>
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE&#160;19:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>SHARE-BASED PAYMENT TRANSACTIONS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c7_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Movement during the year:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 120px; font-size: 10pt">&#160;</td> <td style="width: 48px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="text-align: justify; font-size: 10pt"><ix:nonNumeric contextRef="c7" continuedAt="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock-c7_cont_1" escape="true" name="sprcy:DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" id="ixv-33439"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table lists the number of Share Options, the weighted average exercise prices of share options and changes in directors (and former directors), officers, employees and consultants share options during the years ended on December 31, 2022, and 2021:</span></ix:nonNumeric></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock-c7_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/>
Share<br/>
Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/>
average<br/>
exercise<br/>
price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">2022</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfOutstandingShareOption" scale="0" unitRef="shares" id="ixv-38569">5,431</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="sprcy:WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement" scale="0" unitRef="usdPershares" id="ixv-38570">2.95</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options granted during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfShareOptionGranted" scale="0" unitRef="shares" id="ixv-38571">178,140</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="sprcy:WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement" scale="0" unitRef="usdPershares" id="ixv-38572">6.50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the end of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfOutstandingShareOption" scale="0" unitRef="shares" id="ixv-38573">183,571</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="sprcy:WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement" scale="0" unitRef="usdPershares" id="ixv-38574">6.39</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options exercisable at the end of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfShareOptionsShareOptionsExercisableAtTheEndOfTheYear" scale="0" unitRef="shares" id="ixv-38575">107,679</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-38576">6.30</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">2021:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the beginning of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfOutstandingShareOption" scale="0" unitRef="shares" id="ixv-38577">5,643</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c96" decimals="2" format="ixt:num-dot-decimal" name="sprcy:WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement" scale="0" unitRef="usdPershares" id="ixv-38578">2.41</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options granted during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-266">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-267">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options forfeited during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfShareOptionForfeitedInSharebasedPaymentArrangement" scale="0" sign="-" unitRef="shares" id="ixv-38579">212</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="sprcy:WeightedAverageExercisePriceOfShareOptionForfeitedInSharebasedPaymentArrangement" scale="0" unitRef="usdPershares" id="ixv-38580">2.50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Share Options expired during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-268">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-269">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfOutstandingShareOption" scale="0" unitRef="shares" id="ixv-38581">5,431</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="sprcy:WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement" scale="0" unitRef="usdPershares" id="ixv-38582">2.95</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Share Options exercisable at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfShareOptionsShareOptionsExercisableAtTheEndOfTheYear" scale="0" unitRef="shares" id="ixv-38583">4,416</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-38584">3.28</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">No Share Options were granted during 2021.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 120px; font-size: 10pt">&#160;</td> <td style="width: 48px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average remaining contractual life of the Share Options outstanding was <ix:nonNumeric contextRef="c7" format="ixt-sec:duryear" name="sprcy:WeightedAverageRemainingContractualLifesOfOutstandingShareOption" id="ixv-38585">5.03</ix:nonNumeric> years and <ix:nonNumeric contextRef="c11" format="ixt-sec:duryear" name="sprcy:WeightedAverageRemainingContractualLifesOfOutstandingShareOption" id="ixv-38586">6.35</ix:nonNumeric> years as of December 31, 2022, and 2021, respectively.</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 120px; font-size: 10pt">&#160;</td> <td style="width: 48px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The range of exercise prices of Share Options outstanding at the end of the year was $<ix:nonFraction contextRef="c288" decimals="1" format="ixt:num-dot-decimal" name="sprcy:ShareOptionsOutstandingParValue" scale="0" unitRef="usdPershares" id="ixv-38587">6.5</ix:nonFraction> - $<ix:nonFraction contextRef="c289" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ShareOptionsOutstandingParValue" scale="0" unitRef="usdPershares" id="ixv-38588">844</ix:nonFraction> (inclusive) as of December 31, 2022, and $<ix:nonFraction contextRef="c290" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ShareOptionsOutstandingParValue" scale="0" unitRef="usdPershares" id="ixv-38589">210</ix:nonFraction> - $<ix:nonFraction contextRef="c291" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ShareOptionsOutstandingParValue" scale="0" unitRef="usdPershares" id="ixv-38590">955</ix:nonFraction> (inclusive) as of December 31, 2021.</span></td></tr> </table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 225; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" escape="true" name="ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory" id="ixv-33672"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;20:-</b></span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REVENUES AND COST OF REVENUES</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><ix:nonNumeric contextRef="c7" continuedAt="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock-c7_cont_1" escape="true" name="sprcy:ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" id="ixv-38591">Our revenues consist of revenue derived
from sales on Amazon. The following table discloses the breakdown of our revenues, cost of sales and gross profit for the periods set
forth below:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock-c7_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="3" unitRef="usd" id="ixv-38592">1,347</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-270">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cost of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-38593">322</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-271">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Gross profit</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="3" unitRef="usd" id="ixv-38594">1,025</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-272">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" escape="true" name="ifrs-full:DisclosureOfAdditionalInformationExplanatory" id="ixv-33745"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;21:- </b></span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c7" escape="true" name="sprcy:DisclosureOfInformationToTheItemsOfProfitOrLoss" id="ixv-33755"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year ended December&#160;31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%; font-style: italic">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-decoration: underline; width: 57%; font-style: italic; text-align: left">Research and development expenses:</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Wages and related expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c142" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-38595">436</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c296" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-38596">357</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c297" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-38597">322</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c145" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-38598">264</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c298" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-38599">27</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c299" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-38600">69</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Regulatory, professional and other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c151" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-38601">750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c300" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-38602">934</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c301" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-38603">119</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Research and preclinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c154" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-38604">703</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c302" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-38605">165</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c303" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-38606">139</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Clinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c148" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-38607">369</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c304" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-38608">172</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-273">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left">Chemistry and formulations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c157" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-38609">281</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c306" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-38610">335</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-274">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-38611">2,803</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-38612">1,990</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-38613">649</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-decoration: underline; font-style: italic; text-align: left">General and administrative expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Wages and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c142" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38614">437</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c296" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38615">256</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c297" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38616">237</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c145" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38617">633</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c298" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38618">16</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c299" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38619">22</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Professional and directors&#8217; fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c160" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38620">2,499</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c308" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38621">2,417</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c309" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38622">1,283</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Business development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c163" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38623">161</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c310" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38624">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c311" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38625">58</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Regulatory expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c175" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38626">162</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c312" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38627">165</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c313" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38628">98</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Office maintenance, rent and other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c166" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38629">224</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c314" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38630">135</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c315" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38631">182</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Wellution operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c172" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38632">907</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-275">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-276">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left">Investor relations and business expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c169" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38633">1,486</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c318" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38634">784</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c319" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38635">22</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt"><i><span style="text-decoration:underline">General and administrative expenses:</span></i></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38636">6,509</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38637">3,778</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38638">1,902</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-decoration: underline; font-style: italic; text-align: left">Other expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left">Impairment of company accounted for at equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-277">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-278">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c322" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherOperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-38639">742</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left">Group&#8217;s share of losses of company accounted for at equity, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c323" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherOperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-38640">109</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-279">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-280">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherOperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-38641">109</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-281">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherOperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-38642">742</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-decoration: underline; font-style: italic; text-align: left">Finance income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Net change in fair value of financial liabilities designated at fair value through profit or loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:FinanceIncomeFromConvertibleLoan" scale="3" sign="-" unitRef="usd" id="ixv-38643">7,832</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-282">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:FinanceIncomeFromConvertibleLoan" scale="3" sign="-" unitRef="usd" id="ixv-38644">630</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncomeCost" scale="3" unitRef="usd" id="ixv-38645">7,832</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-283">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncomeCost" scale="3" unitRef="usd" id="ixv-38646">630</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-style: italic; text-align: left">Finance expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance expenses related to warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueExpensesRelatedToIssuanceOfWarrants" scale="3" unitRef="usd" id="ixv-38647">1,204</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueExpensesRelatedToIssuanceOfWarrants" scale="3" unitRef="usd" id="ixv-38648">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueExpensesRelatedToIssuanceOfWarrants" scale="3" unitRef="usd" id="ixv-38649">835</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Exchange rate differences, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:FinanceExpensesFromExchangeRateDifferences" scale="3" unitRef="usd" id="ixv-38650">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:FinanceExpensesFromExchangeRateDifferences" scale="3" unitRef="usd" id="ixv-38651">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:FinanceExpensesFromExchangeRateDifferences" scale="3" unitRef="usd" id="ixv-38652">12</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Losses from remeasurement of investment in financial assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" scale="3" unitRef="usd" id="ixv-38653">770</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-284">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-285">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Finance expense in respect of leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InterestExpenseInRespectOfLeases" scale="3" unitRef="usd" id="ixv-38654">15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InterestExpenseInRespectOfLeases" scale="3" unitRef="usd" id="ixv-38655">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InterestExpenseInRespectOfLeases" scale="3" unitRef="usd" id="ixv-38656">7</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left">Finance expenses from interest and commissions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:FinanceExpensesFromInterestAndCommissions" scale="3" unitRef="usd" id="ixv-38657">21</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:FinanceExpensesFromInterestAndCommissions" scale="3" unitRef="usd" id="ixv-38658">8</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:FinanceExpensesFromInterestAndCommissions" scale="3" unitRef="usd" id="ixv-38659">18</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InsuranceFinanceIncomeExpenses" scale="3" unitRef="usd" id="ixv-38660">2,014</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InsuranceFinanceIncomeExpenses" scale="3" unitRef="usd" id="ixv-38661">21</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InsuranceFinanceIncomeExpenses" scale="3" unitRef="usd" id="ixv-38662">872</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 226; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" escape="true" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" id="ixv-34492"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-size: 10pt"><b>NOTE 22:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>LOSS PER SHARE/ADS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt">a.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c7" continuedAt="sprcy_DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory-c7_cont_1" escape="true" name="sprcy:DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory" id="ixv-34508"><span style="font-size: 10pt">Details of the number of shares and loss used in the computation of loss per share:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="sprcy_DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory-c7_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="22" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended December&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amounts used in the computation of basic and diluted&#160;loss</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/>
number of<br/>
shares (*)</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/>
number of<br/>
shares (*)</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/>
number of<br/>
shares (*)</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>In<br/>
thousands</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>USD</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>In</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>thousands</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>USD</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>In<br/>
thousands</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>USD</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Continuing operations:</i></b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic loss per share</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c326" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares" id="ixv-38663">4,575</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c326" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" scale="3" sign="-" unitRef="usd" id="ixv-38664">2,592</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c327" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares" id="ixv-38665">2,049</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c327" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" scale="3" sign="-" unitRef="usd" id="ixv-38666">5,789</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c328" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares" id="ixv-38667">258</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c328" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" scale="3" sign="-" unitRef="usd" id="ixv-38668">3,482</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect of potential dilutive ordinary shares</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c329" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares" id="ixv-38669">7</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c329" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" scale="3" sign="-" unitRef="usd" id="ixv-38670">468</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted loss per share</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c330" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares" id="ixv-38671">4,575</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c330" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" scale="3" sign="-" unitRef="usd" id="ixv-38672">2,592</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c331" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares" id="ixv-38673">2,049</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c331" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" scale="3" sign="-" unitRef="usd" id="ixv-38674">5,789</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c332" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares" id="ixv-38675">265</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c332" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" scale="3" sign="-" unitRef="usd" id="ixv-38676">3,950</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The computation of diluted loss per share did not include the following convertible securities since their inclusion would decrease the loss per share (anti-dilutive effect):</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Share Options to employees, officers, directors and consultants; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Non-marketable warrants to investors.</span></td></tr>
  </table></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 227; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" continuedAt="_DisclosureOfEntitysReportableSegmentsExplanatory-c7_cont_1" escape="true" name="ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory" id="ixv-34873"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE&#160;23:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>OPERATING SEGMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company applies the principles
of IFRS 8,&#160;&#8220;<i>Operating Segments</i>&#8221;<i>&#160;</i>(&#8220;IFRS 8&#8221;), regarding operating segments. The segment
reporting is based on internal management reports of the Company&#8217;s management, which are regularly reviewed by the chief operating
decision maker to make decisions about resources to be allocated and assess performance. According to the principles of IFRS 8, the Company&#8217;s
management determined that as of December 31, 2022, the Company has two reportable segments &#8211; (1) development of drugs based on
cannabinoid molecules to be approved by an official regulatory authority (the Company&#8217;s operation); and (2) online sales of a various
range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial
creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c7" continuedAt="_DisclosureOfOperatingSegmentsExplanatory-c7_cont_1" escape="true" name="ifrs-full:DisclosureOfOperatingSegmentsExplanatory" id="ixv-34887"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December&#160;31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Drug Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Online Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">External</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-286">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c334" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExternalRevenues" scale="3" unitRef="usd" id="ixv-38677">1,347</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExternalRevenues" scale="3" unitRef="usd" id="ixv-38678">1,347</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Inter-segment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-287">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-288">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-289">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-style: italic">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-290">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c334" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromSaleOfGoods" scale="3" unitRef="usd" id="ixv-38679">1,347</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromSaleOfGoods" scale="3" unitRef="usd" id="ixv-38680">1,347</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt">Segment loss (gain)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c333" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-38681">8,405</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c334" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-38682">118</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-38683">8,287</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Company&#8217;s share of losses of company accounted for at equity, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" scale="3" unitRef="usd" id="ixv-38684">109</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance expense (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestRevenueExpense" scale="3" sign="-" unitRef="usd" id="ixv-38685">5,818</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:TaxExpense" scale="3" unitRef="usd" id="ixv-38686">14</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-38687">2,592</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DisclosureOfOperatingSegmentsExplanatory-c7_cont_2" id="_DisclosureOfOperatingSegmentsExplanatory-c7_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/>
Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/>
Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -9pt; padding-left: 9pt">External</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-291">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-292">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-293">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Inter-segment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-294">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-295">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-296">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-297">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-298">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-299">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c335" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-38688">5,768</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-300">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-38689">5,768</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Finance expense (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestRevenueExpense" scale="3" unitRef="usd" id="ixv-38690">21</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-38691">5,789</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DisclosureOfOperatingSegmentsExplanatory-c7_cont_3" id="_DisclosureOfOperatingSegmentsExplanatory-c7_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/>
Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/>
Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -9pt; padding-left: 9pt">External</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-301">&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-302">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-303">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Inter-segment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-304">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-305">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-306">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-307">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-308">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-309">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c337" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-38692">3,293</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-310">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-38693">3,293</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Finance expense (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestRevenueExpense" scale="3" unitRef="usd" id="ixv-38694">242</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-38695">3,535</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 228; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD
in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: justify; width: 72px"><span style="font-size: 10pt"><b>NOTE&#160;23:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>OPERATING SEGMENTS (CONT.)</b></span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><ix:continuation id="_DisclosureOfEntitysReportableSegmentsExplanatory-c7_cont_1"><ix:continuation continuedAt="_DisclosureOfOperatingSegmentsExplanatory-c7_cont_4" id="_DisclosureOfOperatingSegmentsExplanatory-c7_cont_3"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December&#160;31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Drug<br/> Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Online<br/> Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Segment Assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c339" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-38696">9,664</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c340" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-38697">941</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-38698">10,605</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c339" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-38699">4,021</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c340" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-38700">135</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-38701">4,156</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DisclosureOfOperatingSegmentsExplanatory-c7_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/>
Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/>
Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Segment Assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c341" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-38702">9,916</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-311">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-38703">9,916</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c341" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-38704">1,775</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-312">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-38705">1,775</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" escape="true" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" id="ixv-35542"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE&#160;24:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>TRANSACTIONS AND BALANCES WITH RELATED PARTIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">a.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c7" continuedAt="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory-c7_cont_1" escape="true" name="sprcy:DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" id="ixv-35558"><span style="font-size: 10pt">Balances with related parties:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c7" escape="true" name="sprcy:DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" id="ixv-35561"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/>
management<br/>
personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/>
related<br/>
parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/>
management<br/>
personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/>
related<br/>
parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Current liabilities</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c344" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-38706">70</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c345" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-38707">55</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c346" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-38708">447</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 48px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions with related parties (not including amounts described in Note 24c):</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory-c7_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses" scale="3" unitRef="usd" id="ixv-38709">208</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-313">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-314">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">c.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c7" continuedAt="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c7_cont_1" escape="true" name="ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" id="ixv-35663"><span style="font-size: 10pt">Benefits to key management personnel (including directors):</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c7_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Short-term benefits</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" unitRef="usd" id="ixv-38710">1,940</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" unitRef="usd" id="ixv-38711">962</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" unitRef="usd" id="ixv-38712">746</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Cost of share-based payment</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" unitRef="usd" id="ixv-38713">779</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" unitRef="usd" id="ixv-38714">43</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" unitRef="usd" id="ixv-38715">91</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 48px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Oz Adler, our Chief Executive Officer and Chief Financial Officer, is the chairman of the board of directors of&#160;Jeffs&#8217;&#160;Brands.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt">&#160;</td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 7, 2022, we entered into the Cooperation Agreement with Clearmind, a company in which Dr. Adi Zuloff-Shani, our Chief Technologies Officer, Mr. Weiss, our President, and Mr. Adler, our Chief Executive Officer and Chief Financial Officer serve as officers and directors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2022, the Company recognized expenses in respect of the Cooperation Agreement with Clearmind in the amount of $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CooperationAgreementWithClearmindAmount" scale="3" unitRef="usd" id="ixv-38716">208</ix:nonFraction>, and the balance owed to Clearmind as of December 31, 2022, was $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:BalanceOwedToClearmind" scale="3" unitRef="usd" id="ixv-38717">55</ix:nonFraction>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 17, 2022, we invested $<ix:nonFraction contextRef="c343" decimals="-5" format="ixt:num-dot-decimal" name="sprcy:InvestedAmountInClearmind" scale="6" unitRef="usd" id="ixv-38718">1.5</ix:nonFraction> million
in Clearmind in connection with its initial public offering on the Nasdaq Capital Market, in exchange for <ix:nonFraction contextRef="c343" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ExchangeCommonSharesOfClearmind" scale="0" unitRef="shares" id="ixv-38719">230,769</ix:nonFraction> common shares of Clearmind,
representing <ix:nonFraction contextRef="c343" decimals="4" format="ixt:num-dot-decimal" name="sprcy:ClearmindOutstandingShareCapitalPercentage" scale="-2" unitRef="pure" id="ixv-38720">9.33</ix:nonFraction>% of the outstanding share capital of Clearmind (see also note 8).</p></td></tr> </table></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 229; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c7" escape="true" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="ixv-35776"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE&#160;25:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>EVENTS AFTER THE REPORTING DATE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; background-color: white">On
February 23, 2023, the Company signed an agreement with Jeffs&#8217; Brands Holdings (&#8220;NewCo&#8221;) Inc. a recently newly-formed
wholly owned subsidiary of Jeffs&#8217; Brands and Jeffs&#8217; Brands, pursuant to which, at the closing and upon the terms and conditions
set forth in the Agreement, NewCo Inc. will acquire from the Company a number of shares of stock equal to approximately a <ix:nonFraction contextRef="c347" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfStockEqual" scale="-2" unitRef="pure" id="ixv-38721">49</ix:nonFraction>% interest
in the Company&#8217;s wholly owned subsidiary, SciSparc Nutraceuticals Inc., which owns Wellution<sup>TM</sup>&#160;, for $<ix:nonFraction contextRef="c348" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="3" unitRef="usd" id="ixv-38722">2,500</ix:nonFraction> in cash,
and additional deferred cash payments of approximately $<ix:nonFraction contextRef="c347" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdditionalAgreedInvest" scale="3" unitRef="usd" id="ixv-38723">489,330</ix:nonFraction> accounting for price adjustments related to inventory and working capital,
which will be paid in <ix:nonFraction contextRef="c349" decimals="2" format="ixt-sec:numwordsen" name="sprcy:OwnershipAgreement" scale="-2" unitRef="pure" id="ixv-38724">five</ix:nonFraction> equal monthly installments beginning in May 2023 (the &#8220;Price Adjusment&#8221;). As collateral for the
payment in full of the Price Adjustment, SciSparc will hold back such number of shares of common stock of SciSparc Nutraceuticals, equal
to the outstanding due amount of the Price Adjustment (the &#8220;Holdback Shares&#8221;). Following the closing of the transaction on
March 22, 2023, which included an equity conversion of financing amounts previously provided to SciSparc Nutraceuticals Inc. by the Company
for working capital, and the release of the Holdback Shares upon the payment in full of the Price Adjustment the Company will hold approximately
<ix:nonFraction contextRef="c350" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfWorkingCapital" scale="-2" unitRef="pure" id="ixv-38725">51</ix:nonFraction>% of SciSparc Nutraceuticals Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; background-color: white">Pursuant
to the agreement, at the closing of the transaction, Jeffs&#8217; Brands and SciSparc Nutraceuticals Inc. entered into a consulting agreement,
pursuant to which Jeffs&#8217; Brands will provide management services to SciSparc Nutraceuticals Inc. for the Wellution<sup>TM</sup>
brand for a monthly fee of $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:MonthlyFee" scale="3" unitRef="usd" id="ixv-38726">20</ix:nonFraction> and Jeffs&#8217; Brands will receive a one-time signing bonus in the amount of $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:BonusAmount" scale="3" unitRef="usd" id="ixv-38727">51</ix:nonFraction>. The consulting agreement
is for an undefined period of time and may be terminated by either party with 30 days advance notice.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, in connection with the closing of the transaction, the Company and Jeffs&#8217; Brands, engaged in a mutual share exchange in
the amount of $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapitalOrdinaryShares" scale="3" unitRef="usd" id="ixv-38728">288,238</ix:nonFraction> of ordinary shares from each of us and Jeffs&#8217; Brands. The number of shares in the share exchange was calculated
based on the average closing price of the relevant company&#8217;s shares for 30 consecutive trading days ending on the third trading
day immediately prior to the closing. Accordingly, the Company acquired <ix:nonFraction contextRef="c351" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-38729">247,415</ix:nonFraction> ordinary shares of Jeffs&#8217; Brands and Jeffs&#8217;
Brands acquired <ix:nonFraction contextRef="c352" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-38730">360,297</ix:nonFraction> ordinary shares of us having an aggregate value of $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AggregateValue" scale="3" unitRef="usd" id="ixv-38731">288,238</ix:nonFraction>, which was adjusted from $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdjustedAmountOfAggregateValue" scale="3" unitRef="usd" id="ixv-38732">300,000</ix:nonFraction> according to the
<ix:nonFraction contextRef="c7" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInJointOperation" scale="-2" unitRef="pure" id="ixv-38733">4.99</ix:nonFraction>% ownership limit included in the definitive agreements.</p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">-
- - - - - - - - - - - - - - - - - - - - - - - -</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><!-- Field: Page; Sequence: 230; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Up to 5,402,887 Ordinary Shares</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SciSparc Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PROSPECTUS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">, 2024</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 231; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INFORMATION NOT REQUIRED IN PROSPECTUS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item&#160;6. Indemnification of Directors,
Officers and Employees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Indemnification</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law,
a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate an
office holder in advance from liability to the Company, in whole or in part, for damages caused to the Company as a result of a breach
of duty of care but only if a provision authorizing such exculpation is included in its articles of association. Our Articles of Association
contain such a provision. An Israeli company may not exculpate a director from liability arising out of a prohibited dividend or distribution
to shareholders.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An Israeli company may indemnify
an office holder in respect of the following liabilities and expenses incurred for acts performed as an office holder, either in advance
of an event or following an event provided a provision authorizing such indemnification is contained in its articles of association:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator&#8217;s
    award approved by a court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in
    advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based
    on the Company&#8217;s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined
    by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned events and
    amount or criteria;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable
    litigation expenses, including legal fees, incurred by the office holder (a) as a result of an investigation or proceeding instituted
    against him or her by an authority authorized to conduct such investigation or proceeding, provided that (i) no indictment was filed
    against such office holder as a result of such investigation or proceeding; and (ii) no financial liability, such as a criminal penalty,
    was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such
    financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and (b)
    in connection with a monetary sanction;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable
    litigation expenses, including legal fees, incurred by the office holder or imposed by a court (i) in proceedings instituted against
    him or her by the Company, on its behalf or by a third party, or (ii) in connection with criminal proceedings in which the office
    holder was acquitted, or (iii) as a result of a conviction for a crime that does not require proof of criminal intent; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses,
    including reasonable litigation expenses and legal fees, incurred by an office holder in relation to an administrative proceeding
    instituted against such office holder, or certain compensation payments made to an injured party imposed on an office holder by an
    administrative proceeding, pursuant to certain provisions of the Israeli Securities Law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 232; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An Israeli company
may insure an office holder against the following liabilities incurred for acts performed as an office holder if and to the extent provided
in the Company&#8217;s articles of association:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    breach of the duty of loyalty to the Company, to the extent that the office holder acted in good faith and had a reasonable basis
    to believe that the act would not prejudice the Company;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    breach of the duty of care to the Company or to a third party, including a breach arising out of the negligent conduct of the office
    holder;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    financial liability imposed on the office holder in favor of a third party;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    financial liability imposed on the office holder in favor of a third party harmed by a breach in an administrative proceeding; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses,
    including reasonable litigation expenses and legal fees, incurred by the office holder as a result of an administrative proceeding
    instituted against him or her, pursuant to certain provisions of the Israeli Securities Law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An Israeli company may not
indemnify or insure an office holder against any of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    breach of the duty of loyalty, except to the extent that the office holder acted in good faith and had a reasonable basis to believe
    that the act would not prejudice the Company;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    breach of duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office
    holder;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    act or omission committed with intent to derive illegal personal benefit; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    fine, monetary sanction or forfeit levied against the office holder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, exculpation, indemnification and insurance of office holders must be approved by the compensation committee, the board of directors
(and, with respect to directors and the chief executive officer, by the shareholders). However, under regulations promulgated under the
Companies Law, the insurance of office holders shall not require shareholder approval and may be approved by only the compensation committee,
if the engagement terms are determined in accordance with the Company&#8217;s compensation policy and that policy was approved by the
shareholders by the same special majority required to approve a compensation policy, provided that the insurance policy is on market
terms and the insurance policy is not likely to materially impact the Company&#8217;s profitability, assets or obligations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Articles of Association
allow us to exculpate, indemnify and insure our office holders for any liability imposed on them as a consequence of an act (including
any omission) which was performed by virtue of being an office holder. Our office holders are currently covered by a directors and officers&#8217;
liability insurance policy.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into agreements
with each of our directors and executive officers exculpating them in advance from liability to us for damages caused to us as a result
of a breach of duty of care, and undertaking to indemnify them. This exculpation and indemnification is limited both in terms of amount
and coverage and it covers certain amounts regarding administrative proceedings insurable or indemnifiable under the Companies Law and
our Articles of Association.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the opinion of the SEC,
however, indemnification of directors and office holders for liabilities arising under the Securities Act, is against public policy and
therefore unenforceable.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no pending litigation
or proceeding against any of our office holders as to which indemnification is being sought, nor are we aware of any pending or threatened
litigation that may result in claims for indemnification by any office holder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 233; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item&#160;7. Recent Sales of Unregistered Securities </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Set forth below are the
sales of all securities by the Company since February 1, 2021, which were not registered under the Securities Act. The Company
believes that each of such issuances was exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the
Securities Act, Rule 701 and/or Regulation S under the Securities Act. The conversions described below were exempt from registration
under Securities Act in reliance on Section 3(a)(9) of the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 4, 2021, we issued
an aggregate of 1,152,628 units, as follows: (a) 916,316 units at an offering price of $7.07 per unit, consisting of 1 ADS, a Series
A Warrant to purchase an equal number of Units purchased and a Series B Warrant to purchase half the number of Units and (b) 236,312
pre-funded units at a price of $7.069 per unit, consisting of 1 pre-funded warrant to purchase one ADS, a Series A Warrant to purchase
an equal number of Units purchased and a Series B Warrant to purchase half the number of units.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 1, 2022, in connection
with the 2022 Private Placement. In connection with the 2022 Private Placement, we issued 3,546,100 units and pre-funded units at a purchase
price of $2.82 per unit (or $0.001 less per pre-funded unit) to an institutional investor. Each unit and pre-funded unit consisted of
one Ordinary Share (or Ordinary Share equivalent) and two non-tradable warrants each exercisable for one Ordinary Share for $2.57 (for
a total of 7,092,200 shares underlying the warrants).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 30, 2022, we and
the institutional investor entered into a letter agreement and agreed, among other things, to amend certain terms of the 2022 Private
Placement. On August 19, 2022, 3,211,100 of the pre-funded warrants were fully exercised at a nominal exercise price of $0.001 per share,
which resulted in an issuance of 3,211,100 Ordinary Shares.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 30, 2022, in
connection with the closing of the Wellution Acquisition Agreement, we issued the M.R.M Warrant to M.R.M to purchase up to 82,418 of
our Ordinary Shares.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 12, 2023, in connection
with the 2023 Private Placement, we sold units to an institutional investor at a purchase price of $3.72 per unit, consisting of 1,930,108
pre-funded Ordinary Share purchase warrants to purchase up to 1,930,108 Ordinary Shares, and an additional accompanying pre-funded warrant
to purchase up to 1,930,108 Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pre-funded warrants were
exercisable immediately upon issuance and have an exercise price of $0.001 per share. Following the transaction and as of February 26,
2024, we have issued 25,000 Ordinary Shares in respect of the exercise of 25,000 pre-funded warrants.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 234; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item&#160;8. Exhibits and Financial Statement Schedules </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Exhibits:</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<tr style="vertical-align: bottom"><td style="border-bottom: Black 1.5pt solid; text-align: left; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
                                   No.</b></span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit Description</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>File No.</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit<br/>
No.</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 17%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing Date</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filed/<br/>
Furnished</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390023012516/ea172999ex3-1_scisparc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Articles
    of Association of SciSparc Ltd.</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269839&#160;</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 16, 2023</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390020007166/ea119823ex99-4_therapix.htm">Form of Warrant, pursuant to Securities Purchase Agreement, dated March 19, 2020</a>&#160;</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.4</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 23, 2020</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390020038984/ea130376ex4-2_therapixbio.htm">Form of Warrant&#160;</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 24, 2020</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390021012886/ea136813ex99-4_scisparcltd.htm">Form of Pre-Funded Warrant</a>&#160;</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.4</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2, 2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390021012886/ea136813ex99-5_scisparcltd.htm">Form of Series A Warrant</a>&#160;</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.5</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2, 2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390021012886/ea136813ex99-6_scisparcltd.htm">Form of Series B Warrant</a>&#160;</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.6</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2, 2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390022030109/ea160740ex99-5_scisparcltd.htm">Form of Ordinary Share Purchase Warrant, pursuant to Securities Purchase Agreement, dated May 27, 2022</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.5</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 27, 2022</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390022060388/ea166507ex99-4_scisparc.htm">Share Purchase Warrant, pursuant to Assignment and Assumption Agreement dated September 12, 2022</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.4</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2022</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390022060388/ea166507ex99-4_scisparc.htm">Share Purchase Warrant</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.4</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2022</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390023067123/ea183435ex4-1_scisparc.htm">Form of Pre-Funded Warrant</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 14, 2023</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000101376223003323/ea186598ex4-1_scisparc.htm">Form of Pre-Funded Warrant</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 12, 2023</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390023090549/ea189134ex4-1_scisparc.htm">Rights Agreement, dated as of November 28, 2023, between SciSparc Ltd. and VStock Transfer LLC., as rights agent, which includes the Form of Right Certificate (Exhibit A) and the Form of Summary of Rights (Exhibit B)</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 28, 2023</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390024006291/ea192120ex4-1_scisparc.htm">Form of Promissory Note between SciSparc Ltd. and YA II PN Ltd, which includes the Repayment Schedule (Exhibit 1)</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 25, 2024</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea0200391ex5-1_scisparcltd.htm">Opinion of Meitar Law Offices.</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390017004433/f20f2016ex4xii_therapixbio.htm">Form of Indemnification Agreement</a>&#160;</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-F</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 1, 2017</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390021018407/f20f2020ex4-5_scisparcltd.htm">Form of Exculpation Agreement</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-F</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 30, 2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390022022294/f20f2021ex4-3_scisparcltd.htm">Compensation Policy for Executive Officers and Directors</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-F</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 28, 2022</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4&#8224;</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390016019159/ff12016a2ex10i_therapix.htm">License Agreement dated May 20, 2015, by and between the Company and Dekel Pharmaceuticals Ltd.</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-214458</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 6, 2016</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5&#8224;&#8224;</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390019008868/f20f2018ex4-2_therapixbio.htm">License Agreement dated June 29, 2018, by and between the Company and Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-F</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 15, 2019</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>

<tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390016017994/ff12016ex10v_therapix.htm">Israeli Share Option Plan (2015)</a>&#160;</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-214458</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 4, 2016</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea0200391ex10-7_scisparcltd.htm">2023 Share Incentive Plan</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390020014990/f20f2019ex4-8_therapixbio.htm">First Amendment to License Agreement dated as of August 19, 2015, by and between the Company and Dekel Pharmaceuticals Ltd.</a>&#160; </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-F</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 15, 2020</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390020014990/f20f2019ex4-9_therapixbio.htm">Third Amendment to License Agreement dated as of July 14, 2019, by and between the Company and Dekel Pharmaceuticals Ltd.</a>&#160;</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-F</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041 </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 15, 2020</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
</table><div>
</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 235; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390020012970/ea122045ex99-1_therapix.htm">Share Transfer Agreement, by and among Capital Point Ltd., Therapix Biosciences, Ltd. and Evero Health Ltd., dated May 15, 2020</a>&#160;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041 </span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 17%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 19, 2020</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 4%">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390020012970/ea122045ex99-2_therapix.htm">Asset Purchase Agreement, by and between Therapix Biosciences, Ltd. and Evero Health Ltd., dated May 15, 2020</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041 </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 19, 2020</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390020038984/ea130376ex4-1_therapixbio.htm">Warrant Agent Agreement, dated November 23, 2020</a>&#160;</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041 </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 24, 2020</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390023014561/ea174175ex99-2_scisparc.htm">Stock Purchase Agreement, dated February 23, 2023, by and between SciSparc Ltd., NewCo Inc. and Jeffs&#8217; Brands Ltd.</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 27, 2023</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390023026713/ea176389ex10-2_scisparcltd.htm">Addendum No. 1 to Stock Purchase Agreement, dated March 22, 2023, by and between Jeffs&#8217; Brands Ltd, Jeffs&#8217; Brands Holdings Inc. and SciSparc Ltd.</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041 </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 4, 2023</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390023026713/ea176389ex10-3_scisparcltd.htm">Consulting Agreement, dated March 22, 2023, by and between Jeffs&#8217; Brands Ltd and SciSparc Nutraceuticals Inc.</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 4, 2023</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390023067123/ea183435ex1-1_scisparc.htm">Underwriting Agreement, dated August 10, 2023, by and between the Company and the Underwriter</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 14, 2023</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000101376223003323/ea186598ex10-1_scisparc.htm">Securities Purchase Agreement dated October 11, 2023</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041 </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 12, 2023 </span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000101376223003323/ea186598ex10-2_scisparc.htm">Registration Rights Agreement dated October 11, 2023</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 12, 2023 </span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000101376223003323/ea186598ex10-3_scisparc.htm">Form of Confession of Judgment</a>&#160;</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 12, 2023 </span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000101376223003323/ea186598ex10-4_scisparc.htm">Letter Agreement with Aegis Capital Corp. dated October 10, 2023</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041 </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 12, 2023 </span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390024006291/ea192120ex10-1_scisparc.htm">Standby Equity Purchase Agreement dated January 21, 2024 between YA II PN Ltd. and the Company</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 25, 2024</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.22</td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="ea0200391ex10-22_scisparcltd.htm">First Amendment to the Standby Equity Purchase Agreement, dated as of February 26, 2024, between SciSparc Ltd. and YA II PN, Ltd</a></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">*</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="ea0200391ex21-1_scisparcltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of Subsidiaries</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">*</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>23.1</td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="ea0200391ex23-1_scisparcltd.htm">Consent of Kost Forer Gabbay &amp; Kasierer, a member of Ernst &amp; Young Global, independent registered accounting firm for the Registrant.</a></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">*</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>24.1</td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="#b_020">Power of Attorney</a></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">*</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>107</td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="ea0200391ex-fee_scisparcltd.htm">Calculation of Registration Fee Table</a></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">*</td></tr>
  </table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential
    treatment was granted with respect to certain portions of this exhibit pursuant to 17.C.F.R. &#167;240.24b-2. Omitted portions were
    filed separately with the SEC.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;&#8224;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    identified information in the exhibit has been excluded from the exhibit because it is both (i) not material and (ii) is the type
    that SciSparc Ltd. treats as private or confidential.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 236; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item&#160;9. Undertakings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) The undersigned Registrant hereby undertakes:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, for the purpose of determining liability under
    the Securities Act of 1933 to any purchaser: </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i. </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the registrant is relying on Rule 430B: </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A. </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each prospectus filed by the registrant pursuant to
    Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and
    included in the registration statement; and </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B. </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each prospectus required to be filed pursuant to Rule
    424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to
    Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act of
    1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus
    is first used after effectiveness of the date of the first contract or sale of securities in the offering described in the prospectus.
    As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date and underwriter, such date shall
    be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which
    that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    <i>Provided, however</i>, that no statement made in a registration statement or prospectus that is part of the registration statement
    or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part
    of the registration statement will, as to a purchaser with a time of contract sale prior to such effective date, supersede or modify
    any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any
    such document immediately prior to such effective date; or </span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.75in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii. </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the registrant is subject to Rule 430C, each prospectus
    filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying
    on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration
    statement as of the date it is first used after effectiveness. <i>Provided, however</i>, that no statement made in a registration
    statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference
    into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract
    of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that
    was part of the registration statement or made in any such document immediately prior to such date of first use. </span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 237; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, for the purpose of determining liability of the
    registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant
    undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless
    of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser
    by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered
    to offer or sell securities to such purchaser: </span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 72px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i. </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any preliminary prospectus or prospectus of the undersigned
    registrant relating to the offering required to be filed pursuant to Rule 424; </span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 72px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii. </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any free writing prospectus relating to the offering
    prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 72px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii. </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The portion of any other free writing prospectus relating
    to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the
    undersigned registrant; and </span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 72px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv. </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any other communication that is an offer in the offering
    made by the undersigned registrant to the purchaser. </span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar as indemnification for liabilities arising
    under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the
    foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission
    such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim
    for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director,
    officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such
    director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion
    of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether
    such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such
    issue. </span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The undersigned registrant hereby undertakes that:
    </span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-indent: 28.35pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That
for purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed
as part of this registration statement in reliance upon Rule&#160;430A and contained in a form of prospectus filed by the registrant
pursuant to Rule&#160;424(b)(1) or (4), or 497(h) under the Securities Act shall be deemed to be part of this registration statement
as of the time it was declared effective.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-indent: 28.35pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That
for the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of
prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial&#160;bona fide&#160;offering thereof.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt"></p><div>

</div><!-- Field: Page; Sequence: 238; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of&#160;1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form F-1 and has duly caused this registration statement on Form F-1 to be signed on its behalf by the undersigned, thereunto
duly authorized, in Tel Aviv, State of Israel, on February 27, 2024.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCISPARC LTD.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 36%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </span></td>
    <td style="white-space: nowrap; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;/s/ Oz Adler</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oz Adler</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer </span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="b_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>POWER OF ATTORNEY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned officers
and directors of SciSparc Ltd. hereby constitute and appoint Oz Adler as our true and lawful attorney-in-fact and agent to take any actions
to enable the Company to comply with the Securities Act, and any rules, regulations and requirements of the SEC, in connection with this
registration statement on Form F-1, including the power and authority to sign for us in our names in the capacities indicated below any
and all further amendments to this registration statement and any other registration statement filed pursuant to the provisions of Rule
462 under the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Act of 1933, this amendment to the registration statement on Form F-1 has been signed by the following persons in the capacities and
on the dates indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 30%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 53%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Oz Adler</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and Chief Financial Officer</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 27, 2024</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oz Adler</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer and Principal Accounting Officer)</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Amitay Weiss</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board of Directors</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 27, 2024</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amitay Weiss</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Amnon Ben Shay</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 27, 2024</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amnon Ben Shay</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Alon Dayan</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 27, 2024</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alon Dayan</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Moshe Revach</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 27, 2024</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moshe Revach</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Itschak Shrem</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 27, 2024</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Itschak Shrem</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Liat Sidi</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 27, 2024</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liat Sidi</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Lior Vider</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 27, 2024</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lior Vider</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 239; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE
UNITED STATES</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Securities
Act of 1933, as amended, the undersigned, Puglisi &amp; Associates, the duly authorized representative in the United States of SciSparc
Ltd., has signed this registration statement on February 27, 2024.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PUGLISIGI &amp; ASSOCIATES</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>By: </b></span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 35%">/s/ <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Donald J. Puglisi</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Donald J. Puglisi</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Managing Director</span></td></tr>
  </table><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">II-9</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>


</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c3" id="hidden-fact-0" name="ifrs-full:CurrentTradeReceivables" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-1" name="ifrs-full:Inventories" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-3" name="ifrs-full:OtherNoncurrentFinancialAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-4" name="ifrs-full:CurrentLeaseLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-5" name="ifrs-full:NoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-7" name="ifrs-full:InvestmentsInAssociates" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-8" name="ifrs-full:NoncurrentLeaseLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-9" name="ifrs-full:Revenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-10" name="ifrs-full:CostOfSales" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-11" name="ifrs-full:GrossProfit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-12" name="ifrs-full:SalesAndMarketingExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-13" name="ifrs-full:SalesAndMarketingExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-14" name="ifrs-full:FinanceIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-15" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-16" name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-17" name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-18" name="ifrs-full:Revenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-19" name="ifrs-full:Revenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-20" name="ifrs-full:GrossProfit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-21" name="ifrs-full:GrossProfit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-22" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-23" name="ifrs-full:FinanceIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-24" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-25" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-26" name="sprcy:ComprehensiveIncomeAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-27" name="sprcy:ComprehensiveIncomeAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-28" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-29" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-30" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-31" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-32" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-33" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-34" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-35" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-36" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-37" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-38" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-39" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-40" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-41" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-42" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-43" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-44" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-45" name="sprcy:IssueOfSharesNetOfIssueExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-46" name="sprcy:IssueOfSharesNetOfIssueExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-47" name="sprcy:IssueOfSharesNetOfIssueExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-48" name="sprcy:IssueOfSharesNetOfIssueExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-49" name="sprcy:IssueOfSharesNetOfIssueExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-50" name="sprcy:IssueOfSharesNetOfIssueExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-51" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-52" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-53" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-54" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-55" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-56" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-57" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-58" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-59" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-60" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-61" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-62" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-63" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-64" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-65" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-66" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-67" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-68" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-69" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-70" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-71" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-72" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-73" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-74" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-75" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-76" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-77" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c61" id="hidden-fact-78" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c62" id="hidden-fact-79" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-80" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-81" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c65" id="hidden-fact-82" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c68" id="hidden-fact-83" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c62" id="hidden-fact-84" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-85" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-86" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c65" id="hidden-fact-87" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c66" id="hidden-fact-88" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c68" id="hidden-fact-89" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-90" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-91" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c65" id="hidden-fact-92" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c66" id="hidden-fact-93" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c68" id="hidden-fact-94" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-95" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c77" id="hidden-fact-96" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c79" id="hidden-fact-97" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c80" id="hidden-fact-98" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c81" id="hidden-fact-99" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c82" id="hidden-fact-100" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c83" id="hidden-fact-101" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c80" id="hidden-fact-102" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c82" id="hidden-fact-103" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c83" id="hidden-fact-104" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c84" id="hidden-fact-105" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c86" id="hidden-fact-106" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c80" id="hidden-fact-107" name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c81" id="hidden-fact-108" name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c82" id="hidden-fact-109" name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c83" id="hidden-fact-110" name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c84" id="hidden-fact-111" name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c86" id="hidden-fact-112" name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c79" id="hidden-fact-113" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c80" id="hidden-fact-114" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c81" id="hidden-fact-115" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c83" id="hidden-fact-116" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c84" id="hidden-fact-117" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c81" id="hidden-fact-118" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c82" id="hidden-fact-119" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c83" id="hidden-fact-120" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c84" id="hidden-fact-121" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c85" id="hidden-fact-122" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c86" id="hidden-fact-123" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-124" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c79" id="hidden-fact-125" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c81" id="hidden-fact-126" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c82" id="hidden-fact-127" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c83" id="hidden-fact-128" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c84" id="hidden-fact-129" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c86" id="hidden-fact-130" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c95" id="hidden-fact-131" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c97" id="hidden-fact-132" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c98" id="hidden-fact-133" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c99" id="hidden-fact-134" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-135" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c101" id="hidden-fact-136" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c104" id="hidden-fact-137" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c98" id="hidden-fact-138" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-139" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c101" id="hidden-fact-140" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c102" id="hidden-fact-141" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c104" id="hidden-fact-142" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c98" id="hidden-fact-143" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-144" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c101" id="hidden-fact-145" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c102" id="hidden-fact-146" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c104" id="hidden-fact-147" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c99" id="hidden-fact-148" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-149" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c101" id="hidden-fact-150" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c102" id="hidden-fact-151" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c103" id="hidden-fact-152" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c104" id="hidden-fact-153" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-154" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c97" id="hidden-fact-155" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c99" id="hidden-fact-156" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-157" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c101" id="hidden-fact-158" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c102" id="hidden-fact-159" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c104" id="hidden-fact-160" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-161" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c61" id="hidden-fact-162" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c62" id="hidden-fact-163" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-164" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-165" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c65" id="hidden-fact-166" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c68" id="hidden-fact-167" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c62" id="hidden-fact-168" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-169" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-170" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c65" id="hidden-fact-171" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c66" id="hidden-fact-172" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c68" id="hidden-fact-173" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-174" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-175" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c65" id="hidden-fact-176" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c66" id="hidden-fact-177" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c68" id="hidden-fact-178" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-179" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-180" name="sprcy:AdjustmentsForImpairmentOfInvestmentInAssociate" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-181" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-182" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-183" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-184" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-185" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-186" name="sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-187" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-188" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-189" name="sprcy:InterestPaidOnLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-190" name="sprcy:InterestPaidOnLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-191" name="ifrs-full:ProceedsFromIssuingShares" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-192" name="ifrs-full:ProceedsFromIssuingShares" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-193" name="ifrs-full:ProceedsFromExerciseOfOptions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-194" name="ifrs-full:ProceedsFromExerciseOfOptions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-195" name="sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-196" name="sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-197" name="sprcy:MutualShareExchangeOfOrdinarySharessee" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-198" name="sprcy:MutualShareExchangeOfOrdinarySharessee" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-199" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-200" name="sprcy:AdjustmentsForImpairmentOfInvestmentInAssociate" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-201" name="sprcy:AdjustmentsForImpairmentOfInvestmentInAssociate" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-202" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-203" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-204" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-205" name="sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-206" name="sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-207" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-208" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-209" name="sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-210" name="sprcy:InterestPaidOnLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-211" name="sprcy:RepaymentOfShorttermCredit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-212" name="sprcy:ReceiptofShortTermCreditFromOthers" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-213" name="sprcy:ReceiptofShortTermCreditFromOthers" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-214" name="sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-215" name="sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-216" name="sprcy:RegistrationOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-217" name="sprcy:RegistrationOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-218" name="sprcy:UnpaidIssueExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-219" name="sprcy:UnpaidIssueExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-220" name="ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-221" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-222" name="ifrs-full:ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-223" name="ifrs-full:TradeReceivables" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-224" name="ifrs-full:FinancialAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-225" name="sprcy:CreditFromOthers" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-226" name="sprcy:CreditFromOthers" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-227" name="ifrs-full:LeaseLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-228" name="ifrs-full:PlanAssetsAtFairValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c123" id="hidden-fact-229" name="sprcy:NoParValuePerShare" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c155" id="hidden-fact-230" name="ifrs-full:ResearchAndDevelopmentExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c171" id="hidden-fact-231" name="ifrs-full:GeneralAndAdministrativeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c185" id="hidden-fact-232" name="ifrs-full:ParValuePerShare" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c198" id="hidden-fact-233" name="sprcy:LeaseholdImprovements" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-234" name="ifrs-full:CurrentInventoriesInTransit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-235" name="ifrs-full:FinishedGoods" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-236" name="sprcy:InventoriesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-237" name="ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c217" id="hidden-fact-238" name="sprcy:BeginningBalanceCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c222" id="hidden-fact-239" name="sprcy:PurchasesOfCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c198" id="hidden-fact-240" name="sprcy:PurchasesOfCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c222" id="hidden-fact-241" name="sprcy:BeginningBalanceCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c217" id="hidden-fact-242" name="sprcy:PropertyPlantAndEquipmentCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c225" id="hidden-fact-243" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c222" id="hidden-fact-244" name="sprcy:PropertyPlantAndEquipmentCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c222" id="hidden-fact-245" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c231" id="hidden-fact-246" name="sprcy:BeginningBalanceCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c216" id="hidden-fact-247" name="sprcy:NewLeases" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c217" id="hidden-fact-248" name="sprcy:NewLeases" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c218" id="hidden-fact-249" name="sprcy:NewLeases" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c217" id="hidden-fact-250" name="sprcy:PurchasesOfCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c219" id="hidden-fact-251" name="sprcy:PurchasesOfCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c236" id="hidden-fact-252" name="ifrs-full:DisposalsPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c217" id="hidden-fact-253" name="sprcy:BeginningBalanceCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c231" id="hidden-fact-254" name="sprcy:PropertyPlantAndEquipmentCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c233" id="hidden-fact-255" name="sprcy:AccumulatedTerminationOfLeases" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c234" id="hidden-fact-256" name="sprcy:AccumulatedTerminationOfLeases" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c235" id="hidden-fact-257" name="sprcy:AccumulatedTerminationOfLeases" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c234" id="hidden-fact-258" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c236" id="hidden-fact-259" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c236" id="hidden-fact-260" name="ifrs-full:DisposalsPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c217" id="hidden-fact-261" name="sprcy:PropertyPlantAndEquipmentCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c217" id="hidden-fact-262" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-263" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-264" name="sprcy:InvestmentsInFinancialAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c278" decimals="0" id="hidden-fact-265" name="sprcy:UnderlyingOrdinarySharePrice" unitRef="usdPershares">287</ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-266" name="sprcy:NumberOfShareOptionGranted" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-267" name="sprcy:WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-268" name="sprcy:ShareadsOptionsExpiredDuringYear" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-269" name="sprcy:ShareadsOptionsExpiredDuringYearWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-270" name="ifrs-full:Revenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-271" name="ifrs-full:CostOfSales" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-272" name="ifrs-full:GrossProfit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c305" id="hidden-fact-273" name="sprcy:ResearchAndDevelopmentExpenses1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c307" id="hidden-fact-274" name="sprcy:ResearchAndDevelopmentExpenses1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c316" id="hidden-fact-275" name="ifrs-full:SellingGeneralAndAdministrativeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c317" id="hidden-fact-276" name="ifrs-full:SellingGeneralAndAdministrativeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c320" id="hidden-fact-277" name="ifrs-full:OtherOperatingIncomeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c321" id="hidden-fact-278" name="ifrs-full:OtherOperatingIncomeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c324" id="hidden-fact-279" name="ifrs-full:OtherOperatingIncomeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c325" id="hidden-fact-280" name="ifrs-full:OtherOperatingIncomeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-281" name="ifrs-full:OtherOperatingIncomeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-282" name="sprcy:FinanceIncomeFromConvertibleLoan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-283" name="ifrs-full:FinanceIncomeCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-284" name="ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-285" name="ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c333" id="hidden-fact-286" name="sprcy:ExternalRevenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c333" id="hidden-fact-287" name="sprcy:Intersegment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c334" id="hidden-fact-288" name="sprcy:Intersegment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-289" name="sprcy:Intersegment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c333" id="hidden-fact-290" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c335" id="hidden-fact-291" name="sprcy:ExternalRevenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c336" id="hidden-fact-292" name="sprcy:ExternalRevenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-293" name="sprcy:ExternalRevenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c335" id="hidden-fact-294" name="sprcy:Intersegment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c336" id="hidden-fact-295" name="sprcy:Intersegment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-296" name="sprcy:Intersegment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c335" id="hidden-fact-297" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c336" id="hidden-fact-298" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-299" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c336" id="hidden-fact-300" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c337" id="hidden-fact-301" name="sprcy:ExternalRevenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c338" id="hidden-fact-302" name="sprcy:ExternalRevenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-303" name="sprcy:ExternalRevenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c337" id="hidden-fact-304" name="sprcy:Intersegment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c338" id="hidden-fact-305" name="sprcy:Intersegment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-306" name="sprcy:Intersegment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c337" id="hidden-fact-307" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c338" id="hidden-fact-308" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-309" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c338" id="hidden-fact-310" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c342" id="hidden-fact-311" name="ifrs-full:OtherAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c342" id="hidden-fact-312" name="ifrs-full:OtherLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-313" name="sprcy:ResearchAndDevelopmentExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-314" name="sprcy:ResearchAndDevelopmentExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-39051">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-39052">0001611746</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="sprcy-20230630.xsd" xlink:type="simple"/></ix:references>
<ix:resources><ix:relationship fromRefs="ix_0_fact hidden-fact-102 ix_1_fact hidden-fact-103 hidden-fact-104 hidden-fact-105 ix_2_fact hidden-fact-106 ix_3_fact" toRefs="ix_0_footnote"></ix:relationship>
<ix:relationship fromRefs="ix_4_fact hidden-fact-143 ix_5_fact hidden-fact-144 hidden-fact-145 hidden-fact-146 ix_6_fact hidden-fact-147 ix_7_fact" toRefs="ix_1_footnote"></ix:relationship>
<ix:relationship fromRefs="ix_8_fact hidden-fact-138 ix_9_fact hidden-fact-139 hidden-fact-140 hidden-fact-141 ix_10_fact hidden-fact-142 ix_11_fact" toRefs="ix_2_footnote"></ix:relationship>
<xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:TotalEquityHolderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:TotalEquityHolderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:TotalEquityHolderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:TotalEquityHolderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:TotalEquityHolderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:TotalEquityHolderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:TotalEquityHolderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:TotalEquityHolderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:TotalEquityHolderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:TotalEquityHolderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:TotalEquityHolderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-01</xbrli:startDate>
    <xbrli:endDate>2023-08-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-10</xbrli:startDate>
    <xbrli:endDate>2022-03-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-10</xbrli:startDate>
    <xbrli:endDate>2022-03-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-31</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-17</xbrli:startDate>
    <xbrli:endDate>2023-02-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-17</xbrli:startDate>
    <xbrli:endDate>2023-02-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-17</xbrli:startDate>
    <xbrli:endDate>2023-02-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AutoMaxSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AutoMaxSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-11-17</xbrli:startDate>
    <xbrli:endDate>2022-11-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-06-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-08-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-11-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">sprcy:March2021FinancingRoundMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:SeriesAWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:SeriesBWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">sprcy:SeriesAWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">sprcy:June2022FinancingRoundMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">sprcy:June2022WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-06-01</xbrli:startDate>
    <xbrli:endDate>2023-06-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">sprcy:June2022WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2w4dODRyrf2cKq4MnlNojKY2vawGlGpB5CaguD0HWK7+MXGfIzhA2ezfWaTq7hAnt683nzSc747v3s9ubzeRZw15+aEvNutYTqGoMIIBc15Xh4havgCm8tamhX0Z9ZkXtnE0CLGLW6Ak=] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WellutionOperatingExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WellutionOperatingExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WellutionOperatingExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:NewCoIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-23</xbrli:startDate>
    <xbrli:endDate>2023-02-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">sprcy:CapitalPointWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-01</xbrli:startDate>
    <xbrli:endDate>2023-08-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">sprcy:SCISPARCLTDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-08-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">sprcy:SCISPARCLTDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-01</xbrli:startDate>
    <xbrli:endDate>2023-08-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-01</xbrli:startDate>
    <xbrli:endDate>2023-08-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-08-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-10-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-03-15</xbrli:startDate>
    <xbrli:endDate>2017-03-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:EveroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-05-15</xbrli:startDate>
    <xbrli:endDate>2020-05-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:EveroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-05-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-05-15</xbrli:startDate>
    <xbrli:endDate>2020-05-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:CapitalPointMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-05-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:CapitalPointMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-05-15</xbrli:startDate>
    <xbrli:endDate>2020-05-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:CapitalPointWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:EveroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-11-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-11-16</xbrli:startDate>
    <xbrli:endDate>2020-11-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-17</xbrli:startDate>
    <xbrli:endDate>2023-02-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-17</xbrli:startDate>
    <xbrli:endDate>2023-02-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-17</xbrli:startDate>
    <xbrli:endDate>2023-02-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-11-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-09-01</xbrli:startDate>
    <xbrli:endDate>2020-09-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:LeaseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c224">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c225">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c226">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c227">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c228">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c229">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c230">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c231">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c232">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c233">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c234">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c235">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c236">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c237">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c238">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-01-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c239">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-04-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c240">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-09-08</xbrli:startDate>
    <xbrli:endDate>2020-09-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c241">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-03-19</xbrli:startDate>
    <xbrli:endDate>2020-03-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c242">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c243">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:ADSsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c244">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sprcy:PrivatePlacementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-03-19</xbrli:startDate>
    <xbrli:endDate>2020-03-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c245">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-03-01</xbrli:startDate>
    <xbrli:endDate>2020-03-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c246">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-11-02</xbrli:startDate>
    <xbrli:endDate>2019-11-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c247">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-04-01</xbrli:startDate>
    <xbrli:endDate>2017-04-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c248">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-12-02</xbrli:startDate>
    <xbrli:endDate>2021-12-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c249">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-27</xbrli:startDate>
    <xbrli:endDate>2022-07-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c250">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-02</xbrli:startDate>
    <xbrli:endDate>2020-08-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c251">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-09-01</xbrli:startDate>
    <xbrli:endDate>2020-09-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c252">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-09-01</xbrli:startDate>
    <xbrli:endDate>2020-09-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c253">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-09-01</xbrli:startDate>
    <xbrli:endDate>2020-09-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c254">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2020-10-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c255">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2020-10-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c256">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2020-10-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c257">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">sprcy:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2020-10-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c258">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-01</xbrli:startDate>
    <xbrli:endDate>2021-03-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c259">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-01</xbrli:startDate>
    <xbrli:endDate>2021-03-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c260">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-09-15</xbrli:startDate>
    <xbrli:endDate>2022-09-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c261">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:AgreementTypeAxis">sprcy:AprilTwoThousandTwentyPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-03-20</xbrli:startDate>
    <xbrli:endDate>2020-04-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c262">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-11-02</xbrli:startDate>
    <xbrli:endDate>2020-11-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c263">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">sprcy:November2020FinancingRoundMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-11-20</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c264">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c265">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-11-30</xbrli:startDate>
    <xbrli:endDate>2020-11-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c266">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-21</xbrli:startDate>
    <xbrli:endDate>2021-07-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c267">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-02</xbrli:startDate>
    <xbrli:endDate>2022-08-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c268">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-11-01</xbrli:startDate>
    <xbrli:endDate>2022-11-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c269">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-04</xbrli:startDate>
    <xbrli:endDate>2021-03-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c270">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:SeriesAWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c271">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:SeriesBWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c272">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:SeriesAWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c273">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">sprcy:March2021FinancingRoundMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c274">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">sprcy:March2021FinancingRoundMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c275">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c276">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c277">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c278">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-02</xbrli:startDate>
    <xbrli:endDate>2023-06-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c279">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-11-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c280">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-04-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c281">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-03-01</xbrli:startDate>
    <xbrli:endDate>2019-03-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c282">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-03-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c283">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2019-10-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c284">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c285">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-01-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c286">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-02-01</xbrli:startDate>
    <xbrli:endDate>2022-02-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c287">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">sprcy:OrdinaryShareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c288">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c289">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c290">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c291">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c292">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-12-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c293">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-09-11</xbrli:startDate>
    <xbrli:endDate>2019-10-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c294">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-04</xbrli:startDate>
    <xbrli:endDate>2022-02-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c295">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-12-04</xbrli:startDate>
    <xbrli:endDate>2022-01-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c296">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c297">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c298">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c299">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c300">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c301">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c302">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c303">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c304">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c305">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c306">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c307">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c308">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c309">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c310">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c311">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c312">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c313">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c314">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c315">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c316">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WellutionOperatingExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c317">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WellutionOperatingExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c318">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c319">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c320">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ImpairmentOfInvestmentInAssociateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c321">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ImpairmentOfInvestmentInAssociateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c322">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ImpairmentOfInvestmentInAssociateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c323">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:GroupsShareOfLossesOfCompanyAccountedForAtEquityNetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c324">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:GroupsShareOfLossesOfCompanyAccountedForAtEquityNetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c325">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:GroupsShareOfLossesOfCompanyAccountedForAtEquityNetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c326">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">sprcy:ADSMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c327">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">sprcy:ADSMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c328">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">sprcy:ADSMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c329">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">sprcy:OrdinaryShareMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c330">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c331">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c332">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c333">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c334">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c335">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c336">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c337">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c338">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c339">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c340">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c341">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c342">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c343">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-11-01</xbrli:startDate>
    <xbrli:endDate>2022-11-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c344">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c345">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c346">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c347">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c348">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c349">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c350">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-22</xbrli:startDate>
    <xbrli:endDate>2023-03-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c351">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c352">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">sprcy:SCISPARCLTDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="ils">
  <xbrli:measure>iso4217:ILS</xbrli:measure>
</xbrli:unit><xbrli:unit id="ilsPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:ILS</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ea0200391ex5-1_scisparcltd.htm
<DESCRIPTION>OPINION OF MEITAR LAW OFFICES.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex5-1_001i.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">February 27, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SciSparc Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">20 Raul Wallenberg Street, Tower A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel Aviv 6971916</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Re:&nbsp;<B><U>SciSparc Ltd.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have acted as Israeli counsel to SciSparc Ltd., a company organized
under the laws of the State of Israel (the &ldquo;<B>Company</B>&rdquo;), in connection with the filing by the Company of a registration
statement on Form F-1 (the &ldquo;<B>Registration Statement</B>&rdquo;) with the Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;)
pursuant to Rule 415 promulgated under the Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;), relating to the
resale by the selling shareholder identified in the Registration Statement (the &ldquo;<B>Selling Shareholder</B>&rdquo;) of up to: (i)
5,347,594 ordinary shares, no par value (the &ldquo;<B>Ordinary Shares</B>&rdquo;), which may be issued from time to time by the Company
to the Selling Shareholder pursuant to a Standby Equity Purchase Agreement (the &ldquo;<B>Advance Shares</B>&rdquo; and the &ldquo;<B>SEPA</B>&rdquo;,
respectively) with the Selling Shareholder, dated January 21, 2024, and as amended on February 26, 2024 and (ii) 55,293 Ordinary Shares
issued to an affiliate of the Selling Shareholder, as consideration for Selling Shareholder&rsquo;s irrevocable commitment to purchase
our Ordinary Shares under the SEPA (the &ldquo;<B>Commitment Fee Shares</B>&rdquo;), as further described in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection herewith, we
have examined the originals, photocopies or copies, certified or otherwise identified to our satisfaction, of: (i) the Registration Statement
to which this opinion is attached as an exhibit; (ii) the articles of association of the Company, as currently in effect (the &ldquo;<B>Articles</B>&rdquo;);
(iii) resolutions of the board of directors (the &ldquo;<B>Board</B>&rdquo;) of the Company which have heretofore been approved and relate
to the Company&rsquo;s issuance and sale of the Commitment Fee Shares and potential issuance of the Advance Shares, filing of the Registration
Statement and other actions to be taken in connection with such issuance and sale; and (iv) such other corporate records, agreements,
documents and other instruments, and such certificates or comparable documents of public officials and of officers of the Company as
we have deemed relevant and necessary as a basis for the opinions hereafter set forth. We have also made inquiries of such officers as
we have deemed relevant and necessary as a basis for the opinions hereafter set forth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In such examination, we have
assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of all documents submitted to
us as originals, the conformity to original documents of all documents submitted to us as certified copies or confirmed as photostatic
copies, and the authenticity of the originals of such latter documents. We have also assumed the truth of all facts communicated to us
by the Company and that all minutes of meetings of the Board and the shareholders of the Company that have been provided to us are true
and accurate and have been properly prepared in accordance with the Articles and all applicable laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have further assumed that
at the time of issuance and to the extent any such issuance would exceed the maximum share capital of the Company currently authorized,
the number of Ordinary Shares that the Company is authorized to issue shall have been increased in accordance with the Company&rsquo;s
Articles such that a sufficient number of Ordinary Shares are authorized and available for issuance under the Articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: left"><IMG SRC="ex5-1_002i.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based upon and subject to
the foregoing, we are of the opinion that: (i) the Advance Shares, assuming that prior to the issuance of any Advance Shares under the
SEPA, the price, number of Advance Shares and certain other terms of issuance with respect to any specific advance notice delivered under
the SEPA will be authorized and approved by the Board or a pricing committee of the Board in accordance with Israeli Law, all corporate
proceedings necessary for the authorization, issuance and delivery of the Advance Shares shall have been taken and, upon issuance pursuant
to the terms of the SEPA and in accordance with resolutions of the Board related to the offering of the Advance Shares, the Advance Shares
will be validly issued, fully paid and non-assessable and (ii) the Commitment Fee Shares, as described in the Registration Statement,
are validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Members of our firm are admitted
to the Bar in the State of Israel, and we do not express any opinion as to the laws of any other jurisdiction. This opinion is limited
to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly stated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We consent to the filing
of this opinion as an exhibit to the Registration Statement and to the reference to our firm appearing under the caption &ldquo;Legal
Matters&rdquo; and &ldquo;Enforceability of Civil Liabilities&rdquo; in the prospectus forming part of the Registration Statement. In
giving this consent, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of
the Securities Act, the rules and regulations of the SEC promulgated thereunder or Item 509 of the SEC&rsquo;s Regulation S-K promulgated
under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This opinion letter is rendered
as of the date hereof and we disclaim any obligation to advise you of facts, circumstances, events or developments that may be brought
to our attention after the date of the Registration Statement that may alter, affect or modify the opinions expressed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 40%; text-align: justify"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">/s/ Meitar | Law Offices</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Meitar | Law Offices</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>3
<FILENAME>ea0200391ex10-7_scisparcltd.htm
<DESCRIPTION>2023 SHARE INCENTIVE PLAN
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.7</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 40%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>SciSparc
Ltd.</B></FONT></P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>Share
Incentive Plan</B></FONT></P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 40%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Unless otherwise defined, terms used herein
shall have the meaning ascribed to them in Section 2 hereof.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify"><B><U>PURPOSE; TYPES OF AWARDS; CONSTRUCTION</U></B>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1. <U>Purpose</U>.
The purpose of this 2023 Share Incentive Plan (as amended, this &ldquo;<B>Plan</B>&rdquo;) is to afford an incentive to Service Providers
of SciSparc Ltd., an Israeli company (together with any successor corporation thereto, the &ldquo;<B>Company</B>&rdquo;), or any Affiliate
of the Company, which now exists or hereafter is organized or acquired by the Company or its Affiliates, to continue as Service Providers,
to increase their efforts on behalf of the Company or its Affiliates and to promote the success of the Company&rsquo;s business, by providing
such Service Providers with opportunities to acquire a proprietary interest in the Company by the issuance of Shares or restricted Shares
(&ldquo;<B>Restricted Shares</B>&rdquo;) of the Company, and by the grant of options to purchase Shares (&ldquo;<B>Options</B>&rdquo;),
Restricted Share Units (&ldquo;<B>RSUs</B>&rdquo;), share appreciation rights and other Share-based Awards pursuant to Sections &lrm;11
through &lrm;13 of this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.2. <U>Types
of Awards</U>. This Plan is intended to enable the Company to issue Awards under various tax regimes, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i) pursuant
and subject to the provisions of Section 102 of the Ordinance (or the corresponding provision of any subsequently enacted statute, as
amended from time to time), and all regulations and interpretations adopted by any competent authority, including the Israel Tax Authority
(the &ldquo;<B>ITA</B>&rdquo;), including the Income Tax Rules (Tax Benefits in Stock Issuance to Employees) 5763-2003 or such other rules
so adopted from time to time (the &ldquo;<B>Rules</B>&rdquo;) (such Awards that are intended to be (as set forth in the Award Agreement)
and which qualify as such under Section 102 of the Ordinance and the Rules, &ldquo;<B>102 Awards</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii) pursuant
to Section 3(i) of the Ordinance or the corresponding provision of any subsequently enacted statute, as amended from time to time (such
Awards, &ldquo;<B>3(i) Awards</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii) Incentive
Stock Options within the meaning of Section 422 of the Code, or the corresponding provision of any subsequently enacted United States
federal tax statute, as amended from time to time, to be granted to Employees who are deemed to be residents of the United States, for
purposes of taxation, or are otherwise subject to U.S. Federal income tax (such Awards that are intended to be (as set forth in the Award
Agreement) and which qualify as an incentive stock option within the meaning of Section 422(b) of the Code, &ldquo;<B>Incentive Stock
Options</B>&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iv) Options
not intended to be (as set forth in the Award Agreement) or which do not qualify as an Incentive Stock Option to be granted to Service
Providers who are deemed to be residents of the United States for purposes of taxation, or are otherwise subject to U.S. Federal income
tax (&ldquo;<B>Nonqualified Stock Options</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 71.45pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the issuance of Awards under the
relevant tax regimes in the United States of America and the State of Israel, and without derogating from the generality of Section &lrm;24,
this Plan contemplates issuances to Grantees in other jurisdictions or under other tax regimes with respect to which the Committee is
empowered, but is not required, to make the requisite adjustments in this Plan and set forth the relevant conditions in an appendix to
this Plan or in the Company&rsquo;s agreement with the Grantee in order to comply with the requirements of such other tax regimes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.3. <U>Construction</U>.
To the extent any provision herein conflicts with the conditions of any relevant tax law, rule or regulation which are relied upon for
tax relief in respect of a particular Award to a Grantee, the Committee is empowered, but is not required, hereunder to determine that
the provisions of such law, rule or regulation shall prevail over those of this Plan and to interpret and enforce such prevailing provisions.
With respect to 102 Awards, if and to the extent any action or the exercise or application of any provision hereof or authority granted
hereby is conditioned or subject to obtaining a ruling or tax determination from the ITA, to the extent required by applicable law, then
the taking of any such action or the exercise or application of such section or authority with respect to 102 Awards shall be conditioned
upon obtaining such ruling or tax determination, and, if obtained, shall be subject to any condition set forth therein; it being clarified
that there is no obligation to apply for any such ruling or tax determination (which shall be in the sole discretion of the Committee)
and no assurance is made that if applied any such ruling or tax determination will be obtained (or the conditions thereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify"><B><U>DEFINITIONS</U></B>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1. <U>Terms
Generally</U>. Except when otherwise indicated by the context, (i)&nbsp;the singular shall include the plural and the plural shall include
the singular; (ii) any pronoun shall include the corresponding masculine, feminine and neuter forms; (iii) any definition of or reference
to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document
as from time to time amended, restated, supplemented or otherwise modified (subject to any restrictions on such amendments, restatements,
supplements or modifications set forth therein or herein), (iv)&nbsp;references to any law, constitution, statute, treaty, regulation,
rule or ordinance, including any section or other part thereof shall refer to it as amended from time to time and shall include any successor
thereof, (v)&nbsp;reference to a &ldquo;company&rdquo; or &ldquo;entity&rdquo; shall include a, partnership, corporation, limited liability
company, association, trust, unincorporated organization, or a government or agency or political subdivision thereof, and reference to
a &ldquo;person&rdquo; shall mean any of the foregoing or an individual, (vi) the words &ldquo;herein&rdquo;, &ldquo;hereof&rdquo; and
&ldquo;hereunder&rdquo;, and words of similar import, shall be construed to refer to this Plan in its entirety, and not to any particular
provision hereof, (vii)&nbsp;all references herein to Sections shall be construed to refer to Sections to this Plan; (viii) the words
&ldquo;include&rdquo;, &ldquo;includes&rdquo; and &ldquo;including&rdquo; shall be deemed to be followed by the phrase &ldquo;without
limitation&rdquo;; and (ix) use of the term &ldquo;or&rdquo; is not intended to be exclusive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2. <U>Defined
Terms</U>. The following terms shall have the meanings ascribed to them in this Section 2:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.3. &ldquo;<B>Affiliate</B>&rdquo;
shall mean, with respect to any person, any other person that, directly or indirectly through one or more intermediaries, controls, is
controlled by, or is under common control with, such person (with the term &ldquo;control&rdquo; or &ldquo;controlled by&rdquo; within
the meaning of Rule 405 of Regulation C under the Securities Act), including, without limitation, any Parent or Subsidiary, or Employer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.4.
&ldquo;<B>Applicable Law</B>&rdquo; shall mean any applicable law, rule, regulation, statute, pronouncement, policy, interpretation, judgment,
order or decree of any federal, provincial, state or local governmental, regulatory or adjudicative authority or agency, of any jurisdiction,
and the rules and regulations of any stock exchange, over-the-counter market or trading system on which the Company&rsquo;s shares are
then traded or listed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.5. &ldquo;<B>Award</B>&rdquo;
shall mean any Option, Restricted Share, RSUs, Shares, share appreciation rights or any other Share-based award granted under this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.6. &ldquo;<B>Board</B>&rdquo;
shall mean the Board of Directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.7. &ldquo;<B>Change
in Board Event</B>&rdquo; shall mean any time at which individuals who, as of the Effective Date, constitute the Board (the &ldquo;<B>Incumbent
Board</B>&rdquo;) cease for any reason to constitute at least a majority of the Board; <U>provided</U>, <U>however</U>, that any individual
becoming a director subsequent to the Effective Date whose election, or nomination for election by the Company&rsquo;s shareholders, was
approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual
were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as
a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened
solicitation of proxies or consents by or on behalf of a Person other than the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.8. &ldquo;<B>Code</B>&rdquo;
shall mean the United States Internal Revenue Code of 1986, and any applicable regulations promulgated thereunder, all as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.9. &ldquo;<B>Committee</B>&rdquo;
shall mean a committee established or appointed by the Board to administer this Plan, subject to Section &lrm;3.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.10. &ldquo;<B>Companies
Law</B>&rdquo; shall mean the Israel Companies Law, 5759-1999, and the regulations promulgated thereunder, all as amended from time to
time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.11. &ldquo;<B>Controlling
Shareholder</B>&rdquo; shall have the meaning set forth in Section 32(9) of the Ordinance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.12. &ldquo;<B>Disability</B>&rdquo;
shall mean (i) the inability of a Grantee to engage in any substantial gainful activity or to perform the major duties of the Grantee&rsquo;s
position with the Company or its Affiliates by reason of any medically determinable physical or mental impairment which has lasted or
can be expected to last for a continuous period of not less than 12 months (or such other period as determined by the Committee), as determined
by a qualified doctor acceptable to the Company, (ii) if applicable, a &ldquo;permanent and total disability&rdquo; as defined in Section
22(e)(3) of the Code or Section 409A(a)(2)(c)(i) of the Code, as amended from time to time, or (iii) as defined in a policy of the Company
that the Committee deems applicable to this Plan, or that makes reference to this Plan, for purposes of this definition. Notwithstanding
the foregoing, for Awards that are subject to Section 409A of the Code, Disability shall mean that a Grantee is disabled under Section
409A(a)(2)(C)(i) or (ii) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.13. &ldquo;<B>Employee</B>&rdquo;
shall mean any person treated as an employee (including an officer or a director who is also treated as an employee) in the records of
the Company or any of its Affiliates (and in the case of 102 Awards, subject to Section &lrm;9.3 or in the case of Incentive Stock Options,
who is an employee for purposes of Section 422 of the Code); provided, however, that neither service as a director nor payment of a director&rsquo;s
fee shall be sufficient to constitute employment for purposes of this Plan. The Company shall determine in good faith and in the exercise
of its discretion whether an individual has become or has ceased to be an Employee and the effective date of such individual&rsquo;s employment
or termination of employment, as the case may be. For purposes of a person&rsquo;s rights, if any, under this Plan as of the time of the
Company&rsquo;s determination, all such determinations by the Company shall be final, binding and conclusive, notwithstanding that the
Company or any court of law or governmental agency subsequently makes a contrary determination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.14. &ldquo;<B>Employer</B>&rdquo;
means, for purpose of a 102 Trustee Award, the Company or an Affiliate, Subsidiary or Parent thereof, which is an &ldquo;employing company&rdquo;
within the meaning and subject to the conditions of Section 102(a) of the Ordinance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.15. &ldquo;<B>employment</B>&rdquo;,
&ldquo;<B>employed</B>&rdquo; and words of similar import shall be deemed to refer to the employment of Employees or to the services of
any other Service Provider, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.16. &ldquo;<B>exercise</B>&rdquo;
&ldquo;<B>exercised</B>&rdquo; and words of similar import, when referring to an Award that does not require exercise or that is settled
upon vesting (such as may be the case with RSUs or Restricted Shares, if so determined in their terms), shall be deemed to refer to the
vesting of such an Award (regardless of whether or not the wording included reference to vesting of such an Awards explicitly).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.17. &ldquo;<B>Exchange
Act</B>&rdquo; shall mean the U.S. Securities Exchange Act of 1934, as amended, and all regulations, guidance and other interpretative
authority issued thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.18. &ldquo;<B>Exercise
Period</B>&rdquo; shall mean the period, commencing on the date of grant of an Award, during which an Award shall be exercisable, subject
to any vesting provisions thereof (including any acceleration thereof, if any) and subject to the termination provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.19. &ldquo;<B>Exercise
Price</B>&rdquo; shall mean the exercise price for each Share covered by an Option or the purchase price for each Share covered by any
other Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.20. &ldquo;<B>Fair
Market Value</B>&rdquo; shall mean, as of any date, the value of a Share or other securities, property or rights as determined by the
Board, in its discretion, subject to the following: (i) if, on such date, the Shares are listed on any securities exchange, the average
closing sales price per Share on the securities exchange on which the Shares are principally traded over the thirty (30) trading days
preceding the subject date, as reported in The Wall Street Journal or such other source as the Company deems reliable; (ii) if, on such
date, the Shares are then quoted in an over-the-counter market, the average of the closing bid and asked prices for the Shares in that
market during the thirty (30) trading days preceding the subject date, as reported in The Wall Street Journal or such other source as
the Company deems reliable; or (iii) if, on such date, the Shares are not then listed on a securities exchange or quoted in an over-the-counter
market, or in case of any other securities, property or rights, such value as the Committee, in its sole discretion, shall determine,
with full authority to determine the method for making such determination and which determination shall be conclusive and binding on all
parties, and shall be made after such consultations with outside legal, accounting and other experts as the Committee may deem advisable;
provided, however, that, if applicable, the Fair Market Value of the Shares shall be determined in a manner that is intended to satisfy
the applicable requirements of and subject to Section 409A of the Code, and with respect to Incentive Stock Options, in a manner that
is intended to satisfy the applicable requirements of and subject to Section 422 of the Code, subject to Section 422(c)(7) of the Code.
The Committee shall maintain a written record of its method of determining such value. If the Shares are listed or quoted on more than
one established stock exchange or over-the-counter market, the Committee shall determine the principal such exchange or market and utilize
the price of the Shares on that exchange or market (determined as per the method described in clauses (i) or (ii) above, as applicable)
for the purpose of determining Fair Market Value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.21. &ldquo;<B>Grantee</B>&rdquo;
shall mean a person who has been granted an Award(s) under this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.22. &ldquo;<B>Ordinance</B>&rdquo;
shall mean the Israeli Income Tax Ordinance (New Version) 1961, and the regulations and rules (including the Rules) promulgated thereunder,
all as amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.23. &ldquo;<B>Parent</B>&rdquo;
shall mean any company (other than the Company), which now exists or is hereafter organized, (i) in an unbroken chain of companies ending
with the Company if, at the time of granting an Award, each of the companies (other than the Company) owns stock possessing fifty percent
(50%) or more of the total combined voting power of all classes of stock in one of the other companies in such chain, or (ii) if applicable
and for purposes of Incentive Stock Options, that is a &ldquo;parent corporation&rdquo; of the Company, as defined in Section 424(e) of
the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.24. &ldquo;<B>Retirement</B>&rdquo;
shall mean a Grantee&rsquo;s retirement pursuant to Applicable Law or in accordance with the terms of any tax-qualified retirement plan
maintained by the Company or any of its Affiliates in which the Grantee participates or is subject to.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.25. &ldquo;<B>Securities
Act</B>&rdquo; shall mean the U.S. Securities Act of 1933, and the rules and regulations promulgated thereunder, all as amended from time
to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.26. &ldquo;<B>Service
Provider</B>&rdquo; shall mean an Employee, director, officer, consultant, advisor and any other person or entity who provides services
to the Company or any Parent, Subsidiary or Affiliate thereof. Service Providers shall include prospective Service Providers to whom Awards
are granted in connection with written offers of an employment or other service relationship with the Company or any Parent, Subsidiary
or any Affiliates thereof, provided, however, that such employment or service shall have actually commenced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.27.
&ldquo;<B>Shares</B>&rdquo; shall mean Ordinary Shares, no par value of the Company (as adjusted Recapitalization events), or shares of
such other class of shares of the Company as shall be designated by the Board in respect of the relevant Award(s). &ldquo;<B>Shares</B>&rdquo;
include any securities, property or rights issued or distributed with respect thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.28. &ldquo;<B>Subsidiary</B>&rdquo;
shall mean any company (other than the Company), which now exists or is hereafter organized or acquired by the Company, (i) in an unbroken
chain of companies beginning with the Company if, at the time of granting an Award, each of the companies other than the last company
in the unbroken chain owns stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in
one of the other companies in such chain, or (ii) if applicable and for purposes of Incentive Stock Options, that is a &ldquo;subsidiary
corporation&rdquo; of the Company, as defined in Section 424(f) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.29. &ldquo;<B>tax(es)</B>&rdquo;
shall mean (a) all federal, state, local or foreign taxes, charges, fees, imposts, levies or other assessments, including all income,
capital gains, alternative or add-on minimum, transfer, value added tax, real and personal property, withholding, payroll, employment,
escheat, social security, disability, national security, health tax, wealth surtax, stamp, registration and estimated taxes, customs duties,
fees, assessments and charges of any similar kind whatsoever (including under Section 280G of the Code) or other tax of any kind whatsoever,
(b) all interest, indexation differentials, penalties, fines, additions to tax or additional amounts imposed by any taxing authority in
connection with any item described in clause (a), (c) any transferee or successor liability in respect of any items described in clauses
(a) or (b) payable by reason of contract, assumption, transferee liability, successor liability, operation of Applicable Law, or as a
result of any express or implied obligation to assume Taxes or to indemnify any other person, and (d) any liability for the payment of
any amounts of the type described in clause (a) or (b) payable as a result of being a member of an affiliated, consolidated, combined,
unitary or aggregate or other group for any taxable period, including under U.S. Treasury Regulations Section 1.1502-6(a) (or any predecessor
or successor thereof of any analogous or similar provision under Law) or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.30. &ldquo;<B>Ten
Percent Shareholder</B>&rdquo; shall mean a Grantee who, at the time an Award is granted to the Grantee, owns shares possessing more than
ten percent (10%) of the total combined voting power of all classes of shares of the Company or any Parent or Subsidiary, within the meaning
of Section 422(b)(6) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.31. &ldquo;<B>Trustee</B>&rdquo;
shall mean the trustee appointed by the Committee to hold the Awards (and, in relation with 102 Trustee Awards, approved by the ITA),
if so appointed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2.32. <U>Other
Defined Terms</U>. The following terms shall have the meanings ascribed to them in the Sections set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Term</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">102 Awards</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;1.2&lrm;(i)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">102 Capital Gains Track Awards</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;9.1</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">102 Non-Trustee Awards</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;9.2</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">102 Ordinary Income Track Awards</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;9.1</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">102 Trustee Awards</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;9.1</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">3(i) Awards</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;1.2&lrm;(ii)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Articles of Association</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;3.1</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Award Agreement</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;6</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cause</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;6.6.4.4</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Company</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effective Date</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;23.1</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Election</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;9.2</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Eligible 102 Grantees</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;9.3.1</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Incentive Stock Options</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;1.2(iii) </FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Information</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;16.4</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">ITA</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;1.1&lrm;(i) &nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Market Stand-Off</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&rlm;1</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Market Stand-Off Period</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&rlm;1</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Merger/Sale</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;14.2</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nonqualified Stock Options</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;1.2&lrm;(iv)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Plan</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pool</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;5.1</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prior Plan(s)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;5.2</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Recapitalization</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;14.1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Required Holding Period</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;9.5</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Restricted Period</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;11.2</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Restricted Share Agreement</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;11</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Restricted Share Unit Agreement</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;12</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Restricted Shares</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">RSUs</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Rules</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;1.1&lrm;1.2&lrm;(i)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Securities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&rlm;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Successor Corporation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;14.2.1</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Withholding Obligations</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;17.5</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify"><B><U>ADMINISTRATION</U></B>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">3.1. To
the extent permitted under Applicable Law, the Amended and Restated Articles of Association, as may be amended from time to time (the
&ldquo;<B>Articles of Association</B>&rdquo;) and any other governing document of the Company, this Plan shall be administered by the
Committee. In the event that the Board does not appoint or establish a committee to administer this Plan, this Plan shall be administered
by the Board, and, accordingly, any and all references herein to the Committee shall be construed as references to the Board. In the event
that an action necessary for the administration of this Plan is required under Applicable Law to be taken by the Board without the right
of delegation, or if such action or power was explicitly reserved by the Board in appointing, establishing and empowering the Committee,
then such action shall be so taken by the Board. In any such event, all references herein to the Committee shall be construed as references
to the Board. Even if such a Committee was appointed or established, the Board may take any actions that are stated to be vested in the
Committee, and shall not be restricted or limited from exercising all rights, powers and authorities under this Plan or Applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">3.2. The
Board shall appoint the members of the Committee, may from time to time remove members from, or add members to, the Committee, and shall
fill vacancies in the Committee, however caused, provided that the composition of the Committee shall at all times be in compliance with
any mandatory requirements of Applicable Law, the Articles of Association and any other governing document of the Company. The Committee
may select one of its members as its Chairman and shall hold its meetings at such times and places as it shall determine. The Committee
may appoint a Secretary, who shall keep records of its meetings, and shall make such rules and regulations for the conduct of its business
as it shall deem advisable and subject to mandatory requirements of Applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">3.3. Subject
to the terms and conditions of this Plan, any mandatory provisions of Applicable Law and any provisions of any Company policy required
under mandatory provisions of Applicable Law, and in addition to the Committee&rsquo;s powers contained elsewhere in this Plan, the Committee
shall have full authority, in its discretion, from time to time and at any time, to determine any of the following, or to recommend to
the Board any of the following if it is not authorized to take such action according to Applicable Law:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i) eligible
Grantees,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 71.45pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii) grants
of Awards and setting the terms and provisions of Award Agreements (which need not be identical) and any other agreements or instruments
under which Awards are made, including the number of Shares underlying each Award and the class of Shares underlying each Award (if more
than one class was designated by the Board),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii) the
time or times at which Awards shall be granted,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iv) the
terms, conditions and restrictions applicable to each Award (which need not be identical) and any Shares acquired upon the exercise or
(if applicable) vesting thereof, including (1) designating Awards under Section &lrm;1.2; (2) the vesting schedule, the acceleration thereof
and terms and conditions upon which Awards may be exercised or become vested, (3) the Exercise Price, (4) the method of payment for Shares
purchased upon the exercise or (if applicable) vesting of the Awards, (5) the method for satisfaction of any tax withholding obligation
arising in connection with the Awards or such Shares, including by the withholding or delivery of Shares, (6) the time of the expiration
of the Awards, (7) the effect of the Grantee&rsquo;s termination of employment with the Company or any of its Affiliates, and (8) all
other terms, conditions and restrictions applicable to the Award or the Shares not inconsistent with the terms of this Plan,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v) to
accelerate, continue, extend or defer the exercisability of any Award or the vesting thereof, including with respect to the period following
a Grantee&rsquo;s termination of employment or other service,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vi) the
interpretation of this Plan and any Award Agreement and the meaning, interpretation and applicability of terms referred to in Applicable
Law,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vii) policies,
guidelines, rules and regulations relating to and for carrying out this Plan, and any amendment, supplement or rescission thereof, as
it may deem appropriate,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(viii) to
adopt supplements to, or alternative versions of, this Plan, including, without limitation, as it deems necessary or desirable to comply
with the laws of, or to accommodate the tax regime or custom of, foreign jurisdictions whose citizens or residents may be granted Awards,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ix) the
Fair Market Value of the Shares or other securities, property or rights,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(x) the
tax track (capital gains, ordinary income track or any other track available under the Section 102 of the Ordinance) for the purpose of
102 Awards,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xi) the
authorization and approval of conversion, substitution, cancellation or suspension under and in accordance with this Plan of any or all
Awards or Shares,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xii) unless
otherwise provided under the terms of this Plan, the amendment, modification, waiver or supplement of the terms of any outstanding Award
(including, without limitation, reducing the Exercise Price of an Award), <I>provided</I>, <I>however</I>, that if such amendments increases
the Exercise Price of an Award or reduces the number of Shares underlying an Award, then such amendments shall require the consent of
the applicable Grantee, unless such amendment is made pursuant to the exercise of rights or authorities in accordance with Section &lrm;14
or 24,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xiii) without
limiting the generality of the foregoing, and subject to the provisions of Applicable Law, to grant to a Grantee, who is the holder of
an outstanding Award, in exchange for the cancellation of such Award, a new Award having an Exercise Price lower than that provided in
the Award so canceled and containing such other terms and conditions as the Committee may prescribe in accordance with the provisions
of this Plan or to set a new Exercise Price for the same Award lower than that previously provided in the Award,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xiv) to
correct any defect, supply any omission or reconcile any inconsistency in this Plan or any Award Agreement and all other determinations
and take such other actions with respect to this Plan or any Award as it may deem advisable to the extent not inconsistent with the provisions
of this Plan or Applicable Law, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xv) any
other matter which is necessary or desirable for, or incidental to, the administration of this Plan and any Award thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 71.45pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">3.4. The
authority granted hereunder includes the authority to modify Awards to eligible individuals who are foreign nationals or are individuals
who are employed outside Israel to recognize differences in local law, tax policy or custom, in order to effectuate the purposes of this
Plan but without amending this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">3.5. The
Board and the Committee shall be free at all times to make such determinations and take such actions as they deem fit. The Board and the
Committee need not take the same action or determination with respect to all Awards, with respect to certain types of Awards, with respect
to all Service Providers or any certain type of Service Providers and actions and determinations may differ as among the Grantees, and
as between the Grantees and any other holders of securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.1pt"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">3.6. All
decisions, determinations, and interpretations of the Committee, the Board and the Company under this Plan shall be final and binding
on all Grantees (whether before or after the issuance of Shares pursuant to Awards), unless otherwise determined by the Committee, the
Board or the Company, respectively. The Committee shall have the authority (but not the obligation) to determine the interpretation and
applicability of Applicable Law to any Grantee or any Awards. No member of the Committee or the Board shall be liable to any Grantee for
any action taken or determination made in good faith with respect to this Plan or any Award granted hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">3.7. Any
officer or authorized signatory of the Company shall have the authority to act on behalf of the Company with respect to any matter, right,
obligation, determination or election which is the responsibility of or which is allocated to the Company herein, provided such person
has apparent authority with respect to such matter, right, obligation, determination or election. Such person or authorized signatory
shall not be liable to any Grantee for any action taken or determination made in good faith with respect to this Plan or any Award granted
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify"><B><U>ELIGIBILITY</U></B>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Awards may be granted to Service
Providers of the Company or any Affiliate thereof, taking into account, at the Committee&rsquo;s discretion and without an obligation
to do so, the qualification under each tax regime pursuant to which such Awards are granted, subject to the limitation on the granting
of Incentive Stock Options set forth in Section &lrm;8.1. A person who has been granted an Award hereunder may be granted additional Awards,
if the Committee shall so determine, subject to the limitations herein. However, eligibility in accordance with this Section &lrm;4 shall
not entitle any person to be granted an Award, or, having been granted an Award, to be granted an additional Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Awards may differ in number
of Shares covered thereby, the terms and conditions applying to them or on the Grantees or in any other respect (including, that there
should not be any expectation (and it is hereby disclaimed) that a certain treatment, interpretation or position granted to one shall
be applied to the other, regardless of whether or not the facts or circumstances are the same or similar).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify"><B><U>SHARES</U></B>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">5.1. The
maximum aggregate number of Shares that may be issued pursuant to Awards under this Plan (the &ldquo;<B>Pool</B>&rdquo;) shall initially
be (a) 1,000,000 authorized but unissued Shares plus (b) any Shares underlying awards under the Prior Plans as of the Effective Date which,
following the Effective Date, become available for issuance under the Plan pursuant to Section 5.2 below; in all events subject to adjustment
as provided in Section&nbsp;14.1. Notwithstanding the foregoing, the total number of Shares that may be issued pursuant to Incentive Stock
Options granted under this Plan shall be 1,013,787, subject to adjustment as provided in Section&nbsp;14.1. The Board may, at its discretion,
increase or reduce the number of Shares that may be issued pursuant to Awards under this Plan, at any time (provided that such reduction
does not derogate from any issuance of Shares in respect of Awards then outstanding and without the need to amend the Plan in case of
such determination).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">5.2. Any
Shares (a) underlying an Award granted hereunder or an award granted under the Company&rsquo;s 2005 Israeli Share Option Plan and the
2015 Israeli Share Option Plan (the &ldquo;<B>Prior Plan(</B>s)&rdquo;) (in an amount not to exceed 13,787 Shares under the Prior Plans(
that has expired, or was cancelled, terminated, forfeited or settled in cash in lieu of issuance of Shares, for any reason, without having
been exercised; (b) if permitted by the Company, tendered to pay the Exercise Price of an Award (or the exercise price or other purchase
price of any option or other award under the Prior Plans), or withholding tax obligations with respect to an Award (or any awards under
the Prior Plans); or (c) if permitted by the Company, subject to an Award (or any award under the Prior Plan(s) that are not delivered
to a Grantee because such Shares are withheld to pay the Exercise Price of such Award (or of any award under the Prior Plan(s), or withholding
tax obligations with respect to such Award (or such other award); shall automatically, and without any further action on the part of the
Company or any Grantee, again be available for grant of Awards and Shares issued upon exercise of (if applicable) vesting thereof for
the purposes of this Plan (unless this Plan shall have been terminated) or unless the Board determines otherwise. Such Shares may be,
in whole or in part, authorized but unissued Shares, (and, subject to obtaining a ruling as it applies to 102 Awards) treasury shares
(dormant shares) or Shares otherwise that shall have been or may be repurchased by the Company (to the extent permitted pursuant to the
Companies Law).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">5.3. Any
Shares under the Pool that are not subject to outstanding or exercised Awards at the termination of this Plan shall cease to be reserved
for the purpose of this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">5.4. From
and after the Effective Date, no further grants or awards shall be made under the Prior Plans; however, Awards made under the Prior Plans
before the Effective Date shall continue in effect in accordance with their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify"><B><U>TERMS AND CONDITIONS OF AWARDS</U></B>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Award granted pursuant to this Plan shall
be evidenced by a written or electronic agreement between the Company and the Grantee or a written or electronic notice delivered by the
Company (the &ldquo;<B>Award Agreement</B>&rdquo;), in substantially such form or forms and containing such terms and conditions, as the
Committee shall from time to time approve. The Award Agreement shall comply with and be subject to the following general terms and conditions
and the provisions of this Plan (except for any provisions applying to Awards under different tax regimes), unless otherwise specifically
provided in such Award Agreement, or the terms referred to in other Sections of this Plan applying to Awards under such applicable tax
regimes, or terms prescribed by Applicable Law. Award Agreements need not be in the same form and may differ in the terms and conditions
included therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">6.1. <U>Number
of Shares</U>. Each Award Agreement shall state the number of Shares covered by the Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">6.2. <U>Type
of Award</U>. Each Award Agreement may state the type of Award granted thereunder, provided that the tax treatment of any Award, whether
or not stated in the Award Agreement, shall be as determined in accordance with Applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">6.3. <U>Exercise
Price</U>. Each Award Agreement shall state the Exercise Price, if applicable. Unless otherwise set forth in this Plan, an Exercise Price
of an Award of less than the par value of the Shares (if shares bear a par value) shall comply with Section 304 of the Companies Law.
Subject to Sections &lrm;7.2 and &lrm;8.2 and to the foregoing, the Committee may reduce the Exercise Price of any outstanding Award without
shareholder approval, on terms and subject to such conditions as it deems advisable. The Exercise Price shall also be subject to adjustment
as provided in Section &lrm;14 hereof. The Exercise Price of any outstanding Award granted to a Grantee who is subject to U.S. federal
income tax shall be determined in accordance with Section 409A of the Code, or, with respect to an Award of Incentive Stock Options, Section
422 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">6.4. <U>Manner
of Exercise</U>. An Award may be exercised, as to any or all Shares as to which the Award has become exercisable, by written notice delivered
in person or by mail (or such other methods of delivery prescribed by the Company) to the Chief Financial Officer of the Company or to
such other person as determined by the Committee, or in any other manner as the Committee shall prescribe from time to time, specifying
the number of Shares with respect to which the Award is being exercised (which may be equal to or lower than the aggregate number of Shares
that have become exercisable at such time, subject to the last sentence of this Section), accompanied by payment of the aggregate Exercise
Price for such Shares in the manner specified in the following sentence. The Exercise Price shall be paid in full with respect to each
Share, at the time of exercise, either in (i) cash, (ii) if the Company&rsquo;s shares are listed for trading on any securities exchange
or over-the-counter market, and if the Committee so determines, all or part of the Exercise Price and any withholding taxes may be paid
by the delivery (on a form prescribed by the Company) of an irrevocable direction to a securities broker approved by the Company to sell
Shares and to deliver all or part of the sales proceeds to the Company or the Trustee, (iii) if the Company&rsquo;s shares are listed
for trading on any securities exchange or over-the-counter market, and if the Committee so determines, all or part of the Exercise Price
and any withholding taxes may be paid by the delivery (on a form prescribed by the Company) of an irrevocable direction to pledge Shares
to a securities broker or lender approved by the Company, as security for a loan, and to deliver all or part of the loan proceeds to the
Company or the Trustee, (v) by applying the Cashless Exercise Mechanism set forth in Section&nbsp;6.4.3 below or (iv) in such other manner
as the Committee shall determine, which may include procedures for cash exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">6.4.1. The
application of cashless exercise with respect to any 102 Awards shall be subject to obtaining a ruling from the ITA, to the extent required
by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">6.4.2. Unless
otherwise determined by the Committee, any and all Options (other than Incentive Stok Options) may be exercised using a cashless exercise
mechanism, in which case the number of the Shares to be issued by the Company upon such exercise shall be calculated pursuant to the following
formula (the &ldquo;<B>Cashless Exercise Mechanism</B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">X =&nbsp;<U>Y * (A &ndash;
B)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Where:</FONT></TD>
    <TD STYLE="vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">X =</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">the number of Shares to be issued to the Grantee.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Y =</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">the number of Shares, as adjusted to the
    date of such calculation, underlying the number of Options being exercised.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">A =</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">the Fair Market Value of one Share at the exercise date.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">B =</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the Exercise Price of the Options being exercised.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.55pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; background-color: white">Upon the
completion of the calculation, if X is a negative number, then X shall be deemed to equal 0 (zero).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.55pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">6.5. <U>Term
and Vesting of Awards</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">6.5.1. Each
Award Agreement shall provide the vesting schedule for the Award as determined by the Committee. The Committee shall have the authority
to determine the vesting schedule and accelerate the vesting of any outstanding Award at such time and under such circumstances as it,
in its sole discretion, deems appropriate. Unless otherwise resolved by the Committee and stated in the Award Agreement, and subject to
Sections &lrm;6.6 and &lrm;6.7 hereof, Awards shall vest and become exercisable under the following schedule: twenty-five percent (25%)
of the Shares covered by the Award, on the first anniversary of the vesting commencement date determined by the Committee (and in the
absence of such determination, of date on which such Award was granted), and six and one-quarter percent (6.25%) of the Shares covered
by the Award at the end of each subsequent three-month period thereafter over the course of the following three (3) years; provided that
the Grantee remains continuously as a Service Provider of the Company or its Affiliates throughout such vesting dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">6.5.2. The
Award Agreement may contain performance goals and measurements (which, in case of 102 Trustee Awards, may, if then required, be subject
to obtaining a specific tax ruling or determination from the ITA), and the provisions with respect to any Award need not be the same as
the provisions with respect to any other Award. Such performance goals may include, but are not limited to, sales, earnings before interest
and taxes, return on investment, earnings per share, any combination of the foregoing or rate of growth of any of the foregoing, as determined
by the Committee. The Committee may adjust performance goals pursuant to Awards previously granted to take into account changes in law
and accounting and tax rules and to make such adjustments as the Committee deems necessary or appropriate to reflect the inclusion or
the exclusion of the impact of extraordinary or unusual items, events or circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.35pt; text-align: justify; text-indent: 45.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.35pt; text-align: justify; text-indent: 45.35pt"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.35pt; text-align: justify; text-indent: 45.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">6.5.3. The
Exercise Period of an Award will be ten (10) years from the date of grant of the Award, unless otherwise determined by the Committee and
stated in the Award Agreement, but subject to the vesting provisions described above and the early termination provisions set forth in
Sections &lrm;6.6 and &lrm;6.7 hereof. At the expiration of the Exercise Period, any Award, or any part thereof, that has not been exercised
within the term of the Award and the Shares covered thereby not paid for in accordance with this Plan and the Award Agreement shall terminate
and become null and void, and all interests and rights of the Grantee in and to the same shall expire.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">6.6. <U>Termination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">6.6.1. Unless
otherwise determined by the Committee or in this &lrm;<U>Section 6.6</U>, and subject to Section &lrm;6.7 hereof, an Award may not be
exercised unless the Grantee is then a Service Provider of the Company or an Affiliate thereof or, in the case of an Incentive Stock Option,
an employee of a company or a parent or subsidiary company of such company issuing or assuming the Option in a transaction to which Section
424(a) of the Code applies, and unless the Grantee has remained continuously so employed since the date of grant of the Award and throughout
the vesting dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">6.6.2. In
the event that the employment or service of a Grantee shall terminate, all Awards of such Grantee that are unvested at the time of such
termination shall terminate on the date of such termination, and (other than by reason of death, Disability or Retirement) all Awards
of such Grantee that are vested and exercisable at the time of such termination may be exercised within up to three (3) months after the
date of such termination (or such different period as the Committee shall prescribe), but in any event no later than the date of expiration
of the Award&rsquo;s term as set forth in the Award Agreement or pursuant to this Plan; <U>provided</U>, <U>however</U>, that if the Company
(or the Subsidiary or Affiliate, when applicable) shall terminate the Grantee&rsquo;s employment or service for Cause (as defined below)
(whether occurring prior to or after termination of employment or service), all Awards theretofore granted to such Grantee (whether vested
or not) shall terminate, unless otherwise determined by the Committee, and any Shares issued upon exercise or (if applicable) vesting
of Awards (including other Shares or securities issued or distributed with respect thereto), whether held by the Grantee or by the Trustee
for the Grantee&rsquo;s benefit, shall be deemed to be irrevocably offered for sale to the Company, any of its Affiliates or any person
designated by the Company to purchase, at the Company&rsquo;s election and subject to Applicable Law, either for no consideration, for
the par value of such Shares (if shares bear a par value) or against payment of the Exercise Price previously received by the Company
for such Shares upon their issuance, as the Committee deems fit, upon written notice to the Grantee at any time prior to, at or after
the Grantee&rsquo;s termination of employment or service. Such Shares or other securities shall be sold and transferred within 30 days
from the date of the Company&rsquo;s notice of its election to exercise its right. If the Grantee fails to transfer such Shares or other
securities to the Company, the Company, at the decision of the Committee, shall be entitled to forfeit or repurchase such Shares and to
authorize any person to execute on behalf of the Grantee any document necessary to effect such transfer, whether or not the share certificates
are surrendered. The Company shall have the right and authority to affect the above either by: (i) repurchasing all of such Shares or
other securities held by the Grantee or by the Trustee for the benefit of the Grantee, or designate the purchaser of all or any part of
such Shares or other securities, for the Exercise Price paid for such Shares, the par value of such Shares (if shares bear a par value)
or for no payment or consideration whatsoever, as the Committee deems fit; (ii) forfeiting all or any part of such Shares or other securities;
(iii) redeeming all or any part of such Shares or other securities, for the Exercise Price paid for such Shares, the par value of such
Shares (if shares bear a par value) or for no payment or consideration whatsoever, as the Committee deems fit; (iv) taking action in order
to have all or any part of such Shares or other securities converted into deferred shares entitling their holder only to their par value
(if shares bear a par value) upon liquidation of the Company; or (v) taking any other action which may be required in order to achieve
similar results; all as shall be determined by the Committee, at its sole and absolute discretion, and the Grantee is deemed to irrevocably
empower the Company or any person which may be designated by it to take any action by, in the name of or on behalf of the Grantee to comply
with and give effect to such actions (including, voting such shares, filling in, signing and delivering share transfer deeds, etc.).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">6.6.3. Notwithstanding
anything to the contrary, the Committee, in its absolute discretion, may, on such terms and conditions as it may determine appropriate,
extend the periods for which Awards held by any Grantee may continue to vest and be exercisable; it being clarified that such Awards may
lose their entitlement to certain tax benefits under Applicable Law (including, without limitation, qualification of an Award as an Incentive
Stock Option) as a result of the modification of such Awards and/or in the event that the Award is exercised beyond the later of: (i)
three (3) months after the date of termination of the employment or service relationship; or (ii) the applicable period under Section
&lrm;6.7 below with respect to a termination of the employment or service relationship because of the death, Disability or Retirement
of Grantee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">6.6.4. For
purposes of this Plan:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.75in">6.6.4.1. A
termination of employment or service of a Grantee shall not be deemed to occur (except to the extent required by the Code with respect
to the Incentive Stock Option status of an Option) in case of (i) a transition or transfer of a Grantee among the Company and its Affiliates,
(ii) a change in the capacity in which the Grantee is employed or renders service to the Company or any of its Affiliates or a change
in the identity of the employing or engagement entity among the Company and its Affiliates, provided, in case of the foregoing clauses
(i) and (ii) above, that the Grantee has remained continuously employed by and/or in the service of the Company and its Affiliates since
the date of grant of the Award and throughout the vesting period; or (iii) if the Grantee takes any unpaid leave as set forth in Section
&lrm;6.8 below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 70.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.75in">6.6.4.2. An
entity or an Affiliate thereof assuming an Award or issuing in substitution thereof in a transaction to which Section 424(a) of the Code
applies or in a Merger/Sale in accordance with Section &lrm;14 shall be deemed as an Affiliate of the Company for purposes of this Section
&lrm;6.6, unless the Committee determines otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 70.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.75in">6.6.4.3. In
the case of a Grantee whose principal employer or service recipient is a Subsidiary or Affiliate, the Grantee&rsquo;s employment shall
also be deemed terminated for purposes of this Section 6.6 as of the date on which such principal employer or service recipient ceases
to be a Subsidiary or Affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 70.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.75in">6.6.4.4. The
term &ldquo;<B>Cause</B>&rdquo; shall mean (irrespective of, and in addition to, any definition included in any other agreement or instrument
applicable to the Grantee, and unless otherwise determined by the Committee) any of the following: (i) any theft, fraud, embezzlement,
dishonesty, willful misconduct, breach of fiduciary duty for personal profit, falsification of any documents or records of the Company
or any of its Affiliates, felony or similar act by the Grantee (whether or not related to the Grantee&rsquo;s relationship with the Company);
(ii) an act of moral turpitude by the Grantee, or any act that causes significant injury to, or is otherwise adversely affecting, the
reputation, business, assets, operations or business relationship of the Company (or a Subsidiary or Affiliate, when applicable); (iii)
any breach by the Grantee of any material agreement with or of any material duty of the Grantee to the Company or any Subsidiary or Affiliate
thereof (including breach of confidentiality, non-disclosure, non-use, non-competition or non-solicitation covenants towards the Company
or any of its Affiliates) or failure to abide by code of conduct or other policies (including, without limitation, policies relating to
confidentiality and reasonable workplace conduct); (iv) any act which constitutes a breach of a Grantee&rsquo;s fiduciary duty towards
the Company or an Affiliate or Subsidiary, including disclosure of confidential or proprietary information thereof or acceptance or solicitation
to receive unauthorized or undisclosed benefits, irrespective of their nature, or funds, or promises to receive either, from individuals,
consultants or corporate entities that the Company or a Subsidiary does business with; (v) the Grantee&rsquo;s unauthorized use, misappropriation,
destruction, or diversion of any tangible or intangible asset or corporate opportunity of the Company or any of its Affiliates (including,
without limitation, the improper use or disclosure of confidential or proprietary information); or (vi) any circumstances that constitute
grounds for termination for cause under the Grantee&rsquo;s employment or service agreement with the Company or Affiliate, to the extent
applicable. For the avoidance of doubt, the determination as to whether a termination is for Cause for purposes of this Plan, shall be
made in good faith by the Committee and shall be final and binding on the Grantee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 70.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 70.8pt"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 70.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">6.7. <U>Death,
Disability or Retirement of Grantee</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">6.7.1. If
a Grantee shall die while employed by, or performing service for, the Company or its Affiliates, or within the three (3) month period
(or such longer period of time as determined by the Committee, in its discretion) after the date of termination of such Grantee&rsquo;s
employment or service (or within such different period as the Committee may have provided pursuant to Section &lrm;6.6 hereof), or if
the Grantee&rsquo;s employment or service shall terminate by reason of Disability, all Awards theretofore granted to such Grantee may
(to the extent otherwise vested and exercisable and unless earlier terminated in accordance with their terms) be exercised by the Grantee
or by the Grantee&rsquo;s estate or by a person who acquired the legal right to exercise such Awards by bequest or inheritance, or by
a person who acquired the legal right to exercise such Awards in accordance with applicable law in the case of Disability of the Grantee,
as the case may be, at any time within one (1) year (or such longer period of time as determined by the Committee, in its discretion)
after the death or Disability of the Grantee (or such different period as the Committee shall prescribe), but in any event no later than
the date of expiration of the Award&rsquo;s term as set forth in the Award Agreement or pursuant to this Plan. In the event that an Award
granted hereunder shall be exercised as set forth above by any person other than the Grantee, written notice of such exercise shall be
accompanied by a certified copy of letters testamentary or proof satisfactory to the Committee of the right of such person to exercise
such Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">6.7.2. In
the event that the employment or service of a Grantee shall terminate on account of such Grantee&rsquo;s Retirement, all Awards of such
Grantee that are exercisable at the time of such Retirement may, unless earlier terminated in accordance with their terms, be exercised
at any time within the three (3) month period after the date of such Retirement (or such different period as the Committee shall prescribe).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">6.8. <U>Suspension
of Vesting</U>. Unless the Committee provides otherwise, vesting of Awards granted hereunder shall be suspended during any unpaid leave
of absence, other than in the case of any (i) leave of absence which was pre-approved by the Company explicitly for purposes of continuing
the vesting of Awards, or (ii) transfers between locations of the Company or any of its Affiliates, or between the Company and any of
its Affiliates, or any respective successor thereof. For clarity, for purposes of this Plan, military leave, statutory maternity or paternity
leave or sick leave are not deemed unpaid leave of absence, unless otherwise determined by the Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">6.9. <U>Securities
Law Restrictions</U>. Except as otherwise provided in the applicable Award Agreement or other agreement between the Service Provider and
the Company, if the exercise of an Award following the termination of the Service Provider&rsquo;s employment or service (other than for
Cause) would be prohibited at any time solely because the issuance of Shares would violate the registration requirements under the Securities
Act or equivalent requirements under equivalent laws of other applicable jurisdictions, then the Award shall remain exercisable and terminate
on the earlier of (i)&nbsp;the expiration of a period of three&nbsp;(3)&nbsp;months (or such longer period of time as determined by the
Committee, in its discretion) after the termination of the Service Provider&rsquo;s employment or service during which the exercise of
the Award would not be in such violation, or (ii)&nbsp;the expiration of the term of the Award as set forth in the Award Agreement or
pursuant to this Plan. In addition, unless otherwise provided in a Grantee&rsquo;s Award Agreement, if the sale of any Shares received
upon exercise or (if applicable) vesting of an Award following the termination of the Grantee&rsquo;s employment or service (other than
for Cause) would violate the Company&rsquo;s insider trading policy, then the Award shall terminate on the earlier of (i)&nbsp;the expiration
of a period equal to the applicable post-termination exercise period after the termination of the Grantee&rsquo;s employment or service
during which the exercise of the Award would not be in violation of the Company&rsquo;s insider trading policy, or (ii)&nbsp;the expiration
of the term of the Award as set forth in the applicable Award Agreement or pursuant to this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">6.10. <U>Other
Provisions</U>. The Award Agreement evidencing Awards under this Plan shall contain such other terms and conditions not inconsistent with
this Plan as the Committee may determine, at or after the date of grant, including provisions in connection with the restrictions on transferring
the Awards or Shares covered by such Awards, which shall be binding upon the Grantees and any purchaser, assignee or transferee of any
Awards, and other terms and conditions as the Committee shall deem appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">7.</TD><TD STYLE="text-align: justify"><B><U>NONQUALIFIED STOCK OPTIONS</U></B>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Awards granted pursuant to this Section &lrm;7
are intended to constitute Nonqualified Stock Options and shall be subject to the general terms and conditions specified in Section &lrm;6
hereof and other provisions of this Plan, except for any provisions of this Plan applying to Awards under different tax laws or regulations.
In the event of any inconsistency or contradictions between the provisions of this Section &lrm;7 and the other terms of this Plan, this
Section &lrm;7 shall prevail. However, if for any reason an Option granted pursuant to Section &lrm;8 (or portion thereof) does not qualify
as an Incentive Stock Option, then, to the extent of such non-qualification, such Option (or portion thereof) shall be regarded as a Nonqualified
Stock Option granted under this Plan. In no event will the Board, the Company or any Parent or Subsidiary or any of their respective employees
or directors have any liability to Grantee (or any other person) due to the failure of the Option to qualify for any reason as an Incentive
Stock Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">7.1. <U>Certain
Limitations on Eligibility for Nonqualified Stock Options</U>. Nonqualified Stock Options may not be granted to a Service Provider who
is deemed to be a resident of the United States for purposes of taxation or who is otherwise subject to United States federal income tax
unless the Shares underlying such Options constitute &ldquo;service recipient stock&rdquo; under Section 409A of the Code or unless such
Options comply with the payment requirements of Section 409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.1pt">7.2. <U>Exercise
Price</U>. The Exercise Price of a Nonqualified Stock Option shall not be less than 100% of the Fair Market Value of a Share on the date
of grant of such Option unless the Committee specifically indicates that the Awards will have a lower Exercise Price and the Award complies
with Section 409A of the Code. Notwithstanding the foregoing, a Nonqualified Stock Option may be granted with an exercise price lower
than the minimum exercise price set forth above if such Award is granted pursuant to an assumption or substitution for another option
in a manner qualifying under the provisions of that complies with Section 424(a) of the Code or 1.409A-1(b)(5)(v)(D) of the U.S. Treasury
Regulations or any successor guidance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.1pt"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .5in">8.</TD><TD STYLE="text-align: justify"><B><U>INCENTIVE STOCK OPTIONS</U></B>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Awards granted pursuant to this Section &lrm;8
are intended to constitute Incentive Stock Options and shall be granted subject to the following special terms and conditions, the general
terms and conditions specified in Section &lrm;6 hereof and other provisions of this Plan, except for any provisions of this Plan applying
to Awards under different tax laws or regulations. In the event of any inconsistency or contradictions between the provisions of this
Section &lrm;8 and the other terms of this Plan, this Section &lrm;8 shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">8.1. <U>Eligibility
for Incentive Stock Options</U>. Incentive Stock Options may be granted only to Employees of the Company, or to Employees of a Parent
or Subsidiary, determined as of the date of grant of such Options. An Incentive Stock Option granted to a prospective Employee upon the
condition that such person become an Employee shall be deemed granted effective on the date such person commences employment, with an
exercise price determined as of such date in accordance with Section &lrm;8.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">8.2. <U>Exercise
Price</U>. The Exercise Price of an Incentive Stock Option shall not be less than one hundred percent (100%) of the Fair Market Value
of the Shares covered by the Awards on the date of grant of such Option or such other price as may be determined pursuant to the Code.
Notwithstanding the foregoing, an Incentive Stock Option may be granted with an exercise price lower than the minimum exercise price set
forth above if such Award is granted pursuant to an assumption or substitution for another option in a manner that complies with the provisions
of Section 424(a) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">8.3. <U>Date
of Grant</U>. Notwithstanding any other provision of this Plan to the contrary, no Incentive Stock Option may be granted under this Plan
after 10 years from the date this Plan is adopted, or the date this Plan is approved by the shareholders, whichever is earlier.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">8.4. <U>Exercise
Period</U>. No Incentive Stock Option shall be exercisable after the expiration of ten (10) years after the effective date of grant of
such Award, subject to Section &lrm;8.6. No Incentive Stock Option granted to a prospective Employee may become exercisable prior to the
date on which such person commences employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">8.5. <U>$100,000
Per Year Limitation</U>. The aggregate Fair Market Value (determined as of the date the Incentive Stock Option is granted) of the Shares
with respect to which all Incentive Stock Options granted under this Plan and all other &ldquo;incentive stock option&rdquo; plans of
the Company, or of any Parent or Subsidiary, become exercisable for the first time by each Grantee during any calendar year shall not
exceed one hundred thousand United States dollars ($100,000) with respect to such Grantee. To the extent that the aggregate Fair Market
Value of Shares with respect to which such Incentive Stock Options and any other such incentive stock options are exercisable for the
first time by any Grantee during any calendar year exceeds one hundred thousand United States dollars ($100,000), such options shall be
treated as Nonqualified Stock Options. The foregoing shall be applied by taking options into account in the order in which they were granted.
If the Code is amended to provide for a different limitation from that set forth in this Section &lrm;8.5, such different limitation shall
be deemed incorporated herein effective as of the date and with respect to such Awards as required or permitted by such amendment to the
Code. If an Option is treated as an Incentive Stock Option in part and as a Nonqualified Stock Option in part by reason of the limitation
set forth in this Section &lrm;8.5, the Grantee may designate which portion of such Option the Grantee is exercising. In the absence of
such designation, the Grantee shall be deemed to have exercised the Incentive Stock Option portion of the Option first. Separate certificates
representing each such portion may be issued upon the exercise of the Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">8.6. <U>Ten
Percent Shareholder</U>. In the case of an Incentive Stock Option granted to a Ten Percent Shareholder, notwithstanding the foregoing
provisions of this Section &lrm;8.6, (i) the Exercise Price shall not be less than one hundred and ten percent (110%) of the Fair Market
Value of a Share on the date of grant of such Incentive Stock Option, and (ii) the Exercise Period shall not exceed five (5) years from
the effective date of grant of such Incentive Stock Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">8.7. <U>Payment
of Exercise Price</U>. Each Award Agreement evidencing an Incentive Stock Option shall state each alternative method by which the Exercise
Price thereof may be paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">8.8. <U>Leave
of Absence</U>. Notwithstanding Section &lrm;6.8, a Grantee&rsquo;s employment shall not be deemed to have terminated if the Grantee takes
any leave as set forth in Section &lrm;6.8(i); provided, however, that if any such leave exceeds three (3) months, on the day that is
three (3) months following the commencement of such leave any Incentive Stock Option held by the Grantee shall cease to be treated as
an Incentive Stock Option and instead shall be treated thereafter as a Nonqualified Stock Option, unless the Grantee&rsquo;s right to
return to employment is guaranteed by statute or contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">8.9. <U>Exercise
Following Termination for Disability</U>. Notwithstanding anything else in this Plan to the contrary, Incentive Stock Options that are
not exercised within three (3) months following termination of the Grantee&rsquo;s employment with the Company or its Parent or Subsidiary
or a corporation or a Parent or Subsidiary of such corporation issuing or assuming an Option in a transaction to which Section 424(a)
of the Code applies, or within one year in case of termination of the Grantee&rsquo;s employment with the Company or its Parent or Subsidiary
due to a Disability (within the meaning of Section 22(e)(3) of the Code), shall be deemed to be Nonqualified Stock Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.10. <U>Adjustments
to Incentive Stock Options</U>. Any Awards Agreement providing for the grant of Incentive Stock Options shall indicate that adjustments
made pursuant to this Plan with respect to Incentive Stock Options could constitute a &ldquo;modification&rdquo; of such Incentive Stock
Options (as that term is defined in Section 424(h) of the Code) or could cause adverse tax consequences for the holder of such Incentive
Stock Options and that the holder should consult with his or her tax advisor regarding the consequences of such &ldquo;modification&rdquo;
on his or her income tax treatment with respect to the Incentive Stock Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.11. <U>Notice
to Company of Disqualifying Disposition</U>. Each Grantee who receives an Incentive Stock Option must agree to notify the Company in writing
immediately after the Grantee makes a Disqualifying Disposition of any Shares received pursuant to the exercise of Incentive Stock Options.
A &ldquo;Disqualifying Disposition&rdquo; is any disposition (including any sale) of such Shares before the later of (i)&nbsp;two years
after the date the Grantee was granted the Incentive Stock Option, or (ii)&nbsp;one year after the date the Grantee acquired Shares by
exercising the Incentive Stock Option. If the Grantee dies before such Shares are sold, these holding period requirements do not apply
and no disposition of the Shares will be deemed a Disqualifying Disposition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .5in">9.</TD><TD STYLE="text-align: justify"><B><U>102 AWARDS</U></B>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Awards granted pursuant to this Section &lrm;9
are intended to constitute 102 Awards and shall be granted subject to the following special terms and conditions, the general terms and
conditions specified in Section 6 hereof and other provisions of this Plan, except for any provisions of this Plan applying to Awards
under different tax laws or regulations. In the event of any inconsistency or contradictions between the provisions of this Section &lrm;9
and the other terms of this Plan, this Section &lrm;9 shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">9.1. <U>Tracks</U>.
Awards granted pursuant to this Section &lrm;9 are intended to be granted pursuant to Section 102 of the Ordinance pursuant to either
(i) Section 102(b)(2) or (3) thereof (as applicable), under the capital gain track (&ldquo;<B>102 Capital Gain Track Awards</B>&rdquo;),
or (ii) Section 102(b)(1) thereof under the ordinary income track (&ldquo;<B>102 Ordinary Income Track Awards</B>&rdquo;, and together
with 102 Capital Gain Track Awards, &ldquo;<B>102 Trustee Awards</B>&rdquo;). 102 Trustee Awards shall be granted subject to the special
terms and conditions contained in this Section &lrm;9, the general terms and conditions specified in Section &lrm;6 hereof and other provisions
of this Plan, except for any provisions of this Plan applying to Options under different tax laws or regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">9.2. <U>Election
of Track</U>. Subject to Applicable Law, the Company may grant only one type of 102 Trustee Awards at any given time to all Grantees who
are to be granted 102 Trustee Awards pursuant to this Plan, and shall file an election with the ITA regarding the type of 102 Trustee
Awards it elects to grant before the date of grant of any 102 Trustee Awards (the &ldquo;<B>Election</B>&rdquo;). Such Election shall
also apply to any other securities, including bonus shares, received by any Grantee as a result of holding the 102 Trustee Awards. The
Company may change the type of 102 Trustee Awards that it elects to grant only after the expiration of at least 12 months from the end
of the year in which the first grant was made in accordance with the previous Election, or as otherwise provided by Applicable Law. Any
Election shall not prevent the Company from granting Awards, pursuant to Section 102(c) of the Ordinance without a Trustee (&ldquo;<B>102
Non-Trustee Awards</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">9.3. <U>Eligibility
for Awards</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">9.3.1. Subject
to Applicable Law, 102 Awards may only be granted to an &quot;employee&quot; within the meaning of Section 102(a) of the Ordinance (which
as of the date of the adoption of this Plan means (i) individuals employed by an Israeli company being the Company or any of its Affiliates,
and (ii) individuals who are serving and are engaged personally (and not through an entity) as &ldquo;office holders&rdquo; by such an
Israeli company), but may not be granted to a Controlling Shareholder (&ldquo;<B>Eligible 102 Grantees</B>&rdquo;). Eligible 102 Grantees
may receive only 102 Awards, which may either be granted to a Trustee or granted under Section 102 of the Ordinance without a Trustee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.4. <U>102
Award Grant Date</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">9.4.1. Each
102 Award will be deemed granted on the date determined by the Committee, subject to Section &lrm;9.4.2, provided that (i) the Grantee
has signed all documents required by the Company or pursuant to Applicable Law, and (ii) with respect to 102 Trustee Award, the Company
has provided all applicable documents to the Trustee in accordance with the guidelines published by the ITA, and if an agreement is not
signed and delivered by the Grantee within 90 days from the date determined by the Committee (subject to Section &lrm;9.4.2), then such
102 Trustee Award shall be deemed granted on such later date as such agreement is signed and delivered and on which the Company has provided
all applicable documents to the Trustee in accordance with the guidelines published by the ITA. In the case of any contradiction, this
provision and the date of grant determined pursuant hereto shall supersede and be deemed to amend any date of grant indicated in any corporate
resolution or Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">9.4.2. Unless
otherwise permitted by the Ordinance, any grants of 102 Trustee Awards that are made on or after the date of the adoption of this Plan
or an amendment to this Plan, as the case may be, that may become effective only at the expiration of thirty (30) days after the filing
of this Plan or any amendment thereof (as the case may be) with the ITA in accordance with the Ordinance shall be conditional upon the
expiration of such 30-day period, such condition shall be read and is incorporated by reference into any corporate resolutions approving
such grants and into any Award Agreement evidencing such grants (whether or not explicitly referring to such condition), and the date
of grant shall be at the expiration of such 30-day period, whether or not the date of grant indicated therein corresponds with this Section.
In the case of any contradiction, this provision and the date of grant determined pursuant hereto shall supersede and be deemed to amend
any date of grant indicated in any corporate resolution or Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">9.5. <U>102
Trustee Awards</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">9.5.1. Each
102 Trustee Award, each Share issued pursuant to the exercise of any 102 Trustee Award, and any rights granted thereunder, including bonus
shares, shall be issued to and registered in the name of the Trustee and shall be held in trust for the benefit of the Grantee for the
requisite period prescribed by the Ordinance (the &ldquo;<B>Required Holding Period</B>&rdquo;). In the event that the requirements under
Section 102 of the Ordinance to qualify an Award as a 102 Trustee Award are not met, then the Award may be treated as a 102 Non-Trustee
Award or 3(i) Award, all in accordance with the provisions of the Ordinance. After expiration of the Required Holding Period, the Trustee
may release such 102 Trustee Awards and any such Shares, provided that (i) the Trustee has received an acknowledgment from the ITA that
the Grantee has paid any applicable taxes due pursuant to the Ordinance, or (ii) the Trustee and/or the Company and/or the Employer withholds
all applicable taxes and compulsory payments due pursuant to the Ordinance arising from the 102 Trustee Awards and/or any Shares issued
upon exercise or (if applicable) vesting of such 102 Trustee Awards. The Trustee shall not release any 102 Trustee Awards or Shares issued
upon exercise or (if applicable) vesting thereof prior to the payment in full of the Grantee&rsquo;s tax and compulsory payments arising
from such 102 Trustee Awards and/or Shares or the withholding referred to in (ii) above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">9.5.2. Each
102 Trustee Award shall be subject to the relevant terms of the Ordinance, the Rules and any determinations, rulings or approvals issued
by the ITA, which shall be deemed an integral part of the 102 Trustee Awards and shall prevail over any term contained in this Plan or
Award Agreement that is not consistent therewith. Any provision of the Ordinance, the Rules and any determinations, rulings or approvals
by the ITA not expressly specified in this Plan or Award Agreement that are necessary to receive or maintain any tax benefit pursuant
to Section 102 of the Ordinance shall be binding on the Grantee. Any Grantee granted a 102 Trustee Awards shall comply with the Ordinance
and the terms and conditions of the trust agreement entered into between the Company and the Trustee. The Grantee shall execute any and
all documents that the Company and/or its Affiliates and/or the Trustee determine from time to time to be necessary in order to comply
with the Ordinance and the Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">9.5.3. During
the Required Holding Period, the Grantee shall not release from trust or sell, assign, transfer or give as collateral, the Shares issuable
upon the exercise or (if applicable) vesting of a 102 Trustee Awards and/or any securities issued or distributed with respect thereto,
until the expiration of the Required Holding Period. Notwithstanding the above, if any such sale, release or other action occurs during
the Required Holding Period it may result in adverse tax consequences to the Grantee under Section 102 of the Ordinance and the Rules,
which shall apply to and shall be borne solely by such Grantee. Subject to the foregoing, the Trustee may, pursuant to a written request
from the Grantee, but subject to the terms of this Plan, release and transfer such Shares to a designated third party, provided that both
of the following conditions have been fulfilled prior to such release or transfer: (i) payment has been made to the ITA of all taxes and
compulsory payments required to be paid upon the release and transfer of the Shares, and confirmation of such payment has been received
by the Trustee and the Company, and (ii) the Trustee has received written confirmation from the Company that all requirements for such
release and transfer have been fulfilled according to the terms of the Company&rsquo;s corporate documents, any agreement governing the
Shares, this Plan, the Award Agreement and any Applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">9.5.4. If
a 102 Trustee Award is exercised or (if applicable) vested, the Shares issued upon such exercise or (if applicable) vesting shall be issued
in the name of the Trustee for the benefit of the Grantee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">9.5.5. Upon
or after receipt of a 102 Trustee Award, if required, the Grantee may be required to sign an undertaking to release the Trustee from any
liability with respect to any action or decision duly taken and executed in good faith by the Trustee in relation to this Plan, or any
102 Trustee Awards or Share granted to such Grantee thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">9.6. <U>102
Non-Trustee Awards</U>. The foregoing provisions of this Section &lrm;9 relating to 102 Trustee Awards shall not apply with respect to
102 Non-Trustee Awards, which shall, however, be subject to the relevant provisions of Section 102 of the Ordinance and the applicable
Rules. The Committee may determine that 102 Non-Trustee Awards, the Shares issuable upon the exercise or (if applicable) vesting of a
102 Non-Trustee Awards and/or any securities issued or distributed with respect thereto, shall be allocated or issued to the Trustee,
who shall hold such 102 Non-Trustee Awards and all accrued rights thereon (if any), in trust for the benefit of the Grantee and/or the
Company, as the case may be, until the full payment of tax arising from the 102 Non-Trustee Awards, the Shares issuable upon the exercise
or (if applicable) vesting of a 102 Non-Trustee Awards and/or any securities issued or distributed with respect thereto. The Company may
choose, alternatively, to force the Grantee to provide it with a guarantee or other security, to the satisfaction of each of the Trustee
and the Company, until the full payment of the applicable taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">9.7. <U>Written
Grantee Undertaking</U>. To the extent and with respect to any 102 Trustee Award, and as required by Section 102 of the Ordinance and
the Rules, by virtue of the receipt of such Award, the Grantee is deemed to have provided, undertaken and confirm the following written
undertaking (and such undertaking is deemed incorporated into any documents signed by the Grantee in connection with the employment or
service of the Grantee and/or the grant of such Award), and which undertaking shall be deemed to apply and relate to all 102 Trustee Awards
granted to the Grantee, whether under this Plan or other plans maintained by the Company, and whether prior to or after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">9.7.1. The
Grantee shall comply with all terms and conditions set forth in Section 102 of the Ordinance with regard to the &ldquo;Capital Gain Track&rdquo;
or the &ldquo;Ordinary Income Track&rdquo;, as applicable, and the applicable rules and regulations promulgated thereunder, as amended
from time to time;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">9.7.2. The
Grantee is familiar with, and understands the provisions of, Section 102 of the Ordinance in general, and the tax arrangement under the
&ldquo;Capital Gain Track&rdquo; or the &ldquo;Ordinary Income Track&rdquo; in particular, and its tax consequences; the Grantee agrees
that the 102 Trustee Awards and Shares that may be issued upon exercise or (if applicable) vesting of the 102 Trustee Awards (or otherwise
in relation to the 102 Trustee Awards), will be held by the Trustee appointed pursuant to Section 102 of the Ordinance for at least the
duration of the &ldquo;Holding Period&rdquo; (as such term is defined in Section 102) under the &ldquo;Capital Gain Track&rdquo; or the
&ldquo;Ordinary Income Track&rdquo;, as applicable. The Grantee understands that any release of such 102 Trustee Awards or Shares from
trust, or any sale of the Share prior to the termination of the Holding Period, as defined above, will result in taxation at marginal
tax rate, in addition to deductions of appropriate social security, health tax contributions or other compulsory payments; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">9.7.3. The
Grantee agrees to the trust agreement signed between the Company, the Employer and the Trustee appointed pursuant to Section 102 of the
Ordinance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .5in">10.</TD><TD STYLE="text-align: justify"><B><U>3(i) AWARDS</U></B>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Awards granted pursuant to this
Section &lrm;10 are intended to constitute 3(i) Awards and shall be granted subject to the general terms and conditions specified in Section
&lrm;6 hereof and other provisions of this Plan, except for any provisions of this Plan applying to Awards under different tax laws or
regulations. In the event of any inconsistency or contradictions between the provisions of this Section &lrm;10 and the other terms of
this Plan, this Section &lrm;10 shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">10.1. To
the extent required by the Ordinance or the ITA or otherwise deemed by the Committee to be advisable, the 3(i) Awards and/or any shares
or other securities issued or distributed with respect thereto granted pursuant to this Plan shall be issued to a Trustee nominated by
the Committee in accordance with the provisions of the Ordinance or the terms of a trust agreement, as applicable. In such event, the
Trustee shall hold such Awards and/or other securities issued or distributed with respect thereto in trust, until exercised or (if applicable)
vested by the Grantee and the full payment of tax arising therefrom, pursuant to the Company&rsquo;s instructions from time to time as
set forth in a trust agreement, which will have been entered into between the Company and the Trustee. If determined by the Board or the
Committee, and subject to such trust agreement, the Trustee will also hold the shares issuable upon exercise or (if applicable) vesting
of the 3(i) Awards, as long as they are held by the Grantee. If determined by the Board or the Committee, and subject to such trust agreement,
the Trustee shall be responsible for withholding any taxes to which a Grantee may become liable upon issuance of Shares, whether due to
the exercise or (if applicable) vesting of Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.2. Shares
pursuant to a 3(i) Award shall not be issued, unless the Grantee delivers to the Company payment in cash or by bank check or such other
form acceptable to the Committee of all withholding taxes due, if any, on account of the Grantee acquired Shares under the Award or gives
other assurance satisfactory to the Committee of the payment of those withholding taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .5in">11.</TD><TD STYLE="text-align: justify"><B><U>RESTRICTED SHARES</U></B>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Committee may award Restricted Shares to any
eligible Grantee, including under Section 102 of the Ordinance. Each Award of Restricted Shares under this Plan shall be evidenced by
a written agreement between the Company and the Grantee (the &ldquo;<B>Restricted Share Agreement</B>&rdquo;), in such form as the Committee
shall from time to time approve. The Restricted Shares shall be subject to all applicable terms of this Plan, which in the case of Restricted
Shares granted under Section 102 of the Ordinance shall include Section &lrm;9 hereof, and may be subject to any other terms that are
not inconsistent with this Plan. The provisions of the various Restricted Shares Agreements entered into under this Plan need not be identical.
The Restricted Share Agreement shall comply with and be subject to Section &lrm;6 and the following terms and conditions, unless otherwise
specifically provided in such Agreement and not inconsistent with this Plan, or Applicable Law:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">11.1. <U>Purchase
Price</U>. Section &rlm;1.1 shall not apply. Each Restricted Share Agreement shall state an amount of Exercise Price to be paid by the
Grantee, if any, in consideration for the issuance of the Restricted Shares and the terms of payment thereof, which may include payment
in cash or, subject to the Committee&rsquo;s approval, by issuance of promissory notes or other evidence of indebtedness on such terms
and conditions as determined by the Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">11.2. <U>Restrictions</U>.
Restricted Shares may not be sold, assigned, transferred, pledged, hypothecated or otherwise disposed of, except by will or the laws of
descent and distribution (in which case they shall be transferred subject to all restrictions then or thereafter applicable thereto),
until such Restricted Shares shall have vested (the period from the date on which the Award is granted until the date of vesting of the
Restricted Share thereunder being referred to herein as the &ldquo;<B>Restricted Period</B>&rdquo;). The Committee may also impose such
additional or alternative restrictions and conditions on the Restricted Shares, as it deems appropriate, including the satisfaction of
performance criteria (which, in case of 102 Trustee Awards, may be subject to obtaining a specific tax ruling or determination from the
ITA). Such performance criteria may include, but are not limited to, sales, earnings before interest and taxes, return on investment,
earnings per share, any combination of the foregoing or rate of growth of any of the foregoing, as determined by the Committee or pursuant
to the provisions of any Company policy required under mandatory provisions of Applicable Law. Certificates for shares issued pursuant
to Restricted Share Awards, if issued, shall bear an appropriate legend referring to such restrictions, and any attempt to dispose of
any such shares in contravention of such restrictions shall be null and void and without effect. Such certificates may, if so determined
by the Committee, be held in escrow by an escrow agent appointed by the Committee, or, if a Restricted Share Award is made pursuant to
Section 102 of the Ordinance, by the Trustee. In determining the Restricted Period of an Award the Committee may provide that the foregoing
restrictions shall lapse with respect to specified percentages of the awarded Restricted Shares on successive anniversaries of the date
of such Award. To the extent required by the Ordinance or the ITA, the Restricted Shares issued pursuant to Section 102 of the Ordinance
shall be issued to the Trustee in accordance with the provisions of the Ordinance and the Restricted Shares shall be held for the benefit
of the Grantee for at least the Required Holding Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">11.3. <U>Forfeiture;
Repurchase</U>. Subject to such exceptions as may be determined by the Committee, if the Grantee&rsquo;s continuous employment with or
service to the Company or any Affiliate thereof shall terminate for any reason prior to the expiration of the Restricted Period of an
Award or prior to the timely payment in full of the Exercise Price of any Restricted Shares, any Shares remaining subject to vesting or
with respect to which the purchase price has not been paid in full, shall thereupon be forfeited, transferred to, and redeemed, repurchased
or cancelled by, as the case may be, in any manner as set forth in Section &lrm;6.6.2(i) through (v), subject to Applicable Law and the
Grantee shall have no further rights with respect to such Restricted Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">11.4. <U>Ownership</U>.
During the Restricted Period the Grantee shall possess all incidents of ownership of such Restricted Shares, subject to Section &rlm;1.1
and Section &lrm;11.2, including the right to vote and receive dividends with respect to such Shares. All securities, if any, received
by a Grantee with respect to Restricted Shares as a result of any stock split, stock dividend, combination of shares, or other similar
transaction shall be subject to the restrictions applicable to the original Award. Notwithstanding anything to the contrary herein, dividends
which are paid to the Company&rsquo;s shareholders prior to the vesting date of any Restricted Shares shall only be paid to the Grantee
of such Restricted Shares to the extent the vesting conditions applicable to such Restricted Shares are subsequently satisfied (and any
such dividends will be paid no later than March 15 of the calendar year following the calendar year in which the right to the dividend
payment becomes nonforfeitable(.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .5in">12.</TD><TD STYLE="text-align: justify"><B><U>RESTRICTED SHARE UNITS</U></B>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">An RSU is an Award covering
a number of Shares that is settled, if vested and (if applicable) exercised, by issuance of those Shares, or, in the discretion of the
Committee, an amount of cash equal to the aggregate Fair Market Value of the Shares underlying the Award (other than with respect to 102
Trustee Awards. An RSU may be awarded to any eligible Grantee, including under Section 102 of the Ordinance. The Award Agreement relating
to the grant of RSUs under this Plan (the &ldquo;<B>Restricted Share Unit Agreement</B>&rdquo;), shall be in such form as the Committee
shall from time to time approve. The RSUs shall be subject to all applicable terms of this Plan, which in the case of RSUs granted under
Section 102 of the Ordinance shall include Section &lrm;9 hereof, and may be subject to any other terms that are not inconsistent with
this Plan. The provisions of the various Restricted Share Unit Agreements entered into under this Plan need not be identical. RSUs may
be granted in consideration of a reduction in the recipient&rsquo;s other compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">12.1. <U>Exercise
Price</U>. No payment of Exercise Price shall be required as consideration for RSUs, unless included in the Award Agreement or as required
by Applicable Law (including, Section 304 of the Companies Law), and Section &rlm;1.1 shall apply, if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">12.2. <U>Shareholders&rsquo;
Rights</U>. The Grantee shall not possess or own any ownership rights in the Shares underlying the RSUs and no rights as a shareholder
shall exist prior to the actual issuance of Shares in the name of the Grantee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">12.3. <U>Settlements
of Awards</U>. Settlement of vested RSUs shall be made in the form of Shares or cash (in case of 102 Trustee Awards, the settlement shall
be made in the form of shares only). Distribution to a Grantee of an amount (or amounts) from settlement of vested RSUs can be deferred
to a date after settlement as determined by the Committee. The amount of a deferred distribution may be increased by an interest factor
or by dividend equivalents. Until the grant of RSUs is settled, the number of Shares underlying such RSUs shall be subject to adjustment
pursuant hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">12.4. <U>Section&nbsp;409A
Restrictions</U>. Notwithstanding anything to the contrary set forth herein, any RSUs granted under this Plan that are not exempt from
the requirements of Section&nbsp;409A of the Code shall contain such restrictions or other provisions so that such RSUs will comply with
the requirements of Section&nbsp;409A of the Code, if applicable to the Company. Such restrictions, if any, shall be determined by the
Committee and contained in the Restricted Share Unit Agreement evidencing such RSU. For example, such restrictions may include a requirement
that any Shares that are to be issued in a year following the year in which the RSU vests must be issued in accordance with a fixed, pre-determined
schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .5in">13.</TD><TD STYLE="text-align: justify"><B><U>OTHER SHARE OR SHARE-BASED AWARDS</U></B>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">13.1. The
Committee may grant other Awards under this Plan pursuant to which Shares (which may, but need not, be Restricted Shares pursuant to Section
11 hereof), cash (in settlement of Share-based Awards) or a combination thereof, are or may in the future be acquired or received, or
Awards denominated in stock units, including units valued on the basis of measures other than market value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">13.2. The
Committee may also grant stock appreciation rights without the grant of an accompanying option, which rights shall permit the Grantees
to receive, at the time of any exercise of such rights, cash equal to the amount by which the Fair Market Value of the Shares in respect
to which the right was granted is so exercised exceeds the exercise price thereof. The exercise price of any such stock appreciation right
granted to a Grantee who is subject to U.S. federal income tax shall be determined in compliance with Section &lrm;7.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">13.3. Such
other Share-based Awards as set forth above may be granted alone, in addition to, or in tandem with any Award of any type granted under
this Plan (without any obligation or assurance that that such Share-based Awards will be entitled to tax benefits under Applicable Law
or to the same tax treatment as other Awards under this Plan).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5pt"></TD><TD STYLE="width: 27.85pt">14.</TD><TD STYLE="text-align: justify"><B><U>EFFECT OF CERTAIN CHANGES</U></B>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">14.1. <U>General</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">14.1.1. In
the event of a division or subdivision of the outstanding share capital of the Company, any distribution of bonus shares (stock split),
consolidation or combination of share capital of the Company (reverse stock split), reclassification with respect to the Shares or any
similar recapitalization events (each, a &ldquo;<B>Recapitalization</B>&rdquo;), a merger (including, a reverse merger and a reverse triangular
merger), consolidation, amalgamation or like transaction of the Company with or into another corporation, a reorganization (which may
include a combination or exchange of shares,&nbsp;spin-off&nbsp;or other corporate divestiture or division, or other similar occurrences,
the Committee shall make, without the need for a consent of any holder of an Award, such adjustments as determined by the Committee to
be appropriate, in its discretion, in order to adjust (i) the number and class of shares reserved and available for grants of Awards,
(ii) the number and class of shares covered by outstanding Awards, (iii) the Exercise Price per share covered by any Award, (iv) the terms
and conditions concerning vesting and exercisability and the term and duration of the outstanding Awards, (v) the type or class of security,
asset or right underlying the Award (which need not be only that of the Company, and may be that of the surviving corporation or any affiliate
thereof or such other entity party to any of the above transactions), and (vi) any other terms of the Award that in the opinion of the
Committee should be adjusted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">14.1.2. Any
fractional shares resulting from adjustment pursuant to this Section &lrm;14.1 shall be treated as determined by the Committee, and in
the absence of such determination shall be rounded to the nearest whole share, and the Company shall have no obligation to make any cash
or other payment with respect to such fractional shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">14.1.3. No
adjustment shall be made by reason of the distribution of subscription rights or rights offering to outstanding shares or other issuance
of shares by the Company, unless the Committee determines otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">14.1.4. The
adjustments determined pursuant to this Section &lrm;14.1 (including a determination that no adjustment is to be made) shall be final,
binding and conclusive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">14.1.5. Notwithstanding
anything to the contrary included herein, and subject to Applicable Law and the applicable accounting standards, in the event of a distribution
of cash dividend by the Company to all holders of Shares, the Committee shall have the authority to determine, without the need for a
consent of any holder of an Award, that the Exercise Price of any Award, which is outstanding and unexercised on the record date of such
distribution, shall be reduced by an amount equal to the per Share gross dividend amount distributed by the Company, and the Committee
may determine that the Exercise Price following such reduction shall be not less than the par value of a Share (if such Shares bear a
par value).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">14.1.6. The
application of this Section with respect to any 102 Awards shall be subject to obtaining a ruling from the ITA, to the extent required
by applicable law and subject to the terms and conditions of any such ruling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.2. <U>Merger/Sale
of Company</U>. In the event of (i) a sale of all or substantially all of the assets of the Company, or a sale (including an exchange)
of all or substantially all of the shares of the Company, to any person, or a purchase by a shareholder of the Company or by an Affiliate
of such shareholder, of all the shares of the Company held by all or substantially all other shareholders or by other shareholders who
are not Affiliated with such acquiring party; (ii) a merger (including, a reverse merger and a reverse triangular merger), consolidation,
amalgamation or like transaction of the Company with or into another corporation,; (iii) a scheme of arrangement for the purpose of effecting
such sale, merger, consolidation, amalgamation or other transaction; (iv) approval by the shareholders of the Company of a complete liquidation
or dissolution of the Company, (v) Change in Board Event or (vi)such other transaction or set of circumstances that is determined by the
Board, in its discretion, to be a transaction subject to the provisions of this Section &lrm;14.2; excluding any of the foregoing transactions
in clauses (i) through (iv) if the Board determines that such transaction should be excluded from the definition hereof and the applicability
of this Section &lrm;14.2 (such transaction, a &ldquo;<B>Merger/Sale</B>&rdquo;), then, without derogating from the general authority
and power of the Board or the Committee under this Plan, without the Grantee&rsquo;s consent and action and without any prior notice requirement,
the Committee may make any determination as to the treatment of Awards, in its sole and absolute discretion, as provided herein:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">14.2.1. Unless
otherwise determined by the Committee, any Award then outstanding shall be assumed or be substituted by the Company, or by the successor
corporation in such Merger/Sale or by any parent or Affiliate thereof, as determined by the Committee in its discretion (the &ldquo;<B>Successor
Corporation</B>&rdquo;), under terms as determined by the Committee or the terms of this Plan applied by the Successor Corporation to
such assumed or substituted Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in">For the purposes of
this Section &lrm;14.2.1, the Award shall be considered assumed or substituted if, following a Merger/Sale, the Award confers on the holder
thereof the right to purchase or receive, for each Share underlying an Award immediately prior to the Merger/Sale, either (i) the consideration
(whether shares or other securities, cash or other property, or rights, or any combination thereof) distributed to or received by holders
of Shares in the Merger/Sale for each Share held on the effective date of the Merger/Sale (and if holders were offered a choice or several
types of consideration, the type of consideration as determined by the Committee, which need not be the same type for all Grantees), or
(ii) regardless of the consideration received by the holders of Shares in the Merger/Sale, solely shares or any type of Awards (or their
equivalent) of the Successor Corporation at a value to be determined by the Committee in its discretion, or a certain type of consideration
(whether shares or other securities, cash or other property, or rights, or any combination thereof) as determined by the Committee. Any
of the consideration referred to in the foregoing clauses (i) and (ii) shall be subject to the same vesting and expiration terms of the
Awards applying immediately prior to the Merger/Sale, unless determined by the Committee, in its discretion, that the consideration shall
be subject to different vesting and expiration terms, or other terms, and the Committee may determine that it be subject to other or additional
terms. The foregoing shall not limit the Committee&rsquo;s authority to determine that in lieu of such assumption or substitution of Awards
for Awards of the Successor Corporation, such Award will be substituted for shares or other securities, cash or other property, or rights,
or any combination thereof, including as set forth in Section 14.2.2 hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">14.2.2. Regardless
of whether or not Awards are assumed or substituted, the Committee may (but shall not be obligated to):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.75in">14.2.2.1. provide
for the Grantee to have the right to exercise the Award in respect of Shares covered by the Award which would otherwise be exercisable
or vested, under such terms and conditions as the Committee shall determine, and the cancellation of all unexercised Awards (whether vested
or unvested) upon or immediately prior to the closing of the Merger/Sale, unless the Committee provides for the Grantee to have the right
to exercise the Award, or otherwise for the acceleration of vesting of such Award, as to all or part of the Shares covered by the Award
which would not otherwise be exercisable or vested, under such terms and conditions as the Committee shall determine;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.75in">14.2.2.2. provide
for the cancellation of each outstanding Award at or immediately prior to the closing of such Merger/Sale, and if and to the extent payment
shall be made to the Grantee of an amount in shares or other securities of the Company, the acquiror or of a corporation or other business
entity which is a party to the Merger/Sale, cash or other property, or rights, or any combination thereof, as determined by the Committee
to be fair in the circumstances, and subject to such terms and conditions as determined by the Committee. The Committee shall have full
authority to select the method for determining the payment (being the intrinsic (&ldquo;spread&rdquo;) value of the option, Black-Scholes
model or any other method). <I>Inter alia</I>, and without limitation of the following determination being made in other circumstances,
the Committee&rsquo;s determination may provide that payment shall be set to zero if the value of the Shares is determined to be less
than the Exercise Price, or in respect of Shares covered by the Award which would not otherwise be exercisable or vested, or that payment
may be made only in excess of the Exercise Price; and/or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.75in">14.2.2.3. provide
that the terms of any Award shall be otherwise amended, modified or terminated, as determined by the Committee to be fair in the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">14.2.3. The
Committee may determine: (i) that any payments made in respect of Awards shall be made or delayed to the same extent that payment of consideration
to the holders of the Shares in connection with the Merger/Sale is made or delayed as a result of escrows, indemnification, earn outs,
holdbacks or any other contingencies or conditions; (ii) the terms and conditions applying to the payment made or payable to the Grantees,
including participation in escrow, indemnification, releases, earn-outs, holdbacks or any other contingencies; and (iii) that any terms
and conditions applying under the applicable definitive transaction agreements shall apply to the Grantees (including, appointment and
engagement of a shareholders or sellers representative, payment of fees or other costs and expenses associated with such services, indemnifying
such representative, and authorization to such representative within the scope of such representative&rsquo;s authority in the applicable
definitive transaction agreements).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">14.2.4. The
Committee may determine to suspend the Grantee&rsquo;s rights to exercise any vested portion of an Award for a period of time prior to
the signing or consummation of a Merger/Sale transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">14.2.5. Without
limiting the generality of this Section &lrm;14, if the consideration in exchange for Awards in a Merger/Sale includes any securities
and due receipt thereof by any Grantee (or by the Trustee for the benefit of such Grantee) may require under applicable law (i) the registration
or qualification of such securities or of any person as a broker or dealer or agent with respect to such securities; or (ii) the provision
to any Grantee of any information under the Securities Act or any other securities laws, then the Committee may determine that the Grantee
shall be paid in lieu thereof, against surrender of the Shares or cancellation of any other Awards, an amount in cash or other property,
or rights, or any combination thereof, as determined by the Committee to be fair in the circumstances, and subject to such terms and conditions
as determined by the Committee. Nothing herein shall entitle any Grantee to receive any form of consideration that such Grantee would
be ineligible to receive as a result of such Grantee&rsquo;s failure to satisfy (in the Committee&rsquo;s sole determination) any condition,
requirement or limitation that is generally applicable to the Company&rsquo;s shareholders, or that is otherwise applicable under the
terms of the Merger/Sale, and in such case, the Committee shall determine the type of consideration and the terms applying to such Grantees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">14.2.6. Neither
the authorities and powers of the Committee under this Section 14.2, nor the exercise or implementation thereof, shall (i) be restricted
or limited in any way by any adverse consequences (tax or otherwise) that may result to any holder of an Award, and (ii) as, <I>inter
alia</I>, being a feature of the Award upon its grant, be deemed to constitute a change or an amendment of the rights of such holder under
this Plan, nor shall any such adverse consequences (as well as any adverse tax consequences that may result from any tax ruling or other
approval or determination of any relevant tax authority) be deemed to constitute a change or an amendment of the rights of such holder
under this Plan, and may be effected without consent of any Grantee and without any liability to the Company or its Affiliates, or to
their respective officers, directors, employees and representatives, and the respective successors and assigns of any of the foregoing.
The Committee need not take the same action with respect to all Awards or with respect to all Service Providers. The Committee may take
different actions with respect to the vested and unvested portions of an Award. The Committee may determine an amount or type of consideration
to be received or distributed in a Merger/Sale which may differ as among the Grantees, and as between the Grantees and any other holders
of shares of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.35pt; text-align: justify; text-indent: 45.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">14.2.7. The
Committee may determine that upon a Merger/Sale any Shares held by Grantees (or for Grantee&rsquo;s benefit) are sold in accordance with
instructions issued by the Committee in connection with such Merger/Sale, which shall be final, conclusive and binding on all Grantees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.35pt; text-align: justify; text-indent: 45.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">14.2.8. All
of the Committee&rsquo;s determinations pursuant to this Section &lrm;14 shall be at its sole and absolute discretion, and shall be final,
conclusive and binding on all Grantees (including, for clarity, as it relates to Shares issued upon exercise or vesting of any Awards
or that are Awards, unless otherwise determined by the Committee) and without any liability to the Company or its Affiliates, or to their
respective officers, directors, employees, shareholders and representatives, and the respective successors and assigns of any of the foregoing,
in connection with the method of treatment, chosen course of action or determinations made hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">14.2.9. If
determined by the Committee, the Grantees shall be subject to the definitive agreement(s) in connection with the Merger/Sale as applying
to holders of Shares including, such terms, conditions, representations, undertakings, liabilities, limitations, releases, indemnities,
appointing and indemnifying shareholders/sellers representative, participating in transaction expenses, shareholders/sellers representative
expense fund and escrow arrangement, in each case as determined by the Committee. Each Grantee shall execute (and authorizes any person
designated by the Company to so execute, as well as (if applicable) the Trustee holding any Shares for the Grantee&rsquo;s behalf) such
separate agreement(s) or instruments as may be requested by the Company, the Successor Corporation or the acquiror in connection with
such in such Merger/Sale or otherwise under or for the purpose of implementing this Section &lrm;14.2, and in the form required by them.
The execution of such separate agreement(s) may be a condition to the receipt of assumed or substituted Awards, payment in lieu of the
Award, the exercise of any Award or otherwise to be entitled to benefit from shares or other securities, cash or other property, or rights,
or any combination thereof, pursuant to this Section &lrm;14.2 (and the Company (and, if applicable, the Trustee) may exercise its authorization
above and sign such agreement on behalf of the Grantee or subject the Grantee to the provisions of such agreements).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.3. <U>Reservation
of Rights</U>. Except as expressly provided in this Section &lrm;14 (if any), the Grantee of an Award hereunder shall have no rights by
reason of any event referred to in this Section &lrm;14. Any issuance by the Company of shares of any class, or securities convertible
into shares of stock of any class, shall not affect, and no adjustment by reason thereof shall be made with respect to, the number, type
or price of shares subject to an Award. The grant of an Award pursuant to this Plan shall not affect in any way the right or power of
the Company to take any action, make any adjustments or enter into any transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .5in">15.</TD><TD STYLE="text-align: justify"><B><U>NON-TRANSFERABILITY OF AWARDS; SURVIVING BENEFICIARY</U></B>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">15.1. All
Awards granted under this Plan by their terms shall not be transferable, other than by will or by the laws of descent and distribution,
unless otherwise determined by the Committee or under this Plan, provided that with respect to Shares issued upon exercise, Shares issued
upon the vesting of Awards or Awards that are Shares, the restrictions on transfer shall be the restrictions referred to in Section &lrm;16
(Conditions upon Issuance of Shares) hereof. Subject to the above provisions, the terms of such Award, this Plan and any applicable Award
Agreement shall be binding upon the beneficiaries, executors, administrators, heirs and successors of such Grantee. Awards may be exercised
or otherwise realized, during the lifetime of the Grantee, only by the Grantee or by his guardian or legal representative, to the extent
provided for herein. Any transfer of an Award not permitted hereunder (including transfers pursuant to any decree of divorce, dissolution
or separate maintenance, any property settlement, any separation agreement or any other agreement with a spouse) and any grant of any
interest in any Award to, or creation in any way of any direct or indirect interest in any Award by, any party other than the Grantee
shall be null and void and shall not confer upon any party or person, other than the Grantee, any rights. A Grantee may file with the
Committee a written designation of a beneficiary, who shall be permitted to exercise such Grantee&rsquo;s Award or to whom any benefit
under this Plan is to be paid, in each case, in the event of the Grantee&rsquo;s death before he or she fully exercises his or her Award
or receives any or all of such benefit, on such form as may be prescribed by the Committee and may, from time to time, amend or revoke
such designation. If no designated beneficiary survives the Grantee, the executor or administrator of the Grantee&rsquo;s estate shall
be deemed to be the Grantee&rsquo;s beneficiary. Notwithstanding the foregoing, upon the request of the Grantee and subject to Applicable
Law the Committee, at its sole discretion, may permit the Grantee to transfer the Award to a trust whose beneficiaries are the Grantee
and/or the Grantee&rsquo;s immediate family members (all or several of them).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">15.2. Notwithstanding
any other provisions of the Plan to the contrary, no Incentive Stock Option may be sold, transferred, pledged, assigned or otherwise alienated
or hypothecated, other than by will or by the laws of descent and distribution or in accordance with a beneficiary designation pursuant
to Section &lrm;15.1. Further, all Incentive Stock Options granted to a Grantee shall be exercisable during his or her lifetime only by
such Grantee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">15.3. As
long as the Shares are held by the Trustee in favor of the Grantee, all rights possessed by the Grantee over the Shares are personal,
and may not be transferred, assigned, pledged or mortgaged, other than by will or laws of descent and distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">15.4. If
and to the extent a Grantee is entitled to transfer an Award and/or Shares underlying an Award in accordance with the terms of the Plan
and any other applicable agreements, such transfer shall be subject (in addition, to any other conditions or terms applying thereto) to
receipt by the Company from such proposed transferee of a written instrument, on a form reasonably acceptable to the Company, pursuant
to which such proposed transferee agrees to be bound by all provisions of the Plan and any other applicable agreements, including without
limitation, any restrictions on transfer of the Award and/or Shares set forth herein (however, failure to so deliver such instrument to
the Company as set forth above shall not derogate from all such provisions applying on any transferee).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">15.5. The
provisions of this Section &lrm;&lrm;15 shall apply to the Grantee and to any purchaser, assignee or transferee of any Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .5in">16.</TD><TD STYLE="text-align: justify"><B><U>CONDITIONS UPON ISSUANCE OF SHARES; GOVERNING PROVISIONS</U></B><U>.</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">16.1. <U>Legal
Compliance</U>. The grant of Awards and the issuance of Shares upon exercise or settlement of Awards shall be subject to compliance with
all Applicable Law as determined by the Company, including, applicable requirements of federal, state and foreign law with respect to
such securities. The Company shall have no obligations to issue Shares pursuant to the exercise or settlement of an Award and Awards may
not be exercised or settled, if the issuance of Shares upon exercise or settlement would constitute a violation of any Applicable Law
as determined by the Company, including, applicable federal, state or foreign securities laws or other law or regulations or the requirements
of any stock exchange or market system upon which the Shares may then be listed. In addition, no Award may be exercised unless (i) a registration
statement under the Securities Act or equivalent law in another jurisdiction shall at the time of exercise or settlement of the Award
be in effect with respect to the shares issuable upon exercise of the Award, or (ii) in the opinion of legal counsel to the Company, the
shares issuable upon exercise of the Award may be issued in accordance with the terms of an applicable exemption from the registration
requirements of the Securities Act or equivalent law in another jurisdiction. The inability of the Company to obtain authority from any
regulatory body having jurisdiction, if any, deemed by the Company to be necessary to the lawful issuance and sale of any Shares hereunder,
and the inability to issue Shares hereunder due to non-compliance with any Company policies with respect to the sale of Shares, shall
relieve the Company of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority or compliance
shall not have been obtained or achieved. As a condition to the exercise of an Award, the Company may require the person exercising such
Award to satisfy any qualifications that may be necessary or appropriate, to evidence compliance with any Applicable Law or regulation
and to make any representation or warranty with respect thereto as may be requested by the Company, including to represent and warrant
at the time of any such exercise that the Shares are being purchased only for investment and without any present intention to sell or
distribute such Shares, all in form and content specified by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">16.2. <U>Provisions
Governing Shares</U>. Shares issued pursuant to an Award shall be subject to this Plan (unless otherwise determined by the Committee),
and shall be subject to the Articles of Association of the Company, any other governing documents of the Company, all policies, manuals
and internal regulations adopted by the Company from time to time, in each case, as may be amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">16.3. <U>Share
Purchase Transactions; Forced Sale</U>. In the event that the Board approves a Merger/Sale effected by way of a forced or compulsory sale
(whether pursuant to the Company&rsquo;s Articles of Association, pursuant to Section 341 of the Companies Law or otherwise) or in the
event of a transaction for the sale of all shares of the Company, then, without derogating from such provisions and in addition thereto,
the Grantee shall be obligated, and shall be deemed to have agreed to the offer to effect the Merger/Sale (and the Shares held by or for
the benefit of the Grantee shall be included in the shares of the Company approving the terms of such Merger/Sale for the purpose of satisfying
the required majority), and shall sell all of the Shares held by or for the benefit of the Grantee on the terms and conditions applying
to the holders of Shares, in accordance with the instructions then issued by the Board, whose determination shall be final. No Grantee
shall contest, bring any claims or demands, or exercise any appraisal rights related to any of the foregoing. Each Grantee shall execute
(and authorizes any person designated by the Company to so execute, as well as (if applicable) the Trustee holding any Shares for the
Grantee&rsquo;s behalf) such documents and agreements, as may be requested by the Company relating to matters set forth in or otherwise
for the purpose of implementing this Section &lrm;16.3. The execution of such separate agreement(s) may be a condition by the Company
to the exercise of any Award and the Company (and, if applicable, the Trustee) may exercise its authorization above and sign such agreement
on behalf of the Grantee or subject the Grantee to the provisions of such agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">16.4. <U>Data
Privacy; Data Transfer</U>. Information related to Grantees and Awards hereunder, as shall be received from Grantee or others, and/or
held by, the Company or its Affiliates from time to time, and which information may include sensitive and personal information related
to Grantees (&ldquo;<B>Information</B>&rdquo;), will be used by the Company or its Affiliates (or third parties appointed by any of them,
including the Trustee) to comply with any applicable legal requirement, or for administration of the Plan as they deems necessary or advisable,
or for the respective business purposes of the Company or its Affiliates (including in connection with transactions related to any of
them). The Company and its Affiliates shall be entitled to transfer the Information among the Company or its Affiliates, and to third
parties for the purposes set forth above, which may include persons located abroad (including, any person administering the Plan or providing
services in respect of the Plan or in order to comply with legal requirements, or the Trustee, their respective officers, directors, employees
and representatives, and the respective successors and assigns of any of the foregoing), and any person so receiving Information shall
be entitled to transfer it for the purposes set forth above. The Company shall use commercially reasonable efforts to ensure that the
transfer of such Information shall be limited to the reasonable and necessary scope. By receiving an Award hereunder, Grantee acknowledges
and agrees that the Information is provided at Grantee&rsquo;s free will and Grantee consents to the storage and transfer of the Information
as set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">16.5. <U>Prohibition
on Executive Officer Loans</U>. Notwithstanding any other provision of the Plan to the contrary, no Grantee who is a member of the Board
or an &ldquo;executive officer&rdquo; of the Company within the meaning of Section&nbsp;13(k) of the Exchange Act shall be permitted to
make payment with respect to any Awards granted under the Plan, or continue any extension of credit with respect to such payment, with
a loan from the Company or a loan arranged by the Company in violation of Section&nbsp;13(k) of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">16.6. <U>Clawback
Provisions</U>. All Awards (including the gross amount of any proceeds, gains or other economic benefit the Grantee actually or constructively
receives upon receipt or exercise of any Award or the receipt or resale of any Shares underlying the Award) will be subject to recoupment
by the Company to the extent required to comply with Applicable Law or any policy of the Company that the Company may be required to adopt
in accordance with, and subject to, Applicable Law providing for the reimbursement of incentive compensation, whether or not such policy
was in place at the time of grant of an Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .5in">17.</TD><TD STYLE="text-align: justify"><B><U>AGREEMENT REGARDING TAXES; DISCLAIMER</U></B>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">17.1. If
the Company shall so require, as a condition of exercise or (if applicable) vesting of an Award, the release of Shares by the Trustee
or the expiration of the Restricted Period, a Grantee shall agree that, no later than the date of such occurrence, the Grantee will pay
to the Company (or the Trustee, as applicable) or make arrangements satisfactory to the Company and the Trustee (if applicable) regarding
payment of any applicable taxes and compulsory payments of any kind required by Applicable Law to be withheld or paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.2. <U>TAX
LIABILITY</U>. ALL TAX CONSEQUENCES UNDER ANY APPLICABLE LAW WHICH MAY ARISE FROM THE GRANT OF ANY AWARDS OR THE EXERCISE OR (IF APPLICABLE)
VESTING THEREOF, THE SALE OR DISPOSITION OF ANY SHARES GRANTED HEREUNDER OR ISSUED UPON EXERCISE OR (IF APPLICABLE) THE VESTING OF ANY
AWARD, THE ASSUMPTION, SUBSTITUTION, CANCELLATION OR PAYMENT IN LIEU OF AWARDS OR FROM ANY OTHER ACTION IN CONNECTION WITH THE FOREGOING
(INCLUDING WITHOUT LIMITATION ANY TAXES AND COMPULSORY PAYMENTS, SUCH AS SOCIAL SECURITY OR HEALTH TAX PAYABLE BY THE GRANTEE OR THE COMPANY
IN CONNECTION THEREWITH) SHALL BE BORNE AND PAID SOLELY BY THE GRANTEE, AND THE GRANTEE SHALL INDEMNIFY THE COMPANY, ITS SUBSIDIARIES
AND AFFILIATES AND THE TRUSTEE, AND SHALL HOLD THEM HARMLESS AGAINST AND FROM ANY LIABILITY FOR ANY SUCH TAX OR PAYMENT OR ANY PENALTY,
INTEREST OR INDEXATION THEREON. EACH GRANTEE AGREES TO, AND UNDERTAKES TO COMPLY WITH, ANY RULING, SETTLEMENT, CLOSING AGREEMENT OR OTHER
SIMILAR AGREEMENT OR ARRANGEMENT WITH ANY TAX AUTHORITY IN CONNECTION WITH THE FOREGOING WHICH IS APPROVED BY THE COMPANY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.1pt"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">17.3. <U>NO
TAX ADVICE</U>. THE GRANTEE IS ADVISED TO CONSULT WITH A TAX ADVISOR WITH RESPECT TO THE TAX CONSEQUENCES OF RECEIVING, EXERCISING OR
DISPOSING OF AWARDS HEREUNDER. THE COMPANY DOES NOT ASSUME ANY RESPONSIBILITY TO ADVISE THE GRANTEE ON SUCH MATTERS, WHICH SHALL REMAIN
SOLELY THE RESPONSIBILITY OF THE GRANTEE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">17.4. <U>TAX
TREATMENT</U>. THE COMPANY AND ITS AFFILIATES (INCLUDING THE EMPLOYER) DO NOT UNDERTAKE OR ASSUME ANY LIABILITY OR RESPONSIBILITY TO THE
EFFECT THAT ANY AWARD SHALL QUALIFY WITH ANY PARTICULAR TAX REGIME OR RULES APPLYING TO PARTICULAR TAX TREATMENT, OR BENEFIT FROM ANY
PARTICULAR TAX TREATMENT OR TAX ADVANTAGE OF ANY TYPE AND THE COMPANY AND ITS AFFILIATES (INCLUDING THE EMPLOYER) SHALL BEAR NO LIABILITY
IN CONNECTION WITH THE MANNER IN WHICH ANY AWARD IS TREATED FOR TAX PURPOSES, REGARDLESS OF WHETHER THE AWARD WAS GRANTED OR WAS INTENDED
TO QUALIFY UNDER ANY PARTICULAR TAX REGIME OR TREATMENT. THIS PROVISION SHALL SUPERSEDE ANY TYPE OF AWARDS OR TAX QUALIFICATION INDICATED
IN ANY CORPORATE RESOLUTION OR AWARD AGREEMENT, WHICH SHALL AT ALL TIMES BE SUBJECT TO THE REQUIREMENTS OF APPLICABLE LAW. THE COMPANY
AND ITS AFFILIATES (INCLUDING THE EMPLOYER) DO NOT UNDERTAKE AND SHALL NOT BE REQUIRED TO TAKE ANY ACTION IN ORDER TO QUALIFY ANY AWARD
WITH THE REQUIREMENT OF ANY PARTICULAR TAX TREATMENT AND NO INDICATION IN ANY DOCUMENT TO THE EFFECT THAT ANY AWARD IS INTENDED TO QUALIFY
FOR ANY TAX TREATMENT SHALL IMPLY SUCH AN UNDERTAKING. THE COMPANY AND ITS AFFILIATES (INCLUDING THE EMPLOYER) DO NOT UNDERTAKE TO REPORT
FOR TAX PURPOSES ANY AWARD IN ANY PARTICULAR MANNER, INCLUDING IN ANY MANNER CONSISTENT WITH ANY PARTICULAR TAX TREATMENT. NO ASSURANCE
IS MADE BY THE COMPANY OR ANY OF ITS AFFILIATES (INCLUDING THE EMPLOYER) THAT ANY PARTICULAR TAX TREATMENT ON THE DATE OF GRANT WILL CONTINUE
TO EXIST OR THAT THE AWARD WOULD QUALIFY AT THE TIME OF EXERCISE, VESTING OR DISPOSITION THEREOF WITH ANY PARTICULAR TAX TREATMENT. THE
COMPANY AND ITS AFFILIATES (INCLUDING THE EMPLOYER) SHALL NOT HAVE ANY LIABILITY OR OBLIGATION OF ANY NATURE IN THE EVENT THAT AN AWARD
DOES NOT QUALIFY FOR ANY PARTICULAR TAX TREATMENT, REGARDLESS OF WHETHER THE COMPANY COULD HAVE OR SHOULD HAVE TAKEN ANY ACTION TO CAUSE
SUCH QUALIFICATION TO BE MET AND SUCH QUALIFICATION REMAINS AT ALL TIMES AND UNDER ALL CIRCUMSTANCES AT THE RISK OF THE GRANTEE. THE COMPANY
DOES NOT UNDERTAKE OR ASSUME ANY LIABILITY TO CONTEST A DETERMINATION OR INTERPRETATION (WHETHER WRITTEN OR UNWRITTEN) OF ANY TAX AUTHORITIES,
INCLUDING IN RESPECT OF THE QUALIFICATION UNDER ANY PARTICULAR TAX REGIME OR RULES APPLYING TO PARTICULAR TAX TREATMENT. IF THE AWARDS
DO NOT QUALIFY UNDER ANY PARTICULAR TAX TREATMENT IT COULD RESULT IN ADVERSE TAX CONSEQUENCES TO THE GRANTEE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">17.5. The
Company or any Subsidiary or Affiliate (including the Employer) may take such action as it may deem necessary or appropriate, in its discretion,
for the purpose of or in connection with withholding of any taxes and compulsory payments which the Trustee, the Company or any Subsidiary
or Affiliate (including the Employer) (or any applicable agent thereof) is required by any Applicable Law to withhold in connection with
any Awards, including, without limitations, any income tax, social benefits, social insurance, health tax, pension, payroll tax, fringe
benefits, excise tax, payment on account or other tax-related items related to the Grantee&rsquo;s participation in the Plan and applicable
by law to the Grantee (collectively, &ldquo;<B>Withholding Obligations</B>&rdquo;). Such actions may include (i) requiring a Grantees
to remit to the Company or the Employer in cash an amount sufficient to satisfy such Withholding Obligations and any other taxes and compulsory
payments, payable by the Company or the Employer in connection with the Award or the exercise or (if applicable) the vesting thereof;
(ii) subject to Applicable Law, allowing the Grantees to surrender Shares to the Company, in an amount that at such time, reflects a value
that the Committee determines to be sufficient to satisfy such Withholding Obligations; (iii) withholding Shares otherwise issuable upon
the exercise of an Award at a value which is determined by the Company to be sufficient to satisfy such Withholding Obligations; or (iv)
any combination of the foregoing. The Company shall not be obligated to allow the exercise or vesting of any Award by or on behalf of
a Grantee until all tax consequences arising therefrom are resolved in a manner acceptable to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">17.6. Each
Grantee shall notify the Company in writing promptly and in any event within ten (10) days after the date on which such Grantee first
obtains knowledge of any tax authority inquiry, audit, assertion, determination, investigation, or question relating in any manner to
the Awards granted or received hereunder or Shares issued thereunder and shall continuously inform the Company of any developments, proceedings,
discussions and negotiations relating to such matter, and shall allow the Company and its representatives to participate in any proceedings
and discussions concerning such matters. Upon request, a Grantee shall provide to the Company any information or document relating to
any matter described in the preceding sentence, which the Company, in its discretion, requires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">17.7. With
respect to 102 Non-Trustee Options, if the Grantee ceases to be employed by the Company, Parent, Subsidiary or any Affiliate (including
the Employer), the Grantee shall extend to the Company and/or the Employer a security or guarantee for the payment of taxes due at the
time of sale of Shares, all in accordance with the provisions of Section 102 of the Ordinance and the Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">17.8. If
a Grantee makes an election under Section 83(b) of the Code to be taxed with respect to an Award as of the date of transfer of Shares
rather than as of the date or dates upon which the Grantee would otherwise be taxable under Section 83(a) of the Code, such Grantee shall
deliver a copy of such election to the Company upon or prior to the filing such election with the U.S. Internal Revenue Service. Neither
the Company nor any Affiliate (including the Employer) shall have any liability or responsibility relating to or arising out of the filing
or not filing of any such election or any defects in its construction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .5in">18.</TD><TD STYLE="text-align: justify"><B><U>RIGHTS AS A SHAREHOLDER; VOTING AND DIVIDENDS</U></B>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">18.1. Subject
to Section &lrm;11.4, a Grantee shall have no rights as a shareholder of the Company with respect to any Shares covered by an Award until
the Grantee shall have exercised or (as applicable) vests in the Award, paid any Exercise Price therefor and becomes the record holder
of the subject Shares. In the case of 102 Awards, the Trustee shall have no rights as a shareholder of the Company with respect to the
Shares covered by such Award until the Trustee becomes the record holder for such Shares for the Grantee&rsquo;s benefit, and the Grantee
shall not be deemed to be a shareholder and shall have no rights as a shareholder of the Company with respect to the Shares covered by
the Award until the date of the release of such Shares from the Trustee to the Grantee and the transfer of record ownership of such Shares
to the Grantee (provided, however, that the Grantee shall be entitled to receive from the Trustee any cash dividend or distribution made
on account of the Shares held by the Trustee for such Grantee&rsquo;s benefit, subject to any tax withholding and compulsory payment).
No adjustment shall be made for dividends (ordinary or extraordinary, whether in shares or other securities, cash or other property, or
rights, or any combination thereof) or distribution of other rights for which the record date is prior to the date on which the Grantee
or Trustee (as applicable) becomes the record holder of the Shares covered by an Award, except as provided in Section &lrm;14 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">18.2. With
respect to all Awards issued in the form of Shares hereunder or upon the exercise or (if applicable) the vesting of Awards hereunder,
any and all voting rights attached to such Shares shall be subject to Section &rlm;1.1, and the Grantee shall be entitled to receive dividends
distributed with respect to such Shares, subject to the provisions of the Company&rsquo;s Articles of Association, as amended from time
to time, and subject to any Applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">18.3. The
Company may, but shall not be obligated to, register or qualify the sale of Shares under any applicable securities law or any other Applicable
Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .5in">19.</TD><TD STYLE="text-align: justify"><B><U>NO REPRESENTATION BY COMPANY</U></B>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By granting the Awards, the Company is not, and
shall not be deemed as, making any representation or warranties to the Grantee regarding the Company, its business affairs, its prospects
or the future value of its Shares and such representations and warranties are hereby disclaimed. The Company shall not be required to
provide to any Grantee any information, documents or material in connection with the Grantee&rsquo;s considering an exercise of an Award.
To the extent that any information, documents or materials are provided, the Company shall have no liability with respect thereto. Any
decision by a Grantee to exercise an Award shall solely be at the risk of the Grantee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.1pt; text-align: justify; text-indent: -28.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">20.</TD><TD STYLE="text-align: justify"><B><U>NO RETENTION RIGHTS</U></B>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Nothing in this Plan, any Award
Agreement or in any Award granted or agreement entered into pursuant hereto shall confer upon any Grantee the right to continue in the
employ of, or be in the service of the Company or any Subsidiary or Affiliate thereof as a Service Provider or to be entitled to any remuneration
or benefits not set forth in this Plan or such agreement, or to interfere with or limit in any way the right of the Company or any such
Subsidiary or Affiliate to terminate such Grantee&rsquo;s employment or service (including, any right of the Company or any of its Affiliates
to immediately cease the Grantee&rsquo;s employment or service or to shorten all or part of the notice period, regardless of whether notice
of termination was given by the Company or its Affiliates or by the Grantee). Awards granted under this Plan shall not be affected by
any change in duties or position of a Grantee, subject to Sections &lrm;6.6 through &lrm;6.8. No Grantee shall be entitled to claim, and
the Grantee hereby waives any claim against the Company or any Subsidiary or Affiliate that he or she was prevented from continuing to
vest Awards as of the date of termination of his or her employment with, or services to, the Company or any Subsidiary or Affiliate. No
Grantee shall be entitled to any compensation in respect of the Awards which would have vested had such Grantee&rsquo;s employment or
engagement with the Company (or any Subsidiary or Affiliate) not been terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>21.</B></TD><TD STYLE="text-align: justify"><B><U>PERIOD DURING WHICH AWARDS MAY BE GRANTED.</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Awards may be granted pursuant
to this Plan from time to time within a period of ten (10) years from the Effective Date, which period may be extended from time to time
by the Board. From and after such date (as extended) no grants of Awards may be made and this Plan shall continue to be in full force
and effect with respect to Awards or Shares issued thereunder that remain outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .5in">22.</TD><TD STYLE="text-align: justify"><B><U>AMENDMENT OF THIS PLAN AND AWARDS</U></B>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">22.1. The
Board at any time and from time to time may suspend, terminate, modify or amend this Plan, whether retroactively or prospectively. Any
amendment effected in accordance with this Section shall be binding upon all Grantees and all Awards, whether granted prior to or after
the date of such amendment, and without the need to obtain the consent of any Grantee. No termination or amendment of this Plan shall
affect any then outstanding Award unless expressly provided by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">22.2. If
required by Applicable Law (and subject to changes in Applicable Law that would permit otherwise), the following shall require the approval
of the Company&rsquo;s shareholders (as and when prescribed by Applicable Law): (i) increase in the maximum aggregate number of Shares
that may be issued under this Plan as Incentive Stock Options (except by operation of the provisions of Section &lrm;14.1), (ii) change
in the class of persons eligible to receive Incentive Stock Options, and (iii) other amendment of this Plan that would require approval
of the Company&rsquo;s shareholders under Applicable Law or the rules of the applicable stock market or exchange, if any, on which the
Shares are principally quoted or traded. Unless not permitted by Applicable Law, if the grant of an Award is subject to approval by shareholders,
the date of grant of the Award shall be determined as if the Award had not been subject to such approval. Failure to obtain approval by
the shareholders shall not in any way derogate from the valid and binding effect of any grant of an Award that is not an Incentive Stock
Option. Upon approval of an amendment to this Plan by the shareholders of the Company as set forth above, all Incentive Stock Options
granted under this Plan on or after such amendment shall be fully effective as if the shareholders of the Company had approved the amendment
on the same date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">22.3. The
Board or the Committee at any time and from time to time may modify or amend any Award theretofore granted, including any Award Agreement,
whether retroactively or prospectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5pt"></TD><TD STYLE="width: 27.85pt">23.</TD><TD STYLE="text-align: justify"><B><U>APPROVAL</U></B>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">23.1. This
Plan shall take effect upon its adoption by the Board (the &ldquo;<B>Effective Date</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">23.2. Solely
with respect to grants of Incentive Stock Options, this Plan shall also be subject to shareholders&rsquo; approval, within one year of
the Effective Date, by a majority of the votes cast on the proposal at a meeting or a written consent of shareholders (however, if the
grant of an Award is subject to approval by shareholders, the date of grant of the Award shall be determined as if the Award had not been
subject to such approval). Failure to obtain such approval by the shareholders within such period shall not in any way derogate from the
valid and binding effect of any grant of an Award, except that any Options previously granted under this Plan may not qualify as Incentive
Stock Options but, rather, shall constitute Nonqualified Stock Options. Upon approval of this Plan by the shareholders of the Company
as set forth above, all Incentive Stock Options granted under this Plan on or after the Effective Date shall be fully effective as if
the shareholders of the Company had approved this Plan on the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">23.3. 102
Awards are conditional upon the filing with or approval by the ITA, if required, as set forth in Section &lrm;9.4. Failure to so file
or obtain such approval shall not in any way derogate from the valid and binding effect of any grant of an Award, which is not a 102 Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .5in">24.</TD><TD STYLE="text-align: justify"><B><U>RULES PARTICULAR TO SPECIFIC COUNTRIES; SECTION 409A</U></B><U>.</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">24.1. Notwithstanding
anything herein to the contrary, the terms and conditions of this Plan may be supplemented or amended with respect to a particular country
or tax regime by means of an appendix to this Plan, and to the extent that the terms and conditions set forth in any appendix conflict
with any provisions of this Plan, the provisions of such appendix shall govern. Terms and conditions set forth in such appendix shall
apply only to Awards granted to Grantees under the jurisdiction of the specific country or such other tax regime that is the subject of
such appendix and shall not apply to Awards issued to a Grantee not under the jurisdiction of such country or such other tax regime. The
adoption of any such appendix shall be subject to the approval of the Board or the Committee, and if determined by the Committee to be
required in connection with the application of certain tax treatment, pursuant to applicable stock exchange rules or regulations or otherwise,
then also the approval of the shareholders of the Company at the required majority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">24.2. This
Section &lrm;24.2 shall only apply to Awards granted to Grantees who are subject to United States Federal income tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">25.2.1 It
is the intention of the Company that no Award shall be deferred compensation subject to Section 409A of the Code unless and to the extent
that the Committee specifically determines otherwise as provided in Section &lrm;25.2.2, and the Plan and the terms and conditions of
all Awards shall be interpreted and administered accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">25.2.2 The
terms and conditions governing any Awards that the Committee determines will be subject to Section 409A of the Code, including any rules
for payment or elective or mandatory deferral of the payment or delivery of Shares or cash pursuant thereto, and any rules regarding treatment
of such Awards in the event of a Merger/Sale, shall be set forth in the applicable Award Agreement and shall be intended to comply in
all respects with Section 409A of the Code, and the Plan and the terms and conditions of such Awards shall be interpreted and administered
accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">25.2.3 The
Company shall have complete discretion to interpret and construe&nbsp;the Plan and any Award Agreement in any manner that establishes
an exemption from (or compliance with) the requirements of Section 409A of the Code. If for any reason, such as imprecision in drafting,
any provision of the Plan and/or any Award Agreement does not accurately reflect its intended establishment of an exemption from (or compliance
with)&nbsp;Code Section 409A, as demonstrated by consistent interpretations or other evidence of intent, such provision shall be considered
ambiguous as to its exemption from (or compliance with) Section 409A of the Code and shall be interpreted by the&nbsp;Company in a manner
consistent&nbsp;with such intent, as determined in the discretion of the&nbsp;Company. If, notwithstanding the foregoing provisions of
this Section &lrm;25.2.3, any provision of the Plan or any such agreement would cause a Grantee to incur any additional tax or interest
under Section 409A of the Code, the Company may reform such provision in a manner intended to avoid the incurrence by such Grantee of
any such additional tax or interest; <U>provided</U> that the Company shall maintain, to the extent reasonably practicable, the original
intent and economic benefit to the Grantee of the applicable provision without violating the provisions of Section 409A of the Code. For
the avoidance of doubt, no provision of this Plan shall be interpreted or construed to transfer any liability for failure to comply with
the requirements of Section 409A from any Grantee or any other individual to the Company or any of its affiliates, employees or agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">25.2.4 Notwithstanding
any other provision in the Plan, any Award Agreement, or any other written document establishing the terms and conditions of an Award,
if any Grantee is a &ldquo;specified employee,&rdquo; within the meaning of Section 409A of the Code, as of the date of his or her &ldquo;separation
from service&rdquo; (as defined under Section 409A of the Code), then, to the extent required by Treasury Regulation Section 1.409A-3(i)(2)
(or any successor provision), any payment made to such Grantee on account of his or her separation from service shall not be made before
a date that is six months after the date of his or her separation from service. The Committee may elect any of the methods of applying
this rule that are permitted under Treasury Regulation Section 1.409A-3(i)(2)(ii) (or any successor provision).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">25.2.5 Notwithstanding
any other provision of this Section &lrm;24.2 to the contrary, although the Company intends to administer the Plan so that Awards will
be exempt from, or will comply with, the requirements of Section 409A of the Code, the Company does not warrant that any Award under the
Plan will qualify for favorable tax treatment under Section 409A of the Code or any other provision of federal, state, local, or non-United
States law. The Company shall not be liable to any Grantee for any tax, interest, or penalties the Grantee might owe as a result of the
grant, holding, vesting, exercise, or payment of any Award under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .5in">25.</TD><TD STYLE="text-align: justify"><B><U>GOVERNING LAW; JURISDICTION</U></B>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">This Plan and all determinations
made, and actions taken pursuant hereto shall be governed by the laws of the State of Israel, except with respect to matters that are
subject to tax laws, regulations and rules of any specific jurisdiction, which shall be governed by the respective laws, regulations and
rules of such jurisdiction. Certain definitions, which refer to laws other than the laws of such jurisdiction, shall be construed in accordance
with such other laws. The competent courts located in Tel-Aviv-Jaffa, Israel shall have exclusive jurisdiction over any dispute arising
out of or in connection with this Plan and any Award granted hereunder. By signing any Award Agreement or any other agreement relating
to an Award, each Grantee irrevocably submits to such exclusive jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .5in">26.</TD><TD STYLE="text-align: justify"><B><U>NON-EXCLUSIVITY OF THIS PLAN</U></B>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The adoption of this Plan shall
not be construed as creating any limitations on the power or authority of the Company to adopt such other or additional incentive or other
compensation arrangements of whatever nature as the Company may deem necessary or desirable or preclude or limit the continuation of any
other plan, practice or arrangement for the payment of compensation or fringe benefits to employees generally, or to any class or group
of employees, which the Company or any Affiliate now has lawfully put into effect, including any retirement, pension, savings and stock
purchase plan, insurance, death and disability benefits and executive short-term or long-term incentive plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .5in">27.</TD><TD STYLE="text-align: justify"><B><U>MISCELLANEOUS</U></B>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">27.1. <U>Survival</U>.
The Grantee shall be bound by and the Shares issued upon exercise or (if applicable) the vesting of any Awards granted hereunder shall
remain subject to this Plan after the exercise or (if applicable) the vesting of Awards, in accordance with the terms of this Plan, whether
or not the Grantee is then or at any time thereafter employed or engaged by the Company or any of its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">27.2. <U>Additional
Terms</U>. Each Award awarded under this Plan may contain such other terms and conditions not inconsistent with this Plan as may be determined
by the Committee, in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">27.3. <U>Fractional
Shares</U>. No fractional Share shall be issuable upon exercise or vesting of any Award. Unless a different rounding rule is applied by
the Company, the number of Shares to be issued shall be rounded down to the nearest whole Share, with any Share remaining at the last
vesting date due to such rounding to be issued upon exercise at such last vesting date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">27.4. <U>Severability</U>.
If any provision of this Plan, any Award Agreement or any other agreement entered into in connection with an Award shall be determined
to be illegal or unenforceable by any court of law in any jurisdiction, the remaining provisions hereof and thereof shall be severable
and enforceable in accordance with their terms, and all provisions shall remain enforceable in any other jurisdiction. In addition, if
any particular provision contained in this Plan, any Award Agreement or any other agreement entered into in connection with an Award shall,
for any reason, be held to be excessively broad as to duration, geographic scope, activity or subject, it shall be construed by limiting
and reducing such provision as to such characteristic so that the provision is enforceable to fullest extent compatible with Applicable
Law as it shall then appear.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">27.5. <U>Captions
and Titles</U>. The use of captions and titles in this Plan or any Award Agreement or any other agreement entered into in connection with
an Award is for the convenience of reference only and shall not affect the meaning or interpretation of any provision of this Plan or
such agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">*&#9;*&#9;*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 35; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22
<SEQUENCE>4
<FILENAME>ea0200391ex10-22_scisparcltd.htm
<DESCRIPTION>FIRST AMENDMENT TO THE STANDBY EQUITY PURCHASE AGREEMENT, DATED AS OF FEBRUARY 26, 2024, BETWEEN SCISPARC LTD. AND YA II PN, LTD
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.22</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FIRST AMENDMENT TO STANDBY EQUITY PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This <B>FIRST AMENDMENT TO
THE STANDBY EQUITY PURCHASE AGREEMENT</B>, dated as of February 26, 2024 (this &ldquo;<U>First Amendment</U>&rdquo;), is entered between
<B>SCISPARC LTD.</B>, a company incorporated in the State of Israel (&ldquo;<U>Company</U>&rdquo;), and <B>YA II PN, LTD.</B>, a Cayman
Islands exempt limited partnership (the &ldquo;<U>Investor</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>PRELIMINARY STATEMENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>A.</B>&nbsp;Reference
is hereby made to that certain Standby Equity Purchase Agreement, dated as of January 21, 2024 (as may be amended, amended and restated,
extended, supplemented or otherwise modified in writing from time to time and in effect immediately prior to the effectiveness of this
First Amendment, the &ldquo;<U>Existing Agreement</U>&rdquo;, and the Existing Agreement, as amended by this First Amendment, the &ldquo;<U>Amended
Agreement</U>&rdquo;), between the Company and the Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>B.</B>&nbsp;The
issuance of the Commitment Shares in accordance with the terms set forth in the Existing Agreement would conflict with the Ownership Limitation
as set forth therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>C</B>. &nbsp;In
order to allow for the issuance of the Commitment Shares, the parties desire to amend certain of the terms and provisions of the Existing
Agreement as specifically set forth in this First Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>D.</B>&nbsp;The
parties are prepared to amend the Existing Agreement, subject to the conditions and in reliance on the representations set forth in this
First Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, in consideration
of the premises and the mutual covenants contained herein, and other good and valuable consideration, the receipt and adequacy of which
are hereby acknowledged, the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>SECTION 1.&nbsp;</B><U>Defined
Terms</U>. Unless otherwise defined herein, all capitalized terms used herein, including in preamble and the preliminary statements hereto,
shall have the meanings assigned to such terms in the Existing Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>SECTION 2.&nbsp;</B><U>Amendments
to Existing Agreement</U>. Subject to the satisfaction of the conditions precedent specified in <U>Section&nbsp;4</U> and in reliance
upon the representations and warranties set forth in <U>Section 5</U>, the Existing Agreement is hereby amended as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;<B><I>Section
2.01(c)(i)</I></B> of the Existing Agreement is hereby amended and restated in its entirety as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify"><U>Ownership Limitation, Commitment Amount</U>. At the request of the Company, the Investor shall inform
the Company of the number of Ordinary Shares the Investor beneficially owns. Notwithstanding anything to the contrary contained in this
Agreement, the Investor shall not be obligated to purchase or acquire, and the Company shall not issue or sell to the Investor, any Ordinary
Shares under this Agreement which, when aggregated with all other Ordinary Shares beneficially owned by the Investor and its affiliates
(as calculated pursuant to Section 13(d) of the Exchange Act and Rule 13d-3 promulgated thereunder), would result in the beneficial ownership
by the Investor and its affiliates (on an aggregated basis) to exceed 9.99% of the then outstanding voting power or number of Ordinary
Shares (the &ldquo;<U>Ownership Limitation</U>&rdquo;). Upon the written request of the Investor, the Company shall promptly (but no later
than the next business day on which the transfer agent for the Ordinary Shares is open for business) confirm orally or in writing to the
Investor the number of Ordinary Shares then outstanding. In connection with each Advance Notice delivered by the Company, any portion
of the Advance that would (i) cause the Investor to exceed the Ownership Limitation or (ii) cause the aggregate number of Shares issued
and sold to the Investor hereunder to exceed the Commitment Amount, shall automatically be withdrawn with no further action required by
the Company, and such Advance Notice shall be deemed automatically modified to reduce the amount of the Advance requested by an amount
equal to such withdrawn portion; provided that in the event of any such automatic withdrawal and automatic modification, the Investor
will promptly notify the Company of such event.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;<B><I>Section
12.04</I></B> of the Existing Agreement is hereby amended and restated in its entirety as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Section 12.04&nbsp;<U>Commitment
and Structuring Fee</U>. Each of the parties shall pay its own fees and expenses&nbsp;(including the fees of any attorneys, accountants,
appraisers or others engaged by such party) in connection with this Agreement and the transactions contemplated hereby, except that the
Company has paid YA Global II SPV, LLC, a subsidiary of the Investor, a structuring fee in the amount of $10,000 and, and the Company
shall pay a commitment fee in an amount equal to 1.00% of the Commitment Amount (the &ldquo;<U>Commitment Fee</U>&rdquo;) by the issuance
to the Investor of 55,293 Ordinary Shares (the &ldquo;<U>Commitment Shares</U>&rdquo;) (based on a price per Ordinary Share equal to $3.6171).
The Commitment Shares shall be issued to the Investor effective as of February 26, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>SECTION 3.&nbsp;</B><U>Conditions
Precedent to Effectiveness of First Amendment</U>. This First Amendment shall become effective as of the date first written above (the
&ldquo;<U>First Amendment Effective Date</U>&rdquo;) upon satisfaction of each of the following conditions precedent (except to the extent
such conditions precedent are subject to <U>Section 4</U>):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;<I>First
Amendment</I>. This First Amendment shall have been duly executed and delivered by each party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>SECTION 4.&nbsp;</B><U>Representations
and Warranties</U>. Except as set forth in the SEC Documents, all representations and warranties contained in the Amended Agreement shall
be true and correct in all respects as of the First Amendment Effective Date as though made on and as of the First Amendment Effective
Date (or, to the extent such representations or warranties are expressly made solely as of an earlier date, such representations and warranties
shall be true and correct as of such earlier date). Each party represents and warrants that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;<I>Authorization;
No Contravention</I>. The execution, delivery and performance by such party of this First Amendment (i) have been duly and validly authorized
by all corporate, stockholder, partnership or limited liability company action required to be taken by such party, and (ii) do not violate
or contravene such party&rsquo;s governing documents or any applicable law or any material agreement or instrument or any court order
which is binding upon such party or its property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;<I>Enforceability</I>.
This First Amendment, and the Amended Agreement is a legal, valid and binding obligation of such party, enforceable against it in accordance
with its terms, except as enforceability may be limited by bankruptcy, insolvency or similar laws affecting the enforcement of creditors&rsquo;
rights generally and by general equitable principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>SECTION 5.&nbsp;</B><U>Survival
of Representations and Warranties</U>. All representations and warranties made in this First Amendment shall survive the execution and
delivery of this First Amendment. Such representations and warranties have been or will be relied upon by the parties and shall continue
in full force and effect as long as any obligation under the Amended Agreement shall remain unpaid or unsatisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>SECTION 6.&nbsp;</B><U>Effect
of First Amendment, Other Agreements, Etc</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;<I>Effect
of First Amendment. </I>After giving effect to this First Amendment on the First Amendment Effective Date, the Amended Agreement shall
be and remain in full force and effect in accordance with its terms and is hereby ratified and confirmed by the parties in all respects.
The execution, delivery, and performance of this First Amendment shall not operate as a waiver of any right, power, or remedy of any party
under the Existing Agreement. Each party hereby acknowledges and agrees that, after giving effect to this First Amendment, all of its
obligations and liabilities under the Existing Agreement to which it is a party, as such obligations and liabilities have been amended
by this First Amendment, are reaffirmed and remain in full force and effect. All references to the Existing Agreement in any document
or instrument delivered in connection therewith shall be deemed to refer to the Amended Agreement. Nothing contained herein shall be construed
as a novation of the obligations outstanding under the Existing Agreement, which shall remain in full force and effect, except as modified
hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;<I>Limited
Effect</I>. This First Amendment relates only to the specific matters expressly covered herein, shall not be considered to be an amendment
or waiver of any rights or remedies that any party may have under the Existing Agreement or under applicable law, and shall not be considered
to create a course of dealing or to otherwise obligate in any respect a party to execute similar or other amendments or waivers or grant
any amendments or waivers under the same or similar or other circumstances in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;<I>SEC
Filings</I>. The Company shall, as soon as practicable following the date hereof, file with the SEC an initial Registration Statement
in accordance with Section 6.01 of the Amended Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;<I>Commitment
Shares</I>. The parties agree that the Investor shall not be deemed to beneficially own any of the Commitment Shares prior to the First
Amendment Effective Date, and the effectiveness of any prior attempt to issue the Commitment Shares shall be deferred until such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>SECTION 7.&nbsp;</B><U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;<I>Headings</I>.
Section headings in this First Amendment are included herein for convenience and do not affect the meanings of the provisions that they
precede.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;<I>Severability</I>.
If any provision of this First Amendment is held invalid or unenforceable, either in its entirety or by virtue of its scope or application
to given circumstances, such provision shall thereupon be deemed modified only to the extent necessary to render same valid, or not applicable
to given circumstances, or excised from this First Amendment, as the situation may require, and this First Amendment shall be construed
and enforced as if such provision had been included herein as so modified in scope or application, or had not been included herein or
therein, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">(c)&nbsp;<I>Binding
Effect</I>. This First Amendment binds and is for the benefit of the successors of each party. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;<B><I>GOVERNING
LAW</I>. THIS FIRST AMENDMENT SHALL BE GOVERNED BY AND INTERPRETED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD
TO THE PRINCIPLES OF CONFLICT OF LAWS. THE PARTIES FURTHER AGREE THAT ANY ACTION BETWEEN THEM SHALL BE HEARD IN NEW YORK COUNTY, NEW YORK,
AND EXPRESSLY CONSENT TO THE JURISDICTION AND VENUE OF THE SUPREME COURT OF NEW YORK, SITTING IN NEW YORK COUNTY, NEW YORK AND THE UNITED
STATES DISTRICT COURT OF THE SOUTHERN DISTRICT OF NEW YORK, SITTING IN NEW YORK, NEW YORK, FOR THE ADJUDICATION OF ANY CIVIL ACTION ASSERTED
PURSUANT TO THIS FIRST AMENDMENT.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;<I>Execution
in Counterparts</I>. This First Amendment may be executed in identical counterparts, both which shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party. Facsimile or other electronically
scanned and delivered signatures, including by e-mail attachment, shall be deemed originals for all purposes of this First Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[<I>Remainder of Page Intentionally
Left Blank; Signature Pages Follow</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the parties hereto have
caused this First Amendment to be executed and delivered as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>SCISPARC LTD.</B></FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font-family: Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">/s/ Oz Adler</P></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:&nbsp;</FONT></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Oz Adler</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">CEO</FONT></TD></TR>
</TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>[Signature Page to First Amendment to
Standby Equity Purchase Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>YA II PN, LTD.</B></FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font-family: Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yorkville Advisors Global, LP</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Its:</FONT></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Investment Manager</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font-family: Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yorkville Advisors Global II, LLC</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Its:</FONT></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">General Partner</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font-family: Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;/s/
  Matt Beckman</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:&nbsp;</FONT></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Matt Beckman</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Member</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>[Signature Page to First Amendment to Standby
Equity Purchase Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>ea0200391ex21-1_scisparcltd.htm
<DESCRIPTION>LIST OF SUBSIDIARIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit
21.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>List
of Subsidiaries</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
  of Subsidiary</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jurisdiction</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ownership
  Interest</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left; background-color: rgb(204,238,255)">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brain Bright Ltd.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left; background-color: White">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evero Health Ltd.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left; background-color: rgb(204,238,255)">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scisparc Nutraceuticals Inc.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50.86%</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>ea0200391ex23-1_scisparcltd.htm
<DESCRIPTION>CONSENT OF KOST FORER GABBAY & KASIERER, A MEMBER OF ERNST & YOUNG GLOBAL, INDEPENDENT REGISTERED ACCOUNTING FIRM FOR THE REGISTRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
consent to the reference to our firm under the caption &ldquo;Experts&rdquo; in the Registration Statement on Form F-1 of our report
dated May 1, 2023 with respect to the consolidated financial statements of SciSparc Ltd. (the &ldquo;Company&rdquo;), included in its
Annual Report (Form 20-F) for the year ended December&nbsp;31, 2022, filed with the U.S. Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="font-family: Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 27, 2024</FONT></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
  Kost Forer Gabbay &amp; Kaiserer</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel-Aviv, Israel</FONT></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kost Forer Gabbay &amp; Kaiserer</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member firm of Ernst &amp; Young Global</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>7
<FILENAME>ea0200391ex-fee_scisparcltd.htm
<DESCRIPTION>CALCULATION OF FILING FEE TABLES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 107</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Calculation of Filing Fee Tables</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM F-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&hellip;&hellip;&hellip;&hellip;..</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Form Type)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCISPARC LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;..&hellip;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Table 1: Newly Registered and Carry Forward
Securities</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Security<BR> Type</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Security<BR> Class<BR> Title</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fee<BR> Calculation<BR> or Carry<BR> Forward<BR> Rule</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount <BR>
    Registered(1)</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Proposed<BR> Maximum<BR> Offering<BR> Price Per<BR> Share(2)(3)</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Maximum<BR> Aggregate<BR> Offering<BR> Price</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fee
    Rate</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount of<BR> Registration<BR> Fee</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="27" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Newly Registered Securities</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; width: 11%; text-align: left">Fees to Be Paid</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 9%; text-align: center">Equity</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 20%; text-align: center">Ordinary Shares, no par value per share</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 11%; text-align: center">Rule 457(c)</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">5,402,887</TD><TD STYLE="width: 0.5%; text-align: left">(4)</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">3.58</TD><TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">19,342,335.46</TD><TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">0.00014760</TD><TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">2,854.93</TD><TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left">Fees Previously Paid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">-</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">-</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">-</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center; padding-left: 3pt">Total Offering Amounts</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">19,342,335.46</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,854.93</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center; padding-left: 3pt">Total Fees Previously Paid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center; padding-left: 3pt">Total Fee Offsets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="9" STYLE="padding-bottom: 4pt; font-weight: bold; text-align: center; padding-left: 3pt">Net Fee Due</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,854.93</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Pursuant to Rule 416 under the Securities Act of 1933, as
amended (or the Securities Act) the Ordinary Shares (or Ordinary Shares) registered hereby also include an indeterminate number of additional
Ordinary Shares as may from time to time become issuable by reason of stock splits, stock dividends, recapitalizations or other similar
transactions.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Estimated solely for purposes of calculating the amount of
the registration fee pursuant to Rule 457(c) under the Securities Act, based upon the average of the high and low sales prices of the
registrant&rsquo;s Ordinary Shares as reported on the Nasdaq Capital Market on February 26, 2024.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: justify">The Registrant will not receive any proceeds from the sale of
its Ordinary Shares by the selling shareholder.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(4)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">All the Ordinary Shares are to
be offered for resale by the selling shareholder named in the prospectus contained in this Registration Statement on Form F-1</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !Q &L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBFY&[;
MD9QG% #JS-7U6#1--EO[D2M%'@;88S([L3@*JCDDD@5S6J^(+W4_$Q\)Z'=&
MROHE,]Y=30;C'#A<&)3PY8MC/08/%5S?^*=(U"Z\/7-[%J5W=V$]QI%\T*Q,
M94 !CD4?+P64@C'&<T :5AXQGFUNUTO5=!O-)>^5VLGN)(W$Q49*D*3L;'.#
MZ&LGPD^MZQXGU6;6-5G,>AWTUG!;0D1I,&^822@?>PCJ .@QGK6#;Z)<ZS8V
M,>E:%?V7B""6*ZN]9UF(AEE0Y*AR27#'(PORA2?85Z/INA)8:_J^JI.Q_M/R
M6D@VC:CHNW<#WR,?E0!Q?A?PYI7C+1+C6?$<!N]6FNIXY7DD8-9;)&41QX/[
MO: #Q@Y.37HMIY0LH!#)YL010DF_?N&.#N[_ %KG]2\!>'M3U">\GM9DDN?^
M/E;>YDB2X_ZZ*K -^/6NAMK>"SM8K:VB2&&)0D<<:X55'   Z"@"S1110 44
M44 %%%% %#5KJ:RT:^N[:'S[B"WDDBB'\;*I(7\2,5YMX>\0>'M,M+75+6XF
M\1^+M5@!E2V?S)R3@LA&=L,:D8P<8QW->F7'VE=LL3J0BL3"0!YIQ\HW?P\_
M6N:CU%!;79\/Z+9Q:Z64W%E<8MG&3R[,H.]>X89!]: .<U>?6-?EGO\ 3]-D
MTCQGH<8E2W=UF6YMI,_)N'#!MK8'&&7WS6[X2LO[9FM_%]UJW]I336YBM%6#
MR8[5"?G4)DG?E0&)/\.*T_#FAW>G37NJ:M<1W6L7Y7SWB4K%&BYV11@\[1D\
MGDDDFNA5%1=J*%7T Q0 ^BBB@ HHHH **** "BBB@ HHHH YC6)+6#Q+8SZL
MX2Q2(FV>4XB2XW=6/0-M^Z3_ +6.:FL)H-6U>XNUCAN+6UV+9W(09WD,)-C=
MUY49'&<^E<_]JUR'P\YN)+BQ>WB9KB2YC65KN[8_ZN-3D>7N.!C&05 Q@UW-
MOO-K$946.38-R+T4XY H L4444 %0F1!*L990[ D+GD@=3C\:FKR#X8>)CXB
M^(GC"6_;_3%98[5&/^KMT=U*J.W.TGU)H ]?KC'^*?@>*1HY/$5JKHQ5AA^"
M.O:NSKS?XB?#:TU[PM<6N@:1I=OJDDR.)O*6,XW9;Y@,\T >BHZR(KJ<JPR#
MZBGU!;HT5M%&V-RH%./4"IZ "BBB@ HHHH 855L;@#@Y&1T-/HHH **** "O
MG[XC^$M9\$>+CX]\*@M [F6ZB09\IC]_<O>-N_H3VXKZ!IA4,I5@"",$'O0!
MY_X&^+&@^,HH[=I%L=6( :TF;&\_],V_B'MU]J]#KR'QQ\#M+UR234/#[C2]
M1)WF(#]Q(WT'*'W''M7&Z/\ $;QG\,]2CT?QI97%W8CA'D.9 HXS')T<>Q/X
MB@#Z0HK(T'7M,\2Z7#J>DW2W%M+T8'!4]U8=01Z&M>@ HHHH **** "BBB@
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M=8065I$(K>!!'&@).U1T&3S5R@ HHHH **** "BBB@ HHHH *\^^*/W/#_\
BV$/_ &1J** .XLO^/"#_ *YC^56:** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !3 $<# 2(  A$! Q$!_\0
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-ZX48HHH DHHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>sprcy-20230630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Feb 27 19:06:21 UTC 2024 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2023" targetNamespace="http://trpx.com/20230630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:sprcy="http://trpx.com/20230630" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="sprcy-20230630_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="sprcy-20230630_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="sprcy-20230630_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="sprcy-20230630_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://trpx.com/role/ConsolidatedBalanceSheet" id="sprcy_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Consolidated Statements of Financial Position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ConsolidatedIncomeStatement" id="sprcy_r_ConsolidatedIncomeStatement">
        <link:definition>002 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ShareholdersEquityType2or3" id="sprcy_r_ShareholdersEquityType2or3">
        <link:definition>003 - Statement - Consolidated Statements of Changes in Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ConsolidatedCashFlow" id="sprcy_r_ConsolidatedCashFlow">
        <link:definition>004 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/General" id="sprcy_r_General">
        <link:definition>005 - Disclosure - General</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/SignificantAccountingPolicies" id="sprcy_r_SignificantAccountingPolicies">
        <link:definition>006 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/InvestmentinAssociate" id="sprcy_r_InvestmentinAssociate">
        <link:definition>007 - Disclosure - Investment in Associate</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/IntangibleAsset" id="sprcy_r_IntangibleAsset">
        <link:definition>008 - Disclosure - Intangible Asset</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/InvestmentinFinancialAssets" id="sprcy_r_InvestmentinFinancialAssets">
        <link:definition>009 - Disclosure - Investment in Financial Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedParties" id="sprcy_r_TransactionsandBalanceswithRelatedParties">
        <link:definition>010 - Disclosure - Transactions and Balances with Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/FinancialInstruments" id="sprcy_r_FinancialInstruments">
        <link:definition>011 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/Warrants" id="sprcy_r_Warrants">
        <link:definition>012 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/Equity" id="sprcy_r_Equity">
        <link:definition>013 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss" id="sprcy_r_AdditionalInformationtotheItemsofProfitorLoss">
        <link:definition>014 - Disclosure - Additional Information to the Items of Profit or Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/SignificantEventsduringtheReportingPeriod" id="sprcy_r_SignificantEventsduringtheReportingPeriod">
        <link:definition>015 - Disclosure - Significant Events during the Reporting Period</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/EventsaftertheReportingPeriod" id="sprcy_r_EventsaftertheReportingPeriod">
        <link:definition>016 - Disclosure - Events after the Reporting Period</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements" id="sprcy_r_SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements">
        <link:definition>017 - Disclosure - Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/Cash" id="sprcy_r_Cash">
        <link:definition>018 - Disclosure - Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/Inventory" id="sprcy_r_Inventory">
        <link:definition>019 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/OtherAccountsReceivable" id="sprcy_r_OtherAccountsReceivable">
        <link:definition>020 - Disclosure - Other Accounts Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvestees" id="sprcy_r_InvestmentinAssociatesandInvestmentsinInvestees">
        <link:definition>021 - Disclosure - Investment in Associates and Investments in Investees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/Leases" id="sprcy_r_Leases">
        <link:definition>022 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/PropertyandEquipmentNet" id="sprcy_r_PropertyandEquipmentNet">
        <link:definition>023 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/TradePayables" id="sprcy_r_TradePayables">
        <link:definition>024 - Disclosure - Trade Payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/OtherAccountsPayable" id="sprcy_r_OtherAccountsPayable">
        <link:definition>025 - Disclosure - Other Accounts Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/EmployeeBenefitLiabilities" id="sprcy_r_EmployeeBenefitLiabilities">
        <link:definition>026 - Disclosure - Employee Benefit Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/TaxesonIncome" id="sprcy_r_TaxesonIncome">
        <link:definition>027 - Disclosure - Taxes on Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens" id="sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiens">
        <link:definition>028 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ShareBasedPaymentTransactions" id="sprcy_r_ShareBasedPaymentTransactions">
        <link:definition>029 - Disclosure - Share-Based Payment Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/RevenuesandCostofRevenues" id="sprcy_r_RevenuesandCostofRevenues">
        <link:definition>030 - Disclosure - Revenues and Cost of Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/LossPerShareAds" id="sprcy_r_LossPerShareAds">
        <link:definition>031 - Disclosure - Loss Per Share/Ads</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/OperatingSegments" id="sprcy_r_OperatingSegments">
        <link:definition>032 - Disclosure - Operating Segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/AccountingPoliciesByPolicy" id="sprcy_r_AccountingPoliciesByPolicy">
        <link:definition>033 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/SignificantAccountingPoliciesTables" id="sprcy_r_SignificantAccountingPoliciesTables">
        <link:definition>034 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/InvestmentinAssociateTables" id="sprcy_r_InvestmentinAssociateTables">
        <link:definition>035 - Disclosure - Investment in Associate (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/IntangibleAssetTables" id="sprcy_r_IntangibleAssetTables">
        <link:definition>036 - Disclosure - Intangible Asset (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables" id="sprcy_r_TransactionsandBalanceswithRelatedPartiesTables">
        <link:definition>037 - Disclosure - Transactions and Balances with Related Parties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/FinancialInstrumentsTables" id="sprcy_r_FinancialInstrumentsTables">
        <link:definition>038 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/WarrantsTables" id="sprcy_r_WarrantsTables">
        <link:definition>039 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/EquityTables" id="sprcy_r_EquityTables">
        <link:definition>040 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables" id="sprcy_r_AdditionalInformationtotheItemsofProfitorLossTables">
        <link:definition>041 - Disclosure - Additional Information to the Items of Profit or Loss (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/CashTables" id="sprcy_r_CashTables">
        <link:definition>042 - Disclosure - Cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/InventoryTables" id="sprcy_r_InventoryTables">
        <link:definition>043 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/OtherAccountsReceivableTables" id="sprcy_r_OtherAccountsReceivableTables">
        <link:definition>044 - Disclosure - Other Accounts Receivable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesTables" id="sprcy_r_InvestmentinAssociatesandInvestmentsinInvesteesTables">
        <link:definition>045 - Disclosure - Investment in Associates and Investments in Investees (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/PropertyandEquipmentNetTables" id="sprcy_r_PropertyandEquipmentNetTables">
        <link:definition>046 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/TradePayablesTables" id="sprcy_r_TradePayablesTables">
        <link:definition>047 - Disclosure - Trade Payables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/OtherAccountsPayableTables" id="sprcy_r_OtherAccountsPayableTables">
        <link:definition>048 - Disclosure - Other Accounts Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/EmployeeBenefitLiabilitiesTables" id="sprcy_r_EmployeeBenefitLiabilitiesTables">
        <link:definition>049 - Disclosure - Employee Benefit Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ShareBasedPaymentTransactionsTables" id="sprcy_r_ShareBasedPaymentTransactionsTables">
        <link:definition>050 - Disclosure - Share-Based Payment Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/RevenuesandCostofRevenuesTables" id="sprcy_r_RevenuesandCostofRevenuesTables">
        <link:definition>051 - Disclosure - Revenues and Cost of Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/LossPerShareAdsTables" id="sprcy_r_LossPerShareAdsTables">
        <link:definition>052 - Disclosure - Loss Per Share/Ads (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/OperatingSegmentsTables" id="sprcy_r_OperatingSegmentsTables">
        <link:definition>053 - Disclosure - Operating Segments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/GeneralDetails" id="sprcy_r_GeneralDetails">
        <link:definition>054 - Disclosure - General (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/SignificantAccountingPoliciesDetails" id="sprcy_r_SignificantAccountingPoliciesDetails">
        <link:definition>055 - Disclosure - Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/InvestmentinAssociateDetails" id="sprcy_r_InvestmentinAssociateDetails">
        <link:definition>056 - Disclosure - Investment in Associate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable" id="sprcy_r_ScheduleofFairValueoftheInvestmentTable">
        <link:definition>057 - Disclosure - Investment in Associate (Details) - Schedule of Fair Value of the Investment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/IntangibleAssetDetails" id="sprcy_r_IntangibleAssetDetails">
        <link:definition>058 - Disclosure - Intangible Asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable" id="sprcy_r_ScheduleofFairValueoftheIntangibleAssetTable">
        <link:definition>059 - Disclosure - Intangible Asset (Details) - Schedule of Fair Value of the Intangible Asset</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/InvestmentinFinancialAssetsDetails" id="sprcy_r_InvestmentinFinancialAssetsDetails">
        <link:definition>060 - Disclosure - Investment in Financial Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails" id="sprcy_r_TransactionsandBalanceswithRelatedPartiesDetails">
        <link:definition>061 - Disclosure - Transactions and Balances with Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/FinancialInstrumentsDetails" id="sprcy_r_FinancialInstrumentsDetails">
        <link:definition>062 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable" id="sprcy_r_ScheduleofFinancialAssetsandFinancialLiabilitiesTable">
        <link:definition>063 - Disclosure - Financial Instruments (Details) - Schedule of Financial Assets and Financial Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/WarrantsDetails" id="sprcy_r_WarrantsDetails">
        <link:definition>064 - Disclosure - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofWarrantsFairValueTable" id="sprcy_r_ScheduleofWarrantsFairValueTable">
        <link:definition>065 - Disclosure - Warrants (Details) - Schedule of Warrants&#8217; Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/EquityDetails" id="sprcy_r_EquityDetails">
        <link:definition>066 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofShareCapitalTable" id="sprcy_r_ScheduleofShareCapitalTable">
        <link:definition>067 - Disclosure - Equity (Details) - Schedule of Share Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable" id="sprcy_r_ScheduleofIssuedandOutstandingShareCapitalTable">
        <link:definition>068 - Disclosure - Equity (Details) - Schedule of Issued and Outstanding Share Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable" id="sprcy_r_ScheduleofAdditionalInformationtotheItemsofProfitorLossTable">
        <link:definition>069 - Disclosure - Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails" id="sprcy_r_SignificantEventsduringtheReportingPeriodDetails">
        <link:definition>070 - Disclosure - Significant Events during the Reporting Period (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/EventsaftertheReportingPeriodDetails" id="sprcy_r_EventsaftertheReportingPeriodDetails">
        <link:definition>071 - Disclosure - Events after the Reporting Period (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" id="sprcy_r_ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable">
        <link:definition>072 - Disclosure - Significant Accounting Policies (Details) - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofCashTable" id="sprcy_r_ScheduleofCashTable">
        <link:definition>073 - Disclosure - Cash (Details) - Schedule of Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofInventoryTable" id="sprcy_r_ScheduleofInventoryTable">
        <link:definition>074 - Disclosure - Inventory (Details) - Schedule of Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofOtherAccountsReceivableTable" id="sprcy_r_ScheduleofOtherAccountsReceivableTable">
        <link:definition>075 - Disclosure - Other Accounts Receivable (Details) - Schedule of Other Accounts Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails" id="sprcy_r_InvestmentinAssociatesandInvestmentsinInvesteesDetails">
        <link:definition>076 - Disclosure - Investment in Associates and Investments in Investees (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable0" id="sprcy_r_ScheduleofFairValueoftheInvestmentTable0">
        <link:definition>077 - Disclosure - Investment in Associates and Investments in Investees (Details) - Schedule of Fair Value of the Investment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/LeasesDetails" id="sprcy_r_LeasesDetails">
        <link:definition>078 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/PropertyandEquipmentNetDetails" id="sprcy_r_PropertyandEquipmentNetDetails">
        <link:definition>079 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable" id="sprcy_r_ScheduleofPropertyandEquipmentNetTable">
        <link:definition>080 - Disclosure - Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable0" id="sprcy_r_ScheduleofFairValueoftheIntangibleAssetTable0">
        <link:definition>081 - Disclosure - Intangible Asset (Details) - Schedule of Fair Value of the Intangible Asset</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofTradePayablesTable" id="sprcy_r_ScheduleofTradePayablesTable">
        <link:definition>082 - Disclosure - Trade Payables (Details) - Schedule of Trade Payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofOtherAccountsPayableTable" id="sprcy_r_ScheduleofOtherAccountsPayableTable">
        <link:definition>083 - Disclosure - Other Accounts Payable (Details) - Schedule of Other Accounts Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0" id="sprcy_r_ScheduleofFinancialAssetsandFinancialLiabilitiesTable0">
        <link:definition>084 - Disclosure - Financial Instruments (Details) - Schedule of Financial Assets and Financial Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable" id="sprcy_r_ScheduleofWarrantsFairValueUsingBlackScholesOPMTable">
        <link:definition>085 - Disclosure - Financial Instruments (Details) - Schedule of Warrants Fair Value Using Black&#8211;Scholes OPM</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofDefinedContributionPlansTable" id="sprcy_r_ScheduleofDefinedContributionPlansTable">
        <link:definition>086 - Disclosure - Employee Benefit Liabilities (Details) - Schedule of Defined Contribution Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/TaxesonIncomeDetails" id="sprcy_r_TaxesonIncomeDetails">
        <link:definition>087 - Disclosure - Taxes on Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails" id="sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiensDetails">
        <link:definition>088 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofShareCapitalTable0" id="sprcy_r_ScheduleofShareCapitalTable0">
        <link:definition>089 - Disclosure - Equity (Details) - Schedule of Share Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable0" id="sprcy_r_ScheduleofIssuedandOutstandingShareCapitalTable0">
        <link:definition>090 - Disclosure - Equity (Details) - Schedule of Issued and Outstanding Share Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable" id="sprcy_r_ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable">
        <link:definition>091 - Disclosure - Equity (Details) - Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ShareBasedPaymentTransactionsDetails" id="sprcy_r_ShareBasedPaymentTransactionsDetails">
        <link:definition>092 - Disclosure - Share-Based Payment Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable" id="sprcy_r_ScheduleofExpensesDuetoShareBasedCompensationTable">
        <link:definition>093 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of Expenses Due to Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable" id="sprcy_r_ScheduleofFairValueforShareOptionsGrantedTable">
        <link:definition>094 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of Fair Value for Share Options Granted</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable" id="sprcy_r_ScheduleofWeightedAverageExercisePricesofShareOptionsTable">
        <link:definition>095 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of Weighted Average Exercise Prices of Share Options</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofRevenuesandCostofRevenuesTable" id="sprcy_r_ScheduleofRevenuesandCostofRevenuesTable">
        <link:definition>096 - Disclosure - Revenues and Cost of Revenues (Details) - Schedule of Revenues and Cost of Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0" id="sprcy_r_ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0">
        <link:definition>097 - Disclosure - Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" id="sprcy_r_ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable">
        <link:definition>098 - Disclosure - Loss Per Share/Ads (Details) - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofOperatingSegmentsTable" id="sprcy_r_ScheduleofOperatingSegmentsTable">
        <link:definition>099 - Disclosure - Operating Segments (Details) - Schedule of Operating Segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2w4dODRyrf2cKq4MnlNojKY2vawGlGpB5CaguD0HWK7+MXGfIzhA2ezfWaTq7hAnt683nzSc747v3s9ubzeRZw15+aEvNutYTqGoMIIBc15Xh4havgCm8tXgpXwh1gfMq7RhsIvEnPjY=] CSR-->
      <link:roleType roleURI="http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable" id="sprcy_r_ScheduleofBalanceswithRelatedPartiesTable">
        <link:definition>100 - Disclosure - Transactions and Balances with Related Parties (Details) - Schedule of Balances with Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable" id="sprcy_r_ScheduleofTransactionswithRelatedPartiesTable">
        <link:definition>101 - Disclosure - Transactions and Balances with Related Parties (Details) - Schedule of Transactions with Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable" id="sprcy_r_ScheduleofBenefitstoKeyManagementPersonnelTable">
        <link:definition>102 - Disclosure - Transactions and Balances with Related Parties (Details) - Schedule of Benefits to Key Management Personnel</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
  <xs:element name="ConsolidatedStatementsOfChangesInEquityDeficitAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ConsolidatedStatementsOfChangesInEquityDeficitAbstract"/>
  <xs:element name="DisclosureOfGeneralExplanatoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfGeneralExplanatoryAbstract"/>
  <xs:element name="ScheduleOfFairValueOfTheInvestmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfFairValueOfTheInvestmentAbstract"/>
  <xs:element name="ScheduleOfFairValueOfTheIntangibleAssetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract"/>
  <xs:element name="ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract"/>
  <xs:element name="WarrantAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantAbstract"/>
  <xs:element name="ScheduleOfWarrantsFairValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfWarrantsFairValueAbstract"/>
  <xs:element name="ScheduleOfShareCapitalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfShareCapitalAbstract"/>
  <xs:element name="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract"/>
  <xs:element name="DisclosureOfAdditionalInformationTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfAdditionalInformationTextBlockAbstract"/>
  <xs:element name="ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract"/>
  <xs:element name="DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract"/>
  <xs:element name="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract"/>
  <xs:element name="ScheduleOfCashAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfCashAbstract"/>
  <xs:element name="ScheduleOfInventoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfInventoryAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfPropertyAndEquipmentNetAbstract"/>
  <xs:element name="ScheduleOfTradePayablesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfTradePayablesAbstract"/>
  <xs:element name="DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentAbstract"/>
  <xs:element name="ScheduleOfOtherAccountsPayableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfOtherAccountsPayableAbstract"/>
  <xs:element name="ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract"/>
  <xs:element name="ScheduleOfDefinedContributionPlansAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfDefinedContributionPlansAbstract"/>
  <xs:element name="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract"/>
  <xs:element name="ScheduleOfExpensesDueToShareBasedCompensationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract"/>
  <xs:element name="ScheduleOfFairValueForShareOptionsGrantedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract"/>
  <xs:element name="ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract"/>
  <xs:element name="ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract"/>
  <xs:element name="ScheduleOfOperatingSegmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfOperatingSegmentsAbstract"/>
  <xs:element name="ScheduleOfBalancesWithRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfTransactionsWithRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfBenefitsToKeyManagementPersonnelAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract4"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract5"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract6"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract7"/>
  <xs:element name="EquityAttributableToEquityHoldersOfTheCompanyAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract"/>
  <xs:element name="UnlabeledAbstract8" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract8"/>
  <xs:element name="UnlabeledAbstract9" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract9"/>
  <xs:element name="UnlabeledAbstract10" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract10"/>
  <xs:element name="UnlabeledAbstract11" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract11"/>
  <xs:element name="UnlabeledAbstract12" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract12"/>
  <xs:element name="UnlabeledAbstract13" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract13"/>
  <xs:element name="NonCurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NonCurrentAssetsAbstract"/>
  <xs:element name="UnlabeledAbstract14" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract14"/>
  <xs:element name="UnlabeledAbstract15" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract15"/>
  <xs:element name="UnlabeledAbstract16" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract16"/>
  <xs:element name="LiabilitiesAndEquityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LiabilitiesAndEquityAbstract"/>
  <xs:element name="UnlabeledAbstract17" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract17"/>
  <xs:element name="UnlabeledAbstract18" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract18"/>
  <xs:element name="UnlabeledAbstract19" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract19"/>
  <xs:element name="UnlabeledAbstract20" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract20"/>
  <xs:element name="EquityAttributableToEquityHoldersOfTheCompanyAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract0"/>
  <xs:element name="UnlabeledAbstract21" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract21"/>
  <xs:element name="UnlabeledAbstract22" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract22"/>
  <xs:element name="UnlabeledAbstract23" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract23"/>
  <xs:element name="UnlabeledAbstract24" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract24"/>
  <xs:element name="UnlabeledAbstract25" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract25"/>
  <xs:element name="UnlabeledAbstract26" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract26"/>
  <xs:element name="UnlabeledAbstract27" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract27"/>
  <xs:element name="BasicLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_BasicLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract"/>
  <xs:element name="DilutedLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DilutedLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract"/>
  <xs:element name="UnlabeledAbstract28" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract28"/>
  <xs:element name="UnlabeledAbstract29" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract29"/>
  <xs:element name="UnlabeledAbstract30" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract30"/>
  <xs:element name="UnlabeledAbstract31" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract31"/>
  <xs:element name="UnlabeledAbstract32" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract32"/>
  <xs:element name="UnlabeledAbstract33" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract33"/>
  <xs:element name="UnlabeledAbstract34" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract34"/>
  <xs:element name="UnlabeledAbstract35" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract35"/>
  <xs:element name="UnlabeledAbstract36" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract36"/>
  <xs:element name="UnlabeledAbstract37" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract37"/>
  <xs:element name="UnlabeledAbstract38" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract38"/>
  <xs:element name="UnlabeledAbstract39" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract39"/>
  <xs:element name="AttributableToAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AttributableToAbstract"/>
  <xs:element name="UnlabeledAbstract40" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract40"/>
  <xs:element name="UnlabeledAbstract41" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract41"/>
  <xs:element name="UnlabeledAbstract42" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract42"/>
  <xs:element name="UnlabeledAbstract43" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract43"/>
  <xs:element name="UnlabeledAbstract44" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract44"/>
  <xs:element name="UnlabeledAbstract45" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract45"/>
  <xs:element name="UnlabeledAbstract46" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract46"/>
  <xs:element name="UnlabeledAbstract47" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract47"/>
  <xs:element name="UnlabeledAbstract48" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract48"/>
  <xs:element name="UnlabeledAbstract49" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract49"/>
  <xs:element name="UnlabeledAbstract50" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract50"/>
  <xs:element name="UnlabeledAbstract51" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract51"/>
  <xs:element name="UnlabeledAbstract52" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract52"/>
  <xs:element name="UnlabeledAbstract53" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract53"/>
  <xs:element name="UnlabeledAbstract54" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract54"/>
  <xs:element name="UnlabeledAbstract55" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract55"/>
  <xs:element name="UnlabeledAbstract56" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract56"/>
  <xs:element name="UnlabeledAbstract57" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract57"/>
  <xs:element name="AdjustmentsToTheProfitOrLossItemsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract"/>
  <xs:element name="UnlabeledAbstract58" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract58"/>
  <xs:element name="UnlabeledAbstract59" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract59"/>
  <xs:element name="UnlabeledAbstract60" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract60"/>
  <xs:element name="WorkingCapitalAdjustmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WorkingCapitalAdjustmentsAbstract"/>
  <xs:element name="UnlabeledAbstract61" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract61"/>
  <xs:element name="UnlabeledAbstract62" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract62"/>
  <xs:element name="UnlabeledAbstract63" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract63"/>
  <xs:element name="UnlabeledAbstract64" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract64"/>
  <xs:element name="UnlabeledAbstract65" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract65"/>
  <xs:element name="UnlabeledAbstract66" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract66"/>
  <xs:element name="UnlabeledAbstract67" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract67"/>
  <xs:element name="UnlabeledAbstract68" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract68"/>
  <xs:element name="UnlabeledAbstract69" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract69"/>
  <xs:element name="UnlabeledAbstract70" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract70"/>
  <xs:element name="UnlabeledAbstract71" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract71"/>
  <xs:element name="UnlabeledAbstract72" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract72"/>
  <xs:element name="UnlabeledAbstract73" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract73"/>
  <xs:element name="UnlabeledAbstract74" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract74"/>
  <xs:element name="AdjustmentsToTheProfitOrLossItemsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract0"/>
  <xs:element name="UnlabeledAbstract75" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract75"/>
  <xs:element name="UnlabeledAbstract76" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract76"/>
  <xs:element name="UnlabeledAbstract77" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract77"/>
  <xs:element name="WorkingCapitalAdjustmentsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WorkingCapitalAdjustmentsAbstract0"/>
  <xs:element name="UnlabeledAbstract78" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract78"/>
  <xs:element name="UnlabeledAbstract79" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract79"/>
  <xs:element name="UnlabeledAbstract80" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract80"/>
  <xs:element name="UnlabeledAbstract81" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract81"/>
  <xs:element name="UnlabeledAbstract82" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract82"/>
  <xs:element name="UnlabeledAbstract83" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract83"/>
  <xs:element name="UnlabeledAbstract84" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract84"/>
  <xs:element name="UnlabeledAbstract85" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract85"/>
  <xs:element name="UnlabeledAbstract86" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract86"/>
  <xs:element name="UnlabeledAbstract87" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract87"/>
  <xs:element name="UnlabeledAbstract88" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract88"/>
  <xs:element name="UnlabeledAbstract89" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract89"/>
  <xs:element name="UnlabeledAbstract90" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract90"/>
  <xs:element name="UnlabeledAbstract91" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract91"/>
  <xs:element name="UnlabeledAbstract92" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract92"/>
  <xs:element name="UnlabeledAbstract93" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract93"/>
  <xs:element name="UnlabeledAbstract94" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract94"/>
  <xs:element name="UnlabeledAbstract95" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract95"/>
  <xs:element name="UnlabeledAbstract96" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract96"/>
  <xs:element name="FinancialAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FinancialAssetsAbstract"/>
  <xs:element name="UnlabeledAbstract97" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract97"/>
  <xs:element name="UnlabeledAbstract98" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract98"/>
  <xs:element name="FinancialLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FinancialLiabilitiesAbstract"/>
  <xs:element name="UnlabeledAbstract99" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract99"/>
  <xs:element name="NumberOfSharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfSharesAbstract"/>
  <xs:element name="UnlabeledAbstract100" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract100"/>
  <xs:element name="UnlabeledAbstract101" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract101"/>
  <xs:element name="UnlabeledAbstract102" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract102"/>
  <xs:element name="UnlabeledAbstract103" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract103"/>
  <xs:element name="AResearchAndDevelopmentExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AResearchAndDevelopmentExpensesAbstract"/>
  <xs:element name="UnlabeledAbstract104" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract104"/>
  <xs:element name="UnlabeledAbstract105" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract105"/>
  <xs:element name="UnlabeledAbstract106" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract106"/>
  <xs:element name="BGeneralAndAdministrativeExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_BGeneralAndAdministrativeExpensesAbstract"/>
  <xs:element name="UnlabeledAbstract107" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract107"/>
  <xs:element name="UnlabeledAbstract108" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract108"/>
  <xs:element name="UnlabeledAbstract109" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract109"/>
  <xs:element name="UnlabeledAbstract110" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract110"/>
  <xs:element name="UnlabeledAbstract111" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract111"/>
  <xs:element name="UnlabeledAbstract112" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract112"/>
  <xs:element name="CostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CostAbstract"/>
  <xs:element name="UnlabeledAbstract113" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract113"/>
  <xs:element name="UnlabeledAbstract114" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract114"/>
  <xs:element name="AccumulatedDepreciationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AccumulatedDepreciationAbstract"/>
  <xs:element name="UnlabeledAbstract115" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract115"/>
  <xs:element name="UnlabeledAbstract116" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract116"/>
  <xs:element name="UnlabeledAbstract117" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract117"/>
  <xs:element name="UnlabeledAbstract118" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract118"/>
  <xs:element name="UnlabeledAbstract119" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract119"/>
  <xs:element name="AccumulatedDepreciationAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AccumulatedDepreciationAbstract0"/>
  <xs:element name="UnlabeledAbstract120" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract120"/>
  <xs:element name="UnlabeledAbstract121" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract121"/>
  <xs:element name="UnlabeledAbstract122" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract122"/>
  <xs:element name="UnlabeledAbstract123" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract123"/>
  <xs:element name="UnlabeledAbstract124" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract124"/>
  <xs:element name="UnlabeledAbstract125" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract125"/>
  <xs:element name="UnlabeledAbstract126" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract126"/>
  <xs:element name="UnlabeledAbstract127" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract127"/>
  <xs:element name="UnlabeledAbstract128" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract128"/>
  <xs:element name="NumberOfSharesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfSharesAbstract0"/>
  <xs:element name="UnlabeledAbstract129" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract129"/>
  <xs:element name="UnlabeledAbstract130" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract130"/>
  <xs:element name="UnlabeledAbstract131" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract131"/>
  <xs:element name="UnlabeledAbstract132" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract132"/>
  <xs:element name="UnlabeledAbstract133" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract133"/>
  <xs:element name="UnlabeledAbstract134" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract134"/>
  <xs:element name="a2022Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_a2022Abstract"/>
  <xs:element name="UnlabeledAbstract135" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract135"/>
  <xs:element name="a2021Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_a2021Abstract"/>
  <xs:element name="UnlabeledAbstract136" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract136"/>
  <xs:element name="UnlabeledAbstract137" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract137"/>
  <xs:element name="UnlabeledAbstract138" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract138"/>
  <xs:element name="AResearchAndDevelopmentExpensesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AResearchAndDevelopmentExpensesAbstract0"/>
  <xs:element name="UnlabeledAbstract139" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract139"/>
  <xs:element name="UnlabeledAbstract140" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract140"/>
  <xs:element name="BGeneralAndAdministrativeExpensesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_BGeneralAndAdministrativeExpensesAbstract0"/>
  <xs:element name="UnlabeledAbstract141" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract141"/>
  <xs:element name="UnlabeledAbstract142" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract142"/>
  <xs:element name="COtherExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_COtherExpensesAbstract"/>
  <xs:element name="UnlabeledAbstract143" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract143"/>
  <xs:element name="UnlabeledAbstract144" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract144"/>
  <xs:element name="UnlabeledAbstract145" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract145"/>
  <xs:element name="ContinuingOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ContinuingOperationsAbstract"/>
  <xs:element name="UnlabeledAbstract146" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract146"/>
  <xs:element name="UnlabeledAbstract147" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract147"/>
  <xs:element name="UnlabeledAbstract148" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract148"/>
  <xs:element name="UnlabeledAbstract149" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract149"/>
  <xs:element name="UnlabeledAbstract150" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract150"/>
  <xs:element name="UnlabeledAbstract151" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract151"/>
  <xs:element name="UnlabeledAbstract152" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract152"/>
  <xs:element name="UnlabeledAbstract153" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract153"/>
  <xs:element name="UnlabeledAbstract154" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract154"/>
  <xs:element name="UnlabeledAbstract155" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract155"/>
  <xs:element name="ComprehensiveIncomeAttributableToNoncontrollingInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ComprehensiveIncomeAttributableToNoncontrollingInterest"/>
  <xs:element name="IssueOfSharesNetOfIssueExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssueOfSharesNetOfIssueExpenses"/>
  <xs:element name="ExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExerciseOfWarrants"/>
  <xs:element name="IssueOfShareCapitalNetOfIssueExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssueOfShareCapitalNetOfIssueExpense"/>
  <xs:element name="AdjustmentsForImpairmentOfInvestmentInAssociate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdjustmentsForImpairmentOfInvestmentInAssociate"/>
  <xs:element name="PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss"/>
  <xs:element name="ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses"/>
  <xs:element name="RepaymentOfLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RepaymentOfLeaseLiabilities"/>
  <xs:element name="InterestPaidOnLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InterestPaidOnLeaseLiability"/>
  <xs:element name="PaymentOfIssuanceExpensesRelatedToPreviousPeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod"/>
  <xs:element name="RepaymentOfShorttermCredit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RepaymentOfShorttermCredit"/>
  <xs:element name="ReceiptofShortTermCreditFromOthers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ReceiptofShortTermCreditFromOthers"/>
  <xs:element name="MutualShareExchangeOfOrdinarySharessee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_MutualShareExchangeOfOrdinarySharessee"/>
  <xs:element name="RightofuseAssetRecognizedWithCorrespondingLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability"/>
  <xs:element name="RegistrationOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RegistrationOfWarrants"/>
  <xs:element name="UnpaidIssueExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnpaidIssueExpenses"/>
  <xs:element name="DisclosureOfGeneralExplanatoryTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfGeneralExplanatoryTextBlock"/>
  <xs:element name="WarrantTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantTextBlock"/>
  <xs:element name="DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock"/>
  <xs:element name="SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock"/>
  <xs:element name="CashTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_CashTable"/>
  <xs:element name="CashLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CashLineItems"/>
  <xs:element name="InvestmentinAssociatesandInvestmentsinInvesteesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTable"/>
  <xs:element name="InvestmentinAssociatesandInvestmentsinInvesteesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesLineItems"/>
  <xs:element name="PropertyandEquipmentNetTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_PropertyandEquipmentNetTable"/>
  <xs:element name="PropertyandEquipmentNetLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PropertyandEquipmentNetLineItems"/>
  <xs:element name="DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent"/>
  <xs:element name="EmployeeBenefitLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_EmployeeBenefitLiabilitiesTable"/>
  <xs:element name="EmployeeBenefitLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EmployeeBenefitLiabilitiesLineItems"/>
  <xs:element name="BasisOfPresentationOfFinancialStatements" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_BasisOfPresentationOfFinancialStatements"/>
  <xs:element name="DescriptionOfAccountingPolicyForoperatingcycleExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory"/>
  <xs:element name="DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements"/>
  <xs:element name="DescriptionOfAcquisitionOfASingleAssetCompany" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany"/>
  <xs:element name="DescriptionOfAccountingPolicyForRestrictedDeposit" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit"/>
  <xs:element name="DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock"/>
  <xs:element name="DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements"/>
  <xs:element name="DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors"/>
  <xs:element name="DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory"/>
  <xs:element name="ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock"/>
  <xs:element name="DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory"/>
  <xs:element name="DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory"/>
  <xs:element name="TransactionsandBalanceswithRelatedPartiesTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_TransactionsandBalanceswithRelatedPartiesTablesTable"/>
  <xs:element name="TransactionsandBalanceswithRelatedPartiesTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TransactionsandBalanceswithRelatedPartiesTablesLineItems"/>
  <xs:element name="DisclosureOfFinancialAssetsAndFinancialLiabilities" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities"/>
  <xs:element name="ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock"/>
  <xs:element name="DisclosureOfIssuedAndOutstandingShareCapital" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfIssuedAndOutstandingShareCapital"/>
  <xs:element name="DisclosureOfInformationToTheItemsOfProfitOrLoss" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss"/>
  <xs:element name="AdditionalInformationtotheItemsofProfitorLossTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_AdditionalInformationtotheItemsofProfitorLossTablesTable"/>
  <xs:element name="AdditionalInformationtotheItemsofProfitorLossTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdditionalInformationtotheItemsofProfitorLossTablesLineItems"/>
  <xs:element name="DisclosueOfCashAndCashEquivalentsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock"/>
  <xs:element name="CashTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_CashTablesTable"/>
  <xs:element name="CashTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CashTablesLineItems"/>
  <xs:element name="DisclourseOfAccountsReceivablesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclourseOfAccountsReceivablesTableTextBlock"/>
  <xs:element name="OtherAccountsReceivableTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_OtherAccountsReceivableTablesTable"/>
  <xs:element name="OtherAccountsReceivableTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OtherAccountsReceivableTablesLineItems"/>
  <xs:element name="DisclosureOfFairValueMeasurementOfAssetstable" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfFairValueMeasurementOfAssetstable"/>
  <xs:element name="InvestmentinAssociatesandInvestmentsinInvesteesTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTablesTable"/>
  <xs:element name="InvestmentinAssociatesandInvestmentsinInvesteesTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTablesLineItems"/>
  <xs:element name="PropertyandEquipmentNetTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_PropertyandEquipmentNetTablesTable"/>
  <xs:element name="PropertyandEquipmentNetTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PropertyandEquipmentNetTablesLineItems"/>
  <xs:element name="DisclosureOfTradePayables" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfTradePayables"/>
  <xs:element name="TradePayablesTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_TradePayablesTablesTable"/>
  <xs:element name="TradePayablesTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TradePayablesTablesLineItems"/>
  <xs:element name="ScheduleOfOtherAccountsPayable" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfOtherAccountsPayable"/>
  <xs:element name="DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory"/>
  <xs:element name="EmployeeBenefitLiabilitiesTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_EmployeeBenefitLiabilitiesTablesTable"/>
  <xs:element name="EmployeeBenefitLiabilitiesTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EmployeeBenefitLiabilitiesTablesLineItems"/>
  <xs:element name="DisclosureOfExpenseRecognizedExplanatoryTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfExpenseRecognizedExplanatoryTableTextBlock"/>
  <xs:element name="DescriptionOfOptionPricingModelShareOptionGranted" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfOptionPricingModelShareOptionGranted"/>
  <xs:element name="DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock"/>
  <xs:element name="ShareBasedPaymentTransactionsTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_ShareBasedPaymentTransactionsTablesTable"/>
  <xs:element name="ShareBasedPaymentTransactionsTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareBasedPaymentTransactionsTablesLineItems"/>
  <xs:element name="ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock"/>
  <xs:element name="DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory"/>
  <xs:element name="LossPerShareAdsTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_LossPerShareAdsTablesTable"/>
  <xs:element name="LossPerShareAdsTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LossPerShareAdsTablesLineItems"/>
  <xs:element name="OperatingSegmentsTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_OperatingSegmentsTablesTable"/>
  <xs:element name="OperatingSegmentsTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OperatingSegmentsTablesLineItems"/>
  <xs:element name="InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentTable"/>
  <xs:element name="InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentLineItems"/>
  <xs:element name="InvestmentDate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentDate"/>
  <xs:element name="EquityLossesFromInvestmentInMitoCareX" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EquityLossesFromInvestmentInMitoCareX"/>
  <xs:element name="PurchaseOfAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchaseOfAssets"/>
  <xs:element name="FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable"/>
  <xs:element name="FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesLineItems"/>
  <xs:element name="GovernmentAuthorities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_GovernmentAuthorities"/>
  <xs:element name="CreditFromOthers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CreditFromOthers"/>
  <xs:element name="WarrantsLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantsLiability"/>
  <xs:element name="WarrantsDetailsScheduleofWarrantsFairValueTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_WarrantsDetailsScheduleofWarrantsFairValueTable"/>
  <xs:element name="WarrantsDetailsScheduleofWarrantsFairValueLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantsDetailsScheduleofWarrantsFairValueLineItems"/>
  <xs:element name="EquityDetailsScheduleofShareCapitalTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_EquityDetailsScheduleofShareCapitalTable"/>
  <xs:element name="EquityDetailsScheduleofShareCapitalLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EquityDetailsScheduleofShareCapitalLineItems"/>
  <xs:element name="NumberOfSharesIssued1" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfSharesIssued1"/>
  <xs:element name="IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate"/>
  <xs:element name="SharesIssuedToConsultants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SharesIssuedToConsultants"/>
  <xs:element name="IssuanceOfShareCapitalInRespectOfShelfProspectus" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus"/>
  <xs:element name="IncomeStatementsLocationsDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IncomeStatementsLocationsDomainDomain"/>
  <xs:element name="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable"/>
  <xs:element name="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems"/>
  <xs:element name="SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"/>
  <xs:element name="SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems"/>
  <xs:element name="PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment"/>
  <xs:element name="StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly"/>
  <xs:element name="LeaseholdImprovements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LeaseholdImprovements"/>
  <xs:element name="CashForImmediateWithdrawal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CashForImmediateWithdrawal"/>
  <xs:element name="CashForImmediateWithdrawalInNIS" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CashForImmediateWithdrawalInNIS"/>
  <xs:element name="InventoriesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InventoriesNet"/>
  <xs:element name="InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentTable"/>
  <xs:element name="InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentLineItems"/>
  <xs:element name="EquityLossesFromInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EquityLossesFromInvestment"/>
  <xs:element name="PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable"/>
  <xs:element name="PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems"/>
  <xs:element name="BeginningBalanceCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_BeginningBalanceCost"/>
  <xs:element name="NewLeases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NewLeases"/>
  <xs:element name="PurchasesOfCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchasesOfCost"/>
  <xs:element name="PropertyPlantAndEquipmentCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PropertyPlantAndEquipmentCost"/>
  <xs:element name="AccumulatedTerminationOfLeases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AccumulatedTerminationOfLeases"/>
  <xs:element name="IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable"/>
  <xs:element name="IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems"/>
  <xs:element name="PurchaseofAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchaseofAssets"/>
  <xs:element name="AccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AccruedExpenses"/>
  <xs:element name="OtherAccountsPayableDetailsScheduleofOtherAccountsPayableTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableTable"/>
  <xs:element name="OtherAccountsPayableDetailsScheduleofOtherAccountsPayableLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableLineItems"/>
  <xs:element name="TradeAndOtherPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TradeAndOtherPayable"/>
  <xs:element name="InvestmentsInFinancialAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentsInFinancialAssets"/>
  <xs:element name="CreditsFromOthers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CreditsFromOthers"/>
  <xs:element name="DividendYield" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DividendYield"/>
  <xs:element name="ExpectedVolatility" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExpectedVolatility"/>
  <xs:element name="RiskFreeInterestRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RiskFreeInterestRate"/>
  <xs:element name="UnderlyingAdsPrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnderlyingAdsPrice"/>
  <xs:element name="ExercisePricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExercisePricePerShare"/>
  <xs:element name="WarrantsFairValueinDollarsPerShares" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantsFairValueinDollarsPerShares"/>
  <xs:element name="ExerciseOfPrefundedWarrantsOne" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExerciseOfPrefundedWarrantsOne"/>
  <xs:element name="ExerciseOfPrefundedWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExerciseOfPrefundedWarrants"/>
  <xs:element name="ShareIssuedToAConsultant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareIssuedToAConsultant"/>
  <xs:element name="UnderlyingOrdinarySharePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnderlyingOrdinarySharePrice"/>
  <xs:element name="ExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExercisePrice"/>
  <xs:element name="WarrantsFairValueinDollarsPerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantsFairValueinDollarsPerShare"/>
  <xs:element name="ResearchAndDevelopmentExpenses01" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ResearchAndDevelopmentExpenses01"/>
  <xs:element name="GeneralAndAdministrativeExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_GeneralAndAdministrativeExpenses"/>
  <xs:element name="ExpensesDueToSharebasedCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExpensesDueToSharebasedCompensation"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1"/>
  <xs:element name="UnderlyingOrdinarySharePrices" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnderlyingOrdinarySharePrices"/>
  <xs:element name="NumberOfOutstandingShareOption" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfOutstandingShareOption"/>
  <xs:element name="WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement"/>
  <xs:element name="NumberOfShareOptionGranted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfShareOptionGranted"/>
  <xs:element name="WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement"/>
  <xs:element name="NumberOfShareOptionsShareOptionsExercisableAtTheEndOfTheYear" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfShareOptionsShareOptionsExercisableAtTheEndOfTheYear"/>
  <xs:element name="NumberOfShareOptionForfeitedInSharebasedPaymentArrangement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement"/>
  <xs:element name="WeightedAverageExercisePriceOfShareOptionForfeitedInSharebasedPaymentArrangement" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WeightedAverageExercisePriceOfShareOptionForfeitedInSharebasedPaymentArrangement"/>
  <xs:element name="ShareadsOptionsExpiredDuringYear" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareadsOptionsExpiredDuringYear"/>
  <xs:element name="ShareadsOptionsExpiredDuringYearWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareadsOptionsExpiredDuringYearWeightedAverageExercisePrice"/>
  <xs:element name="ResearchAndDevelopmentExpenses1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ResearchAndDevelopmentExpenses1"/>
  <xs:element name="FinanceIncomeFromConvertibleLoan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FinanceIncomeFromConvertibleLoan"/>
  <xs:element name="IssueExpensesRelatedToIssuanceOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssueExpensesRelatedToIssuanceOfWarrants"/>
  <xs:element name="FinanceExpensesFromExchangeRateDifferences" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FinanceExpensesFromExchangeRateDifferences"/>
  <xs:element name="InterestExpenseInRespectOfLeases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InterestExpenseInRespectOfLeases"/>
  <xs:element name="FinanceExpensesFromInterestAndCommissions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FinanceExpensesFromInterestAndCommissions"/>
  <xs:element name="LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"/>
  <xs:element name="LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareLineItems"/>
  <xs:element name="OperatingSegmentsDetailsScheduleofOperatingSegmentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_OperatingSegmentsDetailsScheduleofOperatingSegmentsTable"/>
  <xs:element name="ExternalRevenues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExternalRevenues"/>
  <xs:element name="Intersegment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_Intersegment"/>
  <xs:element name="CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet"/>
  <xs:element name="TaxExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TaxExpense"/>
  <xs:element name="TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable"/>
  <xs:element name="TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems"/>
  <xs:element name="ResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ResearchAndDevelopmentExpenses"/>
  <xs:element name="GeneralDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_GeneralDetailsTable"/>
  <xs:element name="GeneralDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_GeneralDetailsLineItems"/>
  <xs:element name="RetainedEarning" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RetainedEarning"/>
  <xs:element name="ProceedsFromIssuanceIPO" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ProceedsFromIssuanceIPO"/>
  <xs:element name="OperatingTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OperatingTerm"/>
  <xs:element name="InvestmentinAssociateDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_InvestmentinAssociateDetailsTable"/>
  <xs:element name="InvestmentinAssociateDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentinAssociateDetailsLineItems"/>
  <xs:element name="InvestedInitialAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestedInitialAmount"/>
  <xs:element name="AdditionalAgreedInvest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdditionalAgreedInvest"/>
  <xs:element name="OwnershipAgreement" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OwnershipAgreement"/>
  <xs:element name="InitialInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InitialInvestment"/>
  <xs:element name="OutstandingSharesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OutstandingSharesPercentage"/>
  <xs:element name="EquityLossesInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EquityLossesInvestment"/>
  <xs:element name="CashPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CashPayment"/>
  <xs:element name="PurchaseCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchaseCosts"/>
  <xs:element name="WarrantsToPurchase" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantsToPurchase"/>
  <xs:element name="ExercisePrice1" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExercisePrice1"/>
  <xs:element name="ExercisePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExercisePeriod"/>
  <xs:element name="PricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PricePerShare"/>
  <xs:element name="AmountTotal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AmountTotal"/>
  <xs:element name="pricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_pricePerShare"/>
  <xs:element name="InvestmentinFinancialAssetsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_InvestmentinFinancialAssetsDetailsTable"/>
  <xs:element name="InvestmentinFinancialAssetsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentinFinancialAssetsDetailsLineItems"/>
  <xs:element name="ExerciseOfPricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExerciseOfPricePerShare"/>
  <xs:element name="InvestmentAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentAmount"/>
  <xs:element name="ShareCapitalPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareCapitalPercentage"/>
  <xs:element name="SharePricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SharePricePerShare"/>
  <xs:element name="ComprehensiveLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ComprehensiveLoss"/>
  <xs:element name="CooperationAgreementWithClearmindAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CooperationAgreementWithClearmindAmount"/>
  <xs:element name="BalanceOwedToClearmind" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_BalanceOwedToClearmind"/>
  <xs:element name="InvestedAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestedAmount"/>
  <xs:element name="ExchangeCommonShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExchangeCommonShares"/>
  <xs:element name="ClearmindOutstandingShareCapitalPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ClearmindOutstandingShareCapitalPercentage"/>
  <xs:element name="InvestedAmountInClearmind" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestedAmountInClearmind"/>
  <xs:element name="ExchangeCommonSharesOfClearmind" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExchangeCommonSharesOfClearmind"/>
  <xs:element name="FinancialInstrumentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_FinancialInstrumentsDetailsTable"/>
  <xs:element name="FinancialInstrumentsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FinancialInstrumentsDetailsLineItems"/>
  <xs:element name="BridgeLoanAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_BridgeLoanAmount"/>
  <xs:element name="AggregateAmountOrCreditAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateAmountOrCreditAmount"/>
  <xs:element name="CreditFacilityAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CreditFacilityAmount"/>
  <xs:element name="CreditFacilityAndRemainingAvailableDrawnAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CreditFacilityAndRemainingAvailableDrawnAmount"/>
  <xs:element name="LoanAmountDueTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LoanAmountDueTerm"/>
  <xs:element name="LoanAmountRaised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LoanAmountRaised"/>
  <xs:element name="PurchasePrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchasePrice"/>
  <xs:element name="MaturityDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_MaturityDate"/>
  <xs:element name="InitialConversionPrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InitialConversionPrice"/>
  <xs:element name="ConversionPrice" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ConversionPrice"/>
  <xs:element name="OrdinaryShareExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OrdinaryShareExercisePrice"/>
  <xs:element name="WarrantsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_WarrantsDetailsTable"/>
  <xs:element name="WarrantsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantsDetailsLineItems"/>
  <xs:element name="GrossProceed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_GrossProceed"/>
  <xs:element name="IssuanceOfAggregateShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuanceOfAggregateShares"/>
  <xs:element name="WarrantsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantsDescription"/>
  <xs:element name="WarrantExpiryPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantExpiryPeriod"/>
  <xs:element name="AgreementTypeDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AgreementTypeDomainDomain"/>
  <xs:element name="EquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_EquityDetailsTable"/>
  <xs:element name="EquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EquityDetailsLineItems"/>
  <xs:element name="StockIssuedDuringPeriodReverseStockSplits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_StockIssuedDuringPeriodReverseStockSplits"/>
  <xs:element name="NoParValuePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NoParValuePerShare"/>
  <xs:element name="DescriptionOfPrivateOffering" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfPrivateOffering"/>
  <xs:element name="DateOfIssuance" type="xbrli:durationItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DateOfIssuance"/>
  <xs:element name="WarrantsAndExercise" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantsAndExercise"/>
  <xs:element name="IssuanceOfShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuanceOfShares"/>
  <xs:element name="DescriptionOfReverseShareSplit" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfReverseShareSplit"/>
  <xs:element name="PurchaseAgreementsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchaseAgreementsDescription"/>
  <xs:element name="GrossProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_GrossProceeds"/>
  <xs:element name="WarrantsExercisePrice" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantsExercisePrice"/>
  <xs:element name="SignificantEventsduringtheReportingPeriodDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable"/>
  <xs:element name="SignificantEventsduringtheReportingPeriodDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems"/>
  <xs:element name="InterestPercentgae" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InterestPercentgae"/>
  <xs:element name="DeferredCashPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DeferredCashPayments"/>
  <xs:element name="FeeExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FeeExpenses"/>
  <xs:element name="BonusAmountReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_BonusAmountReceived"/>
  <xs:element name="MutualShareExchangeAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_MutualShareExchangeAmount"/>
  <xs:element name="OrdinarySharesAcquired" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OrdinarySharesAcquired"/>
  <xs:element name="AggregateValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateValue"/>
  <xs:element name="AdjustedAmountOfAggregateValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdjustedAmountOfAggregateValue"/>
  <xs:element name="OwnershipPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OwnershipPercentage"/>
  <xs:element name="ClaimsOnDamages" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ClaimsOnDamages"/>
  <xs:element name="EventsaftertheReportingPeriodDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_EventsaftertheReportingPeriodDetailsTable"/>
  <xs:element name="EventsaftertheReportingPeriodDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EventsaftertheReportingPeriodDetailsLineItems"/>
  <xs:element name="DescriptionOfPublicOffering" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfPublicOffering"/>
  <xs:element name="AggregateGrossProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateGrossProceeds"/>
  <xs:element name="PercentageOfAggregatePurchasePrice" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PercentageOfAggregatePurchasePrice"/>
  <xs:element name="AggregatePurchasePrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregatePurchasePrice"/>
  <xs:element name="PurchasePricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchasePricePerShare"/>
  <xs:element name="PrefundedOrdinaryShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PrefundedOrdinaryShare"/>
  <xs:element name="PurchaseOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchaseOrdinaryShares"/>
  <xs:element name="TermOfIssuance" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TermOfIssuance"/>
  <xs:element name="PercentageOfStockEqual" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PercentageOfStockEqual"/>
  <xs:element name="PercentageOfWorkingCapital" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PercentageOfWorkingCapital"/>
  <xs:element name="MonthlyFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_MonthlyFee"/>
  <xs:element name="BonusAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_BonusAmount"/>
  <xs:element name="InvestmentinAssociatesandInvestmentsinInvesteesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsTable"/>
  <xs:element name="InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems"/>
  <xs:element name="ConversionOfOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ConversionOfOrdinaryShares"/>
  <xs:element name="OrdinarySharesPerValue" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OrdinarySharesPerValue"/>
  <xs:element name="PercentageOfSharesIssuedAndOutstandingShareCapital" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital"/>
  <xs:element name="FairMarketValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FairMarketValue"/>
  <xs:element name="PurchaseOfOrdinaryShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchaseOfOrdinaryShares"/>
  <xs:element name="ShareholdersAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareholdersAmount"/>
  <xs:element name="IssuedAndOutstandingSharesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuedAndOutstandingSharesPercentage"/>
  <xs:element name="InvestedInitialAmounts" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestedInitialAmounts"/>
  <xs:element name="PreDeterminedValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PreDeterminedValue"/>
  <xs:element name="InitialInvestmentAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InitialInvestmentAmount"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStocks" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStocks"/>
  <xs:element name="LeasesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_LeasesDetailsTable"/>
  <xs:element name="LeasesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LeasesDetailsLineItems"/>
  <xs:element name="SquareMeters" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SquareMeters"/>
  <xs:element name="LeaseFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LeaseFee"/>
  <xs:element name="ExpireTerm" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExpireTerm"/>
  <xs:element name="PropertyandEquipmentNetDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_PropertyandEquipmentNetDetailsTable"/>
  <xs:element name="PropertyandEquipmentNetDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PropertyandEquipmentNetDetailsLineItems"/>
  <xs:element name="TaxesonIncomeDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_TaxesonIncomeDetailsTable"/>
  <xs:element name="TaxesonIncomeDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TaxesonIncomeDetailsLineItems"/>
  <xs:element name="OperatingLossCarryforwardsTaxAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OperatingLossCarryforwardsTaxAmount"/>
  <xs:element name="DekelLicenseAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DekelLicenseAgreementDescription"/>
  <xs:element name="AnnualInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AnnualInvestment"/>
  <xs:element name="AdditionalMilestoneAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdditionalMilestoneAmount"/>
  <xs:element name="InstallmentAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InstallmentAmount"/>
  <xs:element name="TotalAgreementEstimatingAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TotalAgreementEstimatingAmount"/>
  <xs:element name="CapitalProposedToDeposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CapitalProposedToDeposit"/>
  <xs:element name="ShareBasedPaymentTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_ShareBasedPaymentTransactionsDetailsTable"/>
  <xs:element name="ShareBasedPaymentTransactionsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareBasedPaymentTransactionsDetailsLineItems"/>
  <xs:element name="ShareOptionsReserved" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareOptionsReserved"/>
  <xs:element name="NumberOfSharesOptionGrantedInSharebasedPaymentArrangement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfSharesOptionGrantedInSharebasedPaymentArrangement"/>
  <xs:element name="OrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OrdinaryShares"/>
  <xs:element name="FairValueOption" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FairValueOption"/>
  <xs:element name="StockOptionDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_StockOptionDescription"/>
  <xs:element name="FairValueDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FairValueDescription"/>
  <xs:element name="RSUGrantedDiscountRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RSUGrantedDiscountRate"/>
  <xs:element name="FairValueOfTheRSUsGranted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FairValueOfTheRSUsGranted"/>
  <xs:element name="OrdinarySharesIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OrdinarySharesIssued"/>
  <xs:element name="OrdinaryGrantedDiscountRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OrdinaryGrantedDiscountRate"/>
  <xs:element name="WeightedAverageRemainingContractualLifesOfOutstandingShareOption" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption"/>
  <xs:element name="ShareOptionsOutstandingParValue" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareOptionsOutstandingParValue"/>
  <xs:element name="AgreementTypeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="sprcy_AgreementTypeAxis"/>
  <xs:element name="IncomeStatementsLocationsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="sprcy_IncomeStatementsLocationsAxis"/>
  <xs:element name="ADSMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ADSMember"/>
  <xs:element name="ADSsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ADSsMember"/>
  <xs:element name="AprilTwoThousandTwentyPurchaseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AprilTwoThousandTwentyPurchaseAgreementMember"/>
  <xs:element name="AutoMaxSharesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AutoMaxSharesMember"/>
  <xs:element name="BusinessDevelopmentExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_BusinessDevelopmentExpensesMember"/>
  <xs:element name="CapitalPointMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CapitalPointMember"/>
  <xs:element name="CapitalPointWarrantMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CapitalPointWarrantMember"/>
  <xs:element name="ChemistryAndFormulationsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ChemistryAndFormulationsMember"/>
  <xs:element name="ClinicalStudiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ClinicalStudiesMember"/>
  <xs:element name="DrugDevelopmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DrugDevelopmentMember"/>
  <xs:element name="EveroMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EveroMember"/>
  <xs:element name="GroupsShareOfLossesOfCompanyAccountedForAtEquityNetMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_GroupsShareOfLossesOfCompanyAccountedForAtEquityNetMember"/>
  <xs:element name="ImpairmentOfInvestmentInAssociateMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ImpairmentOfInvestmentInAssociateMember"/>
  <xs:element name="InvestorRelationsAndBusinessExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestorRelationsAndBusinessExpensesMember"/>
  <xs:element name="JeffsBrandsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_JeffsBrandsMember"/>
  <xs:element name="June2022FinancingRoundMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_June2022FinancingRoundMember"/>
  <xs:element name="June2022WarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_June2022WarrantsMember"/>
  <xs:element name="LeaseMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LeaseMember"/>
  <xs:element name="March2021FinancingRoundMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_March2021FinancingRoundMember"/>
  <xs:element name="MitoCareXBioLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_MitoCareXBioLtdMember"/>
  <xs:element name="MitoCareXMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_MitoCareXMember"/>
  <xs:element name="NewCoIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NewCoIncMember"/>
  <xs:element name="November2020FinancingRoundMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_November2020FinancingRoundMember"/>
  <xs:element name="OfficeEquipmentsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OfficeEquipmentsMember"/>
  <xs:element name="OfficeMaintenanceRentAndOtherExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OfficeMaintenanceRentAndOtherExpensesMember"/>
  <xs:element name="OnlineSalesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OnlineSalesMember"/>
  <xs:element name="OrdinaryShareMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OrdinaryShareMember"/>
  <xs:element name="PrefundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PrefundedWarrantsMember"/>
  <xs:element name="PrivatePlacementsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PrivatePlacementsMember"/>
  <xs:element name="ProfessionalAndDirectorsFeesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ProfessionalAndDirectorsFeesMember"/>
  <xs:element name="RegulatoryAndOtherExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RegulatoryAndOtherExpensesMember"/>
  <xs:element name="RegulatoryExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RegulatoryExpensesMember"/>
  <xs:element name="ResearchAndPreclinicalStudiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ResearchAndPreclinicalStudiesMember"/>
  <xs:element name="SCISPARCLTDMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SCISPARCLTDMember"/>
  <xs:element name="SeriesAWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SeriesAWarrantsMember"/>
  <xs:element name="SeriesBWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SeriesBWarrantsMember"/>
  <xs:element name="ShareBasedPaymentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareBasedPaymentMember"/>
  <xs:element name="SubsequentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SubsequentMember"/>
  <xs:element name="TotalEquityHolderMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TotalEquityHolderMember"/>
  <xs:element name="WagesAndRelatedExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WagesAndRelatedExpensesMember"/>
  <xs:element name="WellutionOperatingExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WellutionOperatingExpensesMember"/>
  <xs:element name="AccountingPolicyAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AccountingPolicyAbstract"/>
  <xs:element name="ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract"/>
  <xs:element name="FinanceExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FinanceExpensesAbstract"/>
  <xs:element name="FinanceIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FinanceIncomeAbstract"/>
  <xs:element name="FinancialInstrumentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FinancialInstrumentsAbstract"/>
  <xs:element name="InventoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InventoryAbstract"/>
  <xs:element name="InvestmentInFinancialAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentInFinancialAssetsAbstract"/>
  <xs:element name="RevenuesAndCostOfRevenuesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RevenuesAndCostOfRevenuesAbstract"/>
  <xs:element name="ScheduleOfOtherAccountsReceivableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfOtherAccountsReceivableAbstract"/>
  <xs:element name="SegmentReportingRevenueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SegmentReportingRevenueAbstract"/>
  <xs:element name="SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract"/>
  <xs:element name="SignificantNonCashTransactionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SignificantNonCashTransactionsAbstract"/>
  <xs:element name="TaxesOnIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TaxesOnIncomeAbstract"/>
  <xs:element name="TradePayablesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TradePayablesAbstract"/>
  <xs:element name="TransactionsAndBalancesWithRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>sprcy-20230630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Feb 27 19:06:21 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ConsolidatedBalanceSheet" roleURI="http://trpx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ConsolidatedIncomeStatement" roleURI="http://trpx.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ConsolidatedCashFlow" roleURI="http://trpx.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofFinancialAssetsandFinancialLiabilitiesTable" roleURI="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofCashTable" roleURI="http://trpx.com/role/ScheduleofCashTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofInventoryTable" roleURI="http://trpx.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofOtherAccountsReceivableTable" roleURI="http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofTradePayablesTable" roleURI="http://trpx.com/role/ScheduleofTradePayablesTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://trpx.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CashAndCashEquivalents" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentTradeReceivables" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_OtherCurrentReceivables" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_Inventories" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentsInAssociates" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInAssociates"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_InvestmentsInAssociates" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_CurrentAssets" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_NoncurrentAssets" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentWarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentWarrantLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentWarrantLiability" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremium"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_SharePremium" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_WarrantLiability" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEquityInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_OtherEquityInterest" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_RetainedEarnings" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_SharePremium" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_WarrantLiability" order="3" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" order="4" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_OtherEquityInterest" order="5" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_RetainedEarnings" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterests"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_NoncontrollingInterests" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_CurrentLiabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Equity" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://trpx.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_Revenue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_CostOfSales" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_GrossProfit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_SalesAndMarketingExpense" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_FinanceIncome" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_FinanceCosts" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ProfitLossBeforeTax" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" order="2" weight="1"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2w4dODRyrf2cKq4MnlNojKY2vawGlGpB5CaguD0HWK7+MXGfIzhA2ezfWaTq7hAnt683nzSc747v3s9ubzeRZw15+aEvNutYTqGoMIIBc15Xh4havgCm8tcwLQ9KMxcs2cA+tx22gDqg=] CSR-->
    <loc xlink:type="locator" xlink:label="sprcy_ComprehensiveIncomeAttributableToNoncontrollingInterest" xlink:href="sprcy-20230630.xsd#sprcy_ComprehensiveIncomeAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="sprcy_ComprehensiveIncomeAttributableToNoncontrollingInterest" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://trpx.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsForImpairmentOfInvestmentInAssociate" xlink:href="sprcy-20230630.xsd#sprcy_AdjustmentsForImpairmentOfInvestmentInAssociate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="sprcy_AdjustmentsForImpairmentOfInvestmentInAssociate" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_ProfitLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="sprcy-20230630.xsd#sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="sprcy_InterestPaidOnLeaseLiability" xlink:href="sprcy-20230630.xsd#sprcy_InterestPaidOnLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="sprcy_InterestPaidOnLeaseLiability" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:href="sprcy-20230630.xsd#sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_ReceiptofShortTermCreditFromOthers" xlink:href="sprcy-20230630.xsd#sprcy_ReceiptofShortTermCreditFromOthers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="sprcy_ReceiptofShortTermCreditFromOthers" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" xlink:href="sprcy-20230630.xsd#sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="sprcy_RepaymentOfLeaseLiabilities" xlink:href="sprcy-20230630.xsd#sprcy_RepaymentOfLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="sprcy_RepaymentOfLeaseLiabilities" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="sprcy_RepaymentOfShorttermCredit" xlink:href="sprcy-20230630.xsd#sprcy_RepaymentOfShorttermCredit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="sprcy_RepaymentOfShorttermCredit" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <loc xlink:type="locator" xlink:label="sprcy_CreditFromOthers" xlink:href="sprcy-20230630.xsd#sprcy_CreditFromOthers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="sprcy_CreditFromOthers" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsLiability" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="sprcy_WarrantsLiability" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_LeaseLiabilities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofCashTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOnHand" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOnHand"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashForImmediateWithdrawal" xlink:href="sprcy-20230630.xsd#sprcy_CashForImmediateWithdrawal"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashOnHand" xlink:to="sprcy_CashForImmediateWithdrawal" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashForImmediateWithdrawalInNIS" xlink:href="sprcy-20230630.xsd#sprcy_CashForImmediateWithdrawalInNIS"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashOnHand" xlink:to="sprcy_CashForImmediateWithdrawalInNIS" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofInventoryTable">
    <loc xlink:type="locator" xlink:label="sprcy_InventoriesNet" xlink:href="sprcy-20230630.xsd#sprcy_InventoriesNet"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInventoriesInTransit" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentInventoriesInTransit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="sprcy_InventoriesNet" xlink:to="ifrs-full_CurrentInventoriesInTransit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinishedGoods"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="sprcy_InventoriesNet" xlink:to="ifrs-full_FinishedGoods" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofOtherAccountsReceivableTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ValueAddedTaxReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ValueAddedTaxReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_ValueAddedTaxReceivables" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherReceivables" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofTradePayablesTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccruedExpenses" xlink:href="sprcy-20230630.xsd#sprcy_AccruedExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="sprcy_AccruedExpenses" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="2" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>sprcy-20230630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Feb 27 19:06:21 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ConsolidatedBalanceSheet" roleURI="http://trpx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ConsolidatedIncomeStatement" roleURI="http://trpx.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ShareholdersEquityType2or3" roleURI="http://trpx.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ConsolidatedCashFlow" roleURI="http://trpx.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_General" roleURI="http://trpx.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_SignificantAccountingPolicies" roleURI="http://trpx.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_InvestmentinAssociate" roleURI="http://trpx.com/role/InvestmentinAssociate"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_IntangibleAsset" roleURI="http://trpx.com/role/IntangibleAsset"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_InvestmentinFinancialAssets" roleURI="http://trpx.com/role/InvestmentinFinancialAssets"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_TransactionsandBalanceswithRelatedParties" roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_FinancialInstruments" roleURI="http://trpx.com/role/FinancialInstruments"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_Warrants" roleURI="http://trpx.com/role/Warrants"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_Equity" roleURI="http://trpx.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_AdditionalInformationtotheItemsofProfitorLoss" roleURI="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_SignificantEventsduringtheReportingPeriod" roleURI="http://trpx.com/role/SignificantEventsduringtheReportingPeriod"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_EventsaftertheReportingPeriod" roleURI="http://trpx.com/role/EventsaftertheReportingPeriod"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements" roleURI="http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_Cash" roleURI="http://trpx.com/role/Cash"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_Inventory" roleURI="http://trpx.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_OtherAccountsReceivable" roleURI="http://trpx.com/role/OtherAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_InvestmentinAssociatesandInvestmentsinInvestees" roleURI="http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvestees"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_Leases" roleURI="http://trpx.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_PropertyandEquipmentNet" roleURI="http://trpx.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_TradePayables" roleURI="http://trpx.com/role/TradePayables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_OtherAccountsPayable" roleURI="http://trpx.com/role/OtherAccountsPayable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_EmployeeBenefitLiabilities" roleURI="http://trpx.com/role/EmployeeBenefitLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_TaxesonIncome" roleURI="http://trpx.com/role/TaxesonIncome"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiens" roleURI="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ShareBasedPaymentTransactions" roleURI="http://trpx.com/role/ShareBasedPaymentTransactions"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_RevenuesandCostofRevenues" roleURI="http://trpx.com/role/RevenuesandCostofRevenues"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_LossPerShareAds" roleURI="http://trpx.com/role/LossPerShareAds"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_OperatingSegments" roleURI="http://trpx.com/role/OperatingSegments"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_AccountingPoliciesByPolicy" roleURI="http://trpx.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_SignificantAccountingPoliciesTables" roleURI="http://trpx.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_InvestmentinAssociateTables" roleURI="http://trpx.com/role/InvestmentinAssociateTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_IntangibleAssetTables" roleURI="http://trpx.com/role/IntangibleAssetTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_TransactionsandBalanceswithRelatedPartiesTables" roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_FinancialInstrumentsTables" roleURI="http://trpx.com/role/FinancialInstrumentsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_WarrantsTables" roleURI="http://trpx.com/role/WarrantsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_EquityTables" roleURI="http://trpx.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_AdditionalInformationtotheItemsofProfitorLossTables" roleURI="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_CashTables" roleURI="http://trpx.com/role/CashTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_InventoryTables" roleURI="http://trpx.com/role/InventoryTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_OtherAccountsReceivableTables" roleURI="http://trpx.com/role/OtherAccountsReceivableTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_InvestmentinAssociatesandInvestmentsinInvesteesTables" roleURI="http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_PropertyandEquipmentNetTables" roleURI="http://trpx.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_TradePayablesTables" roleURI="http://trpx.com/role/TradePayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_OtherAccountsPayableTables" roleURI="http://trpx.com/role/OtherAccountsPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_EmployeeBenefitLiabilitiesTables" roleURI="http://trpx.com/role/EmployeeBenefitLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ShareBasedPaymentTransactionsTables" roleURI="http://trpx.com/role/ShareBasedPaymentTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_RevenuesandCostofRevenuesTables" roleURI="http://trpx.com/role/RevenuesandCostofRevenuesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_LossPerShareAdsTables" roleURI="http://trpx.com/role/LossPerShareAdsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_OperatingSegmentsTables" roleURI="http://trpx.com/role/OperatingSegmentsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofFairValueoftheInvestmentTable" roleURI="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofFairValueoftheIntangibleAssetTable" roleURI="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofFinancialAssetsandFinancialLiabilitiesTable" roleURI="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofWarrantsFairValueTable" roleURI="http://trpx.com/role/ScheduleofWarrantsFairValueTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofShareCapitalTable" roleURI="http://trpx.com/role/ScheduleofShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofIssuedandOutstandingShareCapitalTable" roleURI="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofAdditionalInformationtotheItemsofProfitorLossTable" roleURI="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" roleURI="http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofCashTable" roleURI="http://trpx.com/role/ScheduleofCashTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofInventoryTable" roleURI="http://trpx.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofOtherAccountsReceivableTable" roleURI="http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofFairValueoftheInvestmentTable0" roleURI="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofPropertyandEquipmentNetTable" roleURI="http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofFairValueoftheIntangibleAssetTable0" roleURI="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofTradePayablesTable" roleURI="http://trpx.com/role/ScheduleofTradePayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofOtherAccountsPayableTable" roleURI="http://trpx.com/role/ScheduleofOtherAccountsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofFinancialAssetsandFinancialLiabilitiesTable0" roleURI="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofWarrantsFairValueUsingBlackScholesOPMTable" roleURI="http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofDefinedContributionPlansTable" roleURI="http://trpx.com/role/ScheduleofDefinedContributionPlansTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofShareCapitalTable0" roleURI="http://trpx.com/role/ScheduleofShareCapitalTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofIssuedandOutstandingShareCapitalTable0" roleURI="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable" roleURI="http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofExpensesDuetoShareBasedCompensationTable" roleURI="http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofFairValueforShareOptionsGrantedTable" roleURI="http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofWeightedAverageExercisePricesofShareOptionsTable" roleURI="http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofRevenuesandCostofRevenuesTable" roleURI="http://trpx.com/role/ScheduleofRevenuesandCostofRevenuesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0" roleURI="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" roleURI="http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofOperatingSegmentsTable" roleURI="http://trpx.com/role/ScheduleofOperatingSegmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofBalanceswithRelatedPartiesTable" roleURI="http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofTransactionswithRelatedPartiesTable" roleURI="http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofBenefitstoKeyManagementPersonnelTable" roleURI="http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_GeneralDetails" roleURI="http://trpx.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_SignificantAccountingPoliciesDetails" roleURI="http://trpx.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_InvestmentinAssociateDetails" roleURI="http://trpx.com/role/InvestmentinAssociateDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_IntangibleAssetDetails" roleURI="http://trpx.com/role/IntangibleAssetDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_InvestmentinFinancialAssetsDetails" roleURI="http://trpx.com/role/InvestmentinFinancialAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_TransactionsandBalanceswithRelatedPartiesDetails" roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_FinancialInstrumentsDetails" roleURI="http://trpx.com/role/FinancialInstrumentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_WarrantsDetails" roleURI="http://trpx.com/role/WarrantsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_EquityDetails" roleURI="http://trpx.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_SignificantEventsduringtheReportingPeriodDetails" roleURI="http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_EventsaftertheReportingPeriodDetails" roleURI="http://trpx.com/role/EventsaftertheReportingPeriodDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_InvestmentinAssociatesandInvestmentsinInvesteesDetails" roleURI="http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_LeasesDetails" roleURI="http://trpx.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_PropertyandEquipmentNetDetails" roleURI="http://trpx.com/role/PropertyandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_TaxesonIncomeDetails" roleURI="http://trpx.com/role/TaxesonIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiensDetails" roleURI="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ShareBasedPaymentTransactionsDetails" roleURI="http://trpx.com/role/ShareBasedPaymentTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#DocumentAndEntityInformation" roleURI="http://trpx.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentTradeReceivables" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentReceivables" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_Inventories" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentsInAssociates" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInAssociates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_InvestmentsInAssociates" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Assets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentWarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentWarrantLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentWarrantLiability" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract0" xlink:href="sprcy-20230630.xsd#sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract0" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:href="sprcy-20230630.xsd#sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_SharePremium" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_WarrantLiability" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEquityInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:to="ifrs-full_OtherEquityInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:to="ifrs-full_RetainedEarnings" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterests"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:to="ifrs-full_NoncontrollingInterests" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_Equity" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_EquityAndLiabilities" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PreviouslyStatedMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PreviouslyStatedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_PreviouslyStatedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_Revenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_CostOfSales" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_GrossProfit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_SalesAndMarketingExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_FinanceIncome" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_FinanceCosts" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_ProfitLossBeforeTax" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_ComprehensiveIncome" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AttributableToAbstract" xlink:href="sprcy-20230630.xsd#sprcy_AttributableToAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sprcy_AttributableToAbstract" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ComprehensiveIncomeAttributableToNoncontrollingInterest" xlink:href="sprcy-20230630.xsd#sprcy_ComprehensiveIncomeAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AttributableToAbstract" xlink:to="sprcy_ComprehensiveIncomeAttributableToNoncontrollingInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_ProfitLossAttributableToAbstract" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_BasicLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract" xlink:href="sprcy-20230630.xsd#sprcy_BasicLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sprcy_BasicLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_BasicLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DilutedLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract" xlink:href="sprcy-20230630.xsd#sprcy_DilutedLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sprcy_DilutedLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_DilutedLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_SharePremiumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_WarrantsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterestMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEquityInterestMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_OtherEquityInterestMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_RetainedEarningsMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_TotalEquityHolderMember" xlink:href="sprcy-20230630.xsd#sprcy_TotalEquityHolderMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="sprcy_TotalEquityHolderMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterestsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_NoncontrollingInterestsMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PreviouslyStatedMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PreviouslyStatedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_PreviouslyStatedMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssueOfShareCapitalNetOfIssueExpense" xlink:href="sprcy-20230630.xsd#sprcy_IssueOfShareCapitalNetOfIssueExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="sprcy_IssueOfShareCapitalNetOfIssueExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExerciseOfWarrants" xlink:href="sprcy-20230630.xsd#sprcy_ExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="sprcy_ExerciseOfWarrants" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ShareIssueRelatedCost" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssueOfSharesNetOfIssueExpenses" xlink:href="sprcy-20230630.xsd#sprcy_IssueOfSharesNetOfIssueExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="sprcy_IssueOfSharesNetOfIssueExpenses" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_ProfitLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_AdjustmentsToTheProfitOrLossItemsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsForImpairmentOfInvestmentInAssociate" xlink:href="sprcy-20230630.xsd#sprcy_AdjustmentsForImpairmentOfInvestmentInAssociate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="sprcy_AdjustmentsForImpairmentOfInvestmentInAssociate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WorkingCapitalAdjustmentsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_WorkingCapitalAdjustmentsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="sprcy_WorkingCapitalAdjustmentsAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WorkingCapitalAdjustmentsAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WorkingCapitalAdjustmentsAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WorkingCapitalAdjustmentsAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WorkingCapitalAdjustmentsAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WorkingCapitalAdjustmentsAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WorkingCapitalAdjustmentsAbstract" xlink:to="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WorkingCapitalAdjustmentsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="sprcy-20230630.xsd#sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" xlink:href="sprcy-20230630.xsd#sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RepaymentOfLeaseLiabilities" xlink:href="sprcy-20230630.xsd#sprcy_RepaymentOfLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="sprcy_RepaymentOfLeaseLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RepaymentOfShorttermCredit" xlink:href="sprcy-20230630.xsd#sprcy_RepaymentOfShorttermCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="sprcy_RepaymentOfShorttermCredit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ReceiptofShortTermCreditFromOthers" xlink:href="sprcy-20230630.xsd#sprcy_ReceiptofShortTermCreditFromOthers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="sprcy_ReceiptofShortTermCreditFromOthers" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InterestPaidOnLeaseLiability" xlink:href="sprcy-20230630.xsd#sprcy_InterestPaidOnLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="sprcy_InterestPaidOnLeaseLiability" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:href="sprcy-20230630.xsd#sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantNonCashTransactionsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_SignificantNonCashTransactionsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="sprcy_SignificantNonCashTransactionsAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:href="sprcy-20230630.xsd#sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantNonCashTransactionsAbstract" xlink:to="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegistrationOfWarrants" xlink:href="sprcy-20230630.xsd#sprcy_RegistrationOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantNonCashTransactionsAbstract" xlink:to="sprcy_RegistrationOfWarrants" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnpaidIssueExpenses" xlink:href="sprcy-20230630.xsd#sprcy_UnpaidIssueExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantNonCashTransactionsAbstract" xlink:to="sprcy_UnpaidIssueExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MutualShareExchangeOfOrdinarySharessee" xlink:href="sprcy-20230630.xsd#sprcy_MutualShareExchangeOfOrdinarySharessee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="sprcy_MutualShareExchangeOfOrdinarySharessee" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/General">
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfGeneralExplanatoryAbstract" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfGeneralExplanatoryAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfGeneralExplanatoryTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfGeneralExplanatoryTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_DisclosureOfGeneralExplanatoryAbstract" xlink:to="sprcy_DisclosureOfGeneralExplanatoryTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="sprcy_AccountingPolicyAbstract" xlink:href="sprcy-20230630.xsd#sprcy_AccountingPolicyAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AccountingPolicyAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/InvestmentinAssociate">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/IntangibleAsset">
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/InvestmentinFinancialAssets">
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentInFinancialAssetsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentInFinancialAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentInFinancialAssetsAbstract" xlink:to="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/TransactionsandBalanceswithRelatedParties">
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/FinancialInstruments">
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_FinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/Warrants">
    <loc xlink:type="locator" xlink:label="sprcy_WarrantAbstract" xlink:href="sprcy-20230630.xsd#sprcy_WarrantAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_WarrantTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WarrantAbstract" xlink:to="sprcy_WarrantTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/Equity">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss">
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfAdditionalInformationTextBlockAbstract" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfAdditionalInformationTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAdditionalInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAdditionalInformationExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_DisclosureOfAdditionalInformationTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfAdditionalInformationExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/SignificantEventsduringtheReportingPeriod">
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract" xlink:to="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/EventsaftertheReportingPeriod">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements">
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract" xlink:to="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/Cash">
    <loc xlink:type="locator" xlink:label="sprcy_CashLineItems" xlink:href="sprcy-20230630.xsd#sprcy_CashLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashTable" xlink:href="sprcy-20230630.xsd#sprcy_CashTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_CashLineItems" xlink:to="sprcy_CashTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_CashLineItems" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/Inventory">
    <loc xlink:type="locator" xlink:label="sprcy_InventoryAbstract" xlink:href="sprcy-20230630.xsd#sprcy_InventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InventoryAbstract" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/OtherAccountsReceivable">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvestees">
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociatesandInvestmentsinInvesteesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTable" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesLineItems" xlink:to="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInvestmentPropertyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInvestmentPropertyExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesLineItems" xlink:to="ifrs-full_DisclosureOfInvestmentPropertyExplanatory" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/Leases">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/PropertyandEquipmentNet">
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetLineItems" xlink:href="sprcy-20230630.xsd#sprcy_PropertyandEquipmentNetLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetTable" xlink:href="sprcy-20230630.xsd#sprcy_PropertyandEquipmentNetTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_PropertyandEquipmentNetLineItems" xlink:to="sprcy_PropertyandEquipmentNetTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_PropertyandEquipmentNetLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/TradePayables">
    <loc xlink:type="locator" xlink:label="sprcy_TradePayablesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_TradePayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TradePayablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/OtherAccountsPayable">
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentAbstract" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentAbstract" xlink:to="sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/EmployeeBenefitLiabilities">
    <loc xlink:type="locator" xlink:label="sprcy_EmployeeBenefitLiabilitiesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_EmployeeBenefitLiabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_EmployeeBenefitLiabilitiesTable" xlink:href="sprcy-20230630.xsd#sprcy_EmployeeBenefitLiabilitiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_EmployeeBenefitLiabilitiesLineItems" xlink:to="sprcy_EmployeeBenefitLiabilitiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EmployeeBenefitLiabilitiesLineItems" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/TaxesonIncome">
    <loc xlink:type="locator" xlink:label="sprcy_TaxesOnIncomeAbstract" xlink:href="sprcy-20230630.xsd#sprcy_TaxesOnIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TaxesOnIncomeAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens">
    <loc xlink:type="locator" xlink:label="sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ShareBasedPaymentTransactions">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/RevenuesandCostofRevenues">
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/LossPerShareAds">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/OperatingSegments">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_BasisOfPresentationOfFinancialStatements" xlink:href="sprcy-20230630.xsd#sprcy_BasisOfPresentationOfFinancialStatements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_BasisOfPresentationOfFinancialStatements" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfAcquisitionOfASingleAssetCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" order="24" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/SignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="sprcy_AccountingPolicyAbstract" xlink:href="sprcy-20230630.xsd#sprcy_AccountingPolicyAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AccountingPolicyAbstract" xlink:to="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/InvestmentinAssociateTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/IntangibleAssetTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables">
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesTablesLineItems" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesTablesLineItems" xlink:to="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesTablesLineItems" xlink:to="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesTablesLineItems" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/FinancialInstrumentsTables">
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_FinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsAbstract" xlink:to="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsAbstract" xlink:to="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/WarrantsTables">
    <loc xlink:type="locator" xlink:label="sprcy_WarrantAbstract" xlink:href="sprcy-20230630.xsd#sprcy_WarrantAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WarrantAbstract" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/EquityTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfIssuedAndOutstandingShareCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables">
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossTablesLineItems" xlink:to="sprcy_AdditionalInformationtotheItemsofProfitorLossTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossTablesLineItems" xlink:to="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/CashTables">
    <loc xlink:type="locator" xlink:label="sprcy_CashTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_CashTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_CashTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_CashTablesLineItems" xlink:to="sprcy_CashTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_CashTablesLineItems" xlink:to="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/InventoryTables">
    <loc xlink:type="locator" xlink:label="sprcy_InventoryAbstract" xlink:href="sprcy-20230630.xsd#sprcy_InventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInvestmentEntitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInvestmentEntitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InventoryAbstract" xlink:to="ifrs-full_DisclosureOfInvestmentEntitiesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/OtherAccountsReceivableTables">
    <loc xlink:type="locator" xlink:label="sprcy_OtherAccountsReceivableTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_OtherAccountsReceivableTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_OtherAccountsReceivableTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_OtherAccountsReceivableTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_OtherAccountsReceivableTablesLineItems" xlink:to="sprcy_OtherAccountsReceivableTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_DisclourseOfAccountsReceivablesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_OtherAccountsReceivableTablesLineItems" xlink:to="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesTables">
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTablesLineItems" xlink:to="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfFairValueMeasurementOfAssetstable" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfFairValueMeasurementOfAssetstable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTablesLineItems" xlink:to="sprcy_DisclosureOfFairValueMeasurementOfAssetstable" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/PropertyandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_PropertyandEquipmentNetTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_PropertyandEquipmentNetTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_PropertyandEquipmentNetTablesLineItems" xlink:to="sprcy_PropertyandEquipmentNetTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_PropertyandEquipmentNetTablesLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/TradePayablesTables">
    <loc xlink:type="locator" xlink:label="sprcy_TradePayablesTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_TradePayablesTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_TradePayablesTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_TradePayablesTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_TradePayablesTablesLineItems" xlink:to="sprcy_TradePayablesTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfTradePayables" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfTradePayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TradePayablesTablesLineItems" xlink:to="sprcy_DisclosureOfTradePayables" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/OtherAccountsPayableTables">
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentAbstract" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfOtherAccountsPayable" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfOtherAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentAbstract" xlink:to="sprcy_ScheduleOfOtherAccountsPayable" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/EmployeeBenefitLiabilitiesTables">
    <loc xlink:type="locator" xlink:label="sprcy_EmployeeBenefitLiabilitiesTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_EmployeeBenefitLiabilitiesTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_EmployeeBenefitLiabilitiesTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_EmployeeBenefitLiabilitiesTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_EmployeeBenefitLiabilitiesTablesLineItems" xlink:to="sprcy_EmployeeBenefitLiabilitiesTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EmployeeBenefitLiabilitiesTablesLineItems" xlink:to="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ShareBasedPaymentTransactionsTables">
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_ShareBasedPaymentTransactionsTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_ShareBasedPaymentTransactionsTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_ShareBasedPaymentTransactionsTablesLineItems" xlink:to="sprcy_ShareBasedPaymentTransactionsTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfExpenseRecognizedExplanatoryTableTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfExpenseRecognizedExplanatoryTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsTablesLineItems" xlink:to="sprcy_DisclosureOfExpenseRecognizedExplanatoryTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfOptionPricingModelShareOptionGranted" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfOptionPricingModelShareOptionGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsTablesLineItems" xlink:to="sprcy_DescriptionOfOptionPricingModelShareOptionGranted" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsTablesLineItems" xlink:to="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/RevenuesandCostofRevenuesTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RevenueAbstract" xlink:to="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/LossPerShareAdsTables">
    <loc xlink:type="locator" xlink:label="sprcy_LossPerShareAdsTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_LossPerShareAdsTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_LossPerShareAdsTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_LossPerShareAdsTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_LossPerShareAdsTablesLineItems" xlink:to="sprcy_LossPerShareAdsTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_LossPerShareAdsTablesLineItems" xlink:to="sprcy_DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/OperatingSegmentsTables">
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_OperatingSegmentsTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_OperatingSegmentsTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_OperatingSegmentsTablesLineItems" xlink:to="sprcy_OperatingSegmentsTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_OperatingSegmentsTablesLineItems" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable">
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentLineItems" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentTable" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentLineItems" xlink:to="sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentTable" xlink:to="ifrs-full_SegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentLineItems" xlink:to="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentDate" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentLineItems" xlink:to="sprcy_InvestmentDate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityLossesFromInvestmentInMitoCareX" xlink:href="sprcy-20230630.xsd#sprcy_EquityLossesFromInvestmentInMitoCareX"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentLineItems" xlink:to="sprcy_EquityLossesFromInvestmentInMitoCareX" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseOfAssets" xlink:href="sprcy-20230630.xsd#sprcy_PurchaseOfAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:to="sprcy_PurchaseOfAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationAndAmortisationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:to="ifrs-full_DepreciationAndAmortisationExpense" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable" xlink:href="sprcy-20230630.xsd#sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesLineItems" xlink:to="sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable" xlink:to="ifrs-full_SegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialAssetsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_FinancialAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesLineItems" xlink:to="sprcy_FinancialAssetsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialAssetsAbstract" xlink:to="ifrs-full_TradeReceivables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_GovernmentAuthorities" xlink:href="sprcy-20230630.xsd#sprcy_GovernmentAuthorities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialAssetsAbstract" xlink:to="sprcy_GovernmentAuthorities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialAssetsAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesLineItems" xlink:to="ifrs-full_FinancialAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesLineItems" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialLiabilitiesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_FinancialLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesLineItems" xlink:to="sprcy_FinancialLiabilitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CreditFromOthers" xlink:href="sprcy-20230630.xsd#sprcy_CreditFromOthers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialLiabilitiesAbstract" xlink:to="sprcy_CreditFromOthers" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsLiability" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialLiabilitiesAbstract" xlink:to="sprcy_WarrantsLiability" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesLineItems" xlink:to="ifrs-full_FinancialLiabilities" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofWarrantsFairValueTable">
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsDetailsScheduleofWarrantsFairValueLineItems" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsDetailsScheduleofWarrantsFairValueLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsDetailsScheduleofWarrantsFairValueTable" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsDetailsScheduleofWarrantsFairValueTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_WarrantsDetailsScheduleofWarrantsFairValueLineItems" xlink:to="sprcy_WarrantsDetailsScheduleofWarrantsFairValueTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_WarrantsDetailsScheduleofWarrantsFairValueTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="ifrs-full_WarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WarrantsDetailsScheduleofWarrantsFairValueLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WarrantsDetailsScheduleofWarrantsFairValueLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WarrantsDetailsScheduleofWarrantsFairValueLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WarrantsDetailsScheduleofWarrantsFairValueLineItems" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WarrantsDetailsScheduleofWarrantsFairValueLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LossesOnChangeInFairValueOfDerivatives" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LossesOnChangeInFairValueOfDerivatives"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WarrantsDetailsScheduleofWarrantsFairValueLineItems" xlink:to="ifrs-full_LossesOnChangeInFairValueOfDerivatives" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofShareCapitalTable">
    <loc xlink:type="locator" xlink:label="sprcy_EquityDetailsScheduleofShareCapitalLineItems" xlink:href="sprcy-20230630.xsd#sprcy_EquityDetailsScheduleofShareCapitalLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityDetailsScheduleofShareCapitalTable" xlink:href="sprcy-20230630.xsd#sprcy_EquityDetailsScheduleofShareCapitalTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_EquityDetailsScheduleofShareCapitalLineItems" xlink:to="sprcy_EquityDetailsScheduleofShareCapitalTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EquityDetailsScheduleofShareCapitalTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestatedMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestatedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestatedMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestatedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PreviouslyStatedMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PreviouslyStatedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_PreviouslyStatedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsScheduleofShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesAuthorised" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsScheduleofShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfSharesIssued1" xlink:href="sprcy-20230630.xsd#sprcy_NumberOfSharesIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="sprcy_NumberOfSharesIssued1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" xlink:href="sprcy-20230630.xsd#sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SharesIssuedToConsultants" xlink:href="sprcy-20230630.xsd#sprcy_SharesIssuedToConsultants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="sprcy_SharesIssuedToConsultants" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus" xlink:href="sprcy-20230630.xsd#sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable">
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:href="sprcy-20230630.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable" xlink:href="sprcy-20230630.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:to="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsAxis" xlink:href="sprcy-20230630.xsd#sprcy_IncomeStatementsLocationsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable" xlink:to="sprcy_IncomeStatementsLocationsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsDomainDomain" xlink:href="sprcy-20230630.xsd#sprcy_IncomeStatementsLocationsDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="sprcy_IncomeStatementsLocationsAxis" xlink:to="sprcy_IncomeStatementsLocationsDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsDomainDomain_0" xlink:href="sprcy-20230630.xsd#sprcy_IncomeStatementsLocationsDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="sprcy_IncomeStatementsLocationsAxis" xlink:to="sprcy_IncomeStatementsLocationsDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WagesAndRelatedExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_WagesAndRelatedExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_WagesAndRelatedExpensesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentMember" xlink:href="sprcy-20230630.xsd#sprcy_ShareBasedPaymentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ShareBasedPaymentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ClinicalStudiesMember" xlink:href="sprcy-20230630.xsd#sprcy_ClinicalStudiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ClinicalStudiesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegulatoryAndOtherExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_RegulatoryAndOtherExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_RegulatoryAndOtherExpensesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndPreclinicalStudiesMember" xlink:href="sprcy-20230630.xsd#sprcy_ResearchAndPreclinicalStudiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ResearchAndPreclinicalStudiesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ChemistryAndFormulationsMember" xlink:href="sprcy-20230630.xsd#sprcy_ChemistryAndFormulationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ChemistryAndFormulationsMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ProfessionalAndDirectorsFeesMember" xlink:href="sprcy-20230630.xsd#sprcy_ProfessionalAndDirectorsFeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ProfessionalAndDirectorsFeesMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_BusinessDevelopmentExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_BusinessDevelopmentExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_BusinessDevelopmentExpensesMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OfficeMaintenanceRentAndOtherExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_OfficeMaintenanceRentAndOtherExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_OfficeMaintenanceRentAndOtherExpensesMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestorRelationsAndBusinessExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_InvestorRelationsAndBusinessExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_InvestorRelationsAndBusinessExpensesMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WellutionOperatingExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_WellutionOperatingExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_WellutionOperatingExpensesMember" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegulatoryExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_RegulatoryExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_RegulatoryExpensesMember" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable">
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" xlink:href="sprcy-20230630.xsd#sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" xlink:href="sprcy-20230630.xsd#sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" xlink:to="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" xlink:to="ifrs-full_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CommunicationAndNetworkEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_CommunicationAndNetworkEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_ComputerEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OfficeEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OfficeEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseholdImprovementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_LeaseholdImprovementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" xlink:href="sprcy-20230630.xsd#sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" xlink:to="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" xlink:href="sprcy-20230630.xsd#sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" xlink:to="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" xlink:to="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeaseholdImprovements" xlink:href="sprcy-20230630.xsd#sprcy_LeaseholdImprovements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" xlink:to="sprcy_LeaseholdImprovements" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofCashTable">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfCashAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfCashAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashForImmediateWithdrawal" xlink:href="sprcy-20230630.xsd#sprcy_CashForImmediateWithdrawal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfCashAbstract" xlink:to="sprcy_CashForImmediateWithdrawal" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashForImmediateWithdrawalInNIS" xlink:href="sprcy-20230630.xsd#sprcy_CashForImmediateWithdrawalInNIS"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfCashAbstract" xlink:to="sprcy_CashForImmediateWithdrawalInNIS" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOnHand" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOnHand"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfCashAbstract" xlink:to="ifrs-full_CashOnHand" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofInventoryTable">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfInventoryAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfInventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInventoriesInTransit" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentInventoriesInTransit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfInventoryAbstract" xlink:to="ifrs-full_CurrentInventoriesInTransit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfInventoryAbstract" xlink:to="ifrs-full_FinishedGoods" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InventoriesNet" xlink:href="sprcy-20230630.xsd#sprcy_InventoriesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfInventoryAbstract" xlink:to="sprcy_InventoriesNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofOtherAccountsReceivableTable">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfOtherAccountsReceivableAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfOtherAccountsReceivableAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ValueAddedTaxReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ValueAddedTaxReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfOtherAccountsReceivableAbstract" xlink:to="ifrs-full_ValueAddedTaxReceivables" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfOtherAccountsReceivableAbstract" xlink:to="ifrs-full_OtherReceivables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfOtherAccountsReceivableAbstract" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfOtherAccountsReceivableAbstract" xlink:to="ifrs-full_OtherCurrentReceivables" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable0">
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentLineItems" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentTable" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentLineItems" xlink:to="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentTable" xlink:to="ifrs-full_SegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentLineItems" xlink:to="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentDate" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentLineItems" xlink:to="sprcy_InvestmentDate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityLossesFromInvestment" xlink:href="sprcy-20230630.xsd#sprcy_EquityLossesFromInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentLineItems" xlink:to="sprcy_EquityLossesFromInvestment" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable">
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems" xlink:href="sprcy-20230630.xsd#sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable" xlink:href="sprcy-20230630.xsd#sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems" xlink:to="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OfficeEquipmentsMember" xlink:href="sprcy-20230630.xsd#sprcy_OfficeEquipmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="sprcy_OfficeEquipmentsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseholdImprovementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_LeaseholdImprovementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MotorVehiclesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MotorVehiclesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_MotorVehiclesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CostAbstract" xlink:href="sprcy-20230630.xsd#sprcy_CostAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems" xlink:to="sprcy_CostAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_BeginningBalanceCost" xlink:href="sprcy-20230630.xsd#sprcy_BeginningBalanceCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_CostAbstract" xlink:to="sprcy_BeginningBalanceCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasesOfCost" xlink:href="sprcy-20230630.xsd#sprcy_PurchasesOfCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_CostAbstract" xlink:to="sprcy_PurchasesOfCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NewLeases" xlink:href="sprcy-20230630.xsd#sprcy_NewLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_CostAbstract" xlink:to="sprcy_NewLeases" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_CostAbstract" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccumulatedDepreciationAbstract" xlink:href="sprcy-20230630.xsd#sprcy_AccumulatedDepreciationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems" xlink:to="sprcy_AccumulatedDepreciationAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyPlantAndEquipmentCost" xlink:href="sprcy-20230630.xsd#sprcy_PropertyPlantAndEquipmentCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AccumulatedDepreciationAbstract" xlink:to="sprcy_PropertyPlantAndEquipmentCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AccumulatedDepreciationAbstract" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AccumulatedDepreciationAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccumulatedDepreciationAbstract0" xlink:href="sprcy-20230630.xsd#sprcy_AccumulatedDepreciationAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems" xlink:to="sprcy_AccumulatedDepreciationAbstract0" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccumulatedTerminationOfLeases" xlink:href="sprcy-20230630.xsd#sprcy_AccumulatedTerminationOfLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AccumulatedDepreciationAbstract0" xlink:to="sprcy_AccumulatedTerminationOfLeases" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable0">
    <loc xlink:type="locator" xlink:label="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" xlink:href="sprcy-20230630.xsd#sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable" xlink:href="sprcy-20230630.xsd#sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" xlink:to="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable" xlink:to="ifrs-full_SegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseofAssets" xlink:href="sprcy-20230630.xsd#sprcy_PurchaseofAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" xlink:to="sprcy_PurchaseofAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" xlink:to="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofTradePayablesTable">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfTradePayablesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfTradePayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccruedExpenses" xlink:href="sprcy-20230630.xsd#sprcy_AccruedExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfTradePayablesAbstract" xlink:to="sprcy_AccruedExpenses" order="0" xbrldt:closed="true"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2w4dODRyrf2cKq4MnlNojKY2vawGlGpB5CaguD0HWK7+MXGfIzhA2ezfWaTq7hAnt683nzSc747v3s9ubzeRZw15+aEvNutYTqGoMIIBc15Xh4havgCm8tZwPw/j0J+4eA+o3NQTlVdg=] CSR-->
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfTradePayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfTradePayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofOtherAccountsPayableTable">
    <loc xlink:type="locator" xlink:label="sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableLineItems" xlink:href="sprcy-20230630.xsd#sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableTable" xlink:href="sprcy-20230630.xsd#sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableLineItems" xlink:to="sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableTable" xlink:to="ifrs-full_SegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableLineItems" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Accruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Accruals"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableLineItems" xlink:to="ifrs-full_Accruals" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableLineItems" xlink:to="ifrs-full_OtherPayables" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_TradeAndOtherPayable" xlink:href="sprcy-20230630.xsd#sprcy_TradeAndOtherPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableLineItems" xlink:to="sprcy_TradeAndOtherPayable" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestrictedCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_RestrictedCashAndCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_GovernmentAuthorities" xlink:href="sprcy-20230630.xsd#sprcy_GovernmentAuthorities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="sprcy_GovernmentAuthorities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_OtherReceivables" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentsInFinancialAssets" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentsInFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="sprcy_InvestmentsInFinancialAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialAssetsAtAmortisedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentFinancialAssetsAtAmortisedCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CurrentFinancialAssetsAtAmortisedCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CreditsFromOthers" xlink:href="sprcy-20230630.xsd#sprcy_CreditsFromOthers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="sprcy_CreditsFromOthers" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsLiability" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="sprcy_WarrantsLiability" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilities" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DividendYield" xlink:href="sprcy-20230630.xsd#sprcy_DividendYield"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract" xlink:to="sprcy_DividendYield" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExpectedVolatility" xlink:href="sprcy-20230630.xsd#sprcy_ExpectedVolatility"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract" xlink:to="sprcy_ExpectedVolatility" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RiskFreeInterestRate" xlink:href="sprcy-20230630.xsd#sprcy_RiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract" xlink:to="sprcy_RiskFreeInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnderlyingAdsPrice" xlink:href="sprcy-20230630.xsd#sprcy_UnderlyingAdsPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract" xlink:to="sprcy_UnderlyingAdsPrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExercisePricePerShare" xlink:href="sprcy-20230630.xsd#sprcy_ExercisePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract" xlink:to="sprcy_ExercisePricePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsFairValueinDollarsPerShares" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsFairValueinDollarsPerShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract" xlink:to="sprcy_WarrantsFairValueinDollarsPerShares" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofDefinedContributionPlansTable">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfDefinedContributionPlansAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfDefinedContributionPlansAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfDefinedContributionPlansAbstract" xlink:to="ifrs-full_EmployeeBenefitsExpense" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofShareCapitalTable0">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfShareCapitalAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfSharesAbstract0" xlink:href="sprcy-20230630.xsd#sprcy_NumberOfSharesAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfShareCapitalAbstract" xlink:to="sprcy_NumberOfSharesAbstract0" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_NumberOfSharesAbstract0" xlink:to="ifrs-full_NumberOfSharesAuthorised" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_NumberOfSharesAbstract0" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable0">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="ifrs-full_NumberOfSharesIssued" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExerciseOfPrefundedWarrantsOne" xlink:href="sprcy-20230630.xsd#sprcy_ExerciseOfPrefundedWarrantsOne"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="sprcy_ExerciseOfPrefundedWarrantsOne" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExerciseOfPrefundedWarrants" xlink:href="sprcy-20230630.xsd#sprcy_ExerciseOfPrefundedWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="sprcy_ExerciseOfPrefundedWarrants" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareIssuedToAConsultant" xlink:href="sprcy-20230630.xsd#sprcy_ShareIssuedToAConsultant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="sprcy_ShareIssuedToAConsultant" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnderlyingOrdinarySharePrice" xlink:href="sprcy-20230630.xsd#sprcy_UnderlyingOrdinarySharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="sprcy_UnderlyingOrdinarySharePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExercisePrice" xlink:href="sprcy-20230630.xsd#sprcy_ExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="sprcy_ExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsFairValueinDollarsPerShare" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsFairValueinDollarsPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="sprcy_WarrantsFairValueinDollarsPerShare" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndDevelopmentExpenses01" xlink:href="sprcy-20230630.xsd#sprcy_ResearchAndDevelopmentExpenses01"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:to="sprcy_ResearchAndDevelopmentExpenses01" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_GeneralAndAdministrativeExpenses" xlink:href="sprcy-20230630.xsd#sprcy_GeneralAndAdministrativeExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:to="sprcy_GeneralAndAdministrativeExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExpensesDueToSharebasedCompensation" xlink:href="sprcy-20230630.xsd#sprcy_ExpensesDueToSharebasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:to="sprcy_ExpensesDueToSharebasedCompensation" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" xlink:href="sprcy-20230630.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" xlink:href="sprcy-20230630.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" xlink:href="sprcy-20230630.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" xlink:href="sprcy-20230630.xsd#sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnderlyingOrdinarySharePrices" xlink:href="sprcy-20230630.xsd#sprcy_UnderlyingOrdinarySharePrices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="sprcy_UnderlyingOrdinarySharePrices" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_a2022Abstract" xlink:href="sprcy-20230630.xsd#sprcy_a2022Abstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="sprcy_a2022Abstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfOutstandingShareOption" xlink:href="sprcy-20230630.xsd#sprcy_NumberOfOutstandingShareOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_a2022Abstract" xlink:to="sprcy_NumberOfOutstandingShareOption" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement" xlink:href="sprcy-20230630.xsd#sprcy_WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_a2022Abstract" xlink:to="sprcy_WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfShareOptionGranted" xlink:href="sprcy-20230630.xsd#sprcy_NumberOfShareOptionGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_a2022Abstract" xlink:to="sprcy_NumberOfShareOptionGranted" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement" xlink:href="sprcy-20230630.xsd#sprcy_WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_a2022Abstract" xlink:to="sprcy_WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement" xlink:href="sprcy-20230630.xsd#sprcy_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_a2022Abstract" xlink:to="sprcy_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WeightedAverageExercisePriceOfShareOptionForfeitedInSharebasedPaymentArrangement" xlink:href="sprcy-20230630.xsd#sprcy_WeightedAverageExercisePriceOfShareOptionForfeitedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_a2022Abstract" xlink:to="sprcy_WeightedAverageExercisePriceOfShareOptionForfeitedInSharebasedPaymentArrangement" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareadsOptionsExpiredDuringYear" xlink:href="sprcy-20230630.xsd#sprcy_ShareadsOptionsExpiredDuringYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_a2022Abstract" xlink:to="sprcy_ShareadsOptionsExpiredDuringYear" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareadsOptionsExpiredDuringYearWeightedAverageExercisePrice" xlink:href="sprcy-20230630.xsd#sprcy_ShareadsOptionsExpiredDuringYearWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_a2022Abstract" xlink:to="sprcy_ShareadsOptionsExpiredDuringYearWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfShareOptionsShareOptionsExercisableAtTheEndOfTheYear" xlink:href="sprcy-20230630.xsd#sprcy_NumberOfShareOptionsShareOptionsExercisableAtTheEndOfTheYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_a2022Abstract" xlink:to="sprcy_NumberOfShareOptionsShareOptionsExercisableAtTheEndOfTheYear" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_a2022Abstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofRevenuesandCostofRevenuesTable">
    <loc xlink:type="locator" xlink:label="sprcy_RevenuesAndCostOfRevenuesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_RevenuesAndCostOfRevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_RevenuesAndCostOfRevenuesAbstract" xlink:to="ifrs-full_Revenue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_RevenuesAndCostOfRevenuesAbstract" xlink:to="ifrs-full_CostOfSales" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_RevenuesAndCostOfRevenuesAbstract" xlink:to="ifrs-full_GrossProfit" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0">
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:href="sprcy-20230630.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable" xlink:href="sprcy-20230630.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:to="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsAxis" xlink:href="sprcy-20230630.xsd#sprcy_IncomeStatementsLocationsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable" xlink:to="sprcy_IncomeStatementsLocationsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsDomainDomain" xlink:href="sprcy-20230630.xsd#sprcy_IncomeStatementsLocationsDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="sprcy_IncomeStatementsLocationsAxis" xlink:to="sprcy_IncomeStatementsLocationsDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsDomainDomain_0" xlink:href="sprcy-20230630.xsd#sprcy_IncomeStatementsLocationsDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="sprcy_IncomeStatementsLocationsAxis" xlink:to="sprcy_IncomeStatementsLocationsDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WagesAndRelatedExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_WagesAndRelatedExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_WagesAndRelatedExpensesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentMember" xlink:href="sprcy-20230630.xsd#sprcy_ShareBasedPaymentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ShareBasedPaymentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegulatoryAndOtherExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_RegulatoryAndOtherExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_RegulatoryAndOtherExpensesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndPreclinicalStudiesMember" xlink:href="sprcy-20230630.xsd#sprcy_ResearchAndPreclinicalStudiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ResearchAndPreclinicalStudiesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ClinicalStudiesMember" xlink:href="sprcy-20230630.xsd#sprcy_ClinicalStudiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ClinicalStudiesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ChemistryAndFormulationsMember" xlink:href="sprcy-20230630.xsd#sprcy_ChemistryAndFormulationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ChemistryAndFormulationsMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ProfessionalAndDirectorsFeesMember" xlink:href="sprcy-20230630.xsd#sprcy_ProfessionalAndDirectorsFeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ProfessionalAndDirectorsFeesMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_BusinessDevelopmentExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_BusinessDevelopmentExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_BusinessDevelopmentExpensesMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegulatoryExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_RegulatoryExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_RegulatoryExpensesMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OfficeMaintenanceRentAndOtherExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_OfficeMaintenanceRentAndOtherExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_OfficeMaintenanceRentAndOtherExpensesMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WellutionOperatingExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_WellutionOperatingExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_WellutionOperatingExpensesMember" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestorRelationsAndBusinessExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_InvestorRelationsAndBusinessExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_InvestorRelationsAndBusinessExpensesMember" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ImpairmentOfInvestmentInAssociateMember" xlink:href="sprcy-20230630.xsd#sprcy_ImpairmentOfInvestmentInAssociateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ImpairmentOfInvestmentInAssociateMember" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_GroupsShareOfLossesOfCompanyAccountedForAtEquityNetMember" xlink:href="sprcy-20230630.xsd#sprcy_GroupsShareOfLossesOfCompanyAccountedForAtEquityNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_GroupsShareOfLossesOfCompanyAccountedForAtEquityNetMember" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AResearchAndDevelopmentExpensesAbstract0" xlink:href="sprcy-20230630.xsd#sprcy_AResearchAndDevelopmentExpensesAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:to="sprcy_AResearchAndDevelopmentExpensesAbstract0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndDevelopmentExpenses1" xlink:href="sprcy-20230630.xsd#sprcy_ResearchAndDevelopmentExpenses1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AResearchAndDevelopmentExpensesAbstract0" xlink:to="sprcy_ResearchAndDevelopmentExpenses1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_BGeneralAndAdministrativeExpensesAbstract0" xlink:href="sprcy-20230630.xsd#sprcy_BGeneralAndAdministrativeExpensesAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:to="sprcy_BGeneralAndAdministrativeExpensesAbstract0" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_BGeneralAndAdministrativeExpensesAbstract0" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_COtherExpensesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_COtherExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:to="sprcy_COtherExpensesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherOperatingIncomeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_COtherExpensesAbstract" xlink:to="ifrs-full_OtherOperatingIncomeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinanceIncomeAbstract" xlink:href="sprcy-20230630.xsd#sprcy_FinanceIncomeAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:to="sprcy_FinanceIncomeAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinanceIncomeFromConvertibleLoan" xlink:href="sprcy-20230630.xsd#sprcy_FinanceIncomeFromConvertibleLoan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinanceIncomeAbstract" xlink:to="sprcy_FinanceIncomeFromConvertibleLoan" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinanceIncomeAbstract" xlink:to="ifrs-full_FinanceIncomeCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinanceExpensesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_FinanceExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:to="sprcy_FinanceExpensesAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssueExpensesRelatedToIssuanceOfWarrants" xlink:href="sprcy-20230630.xsd#sprcy_IssueExpensesRelatedToIssuanceOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinanceExpensesAbstract" xlink:to="sprcy_IssueExpensesRelatedToIssuanceOfWarrants" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinanceExpensesFromExchangeRateDifferences" xlink:href="sprcy-20230630.xsd#sprcy_FinanceExpensesFromExchangeRateDifferences"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinanceExpensesAbstract" xlink:to="sprcy_FinanceExpensesFromExchangeRateDifferences" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinanceExpensesAbstract" xlink:to="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InterestExpenseInRespectOfLeases" xlink:href="sprcy-20230630.xsd#sprcy_InterestExpenseInRespectOfLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinanceExpensesAbstract" xlink:to="sprcy_InterestExpenseInRespectOfLeases" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinanceExpensesFromInterestAndCommissions" xlink:href="sprcy-20230630.xsd#sprcy_FinanceExpensesFromInterestAndCommissions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinanceExpensesAbstract" xlink:to="sprcy_FinanceExpensesFromInterestAndCommissions" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InsuranceFinanceIncomeExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InsuranceFinanceIncomeExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinanceExpensesAbstract" xlink:to="ifrs-full_InsuranceFinanceIncomeExpenses" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable">
    <loc xlink:type="locator" xlink:label="sprcy_LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareLineItems" xlink:href="sprcy-20230630.xsd#sprcy_LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" xlink:href="sprcy-20230630.xsd#sprcy_LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareLineItems" xlink:to="sprcy_LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfOrdinarySharesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" xlink:to="ifrs-full_ClassesOfOrdinarySharesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_OrdinarySharesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" xlink:to="ifrs-full_ContinuingAndDiscontinuedOperationsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ContinuingOperationsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContinuingOperationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:to="ifrs-full_ContinuingOperationsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ContinuingOperationsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContinuingOperationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:to="ifrs-full_ContinuingOperationsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ADSMember" xlink:href="sprcy-20230630.xsd#sprcy_ADSMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="sprcy_ADSMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinaryShareMember" xlink:href="sprcy-20230630.xsd#sprcy_OrdinaryShareMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="sprcy_OrdinaryShareMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DiscontinuedOperationsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DiscontinuedOperationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ContinuingOperationsMember" xlink:to="ifrs-full_DiscontinuedOperationsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ContinuingOperationsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ContinuingOperationsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareLineItems" xlink:to="sprcy_ContinuingOperationsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareLineItems" xlink:to="ifrs-full_WeightedAverageShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareLineItems" xlink:to="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofOperatingSegmentsTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsDetailsScheduleofOperatingSegmentsTable" xlink:href="sprcy-20230630.xsd#sprcy_OperatingSegmentsDetailsScheduleofOperatingSegmentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="sprcy_OperatingSegmentsDetailsScheduleofOperatingSegmentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_OperatingSegmentsDetailsScheduleofOperatingSegmentsTable" xlink:to="ifrs-full_SegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DrugDevelopmentMember" xlink:href="sprcy-20230630.xsd#sprcy_DrugDevelopmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SegmentsMember" xlink:to="sprcy_DrugDevelopmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OnlineSalesMember" xlink:href="sprcy-20230630.xsd#sprcy_OnlineSalesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SegmentsMember" xlink:to="sprcy_OnlineSalesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SegmentReportingRevenueAbstract" xlink:href="sprcy-20230630.xsd#sprcy_SegmentReportingRevenueAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="sprcy_SegmentReportingRevenueAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExternalRevenues" xlink:href="sprcy-20230630.xsd#sprcy_ExternalRevenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SegmentReportingRevenueAbstract" xlink:to="sprcy_ExternalRevenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_Intersegment" xlink:href="sprcy-20230630.xsd#sprcy_Intersegment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SegmentReportingRevenueAbstract" xlink:to="sprcy_Intersegment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromSaleOfGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SegmentReportingRevenueAbstract" xlink:to="ifrs-full_RevenueFromSaleOfGoods" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:href="sprcy-20230630.xsd#sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestRevenueExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRevenueExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_InterestRevenueExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_TaxExpense" xlink:href="sprcy-20230630.xsd#sprcy_TaxExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="sprcy_TaxExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_ProfitLoss" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_OtherAssets" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_OtherLiabilities" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable">
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" xlink:href="sprcy-20230630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_OtherRelatedPartiesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems" xlink:to="ifrs-full_CurrentLiabilities" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndDevelopmentExpenses" xlink:href="sprcy-20230630.xsd#sprcy_ResearchAndDevelopmentExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:to="sprcy_ResearchAndDevelopmentExpenses" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:label="sprcy_GeneralDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_GeneralDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_GeneralDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_GeneralDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_GeneralDetailsLineItems" xlink:to="sprcy_GeneralDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_GeneralDetailsLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnNetMonetaryPosition" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnNetMonetaryPosition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_GeneralDetailsLineItems" xlink:to="ifrs-full_GainsLossesOnNetMonetaryPosition" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_GeneralDetailsLineItems" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RetainedEarning" xlink:href="sprcy-20230630.xsd#sprcy_RetainedEarning"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_GeneralDetailsLineItems" xlink:to="sprcy_RetainedEarning" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ProceedsFromIssuanceIPO" xlink:href="sprcy-20230630.xsd#sprcy_ProceedsFromIssuanceIPO"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_GeneralDetailsLineItems" xlink:to="sprcy_ProceedsFromIssuanceIPO" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/SignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="sprcy_AccountingPolicyAbstract" xlink:href="sprcy-20230630.xsd#sprcy_AccountingPolicyAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingTerm" xlink:href="sprcy-20230630.xsd#sprcy_OperatingTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AccountingPolicyAbstract" xlink:to="sprcy_OperatingTerm" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/InvestmentinAssociateDetails">
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociateDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociateDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociateDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociateDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_InvestmentinAssociateDetailsLineItems" xlink:to="sprcy_InvestmentinAssociateDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinAssociateDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinAssociateDetailsTable" xlink:to="ifrs-full_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MitoCareXBioLtdMember" xlink:href="sprcy-20230630.xsd#sprcy_MitoCareXBioLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="sprcy_MitoCareXBioLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MitoCareXMember" xlink:href="sprcy-20230630.xsd#sprcy_MitoCareXMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="sprcy_MitoCareXMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestedInitialAmount" xlink:href="sprcy-20230630.xsd#sprcy_InvestedInitialAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociateDetailsLineItems" xlink:to="sprcy_InvestedInitialAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalAgreedInvest" xlink:href="sprcy-20230630.xsd#sprcy_AdditionalAgreedInvest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociateDetailsLineItems" xlink:to="sprcy_AdditionalAgreedInvest" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OwnershipAgreement" xlink:href="sprcy-20230630.xsd#sprcy_OwnershipAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociateDetailsLineItems" xlink:to="sprcy_OwnershipAgreement" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InitialInvestment" xlink:href="sprcy-20230630.xsd#sprcy_InitialInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociateDetailsLineItems" xlink:to="sprcy_InitialInvestment" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OutstandingSharesPercentage" xlink:href="sprcy-20230630.xsd#sprcy_OutstandingSharesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociateDetailsLineItems" xlink:to="sprcy_OutstandingSharesPercentage" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalProvisionsOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalProvisionsOtherProvisions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociateDetailsLineItems" xlink:to="ifrs-full_AdditionalProvisionsOtherProvisions" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociateDetailsLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityLossesInvestment" xlink:href="sprcy-20230630.xsd#sprcy_EquityLossesInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociateDetailsLineItems" xlink:to="sprcy_EquityLossesInvestment" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/IntangibleAssetDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashPayment" xlink:href="sprcy-20230630.xsd#sprcy_CashPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_CashPayment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseCosts" xlink:href="sprcy-20230630.xsd#sprcy_PurchaseCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_PurchaseCosts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsToPurchase" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsToPurchase"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_WarrantsToPurchase" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExercisePrice1" xlink:href="sprcy-20230630.xsd#sprcy_ExercisePrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_ExercisePrice1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExercisePeriod" xlink:href="sprcy-20230630.xsd#sprcy_ExercisePeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_ExercisePeriod" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PricePerShare" xlink:href="sprcy-20230630.xsd#sprcy_PricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_PricePerShare" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AmountTotal" xlink:href="sprcy-20230630.xsd#sprcy_AmountTotal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_AmountTotal" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_pricePerShare" xlink:href="sprcy-20230630.xsd#sprcy_pricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_pricePerShare" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/InvestmentinFinancialAssetsDetails">
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinFinancialAssetsDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinFinancialAssetsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinFinancialAssetsDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinFinancialAssetsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_InvestmentinFinancialAssetsDetailsLineItems" xlink:to="sprcy_InvestmentinFinancialAssetsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinFinancialAssetsDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_OrdinarySharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AutoMaxSharesMember" xlink:href="sprcy-20230630.xsd#sprcy_AutoMaxSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="sprcy_AutoMaxSharesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinFinancialAssetsDetailsLineItems" xlink:to="ifrs-full_Cash" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinFinancialAssetsDetailsLineItems" xlink:to="ifrs-full_ParValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExerciseOfPricePerShare" xlink:href="sprcy-20230630.xsd#sprcy_ExerciseOfPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinFinancialAssetsDetailsLineItems" xlink:to="sprcy_ExerciseOfPricePerShare" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinFinancialAssetsDetailsLineItems" xlink:to="ifrs-full_OtherComprehensiveIncome" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentAmount" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinFinancialAssetsDetailsLineItems" xlink:to="sprcy_InvestmentAmount" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedButNotFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedButNotFullyPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinFinancialAssetsDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedButNotFullyPaid" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareCapitalPercentage" xlink:href="sprcy-20230630.xsd#sprcy_ShareCapitalPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinFinancialAssetsDetailsLineItems" xlink:to="sprcy_ShareCapitalPercentage" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SharePricePerShare" xlink:href="sprcy-20230630.xsd#sprcy_SharePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinFinancialAssetsDetailsLineItems" xlink:to="sprcy_SharePricePerShare" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ComprehensiveLoss" xlink:href="sprcy-20230630.xsd#sprcy_ComprehensiveLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinFinancialAssetsDetailsLineItems" xlink:to="sprcy_ComprehensiveLoss" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_CooperationAgreementWithClearmindAmount" xlink:href="sprcy-20230630.xsd#sprcy_CooperationAgreementWithClearmindAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:to="sprcy_CooperationAgreementWithClearmindAmount" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_BalanceOwedToClearmind" xlink:href="sprcy-20230630.xsd#sprcy_BalanceOwedToClearmind"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:to="sprcy_BalanceOwedToClearmind" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestedAmount" xlink:href="sprcy-20230630.xsd#sprcy_InvestedAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:to="sprcy_InvestedAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExchangeCommonShares" xlink:href="sprcy-20230630.xsd#sprcy_ExchangeCommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:to="sprcy_ExchangeCommonShares" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ClearmindOutstandingShareCapitalPercentage" xlink:href="sprcy-20230630.xsd#sprcy_ClearmindOutstandingShareCapitalPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:to="sprcy_ClearmindOutstandingShareCapitalPercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestedAmountInClearmind" xlink:href="sprcy-20230630.xsd#sprcy_InvestedAmountInClearmind"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:to="sprcy_InvestedAmountInClearmind" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExchangeCommonSharesOfClearmind" xlink:href="sprcy-20230630.xsd#sprcy_ExchangeCommonSharesOfClearmind"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:to="sprcy_ExchangeCommonSharesOfClearmind" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/FinancialInstrumentsDetails">
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_FinancialInstrumentsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_FinancialInstrumentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_FinancialInstrumentsDetailsLineItems" xlink:to="sprcy_FinancialInstrumentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_FinancialInstrumentsDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_FinancialInstrumentsDetailsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ADSsMember" xlink:href="sprcy-20230630.xsd#sprcy_ADSsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="sprcy_ADSsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PrivatePlacementsMember" xlink:href="sprcy-20230630.xsd#sprcy_PrivatePlacementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="sprcy_PrivatePlacementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_BridgeLoanAmount" xlink:href="sprcy-20230630.xsd#sprcy_BridgeLoanAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsDetailsLineItems" xlink:to="sprcy_BridgeLoanAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsDetailsLineItems" xlink:to="ifrs-full_InterestPayable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateAmountOrCreditAmount" xlink:href="sprcy-20230630.xsd#sprcy_AggregateAmountOrCreditAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsDetailsLineItems" xlink:to="sprcy_AggregateAmountOrCreditAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CreditFacilityAmount" xlink:href="sprcy-20230630.xsd#sprcy_CreditFacilityAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsDetailsLineItems" xlink:to="sprcy_CreditFacilityAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CreditFacilityAndRemainingAvailableDrawnAmount" xlink:href="sprcy-20230630.xsd#sprcy_CreditFacilityAndRemainingAvailableDrawnAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsDetailsLineItems" xlink:to="sprcy_CreditFacilityAndRemainingAvailableDrawnAmount" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_LoanAmountDueTerm" xlink:href="sprcy-20230630.xsd#sprcy_LoanAmountDueTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsDetailsLineItems" xlink:to="sprcy_LoanAmountDueTerm" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_LoanAmountRaised" xlink:href="sprcy-20230630.xsd#sprcy_LoanAmountRaised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsDetailsLineItems" xlink:to="sprcy_LoanAmountRaised" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCompoundFinancialInstrumentsWithMultipleEmbeddedDerivativesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCompoundFinancialInstrumentsWithMultipleEmbeddedDerivativesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsDetailsLineItems" xlink:to="ifrs-full_DisclosureOfCompoundFinancialInstrumentsWithMultipleEmbeddedDerivativesExplanatory" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOutflowForLeases" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOutflowForLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsDetailsLineItems" xlink:to="ifrs-full_CashOutflowForLeases" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsDetailsLineItems" xlink:to="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasePrice" xlink:href="sprcy-20230630.xsd#sprcy_PurchasePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsDetailsLineItems" xlink:to="sprcy_PurchasePrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MaturityDate" xlink:href="sprcy-20230630.xsd#sprcy_MaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsDetailsLineItems" xlink:to="sprcy_MaturityDate" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsDetailsLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InitialConversionPrice" xlink:href="sprcy-20230630.xsd#sprcy_InitialConversionPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsDetailsLineItems" xlink:to="sprcy_InitialConversionPrice" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ConversionPrice" xlink:href="sprcy-20230630.xsd#sprcy_ConversionPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsDetailsLineItems" xlink:to="sprcy_ConversionPrice" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinaryShareExercisePrice" xlink:href="sprcy-20230630.xsd#sprcy_OrdinaryShareExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsDetailsLineItems" xlink:to="sprcy_OrdinaryShareExercisePrice" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/WarrantsDetails">
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_WarrantsDetailsLineItems" xlink:to="sprcy_WarrantsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_WarrantsDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_WarrantsDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AntidilutiveInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AntidilutiveInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_AntidilutiveInstrumentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AntidilutiveInstrumentsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AntidilutiveInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_AntidilutiveInstrumentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_WarrantsMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AntidilutiveInstrumentsMember" xlink:to="ifrs-full_WarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_GrossProceed" xlink:href="sprcy-20230630.xsd#sprcy_GrossProceed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WarrantsDetailsLineItems" xlink:to="sprcy_GrossProceed" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfAggregateShares" xlink:href="sprcy-20230630.xsd#sprcy_IssuanceOfAggregateShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WarrantsDetailsLineItems" xlink:to="sprcy_IssuanceOfAggregateShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsDescription" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WarrantsDetailsLineItems" xlink:to="sprcy_WarrantsDescription" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExerciseOfPricePerShare" xlink:href="sprcy-20230630.xsd#sprcy_ExerciseOfPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WarrantsDetailsLineItems" xlink:to="sprcy_ExerciseOfPricePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantExpiryPeriod" xlink:href="sprcy-20230630.xsd#sprcy_WarrantExpiryPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WarrantsDetailsLineItems" xlink:to="sprcy_WarrantExpiryPeriod" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantReserve" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantReserve"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WarrantsDetailsLineItems" xlink:to="ifrs-full_WarrantReserve" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PlanAssetsAtFairValue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PlanAssetsAtFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WarrantsDetailsLineItems" xlink:to="ifrs-full_PlanAssetsAtFairValue" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/EquityDetails">
    <loc xlink:type="locator" xlink:label="sprcy_EquityDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_EquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_EquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_EquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EquityDetailsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EquityDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EquityDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AntidilutiveInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AntidilutiveInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_AntidilutiveInstrumentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AntidilutiveInstrumentsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AntidilutiveInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_AntidilutiveInstrumentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EquityDetailsTable" xlink:to="ifrs-full_RangeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EquityDetailsTable" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysOwnEquityInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysOwnEquityInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="ifrs-full_EntitysOwnEquityInstrumentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysOwnEquityInstrumentsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysOwnEquityInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="ifrs-full_EntitysOwnEquityInstrumentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfOrdinarySharesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EquityDetailsTable" xlink:to="ifrs-full_ClassesOfOrdinarySharesAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_OrdinarySharesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreationDateAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CreationDateAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EquityDetailsTable" xlink:to="ifrs-full_CreationDateAxis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ifrs-full_DefaultFinancialStatementsDateMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ifrs-full_DefaultFinancialStatementsDateMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AgreementTypeAxis" xlink:href="sprcy-20230630.xsd#sprcy_AgreementTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EquityDetailsTable" xlink:to="sprcy_AgreementTypeAxis" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AgreementTypeDomainDomain" xlink:href="sprcy-20230630.xsd#sprcy_AgreementTypeDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="sprcy_AgreementTypeAxis" xlink:to="sprcy_AgreementTypeDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AgreementTypeDomainDomain_0" xlink:href="sprcy-20230630.xsd#sprcy_AgreementTypeDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="sprcy_AgreementTypeAxis" xlink:to="sprcy_AgreementTypeDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SeriesAWarrantsMember" xlink:href="sprcy-20230630.xsd#sprcy_SeriesAWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="sprcy_SeriesAWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_June2022WarrantsMember" xlink:href="sprcy-20230630.xsd#sprcy_June2022WarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="sprcy_June2022WarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ADSMember" xlink:href="sprcy-20230630.xsd#sprcy_ADSMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="sprcy_ADSMember" order="2" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="sprcy_SeriesAWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SeriesBWarrantsMember" xlink:href="sprcy-20230630.xsd#sprcy_SeriesBWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="sprcy_SeriesBWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantReserveMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantReserveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_WarrantReserveMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AprilTwoThousandTwentyPurchaseAgreementMember" xlink:href="sprcy-20230630.xsd#sprcy_AprilTwoThousandTwentyPurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AgreementTypeDomainDomain" xlink:to="sprcy_AprilTwoThousandTwentyPurchaseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AntidilutiveInstrumentsMember" xlink:to="ifrs-full_WarrantsMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysOwnEquityInstrumentsMember" xlink:to="ifrs-full_WarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PrefundedWarrantsMember" xlink:href="sprcy-20230630.xsd#sprcy_PrefundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysOwnEquityInstrumentsMember" xlink:to="sprcy_PrefundedWarrantsMember" order="1" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_OrdinarySharesMember_0" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_March2021FinancingRoundMember" xlink:href="sprcy-20230630.xsd#sprcy_March2021FinancingRoundMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="sprcy_March2021FinancingRoundMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_June2022FinancingRoundMember" xlink:href="sprcy-20230630.xsd#sprcy_June2022FinancingRoundMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="sprcy_June2022FinancingRoundMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_November2020FinancingRoundMember" xlink:href="sprcy-20230630.xsd#sprcy_November2020FinancingRoundMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="sprcy_November2020FinancingRoundMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_StockIssuedDuringPeriodReverseStockSplits" xlink:href="sprcy-20230630.xsd#sprcy_StockIssuedDuringPeriodReverseStockSplits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_StockIssuedDuringPeriodReverseStockSplits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NoParValuePerShare" xlink:href="sprcy-20230630.xsd#sprcy_NoParValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_NoParValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfPrivateOffering" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfPrivateOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_DescriptionOfPrivateOffering" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DateOfIssuance" xlink:href="sprcy-20230630.xsd#sprcy_DateOfIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_DateOfIssuance" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsAndExercise" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsAndExercise"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_WarrantsAndExercise" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExerciseOfPrefundedWarrants" xlink:href="sprcy-20230630.xsd#sprcy_ExerciseOfPrefundedWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_ExerciseOfPrefundedWarrants" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShares" xlink:href="sprcy-20230630.xsd#sprcy_IssuanceOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_IssuanceOfShares" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfReverseShareSplit" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfReverseShareSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_DescriptionOfReverseShareSplit" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseAgreementsDescription" xlink:href="sprcy-20230630.xsd#sprcy_PurchaseAgreementsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_PurchaseAgreementsDescription" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_GrossProceeds" xlink:href="sprcy-20230630.xsd#sprcy_GrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_GrossProceeds" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfAggregateShares" xlink:href="sprcy-20230630.xsd#sprcy_IssuanceOfAggregateShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_IssuanceOfAggregateShares" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsExercisePrice" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_WarrantsExercisePrice" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails">
    <loc xlink:type="locator" xlink:label="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_SignificantEventsduringtheReportingPeriodDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CapitalPointWarrantMember" xlink:href="sprcy-20230630.xsd#sprcy_CapitalPointWarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="sprcy_CapitalPointWarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NewCoIncMember" xlink:href="sprcy-20230630.xsd#sprcy_NewCoIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="sprcy_NewCoIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_JeffsBrandsMember" xlink:href="sprcy-20230630.xsd#sprcy_JeffsBrandsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="sprcy_JeffsBrandsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InterestPercentgae" xlink:href="sprcy-20230630.xsd#sprcy_InterestPercentgae"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_InterestPercentgae" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_Cash" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DeferredCashPayments" xlink:href="sprcy-20230630.xsd#sprcy_DeferredCashPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_DeferredCashPayments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareCapitalPercentage" xlink:href="sprcy-20230630.xsd#sprcy_ShareCapitalPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_ShareCapitalPercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FeeExpenses" xlink:href="sprcy-20230630.xsd#sprcy_FeeExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_FeeExpenses" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_BonusAmountReceived" xlink:href="sprcy-20230630.xsd#sprcy_BonusAmountReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_BonusAmountReceived" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MutualShareExchangeAmount" xlink:href="sprcy-20230630.xsd#sprcy_MutualShareExchangeAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_MutualShareExchangeAmount" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesAcquired" xlink:href="sprcy-20230630.xsd#sprcy_OrdinarySharesAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_OrdinarySharesAcquired" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateValue" xlink:href="sprcy-20230630.xsd#sprcy_AggregateValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_AggregateValue" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustedAmountOfAggregateValue" xlink:href="sprcy-20230630.xsd#sprcy_AdjustedAmountOfAggregateValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_AdjustedAmountOfAggregateValue" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OwnershipPercentage" xlink:href="sprcy-20230630.xsd#sprcy_OwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_OwnershipPercentage" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsToPurchase" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsToPurchase"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_WarrantsToPurchase" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ClaimsOnDamages" xlink:href="sprcy-20230630.xsd#sprcy_ClaimsOnDamages"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_ClaimsOnDamages" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/EventsaftertheReportingPeriodDetails">
    <loc xlink:type="locator" xlink:label="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_EventsaftertheReportingPeriodDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_EventsaftertheReportingPeriodDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_EventsaftertheReportingPeriodDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_EventsaftertheReportingPeriodDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MitoCareXMember" xlink:href="sprcy-20230630.xsd#sprcy_MitoCareXMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="sprcy_MitoCareXMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_JeffsBrandsMember" xlink:href="sprcy-20230630.xsd#sprcy_JeffsBrandsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="sprcy_JeffsBrandsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MitoCareXBioLtdMember" xlink:href="sprcy-20230630.xsd#sprcy_MitoCareXBioLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="sprcy_MitoCareXBioLtdMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SCISPARCLTDMember" xlink:href="sprcy-20230630.xsd#sprcy_SCISPARCLTDMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="sprcy_SCISPARCLTDMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="sprcy_JeffsBrandsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SubsequentMember" xlink:href="sprcy-20230630.xsd#sprcy_SubsequentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="sprcy_SubsequentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfPublicOffering" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_DescriptionOfPublicOffering" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExerciseOfWarrants" xlink:href="sprcy-20230630.xsd#sprcy_ExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_ExerciseOfWarrants" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExerciseOfPrefundedWarrants" xlink:href="sprcy-20230630.xsd#sprcy_ExerciseOfPrefundedWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_ExerciseOfPrefundedWarrants" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_ParValuePerShare" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateGrossProceeds" xlink:href="sprcy-20230630.xsd#sprcy_AggregateGrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_AggregateGrossProceeds" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfAggregatePurchasePrice" xlink:href="sprcy-20230630.xsd#sprcy_PercentageOfAggregatePurchasePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_PercentageOfAggregatePurchasePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregatePurchasePrice" xlink:href="sprcy-20230630.xsd#sprcy_AggregatePurchasePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_AggregatePurchasePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasePricePerShare" xlink:href="sprcy-20230630.xsd#sprcy_PurchasePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_PurchasePricePerShare" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PrefundedOrdinaryShare" xlink:href="sprcy-20230630.xsd#sprcy_PrefundedOrdinaryShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_PrefundedOrdinaryShare" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesAcquired" xlink:href="sprcy-20230630.xsd#sprcy_OrdinarySharesAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_OrdinarySharesAcquired" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseOrdinaryShares" xlink:href="sprcy-20230630.xsd#sprcy_PurchaseOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_PurchaseOrdinaryShares" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_TermOfIssuance" xlink:href="sprcy-20230630.xsd#sprcy_TermOfIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_TermOfIssuance" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExercisePricePerShare" xlink:href="sprcy-20230630.xsd#sprcy_ExercisePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_ExercisePricePerShare" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfStockEqual" xlink:href="sprcy-20230630.xsd#sprcy_PercentageOfStockEqual"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_PercentageOfStockEqual" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_Cash" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalAgreedInvest" xlink:href="sprcy-20230630.xsd#sprcy_AdditionalAgreedInvest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_AdditionalAgreedInvest" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OwnershipAgreement" xlink:href="sprcy-20230630.xsd#sprcy_OwnershipAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_OwnershipAgreement" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfWorkingCapital" xlink:href="sprcy-20230630.xsd#sprcy_PercentageOfWorkingCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_PercentageOfWorkingCapital" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MonthlyFee" xlink:href="sprcy-20230630.xsd#sprcy_MonthlyFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_MonthlyFee" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_BonusAmount" xlink:href="sprcy-20230630.xsd#sprcy_BonusAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_BonusAmount" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_IssuedCapitalOrdinaryShares" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateValue" xlink:href="sprcy-20230630.xsd#sprcy_AggregateValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_AggregateValue" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustedAmountOfAggregateValue" xlink:href="sprcy-20230630.xsd#sprcy_AdjustedAmountOfAggregateValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_AdjustedAmountOfAggregateValue" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInJointOperation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInJointOperation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInJointOperation" order="26" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails">
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsTable" xlink:to="ifrs-full_RangeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_EveroMember" xlink:href="sprcy-20230630.xsd#sprcy_EveroMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="sprcy_EveroMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CapitalPointMember" xlink:href="sprcy-20230630.xsd#sprcy_CapitalPointMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="sprcy_CapitalPointMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MitoCareXMember" xlink:href="sprcy-20230630.xsd#sprcy_MitoCareXMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="sprcy_MitoCareXMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CapitalPointWarrantMember" xlink:href="sprcy-20230630.xsd#sprcy_CapitalPointWarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="sprcy_CapitalPointWarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SubsequentMember" xlink:href="sprcy-20230630.xsd#sprcy_SubsequentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="sprcy_SubsequentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ConversionOfOrdinaryShares" xlink:href="sprcy-20230630.xsd#sprcy_ConversionOfOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="sprcy_ConversionOfOrdinaryShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesPerValue" xlink:href="sprcy-20230630.xsd#sprcy_OrdinarySharesPerValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="sprcy_OrdinarySharesPerValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital" xlink:href="sprcy-20230630.xsd#sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairMarketValue" xlink:href="sprcy-20230630.xsd#sprcy_FairMarketValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="sprcy_FairMarketValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseOfOrdinaryShares" xlink:href="sprcy-20230630.xsd#sprcy_PurchaseOfOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="sprcy_PurchaseOfOrdinaryShares" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareholdersAmount" xlink:href="sprcy-20230630.xsd#sprcy_ShareholdersAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="sprcy_ShareholdersAmount" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuedAndOutstandingSharesPercentage" xlink:href="sprcy-20230630.xsd#sprcy_IssuedAndOutstandingSharesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="sprcy_IssuedAndOutstandingSharesPercentage" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForAmountsTransferredToInitialCarryingAmountOfHedgedItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForAmountsTransferredToInitialCarryingAmountOfHedgedItems"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="ifrs-full_AdjustmentsForAmountsTransferredToInitialCarryingAmountOfHedgedItems" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestedInitialAmounts" xlink:href="sprcy-20230630.xsd#sprcy_InvestedInitialAmounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="sprcy_InvestedInitialAmounts" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PreDeterminedValue" xlink:href="sprcy-20230630.xsd#sprcy_PreDeterminedValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="sprcy_PreDeterminedValue" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OwnershipPercentage" xlink:href="sprcy-20230630.xsd#sprcy_OwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="sprcy_OwnershipPercentage" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InitialInvestmentAmount" xlink:href="sprcy-20230630.xsd#sprcy_InitialInvestmentAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="sprcy_InitialInvestmentAmount" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStocks" xlink:href="sprcy-20230630.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStocks"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStocks" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="sprcy_LeasesDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_LeasesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeasesDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_LeasesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_LeasesDetailsLineItems" xlink:to="sprcy_LeasesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_LeasesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeaseMember" xlink:href="sprcy-20230630.xsd#sprcy_LeaseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="sprcy_LeaseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SquareMeters" xlink:href="sprcy-20230630.xsd#sprcy_SquareMeters"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_LeasesDetailsLineItems" xlink:to="sprcy_SquareMeters" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeaseFee" xlink:href="sprcy-20230630.xsd#sprcy_LeaseFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_LeasesDetailsLineItems" xlink:to="sprcy_LeaseFee" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExpireTerm" xlink:href="sprcy-20230630.xsd#sprcy_ExpireTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_LeasesDetailsLineItems" xlink:to="sprcy_ExpireTerm" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/PropertyandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_PropertyandEquipmentNetDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_PropertyandEquipmentNetDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_PropertyandEquipmentNetDetailsLineItems" xlink:to="sprcy_PropertyandEquipmentNetDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_PropertyandEquipmentNetDetailsLineItems" xlink:to="ifrs-full_DepreciationExpense" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/TaxesonIncomeDetails">
    <loc xlink:type="locator" xlink:label="sprcy_TaxesonIncomeDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_TaxesonIncomeDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_TaxesonIncomeDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_TaxesonIncomeDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_TaxesonIncomeDetailsLineItems" xlink:to="sprcy_TaxesonIncomeDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TaxesonIncomeDetailsLineItems" xlink:to="ifrs-full_ApplicableTaxRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingLossCarryforwardsTaxAmount" xlink:href="sprcy-20230630.xsd#sprcy_OperatingLossCarryforwardsTaxAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TaxesonIncomeDetailsLineItems" xlink:to="sprcy_OperatingLossCarryforwardsTaxAmount" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails">
    <loc xlink:type="locator" xlink:label="sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DekelLicenseAgreementDescription" xlink:href="sprcy-20230630.xsd#sprcy_DekelLicenseAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="sprcy_DekelLicenseAgreementDescription" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AnnualInvestment" xlink:href="sprcy-20230630.xsd#sprcy_AnnualInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="sprcy_AnnualInvestment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalMilestoneAmount" xlink:href="sprcy-20230630.xsd#sprcy_AdditionalMilestoneAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="sprcy_AdditionalMilestoneAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InstallmentAmount" xlink:href="sprcy-20230630.xsd#sprcy_InstallmentAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="sprcy_InstallmentAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_TotalAgreementEstimatingAmount" xlink:href="sprcy-20230630.xsd#sprcy_TotalAgreementEstimatingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="sprcy_TotalAgreementEstimatingAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CapitalProposedToDeposit" xlink:href="sprcy-20230630.xsd#sprcy_CapitalProposedToDeposit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="sprcy_CapitalProposedToDeposit" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ShareBasedPaymentTransactionsDetails">
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_ShareBasedPaymentTransactionsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_ShareBasedPaymentTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_ShareBasedPaymentTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsTable" xlink:to="ifrs-full_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfOrdinarySharesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsTable" xlink:to="ifrs-full_ClassesOfOrdinarySharesAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_OrdinarySharesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinaryShareMember" xlink:href="sprcy-20230630.xsd#sprcy_OrdinaryShareMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="sprcy_OrdinaryShareMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareOptionsReserved" xlink:href="sprcy-20230630.xsd#sprcy_ShareOptionsReserved"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_ShareOptionsReserved" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfSharesOptionGrantedInSharebasedPaymentArrangement" xlink:href="sprcy-20230630.xsd#sprcy_NumberOfSharesOptionGrantedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_NumberOfSharesOptionGrantedInSharebasedPaymentArrangement" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinaryShares" xlink:href="sprcy-20230630.xsd#sprcy_OrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_OrdinaryShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairValueOption" xlink:href="sprcy-20230630.xsd#sprcy_FairValueOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_FairValueOption" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_StockOptionDescription" xlink:href="sprcy-20230630.xsd#sprcy_StockOptionDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_StockOptionDescription" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairValueDescription" xlink:href="sprcy-20230630.xsd#sprcy_FairValueDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_FairValueDescription" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RSUGrantedDiscountRate" xlink:href="sprcy-20230630.xsd#sprcy_RSUGrantedDiscountRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_RSUGrantedDiscountRate" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairValueOfTheRSUsGranted" xlink:href="sprcy-20230630.xsd#sprcy_FairValueOfTheRSUsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_FairValueOfTheRSUsGranted" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesIssued" xlink:href="sprcy-20230630.xsd#sprcy_OrdinarySharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_OrdinarySharesIssued" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinaryGrantedDiscountRate" xlink:href="sprcy-20230630.xsd#sprcy_OrdinaryGrantedDiscountRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_OrdinaryGrantedDiscountRate" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption" xlink:href="sprcy-20230630.xsd#sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareOptionsOutstandingParValue" xlink:href="sprcy-20230630.xsd#sprcy_ShareOptionsOutstandingParValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_ShareOptionsOutstandingParValue" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain_0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="14" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>sprcy-20230630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Feb 27 19:06:21 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US">Current asset, total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US">Non-current asset total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US">Assets, total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US">Liabilities current, total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl0" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US">Total equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Equity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Equity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US">Total liabilities and equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_GrossProfit_lbl" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_GrossProfit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GrossProfit_lbl0" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_GrossProfit_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US">Loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US">Total comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl" xml:lang="en-US">Profit loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl0" xml:lang="en-US">Income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US">Components of equity [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl" xml:lang="en-US">Total adjustments to the profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl0" xml:lang="en-US">Cash flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents at the beginning of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents at the end of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl1" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl1"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfGeneralExplanatoryAbstract" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfGeneralExplanatoryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfGeneralExplanatoryAbstract_lbl" xml:lang="en-US">General [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfGeneralExplanatoryAbstract" xlink:to="sprcy_DisclosureOfGeneralExplanatoryAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccountingPolicyAbstract" xlink:href="sprcy-20230630.xsd#sprcy_AccountingPolicyAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AccountingPolicyAbstract_lbl" xml:lang="en-US">Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccountingPolicyAbstract" xlink:to="sprcy_AccountingPolicyAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract_lbl" xml:lang="en-US">Investment in Associate [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_NotesAndOtherExplanatoryInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome_lbl" xml:lang="en-US">Balance at January 1, 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:to="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome_lbl0" xml:lang="en-US">Balance at December 31, 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:to="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillAbstract_lbl" xml:lang="en-US">Intangible Asset [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_IntangibleAssetsAndGoodwillAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract_lbl" xml:lang="en-US">Schedule of Fair Value of the Intangible Asset [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:to="sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsAndGoodwill" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsAndGoodwill" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentInFinancialAssetsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentInFinancialAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentInFinancialAssetsAbstract_lbl" xml:lang="en-US">Investment in Financial Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentInFinancialAssetsAbstract" xlink:to="sprcy_InvestmentInFinancialAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract_lbl" xml:lang="en-US">Transactions and Balances with Related Parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:to="sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_FinancialInstrumentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinancialInstrumentsAbstract_lbl" xml:lang="en-US">Financial Instruments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinancialInstrumentsAbstract" xlink:to="sprcy_FinancialInstrumentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of Financial Assets and Financial Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_FinancialLiabilities_lbl" xml:lang="en-US">Total financial and lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialLiabilities_lbl0" xml:lang="en-US">Total financial and lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantAbstract" xlink:href="sprcy-20230630.xsd#sprcy_WarrantAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantAbstract_lbl" xml:lang="en-US">Warrants [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantAbstract" xlink:to="sprcy_WarrantAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWarrantsFairValueAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfWarrantsFairValueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfWarrantsFairValueAbstract_lbl" xml:lang="en-US">Schedule of Warrants&#8217; Fair Value [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfWarrantsFairValueAbstract" xlink:to="sprcy_ScheduleOfWarrantsFairValueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xml:lang="en-US">Types of share-based payment arrangements [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US">Equity [Absract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_lbl" xml:lang="en-US">Retrospective application and retrospective restatement [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract_lbl" xml:lang="en-US">Schedule of Issued and Outstanding Share Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfSharesIssued1" xlink:href="sprcy-20230630.xsd#sprcy_NumberOfSharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="sprcy_NumberOfSharesIssued1_lbl" xml:lang="en-US">Balance at January 1, 2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfSharesIssued1" xlink:to="sprcy_NumberOfSharesIssued1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="sprcy_NumberOfSharesIssued1_lbl0" xml:lang="en-US">Balance at June 30, 2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfSharesIssued1" xlink:to="sprcy_NumberOfSharesIssued1_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfAdditionalInformationTextBlockAbstract" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfAdditionalInformationTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfAdditionalInformationTextBlockAbstract_lbl" xml:lang="en-US">Additional Information to the Items of Profit or Loss [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfAdditionalInformationTextBlockAbstract" xlink:to="sprcy_DisclosureOfAdditionalInformationTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsAxis" xlink:href="sprcy-20230630.xsd#sprcy_IncomeStatementsLocationsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IncomeStatementsLocationsAxis_lbl" xml:lang="en-US">Income Statements Locations [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IncomeStatementsLocationsAxis" xlink:to="sprcy_IncomeStatementsLocationsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract_lbl" xml:lang="en-US">Significant Events during the Reporting Period [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract" xlink:to="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xml:lang="en-US">Events after the Reporting Period [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xml:lang="en-US">Classes of property, plant and equipment [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US">Range [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract_lbl" xml:lang="en-US">Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract" xlink:to="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAbstract_lbl" xml:lang="en-US">Cash [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAbstract" xlink:to="ifrs-full_CashAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfCashAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfCashAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfCashAbstract_lbl" xml:lang="en-US">Schedule of Cash [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfCashAbstract" xlink:to="sprcy_ScheduleOfCashAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOnHand" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOnHand"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashOnHand_lbl" xml:lang="en-US">Total cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOnHand" xlink:to="ifrs-full_CashOnHand_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InventoryAbstract" xlink:href="sprcy-20230630.xsd#sprcy_InventoryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InventoryAbstract_lbl" xml:lang="en-US">Inventory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InventoryAbstract" xlink:to="sprcy_InventoryAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfInventoryAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfInventoryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfInventoryAbstract_lbl" xml:lang="en-US">Schedule of Inventory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfInventoryAbstract" xlink:to="sprcy_ScheduleOfInventoryAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InventoriesNet" xlink:href="sprcy-20230630.xsd#sprcy_InventoriesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="sprcy_InventoriesNet_lbl" xml:lang="en-US">Total Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InventoriesNet" xlink:to="sprcy_InventoriesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract_lbl" xml:lang="en-US">Other Accounts Receivable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_TradeAndOtherReceivablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfOtherAccountsReceivableAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfOtherAccountsReceivableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfOtherAccountsReceivableAbstract_lbl" xml:lang="en-US">Schedule of Other Accounts Receivable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfOtherAccountsReceivableAbstract" xlink:to="sprcy_ScheduleOfOtherAccountsReceivableAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherCurrentReceivables_lbl" xml:lang="en-US">Other accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentReceivables_lbl0" xml:lang="en-US">Other accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_BeginningBalanceCost" xlink:href="sprcy-20230630.xsd#sprcy_BeginningBalanceCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="sprcy_BeginningBalanceCost_lbl" xml:lang="en-US">Beginning Balance , Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BeginningBalanceCost" xlink:to="sprcy_BeginningBalanceCost_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="sprcy_BeginningBalanceCost_lbl0" xml:lang="en-US">Ending Balance, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BeginningBalanceCost" xlink:to="sprcy_BeginningBalanceCost_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyPlantAndEquipmentCost" xlink:href="sprcy-20230630.xsd#sprcy_PropertyPlantAndEquipmentCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="sprcy_PropertyPlantAndEquipmentCost_lbl" xml:lang="en-US">Beginning Balance, Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PropertyPlantAndEquipmentCost" xlink:to="sprcy_PropertyPlantAndEquipmentCost_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="sprcy_PropertyPlantAndEquipmentCost_lbl0" xml:lang="en-US">Ending Balance, Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PropertyPlantAndEquipmentCost" xlink:to="sprcy_PropertyPlantAndEquipmentCost_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_TradePayablesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_TradePayablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TradePayablesAbstract_lbl" xml:lang="en-US">Trade Payables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TradePayablesAbstract" xlink:to="sprcy_TradePayablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfTradePayablesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfTradePayablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfTradePayablesAbstract_lbl" xml:lang="en-US">Schedule of Trade Payables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfTradePayablesAbstract" xlink:to="sprcy_ScheduleOfTradePayablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl0" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentAbstract" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentAbstract_lbl" xml:lang="en-US">Other Accounts Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentAbstract" xlink:to="sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract_lbl" xml:lang="en-US">Schedule of Warrants Fair Value Using Black Scholes OPM [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract" xlink:to="sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfDefinedContributionPlansAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfDefinedContributionPlansAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfDefinedContributionPlansAbstract_lbl" xml:lang="en-US">Schedule of Defined Contribution Plans [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfDefinedContributionPlansAbstract" xlink:to="sprcy_ScheduleOfDefinedContributionPlansAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TaxesOnIncomeAbstract" xlink:href="sprcy-20230630.xsd#sprcy_TaxesOnIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TaxesOnIncomeAbstract_lbl" xml:lang="en-US">Taxes on Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TaxesOnIncomeAbstract" xlink:to="sprcy_TaxesOnIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract_lbl" xml:lang="en-US">Contingent Liabilities Commitments Claims and Liens [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US">Balance at January 1, 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl0" xml:lang="en-US">Balance at December 31, 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl1" xml:lang="en-US">Shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl2" xml:lang="en-US">Shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl2"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract_lbl" xml:lang="en-US">Schedule of warrants fair value was calculated using the Black-Scholes OPM [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract_lbl" xml:lang="en-US">Share-Based Payment Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract_lbl" xml:lang="en-US">Schedule of expenses due to share-based compensation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:to="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract_lbl" xml:lang="en-US">Schedule of fair value for Share Options granted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfOutstandingShareOption" xlink:href="sprcy-20230630.xsd#sprcy_NumberOfOutstandingShareOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="sprcy_NumberOfOutstandingShareOption_lbl" xml:lang="en-US">Number of Share Options ,Share Options outstanding at the beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfOutstandingShareOption" xlink:to="sprcy_NumberOfOutstandingShareOption_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="sprcy_NumberOfOutstandingShareOption_lbl0" xml:lang="en-US">Number of Share Options, Share Options outstanding at the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfOutstandingShareOption" xlink:to="sprcy_NumberOfOutstandingShareOption_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement" xlink:href="sprcy-20230630.xsd#sprcy_WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="sprcy_WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Weighted average exercise price, Share Options outstanding at the beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement" xlink:to="sprcy_WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="sprcy_WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Weighted average exercise price, Share Options outstanding at the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement" xlink:to="sprcy_WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueAbstract_lbl" xml:lang="en-US">Revenues and Cost of Revenues [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_RevenueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RevenuesAndCostOfRevenuesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_RevenuesAndCostOfRevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RevenuesAndCostOfRevenuesAbstract_lbl" xml:lang="en-US">Schedule of Revenues and Cost of Revenues [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RevenuesAndCostOfRevenuesAbstract" xlink:to="sprcy_RevenuesAndCostOfRevenuesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareAbstract_lbl" xml:lang="en-US">Loss Per Share/Ads [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfOrdinarySharesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis_lbl" xml:lang="en-US">Classes of ordinary shares [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_ClassesOfOrdinarySharesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ContinuingAndDiscontinuedOperationsAxis_lbl" xml:lang="en-US">Continuing and discontinued operations [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:to="ifrs-full_ContinuingAndDiscontinuedOperationsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl" xml:lang="en-US">Operating Segments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SegmentsAxis_lbl" xml:lang="en-US">Segments [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule of Balances with Related Parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:to="sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US">Categories of related parties [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule of Transactions with Related Parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:to="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract_lbl" xml:lang="en-US">Schedule of benefits to key management personnel [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:to="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract" xlink:to="sprcy_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl" xml:lang="en-US">Restricted deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentTradeReceivables_lbl" xml:lang="en-US">Trade receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTradeReceivables" xlink:to="ifrs-full_CurrentTradeReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Inventories_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract0" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract0" xlink:to="sprcy_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract1" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract1" xlink:to="sprcy_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Intangible asset, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentsInAssociates" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInAssociates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InvestmentsInAssociates_lbl" xml:lang="en-US">Investment in company account for at equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentsInAssociates" xlink:to="ifrs-full_InvestmentsInAssociates_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets_lbl" xml:lang="en-US">Investments in financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentFinancialAssets" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract2" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract2" xlink:to="sprcy_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract3" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract3" xlink:to="sprcy_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US">LIABILITIES AND EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract4" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract4" xlink:to="sprcy_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US">Other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentWarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentWarrantLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentWarrantLiability_lbl" xml:lang="en-US">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentWarrantLiability" xlink:to="ifrs-full_CurrentWarrantLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract5" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract5" xlink:to="sprcy_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract6" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract6" xlink:to="sprcy_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract7" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract7" xlink:to="sprcy_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:href="sprcy-20230630.xsd#sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract_lbl" xml:lang="en-US">EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharePremium_lbl" xml:lang="en-US">Share capital and premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremium" xlink:to="ifrs-full_SharePremium_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfSharebasedPayments_lbl" xml:lang="en-US">Reserve from share-based payment transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPayments" xlink:to="ifrs-full_ReserveOfSharebasedPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WarrantLiability_lbl" xml:lang="en-US">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantLiability" xlink:to="ifrs-full_WarrantLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl" xml:lang="en-US">Foreign currency translation reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEquityInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherEquityInterest_lbl" xml:lang="en-US">Transactions with non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEquityInterest" xlink:to="ifrs-full_OtherEquityInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract8" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract8"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract8_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract8" xlink:to="sprcy_UnlabeledAbstract8_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterests"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterests" xlink:to="ifrs-full_NoncontrollingInterests_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract9" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract9"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract9_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract9" xlink:to="sprcy_UnlabeledAbstract9_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract10" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract10"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract10_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract10" xlink:to="sprcy_UnlabeledAbstract10_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract11" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract11"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract11_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract11" xlink:to="sprcy_UnlabeledAbstract11_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract12" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract12"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract12_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract12" xlink:to="sprcy_UnlabeledAbstract12_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract13" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract13"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract13_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract13" xlink:to="sprcy_UnlabeledAbstract13_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NonCurrentAssetsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_NonCurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NonCurrentAssetsAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NonCurrentAssetsAbstract" xlink:to="sprcy_NonCurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract14" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract14"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract14_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract14" xlink:to="sprcy_UnlabeledAbstract14_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract15" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract15"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract15_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract15" xlink:to="sprcy_UnlabeledAbstract15_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract16" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract16"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract16_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract16" xlink:to="sprcy_UnlabeledAbstract16_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LiabilitiesAndEquityAbstract" xlink:href="sprcy-20230630.xsd#sprcy_LiabilitiesAndEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LiabilitiesAndEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LiabilitiesAndEquityAbstract" xlink:to="sprcy_LiabilitiesAndEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract17" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract17"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract17_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract17" xlink:to="sprcy_UnlabeledAbstract17_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract18" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract18"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract18_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract18" xlink:to="sprcy_UnlabeledAbstract18_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract19" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract19"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract19_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract19" xlink:to="sprcy_UnlabeledAbstract19_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US">NON-CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract20" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract20"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract20_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract20" xlink:to="sprcy_UnlabeledAbstract20_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract0" xlink:href="sprcy-20230630.xsd#sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract0_lbl" xml:lang="en-US">EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract0" xlink:to="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract21" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract21"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract21_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract21" xlink:to="sprcy_UnlabeledAbstract21_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract22" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract22"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract22_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract22" xlink:to="sprcy_UnlabeledAbstract22_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Revenue_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract23" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract23"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract23_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract23" xlink:to="sprcy_UnlabeledAbstract23_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract24" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract24"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract24_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract24" xlink:to="sprcy_UnlabeledAbstract24_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract25" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract25"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract25_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract25" xlink:to="sprcy_UnlabeledAbstract25_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl" xml:lang="en-US">Sales and marketing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US">Finance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract26" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract26"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract26_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract26" xlink:to="sprcy_UnlabeledAbstract26_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US">Taxes on income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract27" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract27"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract27_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract27" xlink:to="sprcy_UnlabeledAbstract27_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossAttributableToAbstract_lbl" xml:lang="en-US">Attributable to:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity_lbl" xml:lang="en-US">Equity holders of the Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_BasicLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract" xlink:href="sprcy-20230630.xsd#sprcy_BasicLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_BasicLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract_lbl" xml:lang="en-US">Basic loss per share attributable to equity holders of the Company:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BasicLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="sprcy_BasicLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US">Loss from operations (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DilutedLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract" xlink:href="sprcy-20230630.xsd#sprcy_DilutedLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DilutedLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract_lbl" xml:lang="en-US">Diluted loss per share attributable to equity holders of the Company:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DilutedLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="sprcy_DilutedLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US">Loss from operations (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract28" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract28"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract28_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract28" xlink:to="sprcy_UnlabeledAbstract28_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract29" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract29"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract29_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract29" xlink:to="sprcy_UnlabeledAbstract29_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract30" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract30"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract30_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract30" xlink:to="sprcy_UnlabeledAbstract30_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract31" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract31"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract31_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract31" xlink:to="sprcy_UnlabeledAbstract31_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract32" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract32"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract32_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract32" xlink:to="sprcy_UnlabeledAbstract32_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract33" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract33"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract33_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract33" xlink:to="sprcy_UnlabeledAbstract33_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract34" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract34"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract34_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract34" xlink:to="sprcy_UnlabeledAbstract34_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract35" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract35"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract35_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract35" xlink:to="sprcy_UnlabeledAbstract35_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract36" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract36"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract36_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract36" xlink:to="sprcy_UnlabeledAbstract36_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract37" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract37"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract37_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract37" xlink:to="sprcy_UnlabeledAbstract37_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract38" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract38"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract38_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract38" xlink:to="sprcy_UnlabeledAbstract38_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract39" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract39"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract39_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract39" xlink:to="sprcy_UnlabeledAbstract39_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AttributableToAbstract" xlink:href="sprcy-20230630.xsd#sprcy_AttributableToAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AttributableToAbstract_lbl" xml:lang="en-US">Attributable to:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AttributableToAbstract" xlink:to="sprcy_AttributableToAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract40" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract40"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract40_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract40" xlink:to="sprcy_UnlabeledAbstract40_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract41" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract41"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract41_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract41" xlink:to="sprcy_UnlabeledAbstract41_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract42" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract42"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract42_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract42" xlink:to="sprcy_UnlabeledAbstract42_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract43" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract43"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract43_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract43" xlink:to="sprcy_UnlabeledAbstract43_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract44" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract44"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract44_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract44" xlink:to="sprcy_UnlabeledAbstract44_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl" xml:lang="en-US">Issue of share capital in respect of investment in affiliate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_lbl" xml:lang="en-US">Sale of minority interest in subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:to="ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssueOfSharesNetOfIssueExpenses" xlink:href="sprcy-20230630.xsd#sprcy_IssueOfSharesNetOfIssueExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssueOfSharesNetOfIssueExpenses_lbl" xml:lang="en-US">Issue of shares, net of issue expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssueOfSharesNetOfIssueExpenses" xlink:to="sprcy_IssueOfSharesNetOfIssueExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US">Cost of share-based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract45" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract45"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract45_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract45" xlink:to="sprcy_UnlabeledAbstract45_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract46" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract46"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract46_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract46" xlink:to="sprcy_UnlabeledAbstract46_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl" xml:lang="en-US">Expiration of share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract47" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract47"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract47_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract47" xlink:to="sprcy_UnlabeledAbstract47_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract48" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract48"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract48_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract48" xlink:to="sprcy_UnlabeledAbstract48_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExerciseOfWarrants" xlink:href="sprcy-20230630.xsd#sprcy_ExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExerciseOfWarrants" xlink:to="sprcy_ExerciseOfWarrants_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_ExerciseOfWarrants_lbl0" xml:lang="en-US">Warrants and exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExerciseOfWarrants" xlink:to="sprcy_ExerciseOfWarrants_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract49" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract49"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract49_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract49" xlink:to="sprcy_UnlabeledAbstract49_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract50" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract50"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract50_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract50" xlink:to="sprcy_UnlabeledAbstract50_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl" xml:lang="en-US">Warrants reclassification</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssueOfShareCapitalNetOfIssueExpense" xlink:href="sprcy-20230630.xsd#sprcy_IssueOfShareCapitalNetOfIssueExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl" xml:lang="en-US">Issue of share capital, net of issue expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssueOfShareCapitalNetOfIssueExpense" xlink:to="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_lbl" xml:lang="en-US">Conversion of convertible debentures (Note 14b)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:to="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:to="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract51" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract51"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract51_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract51" xlink:to="sprcy_UnlabeledAbstract51_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract52" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract52"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract52_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract52" xlink:to="sprcy_UnlabeledAbstract52_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract53" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract53"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract53_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract53" xlink:to="sprcy_UnlabeledAbstract53_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract54" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract54"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract54_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract54" xlink:to="sprcy_UnlabeledAbstract54_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract55" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract55"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract55_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract55" xlink:to="sprcy_UnlabeledAbstract55_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US">Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProfitLoss_lbl0" xml:lang="en-US">Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract56" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract56"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract56_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract56" xlink:to="sprcy_UnlabeledAbstract56_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl0" xml:lang="en-US">Adjustments to reconcile loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract57" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract57"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract57_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract57" xlink:to="sprcy_UnlabeledAbstract57_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_AdjustmentsToTheProfitOrLossItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract_lbl" xml:lang="en-US">Adjustments to the profit or loss items:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract58" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract58"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract58_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract58" xlink:to="sprcy_UnlabeledAbstract58_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_lbl" xml:lang="en-US">Group&#8217;s share of losses of company accounted for at equity, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:to="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsForImpairmentOfInvestmentInAssociate" xlink:href="sprcy-20230630.xsd#sprcy_AdjustmentsForImpairmentOfInvestmentInAssociate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdjustmentsForImpairmentOfInvestmentInAssociate_lbl" xml:lang="en-US">Losses from remeasurement of investment in financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsForImpairmentOfInvestmentInAssociate" xlink:to="sprcy_AdjustmentsForImpairmentOfInvestmentInAssociate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract59" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract59"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract59_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract59" xlink:to="sprcy_UnlabeledAbstract59_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract60" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract60"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract60_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract60" xlink:to="sprcy_UnlabeledAbstract60_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WorkingCapitalAdjustmentsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_WorkingCapitalAdjustmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WorkingCapitalAdjustmentsAbstract_lbl" xml:lang="en-US">Working capital adjustments:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WorkingCapitalAdjustmentsAbstract" xlink:to="sprcy_WorkingCapitalAdjustmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract61" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract61"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract61_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract61" xlink:to="sprcy_UnlabeledAbstract61_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl" xml:lang="en-US">Decrease (increase) in other accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl" xml:lang="en-US">Increase (decrease) in trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xml:lang="en-US">Increase (decrease) in other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_lbl" xml:lang="en-US">Decrease (increase) in trade receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xml:lang="en-US">Decrease (increase) in inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract62" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract62"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract62_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract62" xlink:to="sprcy_UnlabeledAbstract62_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_lbl" xml:lang="en-US">Working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract63" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract63"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract63_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract63" xlink:to="sprcy_UnlabeledAbstract63_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract64" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract64"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract64_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract64" xlink:to="sprcy_UnlabeledAbstract64_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Investment (withdrawal) in restricted bank deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl" xml:lang="en-US">Investment in a company accounted for at equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="sprcy-20230630.xsd#sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss_lbl" xml:lang="en-US">Purchase of financial assets at fair value through profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract65" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract65"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract65_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract65" xlink:to="sprcy_UnlabeledAbstract65_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract66" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract66"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract66_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract66" xlink:to="sprcy_UnlabeledAbstract66_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract67" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract67"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract67_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract67" xlink:to="sprcy_UnlabeledAbstract67_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InterestPaidOnLeaseLiability" xlink:href="sprcy-20230630.xsd#sprcy_InterestPaidOnLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InterestPaidOnLeaseLiability_lbl" xml:lang="en-US">Interest paid on lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestPaidOnLeaseLiability" xlink:to="sprcy_InterestPaidOnLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US">Proceeds from issuance of shares to minority interests in a subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions_lbl" xml:lang="en-US">Exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfOptions" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:href="sprcy-20230630.xsd#sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod_lbl" xml:lang="en-US">Payment of issuance expenses related to previous period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:to="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract68" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract68"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract68_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract68" xlink:to="sprcy_UnlabeledAbstract68_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract69" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract69"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract69_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract69" xlink:to="sprcy_UnlabeledAbstract69_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract70" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract70"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract70_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract70" xlink:to="sprcy_UnlabeledAbstract70_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantNonCashTransactionsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_SignificantNonCashTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SignificantNonCashTransactionsAbstract_lbl" xml:lang="en-US">(a) Significant non-cash transactions:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantNonCashTransactionsAbstract" xlink:to="sprcy_SignificantNonCashTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract71" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract71"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract71_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract71" xlink:to="sprcy_UnlabeledAbstract71_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_MutualShareExchangeOfOrdinarySharessee" xlink:href="sprcy-20230630.xsd#sprcy_MutualShareExchangeOfOrdinarySharessee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_MutualShareExchangeOfOrdinarySharessee_lbl" xml:lang="en-US">Mutual share exchange of ordinary shares (see note 10)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MutualShareExchangeOfOrdinarySharessee" xlink:to="sprcy_MutualShareExchangeOfOrdinarySharessee_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract72" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract72"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract72_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract72" xlink:to="sprcy_UnlabeledAbstract72_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract73" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract73"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract73_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract73" xlink:to="sprcy_UnlabeledAbstract73_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract74" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract74"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract74_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract74" xlink:to="sprcy_UnlabeledAbstract74_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract0" xlink:href="sprcy-20230630.xsd#sprcy_AdjustmentsToTheProfitOrLossItemsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract0_lbl" xml:lang="en-US">Adjustments to the profit or loss items:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract0" xlink:to="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract75" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract75"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract75_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract75" xlink:to="sprcy_UnlabeledAbstract75_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract76" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract76"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract76_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract76" xlink:to="sprcy_UnlabeledAbstract76_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract77" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract77"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract77_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract77" xlink:to="sprcy_UnlabeledAbstract77_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WorkingCapitalAdjustmentsAbstract0" xlink:href="sprcy-20230630.xsd#sprcy_WorkingCapitalAdjustmentsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WorkingCapitalAdjustmentsAbstract0_lbl" xml:lang="en-US">Working capital adjustments:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WorkingCapitalAdjustmentsAbstract0" xlink:to="sprcy_WorkingCapitalAdjustmentsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract78" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract78"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract78_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract78" xlink:to="sprcy_UnlabeledAbstract78_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract79" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract79"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract79_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract79" xlink:to="sprcy_UnlabeledAbstract79_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract80" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract80"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract80_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract80" xlink:to="sprcy_UnlabeledAbstract80_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract81" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract81"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract81_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract81" xlink:to="sprcy_UnlabeledAbstract81_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract82" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract82"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract82_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract82" xlink:to="sprcy_UnlabeledAbstract82_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract83" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract83"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract83_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract83" xlink:to="sprcy_UnlabeledAbstract83_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract84" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract84"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract84_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract84" xlink:to="sprcy_UnlabeledAbstract84_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ReceiptofShortTermCreditFromOthers" xlink:href="sprcy-20230630.xsd#sprcy_ReceiptofShortTermCreditFromOthers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ReceiptofShortTermCreditFromOthers_lbl" xml:lang="en-US">Receipt of short-term credit from others, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ReceiptofShortTermCreditFromOthers" xlink:to="sprcy_ReceiptofShortTermCreditFromOthers_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract85" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract85"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract85_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract85" xlink:to="sprcy_UnlabeledAbstract85_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract86" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract86"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract86_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract86" xlink:to="sprcy_UnlabeledAbstract86_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract87" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract87"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract87_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract87" xlink:to="sprcy_UnlabeledAbstract87_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract88" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract88"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract88_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract88" xlink:to="sprcy_UnlabeledAbstract88_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:href="sprcy-20230630.xsd#sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl" xml:lang="en-US">Right-of-use asset recognized with corresponding lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:to="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract89" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract89"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract89_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract89" xlink:to="sprcy_UnlabeledAbstract89_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegistrationOfWarrants" xlink:href="sprcy-20230630.xsd#sprcy_RegistrationOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RegistrationOfWarrants_lbl" xml:lang="en-US">Registration of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RegistrationOfWarrants" xlink:to="sprcy_RegistrationOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract90" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract90"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract90_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract90" xlink:to="sprcy_UnlabeledAbstract90_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnpaidIssueExpenses" xlink:href="sprcy-20230630.xsd#sprcy_UnpaidIssueExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnpaidIssueExpenses_lbl" xml:lang="en-US">Unpaid issue expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnpaidIssueExpenses" xlink:to="sprcy_UnpaidIssueExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_CostOfSales_lbl" xml:lang="en-US">Cost of goods sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSales" xlink:to="ifrs-full_CostOfSales_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CostOfSales_lbl0" xml:lang="en-US">Cost of goods sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSales" xlink:to="ifrs-full_CostOfSales_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl" xml:lang="en-US">Company&#8217;s share of losses of companies accounted for at equity, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ComprehensiveIncomeAttributableToNoncontrollingInterest" xlink:href="sprcy-20230630.xsd#sprcy_ComprehensiveIncomeAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="sprcy_ComprehensiveIncomeAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ComprehensiveIncomeAttributableToNoncontrollingInterest" xlink:to="sprcy_ComprehensiveIncomeAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl" xml:lang="en-US">Finance expenses, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US">Purchase of intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" xlink:href="sprcy-20230630.xsd#sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses_lbl" xml:lang="en-US">Proceeds from issue of share capital and warrants (net of issuance expenses) (Note 8)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" xlink:to="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RepaymentOfLeaseLiabilities" xlink:href="sprcy-20230630.xsd#sprcy_RepaymentOfLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="sprcy_RepaymentOfLeaseLiabilities_lbl" xml:lang="en-US">Repayment of lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RepaymentOfLeaseLiabilities" xlink:to="sprcy_RepaymentOfLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RepaymentOfShorttermCredit" xlink:href="sprcy-20230630.xsd#sprcy_RepaymentOfShorttermCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="sprcy_RepaymentOfShorttermCredit_lbl" xml:lang="en-US">Repayment of short-term credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RepaymentOfShorttermCredit" xlink:to="sprcy_RepaymentOfShorttermCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PreviouslyStatedMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PreviouslyStatedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PreviouslyStatedMember_lbl" xml:lang="en-US">Previously stated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PreviouslyStatedMember" xlink:to="ifrs-full_PreviouslyStatedMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_PreviouslyStatedMember_lbl0" xml:lang="en-US">Previously stated [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PreviouslyStatedMember" xlink:to="ifrs-full_PreviouslyStatedMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharePremiumMember_lbl" xml:lang="en-US">Share capital and premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremiumMember" xlink:to="ifrs-full_SharePremiumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl" xml:lang="en-US">Reserve from share-based payment transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WarrantsMember_lbl" xml:lang="en-US">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantsMember" xlink:to="ifrs-full_WarrantsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WarrantsMember_lbl0" xml:lang="en-US">Warrants [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantsMember" xlink:to="ifrs-full_WarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_WarrantsMember_lbl1" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantsMember" xlink:to="ifrs-full_WarrantsMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterestMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEquityInterestMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherEquityInterestMember_lbl" xml:lang="en-US">Transactions with non- controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEquityInterestMember" xlink:to="ifrs-full_OtherEquityInterestMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xml:lang="en-US">Foreign currency translation reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TotalEquityHolderMember" xlink:href="sprcy-20230630.xsd#sprcy_TotalEquityHolderMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_TotalEquityHolderMember_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TotalEquityHolderMember" xlink:to="sprcy_TotalEquityHolderMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterestsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncontrollingInterestsMember_lbl" xml:lang="en-US">Non- controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterestsMember" xlink:to="ifrs-full_NoncontrollingInterestsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfGeneralExplanatoryTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfGeneralExplanatoryTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfGeneralExplanatoryTextBlock_lbl" xml:lang="en-US">GENERAL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfGeneralExplanatoryTextBlock" xlink:to="sprcy_DisclosureOfGeneralExplanatoryTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_lbl" xml:lang="en-US">INVESTMENT IN ASSOCIATE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:to="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory_lbl" xml:lang="en-US">Schedule of Fair Value of the Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentDate" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestmentDate_lbl" xml:lang="en-US">Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentDate" xlink:to="sprcy_InvestmentDate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_InvestmentDate_lbl0" xml:lang="en-US">Investment date March 31, 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentDate" xlink:to="sprcy_InvestmentDate_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityLossesFromInvestmentInMitoCareX" xlink:href="sprcy-20230630.xsd#sprcy_EquityLossesFromInvestmentInMitoCareX"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_EquityLossesFromInvestmentInMitoCareX_lbl" xml:lang="en-US">Equity losses from investment in MitoCareX</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityLossesFromInvestmentInMitoCareX" xlink:to="sprcy_EquityLossesFromInvestmentInMitoCareX_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract91" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract91"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract91_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract91" xlink:to="sprcy_UnlabeledAbstract91_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract92" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract92"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract92_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract92" xlink:to="sprcy_UnlabeledAbstract92_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract93" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract93"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract93_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract93" xlink:to="sprcy_UnlabeledAbstract93_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl" xml:lang="en-US">INTANGIBLE ASSET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of the Intangible Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock" xlink:to="sprcy_ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseOfAssets" xlink:href="sprcy-20230630.xsd#sprcy_PurchaseOfAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchaseOfAssets_lbl" xml:lang="en-US">Purchase date September 30, 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseOfAssets" xlink:to="sprcy_PurchaseOfAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract94" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract94"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract94_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract94" xlink:to="sprcy_UnlabeledAbstract94_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract95" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract95"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract95_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract95" xlink:to="sprcy_UnlabeledAbstract95_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract96" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract96"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract96_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract96" xlink:to="sprcy_UnlabeledAbstract96_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory_lbl" xml:lang="en-US">INVESTMENT IN FINANCIAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl" xml:lang="en-US">TRANSACTIONS AND BALANCES WITH RELATED PARTIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">FINANCIAL INSTRUMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_lbl" xml:lang="en-US">Schedule of Financial Assets and Financial Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialAssetsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_FinancialAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FinancialAssetsAbstract_lbl" xml:lang="en-US">Financial assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinancialAssetsAbstract" xlink:to="sprcy_FinancialAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeReceivables_lbl" xml:lang="en-US">Trade receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeReceivables" xlink:to="ifrs-full_TradeReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_GovernmentAuthorities" xlink:href="sprcy-20230630.xsd#sprcy_GovernmentAuthorities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_GovernmentAuthorities_lbl" xml:lang="en-US">Government authorities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GovernmentAuthorities" xlink:to="sprcy_GovernmentAuthorities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xml:lang="en-US">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialAssets_lbl" xml:lang="en-US">Investments in financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssets" xlink:to="ifrs-full_FinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract97" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract97"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract97_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract97" xlink:to="sprcy_UnlabeledAbstract97_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost_lbl" xml:lang="en-US">Total financial assets at amortized cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCost_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract98" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract98"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract98_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract98" xlink:to="sprcy_UnlabeledAbstract98_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialLiabilitiesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_FinancialLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FinancialLiabilitiesAbstract_lbl" xml:lang="en-US">Financial liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinancialLiabilitiesAbstract" xlink:to="sprcy_FinancialLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CreditFromOthers" xlink:href="sprcy-20230630.xsd#sprcy_CreditFromOthers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CreditFromOthers_lbl" xml:lang="en-US">Credit from others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CreditFromOthers" xlink:to="sprcy_CreditFromOthers_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsLiability" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WarrantsLiability_lbl" xml:lang="en-US">Warrants liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsLiability" xlink:to="sprcy_WarrantsLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseLiabilities_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract99" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract99"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract99_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract99" xlink:to="sprcy_UnlabeledAbstract99_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_WarrantTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WarrantTextBlock_lbl" xml:lang="en-US">WARRANTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantTextBlock" xlink:to="sprcy_WarrantTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xml:lang="en-US">Schedule of Warrants&#8217; Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl" xml:lang="en-US">Dividend yield (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xml:lang="en-US">Expected volatility (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xml:lang="en-US">Risk-free interest rate (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl" xml:lang="en-US">Underlying share price ($) (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl" xml:lang="en-US">Exercise price ($) (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl0" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LossesOnChangeInFairValueOfDerivatives" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LossesOnChangeInFairValueOfDerivatives"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LossesOnChangeInFairValueOfDerivatives_lbl" xml:lang="en-US">Warrants fair value ($) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LossesOnChangeInFairValueOfDerivatives" xlink:to="ifrs-full_LossesOnChangeInFairValueOfDerivatives_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xml:lang="en-US">EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xml:lang="en-US">Schedule of Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfSharesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_NumberOfSharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NumberOfSharesAbstract_lbl" xml:lang="en-US">Number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfSharesAbstract" xlink:to="sprcy_NumberOfSharesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl" xml:lang="en-US">Ordinary shares, authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesAuthorised" xlink:to="ifrs-full_NumberOfSharesAuthorised_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US">Ordinary shares, issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfIssuedAndOutstandingShareCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl" xml:lang="en-US">Schedule of Issued and Outstanding Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" xlink:to="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract100" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract100"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract100_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract100" xlink:to="sprcy_UnlabeledAbstract100_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" xlink:href="sprcy-20230630.xsd#sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate_lbl" xml:lang="en-US">Issuance of share capital &#8211; in respect of investment in affiliate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract101" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract101"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract101_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract101" xlink:to="sprcy_UnlabeledAbstract101_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SharesIssuedToConsultants" xlink:href="sprcy-20230630.xsd#sprcy_SharesIssuedToConsultants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SharesIssuedToConsultants_lbl" xml:lang="en-US">Shares issued to consultants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharesIssuedToConsultants" xlink:to="sprcy_SharesIssuedToConsultants_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract102" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract102"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract102_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract102" xlink:to="sprcy_UnlabeledAbstract102_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus" xlink:href="sprcy-20230630.xsd#sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus_lbl" xml:lang="en-US">Issuance of share capital &#8211; in respect of shelf prospectus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract103" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract103"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract103_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract103" xlink:to="sprcy_UnlabeledAbstract103_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAdditionalInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAdditionalInformationExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfAdditionalInformationExplanatory_lbl" xml:lang="en-US">ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAdditionalInformationExplanatory" xlink:to="ifrs-full_DisclosureOfAdditionalInformationExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss_lbl" xml:lang="en-US">Schedule of Additional Information to the Items of Profit or Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss" xlink:to="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AResearchAndDevelopmentExpensesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_AResearchAndDevelopmentExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AResearchAndDevelopmentExpensesAbstract_lbl" xml:lang="en-US">a. Research and development expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AResearchAndDevelopmentExpensesAbstract" xlink:to="sprcy_AResearchAndDevelopmentExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract104" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract104"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract104_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract104" xlink:to="sprcy_UnlabeledAbstract104_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract105" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract105"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract105_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract105" xlink:to="sprcy_UnlabeledAbstract105_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract106" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract106"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract106_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract106" xlink:to="sprcy_UnlabeledAbstract106_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_BGeneralAndAdministrativeExpensesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_BGeneralAndAdministrativeExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_BGeneralAndAdministrativeExpensesAbstract_lbl" xml:lang="en-US">b. General and administrative expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BGeneralAndAdministrativeExpensesAbstract" xlink:to="sprcy_BGeneralAndAdministrativeExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract107" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract107"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract107_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract107" xlink:to="sprcy_UnlabeledAbstract107_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract108" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract108"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract108_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract108" xlink:to="sprcy_UnlabeledAbstract108_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock_lbl" xml:lang="en-US">SIGNIFICANT EVENTS DURING THE REPORTING PERIOD</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" xlink:to="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US">EVENTS AFTER THE REPORTING PERIOD</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory_lbl" xml:lang="en-US">Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" xlink:to="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" xlink:href="sprcy-20230630.xsd#sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Straight-line basis over useful life of assets at annual rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" xlink:to="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" xlink:href="sprcy-20230630.xsd#sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly_lbl" xml:lang="en-US">Straight-line basis over useful life of assets at annual rates mainly</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" xlink:to="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife_lbl" xml:lang="en-US">Straight-line basis over the useful life of the assets, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" xlink:to="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeaseholdImprovements" xlink:href="sprcy-20230630.xsd#sprcy_LeaseholdImprovements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LeaseholdImprovements_lbl" xml:lang="en-US">Leasehold improvements (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseholdImprovements" xlink:to="sprcy_LeaseholdImprovements_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" xlink:to="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US">CASH</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:to="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashForImmediateWithdrawal" xlink:href="sprcy-20230630.xsd#sprcy_CashForImmediateWithdrawal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CashForImmediateWithdrawal_lbl" xml:lang="en-US">Cash for immediate withdrawal - in USD</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashForImmediateWithdrawal" xlink:to="sprcy_CashForImmediateWithdrawal_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashForImmediateWithdrawalInNIS" xlink:href="sprcy-20230630.xsd#sprcy_CashForImmediateWithdrawalInNIS"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CashForImmediateWithdrawalInNIS_lbl" xml:lang="en-US">Cash for immediate withdrawal - in NIS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashForImmediateWithdrawalInNIS" xlink:to="sprcy_CashForImmediateWithdrawalInNIS_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract109" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract109"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract109_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract109" xlink:to="sprcy_UnlabeledAbstract109_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_lbl" xml:lang="en-US">INVENTORY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInvestmentEntitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInvestmentEntitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInvestmentEntitiesExplanatory_lbl" xml:lang="en-US">Schedule of Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInvestmentEntitiesExplanatory" xlink:to="ifrs-full_DisclosureOfInvestmentEntitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInventoriesInTransit" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentInventoriesInTransit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentInventoriesInTransit_lbl" xml:lang="en-US">Goods in transit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInventoriesInTransit" xlink:to="ifrs-full_CurrentInventoriesInTransit_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinishedGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinishedGoods_lbl" xml:lang="en-US">Finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinishedGoods" xlink:to="ifrs-full_FinishedGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract110" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract110"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract110_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract110" xlink:to="sprcy_UnlabeledAbstract110_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl" xml:lang="en-US">OTHER ACCOUNTS RECEIVABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_DisclourseOfAccountsReceivablesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" xlink:to="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ValueAddedTaxReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ValueAddedTaxReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ValueAddedTaxReceivables_lbl" xml:lang="en-US">Government authorities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ValueAddedTaxReceivables" xlink:to="ifrs-full_ValueAddedTaxReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherReceivables_lbl" xml:lang="en-US">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReceivables" xlink:to="ifrs-full_OtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaidExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract111" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract111"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract111_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract111" xlink:to="sprcy_UnlabeledAbstract111_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInvestmentPropertyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInvestmentPropertyExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInvestmentPropertyExplanatory_lbl" xml:lang="en-US">INVESTMENT IN ASSOCIATES AND INVESTMENTS IN INVESTEES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInvestmentPropertyExplanatory" xlink:to="ifrs-full_DisclosureOfInvestmentPropertyExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfFairValueMeasurementOfAssetstable" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfFairValueMeasurementOfAssetstable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfFairValueMeasurementOfAssetstable_lbl" xml:lang="en-US">Schedule of Fair Value of the Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFairValueMeasurementOfAssetstable" xlink:to="sprcy_DisclosureOfFairValueMeasurementOfAssetstable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract112" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract112"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract112_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract112" xlink:to="sprcy_UnlabeledAbstract112_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xml:lang="en-US">LEASES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">Schedule of Property and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CostAbstract" xlink:href="sprcy-20230630.xsd#sprcy_CostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CostAbstract_lbl" xml:lang="en-US">Cost:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CostAbstract" xlink:to="sprcy_CostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasesOfCost" xlink:href="sprcy-20230630.xsd#sprcy_PurchasesOfCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchasesOfCost_lbl" xml:lang="en-US">Purchases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasesOfCost" xlink:to="sprcy_PurchasesOfCost_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract113" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract113"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract113_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract113" xlink:to="sprcy_UnlabeledAbstract113_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract114" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract114"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract114_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract114" xlink:to="sprcy_UnlabeledAbstract114_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccumulatedDepreciationAbstract" xlink:href="sprcy-20230630.xsd#sprcy_AccumulatedDepreciationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AccumulatedDepreciationAbstract_lbl" xml:lang="en-US">Accumulated depreciation:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccumulatedDepreciationAbstract" xlink:to="sprcy_AccumulatedDepreciationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract115" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract115"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract115_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract115" xlink:to="sprcy_UnlabeledAbstract115_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract116" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract116"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract116_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract116" xlink:to="sprcy_UnlabeledAbstract116_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated_lbl" xml:lang="en-US">Depreciated cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" xlink:to="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract117" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract117"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract117_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract117" xlink:to="sprcy_UnlabeledAbstract117_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NewLeases" xlink:href="sprcy-20230630.xsd#sprcy_NewLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NewLeases_lbl" xml:lang="en-US">New leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NewLeases" xlink:to="sprcy_NewLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract118" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract118"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract118_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract118" xlink:to="sprcy_UnlabeledAbstract118_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract119" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract119"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract119_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract119" xlink:to="sprcy_UnlabeledAbstract119_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccumulatedDepreciationAbstract0" xlink:href="sprcy-20230630.xsd#sprcy_AccumulatedDepreciationAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AccumulatedDepreciationAbstract0_lbl" xml:lang="en-US">Accumulated depreciation:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccumulatedDepreciationAbstract0" xlink:to="sprcy_AccumulatedDepreciationAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccumulatedTerminationOfLeases" xlink:href="sprcy-20230630.xsd#sprcy_AccumulatedTerminationOfLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AccumulatedTerminationOfLeases_lbl" xml:lang="en-US">Depreciation of leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccumulatedTerminationOfLeases" xlink:to="sprcy_AccumulatedTerminationOfLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract120" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract120"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract120_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract120" xlink:to="sprcy_UnlabeledAbstract120_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract121" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract121"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract121_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract121" xlink:to="sprcy_UnlabeledAbstract121_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseofAssets" xlink:href="sprcy-20230630.xsd#sprcy_PurchaseofAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchaseofAssets_lbl" xml:lang="en-US">Purchase date September 30, 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseofAssets" xlink:to="sprcy_PurchaseofAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract122" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract122"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract122_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract122" xlink:to="sprcy_UnlabeledAbstract122_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xml:lang="en-US">TRADE PAYABLES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfTradePayables" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfTradePayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfTradePayables_lbl" xml:lang="en-US">Schedule of Trade Payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfTradePayables" xlink:to="sprcy_DisclosureOfTradePayables_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccruedExpenses" xlink:href="sprcy-20230630.xsd#sprcy_AccruedExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AccruedExpenses_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccruedExpenses" xlink:to="sprcy_AccruedExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xml:lang="en-US">Open debts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract123" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract123"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract123_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract123" xlink:to="sprcy_UnlabeledAbstract123_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent_lbl" xml:lang="en-US">OTHER ACCOUNTS PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent" xlink:to="sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfOtherAccountsPayable" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfOtherAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ScheduleOfOtherAccountsPayable_lbl" xml:lang="en-US">Schedule of Other Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfOtherAccountsPayable" xlink:to="sprcy_ScheduleOfOtherAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl" xml:lang="en-US">Employees and payroll accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Accruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Accruals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Accruals_lbl" xml:lang="en-US">Accrued vacation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Accruals" xlink:to="ifrs-full_Accruals_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherPayables_lbl" xml:lang="en-US">Other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_OtherPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract124" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract124"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract124_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract124" xlink:to="sprcy_UnlabeledAbstract124_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TradeAndOtherPayable" xlink:href="sprcy-20230630.xsd#sprcy_TradeAndOtherPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_TradeAndOtherPayable_lbl" xml:lang="en-US">Other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TradeAndOtherPayable" xlink:to="sprcy_TradeAndOtherPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities_lbl" xml:lang="en-US">Schedule of Financial Assets and Financial Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities" xlink:to="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl" xml:lang="en-US">Financial assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestrictedCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Cash and restricted deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestrictedCashAndCashEquivalents" xlink:to="ifrs-full_RestrictedCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentsInFinancialAssets" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentsInFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestmentsInFinancialAssets_lbl" xml:lang="en-US">Investments in financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentsInFinancialAssets" xlink:to="sprcy_InvestmentsInFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract125" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract125"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract125_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract125" xlink:to="sprcy_UnlabeledAbstract125_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialAssetsAtAmortisedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentFinancialAssetsAtAmortisedCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentFinancialAssetsAtAmortisedCost_lbl" xml:lang="en-US">Total financial assets at amortized cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentFinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_CurrentFinancialAssetsAtAmortisedCost_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract126" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract126"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract126_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract126" xlink:to="sprcy_UnlabeledAbstract126_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl" xml:lang="en-US">Financial liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract127" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract127"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract127_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract127" xlink:to="sprcy_UnlabeledAbstract127_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CreditsFromOthers" xlink:href="sprcy-20230630.xsd#sprcy_CreditsFromOthers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CreditsFromOthers_lbl" xml:lang="en-US">Credit from others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CreditsFromOthers" xlink:to="sprcy_CreditsFromOthers_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract128" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract128"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract128_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract128" xlink:to="sprcy_UnlabeledAbstract128_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrants Fair Value Using Black&#8211;Scholes OPM</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock" xlink:to="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DividendYield" xlink:href="sprcy-20230630.xsd#sprcy_DividendYield"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DividendYield_lbl" xml:lang="en-US">Dividend yield (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DividendYield" xlink:to="sprcy_DividendYield_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExpectedVolatility" xlink:href="sprcy-20230630.xsd#sprcy_ExpectedVolatility"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExpectedVolatility_lbl" xml:lang="en-US">Expected volatility (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExpectedVolatility" xlink:to="sprcy_ExpectedVolatility_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RiskFreeInterestRate" xlink:href="sprcy-20230630.xsd#sprcy_RiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RiskFreeInterestRate" xlink:to="sprcy_RiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnderlyingAdsPrice" xlink:href="sprcy-20230630.xsd#sprcy_UnderlyingAdsPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnderlyingAdsPrice_lbl" xml:lang="en-US">Underlying Share Price ($)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnderlyingAdsPrice" xlink:to="sprcy_UnderlyingAdsPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExercisePricePerShare" xlink:href="sprcy-20230630.xsd#sprcy_ExercisePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExercisePricePerShare_lbl" xml:lang="en-US">Exercise price ($)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExercisePricePerShare" xlink:to="sprcy_ExercisePricePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_ExercisePricePerShare_lbl0" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExercisePricePerShare" xlink:to="sprcy_ExercisePricePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsFairValueinDollarsPerShares" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsFairValueinDollarsPerShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WarrantsFairValueinDollarsPerShares_lbl" xml:lang="en-US">Warrants fair value ($)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsFairValueinDollarsPerShares" xlink:to="sprcy_WarrantsFairValueinDollarsPerShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl" xml:lang="en-US">EMPLOYEE BENEFIT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl" xml:lang="en-US">Schedule of Defined Contribution Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl" xml:lang="en-US">Expenses in respect of defined contribution plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US">TAXES ON INCOME</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xml:lang="en-US">CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfSharesAbstract0" xlink:href="sprcy-20230630.xsd#sprcy_NumberOfSharesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NumberOfSharesAbstract0_lbl" xml:lang="en-US">Number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfSharesAbstract0" xlink:to="sprcy_NumberOfSharesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract129" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract129"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract129_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract129" xlink:to="sprcy_UnlabeledAbstract129_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_lbl" xml:lang="en-US">Issuance of share capital &#8211; June 2022 Financing Round</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract130" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract130"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract130_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract130" xlink:to="sprcy_UnlabeledAbstract130_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExerciseOfPrefundedWarrantsOne" xlink:href="sprcy-20230630.xsd#sprcy_ExerciseOfPrefundedWarrantsOne"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExerciseOfPrefundedWarrantsOne_lbl" xml:lang="en-US">Exercise of pre-funded warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExerciseOfPrefundedWarrantsOne" xlink:to="sprcy_ExerciseOfPrefundedWarrantsOne_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract131" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract131"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract131_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract131" xlink:to="sprcy_UnlabeledAbstract131_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExerciseOfPrefundedWarrants" xlink:href="sprcy-20230630.xsd#sprcy_ExerciseOfPrefundedWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExerciseOfPrefundedWarrants_lbl" xml:lang="en-US">Exercise of pre-funded warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExerciseOfPrefundedWarrants" xlink:to="sprcy_ExerciseOfPrefundedWarrants_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_ExerciseOfPrefundedWarrants_lbl0" xml:lang="en-US">Pre-funded warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExerciseOfPrefundedWarrants" xlink:to="sprcy_ExerciseOfPrefundedWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="sprcy_ExerciseOfPrefundedWarrants_lbl1" xml:lang="en-US">Exercise of pre-funded warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExerciseOfPrefundedWarrants" xlink:to="sprcy_ExerciseOfPrefundedWarrants_lbl1"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract132" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract132"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract132_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract132" xlink:to="sprcy_UnlabeledAbstract132_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareIssuedToAConsultant" xlink:href="sprcy-20230630.xsd#sprcy_ShareIssuedToAConsultant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareIssuedToAConsultant_lbl" xml:lang="en-US">Share issued to a consultant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareIssuedToAConsultant" xlink:to="sprcy_ShareIssuedToAConsultant_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract133" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract133"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract133_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract133" xlink:to="sprcy_UnlabeledAbstract133_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnderlyingOrdinarySharePrice" xlink:href="sprcy-20230630.xsd#sprcy_UnderlyingOrdinarySharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnderlyingOrdinarySharePrice_lbl" xml:lang="en-US">Underlying share price ($)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnderlyingOrdinarySharePrice" xlink:to="sprcy_UnderlyingOrdinarySharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExercisePrice" xlink:href="sprcy-20230630.xsd#sprcy_ExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExercisePrice_lbl" xml:lang="en-US">Exercise price ($)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExercisePrice" xlink:to="sprcy_ExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsFairValueinDollarsPerShare" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsFairValueinDollarsPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WarrantsFairValueinDollarsPerShare_lbl" xml:lang="en-US">Warrants fair value ($)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsFairValueinDollarsPerShare" xlink:to="sprcy_WarrantsFairValueinDollarsPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US">SHARE-BASED PAYMENT TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfExpenseRecognizedExplanatoryTableTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfExpenseRecognizedExplanatoryTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfExpenseRecognizedExplanatoryTableTextBlock_lbl" xml:lang="en-US">Schedule of Expenses Due to Share-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfExpenseRecognizedExplanatoryTableTextBlock" xlink:to="sprcy_DisclosureOfExpenseRecognizedExplanatoryTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndDevelopmentExpenses01" xlink:href="sprcy-20230630.xsd#sprcy_ResearchAndDevelopmentExpenses01"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ResearchAndDevelopmentExpenses01_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndDevelopmentExpenses01" xlink:to="sprcy_ResearchAndDevelopmentExpenses01_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_GeneralAndAdministrativeExpenses" xlink:href="sprcy-20230630.xsd#sprcy_GeneralAndAdministrativeExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_GeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GeneralAndAdministrativeExpenses" xlink:to="sprcy_GeneralAndAdministrativeExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract134" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract134"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract134_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract134" xlink:to="sprcy_UnlabeledAbstract134_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExpensesDueToSharebasedCompensation" xlink:href="sprcy-20230630.xsd#sprcy_ExpensesDueToSharebasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExpensesDueToSharebasedCompensation_lbl" xml:lang="en-US">Expenses due to share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExpensesDueToSharebasedCompensation" xlink:to="sprcy_ExpensesDueToSharebasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfOptionPricingModelShareOptionGranted" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfOptionPricingModelShareOptionGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfOptionPricingModelShareOptionGranted_lbl" xml:lang="en-US">Schedule of Fair Value for Share Options Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfOptionPricingModelShareOptionGranted" xlink:to="sprcy_DescriptionOfOptionPricingModelShareOptionGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" xlink:href="sprcy-20230630.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed_lbl" xml:lang="en-US">Dividend yield (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" xlink:href="sprcy-20230630.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" xlink:href="sprcy-20230630.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" xlink:href="sprcy-20230630.xsd#sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1_lbl" xml:lang="en-US">Expected life of share options (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" xlink:to="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnderlyingOrdinarySharePrices" xlink:href="sprcy-20230630.xsd#sprcy_UnderlyingOrdinarySharePrices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnderlyingOrdinarySharePrices_lbl" xml:lang="en-US">Underlying ordinary share price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnderlyingOrdinarySharePrices" xlink:to="sprcy_UnderlyingOrdinarySharePrices_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock_lbl" xml:lang="en-US">Schedule of Weighted Average Exercise Prices of Share Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" xlink:to="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_a2022Abstract" xlink:href="sprcy-20230630.xsd#sprcy_a2022Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_a2022Abstract_lbl" xml:lang="en-US">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_a2022Abstract" xlink:to="sprcy_a2022Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfShareOptionGranted" xlink:href="sprcy-20230630.xsd#sprcy_NumberOfShareOptionGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NumberOfShareOptionGranted_lbl" xml:lang="en-US">Number of Share Options Share Options granted during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfShareOptionGranted" xlink:to="sprcy_NumberOfShareOptionGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement" xlink:href="sprcy-20230630.xsd#sprcy_WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Weighted average exercise price, Share Options granted during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement" xlink:to="sprcy_WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfShareOptionsShareOptionsExercisableAtTheEndOfTheYear" xlink:href="sprcy-20230630.xsd#sprcy_NumberOfShareOptionsShareOptionsExercisableAtTheEndOfTheYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NumberOfShareOptionsShareOptionsExercisableAtTheEndOfTheYear_lbl" xml:lang="en-US">Number of Share Options, Share Options exercisable at the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfShareOptionsShareOptionsExercisableAtTheEndOfTheYear" xlink:to="sprcy_NumberOfShareOptionsShareOptionsExercisableAtTheEndOfTheYear_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price, Share Options exercisable at the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract135" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract135"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract135_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract135" xlink:to="sprcy_UnlabeledAbstract135_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_a2021Abstract" xlink:href="sprcy-20230630.xsd#sprcy_a2021Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_a2021Abstract_lbl" xml:lang="en-US">2021:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_a2021Abstract" xlink:to="sprcy_a2021Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement" xlink:href="sprcy-20230630.xsd#sprcy_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of Share Options, Share Options forfeited during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement" xlink:to="sprcy_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WeightedAverageExercisePriceOfShareOptionForfeitedInSharebasedPaymentArrangement" xlink:href="sprcy-20230630.xsd#sprcy_WeightedAverageExercisePriceOfShareOptionForfeitedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WeightedAverageExercisePriceOfShareOptionForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Weighted average exercise price, Share Options forfeited during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WeightedAverageExercisePriceOfShareOptionForfeitedInSharebasedPaymentArrangement" xlink:to="sprcy_WeightedAverageExercisePriceOfShareOptionForfeitedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareadsOptionsExpiredDuringYear" xlink:href="sprcy-20230630.xsd#sprcy_ShareadsOptionsExpiredDuringYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareadsOptionsExpiredDuringYear_lbl" xml:lang="en-US">Number of Share Options, Share Options expired during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareadsOptionsExpiredDuringYear" xlink:to="sprcy_ShareadsOptionsExpiredDuringYear_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareadsOptionsExpiredDuringYearWeightedAverageExercisePrice" xlink:href="sprcy-20230630.xsd#sprcy_ShareadsOptionsExpiredDuringYearWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareadsOptionsExpiredDuringYearWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Share Options expired during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareadsOptionsExpiredDuringYearWeightedAverageExercisePrice" xlink:to="sprcy_ShareadsOptionsExpiredDuringYearWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract136" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract136"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract136_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract136" xlink:to="sprcy_UnlabeledAbstract136_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract137" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract137"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract137_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract137" xlink:to="sprcy_UnlabeledAbstract137_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl" xml:lang="en-US">REVENUES AND COST OF REVENUES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock_lbl" xml:lang="en-US">Schedule of Revenues and Cost of Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" xlink:to="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract138" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract138"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract138_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract138" xlink:to="sprcy_UnlabeledAbstract138_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AResearchAndDevelopmentExpensesAbstract0" xlink:href="sprcy-20230630.xsd#sprcy_AResearchAndDevelopmentExpensesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AResearchAndDevelopmentExpensesAbstract0_lbl" xml:lang="en-US">a. Research and development expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AResearchAndDevelopmentExpensesAbstract0" xlink:to="sprcy_AResearchAndDevelopmentExpensesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndDevelopmentExpenses1" xlink:href="sprcy-20230630.xsd#sprcy_ResearchAndDevelopmentExpenses1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ResearchAndDevelopmentExpenses1_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndDevelopmentExpenses1" xlink:to="sprcy_ResearchAndDevelopmentExpenses1_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract139" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract139"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract139_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract139" xlink:to="sprcy_UnlabeledAbstract139_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract140" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract140"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract140_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract140" xlink:to="sprcy_UnlabeledAbstract140_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_BGeneralAndAdministrativeExpensesAbstract0" xlink:href="sprcy-20230630.xsd#sprcy_BGeneralAndAdministrativeExpensesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_BGeneralAndAdministrativeExpensesAbstract0_lbl" xml:lang="en-US">b. General and administrative expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BGeneralAndAdministrativeExpensesAbstract0" xlink:to="sprcy_BGeneralAndAdministrativeExpensesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract141" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract141"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract141_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract141" xlink:to="sprcy_UnlabeledAbstract141_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract142" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract142"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract142_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract142" xlink:to="sprcy_UnlabeledAbstract142_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_COtherExpensesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_COtherExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_COtherExpensesAbstract_lbl" xml:lang="en-US">c. Other expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_COtherExpensesAbstract" xlink:to="sprcy_COtherExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract143" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract143"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract143_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract143" xlink:to="sprcy_UnlabeledAbstract143_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinanceIncomeAbstract" xlink:href="sprcy-20230630.xsd#sprcy_FinanceIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FinanceIncomeAbstract_lbl" xml:lang="en-US">d. Finance income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinanceIncomeAbstract" xlink:to="sprcy_FinanceIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinanceIncomeFromConvertibleLoan" xlink:href="sprcy-20230630.xsd#sprcy_FinanceIncomeFromConvertibleLoan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FinanceIncomeFromConvertibleLoan_lbl" xml:lang="en-US">Net change in fair value of financial liabilities designated at fair value through profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinanceIncomeFromConvertibleLoan" xlink:to="sprcy_FinanceIncomeFromConvertibleLoan_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract144" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract144"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract144_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract144" xlink:to="sprcy_UnlabeledAbstract144_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinanceExpensesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_FinanceExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FinanceExpensesAbstract_lbl" xml:lang="en-US">e. Finance expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinanceExpensesAbstract" xlink:to="sprcy_FinanceExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssueExpensesRelatedToIssuanceOfWarrants" xlink:href="sprcy-20230630.xsd#sprcy_IssueExpensesRelatedToIssuanceOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssueExpensesRelatedToIssuanceOfWarrants_lbl" xml:lang="en-US">Issuance expenses related to warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssueExpensesRelatedToIssuanceOfWarrants" xlink:to="sprcy_IssueExpensesRelatedToIssuanceOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinanceExpensesFromExchangeRateDifferences" xlink:href="sprcy-20230630.xsd#sprcy_FinanceExpensesFromExchangeRateDifferences"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FinanceExpensesFromExchangeRateDifferences_lbl" xml:lang="en-US">Exchange rate differences, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinanceExpensesFromExchangeRateDifferences" xlink:to="sprcy_FinanceExpensesFromExchangeRateDifferences_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss_lbl" xml:lang="en-US">Losses from remeasurement of investment in financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InterestExpenseInRespectOfLeases" xlink:href="sprcy-20230630.xsd#sprcy_InterestExpenseInRespectOfLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InterestExpenseInRespectOfLeases_lbl" xml:lang="en-US">Finance expense in respect of leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestExpenseInRespectOfLeases" xlink:to="sprcy_InterestExpenseInRespectOfLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinanceExpensesFromInterestAndCommissions" xlink:href="sprcy-20230630.xsd#sprcy_FinanceExpensesFromInterestAndCommissions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FinanceExpensesFromInterestAndCommissions_lbl" xml:lang="en-US">Finance expenses from interest and commissions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinanceExpensesFromInterestAndCommissions" xlink:to="sprcy_FinanceExpensesFromInterestAndCommissions_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract145" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract145"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract145_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract145" xlink:to="sprcy_UnlabeledAbstract145_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InsuranceFinanceIncomeExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InsuranceFinanceIncomeExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InsuranceFinanceIncomeExpenses_lbl" xml:lang="en-US">Finance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InsuranceFinanceIncomeExpenses" xlink:to="ifrs-full_InsuranceFinanceIncomeExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl" xml:lang="en-US">LOSS PER SHARE/ADS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory_lbl" xml:lang="en-US">Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ContinuingOperationsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ContinuingOperationsAbstract_lbl" xml:lang="en-US">Continuing operations:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ContinuingOperationsAbstract" xlink:to="sprcy_ContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract146" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract146"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract146_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract146" xlink:to="sprcy_UnlabeledAbstract146_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US">Weighted number of shares used in the computation of basic and diluted loss per</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_lbl" xml:lang="en-US">Amounts used in the computation of basic and diluted loss per</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:to="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract147" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract147"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract147_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract147" xlink:to="sprcy_UnlabeledAbstract147_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract148" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract148"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract148_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract148" xlink:to="sprcy_UnlabeledAbstract148_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl" xml:lang="en-US">OPERATING SEGMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl" xml:lang="en-US">Schedule of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SegmentReportingRevenueAbstract" xlink:href="sprcy-20230630.xsd#sprcy_SegmentReportingRevenueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SegmentReportingRevenueAbstract_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SegmentReportingRevenueAbstract" xlink:to="sprcy_SegmentReportingRevenueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExternalRevenues" xlink:href="sprcy-20230630.xsd#sprcy_ExternalRevenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExternalRevenues_lbl" xml:lang="en-US">External</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExternalRevenues" xlink:to="sprcy_ExternalRevenues_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_Intersegment" xlink:href="sprcy-20230630.xsd#sprcy_Intersegment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_Intersegment_lbl" xml:lang="en-US">Inter-segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_Intersegment" xlink:to="sprcy_Intersegment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromSaleOfGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueFromSaleOfGoods_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromSaleOfGoods" xlink:to="ifrs-full_RevenueFromSaleOfGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract149" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract149"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract149_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract149" xlink:to="sprcy_UnlabeledAbstract149_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome_lbl" xml:lang="en-US">Segment loss (gain)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:to="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:href="sprcy-20230630.xsd#sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl" xml:lang="en-US">Company&#8217;s share of losses of company accounted for at equity, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:to="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestRevenueExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRevenueExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestRevenueExpense_lbl" xml:lang="en-US">Finance expense (income), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestRevenueExpense" xlink:to="ifrs-full_InterestRevenueExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TaxExpense" xlink:href="sprcy-20230630.xsd#sprcy_TaxExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_TaxExpense_lbl" xml:lang="en-US">Tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TaxExpense" xlink:to="sprcy_TaxExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract150" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract150"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract150_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract150" xlink:to="sprcy_UnlabeledAbstract150_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract151" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract151"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract151_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract151" xlink:to="sprcy_UnlabeledAbstract151_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract152" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract152"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract152_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract152" xlink:to="sprcy_UnlabeledAbstract152_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract153" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract153"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract153_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract153" xlink:to="sprcy_UnlabeledAbstract153_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract154" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract154"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract154_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract154" xlink:to="sprcy_UnlabeledAbstract154_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherAssets_lbl" xml:lang="en-US">Segment Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAssets" xlink:to="ifrs-full_OtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherLiabilities_lbl" xml:lang="en-US">Segment Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherLiabilities" xlink:to="ifrs-full_OtherLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory_lbl" xml:lang="en-US">Schedule of Balances with Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory_lbl" xml:lang="en-US">Schedule of Transactions with Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndDevelopmentExpenses" xlink:href="sprcy-20230630.xsd#sprcy_ResearchAndDevelopmentExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndDevelopmentExpenses" xlink:to="sprcy_ResearchAndDevelopmentExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl" xml:lang="en-US">Schedule of Benefits to Key Management Personnel</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl" xml:lang="en-US">Short-term benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract155" xlink:href="sprcy-20230630.xsd#sprcy_UnlabeledAbstract155"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract155_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract155" xlink:to="sprcy_UnlabeledAbstract155_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" xml:lang="en-US">Cost of share-based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationAndAmortisationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_lbl" xml:lang="en-US">Depreciation of intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationAndAmortisationExpense" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityLossesFromInvestment" xlink:href="sprcy-20230630.xsd#sprcy_EquityLossesFromInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="sprcy_EquityLossesFromInvestment_lbl" xml:lang="en-US">Equity losses from investment in MitoCareX</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityLossesFromInvestment" xlink:to="sprcy_EquityLossesFromInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Disposals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost_lbl" xml:lang="en-US">Depreciation of intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost" xlink:to="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherOperatingIncomeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_OtherOperatingIncomeExpense_lbl" xml:lang="en-US">Other expenses, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherOperatingIncomeExpense" xlink:to="ifrs-full_OtherOperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_FinanceIncomeCost_lbl" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_FinanceIncomeCost_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WagesAndRelatedExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_WagesAndRelatedExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WagesAndRelatedExpensesMember_lbl" xml:lang="en-US">Wages and related expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WagesAndRelatedExpensesMember" xlink:to="sprcy_WagesAndRelatedExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentMember" xlink:href="sprcy-20230630.xsd#sprcy_ShareBasedPaymentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareBasedPaymentMember_lbl" xml:lang="en-US">Share-based payment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedPaymentMember" xlink:to="sprcy_ShareBasedPaymentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ClinicalStudiesMember" xlink:href="sprcy-20230630.xsd#sprcy_ClinicalStudiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ClinicalStudiesMember_lbl" xml:lang="en-US">Clinical studies [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ClinicalStudiesMember" xlink:to="sprcy_ClinicalStudiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegulatoryAndOtherExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_RegulatoryAndOtherExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RegulatoryAndOtherExpensesMember_lbl" xml:lang="en-US">Regulatory, professional and other expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RegulatoryAndOtherExpensesMember" xlink:to="sprcy_RegulatoryAndOtherExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndPreclinicalStudiesMember" xlink:href="sprcy-20230630.xsd#sprcy_ResearchAndPreclinicalStudiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ResearchAndPreclinicalStudiesMember_lbl" xml:lang="en-US">Research and preclinical studies [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndPreclinicalStudiesMember" xlink:to="sprcy_ResearchAndPreclinicalStudiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ChemistryAndFormulationsMember" xlink:href="sprcy-20230630.xsd#sprcy_ChemistryAndFormulationsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ChemistryAndFormulationsMember_lbl" xml:lang="en-US">Chemistry and formulations [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ChemistryAndFormulationsMember" xlink:to="sprcy_ChemistryAndFormulationsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ProfessionalAndDirectorsFeesMember" xlink:href="sprcy-20230630.xsd#sprcy_ProfessionalAndDirectorsFeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ProfessionalAndDirectorsFeesMember_lbl" xml:lang="en-US">Professional and directors&#8217; fees [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ProfessionalAndDirectorsFeesMember" xlink:to="sprcy_ProfessionalAndDirectorsFeesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_BusinessDevelopmentExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_BusinessDevelopmentExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_BusinessDevelopmentExpensesMember_lbl" xml:lang="en-US">Business development expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BusinessDevelopmentExpensesMember" xlink:to="sprcy_BusinessDevelopmentExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OfficeMaintenanceRentAndOtherExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_OfficeMaintenanceRentAndOtherExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OfficeMaintenanceRentAndOtherExpensesMember_lbl" xml:lang="en-US">Office maintenance, rent and other expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OfficeMaintenanceRentAndOtherExpensesMember" xlink:to="sprcy_OfficeMaintenanceRentAndOtherExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestorRelationsAndBusinessExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_InvestorRelationsAndBusinessExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestorRelationsAndBusinessExpensesMember_lbl" xml:lang="en-US">Investor relations and business expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestorRelationsAndBusinessExpensesMember" xlink:to="sprcy_InvestorRelationsAndBusinessExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WellutionOperatingExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_WellutionOperatingExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WellutionOperatingExpensesMember_lbl" xml:lang="en-US">Wellution operating expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WellutionOperatingExpensesMember" xlink:to="sprcy_WellutionOperatingExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegulatoryExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_RegulatoryExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RegulatoryExpensesMember_lbl" xml:lang="en-US">Regulatory expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RegulatoryExpensesMember" xlink:to="sprcy_RegulatoryExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CommunicationAndNetworkEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember_lbl" xml:lang="en-US">Lab equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:to="ifrs-full_CommunicationAndNetworkEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComputerEquipmentMember_lbl" xml:lang="en-US">Computers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComputerEquipmentMember" xlink:to="ifrs-full_ComputerEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OfficeEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OfficeEquipmentMember_lbl" xml:lang="en-US">Office furniture and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OfficeEquipmentMember" xlink:to="ifrs-full_OfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseholdImprovementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseholdImprovementsMember" xlink:to="ifrs-full_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US">Bottom of range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl0" xml:lang="en-US">Bottom of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl1" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BottomOfRangeMember_lbl2" xml:lang="en-US">Bottom of Range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl2"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US">Top of range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl0" xml:lang="en-US">Top of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl1" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TopOfRangeMember_lbl2" xml:lang="en-US">Top of Range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl2"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Lab equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OfficeEquipmentsMember" xlink:href="sprcy-20230630.xsd#sprcy_OfficeEquipmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OfficeEquipmentsMember_lbl" xml:lang="en-US">Office furniture and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OfficeEquipmentsMember" xlink:to="sprcy_OfficeEquipmentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MotorVehiclesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MotorVehiclesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_MotorVehiclesMember_lbl" xml:lang="en-US">Motor vehicles [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MotorVehiclesMember" xlink:to="ifrs-full_MotorVehiclesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ImpairmentOfInvestmentInAssociateMember" xlink:href="sprcy-20230630.xsd#sprcy_ImpairmentOfInvestmentInAssociateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ImpairmentOfInvestmentInAssociateMember_lbl" xml:lang="en-US">Impairment of investment in associate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ImpairmentOfInvestmentInAssociateMember" xlink:to="sprcy_ImpairmentOfInvestmentInAssociateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_GroupsShareOfLossesOfCompanyAccountedForAtEquityNetMember" xlink:href="sprcy-20230630.xsd#sprcy_GroupsShareOfLossesOfCompanyAccountedForAtEquityNetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_GroupsShareOfLossesOfCompanyAccountedForAtEquityNetMember_lbl" xml:lang="en-US">Group&#8217;s share of losses of company accounted for at equity, net [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GroupsShareOfLossesOfCompanyAccountedForAtEquityNetMember" xlink:to="sprcy_GroupsShareOfLossesOfCompanyAccountedForAtEquityNetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ADSMember" xlink:href="sprcy-20230630.xsd#sprcy_ADSMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ADSMember_lbl" xml:lang="en-US">ADS [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ADSMember" xlink:to="sprcy_ADSMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DiscontinuedOperationsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DiscontinuedOperationsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DiscontinuedOperationsMember_lbl" xml:lang="en-US">Discontinued operations [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DiscontinuedOperationsMember" xlink:to="ifrs-full_DiscontinuedOperationsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinaryShareMember" xlink:href="sprcy-20230630.xsd#sprcy_OrdinaryShareMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OrdinaryShareMember_lbl" xml:lang="en-US">Ordinary shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinaryShareMember" xlink:to="sprcy_OrdinaryShareMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_OrdinaryShareMember_lbl0" xml:lang="en-US">Ordinary Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinaryShareMember" xlink:to="sprcy_OrdinaryShareMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_DrugDevelopmentMember" xlink:href="sprcy-20230630.xsd#sprcy_DrugDevelopmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DrugDevelopmentMember_lbl" xml:lang="en-US">Drug Development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DrugDevelopmentMember" xlink:to="sprcy_DrugDevelopmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OnlineSalesMember" xlink:href="sprcy-20230630.xsd#sprcy_OnlineSalesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OnlineSalesMember_lbl" xml:lang="en-US">Online Sales [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OnlineSalesMember" xlink:to="sprcy_OnlineSalesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl" xml:lang="en-US">Key management personnel [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherRelatedPartiesMember_lbl" xml:lang="en-US">Other related parties [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherRelatedPartiesMember" xlink:to="ifrs-full_OtherRelatedPartiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfAssetsAxis_lbl" xml:lang="en-US">Classes of assets [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xml:lang="en-US">Classes of share capital [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis_lbl" xml:lang="en-US">Types of antidilutive instruments [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreationDateAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CreationDateAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CreationDateAxis_lbl" xml:lang="en-US">Creation date [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ifrs-full_CreationDateAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AgreementTypeAxis" xlink:href="sprcy-20230630.xsd#sprcy_AgreementTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AgreementTypeAxis_lbl" xml:lang="en-US">Agreement Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AgreementTypeAxis" xlink:to="sprcy_AgreementTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis_lbl" xml:lang="en-US">Classes of entity&apos;s own equity instruments [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xml:lang="en-US">Non-adjusting events after reporting period [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl" xml:lang="en-US">Ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl0" xml:lang="en-US">Ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl1" xml:lang="en-US">Ordinary shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnNetMonetaryPosition" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnNetMonetaryPosition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GainsLossesOnNetMonetaryPosition_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnNetMonetaryPosition" xlink:to="ifrs-full_GainsLossesOnNetMonetaryPosition_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RetainedEarning" xlink:href="sprcy-20230630.xsd#sprcy_RetainedEarning"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RetainedEarning_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RetainedEarning" xlink:to="sprcy_RetainedEarning_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ProceedsFromIssuanceIPO" xlink:href="sprcy-20230630.xsd#sprcy_ProceedsFromIssuanceIPO"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ProceedsFromIssuanceIPO_lbl" xml:lang="en-US">Initial public offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ProceedsFromIssuanceIPO" xlink:to="sprcy_ProceedsFromIssuanceIPO_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingTerm" xlink:href="sprcy-20230630.xsd#sprcy_OperatingTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OperatingTerm_lbl" xml:lang="en-US">Operating term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingTerm" xlink:to="sprcy_OperatingTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestedInitialAmount" xlink:href="sprcy-20230630.xsd#sprcy_InvestedInitialAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestedInitialAmount_lbl" xml:lang="en-US">Invested initial amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestedInitialAmount" xlink:to="sprcy_InvestedInitialAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalAgreedInvest" xlink:href="sprcy-20230630.xsd#sprcy_AdditionalAgreedInvest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdditionalAgreedInvest_lbl" xml:lang="en-US">Additional agreed invest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalAgreedInvest" xlink:to="sprcy_AdditionalAgreedInvest_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OwnershipAgreement" xlink:href="sprcy-20230630.xsd#sprcy_OwnershipAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OwnershipAgreement_lbl" xml:lang="en-US">Ownership agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OwnershipAgreement" xlink:to="sprcy_OwnershipAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InitialInvestment" xlink:href="sprcy-20230630.xsd#sprcy_InitialInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InitialInvestment_lbl" xml:lang="en-US">Initial investment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialInvestment" xlink:to="sprcy_InitialInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OutstandingSharesPercentage" xlink:href="sprcy-20230630.xsd#sprcy_OutstandingSharesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OutstandingSharesPercentage_lbl" xml:lang="en-US">Outstanding shares percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OutstandingSharesPercentage" xlink:to="sprcy_OutstandingSharesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalProvisionsOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalProvisionsOtherProvisions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionalProvisionsOtherProvisions_lbl" xml:lang="en-US">Additional amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionalProvisionsOtherProvisions" xlink:to="ifrs-full_AdditionalProvisionsOtherProvisions_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xml:lang="en-US">Ownership interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl0" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityLossesInvestment" xlink:href="sprcy-20230630.xsd#sprcy_EquityLossesInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_EquityLossesInvestment_lbl" xml:lang="en-US">Equity losses investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityLossesInvestment" xlink:to="sprcy_EquityLossesInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashPayment" xlink:href="sprcy-20230630.xsd#sprcy_CashPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CashPayment_lbl" xml:lang="en-US">Cash payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashPayment" xlink:to="sprcy_CashPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount_lbl" xml:lang="en-US">Exceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount" xlink:to="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseCosts" xlink:href="sprcy-20230630.xsd#sprcy_PurchaseCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchaseCosts_lbl" xml:lang="en-US">Purchase costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseCosts" xlink:to="sprcy_PurchaseCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsToPurchase" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsToPurchase"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WarrantsToPurchase_lbl" xml:lang="en-US">Warrants to purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsToPurchase" xlink:to="sprcy_WarrantsToPurchase_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_WarrantsToPurchase_lbl0" xml:lang="en-US">Purchase of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsToPurchase" xlink:to="sprcy_WarrantsToPurchase_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExercisePrice1" xlink:href="sprcy-20230630.xsd#sprcy_ExercisePrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExercisePrice1_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExercisePrice1" xlink:to="sprcy_ExercisePrice1_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExercisePeriod" xlink:href="sprcy-20230630.xsd#sprcy_ExercisePeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExercisePeriod_lbl" xml:lang="en-US">Exercise period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExercisePeriod" xlink:to="sprcy_ExercisePeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Gross sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PricePerShare" xlink:href="sprcy-20230630.xsd#sprcy_PricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PricePerShare_lbl" xml:lang="en-US">Price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PricePerShare" xlink:to="sprcy_PricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AmountTotal" xlink:href="sprcy-20230630.xsd#sprcy_AmountTotal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AmountTotal_lbl" xml:lang="en-US">Amount total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AmountTotal" xlink:to="sprcy_AmountTotal_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_lbl" xml:lang="en-US">Amortized over period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:to="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_pricePerShare" xlink:href="sprcy-20230630.xsd#sprcy_pricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_pricePerShare_lbl" xml:lang="en-US">Ordinary shares price closes (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_pricePerShare" xlink:to="sprcy_pricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Cash_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US">Par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl0" xml:lang="en-US">Ordinary shares par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExerciseOfPricePerShare" xlink:href="sprcy-20230630.xsd#sprcy_ExerciseOfPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExerciseOfPricePerShare_lbl" xml:lang="en-US">Exercise of price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExerciseOfPricePerShare" xlink:to="sprcy_ExerciseOfPricePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_ExerciseOfPricePerShare_lbl0" xml:lang="en-US">Exercise of price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExerciseOfPricePerShare" xlink:to="sprcy_ExerciseOfPricePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US">Comprehensive income loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentAmount" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestmentAmount_lbl" xml:lang="en-US">Investment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentAmount" xlink:to="sprcy_InvestmentAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedButNotFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedButNotFullyPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssuedButNotFullyPaid_lbl" xml:lang="en-US">Received shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedButNotFullyPaid" xlink:to="ifrs-full_NumberOfSharesIssuedButNotFullyPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareCapitalPercentage" xlink:href="sprcy-20230630.xsd#sprcy_ShareCapitalPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareCapitalPercentage_lbl" xml:lang="en-US">Share capital percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareCapitalPercentage" xlink:to="sprcy_ShareCapitalPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SharePricePerShare" xlink:href="sprcy-20230630.xsd#sprcy_SharePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SharePricePerShare_lbl" xml:lang="en-US">Share price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePricePerShare" xlink:to="sprcy_SharePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ComprehensiveLoss" xlink:href="sprcy-20230630.xsd#sprcy_ComprehensiveLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ComprehensiveLoss_lbl" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ComprehensiveLoss" xlink:to="sprcy_ComprehensiveLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CooperationAgreementWithClearmindAmount" xlink:href="sprcy-20230630.xsd#sprcy_CooperationAgreementWithClearmindAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CooperationAgreementWithClearmindAmount_lbl" xml:lang="en-US">Cooperation agreement with clearmind amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CooperationAgreementWithClearmindAmount" xlink:to="sprcy_CooperationAgreementWithClearmindAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_BalanceOwedToClearmind" xlink:href="sprcy-20230630.xsd#sprcy_BalanceOwedToClearmind"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_BalanceOwedToClearmind_lbl" xml:lang="en-US">Balance owed to clearmind</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BalanceOwedToClearmind" xlink:to="sprcy_BalanceOwedToClearmind_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestedAmount" xlink:href="sprcy-20230630.xsd#sprcy_InvestedAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestedAmount_lbl" xml:lang="en-US">Invested amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestedAmount" xlink:to="sprcy_InvestedAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExchangeCommonShares" xlink:href="sprcy-20230630.xsd#sprcy_ExchangeCommonShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExchangeCommonShares_lbl" xml:lang="en-US">Exchange common shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExchangeCommonShares" xlink:to="sprcy_ExchangeCommonShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ClearmindOutstandingShareCapitalPercentage" xlink:href="sprcy-20230630.xsd#sprcy_ClearmindOutstandingShareCapitalPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ClearmindOutstandingShareCapitalPercentage_lbl" xml:lang="en-US">Clearmind outstanding share capital percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ClearmindOutstandingShareCapitalPercentage" xlink:to="sprcy_ClearmindOutstandingShareCapitalPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestedAmountInClearmind" xlink:href="sprcy-20230630.xsd#sprcy_InvestedAmountInClearmind"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestedAmountInClearmind_lbl" xml:lang="en-US">Invested amount in clearmind</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestedAmountInClearmind" xlink:to="sprcy_InvestedAmountInClearmind_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExchangeCommonSharesOfClearmind" xlink:href="sprcy-20230630.xsd#sprcy_ExchangeCommonSharesOfClearmind"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExchangeCommonSharesOfClearmind_lbl" xml:lang="en-US">Exchange common shares of clearmind (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExchangeCommonSharesOfClearmind" xlink:to="sprcy_ExchangeCommonSharesOfClearmind_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_BridgeLoanAmount" xlink:href="sprcy-20230630.xsd#sprcy_BridgeLoanAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_BridgeLoanAmount_lbl" xml:lang="en-US">Bridge loan amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BridgeLoanAmount" xlink:to="sprcy_BridgeLoanAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestPayable_lbl" xml:lang="en-US">Interest payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPayable" xlink:to="ifrs-full_InterestPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateAmountOrCreditAmount" xlink:href="sprcy-20230630.xsd#sprcy_AggregateAmountOrCreditAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateAmountOrCreditAmount_lbl" xml:lang="en-US">Aggregate amount or credit amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateAmountOrCreditAmount" xlink:to="sprcy_AggregateAmountOrCreditAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CreditFacilityAmount" xlink:href="sprcy-20230630.xsd#sprcy_CreditFacilityAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CreditFacilityAmount_lbl" xml:lang="en-US">Credit facility amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CreditFacilityAmount" xlink:to="sprcy_CreditFacilityAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CreditFacilityAndRemainingAvailableDrawnAmount" xlink:href="sprcy-20230630.xsd#sprcy_CreditFacilityAndRemainingAvailableDrawnAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CreditFacilityAndRemainingAvailableDrawnAmount_lbl" xml:lang="en-US">Credit facility and remaining available drawn amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CreditFacilityAndRemainingAvailableDrawnAmount" xlink:to="sprcy_CreditFacilityAndRemainingAvailableDrawnAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LoanAmountDueTerm" xlink:href="sprcy-20230630.xsd#sprcy_LoanAmountDueTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LoanAmountDueTerm_lbl" xml:lang="en-US">Loan amount due term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LoanAmountDueTerm" xlink:to="sprcy_LoanAmountDueTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LoanAmountRaised" xlink:href="sprcy-20230630.xsd#sprcy_LoanAmountRaised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LoanAmountRaised_lbl" xml:lang="en-US">Loan amount raised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LoanAmountRaised" xlink:to="sprcy_LoanAmountRaised_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCompoundFinancialInstrumentsWithMultipleEmbeddedDerivativesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCompoundFinancialInstrumentsWithMultipleEmbeddedDerivativesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCompoundFinancialInstrumentsWithMultipleEmbeddedDerivativesExplanatory_lbl" xml:lang="en-US">Description of Issuance of convertible debentures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCompoundFinancialInstrumentsWithMultipleEmbeddedDerivativesExplanatory" xlink:to="ifrs-full_DisclosureOfCompoundFinancialInstrumentsWithMultipleEmbeddedDerivativesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOutflowForLeases" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOutflowForLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashOutflowForLeases_lbl" xml:lang="en-US">Cash paid for principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOutflowForLeases" xlink:to="ifrs-full_CashOutflowForLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash_lbl" xml:lang="en-US">Purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash" xlink:to="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl" xml:lang="en-US">Issued of warrant (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl0" xml:lang="en-US">Ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasePrice" xlink:href="sprcy-20230630.xsd#sprcy_PurchasePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchasePrice_lbl" xml:lang="en-US">Purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasePrice" xlink:to="sprcy_PurchasePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_MaturityDate" xlink:href="sprcy-20230630.xsd#sprcy_MaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_MaturityDate_lbl" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MaturityDate" xlink:to="sprcy_MaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BorrowingsInterestRate_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InitialConversionPrice" xlink:href="sprcy-20230630.xsd#sprcy_InitialConversionPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InitialConversionPrice_lbl" xml:lang="en-US">Initial conversion price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialConversionPrice" xlink:to="sprcy_InitialConversionPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ConversionPrice" xlink:href="sprcy-20230630.xsd#sprcy_ConversionPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ConversionPrice_lbl" xml:lang="en-US">Conversion price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ConversionPrice" xlink:to="sprcy_ConversionPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinaryShareExercisePrice" xlink:href="sprcy-20230630.xsd#sprcy_OrdinaryShareExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OrdinaryShareExercisePrice_lbl" xml:lang="en-US">Ordinary share exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinaryShareExercisePrice" xlink:to="sprcy_OrdinaryShareExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_GrossProceed" xlink:href="sprcy-20230630.xsd#sprcy_GrossProceed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_GrossProceed_lbl" xml:lang="en-US">Gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GrossProceed" xlink:to="sprcy_GrossProceed_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfAggregateShares" xlink:href="sprcy-20230630.xsd#sprcy_IssuanceOfAggregateShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuanceOfAggregateShares_lbl" xml:lang="en-US">Issuance of aggregate shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfAggregateShares" xlink:to="sprcy_IssuanceOfAggregateShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_IssuanceOfAggregateShares_lbl0" xml:lang="en-US">Issuance of aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfAggregateShares" xlink:to="sprcy_IssuanceOfAggregateShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsDescription" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WarrantsDescription_lbl" xml:lang="en-US">Warrants description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsDescription" xlink:to="sprcy_WarrantsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantExpiryPeriod" xlink:href="sprcy-20230630.xsd#sprcy_WarrantExpiryPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WarrantExpiryPeriod_lbl" xml:lang="en-US">Warrant expiry period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantExpiryPeriod" xlink:to="sprcy_WarrantExpiryPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantReserve" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantReserve"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WarrantReserve_lbl" xml:lang="en-US">Warrant amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantReserve" xlink:to="ifrs-full_WarrantReserve_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PlanAssetsAtFairValue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PlanAssetsAtFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PlanAssetsAtFairValue_lbl" xml:lang="en-US">Fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PlanAssetsAtFairValue" xlink:to="ifrs-full_PlanAssetsAtFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_StockIssuedDuringPeriodReverseStockSplits" xlink:href="sprcy-20230630.xsd#sprcy_StockIssuedDuringPeriodReverseStockSplits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_StockIssuedDuringPeriodReverseStockSplits_lbl" xml:lang="en-US">Reverse split ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_StockIssuedDuringPeriodReverseStockSplits" xlink:to="sprcy_StockIssuedDuringPeriodReverseStockSplits_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NoParValuePerShare" xlink:href="sprcy-20230630.xsd#sprcy_NoParValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NoParValuePerShare_lbl" xml:lang="en-US">Ordinary shares no par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NoParValuePerShare" xlink:to="sprcy_NoParValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfPrivateOffering" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfPrivateOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfPrivateOffering_lbl" xml:lang="en-US">Description of private offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfPrivateOffering" xlink:to="sprcy_DescriptionOfPrivateOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DateOfIssuance" xlink:href="sprcy-20230630.xsd#sprcy_DateOfIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DateOfIssuance_lbl" xml:lang="en-US">Date of issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DateOfIssuance" xlink:to="sprcy_DateOfIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsAndExercise" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsAndExercise"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WarrantsAndExercise_lbl" xml:lang="en-US">Warrants and exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsAndExercise" xlink:to="sprcy_WarrantsAndExercise_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShares" xlink:href="sprcy-20230630.xsd#sprcy_IssuanceOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuanceOfShares_lbl" xml:lang="en-US">Share issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShares" xlink:to="sprcy_IssuanceOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfReverseShareSplit" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfReverseShareSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfReverseShareSplit_lbl" xml:lang="en-US">Description of reverse share split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfReverseShareSplit" xlink:to="sprcy_DescriptionOfReverseShareSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseAgreementsDescription" xlink:href="sprcy-20230630.xsd#sprcy_PurchaseAgreementsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchaseAgreementsDescription_lbl" xml:lang="en-US">Purchase agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseAgreementsDescription" xlink:to="sprcy_PurchaseAgreementsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_GrossProceeds" xlink:href="sprcy-20230630.xsd#sprcy_GrossProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_GrossProceeds_lbl" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GrossProceeds" xlink:to="sprcy_GrossProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_lbl" xml:lang="en-US">Exercise warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:to="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsExercisePrice" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WarrantsExercisePrice_lbl" xml:lang="en-US">Warrants exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsExercisePrice" xlink:to="sprcy_WarrantsExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InterestPercentgae" xlink:href="sprcy-20230630.xsd#sprcy_InterestPercentgae"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InterestPercentgae_lbl" xml:lang="en-US">Interest percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestPercentgae" xlink:to="sprcy_InterestPercentgae_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DeferredCashPayments" xlink:href="sprcy-20230630.xsd#sprcy_DeferredCashPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DeferredCashPayments_lbl" xml:lang="en-US">Deferred cash payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DeferredCashPayments" xlink:to="sprcy_DeferredCashPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FeeExpenses" xlink:href="sprcy-20230630.xsd#sprcy_FeeExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FeeExpenses_lbl" xml:lang="en-US">Fee expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FeeExpenses" xlink:to="sprcy_FeeExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_BonusAmountReceived" xlink:href="sprcy-20230630.xsd#sprcy_BonusAmountReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_BonusAmountReceived_lbl" xml:lang="en-US">Bonus amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BonusAmountReceived" xlink:to="sprcy_BonusAmountReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_MutualShareExchangeAmount" xlink:href="sprcy-20230630.xsd#sprcy_MutualShareExchangeAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_MutualShareExchangeAmount_lbl" xml:lang="en-US">Mutual share exchange amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MutualShareExchangeAmount" xlink:to="sprcy_MutualShareExchangeAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesAcquired" xlink:href="sprcy-20230630.xsd#sprcy_OrdinarySharesAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OrdinarySharesAcquired_lbl" xml:lang="en-US">Acquired ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesAcquired" xlink:to="sprcy_OrdinarySharesAcquired_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_OrdinarySharesAcquired_lbl0" xml:lang="en-US">Purchase of ordinary share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesAcquired" xlink:to="sprcy_OrdinarySharesAcquired_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateValue" xlink:href="sprcy-20230630.xsd#sprcy_AggregateValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateValue_lbl" xml:lang="en-US">Aggregate value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateValue" xlink:to="sprcy_AggregateValue_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustedAmountOfAggregateValue" xlink:href="sprcy-20230630.xsd#sprcy_AdjustedAmountOfAggregateValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdjustedAmountOfAggregateValue_lbl" xml:lang="en-US">Adjusted amount of aggregate value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustedAmountOfAggregateValue" xlink:to="sprcy_AdjustedAmountOfAggregateValue_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OwnershipPercentage" xlink:href="sprcy-20230630.xsd#sprcy_OwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OwnershipPercentage_lbl" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OwnershipPercentage" xlink:to="sprcy_OwnershipPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ClaimsOnDamages" xlink:href="sprcy-20230630.xsd#sprcy_ClaimsOnDamages"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ClaimsOnDamages_lbl" xml:lang="en-US">Claims on damages</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ClaimsOnDamages" xlink:to="sprcy_ClaimsOnDamages_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfPublicOffering" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfPublicOffering_lbl" xml:lang="en-US">Description of public offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfPublicOffering" xlink:to="sprcy_DescriptionOfPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateGrossProceeds" xlink:href="sprcy-20230630.xsd#sprcy_AggregateGrossProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateGrossProceeds_lbl" xml:lang="en-US">Aggregate gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateGrossProceeds" xlink:to="sprcy_AggregateGrossProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfAggregatePurchasePrice" xlink:href="sprcy-20230630.xsd#sprcy_PercentageOfAggregatePurchasePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PercentageOfAggregatePurchasePrice_lbl" xml:lang="en-US">Percentage of aggregate purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfAggregatePurchasePrice" xlink:to="sprcy_PercentageOfAggregatePurchasePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregatePurchasePrice" xlink:href="sprcy-20230630.xsd#sprcy_AggregatePurchasePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregatePurchasePrice_lbl" xml:lang="en-US">Aggregate purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregatePurchasePrice" xlink:to="sprcy_AggregatePurchasePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasePricePerShare" xlink:href="sprcy-20230630.xsd#sprcy_PurchasePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchasePricePerShare_lbl" xml:lang="en-US">Purchase price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasePricePerShare" xlink:to="sprcy_PurchasePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PrefundedOrdinaryShare" xlink:href="sprcy-20230630.xsd#sprcy_PrefundedOrdinaryShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PrefundedOrdinaryShare_lbl" xml:lang="en-US">Pre-funded ordinary share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrefundedOrdinaryShare" xlink:to="sprcy_PrefundedOrdinaryShare_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseOrdinaryShares" xlink:href="sprcy-20230630.xsd#sprcy_PurchaseOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchaseOrdinaryShares_lbl" xml:lang="en-US">Purchase ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseOrdinaryShares" xlink:to="sprcy_PurchaseOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TermOfIssuance" xlink:href="sprcy-20230630.xsd#sprcy_TermOfIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_TermOfIssuance_lbl" xml:lang="en-US">Term of issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TermOfIssuance" xlink:to="sprcy_TermOfIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfStockEqual" xlink:href="sprcy-20230630.xsd#sprcy_PercentageOfStockEqual"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PercentageOfStockEqual_lbl" xml:lang="en-US">Percentage of stock equal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfStockEqual" xlink:to="sprcy_PercentageOfStockEqual_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfWorkingCapital" xlink:href="sprcy-20230630.xsd#sprcy_PercentageOfWorkingCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PercentageOfWorkingCapital_lbl" xml:lang="en-US">Percentage of working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfWorkingCapital" xlink:to="sprcy_PercentageOfWorkingCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_MonthlyFee" xlink:href="sprcy-20230630.xsd#sprcy_MonthlyFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_MonthlyFee_lbl" xml:lang="en-US">Monthly fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MonthlyFee" xlink:to="sprcy_MonthlyFee_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_BonusAmount" xlink:href="sprcy-20230630.xsd#sprcy_BonusAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_BonusAmount_lbl" xml:lang="en-US">Bonus amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BonusAmount" xlink:to="sprcy_BonusAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares_lbl" xml:lang="en-US">Ordinary shares value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalOrdinaryShares" xlink:to="ifrs-full_IssuedCapitalOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInJointOperation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInJointOperation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProportionOfOwnershipInterestInJointOperation_lbl" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInJointOperation" xlink:to="ifrs-full_ProportionOfOwnershipInterestInJointOperation_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ConversionOfOrdinaryShares" xlink:href="sprcy-20230630.xsd#sprcy_ConversionOfOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ConversionOfOrdinaryShares_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ConversionOfOrdinaryShares" xlink:to="sprcy_ConversionOfOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesPerValue" xlink:href="sprcy-20230630.xsd#sprcy_OrdinarySharesPerValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OrdinarySharesPerValue_lbl" xml:lang="en-US">Ordinary shares per value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesPerValue" xlink:to="sprcy_OrdinarySharesPerValue_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital" xlink:href="sprcy-20230630.xsd#sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital_lbl" xml:lang="en-US">Percentage of shares issued and outstanding share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital" xlink:to="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairMarketValue" xlink:href="sprcy-20230630.xsd#sprcy_FairMarketValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FairMarketValue_lbl" xml:lang="en-US">Fair market value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairMarketValue" xlink:to="sprcy_FairMarketValue_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_lbl" xml:lang="en-US">Transaction costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:to="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseOfOrdinaryShares" xlink:href="sprcy-20230630.xsd#sprcy_PurchaseOfOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchaseOfOrdinaryShares_lbl" xml:lang="en-US">Purchase of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseOfOrdinaryShares" xlink:to="sprcy_PurchaseOfOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareholdersAmount" xlink:href="sprcy-20230630.xsd#sprcy_ShareholdersAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareholdersAmount_lbl" xml:lang="en-US">Shareholders amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareholdersAmount" xlink:to="sprcy_ShareholdersAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuedAndOutstandingSharesPercentage" xlink:href="sprcy-20230630.xsd#sprcy_IssuedAndOutstandingSharesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuedAndOutstandingSharesPercentage_lbl" xml:lang="en-US">Issued and outstanding shares percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuedAndOutstandingSharesPercentage" xlink:to="sprcy_IssuedAndOutstandingSharesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForAmountsTransferredToInitialCarryingAmountOfHedgedItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForAmountsTransferredToInitialCarryingAmountOfHedgedItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForAmountsTransferredToInitialCarryingAmountOfHedgedItems_lbl" xml:lang="en-US">Initial amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForAmountsTransferredToInitialCarryingAmountOfHedgedItems" xlink:to="ifrs-full_AdjustmentsForAmountsTransferredToInitialCarryingAmountOfHedgedItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestedInitialAmounts" xlink:href="sprcy-20230630.xsd#sprcy_InvestedInitialAmounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestedInitialAmounts_lbl" xml:lang="en-US">Invested initial amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestedInitialAmounts" xlink:to="sprcy_InvestedInitialAmounts_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PreDeterminedValue" xlink:href="sprcy-20230630.xsd#sprcy_PreDeterminedValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PreDeterminedValue_lbl" xml:lang="en-US">Pre determined</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PreDeterminedValue" xlink:to="sprcy_PreDeterminedValue_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InitialInvestmentAmount" xlink:href="sprcy-20230630.xsd#sprcy_InitialInvestmentAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InitialInvestmentAmount_lbl" xml:lang="en-US">Initial investment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialInvestmentAmount" xlink:to="sprcy_InitialInvestmentAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStocks" xlink:href="sprcy-20230630.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStocks"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStocks_lbl" xml:lang="en-US">Outstanding shares percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStocks" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStocks_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SquareMeters" xlink:href="sprcy-20230630.xsd#sprcy_SquareMeters"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SquareMeters_lbl" xml:lang="en-US">Square meters</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SquareMeters" xlink:to="sprcy_SquareMeters_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeaseFee" xlink:href="sprcy-20230630.xsd#sprcy_LeaseFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LeaseFee_lbl" xml:lang="en-US">Lease fee (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseFee" xlink:to="sprcy_LeaseFee_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExpireTerm" xlink:href="sprcy-20230630.xsd#sprcy_ExpireTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExpireTerm_lbl" xml:lang="en-US">Lease expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExpireTerm" xlink:to="sprcy_ExpireTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationExpense_lbl" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationExpense" xlink:to="ifrs-full_DepreciationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ApplicableTaxRate_lbl" xml:lang="en-US">Israeli corporate income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ApplicableTaxRate" xlink:to="ifrs-full_ApplicableTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingLossCarryforwardsTaxAmount" xlink:href="sprcy-20230630.xsd#sprcy_OperatingLossCarryforwardsTaxAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OperatingLossCarryforwardsTaxAmount_lbl" xml:lang="en-US">Carry forward tax losses, total (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingLossCarryforwardsTaxAmount" xlink:to="sprcy_OperatingLossCarryforwardsTaxAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DekelLicenseAgreementDescription" xlink:href="sprcy-20230630.xsd#sprcy_DekelLicenseAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DekelLicenseAgreementDescription_lbl" xml:lang="en-US">Dekel license agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DekelLicenseAgreementDescription" xlink:to="sprcy_DekelLicenseAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AnnualInvestment" xlink:href="sprcy-20230630.xsd#sprcy_AnnualInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AnnualInvestment_lbl" xml:lang="en-US">Annual investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AnnualInvestment" xlink:to="sprcy_AnnualInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalMilestoneAmount" xlink:href="sprcy-20230630.xsd#sprcy_AdditionalMilestoneAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdditionalMilestoneAmount_lbl" xml:lang="en-US">Additional milestone amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalMilestoneAmount" xlink:to="sprcy_AdditionalMilestoneAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InstallmentAmount" xlink:href="sprcy-20230630.xsd#sprcy_InstallmentAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InstallmentAmount_lbl" xml:lang="en-US">Installment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentAmount" xlink:to="sprcy_InstallmentAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TotalAgreementEstimatingAmount" xlink:href="sprcy-20230630.xsd#sprcy_TotalAgreementEstimatingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_TotalAgreementEstimatingAmount_lbl" xml:lang="en-US">Total estimated amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TotalAgreementEstimatingAmount" xlink:to="sprcy_TotalAgreementEstimatingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CapitalProposedToDeposit" xlink:href="sprcy-20230630.xsd#sprcy_CapitalProposedToDeposit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CapitalProposedToDeposit_lbl" xml:lang="en-US">Capital proposed to deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CapitalProposedToDeposit" xlink:to="sprcy_CapitalProposedToDeposit_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_lbl" xml:lang="en-US">Additional number of share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:to="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareOptionsReserved" xlink:href="sprcy-20230630.xsd#sprcy_ShareOptionsReserved"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareOptionsReserved_lbl" xml:lang="en-US">Share Options reserved</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareOptionsReserved" xlink:to="sprcy_ShareOptionsReserved_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfSharesOptionGrantedInSharebasedPaymentArrangement" xlink:href="sprcy-20230630.xsd#sprcy_NumberOfSharesOptionGrantedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NumberOfSharesOptionGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Available for grant shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfSharesOptionGrantedInSharebasedPaymentArrangement" xlink:to="sprcy_NumberOfSharesOptionGrantedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinaryShares" xlink:href="sprcy-20230630.xsd#sprcy_OrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OrdinaryShares_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinaryShares" xlink:to="sprcy_OrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairValueOption" xlink:href="sprcy-20230630.xsd#sprcy_FairValueOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FairValueOption_lbl" xml:lang="en-US">Fair value of share options (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOption" xlink:to="sprcy_FairValueOption_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_StockOptionDescription" xlink:href="sprcy-20230630.xsd#sprcy_StockOptionDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_StockOptionDescription_lbl" xml:lang="en-US">Stock option, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_StockOptionDescription" xlink:to="sprcy_StockOptionDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairValueDescription" xlink:href="sprcy-20230630.xsd#sprcy_FairValueDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FairValueDescription_lbl" xml:lang="en-US">Fair value, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueDescription" xlink:to="sprcy_FairValueDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RSUGrantedDiscountRate" xlink:href="sprcy-20230630.xsd#sprcy_RSUGrantedDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RSUGrantedDiscountRate_lbl" xml:lang="en-US">RSU granted discount rate</label>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2w4dODRyrf2cKq4MnlNojKY2vawGlGpB5CaguD0HWK7+MXGfIzhA2ezfWaTq7hAnt683nzSc747v3s9ubzeRZw15+aEvNutYTqGoMIIBc15Xh4havgCm8tS4Bj7akcreuoiwU1Nvoijg=] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RSUGrantedDiscountRate" xlink:to="sprcy_RSUGrantedDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairValueOfTheRSUsGranted" xlink:href="sprcy-20230630.xsd#sprcy_FairValueOfTheRSUsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FairValueOfTheRSUsGranted_lbl" xml:lang="en-US">Fair value of the RSU&#8217;s granted (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfTheRSUsGranted" xlink:to="sprcy_FairValueOfTheRSUsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesIssued" xlink:href="sprcy-20230630.xsd#sprcy_OrdinarySharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OrdinarySharesIssued_lbl" xml:lang="en-US">Ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesIssued" xlink:to="sprcy_OrdinarySharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinaryGrantedDiscountRate" xlink:href="sprcy-20230630.xsd#sprcy_OrdinaryGrantedDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OrdinaryGrantedDiscountRate_lbl" xml:lang="en-US">Ordinary granted discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinaryGrantedDiscountRate" xlink:to="sprcy_OrdinaryGrantedDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption" xlink:href="sprcy-20230630.xsd#sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption_lbl" xml:lang="en-US">Weighted average remaining contractual life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption" xlink:to="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareOptionsOutstandingParValue" xlink:href="sprcy-20230630.xsd#sprcy_ShareOptionsOutstandingParValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareOptionsOutstandingParValue_lbl" xml:lang="en-US">Share options outstanding (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareOptionsOutstandingParValue" xlink:to="sprcy_ShareOptionsOutstandingParValue_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xml:lang="en-US">Unaudited Interim Financial Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_BasisOfPresentationOfFinancialStatements" xlink:href="sprcy-20230630.xsd#sprcy_BasisOfPresentationOfFinancialStatements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_BasisOfPresentationOfFinancialStatements_lbl" xml:lang="en-US">Basis of presentation of the financial statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BasisOfPresentationOfFinancialStatements" xlink:to="sprcy_BasisOfPresentationOfFinancialStatements_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl" xml:lang="en-US">The operating cycle</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:to="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl" xml:lang="en-US">Consolidated financial statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:to="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" xml:lang="en-US">Functional currency and foreign currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfAcquisitionOfASingleAssetCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl" xml:lang="en-US">Acquisition of a single asset company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" xlink:to="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit_lbl" xml:lang="en-US">Restricted deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit" xlink:to="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory_lbl" xml:lang="en-US">Investment in joint arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates_lbl" xml:lang="en-US">Investments in associates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock_lbl" xml:lang="en-US">Investments accounted for using the equity method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" xlink:to="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl" xml:lang="en-US">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl" xml:lang="en-US">Impairment of non-financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">Financial instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US">Research and development expenditures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_lbl" xml:lang="en-US">Finance income and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl" xml:lang="en-US">Fair value measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_lbl" xml:lang="en-US">Taxes on income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl" xml:lang="en-US">Share-based payment transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl" xml:lang="en-US">Earnings (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl" xml:lang="en-US">Employee benefit liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl" xml:lang="en-US">Provisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements_lbl" xml:lang="en-US">Amendment to IAS 1, &#8220;Presentation of Financial Statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements" xlink:to="sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors_lbl" xml:lang="en-US">Amendment to IAS 8, &#8220;Accounting Policies, Changes to Accounting Estimates and Errors&#8221;</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" xlink:to="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_MitoCareXBioLtdMember" xlink:href="sprcy-20230630.xsd#sprcy_MitoCareXBioLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_MitoCareXBioLtdMember_lbl" xml:lang="en-US">MitoCareX Bio Ltd. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MitoCareXBioLtdMember" xlink:to="sprcy_MitoCareXBioLtdMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_MitoCareXBioLtdMember_lbl0" xml:lang="en-US">MitoCare X Bio Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MitoCareXBioLtdMember" xlink:to="sprcy_MitoCareXBioLtdMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_MitoCareXMember" xlink:href="sprcy-20230630.xsd#sprcy_MitoCareXMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_MitoCareXMember_lbl" xml:lang="en-US">MitoCareX [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MitoCareXMember" xlink:to="sprcy_MitoCareXMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US">Ordinary Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OrdinarySharesMember_lbl0" xml:lang="en-US">Ordinary shares [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_AutoMaxSharesMember" xlink:href="sprcy-20230630.xsd#sprcy_AutoMaxSharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AutoMaxSharesMember_lbl" xml:lang="en-US">AutoMax Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AutoMaxSharesMember" xlink:to="sprcy_AutoMaxSharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ADSsMember" xlink:href="sprcy-20230630.xsd#sprcy_ADSsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ADSsMember_lbl" xml:lang="en-US">ADSs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ADSsMember" xlink:to="sprcy_ADSsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PrivatePlacementsMember" xlink:href="sprcy-20230630.xsd#sprcy_PrivatePlacementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PrivatePlacementsMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrivatePlacementsMember" xlink:to="sprcy_PrivatePlacementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_March2021FinancingRoundMember" xlink:href="sprcy-20230630.xsd#sprcy_March2021FinancingRoundMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_March2021FinancingRoundMember_lbl" xml:lang="en-US">March 2021 Financing Round [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_March2021FinancingRoundMember" xlink:to="sprcy_March2021FinancingRoundMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SeriesAWarrantsMember" xlink:href="sprcy-20230630.xsd#sprcy_SeriesAWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SeriesAWarrantsMember_lbl" xml:lang="en-US">Series A Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SeriesAWarrantsMember" xlink:to="sprcy_SeriesAWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SeriesBWarrantsMember" xlink:href="sprcy-20230630.xsd#sprcy_SeriesBWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SeriesBWarrantsMember_lbl" xml:lang="en-US">Series B Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SeriesBWarrantsMember" xlink:to="sprcy_SeriesBWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_June2022FinancingRoundMember" xlink:href="sprcy-20230630.xsd#sprcy_June2022FinancingRoundMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_June2022FinancingRoundMember_lbl" xml:lang="en-US">June 2022 Financing Round [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_June2022FinancingRoundMember" xlink:to="sprcy_June2022FinancingRoundMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_June2022WarrantsMember" xlink:href="sprcy-20230630.xsd#sprcy_June2022WarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_June2022WarrantsMember_lbl" xml:lang="en-US">June 2022 Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_June2022WarrantsMember" xlink:to="sprcy_June2022WarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AprilTwoThousandTwentyPurchaseAgreementMember" xlink:href="sprcy-20230630.xsd#sprcy_AprilTwoThousandTwentyPurchaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AprilTwoThousandTwentyPurchaseAgreementMember_lbl" xml:lang="en-US">April 2020 Purchase Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AprilTwoThousandTwentyPurchaseAgreementMember" xlink:to="sprcy_AprilTwoThousandTwentyPurchaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_November2020FinancingRoundMember" xlink:href="sprcy-20230630.xsd#sprcy_November2020FinancingRoundMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_November2020FinancingRoundMember_lbl" xml:lang="en-US">November 2020 Financing Round [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_November2020FinancingRoundMember" xlink:to="sprcy_November2020FinancingRoundMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PrefundedWarrantsMember" xlink:href="sprcy-20230630.xsd#sprcy_PrefundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PrefundedWarrantsMember_lbl" xml:lang="en-US">Pre-funded warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrefundedWarrantsMember" xlink:to="sprcy_PrefundedWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantReserveMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantReserveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WarrantReserveMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantReserveMember" xlink:to="ifrs-full_WarrantReserveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NewCoIncMember" xlink:href="sprcy-20230630.xsd#sprcy_NewCoIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NewCoIncMember_lbl" xml:lang="en-US">NewCo Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NewCoIncMember" xlink:to="sprcy_NewCoIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_JeffsBrandsMember" xlink:href="sprcy-20230630.xsd#sprcy_JeffsBrandsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_JeffsBrandsMember_lbl" xml:lang="en-US">Jeffs&#8217; Brands [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_JeffsBrandsMember" xlink:to="sprcy_JeffsBrandsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CapitalPointWarrantMember" xlink:href="sprcy-20230630.xsd#sprcy_CapitalPointWarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CapitalPointWarrantMember_lbl" xml:lang="en-US">Capital Point Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CapitalPointWarrantMember" xlink:to="sprcy_CapitalPointWarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SCISPARCLTDMember" xlink:href="sprcy-20230630.xsd#sprcy_SCISPARCLTDMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SCISPARCLTDMember_lbl" xml:lang="en-US">SCISPARC LTD [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SCISPARCLTDMember" xlink:to="sprcy_SCISPARCLTDMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SubsequentMember" xlink:href="sprcy-20230630.xsd#sprcy_SubsequentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SubsequentMember_lbl" xml:lang="en-US">Subsequent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SubsequentMember" xlink:to="sprcy_SubsequentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EveroMember" xlink:href="sprcy-20230630.xsd#sprcy_EveroMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_EveroMember_lbl" xml:lang="en-US">Evero [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EveroMember" xlink:to="sprcy_EveroMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CapitalPointMember" xlink:href="sprcy-20230630.xsd#sprcy_CapitalPointMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CapitalPointMember_lbl" xml:lang="en-US">Capital Point [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CapitalPointMember" xlink:to="sprcy_CapitalPointMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeaseMember" xlink:href="sprcy-20230630.xsd#sprcy_LeaseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LeaseMember_lbl" xml:lang="en-US">2021 Lease [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseMember" xlink:to="sprcy_LeaseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityMember_lbl" xml:lang="en-US">Equity [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_EquityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US">Statement of changes in equity [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US">Statement of changes in equity [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashTable" xlink:href="sprcy-20230630.xsd#sprcy_CashTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CashTable_lbl" xml:lang="en-US">Cash [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashTable" xlink:to="sprcy_CashTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashLineItems" xlink:href="sprcy-20230630.xsd#sprcy_CashLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CashLineItems_lbl" xml:lang="en-US">Cash [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashLineItems" xlink:to="sprcy_CashLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTable" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTable_lbl" xml:lang="en-US">Investment in Associates and Investments in Investees [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTable" xlink:to="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociatesandInvestmentsinInvesteesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesLineItems_lbl" xml:lang="en-US">Investment in Associates and Investments in Investees [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesLineItems" xlink:to="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetTable" xlink:href="sprcy-20230630.xsd#sprcy_PropertyandEquipmentNetTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PropertyandEquipmentNetTable_lbl" xml:lang="en-US">Property and Equipment, Net [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PropertyandEquipmentNetTable" xlink:to="sprcy_PropertyandEquipmentNetTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetLineItems" xlink:href="sprcy-20230630.xsd#sprcy_PropertyandEquipmentNetLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PropertyandEquipmentNetLineItems_lbl" xml:lang="en-US">Property and Equipment, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PropertyandEquipmentNetLineItems" xlink:to="sprcy_PropertyandEquipmentNetLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EmployeeBenefitLiabilitiesTable" xlink:href="sprcy-20230630.xsd#sprcy_EmployeeBenefitLiabilitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EmployeeBenefitLiabilitiesTable_lbl" xml:lang="en-US">Employee Benefit Liabilities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EmployeeBenefitLiabilitiesTable" xlink:to="sprcy_EmployeeBenefitLiabilitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EmployeeBenefitLiabilitiesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_EmployeeBenefitLiabilitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EmployeeBenefitLiabilitiesLineItems_lbl" xml:lang="en-US">Employee Benefit Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EmployeeBenefitLiabilitiesLineItems" xlink:to="sprcy_EmployeeBenefitLiabilitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesTablesTable_lbl" xml:lang="en-US">Transactions and Balances with Related Parties (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesTablesTable" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesTablesLineItems_lbl" xml:lang="en-US">Transactions and Balances With Related Parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesTablesLineItems" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossTablesTable_lbl" xml:lang="en-US">Additional Information to the Items of Profit or Loss (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossTablesTable" xlink:to="sprcy_AdditionalInformationtotheItemsofProfitorLossTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossTablesLineItems_lbl" xml:lang="en-US">Additional Information to the Items of Profit or Loss [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossTablesLineItems" xlink:to="sprcy_AdditionalInformationtotheItemsofProfitorLossTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_CashTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CashTablesTable_lbl" xml:lang="en-US">Cash (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashTablesTable" xlink:to="sprcy_CashTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_CashTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CashTablesLineItems_lbl" xml:lang="en-US">Disclosure of Cash [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashTablesLineItems" xlink:to="sprcy_CashTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OtherAccountsReceivableTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_OtherAccountsReceivableTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OtherAccountsReceivableTablesTable_lbl" xml:lang="en-US">Other Accounts Receivable (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OtherAccountsReceivableTablesTable" xlink:to="sprcy_OtherAccountsReceivableTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OtherAccountsReceivableTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_OtherAccountsReceivableTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OtherAccountsReceivableTablesLineItems_lbl" xml:lang="en-US">Disclosure of Other Accounts Receivable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OtherAccountsReceivableTablesLineItems" xlink:to="sprcy_OtherAccountsReceivableTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTablesTable_lbl" xml:lang="en-US">Investment in Associates and Investments in Investees (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTablesTable" xlink:to="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTablesLineItems_lbl" xml:lang="en-US">Investment in Associates and Investments in Investees [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTablesLineItems" xlink:to="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_PropertyandEquipmentNetTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PropertyandEquipmentNetTablesTable_lbl" xml:lang="en-US">Property and Equipment, Net (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PropertyandEquipmentNetTablesTable" xlink:to="sprcy_PropertyandEquipmentNetTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_PropertyandEquipmentNetTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PropertyandEquipmentNetTablesLineItems_lbl" xml:lang="en-US">Discourse of Property and Equipment, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PropertyandEquipmentNetTablesLineItems" xlink:to="sprcy_PropertyandEquipmentNetTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TradePayablesTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_TradePayablesTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TradePayablesTablesTable_lbl" xml:lang="en-US">Trade Payables (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TradePayablesTablesTable" xlink:to="sprcy_TradePayablesTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TradePayablesTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_TradePayablesTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TradePayablesTablesLineItems_lbl" xml:lang="en-US">Disclosure of Trade Payables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TradePayablesTablesLineItems" xlink:to="sprcy_TradePayablesTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EmployeeBenefitLiabilitiesTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_EmployeeBenefitLiabilitiesTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EmployeeBenefitLiabilitiesTablesTable_lbl" xml:lang="en-US">Employee Benefit Liabilities (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EmployeeBenefitLiabilitiesTablesTable" xlink:to="sprcy_EmployeeBenefitLiabilitiesTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EmployeeBenefitLiabilitiesTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_EmployeeBenefitLiabilitiesTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_EmployeeBenefitLiabilitiesTablesLineItems_lbl" xml:lang="en-US">Employee Benefit Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EmployeeBenefitLiabilitiesTablesLineItems" xlink:to="sprcy_EmployeeBenefitLiabilitiesTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_ShareBasedPaymentTransactionsTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedPaymentTransactionsTablesTable_lbl" xml:lang="en-US">Share-Based Payment Transactions (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedPaymentTransactionsTablesTable" xlink:to="sprcy_ShareBasedPaymentTransactionsTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_ShareBasedPaymentTransactionsTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedPaymentTransactionsTablesLineItems_lbl" xml:lang="en-US">Share-based Payment Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedPaymentTransactionsTablesLineItems" xlink:to="sprcy_ShareBasedPaymentTransactionsTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LossPerShareAdsTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_LossPerShareAdsTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LossPerShareAdsTablesTable_lbl" xml:lang="en-US">Loss Per Share/Ads (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LossPerShareAdsTablesTable" xlink:to="sprcy_LossPerShareAdsTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LossPerShareAdsTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_LossPerShareAdsTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LossPerShareAdsTablesLineItems_lbl" xml:lang="en-US">Disclosure of Loss Per Share Or Ads [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LossPerShareAdsTablesLineItems" xlink:to="sprcy_LossPerShareAdsTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_OperatingSegmentsTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OperatingSegmentsTablesTable_lbl" xml:lang="en-US">Operating Segments (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingSegmentsTablesTable" xlink:to="sprcy_OperatingSegmentsTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_OperatingSegmentsTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OperatingSegmentsTablesLineItems_lbl" xml:lang="en-US">Operating Segments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingSegmentsTablesLineItems" xlink:to="sprcy_OperatingSegmentsTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentTable" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentTable_lbl" xml:lang="en-US">Investment in Associate (Details) - Schedule of Fair Value of the Investment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentTable" xlink:to="sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentLineItems" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentLineItems_lbl" xml:lang="en-US">Investment in Associate [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentLineItems" xlink:to="sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable" xlink:href="sprcy-20230630.xsd#sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable_lbl" xml:lang="en-US">Financial Instruments (Details) - Schedule of Financial Assets and Financial Liabilities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable" xlink:to="sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesLineItems_lbl" xml:lang="en-US">Financial Instruments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesLineItems" xlink:to="sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xml:lang="en-US">Share-based payment arrangements [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsDetailsScheduleofWarrantsFairValueTable" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsDetailsScheduleofWarrantsFairValueTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsDetailsScheduleofWarrantsFairValueTable_lbl" xml:lang="en-US">Warrants (Details) - Schedule of Warrants&#8217; Fair Value [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsDetailsScheduleofWarrantsFairValueTable" xlink:to="sprcy_WarrantsDetailsScheduleofWarrantsFairValueTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsDetailsScheduleofWarrantsFairValueLineItems" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsDetailsScheduleofWarrantsFairValueLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsDetailsScheduleofWarrantsFairValueLineItems_lbl" xml:lang="en-US">Warrants (Details) - Schedule of Warrants&#8217; Fair Value [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsDetailsScheduleofWarrantsFairValueLineItems" xlink:to="sprcy_WarrantsDetailsScheduleofWarrantsFairValueLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestatedMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestatedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RestatedMember_lbl" xml:lang="en-US">Currently stated [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_RestatedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityDetailsScheduleofShareCapitalTable" xlink:href="sprcy-20230630.xsd#sprcy_EquityDetailsScheduleofShareCapitalTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EquityDetailsScheduleofShareCapitalTable_lbl" xml:lang="en-US">Equity (Details) - Schedule of Share Capital [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityDetailsScheduleofShareCapitalTable" xlink:to="sprcy_EquityDetailsScheduleofShareCapitalTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityDetailsScheduleofShareCapitalLineItems" xlink:href="sprcy-20230630.xsd#sprcy_EquityDetailsScheduleofShareCapitalLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EquityDetailsScheduleofShareCapitalLineItems_lbl" xml:lang="en-US">Equity (Details) - Schedule of Share Capital [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityDetailsScheduleofShareCapitalLineItems" xlink:to="sprcy_EquityDetailsScheduleofShareCapitalLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsDomainDomain" xlink:href="sprcy-20230630.xsd#sprcy_IncomeStatementsLocationsDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IncomeStatementsLocationsDomainDomain_lbl" xml:lang="en-US">IncomeStatementsLocationsDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_IncomeStatementsLocationsDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable" xlink:href="sprcy-20230630.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable_lbl" xml:lang="en-US">Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable" xlink:to="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:href="sprcy-20230630.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems_lbl" xml:lang="en-US">Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:to="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Property, plant and equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangesMember_lbl" xml:lang="en-US">Ranges [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_RangesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" xlink:href="sprcy-20230630.xsd#sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable_lbl" xml:lang="en-US">Significant Accounting Policies (Details) - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" xlink:to="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" xlink:href="sprcy-20230630.xsd#sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems_lbl" xml:lang="en-US">Significant Accounting Policies (Details) - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" xlink:to="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentTable" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentTable_lbl" xml:lang="en-US">Investment in Associates and Investments in Investees (Details) - Schedule of Fair Value of the Investment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentTable" xlink:to="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentLineItems" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentLineItems_lbl" xml:lang="en-US">Schedule of Fair Value of the Investment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentLineItems" xlink:to="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable" xlink:href="sprcy-20230630.xsd#sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable_lbl" xml:lang="en-US">Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable" xlink:to="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems" xlink:href="sprcy-20230630.xsd#sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems_lbl" xml:lang="en-US">Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems" xlink:to="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable" xlink:href="sprcy-20230630.xsd#sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable_lbl" xml:lang="en-US">Intangible Asset (Details) - Schedule of Fair Value of the Intangible Asset [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable" xlink:to="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" xlink:href="sprcy-20230630.xsd#sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems_lbl" xml:lang="en-US">Schedule of Fair Value of the Intangible Asset [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" xlink:to="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableTable" xlink:href="sprcy-20230630.xsd#sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableTable_lbl" xml:lang="en-US">Other Accounts Payable (Details) - Schedule of Other Accounts Payable [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableTable" xlink:to="sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableLineItems" xlink:href="sprcy-20230630.xsd#sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableLineItems_lbl" xml:lang="en-US">Schedule of Other Accounts Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableLineItems" xlink:to="sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OrdinarySharesMember_lbl1" xml:lang="en-US">Ordinary shares [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ContinuingOperationsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContinuingOperationsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ContinuingOperationsMember_lbl" xml:lang="en-US">Continuing operations [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContinuingOperationsMember" xlink:to="ifrs-full_ContinuingOperationsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" xlink:href="sprcy-20230630.xsd#sprcy_LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable_lbl" xml:lang="en-US">Loss Per Share/Ads (Details) - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" xlink:to="sprcy_LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareLineItems" xlink:href="sprcy-20230630.xsd#sprcy_LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareLineItems_lbl" xml:lang="en-US">Loss Per Share/Ads (Details) - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareLineItems" xlink:to="sprcy_LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SegmentsMember_lbl" xml:lang="en-US">Segments [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SegmentsMember" xlink:to="ifrs-full_SegmentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsDetailsScheduleofOperatingSegmentsTable" xlink:href="sprcy-20230630.xsd#sprcy_OperatingSegmentsDetailsScheduleofOperatingSegmentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OperatingSegmentsDetailsScheduleofOperatingSegmentsTable_lbl" xml:lang="en-US">Operating Segments (Details) - Schedule of Operating Segments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingSegmentsDetailsScheduleofOperatingSegmentsTable" xlink:to="sprcy_OperatingSegmentsDetailsScheduleofOperatingSegmentsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems_lbl" xml:lang="en-US">Schedule of Operating Segments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xml:lang="en-US">Entity&apos;s total for related parties [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" xlink:href="sprcy-20230630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable_lbl" xml:lang="en-US">Transactions and Balances with Related Parties (Details) - Schedule of Balances with Related Parties [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems_lbl" xml:lang="en-US">Transactions and Balances with Related Parties (Details) - Schedule of Balances with Related Parties [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_GeneralDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_GeneralDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_GeneralDetailsTable_lbl" xml:lang="en-US">General (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GeneralDetailsTable" xlink:to="sprcy_GeneralDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_GeneralDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_GeneralDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_GeneralDetailsLineItems_lbl" xml:lang="en-US">General [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GeneralDetailsLineItems" xlink:to="sprcy_GeneralDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociateDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociateDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinAssociateDetailsTable_lbl" xml:lang="en-US">Investment in Associate (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinAssociateDetailsTable" xlink:to="sprcy_InvestmentinAssociateDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociateDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociateDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinAssociateDetailsLineItems_lbl" xml:lang="en-US">Investment in Associate [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinAssociateDetailsLineItems" xlink:to="sprcy_InvestmentinAssociateDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinFinancialAssetsDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinFinancialAssetsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinFinancialAssetsDetailsTable_lbl" xml:lang="en-US">Investment in Financial Assets (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinFinancialAssetsDetailsTable" xlink:to="sprcy_InvestmentinFinancialAssetsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinFinancialAssetsDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinFinancialAssetsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinFinancialAssetsDetailsLineItems_lbl" xml:lang="en-US">Investment in Financial Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinFinancialAssetsDetailsLineItems" xlink:to="sprcy_InvestmentinFinancialAssetsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfAssetsMember_lbl" xml:lang="en-US">Assets [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_ClassesOfAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_FinancialInstrumentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinancialInstrumentsDetailsTable_lbl" xml:lang="en-US">Financial Instruments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinancialInstrumentsDetailsTable" xlink:to="sprcy_FinancialInstrumentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_FinancialInstrumentsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinancialInstrumentsDetailsLineItems_lbl" xml:lang="en-US">Financial Instruments (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinancialInstrumentsDetailsLineItems" xlink:to="sprcy_FinancialInstrumentsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalMember_lbl" xml:lang="en-US">Share capital [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_ClassesOfShareCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AntidilutiveInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AntidilutiveInstrumentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AntidilutiveInstrumentsMember_lbl" xml:lang="en-US">Antidilutive instruments [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AntidilutiveInstrumentsMember" xlink:to="ifrs-full_AntidilutiveInstrumentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsDetailsTable_lbl" xml:lang="en-US">Warrants (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsDetailsTable" xlink:to="sprcy_WarrantsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsDetailsLineItems_lbl" xml:lang="en-US">Warrants [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsDetailsLineItems" xlink:to="sprcy_WarrantsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysOwnEquityInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysOwnEquityInstrumentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysOwnEquityInstrumentsMember_lbl" xml:lang="en-US">Entity&apos;s own equity instruments [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysOwnEquityInstrumentsMember" xlink:to="ifrs-full_EntitysOwnEquityInstrumentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember_lbl" xml:lang="en-US">Default financial statements date [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="ifrs-full_DefaultFinancialStatementsDateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AgreementTypeDomainDomain" xlink:href="sprcy-20230630.xsd#sprcy_AgreementTypeDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AgreementTypeDomainDomain_lbl" xml:lang="en-US">AgreementTypeDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AgreementTypeDomainDomain" xlink:to="sprcy_AgreementTypeDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_EquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EquityDetailsTable_lbl" xml:lang="en-US">Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityDetailsTable" xlink:to="sprcy_EquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_EquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EquityDetailsLineItems_lbl" xml:lang="en-US">Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_EquityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_SignificantEventsduringtheReportingPeriodDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable_lbl" xml:lang="en-US">Significant Events during the Reporting Period (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable" xlink:to="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems_lbl" xml:lang="en-US">Significant Events during the Reporting Period (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsMember_lbl" xml:lang="en-US">Non-adjusting events after reporting period [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="ifrs-full_NonadjustingEventsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EventsaftertheReportingPeriodDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_EventsaftertheReportingPeriodDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EventsaftertheReportingPeriodDetailsTable_lbl" xml:lang="en-US">Events after the Reporting Period (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsTable" xlink:to="sprcy_EventsaftertheReportingPeriodDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_EventsaftertheReportingPeriodDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EventsaftertheReportingPeriodDetailsLineItems_lbl" xml:lang="en-US">Events after the Reporting Period (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EventsaftertheReportingPeriodDetailsLineItems" xlink:to="sprcy_EventsaftertheReportingPeriodDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsTable_lbl" xml:lang="en-US">Investment in Associates and Investments in Investees (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsTable" xlink:to="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems_lbl" xml:lang="en-US">Investment in Associates and Investments in Investees (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeasesDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_LeasesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LeasesDetailsTable_lbl" xml:lang="en-US">Leases (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeasesDetailsTable" xlink:to="sprcy_LeasesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeasesDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_LeasesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LeasesDetailsLineItems_lbl" xml:lang="en-US">Leases (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeasesDetailsLineItems" xlink:to="sprcy_LeasesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_PropertyandEquipmentNetDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PropertyandEquipmentNetDetailsTable_lbl" xml:lang="en-US">Property and Equipment, Net (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PropertyandEquipmentNetDetailsTable" xlink:to="sprcy_PropertyandEquipmentNetDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_PropertyandEquipmentNetDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PropertyandEquipmentNetDetailsLineItems_lbl" xml:lang="en-US">Disclosure of property, plant and equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PropertyandEquipmentNetDetailsLineItems" xlink:to="sprcy_PropertyandEquipmentNetDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TaxesonIncomeDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_TaxesonIncomeDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TaxesonIncomeDetailsTable_lbl" xml:lang="en-US">Taxes on Income (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TaxesonIncomeDetailsTable" xlink:to="sprcy_TaxesonIncomeDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TaxesonIncomeDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_TaxesonIncomeDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TaxesonIncomeDetailsLineItems_lbl" xml:lang="en-US">Disclosure of income tax [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TaxesonIncomeDetailsLineItems" xlink:to="sprcy_TaxesonIncomeDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_ShareBasedPaymentTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedPaymentTransactionsDetailsTable_lbl" xml:lang="en-US">Share-Based Payment Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsTable" xlink:to="sprcy_ShareBasedPaymentTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_ShareBasedPaymentTransactionsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedPaymentTransactionsDetailsLineItems_lbl" xml:lang="en-US">Share-Based Payment Transactions (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_ShareBasedPaymentTransactionsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AccumulatedTerminationOfLeases_lbl0" xml:lang="en-US">Accumulated termination of leases.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccumulatedTerminationOfLeases" xlink:to="sprcy_AccumulatedTerminationOfLeases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AdditionalAgreedInvest_lbl0" xml:lang="en-US">Additional agreed invest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalAgreedInvest" xlink:to="sprcy_AdditionalAgreedInvest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AdjustedAmountOfAggregateValue_lbl0" xml:lang="en-US">The adjusted amount of aggregate value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustedAmountOfAggregateValue" xlink:to="sprcy_AdjustedAmountOfAggregateValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AdjustmentsForImpairmentOfInvestmentInAssociate_lbl0" xml:lang="en-US">Adjustments for impairment of investment in associate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsForImpairmentOfInvestmentInAssociate" xlink:to="sprcy_AdjustmentsForImpairmentOfInvestmentInAssociate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateAmountOrCreditAmount_lbl0" xml:lang="en-US">An aggregate amount or score is made up of several smaller amounts or scores added together. The rate of growth of GNP will depend upon the rate of growth of aggregate demand.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateAmountOrCreditAmount" xlink:to="sprcy_AggregateAmountOrCreditAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateGrossProceeds_lbl0" xml:lang="en-US">Aggregate Gross Proceeds means the aggregate of the proceeds from any sale of shares of Common Stock by the Underwriter pursuant to this Agreement, before the deduction of Commissions and Placement Fees payable with respect to those shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateGrossProceeds" xlink:to="sprcy_AggregateGrossProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregatePurchasePrice_lbl0" xml:lang="en-US">Aggregate purchase price is the final calculation of the purchase price for a company.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregatePurchasePrice" xlink:to="sprcy_AggregatePurchasePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateValue_lbl0" xml:lang="en-US">The amount of ordinary shares of aggregate value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateValue" xlink:to="sprcy_AggregateValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AnnualInvestment_lbl0" xml:lang="en-US">Amount of annual investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AnnualInvestment" xlink:to="sprcy_AnnualInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_BalanceOwedToClearmind_lbl0" xml:lang="en-US">The amount of balance owed to clearmind.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BalanceOwedToClearmind" xlink:to="sprcy_BalanceOwedToClearmind_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_BasisOfPresentationOfFinancialStatements_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy changes inrBasis of presentation of the financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BasisOfPresentationOfFinancialStatements" xlink:to="sprcy_BasisOfPresentationOfFinancialStatements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_BeginningBalanceCost_lbl1" xml:lang="en-US">Amount of beginning balance, cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BeginningBalanceCost" xlink:to="sprcy_BeginningBalanceCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_BonusAmount_lbl0" xml:lang="en-US">Amount of bonus amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BonusAmount" xlink:to="sprcy_BonusAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_BonusAmountReceived_lbl0" xml:lang="en-US">Bonus amount received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BonusAmountReceived" xlink:to="sprcy_BonusAmountReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_BridgeLoanAmount_lbl0" xml:lang="en-US">Short-Term financing which is expected to be paid back relatively quickly, such as by a subsequent longer-term loan. Also called swing loan or bridge Loan financing.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BridgeLoanAmount" xlink:to="sprcy_BridgeLoanAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CashForImmediateWithdrawal_lbl0" xml:lang="en-US">The amount of cash withdrawal.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashForImmediateWithdrawal" xlink:to="sprcy_CashForImmediateWithdrawal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CashForImmediateWithdrawalInNIS_lbl0" xml:lang="en-US">Cash for Immediate withdrawal in NIS currency.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashForImmediateWithdrawalInNIS" xlink:to="sprcy_CashForImmediateWithdrawalInNIS_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ClaimsOnDamages_lbl0" xml:lang="en-US">Claims on damages.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ClaimsOnDamages" xlink:to="sprcy_ClaimsOnDamages_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ClearmindOutstandingShareCapitalPercentage_lbl0" xml:lang="en-US">The percentage of clearmind outstanding share capital percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ClearmindOutstandingShareCapitalPercentage" xlink:to="sprcy_ClearmindOutstandingShareCapitalPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl0" xml:lang="en-US">Company&#8217;s share of losses of company accounted for at equity, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:to="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ComprehensiveIncomeAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ComprehensiveIncomeAttributableToNoncontrollingInterest" xlink:to="sprcy_ComprehensiveIncomeAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ComprehensiveLoss_lbl0" xml:lang="en-US">Comprehensive loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ComprehensiveLoss" xlink:to="sprcy_ComprehensiveLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CooperationAgreementWithClearmindAmount_lbl0" xml:lang="en-US">The amount of cooperation Agreement with Clearmind amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CooperationAgreementWithClearmindAmount" xlink:to="sprcy_CooperationAgreementWithClearmindAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CreditFacilityAmount_lbl0" xml:lang="en-US">A credit facility is a type of loan made in a business or corporate finance context. It allows the borrowing business to take out money over an extended period of time rather than reapplying for a loan each time it needs money.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CreditFacilityAmount" xlink:to="sprcy_CreditFacilityAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CreditFacilityAndRemainingAvailableDrawnAmount_lbl0" xml:lang="en-US">Credit Facility and remaining available drawn amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CreditFacilityAndRemainingAvailableDrawnAmount" xlink:to="sprcy_CreditFacilityAndRemainingAvailableDrawnAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CreditFromOthers_lbl0" xml:lang="en-US">The amount of credit of others.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CreditFromOthers" xlink:to="sprcy_CreditFromOthers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CreditsFromOthers_lbl0" xml:lang="en-US">Credit from others.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CreditsFromOthers" xlink:to="sprcy_CreditsFromOthers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DeferredCashPayments_lbl0" xml:lang="en-US">Deferred cash payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DeferredCashPayments" xlink:to="sprcy_DeferredCashPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DekelLicenseAgreementDescription_lbl0" xml:lang="en-US">Dekel license agreement description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DekelLicenseAgreementDescription" xlink:to="sprcy_DekelLicenseAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy changes in Consolidated financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:to="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy for investments in associates. The description of the entity&apos;s material accounting policy information for investments accounted for using the equity method.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" xlink:to="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy changes in operating cycle Explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:to="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy for acquisition of a single asset company.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" xlink:to="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy for amendment to IAS. The description of the entity&apos;s material accounting policy information for amendment to IAS 1, presentation of financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements" xlink:to="sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy for changes to accounting estimates and errors.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" xlink:to="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfPrivateOffering_lbl0" xml:lang="en-US">Description of private offering.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfPrivateOffering" xlink:to="sprcy_DescriptionOfPrivateOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfPublicOffering_lbl0" xml:lang="en-US">Description of public offering.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfPublicOffering" xlink:to="sprcy_DescriptionOfPublicOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl0" xml:lang="en-US">The entire disclosue of cash and cash equivalents.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:to="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent_lbl0" xml:lang="en-US">The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent" xlink:to="sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory_lbl0" xml:lang="en-US">Disclosure of detailed information about balance with relate parties explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl0" xml:lang="en-US">Disclosure of detailed information about defined contribution plans explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory_lbl0" xml:lang="en-US">The disclosure of detailed information about earning per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory_lbl0" xml:lang="en-US">Disclosure of detailed information about transactions with relate parties explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfExpenseRecognizedExplanatoryTableTextBlock_lbl0" xml:lang="en-US">The tabular disclosure of expense recognized.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfExpenseRecognizedExplanatoryTableTextBlock" xlink:to="sprcy_DisclosureOfExpenseRecognizedExplanatoryTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfFairValueMeasurementOfAssetstable_lbl0" xml:lang="en-US">Schedule disclosing information related to the fair value measurement of assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFairValueMeasurementOfAssetstable" xlink:to="sprcy_DisclosureOfFairValueMeasurementOfAssetstable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities_lbl0" xml:lang="en-US">The tabular disclosure of financial assets and financial liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities" xlink:to="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfGeneralExplanatoryTextBlock_lbl0" xml:lang="en-US">The entire disclosure for general information.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfGeneralExplanatoryTextBlock" xlink:to="sprcy_DisclosureOfGeneralExplanatoryTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss_lbl0" xml:lang="en-US">Tabular disclosure of disclosure of information to the items of profit or loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss" xlink:to="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl0" xml:lang="en-US">Disclosure of detailed inforamtion about issued and outstanding share capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" xlink:to="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock_lbl0" xml:lang="en-US">The tabular disclosure of share options and weighted average exercise prices of share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" xlink:to="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfTradePayables_lbl0" xml:lang="en-US">The disclosure of trade payables.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfTradePayables" xlink:to="sprcy_DisclosureOfTradePayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory_lbl0" xml:lang="en-US">The entire disclosure for useful life of the assets at annual rates.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" xlink:to="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl0" xml:lang="en-US">The disclosure of accounts receivables.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" xlink:to="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DividendYield_lbl0" xml:lang="en-US">The percentage of an expected dividend used to calculate the fair value of share options granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DividendYield" xlink:to="sprcy_DividendYield_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_EquityLossesFromInvestment_lbl0" xml:lang="en-US">Amount of equity losses from investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityLossesFromInvestment" xlink:to="sprcy_EquityLossesFromInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_EquityLossesFromInvestmentInMitoCareX_lbl0" xml:lang="en-US">Amount of equity losses from investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityLossesFromInvestmentInMitoCareX" xlink:to="sprcy_EquityLossesFromInvestmentInMitoCareX_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_EquityLossesInvestment_lbl0" xml:lang="en-US">The amount of equity losses investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityLossesInvestment" xlink:to="sprcy_EquityLossesInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ExchangeCommonShares_lbl0" xml:lang="en-US">The number of exchange common shares of clearmind.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExchangeCommonShares" xlink:to="sprcy_ExchangeCommonShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ExchangeCommonSharesOfClearmind_lbl0" xml:lang="en-US">The number of exchange common shares of clearmind.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExchangeCommonSharesOfClearmind" xlink:to="sprcy_ExchangeCommonSharesOfClearmind_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ExerciseOfPrefundedWarrants_lbl2" xml:lang="en-US">Exercise of Pre-funded warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExerciseOfPrefundedWarrants" xlink:to="sprcy_ExerciseOfPrefundedWarrants_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ExerciseOfPrefundedWarrantsOne_lbl0" xml:lang="en-US">Exercise of Pre-funded warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExerciseOfPrefundedWarrantsOne" xlink:to="sprcy_ExerciseOfPrefundedWarrantsOne_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ExerciseOfPricePerShare_lbl1" xml:lang="en-US">Exercise of price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExerciseOfPricePerShare" xlink:to="sprcy_ExerciseOfPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ExerciseOfWarrants_lbl1" xml:lang="en-US">Amount of exercise of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExerciseOfWarrants" xlink:to="sprcy_ExerciseOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ExercisePrice_lbl0" xml:lang="en-US">Exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExercisePrice" xlink:to="sprcy_ExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ExpectedVolatility_lbl0" xml:lang="en-US">The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExpectedVolatility" xlink:to="sprcy_ExpectedVolatility_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ExternalRevenues_lbl0" xml:lang="en-US">Amount of external revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExternalRevenues" xlink:to="sprcy_ExternalRevenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_FairMarketValue_lbl0" xml:lang="en-US">Fair market value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairMarketValue" xlink:to="sprcy_FairMarketValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_FairValueOfTheRSUsGranted_lbl0" xml:lang="en-US">The amount of fair value of the RSU&#8217;s granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfTheRSUsGranted" xlink:to="sprcy_FairValueOfTheRSUsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_FeeExpenses_lbl0" xml:lang="en-US">Fee expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FeeExpenses" xlink:to="sprcy_FeeExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_FinanceExpensesFromExchangeRateDifferences_lbl0" xml:lang="en-US">The amount of expenses related to exchange rate differences.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinanceExpensesFromExchangeRateDifferences" xlink:to="sprcy_FinanceExpensesFromExchangeRateDifferences_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_FinanceExpensesFromInterestAndCommissions_lbl0" xml:lang="en-US">The amount of finance expenses from interest and commissions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinanceExpensesFromInterestAndCommissions" xlink:to="sprcy_FinanceExpensesFromInterestAndCommissions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_GovernmentAuthorities_lbl0" xml:lang="en-US">Government authorities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GovernmentAuthorities" xlink:to="sprcy_GovernmentAuthorities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_GrossProceed_lbl0" xml:lang="en-US">Gross proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GrossProceed" xlink:to="sprcy_GrossProceed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_GrossProceeds_lbl0" xml:lang="en-US">Gross proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GrossProceeds" xlink:to="sprcy_GrossProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InitialConversionPrice_lbl0" xml:lang="en-US">Initial conversion price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialConversionPrice" xlink:to="sprcy_InitialConversionPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InitialInvestment_lbl0" xml:lang="en-US">Initial investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialInvestment" xlink:to="sprcy_InitialInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InstallmentAmount_lbl0" xml:lang="en-US">Amount of installment amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentAmount" xlink:to="sprcy_InstallmentAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InterestPercentgae_lbl0" xml:lang="en-US">Interest percentgae.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestPercentgae" xlink:to="sprcy_InterestPercentgae_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_Intersegment_lbl0" xml:lang="en-US">Amount of inter-segment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_Intersegment" xlink:to="sprcy_Intersegment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InventoriesNet_lbl0" xml:lang="en-US">The amount of inventory, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InventoriesNet" xlink:to="sprcy_InventoriesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InvestedAmount_lbl0" xml:lang="en-US">The amount of invested amount in clearmind.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestedAmount" xlink:to="sprcy_InvestedAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InvestedAmountInClearmind_lbl0" xml:lang="en-US">The amount of invested amount in clearmind.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestedAmountInClearmind" xlink:to="sprcy_InvestedAmountInClearmind_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InvestedInitialAmount_lbl0" xml:lang="en-US">Invested initial amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestedInitialAmount" xlink:to="sprcy_InvestedInitialAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InvestmentAmount_lbl0" xml:lang="en-US">Investment amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentAmount" xlink:to="sprcy_InvestmentAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InvestmentDate_lbl1" xml:lang="en-US">The amount of investments in equity instruments that the entity has designated at fair value through other comprehensive income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentDate" xlink:to="sprcy_InvestmentDate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssuanceOfAggregateShares_lbl1" xml:lang="en-US">The issuance of aggregate shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfAggregateShares" xlink:to="sprcy_IssuanceOfAggregateShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate_lbl0" xml:lang="en-US">Issuance of share capital &#8211; in respect of investment in affiliate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus_lbl0" xml:lang="en-US">Issuance of share capital &#8211; in respect of shelf prospectus.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssuanceOfShares_lbl0" xml:lang="en-US">Issuance of shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShares" xlink:to="sprcy_IssuanceOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl0" xml:lang="en-US">Issue of share capital, net of issue expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssueOfShareCapitalNetOfIssueExpense" xlink:to="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssueOfSharesNetOfIssueExpenses_lbl0" xml:lang="en-US">Issue of shares, net of issue expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssueOfSharesNetOfIssueExpenses" xlink:to="sprcy_IssueOfSharesNetOfIssueExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssuedAndOutstandingSharesPercentage_lbl0" xml:lang="en-US">Issued and outstanding shares, percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuedAndOutstandingSharesPercentage" xlink:to="sprcy_IssuedAndOutstandingSharesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_LeaseholdImprovements_lbl0" xml:lang="en-US">Leasehold improvements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseholdImprovements" xlink:to="sprcy_LeaseholdImprovements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_LoanAmountDueTerm_lbl0" xml:lang="en-US">Loan Amount Due Term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LoanAmountDueTerm" xlink:to="sprcy_LoanAmountDueTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_MonthlyFee_lbl0" xml:lang="en-US">Amount of  monthly fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MonthlyFee" xlink:to="sprcy_MonthlyFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_MutualShareExchangeAmount_lbl0" xml:lang="en-US">Mutual share exchange amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MutualShareExchangeAmount" xlink:to="sprcy_MutualShareExchangeAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_NoParValuePerShare_lbl0" xml:lang="en-US">Represent  of having no par value per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NoParValuePerShare" xlink:to="sprcy_NoParValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_NumberOfOutstandingShareOption_lbl1" xml:lang="en-US">The number of share option outstanding in a share-based payment arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfOutstandingShareOption" xlink:to="sprcy_NumberOfOutstandingShareOption_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">The number of share option forfeited in a share-based payment arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement" xlink:to="sprcy_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_NumberOfShareOptionGranted_lbl0" xml:lang="en-US">The number of share options granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfShareOptionGranted" xlink:to="sprcy_NumberOfShareOptionGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_NumberOfSharesIssued1_lbl1" xml:lang="en-US">The number of shares issued by the entity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfSharesIssued1" xlink:to="sprcy_NumberOfSharesIssued1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_NumberOfSharesOptionGrantedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">The number of shares option granted in a share-based payment arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfSharesOptionGrantedInSharebasedPaymentArrangement" xlink:to="sprcy_NumberOfSharesOptionGrantedInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OperatingLossCarryforwardsTaxAmount_lbl0" xml:lang="en-US">The amount of net operating loss carryforward tax as of the reporting date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingLossCarryforwardsTaxAmount" xlink:to="sprcy_OperatingLossCarryforwardsTaxAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OrdinaryShares_lbl0" xml:lang="en-US">ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinaryShares" xlink:to="sprcy_OrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OrdinarySharesAcquired_lbl1" xml:lang="en-US">Ordinary shares acquired.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesAcquired" xlink:to="sprcy_OrdinarySharesAcquired_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OutstandingSharesPercentage_lbl0" xml:lang="en-US">Outstanding shares percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OutstandingSharesPercentage" xlink:to="sprcy_OutstandingSharesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OwnershipAgreement_lbl0" xml:lang="en-US">Ownership agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OwnershipAgreement" xlink:to="sprcy_OwnershipAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PercentageOfAggregatePurchasePrice_lbl0" xml:lang="en-US">Purchase Percentage means, with respect to any Purchased Asset, the ratio (expressed as a percentage) of the outstanding Purchase Price with respect to such Purchased Asset to the outstanding unpaid principal balance of such Purchased Asset.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfAggregatePurchasePrice" xlink:to="sprcy_PercentageOfAggregatePurchasePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital_lbl0" xml:lang="en-US">The percentage of shares issued and outstanding share capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital" xlink:to="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PercentageOfStockEqual_lbl0" xml:lang="en-US">Percentage of stock equal.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfStockEqual" xlink:to="sprcy_PercentageOfStockEqual_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment_lbl0" xml:lang="en-US">The useful lives or depreciation rates used for property, plant and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" xlink:to="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PercentageOfWorkingCapital_lbl0" xml:lang="en-US">Percentage of working capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfWorkingCapital" xlink:to="sprcy_PercentageOfWorkingCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PrefundedOrdinaryShare_lbl0" xml:lang="en-US">Pre-funded warrants allow investors who are otherwise restricted from owning a company&apos;s voting securities above a certain threshold (usually, 9.99% or 19.99%) to invest in the company without violating the applicable ownership restrictions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrefundedOrdinaryShare" xlink:to="sprcy_PrefundedOrdinaryShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PricePerShare_lbl0" xml:lang="en-US">price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PricePerShare" xlink:to="sprcy_PricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ProceedsFromIssuanceIPO_lbl0" xml:lang="en-US">The cash inflow associated with the amount received from entity&apos;s first offering of stock to the public.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ProceedsFromIssuanceIPO" xlink:to="sprcy_ProceedsFromIssuanceIPO_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses_lbl0" xml:lang="en-US">The amount of proceeds from issue of share capital and warrants net of issuance expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" xlink:to="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PurchaseOfAssets_lbl0" xml:lang="en-US">Purchase of assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseOfAssets" xlink:to="sprcy_PurchaseOfAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss_lbl0" xml:lang="en-US">Purchase of financial assets at fair value through profit or loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PurchaseOfOrdinaryShares_lbl0" xml:lang="en-US">Purchase of ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseOfOrdinaryShares" xlink:to="sprcy_PurchaseOfOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PurchaseOrdinaryShares_lbl0" xml:lang="en-US">Owning ordinary shares in a business means owning a fraction of that business, and being able to vote on decisions taken at shareholder meetings. Ordinary shares offer the chance of higher financial gains than other types of share; however, you also have a higher risk of making no gains.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseOrdinaryShares" xlink:to="sprcy_PurchaseOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PurchasePricePerShare_lbl0" xml:lang="en-US">The purchase price is the price an investor pays for an investment, and the price becomes the investor&apos;s cost basis for calculating gain or loss when selling the investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasePricePerShare" xlink:to="sprcy_PurchasePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PurchasesOfCost_lbl0" xml:lang="en-US">The cost of purchases.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasesOfCost" xlink:to="sprcy_PurchasesOfCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_RegistrationOfWarrants_lbl0" xml:lang="en-US">Registration of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RegistrationOfWarrants" xlink:to="sprcy_RegistrationOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ResearchAndDevelopmentExpenses01_lbl0" xml:lang="en-US">The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndDevelopmentExpenses01" xlink:to="sprcy_ResearchAndDevelopmentExpenses01_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ResearchAndDevelopmentExpenses1_lbl0" xml:lang="en-US">The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndDevelopmentExpenses1" xlink:to="sprcy_ResearchAndDevelopmentExpenses1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_RetainedEarning_lbl0" xml:lang="en-US">A component of equity representing the entity&apos;s cumulative undistributed earnings or deficit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RetainedEarning" xlink:to="sprcy_RetainedEarning_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl0" xml:lang="en-US">Right-of-use asset recognized with corresponding lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:to="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_RiskFreeInterestRate_lbl0" xml:lang="en-US">The risk-free interest rate for the option contractual term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RiskFreeInterestRate" xlink:to="sprcy_RiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock_lbl0" xml:lang="en-US">Schedule of fair value of the intangible asset.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock" xlink:to="sprcy_ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ScheduleOfOtherAccountsPayable_lbl0" xml:lang="en-US">The entire disclosure of other accounts payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfOtherAccountsPayable" xlink:to="sprcy_ScheduleOfOtherAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ShareCapitalPercentage_lbl0" xml:lang="en-US">Share capital percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareCapitalPercentage" xlink:to="sprcy_ShareCapitalPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ShareIssuedToAConsultant_lbl0" xml:lang="en-US">The shares were issued to a consultant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareIssuedToAConsultant" xlink:to="sprcy_ShareIssuedToAConsultant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ShareOptionsOutstandingParValue_lbl0" xml:lang="en-US">Share options outstanding par value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareOptionsOutstandingParValue" xlink:to="sprcy_ShareOptionsOutstandingParValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_SharePricePerShare_lbl0" xml:lang="en-US">Share price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePricePerShare" xlink:to="sprcy_SharePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ShareholdersAmount_lbl0" xml:lang="en-US">The amount of shareholders.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareholdersAmount" xlink:to="sprcy_ShareholdersAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_SharesIssuedToConsultants_lbl0" xml:lang="en-US">Shares issued to consultants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharesIssuedToConsultants" xlink:to="sprcy_SharesIssuedToConsultants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock_lbl0" xml:lang="en-US">The entire disclosure for significant accounting judgments estimates and assumptions used in the preparation of the financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" xlink:to="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_StockIssuedDuringPeriodReverseStockSplits_lbl0" xml:lang="en-US">Represent the number of stock issued during period reverse stock splits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_StockIssuedDuringPeriodReverseStockSplits" xlink:to="sprcy_StockIssuedDuringPeriodReverseStockSplits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_TaxExpense_lbl0" xml:lang="en-US">Tax expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TaxExpense" xlink:to="sprcy_TaxExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_TermOfIssuance_lbl0" xml:lang="en-US">Term of issuance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TermOfIssuance" xlink:to="sprcy_TermOfIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_TotalAgreementEstimatingAmount_lbl0" xml:lang="en-US">Total agreement estimating amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TotalAgreementEstimatingAmount" xlink:to="sprcy_TotalAgreementEstimatingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_TradeAndOtherPayable_lbl0" xml:lang="en-US">The amount of trade payables and other payables. [Refer: Trade payables; Other payables]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TradeAndOtherPayable" xlink:to="sprcy_TradeAndOtherPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_UnderlyingOrdinarySharePrice_lbl0" xml:lang="en-US">Underlying ordinary share price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnderlyingOrdinarySharePrice" xlink:to="sprcy_UnderlyingOrdinarySharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_UnderlyingOrdinarySharePrices_lbl0" xml:lang="en-US">Underlying ordinary share price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnderlyingOrdinarySharePrices" xlink:to="sprcy_UnderlyingOrdinarySharePrices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_UnpaidIssueExpenses_lbl0" xml:lang="en-US">Unpaid issue expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnpaidIssueExpenses" xlink:to="sprcy_UnpaidIssueExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_WarrantExpiryPeriod_lbl0" xml:lang="en-US">Warrant expiry period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantExpiryPeriod" xlink:to="sprcy_WarrantExpiryPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_WarrantTextBlock_lbl0" xml:lang="en-US">Disclosure of warrant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantTextBlock" xlink:to="sprcy_WarrantTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_WarrantsDescription_lbl0" xml:lang="en-US">Warrants description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsDescription" xlink:to="sprcy_WarrantsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_WarrantsExercisePrice_lbl0" xml:lang="en-US">Warrants exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsExercisePrice" xlink:to="sprcy_WarrantsExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_WeightedAverageExercisePriceOfShareOptionForfeitedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">The weighted average exercise price of share option forfeited in a share-based payment arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WeightedAverageExercisePriceOfShareOptionForfeitedInSharebasedPaymentArrangement" xlink:to="sprcy_WeightedAverageExercisePriceOfShareOptionForfeitedInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">The weighted average exercise price of share option granted in a share-based payment arrangement.&amp;amp;amp;amp;amp;#160;</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement" xlink:to="sprcy_WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement_lbl1" xml:lang="en-US">The weighted average exercise price of share option outstanding in a share-based payment arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement" xlink:to="sprcy_WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption_lbl0" xml:lang="en-US">The weighted average remaining contractual lifes of outstanding share options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption" xlink:to="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AddressTypeDomain_lbl" xml:lang="en-US">Address Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl1" xml:lang="en-US">Proportion of ownership interest in subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ResearchAndDevelopmentExpenses_lbl0" xml:lang="en-US">Research And Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndDevelopmentExpenses" xlink:to="sprcy_ResearchAndDevelopmentExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WagesAndRelatedExpensesMember_lbl0" xml:lang="en-US">Wages And Related Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WagesAndRelatedExpensesMember" xlink:to="sprcy_WagesAndRelatedExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract103_lbl0" xml:lang="en-US">Unlabeled Abstract103</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract103" xlink:to="sprcy_UnlabeledAbstract103_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract102_lbl0" xml:lang="en-US">Unlabeled Abstract102</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract102" xlink:to="sprcy_UnlabeledAbstract102_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract101_lbl0" xml:lang="en-US">Unlabeled Abstract101</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract101" xlink:to="sprcy_UnlabeledAbstract101_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract100_lbl0" xml:lang="en-US">Unlabeled Abstract100</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract100" xlink:to="sprcy_UnlabeledAbstract100_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract107_lbl0" xml:lang="en-US">Unlabeled Abstract107</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract107" xlink:to="sprcy_UnlabeledAbstract107_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract106_lbl0" xml:lang="en-US">Unlabeled Abstract106</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract106" xlink:to="sprcy_UnlabeledAbstract106_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl0" xml:lang="en-US">Adjustments for increase (decrease) in trade accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract105_lbl0" xml:lang="en-US">Unlabeled Abstract105</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract105" xlink:to="sprcy_UnlabeledAbstract105_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract104_lbl0" xml:lang="en-US">Unlabeled Abstract104</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract104" xlink:to="sprcy_UnlabeledAbstract104_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract109_lbl0" xml:lang="en-US">Unlabeled Abstract109</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract109" xlink:to="sprcy_UnlabeledAbstract109_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract108_lbl0" xml:lang="en-US">Unlabeled Abstract108</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract108" xlink:to="sprcy_UnlabeledAbstract108_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl0" xml:lang="en-US">Categories of financial assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RegulatoryAndOtherExpensesMember_lbl0" xml:lang="en-US">Regulatory And Other Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RegulatoryAndOtherExpensesMember" xlink:to="sprcy_RegulatoryAndOtherExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ResearchAndDevelopmentExpenses01_lbl1" xml:lang="en-US">Research And Development Expenses01</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndDevelopmentExpenses01" xlink:to="sprcy_ResearchAndDevelopmentExpenses01_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory_lbl1" xml:lang="en-US">Disclosure Of Useful Life Of Assets At Annual Rates Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" xlink:to="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_lbl0" xml:lang="en-US">Equity attributable to owners of parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestRevenueExpense_lbl0" xml:lang="en-US">Interest income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestRevenueExpense" xlink:to="ifrs-full_InterestRevenueExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl0" xml:lang="en-US">Disclosure of events after reporting period [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl1" xml:lang="en-US">Number of shares issued and fully paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract110_lbl0" xml:lang="en-US">Unlabeled Abstract110</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract110" xlink:to="sprcy_UnlabeledAbstract110_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExerciseOfPrefundedWarrantsOne_lbl1" xml:lang="en-US">Exercise Of Prefunded Warrants One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExerciseOfPrefundedWarrantsOne" xlink:to="sprcy_ExerciseOfPrefundedWarrantsOne_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract114_lbl0" xml:lang="en-US">Unlabeled Abstract114</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract114" xlink:to="sprcy_UnlabeledAbstract114_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExchangeCommonSharesOfClearmind_lbl1" xml:lang="en-US">Exchange Common Shares Of Clearmind</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExchangeCommonSharesOfClearmind" xlink:to="sprcy_ExchangeCommonSharesOfClearmind_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl1" xml:lang="en-US">Exercise price, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract113_lbl0" xml:lang="en-US">Unlabeled Abstract113</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract113" xlink:to="sprcy_UnlabeledAbstract113_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract112_lbl0" xml:lang="en-US">Unlabeled Abstract112</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract112" xlink:to="sprcy_UnlabeledAbstract112_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuedAndOutstandingSharesPercentage_lbl1" xml:lang="en-US">Issued And Outstanding Shares Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuedAndOutstandingSharesPercentage" xlink:to="sprcy_IssuedAndOutstandingSharesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract111_lbl0" xml:lang="en-US">Unlabeled Abstract111</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract111" xlink:to="sprcy_UnlabeledAbstract111_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsDescription_lbl1" xml:lang="en-US">Warrants Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsDescription" xlink:to="sprcy_WarrantsDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RepaymentOfLeaseLiabilities_lbl0" xml:lang="en-US">Repayment Of Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RepaymentOfLeaseLiabilities" xlink:to="sprcy_RepaymentOfLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract118_lbl0" xml:lang="en-US">Unlabeled Abstract118</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract118" xlink:to="sprcy_UnlabeledAbstract118_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract117_lbl0" xml:lang="en-US">Unlabeled Abstract117</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract117" xlink:to="sprcy_UnlabeledAbstract117_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract116_lbl0" xml:lang="en-US">Unlabeled Abstract116</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract116" xlink:to="sprcy_UnlabeledAbstract116_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract115_lbl0" xml:lang="en-US">Unlabeled Abstract115</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract115" xlink:to="sprcy_UnlabeledAbstract115_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract119_lbl0" xml:lang="en-US">Unlabeled Abstract119</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract119" xlink:to="sprcy_UnlabeledAbstract119_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OnlineSalesMember_lbl0" xml:lang="en-US">Online Sales Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OnlineSalesMember" xlink:to="sprcy_OnlineSalesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RegistrationOfWarrants_lbl1" xml:lang="en-US">Registration Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RegistrationOfWarrants" xlink:to="sprcy_RegistrationOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInvestmentEntitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of investment entities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInvestmentEntitiesExplanatory" xlink:to="ifrs-full_DisclosureOfInvestmentEntitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract121_lbl0" xml:lang="en-US">Unlabeled Abstract121</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract121" xlink:to="sprcy_UnlabeledAbstract121_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract120_lbl0" xml:lang="en-US">Unlabeled Abstract120</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract120" xlink:to="sprcy_UnlabeledAbstract120_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnderlyingOrdinarySharePrices_lbl1" xml:lang="en-US">Underlying Ordinary Share Prices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnderlyingOrdinarySharePrices" xlink:to="sprcy_UnderlyingOrdinarySharePrices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl0" xml:lang="en-US">Intangible assets other than goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract125_lbl0" xml:lang="en-US">Unlabeled Abstract125</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract125" xlink:to="sprcy_UnlabeledAbstract125_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract124_lbl0" xml:lang="en-US">Unlabeled Abstract124</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract124" xlink:to="sprcy_UnlabeledAbstract124_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract123_lbl0" xml:lang="en-US">Unlabeled Abstract123</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract123" xlink:to="sprcy_UnlabeledAbstract123_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract122_lbl0" xml:lang="en-US">Unlabeled Abstract122</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract122" xlink:to="sprcy_UnlabeledAbstract122_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract129_lbl0" xml:lang="en-US">Unlabeled Abstract129</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract129" xlink:to="sprcy_UnlabeledAbstract129_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract128_lbl0" xml:lang="en-US">Unlabeled Abstract128</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract128" xlink:to="sprcy_UnlabeledAbstract128_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract127_lbl0" xml:lang="en-US">Unlabeled Abstract127</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract127" xlink:to="sprcy_UnlabeledAbstract127_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract126_lbl0" xml:lang="en-US">Unlabeled Abstract126</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract126" xlink:to="sprcy_UnlabeledAbstract126_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ValueAddedTaxReceivables_lbl0" xml:lang="en-US">Value added tax receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ValueAddedTaxReceivables" xlink:to="ifrs-full_ValueAddedTaxReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_a2022Abstract_lbl0" xml:lang="en-US">a2022 Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_a2022Abstract" xlink:to="sprcy_a2022Abstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl0" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InsuranceFinanceIncomeExpenses_lbl0" xml:lang="en-US">Insurance finance income (expenses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InsuranceFinanceIncomeExpenses" xlink:to="ifrs-full_InsuranceFinanceIncomeExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OperatingSegmentsTablesLineItems_lbl0" xml:lang="en-US">Operating Segments Tables Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingSegmentsTablesLineItems" xlink:to="sprcy_OperatingSegmentsTablesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_lbl0" xml:lang="en-US">Reversal of impairment loss recognised in other comprehensive income, intangible assets other than goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for provisions [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement_lbl1" xml:lang="en-US">Weighted Average Exercise Price Of Share Option Granted In Sharebased Payment Arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement" xlink:to="sprcy_WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for intangible assets and goodwill [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CapitalPointWarrantMember_lbl0" xml:lang="en-US">Capital Point Warrant Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CapitalPointWarrantMember" xlink:to="sprcy_CapitalPointWarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl0" xml:lang="en-US">Adjustments for depreciation and amortisation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract132_lbl0" xml:lang="en-US">Unlabeled Abstract132</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract132" xlink:to="sprcy_UnlabeledAbstract132_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_BeginningBalanceCost_lbl2" xml:lang="en-US">Beginning Balance Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BeginningBalanceCost" xlink:to="sprcy_BeginningBalanceCost_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract131_lbl0" xml:lang="en-US">Unlabeled Abstract131</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract131" xlink:to="sprcy_UnlabeledAbstract131_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for employee benefits [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract130_lbl0" xml:lang="en-US">Unlabeled Abstract130</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract130" xlink:to="sprcy_UnlabeledAbstract130_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract136_lbl0" xml:lang="en-US">Unlabeled Abstract136</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract136" xlink:to="sprcy_UnlabeledAbstract136_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract135_lbl0" xml:lang="en-US">Unlabeled Abstract135</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract135" xlink:to="sprcy_UnlabeledAbstract135_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract134_lbl0" xml:lang="en-US">Unlabeled Abstract134</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract134" xlink:to="sprcy_UnlabeledAbstract134_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract133_lbl0" xml:lang="en-US">Unlabeled Abstract133</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract133" xlink:to="sprcy_UnlabeledAbstract133_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract139_lbl0" xml:lang="en-US">Unlabeled Abstract139</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract139" xlink:to="sprcy_UnlabeledAbstract139_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract138_lbl0" xml:lang="en-US">Unlabeled Abstract138</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract138" xlink:to="sprcy_UnlabeledAbstract138_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract137_lbl0" xml:lang="en-US">Unlabeled Abstract137</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract137" xlink:to="sprcy_UnlabeledAbstract137_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate_lbl1" xml:lang="en-US">Issuance Of Share Capital In Respect Of Investment In Affiliate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InterestPercentgae_lbl1" xml:lang="en-US">Interest Percentgae</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestPercentgae" xlink:to="sprcy_InterestPercentgae_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl1" xml:lang="en-US">Disclosure Of Issued And Outstanding Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" xlink:to="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OrdinarySharesPerValue_lbl0" xml:lang="en-US">Ordinary Shares Per Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesPerValue" xlink:to="sprcy_OrdinarySharesPerValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssueOfSharesNetOfIssueExpenses_lbl1" xml:lang="en-US">Issue Of Shares Net Of Issue Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssueOfSharesNetOfIssueExpenses" xlink:to="sprcy_IssueOfSharesNetOfIssueExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl0" xml:lang="en-US">Disclosure of information about key management personnel [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost_lbl0" xml:lang="en-US">Intangible asset fair value used as deemed cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost" xlink:to="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OrdinarySharesAcquired_lbl2" xml:lang="en-US">Ordinary Shares Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesAcquired" xlink:to="sprcy_OrdinarySharesAcquired_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestedAmount_lbl1" xml:lang="en-US">Invested Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestedAmount" xlink:to="sprcy_InvestedAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OutstandingSharesPercentage_lbl1" xml:lang="en-US">Outstanding Shares Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OutstandingSharesPercentage" xlink:to="sprcy_OutstandingSharesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NewCoIncMember_lbl0" xml:lang="en-US">New Co Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NewCoIncMember" xlink:to="sprcy_NewCoIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl0" xml:lang="en-US">Key management personnel compensation, share-based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuanceOfShares_lbl1" xml:lang="en-US">Issuance Of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShares" xlink:to="sprcy_IssuanceOfShares_lbl1"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfShareCapitalAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfShareCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfShareCapitalAbstract_lbl" xml:lang="en-US">Schedule Of Share Capital Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfShareCapitalAbstract" xlink:to="sprcy_ScheduleOfShareCapitalAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl0" xml:lang="en-US">Adjustments for decrease (increase) in inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinishedGoods_lbl0" xml:lang="en-US">Current finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinishedGoods" xlink:to="ifrs-full_FinishedGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl0" xml:lang="en-US">Proceeds from issuing shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SquareMeters_lbl0" xml:lang="en-US">Square Meters</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SquareMeters" xlink:to="sprcy_SquareMeters_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsFairValueinDollarsPerShares_lbl0" xml:lang="en-US">Warrants Fair Valuein Dollars Per Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsFairValueinDollarsPerShares" xlink:to="sprcy_WarrantsFairValueinDollarsPerShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DrugDevelopmentMember_lbl0" xml:lang="en-US">Drug Development Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DrugDevelopmentMember" xlink:to="sprcy_DrugDevelopmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfGeneralExplanatoryTextBlock_lbl1" xml:lang="en-US">Disclosure Of General Explanatory Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfGeneralExplanatoryTextBlock" xlink:to="sprcy_DisclosureOfGeneralExplanatoryTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnderlyingOrdinarySharePrice_lbl1" xml:lang="en-US">Underlying Ordinary Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnderlyingOrdinarySharePrice" xlink:to="sprcy_UnderlyingOrdinarySharePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestedInitialAmounts_lbl0" xml:lang="en-US">Invested Initial Amounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestedInitialAmounts" xlink:to="sprcy_InvestedInitialAmounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital_lbl1" xml:lang="en-US">Percentage Of Shares Issued And Outstanding Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital" xlink:to="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl0" xml:lang="en-US">Disclosure of intangible assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantTextBlock_lbl1" xml:lang="en-US">Warrant Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantTextBlock" xlink:to="sprcy_WarrantTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExercisePricePerShare_lbl1" xml:lang="en-US">Exercise Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExercisePricePerShare" xlink:to="sprcy_ExercisePricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TotalEquityHolderMember_lbl0" xml:lang="en-US">Total Equity Holder Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TotalEquityHolderMember" xlink:to="sprcy_TotalEquityHolderMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl0" xml:lang="en-US">Number of shares authorised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesAuthorised" xlink:to="ifrs-full_NumberOfSharesAuthorised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Disposals, property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WarrantReserve_lbl0" xml:lang="en-US">Warrant reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantReserve" xlink:to="ifrs-full_WarrantReserve_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl0" xml:lang="en-US">Sales and marketing expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareIssuedToAConsultant_lbl1" xml:lang="en-US">Share Issued To AConsultant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareIssuedToAConsultant" xlink:to="sprcy_ShareIssuedToAConsultant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInvestmentPropertyExplanatory_lbl0" xml:lang="en-US">Disclosure of investment property [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInvestmentPropertyExplanatory" xlink:to="ifrs-full_DisclosureOfInvestmentPropertyExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl0" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsToPurchase_lbl1" xml:lang="en-US">Warrants To Purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsToPurchase" xlink:to="sprcy_WarrantsToPurchase_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl1" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl1" xml:lang="en-US">Description Of Accounting Policy For Consolidatedfinancialstatements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:to="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl0" xml:lang="en-US">Other property, plant and equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentInventoriesInTransit_lbl0" xml:lang="en-US">Current inventories in transit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInventoriesInTransit" xlink:to="ifrs-full_CurrentInventoriesInTransit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AprilTwoThousandTwentyPurchaseAgreementMember_lbl0" xml:lang="en-US">April Two Thousand Twenty Purchase Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AprilTwoThousandTwentyPurchaseAgreementMember" xlink:to="sprcy_AprilTwoThousandTwentyPurchaseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RetainedEarning_lbl1" xml:lang="en-US">Retained Earning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RetainedEarning" xlink:to="sprcy_RetainedEarning_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FairValueOption_lbl0" xml:lang="en-US">Fair Value Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOption" xlink:to="sprcy_FairValueOption_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl0" xml:lang="en-US">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfFairValueMeasurementOfAssetstable_lbl1" xml:lang="en-US">Disclosure Of Fair Value Measurement Of Assetstable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFairValueMeasurementOfAssetstable" xlink:to="sprcy_DisclosureOfFairValueMeasurementOfAssetstable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_lbl0" xml:lang="en-US">Adjustments to reconcile profit (loss) other than changes in working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus_lbl1" xml:lang="en-US">Issuance Of Share Capital In Respect Of Shelf Prospectus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilities_lbl1" xml:lang="en-US">Financial liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToAbstract_lbl0" xml:lang="en-US">Profit (loss), attributable to [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PlanAssetsAtFairValue_lbl0" xml:lang="en-US">Plan assets, at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PlanAssetsAtFairValue" xlink:to="ifrs-full_PlanAssetsAtFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl0" xml:lang="en-US">Reserve of share-based payments [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WarrantsMember_lbl2" xml:lang="en-US">Warrants [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantsMember" xlink:to="ifrs-full_WarrantsMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_BalanceOwedToClearmind_lbl1" xml:lang="en-US">Balance Owed To Clearmind</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BalanceOwedToClearmind" xlink:to="sprcy_BalanceOwedToClearmind_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCompoundFinancialInstrumentsWithMultipleEmbeddedDerivativesExplanatory_lbl0" xml:lang="en-US">Description of compound financial instruments with multiple embedded derivatives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCompoundFinancialInstrumentsWithMultipleEmbeddedDerivativesExplanatory" xlink:to="ifrs-full_DisclosureOfCompoundFinancialInstrumentsWithMultipleEmbeddedDerivativesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CooperationAgreementWithClearmindAmount_lbl1" xml:lang="en-US">Cooperation Agreement With Clearmind Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CooperationAgreementWithClearmindAmount" xlink:to="sprcy_CooperationAgreementWithClearmindAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife_lbl0" xml:lang="en-US">Description of intangible assets with indefinite useful life supporting assessment of indefinite useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" xlink:to="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate_lbl0" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl0" xml:lang="en-US">Disclosure of transactions between related parties [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ConversionPrice_lbl0" xml:lang="en-US">Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ConversionPrice" xlink:to="sprcy_ConversionPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OwnershipPercentage_lbl0" xml:lang="en-US">Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OwnershipPercentage" xlink:to="sprcy_OwnershipPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTablesLineItems_lbl0" xml:lang="en-US">Investmentin Associatesand Investmentsin Investees Tables Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTablesLineItems" xlink:to="sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTablesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExercisePeriod_lbl0" xml:lang="en-US">Exercise Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExercisePeriod" xlink:to="sprcy_ExercisePeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_lbl0" xml:lang="en-US">Dilutive effect of share options on weighted average number of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:to="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for financial instruments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfSharesIssued1_lbl2" xml:lang="en-US">Number Of Shares Issued1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfSharesIssued1" xlink:to="sprcy_NumberOfSharesIssued1_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OrdinaryShares_lbl1" xml:lang="en-US">Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinaryShares" xlink:to="sprcy_OrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LiabilitiesAndEquityAbstract_lbl0" xml:lang="en-US">Liabilities And Equity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LiabilitiesAndEquityAbstract" xlink:to="sprcy_LiabilitiesAndEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherRelatedPartiesMember_lbl0" xml:lang="en-US">Other related parties [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherRelatedPartiesMember" xlink:to="ifrs-full_OtherRelatedPartiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock_lbl0" xml:lang="en-US">Disclosure Of Significant Events During The Reporting Period Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" xlink:to="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareholdersAmount_lbl1" xml:lang="en-US">Shareholders Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareholdersAmount" xlink:to="sprcy_ShareholdersAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PercentageOfStockEqual_lbl1" xml:lang="en-US">Percentage Of Stock Equal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfStockEqual" xlink:to="sprcy_PercentageOfStockEqual_lbl1"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfOperatingSegmentsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfOperatingSegmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfOperatingSegmentsAbstract_lbl" xml:lang="en-US">Schedule Of Operating Segments Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfOperatingSegmentsAbstract" xlink:to="sprcy_ScheduleOfOperatingSegmentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl0" xml:lang="en-US">Risk free interest rate, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfTradePayables_lbl1" xml:lang="en-US">Disclosure Of Trade Payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfTradePayables" xlink:to="sprcy_DisclosureOfTradePayables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_lbl0" xml:lang="en-US">Depreciation and amortisation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationAndAmortisationExpense" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl0" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TermOfIssuance_lbl1" xml:lang="en-US">Term Of Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TermOfIssuance" xlink:to="sprcy_TermOfIssuance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Balance With Relate Parties Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for impairment of non-financial assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_lbl0" xml:lang="en-US">Comprehensive income, attributable to non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock_lbl1" xml:lang="en-US">Description Of Accounting Policy For Investment Accounted For Using The Equity Methodtext Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" xlink:to="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForAmountsTransferredToInitialCarryingAmountOfHedgedItems_lbl0" xml:lang="en-US">Amounts removed from equity and included in carrying amount of non-financial asset (liability) whose acquisition or incurrence was hedged highly probable forecast transaction, net of tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForAmountsTransferredToInitialCarryingAmountOfHedgedItems" xlink:to="ifrs-full_AdjustmentsForAmountsTransferredToInitialCarryingAmountOfHedgedItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod_lbl0" xml:lang="en-US">Payment Of Issuance Expenses Related To Previous Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:to="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStocks_lbl0" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stocks</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStocks" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStocks_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl0" xml:lang="en-US">Trade and other current payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for fair value measurement [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl0" xml:lang="en-US">Disclosure of cash and cash equivalents [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_pricePerShare_lbl0" xml:lang="en-US">price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_pricePerShare" xlink:to="sprcy_pricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DateOfIssuance_lbl0" xml:lang="en-US">Date Of Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DateOfIssuance" xlink:to="sprcy_DateOfIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl0" xml:lang="en-US">Equity and liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl0" xml:lang="en-US">Short-term employee benefits accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OrdinaryShareExercisePrice_lbl0" xml:lang="en-US">Ordinary Share Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinaryShareExercisePrice" xlink:to="sprcy_OrdinaryShareExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract143_lbl0" xml:lang="en-US">Unlabeled Abstract143</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract143" xlink:to="sprcy_UnlabeledAbstract143_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract142_lbl0" xml:lang="en-US">Unlabeled Abstract142</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract142" xlink:to="sprcy_UnlabeledAbstract142_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract141_lbl0" xml:lang="en-US">Unlabeled Abstract141</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract141" xlink:to="sprcy_UnlabeledAbstract141_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract140_lbl0" xml:lang="en-US">Unlabeled Abstract140</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract140" xlink:to="sprcy_UnlabeledAbstract140_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract147_lbl0" xml:lang="en-US">Unlabeled Abstract147</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract147" xlink:to="sprcy_UnlabeledAbstract147_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract146_lbl0" xml:lang="en-US">Unlabeled Abstract146</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract146" xlink:to="sprcy_UnlabeledAbstract146_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsLiability_lbl0" xml:lang="en-US">Warrants Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsLiability" xlink:to="sprcy_WarrantsLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract145_lbl0" xml:lang="en-US">Unlabeled Abstract145</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract145" xlink:to="sprcy_UnlabeledAbstract145_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfFairValueOfTheInvestmentAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfFairValueOfTheInvestmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfFairValueOfTheInvestmentAbstract_lbl" xml:lang="en-US">Schedule Of Fair Value Of The Investment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="sprcy_ScheduleOfFairValueOfTheInvestmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract144_lbl0" xml:lang="en-US">Unlabeled Abstract144</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract144" xlink:to="sprcy_UnlabeledAbstract144_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ResearchAndPreclinicalStudiesMember_lbl0" xml:lang="en-US">Research And Preclinical Studies Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndPreclinicalStudiesMember" xlink:to="sprcy_ResearchAndPreclinicalStudiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract149_lbl0" xml:lang="en-US">Unlabeled Abstract149</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract149" xlink:to="sprcy_UnlabeledAbstract149_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract148_lbl0" xml:lang="en-US">Unlabeled Abstract148</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract148" xlink:to="sprcy_UnlabeledAbstract148_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_BGeneralAndAdministrativeExpensesAbstract_lbl0" xml:lang="en-US">BGeneral And Administrative Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BGeneralAndAdministrativeExpensesAbstract" xlink:to="sprcy_BGeneralAndAdministrativeExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock_lbl1" xml:lang="en-US">Disclosure Of Share Options And Weighted Average Exercise Prices Explanatory Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" xlink:to="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract154_lbl0" xml:lang="en-US">Unlabeled Abstract154</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract154" xlink:to="sprcy_UnlabeledAbstract154_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract153_lbl0" xml:lang="en-US">Unlabeled Abstract153</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract153" xlink:to="sprcy_UnlabeledAbstract153_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract152_lbl0" xml:lang="en-US">Unlabeled Abstract152</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract152" xlink:to="sprcy_UnlabeledAbstract152_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract151_lbl0" xml:lang="en-US">Unlabeled Abstract151</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract151" xlink:to="sprcy_UnlabeledAbstract151_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AccruedExpenses_lbl0" xml:lang="en-US">Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccruedExpenses" xlink:to="sprcy_AccruedExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract155_lbl0" xml:lang="en-US">Unlabeled Abstract155</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract155" xlink:to="sprcy_UnlabeledAbstract155_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AttributableToAbstract_lbl0" xml:lang="en-US">Attributable To Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AttributableToAbstract" xlink:to="sprcy_AttributableToAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAdditionalInformationExplanatory_lbl0" xml:lang="en-US">Disclosure of additional information [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAdditionalInformationExplanatory" xlink:to="ifrs-full_DisclosureOfAdditionalInformationExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentFinancialAssetsAtAmortisedCost_lbl0" xml:lang="en-US">Current financial assets at amortised cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentFinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_CurrentFinancialAssetsAtAmortisedCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract150_lbl0" xml:lang="en-US">Unlabeled Abstract150</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract150" xlink:to="sprcy_UnlabeledAbstract150_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfPublicOffering_lbl1" xml:lang="en-US">Description Of Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfPublicOffering" xlink:to="sprcy_DescriptionOfPublicOffering_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InvestmentsInAssociates_lbl0" xml:lang="en-US">Investments in associates reported in separate financial statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentsInAssociates" xlink:to="ifrs-full_InvestmentsInAssociates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RiskFreeInterestRate_lbl1" xml:lang="en-US">Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RiskFreeInterestRate" xlink:to="sprcy_RiskFreeInterestRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PreDeterminedValue_lbl0" xml:lang="en-US">Pre Determined Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PreDeterminedValue" xlink:to="sprcy_PreDeterminedValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InitialInvestment_lbl1" xml:lang="en-US">Initial Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialInvestment" xlink:to="sprcy_InitialInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareOptionsReserved_lbl0" xml:lang="en-US">Share Options Reserved</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareOptionsReserved" xlink:to="sprcy_ShareOptionsReserved_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl0" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl0" xml:lang="en-US">Tax expense (income)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl1" xml:lang="en-US">Description Of Accounting Policy Foroperatingcycle Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:to="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl1"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract_lbl" xml:lang="en-US">Schedule Of Additional Information To The Items Of Profit Or Loss Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract" xlink:to="sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageShares_lbl0" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeReceivables_lbl0" xml:lang="en-US">Trade receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeReceivables" xlink:to="ifrs-full_TradeReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssets_lbl0" xml:lang="en-US">Financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssets" xlink:to="ifrs-full_FinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AccumulatedTerminationOfLeases_lbl1" xml:lang="en-US">Accumulated Termination Of Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccumulatedTerminationOfLeases" xlink:to="sprcy_AccumulatedTerminationOfLeases_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnderlyingAdsPrice_lbl0" xml:lang="en-US">Underlying Ads Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnderlyingAdsPrice" xlink:to="sprcy_UnderlyingAdsPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_lbl0" xml:lang="en-US">Disclosure of investments accounted for using equity method [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:to="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinanceExpensesFromInterestAndCommissions_lbl1" xml:lang="en-US">Finance Expenses From Interest And Commissions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinanceExpensesFromInterestAndCommissions" xlink:to="sprcy_FinanceExpensesFromInterestAndCommissions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl1" xml:lang="en-US">Intangible assets and goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsAndGoodwill" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ComprehensiveIncomeAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US">Comprehensive Income Attributable To Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ComprehensiveIncomeAttributableToNoncontrollingInterest" xlink:to="sprcy_ComprehensiveIncomeAttributableToNoncontrollingInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_June2022FinancingRoundMember_lbl0" xml:lang="en-US">June2022 Financing Round Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_June2022FinancingRoundMember" xlink:to="sprcy_June2022FinancingRoundMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfSharebasedPayments_lbl0" xml:lang="en-US">Reserve of share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPayments" xlink:to="ifrs-full_ReserveOfSharebasedPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AResearchAndDevelopmentExpensesAbstract_lbl0" xml:lang="en-US">AResearch And Development Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AResearchAndDevelopmentExpensesAbstract" xlink:to="sprcy_AResearchAndDevelopmentExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OwnershipAgreement_lbl1" xml:lang="en-US">Ownership Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OwnershipAgreement" xlink:to="sprcy_OwnershipAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ClinicalStudiesMember_lbl0" xml:lang="en-US">Clinical Studies Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ClinicalStudiesMember" xlink:to="sprcy_ClinicalStudiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl0" xml:lang="en-US">Basic earnings (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAbstract_lbl0" xml:lang="en-US">Assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract_lbl0" xml:lang="en-US">Equity Attributable To Equity Holders Of The Company Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossTablesLineItems_lbl0" xml:lang="en-US">Additional Informationtothe Itemsof Profitor Loss Tables Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossTablesLineItems" xlink:to="sprcy_AdditionalInformationtotheItemsofProfitorLossTablesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchasesOfCost_lbl1" xml:lang="en-US">Purchases Of Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasesOfCost" xlink:to="sprcy_PurchasesOfCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExerciseOfPrefundedWarrants_lbl3" xml:lang="en-US">Exercise Of Prefunded Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExerciseOfPrefundedWarrants" xlink:to="sprcy_ExerciseOfPrefundedWarrants_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ClearmindOutstandingShareCapitalPercentage_lbl1" xml:lang="en-US">Clearmind Outstanding Share Capital Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ClearmindOutstandingShareCapitalPercentage" xlink:to="sprcy_ClearmindOutstandingShareCapitalPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_lbl0" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdditionalMilestoneAmount_lbl0" xml:lang="en-US">Additional Milestone Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalMilestoneAmount" xlink:to="sprcy_AdditionalMilestoneAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Warrants Fair Value Using Blackscholes Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock" xlink:to="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncontrollingInterests_lbl0" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterests" xlink:to="ifrs-full_NoncontrollingInterests_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchaseOfAssets_lbl1" xml:lang="en-US">Purchase Of Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseOfAssets" xlink:to="sprcy_PurchaseOfAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl0" xml:lang="en-US">Disclosure of income tax [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LeaseholdImprovements_lbl1" xml:lang="en-US">Leasehold Improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseholdImprovements" xlink:to="sprcy_LeaseholdImprovements_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_lbl0" xml:lang="en-US">Adjustments for losses (gains) on disposal of non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:to="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_GroupsShareOfLossesOfCompanyAccountedForAtEquityNetMember_lbl0" xml:lang="en-US">Groups Share Of Losses Of Company Accounted For At Equity Net Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GroupsShareOfLossesOfCompanyAccountedForAtEquityNetMember" xlink:to="sprcy_GroupsShareOfLossesOfCompanyAccountedForAtEquityNetMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantNonCashTransactionsAbstract_lbl0" xml:lang="en-US">Significant Non Cash Transactions Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantNonCashTransactionsAbstract" xlink:to="sprcy_SignificantNonCashTransactionsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RSUGrantedDiscountRate_lbl0" xml:lang="en-US">RSUGranted Discount Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RSUGrantedDiscountRate" xlink:to="sprcy_RSUGrantedDiscountRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained earnings [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SCISPARCLTDMember_lbl0" xml:lang="en-US">SCISPARCLTDMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SCISPARCLTDMember" xlink:to="sprcy_SCISPARCLTDMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateAmountOrCreditAmount_lbl1" xml:lang="en-US">Aggregate Amount Or Credit Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateAmountOrCreditAmount" xlink:to="sprcy_AggregateAmountOrCreditAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CostAbstract_lbl0" xml:lang="en-US">Cost Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CostAbstract" xlink:to="sprcy_CostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl0" xml:lang="en-US">Adjustments to reconcile profit (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_lbl0" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentWarrantLiability_lbl0" xml:lang="en-US">Current warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentWarrantLiability" xlink:to="ifrs-full_CurrentWarrantLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl0" xml:lang="en-US">Expected dividend as percentage, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchaseofAssets_lbl0" xml:lang="en-US">Purchaseof Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseofAssets" xlink:to="sprcy_PurchaseofAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl0" xml:lang="en-US">Disclosure of finance income (cost) [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_lbl0" xml:lang="en-US">Number of shares reserved for issue under options and contracts for sale of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:to="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl0" xml:lang="en-US">Increase (decrease) in cash and cash equivalents after effect of exchange rate changes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareadsOptionsExpiredDuringYear_lbl0" xml:lang="en-US">Shareads Options Expired During Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareadsOptionsExpiredDuringYear" xlink:to="sprcy_ShareadsOptionsExpiredDuringYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome_lbl0" xml:lang="en-US">Impairment loss recognised in other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:to="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl0" xml:lang="en-US">Expected volatility, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_MitoCareXBioLtdMember_lbl1" xml:lang="en-US">Mito Care XBio Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MitoCareXBioLtdMember" xlink:to="sprcy_MitoCareXBioLtdMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl0" xml:lang="en-US">Disclosure of operating segments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationExpense_lbl0" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationExpense" xlink:to="ifrs-full_DepreciationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash_lbl0" xml:lang="en-US">Prices specified in forward agreements to purchase financial assets for cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash" xlink:to="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TaxExpense_lbl1" xml:lang="en-US">Tax Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TaxExpense" xlink:to="sprcy_TaxExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_StockIssuedDuringPeriodReverseStockSplits_lbl1" xml:lang="en-US">Stock Issued During Period Reverse Stock Splits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_StockIssuedDuringPeriodReverseStockSplits" xlink:to="sprcy_StockIssuedDuringPeriodReverseStockSplits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LeaseFee_lbl0" xml:lang="en-US">Lease Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseFee" xlink:to="sprcy_LeaseFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent_lbl1" xml:lang="en-US">Disclosure Of Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent" xlink:to="sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComputerEquipmentMember" xlink:to="ifrs-full_ComputerEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_BGeneralAndAdministrativeExpensesAbstract0_lbl0" xml:lang="en-US">BGeneral And Administrative Expenses Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BGeneralAndAdministrativeExpensesAbstract0" xlink:to="sprcy_BGeneralAndAdministrativeExpensesAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedPaymentMember_lbl0" xml:lang="en-US">Share Based Payment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedPaymentMember" xlink:to="sprcy_ShareBasedPaymentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl0" xml:lang="en-US">Disclosure of trade and other payables [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_GeneralAndAdministrativeExpenses_lbl0" xml:lang="en-US">General And Administrative Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GeneralAndAdministrativeExpenses" xlink:to="sprcy_GeneralAndAdministrativeExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl1" xml:lang="en-US">Profit (loss), attributable to non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl1" xml:lang="en-US">Disclourse Of Accounts Receivables Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" xlink:to="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NonCurrentAssetsAbstract_lbl0" xml:lang="en-US">Non Current Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NonCurrentAssetsAbstract" xlink:to="sprcy_NonCurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WellutionOperatingExpensesMember_lbl0" xml:lang="en-US">Wellution Operating Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WellutionOperatingExpensesMember" xlink:to="sprcy_WellutionOperatingExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FairValueDescription_lbl0" xml:lang="en-US">Fair Value Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueDescription" xlink:to="sprcy_FairValueDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfOutstandingShareOption_lbl2" xml:lang="en-US">Number Of Outstanding Share Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfOutstandingShareOption" xlink:to="sprcy_NumberOfOutstandingShareOption_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PrefundedOrdinaryShare_lbl1" xml:lang="en-US">Prefunded Ordinary Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrefundedOrdinaryShare" xlink:to="sprcy_PrefundedOrdinaryShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchaseCosts_lbl0" xml:lang="en-US">Purchase Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseCosts" xlink:to="sprcy_PurchaseCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl0" xml:lang="en-US">Non-current liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Accruals_lbl0" xml:lang="en-US">Accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Accruals" xlink:to="ifrs-full_Accruals_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities_lbl1" xml:lang="en-US">Disclosure Of Financial Assets And Financial Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities" xlink:to="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentAmount_lbl1" xml:lang="en-US">Investment Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentAmount" xlink:to="sprcy_InvestmentAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherLiabilities_lbl0" xml:lang="en-US">Other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherLiabilities" xlink:to="ifrs-full_OtherLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl0" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl0" xml:lang="en-US">Reversal of impairment loss recognised in profit or loss, intangible assets other than goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_Intersegment_lbl1" xml:lang="en-US">Intersegment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_Intersegment" xlink:to="sprcy_Intersegment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsExercisePrice_lbl1" xml:lang="en-US">Warrants Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsExercisePrice" xlink:to="sprcy_WarrantsExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ComprehensiveLoss_lbl1" xml:lang="en-US">Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ComprehensiveLoss" xlink:to="sprcy_ComprehensiveLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity_lbl0" xml:lang="en-US">Profit (loss) from continuing operations attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_BonusAmountReceived_lbl1" xml:lang="en-US">Bonus Amount Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BonusAmountReceived" xlink:to="sprcy_BonusAmountReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl0" xml:lang="en-US">Categories of financial liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinanceIncomeAbstract_lbl0" xml:lang="en-US">Finance Income Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinanceIncomeAbstract" xlink:to="sprcy_FinanceIncomeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfExpenseRecognizedExplanatoryTableTextBlock_lbl1" xml:lang="en-US">Disclosure Of Expense Recognized Explanatory Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfExpenseRecognizedExplanatoryTableTextBlock" xlink:to="sprcy_DisclosureOfExpenseRecognizedExplanatoryTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchasePrice_lbl0" xml:lang="en-US">Purchase Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasePrice" xlink:to="sprcy_PurchasePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl0" xml:lang="en-US">Number of shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract_lbl" xml:lang="en-US">Schedule Of Depreciation Is Calculated On AStraight Line Basis Over The Useful Life Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract" xlink:to="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl0" xml:lang="en-US">Current prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaidExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl0" xml:lang="en-US">Reserve of exchange differences on translation [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl0" xml:lang="en-US">Disclosure of detailed information about financial instruments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CashForImmediateWithdrawal_lbl1" xml:lang="en-US">Cash For Immediate Withdrawal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashForImmediateWithdrawal" xlink:to="sprcy_CashForImmediateWithdrawal_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PrefundedWarrantsMember_lbl0" xml:lang="en-US">Prefunded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrefundedWarrantsMember" xlink:to="sprcy_PrefundedWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestedAmountInClearmind_lbl1" xml:lang="en-US">Invested Amount In Clearmind</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestedAmountInClearmind" xlink:to="sprcy_InvestedAmountInClearmind_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AmountTotal_lbl0" xml:lang="en-US">Amount Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AmountTotal" xlink:to="sprcy_AmountTotal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssuedButNotFullyPaid_lbl0" xml:lang="en-US">Number of shares issued but not fully paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedButNotFullyPaid" xlink:to="ifrs-full_NumberOfSharesIssuedButNotFullyPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract_lbl0" xml:lang="en-US">Adjustments To The Profit Or Loss Items Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl0" xml:lang="en-US">Current lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfOptionPricingModelShareOptionGranted_lbl0" xml:lang="en-US">Description Of Option Pricing Model Share Option Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfOptionPricingModelShareOptionGranted" xlink:to="sprcy_DescriptionOfOptionPricingModelShareOptionGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl0" xml:lang="en-US">Non-current assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RegulatoryExpensesMember_lbl0" xml:lang="en-US">Regulatory Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RegulatoryExpensesMember" xlink:to="sprcy_RegulatoryExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CreditFromOthers_lbl1" xml:lang="en-US">Credit From Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CreditFromOthers" xlink:to="sprcy_CreditFromOthers_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl0" xml:lang="en-US">Current trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExerciseOfPricePerShare_lbl2" xml:lang="en-US">Exercise Of Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExerciseOfPricePerShare" xlink:to="sprcy_ExerciseOfPricePerShare_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory_lbl0" xml:lang="en-US">Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_JeffsBrandsMember_lbl0" xml:lang="en-US">Jeffs Brands Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_JeffsBrandsMember" xlink:to="sprcy_JeffsBrandsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchasePricePerShare_lbl1" xml:lang="en-US">Purchase Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasePricePerShare" xlink:to="sprcy_PurchasePricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory_lbl0" xml:lang="en-US">Disclosure of effect of change of investment entity status on financial statements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of financial position [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OrdinaryShareMember_lbl1" xml:lang="en-US">Ordinary Share Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinaryShareMember" xlink:to="sprcy_OrdinaryShareMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ADSMember_lbl0" xml:lang="en-US">ADSMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ADSMember" xlink:to="sprcy_ADSMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_lbl0" xml:lang="en-US">Increase (decrease) in number of shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_November2020FinancingRoundMember_lbl0" xml:lang="en-US">November2020 Financing Round Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_November2020FinancingRoundMember" xlink:to="sprcy_November2020FinancingRoundMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for investment in associates and joint ventures [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OrdinarySharesIssued_lbl0" xml:lang="en-US">Ordinary Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesIssued" xlink:to="sprcy_OrdinarySharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantExpiryPeriod_lbl1" xml:lang="en-US">Warrant Expiry Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantExpiryPeriod" xlink:to="sprcy_WarrantExpiryPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DividendYield_lbl1" xml:lang="en-US">Dividend Yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DividendYield" xlink:to="sprcy_DividendYield_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EquityLossesInvestment_lbl1" xml:lang="en-US">Equity Losses Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityLossesInvestment" xlink:to="sprcy_EquityLossesInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherPayables_lbl0" xml:lang="en-US">Other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_OtherPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl0" xml:lang="en-US">Current assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl0" xml:lang="en-US">Disclosure of trade and other receivables [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromSaleOfGoods_lbl0" xml:lang="en-US">Revenue from sale of goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromSaleOfGoods" xlink:to="ifrs-full_RevenueFromSaleOfGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FeeExpenses_lbl1" xml:lang="en-US">Fee Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FeeExpenses" xlink:to="sprcy_FeeExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome_lbl1" xml:lang="en-US">Financial assets measured at fair value through other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:to="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract80_lbl0" xml:lang="en-US">Unlabeled Abstract80</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract80" xlink:to="sprcy_UnlabeledAbstract80_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AutoMaxSharesMember_lbl0" xml:lang="en-US">Auto Max Shares Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AutoMaxSharesMember" xlink:to="sprcy_AutoMaxSharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract83_lbl0" xml:lang="en-US">Unlabeled Abstract83</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract83" xlink:to="sprcy_UnlabeledAbstract83_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract84_lbl0" xml:lang="en-US">Unlabeled Abstract84</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract84" xlink:to="sprcy_UnlabeledAbstract84_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfOtherAccountsPayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfOtherAccountsPayableAbstract_lbl" xml:lang="en-US">Schedule Of Other Accounts Payable Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:to="sprcy_ScheduleOfOtherAccountsPayableAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract81_lbl0" xml:lang="en-US">Unlabeled Abstract81</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract81" xlink:to="sprcy_UnlabeledAbstract81_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract82_lbl0" xml:lang="en-US">Unlabeled Abstract82</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract82" xlink:to="sprcy_UnlabeledAbstract82_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract87_lbl0" xml:lang="en-US">Unlabeled Abstract87</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract87" xlink:to="sprcy_UnlabeledAbstract87_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract88_lbl0" xml:lang="en-US">Unlabeled Abstract88</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract88" xlink:to="sprcy_UnlabeledAbstract88_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock_lbl1" xml:lang="en-US">Significant Accounting Judgments Estimates And Assumptions Used In Preparation Of Financial Statements Explanatory Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" xlink:to="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract85_lbl0" xml:lang="en-US">Unlabeled Abstract85</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract85" xlink:to="sprcy_UnlabeledAbstract85_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract86_lbl0" xml:lang="en-US">Unlabeled Abstract86</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract86" xlink:to="sprcy_UnlabeledAbstract86_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract89_lbl0" xml:lang="en-US">Unlabeled Abstract89</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract89" xlink:to="sprcy_UnlabeledAbstract89_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OfficeEquipmentsMember_lbl0" xml:lang="en-US">Office Equipments Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OfficeEquipmentsMember" xlink:to="sprcy_OfficeEquipmentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract90_lbl0" xml:lang="en-US">Unlabeled Abstract90</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract90" xlink:to="sprcy_UnlabeledAbstract90_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncontrollingInterestsMember_lbl0" xml:lang="en-US">Non-controlling interests [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterestsMember" xlink:to="ifrs-full_NoncontrollingInterestsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract91_lbl0" xml:lang="en-US">Unlabeled Abstract91</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract91" xlink:to="sprcy_UnlabeledAbstract91_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateValue_lbl1" xml:lang="en-US">Aggregate Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateValue" xlink:to="sprcy_AggregateValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract94_lbl0" xml:lang="en-US">Unlabeled Abstract94</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract94" xlink:to="sprcy_UnlabeledAbstract94_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract95_lbl0" xml:lang="en-US">Unlabeled Abstract95</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract95" xlink:to="sprcy_UnlabeledAbstract95_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract92_lbl0" xml:lang="en-US">Unlabeled Abstract92</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract92" xlink:to="sprcy_UnlabeledAbstract92_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract93_lbl0" xml:lang="en-US">Unlabeled Abstract93</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract93" xlink:to="sprcy_UnlabeledAbstract93_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract98_lbl0" xml:lang="en-US">Unlabeled Abstract98</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract98" xlink:to="sprcy_UnlabeledAbstract98_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract99_lbl0" xml:lang="en-US">Unlabeled Abstract99</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract99" xlink:to="sprcy_UnlabeledAbstract99_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract96_lbl0" xml:lang="en-US">Unlabeled Abstract96</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract96" xlink:to="sprcy_UnlabeledAbstract96_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract97_lbl0" xml:lang="en-US">Unlabeled Abstract97</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract97" xlink:to="sprcy_UnlabeledAbstract97_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SubsequentMember_lbl0" xml:lang="en-US">Subsequent Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SubsequentMember" xlink:to="sprcy_SubsequentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CostOfSales_lbl1" xml:lang="en-US">Cost of sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSales" xlink:to="ifrs-full_CostOfSales_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract61_lbl0" xml:lang="en-US">Unlabeled Abstract61</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract61" xlink:to="sprcy_UnlabeledAbstract61_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract62_lbl0" xml:lang="en-US">Unlabeled Abstract62</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract62" xlink:to="sprcy_UnlabeledAbstract62_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract60_lbl0" xml:lang="en-US">Unlabeled Abstract60</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract60" xlink:to="sprcy_UnlabeledAbstract60_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract65_lbl0" xml:lang="en-US">Unlabeled Abstract65</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract65" xlink:to="sprcy_UnlabeledAbstract65_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentsInFinancialAssets_lbl0" xml:lang="en-US">Investments In Financial Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentsInFinancialAssets" xlink:to="sprcy_InvestmentsInFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract66_lbl0" xml:lang="en-US">Unlabeled Abstract66</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract66" xlink:to="sprcy_UnlabeledAbstract66_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract63_lbl0" xml:lang="en-US">Unlabeled Abstract63</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract63" xlink:to="sprcy_UnlabeledAbstract63_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of financial liabilities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract64_lbl0" xml:lang="en-US">Unlabeled Abstract64</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract64" xlink:to="sprcy_UnlabeledAbstract64_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract69_lbl0" xml:lang="en-US">Unlabeled Abstract69</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract69" xlink:to="sprcy_UnlabeledAbstract69_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuanceOfAggregateShares_lbl2" xml:lang="en-US">Issuance Of Aggregate Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfAggregateShares" xlink:to="sprcy_IssuanceOfAggregateShares_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract67_lbl0" xml:lang="en-US">Unlabeled Abstract67</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract67" xlink:to="sprcy_UnlabeledAbstract67_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract68_lbl0" xml:lang="en-US">Unlabeled Abstract68</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract68" xlink:to="sprcy_UnlabeledAbstract68_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_BasisOfPresentationOfFinancialStatements_lbl1" xml:lang="en-US">Basis Of Presentation Of Financial Statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BasisOfPresentationOfFinancialStatements" xlink:to="sprcy_BasisOfPresentationOfFinancialStatements_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl0" xml:lang="en-US">Disclosure of employee benefits [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncomeCost_lbl0" xml:lang="en-US">Finance income (cost)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_FinanceIncomeCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_lbl0" xml:lang="en-US">Remaining amortisation period of intangible assets material to entity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:to="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract72_lbl0" xml:lang="en-US">Unlabeled Abstract72</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract72" xlink:to="sprcy_UnlabeledAbstract72_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract73_lbl0" xml:lang="en-US">Unlabeled Abstract73</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract73" xlink:to="sprcy_UnlabeledAbstract73_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract70_lbl0" xml:lang="en-US">Unlabeled Abstract70</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract70" xlink:to="sprcy_UnlabeledAbstract70_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract71_lbl0" xml:lang="en-US">Unlabeled Abstract71</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract71" xlink:to="sprcy_UnlabeledAbstract71_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract76_lbl0" xml:lang="en-US">Unlabeled Abstract76</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract76" xlink:to="sprcy_UnlabeledAbstract76_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract77_lbl0" xml:lang="en-US">Unlabeled Abstract77</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract77" xlink:to="sprcy_UnlabeledAbstract77_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract74_lbl0" xml:lang="en-US">Unlabeled Abstract74</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract74" xlink:to="sprcy_UnlabeledAbstract74_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract75_lbl0" xml:lang="en-US">Unlabeled Abstract75</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract75" xlink:to="sprcy_UnlabeledAbstract75_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NewLeases_lbl0" xml:lang="en-US">New Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NewLeases" xlink:to="sprcy_NewLeases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract78_lbl0" xml:lang="en-US">Unlabeled Abstract78</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract78" xlink:to="sprcy_UnlabeledAbstract78_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract79_lbl0" xml:lang="en-US">Unlabeled Abstract79</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract79" xlink:to="sprcy_UnlabeledAbstract79_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses_lbl1" xml:lang="en-US">Proceeds From Issue Of Share Capital And Warrantsnet Of Issuance Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" xlink:to="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ResearchAndDevelopmentExpenses1_lbl1" xml:lang="en-US">Research And Development Expenses1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndDevelopmentExpenses1" xlink:to="sprcy_ResearchAndDevelopmentExpenses1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract38_lbl0" xml:lang="en-US">Unlabeled Abstract38</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract38" xlink:to="sprcy_UnlabeledAbstract38_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract39_lbl0" xml:lang="en-US">Unlabeled Abstract39</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract39" xlink:to="sprcy_UnlabeledAbstract39_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl0" xml:lang="en-US">Share of profit (loss) of associates and joint ventures accounted for using equity method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IncomeStatementsLocationsAxis_lbl0" xml:lang="en-US">Income Statements Locations Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IncomeStatementsLocationsAxis" xlink:to="sprcy_IncomeStatementsLocationsAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AnnualInvestment_lbl1" xml:lang="en-US">Annual Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AnnualInvestment" xlink:to="sprcy_AnnualInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SegmentReportingRevenueAbstract_lbl0" xml:lang="en-US">Segment Reporting Revenue Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SegmentReportingRevenueAbstract" xlink:to="sprcy_SegmentReportingRevenueAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost_lbl0" xml:lang="en-US">Financial liabilities at amortised cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_lbl1" xml:lang="en-US">Profit (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ContinuingOperationsAbstract_lbl0" xml:lang="en-US">Continuing Operations Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ContinuingOperationsAbstract" xlink:to="sprcy_ContinuingOperationsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExerciseOfWarrants_lbl2" xml:lang="en-US">Exercise Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExerciseOfWarrants" xlink:to="sprcy_ExerciseOfWarrants_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdjustedAmountOfAggregateValue_lbl1" xml:lang="en-US">Adjusted Amount Of Aggregate Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustedAmountOfAggregateValue" xlink:to="sprcy_AdjustedAmountOfAggregateValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract40_lbl0" xml:lang="en-US">Unlabeled Abstract40</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract40" xlink:to="sprcy_UnlabeledAbstract40_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract43_lbl0" xml:lang="en-US">Unlabeled Abstract43</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract43" xlink:to="sprcy_UnlabeledAbstract43_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract44_lbl0" xml:lang="en-US">Unlabeled Abstract44</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract44" xlink:to="sprcy_UnlabeledAbstract44_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract41_lbl0" xml:lang="en-US">Unlabeled Abstract41</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract41" xlink:to="sprcy_UnlabeledAbstract41_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract42_lbl0" xml:lang="en-US">Unlabeled Abstract42</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract42" xlink:to="sprcy_UnlabeledAbstract42_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_lbl2" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract47_lbl0" xml:lang="en-US">Unlabeled Abstract47</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract47" xlink:to="sprcy_UnlabeledAbstract47_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract48_lbl0" xml:lang="en-US">Unlabeled Abstract48</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract48" xlink:to="sprcy_UnlabeledAbstract48_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract45_lbl0" xml:lang="en-US">Unlabeled Abstract45</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract45" xlink:to="sprcy_UnlabeledAbstract45_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract46_lbl0" xml:lang="en-US">Unlabeled Abstract46</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract46" xlink:to="sprcy_UnlabeledAbstract46_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExpectedVolatility_lbl1" xml:lang="en-US">Expected Volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExpectedVolatility" xlink:to="sprcy_ExpectedVolatility_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract49_lbl0" xml:lang="en-US">Unlabeled Abstract49</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract49" xlink:to="sprcy_UnlabeledAbstract49_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ChemistryAndFormulationsMember_lbl0" xml:lang="en-US">Chemistry And Formulations Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ChemistryAndFormulationsMember" xlink:to="sprcy_ChemistryAndFormulationsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CashLineItems_lbl0" xml:lang="en-US">Cash Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashLineItems" xlink:to="sprcy_CashLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeStatementAbstract_lbl" xml:lang="en-US">Profit or loss [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl0" xml:lang="en-US">Profit (loss) before tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember_lbl0" xml:lang="en-US">Communication and network equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:to="ifrs-full_CommunicationAndNetworkEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_MutualShareExchangeAmount_lbl1" xml:lang="en-US">Mutual Share Exchange Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MutualShareExchangeAmount" xlink:to="sprcy_MutualShareExchangeAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ReceiptofShortTermCreditFromOthers_lbl0" xml:lang="en-US">Receiptof Short Term Credit From Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ReceiptofShortTermCreditFromOthers" xlink:to="sprcy_ReceiptofShortTermCreditFromOthers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1_lbl0" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumption Expected Term1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" xlink:to="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_lbl0" xml:lang="en-US">Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:to="ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl0" xml:lang="en-US">Adjustments for decrease (increase) in other operating receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract50_lbl0" xml:lang="en-US">Unlabeled Abstract50</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract50" xlink:to="sprcy_UnlabeledAbstract50_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract51_lbl0" xml:lang="en-US">Unlabeled Abstract51</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract51" xlink:to="sprcy_UnlabeledAbstract51_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract54_lbl0" xml:lang="en-US">Unlabeled Abstract54</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract54" xlink:to="sprcy_UnlabeledAbstract54_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract55_lbl0" xml:lang="en-US">Unlabeled Abstract55</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract55" xlink:to="sprcy_UnlabeledAbstract55_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract52_lbl0" xml:lang="en-US">Unlabeled Abstract52</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract52" xlink:to="sprcy_UnlabeledAbstract52_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract53_lbl0" xml:lang="en-US">Unlabeled Abstract53</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract53" xlink:to="sprcy_UnlabeledAbstract53_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract58_lbl0" xml:lang="en-US">Unlabeled Abstract58</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract58" xlink:to="sprcy_UnlabeledAbstract58_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract59_lbl0" xml:lang="en-US">Unlabeled Abstract59</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract59" xlink:to="sprcy_UnlabeledAbstract59_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReceivables_lbl0" xml:lang="en-US">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReceivables" xlink:to="ifrs-full_OtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract56_lbl0" xml:lang="en-US">Unlabeled Abstract56</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract56" xlink:to="sprcy_UnlabeledAbstract56_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncome_lbl0" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract57_lbl0" xml:lang="en-US">Unlabeled Abstract57</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract57" xlink:to="sprcy_UnlabeledAbstract57_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract18_lbl0" xml:lang="en-US">Unlabeled Abstract18</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract18" xlink:to="sprcy_UnlabeledAbstract18_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract19_lbl0" xml:lang="en-US">Unlabeled Abstract19</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract19" xlink:to="sprcy_UnlabeledAbstract19_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract16_lbl0" xml:lang="en-US">Unlabeled Abstract16</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract16" xlink:to="sprcy_UnlabeledAbstract16_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExternalRevenues_lbl1" xml:lang="en-US">External Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExternalRevenues" xlink:to="sprcy_ExternalRevenues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract17_lbl0" xml:lang="en-US">Unlabeled Abstract17</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract17" xlink:to="sprcy_UnlabeledAbstract17_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestedInitialAmount_lbl1" xml:lang="en-US">Invested Initial Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestedInitialAmount" xlink:to="sprcy_InvestedInitialAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl1" xml:lang="en-US">Issue Of Share Capital Net Of Issue Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssueOfShareCapitalNetOfIssueExpense" xlink:to="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements_lbl1" xml:lang="en-US">Description Of Amendment To IAS1 Presentation Of Financial Statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements" xlink:to="sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract21_lbl0" xml:lang="en-US">Unlabeled Abstract21</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract21" xlink:to="sprcy_UnlabeledAbstract21_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract22_lbl0" xml:lang="en-US">Unlabeled Abstract22</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract22" xlink:to="sprcy_UnlabeledAbstract22_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract20_lbl0" xml:lang="en-US">Unlabeled Abstract20</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract20" xlink:to="sprcy_UnlabeledAbstract20_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PreviouslyStatedMember_lbl1" xml:lang="en-US">Previously stated [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PreviouslyStatedMember" xlink:to="ifrs-full_PreviouslyStatedMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CreditFacilityAndRemainingAvailableDrawnAmount_lbl1" xml:lang="en-US">Credit Facility And Remaining Available Drawn Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CreditFacilityAndRemainingAvailableDrawnAmount" xlink:to="sprcy_CreditFacilityAndRemainingAvailableDrawnAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract25_lbl0" xml:lang="en-US">Unlabeled Abstract25</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract25" xlink:to="sprcy_UnlabeledAbstract25_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract26_lbl0" xml:lang="en-US">Unlabeled Abstract26</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract26" xlink:to="sprcy_UnlabeledAbstract26_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract23_lbl0" xml:lang="en-US">Unlabeled Abstract23</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract23" xlink:to="sprcy_UnlabeledAbstract23_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract24_lbl0" xml:lang="en-US">Unlabeled Abstract24</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract24" xlink:to="sprcy_UnlabeledAbstract24_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract29_lbl0" xml:lang="en-US">Unlabeled Abstract29</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract29" xlink:to="sprcy_UnlabeledAbstract29_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract27_lbl0" xml:lang="en-US">Unlabeled Abstract27</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract27" xlink:to="sprcy_UnlabeledAbstract27_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract28_lbl0" xml:lang="en-US">Unlabeled Abstract28</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract28" xlink:to="sprcy_UnlabeledAbstract28_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl0" xml:lang="en-US">Key management personnel of entity or parent [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl0" xml:lang="en-US">Short-term deposits, classified as cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl2" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashOutflowForLeases_lbl0" xml:lang="en-US">Cash outflow for leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOutflowForLeases" xlink:to="ifrs-full_CashOutflowForLeases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EveroMember_lbl0" xml:lang="en-US">Evero Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EveroMember" xlink:to="sprcy_EveroMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract32_lbl0" xml:lang="en-US">Unlabeled Abstract32</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract32" xlink:to="sprcy_UnlabeledAbstract32_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract33_lbl0" xml:lang="en-US">Unlabeled Abstract33</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract33" xlink:to="sprcy_UnlabeledAbstract33_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract30_lbl0" xml:lang="en-US">Unlabeled Abstract30</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract30" xlink:to="sprcy_UnlabeledAbstract30_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinancialLiabilitiesAbstract_lbl0" xml:lang="en-US">Financial Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinancialLiabilitiesAbstract" xlink:to="sprcy_FinancialLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract31_lbl0" xml:lang="en-US">Unlabeled Abstract31</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract31" xlink:to="sprcy_UnlabeledAbstract31_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_March2021FinancingRoundMember_lbl0" xml:lang="en-US">March2021 Financing Round Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_March2021FinancingRoundMember" xlink:to="sprcy_March2021FinancingRoundMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract36_lbl0" xml:lang="en-US">Unlabeled Abstract36</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract36" xlink:to="sprcy_UnlabeledAbstract36_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract37_lbl0" xml:lang="en-US">Unlabeled Abstract37</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract37" xlink:to="sprcy_UnlabeledAbstract37_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinanceExpensesAbstract_lbl0" xml:lang="en-US">Finance Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinanceExpensesAbstract" xlink:to="sprcy_FinanceExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract34_lbl0" xml:lang="en-US">Unlabeled Abstract34</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract34" xlink:to="sprcy_UnlabeledAbstract34_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareOptionsOutstandingParValue_lbl1" xml:lang="en-US">Share Options Outstanding Par Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareOptionsOutstandingParValue" xlink:to="sprcy_ShareOptionsOutstandingParValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract35_lbl0" xml:lang="en-US">Unlabeled Abstract35</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract35" xlink:to="sprcy_UnlabeledAbstract35_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EquityLossesFromInvestmentInMitoCareX_lbl1" xml:lang="en-US">Equity Losses From Investment In Mito Care X</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityLossesFromInvestmentInMitoCareX" xlink:to="sprcy_EquityLossesFromInvestmentInMitoCareX_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AResearchAndDevelopmentExpensesAbstract0_lbl0" xml:lang="en-US">AResearch And Development Expenses Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AResearchAndDevelopmentExpensesAbstract0" xlink:to="sprcy_AResearchAndDevelopmentExpensesAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for taxes other than income tax [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ImpairmentOfInvestmentInAssociateMember_lbl0" xml:lang="en-US">Impairment Of Investment In Associate Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ImpairmentOfInvestmentInAssociateMember" xlink:to="sprcy_ImpairmentOfInvestmentInAssociateMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_BasicLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract_lbl0" xml:lang="en-US">Basic Loss Per Share Attributable To Equity Holders Of The Company Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BasicLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="sprcy_BasicLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for research and development expense [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Fair Value Of The Intangible Asset Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock" xlink:to="sprcy_ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchaseOrdinaryShares_lbl1" xml:lang="en-US">Purchase Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseOrdinaryShares" xlink:to="sprcy_PurchaseOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl0" xml:lang="en-US">Property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdjustmentsForImpairmentOfInvestmentInAssociate_lbl1" xml:lang="en-US">Adjustments For Impairment Of Investment In Associate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsForImpairmentOfInvestmentInAssociate" xlink:to="sprcy_AdjustmentsForImpairmentOfInvestmentInAssociate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates_lbl0" xml:lang="en-US">Description of accounting policy for investment in associates [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl0" xml:lang="en-US">Diluted earnings (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestPayable_lbl0" xml:lang="en-US">Interest payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPayable" xlink:to="ifrs-full_InterestPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold improvements [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseholdImprovementsMember" xlink:to="ifrs-full_LeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract10_lbl0" xml:lang="en-US">Unlabeled Abstract10</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract10" xlink:to="sprcy_UnlabeledAbstract10_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract11_lbl0" xml:lang="en-US">Unlabeled Abstract11</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract11" xlink:to="sprcy_UnlabeledAbstract11_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract14_lbl0" xml:lang="en-US">Unlabeled Abstract14</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract14" xlink:to="sprcy_UnlabeledAbstract14_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract15_lbl0" xml:lang="en-US">Unlabeled Abstract15</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract15" xlink:to="sprcy_UnlabeledAbstract15_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract12_lbl0" xml:lang="en-US">Unlabeled Abstract12</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract12" xlink:to="sprcy_UnlabeledAbstract12_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract13_lbl0" xml:lang="en-US">Unlabeled Abstract13</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract13" xlink:to="sprcy_UnlabeledAbstract13_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinanceIncomeFromConvertibleLoan_lbl0" xml:lang="en-US">Finance Income From Convertible Loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinanceIncomeFromConvertibleLoan" xlink:to="sprcy_FinanceIncomeFromConvertibleLoan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement_lbl1" xml:lang="en-US">Number Of Share Option Forfeited In Sharebased Payment Arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement" xlink:to="sprcy_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_StockOptionDescription_lbl0" xml:lang="en-US">Stock Option Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_StockOptionDescription" xlink:to="sprcy_StockOptionDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InitialConversionPrice_lbl1" xml:lang="en-US">Initial Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialConversionPrice" xlink:to="sprcy_InitialConversionPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WeightedAverageExercisePriceOfShareOptionForfeitedInSharebasedPaymentArrangement_lbl1" xml:lang="en-US">Weighted Average Exercise Price Of Share Option Forfeited In Sharebased Payment Arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WeightedAverageExercisePriceOfShareOptionForfeitedInSharebasedPaymentArrangement" xlink:to="sprcy_WeightedAverageExercisePriceOfShareOptionForfeitedInSharebasedPaymentArrangement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilities_lbl0" xml:lang="en-US">Equity and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ADSsMember_lbl0" xml:lang="en-US">ADSs Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ADSsMember" xlink:to="sprcy_ADSsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract0_lbl0" xml:lang="en-US">Adjustments To The Profit Or Loss Items Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract0" xlink:to="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsInterestRate_lbl0" xml:lang="en-US">Borrowings, interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract2" xlink:to="sprcy_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract1" xlink:to="sprcy_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract4" xlink:to="sprcy_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract3" xlink:to="sprcy_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PercentageOfWorkingCapital_lbl1" xml:lang="en-US">Percentage Of Working Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfWorkingCapital" xlink:to="sprcy_PercentageOfWorkingCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract0" xlink:to="sprcy_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract9_lbl0" xml:lang="en-US">Unlabeled Abstract9</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract9" xlink:to="sprcy_UnlabeledAbstract9_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment_lbl1" xml:lang="en-US">Percentage Of Useful Lives Or Depreciation Rates Property Plant And Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" xlink:to="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MotorVehiclesMember_lbl0" xml:lang="en-US">Motor vehicles [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MotorVehiclesMember" xlink:to="ifrs-full_MotorVehiclesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract6" xlink:to="sprcy_UnlabeledAbstract6_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of cash flows [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract5" xlink:to="sprcy_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract8_lbl0" xml:lang="en-US">Unlabeled Abstract8</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract8" xlink:to="sprcy_UnlabeledAbstract8_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract7" xlink:to="sprcy_UnlabeledAbstract7_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Selling, general and administrative expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTradeReceivables_lbl0" xml:lang="en-US">Current trade receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTradeReceivables" xlink:to="ifrs-full_CurrentTradeReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremiumMember_lbl0" xml:lang="en-US">Share premium [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremiumMember" xlink:to="ifrs-full_SharePremiumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl0" xml:lang="en-US">Business Contact [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SeriesAWarrantsMember_lbl0" xml:lang="en-US">Series AWarrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SeriesAWarrantsMember" xlink:to="sprcy_SeriesAWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentReceivables_lbl1" xml:lang="en-US">Other current receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl0" xml:lang="en-US">Disclosure of leases [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract" xlink:to="sprcy_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RepaymentOfShorttermCredit_lbl0" xml:lang="en-US">Repayment Of Shortterm Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RepaymentOfShorttermCredit" xlink:to="sprcy_RepaymentOfShorttermCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl0" xml:lang="en-US">Other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilities_lbl1" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WorkingCapitalAdjustmentsAbstract0_lbl0" xml:lang="en-US">Working Capital Adjustments Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WorkingCapitalAdjustmentsAbstract0" xlink:to="sprcy_WorkingCapitalAdjustmentsAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LeaseMember_lbl0" xml:lang="en-US">Lease Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseMember" xlink:to="sprcy_LeaseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfPrivateOffering_lbl1" xml:lang="en-US">Description Of Private Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfPrivateOffering" xlink:to="sprcy_DescriptionOfPrivateOffering_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CashPayment_lbl0" xml:lang="en-US">Cash Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashPayment" xlink:to="sprcy_CashPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated_lbl0" xml:lang="en-US">Property, plant and equipment, gross carrying amount of fully depreciated assets still in use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" xlink:to="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl2" xml:lang="en-US">Increase (decrease) in number of ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateGrossProceeds_lbl1" xml:lang="en-US">Aggregate Gross Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateGrossProceeds" xlink:to="sprcy_AggregateGrossProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests_lbl0" xml:lang="en-US">Proceeds from contributions of non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:to="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl1" xml:lang="en-US">Disclosue Of Cash And Cash Equivalents Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:to="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GrossProfit_lbl1" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_GrossProfit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares_lbl0" xml:lang="en-US">Issued capital, ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalOrdinaryShares" xlink:to="ifrs-full_IssuedCapitalOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EmployeeBenefitLiabilitiesTablesLineItems_lbl0" xml:lang="en-US">Employee Benefit Liabilities Tables Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EmployeeBenefitLiabilitiesTablesLineItems" xlink:to="sprcy_EmployeeBenefitLiabilitiesTablesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DiscontinuedOperationsMember_lbl0" xml:lang="en-US">Discontinued operations [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DiscontinuedOperationsMember" xlink:to="ifrs-full_DiscontinuedOperationsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and administrative expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DekelLicenseAgreementDescription_lbl1" xml:lang="en-US">Dekel License Agreement Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DekelLicenseAgreementDescription" xlink:to="sprcy_DekelLicenseAgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl1" xml:lang="en-US">Description Of Acquisition Of ASingle Asset Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" xlink:to="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SharesIssuedToConsultants_lbl1" xml:lang="en-US">Shares Issued To Consultants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharesIssuedToConsultants" xlink:to="sprcy_SharesIssuedToConsultants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherEquityInterest_lbl0" xml:lang="en-US">Other equity interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEquityInterest" xlink:to="ifrs-full_OtherEquityInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl0" xml:lang="en-US">Non-current lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Depreciation, property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl0" xml:lang="en-US">Increase (decrease) through exercise of warrants, equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WorkingCapitalAdjustmentsAbstract_lbl0" xml:lang="en-US">Working Capital Adjustments Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WorkingCapitalAdjustmentsAbstract" xlink:to="sprcy_WorkingCapitalAdjustmentsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl0" xml:lang="en-US">Adjustments for increase (decrease) in trade and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_GrossProceeds_lbl1" xml:lang="en-US">Gross Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GrossProceeds" xlink:to="sprcy_GrossProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_lbl0" xml:lang="en-US">Disclosure of fair value of financial instruments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl0" xml:lang="en-US">Adjustments for share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SeriesBWarrantsMember_lbl0" xml:lang="en-US">Series BWarrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SeriesBWarrantsMember" xlink:to="sprcy_SeriesBWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Revenue_lbl0" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Defined Contribution Plans Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExercisePrice1_lbl0" xml:lang="en-US">Exercise Price1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExercisePrice1" xlink:to="sprcy_ExercisePrice1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TradeAndOtherPayable_lbl1" xml:lang="en-US">Trade And Other Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TradeAndOtherPayable" xlink:to="sprcy_TradeAndOtherPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ApplicableTaxRate_lbl0" xml:lang="en-US">Applicable tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ApplicableTaxRate" xlink:to="ifrs-full_ApplicableTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AccumulatedDepreciationAbstract0_lbl0" xml:lang="en-US">Accumulated Depreciation Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccumulatedDepreciationAbstract0" xlink:to="sprcy_AccumulatedDepreciationAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ConversionOfOrdinaryShares_lbl0" xml:lang="en-US">Conversion Of Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ConversionOfOrdinaryShares" xlink:to="sprcy_ConversionOfOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareCapitalPercentage_lbl1" xml:lang="en-US">Share Capital Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareCapitalPercentage" xlink:to="sprcy_ShareCapitalPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_MutualShareExchangeOfOrdinarySharessee_lbl0" xml:lang="en-US">Mutual Share Exchange Of Ordinary Sharessee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MutualShareExchangeOfOrdinarySharessee" xlink:to="sprcy_MutualShareExchangeOfOrdinarySharessee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfSharesAbstract0_lbl0" xml:lang="en-US">Number Of Shares Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfSharesAbstract0" xlink:to="sprcy_NumberOfSharesAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsFairValueinDollarsPerShare_lbl0" xml:lang="en-US">Warrants Fair Valuein Dollars Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsFairValueinDollarsPerShare" xlink:to="sprcy_WarrantsFairValueinDollarsPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WarrantLiability_lbl0" xml:lang="en-US">Warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantLiability" xlink:to="ifrs-full_WarrantLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Cash_lbl0" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceCosts_lbl0" xml:lang="en-US">Finance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl0" xml:lang="en-US">Profit (loss) from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_MitoCareXMember_lbl0" xml:lang="en-US">Mito Care XMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MitoCareXMember" xlink:to="sprcy_MitoCareXMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl0" xml:lang="en-US">Disclosure of changes in accounting policies [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_MonthlyFee_lbl1" xml:lang="en-US">Monthly Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MonthlyFee" xlink:to="sprcy_MonthlyFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption_lbl1" xml:lang="en-US">Weighted Average Remaining Contractual Lifes Of Outstanding Share Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption" xlink:to="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfSharesOptionGrantedInSharebasedPaymentArrangement_lbl1" xml:lang="en-US">Number Of Shares Option Granted In Sharebased Payment Arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfSharesOptionGrantedInSharebasedPaymentArrangement" xlink:to="sprcy_NumberOfSharesOptionGrantedInSharebasedPaymentArrangement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinanceExpensesFromExchangeRateDifferences_lbl1" xml:lang="en-US">Finance Expenses From Exchange Rate Differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinanceExpensesFromExchangeRateDifferences" xlink:to="sprcy_FinanceExpensesFromExchangeRateDifferences_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl1" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_MaturityDate_lbl0" xml:lang="en-US">Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MaturityDate" xlink:to="sprcy_MaturityDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CapitalPointMember_lbl0" xml:lang="en-US">Capital Point Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CapitalPointMember" xlink:to="sprcy_CapitalPointMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OrdinaryGrantedDiscountRate_lbl0" xml:lang="en-US">Ordinary Granted Discount Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinaryGrantedDiscountRate" xlink:to="sprcy_OrdinaryGrantedDiscountRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssueExpensesRelatedToIssuanceOfWarrants_lbl0" xml:lang="en-US">Issue Expenses Related To Issuance Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssueExpensesRelatedToIssuanceOfWarrants" xlink:to="sprcy_IssueExpensesRelatedToIssuanceOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl0" xml:lang="en-US">Retained earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl0" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NoParValuePerShare_lbl1" xml:lang="en-US">No Par Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NoParValuePerShare" xlink:to="sprcy_NoParValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InterestExpenseInRespectOfLeases_lbl0" xml:lang="en-US">Interest Expense In Respect Of Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestExpenseInRespectOfLeases" xlink:to="sprcy_InterestExpenseInRespectOfLeases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DilutedLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract_lbl0" xml:lang="en-US">Diluted Loss Per Share Attributable To Equity Holders Of The Company Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DilutedLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="sprcy_DilutedLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed_lbl0" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Range Of Dividend Used</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncome_lbl0" xml:lang="en-US">Comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents_lbl0" xml:lang="en-US">Cash flows from (used in) decrease (increase) in restricted cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestorRelationsAndBusinessExpensesMember_lbl0" xml:lang="en-US">Investor Relations And Business Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestorRelationsAndBusinessExpensesMember" xlink:to="sprcy_InvestorRelationsAndBusinessExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherEquityInterestMember_lbl0" xml:lang="en-US">Other equity interest [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEquityInterestMember" xlink:to="ifrs-full_OtherEquityInterestMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ProceedsFromIssuanceIPO_lbl1" xml:lang="en-US">Proceeds From Issuance IPO</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ProceedsFromIssuanceIPO" xlink:to="sprcy_ProceedsFromIssuanceIPO_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnpaidIssueExpenses_lbl1" xml:lang="en-US">Unpaid Issue Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnpaidIssueExpenses" xlink:to="sprcy_UnpaidIssueExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CreditFacilityAmount_lbl1" xml:lang="en-US">Credit Facility Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CreditFacilityAmount" xlink:to="sprcy_CreditFacilityAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of commitments and contingent liabilities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentLineItems_lbl0" xml:lang="en-US">Investmentin Associate Details Scheduleof Fair Valueofthe Investment Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentLineItems" xlink:to="sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount_lbl0" xml:lang="en-US">Amount by which unit&apos;s recoverable amount exceeds its carrying amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount" xlink:to="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OperatingTerm_lbl0" xml:lang="en-US">Operating Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingTerm" xlink:to="sprcy_OperatingTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LoanAmountRaised_lbl0" xml:lang="en-US">Loan Amount Raised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LoanAmountRaised" xlink:to="sprcy_LoanAmountRaised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PrivatePlacementsMember_lbl0" xml:lang="en-US">Private Placements Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrivatePlacementsMember" xlink:to="sprcy_PrivatePlacementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl0" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherOperatingIncomeExpense_lbl0" xml:lang="en-US">Other operating income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherOperatingIncomeExpense" xlink:to="ifrs-full_OtherOperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl0" xml:lang="en-US">Cash flows from (used in) decrease (increase) in short-term deposits and investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_GovernmentAuthorities_lbl1" xml:lang="en-US">Government Authorities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GovernmentAuthorities" xlink:to="sprcy_GovernmentAuthorities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit_lbl0" xml:lang="en-US">Description Of Accounting Policy For Restricted Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit" xlink:to="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OfficeMaintenanceRentAndOtherExpensesMember_lbl0" xml:lang="en-US">Office Maintenance Rent And Other Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OfficeMaintenanceRentAndOtherExpensesMember" xlink:to="sprcy_OfficeMaintenanceRentAndOtherExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LossesOnChangeInFairValueOfDerivatives_lbl0" xml:lang="en-US">Losses on change in fair value of derivatives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LossesOnChangeInFairValueOfDerivatives" xlink:to="ifrs-full_LossesOnChangeInFairValueOfDerivatives_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OperatingLossCarryforwardsTaxAmount_lbl1" xml:lang="en-US">Operating Loss Carryforwards Tax Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingLossCarryforwardsTaxAmount" xlink:to="sprcy_OperatingLossCarryforwardsTaxAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInJointOperation_lbl0" xml:lang="en-US">Proportion of ownership interest in joint operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInJointOperation" xlink:to="ifrs-full_ProportionOfOwnershipInterestInJointOperation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfOtherAccountsPayable_lbl1" xml:lang="en-US">Schedule Of Other Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfOtherAccountsPayable" xlink:to="sprcy_ScheduleOfOtherAccountsPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss_lbl1" xml:lang="en-US">Purchase Of Financial Assets At Fair Value Through Profit Or Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl0" xml:lang="en-US">Weighted average share price, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_BusinessDevelopmentExpensesMember_lbl0" xml:lang="en-US">Business Development Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BusinessDevelopmentExpensesMember" xlink:to="sprcy_BusinessDevelopmentExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly_lbl0" xml:lang="en-US">Straightline Basis Over Useful Life Of Assets At Annual Rates Mainly</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" xlink:to="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssued_lbl3" xml:lang="en-US">Number of shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CashForImmediateWithdrawalInNIS_lbl1" xml:lang="en-US">Cash For Immediate Withdrawal In NIS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashForImmediateWithdrawalInNIS" xlink:to="sprcy_CashForImmediateWithdrawalInNIS_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ClaimsOnDamages_lbl1" xml:lang="en-US">Claims On Damages</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ClaimsOnDamages" xlink:to="sprcy_ClaimsOnDamages_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PricePerShare_lbl1" xml:lang="en-US">Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PricePerShare" xlink:to="sprcy_PricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParValuePerShare_lbl1" xml:lang="en-US">Par value per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl0" xml:lang="en-US">Disclosure of earnings per share [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionalProvisionsOtherProvisions_lbl0" xml:lang="en-US">Additional provisions, other provisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionalProvisionsOtherProvisions" xlink:to="ifrs-full_AdditionalProvisionsOtherProvisions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors_lbl1" xml:lang="en-US">Description Of Amendment To IAS8 Accounting Policies Changes To Accounting Estimates And Errors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" xlink:to="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors_lbl1"/>
    <loc xlink:type="locator" xlink:label="sprcy_ConsolidatedStatementsOfChangesInEquityDeficitAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ConsolidatedStatementsOfChangesInEquityDeficitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ConsolidatedStatementsOfChangesInEquityDeficitAbstract_lbl" xml:lang="en-US">Consolidated Statements Of Changes In Equity Deficit Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ConsolidatedStatementsOfChangesInEquityDeficitAbstract" xlink:to="sprcy_ConsolidatedStatementsOfChangesInEquityDeficitAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for leases [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl0" xml:lang="en-US">Disclosure of classes of share capital [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExchangeCommonShares_lbl1" xml:lang="en-US">Exchange Common Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExchangeCommonShares" xlink:to="sprcy_ExchangeCommonShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsAndExercise_lbl0" xml:lang="en-US">Warrants And Exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsAndExercise" xlink:to="sprcy_WarrantsAndExercise_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnNetMonetaryPosition_lbl0" xml:lang="en-US">Gains (losses) on net monetary position</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnNetMonetaryPosition" xlink:to="ifrs-full_GainsLossesOnNetMonetaryPosition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfReverseShareSplit_lbl0" xml:lang="en-US">Description Of Reverse Share Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfReverseShareSplit" xlink:to="sprcy_DescriptionOfReverseShareSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_lbl0" xml:lang="en-US">Adjustments for decrease (increase) in trade accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CreditsFromOthers_lbl1" xml:lang="en-US">Credits From Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CreditsFromOthers" xlink:to="sprcy_CreditsFromOthers_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DeferredCashPayments_lbl1" xml:lang="en-US">Deferred Cash Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DeferredCashPayments" xlink:to="sprcy_DeferredCashPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WarrantReserveMember_lbl0" xml:lang="en-US">Warrant reserve [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantReserveMember" xlink:to="ifrs-full_WarrantReserveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss_lbl1" xml:lang="en-US">Disclosure Of Information To The Items Of Profit Or Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss" xlink:to="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl0" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_COtherExpensesAbstract_lbl0" xml:lang="en-US">COther Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_COtherExpensesAbstract" xlink:to="sprcy_COtherExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremium_lbl0" xml:lang="en-US">Share premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremium" xlink:to="ifrs-full_SharePremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InterestPaidOnLeaseLiability_lbl0" xml:lang="en-US">Interest Paid On Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestPaidOnLeaseLiability" xlink:to="sprcy_InterestPaidOnLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Revenues And Cost Of Revenues Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" xlink:to="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_a2021Abstract_lbl0" xml:lang="en-US">a2021 Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_a2021Abstract" xlink:to="sprcy_a2021Abstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfShareOptionsShareOptionsExercisableAtTheEndOfTheYear_lbl0" xml:lang="en-US">Number Of Share Options Share Options Exercisable At The End Of The Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfShareOptionsShareOptionsExercisableAtTheEndOfTheYear" xlink:to="sprcy_NumberOfShareOptionsShareOptionsExercisableAtTheEndOfTheYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfShareOptionGranted_lbl1" xml:lang="en-US">Number Of Share Option Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfShareOptionGranted" xlink:to="sprcy_NumberOfShareOptionGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregatePurchasePrice_lbl1" xml:lang="en-US">Aggregate Purchase Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregatePurchasePrice" xlink:to="sprcy_AggregatePurchasePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_lbl0" xml:lang="en-US">Profit (loss), attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:to="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CapitalProposedToDeposit_lbl0" xml:lang="en-US">Capital Proposed To Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CapitalProposedToDeposit" xlink:to="sprcy_CapitalProposedToDeposit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Earnings Per Share Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl0" xml:lang="en-US">Reserve of exchange differences on translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_BridgeLoanAmount_lbl1" xml:lang="en-US">Bridge Loan Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BridgeLoanAmount" xlink:to="sprcy_BridgeLoanAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Inventories_lbl0" xml:lang="en-US">Current inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl0" xml:lang="en-US">Share issue related cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FairMarketValue_lbl1" xml:lang="en-US">Fair Market Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairMarketValue" xlink:to="sprcy_FairMarketValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for finance income and costs [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_June2022WarrantsMember_lbl0" xml:lang="en-US">June2022 Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_June2022WarrantsMember" xlink:to="sprcy_June2022WarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchaseAgreementsDescription_lbl0" xml:lang="en-US">Purchase Agreements Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseAgreementsDescription" xlink:to="sprcy_PurchaseAgreementsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract0_lbl0" xml:lang="en-US">Equity Attributable To Equity Holders Of The Company Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract0" xlink:to="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OfficeEquipmentMember" xlink:to="ifrs-full_OfficeEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl0" xml:lang="en-US">Employee benefits expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FairValueOfTheRSUsGranted_lbl1" xml:lang="en-US">Fair Value Of The RSUs Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfTheRSUsGranted" xlink:to="sprcy_FairValueOfTheRSUsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_lbl0" xml:lang="en-US">Increase (decrease) through conversion of convertible instruments, equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:to="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate_lbl0" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement_lbl2" xml:lang="en-US">Weighted Average Exercise Price Of Share Option Outstanding In Sharebased Payment Arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement" xlink:to="sprcy_WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SharePricePerShare_lbl1" xml:lang="en-US">Share Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePricePerShare" xlink:to="sprcy_SharePricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LoanAmountDueTerm_lbl1" xml:lang="en-US">Loan Amount Due Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LoanAmountDueTerm" xlink:to="sprcy_LoanAmountDueTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl0" xml:lang="en-US">Exercise price of outstanding share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AccumulatedDepreciationAbstract_lbl0" xml:lang="en-US">Accumulated Depreciation Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccumulatedDepreciationAbstract" xlink:to="sprcy_AccumulatedDepreciationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchaseOfOrdinaryShares_lbl1" xml:lang="en-US">Purchase Of Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseOfOrdinaryShares" xlink:to="sprcy_PurchaseOfOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl0" xml:lang="en-US">Adjustments for finance income (cost)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinancialAssetsAbstract_lbl0" xml:lang="en-US">Financial Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinancialAssetsAbstract" xlink:to="sprcy_FinancialAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PercentageOfAggregatePurchasePrice_lbl1" xml:lang="en-US">Percentage Of Aggregate Purchase Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfAggregatePurchasePrice" xlink:to="sprcy_PercentageOfAggregatePurchasePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InitialInvestmentAmount_lbl0" xml:lang="en-US">Initial Investment Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialInvestmentAmount" xlink:to="sprcy_InitialInvestmentAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ProfessionalAndDirectorsFeesMember_lbl0" xml:lang="en-US">Professional And Directors Fees Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ProfessionalAndDirectorsFeesMember" xlink:to="sprcy_ProfessionalAndDirectorsFeesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashOnHand_lbl0" xml:lang="en-US">Cash on hand</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOnHand" xlink:to="ifrs-full_CashOnHand_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_lbl0" xml:lang="en-US">Disclosure of inventories [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets_lbl0" xml:lang="en-US">Other non-current financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentFinancialAssets" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl0" xml:lang="en-US">Purchase of intangible assets, classified as investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExpireTerm_lbl0" xml:lang="en-US">Expire Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExpireTerm" xlink:to="sprcy_ExpireTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl0" xml:lang="en-US">Disclosure of entity&apos;s operating segments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherAssets_lbl0" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAssets" xlink:to="ifrs-full_OtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems_lbl0" xml:lang="en-US">Intangible Asset Details Scheduleof Fair Valueofthe Intangible Asset Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" xlink:to="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfPropertyAndEquipmentNetAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="sprcy_ScheduleOfPropertyAndEquipmentNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfSharesAbstract_lbl0" xml:lang="en-US">Number Of Shares Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfSharesAbstract" xlink:to="sprcy_NumberOfSharesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdditionalAgreedInvest_lbl1" xml:lang="en-US">Additional Agreed Invest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalAgreedInvest" xlink:to="sprcy_AdditionalAgreedInvest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InstallmentAmount_lbl1" xml:lang="en-US">Installment Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentAmount" xlink:to="sprcy_InstallmentAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AgreementTypeAxis_lbl0" xml:lang="en-US">Agreement Type Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AgreementTypeAxis" xlink:to="sprcy_AgreementTypeAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents_lbl0" xml:lang="en-US">Restricted cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestrictedCashAndCashEquivalents" xlink:to="ifrs-full_RestrictedCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_GrossProceed_lbl1" xml:lang="en-US">Gross Proceed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GrossProceed" xlink:to="sprcy_GrossProceed_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl1" xml:lang="en-US">Companys Share Of Losses Of Company Accounted For At Equity Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:to="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl0" xml:lang="en-US">Current liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PropertyPlantAndEquipmentCost_lbl1" xml:lang="en-US">Property Plant And Equipment Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PropertyPlantAndEquipmentCost" xlink:to="sprcy_PropertyPlantAndEquipmentCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_lbl0" xml:lang="en-US">Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:to="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TotalAgreementEstimatingAmount_lbl1" xml:lang="en-US">Total Agreement Estimating Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TotalAgreementEstimatingAmount" xlink:to="sprcy_TotalAgreementEstimatingAmount_lbl1"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract_lbl" xml:lang="en-US">Schedule Of Weighted Average Exercise Prices Of Share Options Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions_lbl0" xml:lang="en-US">Proceeds from exercise of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfOptions" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract_lbl" xml:lang="en-US">Schedule Of Number Of Shares And Loss Used In The Computation Of Loss Per Share Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:to="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl1" xml:lang="en-US">Rightofuse Asset Recognized With Corresponding Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:to="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl0" xml:lang="en-US">Increase (decrease) through exercise of options, equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareadsOptionsExpiredDuringYearWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Shareads Options Expired During Year Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareadsOptionsExpiredDuringYearWeightedAverageExercisePrice" xlink:to="sprcy_ShareadsOptionsExpiredDuringYearWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InventoriesNet_lbl1" xml:lang="en-US">Inventories Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InventoriesNet" xlink:to="sprcy_InventoriesNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_lbl0" xml:lang="en-US">Trade and other current receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EquityLossesFromInvestment_lbl1" xml:lang="en-US">Equity Losses From Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityLossesFromInvestment" xlink:to="sprcy_EquityLossesFromInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl1" xml:lang="en-US">Cash flows from (used in) operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExpensesDueToSharebasedCompensation_lbl0" xml:lang="en-US">Expenses Due To Sharebased Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExpensesDueToSharebasedCompensation" xlink:to="sprcy_ExpensesDueToSharebasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExercisePrice_lbl1" xml:lang="en-US">Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExercisePrice" xlink:to="sprcy_ExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Transactions With Relate Parties Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss_lbl0" xml:lang="en-US">Gains (losses) on financial assets at fair value through profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for earnings per share [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilities_lbl0" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentDate_lbl2" xml:lang="en-US">Investment Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentDate" xlink:to="sprcy_InvestmentDate_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl0" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_BonusAmount_lbl1" xml:lang="en-US">Bonus Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BonusAmount" xlink:to="sprcy_BonusAmount_lbl1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>sprcy-20230630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Feb 27 19:06:21 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ConsolidatedBalanceSheet" roleURI="http://trpx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ConsolidatedIncomeStatement" roleURI="http://trpx.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ShareholdersEquityType2or3" roleURI="http://trpx.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ConsolidatedCashFlow" roleURI="http://trpx.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_General" roleURI="http://trpx.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_SignificantAccountingPolicies" roleURI="http://trpx.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_InvestmentinAssociate" roleURI="http://trpx.com/role/InvestmentinAssociate"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_IntangibleAsset" roleURI="http://trpx.com/role/IntangibleAsset"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_InvestmentinFinancialAssets" roleURI="http://trpx.com/role/InvestmentinFinancialAssets"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_TransactionsandBalanceswithRelatedParties" roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_FinancialInstruments" roleURI="http://trpx.com/role/FinancialInstruments"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_Warrants" roleURI="http://trpx.com/role/Warrants"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_Equity" roleURI="http://trpx.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_AdditionalInformationtotheItemsofProfitorLoss" roleURI="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_SignificantEventsduringtheReportingPeriod" roleURI="http://trpx.com/role/SignificantEventsduringtheReportingPeriod"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_EventsaftertheReportingPeriod" roleURI="http://trpx.com/role/EventsaftertheReportingPeriod"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements" roleURI="http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_Cash" roleURI="http://trpx.com/role/Cash"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_Inventory" roleURI="http://trpx.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_OtherAccountsReceivable" roleURI="http://trpx.com/role/OtherAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_InvestmentinAssociatesandInvestmentsinInvestees" roleURI="http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvestees"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_Leases" roleURI="http://trpx.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_PropertyandEquipmentNet" roleURI="http://trpx.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_TradePayables" roleURI="http://trpx.com/role/TradePayables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_OtherAccountsPayable" roleURI="http://trpx.com/role/OtherAccountsPayable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_EmployeeBenefitLiabilities" roleURI="http://trpx.com/role/EmployeeBenefitLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_TaxesonIncome" roleURI="http://trpx.com/role/TaxesonIncome"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiens" roleURI="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ShareBasedPaymentTransactions" roleURI="http://trpx.com/role/ShareBasedPaymentTransactions"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_RevenuesandCostofRevenues" roleURI="http://trpx.com/role/RevenuesandCostofRevenues"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_LossPerShareAds" roleURI="http://trpx.com/role/LossPerShareAds"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_OperatingSegments" roleURI="http://trpx.com/role/OperatingSegments"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_AccountingPoliciesByPolicy" roleURI="http://trpx.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_SignificantAccountingPoliciesTables" roleURI="http://trpx.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_InvestmentinAssociateTables" roleURI="http://trpx.com/role/InvestmentinAssociateTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_IntangibleAssetTables" roleURI="http://trpx.com/role/IntangibleAssetTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_TransactionsandBalanceswithRelatedPartiesTables" roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_FinancialInstrumentsTables" roleURI="http://trpx.com/role/FinancialInstrumentsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_WarrantsTables" roleURI="http://trpx.com/role/WarrantsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_EquityTables" roleURI="http://trpx.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_AdditionalInformationtotheItemsofProfitorLossTables" roleURI="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_CashTables" roleURI="http://trpx.com/role/CashTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_InventoryTables" roleURI="http://trpx.com/role/InventoryTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_OtherAccountsReceivableTables" roleURI="http://trpx.com/role/OtherAccountsReceivableTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_InvestmentinAssociatesandInvestmentsinInvesteesTables" roleURI="http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_PropertyandEquipmentNetTables" roleURI="http://trpx.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_TradePayablesTables" roleURI="http://trpx.com/role/TradePayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_OtherAccountsPayableTables" roleURI="http://trpx.com/role/OtherAccountsPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_EmployeeBenefitLiabilitiesTables" roleURI="http://trpx.com/role/EmployeeBenefitLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ShareBasedPaymentTransactionsTables" roleURI="http://trpx.com/role/ShareBasedPaymentTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_RevenuesandCostofRevenuesTables" roleURI="http://trpx.com/role/RevenuesandCostofRevenuesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_LossPerShareAdsTables" roleURI="http://trpx.com/role/LossPerShareAdsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_OperatingSegmentsTables" roleURI="http://trpx.com/role/OperatingSegmentsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofFairValueoftheInvestmentTable" roleURI="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofFairValueoftheIntangibleAssetTable" roleURI="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofFinancialAssetsandFinancialLiabilitiesTable" roleURI="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofWarrantsFairValueTable" roleURI="http://trpx.com/role/ScheduleofWarrantsFairValueTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofShareCapitalTable" roleURI="http://trpx.com/role/ScheduleofShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofIssuedandOutstandingShareCapitalTable" roleURI="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofAdditionalInformationtotheItemsofProfitorLossTable" roleURI="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" roleURI="http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofCashTable" roleURI="http://trpx.com/role/ScheduleofCashTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofInventoryTable" roleURI="http://trpx.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofOtherAccountsReceivableTable" roleURI="http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofFairValueoftheInvestmentTable0" roleURI="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofPropertyandEquipmentNetTable" roleURI="http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofFairValueoftheIntangibleAssetTable0" roleURI="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofTradePayablesTable" roleURI="http://trpx.com/role/ScheduleofTradePayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofOtherAccountsPayableTable" roleURI="http://trpx.com/role/ScheduleofOtherAccountsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofFinancialAssetsandFinancialLiabilitiesTable0" roleURI="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofWarrantsFairValueUsingBlackScholesOPMTable" roleURI="http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofDefinedContributionPlansTable" roleURI="http://trpx.com/role/ScheduleofDefinedContributionPlansTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofShareCapitalTable0" roleURI="http://trpx.com/role/ScheduleofShareCapitalTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofIssuedandOutstandingShareCapitalTable0" roleURI="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable" roleURI="http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofExpensesDuetoShareBasedCompensationTable" roleURI="http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofFairValueforShareOptionsGrantedTable" roleURI="http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofWeightedAverageExercisePricesofShareOptionsTable" roleURI="http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofRevenuesandCostofRevenuesTable" roleURI="http://trpx.com/role/ScheduleofRevenuesandCostofRevenuesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0" roleURI="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" roleURI="http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofOperatingSegmentsTable" roleURI="http://trpx.com/role/ScheduleofOperatingSegmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofBalanceswithRelatedPartiesTable" roleURI="http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofTransactionswithRelatedPartiesTable" roleURI="http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ScheduleofBenefitstoKeyManagementPersonnelTable" roleURI="http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_GeneralDetails" roleURI="http://trpx.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_SignificantAccountingPoliciesDetails" roleURI="http://trpx.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_InvestmentinAssociateDetails" roleURI="http://trpx.com/role/InvestmentinAssociateDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_IntangibleAssetDetails" roleURI="http://trpx.com/role/IntangibleAssetDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_InvestmentinFinancialAssetsDetails" roleURI="http://trpx.com/role/InvestmentinFinancialAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_TransactionsandBalanceswithRelatedPartiesDetails" roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_FinancialInstrumentsDetails" roleURI="http://trpx.com/role/FinancialInstrumentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_WarrantsDetails" roleURI="http://trpx.com/role/WarrantsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_EquityDetails" roleURI="http://trpx.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_SignificantEventsduringtheReportingPeriodDetails" roleURI="http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_EventsaftertheReportingPeriodDetails" roleURI="http://trpx.com/role/EventsaftertheReportingPeriodDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_InvestmentinAssociatesandInvestmentsinInvesteesDetails" roleURI="http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_LeasesDetails" roleURI="http://trpx.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_PropertyandEquipmentNetDetails" roleURI="http://trpx.com/role/PropertyandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_TaxesonIncomeDetails" roleURI="http://trpx.com/role/TaxesonIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiensDetails" roleURI="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#sprcy_r_ShareBasedPaymentTransactionsDetails" roleURI="http://trpx.com/role/ShareBasedPaymentTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20230630.xsd#DocumentAndEntityInformation" roleURI="http://trpx.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentTradeReceivables" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentReceivables" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_Inventories" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentsInAssociates" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInAssociates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_InvestmentsInAssociates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Assets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentWarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentWarrantLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentWarrantLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityAttributableToEquityHoldersOfTheCompanyAbstract0" xlink:href="sprcy-20230630.xsd#sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="EquityAttributableToEquityHoldersOfTheCompanyAbstract0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:href="sprcy-20230630.xsd#sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="EquityAttributableToEquityHoldersOfTheCompanyAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_SharePremium" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_WarrantLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEquityInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:to="ifrs-full_OtherEquityInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:to="ifrs-full_RetainedEarnings" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterests"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:to="ifrs-full_NoncontrollingInterests" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_Equity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_EquityAndLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PreviouslyStatedMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PreviouslyStatedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_PreviouslyStatedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_Revenue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_CostOfSales" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_SalesAndMarketingExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_FinanceIncome" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_FinanceCosts" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_ProfitLossBeforeTax" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_ComprehensiveIncome" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="AttributableToAbstract" xlink:href="sprcy-20230630.xsd#sprcy_AttributableToAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="AttributableToAbstract" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ComprehensiveIncomeAttributableToNoncontrollingInterest" xlink:href="sprcy-20230630.xsd#sprcy_ComprehensiveIncomeAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AttributableToAbstract" xlink:to="ComprehensiveIncomeAttributableToNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_ProfitLossAttributableToAbstract" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="BasicLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract" xlink:href="sprcy-20230630.xsd#sprcy_BasicLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="BasicLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BasicLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DilutedLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract" xlink:href="sprcy-20230630.xsd#sprcy_DilutedLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="DilutedLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DilutedLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsOfChangesInEquityDeficitAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ConsolidatedStatementsOfChangesInEquityDeficitAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsOfChangesInEquityDeficitAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_SharePremiumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_WarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterestMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEquityInterestMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_OtherEquityInterestMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_RetainedEarningsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalEquityHolderMember" xlink:href="sprcy-20230630.xsd#sprcy_TotalEquityHolderMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="TotalEquityHolderMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterestsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_NoncontrollingInterestsMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PreviouslyStatedMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PreviouslyStatedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_PreviouslyStatedMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="9.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssueOfShareCapitalNetOfIssueExpense" xlink:href="sprcy-20230630.xsd#sprcy_IssueOfShareCapitalNetOfIssueExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="IssueOfShareCapitalNetOfIssueExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfWarrants" xlink:href="sprcy-20230630.xsd#sprcy_ExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ExerciseOfWarrants" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ShareIssueRelatedCost" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssueOfSharesNetOfIssueExpenses" xlink:href="sprcy-20230630.xsd#sprcy_IssueOfSharesNetOfIssueExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="IssueOfSharesNetOfIssueExpenses" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity_0" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsToTheProfitOrLossItemsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_AdjustmentsToTheProfitOrLossItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="AdjustmentsToTheProfitOrLossItemsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsForImpairmentOfInvestmentInAssociate" xlink:href="sprcy-20230630.xsd#sprcy_AdjustmentsForImpairmentOfInvestmentInAssociate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="AdjustmentsForImpairmentOfInvestmentInAssociate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="WorkingCapitalAdjustmentsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_WorkingCapitalAdjustmentsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="WorkingCapitalAdjustmentsAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WorkingCapitalAdjustmentsAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WorkingCapitalAdjustmentsAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WorkingCapitalAdjustmentsAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WorkingCapitalAdjustmentsAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WorkingCapitalAdjustmentsAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WorkingCapitalAdjustmentsAbstract" xlink:to="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WorkingCapitalAdjustmentsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="sprcy-20230630.xsd#sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" xlink:href="sprcy-20230630.xsd#sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="RepaymentOfLeaseLiabilities" xlink:href="sprcy-20230630.xsd#sprcy_RepaymentOfLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="RepaymentOfLeaseLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="RepaymentOfShorttermCredit" xlink:href="sprcy-20230630.xsd#sprcy_RepaymentOfShorttermCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="RepaymentOfShorttermCredit" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ReceiptofShortTermCreditFromOthers" xlink:href="sprcy-20230630.xsd#sprcy_ReceiptofShortTermCreditFromOthers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ReceiptofShortTermCreditFromOthers" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestPaidOnLeaseLiability" xlink:href="sprcy-20230630.xsd#sprcy_InterestPaidOnLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="InterestPaidOnLeaseLiability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:href="sprcy-20230630.xsd#sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="PaymentOfIssuanceExpensesRelatedToPreviousPeriod" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="SignificantNonCashTransactionsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_SignificantNonCashTransactionsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="SignificantNonCashTransactionsAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:href="sprcy-20230630.xsd#sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantNonCashTransactionsAbstract" xlink:to="RightofuseAssetRecognizedWithCorrespondingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegistrationOfWarrants" xlink:href="sprcy-20230630.xsd#sprcy_RegistrationOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantNonCashTransactionsAbstract" xlink:to="RegistrationOfWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnpaidIssueExpenses" xlink:href="sprcy-20230630.xsd#sprcy_UnpaidIssueExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantNonCashTransactionsAbstract" xlink:to="UnpaidIssueExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SignificantNonCashTransactionsAbstract_0" xlink:href="sprcy-20230630.xsd#sprcy_SignificantNonCashTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="MutualShareExchangeOfOrdinarySharessee" xlink:href="sprcy-20230630.xsd#sprcy_MutualShareExchangeOfOrdinarySharessee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="MutualShareExchangeOfOrdinarySharessee" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/General">
    <loc xlink:type="locator" xlink:label="DisclosureOfGeneralExplanatoryAbstract" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfGeneralExplanatoryAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfGeneralExplanatoryTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfGeneralExplanatoryTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfGeneralExplanatoryAbstract" xlink:to="DisclosureOfGeneralExplanatoryTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="AccountingPolicyAbstract" xlink:href="sprcy-20230630.xsd#sprcy_AccountingPolicyAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPolicyAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/InvestmentinAssociate">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/IntangibleAsset">
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/InvestmentinFinancialAssets">
    <loc xlink:type="locator" xlink:label="InvestmentInFinancialAssetsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentInFinancialAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentInFinancialAssetsAbstract" xlink:to="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/TransactionsandBalanceswithRelatedParties">
    <loc xlink:type="locator" xlink:label="TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/FinancialInstruments">
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_FinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/Warrants">
    <loc xlink:type="locator" xlink:label="WarrantAbstract" xlink:href="sprcy-20230630.xsd#sprcy_WarrantAbstract"/>
    <loc xlink:type="locator" xlink:label="WarrantTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_WarrantTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantAbstract" xlink:to="WarrantTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/Equity">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss">
    <loc xlink:type="locator" xlink:label="DisclosureOfAdditionalInformationTextBlockAbstract" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfAdditionalInformationTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAdditionalInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAdditionalInformationExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfAdditionalInformationTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfAdditionalInformationExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/SignificantEventsduringtheReportingPeriod">
    <loc xlink:type="locator" xlink:label="DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract" xlink:to="DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/EventsaftertheReportingPeriod">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements">
    <loc xlink:type="locator" xlink:label="SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract" xlink:to="SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/Cash">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAbstract"/>
    <loc xlink:type="locator" xlink:label="CashTable" xlink:href="sprcy-20230630.xsd#sprcy_CashTable"/>
    <loc xlink:type="locator" xlink:label="CashLineItems" xlink:href="sprcy-20230630.xsd#sprcy_CashLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAbstract" xlink:to="CashTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashTable" xlink:to="CashLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashLineItems" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/Inventory">
    <loc xlink:type="locator" xlink:label="InventoryAbstract" xlink:href="sprcy-20230630.xsd#sprcy_InventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryAbstract" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/OtherAccountsReceivable">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvestees">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="InvestmentinAssociatesandInvestmentsinInvesteesTable" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTable"/>
    <loc xlink:type="locator" xlink:label="InvestmentinAssociatesandInvestmentsinInvesteesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociatesandInvestmentsinInvesteesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="InvestmentinAssociatesandInvestmentsinInvesteesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesTable" xlink:to="InvestmentinAssociatesandInvestmentsinInvesteesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInvestmentPropertyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInvestmentPropertyExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesLineItems" xlink:to="ifrs-full_DisclosureOfInvestmentPropertyExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/Leases">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/PropertyandEquipmentNet">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentNetTable" xlink:href="sprcy-20230630.xsd#sprcy_PropertyandEquipmentNetTable"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentNetLineItems" xlink:href="sprcy-20230630.xsd#sprcy_PropertyandEquipmentNetLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="PropertyandEquipmentNetTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetTable" xlink:to="PropertyandEquipmentNetLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/TradePayables">
    <loc xlink:type="locator" xlink:label="TradePayablesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_TradePayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradePayablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/OtherAccountsPayable">
    <loc xlink:type="locator" xlink:label="DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentAbstract" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentAbstract" xlink:to="DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/EmployeeBenefitLiabilities">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitLiabilitiesTable" xlink:href="sprcy-20230630.xsd#sprcy_EmployeeBenefitLiabilitiesTable"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitLiabilitiesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_EmployeeBenefitLiabilitiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="EmployeeBenefitLiabilitiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitLiabilitiesTable" xlink:to="EmployeeBenefitLiabilitiesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitLiabilitiesLineItems" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/TaxesonIncome">
    <loc xlink:type="locator" xlink:label="TaxesOnIncomeAbstract" xlink:href="sprcy-20230630.xsd#sprcy_TaxesOnIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesOnIncomeAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens">
    <loc xlink:type="locator" xlink:label="ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ShareBasedPaymentTransactions">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/RevenuesandCostofRevenues">
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/LossPerShareAds">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/OperatingSegments">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BasisOfPresentationOfFinancialStatements" xlink:href="sprcy-20230630.xsd#sprcy_BasisOfPresentationOfFinancialStatements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="BasisOfPresentationOfFinancialStatements" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForoperatingcycleExplanatory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAcquisitionOfASingleAssetCompany" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfAcquisitionOfASingleAssetCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAcquisitionOfASingleAssetCompany" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForRestrictedDeposit" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForRestrictedDeposit" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/SignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="AccountingPolicyAbstract" xlink:href="sprcy-20230630.xsd#sprcy_AccountingPolicyAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPolicyAbstract" xlink:to="DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/InvestmentinAssociateTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/IntangibleAssetTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables">
    <loc xlink:type="locator" xlink:label="TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesTablesTable"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:to="TransactionsandBalanceswithRelatedPartiesTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesTablesTable" xlink:to="TransactionsandBalanceswithRelatedPartiesTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesTablesLineItems" xlink:to="DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesTablesLineItems" xlink:to="DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesTablesLineItems" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/FinancialInstrumentsTables">
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_FinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfFinancialAssetsAndFinancialLiabilities" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAbstract" xlink:to="DisclosureOfFinancialAssetsAndFinancialLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAbstract" xlink:to="ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/WarrantsTables">
    <loc xlink:type="locator" xlink:label="WarrantAbstract" xlink:href="sprcy-20230630.xsd#sprcy_WarrantAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantAbstract" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/EquityTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfIssuedAndOutstandingShareCapital" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfIssuedAndOutstandingShareCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="DisclosureOfIssuedAndOutstandingShareCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfAdditionalInformationTextBlockAbstract" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfAdditionalInformationTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="AdditionalInformationtotheItemsofProfitorLossTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossTablesTable"/>
    <loc xlink:type="locator" xlink:label="AdditionalInformationtotheItemsofProfitorLossTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfAdditionalInformationTextBlockAbstract" xlink:to="AdditionalInformationtotheItemsofProfitorLossTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossTablesTable" xlink:to="AdditionalInformationtotheItemsofProfitorLossTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfInformationToTheItemsOfProfitOrLoss" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossTablesLineItems" xlink:to="DisclosureOfInformationToTheItemsOfProfitOrLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/CashTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAbstract"/>
    <loc xlink:type="locator" xlink:label="CashTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_CashTablesTable"/>
    <loc xlink:type="locator" xlink:label="CashTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_CashTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAbstract" xlink:to="CashTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashTablesTable" xlink:to="CashTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashTablesLineItems" xlink:to="DisclosueOfCashAndCashEquivalentsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/InventoryTables">
    <loc xlink:type="locator" xlink:label="InventoryAbstract" xlink:href="sprcy-20230630.xsd#sprcy_InventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInvestmentEntitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInvestmentEntitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryAbstract" xlink:to="ifrs-full_DisclosureOfInvestmentEntitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/OtherAccountsReceivableTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherAccountsReceivableTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_OtherAccountsReceivableTablesTable"/>
    <loc xlink:type="locator" xlink:label="OtherAccountsReceivableTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_OtherAccountsReceivableTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="OtherAccountsReceivableTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAccountsReceivableTablesTable" xlink:to="OtherAccountsReceivableTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DisclourseOfAccountsReceivablesTableTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_DisclourseOfAccountsReceivablesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAccountsReceivableTablesLineItems" xlink:to="DisclourseOfAccountsReceivablesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="InvestmentinAssociatesandInvestmentsinInvesteesTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTablesTable"/>
    <loc xlink:type="locator" xlink:label="InvestmentinAssociatesandInvestmentsinInvesteesTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="InvestmentinAssociatesandInvestmentsinInvesteesTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesTablesTable" xlink:to="InvestmentinAssociatesandInvestmentsinInvesteesTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfFairValueMeasurementOfAssetstable" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfFairValueMeasurementOfAssetstable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesTablesLineItems" xlink:to="DisclosureOfFairValueMeasurementOfAssetstable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/PropertyandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentNetTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_PropertyandEquipmentNetTablesTable"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentNetTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_PropertyandEquipmentNetTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="PropertyandEquipmentNetTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetTablesTable" xlink:to="PropertyandEquipmentNetTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetTablesLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/TradePayablesTables">
    <loc xlink:type="locator" xlink:label="TradePayablesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_TradePayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="TradePayablesTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_TradePayablesTablesTable"/>
    <loc xlink:type="locator" xlink:label="TradePayablesTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_TradePayablesTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradePayablesAbstract" xlink:to="TradePayablesTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradePayablesTablesTable" xlink:to="TradePayablesTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfTradePayables" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfTradePayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradePayablesTablesLineItems" xlink:to="DisclosureOfTradePayables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/OtherAccountsPayableTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentAbstract" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherAccountsPayable" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfOtherAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentAbstract" xlink:to="ScheduleOfOtherAccountsPayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/EmployeeBenefitLiabilitiesTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitLiabilitiesTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_EmployeeBenefitLiabilitiesTablesTable"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitLiabilitiesTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_EmployeeBenefitLiabilitiesTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="EmployeeBenefitLiabilitiesTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitLiabilitiesTablesTable" xlink:to="EmployeeBenefitLiabilitiesTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitLiabilitiesTablesLineItems" xlink:to="DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ShareBasedPaymentTransactionsTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_ShareBasedPaymentTransactionsTablesTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_ShareBasedPaymentTransactionsTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ShareBasedPaymentTransactionsTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsTablesTable" xlink:to="ShareBasedPaymentTransactionsTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfExpenseRecognizedExplanatoryTableTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfExpenseRecognizedExplanatoryTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsTablesLineItems" xlink:to="DisclosureOfExpenseRecognizedExplanatoryTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfOptionPricingModelShareOptionGranted" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfOptionPricingModelShareOptionGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsTablesLineItems" xlink:to="DescriptionOfOptionPricingModelShareOptionGranted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsTablesLineItems" xlink:to="DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/RevenuesandCostofRevenuesTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/LossPerShareAdsTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="LossPerShareAdsTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_LossPerShareAdsTablesTable"/>
    <loc xlink:type="locator" xlink:label="LossPerShareAdsTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_LossPerShareAdsTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="LossPerShareAdsTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareAdsTablesTable" xlink:to="LossPerShareAdsTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareAdsTablesLineItems" xlink:to="DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/OperatingSegmentsTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingSegmentsTablesTable" xlink:href="sprcy-20230630.xsd#sprcy_OperatingSegmentsTablesTable"/>
    <loc xlink:type="locator" xlink:label="OperatingSegmentsTablesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_OperatingSegmentsTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="OperatingSegmentsTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingSegmentsTablesTable" xlink:to="OperatingSegmentsTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingSegmentsTablesLineItems" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfTheInvestmentAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfFairValueOfTheInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentTable" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentTable"/>
    <loc xlink:type="locator" xlink:label="InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentLineItems" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentTable" xlink:to="InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentLineItems" xlink:to="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentDate" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentLineItems" xlink:to="InvestmentDate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityLossesFromInvestmentInMitoCareX" xlink:href="sprcy-20230630.xsd#sprcy_EquityLossesFromInvestmentInMitoCareX"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentLineItems" xlink:to="EquityLossesFromInvestmentInMitoCareX" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentLineItems" xlink:to="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOfAssets" xlink:href="sprcy-20230630.xsd#sprcy_PurchaseOfAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:to="PurchaseOfAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationAndAmortisationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:to="ifrs-full_DepreciationAndAmortisationExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable" xlink:href="sprcy-20230630.xsd#sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable" xlink:to="FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="FinancialAssetsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_FinancialAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesLineItems" xlink:to="FinancialAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialAssetsAbstract" xlink:to="ifrs-full_TradeReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GovernmentAuthorities" xlink:href="sprcy-20230630.xsd#sprcy_GovernmentAuthorities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialAssetsAbstract" xlink:to="GovernmentAuthorities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialAssetsAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesLineItems" xlink:to="ifrs-full_FinancialAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesLineItems" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialLiabilitiesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_FinancialLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesLineItems" xlink:to="FinancialLiabilitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CreditFromOthers" xlink:href="sprcy-20230630.xsd#sprcy_CreditFromOthers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialLiabilitiesAbstract" xlink:to="CreditFromOthers" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsLiability" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialLiabilitiesAbstract" xlink:to="WarrantsLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesLineItems" xlink:to="ifrs-full_FinancialLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofWarrantsFairValueTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantsFairValueAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfWarrantsFairValueAbstract"/>
    <loc xlink:type="locator" xlink:label="WarrantsDetailsScheduleofWarrantsFairValueTable" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsDetailsScheduleofWarrantsFairValueTable"/>
    <loc xlink:type="locator" xlink:label="WarrantsDetailsScheduleofWarrantsFairValueLineItems" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsDetailsScheduleofWarrantsFairValueLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueAbstract" xlink:to="WarrantsDetailsScheduleofWarrantsFairValueTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofWarrantsFairValueTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_WarrantsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofWarrantsFairValueTable" xlink:to="WarrantsDetailsScheduleofWarrantsFairValueLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofWarrantsFairValueLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofWarrantsFairValueLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofWarrantsFairValueLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofWarrantsFairValueLineItems" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofWarrantsFairValueLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LossesOnChangeInFairValueOfDerivatives" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LossesOnChangeInFairValueOfDerivatives"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofWarrantsFairValueLineItems" xlink:to="ifrs-full_LossesOnChangeInFairValueOfDerivatives" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofShareCapitalTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareCapitalAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsScheduleofShareCapitalTable" xlink:href="sprcy-20230630.xsd#sprcy_EquityDetailsScheduleofShareCapitalTable"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsScheduleofShareCapitalLineItems" xlink:href="sprcy-20230630.xsd#sprcy_EquityDetailsScheduleofShareCapitalLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareCapitalAbstract" xlink:to="EquityDetailsScheduleofShareCapitalTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofShareCapitalTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PreviouslyStatedMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PreviouslyStatedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_PreviouslyStatedMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofShareCapitalTable" xlink:to="EquityDetailsScheduleofShareCapitalLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesAuthorised" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesIssued1" xlink:href="sprcy-20230630.xsd#sprcy_NumberOfSharesIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="NumberOfSharesIssued1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" xlink:href="sprcy-20230630.xsd#sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesIssuedToConsultants" xlink:href="sprcy-20230630.xsd#sprcy_SharesIssuedToConsultants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="SharesIssuedToConsultants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfShareCapitalInRespectOfShelfProspectus" xlink:href="sprcy-20230630.xsd#sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="IssuanceOfShareCapitalInRespectOfShelfProspectus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesIssued1_0" xlink:href="sprcy-20230630.xsd#sprcy_NumberOfSharesIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="NumberOfSharesIssued1_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract"/>
    <loc xlink:type="locator" xlink:label="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable" xlink:href="sprcy-20230630.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable"/>
    <loc xlink:type="locator" xlink:label="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:href="sprcy-20230630.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract" xlink:to="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="IncomeStatementsLocationsAxis" xlink:href="sprcy-20230630.xsd#sprcy_IncomeStatementsLocationsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable" xlink:to="IncomeStatementsLocationsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeStatementsLocationsDomainDomain" xlink:href="sprcy-20230630.xsd#sprcy_IncomeStatementsLocationsDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="IncomeStatementsLocationsDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="WagesAndRelatedExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_WagesAndRelatedExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="WagesAndRelatedExpensesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentMember" xlink:href="sprcy-20230630.xsd#sprcy_ShareBasedPaymentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ShareBasedPaymentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClinicalStudiesMember" xlink:href="sprcy-20230630.xsd#sprcy_ClinicalStudiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ClinicalStudiesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegulatoryAndOtherExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_RegulatoryAndOtherExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="RegulatoryAndOtherExpensesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndPreclinicalStudiesMember" xlink:href="sprcy-20230630.xsd#sprcy_ResearchAndPreclinicalStudiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ResearchAndPreclinicalStudiesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChemistryAndFormulationsMember" xlink:href="sprcy-20230630.xsd#sprcy_ChemistryAndFormulationsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ChemistryAndFormulationsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProfessionalAndDirectorsFeesMember" xlink:href="sprcy-20230630.xsd#sprcy_ProfessionalAndDirectorsFeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ProfessionalAndDirectorsFeesMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessDevelopmentExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_BusinessDevelopmentExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="BusinessDevelopmentExpensesMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfficeMaintenanceRentAndOtherExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_OfficeMaintenanceRentAndOtherExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="OfficeMaintenanceRentAndOtherExpensesMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestorRelationsAndBusinessExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_InvestorRelationsAndBusinessExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="InvestorRelationsAndBusinessExpensesMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WellutionOperatingExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_WellutionOperatingExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="WellutionOperatingExpensesMember" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegulatoryExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_RegulatoryExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="RegulatoryExpensesMember" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable" xlink:to="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" xlink:href="sprcy-20230630.xsd#sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" xlink:href="sprcy-20230630.xsd#sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract" xlink:to="SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CommunicationAndNetworkEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_CommunicationAndNetworkEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OfficeEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_OfficeEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseholdImprovementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_LeaseholdImprovementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" xlink:to="ifrs-full_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" xlink:to="SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" xlink:href="sprcy-20230630.xsd#sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" xlink:to="PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" xlink:href="sprcy-20230630.xsd#sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" xlink:to="StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" xlink:to="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseholdImprovements" xlink:href="sprcy-20230630.xsd#sprcy_LeaseholdImprovements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" xlink:to="LeaseholdImprovements" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofCashTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCashAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfCashAbstract"/>
    <loc xlink:type="locator" xlink:label="CashForImmediateWithdrawal" xlink:href="sprcy-20230630.xsd#sprcy_CashForImmediateWithdrawal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashAbstract" xlink:to="CashForImmediateWithdrawal" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashForImmediateWithdrawalInNIS" xlink:href="sprcy-20230630.xsd#sprcy_CashForImmediateWithdrawalInNIS"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashAbstract" xlink:to="CashForImmediateWithdrawalInNIS" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOnHand" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOnHand"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashAbstract" xlink:to="ifrs-full_CashOnHand" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofInventoryTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfInventoryAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfInventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInventoriesInTransit" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentInventoriesInTransit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="ifrs-full_CurrentInventoriesInTransit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="ifrs-full_FinishedGoods" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InventoriesNet" xlink:href="sprcy-20230630.xsd#sprcy_InventoriesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="InventoriesNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofOtherAccountsReceivableTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherAccountsReceivableAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfOtherAccountsReceivableAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ValueAddedTaxReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ValueAddedTaxReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsReceivableAbstract" xlink:to="ifrs-full_ValueAddedTaxReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsReceivableAbstract" xlink:to="ifrs-full_OtherReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsReceivableAbstract" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsReceivableAbstract" xlink:to="ifrs-full_OtherCurrentReceivables" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfTheInvestmentAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfFairValueOfTheInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentTable" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentTable"/>
    <loc xlink:type="locator" xlink:label="InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentLineItems" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentTable" xlink:to="InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentLineItems" xlink:to="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentDate" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentLineItems" xlink:to="InvestmentDate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityLossesFromInvestment" xlink:href="sprcy-20230630.xsd#sprcy_EquityLossesFromInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentLineItems" xlink:to="EquityLossesFromInvestment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentLineItems" xlink:to="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable" xlink:href="sprcy-20230630.xsd#sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems" xlink:href="sprcy-20230630.xsd#sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ComputerEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfficeEquipmentsMember" xlink:href="sprcy-20230630.xsd#sprcy_OfficeEquipmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="OfficeEquipmentsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseholdImprovementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_LeaseholdImprovementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MotorVehiclesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MotorVehiclesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_MotorVehiclesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable" xlink:to="PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CostAbstract" xlink:href="sprcy-20230630.xsd#sprcy_CostAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems" xlink:to="CostAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BeginningBalanceCost" xlink:href="sprcy-20230630.xsd#sprcy_BeginningBalanceCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostAbstract" xlink:to="BeginningBalanceCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasesOfCost" xlink:href="sprcy-20230630.xsd#sprcy_PurchasesOfCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostAbstract" xlink:to="PurchasesOfCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BeginningBalanceCost_0" xlink:href="sprcy-20230630.xsd#sprcy_BeginningBalanceCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostAbstract" xlink:to="BeginningBalanceCost_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="NewLeases" xlink:href="sprcy-20230630.xsd#sprcy_NewLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostAbstract" xlink:to="NewLeases" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostAbstract" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedDepreciationAbstract" xlink:href="sprcy-20230630.xsd#sprcy_AccumulatedDepreciationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems" xlink:to="AccumulatedDepreciationAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PropertyPlantAndEquipmentCost" xlink:href="sprcy-20230630.xsd#sprcy_PropertyPlantAndEquipmentCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDepreciationAbstract" xlink:to="PropertyPlantAndEquipmentCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDepreciationAbstract" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PropertyPlantAndEquipmentCost_0" xlink:href="sprcy-20230630.xsd#sprcy_PropertyPlantAndEquipmentCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDepreciationAbstract" xlink:to="PropertyPlantAndEquipmentCost_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDepreciationAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2w4dODRyrf2cKq4MnlNojKY2vawGlGpB5CaguD0HWK7+MXGfIzhA2ezfWaTq7hAnt683nzSc747v3s9ubzeRZw15+aEvNutYTqGoMIIBc15Xh4havgCm8tXxWD/WWUoronH/DHJ0GUoA=] CSR-->
    <loc xlink:type="locator" xlink:label="AccumulatedDepreciationAbstract0" xlink:href="sprcy-20230630.xsd#sprcy_AccumulatedDepreciationAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems" xlink:to="AccumulatedDepreciationAbstract0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedTerminationOfLeases" xlink:href="sprcy-20230630.xsd#sprcy_AccumulatedTerminationOfLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDepreciationAbstract0" xlink:to="AccumulatedTerminationOfLeases" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable" xlink:href="sprcy-20230630.xsd#sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" xlink:href="sprcy-20230630.xsd#sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:to="IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable" xlink:to="IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseofAssets" xlink:href="sprcy-20230630.xsd#sprcy_PurchaseofAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" xlink:to="PurchaseofAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" xlink:to="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofTradePayablesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfTradePayablesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfTradePayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="AccruedExpenses" xlink:href="sprcy-20230630.xsd#sprcy_AccruedExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTradePayablesAbstract" xlink:to="AccruedExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTradePayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTradePayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofOtherAccountsPayableTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherAccountsPayableAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfOtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherAccountsPayableDetailsScheduleofOtherAccountsPayableTable" xlink:href="sprcy-20230630.xsd#sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableTable"/>
    <loc xlink:type="locator" xlink:label="OtherAccountsPayableDetailsScheduleofOtherAccountsPayableLineItems" xlink:href="sprcy-20230630.xsd#sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="OtherAccountsPayableDetailsScheduleofOtherAccountsPayableTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAccountsPayableDetailsScheduleofOtherAccountsPayableTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAccountsPayableDetailsScheduleofOtherAccountsPayableTable" xlink:to="OtherAccountsPayableDetailsScheduleofOtherAccountsPayableLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAccountsPayableDetailsScheduleofOtherAccountsPayableLineItems" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Accruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Accruals"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAccountsPayableDetailsScheduleofOtherAccountsPayableLineItems" xlink:to="ifrs-full_Accruals" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAccountsPayableDetailsScheduleofOtherAccountsPayableLineItems" xlink:to="ifrs-full_OtherPayables" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TradeAndOtherPayable" xlink:href="sprcy-20230630.xsd#sprcy_TradeAndOtherPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAccountsPayableDetailsScheduleofOtherAccountsPayableLineItems" xlink:to="TradeAndOtherPayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestrictedCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_RestrictedCashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GovernmentAuthorities" xlink:href="sprcy-20230630.xsd#sprcy_GovernmentAuthorities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="GovernmentAuthorities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_OtherReceivables" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentsInFinancialAssets" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentsInFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="InvestmentsInFinancialAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialAssetsAtAmortisedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentFinancialAssetsAtAmortisedCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CurrentFinancialAssetsAtAmortisedCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CreditsFromOthers" xlink:href="sprcy-20230630.xsd#sprcy_CreditsFromOthers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="CreditsFromOthers" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsLiability" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="WarrantsLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract"/>
    <loc xlink:type="locator" xlink:label="DividendYield" xlink:href="sprcy-20230630.xsd#sprcy_DividendYield"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract" xlink:to="DividendYield" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpectedVolatility" xlink:href="sprcy-20230630.xsd#sprcy_ExpectedVolatility"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract" xlink:to="ExpectedVolatility" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RiskFreeInterestRate" xlink:href="sprcy-20230630.xsd#sprcy_RiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract" xlink:to="RiskFreeInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnderlyingAdsPrice" xlink:href="sprcy-20230630.xsd#sprcy_UnderlyingAdsPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract" xlink:to="UnderlyingAdsPrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePricePerShare" xlink:href="sprcy-20230630.xsd#sprcy_ExercisePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract" xlink:to="ExercisePricePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsFairValueinDollarsPerShares" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsFairValueinDollarsPerShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract" xlink:to="WarrantsFairValueinDollarsPerShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofDefinedContributionPlansTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDefinedContributionPlansAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfDefinedContributionPlansAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDefinedContributionPlansAbstract" xlink:to="ifrs-full_EmployeeBenefitsExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofShareCapitalTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareCapitalAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesAbstract0" xlink:href="sprcy-20230630.xsd#sprcy_NumberOfSharesAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareCapitalAbstract" xlink:to="NumberOfSharesAbstract0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfSharesAbstract0" xlink:to="ifrs-full_NumberOfSharesAuthorised" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfSharesAbstract0" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="ifrs-full_NumberOfSharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfPrefundedWarrantsOne" xlink:href="sprcy-20230630.xsd#sprcy_ExerciseOfPrefundedWarrantsOne"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="ExerciseOfPrefundedWarrantsOne" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfPrefundedWarrants" xlink:href="sprcy-20230630.xsd#sprcy_ExerciseOfPrefundedWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="ExerciseOfPrefundedWarrants" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareIssuedToAConsultant" xlink:href="sprcy-20230630.xsd#sprcy_ShareIssuedToAConsultant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="ShareIssuedToAConsultant" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="ifrs-full_NumberOfSharesIssued_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnderlyingOrdinarySharePrice" xlink:href="sprcy-20230630.xsd#sprcy_UnderlyingOrdinarySharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="UnderlyingOrdinarySharePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice" xlink:href="sprcy-20230630.xsd#sprcy_ExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsFairValueinDollarsPerShare" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsFairValueinDollarsPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="WarrantsFairValueinDollarsPerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpenses01" xlink:href="sprcy-20230630.xsd#sprcy_ResearchAndDevelopmentExpenses01"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:to="ResearchAndDevelopmentExpenses01" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GeneralAndAdministrativeExpenses" xlink:href="sprcy-20230630.xsd#sprcy_GeneralAndAdministrativeExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:to="GeneralAndAdministrativeExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpensesDueToSharebasedCompensation" xlink:href="sprcy-20230630.xsd#sprcy_ExpensesDueToSharebasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:to="ExpensesDueToSharebasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" xlink:href="sprcy-20230630.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" xlink:href="sprcy-20230630.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" xlink:href="sprcy-20230630.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" xlink:href="sprcy-20230630.xsd#sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnderlyingOrdinarySharePrices" xlink:href="sprcy-20230630.xsd#sprcy_UnderlyingOrdinarySharePrices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="UnderlyingOrdinarySharePrices" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="a2022Abstract" xlink:href="sprcy-20230630.xsd#sprcy_a2022Abstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="a2022Abstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfOutstandingShareOption" xlink:href="sprcy-20230630.xsd#sprcy_NumberOfOutstandingShareOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2022Abstract" xlink:to="NumberOfOutstandingShareOption" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement" xlink:href="sprcy-20230630.xsd#sprcy_WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2022Abstract" xlink:to="WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfShareOptionGranted" xlink:href="sprcy-20230630.xsd#sprcy_NumberOfShareOptionGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2022Abstract" xlink:to="NumberOfShareOptionGranted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement" xlink:href="sprcy-20230630.xsd#sprcy_WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2022Abstract" xlink:to="WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfShareOptionForfeitedInSharebasedPaymentArrangement" xlink:href="sprcy-20230630.xsd#sprcy_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2022Abstract" xlink:to="NumberOfShareOptionForfeitedInSharebasedPaymentArrangement" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceOfShareOptionForfeitedInSharebasedPaymentArrangement" xlink:href="sprcy-20230630.xsd#sprcy_WeightedAverageExercisePriceOfShareOptionForfeitedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2022Abstract" xlink:to="WeightedAverageExercisePriceOfShareOptionForfeitedInSharebasedPaymentArrangement" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareadsOptionsExpiredDuringYear" xlink:href="sprcy-20230630.xsd#sprcy_ShareadsOptionsExpiredDuringYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2022Abstract" xlink:to="ShareadsOptionsExpiredDuringYear" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareadsOptionsExpiredDuringYearWeightedAverageExercisePrice" xlink:href="sprcy-20230630.xsd#sprcy_ShareadsOptionsExpiredDuringYearWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2022Abstract" xlink:to="ShareadsOptionsExpiredDuringYearWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfOutstandingShareOption_0" xlink:href="sprcy-20230630.xsd#sprcy_NumberOfOutstandingShareOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2022Abstract" xlink:to="NumberOfOutstandingShareOption_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement_0" xlink:href="sprcy-20230630.xsd#sprcy_WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2022Abstract" xlink:to="WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfShareOptionsShareOptionsExercisableAtTheEndOfTheYear" xlink:href="sprcy-20230630.xsd#sprcy_NumberOfShareOptionsShareOptionsExercisableAtTheEndOfTheYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2022Abstract" xlink:to="NumberOfShareOptionsShareOptionsExercisableAtTheEndOfTheYear" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2022Abstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofRevenuesandCostofRevenuesTable">
    <loc xlink:type="locator" xlink:label="RevenuesAndCostOfRevenuesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_RevenuesAndCostOfRevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesAndCostOfRevenuesAbstract" xlink:to="ifrs-full_Revenue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesAndCostOfRevenuesAbstract" xlink:to="ifrs-full_CostOfSales" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesAndCostOfRevenuesAbstract" xlink:to="ifrs-full_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract"/>
    <loc xlink:type="locator" xlink:label="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable" xlink:href="sprcy-20230630.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable"/>
    <loc xlink:type="locator" xlink:label="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:href="sprcy-20230630.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract" xlink:to="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="IncomeStatementsLocationsAxis" xlink:href="sprcy-20230630.xsd#sprcy_IncomeStatementsLocationsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable" xlink:to="IncomeStatementsLocationsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeStatementsLocationsDomainDomain" xlink:href="sprcy-20230630.xsd#sprcy_IncomeStatementsLocationsDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="IncomeStatementsLocationsDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="WagesAndRelatedExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_WagesAndRelatedExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="WagesAndRelatedExpensesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentMember" xlink:href="sprcy-20230630.xsd#sprcy_ShareBasedPaymentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ShareBasedPaymentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegulatoryAndOtherExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_RegulatoryAndOtherExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="RegulatoryAndOtherExpensesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndPreclinicalStudiesMember" xlink:href="sprcy-20230630.xsd#sprcy_ResearchAndPreclinicalStudiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ResearchAndPreclinicalStudiesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClinicalStudiesMember" xlink:href="sprcy-20230630.xsd#sprcy_ClinicalStudiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ClinicalStudiesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChemistryAndFormulationsMember" xlink:href="sprcy-20230630.xsd#sprcy_ChemistryAndFormulationsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ChemistryAndFormulationsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProfessionalAndDirectorsFeesMember" xlink:href="sprcy-20230630.xsd#sprcy_ProfessionalAndDirectorsFeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ProfessionalAndDirectorsFeesMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessDevelopmentExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_BusinessDevelopmentExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="BusinessDevelopmentExpensesMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegulatoryExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_RegulatoryExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="RegulatoryExpensesMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfficeMaintenanceRentAndOtherExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_OfficeMaintenanceRentAndOtherExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="OfficeMaintenanceRentAndOtherExpensesMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WellutionOperatingExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_WellutionOperatingExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="WellutionOperatingExpensesMember" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestorRelationsAndBusinessExpensesMember" xlink:href="sprcy-20230630.xsd#sprcy_InvestorRelationsAndBusinessExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="InvestorRelationsAndBusinessExpensesMember" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ImpairmentOfInvestmentInAssociateMember" xlink:href="sprcy-20230630.xsd#sprcy_ImpairmentOfInvestmentInAssociateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ImpairmentOfInvestmentInAssociateMember" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GroupsShareOfLossesOfCompanyAccountedForAtEquityNetMember" xlink:href="sprcy-20230630.xsd#sprcy_GroupsShareOfLossesOfCompanyAccountedForAtEquityNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="GroupsShareOfLossesOfCompanyAccountedForAtEquityNetMember" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable" xlink:to="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AResearchAndDevelopmentExpensesAbstract0" xlink:href="sprcy-20230630.xsd#sprcy_AResearchAndDevelopmentExpensesAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:to="AResearchAndDevelopmentExpensesAbstract0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpenses1" xlink:href="sprcy-20230630.xsd#sprcy_ResearchAndDevelopmentExpenses1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AResearchAndDevelopmentExpensesAbstract0" xlink:to="ResearchAndDevelopmentExpenses1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BGeneralAndAdministrativeExpensesAbstract0" xlink:href="sprcy-20230630.xsd#sprcy_BGeneralAndAdministrativeExpensesAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:to="BGeneralAndAdministrativeExpensesAbstract0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BGeneralAndAdministrativeExpensesAbstract0" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="COtherExpensesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_COtherExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:to="COtherExpensesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherOperatingIncomeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COtherExpensesAbstract" xlink:to="ifrs-full_OtherOperatingIncomeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceIncomeAbstract" xlink:href="sprcy-20230630.xsd#sprcy_FinanceIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:to="FinanceIncomeAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceIncomeFromConvertibleLoan" xlink:href="sprcy-20230630.xsd#sprcy_FinanceIncomeFromConvertibleLoan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeAbstract" xlink:to="FinanceIncomeFromConvertibleLoan" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeAbstract" xlink:to="ifrs-full_FinanceIncomeCost" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceExpensesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_FinanceExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:to="FinanceExpensesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssueExpensesRelatedToIssuanceOfWarrants" xlink:href="sprcy-20230630.xsd#sprcy_IssueExpensesRelatedToIssuanceOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpensesAbstract" xlink:to="IssueExpensesRelatedToIssuanceOfWarrants" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceExpensesFromExchangeRateDifferences" xlink:href="sprcy-20230630.xsd#sprcy_FinanceExpensesFromExchangeRateDifferences"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpensesAbstract" xlink:to="FinanceExpensesFromExchangeRateDifferences" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpensesAbstract" xlink:to="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestExpenseInRespectOfLeases" xlink:href="sprcy-20230630.xsd#sprcy_InterestExpenseInRespectOfLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpensesAbstract" xlink:to="InterestExpenseInRespectOfLeases" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceExpensesFromInterestAndCommissions" xlink:href="sprcy-20230630.xsd#sprcy_FinanceExpensesFromInterestAndCommissions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpensesAbstract" xlink:to="FinanceExpensesFromInterestAndCommissions" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InsuranceFinanceIncomeExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InsuranceFinanceIncomeExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpensesAbstract" xlink:to="ifrs-full_InsuranceFinanceIncomeExpenses" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" xlink:href="sprcy-20230630.xsd#sprcy_LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"/>
    <loc xlink:type="locator" xlink:label="LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareLineItems" xlink:href="sprcy-20230630.xsd#sprcy_LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:to="LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfOrdinarySharesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" xlink:to="ifrs-full_ClassesOfOrdinarySharesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ADSMember" xlink:href="sprcy-20230630.xsd#sprcy_ADSMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ADSMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinaryShareMember" xlink:href="sprcy-20230630.xsd#sprcy_OrdinaryShareMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="OrdinaryShareMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" xlink:to="ifrs-full_ContinuingAndDiscontinuedOperationsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DiscontinuedOperationsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DiscontinuedOperationsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:to="ifrs-full_DiscontinuedOperationsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" xlink:to="LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ContinuingOperationsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ContinuingOperationsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareLineItems" xlink:to="ContinuingOperationsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareLineItems" xlink:to="ifrs-full_WeightedAverageShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareLineItems" xlink:to="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofOperatingSegmentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOperatingSegmentsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfOperatingSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingSegmentsDetailsScheduleofOperatingSegmentsTable" xlink:href="sprcy-20230630.xsd#sprcy_OperatingSegmentsDetailsScheduleofOperatingSegmentsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingSegmentsAbstract" xlink:to="OperatingSegmentsDetailsScheduleofOperatingSegmentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingSegmentsDetailsScheduleofOperatingSegmentsTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DrugDevelopmentMember" xlink:href="sprcy-20230630.xsd#sprcy_DrugDevelopmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="DrugDevelopmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OnlineSalesMember" xlink:href="sprcy-20230630.xsd#sprcy_OnlineSalesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="OnlineSalesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingSegmentsDetailsScheduleofOperatingSegmentsTable" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SegmentReportingRevenueAbstract" xlink:href="sprcy-20230630.xsd#sprcy_SegmentReportingRevenueAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="SegmentReportingRevenueAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExternalRevenues" xlink:href="sprcy-20230630.xsd#sprcy_ExternalRevenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingRevenueAbstract" xlink:to="ExternalRevenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Intersegment" xlink:href="sprcy-20230630.xsd#sprcy_Intersegment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingRevenueAbstract" xlink:to="Intersegment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromSaleOfGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingRevenueAbstract" xlink:to="ifrs-full_RevenueFromSaleOfGoods" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:href="sprcy-20230630.xsd#sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestRevenueExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRevenueExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_InterestRevenueExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TaxExpense" xlink:href="sprcy-20230630.xsd#sprcy_TaxExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="TaxExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_ProfitLoss" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_OtherAssets" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_OtherLiabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" xlink:href="sprcy-20230630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems" xlink:href="sprcy-20230630.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:to="TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_OtherRelatedPartiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" xlink:to="TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems" xlink:to="ifrs-full_CurrentLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpenses" xlink:href="sprcy-20230630.xsd#sprcy_ResearchAndDevelopmentExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:to="ResearchAndDevelopmentExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:label="DisclosureOfGeneralExplanatoryAbstract" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfGeneralExplanatoryAbstract"/>
    <loc xlink:type="locator" xlink:label="GeneralDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_GeneralDetailsTable"/>
    <loc xlink:type="locator" xlink:label="GeneralDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_GeneralDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfGeneralExplanatoryAbstract" xlink:to="GeneralDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsTable" xlink:to="GeneralDetailsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnNetMonetaryPosition" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnNetMonetaryPosition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="ifrs-full_GainsLossesOnNetMonetaryPosition" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RetainedEarning" xlink:href="sprcy-20230630.xsd#sprcy_RetainedEarning"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="RetainedEarning" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromIssuanceIPO" xlink:href="sprcy-20230630.xsd#sprcy_ProceedsFromIssuanceIPO"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="ProceedsFromIssuanceIPO" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/SignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="AccountingPolicyAbstract" xlink:href="sprcy-20230630.xsd#sprcy_AccountingPolicyAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingTerm" xlink:href="sprcy-20230630.xsd#sprcy_OperatingTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPolicyAbstract" xlink:to="OperatingTerm" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/InvestmentinAssociateDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="InvestmentinAssociateDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociateDetailsTable"/>
    <loc xlink:type="locator" xlink:label="InvestmentinAssociateDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociateDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="InvestmentinAssociateDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociateDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MitoCareXBioLtdMember" xlink:href="sprcy-20230630.xsd#sprcy_MitoCareXBioLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="MitoCareXBioLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MitoCareXMember" xlink:href="sprcy-20230630.xsd#sprcy_MitoCareXMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="MitoCareXMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociateDetailsTable" xlink:to="ifrs-full_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociateDetailsTable" xlink:to="InvestmentinAssociateDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="InvestedInitialAmount" xlink:href="sprcy-20230630.xsd#sprcy_InvestedInitialAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociateDetailsLineItems" xlink:to="InvestedInitialAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalAgreedInvest" xlink:href="sprcy-20230630.xsd#sprcy_AdditionalAgreedInvest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociateDetailsLineItems" xlink:to="AdditionalAgreedInvest" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OwnershipAgreement" xlink:href="sprcy-20230630.xsd#sprcy_OwnershipAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociateDetailsLineItems" xlink:to="OwnershipAgreement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InitialInvestment" xlink:href="sprcy-20230630.xsd#sprcy_InitialInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociateDetailsLineItems" xlink:to="InitialInvestment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OutstandingSharesPercentage" xlink:href="sprcy-20230630.xsd#sprcy_OutstandingSharesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociateDetailsLineItems" xlink:to="OutstandingSharesPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalProvisionsOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalProvisionsOtherProvisions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociateDetailsLineItems" xlink:to="ifrs-full_AdditionalProvisionsOtherProvisions" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociateDetailsLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityLossesInvestment" xlink:href="sprcy-20230630.xsd#sprcy_EquityLossesInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociateDetailsLineItems" xlink:to="EquityLossesInvestment" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/IntangibleAssetDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <loc xlink:type="locator" xlink:label="CashPayment" xlink:href="sprcy-20230630.xsd#sprcy_CashPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="CashPayment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseCosts" xlink:href="sprcy-20230630.xsd#sprcy_PurchaseCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="PurchaseCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchase" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsToPurchase"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="WarrantsToPurchase" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice1" xlink:href="sprcy-20230630.xsd#sprcy_ExercisePrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ExercisePrice1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePeriod" xlink:href="sprcy-20230630.xsd#sprcy_ExercisePeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ExercisePeriod" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PricePerShare" xlink:href="sprcy-20230630.xsd#sprcy_PricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="PricePerShare" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmountTotal" xlink:href="sprcy-20230630.xsd#sprcy_AmountTotal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="AmountTotal" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="pricePerShare" xlink:href="sprcy-20230630.xsd#sprcy_pricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="pricePerShare" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/InvestmentinFinancialAssetsDetails">
    <loc xlink:type="locator" xlink:label="InvestmentInFinancialAssetsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentInFinancialAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="InvestmentinFinancialAssetsDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinFinancialAssetsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="InvestmentinFinancialAssetsDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinFinancialAssetsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentInFinancialAssetsAbstract" xlink:to="InvestmentinFinancialAssetsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinFinancialAssetsDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AutoMaxSharesMember" xlink:href="sprcy-20230630.xsd#sprcy_AutoMaxSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="AutoMaxSharesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinFinancialAssetsDetailsTable" xlink:to="InvestmentinFinancialAssetsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinFinancialAssetsDetailsLineItems" xlink:to="ifrs-full_Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinFinancialAssetsDetailsLineItems" xlink:to="ifrs-full_ParValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfPricePerShare" xlink:href="sprcy-20230630.xsd#sprcy_ExerciseOfPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinFinancialAssetsDetailsLineItems" xlink:to="ExerciseOfPricePerShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinFinancialAssetsDetailsLineItems" xlink:to="ifrs-full_OtherComprehensiveIncome" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentAmount" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinFinancialAssetsDetailsLineItems" xlink:to="InvestmentAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedButNotFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedButNotFullyPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinFinancialAssetsDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedButNotFullyPaid" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalPercentage" xlink:href="sprcy-20230630.xsd#sprcy_ShareCapitalPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinFinancialAssetsDetailsLineItems" xlink:to="ShareCapitalPercentage" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharePricePerShare" xlink:href="sprcy-20230630.xsd#sprcy_SharePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinFinancialAssetsDetailsLineItems" xlink:to="SharePricePerShare" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ComprehensiveLoss" xlink:href="sprcy-20230630.xsd#sprcy_ComprehensiveLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinFinancialAssetsDetailsLineItems" xlink:to="ComprehensiveLoss" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:label="TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:href="sprcy-20230630.xsd#sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="CooperationAgreementWithClearmindAmount" xlink:href="sprcy-20230630.xsd#sprcy_CooperationAgreementWithClearmindAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:to="CooperationAgreementWithClearmindAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BalanceOwedToClearmind" xlink:href="sprcy-20230630.xsd#sprcy_BalanceOwedToClearmind"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:to="BalanceOwedToClearmind" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestedAmount" xlink:href="sprcy-20230630.xsd#sprcy_InvestedAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:to="InvestedAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeCommonShares" xlink:href="sprcy-20230630.xsd#sprcy_ExchangeCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:to="ExchangeCommonShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClearmindOutstandingShareCapitalPercentage" xlink:href="sprcy-20230630.xsd#sprcy_ClearmindOutstandingShareCapitalPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:to="ClearmindOutstandingShareCapitalPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestedAmountInClearmind" xlink:href="sprcy-20230630.xsd#sprcy_InvestedAmountInClearmind"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:to="InvestedAmountInClearmind" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeCommonSharesOfClearmind" xlink:href="sprcy-20230630.xsd#sprcy_ExchangeCommonSharesOfClearmind"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:to="ExchangeCommonSharesOfClearmind" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/FinancialInstrumentsDetails">
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsAbstract" xlink:href="sprcy-20230630.xsd#sprcy_FinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_FinancialInstrumentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_FinancialInstrumentsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAbstract" xlink:to="FinancialInstrumentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ADSsMember" xlink:href="sprcy-20230630.xsd#sprcy_ADSsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ADSsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PrivatePlacementsMember" xlink:href="sprcy-20230630.xsd#sprcy_PrivatePlacementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="PrivatePlacementsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsTable" xlink:to="FinancialInstrumentsDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BridgeLoanAmount" xlink:href="sprcy-20230630.xsd#sprcy_BridgeLoanAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsLineItems" xlink:to="BridgeLoanAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsLineItems" xlink:to="ifrs-full_InterestPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateAmountOrCreditAmount" xlink:href="sprcy-20230630.xsd#sprcy_AggregateAmountOrCreditAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsLineItems" xlink:to="AggregateAmountOrCreditAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CreditFacilityAmount" xlink:href="sprcy-20230630.xsd#sprcy_CreditFacilityAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsLineItems" xlink:to="CreditFacilityAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CreditFacilityAndRemainingAvailableDrawnAmount" xlink:href="sprcy-20230630.xsd#sprcy_CreditFacilityAndRemainingAvailableDrawnAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsLineItems" xlink:to="CreditFacilityAndRemainingAvailableDrawnAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LoanAmountDueTerm" xlink:href="sprcy-20230630.xsd#sprcy_LoanAmountDueTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsLineItems" xlink:to="LoanAmountDueTerm" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LoanAmountRaised" xlink:href="sprcy-20230630.xsd#sprcy_LoanAmountRaised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsLineItems" xlink:to="LoanAmountRaised" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCompoundFinancialInstrumentsWithMultipleEmbeddedDerivativesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCompoundFinancialInstrumentsWithMultipleEmbeddedDerivativesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsLineItems" xlink:to="ifrs-full_DisclosureOfCompoundFinancialInstrumentsWithMultipleEmbeddedDerivativesExplanatory" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOutflowForLeases" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOutflowForLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsLineItems" xlink:to="ifrs-full_CashOutflowForLeases" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsLineItems" xlink:to="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasePrice" xlink:href="sprcy-20230630.xsd#sprcy_PurchasePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsLineItems" xlink:to="PurchasePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaturityDate" xlink:href="sprcy-20230630.xsd#sprcy_MaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsLineItems" xlink:to="MaturityDate" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InitialConversionPrice" xlink:href="sprcy-20230630.xsd#sprcy_InitialConversionPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsLineItems" xlink:to="InitialConversionPrice" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionPrice" xlink:href="sprcy-20230630.xsd#sprcy_ConversionPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsLineItems" xlink:to="ConversionPrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinaryShareExercisePrice" xlink:href="sprcy-20230630.xsd#sprcy_OrdinaryShareExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsLineItems" xlink:to="OrdinaryShareExercisePrice" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/WarrantsDetails">
    <loc xlink:type="locator" xlink:label="WarrantAbstract" xlink:href="sprcy-20230630.xsd#sprcy_WarrantAbstract"/>
    <loc xlink:type="locator" xlink:label="WarrantsDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="WarrantsDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantAbstract" xlink:to="WarrantsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_WarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AntidilutiveInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AntidilutiveInstrumentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_AntidilutiveInstrumentsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_WarrantsMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsTable" xlink:to="WarrantsDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="GrossProceed" xlink:href="sprcy-20230630.xsd#sprcy_GrossProceed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="GrossProceed" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfAggregateShares" xlink:href="sprcy-20230630.xsd#sprcy_IssuanceOfAggregateShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="IssuanceOfAggregateShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsDescription" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="WarrantsDescription" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfPricePerShare" xlink:href="sprcy-20230630.xsd#sprcy_ExerciseOfPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="ExerciseOfPricePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantExpiryPeriod" xlink:href="sprcy-20230630.xsd#sprcy_WarrantExpiryPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="WarrantExpiryPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantReserve" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantReserve"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="ifrs-full_WarrantReserve" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PlanAssetsAtFairValue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PlanAssetsAtFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="ifrs-full_PlanAssetsAtFairValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/EquityDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_EquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_EquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="EquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesAWarrantsMember" xlink:href="sprcy-20230630.xsd#sprcy_SeriesAWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="SeriesAWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBWarrantsMember" xlink:href="sprcy-20230630.xsd#sprcy_SeriesBWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="SeriesBWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantReserveMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantReserveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_WarrantReserveMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AntidilutiveInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AntidilutiveInstrumentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_AntidilutiveInstrumentsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_WarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysOwnEquityInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysOwnEquityInstrumentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="ifrs-full_EntitysOwnEquityInstrumentsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="ifrs-full_WarrantsMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PrefundedWarrantsMember" xlink:href="sprcy-20230630.xsd#sprcy_PrefundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="PrefundedWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfOrdinarySharesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_ClassesOfOrdinarySharesAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_OrdinarySharesMember_0" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesAWarrantsMember_0" xlink:href="sprcy-20230630.xsd#sprcy_SeriesAWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="SeriesAWarrantsMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="June2022WarrantsMember" xlink:href="sprcy-20230630.xsd#sprcy_June2022WarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="June2022WarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ADSMember" xlink:href="sprcy-20230630.xsd#sprcy_ADSMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ADSMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreationDateAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CreationDateAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_CreationDateAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ifrs-full_DefaultFinancialStatementsDateMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="March2021FinancingRoundMember" xlink:href="sprcy-20230630.xsd#sprcy_March2021FinancingRoundMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="March2021FinancingRoundMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="June2022FinancingRoundMember" xlink:href="sprcy-20230630.xsd#sprcy_June2022FinancingRoundMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="June2022FinancingRoundMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="November2020FinancingRoundMember" xlink:href="sprcy-20230630.xsd#sprcy_November2020FinancingRoundMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="November2020FinancingRoundMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementTypeAxis" xlink:href="sprcy-20230630.xsd#sprcy_AgreementTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="AgreementTypeAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementTypeDomainDomain" xlink:href="sprcy-20230630.xsd#sprcy_AgreementTypeDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementTypeAxis" xlink:to="AgreementTypeDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AprilTwoThousandTwentyPurchaseAgreementMember" xlink:href="sprcy-20230630.xsd#sprcy_AprilTwoThousandTwentyPurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementTypeAxis" xlink:to="AprilTwoThousandTwentyPurchaseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="EquityDetailsLineItems" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodReverseStockSplits" xlink:href="sprcy-20230630.xsd#sprcy_StockIssuedDuringPeriodReverseStockSplits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="StockIssuedDuringPeriodReverseStockSplits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NoParValuePerShare" xlink:href="sprcy-20230630.xsd#sprcy_NoParValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="NoParValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfPrivateOffering" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfPrivateOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="DescriptionOfPrivateOffering" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="DateOfIssuance" xlink:href="sprcy-20230630.xsd#sprcy_DateOfIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="DateOfIssuance" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsAndExercise" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsAndExercise"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="WarrantsAndExercise" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfPrefundedWarrants" xlink:href="sprcy-20230630.xsd#sprcy_ExerciseOfPrefundedWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ExerciseOfPrefundedWarrants" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfShares" xlink:href="sprcy-20230630.xsd#sprcy_IssuanceOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="IssuanceOfShares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfReverseShareSplit" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfReverseShareSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="DescriptionOfReverseShareSplit" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseAgreementsDescription" xlink:href="sprcy-20230630.xsd#sprcy_PurchaseAgreementsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="PurchaseAgreementsDescription" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrossProceeds" xlink:href="sprcy-20230630.xsd#sprcy_GrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="GrossProceeds" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfAggregateShares" xlink:href="sprcy-20230630.xsd#sprcy_IssuanceOfAggregateShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="IssuanceOfAggregateShares" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsExercisePrice" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="WarrantsExercisePrice" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails">
    <loc xlink:type="locator" xlink:label="DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract" xlink:href="sprcy-20230630.xsd#sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantEventsduringtheReportingPeriodDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_SignificantEventsduringtheReportingPeriodDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract" xlink:to="SignificantEventsduringtheReportingPeriodDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CapitalPointWarrantMember" xlink:href="sprcy-20230630.xsd#sprcy_CapitalPointWarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="CapitalPointWarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NewCoIncMember" xlink:href="sprcy-20230630.xsd#sprcy_NewCoIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="NewCoIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JeffsBrandsMember" xlink:href="sprcy-20230630.xsd#sprcy_JeffsBrandsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="JeffsBrandsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsTable" xlink:to="SignificantEventsduringtheReportingPeriodDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="InterestPercentgae" xlink:href="sprcy-20230630.xsd#sprcy_InterestPercentgae"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="InterestPercentgae" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_Cash" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredCashPayments" xlink:href="sprcy-20230630.xsd#sprcy_DeferredCashPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="DeferredCashPayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalPercentage" xlink:href="sprcy-20230630.xsd#sprcy_ShareCapitalPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="ShareCapitalPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FeeExpenses" xlink:href="sprcy-20230630.xsd#sprcy_FeeExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="FeeExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BonusAmountReceived" xlink:href="sprcy-20230630.xsd#sprcy_BonusAmountReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="BonusAmountReceived" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MutualShareExchangeAmount" xlink:href="sprcy-20230630.xsd#sprcy_MutualShareExchangeAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="MutualShareExchangeAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesAcquired" xlink:href="sprcy-20230630.xsd#sprcy_OrdinarySharesAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="OrdinarySharesAcquired" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateValue" xlink:href="sprcy-20230630.xsd#sprcy_AggregateValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="AggregateValue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustedAmountOfAggregateValue" xlink:href="sprcy-20230630.xsd#sprcy_AdjustedAmountOfAggregateValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="AdjustedAmountOfAggregateValue" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OwnershipPercentage" xlink:href="sprcy-20230630.xsd#sprcy_OwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="OwnershipPercentage" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchase" xlink:href="sprcy-20230630.xsd#sprcy_WarrantsToPurchase"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="WarrantsToPurchase" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ClaimsOnDamages" xlink:href="sprcy-20230630.xsd#sprcy_ClaimsOnDamages"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="ClaimsOnDamages" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/EventsaftertheReportingPeriodDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="EventsaftertheReportingPeriodDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_EventsaftertheReportingPeriodDetailsTable"/>
    <loc xlink:type="locator" xlink:label="EventsaftertheReportingPeriodDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_EventsaftertheReportingPeriodDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="EventsaftertheReportingPeriodDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SubsequentMember" xlink:href="sprcy-20230630.xsd#sprcy_SubsequentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="SubsequentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SCISPARCLTDMember" xlink:href="sprcy-20230630.xsd#sprcy_SCISPARCLTDMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="SCISPARCLTDMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JeffsBrandsMember" xlink:href="sprcy-20230630.xsd#sprcy_JeffsBrandsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="JeffsBrandsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MitoCareXMember" xlink:href="sprcy-20230630.xsd#sprcy_MitoCareXMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="MitoCareXMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JeffsBrandsMember_0" xlink:href="sprcy-20230630.xsd#sprcy_JeffsBrandsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="JeffsBrandsMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MitoCareXBioLtdMember" xlink:href="sprcy-20230630.xsd#sprcy_MitoCareXBioLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="MitoCareXBioLtdMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsTable" xlink:to="EventsaftertheReportingPeriodDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfPublicOffering" xlink:href="sprcy-20230630.xsd#sprcy_DescriptionOfPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsLineItems" xlink:to="DescriptionOfPublicOffering" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfWarrants" xlink:href="sprcy-20230630.xsd#sprcy_ExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsLineItems" xlink:to="ExerciseOfWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfPrefundedWarrants" xlink:href="sprcy-20230630.xsd#sprcy_ExerciseOfPrefundedWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsLineItems" xlink:to="ExerciseOfPrefundedWarrants" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_ParValuePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateGrossProceeds" xlink:href="sprcy-20230630.xsd#sprcy_AggregateGrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsLineItems" xlink:to="AggregateGrossProceeds" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfAggregatePurchasePrice" xlink:href="sprcy-20230630.xsd#sprcy_PercentageOfAggregatePurchasePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsLineItems" xlink:to="PercentageOfAggregatePurchasePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregatePurchasePrice" xlink:href="sprcy-20230630.xsd#sprcy_AggregatePurchasePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsLineItems" xlink:to="AggregatePurchasePrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasePricePerShare" xlink:href="sprcy-20230630.xsd#sprcy_PurchasePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsLineItems" xlink:to="PurchasePricePerShare" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrefundedOrdinaryShare" xlink:href="sprcy-20230630.xsd#sprcy_PrefundedOrdinaryShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsLineItems" xlink:to="PrefundedOrdinaryShare" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesAcquired" xlink:href="sprcy-20230630.xsd#sprcy_OrdinarySharesAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsLineItems" xlink:to="OrdinarySharesAcquired" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOrdinaryShares" xlink:href="sprcy-20230630.xsd#sprcy_PurchaseOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsLineItems" xlink:to="PurchaseOrdinaryShares" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TermOfIssuance" xlink:href="sprcy-20230630.xsd#sprcy_TermOfIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsLineItems" xlink:to="TermOfIssuance" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePricePerShare" xlink:href="sprcy-20230630.xsd#sprcy_ExercisePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsLineItems" xlink:to="ExercisePricePerShare" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfStockEqual" xlink:href="sprcy-20230630.xsd#sprcy_PercentageOfStockEqual"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsLineItems" xlink:to="PercentageOfStockEqual" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_Cash" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalAgreedInvest" xlink:href="sprcy-20230630.xsd#sprcy_AdditionalAgreedInvest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsLineItems" xlink:to="AdditionalAgreedInvest" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OwnershipAgreement" xlink:href="sprcy-20230630.xsd#sprcy_OwnershipAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsLineItems" xlink:to="OwnershipAgreement" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfWorkingCapital" xlink:href="sprcy-20230630.xsd#sprcy_PercentageOfWorkingCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsLineItems" xlink:to="PercentageOfWorkingCapital" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MonthlyFee" xlink:href="sprcy-20230630.xsd#sprcy_MonthlyFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsLineItems" xlink:to="MonthlyFee" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BonusAmount" xlink:href="sprcy-20230630.xsd#sprcy_BonusAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsLineItems" xlink:to="BonusAmount" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_IssuedCapitalOrdinaryShares" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateValue" xlink:href="sprcy-20230630.xsd#sprcy_AggregateValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsLineItems" xlink:to="AggregateValue" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustedAmountOfAggregateValue" xlink:href="sprcy-20230630.xsd#sprcy_AdjustedAmountOfAggregateValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsLineItems" xlink:to="AdjustedAmountOfAggregateValue" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInJointOperation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInJointOperation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsaftertheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInJointOperation" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="InvestmentinAssociatesandInvestmentsinInvesteesDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="InvestmentinAssociatesandInvestmentsinInvesteesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesDetailsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CapitalPointWarrantMember" xlink:href="sprcy-20230630.xsd#sprcy_CapitalPointWarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="CapitalPointWarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesDetailsTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SubsequentMember" xlink:href="sprcy-20230630.xsd#sprcy_SubsequentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="SubsequentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EveroMember" xlink:href="sprcy-20230630.xsd#sprcy_EveroMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="EveroMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CapitalPointMember" xlink:href="sprcy-20230630.xsd#sprcy_CapitalPointMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="CapitalPointMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MitoCareXMember" xlink:href="sprcy-20230630.xsd#sprcy_MitoCareXMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="MitoCareXMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesDetailsTable" xlink:to="ifrs-full_RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesDetailsTable" xlink:to="InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ConversionOfOrdinaryShares" xlink:href="sprcy-20230630.xsd#sprcy_ConversionOfOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="ConversionOfOrdinaryShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesPerValue" xlink:href="sprcy-20230630.xsd#sprcy_OrdinarySharesPerValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="OrdinarySharesPerValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfSharesIssuedAndOutstandingShareCapital" xlink:href="sprcy-20230630.xsd#sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="PercentageOfSharesIssuedAndOutstandingShareCapital" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairMarketValue" xlink:href="sprcy-20230630.xsd#sprcy_FairMarketValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="FairMarketValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOfOrdinaryShares" xlink:href="sprcy-20230630.xsd#sprcy_PurchaseOfOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="PurchaseOfOrdinaryShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareholdersAmount" xlink:href="sprcy-20230630.xsd#sprcy_ShareholdersAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="ShareholdersAmount" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuedAndOutstandingSharesPercentage" xlink:href="sprcy-20230630.xsd#sprcy_IssuedAndOutstandingSharesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="IssuedAndOutstandingSharesPercentage" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForAmountsTransferredToInitialCarryingAmountOfHedgedItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForAmountsTransferredToInitialCarryingAmountOfHedgedItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="ifrs-full_AdjustmentsForAmountsTransferredToInitialCarryingAmountOfHedgedItems" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestedInitialAmounts" xlink:href="sprcy-20230630.xsd#sprcy_InvestedInitialAmounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="InvestedInitialAmounts" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreDeterminedValue" xlink:href="sprcy-20230630.xsd#sprcy_PreDeterminedValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="PreDeterminedValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OwnershipPercentage" xlink:href="sprcy-20230630.xsd#sprcy_OwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="OwnershipPercentage" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InitialInvestmentAmount" xlink:href="sprcy-20230630.xsd#sprcy_InitialInvestmentAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="InitialInvestmentAmount" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStocks" xlink:href="sprcy-20230630.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStocks"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStocks" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_LeasesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_LeasesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="LeasesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LeaseMember" xlink:href="sprcy-20230630.xsd#sprcy_LeaseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="LeaseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="LeasesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SquareMeters" xlink:href="sprcy-20230630.xsd#sprcy_SquareMeters"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="SquareMeters" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseFee" xlink:href="sprcy-20230630.xsd#sprcy_LeaseFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="LeaseFee" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpireTerm" xlink:href="sprcy-20230630.xsd#sprcy_ExpireTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="ExpireTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/PropertyandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentNetDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_PropertyandEquipmentNetDetailsTable"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentNetDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_PropertyandEquipmentNetDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="PropertyandEquipmentNetDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsTable" xlink:to="PropertyandEquipmentNetDetailsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsLineItems" xlink:to="ifrs-full_DepreciationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/TaxesonIncomeDetails">
    <loc xlink:type="locator" xlink:label="TaxesOnIncomeAbstract" xlink:href="sprcy-20230630.xsd#sprcy_TaxesOnIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="TaxesonIncomeDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_TaxesonIncomeDetailsTable"/>
    <loc xlink:type="locator" xlink:label="TaxesonIncomeDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_TaxesonIncomeDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesOnIncomeAbstract" xlink:to="TaxesonIncomeDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsTable" xlink:to="TaxesonIncomeDetailsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsLineItems" xlink:to="ifrs-full_ApplicableTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLossCarryforwardsTaxAmount" xlink:href="sprcy-20230630.xsd#sprcy_OperatingLossCarryforwardsTaxAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsLineItems" xlink:to="OperatingLossCarryforwardsTaxAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails">
    <loc xlink:type="locator" xlink:label="ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:href="sprcy-20230630.xsd#sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract"/>
    <loc xlink:type="locator" xlink:label="DekelLicenseAgreementDescription" xlink:href="sprcy-20230630.xsd#sprcy_DekelLicenseAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="DekelLicenseAgreementDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AnnualInvestment" xlink:href="sprcy-20230630.xsd#sprcy_AnnualInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="AnnualInvestment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalMilestoneAmount" xlink:href="sprcy-20230630.xsd#sprcy_AdditionalMilestoneAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="AdditionalMilestoneAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InstallmentAmount" xlink:href="sprcy-20230630.xsd#sprcy_InstallmentAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="InstallmentAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalAgreementEstimatingAmount" xlink:href="sprcy-20230630.xsd#sprcy_TotalAgreementEstimatingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="TotalAgreementEstimatingAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CapitalProposedToDeposit" xlink:href="sprcy-20230630.xsd#sprcy_CapitalProposedToDeposit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="CapitalProposedToDeposit" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ShareBasedPaymentTransactionsDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsDetailsTable" xlink:href="sprcy-20230630.xsd#sprcy_ShareBasedPaymentTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsDetailsLineItems" xlink:href="sprcy-20230630.xsd#sprcy_ShareBasedPaymentTransactionsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ShareBasedPaymentTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsTable" xlink:to="ifrs-full_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfOrdinarySharesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsTable" xlink:to="ifrs-full_ClassesOfOrdinarySharesAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OrdinaryShareMember" xlink:href="sprcy-20230630.xsd#sprcy_OrdinaryShareMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="OrdinaryShareMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsTable" xlink:to="ShareBasedPaymentTransactionsDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareOptionsReserved" xlink:href="sprcy-20230630.xsd#sprcy_ShareOptionsReserved"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="ShareOptionsReserved" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesOptionGrantedInSharebasedPaymentArrangement" xlink:href="sprcy-20230630.xsd#sprcy_NumberOfSharesOptionGrantedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="NumberOfSharesOptionGrantedInSharebasedPaymentArrangement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinaryShares" xlink:href="sprcy-20230630.xsd#sprcy_OrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="OrdinaryShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOption" xlink:href="sprcy-20230630.xsd#sprcy_FairValueOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="FairValueOption" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptionDescription" xlink:href="sprcy-20230630.xsd#sprcy_StockOptionDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="StockOptionDescription" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueDescription" xlink:href="sprcy-20230630.xsd#sprcy_FairValueDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="FairValueDescription" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RSUGrantedDiscountRate" xlink:href="sprcy-20230630.xsd#sprcy_RSUGrantedDiscountRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="RSUGrantedDiscountRate" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfTheRSUsGranted" xlink:href="sprcy-20230630.xsd#sprcy_FairValueOfTheRSUsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="FairValueOfTheRSUsGranted" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesIssued" xlink:href="sprcy-20230630.xsd#sprcy_OrdinarySharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="OrdinarySharesIssued" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinaryGrantedDiscountRate" xlink:href="sprcy-20230630.xsd#sprcy_OrdinaryGrantedDiscountRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="OrdinaryGrantedDiscountRate" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingContractualLifesOfOutstandingShareOption" xlink:href="sprcy-20230630.xsd#sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="WeightedAverageRemainingContractualLifesOfOutstandingShareOption" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareOptionsOutstandingParValue" xlink:href="sprcy-20230630.xsd#sprcy_ShareOptionsOutstandingParValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="ShareOptionsOutstandingParValue" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="sprcy-20230630.xsd#sprcy_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_BusinessContactMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ex5-1_001i.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001i.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !D E,# 2(  A$! Q$!_\0
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M.'@V36?M/C&;4K=]/COU^TQRV-IJEY<7:SQEH/LZ6LBN9,2%(P[H"::W/]'
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M/^AB;_P2^(?_ )44 >K45Y3_ ,+M^&G_ $,3?^"7Q#_\J*/^%V_#3_H8F_\
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M@R/[\A \V],9W ,-Z8?$D>0)$W(2 Q(^'VZ#_>3_ -#6ON3_ ()F''_!0?\
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MC,J0M&T%P5"KE'2Y6".&?S&V"*:6,%09 ^ P4 G\M?\ *Q__ !%'EK_E8_\
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M"67*E#D G\M?\K'_ /$4>6O^5C_^(J$W#KM#0LK-M3;EW*2.KLIE,4;JEO\
M*%-R"R*Y*LHV$TBWB/L= 9(9$#K+$LDZ.)"QA,36\4L4BLD<C.PE'E'R5*L+
MA&H G\M?\K'_ /$4>6O^5C_^(J 71+NAB.8Y(X7*-YZK-(C.(V$"RR1!4,$K
M/<1P((;B.0GJI<+E"\:<*97V)O=$+'[.+C$:$[I&"GYE0':JR,Q 3D E\M?\
MK'_\11Y:_P"5C_\ B*DHH C\M?\ *Q__ !%'EK_E8_\ XBI** (_+7_*Q_\
MQ%'EK_E8_P#XBI** (_+7_*Q_P#Q%'EK_E8__B*DHH C\M?\K'_\11Y:_P"5
MC_\ B*DHH C\M?\ *Q__ !%'EK_E8_\ XBI** (_+7_*Q_\ Q%'EK_E8_P#X
MBI** (C'@94X((/W4Y ()'"@\C(R"",Y'->;>#4V^-_BMDG_ )#WAMU52Z1(
MI\%:%$R+"',8+2P23E\9)G*$$H9']-;H?H?Y5YMX0_Y'?XJ_]AKPU_ZB6ET
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MPYI/A'PY;R731F::#0=!M;'28;B58;=)9X;2.1UA1%*0A8E .XHHHH ****
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MSRY@L91< 'TK_P %5_'.C_ 'P_\ #;_@F3\";'5[#X"_!RTM/&7Q+\47EK'
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MSRVZ6WV>[:"WDCDBD>ZB /B(]1_VU_\ 0+*BCOG_ 'O_ !X0C]/)_'=[<E
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M+$/FDAB,SQJ2TZQD2^6\EL%-Q&LKV]PD4CQB*4Q8BDD=@E?EGIGP4^/?@_\
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M#:P(R5) )!VG# 9%,"X5 )) Z$C>JVR$PC)2(,+;S%"O@L5D&] 8R &)IU%
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M]]K46M^)X/"?@F?5+Z6VGM/#5AK=S>0WT[BTNUTG2#)>-<3SGR#S'B;]JM?
M^N>*],\0?#O4;&#PSH7BD7^KVWB/3-1$WCSP3\'[+XZ>(_!EM!<06ES<:78^
M$M6<VOBV:>ST^XND;3K73;:8JP]MO_@1\+M3\/OX5O/"UJ?#K>%YO!<>D6MW
MJUA;VGAJ75[/6ULM.EL=1@O-.NH-2L+6^M=7L;J#5K'4(4O=.O+.1544_P#A
MGGX3R:O=:]=>%HKS5[_P:_@;4KRZU7Q%>?VEHEQHR^'KYK^VU#6KVTO-7OM#
MBM])N_%%U!-XOO-,A.GZAXAO;*62W8 \S^!7[2MS\5?'6M_#W4_A;K'P[O\
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M$OX?&*W!_/8:3_B'W_X*-?\ 0M?"?_P\=M_\:H#GCW_!GXZ?\(/XQ_Z%R_\
M^_EA_P#)E'_"#^,?^A<O_P#OY8?_ "97[%_\0^__  4:_P"A:^$__AX[;_XU
M1_Q#[_\ !1K_ *%KX3_^'CMO_C5 <\>_X,_'3_A!_&/_ $+E_P#]_+#_ .3*
M/^$'\8_]"Y?_ /?RP_\ DROV+_XA]_\ @HU_T+7PG_\ #QVW_P :H_XA]_\
M@HU_T+7PG_\ #QVW_P :H#GCW_!GXZ?\(/XP')\.7X'_ %TL#_[>TG_"$^+S
MP/#NH$_[]@/_ &]K]C/^(??_ (*-C_F6OA-^/QCMB/R\L4O_ !#\?\%&S_S+
M7PE_#XQ6X/Y[#0'/'O\ @S\<_P#A!_& Y/AR_ _ZZ6!_]O:3_A"?%W_0O:A_
MWW8?_)M?L9_Q#[_\%&Q_S+7PF_'XQVQ'Y>6*7_B'X_X*.?\ 0L_"3_P\-O\
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MV?AS_P!#=I/_ ']?_P"-T?\ "V?AS_T-VD_]_7_^-UZ'@^I_3_"C!]3^G^%
MCSS_ (6S\.?^ANTG_OZ__P ;H_X6S\.?^ANTG_OZ_P#\;KT/!]3^G^%&#ZG]
M/\* ///^%L_#G_H;M)_[^O\ _&Z/^%L_#G_H;M)_[^O_ /&Z]#P?4_I_A1@^
MI_3_  H \\_X6S\.?^ANTG_OZ_\ \;H_X6S\.?\ H;M)_P"_K_\ QNO0\'U/
MZ?X48/J?T_PH \\_X6S\.?\ H;M)_P"_K_\ QNC_ (6S\.?^ANTG_OZ__P ;
MKT/!]3^G^%&#ZG]/\* ///\ A;/PY_Z&[2?^_K__ !NC_A;/PY_Z&[2?^_K_
M /QNO0\'U/Z?X48/J?T_PH \\_X6S\.?^ANTG_OZ_P#\;H_X6S\.?^ANTG_O
MZ_\ \;KT/!]3^G^%&#ZG]/\ "@#SS_A;/PY_Z&[2?^_K_P#QNC_A;/PY_P"A
MNTG_ +^O_P#&Z]#P?4_I_A1@^I_3_"@#SS_A;/PY_P"ANTG_ +^O_P#&Z/\
MA;/PY_Z&[2?^_K__ !NO0\'U/Z?X48/J?T_PH \\_P"%L_#G_H;M)_[^O_\
M&Z/^%L_#G_H;M)_[^O\ _&Z]#P?4_I_A1@^I_3_"@#SS_A;/PY_Z&[2?^_K_
M /QNC_A;/PY_Z&[2?^_K_P#QNO0\'U/Z?X48/J?T_P * ///^%L_#G_H;M)_
M[^O_ /&Z/^%L_#G_ *&[2?\ OZ__ ,;KT/!]3^G^%&#ZG]/\* ///^%L_#G_
M *&[2?\ OZ__ ,;H_P"%L_#G_H;M)_[^O_\ &Z]#P?4_I_A1@^I_3_"@#SS_
M (6S\.?^ANTG_OZ__P ;H_X6S\.?^ANTG_OZ_P#\;KT/!]3^G^%&#ZG]/\*
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>1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ex5-1_002i.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_002i.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  R +T# 2(  A$! Q$!_\0
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MY[U8Q10!5CNMUHL[@#+8// ^;%#W06=X@A.U-V>Q/I^56 BJNT* OH!Q3L4
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04 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786326053808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SCISPARC LTD.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">F-1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001611746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Puglisi & Associates<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Newark<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(302)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">738-6680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">20 Raul Wallenberg Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Tower A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tel Aviv<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">6971916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(+972)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">(3) 610-3100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786325605744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Financial Position - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,081<span></span>
</td>
<td class="nump">$ 3,574<span></span>
</td>
<td class="nump">$ 12,945<span></span>
</td>
<td class="nump">$ 6,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Restricted deposit</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other accounts receivable</a></td>
<td class="nump">815<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="nump">699<span></span>
</td>
<td class="nump">2,904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventory</a></td>
<td class="nump">660<span></span>
</td>
<td class="nump">668<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Current asset, total</a></td>
<td class="nump">3,643<span></span>
</td>
<td class="nump">4,510<span></span>
</td>
<td class="nump">13,684<span></span>
</td>
<td class="nump">9,824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible asset, net</a></td>
<td class="nump">4,474<span></span>
</td>
<td class="nump">4,717<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInAssociates', window );">Investment in company account for at equity</a></td>
<td class="nump">893<span></span>
</td>
<td class="nump">591<span></span>
</td>
<td class="nump">659<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialAssets', window );">Investments in financial assets</a></td>
<td class="nump">849<span></span>
</td>
<td class="nump">730<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current asset total</a></td>
<td class="nump">6,249<span></span>
</td>
<td class="nump">6,095<span></span>
</td>
<td class="nump">738<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Assets, total</a></td>
<td class="nump">9,892<span></span>
</td>
<td class="nump">10,605<span></span>
</td>
<td class="nump">14,422<span></span>
</td>
<td class="nump">9,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">1,247<span></span>
</td>
<td class="nump">1,199<span></span>
</td>
<td class="nump">874<span></span>
</td>
<td class="nump">1,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Other accounts payable</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentWarrantLiability', window );">Warrants</a></td>
<td class="nump">1,714<span></span>
</td>
<td class="nump">2,737<span></span>
</td>
<td class="nump">10,252<span></span>
</td>
<td class="nump">359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Liabilities current, total</a></td>
<td class="nump">3,114<span></span>
</td>
<td class="nump">4,156<span></span>
</td>
<td class="nump">11,385<span></span>
</td>
<td class="nump">1,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>NON-CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract', window );"><strong>EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Share capital and premium</a></td>
<td class="nump">58,898<span></span>
</td>
<td class="nump">58,592<span></span>
</td>
<td class="nump">58,547<span></span>
</td>
<td class="nump">58,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfSharebasedPayments', window );">Reserve from share-based payment transactions</a></td>
<td class="nump">5,248<span></span>
</td>
<td class="nump">5,180<span></span>
</td>
<td class="nump">4,980<span></span>
</td>
<td class="nump">4,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrants</a></td>
<td class="nump">5,190<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation', window );">Foreign currency translation reserve</a></td>
<td class="nump">497<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="nump">497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherEquityInterest', window );">Transactions with non-controlling interests</a></td>
<td class="nump">712<span></span>
</td>
<td class="nump">559<span></span>
</td>
<td class="nump">559<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">(66,449)<span></span>
</td>
<td class="num">(63,569)<span></span>
</td>
<td class="num">(66,736)<span></span>
</td>
<td class="num">(60,977)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Total</a></td>
<td class="nump">4,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="nump">2,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">6,778<span></span>
</td>
<td class="nump">6,449<span></span>
</td>
<td class="nump">3,037<span></span>
</td>
<td class="nump">8,141<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total liabilities and equity</a></td>
<td class="nump">$ 9,892<span></span>
</td>
<td class="nump">$ 10,605<span></span>
</td>
<td class="nump">$ 14,422<span></span>
</td>
<td class="nump">$ 9,916<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current warrant liabilities. [Refer: Warrant liability]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph r<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in associates in an entity's separate financial statements. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 12<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_12_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 10<br> -IssueDate 2023-01-01<br> -Paragraph 22<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=10&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_22&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph q<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_q&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2023-01-01<br> -Paragraph 52<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_52_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity resulting from share-based payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786325747424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenues</a></td>
<td class="nump">$ 1,972<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,347<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="num">(1,267)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(322)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="nump">705<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,025<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">781<span></span>
</td>
<td class="nump">1,474<span></span>
</td>
<td class="nump">2,803<span></span>
</td>
<td class="nump">1,990<span></span>
</td>
<td class="nump">649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">397<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">2,494<span></span>
</td>
<td class="nump">3,339<span></span>
</td>
<td class="nump">6,509<span></span>
</td>
<td class="nump">3,778<span></span>
</td>
<td class="nump">1,902<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating loss</a></td>
<td class="nump">2,967<span></span>
</td>
<td class="nump">4,813<span></span>
</td>
<td class="nump">8,287<span></span>
</td>
<td class="nump">5,768<span></span>
</td>
<td class="nump">3,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Company&#8217;s share of losses of companies accounted for at equity, net</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="num">(1,024)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,832)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(630)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="nump">877<span></span>
</td>
<td class="nump">905<span></span>
</td>
<td class="nump">2,014<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">872<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before income taxes</a></td>
<td class="nump">2,919<span></span>
</td>
<td class="nump">5,759<span></span>
</td>
<td class="nump">2,578<span></span>
</td>
<td class="nump">5,789<span></span>
</td>
<td class="nump">3,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Taxes on income</a></td>
<td class="nump">13<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="nump">2,932<span></span>
</td>
<td class="nump">5,759<span></span>
</td>
<td class="nump">2,592<span></span>
</td>
<td class="nump">5,789<span></span>
</td>
<td class="nump">3,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AttributableToAbstract', window );"><strong>Attributable to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ComprehensiveIncomeAttributableToNoncontrollingInterest', window );">Non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToAbstract', window );"><strong>Attributable to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity', window );">Equity holders of the Company</a></td>
<td class="nump">2,880<span></span>
</td>
<td class="nump">5,759<span></span>
</td>
<td class="nump">2,592<span></span>
</td>
<td class="nump">5,789<span></span>
</td>
<td class="nump">3,482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="nump">52<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Profit loss</a></td>
<td class="nump">$ 2,932<span></span>
</td>
<td class="nump">$ 5,759<span></span>
</td>
<td class="nump">$ 2,592<span></span>
</td>
<td class="nump">$ 5,789<span></span>
</td>
<td class="nump">$ 3,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BasicLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract', window );"><strong>Basic loss per share attributable to equity holders of the Company:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Loss from operations (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.57<span></span>
</td>
<td class="nump">$ 2.83<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DilutedLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract', window );"><strong>Diluted loss per share attributable to equity holders of the Company:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Loss from operations (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.57<span></span>
</td>
<td class="nump">$ 2.83<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_PreviouslyStatedMember', window );">Previously stated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToAbstract', window );"><strong>Attributable to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Profit loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BasicLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract', window );"><strong>Basic loss per share attributable to equity holders of the Company:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Loss from operations (in Dollars per share)</a></td>
<td class="nump">$ 10.85<span></span>
</td>
<td class="nump">$ 46.8<span></span>
</td>
<td class="nump">14.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DilutedLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract', window );"><strong>Diluted loss per share attributable to equity holders of the Company:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Loss from operations (in Dollars per share)</a></td>
<td class="nump">$ 10.85<span></span>
</td>
<td class="nump">$ 46.8<span></span>
</td>
<td class="nump">$ 14.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations attributable to ordinary equity holders of the parent entity. [Refer: Continuing operations [member]; Profit (loss) from continuing operations]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2023-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_BasicLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_BasicLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ComprehensiveIncomeAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ComprehensiveIncomeAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DilutedLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DilutedLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_PreviouslyStatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_PreviouslyStatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786303237296">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Share capital and premium</div></th>
<th class="th"><div>Reserve from share-based payment transactions</div></th>
<th class="th"><div>Warrants</div></th>
<th class="th"><div>Transactions with non- controlling interests</div></th>
<th class="th"><div>Foreign currency translation reserve</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Non- controlling interests</div></th>
<th class="th"><div>Previously stated</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 45,636<span></span>
</td>
<td class="nump">$ 4,862<span></span>
</td>
<td class="nump">$ 464<span></span>
</td>
<td class="nump">$ 261<span></span>
</td>
<td class="nump">$ 497<span></span>
</td>
<td class="num">$ (51,706)<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,482)<span></span>
</td>
<td class="num">(3,482)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="num">$ (3,535)<span></span>
</td>
<td class="num">(3,535)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Warrants reclassification</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(464)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(464)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(464)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IssueOfShareCapitalNetOfIssueExpense', window );">Issue of share capital, net of issue expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,763<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,207<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,970<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments', window );">Conversion of convertible debentures (Note 14b)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">298<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">298<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Expiration of share options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">638<span></span>
</td>
<td class="num">(638)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of share-based payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49,040<span></span>
</td>
<td class="nump">4,315<span></span>
</td>
<td class="nump">2,207<span></span>
</td>
<td class="nump">559<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="num">(55,188)<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,789)<span></span>
</td>
<td class="num">(5,789)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,789)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IssueOfShareCapitalNetOfIssueExpense', window );">Issue of share capital, net of issue expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">3,364<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,335<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,699<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">6,110<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,352)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,758<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Expiration of share options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of share-based payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">58,541<span></span>
</td>
<td class="nump">4,331<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
<td class="nump">559<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="num">(60,977)<span></span>
</td>
<td class="nump">8,141<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,759)<span></span>
</td>
<td class="num">(5,759)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,759)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Expiration of share options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of share-based payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">655<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">655<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">655<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">58,547<span></span>
</td>
<td class="nump">4,980<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
<td class="nump">559<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="num">(66,736)<span></span>
</td>
<td class="nump">3,037<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,037<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">58,541<span></span>
</td>
<td class="nump">4,331<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
<td class="nump">559<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="num">(60,977)<span></span>
</td>
<td class="nump">8,141<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,592)<span></span>
</td>
<td class="num">(2,592)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,592)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of share-based payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">48<span></span>
</td>
<td class="nump">849<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">897<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">897<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">58,592<span></span>
</td>
<td class="nump">5,180<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
<td class="nump">559<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="num">(63,569)<span></span>
</td>
<td class="nump">6,449<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,449<span></span>
</td>
<td class="nump">6,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,880)<span></span>
</td>
<td class="num">(2,880)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,932)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Issue of share capital in respect of investment in affiliate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">288<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl', window );">Sale of minority interest in subsidiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="nump">2,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IssueOfSharesNetOfIssueExpenses', window );">Issue of shares, net of issue expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(45)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of share-based payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">63<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 58,898<span></span>
</td>
<td class="nump">$ 5,248<span></span>
</td>
<td class="nump">$ 5,190<span></span>
</td>
<td class="nump">$ 712<span></span>
</td>
<td class="nump">$ 497<span></span>
</td>
<td class="num">$ (66,449)<span></span>
</td>
<td class="nump">$ 4,096<span></span>
</td>
<td class="nump">$ 2,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,778<span></span>
</td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">Net of issue expenses of $784</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">Net of issue expenses of $449</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">Net of issue expenses of $358</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity through changes in ownership interests in subsidiaries that do not result in loss of control. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the conversion of convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from proceeds from contributions of non-controlling interests. [Refer: Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssueOfShareCapitalNetOfIssueExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of share capital, net of issue expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssueOfShareCapitalNetOfIssueExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssueOfSharesNetOfIssueExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of shares, net of issue expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssueOfSharesNetOfIssueExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786326121328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss</a></td>
<td class="num">$ (2,932)<span></span>
</td>
<td class="num">$ (5,759)<span></span>
</td>
<td class="num">$ (2,592)<span></span>
</td>
<td class="num">$ (5,789)<span></span>
</td>
<td class="num">$ (3,535)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdjustmentsToTheProfitOrLossItemsAbstract', window );"><strong>Adjustments to the profit or loss items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation and amortization</a></td>
<td class="nump">267<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of share-based payment</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">655<span></span>
</td>
<td class="nump">897<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncomeCost', window );">Finance expenses, net</a></td>
<td class="num">(1,023)<span></span>
</td>
<td class="nump">913<span></span>
</td>
<td class="num">(6,585)<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="num">(476)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets', window );">Group&#8217;s share of losses of company accounted for at equity, net</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdjustmentsForImpairmentOfInvestmentInAssociate', window );">Losses from remeasurement of investment in financial assets</a></td>
<td class="nump">855<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">770<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLoss', window );">Total adjustments to the profit or loss</a></td>
<td class="nump">328<span></span>
</td>
<td class="nump">1,630<span></span>
</td>
<td class="num">(4,622)<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WorkingCapitalAdjustmentsAbstract', window );"><strong>Working capital adjustments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables', window );">Decrease (increase) in other accounts receivable</a></td>
<td class="num">(684)<span></span>
</td>
<td class="nump">2,205<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="num">(519)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Increase (decrease) in trade payables</a></td>
<td class="nump">48<span></span>
</td>
<td class="num">(324)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">353<span></span>
</td>
<td class="num">(752)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Increase (decrease) in other accounts payable</a></td>
<td class="num">(40)<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable', window );">Decrease (increase) in trade receivables</a></td>
<td class="nump">39<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">Decrease (increase) in inventory</a></td>
<td class="nump">8<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(668)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital', window );">Working capital</a></td>
<td class="num">(629)<span></span>
</td>
<td class="nump">1,941<span></span>
</td>
<td class="num">(703)<span></span>
</td>
<td class="nump">643<span></span>
</td>
<td class="num">(1,346)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(3,233)<span></span>
</td>
<td class="num">(2,188)<span></span>
</td>
<td class="num">(7,917)<span></span>
</td>
<td class="num">(5,061)<span></span>
</td>
<td class="num">(4,307)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents', window );">Investment (withdrawal) in restricted bank deposits</a></td>
<td class="nump">16<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Purchase of property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments', window );">Investment in a company accounted for at equity</a></td>
<td class="num">(400)<span></span>
</td>
<td class="num">(700)<span></span>
</td>
<td class="num">(700)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss', window );">Purchase of financial assets at fair value through profit or loss</a></td>
<td class="num">(687)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Purchase of intangible asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,861)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="num">(1,071)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(7,084)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses', window );">Proceeds from issue of share capital and warrants (net of issuance expenses) (Note 8)</a></td>
<td class="num">(50)<span></span>
</td>
<td class="nump">9,005<span></span>
</td>
<td class="nump">9,005<span></span>
</td>
<td class="nump">7,699<span></span>
</td>
<td class="nump">2,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_RepaymentOfLeaseLiabilities', window );">Repayment of lease liability</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_RepaymentOfShorttermCredit', window );">Repayment of short-term credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(188)<span></span>
</td>
<td class="num">(1,410)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ReceiptofShortTermCreditFromOthers', window );">Receipt of short-term credit from others, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InterestPaidOnLeaseLiability', window );">Interest paid on lease liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issuance of shares to minority interests in a subsidiary</a></td>
<td class="nump">2,887<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfOptions', window );">Exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,770<span></span>
</td>
<td class="nump">2,568<span></span>
</td>
<td class="nump">2,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod', window );">Payment of issuance expenses related to previous period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,811<span></span>
</td>
<td class="nump">8,966<span></span>
</td>
<td class="nump">11,700<span></span>
</td>
<td class="nump">10,060<span></span>
</td>
<td class="nump">5,359<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(1,493)<span></span>
</td>
<td class="nump">6,070<span></span>
</td>
<td class="num">(3,301)<span></span>
</td>
<td class="nump">4,929<span></span>
</td>
<td class="nump">1,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at the beginning of the period</a></td>
<td class="nump">3,574<span></span>
</td>
<td class="nump">6,875<span></span>
</td>
<td class="nump">6,875<span></span>
</td>
<td class="nump">1,946<span></span>
</td>
<td class="nump">870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at the end of the period</a></td>
<td class="nump">2,081<span></span>
</td>
<td class="nump">12,945<span></span>
</td>
<td class="nump">3,574<span></span>
</td>
<td class="nump">6,875<span></span>
</td>
<td class="nump">1,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantNonCashTransactionsAbstract', window );"><strong>(a) Significant non-cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability', window );">Right-of-use asset recognized with corresponding lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_RegistrationOfWarrants', window );">Registration of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,480<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_UnpaidIssueExpenses', window );">Unpaid issue expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 290<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_MutualShareExchangeOfOrdinarySharessee', window );">Mutual share exchange of ordinary shares (see note 10)</a></td>
<td class="nump">$ 288<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for losses (gains) on disposal of non-current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Non-current assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 14<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_14&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments, other than changes in working capital, to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) due to a decrease (increase) in restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdjustmentsForImpairmentOfInvestmentInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for impairment of investment in associate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdjustmentsForImpairmentOfInvestmentInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdjustmentsToTheProfitOrLossItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdjustmentsToTheProfitOrLossItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InterestPaidOnLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InterestPaidOnLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_MutualShareExchangeOfOrdinarySharessee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_MutualShareExchangeOfOrdinarySharessee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of proceeds from issue of share capital and warrants net of issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of financial assets at fair value through profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ReceiptofShortTermCreditFromOthers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ReceiptofShortTermCreditFromOthers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RegistrationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Registration of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RegistrationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RepaymentOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RepaymentOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RepaymentOfShorttermCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RepaymentOfShorttermCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-of-use asset recognized with corresponding lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SignificantNonCashTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SignificantNonCashTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_UnpaidIssueExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unpaid issue expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_UnpaidIssueExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WorkingCapitalAdjustmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WorkingCapitalAdjustmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786307543360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfGeneralExplanatoryAbstract', window );"><strong>General [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfGeneralExplanatoryTextBlock', window );">GENERAL</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
1:- GENERAL</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">SciSparc
    Ltd. (formerly known as Therapix Biosciences Ltd.) (&#8220;SciSparc&#8221; or the &#8220;Company&#8221; or the &#8220;Group&#8221;),
    a pharmaceutical company, was incorporated in Israel and commenced its operations on August 23, 2004. Until March 2014, SciSparc
    and its subsidiaries at the time were mainly engaged in developing several innovative immunotherapy products and SciSparc&#8217;s
    own patents in the immunotherapy field. In August 2015, the Company decided to adopt a different business strategy and began focusing
    on developing a portfolio of approved drugs based on cannabinoid molecules. With this focus, the Company is currently engaged in
    development programs based on &#916;9-tetrahydrocannabinol (&#8220;THC&#8221;) and/or non-psychoactive cannabidiol for the treatment
    of Tourette syndrome, Alzheimer&#8217;s disease and agitation, pain, autism spectrum disorder and Status Epilepticus. The headquarters
    of the Company are located in Tel Aviv, Israel.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
    September 30, 2022, the Company announced the closing of the acquisition of Wellution<sup>TM</sup>, a top seller Amazon.com Marketplace
    account (the &#8220;Brand&#8221;), American food supplements and cosmetics brand and trademark (the &#8220;Acquisition&#8221;). In
    connection with the Acquisition, the Company incorporated a new wholly owned Delaware subsidiary, SciSparc Nutraceuticals Inc. (&#8220;SciSparc
    US&#8221;), to hold the new assets.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company&#8217;s ordinary shares are listed on Nasdaq and are trading under the symbol &#8220;SPRC&#8221;.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As of June 30, 2023, the Company had three private subsidiaries, including a company incorporated under the laws of Israel: Evero Health Ltd (&#8220;Evero&#8221;); an inactive company incorporated under the laws of Israel: Brain Bright Ltd (&#8220;Brain Bright&#8221;); and a company incorporated under the laws of the State of Delaware: Scisparc US (together with Evero and Brain Bright, the &#8220;Subsidiaries&#8221;).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On August 18, 2023, the Company convened a general meeting of its shareholders, whereby the shareholders approved, inter alia, a reverse split of the Company&#8217;s share capital up to a ratio of 30:1 (the &#8220;Reverse Split&#8221;). Following the implementation of the reverse split, the Company&#8217;s authorized share capital will not be adjusted under the Company&#8217;s articles of association, as currently in effect (the &#8220;Articles&#8221;), which as of the date hereof consists of 75,000,000 Ordinary Shares, no par value.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
September 14, 2023, the Company&#8217;s Board resolved that the final ratio for the Reverse Split will be 26:1, which became effective
on September 28, 2023.&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Consequently,
all share numbers, share prices, and exercise prices have been retroactively adjusted in these interim consolidated financial statements
for all periods presented.</span>&#160;</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These interim consolidated
    financial statements should be read in conjunction with the Company&#8217;s annual financial statements for the year ended December
    31, 2022, and accompanying notes, that were approved on April 27, 2023, and signed on May 1, 2023 (the &#8220;2022 Annual Consolidated
    Financial Statements&#8221;).</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company incurred a net loss of $2,932 and had negative cash flows from operating activities of $3,233 for the six month period ended June 30, 2023. As of June 30, 2023, the Company had an accumulated deficit of $66,449 as a result of recurring operating losses. At June 30, 2023, the Company&#8217;s cash and cash equivalents position is not sufficient to fund the Company&#8217;s planned operations for at least a year beyond the date of the filing date of the consolidated financial statements.. The Company&#8217;s pharmaceuticals operations are dependent on its ability to raise additional funds from existing and/or new investors. This dependency will continue until the Group will be able to completely finance its operations by generating revenue from its pharmaceutical products. These abovementioned factors raise substantial doubt about the Group&#8217;s ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529"><span style="font-family: Times New Roman, Times, Serif">The Company intends to finance operating costs over the next twelve months through a combination of actions that may include existing cash on hand, reducing operating expenses and issuing equity and/or debt securities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529"><span style="font-family: Times New Roman, Times, Serif">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The interim consolidated financial statements for the period ended June 30, 2023, do not include any adjustments to the carrying amounts and classifications of assets and liabilities that might result should the Group be unable to continue as a going concern.</span></p>
</td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The interim consolidated financial statements
    of the Company for the six-month period ended on June&#160;30, 2023, were approved for issuance on October 2, 2023 (the &#8220;Approval
    Date&#8221;). In connection with the preparation of the interim consolidated financial statements and in accordance with authoritative
    guidance for subsequent events, the Company evaluated subsequent events after the consolidated statements of financial position date
    of June 30, 2023, through September 27, 2023, the date on which the unaudited interim consolidated financial statements were available
    to be issued.</span></td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-size: 10pt"><b>NOTE 1:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>GENERAL</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) (&#8220;SciSparc&#8221;
or the &#8220;Company&#8221; or the &#8220;Group&#8221;), a pharmaceutical company, was incorporated in Israel and commenced its operations
on August 23, 2004. Until March 2014, SciSparc and its subsidiaries at the time (the &#8220;Group&#8221;) were mainly engaged in developing
several innovative immunotherapy products and SciSparc&#8217;s own patents in the immunotherapy field. In August 2015, the Company decided
to adopt a different business strategy and began focusing on developing a&#160;portfolio of approved drugs based on cannabinoid molecules.
With this focus, the Company is currently engaged in the following development programs based on &#916;9-tetrahydrocannabinol (&#8220;THC&#8221;)
and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer&#8217;s disease&#160;and agitation, pain, autism
spectrum disorder and Status Epilepticus. The headquarters of the Company are located in Tel Aviv, Israel.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company was previously a dual-listed
company, whereby it listed (a) its ordinary shares, no par value each (&#8220;ordinary shares&#8221;), on the Tel-Aviv Stock Exchange
(&#8220;TASE&#8221;) from December 26, 2005 until its delisting on August 7, 2018, and (b) its American Depository Shares (&#8220;ADSs&#8221;)
on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) following its initial public offering (&#8220;IPO&#8221;) on March 27, 2017, at which
time it raised $13,700, until its suspension from listing, and subsequent delisting, from Nasdaq on July 2, 2020 and September 21, 2020,
respectively. Following the delisting of the ADSs from Nasdaq, the Company&#8217;s ADSs were listed on the Pink Sheets and then subsequently
upgraded to the OTCQB on December 8, 2020. On August 26, 2021, the Company&#8217;s ADSs were mandatorily cancelled and were exchanged
for ordinary shares at a one-for-one ratio.&#160;On December 22, 2021, the Company&#8217;s ordinary shares were re-listed on Nasdaq and
began trading under the symbol &#8220;SPRC&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As of December 31, 2022, the Company
had three private subsidiaries, including a company incorporated under the laws of Israel: Evero Health Ltd (&#8220;Evero&#8221;); an
inactive company incorporated under the laws of Israel: Brain Bright Ltd (&#8220;Brain Bright&#8221;); and a company incorporated under
the laws of the State of Delaware: Scisparc Nutraceuticals Inc. (&#8220;Scisparc US&#8221; and together with Evero and Brain Bright, the
&#8220;Subsidiaries&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The consolidated financial statements
of the Company for the year ended December&#160;31, 2022, were approved on April 27, 2023, and signed on May 1, 2023 (the &#8220;Approval
Date&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">The Group incurred operating losses since its incorporation and expects
to continue to incur operating losses for the foreseeable future. As of December 31, 2022, the Group had an accumulated deficit of approximately
$64,009 as a result of recurring operating losses.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A<span style="background-color: white">s
of the Approval Date, the Group has started recognizing revenues from sales. However, its pharmaceuticals operations are dependent on
its ability to raise additional funds from existing and/or new investors. This dependency will continue until the Group will be able to
completely finance its operations by generating revenue from its products. These abovementioned factors raise substantial doubt about
the Group&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments to the carrying amounts
and classifications of assets and liabilities that might result should the Group be unable to continue as a going concern.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Definitions and Meanings:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 10%; text-align: justify"><span style="font-size: 10pt">The Company</span></td>
    <td style="width: 2%; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Group</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">SciSparc Ltd. (formerly Therapix Biosciences Ltd.) and its Subsidiaries, as detailed in Note 1a.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Subsidiaries</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Companies that are controlled by the Company, as defined in IFRS 10, &#8220;<i>Consolidated Financial Statements</i>&#8221;, and whose accounts are consolidated with those of the Company (if active).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Associates</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">An entity over which the Company has significant influence, as defined in IAS 28, &#8220;<i>Investment in Associates and Joint Ventures</i>&#8221; and is not a Subsidiary.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Related Parties</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">As defined in IAS 24, &#8220;<i>Related Party Disclosures</i>&#8221;. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">IAS</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">International Accounting Standards issued by the International Accounting Standards Board (&#8220;IASB&#8221;).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">IFRS</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">International Financial Reporting Standards issued by the IASB.</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfGeneralExplanatoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfGeneralExplanatoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfGeneralExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfGeneralExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786307091712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccountingPolicyAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
2:- SIGNIFICANT ACCOUNTING POLICIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Unaudited
Interim Financial Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s unaudited condensed consolidated financial statements have been prepared in accordance with International Accounting
Standard (&#8220;IAS&#8221;) 34, &#8220;Interim Financial Reporting&#8221;. The significant accounting policies adopted in the preparation
of the interim consolidated financial statements are consistent with those followed in the preparation of the 2022 Annual Consolidated
Financial Statements. Accordingly, these condensed consolidated financial statements should be read in conjunction with the 2022 Annual
Consolidated Financial Statements. The results for any interim period are not necessarily indicative of results for any future period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
unaudited condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the
opinion of the Company&#8217;s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments
that are necessary to present fairly the Company&#8217;s financial position and results of operations for the interim periods presented.
The results for the six month period ended June 30, 2023, are not necessarily indicative of the results for the year ending December&#160;31,
2023, or for any future period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of June 30, 2023, there have been no material changes in the Company&#8217;s significant accounting policies from those that were disclosed
in the 2022 Annual Consolidated Financial Statements.<b>&#160;</b></span></p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td><span style="font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following accounting policies have
been applied consistently in the financial statements for all periods presented, unless otherwise stated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Basis of presentation of the financial statements:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">These financial statements have been
prepared in accordance with IFRS, as issued by the IASB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s financial statements
have been prepared on a cost basis, unless otherwise indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has elected to present
the profit or loss items using the function of expense method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements are presented
in USD and all values are rounded to the nearest thousand (&#8217;000), except when otherwise indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">The operating cycle:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The operating cycle of the Company
is one year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Consolidated financial statements:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The consolidated financial statements
comprise the financial statements of companies that are controlled by the Company (Subsidiaries). Control of a company is achieved when
the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those
returns through its power over the investee. Potential voting rights are considered when assessing whether an entity has control over
the other entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such
control ceases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements of the Company
and of the Subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform
accounting policies by all companies in the Group. Significant intra-Group balances and transactions and gains or losses resulting from
intra-Group transactions are eliminated in full in the consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Non-controlling interests in subsidiaries
represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in
equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive
income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they
result in a negative balance of non-controlling interests in the consolidated statement of financial position.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 72px"></td><td style="width: 48px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td><td style="text-align: justify">Functional currency and foreign currency:</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The functional currency of the Company, which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions is the U.S. Dollar (&#8220;USD&#8221; or &#8220;$&#8221;), since it&#8217;s the primary currency of the economic environment in which the Company operates. The consolidated financial statements are also presented in USD since the Company believes that preparing the consolidated financial statements in USD provides more relevant information to the users of the consolidated financial statements.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Acquisition of a single asset company:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Upon the acquisition
of a single asset company, the Group evaluates whether it is the acquisition of a business or of an asset. To be considered a business,
the acquisition must include, at a minimum, an input and a substantive process that together can significantly contribute to the creation
of outputs. The acquisition is accounted for as a business combination if the single asset company is a business. If it is not a business,
the acquisition is accounted for as the acquisition of assets and liabilities. In such an acquisition, the cost of the acquisition includes
transaction costs which are allocated to the identifiable acquired assets and liabilities proportionally based on their fair value on
the acquisition date. In such case, goodwill and deferred taxes in respect of the temporary differences existing as of the acquisition
date are not recognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify; font-size: 10pt">&#160;</td> <td style="width: 48px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted deposits:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">A restricted deposit is cash invested
in a short-term deposit (between three months and one year) or in a long-term deposit (with a maturity of more than one year from the
date of investment). Restricted deposits are designated to secure the Company&#8217;s office facilities lease agreements and its credit
cards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 72px"></td><td style="width: 48px">g.</td><td style="text-align: justify">Investment in joint arrangements:</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Joint arrangements
are arrangements in which the Company has joint control. Joint control is the contractually agreed sharing of control of an arrangement,
which exists only when decisions about the relevant activities require the unanimous consent of the parties sharing control.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 1.25in"></td><td style="width: 0.5in">1.</td><td style="text-align: justify">Joint ventures:</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in">In joint ventures
the parties that have joint control of the arrangement have rights to the net assets of the arrangement. A joint venture is accounted
for at equity</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 1.25in"></td><td style="width: 0.5in">2.</td><td style="text-align: justify">Joint operations:</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in">In joint operations
the parties that have joint control of the arrangement have rights to the assets and obligations for the liabilities relating to the arrangement.
The Company recognizes in relation to its interest its share of the assets, liabilities, revenues and expenses of the joint operation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in">The acquisition
of interests in a joint operation which represents a business, as defined in IFRS 3, is accounted for using the acquisition method, including
the measurement of the identifiable assets and liabilities at fair value, the recognition of deferred taxes arising from this measurement,
the accounting treatment of the related transaction costs and the recognition of goodwill or bargain purchase gains. This applies to the
acquisition of the initial interest and additional interests in a joint operation that represents a business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 72px"></td><td style="width: 48px">h.</td><td style="text-align: justify">Investments in associates:</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"><span style="text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Associates are companies in which the Group has significant
influence over the financial and operating policies without having control. The investment in an associate is accounted for using the
equity method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 72px"></td><td style="width: 48px">i.</td><td style="text-align: justify">Investments accounted for using the equity method:</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"><span style="text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Group&#8217;s investments
in associates and joint ventures are accounted for using the equity method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Under the equity
method, the investment in the associate or in the joint venture is presented at cost with the addition of post-acquisition changes in
the Group&#8217;s share of net assets, including other comprehensive income of the associate or the joint venture. Gains and losses resulting
from transactions between the Group and the associate or the joint venture are eliminated to the extent of the interest in the associate
or in the joint venture. The cost of the investment includes transaction costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Goodwill relating
to the acquisition of an associate or a joint venture is presented as part of the investment in the associate or the joint venture, measured
at cost and not systematically amortized. Goodwill is evaluated for impairment as part of the investment in the associate or in the joint
venture as a whole.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The financial statements
of the Company and of the associate or joint venture are prepared as of the same dates and periods. The accounting policies applied in
the financial statements of the associate or the joint venture are uniform and consistent with the policies applied in the financial statements
of the Group.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Upon the acquisition
of an associate or a joint venture achieved in stages when the former investment in the acquiree was accounted for pursuant to the provisions
of IFRS 9, the Group applies the principles of IFRS 3 regarding business combinations achieved in stages. Consequently, equity interests
in the acquiree that had been held by the Group prior to achieving significant influence or joint control are measured at fair value on
the acquisition date and are included in the acquisition consideration while recognizing a gain or loss resulting from the fair value
measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The equity method
is applied until the loss of significant influence in the associate or loss of joint control in the joint venture or classification as
investment held for sale.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">j.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Property and equipment, net:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Property and equipment are measured
at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment
grants and excluding day-to-day servicing expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>%</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Mainly %</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Lab equipment</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 9%">6-50</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">33</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Computers</td>
    <td>&#160;</td>
    <td style="text-align: center">33-50</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">33</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office furniture and equipment</td>
    <td>&#160;</td>
    <td style="text-align: center">20-33</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">25</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td>
    <td>&#160;</td>
    <td style="text-align: center">see below</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-233">-</div></td>
    <td style="text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including the extension option held by a company and intended to be exercised)
and the expected life of the improvement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The useful life, depreciation method
and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting
estimate. Depreciation of an asset ceases at the earlier of: the date that the asset is classified as held for sale and the date that
the asset is derecognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">k.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Intangible assets:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Separately acquired intangible assets
are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination
are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized
development costs, are recognized in profit or loss when incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Intangible assets with a finite useful
life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired.
The amortization period and the amortization method for an intangible asset are reviewed at least at each year end.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">l.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Impairment of non-financial assets:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company evaluates the need to record
an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.
If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount. The
recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future cash
flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset that
does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses are
recognized in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">m.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Financial instruments:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial assets:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets are measured upon
initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except
for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company classifies and measures
debt instruments in the financial statements based on the following criteria:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Company&#8217;s business model for managing financial assets; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The contractual cash flow terms of the financial asset.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">a)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Debt instruments are measured at amortized cost when:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">The Company&#8217;s business model
is to hold the financial assets in order to collect their contractual cash flows, and the contractual terms of the financial assets give
rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial
recognition, the instruments in this category are measured according to their terms at amortized cost using the effective interest rate
method, less any provision for impairment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">On the date of initial recognition,
the Company may irrevocably designate a debt instrument as measured at fair value through profit or loss if doing so eliminates or significantly
reduces a measurement or recognition inconsistency, such as when a related financial liability is also measured at fair value through
profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">b)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Debt instruments are measured at fair value through profit or loss when:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">A financial asset which is a debt instrument
does not meet the criteria for measurement at amortized cost or at fair value through other comprehensive income. After initial recognition,
the financial asset is measured at fair value and gains or losses from fair value adjustments are recognized in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">c)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Equity instruments and other financial assets held for trading:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Investments in equity instruments do
not meet the above criteria and accordingly are measured at fair value through profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Other financial assets held for trading
such as derivatives, including embedded derivatives separated from the host contract, are measured at fair value through profit or loss
unless they are designated as effective hedging instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Dividends from investments in equity
instruments are recognized in profit or loss when the right to receive the dividends is established.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Derecognition of financial assets:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial asset is derecognized only
when:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The contractual rights to the cash flows from the financial asset have expired;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Company has transferred substantially all the risks and rewards deriving from the contractual rights to receive cash flows from the financial asset or has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset; or</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Company has retained its contractual rights to receive cash flows from the financial asset but has assumed a contractual obligation to pay the cash flows in full without material delay to a third party.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial liabilities:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">a)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial liabilities measured at amortized cost:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Financial liabilities are initially
recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, the Company
measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair
value through profit or loss such as derivatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">b)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial liabilities measured at fair value through profit or loss:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">At initial recognition, the Company
measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, changes
in fair value are recognized in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Derecognition of financial liabilities:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial liability is derecognized
only when it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires. A financial
liability is extinguished when the debtor discharges the liability by paying in cash, other financial assets, goods or services, or is
legally released from the liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Offsetting financial instruments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets and financial liabilities
are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off the
recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously.
The right of set-off must be legally enforceable not only during the ordinary course of business of the parties to the contract but also
in the event of bankruptcy or insolvency of one of the parties. In order for the right of set-off to be currently available, it must not
be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events that
will cause the right to expire.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Compound financial instruments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Convertible debentures which contain
both an equity/derivative component and a liability component are separated into two components. This separation is performed by first
determining the liability component based on the fair value of an equivalent non-convertible liability. The value of the conversion component
is determined to be the residual amount. Directly attributable transaction costs are apportioned between the equity component and the
liability component based on the allocation of proceeds to the equity and liability components.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">7.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Issue of a unit of securities:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The issue of a unit of securities involves
the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following order: financial
derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for financial liabilities
that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual amount. Issue costs
are allocated to each component pro rata to the amounts determined for each component in the unit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">n.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Research and development expenditures:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Research expenditures are recognized
in profit or loss when incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The conditions enabling capitalization
of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss when
incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">o.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Finance income and expenses:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Finance income and expenses comprise
interest income on amounts invested and exchange rate gains and losses. Interest income is recognized as it accrues using the effective
interest method. Finance income and expenses derive also from changes in the fair value of financial liabilities measured at fair value
through profit or loss. Borrowing costs are recognized in profit or loss using the effective interest method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">p.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Fair value measurement:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Fair value measurement is based on the assumption that the transaction will take place in the asset&#8217;s or the liability&#8217;s
principal market, or in the absence of a principal market, in the most advantageous market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The fair value of an asset or a liability
is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants
act in their economic best interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value measurement of a non-financial
asset takes into account a market participant&#8217;s ability to generate economic benefits by using the asset in its highest and best
use or by selling it to another market participant that would use the asset in its highest and best use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company uses valuation techniques
that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant
observable inputs and minimizing the use of unobservable inputs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">All assets and liabilities measured
at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level
input that is significant to the entire fair value measurement:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">Level 1</span></td>
    <td style="width: 2%; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 2</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Inputs other than quoted prices included within Level 1 that are observable directly or indirectly.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 3</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">q.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Taxes on income:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Current or deferred taxes are recognized
in profit or loss, except to the extent that they relate to items which are recognized in other comprehensive income or equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Current taxes:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A current tax liability is measured
using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required
in connection with the tax liability in respect of previous years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Deferred taxes:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are computed in respect
of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are measured at the
tax rate that is expected to apply when the asset is realized, or the liability is settled, based on tax laws that have been enacted or
substantively enacted by the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred tax assets are reviewed at
each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and temporary
differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred tax asset
is recognized to the extent that their utilization is probable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes that would apply in the event
of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of the
investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution
of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends
does not involve an additional tax liability or since it is the Company&#8217;s policy not to initiate distribution of dividends from
a subsidiary that would trigger an additional tax liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes on income that relate to distributions
of an equity instrument and to transaction costs of an equity transaction are accounted for pursuant to IAS 12, &#8220;<i>Income Taxes</i>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are offset if there
is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same
taxpayer and the same taxation authority.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">r.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Share-based payment transactions:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s employees and other
service providers may receive remuneration in the form of share-based payments (&#8220;Equity-settled transactions&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Equity-settled transactions:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable
option pricing model (&#8220;OPM&#8221;). As for service providers, the cost of the transactions is measured at the fair value of the
goods or services received as consideration for equity instruments granted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
is recognized in profit or loss together with a corresponding increase in equity during the period in which the performance and/or service
conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award (the &#8220;Vesting Period&#8221;).
The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects
the extent to which the Vesting Period has expired and the Company&#8217;s best estimate of the number of equity instruments that will
ultimately vest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">No expense is recognized for awards
that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective
of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If the Company modifies the conditions
on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value
of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If a grant of an equity instrument
is cancelled, it is accounted for as if it had vested on the cancellation date and any expense not yet recognized for the grant is recognized
immediately. However, if a new grant replaces the cancelled grant and is identified as a replacement grant on the grant date, the cancelled
and new grants are accounted for as a modification of the original grant, as described above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">s.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Earnings (loss) per share:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Earnings (loss) per share are calculated
by dividing the income (loss) attributable to equity holders of the Company by the weighted number of ordinary shares outstanding during
the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Basic loss per ordinary share includes
only ordinary shares that were outstanding during the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Potential ordinary shares are included
in the computation of diluted loss per ordinary share when their conversion increases loss per ordinary share from continuing operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt; text-align: justify">&#160;</td> <td style="width: 48px; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">t.</span></td> <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Employee benefit liabilities:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The Company has several employee-benefit
plans:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Short-term employee benefits:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">Short-term employee benefits are benefits
that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render
the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions
and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and a
reliable estimate of the amount can be made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Post-employment benefits:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">The plans are normally financed by contributions
to insurance companies and classified as defined contribution plans or as defined benefit plans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">The Company has defined contribution
plans to its employees according to the specific laws per country.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">u.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Provisions:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">A provision in accordance with IAS 37,
&#8220;<i>Provisions, Contingent Liabilities and Contingent Assets</i>&#8221;, is recognized when the Company has a present obligation
(legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required
to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects part or all of
the expense to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when
the reimbursement is virtually certain. The expense is recognized in the statement of profit or loss net of any reimbursement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">Following are the types of provisions
included in the financial statements:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"><i>Legal claims:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">A provision for claims is recognized
when the Company has a present legal or constructive obligation as a result of a past event, it is more likely than not that an outflow
of resources embodying economic benefits will be required by the Company to settle the obligation and a reliable estimate can be made
of the amount of the obligation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">v.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Leases:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The Company elected to apply the provisions
of IFRS 16, &#8220;<i>Leases</i>&#8221; (&#8220;IFRS 16&#8221;) using the modified retrospective method (without restatement of comparative
data).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The accounting policy for leases applied
effective from January 1, 2019, is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The Company accounts for a contract as
a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Company as a lessee:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">For leases in which the Company is the
lessee, the Company recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases whose
term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Company has elected
to recognize lease payments as an expense in profit or loss on a straight-line basis over the lease term (see Note 9). In measuring the
lease liability, the Company has elected to apply the practical expedient in IFRS 16 and separates the lease components from the non-lease
components (such as management and maintenance services, etc.) included in a single contract.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">On the commencement date, the lease
liability includes all unpaid lease payments discounted at the interest rate implicit in the lease, if that rate can be readily determined,
or otherwise using the Company&#8217;s incremental borrowing rate. After the commencement date, the Company measures the lease liability
using the effective interest rate method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">On the commencement date, the right-of-use
asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and
initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful
life and the lease term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">The Company tests for impairment of
the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36, &#8220;<i>Impairment of Assets</i>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Lease extension and termination options:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">A non-cancelable lease term includes
both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised, and
the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">In the event of any change in the expected
exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Company remeasures the lease
liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total change
is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized
in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Lease modifications:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">If a lease modification does not reduce
the scope of the lease and does not result in a separate lease, the Company remeasures the lease liability based on the modified lease
terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the
right-of-use asset.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">If a lease modification reduces the
scope of the lease, the Company recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use
asset and the lease liability. The Company subsequently remeasures the carrying amount of the lease liability according to the revised
lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment to
the right-of-use asset.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 72px"></td><td style="width: 48px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">w.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
to IAS 1, &#8220;Presentation of Financial Statements&#8221;:</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">In January 2020, the IASB issued
an amendment to IAS 1, &#8220;Presentation of Financial Statements&#8221; regarding the criteria for determining the classification of liabilities
as current or non-current (&#8220;the Original Amendment&#8221;). In October 2022, the IASB issued a subsequent amendment (&#8220;the Subsequent
Amendment&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-indent: 0pt">&#160;</p>

<p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">According to the Subsequent Amendment:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-indent: 0pt">&#160;</p>

<p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">Only covenants with which an entity
must comply on or before the reporting date will affect a liability&#8217;s classification as current or non-current.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-indent: 0pt">&#160;</p>

<p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">An entity should provide disclosure
when a liability arising from a loan agreement is classified as non-current and the entity&#8217;s right to defer settlement is contingent on
compliance with future covenants within twelve months from the reporting date. This disclosure is required to include information about
the covenants and the related liabilities. The disclosures must include information about the nature of the future covenants and when
compliance is applicable, as well as the carrying amount of the related liabilities. The purpose of this information is to allow users
to understand the nature of the future covenants and to assess the risk that a liability classified as non-current could become repayable
within twelve months. Furthermore, if facts and circumstances indicate that an entity may have difficulty in complying with such covenants,
those facts and circumstances should be disclosed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">According to the Original Amendment,
the conversion option of a liability affects the classification of the entire liability as current or non-current unless the conversion
component is an equity instrument.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-indent: 0pt">&#160;</p>

<p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">The Original Amendment and Subsequent
Amendment are both effective for annual periods beginning on or after January 1, 2024, and must be applied retrospectively. Early application
is permitted.</p>

<p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">&#160;</p>

<p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">The Company is evaluating the
effects of the Amendments on its financial statements.</p>

<p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 72px"></td><td style="width: 48px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">x.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
to IAS 8, &#8220;Accounting Policies, Changes to Accounting Estimates and Errors&#8221;:</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -10.1pt">&#160;</p>

<p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in">In February 2021, the IASB issued an amendment to IAS 8,
&#8220;Accounting Policies, Changes to Accounting Estimates and Errors&#8221; (&#8220;the Amendment&#8221;), in which it introduces a new
definition of &#8220;accounting estimates&#8221;.</p>

<p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">&#160;</p>

<p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">Accounting estimates are defined as
&#8220;monetary amounts in financial statements that are subject to measurement uncertainty&#8221;. The Amendment clarifies the distinction
between changes in accounting estimates and changes in accounting policies and the correction of errors.</p>

<p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">&#160;</p>

<p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">The Amendment is to be applied prospectively
for annual reporting periods beginning on or after January 1, 2023 and is applicable to changes in accounting policies and changes in
accounting estimates that occur on or after the start of that period. Early application is permitted.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of changes made to accounting policies by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AccountingPolicyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AccountingPolicyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786303955216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Associate<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Investment in Associate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory', window );">INVESTMENT IN ASSOCIATE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
3:- INVESTMENT IN ASSOCIATE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
March 10, 2022, the Company entered into a Founders and Investment Agreement with Dr. Alon Silberman, or the MitoCareX Agreement. Pursuant
to the MitoCareX Agreement, the Company invested an initial amount of $700, and agreed to invest over the next&#160;two years, an additional
$1,000, subject to the achievement of certain pre-determined milestones as agreed upon in the MitoCareX Agreement, for up to a&#160;50.01%
ownership in MitoCareX Bio Ltd. (&#8220;MitoCareX&#8221;). MitoCareX is focused on the discovery and development of potential drugs for
cancers and other life-threatening conditions. The MitoCareX Agreement also contains customary representations, warranties, covenants,
and indemnification provisions. On March 31, 2022, the closing conditions were met, and the Company paid the initial investment amount
of $700&#160;to MitoCareX. As of December 31, 2022, the Company owns&#160;31.48% of the outstanding shares of MitoCareX.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
February 17, 2023, MitoCareX achieved its first milestone pursuant to the MitoCareX Agreement. The first milestone refers to the establishment
of MitoCareX&#8217;s cloud-based computing infrastructure that is expected to allow its future expansion into machine learning system.
The system is harnessed to investigating mitochondrial carriers that are crucial for cell viability. As a result of MitoCareX meeting
this milestone, the Company will invest an additional $400&#160;in MitoCareX and increase its share ownership in MitoCareX Bio from&#160;31.48%
to&#160;41.92%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
table below summarizes the fair value of the investment in MitoCareX:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance at January
    1, 2022</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-220; font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Investment
    date March 31, 2022</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">700</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Equity
    losses from investment in MitoCareX</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(109</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance at December
    31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">591</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Investment date March
    31, 2023</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">400</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Equity
    losses from investment in MitoCareX</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(98</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    at June 30, 2023</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">893</span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During
the six months ended June 30, 2023, and 2022, the Company recorded equity losses from the investment in MitoCareX in the amount of $98
and $41, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786326665600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Asset<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract', window );"><strong>Intangible Asset [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory', window );">INTANGIBLE ASSET</a></td>
<td class="text"><p style="text-align: justify; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4:- INTANGIBLE ASSET</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
September 30, 2022, the Company announced the closing of the Acquisition. In connection with the Acquisition, the Company incorporated
a new wholly owned Delaware subsidiary, SciSparc US, to hold the new assets. The definitive agreement for the acquisition of the Brand
was entered into with Merhavit M.R.M Holding and Management Ltd (&#8220;M.R.M&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">At
the closing, the Company paid a base cash payment of $4,540 and in 12 months following the closing agreed to pay an additional deferred
cash payment equal to a multiple of 3 times the amount by which the Brand&#8217;s EBITDA exceeds $1,120 during the 12-month period following
the closing of the Acquisition. The Company paid an additional $321 as purchase costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
addition, the Company issued to M.R.M $15,000 worth of warrants to purchase ordinary shares of the Company at an exercise price of $7.00
per share (with a cashless exercise mechanism) and with an exercise period of five years from the closing of the Acquisition (the &#8220;September
2022 Warrants&#8221;). The September 2022 Warrants will become exercisable upon the earlier of (i) an achievement of $100,000 of gross
sales by the Brand in the aggregate or (ii) if the price of our Ordinary Shares closes at $10.00 or above.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company reviewed the transaction and deemed it to be the purchase of assets for accounting purposes under generally accepted accounting
principles and not as a business combination. The Company reviewed the guidance under IFRS 3 for the transaction and determined that
the fair value of the gross assets acquired was concentrated in a single identifiable asset, a brand. Accordingly, the Company treated
the transaction as an asset acquisition. On the closing date of the Acquisition, the Company fully recognized the acquisition amount
total of $4,861 as an intangible asset, to be amortized over a period of 10 years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
table below summarizes the fair value of the intangible asset:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance at January
    1, 2022</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-221; font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Purchase
    date September 30, 2022</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,861</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Depreciation
    of intangible asset</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(144</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance at December
    31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,717</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Depreciation
    of intangible asset</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(243</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    at June 30, 2023</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,474</span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During
the year ended December 31, 2022, the Company recognized depreciation expenses in respect to intangible asset in the amount of $144.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
estimated fair values of the tangible and intangible assets in respect of the Acquisition of&#160;the Wellution&#8482; brand are provisional
and are based on information that was available as of the Acquisition date to estimate the fair value of these amounts. The Group&#8217;s
management believes the information provides a reasonable basis for estimating the fair values of these amounts but is waiting for additional
information necessary to finalize those fair values. Therefore, provisional measurements of fair value that appear are subject to change.
The Group expects to finalize the tangible and intangible assets valuation and complete the Acquisition accounting as soon as practicable
but no later than the measurement period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During
the six months ended June 30, 2023, and 2022, the Company recorded depreciation expenses with respect to intangible asset in the amount
of $243 and $ <span style="-sec-ix-hidden: hidden-fact-222">nil</span>, respectively.</span></p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 11:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>INTANGIBLE ASSET</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">On September 30, 2022, the Company announced
the closing of the acquisition of Wellution<sup>TM</sup>, a top seller Amazon.com Marketplace account (the &#8220;Brand&#8221;), American
food supplements and cosmetics brand and trademark (the &#8220;Acquisition&#8221;). In connection with the Acquisition, the Company incorporated
a new wholly owned Delaware subsidiary, SciSparc Nutraceuticals Inc., to hold the new assets. The definitive agreement for the acquisition
of the Brand was entered into with Merhavit M.R.M Holding and Management Ltd (&#8220;M.R.M&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">At the closing, the Company paid a
base cash payment of $4,540 and in 12 months following the closing agreed to pay an additional deferred cash payment equal to a multiple
of 3 times the amount by which the Brand&#8217;s EBITDA exceeds $1,120 during the 12-month period following the closing of the Acquisition.
The Company paid an additional $321 as purchase costs.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In addition, the Company issued to
M.R.M $15,000 worth of warrants to purchase ordinary shares of the Company at an exercise price of $7.00 per share (with a cashless exercise
mechanism) and with an exercise period of five years from the closing of the Acquisition (the &#8220;September 2022 Warrants&#8221;).
The September 2022 Warrants will become exercisable upon the earlier of (i) an achievement of $100 million of gross sales by the Brand
in the aggregate or (ii) if the price of our Ordinary Shares closes at $10.00 or above.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company reviewed the transaction
and deemed it to be the purchase of assets for accounting purposes under generally accepted accounting principles and not as a business
combination. The Company reviewed the guidance under IFRS 3 for the transaction and determined that the fair value of the gross assets
acquired was concentrated in a single identifiable asset, a brand. Accordingly, the Company treated the transaction as an asset acquisition.
On the closing date of the acquisition, the Company fully recognized the acquisition amount total of $4,861 as an intangible asset, to
be amortized over a period of 10 years.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">The table below
summarizes the fair value of the intangible asset:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-263">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%">Purchase date September 30, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,861</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation of intangible asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(144</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance at December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,717</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">During the year ended December 31,
2022, the Company recognized depreciation expenses in respect to intangible asset in the amount of $144.&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The estimated fair values of the tangible
and intangible assets in respect of the acquisition of&#160;the Wellution&#8482; brand are provisional and are based on information that
was available as of the acquisition date to estimate the fair value of these amounts. The Group&#8217;s management believes the information
provides a reasonable basis for estimating the fair values of these amounts but is waiting for additional information necessary to finalize
those fair values. Therefore, provisional measurements of fair value that appear are subject to change. The Group expects to finalize
the tangible and intangible assets valuation and complete the acquisition accounting as soon as practicable but no later than the measurement
period.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS38_g118-128_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786325937616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Financial Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentInFinancialAssetsAbstract', window );"><strong>Investment in Financial Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory', window );">INVESTMENT IN FINANCIAL ASSETS</a></td>
<td class="text"><p style="text-align: justify; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5:- INVESTMENT IN FINANCIAL ASSETS</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
June 25, 2023, the Company entered into a Share Purchase Agreement (the &#8220;Agreement&#8221;) with AutoMax Motors Ltd. (&#8220;AutoMax&#8221;),
an Israeli company traded on the Tel Aviv Stock Exchange (&#8220;TASE&#8221;) and the leading parallel importer and distributor of vehicles
in Israel, pursuant to which, at the closing and upon the terms and conditions set forth in the Agreement, the Company will invest NIS
2,500,000 in cash, in exchange for ordinary shares, NIS 0.05 par value, of AutoMax (the &#8220;AutoMax Shares&#8221;) based on a price
per share of NIS 0.5. As of June 30, 2023, the listed share price of AutoMax on the TASE was NIS 0.41, and the Company has recorded a
loss in its statements of comprehensive loss of $133 on its investment. &#160;</span></p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8:-</b></span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVESTMENT IN FINANCIAL ASSETS</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On November 17, 2022, the Company invested
$1,500 in the initial public offering of Clearmind Medicine Inc. (&#8220;Clearmind&#8221;) and received 230,769 common shares of Clearmind,
resulting in the Company holding 9.33% of share capital of Clearmind. Clearmind is a psychedelic pharmaceutical biotech company focused
on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including
alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as
regulated medicines, foods or supplements. Shares of Clearmind are listed for trading on Nasdaq and the Canadian Securities Exchange under
the symbol &#8220;CMND&#8221; and the Frankfurt Stock Exchange under the symbol &#8220;CWY.&#8221; &#160; As of December 31, 2022, the
listed share price of Clearmind on Nasdaq was $3.16, and the Company has recorded a loss in its statements of comprehensive loss of $771
on its investment. &#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: Investments in equity instruments designated at fair value through other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 11A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_11A_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentInFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentInFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786325938448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract', window );"><strong>Transactions and Balances with Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">TRANSACTIONS AND BALANCES WITH RELATED PARTIES</a></td>
<td class="text"><p style="text-align: justify; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6:- TRANSACTIONS AND BALANCES WITH RELATED PARTIES</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Mr. Oz Adler, the Company&#8217;s Chief Executive Officer and Chief Financial Officer, is the chairman of the board of directors of&#160;Jeffs&#8217;&#160;Brands Ltd. (&#8220;Jeffs&#8217; Brands&#8221;) (see Note 11).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On March 7, 2022, the Company entered into the Cooperation Agreement with Clearmind Medicine Inc. (&#8220;Clearmind&#8221;), a company in which Dr. Adi Zuloff-Shani, the Company&#8217;s Chief Technologies Officer, Mr. Weiss, the Company&#8217;s President, and Mr. Adler, the Company&#8217;s Chief Executive Officer and Chief Financial Officer, serve as officers and directors.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During
the year ended December 31, 2022, the Company recognized expenses in respect of the Cooperation Agreement with Clearmind in the amount
of $208, and the balance owed to Clearmind as of December 31, 2022, was $55.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
November 17, 2022, the Company invested $1,500 thousand in Clearmind in connection with its initial public offering on the Nasdaq Capital
Market, in exchange for 230,769 common shares of Clearmind, representing 9.33% of the outstanding share capital of Clearmind.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Mr. Amitai Weiss, our chairman of the board of directors, is the chairman of the board of directors of&#160;AutoMax (see Note 5).</span></td></tr> </table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE&#160;24:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>TRANSACTIONS AND BALANCES WITH RELATED PARTIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Balances with related parties:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/>
management<br/>
personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/>
related<br/>
parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/>
management<br/>
personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/>
related<br/>
parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Current liabilities</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;70</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;55</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;447</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 48px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions with related parties (not including amounts described in Note 24c):</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">208</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-313">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-314">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Benefits to key management personnel (including directors):</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Short-term benefits</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">1,940</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">962</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">746</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Cost of share-based payment</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">779</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">43</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">91</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 48px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Oz Adler, our Chief Executive Officer and Chief Financial Officer, is the chairman of the board of directors of&#160;Jeffs&#8217;&#160;Brands.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt">&#160;</td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 7, 2022, we entered into the Cooperation Agreement with Clearmind, a company in which Dr. Adi Zuloff-Shani, our Chief Technologies Officer, Mr. Weiss, our President, and Mr. Adler, our Chief Executive Officer and Chief Financial Officer serve as officers and directors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2022, the Company recognized expenses in respect of the Cooperation Agreement with Clearmind in the amount of $208, and the balance owed to Clearmind as of December 31, 2022, was $55.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 17, 2022, we invested $1.5 million
in Clearmind in connection with its initial public offering on the Nasdaq Capital Market, in exchange for 230,769 common shares of Clearmind,
representing 9.33% of the outstanding share capital of Clearmind (see also note 8).</p></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786325732560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory', window );">FINANCIAL INSTRUMENTS</a></td>
<td class="text"><p style="text-align: justify; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7:- FINANCIAL INSTRUMENTS</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Calibri, Helvetica, Sans-Serif; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification
of financial assets and financial liabilities:</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
financial assets and financial liabilities in the consolidated statements of financial position are classified by groups of financial
instruments pursuant to IFRS 9, &#8220;<i>Financial Instruments</i>&#8221;:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Unaudited</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Audited</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Note</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD
    in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Financial assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 52%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,081</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,945</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,574</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Trade receivables</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">43</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-223; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">60</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Government authorities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">77</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">45</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other
    receivables</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">715</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">622</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">86</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Investments in financial
    assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">849</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-224; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">730</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,778</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,644</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,495</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Financial liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Credit from others</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-225; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-226; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">102</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Warrants liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,714</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,252</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,737</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Lease
    liability</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-227; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total financial and
    lease liabilities</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,714</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,297</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,866</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 14:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>FINANCIAL INSTRUMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Classification of financial assets and financial liabilities:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The financial assets and financial liabilities
in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9, &#8220;<i>Financial
Instruments</i>&#8221; (&#8220;IFRS 9&#8221;):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">Financial assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and restricted deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,634</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,920</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Government authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other receivables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,504</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Investments in financial assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">591</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-264">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total financial assets at amortized cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,316</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9,476</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">Financial liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Credit from others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,737</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">359</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total financial and lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,866</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">422</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 14:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>FINANCIAL INSTRUMENTS (CONT.)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px">b<span style="font-size: 10pt">.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Bridge Loan</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On January 15, 2020, the Company entered
into a bridge loan agreement (the &#8220;Bridge Loan&#8221;) with a third party, in which the third party lent to the Company $50 (the
&#8220;Bridge Loan Amount&#8221;). On April 17, 2020, the Bridge Loan Amount was fully repaid by the Company, including interest in the
amount of $2. Accordingly, the Bridge Loan was terminated with no further effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px">c<span style="font-size: 10pt">.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Line of Credit</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On September 8, 2020, the Company entered
into a certain credit agreement (the &#8220;Credit Facility&#8221;), with M.R.M. Merchavit Holdings and Management Ltd. (the &#8220;Lender&#8221;),
whereby the Lender agreed to extend a line of credit to the Company in the aggregate amount of $200, or the Credit Amount. According to
the terms of the Credit Facility, $100 of the Credit Amount (the &#8220;Loan Amount&#8221;), was immediately drawn on the date of the
Credit Facility, and the remaining $100 was available be drawn on an as-needed basis. The Loan Amount was due upon the earlier of one
year from September 8, 2020 or at such time that the Company raised $1,500. The Lender was entitled to a transaction and interest fee
of $5 (plus VAT) that was offset from the Credit Facility for the immediately drawn $100 and 5% from any additional withdrawal amount
from the Credit Facility. On November 24, 2020, the Loan Amount was fully repaid by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px">d<span style="font-size: 10pt">.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Dekel</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On March 19, 2020, the Company entered
into a securities purchase agreement with Dekel Pharmaceutical Ltd. (&#8220;Dekel&#8221;) pursuant to which Dekel agreed to invest in
the Company through a private placement transaction (the &#8220;Private Placement&#8221;). At the time of the Private Placement, Dekel
was considered as a related party to the Company; however, it is no longer a related party to the Company. In connection with the Private
Placement, Dekel received convertible promissory notes (the &#8220;Notes&#8221;), with an aggregate original principal amount of approximately
$350, at an aggregate purchase price of $315 to be paid in several tranches spread across a twelve-month period. In addition, the Company
issued a warrant to purchase up to 314,285 ordinary shares of the Company (the &#8220;Private Placement Warrant&#8221;) and 40,000 ordinary
shares. The initial tranche of the Private Placement was for a principal amount of $220 at a purchase price of $198. The Notes are unsecured,
have a maturity date of March 23, 2021, bear interest at a rate of 12% per annum, and may be converted, at the election of the holder,
into ordinary shares at an initial conversion price of $0.35 per ordinary share (the &#8220;Fixed Conversion Price&#8221;), subject to
adjustments. After the six-month anniversary of the issuance of the Notes, the conversion price shall be equal to the lower of the Fixed
Conversion Price or 70% of the lowest trading price of the ordinary shares as reported on Nasdaq or any exchange upon which the ordinary
shares of the Company are traded at such time, for the 20 prior trading days including the day upon which a notice of conversion is received
by the Company or its transfer agent. The Private Placement Warrant is exercisable at any time on or after the actual closing date and
on or prior to the close of business on the five-year anniversary of the date of issuance, at an initial exercise price of $0.35 per ordinary
share, subject to adjustment. On November 8, 2020, the Notes were terminated and the initial tranche was fully repaid by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"><i>General Overview of Valuation Approaches
used in the Valuation:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">Fair value is the price that would be
received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"><i>Economic methodology:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The warrants&#8217; fair value was calculated
using the Black&#8211;Scholes OPM, which takes into account the parameters as disclosed below for each period valuated, in which a valuation
was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;23,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">148</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122.01</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.87</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.38</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Underlying Share Price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.756</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.43</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants fair value ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.36</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify">e<span style="font-size: 10pt">.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial risk factors:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The Company&#8217;s activities expose
it to various financial risks such as market risks (foreign currency risk and interest risk), credit risk and liquidity risk. The Company&#8217;s
comprehensive risk management plan focuses on activities that reduce to a minimum any possible adverse effects on the Company&#8217;s
financial performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">Risk management is performed by management
in accordance with the policies approved by the Company&#8217;s board of directors (the &#8220;Board&#8221;). The Board establishes written
principles for the overall risk management activities as well as specific policies with respect to certain exposures to risks such as
exchange rate risk, credit risk and the investments of surplus funds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Market risks:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"><i>Foreign currency risk:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">The Company is exposed to exchange rate
risk resulting from the exposure to different currencies, mainly from transactions in NIS. Exchange rate risk arises from recognized liabilities
that are denominated in a foreign currency other than the functional currency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Credit risks:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">All cash and restricted deposits related
to the Company are held in two banks in Israel which are considered financially solid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Liquidity risk:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">The Company monitors the risk of a shortage
of funds on a regular basis and acts to raise funds to satisfy its liabilities. As of December 31, 2022, the Company expects to settle
all of its financial liabilities in less than one year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">The carrying amounts of cash and restricted
deposits, and all other financial assets and liabilities approximate their fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">Refer to Note 1c for more information.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35K<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35K&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786325971120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantTextBlock', window );">WARRANTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
8:- WARRANTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
June 1, 2022, the Company completed a private offering with an investor for gross proceeds of $10,210 (the &#8220;June 2022 Private Placement&#8221;),
providing for the issuance of an aggregate of 136,388 units and pre-funded units, as follows: (a) 12,884 units at a price of $74.88 per
unit, each consisting of (i) one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#8220;June
2022 Warrants&#8221;), and (b) 123,504 pre-funded units at a price of $73.294 per unit, each consisting of (i) one pre-funded warrant
to purchase one ordinary share and (ii) two June 2022 Warrants.</span></p>

<p style="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
June 2022 Warrants have an exercise price of $68.38 per ordinary share. The June 2022 Warrants were exercisable upon issuance and will
expire seven years from the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>General
Overview of Valuation Approaches used in the Valuation:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Fair
value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants
at the measurement date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Economic
methodology:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
June 2022 Warrants&#8217; fair value was calculated using the Black&#8211;Scholes option pricing model, which takes into account the
parameters as disclosed below for each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting
date with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,<br/>
    2022</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30,<br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend
    yield (%)</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected
    volatility (%)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">72</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">72</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free
    interest rate (%)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.97</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.97</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Underlying share
    price ($)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19.656</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14.274</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercise price ($)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">68.38</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">68.38</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Warrants fair value
    ($)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,396</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,373</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
June 2022 Warrants are classified as current warrant liability in the Company&#8217;s balance sheet, as they are exercisable at any given
time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During
the six months ended June 30, 2023, and 2022, the Company recorded finance income from the change in fair value of the June 2022 Warrants
in the amount of $1,023 and $<span style="-sec-ix-hidden: hidden-fact-228">nil</span>, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786325913232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity [Absract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
9:- EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Reverse
Share Splits</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
August 18, 2023, the Company convened a general meeting of its shareholders, whereby the shareholders approved, inter alia, a reverse
split of the Company&#8217;s share capital up to a ratio of 30:1. Following the implementation of the Reverse Split, the Company&#8217;s
authorized share capital will not be adjusted under the Company&#8217;s Articles, which as of the date hereof consists of 75,000,000
Ordinary Shares, <span style="-sec-ix-hidden: hidden-fact-229">no</span> par value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
September 14, 2023, the Company&#8217;s Board resolved that the final ratio for the Reverse Split will be 26:1, which became effective
on September 28, 2023.&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition of share capital as of June 30, 2023, June 30, 2022, and December 31, 2022:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2023</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2022</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2022</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Authorized</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Issued
    and<br/> outstanding</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Authorized</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Issued
    and<br/> outstanding</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Authorized</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Issued
    and<br/> outstanding</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of shares</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 28%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Ordinary
    Shares of no par value each</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">75,000,000</span></td><td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">282,782</span></td><td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">75,000,000</span></td><td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">261,494</span></td><td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,714,286</span></td><td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">135,644</span></td><td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in share capital:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Issued
and outstanding share capital:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/> ordinary<br/> shares</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance
    at January 1, 2023</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">261,494</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of share capital &#8211; in respect of investment in affiliate (Note 6e)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,858</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares
    issued to consultants (Note 6e)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,134</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of share capital &#8211; in respect of shelf prospectus (Note 6e)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">296</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    at June 30, 2023</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">282,782</span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights attached to shares:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Voting
rights at shareholders meetings, right to dividends, rights upon liquidation of the Company and right to nominate the directors in the
Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital management in the
    Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s capital management objectives are to preserve the Company&#8217;s ability to ensure business continuity thereby creating
a return for the shareholders, investors and other interested parties. The Company is not under any minimal equity requirements nor is
it required to attain a certain level of capital return.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional issuance of
    ordinary shares:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
August 2, 2022, the Company issued a consultant 923 ordinary shares in respect of services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
November 1, 2022, the Company issued a consultant 1,423 ordinary shares in respect of services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
March 22, 2023, the Company issued 13,858 ordinary shares in respect of the stock purchase<span style="text-transform: uppercase"><b>&#160;</b></span>agreement
entered into by and among Jeffs&#8217; Brands and Jeffs&#8217; Brands Holdings Inc. (&#8220;NewCo&#8221;) (see also note 8a)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
May 31, 2023, the Company issued 7,134 ordinary shares to consultants in respect of services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2021 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
March 4, 2021, the Company completed a private offering with several accredited and institutional investors for gross proceeds of $8,150,
providing for the issuance of an aggregate of 44,331 units, as follows: (a) 35,242 units at a price of $183,82 per unit, consisting of
(i) one ordinary share of the Company, and (ii) a Series A Warrant to purchase an equal number of units purchased (the &#8220;2021 Series
A Warrants&#8221;) and a Series B Warrant (the &#8220;2021 Series B Warrants&#8221; and, collectively with the 2021 Series A Warrants,
the March 2021 Warrants) to purchase half the number of units, and (b) 9,089 pre-funded units at a price of $183.794 per unit, consisting
of (i) one pre-funded warrant to purchase one ordinary share and (ii) one 2021 Series A Warrant and one 2021 Series B Warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Series A Warrants have an exercise price of&#160;$183.82&#160;per ordinary share and the Series B Warrants have an exercise price of&#160;$275.60&#160;per
ordinary share). Both were exercisable upon issuance and will expire five years from the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
March 2021 Warrants are classified as issued warrants in the Company&#8217;s equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During
the year ended December 31, 2021, the Company issued 4,929 ordinary shares in respect of the exercise of 385 2021 Series A Warrants and
the exercise of 4,544 of pre-funded warrants.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During
the year ended December 31, 2022, the Company issued 3,846 ordinary shares in respect of the exercise of 3,846 pre-funded warrants. During
the six months ended June 30, 2023, there were no exercises of 2021 Series A Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 2022 Financing Round
    (see also note 8)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
June 1, 2022, the Company completed the June 2022 Private Placement with an investor for gross proceeds of $10,210, providing for the
issuance of an aggregate of 136,388 units and pre-funded units, as follows: (a) 12,884 units at a price of $74.88 per unit, each consisting
of (i) one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#8220;June 2022 Warrants&#8221;),
and (b) 123,504 pre-funded units at a price of $73.294 per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary
share and (ii) two June 2022 Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
June 2022 Warrants have an exercise price of&#160;$68.38&#160;per ordinary share. The June 2022 Warrants were exercisable upon issuance
and will expire seven years from the date of issuance.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
June 2022 Warrants are classified as current warrant liability in the Company&#8217;s balance sheet, as they are exercisable at any given
time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During
the year ended December 31, 2022, the Company issued 123,504 ordinary shares in respect of the exercise of 123,504 pre-funded warrants.
During the six months ended June 30, 2023, there were no exercises of June 2022 Warrants.</span></p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 18:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>EQUITY</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Composition of share capital:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and<br/>
outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and<br/>
outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 4pt">Ordinary shares</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">75,000,000</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">6,798,840</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">25,714,285</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">3,091,740</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"><i>Reverse Share Splits</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On September 17, 2020, the Company convened
a special general meeting of its shareholders, whereby the shareholders approved, inter alia, (i) an increase to the Company&#8217;s share
capital from 500,000,000 ordinary shares to 750,000,000 ordinary shares; and (ii) a reverse split of the Company&#8217;s share capital
up to a ratio of 20:1 (the &#8220;Reverse Split&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On October 16, 2020, the Company convened
a special general meeting of its shareholders, whereby the shareholders approved an increase to the Company&#8217;s share capital from
750,000,000 ordinary shares to 1,800,000,000 ordinary shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On October 1, 2020, the Company&#8217;s
Board resolved that the final ratio for the Reverse Split will be 20:1, which went effective on October 16, 2020.&#160;Concurrently with
the Reverse Split, a change to the ratio of its ADSs to its ordinary shares was effective pursuant to which each ADS representing 40 ordinary
shares changed to each ADS representing 140 ordinary shares. This resulted in a reverse split on the Company&#8217;s American Depositary
Receipt program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On March 2, 2021, the Company convened
a special general meeting of its shareholders, whereby the shareholders approved to eliminate the par value of the ordinary shares and
an increase to the Company&#8217;s share capital from 1,800,000,000 ordinary shares to 3,600,000,000 ordinary shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;On July 19, 2021, the Company&#8217;s
Board resolved that the final ratio for the Second Reverse Split will be 140:1, which went effective on August 9, 2021.&#160;Concurrently
with the Second Reverse Split, a change to the ratio of its ADSs to its Ordinary Shares was effective pursuant to which each ADS representing
140 ordinary shares changed to each ADS representing 1 ordinary share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">Consequently, all share numbers, share
prices, and exercise prices have been retroactively adjusted in these consolidated financial statements for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On September 15, 2022, the Company convened
an annual general meeting of its shareholders, whereby the shareholders approved to increase to the Company&#8217;s share capital to 75,000,000
ordinary shares with no par value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Changes in share capital:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"><i>Issued and outstanding share capital:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of<br/> ordinary</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">shares</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,091,740</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of share capital &#8211; June 2022 Financing Round (Note 18h)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">335,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Exercise of pre-funded warrants (Note 18g)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise of pre-funded warrants (Note 18h)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,211,100</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Share issued to a consultant (Note 18f)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">61,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,798,840</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Rights attached to shares:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">Voting rights at the shareholders meeting,
right to dividends, rights upon liquidation of the Company and right to nominate the directors in the Company.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">d.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Capital management in the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The Company&#8217;s capital management
objectives are to preserve the Company&#8217;s ability to ensure business continuity thereby creating a return for the shareholders, investors
and other interested parties. The Company is not under any minimal equity requirements nor is it required to attain a certain level of
capital return.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">e.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financing Rounds: (Cont.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; font-size: 10pt">&#160;</td>
    <td style="width: 48px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2020 Financing Round</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">On April 1, 2020, the Company entered
into a definitive securities purchase agreement (the &#8220;April 2020 Purchase Agreement&#8221;) with institutional investors to purchase
of 4,166,168 units, each consisting of (i) one pre-funded warrant to purchase one ordinary share and (ii) one Series B warrant to purchase
one ordinary share, at a purchase price of $0.2999 per unit. The Series B warrants have an exercise price of $0.43 per ordinary share,
are exercisable upon issuance and expire five years from the date of issuance. The offering resulted in gross proceeds to the Company
of approximately $1,250. The closing of the sale of the securities took place on April 3, 2020. After the closing of the April 2020 Purchase
Agreement and until the Approval Date, all pre-funded warrants were exercised. In addition, 4,166,168 of the Series B warrants were exercised
pursuant to a cashless exercise mechanism as described in the April 2020 Purchase Agreement for no further consideration to the Company.
As of the Approval Date, all Series B warrants were exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">The Series B warrants are classified
as a financial liability that will be measured at fair value, through profit or loss, as of the issuance date and on any following financial
reporting date (accordingly, issue expenses related to the Series B warrants will be recorded through profit or loss). No consideration
will be left to attribute to the pre-funded warrants, which is an equity instrument.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">The valuation of the conversion component
of the Series B warrants was set at fair value, as required in IFRS 9, and in accordance with IFRS 13, and was categorized as Level 3
by the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">November 2020 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">On November 20, 2020, the Company completed
an offering for gross proceeds of $4,200 by way of the issuance of an aggregate of 835,447 units, each consisting of (i) one ordinary
share and (ii) two warrants to purchase one ordinary share each, at a purchase price of&#160;$5.02&#160;per unit (&#8220;November 2020
Warrants&#8221;). The November 2020 Warrants have an exercise price of&#160;$5.02&#160;per ordinary share, will be exercisable upon issuance
and will expire five years from the date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">The November 2020 Warrants are classified
as issued warrants in the Company&#8217;s equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">During the year ended December 31,
2021, the Company issued 1,004,494 ordinary shares in respect of the exercise of 1,004,494 November 2020 Warrants. During the year ended
December 31, 2022, there were no exercises of November 2020 Warrants.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">f.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Additional issuance of ordinary shares:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On July 21, 2021, the Company issued
a consultant 6,000 ordinary shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 2, 2022, the Company issued
a consultant 24,000 ordinary shares in respect of services rendered.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 1, 2022, the Company issued
a consultant 37,000 ordinary shares in respect of services rendered.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">g.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">March 2021 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On March 4, 2021, the Company completed
a private offering with several accredited and institutional investors for gross proceeds of $8,150, providing for the issuance of an
aggregate of 1,152,628 units, as follows: (a) 916,316 units at a price of $7.07 per unit, consisting of (i) one ordinary share of the
Company, and (ii) a Series A Warrant to purchase an equal number of units purchased (the &#8220;2021 Series A Warrants&#8221;) and a Series
B Warrant (the &#8220;2021 Series B Warrants&#8221; and, collectively with the 2021 Series A Warrants, the March 2021 Warrants) to purchase
half the number of units, and (b) 236,312 pre-funded units at a price of $7.069 per unit, consisting of (i) one pre-funded warrant to
purchase one ordinary share and (ii) one 2021 Series A Warrant and one 2021 Series B Warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The Series A Warrants have an exercise
price of&#160;$7.07&#160;per ordinary share and the Series B Warrants have an exercise price of&#160;$10.60&#160;per ordinary share).
Both were exercisable upon issuance and will expire five years from the date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The March 2021 Warrants are classified
as issued warrants in the Company&#8217;s equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">During the year ended December 31, 2021,
the Company issued 128,156 ordinary shares in respect of the exercise of 10,000 2021 Series A Warrants and the exercise of 118,156 of
pre-funded warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">During the year ended December 31, 2022,
the Company issued 100,000 ordinary shares in respect of the exercise of 100,000 pre-funded warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">h.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">June 2022 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On June 1, 2022, the Company completed
a private offering with an investor for gross proceeds of $10,210 (the &#8220;June 2022 Private Placement&#8221;), providing for the issuance
of an aggregate of 3,546,100 units and pre-funded units, as follows: (a) 335,000 units at a price of $2.88 per unit, each consisting of
(i) one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#8220;June 2022 Warrants&#8221;),
and (b) 3,211,100 pre-funded units at a price of $2.819 per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary
share and (ii) two June 2022 Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The June 2022 Warrants have an exercise
price of&#160;$2.63&#160;per ordinary share. The June 2022 Warrants were exercisable upon issuance and will expire seven years from the
date of issuance.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"><i>General Overview of Valuation Approaches
used in the Valuation:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">Fair value is the price that would be
received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"><i>Economic methodology:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The June 2022 Warrants&#8217; fair value
was calculated using the Black&#8211;Scholes option pricing model, which takes into account the parameters as disclosed below for each
period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 1,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.97</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.74</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Underlying share price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.756</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-265">2,87</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Exercise price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.63</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.63</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Warrants fair value ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,396</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,209</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The June 2022 Warrants are classified
as current warrant liability in the Company&#8217;s balance sheet, as they are exercisable at any given time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">During the year ended December 31, 2022,
the Company issued 3,211,100 ordinary shares in respect of the exercise of 3,211,100 pre-funded warrants.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786325849216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Information to the Items of Profit or Loss<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfAdditionalInformationTextBlockAbstract', window );"><strong>Additional Information to the Items of Profit or Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAdditionalInformationExplanatory', window );">ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
10:- ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    months ended<br/> June 30,</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended<br/> December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Unaudited</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Audited</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD
    in thousands</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; font-style: italic; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">a.
    Research and development expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Wages
    and related expenses</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">202</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">243</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">436</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Share-based
    payment</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">23</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">224</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">264</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Clinical
    studies</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">145</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">106</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">369</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Regulatory,
    professional and other expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">366</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">373</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">750</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Research
    and preclinical studies</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">410</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">703</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Chemistry
    and formulations</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-230; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">118</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">281</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">781</span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,474</span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,803</span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; font-style: italic; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">b.
    General and administrative expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Wages
    and related expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">217</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">245</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">437</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Share-based
    payment</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">431</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">633</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Professional
    and directors&#8217; fees</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,366</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,292</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,499</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Business
    development expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">38</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">161</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Office
    maintenance, rent and other expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">48</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">63</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">224</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Investor
    relations and business expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">310</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,193</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,486</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Wellution
    operating expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">366</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-231; font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">907</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Regulatory
    expenses</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">104</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">113</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">162</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,494</span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,339</span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,509</span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;21:- </b></span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year ended December&#160;31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%; font-style: italic">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-decoration: underline; width: 57%; font-style: italic; text-align: left">Research and development expenses:</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Wages and related expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">436</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">357</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">322</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">264</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Regulatory, professional and other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">934</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">119</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Research and preclinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">703</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">139</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Clinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">369</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">172</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-273">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left">Chemistry and formulations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">281</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">335</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-274">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,803</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,990</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">649</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-decoration: underline; font-style: italic; text-align: left">General and administrative expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Wages and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">437</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">256</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">237</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">633</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Professional and directors&#8217; fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,499</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,417</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,283</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Business development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">161</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Regulatory expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">162</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Office maintenance, rent and other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">224</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">135</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">182</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Wellution operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">907</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-275">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-276">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left">Investor relations and business expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,486</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">784</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt"><i><span style="text-decoration:underline">General and administrative expenses:</span></i></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,509</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,778</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,902</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-decoration: underline; font-style: italic; text-align: left">Other expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left">Impairment of company accounted for at equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-277">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-278">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">742</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left">Group&#8217;s share of losses of company accounted for at equity, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">109</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-279">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-280">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">109</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-281">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">742</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-decoration: underline; font-style: italic; text-align: left">Finance income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Net change in fair value of financial liabilities designated at fair value through profit or loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,832</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-282">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(630</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(7,832</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-283">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(630</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-style: italic; text-align: left">Finance expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance expenses related to warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,204</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">835</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Exchange rate differences, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Losses from remeasurement of investment in financial assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">770</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-284">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-285">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Finance expense in respect of leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left">Finance expenses from interest and commissions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,014</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">21</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">872</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAdditionalInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of additional information that is not presented elsewhere in the financial statements, but that is relevant to an understanding of them.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAdditionalInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfAdditionalInformationTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfAdditionalInformationTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786325927376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Events during the Reporting Period<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract', window );"><strong>Significant Events during the Reporting Period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock', window );">SIGNIFICANT EVENTS DURING THE REPORTING PERIOD</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
11:- SIGNIFICANT EVENTS DURING THE REPORTING PERIOD </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 48px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">a.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On February 23, 2023, the Company entered into an agreement with Jeffs&#8217; Brands and NewCo, a newly-formed wholly owned subsidiary of Jeffs&#8217; Brands, pursuant to which, at the closing and upon the terms and conditions set forth in the Agreement, NewCo Inc. acquired from the Company a number of shares of stock equal to approximately a 49% interest in the Company&#8217;s wholly owned subsidiary, SciSparc US which owns Wellution<sup>TM</sup>&#160;, for $2,500 in cash, and additional deferred cash payments of approximately $489,330 accounting for price adjustments related to inventory and working capital, which is to be paid in five equal monthly installments beginning in May 2023 (the &#8220;Price Adjustment&#8221;). As collateral for the payment in full of the Price Adjustment, SciSparc held back such number of shares of common stock of SciSparc US, equal to the outstanding due amount of the Price Adjustment (the &#8220;Holdback Shares&#8221;). Following the closing of the transaction on March 22, 2023, which included an equity conversion of financing amounts previously provided to SciSparc US. by the Company for working capital, and the release of the Holdback Shares upon the payment in full of the Price Adjustment the Company will hold approximately 51% of the share capital of SciSparc US.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Pursuant to the agreement, at the closing of the transaction, Jeffs&#8217; Brands and SciSparc US. entered into a consulting agreement, pursuant to which Jeffs&#8217; Brands will provide management services to SciSparc US for the WellutionTM brand for a monthly fee of $20 and Jeffs&#8217; Brands will receive a one-time signing bonus in the amount of $51. The consulting agreement is for an undefined period of time and may be terminated by either party with 30 days advance notice.&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In addition, in connection with the closing of the transaction, the Company and Jeffs&#8217; Brands, engaged in a mutual share exchange in the amount of $288,238 of ordinary shares from each of the Company and Jeffs&#8217; Brands. The number of shares in the share exchange was calculated based on the average closing price of the relevant company&#8217;s shares for 30 consecutive trading days ending on the third trading day immediately prior to the closing. Accordingly, the Company acquired 247,415 ordinary shares of Jeffs&#8217; Brands and Jeffs&#8217; Brands acquired 13,858 ordinary shares of the Company having an aggregate value of $288,238, which was adjusted from $300,000 according to the 4.99% ownership limit included in the definitive agreements.</span></p></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">b.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On May 2, 2023, Capital Point Ltd. (&#8220;Capital Point&#8221;) filed with the Tel Aviv-Jaffa District Court (the &#8220;Court&#8221;) a suit against the Company, case number 2050-05-23 (the &#8220;Suit&#8221;). The Suit names the Company as the sole defendant and includes allegations of breaches of contract by the Company under the Israeli Contracts Law, 1973, unjust enrichment under the Israeli Unjust Enrichment Law, 1979 and breaches of the Company under the Israeli Torts Ordinance, 1968.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Suit challenges a certain warrant issued by the Company to Capital Point (the &#8220;Capital Point Warrant&#8221;) to purchase $340,000 of ordinary shares of the Company (the &#8220;Warrant Shares&#8221;). The Capital Point Warrant was exercisable for 12 months from May 15, 2021, to May 15, 2022 and was issued in connection with the joint venture transaction, entered on May 15, 2020, by and between the Company, Capital Point and Evero Health Ltd., a majority owned subsidiary of the Company, as further described in the Company&#8217;s Report on Form 6-K, filed on May 19, 2020. The Suit claims that the Company unlawfully refused to accept the Capital Point Warrant exercise notice as of November 4, 2021 and accordingly the Company did not issue to Capital Point the Warrant Shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Suit claims damages in the amount of NIS 10,000,000 (approximately $2.75 million), which accounts for, as of the date of the filing of the Suit, the agreed compensation according to Section 2(d)(i) of the Capital Point Warrant, an injunction order for the Company to issue the Warrant Shares to Capital Point, return of any unlawful profits received by the Company and punitive damages.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">As of the Approval Date, the Company cannot predict the likelihood of success of the Suit.</span></p></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786325987440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Events after the Reporting Period<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Events after the Reporting Period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">EVENTS AFTER THE REPORTING PERIOD</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
12:- EVENTS AFTER THE REPORTING PERIOD </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 48px"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">a.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On August 1, 2023, the Company issued a consultant 807 ordinary shares in respect of services rendered.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">b.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; background-color: white">On August 14, 2023, the Company closed an underwritten public offering (the &#8220;Public Offering&#8221;) of 212,500 ordinary shares, at a purchase price of $5.20 per ordinary share and pre-funded warrants to purchase up to 37,500 ordinary shares at a purchase price of $5.174 per pre-funded warrant, for aggregate gross proceeds of approximately $1.3 million, pursuant to an underwriting agreement between the Company and Aegis Capital Corp (&#8220;Aegis&#8221;), the underwriter in the Public Offering, dated August 10, 2023. Pursuant to the terms of the underwriting agreement, the Company also granted the underwriter a 45-day option to purchase up to an additional 37,500 ordinary shares solely to cover over-allotments, if any, at the share price of the Public Offering less underwriting discounts and commissions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; background-color: white">The pre-funded warrants were exercisable immediately upon issuance and have an exercise price of $0.026 per share. Following the offering and </span><span style="font-family: Times New Roman, Times, Serif">as of the Approval Date, the Company issued 25,000 ordinary shares in respect of the exercise of 25,000 pre-funded warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On August 18, 2023, the Company convened a general meeting of its shareholders, whereby the shareholders approved, inter alia, a reverse split of the Company&#8217;s share capital up to a ratio of 30:1. Following the implementation of the Reverse Split, the Company&#8217;s authorized share capital will not be adjusted under the Company&#8217;s Articles, which as of the date hereof consists of 75,000,000 Ordinary Shares, <span style="-sec-ix-hidden: hidden-fact-232">no</span> par value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On September 14, 2023, the Company&#8217;s Board resolved that the final ratio for the Reverse Split will be 26:1, which became effective on September 28, 2023.&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
</td></tr>
<tr style="vertical-align: top"> <td style="font-size: 10pt; width: 72px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: justify; font-size: 10pt; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On October 11, 2023, the Company entered into a private placement transaction (the &#8220;Private Placement&#8221;), pursuant to a Securities Purchase Agreement (the &#8220;Agreement&#8221;) and a Registration Rights Agreement (the &#8220;Registration Rights Agreement&#8221;) with an institutional investor (the &#8220;Purchaser&#8221;) for aggregate gross proceeds of approximately $5 million (representing a 30% original issue discount to the aggregate purchase price of approximately $7.18 million), before deducting fees to the placement agent and other expenses payable by the Company in connection with the Private Placement. The Company intends to use the net proceeds from the Private Placement for general corporate purposes, including working capital. Aegis, acted as the exclusive placement agent for the Private Placement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
part of the Private Placement, the Company issued units (the &#8220;Units&#8221;), at a purchase price of $3.72 per Unit, consisting
of 1,930,108 pre-funded ordinary share purchase warrants (the &#8220;Pre-Funded Warrant&#8221;) to purchase up to 1,930,108 ordinary
shares of the Company, no par value per share (the &#8220;Ordinary Shares&#8221;), and an additional accompanying Pre-Funded Warrant
to purchase up to 1,930,108 Ordinary Shares. The Pre-Funded Warrants are immediately exercisable upon issuance and have a term of five
years from issuance at an exercise price of $0.001 per Ordinary Share.</span></p></td></tr> </table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE&#160;25:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>EVENTS AFTER THE REPORTING DATE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; background-color: white">On
February 23, 2023, the Company signed an agreement with Jeffs&#8217; Brands Holdings (&#8220;NewCo&#8221;) Inc. a recently newly-formed
wholly owned subsidiary of Jeffs&#8217; Brands and Jeffs&#8217; Brands, pursuant to which, at the closing and upon the terms and conditions
set forth in the Agreement, NewCo Inc. will acquire from the Company a number of shares of stock equal to approximately a 49% interest
in the Company&#8217;s wholly owned subsidiary, SciSparc Nutraceuticals Inc., which owns Wellution<sup>TM</sup>&#160;, for $2,500 in cash,
and additional deferred cash payments of approximately $489,330 accounting for price adjustments related to inventory and working capital,
which will be paid in five equal monthly installments beginning in May 2023 (the &#8220;Price Adjusment&#8221;). As collateral for the
payment in full of the Price Adjustment, SciSparc will hold back such number of shares of common stock of SciSparc Nutraceuticals, equal
to the outstanding due amount of the Price Adjustment (the &#8220;Holdback Shares&#8221;). Following the closing of the transaction on
March 22, 2023, which included an equity conversion of financing amounts previously provided to SciSparc Nutraceuticals Inc. by the Company
for working capital, and the release of the Holdback Shares upon the payment in full of the Price Adjustment the Company will hold approximately
51% of SciSparc Nutraceuticals Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; background-color: white">Pursuant
to the agreement, at the closing of the transaction, Jeffs&#8217; Brands and SciSparc Nutraceuticals Inc. entered into a consulting agreement,
pursuant to which Jeffs&#8217; Brands will provide management services to SciSparc Nutraceuticals Inc. for the Wellution<sup>TM</sup>
brand for a monthly fee of $20 and Jeffs&#8217; Brands will receive a one-time signing bonus in the amount of $51. The consulting agreement
is for an undefined period of time and may be terminated by either party with 30 days advance notice.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, in connection with the closing of the transaction, the Company and Jeffs&#8217; Brands, engaged in a mutual share exchange in
the amount of $288,238 of ordinary shares from each of us and Jeffs&#8217; Brands. The number of shares in the share exchange was calculated
based on the average closing price of the relevant company&#8217;s shares for 30 consecutive trading days ending on the third trading
day immediately prior to the closing. Accordingly, the Company acquired 247,415 ordinary shares of Jeffs&#8217; Brands and Jeffs&#8217;
Brands acquired 360,297 ordinary shares of us having an aggregate value of $288,238, which was adjusted from $300,000 according to the
4.99% ownership limit included in the definitive agreements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786303088544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract', window );"><strong>Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock', window );">SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 3:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">In the process of applying the significant
accounting policies, the Company has made the following judgments which have the most significant effect on the amounts recognized in
the financial statements:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Judgments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Discount rate for a lease liability:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">When a company in the Group is unable
to readily determine the discount rate implicit in a lease in order to measure the lease liability, such company uses an incremental borrowing
rate. That rate represents the rate of interest that the Company would have to pay to borrow over a similar term and with similar security,
the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment. When there are no
financing transactions that can serve as a basis, said company determines the incremental borrowing rate based on its credit risk, the
lease term and other economic variables deriving from the lease contract&#8217;s conditions and restrictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Effective control:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">The Company assesses whether it controls
a company in which it holds less than the majority of the voting rights by, among others, reference to the size of its holding of voting
rights relative to the size and dispersion of holdings of the other vote holders including voting patterns at previous shareholders&#8217;
meetings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Determining the fair value of share-based payment transactions:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">The fair value of share-based payment
transactions is determined upon initial recognition by an acceptable OPM. The inputs to the model include share price, exercise price
and assumptions regarding expected volatility, expected life of share option, risk-free interest and expected dividend yield.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Estimates and assumptions:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The preparation of the financial statements
requires management to make estimates and assumptions that have an effect on the application of the accounting policies and on the reported
amounts of assets, liabilities, revenues and expenses. Changes in accounting estimates are reported in the period of the change in estimate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The key assumptions made in the financial
statements concerning uncertainties at the reporting date and the critical estimates computed by the Company that may result in a material
adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Legal claims:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">In estimating the likelihood of outcome
of legal claims filed or threatened to commence against the Company and/or its Subsidiaries and/or affiliates, the Company relies on its
management&#8217;s best knowledge and estimations and where applicable, on the opinion of their legal counsels. These estimates are based,
among others, on management&#8217;s familiarity of and proximity to the circumstances, and also on the legal counsels&#8217; best professional
judgment, taking into account the stage of proceedings and legal precedents in respect of the different issues. Since the outcome of the
claims might be determined in courts and/or other quasi-judicial tribunals, the results could differ from these estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Lease extension and/or termination options:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">In evaluating whether it is reasonably
certain that a company of the Group will exercise an option to extend a lease or not exercise an option to terminate a lease, the Company
considers all relevant facts and circumstances that create an economic incentive for the Company to exercise the option to extend or not
exercise the option to terminate such as: significant amounts invested in leasehold improvements, the significance of the underlying asset
to the Company&#8217;s operation and whether it is a specialized asset, the company&#8217;s past experience with similar leases, etc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">After the commencement date, the Company
reassesses the term of the lease upon the occurrence of a significant event or a significant change in circumstances that affects whether
the company is reasonably certain to exercise an option or not exercise an option previously included in the determination of the lease
term, such as significant leasehold improvements that had not been anticipated on the lease commencement date, sublease of the underlying
asset for a period that exceeds the end of the previously determined lease period, etc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Fair value of financial instruments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">When the fair values of financial assets
and financial liabilities recorded in the statement of financial position cannot be derived from active markets, their fair value is determined
using a variety of valuation techniques that include the use of valuation models. The inputs to these models are taken from observable
markets where possible, but where this is not feasible, estimation is required in establishing fair values. The models are tested for
validity by calibrating to prices from any observable current market transactions in the same instrument when available.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting judgments estimates and assumptions used in the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786307504960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CashLineItems', window );"><strong>Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory', window );">CASH</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4:-</b></span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CASH</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash for immediate withdrawal - in USD</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,443</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,590</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash for immediate withdrawal - in NIS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">131</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">285</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,574</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,875</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CashLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CashLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786305444944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InventoryAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInventoriesExplanatory', window );">INVENTORY</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5:-</b></span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVENTORY</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Goods in transit</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">198</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-234">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">470</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-235">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">668</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-236">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS02_g36-39_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InventoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InventoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786307336112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Other Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory', window );">OTHER ACCOUNTS RECEIVABLE</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6:-</b></span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OTHER ACCOUNTS RECEIVABLE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Government authorities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">45</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">52</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,504</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Prepaid expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif">40</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">348</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">131</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,904</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other receivables. [Refer: Trade and other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786307518832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Associates and Investments in Investees<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesandInvestmentsinInvesteesLineItems', window );"><strong>Investment in Associates and Investments in Investees [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInvestmentPropertyExplanatory', window );">INVESTMENT IN ASSOCIATES AND INVESTMENTS IN INVESTEES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7:-</b></span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVESTMENT IN ASSOCIATES AND INVESTMENTS IN INVESTEES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Sale of Orimmune Bio Ltd.:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On June 22, 2016, the Company entered
into a share transfer agreement (the &#8220;Transfer Agreement&#8221;) with its then wholly owned subsidiary, Orimmune Bio Ltd. (&#8220;Orimmune&#8221;)
and Karma Link Ltd. (the &#8220;Buyer&#8221;), whereby the Company would sell its interests in Orimmune to the Buyer, and also use its
best efforts to transfer to and assign Orimmune its rights in the Anti-CD3 technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On December 13, 2018, an additional amendment
to the Transfer Agreement was signed (the &#8220;Second Amendment&#8221;) between the parties, under which it was agreed that Orimmune
will be assigned certain rights in intellectual property (&#8220;IP&#8221;) related to the licensed technology owned by the Company subject
to certain conditions precedent which were still not met as of December 31, 2022. As of the Approval Date, the conditions precedent have
not yet been completed and the assignment of the IP related to the licensed technology owned by us has not yet been transferred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.5in; text-align: left"><span style="font-size: 10pt">b.</span></td><td style="text-align: justify"><span style="font-size: 10pt">Coeruleus - Joint Venture Transaction</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; margin-top: 0pt; margin-bottom: 0pt">On May 15, 2020, the Company entered into a series of transactions (together, the &#8220;Joint Venture Transaction&#8221;), including a definitive share transfer agreement with Capital Point Ltd. (&#8220;Capital Point&#8221;), an Israeli holding company traded on the TASE, and Evero, pursuant to which Capital Point sold to Evero 5,952,469 ordinary shares, NIS 0.01 par value each, of Coeruleus Ltd. (the &#8220;Purchased Coeruleus Shares&#8221; and &#8220;Coeruleus,&#8221; respectively), an Israeli company and a subsidiary of Capital Point (owns approximately 46%), engaged in, among others, developing innovative medications based on the active generic substance flumazenil, including a sublingual spray to reduce the side effects of hypnotic sleep medication, and a sublingual spray to improve function and quality of life in patients with hepatic encephalopathy. The Purchased Coeruleus Shares represented approximately 35% of the issued and outstanding share capital of Coeruleus. In consideration thereof, Evero issued and sold to Capital Point 176,470 ordinary shares, NIS 1.00 par value each, constituting 15% of the issued and outstanding share capital of Evero, which was valued at $351, based on apportionment of the fair market value of the Company as reflected on Nasdaq as of May 15, 2020. Following the transaction, Capital Point held approximately 11% of Coeruleus&#8217; issued and outstanding share capital. The transaction costs of $51 were also capitalized as part of the investment in associate.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">As part of the Joint Venture Transaction,
the Company transferred to Evero its SCI-110 sleep technology, to be fully owned by Evero, under the terms and conditions of an asset
purchase agreement. In addition, the Company issued to Capital Point a warrant (the &#8220;Capital Point Warrant&#8221;) to purchase $340
of ordinary shares of the Company. Pursuant to the terms of the Capital Point Warrant, the exercise price per ordinary share is equal
to the closing price of the Company&#8217;s ordinary shares on the trading day on which the notice of exercise was actually received by
the Company and shall be paid by transferring to the Company a duly executed share transfer deed for 9,577 ordinary shares of Evero. The
Capital Point Warrant is exercisable for twelve months starting from May 15, 2021, until May 15, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 29, 2020, the shareholders
of Coeruleus approved an investment from its shareholders of approximately $30. The Company did not participate in this investment in
Coeruleus and therefore, as of the completion of such financing, the Company held less than 1% of the issued and outstanding shares of
Coeruleus. As of December 31, 2022, the fair value of the Company&#8217;s investment in Coeruleus is $nil.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">MitocareX - Joint Venture Transaction</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">On March 10, 2022, the Company entered into a Founders and Investment Agreement with Dr. Alon Silberman, or the MitoCareX Agreement. Pursuant to the MitoCareX Agreement, the Company invested an initial amount of $700, and agreed to invest over the next two years, an additional $1,000, subject to the achievement of certain pre-determined milestones as agreed upon in the MitoCareX Agreement, for up to a 50.01% ownership in MitoCareX Bio Ltd. (&#8220;MitoCareX&#8221;). MitoCareX is focused on the discovery and development of potential drugs for cancers and other life-threatening conditions. The MitoCareX Agreement also contains customary representations, warranties, covenants, and indemnification provisions. On March 31, 2022, the closing conditions were met, and the Company paid the initial investment amount of $700 to MitoCareX. As of December 31, 2022, the Company owns 31.48% of the outstanding shares of MitocareX.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">On February 17, 2023, MitoCareX achieved its first milestone pursuant to the MitoCare X Agreement. The first milestone refers to the establishment of MitoCareX&#8217;s cloud-based computing infrastructure that is expected to allow its future expansion into machine learning system. The system is harnessed to investigating mitochondrial carriers that are crucial for cell viability. As a result of MitoCareX meeting this milestone, the Company will invest an additional $400 in MitoCareX and increase its share ownership in MitoCareX Bio from 31.48% to 41.92%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">During the year ended December 31, 2022, the Company recorded equity losses from the investment in MitoCareX in the amount of $109.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The table below summarizes the fair value of the
investment in MitoCareX:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-237">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%">Investment date March 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">700</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(109</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance at December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">591</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInvestmentPropertyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 40<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=40&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS40_g74-79_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInvestmentPropertyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentinAssociatesandInvestmentsinInvesteesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentinAssociatesandInvestmentsinInvesteesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786302706480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">LEASES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 9:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>LEASES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">On September 1, 2020, the Company entered
into a one-year lease agreement (&#8220;the 2020 Lease&#8221;) with a third party for an area of approximately 100 square meters for the
Company&#8217;s offices in the district of Tel Aviv, Israel. The yearly lease fee was set at approximately $44, linked to the NIS. The
lease expired on August 31, 2021. The Company did not exercise its option to extend the lease until August 31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">On July 1, 2021, the Company entered
into a two-year joint lease agreement (&#8220;the 2021 Lease&#8221;) with a third party and for a total area of approximately 240 square
meters, whereby the Company occupies approximately 120 square meters for the Company&#8217;s offices, in the district of Tel Aviv, Israel.
The Company and the third party have an option to extend for an additional three-year term. The yearly lease fee was set at approximately
$40, linked to the NIS.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786302706608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PropertyandEquipmentNetLineItems', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 10:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>PROPERTY AND EQUIPMENT, NET</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="11" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Assets owned and used by the Company</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Right-of-<br/> use assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Computers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Lab<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Office<br/> furniture<br/> and<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Leasehold<br/> office</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic">Cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">7</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-238">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">29</td><td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">78</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">114</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Purchases</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-239">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-240">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-241">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">78</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">122</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance at January&#160;1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-242">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-243">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-244">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">59</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">65</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Depreciated cost at December 31, 2022</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">8</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-245">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">30</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">19</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">57</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2021</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">23</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-246">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">55</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">New leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-247">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-248">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-249">-</div></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Purchases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-250">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-251">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Disposals</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23</td><td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-252">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(54</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-253">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">78</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">114</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance at January&#160;1, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-254">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Depreciation of leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-255">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-256">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-257">-</div></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-258">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-259">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Disposals</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23</td><td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-260">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(54</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-261">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Depreciated cost at December 31, 2021</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">6</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-262">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">28</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">58</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">92</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Depreciation expenses for the years
ended December 31, 2022, 2021 and 2020 amounted to $43, $32 and $7, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PropertyandEquipmentNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PropertyandEquipmentNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786305449760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade Payables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_TradePayablesAbstract', window );"><strong>Trade Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">TRADE PAYABLES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 12:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>TRADE PAYABLES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 78%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">901</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">758</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Open debts</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">298</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">441</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,199</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,199</span></td>
    <td>&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_TradePayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_TradePayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786326145888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentAbstract', window );"><strong>Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent', window );">OTHER ACCOUNTS PAYABLE</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 13:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>OTHER ACCOUNTS PAYABLE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Employees and payroll accruals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">102</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">45</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">71</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">193</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">154</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786325916432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EmployeeBenefitLiabilitiesLineItems', window );"><strong>Employee Benefit Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory', window );">EMPLOYEE BENEFIT LIABILITIES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 15:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>EMPLOYEE BENEFIT LIABILITIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">Employee benefits consist of short-term
benefits and post-employment benefits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify"><i>Post-employment benefits:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">According to the labor laws and the Israeli
Severance Pay Law, 1963 (the &#8220;Severance Pay Law&#8221;), the Company is required to pay compensation to an employee upon dismissal
or retirement or to make current contributions in defined contribution plans pursuant to Section 14 of the Severance Pay Law, as specified
below. The Company&#8217;s liability is accounted for as a post-employment benefit. The computation of the Company&#8217;s employee benefit
liability is made in accordance with a valid employment contract based on the employee&#8217;s salary and employment term which establish
the entitlement to receive the compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">The post-employment benefits are normally
financed by contributions classified as defined benefit plans or as defined contribution plans as detailed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify"><i>Defined contribution plans:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">Section 14 of the Severance Pay Law applies
to a substantial part of the compensation payments, pursuant to which the fixed contributions paid by the Company into pension funds and/or
policies of insurance companies release the Company from any additional liability to employees for whom said contributions were made.
These contributions and contributions for compensation represent defined contribution plans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Expenses in respect of defined contribution plans</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">115</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">98</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">52</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for employee benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS19_g2-7_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EmployeeBenefitLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EmployeeBenefitLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786302706480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_TaxesOnIncomeAbstract', window );"><strong>Taxes on Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">TAXES ON INCOME</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 16:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>TAXES ON INCOME</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Tax rates applicable to the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The Israeli statutory corporate tax rate
and real capital gains tax rate were 23% in 2022, 2021, and 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Tax assessments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The assessments of the Company are
deemed final through the 2016 tax year.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Carryforward tax losses and other temporary differences:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The Company has accumulated tax losses
since its inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">As of December 31, 2022, the Company&#8217;s
net carryforward tax losses are estimated to grow to approximately $58,000.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_TaxesOnIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_TaxesOnIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786307101408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Liabilities, Commitments, Claims and Liens<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract', window );"><strong>Contingent Liabilities Commitments Claims and Liens [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory', window );">CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE 17:-</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; font-size: 10pt; text-align: justify">&#160;</td>
    <td style="width: 48px; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">a.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">License Agreement with Dekel Pharmaceuticals Ltd.:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">In May 2015, the Company entered into
an exclusive, irrevocable, worldwide license agreement with Dekel for certain technology and one granted U.S. patent related to compositions
and methods for treating inflammatory disorders (the &#8220;Dekel License Agreement&#8221;). The Dekel License Agreement became effective
in August 2015.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">Pursuant to the Dekel License Agreement,
the Company is obligated to pay Dekel fees based on specific milestones and royalties upon commercialization. The milestone payments include:
(i) $25 upon the successful completion of preclinical trials (which milestone was met in November 2016; this milestone was paid in cash
in March 2017); (ii) $75 upon the successful completion of a Phase I/IIa trial; and (iii) $75 upon the earlier of generating net revenues
of at least $200 from the commercialization of the technology or the approval of the U.S. Food and Drug Administration or the European
Medicines Agency, of a drug based on the licensed assets. In each case, and subject to the Company&#8217;s discretion, the respective
milestone payments are payable in cash or equity based on a price per ordinary share of NIS 0.5. The royalty payments are 8% for commercialization
and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of any patents maturing from this application would
likely be 2029.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On July 14, 2019, an amendment to the
Dekel License Agreement was signed (the &#8220;Amendment&#8221;), which encompasses the Company and Dekel&#8217;s original intention to
exclude certain consumer packaged goods (meaning, inter alia, food, beverage, cosmetics, pet products and hemp based products, which are
sources of nutrients or other substances which may have a nutritional effect) from the scope of the licensed products and the field of
activity of the Company described in the Dekel License Agreement. The parties agreed to amend the Dekel License Agreement to reflect the
foregoing clarification, as well as certain additional less material matters as discussed in the Amendment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The Amendment also prescribes for a specific
development plan under the Dekel License Agreement requiring the Company to invest in the licensed technology (as defined under the License
Agreement) formulation development and maintenance a total annual investment to be capped at $350. The Amendment also included a non-compete
and non-solicitation obligation by Dekel and Dr. Ascher Shmulewitz, the Company&#8217;s former Executive Chairman of the Board and former
interim Chief Executive Officer, towards the Company&#8217;s field of activity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On November 13, 2019, an additional milestone
under the Dekel License Agreement, in the amount of $75, was reached upon the successful completion of a Phase IIa clinical trial. The
Company paid the milestone amount on April 13, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">License Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (&#8220;Yissum&#8221;):</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On July 29, 2018, the Company entered
into an exclusive, worldwide, sublicensable, royalty-bearing license with Yissum for a license to make commercial use of the licensed
technology, in order to develop, obtain regulatory approvals, manufacture, market, distribute or sell products, all within the field and
the territory only, as determined in the agreement (the &#8220;Yissum License Agreement&#8221;). According to the Yissum License Agreement,
the Company shall pay Yissum royalties at the rates of future net sales, subject to the royalty reductions as described in the Yissum
License Agreement. The Company is also obligated to pay sublicense fees out of the sublicense consideration. All right, title and interest
in and to the Yissum License Agreement shall vest solely in Yissum, and the Company shall hold and make use of the rights granted. All
rights in the development results shall be solely owned by the Company, except to the extent that an employee of Yissum, including the
researcher, is considered an inventor of a patentable invention arising from the development results, in which case such invention and
all patent applications and/or patents claiming such invention shall be owned jointly by the Company and Yissum, as appropriate, and Yissum&#8217;s
share in such joint patents shall be automatically included in the Yissum License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Agreement with Hannover Medical School:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On April 11, 2017, the Company entered
into an investigator-initiated study contract with Hannover Medical School (&#8220;MHH&#8221;) to conduct during 2018 a phase IIb clinical
trial titled &#8220;A Randomized, Double-Blind, Placebo controlled study to Evaluate the Safety, Tolerability and Efficacy of Up to Twice
Daily Oral SCI-110 in Treating Adults with Tourette Syndrome&#8221; in treating approximately 20 Tourette syndrome subjects aged 18 to
65. Upon the execution of the agreement the Company paid the first installment in the amount of $122 out of a total estimated amount of
approximately $776. Due to regulatory and strategic reasons, the Company decided to change the study design from investigator-initiated
to an industry sponsored trial. During October 2017, a discussion was carried out between the Company and MHH and the latter was informed
about this change and a termination letter stating the above was sent to MHH on November 19, 2017. MHH has acknowledged that part of the
first instalment that was paid by the Company, in accordance with the initial agreement, will be used to set-off amounts owed under a
new agreement or will be paid back to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">On August 13, 2018, the Company entered
into an agreement with MHH to conduct a clinical investigation and laboratory services for a randomized, double-blind, placebo-controlled
proof of concept study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating adults with Tourette syndrome,
which agreement was subsequently updated on December 2, 2021, in an estimated amount of $1,385.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-size: 10pt">d.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Agreement with Yale University:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 27, 2022, the Company entered into an agreement with Yale University to conduct a clinical investigation and laboratory services for a randomized, double-blind, placebo-controlled, cross over study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating adults with Tourette syndrome in treating approximately 10 Tourette syndrome subjects aged 18 to 65. The total estimated amount of the agreement is approximately $370.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify">e<span style="font-size: 10pt">.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 23, 2020, the Company submitted to the Tel Aviv-Jaffa District Court (the &#8220;Court&#8221;) a petition pursuant to the Israeli Insolvency and Economic Rehabilitation Law, 2018, to commence proceedings for the economic rehabilitation of the Company (the &#8220;Petition&#8221;). In the Petition submitted to the Court, the Company stated that it is insolvent (as determined by the cash flow test) and unable to pay its debts to the Company&#8217;s creditors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 6, 2020, L.I.A. Pure Capital Ltd. (&#8220;Pure Capital&#8221;) filed with the Court a demand, requesting an order to have the results of the Company&#8217;s annual general meeting held on August 4, 2020, declared invalid, mainly due to the Company&#8217;s reliance on discretionary voting of the depositary bank for the Company&#8217;s then outstanding ADSs. The Court asked for the Company and directors&#8217; response by no later than August 13, 2020, which was subsequently extended.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 11, 2020, Pure Capital proposed to deposit $1,500 with the Company&#8217;s temporary trustee nominated by the Court to cover and pay all of the Company&#8217;s debts, without derogating from any other creditor&#8217;s rights towards the Company (the &#8220;Pure Capital Proposal&#8221;). The Pure Capital Proposal was made subject to the replacement of the Company&#8217;s Board as of the date of the Pure Capital Proposal (the &#8220;Prior Board&#8221;) with Pure Capital&#8217;s designated nominees that were voted upon at the adjourned annual general meeting of the Company&#8217;s shareholders on August 4, 2020 (as discussed below). The Court&#160;issued an order on August 14, 2020 (the &#8220;Order&#8221;), approving the Pure Capital Proposal and settlement agreement submitted to the Court by the parties thereto.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the terms of the Order and following the deposit by Pure Capital, the Prior Board was replaced with: Itschak Shrem (chairman), Amity Weiss (also appointed to act as the Company&#8217;s Chief Executive Officer), Moshe Revach, Lior Amit, Lior Vider and Liat Sidi. Following the issuance of the Order, a related case that was filed by Pure Capital with the Court was withdrawn as well.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 15, 2020, Mr. Lior Amit tendered his resignation from the Board and on March 13, 2022, Mr. Moshe Revach tendered his resignation from the Board and then later re-joined the Board in September 2022.</p></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786305591792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract', window );"><strong>Share-Based Payment Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">SHARE-BASED PAYMENT TRANSACTIONS</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE 19:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>SHARE-BASED PAYMENT TRANSACTIONS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The cost of share-based payment recognized in the financial statements:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The expenses due to share-based compensation
for the years ended December 31, 2022, 2021 and 2020, recognized in the financial statements in respect of the share option plan of the
Company is shown in the following table, detailed by departments:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">264</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">27</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">69</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">633</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">897</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">43</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">91</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The 2005 and 2015 ESOP of the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify">During 2005, the Board adopted the 2005
Employees Share Option Plan (the &#8220;2005 ESOP&#8221;). Ten years later the Board adopted a new plan - the 2015 Employees Share Option
Plan (the &#8220;2015 ESOP&#8221;). Under both the 2005 ESOP and 2015 ESOP, the Company may grant its employees and other service providers
options to purchase the Company&#8217;s ordinary shares (&#8220;Share Options&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify">On November 13, 2019, the Board reserved
an additional number of 6,788 Share Options for the purposes of the 2015 ESOP, bringing the amount of Share Options reserved under the
2015 ESOP to 15,714.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">On April 21, 2021, the Board reserved
an additional number of 338,929&#160;Share Options for the purposes of the 2015 ESOP, bringing the amount of Share Options reserved under
the 2015 ESOP to 357,143, out of which a total of 161,114 were still available for grant as of December 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On March 12, 2019, the Board approved and granted 1,171 ordinary shares under the 2015 ESOP to a new consultant of the Company. The exercise price was set at $420.00 per share Option.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"><i>The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.61</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expected life of share options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">The fair value of the Share Options
was set at $224 per Share Option.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On October 10, 2019 (the &#8220;2019 Grant Date&#8221;), the Board approved the grant of 72 Share Options under the 2015 ESOP to directors, officers and employees, some of which required the approval of the general meeting of the Company&#8217;s shareholders (the &#8220;2019 General Meeting&#8221;), which occurred on January 15, 2020. Following the resignation of some directors and employees on December 31, 2019, 15 Share Options (were not granted. Out of the 57 Share Options that were granted, 10 Share Options didn&#8217;t require the General Meeting&#8217;s approval. The date of commencement for all Share Options granted, the date on which the vesting started, was the 2019 Grant Date. The exercise price was set at $210.00 per Share Option.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">According to IFRS 2, &#8220;<i>Share-based
Payment</i>&#8221;, the fair value of the Share Options was estimated using the Black-Scholes OPM, in which the fair value estimation
for the Share Options which required the 2019 General Meeting&#8217;s approval was calculated based on parameters as of December 31, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"><i>Based on the above-mentioned, hereinafter
are the parameters used in order to estimate the fair value of the Share Options using the Black-Scholes OPM:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>
2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">October&#160;10,<br/>
2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Underlying ordinary share price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">78.12</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">154</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.67</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected life of Share Options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.78</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">The fair value of the Share Options
approved on October 10, 2019 by the Board, and on January 15, 2020 at the General Meeting (valuated as of December 31, 2019) was set at
$114.1 and $51.1, per Share Option, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On January 3, 2022 (the &#8220;2022 Grant Date&#8221;), the Board approved the grant of 178,140 Share Options under the 2015 ESOP to directors, officers, employees and consultants, some of which required the approval of the general meeting of the Company&#8217;s shareholders (the &#8220;2022 General Meeting&#8221;), which occurred on February 10, 2022. The date of commencement for all Share Options granted, the date on which the vesting started, was the 2022 Grant Date. The exercise price was set at $6.50 per Share Option.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"><i>The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">February&#160;2,<br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 3,<br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Underlying ordinary share price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.99</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6.73</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">134</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.46</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected life of Share Options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">The fair value of the Share Options
granted on January 3, 2022, was set at $6.09 per Share Option, and the fair value of the Share Options granted on February 10, 2022, was
set at $4.41 per Share Option.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 120px; font-size: 10pt">&#160;</td> <td style="width: 48px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company granted consultants Restricted Share Units (&#8220;RSUs&#8221;) in respect of services rendered. The RSU&#8217;s were granted at a discount rate of 25% to share price quoted on the date of each grant. The total fair value of the RSU&#8217;s granted to consultants was $70. </span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 120px; font-size: 10pt">&#160;</td> <td style="width: 48px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company issued consultants 61,000 ordinary shares in respect of services rendered. The ordinary were granted at a discount rate of 25% to share price quoted on the date of each grant. The total fair value of the RSU&#8217;s granted to consultants was $48. </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Movement during the year:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 120px; font-size: 10pt">&#160;</td> <td style="width: 48px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table lists the number of Share Options, the weighted average exercise prices of share options and changes in directors (and former directors), officers, employees and consultants share options during the years ended on December 31, 2022, and 2021:</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/>
Share<br/>
Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/>
average<br/>
exercise<br/>
price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">2022</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,431</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.95</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options granted during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">178,140</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the end of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">183,571</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.39</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options exercisable at the end of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">107,679</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.30</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">2021:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the beginning of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,643</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.41</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options granted during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-266">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-267">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options forfeited during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(212</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Share Options expired during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-268">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-269">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,431</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2.95</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Share Options exercisable at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,416</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3.28</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">No Share Options were granted during 2021.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 120px; font-size: 10pt">&#160;</td> <td style="width: 48px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average remaining contractual life of the Share Options outstanding was 5.03 years and 6.35 years as of December 31, 2022, and 2021, respectively.</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 120px; font-size: 10pt">&#160;</td> <td style="width: 48px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The range of exercise prices of Share Options outstanding at the end of the year was $6.5 - $844 (inclusive) as of December 31, 2022, and $210 - $955 (inclusive) as of December 31, 2021.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786307557616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues and Cost of Revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenues and Cost of Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory', window );">REVENUES AND COST OF REVENUES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;20:-</b></span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REVENUES AND COST OF REVENUES</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Our revenues consist of revenue derived
from sales on Amazon. The following table discloses the breakdown of our revenues, cost of sales and gross profit for the periods set
forth below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,347</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-270">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cost of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">322</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-271">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Gross profit</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,025</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-272">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance income (cost). [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786307511328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share/Ads<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Loss Per Share/Ads [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">LOSS PER SHARE/ADS</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-size: 10pt"><b>NOTE 22:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>LOSS PER SHARE/ADS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Details of the number of shares and loss used in the computation of loss per share:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="22" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended December&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amounts used in the computation of basic and diluted&#160;loss</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/>
number of<br/>
shares (*)</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/>
number of<br/>
shares (*)</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/>
number of<br/>
shares (*)</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>In<br/>
thousands</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>USD</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>In</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>thousands</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>USD</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>In<br/>
thousands</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>USD</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Continuing operations:</i></b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic loss per share</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,575</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,592</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,049</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,789</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">258</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,482</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect of potential dilutive ordinary shares</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(468</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted loss per share</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,575</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,592</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,049</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,789</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">265</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,950</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The computation of diluted loss per share did not include the following convertible securities since their inclusion would decrease the loss per share (anti-dilutive effect):</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Share Options to employees, officers, directors and consultants; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Non-marketable warrants to investors.</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786307101408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Segments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Operating Segments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory', window );">OPERATING SEGMENTS</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-size: 10pt"><b>NOTE&#160;23:-</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>OPERATING SEGMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company applies the principles
of IFRS 8,&#160;&#8220;<i>Operating Segments</i>&#8221;<i>&#160;</i>(&#8220;IFRS 8&#8221;), regarding operating segments. The segment
reporting is based on internal management reports of the Company&#8217;s management, which are regularly reviewed by the chief operating
decision maker to make decisions about resources to be allocated and assess performance. According to the principles of IFRS 8, the Company&#8217;s
management determined that as of December 31, 2022, the Company has two reportable segments &#8211; (1) development of drugs based on
cannabinoid molecules to be approved by an official regulatory authority (the Company&#8217;s operation); and (2) online sales of a various
range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial
creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December&#160;31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Drug Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Online Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">External</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-286">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,347</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,347</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Inter-segment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-287">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-288">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-289">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-style: italic">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-290">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,347</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,347</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt">Segment loss (gain)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,405</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(118</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,287</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Company&#8217;s share of losses of company accounted for at equity, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance expense (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,818</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,592</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/>
Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/>
Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -9pt; padding-left: 9pt">External</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-291">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-292">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-293">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Inter-segment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-294">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-295">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-296">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-297">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-298">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-299">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,768</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-300">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,768</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Finance expense (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,789</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/>
Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/>
Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -9pt; padding-left: 9pt">External</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-301">&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-302">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-303">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Inter-segment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-304">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-305">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-306">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-307">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-308">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-309">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,293</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-310">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,293</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Finance expense (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">242</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,535</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December&#160;31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Drug<br/> Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Online<br/> Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Segment Assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,664</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">941</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,605</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,021</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">135</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,156</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/>
Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/>
Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Segment Assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,916</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-311">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,916</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,775</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-312">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,775</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS08_g20-24_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786325801424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Unaudited Interim Financial Information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Unaudited
Interim Financial Information</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s unaudited condensed consolidated financial statements have been prepared in accordance with International Accounting
Standard (&#8220;IAS&#8221;) 34, &#8220;Interim Financial Reporting&#8221;. The significant accounting policies adopted in the preparation
of the interim consolidated financial statements are consistent with those followed in the preparation of the 2022 Annual Consolidated
Financial Statements. Accordingly, these condensed consolidated financial statements should be read in conjunction with the 2022 Annual
Consolidated Financial Statements. The results for any interim period are not necessarily indicative of results for any future period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
unaudited condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the
opinion of the Company&#8217;s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments
that are necessary to present fairly the Company&#8217;s financial position and results of operations for the interim periods presented.
The results for the six month period ended June 30, 2023, are not necessarily indicative of the results for the year ending December&#160;31,
2023, or for any future period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of June 30, 2023, there have been no material changes in the Company&#8217;s significant accounting policies from those that were disclosed
in the 2022 Annual Consolidated Financial Statements.<b>&#160;</b></span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BasisOfPresentationOfFinancialStatements', window );">Basis of presentation of the financial statements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Basis of presentation of the financial statements:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">These financial statements have been
prepared in accordance with IFRS, as issued by the IASB.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s financial statements
have been prepared on a cost basis, unless otherwise indicated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has elected to present
the profit or loss items using the function of expense method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements are presented
in USD and all values are rounded to the nearest thousand (&#8217;000), except when otherwise indicated.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory', window );">The operating cycle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">The operating cycle:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The operating cycle of the Company
is one year.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements', window );">Consolidated financial statements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Consolidated financial statements:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The consolidated financial statements
comprise the financial statements of companies that are controlled by the Company (Subsidiaries). Control of a company is achieved when
the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those
returns through its power over the investee. Potential voting rights are considered when assessing whether an entity has control over
the other entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such
control ceases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements of the Company
and of the Subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform
accounting policies by all companies in the Group. Significant intra-Group balances and transactions and gains or losses resulting from
intra-Group transactions are eliminated in full in the consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Non-controlling interests in subsidiaries
represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in
equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive
income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they
result in a negative balance of non-controlling interests in the consolidated statement of financial position.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Functional currency and foreign currency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 72px"></td><td style="width: 48px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td><td style="text-align: justify">Functional currency and foreign currency:</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The functional currency of the Company, which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions is the U.S. Dollar (&#8220;USD&#8221; or &#8220;$&#8221;), since it&#8217;s the primary currency of the economic environment in which the Company operates. The consolidated financial statements are also presented in USD since the Company believes that preparing the consolidated financial statements in USD provides more relevant information to the users of the consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DescriptionOfAcquisitionOfASingleAssetCompany', window );">Acquisition of a single asset company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Acquisition of a single asset company:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Upon the acquisition
of a single asset company, the Group evaluates whether it is the acquisition of a business or of an asset. To be considered a business,
the acquisition must include, at a minimum, an input and a substantive process that together can significantly contribute to the creation
of outputs. The acquisition is accounted for as a business combination if the single asset company is a business. If it is not a business,
the acquisition is accounted for as the acquisition of assets and liabilities. In such an acquisition, the cost of the acquisition includes
transaction costs which are allocated to the identifiable acquired assets and liabilities proportionally based on their fair value on
the acquisition date. In such case, goodwill and deferred taxes in respect of the temporary differences existing as of the acquisition
date are not recognized.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit', window );">Restricted deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify; font-size: 10pt">&#160;</td> <td style="width: 48px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted deposits:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">A restricted deposit is cash invested
in a short-term deposit (between three months and one year) or in a long-term deposit (with a maturity of more than one year from the
date of investment). Restricted deposits are designated to secure the Company&#8217;s office facilities lease agreements and its credit
cards.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory', window );">Investment in joint arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 72px"></td><td style="width: 48px">g.</td><td style="text-align: justify">Investment in joint arrangements:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Joint arrangements
are arrangements in which the Company has joint control. Joint control is the contractually agreed sharing of control of an arrangement,
which exists only when decisions about the relevant activities require the unanimous consent of the parties sharing control.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 1.25in"></td><td style="width: 0.5in">1.</td><td style="text-align: justify">Joint ventures:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in">In joint ventures
the parties that have joint control of the arrangement have rights to the net assets of the arrangement. A joint venture is accounted
for at equity</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 1.25in"></td><td style="width: 0.5in">2.</td><td style="text-align: justify">Joint operations:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in">In joint operations
the parties that have joint control of the arrangement have rights to the assets and obligations for the liabilities relating to the arrangement.
The Company recognizes in relation to its interest its share of the assets, liabilities, revenues and expenses of the joint operation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in">The acquisition
of interests in a joint operation which represents a business, as defined in IFRS 3, is accounted for using the acquisition method, including
the measurement of the identifiable assets and liabilities at fair value, the recognition of deferred taxes arising from this measurement,
the accounting treatment of the related transaction costs and the recognition of goodwill or bargain purchase gains. This applies to the
acquisition of the initial interest and additional interests in a joint operation that represents a business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates', window );">Investments in associates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 72px"></td><td style="width: 48px">h.</td><td style="text-align: justify">Investments in associates:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Associates are companies in which the Group has significant
influence over the financial and operating policies without having control. The investment in an associate is accounted for using the
equity method.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock', window );">Investments accounted for using the equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 72px"></td><td style="width: 48px">i.</td><td style="text-align: justify">Investments accounted for using the equity method:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Group&#8217;s investments
in associates and joint ventures are accounted for using the equity method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Under the equity
method, the investment in the associate or in the joint venture is presented at cost with the addition of post-acquisition changes in
the Group&#8217;s share of net assets, including other comprehensive income of the associate or the joint venture. Gains and losses resulting
from transactions between the Group and the associate or the joint venture are eliminated to the extent of the interest in the associate
or in the joint venture. The cost of the investment includes transaction costs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Goodwill relating
to the acquisition of an associate or a joint venture is presented as part of the investment in the associate or the joint venture, measured
at cost and not systematically amortized. Goodwill is evaluated for impairment as part of the investment in the associate or in the joint
venture as a whole.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The financial statements
of the Company and of the associate or joint venture are prepared as of the same dates and periods. The accounting policies applied in
the financial statements of the associate or the joint venture are uniform and consistent with the policies applied in the financial statements
of the Group.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Upon the acquisition
of an associate or a joint venture achieved in stages when the former investment in the acquiree was accounted for pursuant to the provisions
of IFRS 9, the Group applies the principles of IFRS 3 regarding business combinations achieved in stages. Consequently, equity interests
in the acquiree that had been held by the Group prior to achieving significant influence or joint control are measured at fair value on
the acquisition date and are included in the acquisition consideration while recognizing a gain or loss resulting from the fair value
measurement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The equity method
is applied until the loss of significant influence in the associate or loss of joint control in the joint venture or classification as
investment held for sale.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">j.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Property and equipment, net:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Property and equipment are measured
at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment
grants and excluding day-to-day servicing expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>%</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Mainly %</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Lab equipment</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 9%">6-50</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">33</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Computers</td>
    <td>&#160;</td>
    <td style="text-align: center">33-50</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">33</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office furniture and equipment</td>
    <td>&#160;</td>
    <td style="text-align: center">20-33</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">25</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td>
    <td>&#160;</td>
    <td style="text-align: center">see below</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-233">-</div></td>
    <td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including the extension option held by a company and intended to be exercised)
and the expected life of the improvement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The useful life, depreciation method
and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting
estimate. Depreciation of an asset ceases at the earlier of: the date that the asset is classified as held for sale and the date that
the asset is derecognized.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">k.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Intangible assets:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Separately acquired intangible assets
are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination
are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized
development costs, are recognized in profit or loss when incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Intangible assets with a finite useful
life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired.
The amortization period and the amortization method for an intangible asset are reviewed at least at each year end.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory', window );">Impairment of non-financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">l.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Impairment of non-financial assets:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company evaluates the need to record
an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.
If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount. The
recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future cash
flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset that
does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses are
recognized in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory', window );">Financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">m.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Financial instruments:</span></td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial assets:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets are measured upon
initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except
for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company classifies and measures
debt instruments in the financial statements based on the following criteria:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Company&#8217;s business model for managing financial assets; and</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The contractual cash flow terms of the financial asset.</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">a)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Debt instruments are measured at amortized cost when:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">The Company&#8217;s business model
is to hold the financial assets in order to collect their contractual cash flows, and the contractual terms of the financial assets give
rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial
recognition, the instruments in this category are measured according to their terms at amortized cost using the effective interest rate
method, less any provision for impairment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">On the date of initial recognition,
the Company may irrevocably designate a debt instrument as measured at fair value through profit or loss if doing so eliminates or significantly
reduces a measurement or recognition inconsistency, such as when a related financial liability is also measured at fair value through
profit or loss.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">b)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Debt instruments are measured at fair value through profit or loss when:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">A financial asset which is a debt instrument
does not meet the criteria for measurement at amortized cost or at fair value through other comprehensive income. After initial recognition,
the financial asset is measured at fair value and gains or losses from fair value adjustments are recognized in profit or loss.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">c)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Equity instruments and other financial assets held for trading:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Investments in equity instruments do
not meet the above criteria and accordingly are measured at fair value through profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Other financial assets held for trading
such as derivatives, including embedded derivatives separated from the host contract, are measured at fair value through profit or loss
unless they are designated as effective hedging instruments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Dividends from investments in equity
instruments are recognized in profit or loss when the right to receive the dividends is established.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Derecognition of financial assets:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial asset is derecognized only
when:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The contractual rights to the cash flows from the financial asset have expired;</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Company has transferred substantially all the risks and rewards deriving from the contractual rights to receive cash flows from the financial asset or has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset; or</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Company has retained its contractual rights to receive cash flows from the financial asset but has assumed a contractual obligation to pay the cash flows in full without material delay to a third party.</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial liabilities:</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">a)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial liabilities measured at amortized cost:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Financial liabilities are initially
recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, the Company
measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair
value through profit or loss such as derivatives.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">b)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial liabilities measured at fair value through profit or loss:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">At initial recognition, the Company
measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, changes
in fair value are recognized in profit or loss.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Derecognition of financial liabilities:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial liability is derecognized
only when it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires. A financial
liability is extinguished when the debtor discharges the liability by paying in cash, other financial assets, goods or services, or is
legally released from the liability.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Offsetting financial instruments:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets and financial liabilities
are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off the
recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously.
The right of set-off must be legally enforceable not only during the ordinary course of business of the parties to the contract but also
in the event of bankruptcy or insolvency of one of the parties. In order for the right of set-off to be currently available, it must not
be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events that
will cause the right to expire.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Compound financial instruments:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Convertible debentures which contain
both an equity/derivative component and a liability component are separated into two components. This separation is performed by first
determining the liability component based on the fair value of an equivalent non-convertible liability. The value of the conversion component
is determined to be the residual amount. Directly attributable transaction costs are apportioned between the equity component and the
liability component based on the allocation of proceeds to the equity and liability components.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">7.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Issue of a unit of securities:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The issue of a unit of securities involves
the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following order: financial
derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for financial liabilities
that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual amount. Issue costs
are allocated to each component pro rata to the amounts determined for each component in the unit.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and development expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">n.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Research and development expenditures:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Research expenditures are recognized
in profit or loss when incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The conditions enabling capitalization
of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss when
incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory', window );">Finance income and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">o.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Finance income and expenses:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Finance income and expenses comprise
interest income on amounts invested and exchange rate gains and losses. Interest income is recognized as it accrues using the effective
interest method. Finance income and expenses derive also from changes in the fair value of financial liabilities measured at fair value
through profit or loss. Borrowing costs are recognized in profit or loss using the effective interest method.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">p.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Fair value measurement:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Fair value measurement is based on the assumption that the transaction will take place in the asset&#8217;s or the liability&#8217;s
principal market, or in the absence of a principal market, in the most advantageous market.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The fair value of an asset or a liability
is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants
act in their economic best interest.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value measurement of a non-financial
asset takes into account a market participant&#8217;s ability to generate economic benefits by using the asset in its highest and best
use or by selling it to another market participant that would use the asset in its highest and best use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company uses valuation techniques
that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant
observable inputs and minimizing the use of unobservable inputs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">All assets and liabilities measured
at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level
input that is significant to the entire fair value measurement:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">Level 1</span></td>
    <td style="width: 2%; text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 2</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Inputs other than quoted prices included within Level 1 that are observable directly or indirectly.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 3</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory', window );">Taxes on income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">q.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Taxes on income:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Current or deferred taxes are recognized
in profit or loss, except to the extent that they relate to items which are recognized in other comprehensive income or equity.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Current taxes:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A current tax liability is measured
using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required
in connection with the tax liability in respect of previous years.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Deferred taxes:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are computed in respect
of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are measured at the
tax rate that is expected to apply when the asset is realized, or the liability is settled, based on tax laws that have been enacted or
substantively enacted by the reporting date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred tax assets are reviewed at
each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and temporary
differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred tax asset
is recognized to the extent that their utilization is probable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes that would apply in the event
of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of the
investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution
of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends
does not involve an additional tax liability or since it is the Company&#8217;s policy not to initiate distribution of dividends from
a subsidiary that would trigger an additional tax liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes on income that relate to distributions
of an equity instrument and to transaction costs of an equity transaction are accounted for pursuant to IAS 12, &#8220;<i>Income Taxes</i>&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are offset if there
is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same
taxpayer and the same taxation authority.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share-based payment transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">r.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Share-based payment transactions:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s employees and other
service providers may receive remuneration in the form of share-based payments (&#8220;Equity-settled transactions&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Equity-settled transactions:</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable
option pricing model (&#8220;OPM&#8221;). As for service providers, the cost of the transactions is measured at the fair value of the
goods or services received as consideration for equity instruments granted.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
is recognized in profit or loss together with a corresponding increase in equity during the period in which the performance and/or service
conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award (the &#8220;Vesting Period&#8221;).
The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects
the extent to which the Vesting Period has expired and the Company&#8217;s best estimate of the number of equity instruments that will
ultimately vest.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">No expense is recognized for awards
that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective
of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If the Company modifies the conditions
on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value
of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If a grant of an equity instrument
is cancelled, it is accounted for as if it had vested on the cancellation date and any expense not yet recognized for the grant is recognized
immediately. However, if a new grant replaces the cancelled grant and is identified as a replacement grant on the grant date, the cancelled
and new grants are accounted for as a modification of the original grant, as described above.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Earnings (loss) per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">s.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Earnings (loss) per share:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Earnings (loss) per share are calculated
by dividing the income (loss) attributable to equity holders of the Company by the weighted number of ordinary shares outstanding during
the period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Basic loss per ordinary share includes
only ordinary shares that were outstanding during the period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Potential ordinary shares are included
in the computation of diluted loss per ordinary share when their conversion increases loss per ordinary share from continuing operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory', window );">Employee benefit liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt; text-align: justify">&#160;</td> <td style="width: 48px; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">t.</span></td> <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Employee benefit liabilities:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The Company has several employee-benefit
plans:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Short-term employee benefits:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">Short-term employee benefits are benefits
that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render
the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions
and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and a
reliable estimate of the amount can be made.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Post-employment benefits:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">The plans are normally financed by contributions
to insurance companies and classified as defined contribution plans or as defined benefit plans.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">The Company has defined contribution
plans to its employees according to the specific laws per country.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory', window );">Provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">u.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Provisions:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">A provision in accordance with IAS 37,
&#8220;<i>Provisions, Contingent Liabilities and Contingent Assets</i>&#8221;, is recognized when the Company has a present obligation
(legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required
to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects part or all of
the expense to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when
the reimbursement is virtually certain. The expense is recognized in the statement of profit or loss net of any reimbursement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">Following are the types of provisions
included in the financial statements:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"><i>Legal claims:</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">A provision for claims is recognized
when the Company has a present legal or constructive obligation as a result of a past event, it is more likely than not that an outflow
of resources embodying economic benefits will be required by the Company to settle the obligation and a reliable estimate can be made
of the amount of the obligation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">v.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Leases:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The Company elected to apply the provisions
of IFRS 16, &#8220;<i>Leases</i>&#8221; (&#8220;IFRS 16&#8221;) using the modified retrospective method (without restatement of comparative
data).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The accounting policy for leases applied
effective from January 1, 2019, is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify">The Company accounts for a contract as
a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Company as a lessee:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">For leases in which the Company is the
lessee, the Company recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases whose
term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Company has elected
to recognize lease payments as an expense in profit or loss on a straight-line basis over the lease term (see Note 9). In measuring the
lease liability, the Company has elected to apply the practical expedient in IFRS 16 and separates the lease components from the non-lease
components (such as management and maintenance services, etc.) included in a single contract.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">On the commencement date, the lease
liability includes all unpaid lease payments discounted at the interest rate implicit in the lease, if that rate can be readily determined,
or otherwise using the Company&#8217;s incremental borrowing rate. After the commencement date, the Company measures the lease liability
using the effective interest rate method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">On the commencement date, the right-of-use
asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and
initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful
life and the lease term.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">The Company tests for impairment of
the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36, &#8220;<i>Impairment of Assets</i>&#8221;.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Lease extension and termination options:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">A non-cancelable lease term includes
both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised, and
the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">In the event of any change in the expected
exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Company remeasures the lease
liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total change
is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized
in profit or loss.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Lease modifications:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">If a lease modification does not reduce
the scope of the lease and does not result in a separate lease, the Company remeasures the lease liability based on the modified lease
terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the
right-of-use asset.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify">If a lease modification reduces the
scope of the lease, the Company recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use
asset and the lease liability. The Company subsequently remeasures the carrying amount of the lease liability according to the revised
lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment to
the right-of-use asset.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements', window );">Amendment to IAS 1, &#8220;Presentation of Financial Statements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 72px"></td><td style="width: 48px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">w.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
to IAS 1, &#8220;Presentation of Financial Statements&#8221;:</span></td>
</tr></table><p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">In January 2020, the IASB issued
an amendment to IAS 1, &#8220;Presentation of Financial Statements&#8221; regarding the criteria for determining the classification of liabilities
as current or non-current (&#8220;the Original Amendment&#8221;). In October 2022, the IASB issued a subsequent amendment (&#8220;the Subsequent
Amendment&#8221;).</p><p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">According to the Subsequent Amendment:</p><p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">Only covenants with which an entity
must comply on or before the reporting date will affect a liability&#8217;s classification as current or non-current.</p><p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">An entity should provide disclosure
when a liability arising from a loan agreement is classified as non-current and the entity&#8217;s right to defer settlement is contingent on
compliance with future covenants within twelve months from the reporting date. This disclosure is required to include information about
the covenants and the related liabilities. The disclosures must include information about the nature of the future covenants and when
compliance is applicable, as well as the carrying amount of the related liabilities. The purpose of this information is to allow users
to understand the nature of the future covenants and to assess the risk that a liability classified as non-current could become repayable
within twelve months. Furthermore, if facts and circumstances indicate that an entity may have difficulty in complying with such covenants,
those facts and circumstances should be disclosed.</p><p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">According to the Original Amendment,
the conversion option of a liability affects the classification of the entire liability as current or non-current unless the conversion
component is an equity instrument.</p><p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">The Original Amendment and Subsequent
Amendment are both effective for annual periods beginning on or after January 1, 2024, and must be applied retrospectively. Early application
is permitted.</p><p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">The Company is evaluating the
effects of the Amendments on its financial statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors', window );">Amendment to IAS 8, &#8220;Accounting Policies, Changes to Accounting Estimates and Errors&#8221;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 72px"></td><td style="width: 48px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">x.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
to IAS 8, &#8220;Accounting Policies, Changes to Accounting Estimates and Errors&#8221;:</span></td>
</tr></table><p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in">In February 2021, the IASB issued an amendment to IAS 8,
&#8220;Accounting Policies, Changes to Accounting Estimates and Errors&#8221; (&#8220;the Amendment&#8221;), in which it introduces a new
definition of &#8220;accounting estimates&#8221;.</p><p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">Accounting estimates are defined as
&#8220;monetary amounts in financial statements that are subject to measurement uncertainty&#8221;. The Amendment clarifies the distinction
between changes in accounting estimates and changes in accounting policies and the correction of errors.</p><p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">The Amendment is to be applied prospectively
for annual reporting periods beginning on or after January 1, 2023 and is applicable to changes in accounting policies and changes in
accounting estimates that occur on or after the start of that period. Early application is permitted.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for finance income and costs. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for investments in associates. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for investment in associates and joint ventures. [Refer: Associates [member]; Joint ventures [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for taxes other than income tax. [Refer: Tax expense other than income tax expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_BasisOfPresentationOfFinancialStatements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy changes inrBasis of presentation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_BasisOfPresentationOfFinancialStatements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy changes in Consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for investments in associates. The description of the entity's material accounting policy information for investments accounted for using the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy changes in operating cycle Explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAcquisitionOfASingleAssetCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for acquisition of a single asset company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAcquisitionOfASingleAssetCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for amendment to IAS. The description of the entity's material accounting policy information for amendment to IAS 1, presentation of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for changes to accounting estimates and errors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786303215888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccountingPolicyAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory', window );">Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life</a></td>
<td class="text">Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>%</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Mainly %</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Lab equipment</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 9%">6-50</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">33</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Computers</td>
    <td>&#160;</td>
    <td style="text-align: center">33-50</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">33</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office furniture and equipment</td>
    <td>&#160;</td>
    <td style="text-align: center">20-33</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">25</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td>
    <td>&#160;</td>
    <td style="text-align: center">see below</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-233">-</div></td>
    <td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AccountingPolicyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AccountingPolicyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for useful life of the assets at annual rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786305585936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Associate (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Investment in Associate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory', window );">Schedule of Fair Value of the Investment</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The
table below summarizes the fair value of the investment in MitoCareX:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance at January
    1, 2022</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-220; font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Investment
    date March 31, 2022</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">700</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Equity
    losses from investment in MitoCareX</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(109</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance at December
    31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">591</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Investment date March
    31, 2023</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">400</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Equity
    losses from investment in MitoCareX</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(98</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    at June 30, 2023</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">893</span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the effect of the change of investment entity status on the financial statements. [Refer: Disclosure of investment entities [text block]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 9B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_9B&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786302706608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Asset (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract', window );"><strong>Intangible Asset [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock', window );">Schedule of Fair Value of the Intangible Asset</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The
table below summarizes the fair value of the intangible asset:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance at January
    1, 2022</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-221; font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Purchase
    date September 30, 2022</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,861</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Depreciation
    of intangible asset</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(144</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance at December
    31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,717</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Depreciation
    of intangible asset</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(243</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    at June 30, 2023</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,474</span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text">The table below
summarizes the fair value of the intangible asset:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-263">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%">Purchase date September 30, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,861</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation of intangible asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(144</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance at December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,717</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of fair value of the intangible asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786307660128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_TransactionsandBalanceswithRelatedPartiesTablesLineItems', window );"><strong>Transactions and Balances With Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory', window );">Schedule of Balances with Related Parties</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/>
management<br/>
personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/>
related<br/>
parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/>
management<br/>
personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/>
related<br/>
parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Current liabilities</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;70</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;55</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;447</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory', window );">Schedule of Transactions with Related Parties</a></td>
<td class="text"><span style="font-size: 10pt">Balances with related parties:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">208</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-313">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-314">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory', window );">Schedule of Benefits to Key Management Personnel</a></td>
<td class="text"><span style="font-size: 10pt">Benefits to key management personnel (including directors):</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Short-term benefits</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">1,940</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">962</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">746</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Cost of share-based payment</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">779</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">43</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">91</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about balance with relate parties explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about transactions with relate parties explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_TransactionsandBalanceswithRelatedPartiesTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_TransactionsandBalanceswithRelatedPartiesTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786325678512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory', window );">Schedule of Financial Assets and Financial Liabilities</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The
financial assets and financial liabilities in the consolidated statements of financial position are classified by groups of financial
instruments pursuant to IFRS 9, &#8220;<i>Financial Instruments</i>&#8221;:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Unaudited</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Audited</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Note</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD
    in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Financial assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 52%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,081</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,945</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,574</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Trade receivables</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">43</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-223; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">60</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Government authorities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">77</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">45</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other
    receivables</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">715</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">622</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">86</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Investments in financial
    assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">849</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-224; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">730</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,778</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,644</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,495</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Financial liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Credit from others</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-225; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-226; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">102</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Warrants liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,714</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,252</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,737</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Lease
    liability</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-227; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total financial and
    lease liabilities</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,714</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,297</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,866</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities', window );">Schedule of Financial Assets and Financial Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The financial assets and financial liabilities
in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9, &#8220;<i>Financial
Instruments</i>&#8221; (&#8220;IFRS 9&#8221;):<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">Financial assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and restricted deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,634</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,920</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Government authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other receivables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,504</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Investments in financial assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">591</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-264">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total financial assets at amortized cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,316</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9,476</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">Financial liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Credit from others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,737</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">359</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total financial and lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,866</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">422</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock', window );">Schedule of Warrants Fair Value Using Black&#8211;Scholes OPM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The warrants&#8217; fair value was calculated
using the Black&#8211;Scholes OPM, which takes into account the parameters as disclosed below for each period valuated, in which a valuation
was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;23,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">148</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122.01</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.87</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.38</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Underlying Share Price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.756</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.43</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants fair value ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.36</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of financial assets and financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786303909216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Schedule of Warrants&#8217; Fair Value</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The
June 2022 Warrants&#8217; fair value was calculated using the Black&#8211;Scholes option pricing model, which takes into account the
parameters as disclosed below for each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting
date with the following assumptions:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,<br/>
    2022</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30,<br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend
    yield (%)</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected
    volatility (%)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">72</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">72</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free
    interest rate (%)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.97</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.97</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Underlying share
    price ($)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19.656</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14.274</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercise price ($)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">68.38</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">68.38</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Warrants fair value
    ($)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,396</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,373</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786303292976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity [Absract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Schedule of Share Capital</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition of share capital as of June 30, 2023, June 30, 2022, and December 31, 2022:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2023</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2022</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2022</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Authorized</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Issued
    and<br/> outstanding</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Authorized</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Issued
    and<br/> outstanding</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Authorized</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Issued
    and<br/> outstanding</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of shares</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 28%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Ordinary
    Shares of no par value each</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">75,000,000</span></td><td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">282,782</span></td><td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">75,000,000</span></td><td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">261,494</span></td><td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,714,286</span></td><td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">135,644</span></td><td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><span style="font-size: 10pt">Composition of share capital:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and<br/>
outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and<br/>
outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 4pt">Ordinary shares</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">75,000,000</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">6,798,840</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">25,714,285</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">3,091,740</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfIssuedAndOutstandingShareCapital', window );">Schedule of Issued and Outstanding Share Capital</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif"><i>Issued
and outstanding share capital:</i></span><table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/> ordinary<br/> shares</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance
    at January 1, 2023</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">261,494</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of share capital &#8211; in respect of investment in affiliate (Note 6e)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,858</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares
    issued to consultants (Note 6e)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,134</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of share capital &#8211; in respect of shelf prospectus (Note 6e)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">296</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    at June 30, 2023</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">282,782</span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
<td class="text"><i>Issued and outstanding share capital:</i><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of<br/> ordinary</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">shares</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,091,740</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of share capital &#8211; June 2022 Financing Round (Note 18h)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">335,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Exercise of pre-funded warrants (Note 18g)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise of pre-funded warrants (Note 18h)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,211,100</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Share issued to a consultant (Note 18f)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">61,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,798,840</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory', window );">Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The June 2022 Warrants&#8217; fair value
was calculated using the Black&#8211;Scholes option pricing model, which takes into account the parameters as disclosed below for each
period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 1,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.97</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.74</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Underlying share price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.756</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-265">2,87</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Exercise price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.63</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.63</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Warrants fair value ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,396</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,209</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Share capital [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value of financial instruments. [Refer: Financial instruments, class [member]; At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfIssuedAndOutstandingShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed inforamtion about issued and outstanding share capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfIssuedAndOutstandingShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786306998272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Information to the Items of Profit or Loss (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdditionalInformationtotheItemsofProfitorLossTablesLineItems', window );"><strong>Additional Information to the Items of Profit or Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss', window );">Schedule of Additional Information to the Items of Profit or Loss</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    months ended<br/> June 30,</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended<br/> December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Unaudited</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Audited</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">USD
    in thousands</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; font-style: italic; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">a.
    Research and development expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Wages
    and related expenses</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">202</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">243</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">436</span></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Share-based
    payment</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">23</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">224</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">264</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Clinical
    studies</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">145</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">106</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">369</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Regulatory,
    professional and other expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">366</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">373</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">750</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Research
    and preclinical studies</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">410</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">703</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Chemistry
    and formulations</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-230; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">118</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">281</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">781</span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,474</span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,803</span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; font-style: italic; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">b.
    General and administrative expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Wages
    and related expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">217</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">245</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">437</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Share-based
    payment</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">431</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">633</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Professional
    and directors&#8217; fees</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,366</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,292</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,499</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Business
    development expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">38</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">161</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Office
    maintenance, rent and other expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">48</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">63</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">224</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Investor
    relations and business expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">310</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,193</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,486</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Wellution
    operating expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">366</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-231; font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">907</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Regulatory
    expenses</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">104</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">113</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">162</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,494</span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,339</span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,509</span></td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year ended December&#160;31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%; font-style: italic">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-decoration: underline; width: 57%; font-style: italic; text-align: left">Research and development expenses:</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Wages and related expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">436</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">357</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">322</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">264</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Regulatory, professional and other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">934</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">119</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Research and preclinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">703</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">139</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Clinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">369</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">172</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-273">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left">Chemistry and formulations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">281</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">335</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-274">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,803</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,990</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">649</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-decoration: underline; font-style: italic; text-align: left">General and administrative expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Wages and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">437</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">256</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">237</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">633</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Professional and directors&#8217; fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,499</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,417</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,283</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Business development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">161</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Regulatory expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">162</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Office maintenance, rent and other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">224</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">135</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">182</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Wellution operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">907</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-275">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-276">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left">Investor relations and business expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,486</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">784</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt"><i><span style="text-decoration:underline">General and administrative expenses:</span></i></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,509</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,778</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,902</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-decoration: underline; font-style: italic; text-align: left">Other expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left">Impairment of company accounted for at equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-277">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-278">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">742</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left">Group&#8217;s share of losses of company accounted for at equity, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">109</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-279">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-280">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">109</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-281">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">742</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-decoration: underline; font-style: italic; text-align: left">Finance income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Net change in fair value of financial liabilities designated at fair value through profit or loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,832</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-282">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(630</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(7,832</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-283">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(630</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-style: italic; text-align: left">Finance expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance expenses related to warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,204</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">835</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Exchange rate differences, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Losses from remeasurement of investment in financial assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">770</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-284">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-285">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Finance expense in respect of leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left">Finance expenses from interest and commissions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,014</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">21</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">872</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdditionalInformationtotheItemsofProfitorLossTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdditionalInformationtotheItemsofProfitorLossTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disclosure of information to the items of profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786307354560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CashTablesLineItems', window );"><strong>Disclosure of Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash for immediate withdrawal - in USD</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,443</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,590</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash for immediate withdrawal - in NIS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">131</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">285</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,574</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,875</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CashTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CashTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosue of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786307347328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InventoryAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInvestmentEntitiesExplanatory', window );">Schedule of Inventory</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Goods in transit</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">198</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-234">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">470</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-235">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">668</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-236">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInvestmentEntitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of investment entities. An investment entity is an entity that: (a) obtains funds from one or more investors for the purpose of providing those investor(s) with investment management services; (b) commits to its investor(s) that its business purpose is to invest funds solely for returns from capital appreciation, investment income, or both; and (c) measures and evaluates the performance of substantially all of its investments on a fair value basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Section Investment entity status<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS12_g9A-9B_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInvestmentEntitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InventoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InventoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786326034848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OtherAccountsReceivableTablesLineItems', window );"><strong>Disclosure of Other Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclourseOfAccountsReceivablesTableTextBlock', window );">Schedule of Other Accounts Receivable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Government authorities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">45</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">52</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,504</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Prepaid expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif">40</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">348</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">131</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,904</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclourseOfAccountsReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of accounts receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclourseOfAccountsReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OtherAccountsReceivableTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OtherAccountsReceivableTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786325635776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Associates and Investments in Investees (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTablesLineItems', window );"><strong>Investment in Associates and Investments in Investees [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfFairValueMeasurementOfAssetstable', window );">Schedule of Fair Value of the Investment</a></td>
<td class="text">The table below summarizes the fair value of the
investment in MitoCareX:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-237">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%">Investment date March 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">700</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(109</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance at December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">591</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfFairValueMeasurementOfAssetstable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule disclosing information related to the fair value measurement of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfFairValueMeasurementOfAssetstable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786325918368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PropertyandEquipmentNetTablesLineItems', window );"><strong>Discourse of Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="11" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Assets owned and used by the Company</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Right-of-<br/> use assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Computers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Lab<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Office<br/> furniture<br/> and<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Leasehold<br/> office</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic">Cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">7</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-238">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">29</td><td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">78</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">114</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Purchases</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-239">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-240">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-241">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">78</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">122</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance at January&#160;1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-242">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-243">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-244">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">59</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">65</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Depreciated cost at December 31, 2022</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">8</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-245">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">30</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">19</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">57</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2021</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">23</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-246">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">55</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">New leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-247">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-248">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-249">-</div></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Purchases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-250">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-251">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Disposals</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23</td><td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-252">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(54</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-253">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">78</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">114</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance at January&#160;1, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-254">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Depreciation of leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-255">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-256">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-257">-</div></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-258">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-259">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Disposals</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23</td><td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-260">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(54</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-261">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Depreciated cost at December 31, 2021</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">6</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-262">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">28</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">58</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">92</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PropertyandEquipmentNetTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PropertyandEquipmentNetTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786325964448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade Payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_TradePayablesTablesLineItems', window );"><strong>Disclosure of Trade Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfTradePayables', window );">Schedule of Trade Payables</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 78%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">901</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">758</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Open debts</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">298</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">441</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,199</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,199</span></td>
    <td>&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfTradePayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfTradePayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_TradePayablesTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_TradePayablesTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786307347328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentAbstract', window );"><strong>Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfOtherAccountsPayable', window );">Schedule of Other Accounts Payable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Employees and payroll accruals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">102</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">45</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">71</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">193</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">154</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of other accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786325918496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EmployeeBenefitLiabilitiesTablesLineItems', window );"><strong>Employee Benefit Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory', window );">Schedule of Defined Contribution Plans</a></td>
<td class="text">These contributions and contributions for compensation represent defined contribution plans.<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Expenses in respect of defined contribution plans</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">115</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">98</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">52</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about defined contribution plans explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EmployeeBenefitLiabilitiesTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EmployeeBenefitLiabilitiesTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786303194016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareBasedPaymentTransactionsTablesLineItems', window );"><strong>Share-based Payment Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfExpenseRecognizedExplanatoryTableTextBlock', window );">Schedule of Expenses Due to Share-Based Compensation</a></td>
<td class="text">The expenses due to share-based compensation
for the years ended December 31, 2022, 2021 and 2020, recognized in the financial statements in respect of the share option plan of the
Company is shown in the following table, detailed by departments:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">264</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">27</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">69</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">633</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">897</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">43</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">91</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DescriptionOfOptionPricingModelShareOptionGranted', window );">Schedule of Fair Value for Share Options Granted</a></td>
<td class="text"><i>The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:</i><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.61</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expected life of share options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td></tr>
  </table><i>Based on the above-mentioned, hereinafter
are the parameters used in order to estimate the fair value of the Share Options using the Black-Scholes OPM:</i><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>
2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">October&#160;10,<br/>
2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Underlying ordinary share price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">78.12</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">154</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.67</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected life of Share Options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.78</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td></tr>
  </table><i>The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:</i><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">February&#160;2,<br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 3,<br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Underlying ordinary share price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.99</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6.73</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">134</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.46</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected life of Share Options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock', window );">Schedule of Weighted Average Exercise Prices of Share Options</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table lists the number of Share Options, the weighted average exercise prices of share options and changes in directors (and former directors), officers, employees and consultants share options during the years ended on December 31, 2022, and 2021:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/>
Share<br/>
Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/>
average<br/>
exercise<br/>
price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">2022</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,431</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.95</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options granted during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">178,140</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the end of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">183,571</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.39</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options exercisable at the end of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">107,679</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.30</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">2021:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the beginning of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,643</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.41</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options granted during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-266">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-267">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options forfeited during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(212</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Share Options expired during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-268">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-269">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,431</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2.95</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Share Options exercisable at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,416</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3.28</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfOptionPricingModelShareOptionGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfOptionPricingModelShareOptionGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfExpenseRecognizedExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of expense recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfExpenseRecognizedExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of share options and weighted average exercise prices of share options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareBasedPaymentTransactionsTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareBasedPaymentTransactionsTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786306524432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues and Cost of Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenues and Cost of Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock', window );">Schedule of Revenues and Cost of Revenues</a></td>
<td class="text">Our revenues consist of revenue derived
from sales on Amazon. The following table discloses the breakdown of our revenues, cost of sales and gross profit for the periods set
forth below:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,347</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-270">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cost of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">322</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-271">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Gross profit</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,025</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-272">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786302712832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share/Ads (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_LossPerShareAdsTablesLineItems', window );"><strong>Disclosure of Loss Per Share Or Ads [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory', window );">Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share</a></td>
<td class="text"><span style="font-size: 10pt">Details of the number of shares and loss used in the computation of loss per share:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="22" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended December&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amounts used in the computation of basic and diluted&#160;loss</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/>
number of<br/>
shares (*)</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/>
number of<br/>
shares (*)</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/>
number of<br/>
shares (*)</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>In<br/>
thousands</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>USD</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>In</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>thousands</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>USD</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>In<br/>
thousands</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>USD</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Continuing operations:</i></b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic loss per share</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,575</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,592</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,049</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,789</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">258</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,482</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect of potential dilutive ordinary shares</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(468</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted loss per share</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,575</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,592</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,049</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,789</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">265</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,950</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about earning per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_LossPerShareAdsTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_LossPerShareAdsTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786325848624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OperatingSegmentsTablesLineItems', window );"><strong>Operating Segments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory', window );">Schedule of Operating Segments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December&#160;31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Drug Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Online Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">External</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-286">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,347</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,347</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Inter-segment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-287">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-288">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-289">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-style: italic">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-290">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,347</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,347</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt">Segment loss (gain)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,405</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(118</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,287</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Company&#8217;s share of losses of company accounted for at equity, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance expense (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,818</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,592</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/>
Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/>
Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -9pt; padding-left: 9pt">External</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-291">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-292">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-293">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Inter-segment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-294">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-295">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-296">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-297">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-298">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-299">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,768</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-300">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,768</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Finance expense (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,789</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/>
Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/>
Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -9pt; padding-left: 9pt">External</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-301">&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-302">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-303">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Inter-segment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-304">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-305">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-306">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-307">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-308">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-309">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,293</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-310">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,293</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Finance expense (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">242</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,535</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December&#160;31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Drug<br/> Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Online<br/> Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Segment Assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,664</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">941</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,605</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,021</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">135</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,156</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/>
Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/>
Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Segment Assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,916</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-311">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,916</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,775</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-312">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,775</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating segments. [Refer: Operating segments [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OperatingSegmentsTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OperatingSegmentsTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786304030608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2022</div></th>
<th class="th"><div>Sep. 15, 2022</div></th>
<th class="th"><div>Aug. 02, 2022</div></th>
<th class="th"><div>Jul. 21, 2021</div></th>
<th class="th"><div>Oct. 01, 2020</div></th>
<th class="th"><div>Mar. 27, 2017</div></th>
<th class="th"><div>Aug. 18, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_GeneralDetailsLineItems', window );"><strong>General [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares (in Shares)</a></td>
<td class="nump">37,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnNetMonetaryPosition', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Cash flows from operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,233)<span></span>
</td>
<td class="num">$ (2,188)<span></span>
</td>
<td class="num">$ (7,917)<span></span>
</td>
<td class="num">$ (5,061)<span></span>
</td>
<td class="num">$ (4,307)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_RetainedEarning', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ProceedsFromIssuanceIPO', window );">Initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnNetMonetaryPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) representing the difference resulting from the restatement of non-monetary assets, owners' equity and items in the statement of comprehensive income and the adjustment of index linked assets and liabilities in hyperinflationary reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 29<br> -IssueDate 2023-01-01<br> -Paragraph 9<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=29&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnNetMonetaryPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_GeneralDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_GeneralDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ProceedsFromIssuanceIPO">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ProceedsFromIssuanceIPO</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RetainedEarning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RetainedEarning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786325918368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccountingPolicyAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OperatingTerm', window );">Operating term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AccountingPolicyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AccountingPolicyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OperatingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OperatingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786303674640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Associate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 17, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 10, 2022</div></th>
<th class="th"><div>May 15, 2020</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociateDetailsLineItems', window );"><strong>Investment in Associate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestedInitialAmount', window );">Invested initial amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdditionalAgreedInvest', window );">Additional agreed invest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OutstandingSharesPercentage', window );">Outstanding shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.48%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Additional amount</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityLossesInvestment', window );">Equity losses investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociateDetailsLineItems', window );"><strong>Investment in Associate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership interest</a></td>
<td class="nump">31.48%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociateDetailsLineItems', window );"><strong>Investment in Associate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership interest</a></td>
<td class="nump">41.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXBioLtdMember', window );">MitoCareX Bio Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociateDetailsLineItems', window );"><strong>Investment in Associate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OwnershipAgreement', window );">Ownership agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember', window );">MitoCareX [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociateDetailsLineItems', window );"><strong>Investment in Associate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdditionalAgreedInvest', window );">Additional agreed invest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 489,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InitialInvestment', window );">Initial investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityLossesInvestment', window );">Equity losses investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalProvisionsOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional other provisions made. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalProvisionsOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdditionalAgreedInvest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional agreed invest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdditionalAgreedInvest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EquityLossesInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity losses investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EquityLossesInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InitialInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InitialInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestedInitialAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Invested initial amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestedInitialAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentinAssociateDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentinAssociateDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OutstandingSharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Outstanding shares percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OutstandingSharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OwnershipAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OwnershipAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXBioLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXBioLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786305538448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Associate (Details) - Schedule of Fair Value of the Investment - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentLineItems', window );"><strong>Investment in Associate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome', window );">Balance at January 1, 2022</a></td>
<td class="nump">$ 591<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentDate', window );">Investment</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityLossesFromInvestmentInMitoCareX', window );">Equity losses from investment in MitoCareX</a></td>
<td class="num">(98)<span></span>
</td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome', window );">Balance at December 31, 2022</a></td>
<td class="nump">$ 893<span></span>
</td>
<td class="nump">$ 591<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets that are measured at fair value through other comprehensive income. A financial asset shall be measured at fair value through other comprehensive income if both of the following conditions are met: (a) the financial asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets and (b) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. [Refer: At fair value [member]; Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_8_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EquityLossesFromInvestmentInMitoCareX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity losses from investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EquityLossesFromInvestmentInMitoCareX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in equity instruments that the entity has designated at fair value through other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786303866144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Asset (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract', window );"><strong>Intangible Asset [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CashPayment', window );">Cash payment</a></td>
<td class="nump">$ 4,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount', window );">Exceeds</a></td>
<td class="nump">1,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchaseCosts', window );">Purchase costs</a></td>
<td class="nump">321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsToPurchase', window );">Warrants to purchase</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExercisePrice1', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExercisePeriod', window );">Exercise period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AmountTotal', window );">Amount total</a></td>
<td class="nump">$ 4,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019', window );">Amortized over period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill', window );">Intangible asset</a></td>
<td class="nump">$ 243<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_pricePerShare', window );">Ordinary shares price closes (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount by which a cash-generating unit's (group of units') recoverable amount exceeds its carrying amount. [Refer: Carrying amount [member]; Cash-generating units [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 134<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_134_f_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 135<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_135_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining amortisation period of individual intangible assets that are material to the entity&#8217;s financial statements. [Refer: Depreciation and amortisation expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 122<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_122_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reversal of impairment loss recognised in other comprehensive income for intangible assets other than goodwill. [Refer: Reversal of impairment loss recognised in other comprehensive income; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reversal of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Reversal of impairment loss recognised in profit or loss; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_v&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AmountTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AmountTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExercisePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExercisePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchaseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchaseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_pricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_pricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786307314720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Asset (Details) - Schedule of Fair Value of the Intangible Asset - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract', window );"><strong>Schedule of Fair Value of the Intangible Asset [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Balance</a></td>
<td class="nump">$ 4,717<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchaseOfAssets', window );">Purchase date September 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation of intangible asset</a></td>
<td class="num">(243)<span></span>
</td>
<td class="num">(144)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Balance</a></td>
<td class="nump">$ 4,474<span></span>
</td>
<td class="nump">$ 4,717<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786304150528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Financial Assets (Details)<br> &#8362; / shares in Units, $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 23, 2023</div></th>
<th class="th">
<div>Nov. 17, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>ILS (&#8362;) </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinFinancialAssetsDetailsLineItems', window );"><strong>Investment in Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash | &#8362;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Comprehensive income loss | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentAmount', window );">Investment amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedButNotFullyPaid', window );">Received shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareCapitalPercentage', window );">Share capital percentage</a></td>
<td class="nump">51.00%<span></span>
</td>
<td class="nump">9.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SharePricePerShare', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ComprehensiveLoss', window );">Comprehensive loss | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 771<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinFinancialAssetsDetailsLineItems', window );"><strong>Investment in Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_AutoMaxSharesMember', window );">AutoMax Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinFinancialAssetsDetailsLineItems', window );"><strong>Investment in Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExerciseOfPricePerShare', window );">Exercise of price | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedButNotFullyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity, for which full payment has not been received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedButNotFullyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ComprehensiveLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Comprehensive loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ComprehensiveLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExerciseOfPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExerciseOfPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentinFinancialAssetsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentinFinancialAssetsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareCapitalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share capital percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareCapitalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SharePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SharePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_AutoMaxSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_AutoMaxSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786302811824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 17, 2022</div></th>
<th class="th"><div>Nov. 17, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract', window );"><strong>Transactions and Balances with Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CooperationAgreementWithClearmindAmount', window );">Cooperation agreement with clearmind amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BalanceOwedToClearmind', window );">Balance owed to clearmind</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestedAmount', window );">Invested amount</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExchangeCommonShares', window );">Exchange common shares (in Shares)</a></td>
<td class="nump">230,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ClearmindOutstandingShareCapitalPercentage', window );">Clearmind outstanding share capital percentage</a></td>
<td class="nump">9.33%<span></span>
</td>
<td class="nump">9.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestedAmountInClearmind', window );">Invested amount in clearmind</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExchangeCommonSharesOfClearmind', window );">Exchange common shares of clearmind (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_BalanceOwedToClearmind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of balance owed to clearmind.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_BalanceOwedToClearmind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ClearmindOutstandingShareCapitalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of clearmind outstanding share capital percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ClearmindOutstandingShareCapitalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CooperationAgreementWithClearmindAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cooperation Agreement with Clearmind amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CooperationAgreementWithClearmindAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExchangeCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of exchange common shares of clearmind.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExchangeCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExchangeCommonSharesOfClearmind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of exchange common shares of clearmind.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExchangeCommonSharesOfClearmind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of invested amount in clearmind.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestedAmountInClearmind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of invested amount in clearmind.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestedAmountInClearmind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786303322432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 08, 2020</div></th>
<th class="th"><div>Mar. 19, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 17, 2020</div></th>
<th class="th"><div>Jan. 15, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FinancialInstrumentsDetailsLineItems', window );"><strong>Financial Instruments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BridgeLoanAmount', window );">Bridge loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPayable', window );">Interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AggregateAmountOrCreditAmount', window );">Aggregate amount or credit amount</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CreditFacilityAmount', window );">Credit facility amount</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CreditFacilityAndRemainingAvailableDrawnAmount', window );">Credit facility and remaining available drawn amount</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_LoanAmountDueTerm', window );">Loan amount due term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_LoanAmountRaised', window );">Loan amount raised</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCompoundFinancialInstrumentsWithMultipleEmbeddedDerivativesExplanatory', window );">Description of Issuance of convertible debentures</a></td>
<td class="text">The Lender was entitled to a transaction and interest fee
of $5 (plus VAT) that was offset from the Credit Facility for the immediately drawn $100 and 5% from any additional withdrawal amount
from the Credit Facility. On November 24, 2020, the Loan Amount was fully repaid by the Company.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Cash paid for principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Issued of warrant (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314,285<span></span>
</td>
<td class="nump">123,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_MaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 23,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InitialConversionPrice', window );">Initial conversion price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ConversionPrice', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OrdinaryShareExercisePrice', window );">Ordinary share exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=sprcy_PrivatePlacementsMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FinancialInstrumentsDetailsLineItems', window );"><strong>Financial Instruments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Cash paid for principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchasePrice', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_ADSsMember', window );">ADSs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FinancialInstrumentsDetailsLineItems', window );"><strong>Financial Instruments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Issued of warrant (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCompoundFinancialInstrumentsWithMultipleEmbeddedDerivativesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of financial instruments with both a liability and an equity component that have multiple embedded derivatives whose values are interdependent (such as a callable convertible debt instrument). [Refer: Derivatives [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCompoundFinancialInstrumentsWithMultipleEmbeddedDerivativesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest recognised as a liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity, for which full payment has been received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAndFullyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prices specified in forward agreements to purchase financial assets for cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph B11D<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B11D_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateAmountOrCreditAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An aggregate amount or score is made up of several smaller amounts or scores added together. The rate of growth of GNP will depend upon the rate of growth of aggregate demand.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateAmountOrCreditAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_BridgeLoanAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-Term financing which is expected to be paid back relatively quickly, such as by a subsequent longer-term loan. Also called swing loan or bridge Loan financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_BridgeLoanAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CreditFacilityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A credit facility is a type of loan made in a business or corporate finance context. It allows the borrowing business to take out money over an extended period of time rather than reapplying for a loan each time it needs money.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CreditFacilityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CreditFacilityAndRemainingAvailableDrawnAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Credit Facility and remaining available drawn amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CreditFacilityAndRemainingAvailableDrawnAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FinancialInstrumentsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FinancialInstrumentsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InitialConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial conversion price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InitialConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_LoanAmountDueTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan Amount Due Term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_LoanAmountDueTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_LoanAmountRaised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_LoanAmountRaised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_MaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_MaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OrdinaryShareExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OrdinaryShareExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sprcy_PrivatePlacementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sprcy_PrivatePlacementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_ADSsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_ADSsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786303597504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - Schedule of Financial Assets and Financial Liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FinancialAssetsAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,081<span></span>
</td>
<td class="nump">$ 3,574<span></span>
</td>
<td class="nump">$ 12,945<span></span>
</td>
<td class="nump">$ 6,875<span></span>
</td>
<td class="nump">$ 1,946<span></span>
</td>
<td class="nump">$ 870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Trade receivables</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_GovernmentAuthorities', window );">Government authorities</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Other receivables</a></td>
<td class="nump">715<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="nump">622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Investments in financial assets</a></td>
<td class="nump">849<span></span>
</td>
<td class="nump">730<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtAmortisedCost', window );">Total financial assets at amortized cost</a></td>
<td class="nump">3,778<span></span>
</td>
<td class="nump">4,495<span></span>
</td>
<td class="nump">13,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FinancialLiabilitiesAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CreditFromOthers', window );">Credit from others</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsLiability', window );">Warrants liability</a></td>
<td class="nump">1,714<span></span>
</td>
<td class="nump">2,737<span></span>
</td>
<td class="nump">10,252<span></span>
</td>
<td class="nump">359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial and lease liabilities</a></td>
<td class="nump">$ 1,714<span></span>
</td>
<td class="nump">$ 2,866<span></span>
</td>
<td class="nump">$ 10,297<span></span>
</td>
<td class="nump">$ 422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35M<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35N<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35I<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtAmortisedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities at amortised cost. The amortised cost is the amount at which financial liabilities are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_8_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtAmortisedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount due from customers for goods and services sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CreditFromOthers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of credit of others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CreditFromOthers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_GovernmentAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_GovernmentAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786303118352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsDetailsLineItems', window );"><strong>Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_GrossProceed', window );">Gross proceeds</a></td>
<td class="nump">$ 10,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IssuanceOfAggregateShares', window );">Issuance of aggregate shares (in Shares)</a></td>
<td class="nump">3,546,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsDescription', window );">Warrants description</a></td>
<td class="text">(a) 12,884 units at a price of $74.88 per
unit, each consisting of (i) one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#8220;June
2022 Warrants&#8221;), and (b) 123,504 pre-funded units at a price of $73.294 per unit, each consisting of (i) one pre-funded warrant
to purchase one ordinary share and (ii) two June 2022 Warrants.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantExpiryPeriod', window );">Warrant expiry period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantReserve', window );">Warrant amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsDetailsLineItems', window );"><strong>Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExerciseOfPricePerShare', window );">Exercise of price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsDetailsLineItems', window );"><strong>Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IssuanceOfAggregateShares', window );">Issuance of aggregate shares (in Shares)</a></td>
<td class="nump">136,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PlanAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of defined benefit plan assets. Plan assets comprise assets held by a long-term employee benefit fund and qualifying insurance policies. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 57<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PlanAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WarrantReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WarrantReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExerciseOfPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExerciseOfPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_GrossProceed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_GrossProceed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuanceOfAggregateShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The issuance of aggregate shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuanceOfAggregateShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantExpiryPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant expiry period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantExpiryPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786303968848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details) - Schedule of Warrants&#8217; Fair Value - Warrants [member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsDetailsScheduleofWarrantsFairValueLineItems', window );"><strong>Warrants (Details) - Schedule of Warrants&#8217; Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend yield (%)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (%)</a></td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="nump">3.97%<span></span>
</td>
<td class="nump">3.97%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Underlying share price ($) (in Dollars per share)</a></td>
<td class="nump">$ 14.274<span></span>
</td>
<td class="nump">$ 19.656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price ($) (in Dollars per share)</a></td>
<td class="nump">$ 68.38<span></span>
</td>
<td class="nump">$ 68.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LossesOnChangeInFairValueOfDerivatives', window );">Warrants fair value ($) (in Dollars)</a></td>
<td class="nump">$ 1,373<span></span>
</td>
<td class="nump">$ 2,396<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The losses resulting from changes in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsDetailsScheduleofWarrantsFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsDetailsScheduleofWarrantsFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786296284256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 01, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 01, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 15, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 02, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 01, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 21, 2021 </div>
<div>shares</div>
</th>
<th class="th"><div>Mar. 04, 2021</div></th>
<th class="th">
<div>Mar. 02, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 01, 2020 </div>
<div>shares</div>
</th>
<th class="th"><div>Apr. 01, 2020</div></th>
<th class="th">
<div>Aug. 18, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 20, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 16, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 17, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 22, 2023 </div>
<div>shares</div>
</th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th">
<div>Mar. 19, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_StockIssuedDuringPeriodReverseStockSplits', window );">Reverse split ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_NoParValuePerShare', window );">Ordinary shares no par value (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,798,840<span></span>
</td>
<td class="nump">3,091,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DescriptionOfPrivateOffering', window );">Description of private offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company completed
a private offering with an investor for gross proceeds of $10,210 (the &#8220;June 2022 Private Placement&#8221;), providing for the issuance
of an aggregate of 3,546,100 units and pre-funded units, as follows: (a) 335,000 units at a price of $2.88 per unit, each consisting of
(i) one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#8220;June 2022 Warrants&#8221;),
and (b) 3,211,100 pre-funded units at a price of $2.819 per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary
share and (ii) two June 2022 Warrants.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company completed
a private offering with several accredited and institutional investors for gross proceeds of $8,150, providing for the issuance of an
aggregate of 1,152,628 units, as follows: (a) 916,316 units at a price of $7.07 per unit, consisting of (i) one ordinary share of the
Company, and (ii) a Series A Warrant to purchase an equal number of units purchased (the &#8220;2021 Series A Warrants&#8221;) and a Series
B Warrant (the &#8220;2021 Series B Warrants&#8221; and, collectively with the 2021 Series A Warrants, the March 2021 Warrants) to purchase
half the number of units, and (b) 236,312 pre-funded units at a price of $7.069 per unit, consisting of (i) one pre-funded warrant to
purchase one ordinary share and (ii) one 2021 Series A Warrant and one 2021 Series B Warrant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DateOfIssuance', window );">Date of issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsAndExercise', window );">Warrants and exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,504<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExerciseOfPrefundedWarrants', window );">Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,211,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DescriptionOfReverseShareSplit', window );">Description of reverse share split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company convened
a special general meeting of its shareholders, whereby the shareholders approved, inter alia, (i) an increase to the Company&#8217;s share
capital from 500,000,000 ordinary shares to 750,000,000 ordinary shares; and (ii) a reverse split of the Company&#8217;s share capital
up to a ratio of 20:1 (the &#8220;Reverse Split&#8221;).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchaseAgreementsDescription', window );">Purchase agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) one ordinary
share and (ii) two warrants to purchase one ordinary share each, at a purchase price of&#160;$5.02&#160;per unit (&#8220;November 2020
Warrants&#8221;). The November 2020 Warrants have an exercise price of&#160;$5.02&#160;per ordinary share, will be exercisable upon issuance
and will expire five years from the date of issuance.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_GrossProceeds', window );">Gross proceeds (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares', window );">Exercise warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,004,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IssuanceOfAggregateShares', window );">Issuance of aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,546,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsExercisePrice', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AgreementTypeAxis=sprcy_AprilTwoThousandTwentyPurchaseAgreementMember', window );">April 2020 Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchaseAgreementsDescription', window );">Purchase agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company entered
into a definitive securities purchase agreement (the &#8220;April 2020 Purchase Agreement&#8221;) with institutional investors to purchase
of 4,166,168 units, each consisting of (i) one pre-funded warrant to purchase one ordinary share and (ii) one Series B warrant to purchase
one ordinary share, at a purchase price of $0.2999 per unit. The Series B warrants have an exercise price of $0.43 per ordinary share,
are exercisable upon issuance and expire five years from the date of issuance. The offering resulted in gross proceeds to the Company
of approximately $1,250. The closing of the sale of the securities took place on April 3, 2020. After the closing of the April 2020 Purchase
Agreement and until the Approval Date, all pre-funded warrants were exercised. In addition, 4,166,168 of the Series B warrants were exercised
pursuant to a cashless exercise mechanism as described in the April 2020 Purchase Agreement for no further consideration to the Company.
As of the Approval Date, all Series B warrants were exercised.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=sprcy_March2021FinancingRoundMember', window );">March 2021 Financing Round [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DescriptionOfPrivateOffering', window );">Description of private offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company completed a private offering with several accredited and institutional investors for gross proceeds of $8,150,
providing for the issuance of an aggregate of 44,331 units, as follows: (a) 35,242 units at a price of $183,82 per unit, consisting of
(i) one ordinary share of the Company, and (ii) a Series A Warrant to purchase an equal number of units purchased (the &#8220;2021 Series
A Warrants&#8221;) and a Series B Warrant (the &#8220;2021 Series B Warrants&#8221; and, collectively with the 2021 Series A Warrants,
the March 2021 Warrants) to purchase half the number of units, and (b) 9,089 pre-funded units at a price of $183.794 per unit, consisting
of (i) one pre-funded warrant to purchase one ordinary share and (ii) one 2021 Series A Warrant and one 2021 Series B Warrant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsAndExercise', window );">Warrants and exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=sprcy_June2022FinancingRoundMember', window );">June 2022 Financing Round [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DescriptionOfPrivateOffering', window );">Description of private offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company completed the June 2022 Private Placement with an investor for gross proceeds of $10,210, providing for the
issuance of an aggregate of 136,388 units and pre-funded units, as follows: (a) 12,884 units at a price of $74.88 per unit, each consisting
of (i) one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#8220;June 2022 Warrants&#8221;),
and (b) 123,504 pre-funded units at a price of $73.294 per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary
share and (ii) two June 2022 Warrants.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=sprcy_November2020FinancingRoundMember', window );">November 2020 Financing Round [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">835,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfOrdinarySharesAxis=sprcy_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsAndExercise', window );">Warrants and exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfOrdinarySharesAxis=sprcy_June2022WarrantsMember', window );">June 2022 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 68.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DateOfIssuance', window );">Date of issuance</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfOrdinarySharesAxis=sprcy_ADSMember', window );">ADS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=ifrs-full_WarrantsMember', window );">Warrants [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,004,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=sprcy_PrefundedWarrantsMember', window );">Pre-funded warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,211,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000,000<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember', window );">Warrants [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExerciseOfPrefundedWarrants', window );">Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IssuanceOfShares', window );">Share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,134<span></span>
</td>
<td class="nump">13,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sprcy_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 183,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsAndExercise', window );">Warrants and exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sprcy_SeriesBWarrantsMember', window );">Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_WarrantReserveMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsAndExercise', window );">Warrants and exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,211,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The potential dilutive effect on the weighted average number of ordinary shares that relate to the assumed exercise of the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity, for which full payment has been received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAndFullyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DateOfIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DateOfIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfPrivateOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of private offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfPrivateOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfReverseShareSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfReverseShareSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExerciseOfPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of Pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExerciseOfPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_GrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_GrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuanceOfAggregateShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The issuance of aggregate shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuanceOfAggregateShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuanceOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuanceOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NoParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent  of having no par value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NoParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchaseAgreementsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchaseAgreementsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_StockIssuedDuringPeriodReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the number of stock issued during period reverse stock splits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_StockIssuedDuringPeriodReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsAndExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsAndExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AgreementTypeAxis=sprcy_AprilTwoThousandTwentyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AgreementTypeAxis=sprcy_AprilTwoThousandTwentyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=sprcy_March2021FinancingRoundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=sprcy_March2021FinancingRoundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=sprcy_June2022FinancingRoundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=sprcy_June2022FinancingRoundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=sprcy_November2020FinancingRoundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=sprcy_November2020FinancingRoundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfOrdinarySharesAxis=sprcy_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfOrdinarySharesAxis=sprcy_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfOrdinarySharesAxis=sprcy_June2022WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfOrdinarySharesAxis=sprcy_June2022WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfOrdinarySharesAxis=sprcy_ADSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfOrdinarySharesAxis=sprcy_ADSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=sprcy_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=sprcy_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=sprcy_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=sprcy_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=sprcy_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=sprcy_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_WarrantReserveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_WarrantReserveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786303932048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity (Details) - Schedule of Share Capital - Previously stated [member] - shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityDetailsScheduleofShareCapitalLineItems', window );"><strong>Equity (Details) - Schedule of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Ordinary shares, authorized</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">25,714,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Ordinary shares, issued and outstanding</a></td>
<td class="nump">282,782<span></span>
</td>
<td class="nump">261,494<span></span>
</td>
<td class="nump">135,644<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesAuthorised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesAuthorised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EquityDetailsScheduleofShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EquityDetailsScheduleofShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786325651072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - Schedule of Issued and Outstanding Share Capital<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract', window );"><strong>Schedule of Issued and Outstanding Share Capital [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_NumberOfSharesIssued1', window );">Balance at January 1, 2023</a></td>
<td class="nump">261,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate', window );">Issuance of share capital &#8211; in respect of investment in affiliate</a></td>
<td class="nump">13,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SharesIssuedToConsultants', window );">Shares issued to consultants</a></td>
<td class="nump">7,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus', window );">Issuance of share capital &#8211; in respect of shelf prospectus</a></td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_NumberOfSharesIssued1', window );">Balance at June 30, 2023</a></td>
<td class="nump">282,782<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of share capital &#8211; in respect of investment in affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of share capital &#8211; in respect of shelf prospectus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SharesIssuedToConsultants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued to consultants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SharesIssuedToConsultants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786303397328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems', window );"><strong>Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 781<span></span>
</td>
<td class="nump">$ 1,474<span></span>
</td>
<td class="nump">$ 2,803<span></span>
</td>
<td class="nump">$ 1,990<span></span>
</td>
<td class="nump">$ 649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">2,494<span></span>
</td>
<td class="nump">3,339<span></span>
</td>
<td class="nump">6,509<span></span>
</td>
<td class="nump">$ 3,778<span></span>
</td>
<td class="nump">$ 1,902<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_WagesAndRelatedExpensesMember', window );">Wages and related expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems', window );"><strong>Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">243<span></span>
</td>
<td class="nump">436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">245<span></span>
</td>
<td class="nump">437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ShareBasedPaymentMember', window );">Share-based payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems', window );"><strong>Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">431<span></span>
</td>
<td class="nump">633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ClinicalStudiesMember', window );">Clinical studies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems', window );"><strong>Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="nump">369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryAndOtherExpensesMember', window );">Regulatory, professional and other expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems', window );"><strong>Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">366<span></span>
</td>
<td class="nump">373<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ResearchAndPreclinicalStudiesMember', window );">Research and preclinical studies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems', window );"><strong>Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">410<span></span>
</td>
<td class="nump">703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ChemistryAndFormulationsMember', window );">Chemistry and formulations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems', window );"><strong>Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ProfessionalAndDirectorsFeesMember', window );">Professional and directors&#8217; fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems', window );"><strong>Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">1,366<span></span>
</td>
<td class="nump">1,292<span></span>
</td>
<td class="nump">2,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_BusinessDevelopmentExpensesMember', window );">Business development expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems', window );"><strong>Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_OfficeMaintenanceRentAndOtherExpensesMember', window );">Office maintenance, rent and other expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems', window );"><strong>Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_InvestorRelationsAndBusinessExpensesMember', window );">Investor relations and business expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems', window );"><strong>Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">310<span></span>
</td>
<td class="nump">1,193<span></span>
</td>
<td class="nump">1,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_WellutionOperatingExpensesMember', window );">Wellution operating expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems', window );"><strong>Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">366<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryExpensesMember', window );">Regulatory expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems', window );"><strong>Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
<td class="nump">$ 162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_WagesAndRelatedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_WagesAndRelatedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ShareBasedPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ShareBasedPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ClinicalStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ClinicalStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryAndOtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryAndOtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ResearchAndPreclinicalStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ResearchAndPreclinicalStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ChemistryAndFormulationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ChemistryAndFormulationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ProfessionalAndDirectorsFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ProfessionalAndDirectorsFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_BusinessDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_BusinessDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_OfficeMaintenanceRentAndOtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_OfficeMaintenanceRentAndOtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_InvestorRelationsAndBusinessExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_InvestorRelationsAndBusinessExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_WellutionOperatingExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_WellutionOperatingExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786303333008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Events during the Reporting Period (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 23, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Nov. 17, 2022</div></th>
<th class="th"><div>Mar. 10, 2022</div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>ILS (&#8362;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems', window );"><strong>Significant Events during the Reporting Period (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InterestPercentgae', window );">Interest percentage</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash | &#8362;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DeferredCashPayments', window );">Deferred cash payments</a></td>
<td class="nump">$ 489,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareCapitalPercentage', window );">Share capital percentage</a></td>
<td class="nump">51.00%<span></span>
</td>
<td class="nump">9.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FeeExpenses', window );">Fee expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BonusAmountReceived', window );">Bonus amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_MutualShareExchangeAmount', window );">Mutual share exchange amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 288,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OrdinarySharesAcquired', window );">Acquired ordinary shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247,415<span></span>
</td>
<td class="nump">247,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AggregateValue', window );">Aggregate value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 288,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 288,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdjustedAmountOfAggregateValue', window );">Adjusted amount of aggregate value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.01%<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsToPurchase', window );">Purchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ClaimsOnDamages', window );">Claims on damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,750<span></span>
</td>
<td class="nump">&#8362; 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_NewCoIncMember', window );">NewCo Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems', window );"><strong>Significant Events during the Reporting Period (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_JeffsBrandsMember', window );">Jeffs&#8217; Brands [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems', window );"><strong>Significant Events during the Reporting Period (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OrdinarySharesAcquired', window );">Acquired ordinary shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,858<span></span>
</td>
<td class="nump">13,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdjustedAmountOfAggregateValue', window );">Adjusted amount of aggregate value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=sprcy_CapitalPointWarrantMember', window );">Capital Point Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems', window );"><strong>Significant Events during the Reporting Period (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsToPurchase', window );">Purchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdjustedAmountOfAggregateValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The adjusted amount of aggregate value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdjustedAmountOfAggregateValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of ordinary shares of aggregate value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_BonusAmountReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bonus amount received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_BonusAmountReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ClaimsOnDamages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Claims on damages.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ClaimsOnDamages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DeferredCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred cash payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DeferredCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FeeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fee expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FeeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InterestPercentgae">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest percentgae.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InterestPercentgae</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_MutualShareExchangeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Mutual share exchange amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_MutualShareExchangeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OrdinarySharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares acquired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OrdinarySharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareCapitalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share capital percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareCapitalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_NewCoIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_NewCoIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_JeffsBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_JeffsBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=sprcy_CapitalPointWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=sprcy_CapitalPointWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786301815568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Events after the Reporting Period (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 11, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 14, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Mar. 22, 2023</div></th>
<th class="th">
<div>Nov. 01, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 15, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 02, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 10, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 21, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 01, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 18, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 23, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>ILS (&#8362;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EventsaftertheReportingPeriodDetailsLineItems', window );"><strong>Events after the Reporting Period (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DescriptionOfPublicOffering', window );">Description of public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company closed an underwritten public offering (the &#8220;Public Offering&#8221;) of 212,500 ordinary shares, at a purchase price of $5.20 per ordinary share and pre-funded warrants to purchase up to 37,500 ordinary shares at a purchase price of $5.174 per pre-funded warrant, for aggregate gross proceeds of approximately $1.3 million, pursuant to an underwriting agreement between the Company and Aegis Capital Corp (&#8220;Aegis&#8221;), the underwriter in the Public Offering, dated August 10, 2023. Pursuant to the terms of the underwriting agreement, the Company also granted the underwriter a 45-day option to purchase up to an additional 37,500 ordinary shares solely to cover over-allotments, if any, at the share price of the Public Offering less underwriting discounts and commissions.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExerciseOfWarrants', window );">Warrants and exercise | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 4,758,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,798,840<span></span>
</td>
<td class="nump">3,091,740<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExerciseOfPrefundedWarrants', window );">Exercise of pre-funded warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,211,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OrdinarySharesAcquired', window );">Purchase of ordinary share (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExercisePricePerShare', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.5<span></span>
</td>
<td class="nump">$ 24.5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash | &#8362;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8362; 2,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdditionalAgreedInvest', window );">Additional agreed invest | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_MonthlyFee', window );">Monthly fee | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BonusAmount', window );">Bonus amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapitalOrdinaryShares', window );">Ordinary shares value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288,238,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AggregateValue', window );">Aggregate value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 288,238,000<span></span>
</td>
<td class="nump">288,238,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdjustedAmountOfAggregateValue', window );">Adjusted amount of aggregate value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInJointOperation', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember', window );">MitoCareX [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EventsaftertheReportingPeriodDetailsLineItems', window );"><strong>Events after the Reporting Period (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PercentageOfStockEqual', window );">Percentage of stock equal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdditionalAgreedInvest', window );">Additional agreed invest | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 489,330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PercentageOfWorkingCapital', window );">Percentage of working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_JeffsBrandsMember', window );">Jeffs&#8217; Brands [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EventsaftertheReportingPeriodDetailsLineItems', window );"><strong>Events after the Reporting Period (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OrdinarySharesAcquired', window );">Purchase of ordinary share (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdjustedAmountOfAggregateValue', window );">Adjusted amount of aggregate value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXBioLtdMember', window );">MitoCare X Bio Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EventsaftertheReportingPeriodDetailsLineItems', window );"><strong>Events after the Reporting Period (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OwnershipAgreement', window );">Ownership agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=sprcy_SCISPARCLTDMember', window );">SCISPARC LTD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EventsaftertheReportingPeriodDetailsLineItems', window );"><strong>Events after the Reporting Period (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExerciseOfPrefundedWarrants', window );">Exercise of pre-funded warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=sprcy_JeffsBrandsMember', window );">Jeffs&#8217; Brands [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EventsaftertheReportingPeriodDetailsLineItems', window );"><strong>Events after the Reporting Period (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_SubsequentMember', window );">Subsequent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EventsaftertheReportingPeriodDetailsLineItems', window );"><strong>Events after the Reporting Period (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Ordinary shares par value (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AggregateGrossProceeds', window );">Aggregate gross proceeds | $</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PercentageOfAggregatePurchasePrice', window );">Percentage of aggregate purchase price</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AggregatePurchasePrice', window );">Aggregate purchase price | $</a></td>
<td class="nump">$ 7,180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PrefundedOrdinaryShare', window );">Pre-funded ordinary share (in Shares) | shares</a></td>
<td class="nump">1,930,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OrdinarySharesAcquired', window );">Purchase of ordinary share (in Shares) | shares</a></td>
<td class="nump">1,930,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchaseOrdinaryShares', window );">Purchase ordinary shares (in Shares) | shares</a></td>
<td class="nump">1,930,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_TermOfIssuance', window );">Term of issuance</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExercisePricePerShare', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="17"></td></tr>
<tr><td colspan="17"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">Net of issue expenses of $358</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapitalOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital arising from issuing ordinary shares. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapitalOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInJointOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a joint operation attributable to the entity. [Refer: Joint operations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInJointOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdditionalAgreedInvest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional agreed invest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdditionalAgreedInvest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdjustedAmountOfAggregateValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The adjusted amount of aggregate value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdjustedAmountOfAggregateValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Gross Proceeds means the aggregate of the proceeds from any sale of shares of Common Stock by the Underwriter pursuant to this Agreement, before the deduction of Commissions and Placement Fees payable with respect to those shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate purchase price is the final calculation of the purchase price for a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of ordinary shares of aggregate value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_BonusAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of bonus amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_BonusAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EventsaftertheReportingPeriodDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EventsaftertheReportingPeriodDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExerciseOfPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of Pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExerciseOfPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_MonthlyFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of  monthly fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_MonthlyFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OrdinarySharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares acquired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OrdinarySharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OwnershipAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OwnershipAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PercentageOfAggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Percentage means, with respect to any Purchased Asset, the ratio (expressed as a percentage) of the outstanding Purchase Price with respect to such Purchased Asset to the outstanding unpaid principal balance of such Purchased Asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PercentageOfAggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PercentageOfStockEqual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of stock equal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PercentageOfStockEqual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PercentageOfWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PercentageOfWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PrefundedOrdinaryShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-funded warrants allow investors who are otherwise restricted from owning a company's voting securities above a certain threshold (usually, 9.99% or 19.99%) to invest in the company without violating the applicable ownership restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PrefundedOrdinaryShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchaseOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Owning ordinary shares in a business means owning a fraction of that business, and being able to vote on decisions taken at shareholder meetings. Ordinary shares offer the chance of higher financial gains than other types of share; however, you also have a higher risk of making no gains.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchaseOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The purchase price is the price an investor pays for an investment, and the price becomes the investor's cost basis for calculating gain or loss when selling the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_TermOfIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_TermOfIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_JeffsBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_JeffsBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXBioLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXBioLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=sprcy_SCISPARCLTDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=sprcy_SCISPARCLTDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=sprcy_JeffsBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=sprcy_JeffsBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_SubsequentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_SubsequentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786299730320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_CommunicationAndNetworkEquipmentMember', window );">Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly', window );">Straight-line basis over useful life of assets at annual rates mainly</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_CommunicationAndNetworkEquipmentMember', window );">Lab equipment [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_CommunicationAndNetworkEquipmentMember', window );">Lab equipment [Member] | Top of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly', window );">Straight-line basis over useful life of assets at annual rates mainly</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computers [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computers [Member] | Top of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly', window );">Straight-line basis over useful life of assets at annual rates mainly</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office furniture and equipment [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office furniture and equipment [Member] | Top of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife', window );">Straight-line basis over the useful life of the assets, description</a></td>
<td class="text">see below<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_LeaseholdImprovements', window );">Leasehold improvements (in Dollars)</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of intangible assets with indefinite useful life, supporting the assessment of indefinite useful life. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 122<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_122_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_LeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leasehold improvements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_LeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful lives or depreciation rates used for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_CommunicationAndNetworkEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_CommunicationAndNetworkEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786325880464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash (Details) - Schedule of Cash - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfCashAbstract', window );"><strong>Schedule of Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CashForImmediateWithdrawal', window );">Cash for immediate withdrawal - in USD</a></td>
<td class="nump">$ 3,443<span></span>
</td>
<td class="nump">$ 6,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CashForImmediateWithdrawalInNIS', window );">Cash for immediate withdrawal - in NIS</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOnHand', window );">Total cash and cash equivalents</a></td>
<td class="nump">$ 3,574<span></span>
</td>
<td class="nump">$ 6,875<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOnHand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash held by the entity. This does not include demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOnHand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CashForImmediateWithdrawal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash withdrawal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CashForImmediateWithdrawal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CashForImmediateWithdrawalInNIS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash for Immediate withdrawal in NIS currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CashForImmediateWithdrawalInNIS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786307299600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - Schedule of Inventory - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfInventoryAbstract', window );"><strong>Schedule of Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentInventoriesInTransit', window );">Goods in transit</a></td>
<td class="nump">$ 198<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinishedGoods', window );">Finished goods</a></td>
<td class="nump">470<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InventoriesNet', window );">Total Inventory</a></td>
<td class="nump">$ 668<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentInventoriesInTransit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of inventories in transit. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentInventoriesInTransit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InventoriesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InventoriesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfInventoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfInventoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786304155152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Accounts Receivable (Details) - Schedule of Other Accounts Receivable - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfOtherAccountsReceivableAbstract', window );"><strong>Schedule of Other Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ValueAddedTaxReceivables', window );">Government authorities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other accounts receivable</a></td>
<td class="nump">$ 815<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
<td class="nump">$ 699<span></span>
</td>
<td class="nump">$ 2,904<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ValueAddedTaxReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables related to a value added tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ValueAddedTaxReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfOtherAccountsReceivableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfOtherAccountsReceivableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786300432544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Associates and Investments in Investees (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 17, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 10, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 29, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 15, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 15, 2020 </div>
<div>&#8362; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems', window );"><strong>Investment in Associates and Investments in Investees (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ConversionOfOrdinaryShares', window );">Ordinary shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital', window );">Percentage of shares issued and outstanding share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FairMarketValue', window );">Fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareholdersAmount', window );">Shareholders amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IssuedAndOutstandingSharesPercentage', window );">Issued and outstanding shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForAmountsTransferredToInitialCarryingAmountOfHedgedItems', window );">Initial amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestedInitialAmounts', window );">Invested initial amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PreDeterminedValue', window );">Pre determined</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InitialInvestmentAmount', window );">Initial investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStocks', window );">Outstanding shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.48%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems', window );"><strong>Investment in Associates and Investments in Investees (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership percentage</a></td>
<td class="nump">31.48%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems', window );"><strong>Investment in Associates and Investments in Investees (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership percentage</a></td>
<td class="nump">41.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_EveroMember', window );">Evero [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems', window );"><strong>Investment in Associates and Investments in Investees (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ConversionOfOrdinaryShares', window );">Ordinary shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,952,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OrdinarySharesPerValue', window );">Ordinary shares per value | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital', window );">Percentage of shares issued and outstanding share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_CapitalPointMember', window );">Capital Point [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems', window );"><strong>Investment in Associates and Investments in Investees (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OrdinarySharesPerValue', window );">Ordinary shares per value | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital', window );">Percentage of shares issued and outstanding share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember', window );">MitoCareX [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems', window );"><strong>Investment in Associates and Investments in Investees (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InitialInvestmentAmount', window );">Initial investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_SubsequentMember', window );">Subsequent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems', window );"><strong>Investment in Associates and Investments in Investees (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InitialInvestmentAmount', window );">Initial investment amount</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_SubsequentMember', window );">Subsequent [Member] | Bottom of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems', window );"><strong>Investment in Associates and Investments in Investees (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">31.48%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_SubsequentMember', window );">Subsequent [Member] | Top of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems', window );"><strong>Investment in Associates and Investments in Investees (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">41.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sprcy_CapitalPointWarrantMember', window );">Capital Point Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems', window );"><strong>Investment in Associates and Investments in Investees (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchaseOfOrdinaryShares', window );">Purchase of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of acquisition-related costs for transactions recognised separately from the acquisition of assets and the assumption of liabilities in business combinations. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_m&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForAmountsTransferredToInitialCarryingAmountOfHedgedItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts removed from equity and included in the initial cost or other carrying amount of a non-financial asset (liability) whose acquisition or incurrence was a hedged, highly probable forecast transaction, net of tax. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expired 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_23_e&amp;doctype=Standard&amp;book=b<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForAmountsTransferredToInitialCarryingAmountOfHedgedItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ConversionOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ConversionOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FairMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair market value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FairMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InitialInvestmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InitialInvestmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestedInitialAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestedInitialAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuedAndOutstandingSharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issued and outstanding shares, percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuedAndOutstandingSharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OrdinarySharesPerValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OrdinarySharesPerValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of shares issued and outstanding share capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PreDeterminedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PreDeterminedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchaseOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchaseOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStocks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStocks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareholdersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareholdersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_EveroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_EveroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_CapitalPointMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_CapitalPointMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_SubsequentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_SubsequentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=sprcy_CapitalPointWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=sprcy_CapitalPointWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786326606576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Associates and Investments in Investees (Details) - Schedule of Fair Value of the Investment - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentLineItems', window );"><strong>Schedule of Fair Value of the Investment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome', window );">Balance at January 1, 2022</a></td>
<td class="nump">$ 591<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentDate', window );">Investment date March 31, 2022</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityLossesFromInvestment', window );">Equity losses from investment in MitoCareX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome', window );">Balance at December 31, 2022</a></td>
<td class="nump">$ 893<span></span>
</td>
<td class="nump">$ 591<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets that are measured at fair value through other comprehensive income. A financial asset shall be measured at fair value through other comprehensive income if both of the following conditions are met: (a) the financial asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets and (b) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. [Refer: At fair value [member]; Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_8_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EquityLossesFromInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity losses from investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EquityLossesFromInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in equity instruments that the entity has designated at fair value through other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786302874624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 01, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_LeasesDetailsLineItems', window );"><strong>Leases (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SquareMeters', window );">Square meters</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_LeaseFee', window );">Lease fee (in Dollars)</a></td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExpireTerm', window );">Lease expired</a></td>
<td class="text">Aug. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_LeaseMember', window );">2021 Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_LeasesDetailsLineItems', window );"><strong>Leases (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SquareMeters', window );">Square meters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExpireTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExpireTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_LeaseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_LeaseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_LeasesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_LeasesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SquareMeters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SquareMeters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_LeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_LeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786305591792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PropertyandEquipmentNetDetailsLineItems', window );"><strong>Disclosure of property, plant and equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Depreciation expense</a></td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PropertyandEquipmentNetDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PropertyandEquipmentNetDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786296088976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BeginningBalanceCost', window );">Beginning Balance , Cost</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchasesOfCost', window );">Purchases</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BeginningBalanceCost', window );">Ending Balance, Cost</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_NewLeases', window );">New leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentCost', window );">Beginning Balance, Accumulated depreciation</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentCost', window );">Ending Balance, Accumulated depreciation</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated', window );">Depreciated cost</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccumulatedDepreciationAbstract0', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccumulatedTerminationOfLeases', window );">Depreciation of leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember', window );">Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BeginningBalanceCost', window );">Beginning Balance , Cost</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchasesOfCost', window );">Purchases</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BeginningBalanceCost', window );">Ending Balance, Cost</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_NewLeases', window );">New leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentCost', window );">Beginning Balance, Accumulated depreciation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentCost', window );">Ending Balance, Accumulated depreciation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated', window );">Depreciated cost</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccumulatedDepreciationAbstract0', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccumulatedTerminationOfLeases', window );">Depreciation of leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sprcy_OfficeEquipmentsMember', window );">Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BeginningBalanceCost', window );">Beginning Balance , Cost</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchasesOfCost', window );">Purchases</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BeginningBalanceCost', window );">Ending Balance, Cost</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_NewLeases', window );">New leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentCost', window );">Beginning Balance, Accumulated depreciation</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentCost', window );">Ending Balance, Accumulated depreciation</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated', window );">Depreciated cost</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccumulatedDepreciationAbstract0', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccumulatedTerminationOfLeases', window );">Depreciation of leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BeginningBalanceCost', window );">Beginning Balance , Cost</a></td>
<td class="nump">78<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchasesOfCost', window );">Purchases</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BeginningBalanceCost', window );">Ending Balance, Cost</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_NewLeases', window );">New leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentCost', window );">Beginning Balance, Accumulated depreciation</a></td>
<td class="nump">20<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">39<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentCost', window );">Ending Balance, Accumulated depreciation</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated', window );">Depreciated cost</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccumulatedDepreciationAbstract0', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccumulatedTerminationOfLeases', window );">Depreciation of leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MotorVehiclesMember', window );">Motor vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BeginningBalanceCost', window );">Beginning Balance , Cost</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchasesOfCost', window );">Purchases</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BeginningBalanceCost', window );">Ending Balance, Cost</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_NewLeases', window );">New leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentCost', window );">Beginning Balance, Accumulated depreciation</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentCost', window );">Ending Balance, Accumulated depreciation</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated', window );">Depreciated cost</a></td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccumulatedDepreciationAbstract0', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccumulatedTerminationOfLeases', window );">Depreciation of leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross carrying amount of fully depreciated property, plant and equipment that is still in use. [Refer: Gross carrying amount [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AccumulatedDepreciationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AccumulatedDepreciationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AccumulatedDepreciationAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AccumulatedDepreciationAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AccumulatedTerminationOfLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated termination of leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AccumulatedTerminationOfLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_BeginningBalanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of beginning balance, cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_BeginningBalanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NewLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NewLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PropertyPlantAndEquipmentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PropertyPlantAndEquipmentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchasesOfCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cost of purchases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchasesOfCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sprcy_OfficeEquipmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sprcy_OfficeEquipmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MotorVehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MotorVehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786326125264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Asset (Details) - Schedule of Fair Value of the Intangible Asset<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems', window );"><strong>Schedule of Fair Value of the Intangible Asset [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchaseofAssets', window );">Purchase date September 30, 2022</a></td>
<td class="nump">4,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost', window );">Depreciation of intangible asset</a></td>
<td class="num">(144)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Balance</a></td>
<td class="nump">$ 4,717<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets for which fair value was used as their deemed cost in the opening IFRS statement of financial position. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 30<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_30&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchaseofAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchaseofAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786304114672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade Payables (Details) - Schedule of Trade Payables - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfTradePayablesAbstract', window );"><strong>Schedule of Trade Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccruedExpenses', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Open debts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">$ 1,247<span></span>
</td>
<td class="nump">$ 1,199<span></span>
</td>
<td class="nump">$ 874<span></span>
</td>
<td class="nump">$ 1,199<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfTradePayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfTradePayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786303284160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Accounts Payable (Details) - Schedule of Other Accounts Payable - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableLineItems', window );"><strong>Schedule of Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsAccruals', window );">Employees and payroll accruals</a></td>
<td class="nump">$ 102<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Accruals', window );">Accrued vacation</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherPayables', window );">Other payables</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_TradeAndOtherPayable', window );">Other accounts payable</a></td>
<td class="nump">$ 193<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Accruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Accruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts payable that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_TradeAndOtherPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of trade payables and other payables. [Refer: Trade payables; Other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_TradeAndOtherPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786304118944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - Schedule of Financial Assets and Financial Liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RestrictedCashAndCashEquivalents', window );">Cash and restricted deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_GovernmentAuthorities', window );">Government authorities</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentsInFinancialAssets', window );">Investments in financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssetsAtAmortisedCost', window );">Total financial assets at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CreditsFromOthers', window );">Credit from others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsLiability', window );">Warrants liability</a></td>
<td class="nump">1,714<span></span>
</td>
<td class="nump">2,737<span></span>
</td>
<td class="nump">10,252<span></span>
</td>
<td class="nump">359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial and lease liabilities</a></td>
<td class="nump">$ 1,714<span></span>
</td>
<td class="nump">$ 2,866<span></span>
</td>
<td class="nump">$ 10,297<span></span>
</td>
<td class="nump">$ 422<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialAssetsAtAmortisedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets measured at amortised cost. [Refer: Financial assets at amortised cost]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_8_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialAssetsAtAmortisedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash and cash equivalents whose use or withdrawal is restricted. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CreditsFromOthers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Credit from others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CreditsFromOthers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_GovernmentAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_GovernmentAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentsInFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentsInFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786306907136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details) - Schedule of Warrants Fair Value Using Black&#8211;Scholes OPM - $ / shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 23, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract', window );"><strong>Schedule of Warrants Fair Value Using Black Scholes OPM [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DividendYield', window );">Dividend yield (%)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExpectedVolatility', window );">Expected volatility (%)</a></td>
<td class="nump">122.01%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">148.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_RiskFreeInterestRate', window );">Risk-free interest rate (%)</a></td>
<td class="nump">0.38%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">0.87%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_UnderlyingAdsPrice', window );">Underlying Share Price ($)</a></td>
<td class="nump">$ 0.43<span></span>
</td>
<td class="nump">$ 0.756<span></span>
</td>
<td class="nump">$ 6.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExercisePricePerShare', window );">Exercise price ($)</a></td>
<td class="nump">24.5<span></span>
</td>
<td class="nump">24.5<span></span>
</td>
<td class="nump">24.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsFairValueinDollarsPerShares', window );">Warrants fair value ($)</a></td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4.15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DividendYield">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DividendYield</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExpectedVolatility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExpectedVolatility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate for the option contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_UnderlyingAdsPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_UnderlyingAdsPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsFairValueinDollarsPerShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsFairValueinDollarsPerShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786303303200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Liabilities (Details) - Schedule of Defined Contribution Plans - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfDefinedContributionPlansAbstract', window );"><strong>Schedule of Defined Contribution Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Expenses in respect of defined contribution plans</a></td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfDefinedContributionPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfDefinedContributionPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786306905616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_TaxesonIncomeDetailsLineItems', window );"><strong>Disclosure of income tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Israeli corporate income tax</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OperatingLossCarryforwardsTaxAmount', window );">Carry forward tax losses, total (in Dollars)</a></td>
<td class="nump">$ 58,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OperatingLossCarryforwardsTaxAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net operating loss carryforward tax as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OperatingLossCarryforwardsTaxAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_TaxesonIncomeDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_TaxesonIncomeDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786303838112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Liabilities, Commitments, Claims and Liens (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 02, 2021</div></th>
<th class="th"><div>Aug. 11, 2020</div></th>
<th class="th"><div>Nov. 13, 2019</div></th>
<th class="th"><div>Apr. 11, 2017</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract', window );"><strong>Contingent Liabilities Commitments Claims and Liens [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DekelLicenseAgreementDescription', window );">Dekel license agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) $25 upon the successful completion of preclinical trials (which milestone was met in November 2016; this milestone was paid in cash
in March 2017); (ii) $75 upon the successful completion of a Phase I/IIa trial; and (iii) $75 upon the earlier of generating net revenues
of at least $200 from the commercialization of the technology or the approval of the U.S. Food and Drug Administration or the European
Medicines Agency, of a drug based on the licensed assets. In each case, and subject to the Company&#8217;s discretion, the respective
milestone payments are payable in cash or equity based on a price per ordinary share of NIS 0.5. The royalty payments are 8% for commercialization
and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of any patents maturing from this application would
likely be 2029.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AnnualInvestment', window );">Annual investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdditionalMilestoneAmount', window );">Additional milestone amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InstallmentAmount', window );">Installment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_TotalAgreementEstimatingAmount', window );">Total estimated amount</a></td>
<td class="nump">$ 370<span></span>
</td>
<td class="nump">$ 1,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CapitalProposedToDeposit', window );">Capital proposed to deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdditionalMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdditionalMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AnnualInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of annual investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AnnualInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CapitalProposedToDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CapitalProposedToDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DekelLicenseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dekel license agreement description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DekelLicenseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InstallmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of installment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InstallmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_TotalAgreementEstimatingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total agreement estimating amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_TotalAgreementEstimatingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786308756800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity (Details) - Schedule of Share Capital - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_NumberOfSharesAbstract0', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Ordinary shares, authorized</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">25,714,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Ordinary shares, issued and outstanding</a></td>
<td class="nump">6,798,840<span></span>
</td>
<td class="nump">3,091,740<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesAuthorised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesAuthorised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfSharesAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfSharesAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786302927408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - Schedule of Issued and Outstanding Share Capital<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract', window );"><strong>Schedule of Issued and Outstanding Share Capital [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Balance at January 1, 2022</a></td>
<td class="nump">3,091,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Issuance of share capital &#8211; June 2022 Financing Round</a></td>
<td class="nump">335,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExerciseOfPrefundedWarrantsOne', window );">Exercise of pre-funded warrants</a></td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExerciseOfPrefundedWarrants', window );">Exercise of pre-funded warrants</a></td>
<td class="nump">3,211,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareIssuedToAConsultant', window );">Share issued to a consultant</a></td>
<td class="nump">61,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Balance at December 31, 2022</a></td>
<td class="nump">6,798,840<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExerciseOfPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of Pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExerciseOfPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExerciseOfPrefundedWarrantsOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of Pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExerciseOfPrefundedWarrantsOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareIssuedToAConsultant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The shares were issued to a consultant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareIssuedToAConsultant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786303097760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model - $ / shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract', window );"><strong>Schedule of warrants fair value was calculated using the Black-Scholes OPM [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend yield (%)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (%)</a></td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="nump">2.74%<span></span>
</td>
<td class="nump">3.97%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_UnderlyingOrdinarySharePrice', window );">Underlying share price ($)</a></td>
<td class="nump">$ 287<span></span>
</td>
<td class="nump">$ 0.756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExercisePrice', window );">Exercise price ($)</a></td>
<td class="nump">2.63<span></span>
</td>
<td class="nump">2.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsFairValueinDollarsPerShare', window );">Warrants fair value ($)</a></td>
<td class="nump">$ 10,209<span></span>
</td>
<td class="nump">$ 2,396<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_UnderlyingOrdinarySharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underlying ordinary share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_UnderlyingOrdinarySharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsFairValueinDollarsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsFairValueinDollarsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786301781872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 10, 2022</div></th>
<th class="th"><div>Oct. 10, 2019</div></th>
<th class="th"><div>Mar. 12, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 03, 2022</div></th>
<th class="th"><div>Apr. 21, 2021</div></th>
<th class="th"><div>Nov. 13, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareBasedPaymentTransactionsDetailsLineItems', window );"><strong>Share-Based Payment Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares', window );">Additional number of share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,929<span></span>
</td>
<td class="nump">6,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareOptionsReserved', window );">Share Options reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178,140<span></span>
</td>
<td class="nump">357,143<span></span>
</td>
<td class="nump">15,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_NumberOfSharesOptionGrantedInSharebasedPaymentArrangement', window );">Available for grant shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OrdinaryShares', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 420<span></span>
</td>
<td class="nump">$ 6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FairValueOption', window );">Fair value of share options (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_StockOptionDescription', window );">Stock option, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Board approved the grant of 72 Share Options under the 2015 ESOP to directors, officers and employees, some of which required the approval of the general meeting of the Company&#8217;s shareholders (the &#8220;2019 General Meeting&#8221;), which occurred on January 15, 2020. Following the resignation of some directors and employees on December 31, 2019, 15 Share Options (were not granted. Out of the 57 Share Options that were granted, 10 Share Options didn&#8217;t require the General Meeting&#8217;s approval. The date of commencement for all Share Options granted, the date on which the vesting started, was the 2019 Grant Date. The exercise price was set at $210.00 per Share Option.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FairValueDescription', window );">Fair value, description</a></td>
<td class="text">The fair value of the Share Options
granted on January 3, 2022, was set at $6.09 per Share Option, and the fair value of the Share Options granted on February 10, 2022, was
set at $4.41 per Share Option<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The fair value of the Share Options
approved on October 10, 2019 by the Board, and on January 15, 2020 at the General Meeting (valuated as of December 31, 2019) was set at
$114.1 and $51.1, per Share Option, respectively.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_RSUGrantedDiscountRate', window );">RSU granted discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FairValueOfTheRSUsGranted', window );">Fair value of the RSU&#8217;s granted (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OrdinarySharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OrdinaryGrantedDiscountRate', window );">Ordinary granted discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption', window );">Weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 10 days<span></span>
</td>
<td class="text">6 years 4 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfOrdinarySharesAxis=sprcy_OrdinaryShareMember', window );">Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareBasedPaymentTransactionsDetailsLineItems', window );"><strong>Share-Based Payment Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FairValueOfTheRSUsGranted', window );">Fair value of the RSU&#8217;s granted (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareBasedPaymentTransactionsDetailsLineItems', window );"><strong>Share-Based Payment Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareOptionsOutstandingParValue', window );">Share options outstanding (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.5<span></span>
</td>
<td class="nump">$ 955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareBasedPaymentTransactionsDetailsLineItems', window );"><strong>Share-Based Payment Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareOptionsOutstandingParValue', window );">Share options outstanding (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 844<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issue under options and contracts for the sale of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FairValueDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FairValueDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FairValueOfTheRSUsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fair value of the RSU&#8217;s granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FairValueOfTheRSUsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FairValueOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FairValueOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfSharesOptionGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares option granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfSharesOptionGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OrdinaryGrantedDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OrdinaryGrantedDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RSUGrantedDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RSUGrantedDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareBasedPaymentTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareBasedPaymentTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareOptionsOutstandingParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share options outstanding par value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareOptionsOutstandingParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareOptionsReserved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareOptionsReserved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_StockOptionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_StockOptionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual lifes of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfOrdinarySharesAxis=sprcy_OrdinaryShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfOrdinarySharesAxis=sprcy_OrdinaryShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786303955296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Details) - Schedule of Expenses Due to Share-Based Compensation - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract', window );"><strong>Schedule of expenses due to share-based compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ResearchAndDevelopmentExpenses01', window );">Research and development expenses</a></td>
<td class="nump">$ 264<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_GeneralAndAdministrativeExpenses', window );">General and administrative expenses</a></td>
<td class="nump">633<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExpensesDueToSharebasedCompensation', window );">Expenses due to share-based compensation</a></td>
<td class="nump">$ 897<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExpensesDueToSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExpensesDueToSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_GeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_GeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ResearchAndDevelopmentExpenses01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ResearchAndDevelopmentExpenses01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786302848304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Details) - Schedule of Fair Value for Share Options Granted - $ / shares<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2022</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 10, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract', window );"><strong>Schedule of fair value for Share Options granted [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed', window );">Dividend yield (%)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate', window );">Expected volatility (%)</a></td>
<td class="nump">133.00%<span></span>
</td>
<td class="nump">134.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate', window );">Risk-free interest rate (%)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.46%<span></span>
</td>
<td class="nump">1.91%<span></span>
</td>
<td class="nump">1.67%<span></span>
</td>
<td class="nump">2.61%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1', window );">Expected life of share options (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">9 years 9 months 10 days<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_UnderlyingOrdinarySharePrices', window );">Underlying ordinary share price (in Dollars per share)</a></td>
<td class="nump">$ 4.99<span></span>
</td>
<td class="nump">$ 6.73<span></span>
</td>
<td class="nump">$ 78.12<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_UnderlyingOrdinarySharePrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underlying ordinary share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_UnderlyingOrdinarySharePrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786325899600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Details) - Schedule of Weighted Average Exercise Prices of Share Options - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_a2022Abstract', window );"><strong>2022</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_NumberOfOutstandingShareOption', window );">Number of Share Options ,Share Options outstanding at the beginning of the year</a></td>
<td class="nump">5,431<span></span>
</td>
<td class="nump">5,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement', window );">Weighted average exercise price, Share Options outstanding at the beginning of the year</a></td>
<td class="nump">$ 2.95<span></span>
</td>
<td class="nump">$ 2.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_NumberOfShareOptionGranted', window );">Number of Share Options Share Options granted during the year</a></td>
<td class="nump">178,140<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement', window );">Weighted average exercise price, Share Options granted during the year</a></td>
<td class="nump">$ 6.5<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement', window );">Number of Share Options, Share Options forfeited during the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(212)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WeightedAverageExercisePriceOfShareOptionForfeitedInSharebasedPaymentArrangement', window );">Weighted average exercise price, Share Options forfeited during the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareadsOptionsExpiredDuringYear', window );">Number of Share Options, Share Options expired during the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareadsOptionsExpiredDuringYearWeightedAverageExercisePrice', window );">Weighted average exercise price, Share Options expired during the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_NumberOfOutstandingShareOption', window );">Number of Share Options, Share Options outstanding at the end of the year</a></td>
<td class="nump">183,571<span></span>
</td>
<td class="nump">5,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement', window );">Weighted average exercise price, Share Options outstanding at the end of the year</a></td>
<td class="nump">$ 6.39<span></span>
</td>
<td class="nump">$ 2.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_NumberOfShareOptionsShareOptionsExercisableAtTheEndOfTheYear', window );">Number of Share Options, Share Options exercisable at the end of the year</a></td>
<td class="nump">107,679<span></span>
</td>
<td class="nump">4,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Share Options exercisable at the end of the year</a></td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="nump">$ 3.28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfOutstandingShareOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share option outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfOutstandingShareOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share option forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfShareOptionGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfShareOptionGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfShareOptionsShareOptionsExercisableAtTheEndOfTheYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfShareOptionsShareOptionsExercisableAtTheEndOfTheYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareadsOptionsExpiredDuringYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareadsOptionsExpiredDuringYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareadsOptionsExpiredDuringYearWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareadsOptionsExpiredDuringYearWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WeightedAverageExercisePriceOfShareOptionForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share option forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WeightedAverageExercisePriceOfShareOptionForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share option granted in a share-based payment arrangement.&amp;amp;amp;amp;amp;#160;</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share option outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_a2022Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_a2022Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786306821088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues and Cost of Revenues (Details) - Schedule of Revenues and Cost of Revenues - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_RevenuesAndCostOfRevenuesAbstract', window );"><strong>Schedule of Revenues and Cost of Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenues</a></td>
<td class="nump">$ 1,972<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,347<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="nump">1,267<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">322<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="nump">$ 705<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,025<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RevenuesAndCostOfRevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RevenuesAndCostOfRevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786302620016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract0', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ResearchAndDevelopmentExpenses1', window );">Research and development expenses</a></td>
<td class="nump">$ 2,803<span></span>
</td>
<td class="nump">$ 1,990<span></span>
</td>
<td class="nump">$ 649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BGeneralAndAdministrativeExpensesAbstract0', window );"><strong>b. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">6,509<span></span>
</td>
<td class="nump">3,778<span></span>
</td>
<td class="nump">1,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_COtherExpensesAbstract', window );"><strong>c. Other expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherOperatingIncomeExpense', window );">Other expenses, net</a></td>
<td class="nump">109<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FinanceIncomeAbstract', window );"><strong>d. Finance income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FinanceIncomeFromConvertibleLoan', window );">Net change in fair value of financial liabilities designated at fair value through profit or loss</a></td>
<td class="num">(7,832)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(630)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Finance income</a></td>
<td class="num">(7,832)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(630)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FinanceExpensesAbstract', window );"><strong>e. Finance expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IssueExpensesRelatedToIssuanceOfWarrants', window );">Issuance expenses related to warrants</a></td>
<td class="nump">1,204<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FinanceExpensesFromExchangeRateDifferences', window );">Exchange rate differences, net</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss', window );">Losses from remeasurement of investment in financial assets</a></td>
<td class="nump">770<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InterestExpenseInRespectOfLeases', window );">Finance expense in respect of leases</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FinanceExpensesFromInterestAndCommissions', window );">Finance expenses from interest and commissions</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InsuranceFinanceIncomeExpenses', window );">Finance expenses</a></td>
<td class="nump">2,014<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">872<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_WagesAndRelatedExpensesMember', window );">Wages and related expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract0', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ResearchAndDevelopmentExpenses1', window );">Research and development expenses</a></td>
<td class="nump">436<span></span>
</td>
<td class="nump">357<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BGeneralAndAdministrativeExpensesAbstract0', window );"><strong>b. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">437<span></span>
</td>
<td class="nump">256<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ShareBasedPaymentMember', window );">Share-based payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract0', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ResearchAndDevelopmentExpenses1', window );">Research and development expenses</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BGeneralAndAdministrativeExpensesAbstract0', window );"><strong>b. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">633<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryAndOtherExpensesMember', window );">Regulatory, professional and other expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract0', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ResearchAndDevelopmentExpenses1', window );">Research and development expenses</a></td>
<td class="nump">750<span></span>
</td>
<td class="nump">934<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ResearchAndPreclinicalStudiesMember', window );">Research and preclinical studies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract0', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ResearchAndDevelopmentExpenses1', window );">Research and development expenses</a></td>
<td class="nump">703<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ClinicalStudiesMember', window );">Clinical studies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract0', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ResearchAndDevelopmentExpenses1', window );">Research and development expenses</a></td>
<td class="nump">369<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ChemistryAndFormulationsMember', window );">Chemistry and formulations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract0', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ResearchAndDevelopmentExpenses1', window );">Research and development expenses</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">335<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ProfessionalAndDirectorsFeesMember', window );">Professional and directors&#8217; fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BGeneralAndAdministrativeExpensesAbstract0', window );"><strong>b. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">2,499<span></span>
</td>
<td class="nump">2,417<span></span>
</td>
<td class="nump">1,283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_BusinessDevelopmentExpensesMember', window );">Business development expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BGeneralAndAdministrativeExpensesAbstract0', window );"><strong>b. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryExpensesMember', window );">Regulatory expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BGeneralAndAdministrativeExpensesAbstract0', window );"><strong>b. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_OfficeMaintenanceRentAndOtherExpensesMember', window );">Office maintenance, rent and other expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BGeneralAndAdministrativeExpensesAbstract0', window );"><strong>b. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_WellutionOperatingExpensesMember', window );">Wellution operating expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BGeneralAndAdministrativeExpensesAbstract0', window );"><strong>b. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">907<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_InvestorRelationsAndBusinessExpensesMember', window );">Investor relations and business expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BGeneralAndAdministrativeExpensesAbstract0', window );"><strong>b. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">1,486<span></span>
</td>
<td class="nump">784<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ImpairmentOfInvestmentInAssociateMember', window );">Impairment of investment in associate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_COtherExpensesAbstract', window );"><strong>c. Other expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherOperatingIncomeExpense', window );">Other expenses, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_GroupsShareOfLossesOfCompanyAccountedForAtEquityNetMember', window );">Group&#8217;s share of losses of company accounted for at equity, net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_COtherExpensesAbstract', window );"><strong>c. Other expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherOperatingIncomeExpense', window );">Other expenses, net</a></td>
<td class="nump">$ 109<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income or cost associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) on financial assets at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InsuranceFinanceIncomeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that comprises the change in the carrying amount of the group of insurance contracts arising from: (a) the effect of the time value of money and changes in the time value of money; and (b) the effect of financial risk and changes in financial risk; but (c) excluding any such changes for groups of insurance contracts with direct participation features that would adjust the contractual service margin but do not do so when applying paragraphs 45(b)(ii), 45(b)(iii), 45(c)(ii) or 45(c)(iii) of IFRS 17.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 110<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_110&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InsuranceFinanceIncomeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income (expense) that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AResearchAndDevelopmentExpensesAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AResearchAndDevelopmentExpensesAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_BGeneralAndAdministrativeExpensesAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_BGeneralAndAdministrativeExpensesAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_COtherExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_COtherExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FinanceExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FinanceExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FinanceExpensesFromExchangeRateDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses related to exchange rate differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FinanceExpensesFromExchangeRateDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FinanceExpensesFromInterestAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance expenses from interest and commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FinanceExpensesFromInterestAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FinanceIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FinanceIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FinanceIncomeFromConvertibleLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FinanceIncomeFromConvertibleLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InterestExpenseInRespectOfLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InterestExpenseInRespectOfLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssueExpensesRelatedToIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssueExpensesRelatedToIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ResearchAndDevelopmentExpenses1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ResearchAndDevelopmentExpenses1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_WagesAndRelatedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_WagesAndRelatedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ShareBasedPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ShareBasedPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryAndOtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryAndOtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ResearchAndPreclinicalStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ResearchAndPreclinicalStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ClinicalStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ClinicalStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ChemistryAndFormulationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ChemistryAndFormulationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ProfessionalAndDirectorsFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ProfessionalAndDirectorsFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_BusinessDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_BusinessDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_OfficeMaintenanceRentAndOtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_OfficeMaintenanceRentAndOtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_WellutionOperatingExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_WellutionOperatingExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_InvestorRelationsAndBusinessExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_InvestorRelationsAndBusinessExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ImpairmentOfInvestmentInAssociateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ImpairmentOfInvestmentInAssociateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_GroupsShareOfLossesOfCompanyAccountedForAtEquityNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_GroupsShareOfLossesOfCompanyAccountedForAtEquityNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786296170640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share/Ads (Details) - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share - Discontinued operations [member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ContinuingOperationsAbstract', window );"><strong>Continuing operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted number of shares used in the computation of basic and diluted loss per</a></td>
<td class="nump">4,575<span></span>
</td>
<td class="nump">2,049<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity', window );">Amounts used in the computation of basic and diluted loss per</a></td>
<td class="num">$ (2,592)<span></span>
</td>
<td class="num">$ (5,789)<span></span>
</td>
<td class="num">$ (3,950)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfOrdinarySharesAxis=sprcy_ADSMember', window );">ADS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ContinuingOperationsAbstract', window );"><strong>Continuing operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted number of shares used in the computation of basic and diluted loss per</a></td>
<td class="nump">4,575<span></span>
</td>
<td class="nump">2,049<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity', window );">Amounts used in the computation of basic and diluted loss per</a></td>
<td class="num">$ (2,592)<span></span>
</td>
<td class="num">$ (5,789)<span></span>
</td>
<td class="num">$ (3,482)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfOrdinarySharesAxis=sprcy_OrdinaryShareMember', window );">Ordinary shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ContinuingOperationsAbstract', window );"><strong>Continuing operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted number of shares used in the computation of basic and diluted loss per</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity', window );">Amounts used in the computation of basic and diluted loss per</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (468)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) attributable to ordinary equity holders of the parent entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfOrdinarySharesAxis=sprcy_ADSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfOrdinarySharesAxis=sprcy_ADSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfOrdinarySharesAxis=sprcy_OrdinaryShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfOrdinarySharesAxis=sprcy_OrdinaryShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786295919760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Segments (Details) - Schedule of Operating Segments - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SegmentReportingRevenueAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExternalRevenues', window );">External</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,347<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_Intersegment', window );">Inter-segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome', window );">Segment loss (gain)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,287<span></span>
</td>
<td class="nump">5,768<span></span>
</td>
<td class="nump">3,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet', window );">Company&#8217;s share of losses of company accounted for at equity, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestRevenueExpense', window );">Finance expense (income), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,818)<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_TaxExpense', window );">Tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss</a></td>
<td class="nump">$ 2,932<span></span>
</td>
<td class="nump">$ 5,759<span></span>
</td>
<td class="nump">2,592<span></span>
</td>
<td class="nump">5,789<span></span>
</td>
<td class="nump">3,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Segment Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,605<span></span>
</td>
<td class="nump">9,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherLiabilities', window );">Segment Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,156<span></span>
</td>
<td class="nump">1,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sprcy_DrugDevelopmentMember', window );">Drug Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SegmentReportingRevenueAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExternalRevenues', window );">External</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_Intersegment', window );">Inter-segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome', window );">Segment loss (gain)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,405<span></span>
</td>
<td class="nump">5,768<span></span>
</td>
<td class="nump">3,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Segment Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,664<span></span>
</td>
<td class="nump">9,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherLiabilities', window );">Segment Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,021<span></span>
</td>
<td class="nump">1,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sprcy_OnlineSalesMember', window );">Online Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SegmentReportingRevenueAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExternalRevenues', window );">External</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_Intersegment', window );">Inter-segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome', window );">Segment loss (gain)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(118)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Segment Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">941<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherLiabilities', window );">Segment Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in other comprehensive income. Impairment loss on a revalued asset is recognised in other comprehensive income to the extent that the impairment loss does not exceed the amount in the revaluation surplus for that same asset. [Refer: Impairment loss; Revaluation surplus; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 129<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_129_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestRevenueExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income or expense arising from interest. [Refer: Interest expense; Interest income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestRevenueExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company&#8217;s share of losses of company accounted for at equity, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExternalRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of external revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExternalRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_Intersegment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of inter-segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_Intersegment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SegmentReportingRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SegmentReportingRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_TaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_TaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sprcy_DrugDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sprcy_DrugDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sprcy_OnlineSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sprcy_OnlineSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786302710496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties (Details) - Schedule of Balances with Related Parties - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember', window );">Key management personnel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems', window );"><strong>Transactions and Balances with Related Parties (Details) - Schedule of Balances with Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Current liabilities</a></td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">$ 447<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember', window );">Other related parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems', window );"><strong>Transactions and Balances with Related Parties (Details) - Schedule of Balances with Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Current liabilities</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786307120384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties (Details) - Schedule of Transactions with Related Parties - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract', window );"><strong>Schedule of Transactions with Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ResearchAndDevelopmentExpenses', window );">Research and development expenses</a></td>
<td class="nump">$ 208<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139786307852000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties (Details) - Schedule of Benefits to Key Management Personnel - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract', window );"><strong>Schedule of benefits to key management personnel [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short-term benefits</a></td>
<td class="nump">$ 1,940<span></span>
</td>
<td class="nump">$ 962<span></span>
</td>
<td class="nump">$ 746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Cost of share-based payment</a></td>
<td class="nump">$ 779<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>121
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M_KKB;,&+"B#_O\QS\7Y1O="V?T5R\G]02P,$%     @ :(%;6.\@.AR*!P
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MU:3 _$(%^7CQ#:H$LD [>L"*&(36KRW&"2(M'=Y=F?%4!_!) 3U%/90@%-$
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M>Q"C;!^B$(WL*]!C6S@9\J<TA!.,5V(O'WGS80)44B@&@2]C 4947"7R/X\
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M;")R)[*I,/6HHSZXA8 KG>5</0)72A<J%HE_&J?:2C4'/?.W%_'70EI)3#*
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MEO$>^ZO#]OWP $ /Y!J&8<WP;7@0\=<BZ](@Z% 8A(-]#ATV?R<CF/>]>7C
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MX!;K5069"AN++T]E*#)\0E>>R:@PT"*0FI[K8];B;?8QG2,JM?)NIN\JT35
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M*<'!<NN>;_,B#A-),HG##1>JVD0D"LE13O =Y*MB5="[V<3Q/ __LH]Y%*<
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M_,)W)5"$$X&F_E!!NYTVP<. = ]-3O'!5BXW?'B!S]\!K31$X/R<@1DU7.I
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MR(D808".)V1%Q^Z#14Y6'4;)OR::?Y*!Y3@TFQQ\_:R=I9L:*S^_QLH&-=;
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MGRK@@2ZYHA)Q$Y![QEFDN-F[+B>VX_#$?CBJ7 H<.4W+;^I2CW,.BJIU&VZ
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M)E?UI<AV] /H9584V98^;J0 "\$!\'Z5947U!1>H?T+_\M]02P,$%     @
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M.H^<D4-2V-!MH5>B_@K[? :&+Q&%LE]2-[$!WIALE1;E'HQVR7BSTM=]'8X
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M;0]DW<6UH47E.F<IM.E#M\S-X$-I'<SY2@A],.P%S2A-_@!02P,$%     @
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M>N1J<F#4W/@ -FO V!M@/H-'4>I4P;Q,,#D%<(E92X^]TINQBX@/&-]"X-\
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MY^\N=YYLI7K4&:*!Y[*H])1EQM1CS]-)AJ7075EC12<KJ4IAR%1K3]<*1>I
M9>%QW[_P2I%7+)PXWT*%$[DQ15[A0H'>E*50+S,LY';* K9W+/-U9JS#"R>U
M6.,]FF_U0I'EM2QI7F*E<UF!PM641<%XUK?Q+N![CEM]L >;22SEHS4^IU/F
M6T%88&(L@Z#E":^P*"P1R?BSXV3ME19XN-^S?W*Y4RZQT'@EBQ]Y:K(I&S)(
M<24VA5G*[0WN\AE8OD06VGUAV\3R"P;)1AM9[L"DH,RK9A7/NSH< (;^&P"^
M W"GN[G(J;P61H03);>@;#2QV8U+U:%)7%[9GW)O%)WFA#/A@Q(IPD*\B+A
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MU.]>#ABH9O :P\C:-7LL#8V.VV;T5J&R 72^DM+L#7M!^_J%?P%02P,$%
M  @ :(%;6*\2.(!J @  2P4  !D   !X;"]W;W)K<VAE971S+W-H965T,C8N
M>&ULE53?;]HP$'[GKSAYTYZVYB>%,8@4*%,GK065=M,T[<$D!XEJQYEMH/SW
MLQW(F$21]I+XSO=]_N[.Y^%.R&=5(&IXX:Q2(U)H70\\3V4%<JJN1(V5V5D)
MR:DVIEQ[JI9(<P?BS M]_]KCM*Q(,G2^N4R&8J-96>%<@MIP3N5^C$SL1B0@
M1\=#N2ZT=7C)L*9K7*!^JN?26%[+DI<<*U6*"B2N1B0-!N/8QKN ;R7NU,D:
M;"9+(9ZM\24?$=\*0H:9M@S4_+8X0<8LD9'Q^\!)VB,M\'1]9/_L<C>Y+*G"
MB6#?RUP7(](GD..*;IA^$+M;/.33M7R98,I]8=?$1C&!;*.TX >P4<#+JOG3
MET,=3@!]_Q5 > "$3G=SD%-Y0S5-AE+L0-IHPV87+E6'-N+*RC9EH:79+0U.
M)S-=H(0TR\2FT@KF=$^7#(>>-MPVPLL./..&)WR%)PCA3E2Z4#"M<LS_)?",
MJ%99>%0V#B\RWF!V!5'P'D(_#"_P16VFD>.+_BM3^)DNE9;F<OPZEW1#&9^G
MM ,S4#7-<$3,1"B46R3)NS?!M?_I@N"X%1Q?8D]FC[?3!T@GD]G3_>,"YNF/
M=/QU>D[E19[S*N]GCU,(HL$'.'],QY0?^=)4S+2@8UM@^Q!TIKQF8H^H@%8Y
MU'0O!6-FMC*YH4S!6PC\T'SC;B>U/LQA2S/J!K#7@ZC?:=I0-]57$,30"SH&
M]C&RX&X,YRKGG5QPCG+MQEB!:V5SUUMO^U*DS8#\#6^>F3LJUV6E@.'*0/VK
M7I> ;$:W,;2HW;@LA3;#YY:%>>U0V@"SOQ)"'PU[0/M^)G\ 4$L#!!0    (
M &B!6UA*,@K&> 0  )(*   9    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM
M;)U67V_;-A!_UZ<XJ$.Q 8EM*4Z:.K:!.'51 TEK--F&8M@#+9TM(I2HDE24
M?/O=4;9B9[8Q[(42R;O?_3_>L-;FT6:(#IYS5=A1F#E7#KI=FV28"]O1)19T
ML]0F%XZV9M6UI4&1>J9<=>->[Z*;"UF$XZ$_FYOQ4%=.R0+G!FR5Y\*\3%#I
M>A1&X>;@NUQEC@^ZXV$I5GB/[O=R;FC7;5%2F6-AI2[ X'(47D>#29_I/<$?
M$FN[]0]LR4+K1][,TE'88X508>(80=#G"6]0*08B-7ZN,<-6)#-N_V_0/WO;
MR9:%L'BCU9\R==DHO PAQ:6HE/NNZR^XMN><\1*MK%^A;FC[O1"2RCJ=KYE)
M@UP6S5<\K_VPQ7!YB"%>,\1>[T:0U_*3<&(\-+H&P]2$QC_>5,]-RLF"@W+O
M#-U*XG/C:5XJ_8(($RQP*1W<2K&02CJ)=MAU)('INLD:;=*@Q0?0HACN=.$R
M"],BQ707H$NJM?K%&_TF\5'$3YATX"PZ@;@7QT?PSEI[SSS>V?^P%_ZZ7EAG
M*%'^WF=Z ]S?#\S%,["E2' 44G58-$\8CM^_BRYZ5T?4[K=J]X^ACZ=W\]MO
M/Z93F$R_3C_/'N!V=CV9W<X>9M/[?;H>1=NOZ]=O#U.(S@>G<$P8M Y<- ZT
MD&@J4>M +\%FVKA3AR8/VFM1I%!JZT[1<U)!NY:W _,#-P.X3A)M4EFLP&EP
M&8(2"VUHK1M,/II9(U#)X!Z?T(@B09B+%[@5]0E$'R_.X%<F>O_N,HY[5_^B
M\>?1U6\G'NI&YZ4H7D!:ZC4_*VDP9<$ET29T16U(^#9"9Z( W'BA*NDLE3:7
MU@H5D((&'3%[8VA'Y+EX1"IE8_B(G.6,7%2,94$6W$$H.NG.!91*T&U9&5L)
M8B*0^W47B_KL9U9XC\W"@BTQD4N)*06 &FX''EYM8X.C#U<6U#KGO;6"_%P5
MCE2@%L\0XE"X&C#V1N4:9ZQ5>8N/;W(DV!&8BQ39<N$#["VHI<M([I-0,H4M
MP=XI5(^^\:; [B=Q&_A6'GF>'A2?%5O,G(909S+) *T3"R5M%GC^PDFGFA"1
M:PTF2"^#A]X.=6/NH=0%81 *?AB4>@DHAFQ("HN7-R%.E+#61X1]NXGV&F4=
MZ,;O1S+!WSHAE6?U<?UTD'KP7Y(%1%DJZGD!YS,]R=3X*-.D4)3QQFW8=C*?
M2H$]8$]V$K-Q,!,OY?,;?2B%A?0^V:FP@NMJ_:XOJR+U]=S5)BBUD@DW8A(O
M"ULU&B>>CX\-/>:4"#MH2Z-SX!^1II*%D@FOZ4:2-MEB?7[7&9%;UFI7T1HI
MG)R9G8"B;O'--:?6[@F#[;C'H.^EY)7#@>P$/U 82D!Z'"F"">8+-/R\!?R\
M\1L7\=(+IL\,C+Y#$"H5M8_)D13Y!:+HG-:/E[2<Q[#OT>ENS0DYFI6?AKB!
M4_TW(T-[V@Y<U\V<\4K>3&MWPJPH1*!P2:R]SH?S$$PS 34;ITL_=2RTHQG&
M_V8T-*)A KI?:NTV&Q;0CJ'C?P!02P,$%     @ :(%;6*ABW_X* P  @P8
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M+.C4;J+S0PKJ&AXMU&FVJU^*%\.CL)]$<TV>*^>F3<F6+Q6#OID*9%>.N*4
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M'15Z#]/XY/;.(R()B#0;NXL1E+0TKT&P:@]"2%#$&(1\(T[/5?9YPT5;<3D
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M15XH%OB283X<H!XC:LN95(0CJ@A@@B\F7!:X,+^4L#3""Z]]H"GX#M*T!))
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M7*/>]2@ 78^&6K"J].UXIRPU=[_,:9JB=@:TGRFZ.(W@ K3S>?XO4$L#!!0
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M4RS(OQ^9L\[3KE]+I9E<#IS#],SB5L![:B"QK$5TOZN,MG2FRV@A@-MD9'7
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MH=@K^UJA<X!]@5^.2!2GDD<A)EBVRK(@=\-(YT4 #0$ANMQXRTNFCIN4^?X
M^@_8DRJE_0"J(A/W^"SZSG_"=1_7V<= >0+ELLO/Z >05W5.YXD0PN/&Y 6K
MHOC@!H[06!$$+[%NB.LB9JIPHG@LP*[KZ@#[$LMO-P!P M+)O:^S?[3-F:5#
M7([T84!.VI8)SA[PVNK@.+7^:T"\&[U$6F_>]UVU'7HDL!7HA1W0!BC L#F4
M5/P746&>X9DW_1(4D2"%YTH6-FQT:IA8U%$'4[B^%:SRT[ZM@:#&Z 9D&*L
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MM9%K-3SQ8!?,>();646H97F19"17)=Z/L%$?;N*<0.#/^HZY+6ZLSS1P;7(
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M,Y>P5ODKT,M'6QIK6%[G8+<ZB(>K!P"./A% !S+%4@B0D>^% @$MS%S77-^
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M^==.PO>Z#)=F4&0%GU4FCF,R47QKEI@I4HH>-_BT%N8X@?3(WY+"&:DX!Z/
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M;IKBHPS*&N#_E91FM[ $U3,_^0M02P,$%     @ :(%;6!7X.K>2!0  > \
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M)(#K<XD?4:L7<K"^;$__!E!+ P04    " !H@5M8VB6&_DD#  #%!@  &0
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M=V]R:W-H965T<R]S:&5E=#0Q+GAM;*U7VV[;.!!]UU<,W-VB =18%UNVT\1
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M$96+1;/&*'_Y(KU.WIW)(.LSR,ZQYT]4G64KS^L_)OHL[7'1=/M8+R@$O<#
MOX!_AG3P4:_1*"I0![QUE3;"";1P =F(AA$;=+I,+\="=@WL<I1D@[G!AHL2
M<$O=Q?J3!(;9S> "TF%*:';Y-LG@V#W%!W^]1K,*%6TAY-Y]^WZW;QK3KE;^
MN7<=YX&;E5 6)"X)FER]&45@NBKN#*>;4#D+[:@.P[*BQH?&.]#Y4FNW-WR
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M]_[ " X$X%$ M?_DNW>/,'&=SETT&2RQ[56.6 UDKUB8Q/0<XB,9>V]!@L;
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M84Y_&-0N@.;7BE:E,5R!]I\U_0-02P,$%     @ :(%;6%<;T7%7 P  50@
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M$8P\Y^ZR/B%/P,PY(]%)+TDP39@82\++&=IJVIV&<C7TXM_T8:)OF6FXLD1
M[:3Q[/T5)6:8DB% W87.W&MT?1Z6K?NP@/$)[KS6&H^!OV#Z5!7/4$L#!!0
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M];G^NTCRFR!C_Y#KB),/,CPCW^XT 1::ZH?2;"C-@=)<*,V#TGP4K>W IBQ
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M9D'(LOP ]?L#Y_)Y(V^@7KJX^ ]02P,$%     @ :(%;6%7H0<K< @  &0@
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MZ 0=&;;O*<\E9HD<NDI+-0NZ<2EK4LCR/Y 5HEO.5"K1)4L@:<!/V_$=OX7
MU3FJ$N7O$C7Q6QEO<G:& N\+\CT_:!+4#I]!K.$="_=;Y 35O@66+_C'??LU
M7D@E].7XW93T@K/;S&D*QH5<XQA&CJX($L0&G.CSIT[H?6TR_)_(WMGO5O:[
M;>S1!%/,8D!8H1O,<EU_4&-N"]L%5\]RF;*VB7J#SM#=U-VTKM?L!K48Z55&
M>JU&WO:Q27B!#6O"NYZW)_PPIE^+>2<JK$2%K:(NGW.B7A'E4H)$2\$S?<CJ
MY^V6*#[% GXVB0X/!)T.SO=$-\1TO$&SZGZENO^W9T+?-L@6(#ZX<87._L&I
M.!\$>SH/8^HGIY#IUJIO!F)E'R6)8IXS513B:K1Z]\:VW+MOX<6C>8O%BC")
M*"PUU#OKZY5%\1 5'<77MI8ON-(O@VVF^NT&80+T_))SM>N8!:I_ ]$?4$L#
M!!0    ( &B!6UCA$8A^1P0  )@6   9    >&PO=V]R:W-H965T<R]S:&5E
M=#4Y+GAM;*V8:X^C-A2&_XI%5]6,M!VNN<PTB90$VNY*JXYV.MT/53\X<!*L
M!4QM)YGIKU]S"0F$.,.(+PD&WO<</QCCX\F>LN\\!!#H)8X2/M5"(=('7>=^
M"#'F=S2%1%Y94Q9C(9MLH_.4 0YR41SIEF$,]1B31)M-\G./;#:A6Q&1!!X9
MXMLXQNQU 1'=3S53.YSX2C:AR$[HLTF*-_ $XCE]9+*E5RX!B2'AA":(P7JJ
MS<T'SQQD@OR.OPGL^<DQRKJRHO1[UO@43#4CRP@B\$5F@>7?#I8019F3S.._
MTE2K8F;"T^.#^V]YYV5G5IC#DD;?2"#"J3;64 !KO(W$5[K_ \H.Y0GZ-.+Y
M+]H7]XYL#?E;+FA<BF4&,4F*?_Q2@C@12)]V@54*K*; N2"P2X']U@A.*7":
M@N$%P: 4Y%W7B[[GX%PL\&S"Z!ZQ[&[IEAWD]'.UY$62;* \"2:O$JD3LT^)
MP,F&K") <\[EP+QQ06 2\5OT"WI^<M'-AUOT >F(AY@!1R1!SPD1_*,\*8__
M"NF6XR3@$UW(;#)/W2\C+XK(UH7(0_2%)B+DR$L""%KTKEI_?TWOJ?6FI3#0
M)<:*I75@N;"4CI^WR1VRC8_(,BR[):'EV^56&P^U_ E2I=Q3RUWPI=QLD]=@
MV-7 LG,_^ZT#ZY_YB@LF)X9_V\9*8>:TFV6SY0-/L0]334Z''-@.M-G//YE#
MX]<VSGV:N7V:>3V9U9Z(4ST11^4^6V(>HA2_RFE>M#V"0CW(U=GW93=S!HXQ
MT7>G:)4ANJ+MT\R[DGX-V:!"-E B\UY\@/;)K1 .3\*9IM6DI73O2JM/,^]*
M^C5:PXK64$GK<<O\4'ZTD4^Y:(4V/(MJ6V:#F3)&5V9]FGGJ[&O(1A6RD1+9
M-\P83@1'@J*TQ-<&;G0VN,V!832'FS)65W1]FGG7\J_!&U?PQE?>3F ^D>,M
M9<0'="/7(RZ-(LPX2H$5*Y;;-IKCLVQ&#9+*P%U)]FGFJ7*O4;RO*-Z_D2(P
M0ML64@NUP0"]@F3>]B%6"KMB[-/,>T>7:G1-X[C -I1>OS/*.>(X@O9%LE+=
M=>73JYM;NM5>6\,XFW>\Z_?5V9T4)Z;ZBY*_V-7+W.$55QMWQMJGFUNZU7$U
MD?84L0[>.H*WE.#G,=TF0GZ5!(Y:\5KGJZWQL/DI5P?IC*U/-^]:#^K@CE6/
MJ5S"9^"8(/]#@.A.#M#+<^H5'].X/*NJI9VQ]EK@O*M;==;'>L94%S0G)2;.
M2LQ6S.=E@>78S7'ZCD($M;+LM:)IR=UTG LC]%C2F.J:YD\6D 2SU\..3K%X
M\B/*9:/#!-MG.;+LU<WMU<TKW2Y,U\53T$]VX&)@FWSKD\M"2,ZBQ092=;;:
M7IWGFXJ-\POS85ELDAYMBCW;+YAM2,)1!&MI:=R-9$*LV 8M&H*F^3[?B@I!
MX_PP!!P RVZ0U]>4BD,C"U!M1L]^ %!+ P04    " !H@5M80DVM\] "  !!
M"   &0   'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6RM5FU/VS 0_BM6AB:0
M!GEM@E@;J:5#8Q)210?[,.V#FUP;"\?.;*=E_WZVDX8"(1+3OK1^N>>YY\[7
MNXYW7#S( D"AQY(R.7$*I:H+UY59 2669[P"IF_67)18Z:W8N+(2@',+*JD;
M>%[LEI@P)QW;LX5(Q[Q6E#!8""3KLL3BSPPHWTT<W]D?W))-H<R!FXXKO($E
MJ+MJ(?3.[5AR4@*3A#,D8#UQIO[%96+LK<$]@9T\6",3R8KS![.YSB>.9P0!
MA4P9!JR_MG )E!HB+>-WR^ET+@WP<+UGO[*QZUA66,(EIS](KHJ)<^Z@'-:X
MINJ6[[Y"&\_(\&6<2ON)=JVMYZ"LEHJ7+5@K* EKOO%CFX<#@.;I!P0M('@)
MB-\ A"T@M($VRFQ8<ZQP.A9\AX2QUFQF87-CT3H:PLPK+I70MT3C5'K-%&8;
MLJ* IE+JJCF>@\*$RA-TBI:Z9O):7_$UNL)$H'M,:[M3!:!7T%-TMYRCXZ,3
M=(0(0]\+7DO,<CEVE59J_+E9JVK6J K>4!6C&\Y4(=$7ED/>@[\<QOO! (&K
M4]3E*=CG:18,,GZKV1D*O4\H\(*P3] P? Z9AOL6'@S(";MG"RU?^ ;?.U_F
MYW0EE= _F5]];]&XBOI=F39R(2N<P<31?4*"V(*3?OS@Q][GOCS\)[)G68FZ
MK$1#[.D,4\PRZ(NQ 8XLT'2V;1HE?C)VMX?:!]G[M:,!V:-.]FA0]J(66:%;
M$<JQ K2$2D&Y K$OMZ OGD'&][Y90Q8?)N<\]KOD/ LJ[H**!X.:@_:<$6R;
MM:Y+\E23V-1D7U#Q*QVG012^>*0>(S^*^L4FG=CD7PLG>5TX41*]T-1C=%A=
MC2;WH$N7(#9V>$F4\9JIIF%WI]U\G-JQX#Z9-\/U!HL-81)16&NH=Y9HUZ(9
M6,U&\<KV_!57>H+89:%G/ ACH._7G*O]QCCH_C6D?P%02P,$%     @ :(%;
M6-9MDN?:!   T"   !D   !X;"]W;W)K<VAE971S+W-H965T-C$N>&ULM9KO
M;YLX&,?_%8M54R=- 4-"FBZ)U!;0>EJWJKG>O9CNA4N<!@UPSG:23MH??^9'
M"#!BE=/3O&B ^/NQ>;[&V(\[W3/^0ZPIE>@EB5,Q,]92;BY-4X1KFA Q8!N:
MJE]6C"=$JE/^;(H-IV29BY+8M"W+-1,2I<9\FE^[Y_,IV\HX2ND]1V*;)(3_
MO*8QV\\,;!PN/$3/:YE=,.?3#7FF"RH?-_=<G9D591DE-!412Q&GJYEQA2\#
M/,X$>8F_(KH7M6.4W<H38S^RD]OES+"R%M&8AC)#$/6UHS<TCC.2:L>_)=2H
MZLR$]>,#/<AO7MW,$Q'TAL5_1TNYGAD7!EK2%=G&\H'M/]/RAD89+V2QR/^B
M?5G6,E"X%9(EI5BU((G2XIN\E(&H"?#PA, N!79+8$].")Q2X+0%]@G!L!0,
M6P+'.2$8E8+1:P5N*7#SV!?!RB/M$4GF4\[VB&>E%2T[R.W*U2K 49KUK(7D
MZM=(Z>3\-MU1(557D2A*41"E) TC$J,K(:@4Z-RCDD2Q^(#>O[MP7/L3,I%8
M$TY%5OPQC:3XB,ZZ+ZKC/]=L*TBZ%%-3JL9F59IAV3"O:)A]HF$NNF.I7 OD
MITNZ[- '>CVV-0!31:D*E7T(U;6M)0;T:8!LYR.R+=OI:-"-7OZ5[08(CW.Y
MC1X7'CH_^U#&K2L\>MH?VW2 '*MHS('6@?'[8&Z_+-!Y:?3OCG=YH*=[-%1T
MW+KELQ/$ABE.U7^=O KG__7?[U]4>70K:2+^Z6C_=0$?=L.S4?U2;$A(9X8:
MM@7E.VK,W[_#KO6IRW](F <)\R%A 1"L8?>PLGNHH\]OB%BC7X>NV>6H5M_7
M44B8!PGS"Q@NGKQL^K";VR,K^TS-7=TMH%H;;HTJMT9ZMUBBJ.ML'K*CZOD,
M64)1S(10%IYUF:?%]34/$N85L%$MW-AQFJ'V(2L,@& -W]S*-U?K6VU0)0G;
MJJ\3?FDQ??UR?P_QJ-V=/<@:?4A8  1K&#:N#!MK#7N@(56/V/(P#?MU^I5]
MK27U]:R N?51R+'&[J3E&F2=/B0L ((U7+NH7+O0NK;(/$(AV412S5@VE(?J
MB5/+N2[7"A+&M4A;@Q%NQOFF+&4U2ED3QY[4/RUSM(WL:PXD+ ""-<R95.9,
M7F'.AD<AS48_W2SX6DOJ^TA!PCQ(F \)"PK8N-93G0%VJZ[9\ Q;Q]6LU6/&
MH9MJZ$%]30.E>: T'Y06E+3Z:WH\QB=\JV4AL-:W;WRIEF[\)UH4+[#O=S1Y
MHKQSS:9']78.DN:!TGQ06@!%:UIL'RVVWW*E7M*A7(>D>: T'Y060-&:KA_3
M,UB;#IC?$XYV)-[2XZI=^RK5XWK;#)J2 :7Y)0T[S<G:J+5^AZJTZ=\QWX+U
M"9>KK61WY.55XS)HZ@64YH'2?%!: $5K.GS,T>#1FX[+H#D;4)H'2O-!:0$4
MK>GZ,<.#]2F>WN,R:*H'E.:!TOR2AH?-I79[6'Z+= \^YGNP/N'COU >1H(B
MMJK6J*^R$33[ TKS0&E^26N]7H>X[2-H LBL;<0FE#_G6^8"A5D.M=AHK*Y6
MV_)7^69TZ[J'+_UB<_V(*?;Z[PA_CE*!8KI22&LP5N,(+[;/BQ/)-OEV[Q.3
MDB7YX9J2)>59 ?7[BC%Y.,DJJ/Z)8?X?4$L#!!0    ( &B!6UC6HMT5=@,
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M#A/<NX'0 _#^C'/U=*(#5+O!X"]02P,$%     @ :(%;6/Y(/?ZA!@  ?C
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MN@#\OL@R]7RB]WO7_^5@]B]02P,$%     @ :(%;6'VHY#^D!   ,AH  !D
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MY<5^K+JJT7(\M89=:&!^J)0(R_[.76V%(;6V%:<#&;=W-S_]B"!#+_CPBO,
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M2,+*7[2M^DXG&@H*QDE:@X4%:9Q5__BE%N( X!I' %8-L-X S.D1@%T#[+<
MYPC J0'.J8!)#2A=URO?2^$\S/%R3LD64=E;L,E"J7Z)%GK%F9PH#YR*UEC@
M^/([IA1GG*&!!QS'"1NBS^CQP4.#BR&Z0#IB$:; 4)RAQRSF;"0J1?F/B!0,
M9R&;ZUQ8(;GTH!YQ58UH'1G1M- =R7C$D)^%$+8)=&%^XX.U\^'&ZF7\K<C&
MR#!'R#(LJ\N@?K@'P1C9Q^'>":/;1@FW.^#^Z7"K1PR[":A=\MGO!?3'[Z(%
MW7)(V5\=9MU4-$XWC<Q/5RS' 2PTD8 8T&?0EI\^FE/CNDMAE62>2C)?$5DK
M%DX3"Z>/??D+)8RAG)( H/-5N:GPDQ(O<_KSTC0LTYCKSX?J]HYRKKHJR7Q%
M9"UU)XVZDUYU;QDK<!8 (FN$-QL*&\QAEZ\&(DD]E,5AE^X5\_1 =WOB3$WC
MK?*]%IRKO$HR7Q%92_EIH_RT5_DFQX3  AKG<LGO4KF?98"'R+1&KNN@0BXM
M"'.$Q=L25R&]F#ECUT4YT ^R>80 !Q$*B-BC,!YG&]EG$ \1$5F.T##.Q#ZG
MBKYLX1&@%4ESG+V.D%BH1%?1EV\)VNZ,+_DX07E!@TCL-;J8!I+GTT?7LHQK
MD:GA@\S2:.=_V6!>#^L1GJ0_]FAB.,(+^+PNY/IVQ#=[;%TZTCGTKG,'7+7M
M']ZQNN6O-!NUS!YW9?#>6)T[TU62^8K(6C-]ULSTV2DS'<%+'@MY1;QB$G9-
M]5Z:<U?3?IMFZ!4P[5I./)56^(K(6KJ[C>[N2;KCE!09[Q*\%W^NX"K)/+=K
M3;?;"XNO:,26N)>-N)>]XG[%,47/."F@2]A>[+G"JB3S5)+Y_X$,]6AO&OL#
MEW':XOGC#M(GH)V;\WZ.<Z.@E,U3RN:K8FM'X^#X:ZHY+M4\JB*BDLU3RN:K
M8FM'Q-I'Q.I]/_P7H$',RGU2M6&2NZ1Z.R9V]1Y)$K'\[6L[-_C]@YP=KHIM
M=I#3I^[8=MM)W5,ZJ*^*K1V'_3V"V7LT/C%/*;U%4,KF*67S5;&UH[&_23 =
M17E*Y?E^I93-4\KFJV)K1V1_^V#^?]</YK_O'TQ[:KMO$LJJWX2SY5=Z :&*
MK9)?/[C"3H%NRF\'3)R(Q?:_NLUN:IOO$U_*6WE]W[WZN'&'Z2;.&$I@+:#&
M>"8,I=7W@NJ!D[R\$'\BG).T+$: 0Z"R@VA?$\)W#W* YJO-\A]02P,$%
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M@;S"167 *G8UUF74W:RKX:RM(7BBAF]-=4)"[QT)O" <H,^?IZ>0(=VW]&"
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MB/EUS&84&$:ANP6]XPU$T^.M%!7L_')]ZOS84K6);61&W&)#L1GQKE% S2_
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M;,6;:V_;-A2&_PKA%D4*#+%$6;ZDCH'$NBQ%TP7-NGXH]H&Q:%N;)+HD%;?
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M=(.8BI9L:E"Z7Z*E7R13=3(73#XE$B>";R(&AN["D!:9X.@10B!KO$@ G4]
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MCK%N6@6B[WSE50_W%;,5R3A*8"EAQM5[B6=57U1-!,W+#_^""ME&E,-8MI+
M5(!\OJ14;">JEVB:T^ ?4$L#!!0    ( &B!6UB5V=@FSPD  )^    9
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M!\TE)(5.RZ :;]^(@3^=FALAH--*E&;&3Q=&CKTQ>EUK1KK-MSRG0WLCJ!9
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MQR3)7R^4$[PDZ9?JYLW^!U!+ P04    " !H@5M8$YQ$H/,"  "%"   &0
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M((T#KB^%T#O#;%!]>81_ 5!+ P04    " !H@5M8M7&Z490"   5"0  &0
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M;W)K<VAE971S+W-H965T.# N>&ULK55=3]LP%/TK5H8FD!CYI$PLC40)T_;
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M<+THTZ_#&TR8I3K'0;EP7+D,745P75GP?LW+8&,-$-0'Q]4'KOUQ9^>WV+,
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MUG:M[4#0O6[+ME3()D_?%K+3QTP9R/<[2L730'5Z_7\'J^]02P,$%     @
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M/2NA9[>,]"#XWIV'PL]:B6-7$J?&CJUS 6#=(N3PFD7L?<S]&PZ%OD9;WU'
ME=((WS(OAGBH=^/!'KI"6Z^'[+.'[%OD3L=U!VGP?Q==L7?M?I@ZXTGS/N]8
M5[OUZVSG<@SW%D,WN-+?P^BT+FIOY,R:A.U5M3N_3GBNQ_!5!5D[KS4WV<C"
M?P!9N\S"UL2;M-C:ZUP7>Q?8SO48OFE!=B7CN.,F=YJ [5K,&=G3!J!9:>$2
M8#O=V7+DTWTJ\I:FG"V[YT?=,S;F5ZJKUJWA64W>DG\F3):8',6PE2JMT40:
MQO(N-Q\(FNE&<4.%;#OU8P@D *86R/=;2L5IH#8H_]>P_ ]02P,$%     @
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M_[^H:_GR11]@_VZNZ?\!4$L#!!0    ( &B!6UB3@)/ K ,  *H1   9
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MP+^P\R\<8X\_ZJ("GW'5989H,J/N)40Z3 @H4C35J9/1HE;H0J4(^&\ROIG
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M_9@3G!&N N#]EC%Y;*@!NNN9^#]02P,$%     @ :(%;6+C*CQ-$!@  1S(
M !H   !X;"]W;W)K<VAE971S+W-H965T,3 P+GAM;+6;VV[;.!"&7X5PBZ(!
MFEBD)=E.'0--9&&[:-$B:7<O%GO!V(PM5 =7I'-X^Z4.D4R)9BQE]B:QY)F/
M]/R2K/E-S1Z2]!??,";08Q3&_&*P$6)[/ASRY89%E)\E6Q;+=^Z2-*)";J;K
M(=^FC*[RI"@<$LMRAQ$-XL%\EN_[GLYGR4Z$0<R^IXCOHHBF3Y<L3!XN!GCP
MO.,Z6&]$MF,XGVWIFMTP\7/[/95;PXJR"B(6\R")4<KN+@:?\+E/IEE"'O%7
MP![XWFN4?93;)/F5;7Q>70RL;$8L9$N1(:C\=\^N6!AF)#F/WR5T4(V9)>Z_
M?J;[^8>7'^:6<G:5A'\'*[&Y&$P&:,7NZ"X4U\G#'ZS\0$[&6R8AS_^BAS+6
M&J#ECHLD*I/E#*(@+O[3Q[(0>PF2HT\@90)I)M@'$D9EPJB9X!Y(L,L$^]@1
MG#+!.3;!+1/<O/9%L?)*>U30^2Q-'E":14M:]B*7*\^6!0[B[,BZ$:E\-Y!Y
M8OYMRU(J@GB-;MA:'C&"H_<>$S0(^0DZ13?R2%[M0H:2.Z0)/44_;SST_NT)
M>HN"&/W8)#M.XQ6?#86<6S;"<%G.X[*8!SDP#Q=]36*QX6@1K]A*D^^9\S$Q
M (:R*%5ER'-E+HF1^.<N/D,CZP,B%AEI)G1U?#K1?1YSNL>6,AT?3%\<GXXU
MZ?[QZ9:AEJ/J*!OEO-$!WC6[9_&.:8^+(M/69V87UG.^I4MV,9!73L[2>S:8
MOWN#7>NC3A-(F <)6T#"?""8HJ5=:6F;Z//%HV!I3$.=EL;,KEI"PKP"YN2P
M[-OV?HY']G@VO-_7J,>(2"?/ZSF*,DZEC&-4YG,LE3GEQ<59)X\QO:L\D#"O
M!TQ7^040QW\]1U'0K11TC0K^2(3^Q#*F=54.$N85,-=\8O4842O+ZSF*+.-*
MEK%1EO)^!X4)E[=':WF_?J(3R0CI*A(DS!NW1)J025.D=I S=B=JD-\.&I'I
MJ I2RCNIRCLQEO<JB;8T?GKW9D+P^"-'?$/3_(XSJS?CV:ME$2(;D66RDY>Y
M%9)-%:("L=^[0#Q]0#'37O&, W>5!!+F3=KGC35M* (YH \$4Q2>5@I/C0K[
M04SC)4/L47;$G*'W02P592<'=3/BNNH&"?.F+=U.G0ENG":+=E1V&ZZ<29H0
MF^A/)&S5W9QE_@*AC\]%UO9@QNRN=06E>25-.2/L1EE!1_2A:*I6>YTW-FKU
M15[=M"+AUKVJO,02M117FBAG[#2N(%X9I1QESI0TR]J.<L:3!LO71(V<D7/@
MD"5U&<A17ZZ?Y+5>Z MB!'0^:B%I7DE3K^.NY30KW Z;3K';K##0U%0EZB8=
M&_O&2HDO ;T-PD $^H;=3.DL!VC+7M+VZVQCQVVJT8["X['35./_Z+)QW69C
M<Y_MI;LU\M@]"Y-M+LL_7UETR])_M9J =MZ@- ^4M@"E^5 T5>.Z8<=.;U\,
M@W;KH#0/E+8 I?E0-%72NH/'YA;>9(^94SM+"MK']Z%I+1@HD \ 4C6LVWUL
M[O=?--+,^9V%!.WU^]#T0@*!? "0*F1M+&"SLW#03S/G=180U!GH0],+" 3R
M 4"J@+5O@,W&P9'.FYG264Y0PP"W&_V)W6X0VE$:]TT3==A^([5K0,RNP<LM
MF!G0M<"@-(^TC8.IZS:M UU4NP.#FIDJ1&T)$+,E<&0'9J9T5@.2YI&V2V!;
M3?-KH8G2=&!0,U/5J)T)8G8FON5[T T-&3=V7V9.9SU #0I0V@*4YD/15'UK
MOX/T7Y5 0$T.4)H'2EN TGPHFBII;9J0_HL3S*F=)07U2$K:"S^C]AE3>T,'
M %(%JAT/\LHU"N;\SBJ!VAY]:-H[<RB0#P!2A:Q]#M)SJ8(YK[. H"8'.6JU
M0I\Q]>H .QBD=C (R(H%,Z6S5J ^!FDO-3C%K1]:^XRIUPK8I""U24',)L41
MW1>H6P%*\TA[(</4;MWN0SD14'-7I:KM"'*<'?%2?P9J1X#2O)*FKH1LNA%]
MAM3K!33W0J_AWCKWB*7K_(D$CO(E0<5BY&IO]=3#IWRM?V/_)3Z_PIK]'C[W
MBV<::GSQB,57FJZ#F*.0W<FAK+.Q+&!:/+50;(ADFZ^ROTV$2*+\Y8;1%4NS
M /G^79*(YXUL@.K9D?E_4$L#!!0    ( &B!6U@:JGI+I0(  *()   :
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M+.A^0V4WT/I"2K.=V 3=C9G\ 5!+ P04    " !H@5M8KN%=WM8"  "V!P
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ME9AXW*2.>E1%'1R)V@_(G>"8*?*5IY#N$K@Z!4T>@DT>1L%)QAB2*]+Q/Y'
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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M%&X#D-LHW09@MU&\#4!OJWI;@-Y6];8 O6WU8QN@MU6]+4!OJWI;@-Y6];8
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M              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ :(%;6"8_1Z\E!   7Q$  !@              ("!#@@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( &B!6U@\Q*%W@@<  "XI   8
M              " @6D,  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    " !H@5M8[R Z'(H'  !A,P  &               @($A%   >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ :(%;6)(3AM^%"@
M\E<  !@              ("!X1L  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( &B!6UCB2!CC[0H  &Y#   8              " @9PF
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !H@5M8GP:O
M3)(-  "N*@  &               @(&_,0  >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ :(%;6,T$VTY\*   "HH  !@
M ("!AS\  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( &B!
M6UB2?"=D>P4  (8,   8              " @3EH  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    " !H@5M8!290#3L(   $'0  &
M        @('J;0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ :(%;6)XNNO>+!0  4PT  !D              ("!6W8  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !H@5M8G;87>X@%  "F$
M&0              @($=?   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( &B!6UAZ50T+CPT  "TC   9              " @=R!  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ :(%;6-GNLP*4
M!0  $@P  !D              ("!HH\  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    " !H@5M8-'K4/V\0  !./P  &0
M@(%ME0  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( &B!
M6UCY-(-<]P4  $8/   9              " @1.F  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ :(%;6(16!.>=!P  IQ(  !D
M         ("!0:P  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    " !H@5M8L"@)=Q<)  #G&   &0              @($5M   >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( &B!6UADLSM1 PH   @9
M   9              " @6.]  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ :(%;6%R<A=%' @  %@4  !D              ("!G<<
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !H@5M82"@<
M$3P"  #N!   &0              @($;R@  >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( &B!6UA(%(SW< (  %8%   9
M  " @8[,  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
M:(%;6']JQ]VK"@  HQL  !D              ("!-<\  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    " !H@5M8"&0:C&(#   %"   &0
M            @($7V@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( &B!6U@CH[48C0,  '<(   9              " @;#=  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ :(%;6,+IH4%+ @
M"04  !D              ("!=.$  'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    " !H@5M8KQ(X@&H"  !+!0  &0              @('V
MXP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( &B!6UA*
M,@K&> 0  )(*   9              " @9?F  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ :(%;6*ABW_X* P  @P8  !D
M     ("!1NL  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &B!6U@S[9$.B ,  *8(   9              "
M@50. 0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ :(%;
M6 :>@3.:*@  9Z   !D              ("!$Q(! 'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    " !H@5M8T@RK0;H"  #\!0  &0
M        @('D/ $ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0
M   ( &B!6UBV^<\CG@(  !\&   9              " @=4_ 0!X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ :(%;6$ :%./3 @  _0<
M !D              ("!JD(! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"% ,4    " !H@5M8(*HD#@P#  #R!P  &0              @(&T10$
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( &B!6U@5^#JW
MD@4  '@/   9              " @?=( 0!X;"]W;W)K<VAE971S+W-H965T
M,SDN>&UL4$L! A0#%     @ :(%;6-HEAOY) P  Q08  !D
M ("!P$X! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " !H
M@5M8XLD%A#(%  "^#@  &0              @(% 4@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( &B!6UAEKS?QQ 4  -L.   9
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M970T-BYX;6Q02P$"% ,4    " !H@5M8R%([/DP#   3"   &0
M    @(']9P$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (
M &B!6UBW^NOY2 (  !,%   9              " @8!K 0!X;"]W;W)K<VAE
M971S+W-H965T-#@N>&UL4$L! A0#%     @ :(%;6$\%!+E8 @  /P4  !D
M             ("!_VT! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"
M% ,4    " !H@5M8=\8,!7@"  "<!0  &0              @(&.< $ >&PO
M=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( &B!6U@X_FG6:04
M  H/   9              " @3US 0!X;"]W;W)K<VAE971S+W-H965T-3$N
M>&UL4$L! A0#%     @ :(%;6$#\X=:G @  ] 4  !D              ("!
MW7@! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " !H@5M8
M!;2>*/P"  "_!@  &0              @(&[>P$ >&PO=V]R:W-H965T<R]S
M:&5E=#4S+GAM;%!+ 0(4 Q0    ( &B!6UA7&]%Q5P,  %4(   9
M      " @>Y^ 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%
M  @ :(%;6!1VM&"2!   <QX  !D              ("!?((! 'AL+W=O<FMS
M:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " !H@5M8A>_0!Q$"  "V!
M&0              @(%%AP$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+
M 0(4 Q0    ( &B!6U@*=_95W04  ,8X   9              " @8V) 0!X
M;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ :(%;6%7H0<K<
M @  &0@  !D              ("!H8\! 'AL+W=O<FMS:&5E=',O<VAE970U
M."YX;6Q02P$"% ,4    " !H@5M8X1&(?D<$  "8%@  &0
M@(&TD@$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( &B!
M6UA"3:WST (  $$(   9              " @3*7 0!X;"]W;W)K<VAE971S
M+W-H965T-C N>&UL4$L! A0#%     @ :(%;6-9MDN?:!   T"   !D
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M=#8U+GAM;%!+ 0(4 Q0    ( &B!6UB9Q)WZ1P,  +@)   9
M  " @8^S 0!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @
M:(%;6%'B1^RN'@  GPP" !D              ("!#;<! 'AL+W=O<FMS:&5E
M=',O<VAE970V-RYX;6Q02P$"% ,4    " !H@5M8P&69$88"   *!P  &0
M            @('RU0$ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4
M Q0    ( &B!6UA&;FGXRP(  #\'   9              " @:_8 0!X;"]W
M;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ :(%;6!;P;QTI"
MIU(  !D              ("!L=L! 'AL+W=O<FMS:&5E=',O<VAE970W,"YX
M;6Q02P$"% ,4    " !H@5M8VM_:],8&  "2.0  &0              @($1
MY $ >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( &B!6UB8
MAN4S7A$  /?[   9              " @0[K 0!X;"]W;W)K<VAE971S+W-H
M965T-S(N>&UL4$L! A0#%     @ :(%;6,/3R3IS!   XAT  !D
M     ("!H_P! 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &B!6U@3G$2@\P(  (4(   9              "
M@: 3 @!X;"]W;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%     @ :(%;
M6+5QNE&4 @  %0D  !D              ("!RA8" 'AL+W=O<FMS:&5E=',O
M<VAE970W.2YX;6Q02P$"% ,4    " !H@5M8C,IYCX "  "?!@  &0
M        @(&5&0( >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4 Q0
M   ( &B!6UBY0Q/(O0<  +H\   9              " @4P< @!X;"]W;W)K
M<VAE971S+W-H965T.#$N>&UL4$L! A0#%     @ :(%;6)(,Q$R0 @  A@8
M !D              ("!0"0" 'AL+W=O<FMS:&5E=',O<VAE970X,BYX;6Q0
M2P$"% ,4    " !H@5M8&O) +*H"   _"0  &0              @($')P(
M>&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+ 0(4 Q0    ( &B!6U@E9E82
MBP(   X'   9              " @>@I @!X;"]W;W)K<VAE971S+W-H965T
M.#0N>&UL4$L! A0#%     @ :(%;6 $OEN73 P  1Q   !D
M ("!JBP" 'AL+W=O<FMS:&5E=',O<VAE970X-2YX;6Q02P$"% ,4    " !H
M@5M8OG7O67D#   C"P  &0              @(&T, ( >&PO=V]R:W-H965T
M<R]S:&5E=#@V+GAM;%!+ 0(4 Q0    ( &B!6UABBTE]E@(  .,&   9
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M970Y,2YX;6Q02P$"% ,4    " !H@5M8)T7M]D #  """0  &0
M    @(%Q10( >&PO=V]R:W-H965T<R]S:&5E=#DR+GAM;%!+ 0(4 Q0    (
M &B!6UB[*"WR/0D  &A0   9              " @>A( @!X;"]W;W)K<VAE
M971S+W-H965T.3,N>&UL4$L! A0#%     @ :(%;6$&U*!#Q @  F @  !D
M             ("!7%(" 'AL+W=O<FMS:&5E=',O<VAE970Y-"YX;6Q02P$"
M% ,4    " !H@5M8%V@]^M0#  #]#0  &0              @(&$50( >&PO
M=V]R:W-H965T<R]S:&5E=#DU+GAM;%!+ 0(4 Q0    ( &B!6U@^6Z0SP0,
M '<0   9              " @8]9 @!X;"]W;W)K<VAE971S+W-H965T.38N
M>&UL4$L! A0#%     @ :(%;6#M=@ ,) P  -@P  !D              ("!
MAUT" 'AL+W=O<FMS:&5E=',O<VAE970Y-RYX;6Q02P$"% ,4    " !H@5M8
ME4H<V:0)  "G2P  &0              @(''8 ( >&PO=V]R:W-H965T<R]S
M:&5E=#DX+GAM;%!+ 0(4 Q0    ( &B!6UB3@)/ K ,  *H1   9
M      " @:)J @!X;"]W;W)K<VAE971S+W-H965T.3DN>&UL4$L! A0#%
M  @ :(%;6+C*CQ-$!@  1S(  !H              ("!A6X" 'AL+W=O<FMS
M:&5E=',O<VAE970Q,# N>&UL4$L! A0#%     @ :(%;6!JJ>DNE @  H@D
M !H              ("! 74" 'AL+W=O<FMS:&5E=',O<VAE970Q,#$N>&UL
M4$L! A0#%     @ :(%;6$TW:@V/ @  /0<  !H              ("!WG<"
M 'AL+W=O<FMS:&5E=',O<VAE970Q,#(N>&UL4$L! A0#%     @ :(%;6*[A
M7=[6 @  M@<  !H              ("!I7H" 'AL+W=O<FMS:&5E=',O<VAE
M970Q,#,N>&UL4$L! A0#%     @ :(%;6 A6*"UP P  S!8   T
M     ( !LWT" 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !H@5M8EXJ[',
M   3 @  "P              @ %.@0( 7W)E;',O+G)E;'-02P$"% ,4
M" !H@5M8$R([-\@&   ?0P  #P              @ $W@@( >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ :(%;6 I(4F[K @  ACP  !H
M ( !+(D" 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
M:(%;6(1UFX=C @  83H  !,              ( !3XP" %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&     &\ ;P"$'@  XXX"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>353</ContextCount>
  <ElementCount>442</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>72</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Statements of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Statements of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Changes in Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Changes in Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Investment in Associate</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/InvestmentinAssociate</Role>
      <ShortName>Investment in Associate</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Intangible Asset</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/IntangibleAsset</Role>
      <ShortName>Intangible Asset</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Investment in Financial Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/InvestmentinFinancialAssets</Role>
      <ShortName>Investment in Financial Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Transactions and Balances with Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/TransactionsandBalanceswithRelatedParties</Role>
      <ShortName>Transactions and Balances with Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Additional Information to the Items of Profit or Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss</Role>
      <ShortName>Additional Information to the Items of Profit or Loss</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Significant Events during the Reporting Period</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/SignificantEventsduringtheReportingPeriod</Role>
      <ShortName>Significant Events during the Reporting Period</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Events after the Reporting Period</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/EventsaftertheReportingPeriod</Role>
      <ShortName>Events after the Reporting Period</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements</Role>
      <ShortName>Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/Cash</Role>
      <ShortName>Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Other Accounts Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/OtherAccountsReceivable</Role>
      <ShortName>Other Accounts Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Investment in Associates and Investments in Investees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvestees</Role>
      <ShortName>Investment in Associates and Investments in Investees</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Trade Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/TradePayables</Role>
      <ShortName>Trade Payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Other Accounts Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/OtherAccountsPayable</Role>
      <ShortName>Other Accounts Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Employee Benefit Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/EmployeeBenefitLiabilities</Role>
      <ShortName>Employee Benefit Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Taxes on Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/TaxesonIncome</Role>
      <ShortName>Taxes on Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens</Role>
      <ShortName>Contingent Liabilities, Commitments, Claims and Liens</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Share-Based Payment Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ShareBasedPaymentTransactions</Role>
      <ShortName>Share-Based Payment Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Revenues and Cost of Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/RevenuesandCostofRevenues</Role>
      <ShortName>Revenues and Cost of Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Loss Per Share/Ads</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/LossPerShareAds</Role>
      <ShortName>Loss Per Share/Ads</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Operating Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/OperatingSegments</Role>
      <ShortName>Operating Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://trpx.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Investment in Associate (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/InvestmentinAssociateTables</Role>
      <ShortName>Investment in Associate (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/InvestmentinAssociate</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Intangible Asset (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/IntangibleAssetTables</Role>
      <ShortName>Intangible Asset (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/IntangibleAsset</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Transactions and Balances with Related Parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables</Role>
      <ShortName>Transactions and Balances with Related Parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/TransactionsandBalanceswithRelatedParties</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/FinancialInstruments</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/Warrants</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/Equity</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Additional Information to the Items of Profit or Loss (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables</Role>
      <ShortName>Additional Information to the Items of Profit or Loss (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/CashTables</Role>
      <ShortName>Cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/Cash</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/Inventory</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Other Accounts Receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/OtherAccountsReceivableTables</Role>
      <ShortName>Other Accounts Receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/OtherAccountsReceivable</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Investment in Associates and Investments in Investees (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesTables</Role>
      <ShortName>Investment in Associates and Investments in Investees (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvestees</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Trade Payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/TradePayablesTables</Role>
      <ShortName>Trade Payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/TradePayables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Other Accounts Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/OtherAccountsPayableTables</Role>
      <ShortName>Other Accounts Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/OtherAccountsPayable</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Employee Benefit Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/EmployeeBenefitLiabilitiesTables</Role>
      <ShortName>Employee Benefit Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/EmployeeBenefitLiabilities</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Share-Based Payment Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ShareBasedPaymentTransactionsTables</Role>
      <ShortName>Share-Based Payment Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/ShareBasedPaymentTransactions</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Revenues and Cost of Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/RevenuesandCostofRevenuesTables</Role>
      <ShortName>Revenues and Cost of Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/RevenuesandCostofRevenues</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Loss Per Share/Ads (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/LossPerShareAdsTables</Role>
      <ShortName>Loss Per Share/Ads (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/LossPerShareAds</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Operating Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/OperatingSegmentsTables</Role>
      <ShortName>Operating Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/OperatingSegments</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - General (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/GeneralDetails</Role>
      <ShortName>General (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/General</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Investment in Associate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/InvestmentinAssociateDetails</Role>
      <ShortName>Investment in Associate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/InvestmentinAssociateTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Investment in Associate (Details) - Schedule of Fair Value of the Investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable</Role>
      <ShortName>Investment in Associate (Details) - Schedule of Fair Value of the Investment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/InvestmentinAssociateTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Intangible Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/IntangibleAssetDetails</Role>
      <ShortName>Intangible Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/IntangibleAssetTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>059 - Disclosure - Intangible Asset (Details) - Schedule of Fair Value of the Intangible Asset</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable</Role>
      <ShortName>Intangible Asset (Details) - Schedule of Fair Value of the Intangible Asset</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/IntangibleAssetTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>060 - Disclosure - Investment in Financial Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/InvestmentinFinancialAssetsDetails</Role>
      <ShortName>Investment in Financial Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/InvestmentinFinancialAssets</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>061 - Disclosure - Transactions and Balances with Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails</Role>
      <ShortName>Transactions and Balances with Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>062 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>063 - Disclosure - Financial Instruments (Details) - Schedule of Financial Assets and Financial Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable</Role>
      <ShortName>Financial Instruments (Details) - Schedule of Financial Assets and Financial Liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>064 - Disclosure - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/WarrantsDetails</Role>
      <ShortName>Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/WarrantsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>065 - Disclosure - Warrants (Details) - Schedule of Warrants??? Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofWarrantsFairValueTable</Role>
      <ShortName>Warrants (Details) - Schedule of Warrants??? Fair Value</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/WarrantsTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>066 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/EquityTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>067 - Disclosure - Equity (Details) - Schedule of Share Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofShareCapitalTable</Role>
      <ShortName>Equity (Details) - Schedule of Share Capital</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/EquityTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>068 - Disclosure - Equity (Details) - Schedule of Issued and Outstanding Share Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable</Role>
      <ShortName>Equity (Details) - Schedule of Issued and Outstanding Share Capital</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/EquityTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>069 - Disclosure - Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable</Role>
      <ShortName>Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>070 - Disclosure - Significant Events during the Reporting Period (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails</Role>
      <ShortName>Significant Events during the Reporting Period (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/SignificantEventsduringtheReportingPeriod</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>071 - Disclosure - Events after the Reporting Period (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/EventsaftertheReportingPeriodDetails</Role>
      <ShortName>Events after the Reporting Period (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/EventsaftertheReportingPeriod</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>072 - Disclosure - Significant Accounting Policies (Details) - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable</Role>
      <ShortName>Significant Accounting Policies (Details) - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>073 - Disclosure - Cash (Details) - Schedule of Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofCashTable</Role>
      <ShortName>Cash (Details) - Schedule of Cash</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/CashTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>074 - Disclosure - Inventory (Details) - Schedule of Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofInventoryTable</Role>
      <ShortName>Inventory (Details) - Schedule of Inventory</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/InventoryTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>075 - Disclosure - Other Accounts Receivable (Details) - Schedule of Other Accounts Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofOtherAccountsReceivableTable</Role>
      <ShortName>Other Accounts Receivable (Details) - Schedule of Other Accounts Receivable</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/OtherAccountsReceivableTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>076 - Disclosure - Investment in Associates and Investments in Investees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails</Role>
      <ShortName>Investment in Associates and Investments in Investees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>077 - Disclosure - Investment in Associates and Investments in Investees (Details) - Schedule of Fair Value of the Investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable0</Role>
      <ShortName>Investment in Associates and Investments in Investees (Details) - Schedule of Fair Value of the Investment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>078 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/Leases</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>079 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>080 - Disclosure - Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable</Role>
      <ShortName>Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>081 - Disclosure - Intangible Asset (Details) - Schedule of Fair Value of the Intangible Asset</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable0</Role>
      <ShortName>Intangible Asset (Details) - Schedule of Fair Value of the Intangible Asset</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/IntangibleAssetTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>082 - Disclosure - Trade Payables (Details) - Schedule of Trade Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofTradePayablesTable</Role>
      <ShortName>Trade Payables (Details) - Schedule of Trade Payables</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/TradePayablesTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>083 - Disclosure - Other Accounts Payable (Details) - Schedule of Other Accounts Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofOtherAccountsPayableTable</Role>
      <ShortName>Other Accounts Payable (Details) - Schedule of Other Accounts Payable</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/OtherAccountsPayableTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>084 - Disclosure - Financial Instruments (Details) - Schedule of Financial Assets and Financial Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0</Role>
      <ShortName>Financial Instruments (Details) - Schedule of Financial Assets and Financial Liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>085 - Disclosure - Financial Instruments (Details) - Schedule of Warrants Fair Value Using Black???Scholes OPM</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable</Role>
      <ShortName>Financial Instruments (Details) - Schedule of Warrants Fair Value Using Black???Scholes OPM</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>086 - Disclosure - Employee Benefit Liabilities (Details) - Schedule of Defined Contribution Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofDefinedContributionPlansTable</Role>
      <ShortName>Employee Benefit Liabilities (Details) - Schedule of Defined Contribution Plans</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/EmployeeBenefitLiabilitiesTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>087 - Disclosure - Taxes on Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/TaxesonIncomeDetails</Role>
      <ShortName>Taxes on Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/TaxesonIncome</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>088 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails</Role>
      <ShortName>Contingent Liabilities, Commitments, Claims and Liens (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>089 - Disclosure - Equity (Details) - Schedule of Share Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofShareCapitalTable0</Role>
      <ShortName>Equity (Details) - Schedule of Share Capital</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/EquityTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>090 - Disclosure - Equity (Details) - Schedule of Issued and Outstanding Share Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable0</Role>
      <ShortName>Equity (Details) - Schedule of Issued and Outstanding Share Capital</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/EquityTables</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>091 - Disclosure - Equity (Details) - Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable</Role>
      <ShortName>Equity (Details) - Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/EquityTables</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>092 - Disclosure - Share-Based Payment Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ShareBasedPaymentTransactionsDetails</Role>
      <ShortName>Share-Based Payment Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/ShareBasedPaymentTransactionsTables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>093 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of Expenses Due to Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable</Role>
      <ShortName>Share-Based Payment Transactions (Details) - Schedule of Expenses Due to Share-Based Compensation</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/ShareBasedPaymentTransactionsTables</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>094 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of Fair Value for Share Options Granted</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable</Role>
      <ShortName>Share-Based Payment Transactions (Details) - Schedule of Fair Value for Share Options Granted</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/ShareBasedPaymentTransactionsTables</ParentRole>
      <Position>95</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>095 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of Weighted Average Exercise Prices of Share Options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable</Role>
      <ShortName>Share-Based Payment Transactions (Details) - Schedule of Weighted Average Exercise Prices of Share Options</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/ShareBasedPaymentTransactionsTables</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>096 - Disclosure - Revenues and Cost of Revenues (Details) - Schedule of Revenues and Cost of Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofRevenuesandCostofRevenuesTable</Role>
      <ShortName>Revenues and Cost of Revenues (Details) - Schedule of Revenues and Cost of Revenues</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/RevenuesandCostofRevenuesTables</ParentRole>
      <Position>97</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>097 - Disclosure - Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0</Role>
      <ShortName>Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables</ParentRole>
      <Position>98</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>098 - Disclosure - Loss Per Share/Ads (Details) - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable</Role>
      <ShortName>Loss Per Share/Ads (Details) - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/LossPerShareAdsTables</ParentRole>
      <Position>99</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>099 - Disclosure - Operating Segments (Details) - Schedule of Operating Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofOperatingSegmentsTable</Role>
      <ShortName>Operating Segments (Details) - Schedule of Operating Segments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/OperatingSegmentsTables</ParentRole>
      <Position>100</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>100 - Disclosure - Transactions and Balances with Related Parties (Details) - Schedule of Balances with Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable</Role>
      <ShortName>Transactions and Balances with Related Parties (Details) - Schedule of Balances with Related Parties</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables</ParentRole>
      <Position>101</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>101 - Disclosure - Transactions and Balances with Related Parties (Details) - Schedule of Transactions with Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable</Role>
      <ShortName>Transactions and Balances with Related Parties (Details) - Schedule of Transactions with Related Parties</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables</ParentRole>
      <Position>102</Position>
    </Report>
    <Report instance="ea0200391-f1_scisparcltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>102 - Disclosure - Transactions and Balances with Related Parties (Details) - Schedule of Benefits to Key Management Personnel</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable</Role>
      <ShortName>Transactions and Balances with Related Parties (Details) - Schedule of Benefits to Key Management Personnel</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables</ParentRole>
      <Position>103</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="F-1" isDefinitelyFs="true" isIfrs="true" isUsgaap="true" original="ea0200391-f1_scisparcltd.htm">ea0200391-f1_scisparcltd.htm</File>
    <File>sprcy-20230630.xsd</File>
    <File>sprcy-20230630_cal.xml</File>
    <File>sprcy-20230630_def.xml</File>
    <File>sprcy-20230630_lab.xml</File>
    <File>sprcy-20230630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="20">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="1048">https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>128
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0200391-f1_scisparcltd.htm": {
   "nsprefix": "sprcy",
   "nsuri": "http://trpx.com/20230630",
   "dts": {
    "inline": {
     "local": [
      "ea0200391-f1_scisparcltd.htm"
     ]
    },
    "schema": {
     "local": [
      "sprcy-20230630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "sprcy-20230630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sprcy-20230630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "sprcy-20230630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sprcy-20230630_pre.xml"
     ]
    }
   },
   "keyStandard": 218,
   "keyCustom": 224,
   "axisStandard": 16,
   "axisCustom": 2,
   "memberStandard": 22,
   "memberCustom": 41,
   "hidden": {
    "total": 317,
    "http://trpx.com/20230630": 108,
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 207,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 353,
   "entityCount": 1,
   "segmentCount": 72,
   "elementCount": 712,
   "unitCount": 6,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 1048,
    "http://xbrl.sec.gov/dei/2023": 20
   },
   "report": {
    "R1": {
     "role": "http://trpx.com/role/DocumentAndEntityInformation",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://trpx.com/role/ConsolidatedBalanceSheet",
     "longName": "001 - Statement - Consolidated Statements of Financial Position",
     "shortName": "Consolidated Statements of Financial Position",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://trpx.com/role/ConsolidatedIncomeStatement",
     "longName": "002 - Statement - Consolidated Statements of Comprehensive Loss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:Revenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:SalesAndMarketingExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://trpx.com/role/ShareholdersEquityType2or3",
     "longName": "003 - Statement - Consolidated Statements of Changes in Equity (Deficit)",
     "shortName": "Consolidated Statements of Changes in Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c70",
      "name": "ifrs-full:Equity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c70",
      "name": "ifrs-full:Equity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://trpx.com/role/ConsolidatedCashFlow",
     "longName": "004 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://trpx.com/role/General",
     "longName": "005 - Disclosure - General",
     "shortName": "General",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfGeneralExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfGeneralExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://trpx.com/role/SignificantAccountingPolicies",
     "longName": "006 - Disclosure - Significant Accounting Policies",
     "shortName": "Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://trpx.com/role/InvestmentinAssociate",
     "longName": "007 - Disclosure - Investment in Associate",
     "shortName": "Investment in Associate",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://trpx.com/role/IntangibleAsset",
     "longName": "008 - Disclosure - Intangible Asset",
     "shortName": "Intangible Asset",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://trpx.com/role/InvestmentinFinancialAssets",
     "longName": "009 - Disclosure - Investment in Financial Assets",
     "shortName": "Investment in Financial Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://trpx.com/role/TransactionsandBalanceswithRelatedParties",
     "longName": "010 - Disclosure - Transactions and Balances with Related Parties",
     "shortName": "Transactions and Balances with Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://trpx.com/role/FinancialInstruments",
     "longName": "011 - Disclosure - Financial Instruments",
     "shortName": "Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://trpx.com/role/Warrants",
     "longName": "012 - Disclosure - Warrants",
     "shortName": "Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:WarrantTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:WarrantTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://trpx.com/role/Equity",
     "longName": "013 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss",
     "longName": "014 - Disclosure - Additional Information to the Items of Profit or Loss",
     "shortName": "Additional Information to the Items of Profit or Loss",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://trpx.com/role/SignificantEventsduringtheReportingPeriod",
     "longName": "015 - Disclosure - Significant Events during the Reporting Period",
     "shortName": "Significant Events during the Reporting Period",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://trpx.com/role/EventsaftertheReportingPeriod",
     "longName": "016 - Disclosure - Events after the Reporting Period",
     "shortName": "Events after the Reporting Period",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements",
     "longName": "017 - Disclosure - Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements",
     "shortName": "Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "sprcy:SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "sprcy:SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://trpx.com/role/Cash",
     "longName": "018 - Disclosure - Cash",
     "shortName": "Cash",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://trpx.com/role/Inventory",
     "longName": "019 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://trpx.com/role/OtherAccountsReceivable",
     "longName": "020 - Disclosure - Other Accounts Receivable",
     "shortName": "Other Accounts Receivable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvestees",
     "longName": "021 - Disclosure - Investment in Associates and Investments in Investees",
     "shortName": "Investment in Associates and Investments in Investees",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfInvestmentPropertyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfInvestmentPropertyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://trpx.com/role/Leases",
     "longName": "022 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://trpx.com/role/PropertyandEquipmentNet",
     "longName": "023 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://trpx.com/role/TradePayables",
     "longName": "024 - Disclosure - Trade Payables",
     "shortName": "Trade Payables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://trpx.com/role/OtherAccountsPayable",
     "longName": "025 - Disclosure - Other Accounts Payable",
     "shortName": "Other Accounts Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "sprcy:DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "sprcy:DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://trpx.com/role/EmployeeBenefitLiabilities",
     "longName": "026 - Disclosure - Employee Benefit Liabilities",
     "shortName": "Employee Benefit Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://trpx.com/role/TaxesonIncome",
     "longName": "027 - Disclosure - Taxes on Income",
     "shortName": "Taxes on Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens",
     "longName": "028 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens",
     "shortName": "Contingent Liabilities, Commitments, Claims and Liens",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://trpx.com/role/ShareBasedPaymentTransactions",
     "longName": "029 - Disclosure - Share-Based Payment Transactions",
     "shortName": "Share-Based Payment Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://trpx.com/role/RevenuesandCostofRevenues",
     "longName": "030 - Disclosure - Revenues and Cost of Revenues",
     "shortName": "Revenues and Cost of Revenues",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://trpx.com/role/LossPerShareAds",
     "longName": "031 - Disclosure - Loss Per Share/Ads",
     "shortName": "Loss Per Share/Ads",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://trpx.com/role/OperatingSegments",
     "longName": "032 - Disclosure - Operating Segments",
     "shortName": "Operating Segments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://trpx.com/role/AccountingPoliciesByPolicy",
     "longName": "033 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://trpx.com/role/SignificantAccountingPoliciesTables",
     "longName": "034 - Disclosure - Significant Accounting Policies (Tables)",
     "shortName": "Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "sprcy:DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "sprcy:DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://trpx.com/role/InvestmentinAssociateTables",
     "longName": "035 - Disclosure - Investment in Associate (Tables)",
     "shortName": "Investment in Associate (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://trpx.com/role/IntangibleAssetTables",
     "longName": "036 - Disclosure - Intangible Asset (Tables)",
     "shortName": "Intangible Asset (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables",
     "longName": "037 - Disclosure - Transactions and Balances with Related Parties (Tables)",
     "shortName": "Transactions and Balances with Related Parties (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "sprcy:DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "sprcy:DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://trpx.com/role/FinancialInstrumentsTables",
     "longName": "038 - Disclosure - Financial Instruments (Tables)",
     "shortName": "Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://trpx.com/role/WarrantsTables",
     "longName": "039 - Disclosure - Warrants (Tables)",
     "shortName": "Warrants (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "sprcy:WarrantTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "sprcy:WarrantTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://trpx.com/role/EquityTables",
     "longName": "040 - Disclosure - Equity (Tables)",
     "shortName": "Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables",
     "longName": "041 - Disclosure - Additional Information to the Items of Profit or Loss (Tables)",
     "shortName": "Additional Information to the Items of Profit or Loss (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfInformationToTheItemsOfProfitOrLoss",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfInformationToTheItemsOfProfitOrLoss",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://trpx.com/role/CashTables",
     "longName": "042 - Disclosure - Cash (Tables)",
     "shortName": "Cash (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://trpx.com/role/InventoryTables",
     "longName": "043 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfInvestmentEntitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfInvestmentEntitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://trpx.com/role/OtherAccountsReceivableTables",
     "longName": "044 - Disclosure - Other Accounts Receivable (Tables)",
     "shortName": "Other Accounts Receivable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "sprcy:DisclourseOfAccountsReceivablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "sprcy:DisclourseOfAccountsReceivablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesTables",
     "longName": "045 - Disclosure - Investment in Associates and Investments in Investees (Tables)",
     "shortName": "Investment in Associates and Investments in Investees (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "sprcy:DisclosureOfFairValueMeasurementOfAssetstable",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "sprcy:DisclosureOfFairValueMeasurementOfAssetstable",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://trpx.com/role/PropertyandEquipmentNetTables",
     "longName": "046 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://trpx.com/role/TradePayablesTables",
     "longName": "047 - Disclosure - Trade Payables (Tables)",
     "shortName": "Trade Payables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "sprcy:DisclosureOfTradePayables",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "sprcy:DisclosureOfTradePayables",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://trpx.com/role/OtherAccountsPayableTables",
     "longName": "048 - Disclosure - Other Accounts Payable (Tables)",
     "shortName": "Other Accounts Payable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "sprcy:ScheduleOfOtherAccountsPayable",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sprcy:DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "sprcy:ScheduleOfOtherAccountsPayable",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sprcy:DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://trpx.com/role/EmployeeBenefitLiabilitiesTables",
     "longName": "049 - Disclosure - Employee Benefit Liabilities (Tables)",
     "shortName": "Employee Benefit Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "sprcy:DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "sprcy:DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://trpx.com/role/ShareBasedPaymentTransactionsTables",
     "longName": "050 - Disclosure - Share-Based Payment Transactions (Tables)",
     "shortName": "Share-Based Payment Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "sprcy:DisclosureOfExpenseRecognizedExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "sprcy:DisclosureOfExpenseRecognizedExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://trpx.com/role/RevenuesandCostofRevenuesTables",
     "longName": "051 - Disclosure - Revenues and Cost of Revenues (Tables)",
     "shortName": "Revenues and Cost of Revenues (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "sprcy:ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "sprcy:ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://trpx.com/role/LossPerShareAdsTables",
     "longName": "052 - Disclosure - Loss Per Share/Ads (Tables)",
     "shortName": "Loss Per Share/Ads (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "sprcy:DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "sprcy:DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://trpx.com/role/OperatingSegmentsTables",
     "longName": "053 - Disclosure - Operating Segments (Tables)",
     "shortName": "Operating Segments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://trpx.com/role/GeneralDetails",
     "longName": "054 - Disclosure - General (Details)",
     "shortName": "General (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c268",
      "name": "ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:GainsLossesOnNetMonetaryPosition",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://trpx.com/role/SignificantAccountingPoliciesDetails",
     "longName": "055 - Disclosure - Significant Accounting Policies (Details)",
     "shortName": "Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "sprcy:OperatingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "sprcy:OperatingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://trpx.com/role/InvestmentinAssociateDetails",
     "longName": "056 - Disclosure - Investment in Associate (Details)",
     "shortName": "Investment in Associate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c106",
      "name": "sprcy:InvestedInitialAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c106",
      "name": "sprcy:InvestedInitialAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable",
     "longName": "057 - Disclosure - Investment in Associate (Details) - Schedule of Fair Value of the Investment",
     "shortName": "Investment in Associate (Details) - Schedule of Fair Value of the Investment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:EquityLossesFromInvestmentInMitoCareX",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://trpx.com/role/IntangibleAssetDetails",
     "longName": "058 - Disclosure - Intangible Asset (Details)",
     "shortName": "Intangible Asset (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:CashPayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:CashPayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable",
     "longName": "059 - Disclosure - Intangible Asset (Details) - Schedule of Fair Value of the Intangible Asset",
     "shortName": "Intangible Asset (Details) - Schedule of Fair Value of the Intangible Asset",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "sprcy:PurchaseOfAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
     "longName": "060 - Disclosure - Investment in Financial Assets (Details)",
     "shortName": "Investment in Financial Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:Cash",
      "unitRef": "ils",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:OtherComprehensiveIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails",
     "longName": "061 - Disclosure - Transactions and Balances with Related Parties (Details)",
     "shortName": "Transactions and Balances with Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "sprcy:CooperationAgreementWithClearmindAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "sprcy:CooperationAgreementWithClearmindAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://trpx.com/role/FinancialInstrumentsDetails",
     "longName": "062 - Disclosure - Financial Instruments (Details)",
     "shortName": "Financial Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c238",
      "name": "sprcy:BridgeLoanAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c238",
      "name": "sprcy:BridgeLoanAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable",
     "longName": "063 - Disclosure - Financial Instruments (Details) - Schedule of Financial Assets and Financial Liabilities",
     "shortName": "Financial Instruments (Details) - Schedule of Financial Assets and Financial Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:TradeReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://trpx.com/role/WarrantsDetails",
     "longName": "064 - Disclosure - Warrants (Details)",
     "shortName": "Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c118",
      "name": "sprcy:GrossProceed",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "sprcy:WarrantTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c118",
      "name": "sprcy:GrossProceed",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "sprcy:WarrantTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://trpx.com/role/ScheduleofWarrantsFairValueTable",
     "longName": "065 - Disclosure - Warrants (Details) - Schedule of Warrants\u2019 Fair Value",
     "shortName": "Warrants (Details) - Schedule of Warrants\u2019 Fair Value",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c122",
      "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "sprcy:WarrantTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c122",
      "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "sprcy:WarrantTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://trpx.com/role/EquityDetails",
     "longName": "066 - Disclosure - Equity (Details)",
     "shortName": "Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c105",
      "name": "sprcy:StockIssuedDuringPeriodReverseStockSplits",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c105",
      "name": "sprcy:StockIssuedDuringPeriodReverseStockSplits",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://trpx.com/role/ScheduleofShareCapitalTable",
     "longName": "067 - Disclosure - Equity (Details) - Schedule of Share Capital",
     "shortName": "Equity (Details) - Schedule of Share Capital",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c137",
      "name": "ifrs-full:NumberOfSharesAuthorised",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c137",
      "name": "ifrs-full:NumberOfSharesAuthorised",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable",
     "longName": "068 - Disclosure - Equity (Details) - Schedule of Issued and Outstanding Share Capital",
     "shortName": "Equity (Details) - Schedule of Issued and Outstanding Share Capital",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "sprcy:NumberOfSharesIssued1",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "sprcy:NumberOfSharesIssued1",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
     "longName": "069 - Disclosure - Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss",
     "shortName": "Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c140",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfInformationToTheItemsOfProfitOrLoss",
       "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails",
     "longName": "070 - Disclosure - Significant Events during the Reporting Period (Details)",
     "shortName": "Significant Events during the Reporting Period (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c176",
      "name": "sprcy:InterestPercentgae",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c176",
      "name": "sprcy:InterestPercentgae",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://trpx.com/role/EventsaftertheReportingPeriodDetails",
     "longName": "071 - Disclosure - Events after the Reporting Period (Details)",
     "shortName": "Events after the Reporting Period (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c181",
      "name": "sprcy:DescriptionOfPublicOffering",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c181",
      "name": "sprcy:DescriptionOfPublicOffering",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable",
     "longName": "072 - Disclosure - Significant Accounting Policies (Details) - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life",
     "shortName": "Significant Accounting Policies (Details) - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c190",
      "name": "sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c190",
      "name": "sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://trpx.com/role/ScheduleofCashTable",
     "longName": "073 - Disclosure - Cash (Details) - Schedule of Cash",
     "shortName": "Cash (Details) - Schedule of Cash",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "sprcy:CashForImmediateWithdrawal",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "sprcy:CashForImmediateWithdrawal",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://trpx.com/role/ScheduleofInventoryTable",
     "longName": "074 - Disclosure - Inventory (Details) - Schedule of Inventory",
     "shortName": "Inventory (Details) - Schedule of Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:CurrentInventoriesInTransit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfInvestmentEntitiesExplanatory",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:CurrentInventoriesInTransit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfInvestmentEntitiesExplanatory",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable",
     "longName": "075 - Disclosure - Other Accounts Receivable (Details) - Schedule of Other Accounts Receivable",
     "shortName": "Other Accounts Receivable (Details) - Schedule of Other Accounts Receivable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:ValueAddedTaxReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclourseOfAccountsReceivablesTableTextBlock",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:ValueAddedTaxReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclourseOfAccountsReceivablesTableTextBlock",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails",
     "longName": "076 - Disclosure - Investment in Associates and Investments in Investees (Details)",
     "shortName": "Investment in Associates and Investments in Investees (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c201",
      "name": "sprcy:ConversionOfOrdinaryShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfInvestmentPropertyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c201",
      "name": "sprcy:ConversionOfOrdinaryShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfInvestmentPropertyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable0",
     "longName": "077 - Disclosure - Investment in Associates and Investments in Investees (Details) - Schedule of Fair Value of the Investment",
     "shortName": "Investment in Associates and Investments in Investees (Details) - Schedule of Fair Value of the Investment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "sprcy:EquityLossesFromInvestment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://trpx.com/role/LeasesDetails",
     "longName": "078 - Disclosure - Leases (Details)",
     "shortName": "Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c212",
      "name": "sprcy:SquareMeters",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c212",
      "name": "sprcy:SquareMeters",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://trpx.com/role/PropertyandEquipmentNetDetails",
     "longName": "079 - Disclosure - Property and Equipment, Net (Details)",
     "shortName": "Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DepreciationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:DepreciationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable",
     "longName": "080 - Disclosure - Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net",
     "shortName": "Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c216",
      "name": "sprcy:BeginningBalanceCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c228",
      "name": "sprcy:BeginningBalanceCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable0",
     "longName": "081 - Disclosure - Intangible Asset (Details) - Schedule of Fair Value of the Intangible Asset",
     "shortName": "Intangible Asset (Details) - Schedule of Fair Value of the Intangible Asset",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "sprcy:PurchaseofAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "sprcy:PurchaseofAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://trpx.com/role/ScheduleofTradePayablesTable",
     "longName": "082 - Disclosure - Trade Payables (Details) - Schedule of Trade Payables",
     "shortName": "Trade Payables (Details) - Schedule of Trade Payables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "sprcy:AccruedExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfTradePayables",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "sprcy:AccruedExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfTradePayables",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://trpx.com/role/ScheduleofOtherAccountsPayableTable",
     "longName": "083 - Disclosure - Other Accounts Payable (Details) - Schedule of Other Accounts Payable",
     "shortName": "Other Accounts Payable (Details) - Schedule of Other Accounts Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:ShorttermEmployeeBenefitsAccruals",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:ScheduleOfOtherAccountsPayable",
       "sprcy:DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:ShorttermEmployeeBenefitsAccruals",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:ScheduleOfOtherAccountsPayable",
       "sprcy:DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0",
     "longName": "084 - Disclosure - Financial Instruments (Details) - Schedule of Financial Assets and Financial Liabilities",
     "shortName": "Financial Instruments (Details) - Schedule of Financial Assets and Financial Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:RestrictedCashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:RestrictedCashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable",
     "longName": "085 - Disclosure - Financial Instruments (Details) - Schedule of Warrants Fair Value Using Black\u2013Scholes OPM",
     "shortName": "Financial Instruments (Details) - Schedule of Warrants Fair Value Using Black\u2013Scholes OPM",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c245",
      "name": "sprcy:DividendYield",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c245",
      "name": "sprcy:DividendYield",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://trpx.com/role/ScheduleofDefinedContributionPlansTable",
     "longName": "086 - Disclosure - Employee Benefit Liabilities (Details) - Schedule of Defined Contribution Plans",
     "shortName": "Employee Benefit Liabilities (Details) - Schedule of Defined Contribution Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:EmployeeBenefitsExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:EmployeeBenefitsExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://trpx.com/role/TaxesonIncomeDetails",
     "longName": "087 - Disclosure - Taxes on Income (Details)",
     "shortName": "Taxes on Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:ApplicableTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:ApplicableTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails",
     "longName": "088 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens (Details)",
     "shortName": "Contingent Liabilities, Commitments, Claims and Liens (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "sprcy:DekelLicenseAgreementDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "sprcy:DekelLicenseAgreementDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://trpx.com/role/ScheduleofShareCapitalTable0",
     "longName": "089 - Disclosure - Equity (Details) - Schedule of Share Capital",
     "shortName": "Equity (Details) - Schedule of Share Capital",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:NumberOfSharesAuthorised",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:NumberOfSharesAuthorised",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R91": {
     "role": "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable0",
     "longName": "090 - Disclosure - Equity (Details) - Schedule of Issued and Outstanding Share Capital",
     "shortName": "Equity (Details) - Schedule of Issued and Outstanding Share Capital",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "unique": true
     }
    },
    "R92": {
     "role": "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable",
     "longName": "091 - Disclosure - Equity (Details) - Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model",
     "shortName": "Equity (Details) - Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c278",
      "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c278",
      "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R93": {
     "role": "http://trpx.com/role/ShareBasedPaymentTransactionsDetails",
     "longName": "092 - Disclosure - Share-Based Payment Transactions (Details)",
     "shortName": "Share-Based Payment Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c280",
      "name": "ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c280",
      "name": "ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R94": {
     "role": "http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable",
     "longName": "093 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of Expenses Due to Share-Based Compensation",
     "shortName": "Share-Based Payment Transactions (Details) - Schedule of Expenses Due to Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "sprcy:ResearchAndDevelopmentExpenses01",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "sprcy:ResearchAndDevelopmentExpenses01",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R95": {
     "role": "http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable",
     "longName": "094 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of Fair Value for Share Options Granted",
     "shortName": "Share-Based Payment Transactions (Details) - Schedule of Fair Value for Share Options Granted",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c294",
      "name": "sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c294",
      "name": "sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R96": {
     "role": "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable",
     "longName": "095 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of Weighted Average Exercise Prices of Share Options",
     "shortName": "Share-Based Payment Transactions (Details) - Schedule of Weighted Average Exercise Prices of Share Options",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "sprcy:NumberOfOutstandingShareOption",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c96",
      "name": "sprcy:NumberOfOutstandingShareOption",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "unique": true
     }
    },
    "R97": {
     "role": "http://trpx.com/role/ScheduleofRevenuesandCostofRevenuesTable",
     "longName": "096 - Disclosure - Revenues and Cost of Revenues (Details) - Schedule of Revenues and Cost of Revenues",
     "shortName": "Revenues and Cost of Revenues (Details) - Schedule of Revenues and Cost of Revenues",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:Revenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R98": {
     "role": "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0",
     "longName": "097 - Disclosure - Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss",
     "shortName": "Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "sprcy:ResearchAndDevelopmentExpenses1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfInformationToTheItemsOfProfitOrLoss",
       "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "sprcy:ResearchAndDevelopmentExpenses1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfInformationToTheItemsOfProfitOrLoss",
       "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R99": {
     "role": "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable",
     "longName": "098 - Disclosure - Loss Per Share/Ads (Details) - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share",
     "shortName": "Loss Per Share/Ads (Details) - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c330",
      "name": "ifrs-full:WeightedAverageShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c330",
      "name": "ifrs-full:WeightedAverageShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R100": {
     "role": "http://trpx.com/role/ScheduleofOperatingSegmentsTable",
     "longName": "099 - Disclosure - Operating Segments (Details) - Schedule of Operating Segments",
     "shortName": "Operating Segments (Details) - Schedule of Operating Segments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "sprcy:ExternalRevenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "sprcy:ExternalRevenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R101": {
     "role": "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable",
     "longName": "100 - Disclosure - Transactions and Balances with Related Parties (Details) - Schedule of Balances with Related Parties",
     "shortName": "Transactions and Balances with Related Parties (Details) - Schedule of Balances with Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "c344",
      "name": "ifrs-full:CurrentLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c344",
      "name": "ifrs-full:CurrentLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R102": {
     "role": "http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable",
     "longName": "101 - Disclosure - Transactions and Balances with Related Parties (Details) - Schedule of Transactions with Related Parties",
     "shortName": "Transactions and Balances with Related Parties (Details) - Schedule of Transactions with Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "sprcy:ResearchAndDevelopmentExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "sprcy:ResearchAndDevelopmentExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    },
    "R103": {
     "role": "http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable",
     "longName": "102 - Disclosure - Transactions and Balances with Related Parties (Details) - Schedule of Benefits to Key Management Personnel",
     "shortName": "Transactions and Balances with Related Parties (Details) - Schedule of Benefits to Key Management Personnel",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0200391-f1_scisparcltd.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "sprcy_ADSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ADSMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ADS [Member]",
        "label": "ADSMember"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ADSsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ADSsMember",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ADSs [Member]",
        "label": "ADSs Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AResearchAndDevelopmentExpensesAbstract0": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "AResearchAndDevelopmentExpensesAbstract0",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "a. Research and development expenses:",
        "label": "AResearch And Development Expenses Abstract0"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AccountingPolicyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "AccountingPolicyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Accruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Accruals",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued vacation",
        "label": "Accruals"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "sprcy_AccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "AccruedExpenses",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofTradePayablesTable": {
       "parentTag": "ifrs-full_TradeAndOtherPayablesToTradeSuppliers",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofTradePayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AccumulatedDepreciationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "AccumulatedDepreciationAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated depreciation:",
        "label": "Accumulated Depreciation Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AccumulatedDepreciationAbstract0": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "AccumulatedDepreciationAbstract0",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated depreciation:",
        "label": "Accumulated Depreciation Abstract0"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AccumulatedTerminationOfLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "AccumulatedTerminationOfLeases",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation of leases",
        "documentation": "Accumulated termination of leases.",
        "label": "Accumulated Termination Of Leases"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs",
        "label": "Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of acquisition-related costs for transactions recognised separately from the acquisition of assets and the assumption of liabilities in business combinations. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "sprcy_AdditionalAgreedInvest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "AdditionalAgreedInvest",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails",
      "http://trpx.com/role/InvestmentinAssociateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional agreed invest",
        "documentation": "Additional agreed invest.",
        "label": "Additional Agreed Invest"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdditionalInformationtotheItemsofProfitorLossTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "AdditionalInformationtotheItemsofProfitorLossTablesLineItems",
     "presentation": [
      "http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Information to the Items of Profit or Loss [Abstract]",
        "label": "Additional Informationtothe Itemsof Profitor Loss Tables Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdditionalInformationtotheItemsofProfitorLossTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "AdditionalInformationtotheItemsofProfitorLossTablesTable",
     "presentation": [
      "http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Information to the Items of Profit or Loss (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdditionalMilestoneAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "AdditionalMilestoneAmount",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional milestone amount",
        "label": "Additional Milestone Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdditionalProvisionsOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionalProvisionsOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional amount",
        "label": "Additional provisions, other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additional other provisions made. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdjustedAmountOfAggregateValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "AdjustedAmountOfAggregateValue",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjusted amount of aggregate value",
        "documentation": "The adjusted amount of aggregate value.",
        "label": "Adjusted Amount Of Aggregate Value"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForAmountsTransferredToInitialCarryingAmountOfHedgedItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForAmountsTransferredToInitialCarryingAmountOfHedgedItems",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial amount",
        "label": "Amounts removed from equity and included in carrying amount of non-financial asset (liability) whose acquisition or incurrence was hedged highly probable forecast transaction, net of tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts removed from equity and included in the initial cost or other carrying amount of a non-financial asset (liability) whose acquisition or incurrence was a hedged, highly probable forecast transaction, net of tax. [Refer: Carrying amount [member]]"
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease (increase) in inventory",
        "label": "Adjustments for decrease (increase) in inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease (increase) in other accounts receivable",
        "label": "Adjustments for decrease (increase) in other operating receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease (increase) in trade receivables",
        "label": "Adjustments for decrease (increase) in trade accounts receivable"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDepreciationAndAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Adjustments for depreciation and amortisation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "ifrs-full_AdjustmentsForFinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForFinanceIncomeCost",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance expenses, net",
        "label": "Adjustments for finance income (cost)"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "sprcy_AdjustmentsForImpairmentOfInvestmentInAssociate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "AdjustmentsForImpairmentOfInvestmentInAssociate",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Losses from remeasurement of investment in financial assets",
        "documentation": "Adjustments for impairment of investment in associate.",
        "label": "Adjustments For Impairment Of Investment In Associate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in trade payables",
        "label": "Adjustments for increase (decrease) in trade accounts payable"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in other accounts payable",
        "label": "Adjustments for increase (decrease) in trade and other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Group\u2019s share of losses of company accounted for at equity, net",
        "label": "Adjustments for losses (gains) on disposal of non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for losses (gains) on disposal of non-current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Non-current assets; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "ifrs-full_AdjustmentsForReconcileProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLoss",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total adjustments to the profit or loss",
        "label": "Adjustments to reconcile profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow",
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of share-based payment",
        "label": "Adjustments for share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Working capital",
        "label": "Adjustments to reconcile profit (loss) other than changes in working capital"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments, other than changes in working capital, to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "sprcy_AdjustmentsToTheProfitOrLossItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "AdjustmentsToTheProfitOrLossItemsAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to the profit or loss items:",
        "label": "Adjustments To The Profit Or Loss Items Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateAmountOrCreditAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "AggregateAmountOrCreditAmount",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate amount or credit amount",
        "documentation": "An aggregate amount or score is made up of several smaller amounts or scores added together. The rate of growth of GNP will depend upon the rate of growth of aggregate demand.",
        "label": "Aggregate Amount Or Credit Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateGrossProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "AggregateGrossProceeds",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate gross proceeds",
        "documentation": "Aggregate Gross Proceeds means the aggregate of the proceeds from any sale of shares of Common Stock by the Underwriter pursuant to this Agreement, before the deduction of Commissions and Placement Fees payable with respect to those shares.",
        "label": "Aggregate Gross Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregatePurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "AggregatePurchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate purchase price",
        "documentation": "Aggregate purchase price is the final calculation of the purchase price for a company.",
        "label": "Aggregate Purchase Price"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "AggregateValue",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate value",
        "documentation": "The amount of ordinary shares of aggregate value.",
        "label": "Aggregate Value"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AgreementTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "AgreementTypeAxis",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement Type [Axis]",
        "label": "Agreement Type Axis"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AgreementTypeDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "AgreementTypeDomainDomain",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AgreementTypeDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exceeds",
        "label": "Amount by which unit's recoverable amount exceeds its carrying amount"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount by which a cash-generating unit's (group of units') recoverable amount exceeds its carrying amount. [Refer: Carrying amount [member]; Cash-generating units [member]]"
       }
      }
     },
     "auth_ref": [
      "r78",
      "r79"
     ]
    },
    "sprcy_AmountTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "AmountTotal",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount total",
        "label": "Amount Total"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AnnualInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "AnnualInvestment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual investment",
        "documentation": "Amount of annual investment.",
        "label": "Annual Investment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AntidilutiveInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AntidilutiveInstrumentsMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive instruments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for antidilutive instruments. Instruments are antidilutive when their conversion to ordinary shares would increase earnings per share or decrease loss per share from continuing operations. The calculation of diluted earnings per share does not assume conversion, exercise, or other issue of potential ordinary shares that would have an antidilutive effect on earnings per share. It also represents the standard value for the \u2018Types of antidilutive instruments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ifrs-full_ApplicableTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ApplicableTaxRate",
     "presentation": [
      "http://trpx.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Israeli corporate income tax",
        "label": "Applicable tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "sprcy_AprilTwoThousandTwentyPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "AprilTwoThousandTwentyPurchaseAgreementMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "April 2020 Purchase Agreement [Member]",
        "label": "April Two Thousand Twenty Purchase Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Assets, total",
        "label": "Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r118",
      "r119",
      "r120",
      "r157",
      "r160"
     ]
    },
    "sprcy_AttributableToAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "AttributableToAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attributable to:",
        "label": "Attributable To Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AutoMaxSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "AutoMaxSharesMember",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AutoMax Shares [Member]",
        "label": "Auto Max Shares Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_BGeneralAndAdministrativeExpensesAbstract0": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "BGeneralAndAdministrativeExpensesAbstract0",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "b. General and administrative expenses:",
        "label": "BGeneral And Administrative Expenses Abstract0"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_BalanceOwedToClearmind": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "BalanceOwedToClearmind",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance owed to clearmind",
        "documentation": "The amount of balance owed to clearmind.",
        "label": "Balance Owed To Clearmind"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss from operations (in Dollars per share)",
        "label": "Basic earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r69"
     ]
    },
    "sprcy_BasicLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "BasicLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic loss per share attributable to equity holders of the Company:",
        "label": "Basic Loss Per Share Attributable To Equity Holders Of The Company Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_BasisOfPresentationOfFinancialStatements": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "BasisOfPresentationOfFinancialStatements",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of presentation of the financial statements",
        "documentation": "The description of the entity's accounting policy changes inrBasis of presentation of the financial statements.",
        "label": "Basis Of Presentation Of Financial Statements"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_BeginningBalanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "BeginningBalanceCost",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance , Cost",
        "periodEndLabel": "Ending Balance, Cost",
        "documentation": "Amount of beginning balance, cost.",
        "label": "Beginning Balance Cost"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_BonusAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "BonusAmount",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bonus amount",
        "documentation": "Amount of bonus amount.",
        "label": "Bonus Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_BonusAmountReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "BonusAmountReceived",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bonus amount",
        "documentation": "Bonus amount received.",
        "label": "Bonus Amount Received"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingsInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsInterestRate",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Borrowings, interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/InvestmentinAssociateDetails",
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails",
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable",
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bottom of range [Member]",
        "verboseLabel": "Bottom of range [member]",
        "netLabel": "Minimum [Member]",
        "label": "Bottom of Range [Member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r130",
      "r133",
      "r185",
      "r186",
      "r219"
     ]
    },
    "sprcy_BridgeLoanAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "BridgeLoanAmount",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bridge loan amount",
        "documentation": "Short-Term financing which is expected to be paid back relatively quickly, such as by a subsequent longer-term loan. Also called swing loan or bridge Loan financing.",
        "label": "Bridge Loan Amount"
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Contact",
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195"
     ]
    },
    "sprcy_BusinessDevelopmentExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "BusinessDevelopmentExpensesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business development expenses [Member]",
        "label": "Business Development Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_COtherExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "COtherExpensesAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "c. Other expenses:",
        "label": "COther Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CapitalPointMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "CapitalPointMember",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital Point [Member]",
        "label": "Capital Point Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CapitalPointWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "CapitalPointWarrantMember",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital Point Warrant [Member]",
        "label": "Capital Point Warrant Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CapitalProposedToDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "CapitalProposedToDeposit",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital proposed to deposit",
        "label": "Capital Proposed To Deposit"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "ifrs-full_CashAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ConsolidatedCashFlow",
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at the beginning of the period",
        "periodEndLabel": "Cash and cash equivalents at the end of the period",
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r92",
      "r114"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment (withdrawal) in restricted bank deposits",
        "label": "Cash flows from (used in) decrease (increase) in restricted cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) due to a decrease (increase) in restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in a company accounted for at equity",
        "label": "Cash flows from (used in) decrease (increase) in short-term deposits and investments"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash flows from (used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r93"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Cash flows from (used in) financing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Cash flows from (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r93"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Cash flows from (used in) investing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow",
      "http://trpx.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "terseLabel": "Cash flows from operating activities",
        "label": "Cash flows from (used in) operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r89",
      "r93"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Cash flows from (used in) operating activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CashForImmediateWithdrawal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "CashForImmediateWithdrawal",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofCashTable": {
       "parentTag": "ifrs-full_CashOnHand",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash for immediate withdrawal - in USD",
        "documentation": "The amount of cash withdrawal.",
        "label": "Cash For Immediate Withdrawal"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CashForImmediateWithdrawalInNIS": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "CashForImmediateWithdrawalInNIS",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofCashTable": {
       "parentTag": "ifrs-full_CashOnHand",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash for immediate withdrawal - in NIS",
        "documentation": "Cash for Immediate withdrawal in NIS currency.",
        "label": "Cash For Immediate Withdrawal In NIS"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CashLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "CashLineItems",
     "presentation": [
      "http://trpx.com/role/Cash"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash [Abstract]",
        "label": "Cash Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashOnHand": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashOnHand",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofCashTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cash and cash equivalents",
        "label": "Cash on hand"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash held by the entity. This does not include demand deposits."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "ifrs-full_CashOutflowForLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashOutflowForLeases",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for principal amount",
        "label": "Cash outflow for leases"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for leases."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "sprcy_CashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "CashPayment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash payment",
        "label": "Cash Payment"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CashTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "CashTable",
     "presentation": [
      "http://trpx.com/role/Cash"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CashTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "CashTablesLineItems",
     "presentation": [
      "http://trpx.com/role/CashTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Cash [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CashTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "CashTablesTable",
     "presentation": [
      "http://trpx.com/role/CashTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfFinancialAssetsAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets:",
        "label": "Categories of financial assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails",
      "http://trpx.com/role/FinancialInstrumentsDetails",
      "http://trpx.com/role/InvestmentinAssociateDetails",
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/LeasesDetails",
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "sprcy_ChemistryAndFormulationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ChemistryAndFormulationsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chemistry and formulations [Member]",
        "label": "Chemistry And Formulations Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ClaimsOnDamages": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ClaimsOnDamages",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Claims on damages",
        "documentation": "Claims on damages.",
        "label": "Claims On Damages"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfAssetsAxis",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r77",
      "r121",
      "r126"
     ]
    },
    "ifrs-full_ClassesOfAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfAssetsMember",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r121",
      "r126"
     ]
    },
    "ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfEntitysOwnEquityInstrumentsAxis",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of entity's own equity instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "ifrs-full_ClassesOfOrdinarySharesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfOrdinarySharesAxis",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable",
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of ordinary shares [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable",
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails",
      "http://trpx.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfShareCapitalMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails",
      "http://trpx.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "sprcy_ClearmindOutstandingShareCapitalPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ClearmindOutstandingShareCapitalPercentage",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clearmind outstanding share capital percentage",
        "documentation": "The percentage of clearmind outstanding share capital percentage.",
        "label": "Clearmind Outstanding Share Capital Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ClinicalStudiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ClinicalStudiesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical studies [Member]",
        "label": "Clinical Studies Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CommunicationAndNetworkEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CommunicationAndNetworkEquipmentMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment [Member]",
        "label": "Communication and network equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing communications and network equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "CompanysShareOfLossesOfCompanyAccountedForAtEquityNet",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company\u2019s share of losses of company accounted for at equity, net",
        "documentation": "Company\u2019s share of losses of company accounted for at equity, net.",
        "label": "Companys Share Of Losses Of Company Accounted For At Equity Net"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails",
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total comprehensive loss",
        "label": "Comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r32",
      "r98",
      "r101",
      "r111",
      "r184"
     ]
    },
    "sprcy_ComprehensiveIncomeAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ComprehensiveIncomeAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossAttributableToNoncontrollingInterests",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-controlling interests",
        "documentation": "The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]",
        "label": "Comprehensive Income Attributable To Noncontrolling Interest"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossAttributableToNoncontrollingInterests",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interests",
        "label": "Comprehensive income, attributable to non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r34"
     ]
    },
    "sprcy_ComprehensiveLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ComprehensiveLoss",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive loss",
        "documentation": "Comprehensive loss.",
        "label": "Comprehensive Loss"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable",
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computers [Member]",
        "label": "Computer equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "sprcy_ConsolidatedStatementsOfChangesInEquityDeficitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ConsolidatedStatementsOfChangesInEquityDeficitAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements Of Changes In Equity Deficit Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liabilities Commitments Claims and Liens [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ContinuingAndDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContinuingAndDiscontinuedOperationsAxis",
     "presentation": [
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Continuing and discontinued operations [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "sprcy_ContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ContinuingOperationsAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Continuing operations:",
        "label": "Continuing Operations Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ConversionOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ConversionOfOrdinaryShares",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares",
        "label": "Conversion Of Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ConversionPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ConversionPrice",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price",
        "label": "Conversion Price"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CooperationAgreementWithClearmindAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "CooperationAgreementWithClearmindAmount",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cooperation agreement with clearmind amount",
        "documentation": "The amount of cooperation Agreement with Clearmind amount.",
        "label": "Cooperation Agreement With Clearmind Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "CostAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost:",
        "label": "Cost Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CostOfSales",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/ScheduleofRevenuesandCostofRevenuesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cost of goods sold",
        "terseLabel": "Cost of goods sold",
        "label": "Cost of sales"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r40"
     ]
    },
    "ifrs-full_CreationDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CreationDateAxis",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Creation date [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r96"
     ]
    },
    "sprcy_CreditFacilityAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "CreditFacilityAmount",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit facility amount",
        "documentation": "A credit facility is a type of loan made in a business or corporate finance context. It allows the borrowing business to take out money over an extended period of time rather than reapplying for a loan each time it needs money.",
        "label": "Credit Facility Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CreditFacilityAndRemainingAvailableDrawnAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "CreditFacilityAndRemainingAvailableDrawnAmount",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit facility and remaining available drawn amount",
        "documentation": "Credit Facility and remaining available drawn amount.",
        "label": "Credit Facility And Remaining Available Drawn Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CreditFromOthers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "CreditFromOthers",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit from others",
        "documentation": "The amount of credit of others.",
        "label": "Credit From Others"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CreditsFromOthers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "CreditsFromOthers",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit from others",
        "documentation": "Credit from others.",
        "label": "Credits From Others"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Current asset, total",
        "label": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r19",
      "r108",
      "r184"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT ASSETS:",
        "label": "Current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentFinancialAssetsAtAmortisedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentFinancialAssetsAtAmortisedCost",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total financial assets at amortized cost",
        "label": "Current financial assets at amortised cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial assets measured at amortised cost. [Refer: Financial assets at amortised cost]"
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "ifrs-full_CurrentInventoriesInTransit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentInventoriesInTransit",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofInventoryTable": {
       "parentTag": "sprcy_InventoriesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goods in transit",
        "label": "Current inventories in transit"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of inventories in transit. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Liabilities current, total",
        "terseLabel": "Current liabilities",
        "label": "Current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r110",
      "r184"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT LIABILITIES:",
        "label": "Current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable": {
       "parentTag": "ifrs-full_OtherCurrentReceivables",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Current prepaid expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "ifrs-full_CurrentTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTradeReceivables",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables",
        "label": "Current trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r171",
      "r173"
     ]
    },
    "ifrs-full_CurrentWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentWarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Current warrant liability"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current warrant liabilities. [Refer: Warrant liability]"
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "sprcy_DateOfIssuance": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DateOfIssuance",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Date of issuance",
        "label": "Date Of Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DefaultFinancialStatementsDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DefaultFinancialStatementsDateMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Default financial statements date [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Creation date' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r96"
     ]
    },
    "sprcy_DeferredCashPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DeferredCashPayments",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred cash payments",
        "documentation": "Deferred cash payments.",
        "label": "Deferred Cash Payments"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DekelLicenseAgreementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DekelLicenseAgreementDescription",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dekel license agreement, description",
        "documentation": "Dekel license agreement description.",
        "label": "Dekel License Agreement Description"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationAndAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationAndAmortisationExpense",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation of intangible asset",
        "label": "Depreciation and amortisation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r40",
      "r115",
      "r154",
      "r161",
      "r168"
     ]
    },
    "ifrs-full_DepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationExpense",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationPropertyPlantAndEquipment",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r48",
      "r51"
     ]
    },
    "ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Straight-line basis over the useful life of the assets, description",
        "label": "Description of intangible assets with indefinite useful life supporting assessment of indefinite useful life"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of intangible assets with indefinite useful life, supporting the assessment of indefinite useful life. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DescriptionOfAccountingPolicyForConsolidatedfinancialstatements",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated financial statements",
        "documentation": "The description of the entity's accounting policy changes in Consolidated financial statements.",
        "label": "Description Of Accounting Policy For Consolidatedfinancialstatements"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings (loss) per share",
        "label": "Description of accounting policy for earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee benefit liabilities",
        "label": "Description of accounting policy for employee benefits [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value measurement",
        "label": "Description of accounting policy for fair value measurement [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance income and expenses",
        "label": "Description of accounting policy for finance income and costs [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for finance income and costs. [Refer: Finance income (cost)]"
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial instruments",
        "label": "Description of accounting policy for financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Functional currency and foreign currency",
        "label": "Description of accounting policy for foreign currency translation [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for foreign currency translation."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of non-financial assets",
        "label": "Description of accounting policy for impairment of non-financial assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Description of accounting policy for intangible assets and goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for intangible assets and goodwill. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments accounted for using the equity method",
        "documentation": "The description of the entity's accounting policy for investments in associates. The description of the entity's material accounting policy information for investments accounted for using the equity method.",
        "label": "Description Of Accounting Policy For Investment Accounted For Using The Equity Methodtext Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForInvestmentInAssociates",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in associates",
        "label": "Description of accounting policy for investment in associates [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for investments in associates. [Refer: Associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in joint arrangements",
        "label": "Description of accounting policy for investment in associates and joint ventures [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for investment in associates and joint ventures. [Refer: Associates [member]; Joint ventures [member]]"
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Description of accounting policy for leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Description of accounting policy for property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions",
        "label": "Description of accounting policy for provisions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenditures",
        "label": "Description of accounting policy for research and development expense [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]"
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DescriptionOfAccountingPolicyForRestrictedDeposit",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted deposits",
        "label": "Description Of Accounting Policy For Restricted Deposit"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment transactions",
        "label": "Description of accounting policy for share-based payment transactions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes on income",
        "label": "Description of accounting policy for taxes other than income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for taxes other than income tax. [Refer: Tax expense other than income tax expense]"
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DescriptionOfAccountingPolicyForoperatingcycleExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The operating cycle",
        "documentation": "The description of the entity's accounting policy changes in operating cycle Explanatory.",
        "label": "Description Of Accounting Policy Foroperatingcycle Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DescriptionOfAcquisitionOfASingleAssetCompany": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DescriptionOfAcquisitionOfASingleAssetCompany",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition of a single asset company",
        "documentation": "The description of the entity's accounting policy for acquisition of a single asset company.",
        "label": "Description Of Acquisition Of ASingle Asset Company"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment to IAS 1, \u201cPresentation of Financial Statements",
        "documentation": "The description of the entity's accounting policy for amendment to IAS. The description of the entity's material accounting policy information for amendment to IAS 1, presentation of financial statements.",
        "label": "Description Of Amendment To IAS1 Presentation Of Financial Statements"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment to IAS 8, \u201cAccounting Policies, Changes to Accounting Estimates and Errors\u201d",
        "documentation": "The description of the entity's accounting policy for changes to accounting estimates and errors.",
        "label": "Description Of Amendment To IAS8 Accounting Policies Changes To Accounting Estimates And Errors"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValueTable",
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility (%)",
        "label": "Expected volatility, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "sprcy_DescriptionOfOptionPricingModelShareOptionGranted": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DescriptionOfOptionPricingModelShareOptionGranted",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value for Share Options Granted",
        "label": "Description Of Option Pricing Model Share Option Granted"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DescriptionOfPrivateOffering": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DescriptionOfPrivateOffering",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of private offering",
        "documentation": "Description of private offering.",
        "label": "Description Of Private Offering"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DescriptionOfPublicOffering": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DescriptionOfPublicOffering",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of public offering",
        "documentation": "Description of public offering.",
        "label": "Description Of Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DescriptionOfReverseShareSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DescriptionOfReverseShareSplit",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of reverse share split",
        "label": "Description Of Reverse Share Split"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValueTable",
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate (%)",
        "label": "Risk free interest rate, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss from operations (in Dollars per share)",
        "label": "Diluted earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r68",
      "r69"
     ]
    },
    "sprcy_DilutedLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DilutedLossPerShareAttributableToEquityHoldersOfTheCompanyAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted loss per share attributable to equity holders of the Company:",
        "label": "Diluted Loss Per Share Attributable To Equity Holders Of The Company Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise warrants",
        "label": "Dilutive effect of share options on weighted average number of ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The potential dilutive effect on the weighted average number of ordinary shares that relate to the assumed exercise of the entity's share options."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DisclosueOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://trpx.com/role/CashTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash",
        "documentation": "The entire disclosue of cash and cash equivalents.",
        "label": "Disclosue Of Cash And Cash Equivalents Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent",
     "presentation": [
      "http://trpx.com/role/OtherAccountsPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER ACCOUNTS PAYABLE",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Disclosure Of Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAdditionalInformationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfAdditionalInformationExplanatory",
     "presentation": [
      "http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS",
        "label": "Disclosure of additional information [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of additional information that is not presented elsewhere in the financial statements, but that is relevant to an understanding of them."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "sprcy_DisclosureOfAdditionalInformationTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DisclosureOfAdditionalInformationTextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Information to the Items of Profit or Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unaudited Interim Financial Information",
        "label": "Disclosure of basis of preparation of financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCashAndCashEquivalentsExplanatory",
     "presentation": [
      "http://trpx.com/role/Cash"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH",
        "label": "Disclosure of cash and cash equivalents [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingPoliciesExplanatory",
     "presentation": [
      "http://trpx.com/role/SignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Disclosure of changes in accounting policies [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of changes made to accounting policies by the entity."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "presentation": [
      "http://trpx.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share Capital",
        "label": "Disclosure of classes of share capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]"
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS",
        "label": "Disclosure of commitments and contingent liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]"
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "ifrs-full_DisclosureOfCompoundFinancialInstrumentsWithMultipleEmbeddedDerivativesExplanatory": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCompoundFinancialInstrumentsWithMultipleEmbeddedDerivativesExplanatory",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Issuance of convertible debentures",
        "label": "Description of compound financial instruments with multiple embedded derivatives"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of financial instruments with both a liability and an equity component that have multiple embedded derivatives whose values are interdependent (such as a callable convertible debt instrument). [Refer: Derivatives [member]; Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Balances with Related Parties",
        "documentation": "Disclosure of detailed information about balance with relate parties explanatory.",
        "label": "Disclosure Of Detailed Information About Balance With Relate Parties Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory",
     "presentation": [
      "http://trpx.com/role/EmployeeBenefitLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Defined Contribution Plans",
        "documentation": "Disclosure of detailed information about defined contribution plans explanatory.",
        "label": "Disclosure Of Detailed Information About Defined Contribution Plans Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory",
     "presentation": [
      "http://trpx.com/role/LossPerShareAdsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share",
        "documentation": "The disclosure of detailed information about earning per share.",
        "label": "Disclosure Of Detailed Information About Earnings Per Share Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
     "presentation": [
      "http://trpx.com/role/FinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINANCIAL INSTRUMENTS",
        "label": "Disclosure of detailed information about financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r144",
      "r147",
      "r149"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://trpx.com/role/PropertyandEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment, Net",
        "label": "Disclosure of detailed information about property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Transactions with Related Parties",
        "documentation": "Disclosure of detailed information about transactions with relate parties explanatory.",
        "label": "Disclosure Of Detailed Information About Transactions With Relate Parties Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "presentation": [
      "http://trpx.com/role/LossPerShareAds"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LOSS PER SHARE/ADS",
        "label": "Disclosure of earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ifrs-full_DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociateTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of the Investment",
        "label": "Disclosure of effect of change of investment entity status on financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the effect of the change of investment entity status on the financial statements. [Refer: Disclosure of investment entities [text block]]"
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEmployeeBenefitsExplanatory",
     "presentation": [
      "http://trpx.com/role/EmployeeBenefitLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EMPLOYEE BENEFIT LIABILITIES",
        "label": "Disclosure of employee benefits [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for employee benefits."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEntitysReportableSegmentsExplanatory",
     "presentation": [
      "http://trpx.com/role/OperatingSegments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OPERATING SEGMENTS",
        "label": "Disclosure of entity's operating segments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for operating segments."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriod"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EVENTS AFTER THE REPORTING PERIOD",
        "label": "Disclosure of events after reporting period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "sprcy_DisclosureOfExpenseRecognizedExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DisclosureOfExpenseRecognizedExplanatoryTableTextBlock",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Expenses Due to Share-Based Compensation",
        "documentation": "The tabular disclosure of expense recognized.",
        "label": "Disclosure Of Expense Recognized Explanatory Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosureOfFairValueMeasurementOfAssetstable": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DisclosureOfFairValueMeasurementOfAssetstable",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of the Investment",
        "documentation": "Schedule disclosing information related to the fair value measurement of assets.",
        "label": "Disclosure Of Fair Value Measurement Of Assetstable"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVESTMENT IN FINANCIAL ASSETS",
        "label": "Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: Investments in equity instruments designated at fair value through other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://trpx.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model",
        "label": "Disclosure of fair value of financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value of financial instruments. [Refer: Financial instruments, class [member]; At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinanceIncomeExpenseExplanatory",
     "presentation": [
      "http://trpx.com/role/RevenuesandCostofRevenues"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REVENUES AND COST OF REVENUES",
        "label": "Disclosure of finance income (cost) [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]"
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DisclosureOfFinancialAssetsAndFinancialLiabilities",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Assets and Financial Liabilities",
        "documentation": "The tabular disclosure of financial assets and financial liabilities.",
        "label": "Disclosure Of Financial Assets And Financial Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialLiabilitiesExplanatory",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Assets and Financial Liabilities",
        "label": "Disclosure of financial liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "sprcy_DisclosureOfGeneralExplanatoryAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DisclosureOfGeneralExplanatoryAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "General [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosureOfGeneralExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DisclosureOfGeneralExplanatoryTextBlock",
     "presentation": [
      "http://trpx.com/role/General"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GENERAL",
        "documentation": "The entire disclosure for general information.",
        "label": "Disclosure Of General Explanatory Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://trpx.com/role/TaxesonIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TAXES ON INCOME",
        "label": "Disclosure of income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
     "presentation": [
      "http://trpx.com/role/WarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Warrants\u2019 Fair Value",
        "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Benefits to Key Management Personnel",
        "label": "Disclosure of information about key management personnel [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DisclosureOfInformationToTheItemsOfProfitOrLoss",
     "presentation": [
      "http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Additional Information to the Items of Profit or Loss",
        "documentation": "Tabular disclosure of disclosure of information to the items of profit or loss.",
        "label": "Disclosure Of Information To The Items Of Profit Or Loss"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsExplanatory",
     "presentation": [
      "http://trpx.com/role/IntangibleAsset"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INTANGIBLE ASSET",
        "label": "Disclosure of intangible assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for intangible assets."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "ifrs-full_DisclosureOfInventoriesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInventoriesExplanatory",
     "presentation": [
      "http://trpx.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVENTORY",
        "label": "Disclosure of inventories [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for inventories."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "ifrs-full_DisclosureOfInvestmentEntitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInvestmentEntitiesExplanatory",
     "presentation": [
      "http://trpx.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory",
        "label": "Disclosure of investment entities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of investment entities. An investment entity is an entity that: (a) obtains funds from one or more investors for the purpose of providing those investor(s) with investment management services; (b) commits to its investor(s) that its business purpose is to invest funds solely for returns from capital appreciation, investment income, or both; and (c) measures and evaluates the performance of substantially all of its investments on a fair value basis."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "ifrs-full_DisclosureOfInvestmentPropertyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInvestmentPropertyExplanatory",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvestees"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVESTMENT IN ASSOCIATES AND INVESTMENTS IN INVESTEES",
        "label": "Disclosure of investment property [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for investment property."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVESTMENT IN ASSOCIATE",
        "label": "Disclosure of investments accounted for using equity method [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]"
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "sprcy_DisclosureOfIssuedAndOutstandingShareCapital": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DisclosureOfIssuedAndOutstandingShareCapital",
     "presentation": [
      "http://trpx.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Issued and Outstanding Share Capital",
        "documentation": "Disclosure of detailed inforamtion about issued and outstanding share capital.",
        "label": "Disclosure Of Issued And Outstanding Share Capital"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfLeasesExplanatory",
     "presentation": [
      "http://trpx.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASES",
        "label": "Disclosure of leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128"
     ]
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Events after the Reporting Period [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsExplanatory",
     "presentation": [
      "http://trpx.com/role/OperatingSegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Segments",
        "label": "Disclosure of operating segments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ifrs-full_DisclosureOfOperatingSegmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Operating Segments [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://trpx.com/role/PropertyandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY AND EQUIPMENT, NET",
        "label": "Disclosure of property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "presentation": [
      "http://trpx.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EQUITY",
        "label": "Disclosure of share capital, reserves and other equity interest [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Weighted Average Exercise Prices of Share Options",
        "documentation": "The tabular disclosure of share options and weighted average exercise prices of share options",
        "label": "Disclosure Of Share Options And Weighted Average Exercise Prices Explanatory Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHARE-BASED PAYMENT TRANSACTIONS",
        "label": "Disclosure of share-based payment arrangements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Events during the Reporting Period [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriod"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SIGNIFICANT EVENTS DURING THE REPORTING PERIOD",
        "label": "Disclosure Of Significant Events During The Reporting Period Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "presentation": [
      "http://trpx.com/role/TradePayables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TRADE PAYABLES",
        "label": "Disclosure of trade and other payables [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory",
     "presentation": [
      "http://trpx.com/role/OtherAccountsReceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER ACCOUNTS RECEIVABLE",
        "label": "Disclosure of trade and other receivables [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]"
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "sprcy_DisclosureOfTradePayables": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DisclosureOfTradePayables",
     "presentation": [
      "http://trpx.com/role/TradePayablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Trade Payables",
        "documentation": "The disclosure of trade payables.",
        "label": "Disclosure Of Trade Payables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TRANSACTIONS AND BALANCES WITH RELATED PARTIES",
        "label": "Disclosure of transactions between related parties [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory",
     "presentation": [
      "http://trpx.com/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life",
        "documentation": "The entire disclosure for useful life of the assets at annual rates.",
        "label": "Disclosure Of Useful Life Of Assets At Annual Rates Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclourseOfAccountsReceivablesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DisclourseOfAccountsReceivablesTableTextBlock",
     "presentation": [
      "http://trpx.com/role/OtherAccountsReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Accounts Receivable",
        "documentation": "The disclosure of accounts receivables.",
        "label": "Disclourse Of Accounts Receivables Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DiscontinuedOperationsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued operations [member]",
        "label": "Discontinued operations [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of an entity that either has been disposed of or is classified as held for sale, and that: (a) represents a separate major line of business or geographical area of operations; (b) is part of a single co-ordinated plan to dispose of a separate major line of business or geographical area of operations; or (c) is a subsidiary acquired exclusively with a view to resale. A component of an entity comprises operations and cash flows that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the entity. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ifrs-full_DisposalsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisposalsPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Disposals",
        "label": "Disposals, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "sprcy_DividendYield": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DividendYield",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield (%)",
        "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted.",
        "label": "Dividend Yield"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DocumentAndEntityInformationAbstract",
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DrugDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "DrugDevelopmentMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Drug Development [Member]",
        "label": "Drug Development Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share/Ads [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EmployeeBenefitLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "EmployeeBenefitLiabilitiesLineItems",
     "presentation": [
      "http://trpx.com/role/EmployeeBenefitLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EmployeeBenefitLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "EmployeeBenefitLiabilitiesTable",
     "presentation": [
      "http://trpx.com/role/EmployeeBenefitLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Liabilities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EmployeeBenefitLiabilitiesTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "EmployeeBenefitLiabilitiesTablesLineItems",
     "presentation": [
      "http://trpx.com/role/EmployeeBenefitLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Liabilities [Abstract]",
        "label": "Employee Benefit Liabilities Tables Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EmployeeBenefitLiabilitiesTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "EmployeeBenefitLiabilitiesTablesTable",
     "presentation": [
      "http://trpx.com/role/EmployeeBenefitLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Liabilities (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EmployeeBenefitsExpense",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofDefinedContributionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses in respect of defined contribution plans",
        "label": "Employee benefits expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r40",
      "r168"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "ifrs-full_EntitysOwnEquityInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysOwnEquityInstrumentsMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity's own equity instruments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments issued by the entity. It also represents the standard value for the 'Classes of entity's own equity instruments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForRelatedPartiesMember",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails",
      "http://trpx.com/role/FinancialInstrumentsDetails",
      "http://trpx.com/role/InvestmentinAssociateDetails",
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/LeasesDetails",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity's total for related parties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r22",
      "r97",
      "r100",
      "r118",
      "r119",
      "r120"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Absract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and equity",
        "label": "Equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "EquityAttributableToEquityHoldersOfTheCompanyAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:",
        "label": "Equity Attributable To Equity Holders Of The Company Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract0": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "EquityAttributableToEquityHoldersOfTheCompanyAbstract0",
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:",
        "label": "Equity Attributable To Equity Holders Of The Company Abstract0"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Equity attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "sprcy_EquityDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "EquityDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EquityDetailsScheduleofShareCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "EquityDetailsScheduleofShareCapitalLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) - Schedule of Share Capital [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EquityDetailsScheduleofShareCapitalTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "EquityDetailsScheduleofShareCapitalTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) - Schedule of Share Capital [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "EquityDetailsTable",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EquityLossesFromInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "EquityLossesFromInvestment",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equity losses from investment in MitoCareX",
        "documentation": "Amount of equity losses from investment.",
        "label": "Equity Losses From Investment"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EquityLossesFromInvestmentInMitoCareX": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "EquityLossesFromInvestmentInMitoCareX",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity losses from investment in MitoCareX",
        "documentation": "Amount of equity losses from investment.",
        "label": "Equity Losses From Investment In Mito Care X"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EquityLossesInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "EquityLossesInvestment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity losses investment",
        "documentation": "The amount of equity losses investment.",
        "label": "Equity Losses Investment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityMember",
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails",
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "sprcy_EventsaftertheReportingPeriodDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "EventsaftertheReportingPeriodDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Events after the Reporting Period (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EventsaftertheReportingPeriodDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "EventsaftertheReportingPeriodDetailsTable",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Events after the Reporting Period (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EveroMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "EveroMember",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Evero [Member]",
        "label": "Evero Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExchangeCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ExchangeCommonShares",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange common shares (in Shares)",
        "documentation": "The number of exchange common shares of clearmind.",
        "label": "Exchange Common Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExchangeCommonSharesOfClearmind": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ExchangeCommonSharesOfClearmind",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange common shares of clearmind (in Shares)",
        "documentation": "The number of exchange common shares of clearmind.",
        "label": "Exchange Common Shares Of Clearmind"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExerciseOfPrefundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ExerciseOfPrefundedWarrants",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails",
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of pre-funded warrants",
        "verboseLabel": "Pre-funded warrants",
        "netLabel": "Exercise of pre-funded warrants (in Shares)",
        "documentation": "Exercise of Pre-funded warrants.",
        "label": "Exercise Of Prefunded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExerciseOfPrefundedWarrantsOne": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ExerciseOfPrefundedWarrantsOne",
     "presentation": [
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of pre-funded warrants",
        "documentation": "Exercise of Pre-funded warrants.",
        "label": "Exercise Of Prefunded Warrants One"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExerciseOfPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ExerciseOfPricePerShare",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of price",
        "verboseLabel": "Exercise of price per share (in Dollars per share)",
        "documentation": "Exercise of price per share.",
        "label": "Exercise Of Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails",
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants",
        "verboseLabel": "Warrants and exercise",
        "documentation": "Amount of exercise of warrants.",
        "label": "Exercise Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExercisePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ExercisePeriod",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise period",
        "label": "Exercise Period"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ExercisePrice",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price ($)",
        "documentation": "Exercise price.",
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ExercisePrice1",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in Dollars per share)",
        "label": "Exercise Price1"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in Dollars per share)",
        "label": "Exercise price of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "sprcy_ExercisePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ExercisePricePerShare",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails",
      "http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price ($)",
        "verboseLabel": "Exercise price (in Dollars per share)",
        "label": "Exercise Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExercisePriceShareOptionsGranted2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExercisePriceShareOptionsGranted2019",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/ScheduleofWarrantsFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price ($) (in Dollars per share)",
        "verboseLabel": "Exercise price (in Dollars per share)",
        "label": "Exercise price, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of share options granted."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpectedDividendAsPercentageShareOptionsGranted",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValueTable",
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield (%)",
        "label": "Expected dividend as percentage, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "sprcy_ExpectedVolatility": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ExpectedVolatility",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility (%)",
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.",
        "label": "Expected Volatility"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExpensesDueToSharebasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ExpensesDueToSharebasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses due to share-based compensation",
        "label": "Expenses Due To Sharebased Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExpireTerm": {
     "xbrltype": "dateItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ExpireTerm",
     "presentation": [
      "http://trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease expired",
        "label": "Expire Term"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExternalRevenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ExternalRevenues",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "External",
        "documentation": "Amount of external revenue.",
        "label": "External Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FairMarketValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "FairMarketValue",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair market value",
        "documentation": "Fair market value.",
        "label": "Fair Market Value"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FairValueDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "FairValueDescription",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value, description",
        "label": "Fair Value Description"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FairValueOfTheRSUsGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "FairValueOfTheRSUsGranted",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of the RSU\u2019s granted (in Dollars)",
        "documentation": "The amount of fair value of the RSU\u2019s granted.",
        "label": "Fair Value Of The RSUs Granted"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FairValueOption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "FairValueOption",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of share options (in Dollars)",
        "label": "Fair Value Option"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FeeExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "FeeExpenses",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fee expense",
        "documentation": "Fee expenses.",
        "label": "Fee Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance expenses",
        "label": "Finance costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "sprcy_FinanceExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "FinanceExpensesAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "e. Finance expenses:",
        "label": "Finance Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FinanceExpensesFromExchangeRateDifferences": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "FinanceExpensesFromExchangeRateDifferences",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange rate differences, net",
        "documentation": "The amount of expenses related to exchange rate differences.",
        "label": "Finance Expenses From Exchange Rate Differences"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FinanceExpensesFromInterestAndCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "FinanceExpensesFromInterestAndCommissions",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance expenses from interest and commissions",
        "documentation": "The amount of finance expenses from interest and commissions.",
        "label": "Finance Expenses From Interest And Commissions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance income",
        "label": "Finance income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "sprcy_FinanceIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "FinanceIncomeAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "d. Finance income:",
        "label": "Finance Income Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceIncomeCost",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance income",
        "label": "Finance income (cost)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income or cost associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "sprcy_FinanceIncomeFromConvertibleLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "FinanceIncomeFromConvertibleLoan",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in fair value of financial liabilities designated at fair value through profit or loss",
        "label": "Finance Income From Convertible Loan"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in financial assets",
        "label": "Financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r143",
      "r145",
      "r146",
      "r148",
      "r189"
     ]
    },
    "sprcy_FinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "FinancialAssetsAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets:",
        "label": "Financial Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable",
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at January 1, 2022",
        "periodEndLabel": "Balance at December 31, 2022",
        "label": "Financial assets measured at fair value through other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial assets that are measured at fair value through other comprehensive income. A financial asset shall be measured at fair value through other comprehensive income if both of the following conditions are met: (a) the financial asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets and (b) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. [Refer: At fair value [member]; Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "sprcy_FinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "FinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FinancialInstrumentsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "FinancialInstrumentsDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments (Details) - Schedule of Financial Assets and Financial Liabilities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FinancialInstrumentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "FinancialInstrumentsDetailsTable",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable",
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial and lease liabilities",
        "terseLabel": "Total financial and lease liabilities",
        "label": "Financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "sprcy_FinancialLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "FinancialLiabilitiesAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities:",
        "label": "Financial Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialLiabilitiesAtAmortisedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesAtAmortisedCost",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total financial assets at amortized cost",
        "label": "Financial liabilities at amortised cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities at amortised cost. The amortised cost is the amount at which financial liabilities are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ifrs-full_FinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofInventoryTable": {
       "parentTag": "sprcy_InventoriesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Current finished goods"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r174",
      "r209"
     ]
    },
    "ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Losses from remeasurement of investment in financial assets",
        "label": "Gains (losses) on financial assets at fair value through profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) on financial assets at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "ifrs-full_GainsLossesOnNetMonetaryPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesOnNetMonetaryPosition",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "label": "Gains (losses) on net monetary position"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) representing the difference resulting from the restatement of non-monetary assets, owners' equity and items in the statement of comprehensive income and the adjustment of index linked assets and liabilities in hyperinflationary reporting."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "General and administrative expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "sprcy_GeneralAndAdministrativeExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "GeneralAndAdministrativeExpenses",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "General And Administrative Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_GeneralDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "GeneralDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_GeneralDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "GeneralDetailsTable",
     "presentation": [
      "http://trpx.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_GovernmentAuthorities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "GovernmentAuthorities",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable",
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government authorities",
        "documentation": "Government authorities.",
        "label": "Government Authorities"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_GrossProceed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "GrossProceed",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds",
        "documentation": "Gross proceeds.",
        "label": "Gross Proceed"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_GrossProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "GrossProceeds",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds (in Dollars)",
        "documentation": "Gross proceeds.",
        "label": "Gross Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/ScheduleofRevenuesandCostofRevenuesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "terseLabel": "Gross profit",
        "label": "Gross profit"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]"
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "sprcy_GroupsShareOfLossesOfCompanyAccountedForAtEquityNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "GroupsShareOfLossesOfCompanyAccountedForAtEquityNetMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Group\u2019s share of losses of company accounted for at equity, net [Member]",
        "label": "Groups Share Of Losses Of Company Accounted For At Equity Net Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ImpairmentLossRecognisedInOtherComprehensiveIncome",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment loss (gain)",
        "label": "Impairment loss recognised in other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in other comprehensive income. Impairment loss on a revalued asset is recognised in other comprehensive income to the extent that the impairment loss does not exceed the amount in the revaluation surplus for that same asset. [Refer: Impairment loss; Revaluation surplus; Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r76"
     ]
    },
    "sprcy_ImpairmentOfInvestmentInAssociateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ImpairmentOfInvestmentInAssociateMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of investment in associate [Member]",
        "label": "Impairment Of Investment In Associate Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IncomeStatementsLocationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "IncomeStatementsLocationsAxis",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statements Locations [Axis]",
        "label": "Income Statements Locations Axis"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IncomeStatementsLocationsDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "IncomeStatementsLocationsDomainDomain",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IncomeStatementsLocationsDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes on income",
        "label": "Tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r38",
      "r43",
      "r44",
      "r45",
      "r63",
      "r116",
      "r156"
     ]
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (decrease) in cash and cash equivalents",
        "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails",
      "http://trpx.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares (in Shares)",
        "verboseLabel": "Ordinary shares issued",
        "netLabel": "Ordinary shares issued (in Shares)",
        "label": "Increase (decrease) in number of ordinary shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInNumberOfSharesOutstanding",
     "presentation": [
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of share capital \u2013 June 2022 Financing Round",
        "label": "Increase (decrease) in number of shares outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]"
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of minority interest in subsidiary",
        "label": "Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity through changes in ownership interests in subsidiaries that do not result in loss of control. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughConversionOfConvertibleInstruments",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible debentures (Note 14b)",
        "label": "Increase (decrease) through conversion of convertible instruments, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the conversion of convertible instruments."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughExerciseOfOptions",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants reclassification",
        "label": "Increase (decrease) through exercise of options, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration of share options",
        "label": "Increase (decrease) through exercise of warrants, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of warrants."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "sprcy_InitialConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InitialConversionPrice",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial conversion price (in Dollars per share)",
        "documentation": "Initial conversion price.",
        "label": "Initial Conversion Price"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InitialInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InitialInvestment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial investment amount",
        "documentation": "Initial investment.",
        "label": "Initial Investment"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InitialInvestmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InitialInvestmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial investment amount",
        "label": "Initial Investment Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InstallmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InstallmentAmount",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Installment amount",
        "documentation": "Amount of installment amount.",
        "label": "Installment Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InsuranceFinanceIncomeExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InsuranceFinanceIncomeExpenses",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance expenses",
        "label": "Insurance finance income (expenses)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that comprises the change in the carrying amount of the group of insurance contracts arising from: (a) the effect of the time value of money and changes in the time value of money; and (b) the effect of financial risk and changes in financial risk; but (c) excluding any such changes for groups of insurance contracts with direct participation features that would adjust the contractual service margin but do not do so when applying paragraphs 45(b)(ii), 45(b)(iii), 45(c)(ii) or 45(c)(iii) of IFRS 17."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of the Intangible Asset [Abstract]",
        "label": "Intangible Asset Details Scheduleof Fair Valueofthe Intangible Asset Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset (Details) - Schedule of Fair Value of the Intangible Asset [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetFairValueUsedAsDeemedCost",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation of intangible asset",
        "label": "Intangible asset fair value used as deemed cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of intangible assets for which fair value was used as their deemed cost in the opening IFRS statement of financial position. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "ifrs-full_IntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsAndGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable",
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Intangible assets and goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "ifrs-full_IntangibleAssetsAndGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsAndGoodwillAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset, net",
        "label": "Intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r83"
     ]
    },
    "sprcy_InterestExpenseInRespectOfLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InterestExpenseInRespectOfLeases",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance expense in respect of leases",
        "label": "Interest Expense In Respect Of Leases"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InterestPaidOnLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InterestPaidOnLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid on lease liability",
        "label": "Interest Paid On Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestPayable",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest payable",
        "label": "Interest payable"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest recognised as a liability."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "sprcy_InterestPercentgae": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InterestPercentgae",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest percentage",
        "documentation": "Interest percentgae.",
        "label": "Interest Percentgae"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestRevenueExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestRevenueExpense",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance expense (income), net",
        "label": "Interest income (expense)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income or expense arising from interest. [Refer: Interest expense; Interest income]"
       }
      }
     },
     "auth_ref": [
      "r157",
      "r161",
      "r206"
     ]
    },
    "sprcy_Intersegment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "Intersegment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inter-segment",
        "documentation": "Amount of inter-segment.",
        "label": "Intersegment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Inventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Inventories",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Current inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r12",
      "r54",
      "r171"
     ]
    },
    "sprcy_InventoriesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InventoriesNet",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofInventoryTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Inventory",
        "documentation": "The amount of inventory, net.",
        "label": "Inventories Net"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InventoryAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InventoryAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InvestedAmount",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Invested amount",
        "documentation": "The amount of invested amount in clearmind.",
        "label": "Invested Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestedAmountInClearmind": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InvestedAmountInClearmind",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Invested amount in clearmind",
        "documentation": "The amount of invested amount in clearmind.",
        "label": "Invested Amount In Clearmind"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestedInitialAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InvestedInitialAmount",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Invested initial amount",
        "documentation": "Invested initial amount.",
        "label": "Invested Initial Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestedInitialAmounts": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InvestedInitialAmounts",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Invested initial amount",
        "label": "Invested Initial Amounts"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InvestmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment amount",
        "documentation": "Investment amount.",
        "label": "Investment Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InvestmentDate",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable",
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment",
        "verboseLabel": "Investment date March 31, 2022",
        "documentation": "The amount of investments in equity instruments that the entity has designated at fair value through other comprehensive income.",
        "label": "Investment Date"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentInFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InvestmentInFinancialAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Financial Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentinAssociateDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InvestmentinAssociateDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associate [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in Associate [Abstract]",
        "label": "Investmentin Associate Details Scheduleof Fair Valueofthe Investment Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InvestmentinAssociateDetailsScheduleofFairValueoftheInvestmentTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associate (Details) - Schedule of Fair Value of the Investment [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentinAssociateDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InvestmentinAssociateDetailsTable",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associate (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InvestmentinAssociatesandInvestmentsinInvesteesDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associates and Investments in Investees (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of the Investment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InvestmentinAssociatesandInvestmentsinInvesteesDetailsScheduleofFairValueoftheInvestmentTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associates and Investments in Investees (Details) - Schedule of Fair Value of the Investment [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentinAssociatesandInvestmentsinInvesteesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InvestmentinAssociatesandInvestmentsinInvesteesDetailsTable",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associates and Investments in Investees (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentinAssociatesandInvestmentsinInvesteesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InvestmentinAssociatesandInvestmentsinInvesteesLineItems",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvestees"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associates and Investments in Investees [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InvestmentinAssociatesandInvestmentsinInvesteesTable",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvestees"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associates and Investments in Investees [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InvestmentinAssociatesandInvestmentsinInvesteesTablesLineItems",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in Associates and Investments in Investees [Abstract]",
        "label": "Investmentin Associatesand Investmentsin Investees Tables Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentinAssociatesandInvestmentsinInvesteesTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InvestmentinAssociatesandInvestmentsinInvesteesTablesTable",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associates and Investments in Investees (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentinFinancialAssetsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InvestmentinFinancialAssetsDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Financial Assets [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentinFinancialAssetsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InvestmentinFinancialAssetsDetailsTable",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Financial Assets (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InvestmentsInAssociates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InvestmentsInAssociates",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in company account for at equity",
        "label": "Investments in associates reported in separate financial statements"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investments in associates in an entity's separate financial statements. [Refer: Associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "sprcy_InvestmentsInFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InvestmentsInFinancialAssets",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in financial assets",
        "label": "Investments In Financial Assets"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestorRelationsAndBusinessExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "InvestorRelationsAndBusinessExpensesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investor relations and business expenses [Member]",
        "label": "Investor Relations And Business Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuanceOfAggregateShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "IssuanceOfAggregateShares",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of aggregate shares (in Shares)",
        "verboseLabel": "Issuance of aggregate shares",
        "documentation": "The issuance of aggregate shares.",
        "label": "Issuance Of Aggregate Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate",
     "presentation": [
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of share capital \u2013 in respect of investment in affiliate",
        "documentation": "Issuance of share capital \u2013 in respect of investment in affiliate.",
        "label": "Issuance Of Share Capital In Respect Of Investment In Affiliate"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "IssuanceOfShareCapitalInRespectOfShelfProspectus",
     "presentation": [
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of share capital \u2013 in respect of shelf prospectus",
        "documentation": "Issuance of share capital \u2013 in respect of shelf prospectus.",
        "label": "Issuance Of Share Capital In Respect Of Shelf Prospectus"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuanceOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "IssuanceOfShares",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issued",
        "documentation": "Issuance of shares.",
        "label": "Issuance Of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssueExpensesRelatedToIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "IssueExpensesRelatedToIssuanceOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance expenses related to warrants",
        "label": "Issue Expenses Related To Issuance Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssueOfShareCapitalNetOfIssueExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "IssueOfShareCapitalNetOfIssueExpense",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue of share capital, net of issue expenses",
        "documentation": "Issue of share capital, net of issue expenses.",
        "label": "Issue Of Share Capital Net Of Issue Expense"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssueOfSharesNetOfIssueExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "IssueOfSharesNetOfIssueExpenses",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue of shares, net of issue expenses",
        "documentation": "Issue of shares, net of issue expenses.",
        "label": "Issue Of Shares Net Of Issue Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuedAndOutstandingSharesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "IssuedAndOutstandingSharesPercentage",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued and outstanding shares percentage",
        "documentation": "Issued and outstanding shares, percentage.",
        "label": "Issued And Outstanding Shares Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapitalOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapitalOrdinaryShares",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares value",
        "label": "Issued capital, ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital arising from issuing ordinary shares. [Refer: Issued capital]"
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "sprcy_JeffsBrandsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "JeffsBrandsMember",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jeffs\u2019 Brands [Member]",
        "label": "Jeffs Brands Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_June2022FinancingRoundMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "June2022FinancingRoundMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "June 2022 Financing Round [Member]",
        "label": "June2022 Financing Round Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_June2022WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "June2022WarrantsMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "June 2022 Warrants [Member]",
        "label": "June2022 Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of share-based payment",
        "label": "Key management personnel compensation, share-based payment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term benefits",
        "label": "Key management personnel compensation, short-term employee benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "ifrs-full_KeyManagementPersonnelOfEntityOrParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelOfEntityOrParentMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Key management personnel [Member]",
        "label": "Key management personnel of entity or parent [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "sprcy_LeaseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "LeaseFee",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease fee (in Dollars)",
        "label": "Lease Fee"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable",
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "sprcy_LeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "LeaseMember",
     "presentation": [
      "http://trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Lease [Member]",
        "label": "Lease Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LeaseholdImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "LeaseholdImprovements",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements (in Dollars)",
        "documentation": "Leasehold improvements.",
        "label": "Leasehold Improvements"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable",
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements [Member]",
        "label": "Leasehold improvements [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "sprcy_LeasesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "LeasesDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LeasesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "LeasesDetailsTable",
     "presentation": [
      "http://trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LoanAmountDueTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "LoanAmountDueTerm",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan amount due term",
        "documentation": "Loan Amount Due Term.",
        "label": "Loan Amount Due Term"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LoanAmountRaised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "LoanAmountRaised",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan amount raised",
        "label": "Loan Amount Raised"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share/Ads (Details) - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "LossPerShareAdsDetailsScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share/Ads (Details) - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LossPerShareAdsTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "LossPerShareAdsTablesLineItems",
     "presentation": [
      "http://trpx.com/role/LossPerShareAdsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Loss Per Share Or Ads [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LossPerShareAdsTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "LossPerShareAdsTablesTable",
     "presentation": [
      "http://trpx.com/role/LossPerShareAdsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share/Ads (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LossesOnChangeInFairValueOfDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LossesOnChangeInFairValueOfDerivatives",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants fair value ($) (in Dollars)",
        "label": "Losses on change in fair value of derivatives"
       }
      },
      "en": {
       "role": {
        "documentation": "The losses resulting from changes in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "sprcy_March2021FinancingRoundMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "March2021FinancingRoundMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "March 2021 Financing Round [Member]",
        "label": "March2021 Financing Round Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_MaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "MaturityDate",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity date",
        "label": "Maturity Date"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_MitoCareXBioLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "MitoCareXBioLtdMember",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails",
      "http://trpx.com/role/InvestmentinAssociateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MitoCareX Bio Ltd. [Member]",
        "verboseLabel": "MitoCare X Bio Ltd [Member]",
        "label": "Mito Care XBio Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_MitoCareXMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "MitoCareXMember",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails",
      "http://trpx.com/role/InvestmentinAssociateDetails",
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MitoCareX [Member]",
        "label": "Mito Care XMember"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_MonthlyFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "MonthlyFee",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monthly fee",
        "documentation": "Amount of  monthly fee.",
        "label": "Monthly Fee"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MotorVehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MotorVehiclesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Motor vehicles [Member]",
        "label": "Motor vehicles [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing self-propelled ground vehicles used in the entity's operations. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "sprcy_MutualShareExchangeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "MutualShareExchangeAmount",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mutual share exchange amount",
        "documentation": "Mutual share exchange amount.",
        "label": "Mutual Share Exchange Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_MutualShareExchangeOfOrdinarySharessee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "MutualShareExchangeOfOrdinarySharessee",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mutual share exchange of ordinary shares (see note 10)",
        "label": "Mutual Share Exchange Of Ordinary Sharessee"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_NewCoIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "NewCoIncMember",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NewCo Inc. [Member]",
        "label": "New Co Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_NewLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "NewLeases",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New leases",
        "label": "New Leases"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_NoParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "NoParValuePerShare",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares no par value (in Dollars per share)",
        "documentation": "Represent  of having no par value per share.",
        "label": "No Par Value Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails",
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "ifrs-full_NonadjustingEventsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NonadjustingEventsMember",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails",
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "ifrs-full_NoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interests",
        "label": "Non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r16",
      "r102",
      "r104"
     ]
    },
    "ifrs-full_NoncontrollingInterestsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncontrollingInterestsMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non- controlling interests",
        "label": "Non-controlling interests [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Non-current asset total",
        "label": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r19",
      "r109",
      "r184"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CURRENT ASSETS:",
        "label": "Non-current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Non-current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CURRENT LIABILITIES:",
        "label": "Non-current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NotesAndOtherExplanatoryInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotesAndOtherExplanatoryInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associate [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_November2020FinancingRoundMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "November2020FinancingRoundMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "November 2020 Financing Round [Member]",
        "label": "November2020 Financing Round Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_NumberOfOutstandingShareOption": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "NumberOfOutstandingShareOption",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Share Options ,Share Options outstanding at the beginning of the year",
        "periodEndLabel": "Number of Share Options, Share Options outstanding at the end of the year",
        "documentation": "The number of share option outstanding in a share-based payment arrangement.",
        "label": "Number Of Outstanding Share Option"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "NumberOfShareOptionForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Share Options, Share Options forfeited during the year",
        "documentation": "The number of share option forfeited in a share-based payment arrangement.",
        "label": "Number Of Share Option Forfeited In Sharebased Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_NumberOfShareOptionGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "NumberOfShareOptionGranted",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Share Options Share Options granted during the year",
        "documentation": "The number of share options granted.",
        "label": "Number Of Share Option Granted"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_NumberOfShareOptionsShareOptionsExercisableAtTheEndOfTheYear": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "NumberOfShareOptionsShareOptionsExercisableAtTheEndOfTheYear",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Share Options, Share Options exercisable at the end of the year",
        "label": "Number Of Share Options Share Options Exercisable At The End Of The Year"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_NumberOfSharesAbstract0": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "NumberOfSharesAbstract0",
     "presentation": [
      "http://trpx.com/role/ScheduleofShareCapitalTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares",
        "label": "Number Of Shares Abstract0"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesAuthorised": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesAuthorised",
     "presentation": [
      "http://trpx.com/role/ScheduleofShareCapitalTable",
      "http://trpx.com/role/ScheduleofShareCapitalTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, authorized",
        "label": "Number of shares authorised"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares authorised."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails",
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at January 1, 2022",
        "periodEndLabel": "Balance at December 31, 2022",
        "terseLabel": "Shares issued",
        "verboseLabel": "Shares issued (in Shares)",
        "label": "Number of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "sprcy_NumberOfSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "NumberOfSharesIssued1",
     "presentation": [
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at January 1, 2023",
        "periodEndLabel": "Balance at June 30, 2023",
        "documentation": "The number of shares issued by the entity.",
        "label": "Number Of Shares Issued1"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesIssuedAndFullyPaid": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesIssuedAndFullyPaid",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued of warrant (in Shares)",
        "verboseLabel": "Ordinary shares issued",
        "label": "Number of shares issued and fully paid"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity, for which full payment has been received."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "ifrs-full_NumberOfSharesIssuedButNotFullyPaid": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesIssuedButNotFullyPaid",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Received shares",
        "label": "Number of shares issued but not fully paid"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity, for which full payment has not been received."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "sprcy_NumberOfSharesOptionGrantedInSharebasedPaymentArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "NumberOfSharesOptionGrantedInSharebasedPaymentArrangement",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available for grant shares",
        "documentation": "The number of shares option granted in a share-based payment arrangement.",
        "label": "Number Of Shares Option Granted In Sharebased Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesOutstanding",
     "presentation": [
      "http://trpx.com/role/ScheduleofShareCapitalTable",
      "http://trpx.com/role/ScheduleofShareCapitalTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, issued and outstanding",
        "label": "Number of shares outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "ifrs-full_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office furniture and equipment [Member]",
        "label": "Office equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "sprcy_OfficeEquipmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "OfficeEquipmentsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office furniture and equipment [Member]",
        "label": "Office Equipments Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OfficeMaintenanceRentAndOtherExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "OfficeMaintenanceRentAndOtherExpensesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office maintenance, rent and other expenses [Member]",
        "label": "Office Maintenance Rent And Other Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OnlineSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "OnlineSalesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Online Sales [Member]",
        "label": "Online Sales Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OperatingLossCarryforwardsTaxAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "OperatingLossCarryforwardsTaxAmount",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carry forward tax losses, total (in Dollars)",
        "documentation": "The amount of net operating loss carryforward tax as of the reporting date.",
        "label": "Operating Loss Carryforwards Tax Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OperatingSegmentsDetailsScheduleofOperatingSegmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "OperatingSegmentsDetailsScheduleofOperatingSegmentsTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments (Details) - Schedule of Operating Segments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OperatingSegmentsTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "OperatingSegmentsTablesLineItems",
     "presentation": [
      "http://trpx.com/role/OperatingSegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Segments [Abstract]",
        "label": "Operating Segments Tables Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OperatingSegmentsTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "OperatingSegmentsTablesTable",
     "presentation": [
      "http://trpx.com/role/OperatingSegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OperatingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "OperatingTerm",
     "presentation": [
      "http://trpx.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating term",
        "label": "Operating Term"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OrdinaryGrantedDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "OrdinaryGrantedDiscountRate",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary granted discount rate",
        "label": "Ordinary Granted Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OrdinaryShareExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "OrdinaryShareExercisePrice",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary share exercise price (in Dollars per share)",
        "label": "Ordinary Share Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OrdinaryShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "OrdinaryShareMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable",
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares [Member]",
        "verboseLabel": "Ordinary Shares [Member]",
        "label": "Ordinary Share Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "OrdinaryShares",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares",
        "documentation": "ordinary shares.",
        "label": "Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OrdinarySharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "OrdinarySharesAcquired",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired ordinary shares (in Shares)",
        "verboseLabel": "Purchase of ordinary share (in Shares)",
        "documentation": "Ordinary shares acquired.",
        "label": "Ordinary Shares Acquired"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OrdinarySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "OrdinarySharesIssued",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares issued",
        "label": "Ordinary Shares Issued"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OrdinarySharesMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable",
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Shares [Member]",
        "verboseLabel": "Ordinary shares [member]",
        "label": "Ordinary shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r205"
     ]
    },
    "sprcy_OrdinarySharesPerValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "OrdinarySharesPerValue",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares per value",
        "label": "Ordinary Shares Per Value"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "OtherAccountsPayableDetailsScheduleofOtherAccountsPayableLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Accounts Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OtherAccountsPayableDetailsScheduleofOtherAccountsPayableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "OtherAccountsPayableDetailsScheduleofOtherAccountsPayableTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Payable (Details) - Schedule of Other Accounts Payable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OtherAccountsReceivableTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "OtherAccountsReceivableTablesLineItems",
     "presentation": [
      "http://trpx.com/role/OtherAccountsReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Other Accounts Receivable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OtherAccountsReceivableTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "OtherAccountsReceivableTablesTable",
     "presentation": [
      "http://trpx.com/role/OtherAccountsReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Receivable (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Assets",
        "label": "Other assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncome",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive income loss",
        "label": "Other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r5",
      "r31",
      "r39",
      "r113"
     ]
    },
    "ifrs-full_OtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other accounts receivable",
        "terseLabel": "Other accounts receivable",
        "label": "Other current receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "ifrs-full_OtherEquityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherEquityInterest",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transactions with non-controlling interests",
        "label": "Other equity interest"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "ifrs-full_OtherEquityInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherEquityInterestMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transactions with non- controlling interests",
        "label": "Other equity interest [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ifrs-full_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Liabilities",
        "label": "Other liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "ifrs-full_OtherNoncurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherNoncurrentFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in financial assets",
        "label": "Other non-current financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]"
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ifrs-full_OtherOperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherOperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other expenses, net",
        "label": "Other operating income (expense)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of operating income (expense) that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "ifrs-full_OtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherPayables",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other payables",
        "label": "Other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "Amounts payable that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "ifrs-full_OtherPropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherPropertyPlantAndEquipmentMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment [Member]",
        "label": "Other property, plant and equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing property, plant and equipment that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "ifrs-full_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable": {
       "parentTag": "ifrs-full_OtherCurrentReceivables",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0",
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "ifrs-full_OtherRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherRelatedPartiesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other related parties [Member]",
        "label": "Other related parties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for related parties that the entity does not separately disclose in the same statement or note. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "sprcy_OutstandingSharesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "OutstandingSharesPercentage",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding shares percentage",
        "documentation": "Outstanding shares percentage.",
        "label": "Outstanding Shares Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OwnershipAgreement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "OwnershipAgreement",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails",
      "http://trpx.com/role/InvestmentinAssociateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership agreement",
        "documentation": "Ownership agreement.",
        "label": "Ownership Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "OwnershipPercentage",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "label": "Ownership Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Par value",
        "verboseLabel": "Ordinary shares par value (in Dollars per share)",
        "label": "Par value per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PaymentOfIssuanceExpensesRelatedToPreviousPeriod",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of issuance expenses related to previous period",
        "label": "Payment Of Issuance Expenses Related To Previous Period"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PercentageOfAggregatePurchasePrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PercentageOfAggregatePurchasePrice",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of aggregate purchase price",
        "documentation": "Purchase Percentage means, with respect to any Purchased Asset, the ratio (expressed as a percentage) of the outstanding Purchase Price with respect to such Purchased Asset to the outstanding unpaid principal balance of such Purchased Asset.",
        "label": "Percentage Of Aggregate Purchase Price"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PercentageOfSharesIssuedAndOutstandingShareCapital",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of shares issued and outstanding share capital",
        "documentation": "The percentage of shares issued and outstanding share capital.",
        "label": "Percentage Of Shares Issued And Outstanding Share Capital"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PercentageOfStockEqual": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PercentageOfStockEqual",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of stock equal",
        "documentation": "Percentage of stock equal.",
        "label": "Percentage Of Stock Equal"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Straight-line basis over useful life of assets at annual rates",
        "documentation": "The useful lives or depreciation rates used for property, plant and equipment.",
        "label": "Percentage Of Useful Lives Or Depreciation Rates Property Plant And Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PercentageOfWorkingCapital": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PercentageOfWorkingCapital",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of working capital",
        "documentation": "Percentage of working capital.",
        "label": "Percentage Of Working Capital"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PlanAssetsAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PlanAssetsAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value",
        "label": "Plan assets, at fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value of defined benefit plan assets. Plan assets comprise assets held by a long-term employee benefit fund and qualifying insurance policies. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "sprcy_PreDeterminedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PreDeterminedValue",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre determined",
        "label": "Pre Determined Value"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PrefundedOrdinaryShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PrefundedOrdinaryShare",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded ordinary share (in Shares)",
        "documentation": "Pre-funded warrants allow investors who are otherwise restricted from owning a company's voting securities above a certain threshold (usually, 9.99% or 19.99%) to invest in the company without violating the applicable ownership restrictions.",
        "label": "Prefunded Ordinary Share"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PrefundedWarrantsMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded warrants [Member]",
        "label": "Prefunded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PresentationOfLeasesForLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PresentationOfLeasesForLesseeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PreviouslyStatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PreviouslyStatedMember",
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/ScheduleofShareCapitalTable",
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Previously stated",
        "verboseLabel": "Previously stated [member]",
        "label": "Previously stated [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the information previously stated in the financial statements (ie before retrospective application or retrospective restatement)."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r94",
      "r95",
      "r96"
     ]
    },
    "sprcy_PricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PricePerShare",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per share (in Dollars per share)",
        "documentation": "price per share.",
        "label": "Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price",
        "label": "Prices specified in forward agreements to purchase financial assets for cash"
       }
      },
      "en": {
       "role": {
        "documentation": "Prices specified in forward agreements to purchase financial assets for cash."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "sprcy_PrivatePlacementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PrivatePlacementsMember",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement [Member]",
        "label": "Private Placements Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromContributionsOfNoncontrollingInterests",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interests",
        "label": "Proceeds from contributions of non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from proceeds from contributions of non-controlling interests. [Refer: Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "ifrs-full_ProceedsFromExerciseOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromExerciseOfOptions",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants",
        "label": "Proceeds from exercise of options"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of options."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "sprcy_ProceedsFromIssuanceIPO": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ProceedsFromIssuanceIPO",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial public offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds From Issuance IPO"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Proceeds from issue of share capital and warrants (net of issuance expenses) (Note 8)",
        "documentation": "The amount of proceeds from issue of share capital and warrants net of issuance expenses.",
        "label": "Proceeds From Issue Of Share Capital And Warrantsnet Of Issuance Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromIssuingShares",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of shares to minority interests in a subsidiary",
        "label": "Proceeds from issuing shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "sprcy_ProfessionalAndDirectorsFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ProfessionalAndDirectorsFeesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional and directors\u2019 fees [Member]",
        "label": "Professional And Directors Fees Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss",
        "negatedLabel": "Loss",
        "label": "Profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r4",
      "r30",
      "r90",
      "r98",
      "r101",
      "r157",
      "r159",
      "r184",
      "r187"
     ]
    },
    "ifrs-full_ProfitLossAttributableToAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossAttributableToAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attributable to:",
        "label": "Profit (loss), attributable to [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Profit loss",
        "negatedLabel": "Income (loss)",
        "label": "Profit (loss), attributable to non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r33",
      "r103"
     ]
    },
    "ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts used in the computation of basic and diluted loss per",
        "label": "Profit (loss), attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) attributable to ordinary equity holders of the parent entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Loss before income taxes",
        "label": "Profit (loss) before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r138",
      "r168",
      "r169",
      "r191",
      "r192"
     ]
    },
    "ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossAttributableToNoncontrollingInterests",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity holders of the Company",
        "label": "Profit (loss) from continuing operations attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing operations attributable to ordinary equity holders of the parent entity. [Refer: Continuing operations [member]; Profit (loss) from continuing operations]"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Operating loss",
        "label": "Profit (loss) from operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r181",
      "r206"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r49"
     ]
    },
    "sprcy_PropertyPlantAndEquipmentCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PropertyPlantAndEquipmentCost",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance, Accumulated depreciation",
        "periodEndLabel": "Ending Balance, Accumulated depreciation",
        "label": "Property Plant And Equipment Cost"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciated cost",
        "label": "Property, plant and equipment, gross carrying amount of fully depreciated assets still in use"
       }
      },
      "en": {
       "role": {
        "documentation": "The gross carrying amount of fully depreciated property, plant and equipment that is still in use. [Refer: Gross carrying amount [member]; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "sprcy_PropertyandEquipmentNetDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PropertyandEquipmentNetDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of property, plant and equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PropertyandEquipmentNetDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PropertyandEquipmentNetDetailsTable",
     "presentation": [
      "http://trpx.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PropertyandEquipmentNetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PropertyandEquipmentNetLineItems",
     "presentation": [
      "http://trpx.com/role/PropertyandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PropertyandEquipmentNetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PropertyandEquipmentNetTable",
     "presentation": [
      "http://trpx.com/role/PropertyandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PropertyandEquipmentNetTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PropertyandEquipmentNetTablesLineItems",
     "presentation": [
      "http://trpx.com/role/PropertyandEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discourse of Property and Equipment, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PropertyandEquipmentNetTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PropertyandEquipmentNetTablesTable",
     "presentation": [
      "http://trpx.com/role/PropertyandEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProportionOfOwnershipInterestInJointOperation": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInJointOperation",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "label": "Proportion of ownership interest in joint operation"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a joint operation attributable to the entity. [Refer: Joint operations [member]]"
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociateDetails",
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership interest",
        "verboseLabel": "Ownership percentage",
        "label": "Proportion of ownership interest in subsidiary"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r105"
     ]
    },
    "sprcy_PurchaseAgreementsDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PurchaseAgreementsDescription",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase agreement, description",
        "label": "Purchase Agreements Description"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PurchaseCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PurchaseCosts",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase costs",
        "label": "Purchase Costs"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PurchaseOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PurchaseOfAssets",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase date September 30, 2022",
        "documentation": "Purchase of assets.",
        "label": "Purchase Of Assets"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of financial assets at fair value through profit or loss",
        "documentation": "Purchase of financial assets at fair value through profit or loss.",
        "label": "Purchase Of Financial Assets At Fair Value Through Profit Or Loss"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of intangible asset",
        "label": "Purchase of intangible assets, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "sprcy_PurchaseOfOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PurchaseOfOrdinaryShares",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of ordinary shares",
        "documentation": "Purchase of ordinary shares.",
        "label": "Purchase Of Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Purchase of property, plant and equipment, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "sprcy_PurchaseOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PurchaseOrdinaryShares",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase ordinary shares (in Shares)",
        "documentation": "Owning ordinary shares in a business means owning a fraction of that business, and being able to vote on decisions taken at shareholder meetings. Ordinary shares offer the chance of higher financial gains than other types of share; however, you also have a higher risk of making no gains.",
        "label": "Purchase Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PurchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price",
        "label": "Purchase Price"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PurchasePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PurchasePricePerShare",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price per share (in Dollars per share)",
        "documentation": "The purchase price is the price an investor pays for an investment, and the price becomes the investor's cost basis for calculating gain or loss when selling the investment.",
        "label": "Purchase Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PurchaseofAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PurchaseofAssets",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase date September 30, 2022",
        "label": "Purchaseof Assets"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PurchasesOfCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "PurchasesOfCost",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases",
        "documentation": "The cost of purchases.",
        "label": "Purchases Of Cost"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RSUGrantedDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "RSUGrantedDiscountRate",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSU granted discount rate",
        "label": "RSUGranted Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/InvestmentinAssociateDetails",
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails",
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable",
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r130",
      "r133",
      "r185",
      "r186",
      "r219"
     ]
    },
    "ifrs-full_RangesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangesMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/InvestmentinAssociateDetails",
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails",
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable",
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r130",
      "r133",
      "r185",
      "r186",
      "r219"
     ]
    },
    "sprcy_ReceiptofShortTermCreditFromOthers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ReceiptofShortTermCreditFromOthers",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receipt of short-term credit from others, net",
        "label": "Receiptof Short Term Credit From Others"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RegistrationOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "RegistrationOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registration of warrants",
        "documentation": "Registration of warrants.",
        "label": "Registration Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RegulatoryAndOtherExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "RegulatoryAndOtherExpensesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory, professional and other expenses [Member]",
        "label": "Regulatory And Other Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RegulatoryExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "RegulatoryExpensesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory expenses [Member]",
        "label": "Regulatory Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized over period",
        "label": "Remaining amortisation period of intangible assets material to entity"
       }
      },
      "en": {
       "role": {
        "documentation": "The remaining amortisation period of individual intangible assets that are material to the entity\u2019s financial statements. [Refer: Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "sprcy_RepaymentOfLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "RepaymentOfLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of lease liability",
        "label": "Repayment Of Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RepaymentOfShorttermCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "RepaymentOfShorttermCredit",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of short-term credit",
        "label": "Repayment Of Shortterm Credit"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Research and development expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "sprcy_ResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Research And Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ResearchAndDevelopmentExpenses01": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ResearchAndDevelopmentExpenses01",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.",
        "label": "Research And Development Expenses01"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ResearchAndDevelopmentExpenses1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ResearchAndDevelopmentExpenses1",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.",
        "label": "Research And Development Expenses1"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ResearchAndPreclinicalStudiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ResearchAndPreclinicalStudiesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and preclinical studies [Member]",
        "label": "Research And Preclinical Studies Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation reserve",
        "label": "Reserve of exchange differences on translation"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfExchangeDifferencesOnTranslationMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation reserve",
        "label": "Reserve of exchange differences on translation [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r56",
      "r170"
     ]
    },
    "ifrs-full_ReserveOfSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfSharebasedPayments",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve from share-based payment transactions",
        "label": "Reserve of share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "ifrs-full_ReserveOfSharebasedPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfSharebasedPaymentsMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve from share-based payment transactions",
        "label": "Reserve of share-based payments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "ifrs-full_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and restricted deposits",
        "label": "Restricted cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash and cash equivalents whose use or withdrawal is restricted. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "sprcy_RetainedEarning": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "RetainedEarning",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit.",
        "label": "Retained Earning"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarnings",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained earnings"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176"
     ]
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained earnings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r170"
     ]
    },
    "ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetrospectiveApplicationAndRetrospectiveRestatementAxis",
     "presentation": [
      "http://trpx.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retrospective application and retrospective restatement [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r94",
      "r95",
      "r96"
     ]
    },
    "ifrs-full_Revenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Revenue",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/ScheduleofRevenuesandCostofRevenuesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r112",
      "r138",
      "r153",
      "r158",
      "r163",
      "r164",
      "r165",
      "r168",
      "r169",
      "r184"
     ]
    },
    "ifrs-full_RevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues and Cost of Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RevenueFromSaleOfGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueFromSaleOfGoods",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Revenue from sale of goods"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from the sale of goods. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "sprcy_RevenuesAndCostOfRevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "RevenuesAndCostOfRevenuesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenues and Cost of Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset",
        "label": "Reversal of impairment loss recognised in other comprehensive income, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of reversal of impairment loss recognised in other comprehensive income for intangible assets other than goodwill. [Refer: Reversal of impairment loss recognised in other comprehensive income; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross sales",
        "label": "Reversal of impairment loss recognised in profit or loss, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of reversal of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Reversal of impairment loss recognised in profit or loss; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "RightofuseAssetRecognizedWithCorrespondingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset recognized with corresponding lease liability",
        "documentation": "Right-of-use asset recognized with corresponding lease liability.",
        "label": "Rightofuse Asset Recognized With Corresponding Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "RiskFreeInterestRate",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate (%)",
        "documentation": "The risk-free interest rate for the option contractual term.",
        "label": "Risk Free Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SCISPARCLTDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "SCISPARCLTDMember",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SCISPARC LTD [Member]",
        "label": "SCISPARCLTDMember"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SalesAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SalesAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales and marketing",
        "label": "Sales and marketing expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to the marketing and selling of goods or services."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Additional Information To The Items Of Profit Or Loss Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ScheduleOfBalancesWithRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Balances with Related Parties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ScheduleOfBenefitsToKeyManagementPersonnelAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of benefits to key management personnel [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfCashAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ScheduleOfCashAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfDefinedContributionPlansAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ScheduleOfDefinedContributionPlansAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Defined Contribution Plans [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Depreciation Is Calculated On AStraight Line Basis Over The Useful Life Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ScheduleOfExpensesDueToShareBasedCompensationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of expenses due to share-based compensation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ScheduleOfFairValueForShareOptionsGrantedAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value for Share Options granted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ScheduleOfFairValueOfTheIntangibleAssetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of the Intangible Asset [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of the Intangible Asset",
        "documentation": "Schedule of fair value of the intangible asset.",
        "label": "Schedule Of Fair Value Of The Intangible Asset Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfFairValueOfTheInvestmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ScheduleOfFairValueOfTheInvestmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Of The Investment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial Assets and Financial Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfInventoryAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ScheduleOfInventoryAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ScheduleOfIssuedAndOutstandingShareCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Issued and Outstanding Share Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Number Of Shares And Loss Used In The Computation Of Loss Per Share Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfOperatingSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ScheduleOfOperatingSegmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Operating Segments Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfOtherAccountsPayable": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ScheduleOfOtherAccountsPayable",
     "presentation": [
      "http://trpx.com/role/OtherAccountsPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Accounts Payable",
        "documentation": "The entire disclosure of other accounts payable.",
        "label": "Schedule Of Other Accounts Payable"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfOtherAccountsPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ScheduleOfOtherAccountsPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Other Accounts Payable Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfOtherAccountsReceivableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ScheduleOfOtherAccountsReceivableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Accounts Receivable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfPropertyAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ScheduleOfPropertyAndEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Net Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock",
     "presentation": [
      "http://trpx.com/role/RevenuesandCostofRevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenues and Cost of Revenues",
        "label": "Schedule Of Revenues And Cost Of Revenues Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfShareCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ScheduleOfShareCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Capital Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfTradePayablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ScheduleOfTradePayablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Trade Payables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ScheduleOfTransactionsWithRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Transactions with Related Parties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfWarrantsFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ScheduleOfWarrantsFairValueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants\u2019 Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants Fair Value Using Black Scholes OPM [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Warrants Fair Value Using Black\u2013Scholes OPM",
        "label": "Schedule Of Warrants Fair Value Using Blackscholes Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of warrants fair value was calculated using the Black-Scholes OPM [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Weighted Average Exercise Prices Of Share Options Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SegmentReportingRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "SegmentReportingRevenueAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Segment Reporting Revenue Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SegmentsAxis",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable0",
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable",
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable0",
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable",
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r123",
      "r157",
      "r180",
      "r188"
     ]
    },
    "ifrs-full_SegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SegmentsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable0",
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable",
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable0",
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable",
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r123",
      "r162",
      "r180",
      "r188"
     ]
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "Selling, general and administrative expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to selling, general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "sprcy_SeriesAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "SeriesAWarrantsMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Warrants [Member]",
        "label": "Series AWarrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SeriesBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "SeriesBWarrantsMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Warrants [Member]",
        "label": "Series BWarrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility (%)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Expected Volatility Rate"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield (%)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Range Of Dividend Used"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate (%)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Risk Free Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStocks": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStocks",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding shares percentage",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stocks"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ShareBasedPaymentMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment [Member]",
        "label": "Share Based Payment Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedPaymentTransactionsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ShareBasedPaymentTransactionsDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedPaymentTransactionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ShareBasedPaymentTransactionsDetailsTable",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedPaymentTransactionsTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ShareBasedPaymentTransactionsTablesLineItems",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedPaymentTransactionsTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ShareBasedPaymentTransactionsTablesTable",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareCapitalPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ShareCapitalPercentage",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital percentage",
        "documentation": "Share capital percentage.",
        "label": "Share Capital Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareIssueRelatedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShareIssueRelatedCost",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue of share capital in respect of investment in affiliate",
        "label": "Share issue related cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cost related to the issuance of shares."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "sprcy_ShareIssuedToAConsultant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ShareIssuedToAConsultant",
     "presentation": [
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issued to a consultant",
        "documentation": "The shares were issued to a consultant.",
        "label": "Share Issued To AConsultant"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Company\u2019s share of losses of companies accounted for at equity, net",
        "label": "Share of profit (loss) of associates and joint ventures accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r37",
      "r155",
      "r161"
     ]
    },
    "sprcy_ShareOptionsOutstandingParValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ShareOptionsOutstandingParValue",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share options outstanding (in Dollars per share)",
        "documentation": "Share options outstanding par value.",
        "label": "Share Options Outstanding Par Value"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareOptionsReserved": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ShareOptionsReserved",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Options reserved",
        "label": "Share Options Reserved"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharePremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharePremium",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital and premium",
        "label": "Share premium"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "ifrs-full_SharePremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharePremiumMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital and premium",
        "label": "Share premium [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "sprcy_SharePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "SharePricePerShare",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price",
        "documentation": "Share price.",
        "label": "Share Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareadsOptionsExpiredDuringYear": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ShareadsOptionsExpiredDuringYear",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Share Options, Share Options expired during the year",
        "label": "Shareads Options Expired During Year"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareadsOptionsExpiredDuringYearWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ShareadsOptionsExpiredDuringYearWeightedAverageExercisePrice",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Share Options expired during the year",
        "label": "Shareads Options Expired During Year Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life of share options (years)",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumption Expected Term1"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareholdersAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "ShareholdersAmount",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders amount",
        "documentation": "The amount of shareholders.",
        "label": "Shareholders Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SharesIssuedToConsultants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "SharesIssuedToConsultants",
     "presentation": [
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued to consultants",
        "documentation": "Shares issued to consultants.",
        "label": "Shares Issued To Consultants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional number of share options",
        "label": "Number of shares reserved for issue under options and contracts for sale of shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares reserved for issue under options and contracts for the sale of shares."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShorttermDepositsClassifiedAsCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted deposit",
        "label": "Short-term deposits, classified as cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "ifrs-full_ShorttermEmployeeBenefitsAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShorttermEmployeeBenefitsAccruals",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees and payroll accruals",
        "label": "Short-term employee benefits accruals"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]"
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock",
     "presentation": [
      "http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS",
        "documentation": "The entire disclosure for significant accounting judgments estimates and assumptions used in the preparation of the financial statements.",
        "label": "Significant Accounting Judgments Estimates And Assumptions Used In Preparation Of Financial Statements Explanatory Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies (Details) - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies (Details) - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "SignificantEventsduringtheReportingPeriodDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Events during the Reporting Period (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantEventsduringtheReportingPeriodDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "SignificantEventsduringtheReportingPeriodDetailsTable",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Events during the Reporting Period (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantNonCashTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "SignificantNonCashTransactionsAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(a) Significant non-cash transactions:",
        "label": "Significant Non Cash Transactions Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SquareMeters": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "SquareMeters",
     "presentation": [
      "http://trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Square meters",
        "label": "Square Meters"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_StockIssuedDuringPeriodReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "StockIssuedDuringPeriodReverseStockSplits",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse split ordinary shares",
        "documentation": "Represent the number of stock issued during period reverse stock splits.",
        "label": "Stock Issued During Period Reverse Stock Splits"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_StockOptionDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "StockOptionDescription",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option, description",
        "label": "Stock Option Description"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Straight-line basis over useful life of assets at annual rates mainly",
        "label": "Straightline Basis Over Useful Life Of Assets At Annual Rates Mainly"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SubsequentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "SubsequentMember",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails",
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent [Member]",
        "label": "Subsequent Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "TaxExpense",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax expense",
        "documentation": "Tax expense.",
        "label": "Tax Expense"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TaxesOnIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "TaxesOnIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TaxesonIncomeDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "TaxesonIncomeDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of income tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TaxesonIncomeDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "TaxesonIncomeDetailsTable",
     "presentation": [
      "http://trpx.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Income (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TermOfIssuance": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "TermOfIssuance",
     "presentation": [
      "http://trpx.com/role/EventsaftertheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of issuance",
        "documentation": "Term of issuance.",
        "label": "Term Of Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/InvestmentinAssociateDetails",
      "http://trpx.com/role/InvestmentinAssociatesandInvestmentsinInvesteesDetails",
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable",
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Top of range [Member]",
        "verboseLabel": "Top of range [member]",
        "netLabel": "Maximum [Member]",
        "label": "Top of Range [Member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r130",
      "r133",
      "r185",
      "r186",
      "r219"
     ]
    },
    "sprcy_TotalAgreementEstimatingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "TotalAgreementEstimatingAmount",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total estimated amount",
        "documentation": "Total agreement estimating amount.",
        "label": "Total Agreement Estimating Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TotalEquityHolderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "TotalEquityHolderMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Total Equity Holder Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accounts payable",
        "label": "Trade and other current payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofTradePayablesTable": {
       "parentTag": "ifrs-full_TradeAndOtherPayablesToTradeSuppliers",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofTradePayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Open debts",
        "label": "Current trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      }
     },
     "auth_ref": [
      "r172",
      "r204"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentReceivables",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Trade and other current receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]"
       }
      }
     },
     "auth_ref": [
      "r13",
      "r21"
     ]
    },
    "sprcy_TradeAndOtherPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "TradeAndOtherPayable",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accounts payable",
        "documentation": "The amount of trade payables and other payables. [Refer: Trade payables; Other payables]",
        "label": "Trade And Other Payable"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trpx.com/role/ScheduleofTradePayablesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofTradePayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Trade payables",
        "terseLabel": "Trade payables",
        "label": "Trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "ifrs-full_TradeAndOtherReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Receivable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TradePayablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "TradePayablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade Payables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TradePayablesTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "TradePayablesTablesLineItems",
     "presentation": [
      "http://trpx.com/role/TradePayablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Trade Payables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TradePayablesTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "TradePayablesTablesTable",
     "presentation": [
      "http://trpx.com/role/TradePayablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade Payables (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeReceivables",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables",
        "label": "Trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount due from customers for goods and services sold."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "TransactionsAndBalancesWithRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties (Details) - Schedule of Balances with Related Parties [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties (Details) - Schedule of Balances with Related Parties [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TransactionsandBalanceswithRelatedPartiesTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "TransactionsandBalanceswithRelatedPartiesTablesLineItems",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances With Related Parties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TransactionsandBalanceswithRelatedPartiesTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "TransactionsandBalanceswithRelatedPartiesTablesTable",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfAntidilutiveInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfAntidilutiveInstrumentsAxis",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of antidilutive instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "sprcy_UnderlyingAdsPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "UnderlyingAdsPrice",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Share Price ($)",
        "label": "Underlying Ads Price"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_UnderlyingOrdinarySharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "UnderlyingOrdinarySharePrice",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying share price ($)",
        "documentation": "Underlying ordinary share price.",
        "label": "Underlying Ordinary Share Price"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_UnderlyingOrdinarySharePrices": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "UnderlyingOrdinarySharePrices",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying ordinary share price (in Dollars per share)",
        "documentation": "Underlying ordinary share price.",
        "label": "Underlying Ordinary Share Prices"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_UnpaidIssueExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "UnpaidIssueExpenses",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid issue expenses",
        "documentation": "Unpaid issue expenses.",
        "label": "Unpaid Issue Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ValueAddedTaxReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ValueAddedTaxReceivables",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable": {
       "parentTag": "ifrs-full_OtherCurrentReceivables",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government authorities",
        "label": "Value added tax receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of receivables related to a value added tax."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "sprcy_WagesAndRelatedExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "WagesAndRelatedExpensesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wages and related expenses [Member]",
        "label": "Wages And Related Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WarrantAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "WarrantAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WarrantExpiryPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "WarrantExpiryPeriod",
     "presentation": [
      "http://trpx.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant expiry period",
        "documentation": "Warrant expiry period.",
        "label": "Warrant Expiry Period"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrant liability"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of warrant liabilities."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "ifrs-full_WarrantReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WarrantReserve",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant amount",
        "label": "Warrant reserve"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments]"
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "ifrs-full_WarrantReserveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WarrantReserveMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant [Member]",
        "label": "Warrant reserve [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments [member]]"
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "sprcy_WarrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "WarrantTextBlock",
     "presentation": [
      "http://trpx.com/role/Warrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WARRANTS",
        "documentation": "Disclosure of warrant.",
        "label": "Warrant Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WarrantsAndExercise": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "WarrantsAndExercise",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants and exercise",
        "label": "Warrants And Exercise"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WarrantsDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "WarrantsDescription",
     "presentation": [
      "http://trpx.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants description",
        "documentation": "Warrants description.",
        "label": "Warrants Description"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WarrantsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "WarrantsDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WarrantsDetailsScheduleofWarrantsFairValueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "WarrantsDetailsScheduleofWarrantsFairValueLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants (Details) - Schedule of Warrants\u2019 Fair Value [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WarrantsDetailsScheduleofWarrantsFairValueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "WarrantsDetailsScheduleofWarrantsFairValueTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants (Details) - Schedule of Warrants\u2019 Fair Value [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WarrantsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "WarrantsDetailsTable",
     "presentation": [
      "http://trpx.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WarrantsExercisePrice": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "WarrantsExercisePrice",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercise price",
        "documentation": "Warrants exercise price.",
        "label": "Warrants Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WarrantsFairValueinDollarsPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "WarrantsFairValueinDollarsPerShare",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants fair value ($)",
        "label": "Warrants Fair Valuein Dollars Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WarrantsFairValueinDollarsPerShares": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "WarrantsFairValueinDollarsPerShares",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants fair value ($)",
        "label": "Warrants Fair Valuein Dollars Per Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WarrantsLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "WarrantsLiability",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable",
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants liability",
        "label": "Warrants Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WarrantsMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/ScheduleofWarrantsFairValueTable",
      "http://trpx.com/role/ShareholdersEquityType2or3",
      "http://trpx.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "verboseLabel": "Warrants [member]",
        "netLabel": "Warrants [Member]",
        "label": "Warrants [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of antidilutive instrument representing warrants."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "sprcy_WarrantsToPurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "WarrantsToPurchase",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to purchase",
        "verboseLabel": "Purchase of warrants",
        "label": "Warrants To Purchase"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WeightedAverageExercisePriceOfShareOptionForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "WeightedAverageExercisePriceOfShareOptionForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Share Options forfeited during the year",
        "documentation": "The weighted average exercise price of share option forfeited in a share-based payment arrangement.",
        "label": "Weighted Average Exercise Price Of Share Option Forfeited In Sharebased Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Share Options granted during the year",
        "documentation": "The weighted average exercise price of share option granted in a share-based payment arrangement.&amp;amp;amp;amp;amp;#160;",
        "label": "Weighted Average Exercise Price Of Share Option Granted In Sharebased Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, Share Options outstanding at the beginning of the year",
        "periodEndLabel": "Weighted average exercise price, Share Options outstanding at the end of the year",
        "documentation": "The weighted average exercise price of share option outstanding in a share-based payment arrangement.",
        "label": "Weighted Average Exercise Price Of Share Option Outstanding In Sharebased Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Share Options exercisable at the end of the year",
        "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "WeightedAverageRemainingContractualLifesOfOutstandingShareOption",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual life",
        "documentation": "The weighted average remaining contractual lifes of outstanding share options.",
        "label": "Weighted Average Remaining Contractual Lifes Of Outstanding Share Option"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageSharePriceShareOptionsGranted2019",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying share price ($) (in Dollars per share)",
        "label": "Weighted average share price, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted number of shares used in the computation of basic and diluted loss per",
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "sprcy_WellutionOperatingExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "WellutionOperatingExpensesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wellution operating expenses [Member]",
        "label": "Wellution Operating Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WorkingCapitalAdjustmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "WorkingCapitalAdjustmentsAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Working capital adjustments:",
        "label": "Working Capital Adjustments Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_a2022Abstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "a2022Abstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022",
        "label": "a2022 Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_pricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20230630",
     "localname": "pricePerShare",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares price closes (in Dollars per share)",
        "label": "price Per Share"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "q",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_q&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "r",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_r&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2023-03-23"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2023-03-23"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI",
   "URIDate": "2023-03-23"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI",
   "URIDate": "2023-03-23"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS02_g36-39_TI",
   "URIDate": "2023-03-23"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2023-01-01",
   "Paragraph": "52",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "19",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "19",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "29",
   "IssueDate": "2023-01-01",
   "Paragraph": "9",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=29&code=ifrs-tx-2023-en-r&anchor=para_9&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
   "URIDate": "2023-03-23"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_126_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "129",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_129_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "130",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "134",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_134_f_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "135",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_135_e_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "84",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_v&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "122",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_122_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "122",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_122_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI",
   "URIDate": "2023-03-23"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS40_g74-79_TI",
   "URIDate": "2023-03-23"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_f_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "29",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_29_c_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "49",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_49_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "30",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_30&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Paragraph": "22",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2023-en-r&anchor=para_22&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "12",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "12",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_21_a_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "9B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_9B&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Section": "Investment entity status",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS12_g9A-9B_TI",
   "URIDate": "2023-03-23"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "115",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_115&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI",
   "URIDate": "2023-03-23"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI",
   "URIDate": "2023-03-23"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "110",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_110&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "m",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_m&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2023-01-01",
   "Section": "Presentation and disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS05_g30-42_TI",
   "URIDate": "2023-03-23"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "11A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_11A_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI",
   "URIDate": "2023-03-23"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expired 2023-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_23_e&doctype=Standard&book=b",
   "URIDate": "2023-03-23"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_79_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "138",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "96",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_96_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11D",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11D_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "57",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_57_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "14",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_14&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>129
<FILENAME>0001213900-24-017526-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-017526-xbrl.zip
M4$L#!!0    ( &F!6UBE0N04%K\% .AJ-  <    96$P,C P,SDQ+68Q7W-C
M:7-P87)C;'1D+FAT;>R]:7/;R+(F_!V_ J_/<NT8B-9BR>OQA%J6NW7&BT)R
MCV^_7R9 HDCB& 386"2S8W[\Y%8+-HJ2)5FV>./&:4O"4JC*RLKER2=?_<^O
ML\0_4WD19^F__FMKL/E?ODI'612GDW_]U_[IP='1?_W/U]ZK:0F7P:5I\:*8
MYZ/%OQY,RW+^XO'C,I]_'8RRV>/MS>V=S;V=S0=R653FYJ+S\_/!UV&>#+)\
M\AC^\+A<S!7>L;VQN;.QLZ7OB;^6W??$:1*GZK]_.7D'+PS38ISEL["$(>-#
M-C<VMS>VMIV';!1J5'L0_#R89&=+G[.UN['YS!D,7/FE>S3;FYL[C_'/P[!0
MYGM5;*ZF*_4[X0\T.69\X[S8&%=)PI<7^GK\/3V^#+]F:39;T%TX0=L[C\U-
MYBE%]F1[Z^F2 <H5^@;\8[SL\K0HPW1DO@?6=%Z,[!WR<ZZ*K,I'JL!%MU/>
M]^"M'6?.S5"*^D#.=_0PMA[_]_MWIZ.IFH4;S0%5Q0:*36%N'8?%D&[4?ZE-
M\]=DR<?^]SM8/7=FHL;BR95[C_F/=N17&/C7EB3)?5O/GS]_3'^52_LOPOWW
M />A"J/7GH__]ZJ,RT2]]E\]YG]XWJN9*D-_E*6E2F$CE>IK^9AN]/&Q&^K/
M*C[[UX,#_OO&)YBR!X_AF8_YH:^&6;1X_2J*S_RB7"3J7P_&<.4+?VMS7OJ?
MXIDJ_ _JW#_)9F$:\"\"_U3E\?@!W84#>(S_?36_[ ->^K,PG\3I"Q\OW7SI
MX] WPB2>P*]&,%B5PSN&K_<+?QPG*O+/XW+JEU,%MX^J/"YC>':81O[AU]$T
M3"?*/\AFL[A I>;#_[]5P[P*\X6__33P0$B>O'H\?/WJ\?Q&QYW'DVE)PSY1
MD[@ ?8.*QO^0#?R=G9V-?_YM:V_SY>K_Z]_,F!]T///_V]CPW\8JB5[X)U6B
M-HY#F-&-C9IL\$,VRFQ.#])/W1AF99G-Y'?G<51.<5";_WC0DJR-(OY+P1_Q
MPF&61RKGI_V2A*,O_C8,KLB2.#)_U$_FOV_IOS]XS?,C8V]]P>/6)W1,7EO>
M7OJ7G="E<V%'>;-"YVR6WS\<?3I\XY]^VO]T>'H; N^\^_3PX/>3HT]'AZ?^
M_H<W_N%_'_RV_^'70__@X_OW1Z>G1Q\_W/* /H?%%$R:,H/[WQSXVYN[3Y[?
MYA!N??7?@F4C+XV_ODBS]$,U@_M'?#Q\+4_4^%\/1F"MI>$,7@]&RHLWV0BN
M24LZ&/PX^M>#^.O9QL[3W<V]!Z_?;FR]>EQ[TNN?>OY.#G\].OUTLO\)9)7W
MT/O##Y_\WS^\.3SQ/_UVZ%L1]_8//OD?W_I;SW=V;F].Y'=Q&BE\YN9@-TZ_
MPSRM+%V'*9@I"WT4IN4'^$M=RIX^> W^QNGQ_LF!_^[3FT%3WF[H!.SYM/CU
MP\.OX:BD3_"SL9^;H?MAX1=S-8K',=@B<>K'9>&!X9'#G8]@U'=2 LIPF"BX
M,TGF843NW0-8'_RYF(<C_?.E1^D<\>:D'F5)$LX+.-SUOQ[ XI6Y?CJXFV4\
M"A/].7Q.TC61OJ9QZ _YT!_L6K- WKRS#2^63]H@FPNGXAD>PYWK"E^;ULR0
M<3B+D\6+BS[4-5GH0,=CK@Q+Q1.>C5?2MNQPHLR3D_I"19,PG^?9V2BKTC)?
MJ+2]9X[ '\_G&=N/],H#OO@@BQI;Z-F#UT=%'JJD6U?CM\-_RJ@VU5V2)9.[
M_0\K4(V[?H@%VGZV\^2>?OJ'K.3A[\_G">PVV/W-F8#_R2^],;_+YX R=O=:
M+O\%#U#^^1_P HLH'N$6T1ORU3!__!K4L[-[&O?GDS"-_Z*_B-Y>54QZ9>-[
M3<]Q'L.!L>!1P5RE49A'_--1&E5P<,5APC-RD(3@&8]AH>V4H"KA?X'&&)IC
M[(>=CJ/!R>!TX!_.YDFV4#E_^!$>E(T/[_E<V1J/Z=24D_36CW+8Q7I:NPR?
M.WRB@RM<UQKRT"?/VPIQ=_ $94+_-E%C^\L;UY++CNNM]E&\'T6Y*@KYS[LX
M55OU _CY@]?;F_Y)6"7^YS!)5 K"-?%/RURILGDF!_XWOWV[]O:MS0>O/V7G
M*O?W6^]:=@J:$^^;UZ9'"USGZE_.WUBZ8,^>7[,T'5>3)"YB_Y_A;/[2WR^*
M;!3#J574)K]IF*UR$+?VTX^_AP[@GQ]S$->T+L-;(,,J\??/XK.V WBE-QUG
M11DF_W\\;]G+6]L/7N\]?[KU?&OOTINS:<F+ 8]CZ#+B]5?S5?51[%S%:K^9
MG7J7Y.K9[J;_+A[F&+C?/U.#Y4NRTN9OZ,LG#UZ?5G&I_.W-)Y<3@/ZW]<GU
M[H/7\/5A_N6Z7D0&\<?\&)S'F+)-[MOV'KQ^<WBI_=/_HB7[Y^F#UUNP?WI"
M@Y?P-%H*KCOH[_I8=TE406.]6%T[H8CLYRILSR?X[P__Q_.GVX^NKOK>93"M
MQ],L56S:UE\ )][#G4?^WM;FQ@Y8>%=1.'I):#%NRF+XR99_<Z7EW][$U=F\
MY.IOKKSZVW"V/MUYMK&W]^S"E?^131+P_T1U!>C^)Q6.P/\KGL/$12J@3'&I
M$C7'>?)3FJA@F</[LY^U,&$8C@^\\)NG[<>6&_O9(6Q0^>Y:[/^??WNVO?7T
M9>'/<[@XGH>)K[ZJ457&9Y@E&,<C52P-GMQ-6>K_]' "UZ"UZQ<J/X//DZ^[
MH2#)!8B"6\D-7F$,Y :]/LCFB$0ILQ<\1]>:KKK&F?G.D2//OU!!>(QPZHP@
MW/AQ_C%2D?];F&\<GJDTH*$<%G\._.89V3/([9XQ.EOWNW[>FWS@GTY#3%C2
M.'X+HS /_/WH;-!I!5QAN3J_X9;WXV\9>%N1_XO*OZATF,2E74D*!]-/IU62
MQ&<PMQRR^9PAM!&>X+][=ZSW+W_<+8]^:V]GQ_\ES\+H/%SXWW4H^- _LOQ+
MX'_X S?WUO/O.APRMK>WM@=[>YN#G4UT8D3/=NVLCH<\OI/B^E[%99C[_]=_
M%Y[[']F0^,X2Z.\/AZ'_6YPD*O%/XP2V/HWD)!I\UY&=A+.P]'^%7;N[O;NY
MQ_M:1]"^MV2R_^Z[7C8/QI52HU=O*\&T@I7DWO2?JBCC\>+R($B+*AV^WI_/
M\^QK#&NE_ C_!ZS)43:;J72D$&>&/\,5\ZR X[8(P2(I,P+USBM0UZ,7'D[9
M?@$.?Y8BY&:>AZ.2,]E^.$8EC1>K\5B-R/JF=TQ5KK+QX%KLKLX9<;ZSF;6[
M9IAGY^N;;ZP-J,M0< __H[$7I@N<=YRYPF*GAPH-?_9R8 (C!$V7T[B@*#<Z
M!+@T0W)P])]#/U))N, ?<@I(Q&F55?"HL(#[YE5>5 B5@OL0@,O3\F1KUZ]@
M[+G7P&[OC\K 'TW5Z N-; RF8G:.0QIF7P=Z2LDL^>??GC]]LO?])O@[K^_1
MV%F76,/A89+UVJ$+'V-Z&QQ39X'1?P/!H/7#>>U9G[WMA\-'O$1->/VR):+0
M0 +O;]SDP4W&=R;T>X%!:]K\'#_0LJC"/(GA1[N;>V[##R'A950>?\Y  ^5!
M-IZL94-D(_1!M98;9DH]F+(TXEDDL>D7@M$U"H'?% +O.PO!BG-[I:/OJN?L
MM;W^&H4@6@O!CRH$:80@)^4/%[)0\.<O_OE4(6*.#E\'S8Q2DOHPJ?B$B3_)
ML_-RBI;:'(T%,+PB-8Y31CJCA/A/-G?U:C56&'Z+*/AEYM=//?&'W9-X66CP
MBW'\544;XS#!^M)F6E:_Y%=ZQP&_HI[HV7[PVFR!9I[G%AR *QG&-ZX7^X4<
M=@0XE/-<S<'4+1#.#\HQ#=-1C%:4UC@%;H!P-,KR",L[N0CQ=X09_KJ_?XPY
MD\Y=%_-.<3;<%/:42D"[P9Y*,]*\5:%H6\+G@GI&DP[+D\F0\^?P.5E$^@['
MFRSP ^CEN#]3^'SX2Z[.8O2C[+AQI!6:Y1/\!,*#%CZF+[:?O$2_ZRR.&NK_
M5!%^UGOZ,'ST</O1PU\>=6_S@7_/]:N>Q4\P-6!SSWA:-U_"6GBKK@7=LO42
M+H:3"W,&M)K5G+S8N"@J>  ($L[^6_.<??N<4[.FOV08YX0'H-S:*SQ[Q4$6
M&=BKN,[[\SQ._-W W][<VAY\]_G\KJ_'T$UCAX*7"Y-/ME+AD4'58X7@#]5H
M*@&.G/Y;X*$Y"Q?H,:=JI(H"(4RP0.0QTS(UHA:X8DE33133,$G(2@,K;ESE
M='9;\^U\&L-[I0YI!)<N>%@@2ZC-E@V:GXS/4RP-0P6:Q8VE=&@ZT0Z\5L]
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MEC3L7N>7OXDIFQ[YQPA"OM*.W[O9+;]WO<)/\07IEG&EK]V^K75^>IT?_IY
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M"HNRL/& ;"B1!ZKTY,8M>#R=A7$BQ>;6#9:GJKFB8=LW\'U\G'FL;5"3%J;
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M4N_?5:H8IT&1$#@"*Z3AM\)=9G-P;:V04P0 %_W8R+>.\L#)&A.]EQ$(C 7
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M@30_^%%EB:D!>/QOX2QTOPP\PCS+8YP8)_/G=(/^-?PK1,)V<(&(QR$I%'>
MT]VIU42G"GDH9A^>(_J$888:ACUCR@DXVJ53"5QCKK<]JF/8J:-24ZV;W#2-
MVIE]^/%A#!]KIF8*"XS_CI54'/VF_AKB03,5-YS&D6:$RTSE4+):\L8Q;:OQ
MJ]](I7SOJR^5CGRV3D?VI2-WU^G([U 9_YT[%GSZ[=#_^/;MX<G1AU]OMU/!
M#VNT;V_^XSH/?EB$(^QFEO/T]QL@^O7_Z(06KY+^>/JL[][K^YS347R*74C\
M=V5D&A3\I/;JM0J!C<NBO4<$K]++[U0:1IY:U^,B6;F6J;F^S_N=&L+O!D\V
MMX-GSYZVPBS4G8/C>MGX!=E_TMJOW;S/&$V5/'3GR=-@]_F3GI;= LI%BXT;
M$C::O+7@CS^O>W6MXMJ<;>G(R"B\6L-KVRV2Y!I^^X-)[U:P^7PW>/JL)6)K
M4;F2J'#/2%=*=-/QN# RXK\JJOGKAUN/8(ZK^>L?3&3V@B=/=H*=I\^:(A,0
MD'JF^POKS@BA-&!>HLU(>77VV'Q(A+G\8&)_PX VMHBG6!5U6-T9/'WB,.(R
MLV]1"L\XLE80)[Z)A7?UG 4']$-81.&?^*^W:IA7^,?M/>RIMOWDT7HSK+09
M?B\4$REG(Z6BX@>3Z\_* O@U 3,B\/7GM'M^=&55I%M]Y.NN"DY#K'Z;QW#I
MZA>S =#HD6Y:.X-3511V8%W'_M(6M]I\4(F4&5'@N7\;!DRQN C:)H4NK 4?
M4E')?ZZD44^"@>,)X^6$K,GV139C=RT9_?%"H(W9)\5M);A9(<TGO92P[^W6
MZ[:;>B$Y+L7F44=3>;=->^'KQ!G)#-Z/=5$TAP/_B#H,ID+4ZG0IXT[#,G3N
MN7N<JXWC,([\?6F\JY? ,?;V>19JO;!EO7?M<@_\?5?X]#SI.6IW^^C6JF"A
MM,?4F Z=":2"9$P[G&?Y%^J!(%ELG"_N@X/\"1KB"Y*"'>BQ4DPIW3!.=,"Q
MC'L@3>/6WM+J:O3$:=#W@^G0(ZJ40M'1:L%Z?@Z'^32>8-4AUAJBL""7L-O;
M$'MG,-'(DBZ$NE$A&%IY*3TWJ!EA5R_"@,0Z) 55%840-.DFB)P$XQZ*MJVB
M$.I':A23(4=-Q4R965NKKHV$E:1;[*QB,1MFR0L]K!]*RC]V:%O*-F'WFL@Q
M)JV>Y<_5\GQZ?'(@<GP!H^\Z6KDL6OED_K5+R*YMH=E%NXQ8WNAP/M5,G$[#
MKN5^QC/PF[#Y+&4RVZYH6*#2/4^Q.1(:O.1HZ5IT, MZ7J3#>)AL'"ZX:ATL
M6>;2!DLW+'@C],87ZCXR&3$MOPN+VK''"7\RT6!'JGBQWC"W5$Q@4T@:HCMX
M=KT2+=@$_SN"$YX&FT^>M]TXV >TRM5<? OU%7G R+IE^,Z<$]VN'+.^1[MG
M>W-KEY_E?Z0+I5P)=Q68\3B=Z-/ XJ')8IYM@A1_WQOL/+.!C@[TQ@W7!BS5
M<=UB\<TFS-W[I)]*TO>"O8[\!&)M\C-Q_$CL4RE]",_".#%,R/AG:0,TR3$^
M<)&PKV7V)Y'9[RBR.WM/@KV.B'&_>M;02E<MGQ/-#K%\8_"FKFUA!X3IA#I,
M8DCE[WO/4/-B,&9OY^E@DW1P_?4O<7>LA?OG$.[OJ9!W@IW=Y\&3O58FY9+R
MC9T+L5\P*/%+B?KF8'-SBT0=_K6]UR'J@WXQORE4__>G]7B^QM'UX>CV?D(<
MW77*;PNA]_I5Z,?1OQZ$_V=S<QOE,'Q];:C1'MC;R='I__+?[A]\^GARJF%O
M-]G:R;RZSCQRLR]=0CJY#$X;VPBU)Q'J=@)/PM34X6[@_\)AX%E(&1'0_ X;
M&,:&"\IV+6SPVD:035"9H-A.5!]N+$9Y/%21-U1)=D[L?=)2#RUOT[V3VZ+H
MBWVZV#0()-A)FBSDQC&%'JB_BB03B>;;*4KL>P$R7XRJ/%?4]P\+T:@>L2I<
M^C)[0:343")-\6R&/0+C,.%TE42+^$6-<3,%AB$=;(XK8*(I3S\PZ6'RUH#S
MH)/3.\O='J<.415F\>B]V).0UPNG*,$&&13GXMYQ>!<6MGD9V!UQ2K6>>KEK
M*0J'R&VH$$MO2$/PF85^CGO[*ULIAKORUC9)OX*Z.1W46:XM,4=W$FYG1+?S
M_=9"I++"HY(:-,-&9;I\32U-O76=K+C7E;6FE&Q7ZEIGY=L8@L"76E%)MC=
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M\:WOP=/EEDTU]"9.CB?] CMJ3]B\"5V *F8P5S!W6(("W]H93;O%X+-!7QL
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MK32$0#IH_D*50]#I!=,I#0M2BUC9>H9E:%''&#]1GQ ,GOK3>#(ELP*7)->
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M._\?>V_;)+=Q; E_QZ_H<*PWY C,F*1LR[)W;P1%ZH6^ILD5:6N?_8;N1L]
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MW=/CI<CN."KG"U4KJ-^KYHZ)' (P"A35A1';DJ+OT-*5!<I\[5J/?C<M^G9
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M3,C!@*%ORWP ,-+CF3<V(N.?RD&D1_0>"8E+.>' TA1 UUP\A'_<2YF/H^_
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MG;B/6;5'SNFZMD1^'^LLDR[F; 3"\[+D>GK&')<I">*2IYY"#?F3CA.<GZH
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M=HL_R'J%9 Q0 8D"X0C6& O-<+5,_1A7=)FY9[: Z*C-O[M;X.+@8%YP"A5
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M,Q%/>"9%@P0<"\XW)5V4&[;QG-S2F.4O97?DSHI]_'IYI+^NA12G3^TQL6,
M+8DZD(;2;;E#V?-M:;O@/.I,F#0;O347+%RV6VW'#(:!N.0+RSU?+ 3*_/.+
MO^I&JR[3)@?9HL=.7P3RD]? I&56:KD.JT07O99+PH_"7>U,02@/I*H)]'HX
M+1&"S74I!:*8RTQ13A+.D:514-:2/_^<#'L;D&W,1Q*\ EUDOPBE$ARS5,'J
M8ZAM+$</F<2[BC!0B0GWW\!W]E!];<M03_:LY!,+O)/R87FP<@_MTNVWOZO(
M4X0N2D$TZ*G92#[U/5_(W,R;":GDN"0+\Y@48EV=/'N?.KD[J5U]9%$5<"D(
M09A\&<H7,#&A@JC 5\+<P<*#H8Y%UYZ*.G) ]>9WM.N:B6O(Y(#BZ4VI349>
M$LX*&4MX3$ZWM4J30]RTJZMC ;\KI-QC^@CTS=9^[KT^57)=Z5B8R=H?>PM]
MC']W$O0K0XP!9V:^"6 SW*&W>GLX&CAV(3%5E\/L$G/!JGC\(KXMU&M#T&>R
MOV<7(C'KYHLQ^X=K$%NX0YHB<8:?'K(_2QJ6X"G"@K"-ZCNLZOQ<RP *1BEM
M58 >JBZ,L3QZB*DX!B("F"%F$D(B41^1&]9:[5HU2.-I#^!:IN8*HYN=5VQH
MJB)Q3-CRHU=76BJMECQ=U.7J2PYIR$LWU;UMG6=:G\P_1\6:/IK11YUCKL"Y
M1>6=^I]0G8$?2N@2\%8H\0<;K"5_KJQO2#WG#IX0KF26+$+BMZ;HNO:&XS>Q
M\Q/G/^[A-G##<4T]QZOQ+M!/3IHL#@O=YHLGBCBS.9G=L>58YL+5YGU>9S8/
M%SI*@Q/*3H#EQ.<#@=Q)@!(CR9%+^X\ :K$54HDMJKU&-Z%AM[79:6*ON?)=
M==.>%!$RT2%5[!]*CE?/"6SD$CTWH0 ;.=&3]- ]N/_W8 D?5D5]>*ZB+E91
M_WBNHO["[\*7/'=' A+4,TC_T)$SA=)\]0+C:$B"U?NS*-5ZR7AP/'TK.MJ
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M$00GOE#ZQGM, 008)_T:Z;2X7#E-99HG1ABIK5G-VIKL9[<UN1$$NG@N^S"
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M8V;CK $,Y&WYOD9%#BI>J9IUAAT0P*%<P/ QN4Q_6^^\3KW2T'_;(-@(N*#
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M'*O67ZWH.@2.#Y7RD_GC!86;4<:N'RD0,)<MDT-\/='RTW[27KK'/9,&DIT
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MF1OA49AG6(Q\!(\!5@#\G]71NSUCL]ZB]W1!8B1\%\%2Z"NAR, E_GU\;!#
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MYNA04'<'5[OA!L/PI(,1/?C)B9/-I0(1NA!-@DGYPR,()ZBF2-T*<^L&C7G
MX1S9S*-&DF-NT3 9;9?,.R2\_(/$;#18CH1)T&Q8Y;-WTQ.8#9N&BLMI:TS5
MZ@P%BV&9(K0"6@^QP!:ETB_'@=],6GEI)<C6A.HQ'7^<^XI;"IA08"Z]!6?U
M+1A"1'M@ZEOOK)8UG8=KOY!TMA*>*L%GY5O4-BXR*"P7R,P*V]N-E^&LX')5
MV<OX3,KSDN>PX?I327#65Z'-"Y]P32M8$\B+T_6-R/CZR(G&M&&G:JZH)@TI
MY+%7(]%B4B2"8^#Y8Z+[:W]AK=KV!8;PM.F'@H"K<[?2;F(!(RY75'?(34HX
M+ 3-X)>8D$[9)RIPGE"5.Y5_TAN+RSL&[(_%#E%WLZV8Z$/R UP.-N0*]D!H
M?I6PCBW-E%0K)5*!5:'M(U)L3!C)_J Q:B'G'K3L6.]J@_"5NU1AQJF1_0"$
M$1E3O<<@A <:*T.W32GS):B/8"X>$>WKJK*K6'^MVZX3R.(B0-!.JJ/=N7OJ
M3;S\7F6]'YW+>D^6]3X\E_7^/B0>+_^1NU5Z+<0ZU0[N3D,@YX1TR,:?U]F]
M NEH^['4>H6ZQ!9$39F_E0;&\&3S)08HP%&UH9HM?Q4?A:(*>I]? '#% !#%
M3+@KXB@TE MQ%(IWOZOTS8,7,'HU 826UT5#J$!,O.@'\Y2.1U,-<S#Y22>[
MM+<:$*[=49I=S\[9%!UFNL5^)W2AW=)"^S\_?]8#*EW@72E@8J@1Y(DM8S31
M!R*F:C?A.%BB7;B9B#T-I*E(K'?@YZ0KO;JBBD>R5-;!@8A5D?&A@\6\G/2:
MFRY\.1TS1$DA<XE^ != P *88[,EAN9E]C4 = I:)N]*</'B=+7MO)DMAPB9
MAHK((WZJDI/;9Q3F>/3@BQ "+W;XS<,O<A>14\U!+^L."*,,OQGX[:I<X,'Z
M/EK7X212U69(JQ=AZJ'JMVY6[4MTND\%QT3 F'W*S]\[DL,,5C?.B@.C"7KK
M?$OB=E (E<KM&@%$]^J$= >WO*>C"?BW^'5 Q2,!'/UXFD'Y7VQ9Z@+_A==
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M1A_0>^ATSC9IV!5!Y18UJ>&+6'7OGFT)7$US-Z5^D"(1M6Q:JI&!+-[A(.=
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M5D6H$0[%UXUD)/W0O/1=M)L+O66(^G/]HG=^'T=X;O,NH79FBDW/KO2(\&&
ME$R*5R&R>I2TS5RU#I\ &)4.DKFM"?S"2ANU0$@U:EKL\C\!<\1[S13N$I1'
M$*8<3TMGUA_J%SP63526WKS.491%74(26BPDD?-UAZA<<.)RB1D&@.RXR[%
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M&&"EJ RQ"M<BSP32-<:16 H6"(A#H/IEIB]%V+4&ZC!%9"[]\%J4\T0^0*8
M/\O]6>Y?0^X'EK84M#?*G^F>TS8&0P)WEKFSS/T</VE?50A 52_7564K?KP,
M_DOYS:7&4UF#)0+%C1QG 3P+X.L*X"2AJ8Y,0P"QWU4*?$6W_K-=T9PE[2QI
M;U#5,:^,JCMF,M/ D-;*7GLA1 1>T-"&XUD(ST+X&EFEIB6VRKT61B=X)2;
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MOJI %,0._V7V#_\[LCXXP\_EZ#6QS4EUXM^+FXN'GW_^>0A1)G_*B>RU)9M
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MK?#R-3'R<>BGCZ/T?_%.%Y=P%RSWD_:&F>>X45,)(> .#+,RV@*+</;\IV5
MLC>Y36@/\"E+AR(Y6K8[BPX)0R(RH3_?:R>R:-]_^ $YA+NJ\-?MITQA35OI
MG1XH%3S5JZ94S!W_P4@TBC[\^[QRH"!<>.3'#\(C*?G#,&F(%PD\%'F;?'3D
M9919(=$B9:L7UB%!Z4V_<.F>I0_@+Y$ZY84PXJ[634[7.]V]W/2_)8L[#U&(
M$%;(#1=ZUQZ]_JZYMU#+RF$H<L2 D.#:$AZVXYLWEC-%PTZHG15-@+JP!141
M-:R8G1((X)11A4-/E3P51_*2F6>3F5O&<C^*/9L@7D#T%B6F>UY#U )6^X-W
M7KNCT5:@WAQE[A/8A@(US\C?3&K5D88K*ZZ%1'^5.$R%:]KF I+J39B#$BS4
M*L@Y0A&VE107< 2!Y'G!S8+T^#^0Y9<^367:VZ_M#0'YE;6W'0:_X6V'"CC^
M5^Z"6!;9(R_KNKO9^RJ4']#0AN)%U;#I+7:<C:.M_ 5<7<<T7E"A945),'M"
MR5/1FQ@!'OS)+9W+DJ%6Q7I,%2[4+#LBLU)=7.?IIV\6*KU4M#5C1=]P"[JC
M0WT6[288PZF_K4-:E5Z>OJ:L2R[3)3)QRL[MQ-0B&Y44EOA/X8K\]^A5(*52
MY:-42>,E3>]%RCK^WZ^^SOE6>V'N5HJS70SM!<?;5.GH^V"W-?I9"6>5\.A6
M(\Z<?D.,YV0:>2 'N^( ))B22B>Y/#V@ L17>Z^;T2)50F=5N<?Y._X"+1NV
MQ6NB=@W[WLNOEX C)W!G7U.W/ 3-I4Y1E>+DU5] !QO7);Y' R-+-H1.7QX>
MFB780^G\X2B+(UINPB^6+Q2MJQ3Y#]/UGZ93T4<7@.4-$!+9^Q^>'C,.NJRS
M:&ICS/2+@DY"7' _$C%+T^'NU,3V?PI50F$5323&.X(2"549YP]1B+4J@J@$
MM>&\TNZNJO H40 4)^CH7&E$.8R3P]WE"4HYLL*A;3$%%M]0.D!+@;.>+ 3&
M=>FF-1!!E)YJGOP[RB#[.]?;)]>V9/CI=\_SH+BK6'(0M96T8&&OI^,.&T\!
M+A<>4\Y+C57;UX-:SD/;9A0/D^>GN@7%&U !4BC@%0/K!:L)@@JXG!BH+D(8
MP(Q8.JBB<$/U[PTID:D,B_UEY4LR(5RG 769HQ5)C-UU5?223G#R% G'B3T.
MT4T:G$AE'01F:&IK^V&U(+RZ^U(\3I_@*) HBTE?#6K::RI41L8FB\[_[9K<
M6+F.N?>2[!6.5'AAH9C</OOLDT</EXI+^,IFZ'"!DO"K.;2\/V[B0)!:6]P:
M!&.'SAMH?KJC/V$E5Q\WB&YR[@6'I+RN>V115NW(9QX++KMB[!>ZV3C6P%-Q
M28&3PEMQH2VR343VU#1Z/23^$ O!GD.H+UB&;M^3Q?,^8UH7R*UK;J><'L-+
M?W0KO>2^]Z>?'LR&U==RC3_E:]S_D<)P?5VJ+W^A9N+7XIP^C>9>2,CI+8SC
M&.O"32W,+"/TB_A'7./P:WEC^K;[59 \/%>0G*P@^>Q<07)7F8M1CU\^S6=>
M^EW=O^B]11! ^#1R3B%[M"]3*"=$ EV VWM+XC1O1^$-U6^/TBS0+BR6:,LG
M":@B_REUK>>HA/Q-0!/RCZ_&)YSC#;HIWF .R\NT.)AL\Z^^C&^!&$D!-3DC
M'$KPAP'9)*=Q]%#J/(@'85$G_0)NJZ+T3FT7$-6]\]10B<V. B-HIT():]L/
M2^TAU! CSHY<_I,730Q[].;P8PCW.O2%\'CPPJZ7HG"Z_:5V6YZ5/=8D$F$E
M'%I*?*PISL@@G_4ZQ:-,P$"=F3B\8N](MDSTKH"7)%LAZF*$3)/$OU;/UULA
M6M1E9 $]Z^:ZW5V3W2D+&:CMZ#R/!^T.\0[Z4-0[C<.A["ZD><T>U /EB@1Y
M0WIME;$"KEV1D%R4[4T#XS>!=:W7;KDA)0I-KAU2O)^Q46JB/K)OI6Z=DT;7
M"#?:!0@1%+UJ@OSY/[D@@8K]-BDTB&\*_ ()0_OI*II?.3OT%HC>MTU '_E4
M2R6(:QYWBZ.&]5TQ-NLMA63D<A#!HLB5WBX&\-9<0\N7#SLKWD^H=P-KT0GP
MK>#5!@^1('0=('1S&1=Z\>KKFKKT^E0/#11A(8"-;;VCUMF]W^6BJ0!D(%.A
M;_N5D#*9KET#4Q /[K4F/\K=06A4D0OKO9,N'V0!8ET<GU96Q;"%+_FO$?C&
M-+@7==D4AX,D[].!]Q2K\Z<$,52NTNDK3BT_YXP Y8]77B<.R?7BXO4B58YE
M@A@<@8H+HZ0+[[R10V?N>8H^G# 20 8/($CP?%!*I-J)/UJ;KFZG:X@V(GJ6
M+J=?M!8IZWSQ8M0G]-+B24ZLAHTP :P*>LS])[=:KLJJL.82H12:.:?JC'Z[
M"(H\$;,I/C*^\/=J5312SV1$0L3A0MI'=MS0X]4D53D3YX^JRN_\+YY7A?/C
MV0,8(1@%W[3CL*VS?Q"D3\4U0?]+/W'8B5,(P!'R<QXHJW!HO1..<![@3VXS
MYZR!^(R >OVJ>@ES8>/3?96Q_DC!SK\6S8L\%'Q0U!4O8F5L@+HC+O;3CK0/
M0EU4C\2A4Z.[^=(O!OZ";(<#-A$QQ4H)>&P#EL1)*(1E X$O&.!WOU.FP/,@
MX7025EW[ I6B7@C=3$]/#,10 PX UFF7,G6D<>10PTM7Z%F3<KKG3YY>/'KX
M('O\_$N_9UY\Z*X=N&MIR)ZW?B!%]@\J+"EV[@F<0PWG%CW3 G+*<-AVE9Y7
M;T0.G%KE-K<:@HT"DR#<K:U7X2:$GI1>BQQ787,G-Q13;\"F1:%7IU_<MC?\
M%E8>7C I,B[U5F*+3 Z_(M77-H&.Z9"@LOU5V;C6FMZ%W #LEBMI52-3Z4H@
M=2>O2+_1KZFAG0&B_M&VY3%VK\='1-5XXBFX91\_I%5[_$C\BF'7MB_L!YQ$
M_7ID TPR2WZOI1OREURJD((V1C2];8B1C*WW6J!^,VK^PYI2J^G+@F+WG&X/
M?<=EW8M]*D'U6UKF$W_RW3GA3Y?KS.2*<;W>^FN^]0W* 5WSX4 L7_;A7,WX
M 5HI2$ZNC9XZ /RV;;USQO BWE BU$BU?\(-0MY#=PU3CT&9.I)E;A=B7.2L
MWFM/9_A6S^DCKP<4U&3/Y49TT!8>#14&]>4%B;-E9>[0\"!I(,+N(\?[P),G
M?J>J40 C4@0,\^8]\XVWK&XI]VNH_$G<XP]#JC,ZR9$T(@S*R<N1YT?Q4YA#
M.5(.( *W=/!Z&ET ;=STYH!QX8V'QBV[MH@W9.#]O2AY!^RCR@ENYJI#VIU2
M\%^%D6M1^?S= L73";1U^HC)"E-<7Y\PJ2DC-Y"O;B^$Z/YEX4II-WICQZ&Z
M4K4IKAQ\0>L7:2FG7Y;%D4%5S55QA:61.E64OX.P2P?NBE7/7:\!JD^3[[TD
M#2-P#^-!GA2.FVIRF];><%Y+>2;J\>E=@G\3>,,RAJES)Q8^6>R9&%QZ"_&F
M0F_4]/A@2[S(2QXL5NTOCP(+,/;<^'M?(8ABR1$:J/,EI)+P;BRM^$"E!=WD
M'G?_&*<-T')U+-X&L3M I8+@/!>B#7?WWO] 5\E],TZ/SAFGDQFGS\\9I[=2
MQD^:2[<% -PT "!72_ BK2$D-SG2W@"8\JJ&R7Y+"N_4?6QGN7<8P?T"883L
M[F&$/!8$44Z)GG9@R"IMH.VJSG]7<D@4OO$;TLIKZ4ZH"@![T"_8W B9OB7(
MY1VPL^G2FO)0\2Z$)8/Y-AUV?@<*+=D*@6P*M;@APH2HG[=V=_R1LB.#+L2=
M?HV0^C24?C=GQUY@+KW D$FM&P4MHZ"W>)FP1-:H^R,X,*V\HG4!1OD4#U6L
MX*+O6W3=2PW9C13PZ9KOHV7N;-CSBM[$Z"AB].V._'KE12._PS\7'^'R;$("
M1$(GM"&%LG]T]I5)Q#@>"S"M].+2Y.[F9-LR7'P[LE:*Q[7L2K%?^%AQF'G@
MO_;CA@%FPD2XB3 ZKJ$_B'H_L<1DV,8F+ZR#MA:]#L@7/WIJYH*W3G,;6%1I
M7T_XX1R7! H>WISF)C0(FS1<A),+B9%EL^E=<KZ?B\-KXIHA";L[*BM2R@<X
M,+:BM'R6#+BD"VY\,I-4KZ/>E2I0$TD*W(?0:BCQ3( ,J);X_F\)%?2I(DAU
MH!&ID&.[J?MJ HN%,CP7G7&_0-0)4 %@#.V25 PH#JI92GC%M78/I^J<7%HT
M^)HQD^</X%H2_'H8K>!Z+;A':6;K;<_CVMM11CNUI7XLHN59[_A"R:= %@&>
M.@P_WL%6D:B>31"-)<;*MS&W+Y"V?DX76?9XXS>KH/#L2/CZ!5^-4JDG1;2R
MW=PB[+_Y-Y)+6TK[Y&^Y5")RY%'WES:0;WV];)\0+#0W6K<-%/4SAGA2?^C9
MV-3]-EQ:])6.G"__C_^N&G\%E 3SZT5<&V#I^J(,55_6ZY#=XDYX=$XP!C5I
MT! $ ;3LGH"$2XJ9XJ%.(U FZQ#D+%)?7OKQMA38&EHHRK3=O7W!B0_ZWM^*
MAEUQ[X;SF/PR:7>TEE+[,7;C+D 44V9[W=6K2L-6$E1&9:2,E+0S/$K]O3:'
M]B1\ZUIN,O_%J[!>N"BI$+8?JD."PD=P:VMUK5D2MZ/74N2U4]Z%L#NT\[9J
M#SO>"+\<D+ =.!FTAY-GDIOCI 8;^I95 W"6*&*'(S?7"?(79RC9E'M-ZKVH
MG<&F1X?)S;2,E*=TW,ZX\?9=>X-^%4$IL7*/>O1&FOAI$WFB?1)FYA9A_4N:
M8,YY?2A^$"TJCL-,<5Y4#52A<O:D6O$FZ:J-'PT-75V9:2CM7;H/GYVR/60/
MO U47Y'(X3J"RYNPE6C%QW*@R+L'!=G<TIQ'83XE#]9:YSX8UT28@DTB6I1\
MII_]Y=S;*GA_BU&S4<@X^&<+1['H,@E6FN?$Q/.VZ!E:@4D.)7FO',?!\0E.
MWK]&KR>!JWKTRF"/0BM-UL^K_$VM"2*?Z \<BQUJ;:95>%9&<W_5D95>4X>A
MIG>H-,N6V# X2.LU3TE8E%YO* >C=#YRSXA.9L*+* >(/AITBP5#C/&_F%(N
M1T$'(M9'I6A,&Y=;OJGY'QG3"J"',;[%!+QCMAG?4>."MVQ]3.@E\Y @8PLF
M28CEYMNARZ9C,I;XEVL"4@F2;1HMA97:>J.&YWI?K+LVU!I%R_J2@/.9T(BU
MLEUVE10'6+1]SP;4 1E<[F"0U423DI1!;=KU&$I/D.5<C0-W9Z)L8CR AC.8
M$K*.U+=0QJT/0LJO1O.GEQ%D$W;>YNOYFI#[0G$XJ<$SG'LR#\CT4HDL=E&]
MF].1O(V/!$S./1CL)(JMVIN;?8KFE1C(MV,+3%0^FDNM6:U-J!MMJXHPNBLN
M0(L -FBX7;5%5T:OU4OP+Z#Y?R/ @6<1[R.(2TTUJM@0=/?X,^3W_HC^C1EW
M,["#]J&2XT:822C DGY0.%=P@OY,KCR9!+-G+7XY\+60NB,,^8$ATGM1U>F6
MV?2\O6R64(F,E(PL9 *I</D;H8*]I>@!BNW[R8?OKSZ(OH88>^[O(BZ\I^!2
M:M#<"@M0X43L5FOC:>SF#\W\URVCSS)'WZWR121M$PAS)[)"X:J^S9>;G];;
MEEQI"AVE,K?PP"!\%F")*YR 1XT6_N=JHGSRT<4G'VM/:P))J"Y! A  M!HM
M@$K?BC@FYZPU%G6G88I)@.(:)['P]PEI!]X<\'F"_+,Y_8'$&9GV;91SJ(W#
MP/C*];%\"TBDPL0/!J9>9-4<U&2VITUTJQ1,G%"Z$!OCRX*>C[MC)B1E1>[5
ME+VQ#_R-P NXX8 OM:7U%*(3:WWQP+L>=:17_I+V?F0C-\F]%(.FF46S5(*,
MJB [:!%'!1O%%W=)L32CI0VM&W_E\N&W5JW<+U/YX3E3>2I3^?&#<Z;ROI3-
MLY89"VJA_@55. 4L#P0#K,=QQAB:]CTA^R'0DNP;H3^[I&B*M#+]\^ES]EI2
M3I&0).+-\ ]N-8(E3\GD*9?)O\@5P9,$7([BYF;W@+H2G/SUT4EAC#2Y].*3
M:7=5<.(FGF[ (Y#PT0066!NJI7Z6_ CU>L-@ A*/E2"G5(=PY^$*J^]%%%NX
M6@QX(_UR^=5^R>%5*N9#(.BB?Q'.(.RSB*W-KMVU.IBR0Q1V"#@/]"V*.50%
M(4\@===/OY?I]\*[ZF:C,Y ";E,E1&7%E=1D*7@&/QI?4>8.B(@FYN@70[V7
MHE=\U7P%C]T5%'+R]DEI7F_JI9XJ=AFA4UW#1XACQ[T\[Z*+_9:"LJ%1@N!C
M\M<OK*0N.Z4W,X2[("GO%IG"*SS.X+PS_8F3]/? V+8$&K3C"C9-5H?V0"HJ
MCQ%[FZ^B,%8%D(M]U5U)U05WLC5,=1Q0=W)KYR7(M"[D K*(IA7(2H#1 9 /
MB&I%L1R5U"(YOH#V#;#._@2-,6)A+=^(T?P6:/6W8 @G1<9-1":[D\B8G#Q\
M0XDR;5B.H&@"-0JC<,BN,_ G:&&TUH0B)(ZP9\C3+6NJ'2!_B*M(8[;@:)FU
M1VY;7 BE(-:-QU0=WSPA(JSM%_-@5$")<9P+[MNH<=8"U\$WPZH2Y"#<N(09
MW^X7_?,\S \$Z7I)KBMMR;-4#"NNJY X(:'GIUT[&C>:$=8\GB'E_>4M$+93
M0V#$I'6UVQTHF-A<_==[#][#O_M#L=9_WWN8-W4Y;.FC#_XC>"1(/AUZ;XGK
M3^^1[?R?0Z?/)^Y?2L;HC+R1_IZ8UT.I'Y)'R[SXKV\T3/GGH9R]='&=PT@>
ML=_W>IG'+S)\MJ]_JGCD-)C//_GT<\U%WG5 ;W($,?4IO?ZXRCCG-%2]7#N]
MC;%HO5.&.NB.L0Y1NZ[V(VX3J!20/4C(!PAWWJP@=[+@2Z@/$#]%B%#0+:-H
MR66R-/[_NOL(4MCKNR[KS_C\+SZV/[[0E6TE/7-2?8#.#!-'+P(^E_(\2Q1=
M"GE62GV.6V^W6_BR-N!R&RJD6!.U&H%4L92[Y(OL+()_0!&\M]7%V+>3 #%2
MCMP("HQ$8-X).*,@K_9L%:$F:XU(?J>]HT"\.VNXLW@A5\W&=4$)I%!\;F#$
MJ?SV7RT:)M79'P<P<I+2FB(%HAQ06OCP0$5%H<%(BDK2\'L4N-])%V;O=X#P
ME-9 ZE(@G,0PL@\TFU#QY+48I6 [G'+5HY;[1::&V'$_6 8'A-1"[1M.%; V
MU4O%,@#<!S\U.T[;!:S2>$I1&"TT+W5@6;O]%$>NUE,;\@GG_.BWLJ"']@8-
M&;+6M-LG%G7F/)EMX5Q4@](=U%0PS3:E:N1B+&7?1!Q"'0.9:\'H^O##RP\_
M#",<6N)E".6%92(\C"R]%O*&R,GAU\<;](&)@9M9-3_Y/2@C-C4P$%&HPY\*
M*5$LZ$6 @7K_PS]_%'*OQOF;]$L.C#SK)UKLEET[@LBF@I&0D[-<O1"[>[O4
M9QU\UL%>_-3NA,)1$<VNBW7!& @2+=C4:&B28IMY0.,L37]$:5K C(_XQ/G]
MHWBASV(43"ET?@LYM;[!M+OL5S67'">L"5S9P.D!X^P0.#)CXS^D6RJM9+&W
M%>OQA(?!3)03'99Z4GO3)"R0X_*A9+,I8#-@\($ 14@*>+!2CAC;J1X^F U2
M60VZ^4W57V;/;]^,^;C9!#@<=L=YAWRTQ:72&[A99&^@KSNMY5I5ZV)?&5L
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M: :(6\S*K$>1@L/1P<'>X.3X(*!H&X=-+)&]E7"ZFO=P+-0YA)@ON%]\O=G
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MJ=9BAB%8P@FHH*?6L=,#KP9(9(P/1.F,IE&8&;![0C&]IFXC\OIE8$2D!R^
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M4[D?[.^??"OU*X^45+^S!SWP$U7L3%Y])S*IB$"UKJ?8,WERAQAO<XBTT?'
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MJG9@R7=@"-LR5>%UFI%J&[ZIVZ1[;?JPL(/SG,%5<ZG#X?<GTMLR1NV H.W
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M=L["982R\4'EH$DFZN&Y_1Z5VZK&=[J>0=9#(EO->'H[SVQ'Q_;L%V8,K+,
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MDQ+W-.X^&IBY@N?&W.77UKM<A3$#'_!=?'T7&<?XI3_<Q[<>$E#OK"0]8B;
MKTW T8EWUPPXM[EI&0]-TOGEY\Z"&;_W56:!S]CFD'.==0;C4V63*%?.//1[
M_?Z )&%6QK&GW^8&##1_K/0OZ#S&&4Q6?@%;RP]GA6(AG8I &F$MERGFRXPM
MAA=5'\P#K<]4<YA>55X#--/_C08S;CPW9W8%&S)**K?]=?UMY>UY)>C@[O>.
M^G?>W6L?-,Y6T?I<M%K=^7.L96/G-F8/;\<#YL)_^,Z,FT;L$6K4-1^5KL5,
M4-*QO1IOW?-?DT[0QROHQBE3>$_P:3%CUVI@)EA\?A^#00=?T(>HD6JH^F@
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M1*KE(?7QU"?>+0SQ*H4A&%-1G)?7P?PU92%VO7#!IRJ&>V4KC3$QO28]# N
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M'2C,'F=I@G9IO/),33R,5 K&*$^=^^XWTON +U(/W9-3S[ZJ7CWYD;%$C=S
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MX5)Q\= DAPM"%6*"_<L@!FCV8604S3?*>%RG74199MCQD8$\,E_J?0!/OD(
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M\R6S_MPA?T9/TK"_P(!^.)(UW(!Y?U_08'ZPXS.S:S.S3WQF]HX[$I\R*V=
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M29F<?[HP6\: U0FNEFAH@NVKN!/F%. Y>V2QNS7&>W5<8X?'QW5(&HL:2.<
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MK*)C;?YK$PMC>\+<1S,ICW4=$M6)-@1& MG'VNAMK;K$P@^;O5?*2DN[LZ5
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M$;PB7Q7WS>=L2Z[*T]#IJE0U4>:Z#0+.4LUAL7X4?&1:#3"3N9ZMKP&I78/
MJ0GNM"U=TBZK Y3':]\S 3*EUWI<'[W:4*TT0A4)B]%QTL$NHA&%$4W/>F&B
MY1/1!)6(#VA0H$R:5?$HG=&PTUJ%_4J6F,.6E77OOMAY$RGY)CT<4)S"H$"!
M3U''JJ(U<K]^?:AZM(['JN1H(U2U @9762HRV*ANH% /?W,&D,Y-L\LZD+9/
M._X:C\[36(]*C!BPDB:ERR?A]CH *4*P1 HJNF!WF@L>+&Q398\1@ADW@Z<8
MN\W#AV#](>)$7"988$F.=B=\%XT3O82?AYE"U$XP/ZF"':?BQEI+8WXQ6V+!
M9C"-X:='3$DL5\6YW5E$KQ>XLX?)/W:[^]APPK]YQ $QM"?)0YS9XQ$;ZP/D
M)!Z@U&+3_,& 1YG;RMF'"/7VR,01,TW-E;"V5&(K0LM'!CM5$-VHH1ZQ(7)N
M7D:[G =Q@"'%</DYL(#F7U%09A+A)W!P% JU]'W$49:\"!]>P+/0I,-&J+@'
M(I7_"AH.#TLZ<?<>/QOL/^X.'N\_6@>NIEKCK:83W*%0=8,Y)N0@6'6-.#3[
M,^-=-\'UWH E4 (,V/$[:RJKAT;I2%%G;0-(9(T",CW_MR6+*JG37%%0K6@#
MCFT#EG#B%NDU><=1B%89U;2VN>TF1NHXKPP,RZF&!N_9@[$>V0J_R,P.LBD"
MVU[=],3-Z^%KS("X"+-\;H3(]%1E-K+WP3L@"C[*UD@E"W7;RHHV)<8SM]M8
MDMY@&NHJ)]2-'+?:1+8X"M%GJIO)^ $?NINY>SDY7RNY3 -4/J[II:2K1L!W
MV.6*@.*$H4IQ94$TSS2A?X[MM0I6+SI;@)4M@M4*%1H"*'>@P:_PAW\K1 V@
MG 0FE;5!SD Q\"NH?16^@4U'XR@?1; A0DAX@3H]M!"UTDF*8*F$!%&$+U06
MGH!.=V$<'KY5<_C3KWAG3O),Z9AQ0IL%EV8FHBE,XT1OIK'$K!M'[[0+LD D
M(_X!G9UH.ZO<BAF9#F.2PJBT*94Y,Q^QL*XV;:%E>*/31NFB,C!!N5"/ACXW
M,-81XV <3><,Y5I$,0V'#&I]J-,T'G?MV&(N4S3@,Q&-EZ)84QVGR9U43?$M
M-RU.T&!O56%@AA366$OB6]H#8;-H6]07K>VE;]@-*)W8+%%A;AJ#&7_%L<G1
MN&:83CP$45HR-8B*,C$//HP88A0'JF<4:R-+A,.7C/%"Q!EGBGJ,Z"TRK*MR
MB9P!7?6*1P$QM5'0C#MF:_+,J>>DK+(%I@U6@&EQ[)'95:>:AH:/?,SH_-9;
ML?Y1E<Z6X@3MTH,?O0%*9@.6 /?H0B\*1MM>9R8YNB"*B< WMWU,L<((&PW&
M(,ET[F8$ASHGCON8/@H:<?N6E\I=AF/.QI4=[3RHP\%W]NV=;MF/6%=4==:F
MO-BUWX!#W( E-&;.[K:5?C1^;'"5%#]]3',S>G(DNK-ZAFT\_./B_/*,BLBH
M*L:<8II,4S9X'8Y8QTMY8,/VE!9?QR*D\^(E^%Q3+$4<19AK 3MA&=.,"W"S
M<\0L7PXC<;!/.Z?=,18+P4>*;+DHR)JP]1]4?UZ+@V#4YN.$S3^^U895UUFY
MU#<B?U GL[01K"3NB2Z<5&XQ?BUJW5KRAS<D/U9.[';VPC=$4$0_B-+W2R2O
MFB]FFJD+YLTPG2I#YW_*KUD8T'X,Z?D>K8Y/KDA%\,Y,KS;J5+6%YT>7QG#.
MZZ2Y]]4YCE.^VZ9MKG5=W/*5=Z:$*S/LL (!8Z71XIUP&2MK&<:>7-%'_D!<
M7W?78?? JONVR'7+\,_Q,G^'WE&D.N'*D )2M<M\-%/U:&BXV^7[B_<6#>4H
M21,[O,"?#L[0N[(&VF['R14$QCU@$#6K%3APZ[B;:).E8RX.XS9^-LXML-J'
MXHZV]!ZG:J&#A^=I##<+.12 .OX]S?5B%EZZ3NN' 03714=-65K&A=R4SF90
M'Q.*JRXR@2#E[))/5!$,RPS5+6<[#(0TUKP6D<#$S37E,O[6!@_'?)**1M5\
M:-!^./_!V0I$_4GC,B$M9)$_OW=-T8;4#7U:>GS?I\?7IL<'/CV^)5>BM>#O
M/(V76?1WF@0;LLP-4'%GG.O=[5<%?Z9!(+ %?RXEF]T"AJ;AZV+<HRHH^RM4
M!,,(I^%497>3=%0ZW;:-+EJG;LJ4#,,GHI$.9DLP&*?8N2$%S$YB2+J%$I6C
M:EED:IG;>L1J?76&L+5PX/15+AQ5H34"%]<8P(IC[.UY%U@<;[<'P7AA3@UV
MJXFVH/1O+69OVH;MH# RO<R:;:C^,E/<ZW!)]88_Y^7BE\LW/_^$_XO'E"G>
M?+W"VX483J54D4T-K.*C<NSLBF#9J12<:M.Y*06)0R&DA5K6SFBB-67&*K)R
M\[@"RA0,!/#CH+._O]/9V=FQDQ0,PK!8HR.=%=0(!"9N7J0T==29:)6E2Q47
M E4KQ0LX9&A**&I3C&'3@]&(X3XE,[N-?$"&][9<:H8'2-*H>C@>$3^"74?"
M"$9T>^YA&^)HSDV(,&V45#T<_:>,.&.#E/\3CHR:D&W7UD8L= -.[<P-[O;W
MUI534Q>@(6+H4O>P+F??Z P+IXKP3>]M[TWX6QJ/&8$;_(*JG\[*8/J4*2S1
M7$_*G6H(J*_F6@:YH4#"ZXLOQN >>@[\!KQF&0);YE(E#,XCMOW55FQ[3T$
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MQ"3 4S<&$S[#T+PB<@=++A;5K&X6501CQK:5,]=-@I@UR83F0EUV#?K6,&D
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M$"MS3=\:PC="/8%=P!?APW:K\&_Z<)X#%>WS OQ.%DUG_!I<V&%21-VCE[M
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M.3\^! \$A"!E>^ R-%.&HE?!SB6>'I91C'G&:9P.473:=ZP8'"D&P<#6 &$
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M.91?$,&+=+ZD?!"3RWXQ+A>P.)TMX0WXJ;SD#\#ZU3"-HWS.G\<07EB4()Z
MY][J?!%E^NW[^@D'E7"FU9]='%87H8?<K9-Q2CM65O13=3/^WMW;'$0,2:"\
M71H<G5X@]2GDB'>@H"( JTV"]M@(G296D:89ZS9@\!(E#^AKJ]]([F88>Z ;
M06>?:,21S9? Y:I M>2\V]V5PVR4&@LJ/L):1PJZH!9I;C?3Y:)0[U#]S:)A
M1/OF*@&3$Z=Z.'QZ;L@%&I*$0_48AUEK] E&BF[#<%GCG[$&9D4/8=FC,JDL
M5]/4:,V'7/D+PN[7DQ$J!_[]HP_<+K@Z"Y0?-<E.@:*C%_V.G9<8D+]!(Q-_
MBNBUVHQ0;#]KPXFCZKX9Q9^"@@2-@/X'& A8LJDQ\H3&%:OH.,(B*G,5D%%R
M*B8*3T[_U>WO](.')XTE8-U1M1-8^2,Q*-%WT]V^-\HY+5UFUH^D>*".2"0J
M-)\".L:,4F$BP5KBB7,L^F2#$.O+"T4^)W#<E&JY,K;9@6W2:5)YTS;<*MXO
M^Y>PLW*"F=^,E![;'2B1\"M<;F##L7BS*%<UYB)P1VX[+W?\9RY.J674F-7(
ML23-5CG?=!7:I4\G2(?&%B9);VO86@PNJ<Q%P]9*KZ8#RGYF_2/4(4^7".R_
MF.WJ)3F;9'4CN8/6(MP0<X(3N&>IR!X3-D#%L*KAVH,(%!8F"KIG"A:'5!L!
MW="6!14\U44@YN&WO5+?^/I\:EYNS^?EUN;E^CXOM_'QYS>N)/81:+.$/\$!
M+S,,FL;+*G&&4C4H9E$VYHH'79F[-8W&IJCFR&)5.=*,7N)WL4$#+"%2/ 66
MU(G::/D=*01;3A* .J2?W0@D5E;![['+ E-LF'E<8*E?<WWP+U,P9C:PJ$6-
M[/O_@RDB_N3:C?0"C/E1$]?$$DN/6VA"M88H VA$=RQ%;%2.+78&&JP4%*/:
M%_A07G3UA"W?0C),F Z-YF!82'U8PH7XP1A\G!$>F&2 @39KMTT$K<I<0?5-
M)MY6M,EXRCV3ZD=N[^+I+!UBHI="EB"ZS5Q^Y-(Y U$/9X$>04X\R?GS]0^C
M\BC-E8PQL1%;,^29E?;XUS)CX.8$4BIS#O&CHVA!%868& "?6\6U(#.B/21C
M;#N0K\@3_^(R;V0KZ6*HOM.P7&O"@(/)U[-TCN9J)3\PLB?F<V)[1BI'$>UM
M6AIO6VXA>6*FPB&Q_96CDFI[07,G;+4M%G%$CNV?-@W%%:95U-'YN)C4&*##
M;R[9=!PA@@!<N7RR)!K8VU^W8&OGVL''VO(Y="'3@LY0*@'PP4$TIJ#]TMS_
M6FDJ7_,TP8)Q$Y-!1['*4DU@XYC7H0C0=5K&8Q)M4MD.+W$MW#$\;HE$FZ-#
M0 4>57\CRI%O;KA^-Z7^J\VXA6_954$1^\VU.ZVET9?_;0D!+T?/[=#$Z,ZY
M)L<L90.$[08LX:0EW-[Y:.$G9]V=MEEXLD[RJ"HF19Z31!H< G?LO'IY%!Y2
MU-TZTQ,]IM@-^?8%22GX;UF(DJX>!@XYIY)K47(4P<E4.E^-D]^I%Z^+*>;&
M'4"]85Q187X&8Q;9^)W6$H(7;NE@D3U(5/P=_&:>LEBVP8I.X);==+!^'PAN
M6 U6B*$6^G:FT5FG?^:8=.'78)AB3I6])!K?TS]1!]3#$13_:DWBJ"B&C02F
M"FW),E2A1AB1'OVC=]$+LS)>)2594>;PJF0I]0<Z#0,F!R8M(2!<_RK'$>F"
M7'$,-N>\'F;(\*IE>E)B4@B?1*30!A$I/'UYR!UZ%%&)=5%07&FUI!C.0\5Q
MZY]R'?T->\;C3K&< "UH5+ZXH#)?:&K!"FJ*%#]3/Z@H^:NTBY]$"34+1E=1
MC$L%K6;LPU%&5B;%7%#S4A/V!ES8#5C"^7H>K6RQ6H%+:U*O6"[P^VRRIS%8
M[=3N:NT/I\N%#/8DPDB'O<[4Y%$.YU%.G7>2A44V3"<!V#0GIR]1]L?2\VG3
MG @#)[4<MM ^Y#B#XWF)_\95C& #V2BU&H,=)-69<=PECR>E*H.FVP9.B35Y
M>+5J@E>++KQY,W8 VKY^)"2:G%I1#<S8M*OB[WCU]51ICN826)8]2MKF$V5=
M./P<$I/E56"_XAIQS@%@/B/G@B'3MRR@ !QW+"**[M)WV0F[PF*H>BB84Y74
MC4QY@>5"=Z1$]GW$^PX2D DQBQ?'[W3N>&HS=?ZRT1).TZ3&E;DINPB<^Z'A
M;$N;G@7F/SP_(5(B1\DI27#<O:U5*ZRE/Z6-05XN.[6D+_$#9I8I@Z-R8G[*
MGM.M#"S+8STQLC15,=BJ/$QR2M67[1.OWP;8WV@]6[#]@ U=^&OY5.)2!M=&
M-6E!7H"60F[&B^[J1F-KN)J0-:/KV%35<;^^/N?WFI8\>&_2. WR;3(11$6%
MAQ'01<U)/\F1H#S"C,M4$'O(?HD2I+(RJLF\VOEU"*=<%BTWQ3FIU5B+B"6P
MFKBJ$1,':;XBI*AU,P7"]<+7*15)9O.5/>95\8XC@W-N'S6JEJKOF3]X 6")
M10DF/IEG JD'!XJ5P(B30LJ^D"HHQPS]_*WG[K1P=Z<[!I)=*ZH'HSQG.F;"
M!0W5Q_P%YN:4#!8AJ177MEW!EMF!++! $TUN!E5-.3A,P$ZL2C7P+6BSY@28
M:;X88+>W@8C 5V/<$7G[.LK-Z_!>P*__4^([TD0P<_##>!7(.( %RXYYIP:!
MH<FM_/JH>AV79L+.>\$)ENJB#B1=;7B*J$=1IWQ&402J<AL5@FG!.!"6(YOK
M(.<FR2T4@$N03%]%^MK9C=Q]<H8*^WG*Y*-<Y(=@8,; &"4I-<N'5/I>HV*T
M2GL00Z!;QQ7FSI$8[BX1>=7WOA/[J&&+B85)Q^/Z-549B0/ D"9.BP[0>J8Q
MV@4V3QJ7P,L8LB37HXC(C*IJ6/,2R"\,10V48"G&7'U6/3[->J%9GM&;8I0:
M#:?'S\*'T2-D<U)@'#9?I\0Z\-GV#_]Z=-YA:!N. =IP=S)6&98-<0=(0 W\
M<B,$WHER\;1O\DK-7MW;H'E[E37'EY1-!:I82?ACH(@X[-BXSLC..14D.$<"
M/Y/.$A<ZKXAEE54N.?P"?&!K/*?DSD97.J\MA^4(XAK,$4;'!)M+D2*5HR[V
M2,>:OC43/0!WD *+\GTQN+!D[!B-=;,T\51 !UI,-68];D&P22%RSM%2L8YX
M7EWCIJ-$P1$PXBB'6@35N\P[*@9JVB%APPX1\>*U[&=TX>[[;/_:;/_ 9_OO
M^%VX%&$QISR*T6B%QB E^/IBYDT<R\_(^X($'H4(0"VRA2CNC8T3NO:,)*KR
MRJ!J/%'*TR(V>X;: (619D0H=D60I)6>X]BCZ\6Y/AXGVG.2DZIR0,$M+!-X
MDEXP^#EXJ>^LE=Q05"*BV1VDWP4UB<_^&N%()3D+_<J!P^B-%?*HI1NV"<EN
M:;.H"W#T&M^^8 P?B>!@-Q3]$L^):2T%S@Y*F9/6K]9HR\J$4FT;E?/(HT*+
MHIMA_G!L2P8-/T0Q9=L6A,5'B<Y.@&^=<%@Z;(2E2>V\K9HX:CGB[P3>_/VS
M4_L[^P^'CQX.'IE$'89R?+KJ0TNXT!SBK$B7&L%R%%!N"9C0_K%CZB(9$JWJ
MSE?%[%I1QF.EBA^[_UB,8?ZBUE5"H@3_7N9L92[0 TS+/#:EH)KC:TY[_ 4V
M4TXXS-IQEHTW!_NDJ7XGBL4LA M_"@NZYNQ]@0AR"&8@B 3LIE2"Q7KXKH#
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MI/[;H%\$,^T3DVM,!&0QM,^^*!7<@?16D97S-J@Y8'@$*$T41X[8R+OZ-Y7
M^A*6C1<G9 UK?1_8_["/!@]"N\TD<N\ @.B716L2QA?-W0MQIT%!H"?AHY6T
M5"'B]"AY6Y^VO\@<'(^Y9Y,N;9KA 3QP1&CGB@>86XJ7OE!N*"4X;,.P.H*
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MGML Q#$ DCN<AC%U@FT/;@._L_R@\8F*G3@4C>FW\9T[!?_0EQSZ5<--K'4
M3B6"RI?J]V9O9NN6L-F'A=L\VB4R27JN"O!]!\/<)"59BD9+VB1@WIJ=Y "V
MMNC0^+5BI=CUUR7B<CMC("4KC)5G/6==W%47K/[>-/G?PBO)Z#KB47_&HSZ!
MJ!HH:WAJ^J!SB6%Q"<[K\X*[6S$_ GI<9?.*\-8,J\-BQ3[W%R@%&7&?: N*
M^-IZPHE0VM783FMTT'N*-(7-#HJ6DKH7A']22!]!OXEO< F^<G)$G1ERY^[&
M](LK_U[A<4W[)W Q0[F<,8LCS9AH:L-*5-E';[AS0'N$L8.TZ#I*)3M,DK[D
M$T\3KHQ\^ +=#?V;8R#G./Q^*<?Y\_W\%8>6"H%#<4LQ[8&;5B=*]F?!L'BC
M,,V'?:$R:XQD];H7'2<U)HQ6I7NCX5_4W&D1?6S7?):IM +5$4\PYJ-P!</)
MU)J<TF\<<BJ<6^, YF)9?:@OJ&1<Z-G73+'>4@7VIMICHN%P\697" 0'3[&C
MEN_:]:/+O__J3)E+TO/ SL#P+"FWE#KHR7<X=^C)5F2PZ=#HE?Q&#9/'N*C>
MG_%EJ=U=D0@^*N8E<NCFFZDY[">+M@DI"9!M7BG=B+1@UE]1RAD#OV\MU?ZV
M"7>0M^IH7QM=KYE=^987IN>":CZ2B'T:I2G*B&/T6M2@BD0VTZ%4))HG\$;/
M)QK>027!2D[MM(K\!77&T@5!*&:=LT>/<GL4Y%A0KOSA""F&Z_B'IR+BTA7R
M_[!/'/H#CB"+6_C/S1S5\5C!D[:Y#)>FEP)*2;IPS'GRN $XRA*:E*ZD7+'K
M-9T+ $V94SQHTK#3)!.XK(30H]81M^T\=#9\-#@$4JI"2>8:<3?R-8/T,TN$
M,S1Z75B/Q;$,BCHM2[QN#8<1A2?UR"Z9^]89)S/.0[&%PE5B=/;*CH7(3S7?
MG8;BK]U:<399]0X;$F81B<7 78&92$GB##[0"66MN7RLYOL*C;,O(PS<O/<M
M/<P'(5-]X'YFQ4_Q!!FM^,EQD3>;5=41E,6CAN/9$B7 TA; !1%WEYN:ZTC(
M<U_W ]8HW4'=,@#$+BK/4V+Y^/ABS-YE*JV?V<5F+95TRK$:M"<W7S<<=.&-
MSB0?YGE<>9\$KD[*FN8!&X,HIREX% FRL0I41$?'7[C'9;LY,C*]?3#PJPHE
M=Q[+DU;XA M&;=&=)L/V*8ZN@4UNO=BHB7H7&1(Y_X2]T9:)P><F\A V:947
MFH*)S @]E6:F\*BS>1$II=^GMT)?((-'B,SMD4U=,\UZ$HNX/+0J[SK\-ES!
M"@^,R/*P$Y2QPU#0)U4O\H+9:@VEQ#+).E#&C3?1Y$[V+DJ$(;S9$,K&[+.8
MZ@\>1Y:0 8?](PN>=H!YX3UFP0R>+8B%F)] ME8Z+:5>RB#Z2M8?[!'AZRPR
M=FR6B-@:$C B'09]G\;9U_O0#N5\%?S'85?0=1(^Y8]F?/,ZE<4,@9C&/HSS
MOX8^%',*5T!IDZJ[07;"BD"I$83V"AD("B0LR&$F"LMZX?AV;=&9:_>24%NF
MPQ#('JT1ZZ[1KPW^E>Y89WT"I+>O[:QV8?#@E))P#W.[U8[>Q.5[PU\VO:4G
M)S+HW@"=M7L6$>:6IO+0+!C(I$/)Z;RF!]^!VF!?8SX,KV5[% [$A1+QE+'E
MU7I(?<1"W?",$?Q1FR-R@3""X7J+S/<N"__!]1C-"9ZM+"SB"L"71GPBITD&
MK;;3%R?>M,V2!2GG(C(L;94R@X<_DKWN<WQ*-5),!!*(>M)ML9Q3'G#JJ2*D
M$C.Z- /!_6EW$;8"N!BY^"@!08P1=">!&6S5F>&SQ1N-IHHG^BBM;^=#(X(*
M#:P5>@B14BD/F68VY3#-"7)[0RS6X46IIPS"$0!-8@>?.<,T;U$XW"=,0E[-
M\Z:,>M5E@I=!:'F-S!%AD>('=OH*0W!)1<_X3::*V>!34#-)9M9H[A-19WG?
M7E\1_H>[_ZRJ\,AYTOF9ON'\5US%J$B"%$5NC#U2/G=&9A!CA6-%%UN#>+E#
MF.,XN&+;9%C^<0:.#BHC #08)!>8[*651#&"!:6*!ZT"4(4G";AP>->:E01Z
M( *VL0P\J8)E29]4\]Y4219<H E"X(%1T<-AVR\KN93@T*\Z-XJZB2T7">9$
MN>LJFLJ?C@OL74RM:<E6IE%F$F&&KR6KX;=M0MRI6Q8O/L!BO3A]$[LSA>V<
ME'/9Q[P-8 <XQEZV:@,"O))5:?@'6#M*2:$JYM$$(4^WC.RV/?#6R 0+)\H>
M^#M6BONE@[XT9D$^:#!.TNB/.B>.*HV!#0JZEP";*E0I !JVIT W+IY0-'DD
MZA>V,)P(24 (K_I/*PNS"I$UGS/DKE^S<&VU:#BRRRWJ#A@.:<W[ $3= QC"
M#Q6*NQ70UPW6?^(03QCCX*\S1T).4I6Z&E(9,9249&_H@XI8F&*PP]02MG?+
MB7"FP'B@B#BR(\GY(P68F/')"3+P8[OAQ_J!!'4B)K>!3C)71K*X3\8H,LK-
MDX+W]ZV$(4"T01Z[ %81 926\]:RX5)_\FPBA.8!',H',(1/Q%8\VV$KMF,K
MCG;8BM_Y;3@>68V,P2,Q:#&^)!@Q=EH+%Z4.GR9 <_Z6\]EG'$&,77%&:>&8
M%&;YJBD]RE+"2\Z.P64)\58+[2^:7VDT1E+G%DWHKX"TOZC6M\SD56G05XU[
M+0OQX6C2809Q7%%"_#I(ZSX8.S-!:Q9Q01+(7(1: \FM6$?."5S3QZ>0SU\5
M#*WOMRT!(@2:M^9F8=!J17;/6HS3!5\E@TW&BBI) SL Z+ M-\QI%37C=1VR
MB:TNMB3+/V,;8#KIXM$@$_'P_%@X)W6A$*A.L\/LE($;$WZBAJ]P_!+J&C(H
M-5DV(EJQ+99312=G0ZS#4B,<LS(4AQ:.'B--UWBG5D$WU,_#9Z#+_-G!LT<7
MCZGD%W]"0L&UE_/TLC[OLOVJ7*5Y<@OW$8HA8SO(;[IDLQ:2E;$.D!KL)>1W
MS#HO76IW<,]2>,'1/?""C.$%C'.8C])?/R$X8N8*Z%7.XI0T)+^PN+:#!R<!
MP"2%/PU9L/*(RN&*%K%>/*+Y+2_BV0$&"<?D>.YL+^/G"\?>JPTP/Y9-GWW#
MP?P3NA%2[G+X_/G1SU =]-@7Y(G:YNM+\N/%HJPI$N.2UE*R1I$*SIE]VS9[
MKT1%0/F@KL3!]J$G2ACS^*U^^'R#ML_:S9MU 0<[&"\8]4W3<@P2V/)2Q PA
M)C":S%.IEGWRDI.* 61G4 :J&!46!7:.]'+?[>?'D9&24O3;E_2ZC(GM%NW/
M>RN*H+@IU)D0SJ9+_"*,F'BL6?)1UOC=V].3X[<OPXTFS)LU\]6KO9__O6EO
M)9+'-*JX;T$E5E:DY(K<E8;$+:*2B\4THFKV5WC*R;*LPRT]1J-(R93M;B+?
M1 =< _%I+Y@ BV%:_2II<L3:8]?BI#YUJB :2 P@40 KHSY4=!(U1L:;:TBC
M_?Q<.E59T:\G8\U4ZG?@"6;H7XJ%J1M$52V0V7)5' \;("C?>DU9^,?EP>R-
M2R,*7+_$8,G48+E !)=OL,?L:FF'3+&0TAN!>(HBNZJOS3KU-*$I.-&JT;2^
M5U#(:W3 Y)2,=,)(S$O-_=#%F4CF#T,IB)H#-^BQ+$CE,SXGAFX&"DZ1,)GD
M/2. A[X8-H-<P;C75<]<X_--Y10T '_$?3PH2.>9)$VX^7.].TW7UA]\#0)@
M/;H0@=;1:WN:5PN0S>#R1YX/$=I0OO(M-+U]T_!%J%?.5LZ(PY%*.6$6?<YF
MD3]1X3[V!,?@3C-E_II*A5]1MJJ:[WW+!Q0($@[(757+:R-T%,0Y64(",T_Q
MR&+R8P\S8PGF!N(&&*%O_=>F7$J1/$,W&!&)NB*>V<L/X/8,*_&F@TCG.8=7
MGU?7:YD>34T2;IU@N8C7L@H[L2:OHEUD+[[YYAP-0XTZ$LD_<4H$*K,-[/05
M=BC%/;'NWW07BM?=-*34/4H87/AV$0$.SB9B^V/0)A":XST%F/J".D%H&5E8
M@&!N<'MTK@A@,LFY)/_#>5^")A5=4_YI?7 4&*4LV[/@8#(82K'8=+Y M8Z\
M9.*%M=[@YI-U:&59LYJ1WE?5Q 3VR:BA T<IX^!!CBYW5^6C:TSA6,*0T>O"
MVD#LCD6FW9-TD]/B+I$"29D^(J!94D<QD:V+)K[/14]ESD\1:=TT[QNJ:D-A
M*&0@Q4R1\U/W0(+:J 8!I(I(-!FB<M4"P*B7L^98L\-97=3M%C'(";C;JY;I
M;Q),K>8I0)4YDJU^7"*+C'0-.+[D7B0E!U$[:%93'P88OB[;1, #C&QT9Y>N
MFM+?&0C'3!]'X,V5]3]E[]UMEJB;R+Q0B906WF2'RW3?4I(O.J<-%Z4K;ZK7
MUN'R.M*S7OIA,AI.L*(*BE-9)T&(^P"CT_F^7\HTPW^?[2.@^=-&VI.#_:>#
M<.8#&,WQ.@;3V%(J4I(3!RWU>?KKLH=63BPP'Y$9 #D39:F:;W#K?+T#T?%)
M3L3LKB$9BO/B4P/(*KI(V%ABNTAIKPEV(B$CCUKI%4>FB2.()WK(LD7&#0%'
M;Q_&"Q)O6JSC*HQDC,,9_#N_&N$A0;  [8,2$5Y,=R<=WS2MT&;YWA5H(&3C
MY0%O(G[UKMNLKO/C%$HW%0H,HX/:M[84Y2(=C=FE*/0]"=;7O.0"@'2$^_D9
MAP![/#AR_?GV881T0':WES*_+PZ>)F^[UK C<46?GA5,0<)1/R<"LW/MO_IJ
M&9X=1L3:RI?9)$K%,MQ87)X%H8CC*!X%Y4LZ\81H- \_^_S+_,D73Q\K:DK=
M]5=M&[;TA8:&LY.V7Z&YWS&.*S+P/1.N7=T*JP(TK8M9GP;I1R7HA'7K(R/+
M8-$GIQ%WPN8@_K=2-7(_$'D[<^ E>(7H=ICV]6$!U5,KH@<BD@<@$:K.>E2@
M&@HNC@ML)BUE,L5QDDT!TCT (F)F7S<TO)H.Q/N:;LFM>(AW%?N8507MC>EH
M]%"SRC[V2V^!<6#=D76K,_?QL+ "T&9:QQ6IU_::IA*OW$\8!#YH'@=5,.(]
M'D1:M0K&-E6#!!T.*H>&4'QB?Z KXI))-1M#/>"4O+O2NIR90.,-!TGM3T[/
M$J1C\G>]P-MGD-UOTC@<5%>M4!3;,OF$XI5^@1J?_PF*]!-3T)_M4M#;4]!/
M=BGH!WY'/JW2'P60Y-BR/?!5C>+\Q"S)8OBELB %CG2A(8$@:U?M6II1,3PQ
MMO(T7<5=C.\*#1UPH:KF?F.Q95Z&V:$RSL689O'!V71>G*4SXA\47R625E3,
MEAA45UU1,Y<P]#-BGJ%'',_G"&F&IW]#$0PDQ,XX@@%/,>A3E#.1X1@<INNE
MB]FI[9N)+X8HA 7&D\B6DNKAF1I(%8<J6(L]N__2.5>T?7QC\%^)VX92&-ZB
MA_<:M^FFRC2J$=V"6 ^?Q J&;RCBH.K>"/>&+@2GD^L%_ O2ELXCG*X=C#R/
M$S:28PF*H=3H1C@:G3Q67R?FNY3$BM%I#CO@[N)@9QH) :>[&&SZY@1 RH<G
MEDOQ&KEM+.+AUSBF7_TDID3A#NG3X5@BU!GACS!A.%GB?6(O2;9GZB+20FPB
MK.(C B,(T,S"/>AL?BX"EP&TC*XYD>#21FFQ@5'<@8L$KL'HN*81<9OM"E:G
M5*9(^VKZ"G@?PYJMU:%# 0NR0^1&3$#NME.U3M)7_>*(._SW</_YLX^4\$_W
M#Y[]XF;0SQ@/K-=P>YF$#[' 4\M>OC7VJ&,A!\??WQX73(5X=&0%JQR@B_6)
MJ8_/1RU\$6*8>?C?5W=YM92\/Y\B?VG!8[9GR0N@SZ=.K/>[['%R6NB%@'>L
MR:T@WMBK<+(0G2A[%>6$4PH"@YJ.LS>M3HDWU:%?QF;ZUA9S>*WX1:D]GO^C
M?E\18QG\I\E:S8\HRLQ&19G8%:&\0^Q"'Z8!3JU4UQ)TM*SJDRQ\U+9=90P^
M__JS^O!N@?=U,W<P"SM&BCZ*L8TDZV.'M3)-@QVK:&\U!NR3,KDF96+DUY5G
M$*>AJ2:J) BG$YW*]CP<+N<SB0B<428FD6JM4\]/Y&F1Y"-^$9O]05A%M?BS
M]_/(I(XAQKCG*>IJ*44.3?X<G/OB\L9WQ \</M%/J ,?O&+JR6%,NNCZ,./&
MR#G)>'Y8S*B1V=EVUU<@LX1GS@'-7IX&@'=\)%)F6B2D9#D<T')Z?<QG:,T3
MT.%+PMG@",F"Z/OL#W$QSJF\;V[7(#/<BK3)N0>\(F&IB<0'V^H#P^VBY88<
M#)*D.).I(8!]_/'/)H[_%/5#FL-$-\"I?+U2WVKAOE07MK-9$.>CQ&C,^>QG
M[SA9*0/=4WR>"M+)S/"Z;=_K:2HMGM\)N_#1$S[MW%OAG@>]\ _*."1\I$@E
M/)#U9BT+SD8<.JA$6>7BWI(C2H&\UAJB-)UZ$>S?IA'Z8AKO/HLRNBT93P2Q
MP,8 G'5ST[(#U4X=&Q[ZLS_$=4)-N[]-P3K?S-;2 7[,,Z)P1ZU6L1)MP9B2
M#;/7+O:N*2^^UDIG6?JE^H[A,64G.X:X+YT'SZ><#;$OW,6:-_AI,1H6B%HO
M-L1BIE)26JRP[R>28&IP\+J<M]4S34$8);7!+;4]0[DNP])0=>DL8M^Y<.D1
M8'!0EC *@U<S=Z#;]*6&T<"SPRK_^?/BZ<'!X_W\#9NM VHHNW$<B?:2__=X
M3C^1'OVB1D"Y#[O[[_5_4.QC#[&/[)W/H-$6GDB. = ^ZF6B9'?PSSBZ<!Z,
MGS4@$XQ")VAR%'"T@=^T4M#XMJ)P )OT-TR!:+R%3_A;^:/S_<.C9P<XJ]_L
MO]U_]OS9%X5BW,*WEG>/A1EGQL7NFZ[C>D4ND55B9<AL^@PC#[0@TV%H]M;M
MGB51D,X.:^)(W=D220T<I:\N??)1>"(',,HX2AY!"<BJ",=^D%>-I!%P$@:*
M*[C*"0U,](5_>B:Q%%J"03*#05<C1O.32*="5;X+R/TWR-E:\36C-](&1Q,M
ML36)&+9T__!1]9AZ@Z%3ZCK,CD*.)^V<DX1B-[R-66D4 VJH:9UN(W>.19JQ
M!5M7L%PV:$)R/',M%+::X7H,V,!-5PI #6PJBU,$4H ^+F?A6Y*/(OD&'_F'
MXY,B8]*0)P=[\Y)Y\KAN5MK: 73$1S]"Y+GRMP+2CFN(PYVK9YMP25!*C NB
MA@%K;W>FPM(8V=Q:SA?:B@4OENRQC(G=MR7\;Y6L$V> 'A#DX$;2_.5F7G-3
MM;9)[0(AO=DTH # ]\+T.?P2!LG<*YKFHD+SS4K;P">+K%W@K3%:K/ZGZFH0
MFUS/]17)5WGW%NA#2)$B5X) .V'"AALBIZ4:RIPG5Q<)7SRS^A!6K6Z,)"!Z
M8RKW$.\B9)+SH&70S)4!A=MHVL\X8%6;#:1 ACHDK4.Q";)972J.'(WFKNE7
M?SX\."@.#@ZHY6_8JI;W\9?*]OT/"'1]8L;O\UW&;WO&[^DNX_<_]IZ\<SQQ
M,?Q)05;%(4H(B#N2DV+<],BID0>?DCHY4(3D?SXAA(H8[2TU.Z+LA0A$SJXY
MCD;/:B9X54$<?AQ.%*BH[:@*X6^@2.ZO JMX0 ?HTTJ8PRK%,\!JEB!YDM3)
ME&W0(%U321O'6FO!0/87K8,>K"X <C:H"..66H,RXGP;EU&VH#(HQ[MB["?;
M*29&6.'28ROS8%X1LH\!BEL39QXOA$")!WE;>2<'@+E* \G2R9OB>#DLC<R7
M+DYW&]$<WV%/,+N?*?,=V+I@>]W#MX$J.>2$.7<G%$+H2]IQ-<XG[W&!Z' V
M\?YD?MOF- "7I4#O7??1I/OH*^E_>*((T%T;T@'X);8L5@RP](S,##5;:"::
M*]P\GJ"4 *?T@++\ YLZ"B:\0 TH4X&RF%0FVD2UL5#3B*V!2V[(<[TE6EUA
MLN*!"0$I_CFHERJ#($()2:\(7)K RTV8016DV7<-ZIU*O9'PA"(RTY>O@RH,
M!>6C1+PB-0G5<U%-T$[!-].ATB\H%3QH5HFLIC^S'O.!M$$B$L>CD'@D._M1
MHHS;;9K9X:O/E6PII=A*.FU^4_?4[4#*)"=:72W+34/5QRJ(!LLL+2RE?11/
MWP6!96_28D[P-AL3YIHK]L IE<"$P9ZX*ZXU4I6&S0"[!F%#&(#-T9EKZBB_
MUC"T-;7AW[WF@U[U"OYZRU6D7[4E!? I?O[Z[.U7!1& ]'8UM!J1$Y*DLH&N
M7CJFRC"</6E%GT7NP/P1<P-:K5Q^>$BFP)XC'C3Y\UBS/*OR0[W:K.01])L3
MT!C>03]+'2%)!=2_LX3!L/%W*D#LZSVEM\\NVOF=\LD[+4W$7D)8JO">H5W"
MBU8)Z =ODU(SB954'RA[S"6=F.!\TVE2G 4@)Z![\)%G5+K::HL(046MF3.T
MH5XCO4^5*Y,AT3_$@8SV%ZU1"2YUV=*;N3&J=+[$RM')H WD(P# 2Q8?. R6
M+NJE4IPQ9AZ8+1<Y#9;P1BEDDI%$^PA@1@Z86T'.^A:/Y,;U* I$FUD<6&1'
M>@*@7W*I'C=W;'OA!5K9[R9?2&&&>;P$?T#3B%,^GN7B'^6ME'S&#AYOG0[>
MF4<#\VBDG J0$DLK@5INBN&7F%A"J75<*X)P6[7^5@ "TK.;ZU);%)@YAMHZ
M6F8*+'B5\OI0MR<AL:5"Q5X+,-8* 'Y4[5_NLYA_0[V580B=-D@?A=OU-2O8
MQT7TU%)ZC;_1TLA]=\60^.3Q.CRBJ<ARH"<S3$4,@,FG%*Y\-\[8M27?Z7'+
M2BJ"Y/COYR3+KNJ+>DWII@D6*\08@L9A,#2=00*40BV]-ZH3E!\%*Y$-<##+
M !)X7=[A?WMXG6LIAC4R-CP\R(4-4*QP$;1\%PVC&OTI7 D*5G'"9R;_AODQ
M*_LK\%,V4D$%[U\[VW75K1H7-:7>@D78,*4FYT:(CX;Q?K S[ 0JZV:L,J2B
M4/X'@_+E7V+LJK,")<K?J<@'1_.@3BKHE;CS$L5SP6(1<&ZX^JL</+/HM)9D
M)PNF#)-:I;H!(UB1PKDM76E88MW>I,T1U\>QR4(64++PGBM%>HV0 4!M!#F1
M:AF=Y@XG(U/V*2\P-@T[85K[+ '"F?@"X-F)_=8NM&7!H#FLBU'6JVNRU:1S
MRC77/[ 9:#0K&3M)*+UVA?V1?(A,I>L(&_?-MJC*,Q@[%V0 74O71>/=:E<K
M,B&B'&:2XRZXJ+,-G]:+C38JT5=D6N]GSV4L8WG;Y$TX+.WMDGS)8+IN&$6_
MJH*I!L;ZA1Q*YZ_2P?2Q4W 'SV#T3LR/3[S.+G.C""9-Q<VRK0D"@=!07$Q.
M;/"CE\OJ,JQKA&8Y&4&<>OVZ*B4/BD\*SP9RA]'AL^+$B@X'A9").:1$U>_>
MQ=T>_2];BCDW6N._;E8;*>,0:AEI9RBUD63=\^;-ZBY\F"F1"5%CU9?"L(,>
M/MH :BVL$<W:KZHF2[T,!$Z9'.J1J',XG*:JYGULY13<R_!MDH'+:GYI,0#W
M6 B(B'UNM ,)YQ:KK%X7]CCYW=R*T3=KS6?2C"B3J7T0=*B6HIQX-;DCEUUP
M;^:Q)-)%=#F,V*^7U05<W R,7$$ :4"62,_KE1C]=ZII:S1MC**J%W9OHU!
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MJ:%EMQ+2#XT>Y$1\9\A@?6A/ZU[)7=*O$-E!F'JFS9A&<Q^93S\U=T(*2P$
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MPF-QIY.>IE!E86FUX?J@6[1H<J79B#L"!SHZSWKFPRHIAP 1*H"WP62!XY?
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M$QQW0BV(_\+1SGX'-*]%5L$Z&_$I!VBR<]7*P*55+0FU&MW*@P)+Q:CHK!/
M.6N<_%!@SR6LUV^>B(W#U@;Z^8ZP/:EFS :N6?$S(RYL+4WM< XQSM3:>("2
M%J.21T;C8L!!65*!)K?30G[&<8//"JX\H&J!  !6SC!\;QNH\DG!%0X @DB"
M?Z Y'.B)WK]W!'](+U(*T>2X>&<*+AV&8B;PBM%WS2XYYI'NC^/[1^%!"Y=#
M+E\$MOS">$C*3DZ$^WR *X/JUS:@I&N^G= (L$M]@(7\)L-_(J25O:^]MT^Q
M]_9%ZKG:[.%6J$#Y4Q5NQ!(CCSD$0K49[K-:Z!SNPG:?5((=$IYBO6+-D9Z7
M8,6?+\ N<2L$_ "2]#&"B^(K#YI.G$J4@N4AP5I1K= X$\XJ=[QU-2U0#^;\
MWK!3S[QOZI30)C27I#.Y[F9MZ,;T[B K.I<)YF/D=F<7,J\[J-=>0\B(CN(S
MB')FH,(4+JW==Q/C8"#T]&F/P:R!;-. GS8?LO$#?$(+G@,3=;/_SSC[S]8:
M7^%[)RC*@8*8KS>\CP=M0.OE%2(D995.(;A)?!<P]*>,*C6/[6DX;BYZYVE1
M)5=]%MS5:7&SJO.%GB3M9\<C#QXIHM9!5#D%4*6_LV[M+,.4!RN$TLP0G[0R
MM@0=2+.28?]7"$:BM@=,"0;^\FN:\70.NC#MNP"YOE?1OXKR8V=YZ+W)E$4$
MK>2M5!>%D36JIL%:CQ26%ND?$(V#D,%+:NGO]G#9>P^.I"E44&A8>76)DBS%
MYC;,A3D'9G<.V>ZLQ+S)/ 5S&[W#F"O+"(>DPC37JZ+!B6\?P #BP-4RQP'"
M-EBCZ$9R%NR[!L[.*<A"L5R[0,@6[=X%A3GJ<W"IF*>F(H<"'B:LG\+SP9D!
M08$X!$'%-CHTST!^$*;K+$"9T$^MN"(L['5Z)G&B5K3W[-Z^G!+U$LEQ OZ=
M((+&O8#@K<!5P2?7L9TW)MMX-DMK@@6(0J%'(2^?MZTW#;CA0S;7W7[\;A9N
MP=1,X JP:V-2AM2):5ID[%0UOY@*]\_2%:QHDE!V#D&H-*]MR2EB72G7"=I)
MJ#<3]'B,7/"%(.B?Z:KOE85GWCF>]X\X+QY99\PZ;-0+@8Z8,IA2.QS-/"/5
MMF5N:I$79??6[*K, H%T\FK2<<B@563-<A)8$1<"OR^F'_5<(\V!:O\=WD*N
MN; RTQ<EHU_8BR7#P3>69M!0VM\D*^0M&'V53R\6/QB+Q</%XI.Q6/PG.13&
MHO\/T@_I/'K]O__7R8.3GU A'?PS663DR'>SNN\ZOO*05PM+Q#1>UH+Y<,*B
MIG9Y>XT7.*,1 ^W0RX[!1*+;OCY4$FVT%LDI#(.KXP"9NA%R/_D<)3/$W[B%
M<&]_Z+90/5EL_8?SJ&AJR7MXP0)GQ'I*4P=S#%3))3<ER<Y2%TGE)4Q OP<F
MZ\BD62I."R+VB9Z$DC*ESMV#5(?*6[Y4JCR/-C&E/XN^Q _P3KK@]]P$OUZZ
MU0PEI]8/&2R_:N5JHS.,D+&>( T%ABNWHFQ-;WR]=W9^_N%\GXD)K;<O*_+O
MWZYOOK;%Q+W3IZ_WVSY20)JE3A'W16Q#PU=YB9?!6GKI[]@5Q"K<IL)U87C_
M;J1OE"$, !E]I()JTU\U$@E5T9RQH!/*1ZNS7Z.]#^<'9[^^?_OA_>G+-S]&
MS]\].GAW]O;=J[,#Y/PX>/GA31R]*0ZC>\</GSQZ_%-T]OK#RZ?G/T;P5?SL
MB[/35Q]>X&>/X^CDT>-[#Q_MQW+YZ,W+UR_@!B^?'OQR]N8,OQ?M';\_.G[]
M BS7DP>/#XZ.Z</*>^?"\$4O1\^:J7O7UN7;^_GUS\_WH[VW;UZ]?'-VP.LY
M.OZ?7X[OGQSO6Z]%+FC]S>?H+?/E]IX]_P4N\/3TS9M3^?Z;IQ^.[AT]?@1/
MLG^H3OFH/P&9QK> /$]46\5)T;G_OBA"\\-)ZD_&MBOKK>&%T&\].?J)KG5*
MB$3Z'+U\\X;,0NFSQ\A16RI,09BD>X(@Z4O-'4ENH!^EE32HS+HL8+^XC6IN
MLNS=E#O*HZE[C[Y7?YZHI0XM[X!+HCI]>/SX*%!HMC[1<?LMFL'/IUIQ-3 8
M$5M<('T07B?J5WJ-Q8&F2,NHL0W?,>__@*,;^\;)FJ!8=)9UT8#J9$P"W=/C
MP2&5Z'\@2(@J[P]NAT0'2!8[EUKH.JRV[IV>OMD?BS&;A/'T,C7\N 212R$@
M["NZ4!L ^0Y=M\>DT/IJV/TY-.H)(/KA#A3HN<XJ=-[37!D/R.I8@?X8F?;]
M% _CAFK/2X@0&,["LMZ%+EC[,GW54O6+7F NDA =IBPJE1C>1-G ;OI N*'X
MJ#J/1Y3H!.$M?FT4@W>^C<NU1T]-!CE6:>UC\LBQ\Q(O_M=BR>VZK SBED"*
MB-Y24QLWE9GPE.$99#Q3[:?Y783>Q8.KWJ4&N[$I,?'HH5=$8JP>-G"!XSAO
MLLQ4B$X>M_%QN"#X*J<SK#($@SI'N1#\ 3Z.Z?RU$(2@4!@LD_F^ZZO"$'XS
MS1AVS&+[F 'N#T,X6=YQ+TS1'!$&&DM*LR2.7C\;P3H;^.Q,U>3%8?1S5B#^
M% O"L7I]>$YE88=7X20/%7)[<NULP0P A0!:5G&U@YX EXL7;!4$+19.T7'#
MPT8N/7X#K65A2XQ35V*<!25&L6$I':HLPXU+$_!6/Z#K3I ]-K$I*-J5E&;D
MN.)=)A@UE'Y&D; RUBCRZ;4!$<5)$)R5N"P$MB3Y[[;#^?39BV>M!_2T2/>F
M0S=Q49<R_1L5M73,I+E\10=22M'UHBR:BT4G1!! 8G*0P"%:8Q^'88^G:/+D
MJ /E]0L6$I79JIH*E/9[U@N2+S9E]']P ;H%(/"  EXPC,AB#ZYZ741I$(_*
M!GI^"(=)?/9/K";]\.JI'RF0J2IFZX/G K9\KU>@P*C6^S-8G<N4TJ[66I\G
M15K"IK\54W,.VC*]Q#/Y;O&,_$@;%Z!O+SATRS]3XGR-M>U[>X8[FW-8<<2<
M)0'8O)5/+6K4B-BER]\X857I8 L$SF+XN,(890)1A$.8$B6.%XH&V7(C+8S_
MI+-LY*:TR7KT+9%Q<0FN'F($L%)5RF(>L:C+[FOGPBB.FOCQGJ-U<=X-_^F)
M,5SM7752>7\HCQY3 9)_;9QM@^NNG!=>Y"2H-9RSJ1<^=?8A]H!0*&T.E"N2
M.,6PK+A,*O9FB%Z"0.CX241>8^EP/C=@W'9/EJH=-V.T*A 6SLQ+0PY]-;0W
M75\G0!E'I-1(ZG!ZCUTL:,$EZ+$E^"T9U4V8XG%!=G,=@;?4P(-@6"IMVU($
M (6"F##=5B<>B_K .T2!0?#]K"=-TELX,N003'?[TL/U&"<1_81!F4%F]K(A
M584=J69 CFE]HU,@!!.(\M4S7 77,=QL#&RRM6T"=#!JL&@QPD#(0>DJ).(-
M+FM0Y>C[FJHBTV_&T=.?GQE J/#JOWOU-,9?P7LJIW'T_/R9XD7(-Z@+IDPN
MBGP.>^]=DOM_)<RSRG'*T:+5N1Y:P5IH4XZ+*<E$R050M'!$-&N;_['@;'14
M;8^ARS64X+<N^:(F0^@"3M;:4]#"6.H7#192R6]ZW;N0J]B!)=RP0/1P+! -
M%XCNC06B/U>D H8,,P@,XJDPLHO5\Z=/WT7/3T]?O'L=#92)7!.V UES!CG%
MWA)=TE2](K_BX'$@MFD317B71=27<K4G5M[GFI.U$)+.8N]>MJS$P,!G27X)
M\0DLZ=UI.,>I?<.>2]3)?![P?BAFC@&;3 $XPA&QT2Y8RK-2-C!*NV.OO&C$
M:UZ?(JS-4D2(223H=O^ZZ-$\>(57P>*F0O.3N6:KD\XM$2U5Y=K5W;U>2)N]
M)<:DMAYI%Z-0M, $.KBBBE:/EQ 0)JJ>DAS;"\+U>W=KT::1)46B 1Y?0JY/
M^\6CT>-5?T@:B/XNT,PA--[E)XAGW79.*(_1$$G2#"/[IKUL+Y(>HS@@CI,!
M@13(,GL;\A%JYG-%JC!4.F]6V&5GO[_W^O3\Z5,9%L051J[BR?Y87K0C?W6>
M^ :GT"^B?/"W5<FVOM($TO+Y.5T_*'J>O]$,%Z[XX(P1/YMI:=6>6%IX@\2F
M5\I]*\8KZ4E:JQ<>;4./QI!0)7A4^+\>9!0\]06F 3!B:+T2[\N&@0TS!E38
M;8BNGN"C_'I=*-5W$XAB\86<<A@4/2U3[A8];Y;+1'*PO+%$@9%VU[(+SLXN
M61B7C@<#4!9:&)=,5T10DZ=F;)R$B$"\9QI;& VD "02#Q>U]5KAH4,8MUO;
MXFLZVQS=(!$.9^;<VHC/&P1A-60KY9REJZ(JEEK"2AN],2R=<S^=//'#H.3E
M6KD)E(CN"1Z8/,D+;Z"C1TNB_=H]]T'S(+#C1Z856NAZL8J:KE)9Z[TC5Y#O
M]IZG",N0<C$!XTSCF'U=@L!P*Z<8"$X8)NI!1]28-$  (&K!%9R:JIF"Y:CF
M3>;:#4$+Y =@KVS@[2[OE7PQQ<!XN(K/);8!PJLY:U,=<>='?O +]JCFK8P.
M=]M<Z$M^T8/D!34FX5?@BA.6[_7+#X?1WR;MTS.YK1-$1$;?^N;2@?G>\'F"
M7:W,4G9 L^W $CX0BP0:E+R(>,*PHS_%[5*&.!E3(2T>($=)W*+%]&E?;QG;
MN1-R=UJ"*K[0+CM_EFD+RGCF,\NIUVY+':'=**,MKB\6T%IFW6+B*+:)4BN^
MB;_KL.F7!<]*0 6\]*DUZ MH'LB4FF28]MY1(,!BM>Q[<L+^#43;W/%V91I[
M]'1>D5JX=<'<B2,=[L!X/ ,3 F<((R?R0G".NPE8L'F"O<:+"P2K892;,5F-
MV4L\CJLDI6H6_JWW\ D/Z=*;/4<!&]%PV@-,\RPT#Q\WP_KN'1.%^+U#A<OD
MQ<T*V ;4)J;O'4U;LL0FL<I?3JG3Y:0I*_X @J20DFA%OKL470NF"J1")S?5
MEL5E.N/1:5(E,JF'64.#K&ORX&#+B]DN1%<[L(13Q,?*]H,GCF2R,PDD%+TQ
MS!5@8%[J.>IHR6L@EIDC=:$"C_E+15,17SF\L%\/SR&2+C AB,B5;>1D)U\&
MRRV6Z%:8_LHO_ON[H^_HYPK'V,O/)B'-R?DI/O:JTC]&YE\_X731>H&/</0]
M0DNW>YSO,/G\M[HTU[_$@2D0QI@GXJ3V=Y*BKF>M=6PJ$I!F_?7\6?#BG(*O
M9YV+XJ(/KC2R>N.=L]E/D6R)2Z[C+3JVTK\6; @6/O_[NY/O-ERWKPZQU3.=
M)R!OZQ^>:SWX&+UKYE<2K&+C8]RA+7D'ZAYS&7^;E#_\'>*Q&M0[.;KT,WIR
MN)"WU&W-OSM/(19)2OX!8F,]3^MJ[WA_W%(C90OP7P]D?S!MP__T_92]DZ^S
M7? _Y59*X2>/.0P54E'^&)47D[V3H_OQR;W'\<F#!_M=Q2%:ZN'][\/MR?2\
M9FMQC7?@.0<QMV\3VQU:A"?&?O=NBM&/WSM5O.E3?<O[KTU?>=+Z2HG[_-W?
MC^/CX_LWO]4V2[S=!WER]&=XBL>?]R[LZ?B!S+8QY5^.(?R+> DWO?O&VGO@
M68#&&-8+<)6!,$MUM_KH\ 3<HK[M_AL!EWRMRKFK'Z][&/ILE?ZA^=F_^SN9
M%+R:J#:WB/Y@\(O=^+VV09+/"C:@TBR0:Y6L3=8>_CIC+#W5@#+PDME,,O1.
M>B]ZY^10)"-SQ ZC<_A)>5]>F\@H-AXVSEE#O;I:(<@3Q<S^05* L5E9%;?:
M[F&5/^#D H@0#3Z4*$&(99*;T> [MLU+T2^B/7#V-4551.EHN$=!LTL;%7B.
M_X/=6 B97=1)MFPH;2:-4_NP'O$YI+>%.&2)V"?-960SW$4?7AS&A._%C!&U
MU<W2*IFD-)')?G)?>*76+J4G>UYI)):L<<:/DR)%.J"E -KGWY[J\41_V1-]
M\HU.-!%9(6,C5]$0.(R%]TN:@DJLRX0U@/-*OAM$J"L^#D28+,,Y$,:X)!P]
MCMCC>C\Y@ >(.,GLMZ)5B54T)*J8Z>Q:Z?OJQF=WT6^/1O3;,/KM_HA^N^/9
MLY<\J:N<)4&%WTX_5:^2*T:RL34)4FD&(^3E8XTR K.+B5AJ]UIBLFT!WG&V
M=A]&%<<>!%5;G /#B4ZRI[@:!(_!7Y0_=7@H^_95Q^I\S=()W> TSVD8J[^=
M7^MV?ZE48==AZ,U4G-EZ]%L6S+8#,)#TZ.K<_H"S)Z-SLY6;BW\YGZ,GW=CK
M^GS:DW_*!7K?S%?<S=[[F7RCEVIDUE'*,$INT:85O]JSWO;^72W26A_@0=?H
M=%R5R>IZ=V7K17Q9J77I2WHB2F%&[N=0B5;-2B+U9O7W+R'FN_;FOMA+^E!
M+/SUMF7;S&]7Q[,0X+]_C)#X/9U^UU/ZX75?MVNM-[7AQ[OT[9OO[<XL_2YL
MVV<5(QZ<]*9]OYQ*/%W"H5@CW4%5B19$U(FA ::V6*;B8'AWCZ^3#FG%+Y9'
MWSJ%?G+\9' 1UZ7/O^6Z?3;=+_6_?^F-.'YXD\?_X1M+[;T'G_RR/D<+_89N
MV\VT>D]&<Y, #;[A31_LN^"XF#NPF*]K$;^F%<3.I]-9&OW?)BOF\X-SI%R2
MH("L(5H^V_J"Q /#QN]F[Z.C*7K5P\G7%8IM%G%_!]9PL@MK>-*Q+*."'A=S
M-Q9S=Q7TVS] /V<&I>>4<B<<D2DF^+?G:9[D5"R_36U][[CCS'T#;?WXVZ^A
MZX+?_AKN/>K$@Z.V'A=S-Q9S=[7UR[J:+I*/T?FBU$N76Z<^=D.2'F26.-MT
M.]YT-T5T^WKIX-LO81?4<T_B8U3/XV+NQF+NKGI^A1C??^)L.9?Q-]WAMZ.#
M=T#W[( *OO?MEW#RB?[Q-3T&(\;XZYS<;]8UP+ ) ABK +9GQ[_8YECII,Z+
M_&":5 OD\"PMPT_X5=/Z>D,$^Q>5AIWH\C];KK)B;>%"EC;NU'%((*91==(=
M(ZU,F[*#9EX3J(2ZN>LBNBK3NM:YTMXFNWV5-A&/@#<)-SW2"0^,#*EG# ;U
M,#IE^@ F//>^C.TH.,)A"BLNEC)B%D<'P*V4FZ$#!X6.12WT@O"U.85(.*F+
MJ9C2',=A)'8:48),?KGIQV$2*[SJ8?2BN,*N$P;>:OS:5$M7B>%T"N^GW)JH
M V>"K//+E!H!<N25\GIOLN3J,'HM9[SSN$AK KN^3'/&^ZXCG1+LC:E3FA4L
M_MY1-$O6'K\<>B+F_>0X8$)[S\##O>$*3^AK$7] 2 R8'_(_38KOV0?\(H+X
MNE<6\#E>A4*C2&AZA:!S*2;F-XR)JZ:LFB2G%5PM4OB"N31=35J*9GJ9@P#;
M-<(>+6%WB(@"[%]),L.\!#1&+6R%(BH9WOLLY3=+1-A"5$-#5WD C@5&F]TF
MAB39 O,[VVF$!*8!R5*G%8SH_S0<0DO'.2ERFA- 3X+XZAA'D_Y;WD&";!P'
M,\TR@4]/Q'1B">B[2!N&+X#V"MYG ]N7T3#LVJ"YF=6M!)G[3P-RI&G\$-T0
M[+3&R<V,[/:80'C^5;%<:D.D+X\46!_\ ,J=MNS[- WY,K%<(#^;J7"6.>F0
MR"$3@ELK\_2X+:MD34)/0K[4/&6DH*U(+\W((GI\(0-B:LX:WQ/>:E,R>\.J
M><4T(#KGG9/K]2Q]![3S#BSA.78$1N"O3,MT962#FA1 2BLE;]XT2-&)D;8G
MD%3D\]=VGAJC>+F^<)5K&AO.%)O@$Z4KI+M$SP<'C9M16Z^#ODJ<LT9=$>.[
M^93^JL=C?]5P?]6#L;_JCI^&4\^]"5JJ;6_5-2:M:P.LO8AEIJ482==U5?D:
M"VTX?P$^;SZ':I(F@G@W-FISP(K%T>OR,#(57%ZWK0/P'X."06RY'+F6FZ0E
MDV<87=U],KJ*\K&LQ-2%%A8D&-PWUK/4<2[/@!88'"V<',@>'CV!OYWOX-!/
MF3OVBNC^9/>,D0TV"S[_7$]*\%'6ZOB(VLI._@2D3MLO,\BI;,Z+@@;9G/"T
MSV53*\$3]62_@AS,ETQ\_.__]>3AHR<_!3F*ZU?^19M6_"O1O69P<$N2T1\I
M1D,9_JY56MOJV,A310?(*P_WQ3[+N=:&39F#$)KN]/(\>G 2/S@ZBO;H&/Q.
MS>+P\?\ZOA\_.7XB1.RY.,?B[(J7#Q?@^ :G(9G[5-@^EN*#@TM&?1_FME/D
M4T>5@O0);NYLD"?B1.0U>:)OEX7\2@E&E.T^K/)MI!Y[#L+NG0&R0-TL622K
MWDK.'SZ,C_KD_''\Z,&#&\NYNK&<QQ!K-)6?=[&,(F7854C#X>%FW%5HB%1N
MBY-A=SE3G[4S'Y)/Q4G:=8E3LL:L:2MK.BLH?43)*LG'>2DPGNB(;#XNUV4)
M1RD39$A\* %BXFD9YH$RODBK'U!8O1PL7;/Y%C3=YHZW*YAL?M^A_%%N_VO*
MW^WP#CPMRA4/D/P%=5A.3!#V <?SY85R8#%XG$9JYOMAWIE2JE[*]!(L1=%@
MY<!L[(7;6(D&.2?-N?D@*(Q>87K>)L_]9'2I+QKAUL>#NVRRB\1E^)'O-KA*
M+&O$'YE+F'F#0'?.F&#(I*F)Z+:JB^G'2/^.@ZHO:/B\':W$(Y&K6?*?&*L+
M07[87,.-B(V5I-8*V."BL4DR.ZLBV (.3W&T)>7&:8AKR&9& P5@P66#_$5P
M'[BE'6:$CUA4J9\#3&#1M8NBU8;LJWQC8ESJF8M$V2K3(&O\R(6F39[Q:(VY
MS*JE-9G,MSQ69;+0^$RFN).X@4QV&_@.<N%T;D>WU""MF-TT7T@K<S4*^;/,
M9Y/O7WXDY/0TNA&"?KG+H>JG>ZFT+UNQEX7' #DS_)=Y( CPSO^1Y!@I4Y1,
M!1@S#PE>ZF89J+0*I,#,P0I/P:]&L-L+%.ZXI21XZ:I$2A=<(!2TJY2XPW-X
MEH8(Z":PRY<).%W@4R&]#)S8JJ!:5914/T9[Z3X^DF]2$_-41%$'FT3#PUW^
M0)Z2DQ8F1X'O;P9F-?=/:M0ZJ7LIW TV6\D9I2K<9YU3E'JX*C\$S<Q>>P-\
MK&S9X:4MU:1L.24\39MJ&?Y9[%%SM/HLN>HLF0^V.;W.83;/&"M;; DI!.F*
MLV*)K&=3V.>JT6.))!Q[84464\#P+2S67N+ .MZM:R46I.X]O)[H_M$#3WK/
MF;80Q?=T6A]&:!JCUAWD?9B!&2OT)&M1#IX\*F=0>ZSEROI9:5[5WGBL?MMJ
M!,D< G9O:9H2C^Z8I=4T*T"=!"I;O&,W*,0I0',,\(.76*JLK0?@?7GC#L1F
M"UAC>=MX)@*.FTA*##.TH'^4,3Y(<1E[9P0Y/Z=E.K$EU08L8;4P"T6U) 8'
M@]XU2!LL8^F&85%53&K'<<O,KFS!R\^(*F_AG@&G(7YRUVH!/QQ4M%UP6P@@
M*"=-X\H\6(+@*%BFS+3(XX?FA?I[T:GL*_-B;"Y]8!-!MN9I9L %H!1XJ?R$
M<]M)Y/;%Z<3SLZ=X"N8E55EJ$$\L,K*GM<(?DTJ1PO&\J@6*4N4. RX3)SY6
MC%OI7^2HH&P-=UE0^M[!8BR>1G%99*-*H'?:KW3P!3=AH;<OS+F=^NUMA'$W
M*[H^&8NNPT77AV/1]1ME(OI*&V/V@9?PMA</9$8E96LEDPK(_T'.ZMR$B8?B
M#ME #I0C(JYFMC0M8"98V[^+4C"&_?@C#)I<S% 3D@I-H+FB$H]+')FH[<C0
M;:2>10'91/.(A1D9S"3WK^Z%*?-H013;U8)&B=(PM]S"]X+HD4J]*JUBDZ"_
M3.%=A!^Q?.A]D?^\Y,P 7LH?9BA.9-%D,C9TKDN/,A6<I'*:<BW >PCU[V9V
MP3[B;T2?B@4"OA26S*E_(XY>PULZ3V<IU]%_AI=WOL!$"_[T7E\B4(Z01S3:
M=XV%BU*&8>'L*/)6O&T4B^>M0@R=FC.^$<(T%W&)=)"'28XL!@+QD "D%3E
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M@E=E6B85:\(?H[WC_0Z2R(;NI*0]L*%]\Z*RJ1DC!.\1.)9V2")\R?] T(3
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MS%S<F8#WV%<^A_^ \FD\((?Q+[M?"9S'?77 V*6>9-$*R7PLMQ^7O\1V)WD
MY_$M*B:;$RNI;K-L2HFS/_S%A5170MR=,FQ'P\1IAL;-6GF9M--7DJ!TFU '
M9*"Q9ISYIH"M7;O !GNS> =G"CD$.,PP[6#^-]RE!)SF<'Z12 ^E^B2K)JOW
M(8P<E#0X;ZKFSFIEKS',SNJWIPU<&'R@WH6:-T!D@314T' OAHW4*M@JV(("
M8O%:,\Q)^F7[KN^A'BE[Q,[47\MCX1%QG8,X*N^M$"26=4MYF2-?,2"SH)'\
M\SKA'D'F:HLL88'HPU4S 6WKKFF481O%816=+4%=.=VNG&['LBTFBKI:;$N^
MUW<WH7EM;8WZ4C2OAC5/L,PW(+Z,3:Y\"W;8:YA!-U%X;LT5JUH7^33FV$U<
ME\4@]:I74R0HP ;FV&$^T"T899UR'6*4%6"+VD0H^UE\LON,O[B>4-9QQ2H.
MF <99HT,#B01MB:8'18C3XK4-8S#MR%%B(SKZ=[_ZUG&Y^FL 8^\7$?/;-V/
MJ4RB%UR)MPL+5_K7-I@?.K*>+HG>2<&);Q@H,252&<:PRZ^R8@UN&E(72 F;
M-KH/0G-H3MK;X#/FP(63@_O1)[&C6J*,.L0!_$E;=["_G^D5KK#S>1K\T/EM
MIZ, PKIFZ<9'MIQ7*9&;<SI!^)XYO95P3W(Q7-@I^*H6NU*G-5)VR$[:F(:P
M4K(F!]H"*U@@E26YQQYB2_6"<UJ/-B(WK' '0FP!0Y;]3>21M/K4B]LS?:DS
M^SWZM=1FX"()HG<FF6Y=0] S9.&L5F?"-\'SAGX8?E!-TW+:+!&W-M52S J6
MS,%A^T9R:.1 $ONX]A>VU$E.#D\Q00=JI#P8*0\^^>9>FY#AS4EFEVGE391.
MI+N,&=ZB25DT6&6="VS0P?%(T^+E&!"P2)?XG\NTK!MMH+WFZ'0:PGNY#':V
M)7R4O,^^.;@6PF6.3@F$@GD=-*VM.#PD@UU(X" D@]]F_I6IMMP!>V@].+0O
M*K0O-G <,I-@Z2Z*8A;-$QX)-;-\4C(#JI7L%+1BQVS]N .;,NJ(.ZTC2CTO
M00<P!!;=<XBPYUDZ)1&T^&J_#UDL4"(,8@MB+Z.0L=7$0-2@W"'3_@)K)8,P
M+2VB6R5S.!-E=3T'S\[:K5NG,MG\[3\?OXE(;&0E5KPF)C0T#(V:<9RZ3EVO
MM2><CH):8N"?1NJ<4=ZNES?]^RHK4NDI#>"OZ& UN=<;8]0@U12F.J5$OFU=
MN:!+DH._K'0V1RU(6K$:B9Q&:1Q>@1VA%#2U,O.*[]LC2TLQ;;ARP[ARZ^9W
ME*!878\%)'1;L3XM,CP#JTTW]T--*N&W?-UO3/!TRP'#C2%Q)R,D;A@2]V2$
MQ-VATM&IURWZ7FIW[Y(2+.&',LDK,[: $K=VWMRKY.J;0"^^^R;U*[KK+UQD
MP-ON<-R^"VB3*VZ-YKRG)G279$;7W9P*^65#EHO+![:[D@L)Y)&14T>\\*Y5
MD6I2<93.QX3_F%+Y+([C4 J3*>/N6DD_*@5@IJ6D!@R;YK<]Y].D(9DMERW/
M[8[G]L<HX18X8$,1-'$#2UV>F&XMCY:BS:90.^L=[3F<&K6YP\()3(4=K"+"
M)MS8[X0F=5CU9?0M.6?]T8CG3Q!.F>DBOGE \<T<AV?\[N2-O3,IA)?ROF0V
MC<!U%,-U1B]C&*)C80S23C!P5%IR'-M9M%2.B0V3#U%&QCR)+*G]J?4,+#.<
MR#@6R'HIWME"$K(Y1-^N67H6>ST./OU0#_.)&2[E,0(Q6")G<*$!TRUQ:2E]
MTR4)/N;%5<[!_%(%Y#2<*Z#'^]W  TM'YNFK!L'1&US^7UW<3BW*N?VN#$HW
MP&QUWZA/2(4)PJN%P9>&.1F:89-8 AJ:."U5Q-Z+=BZAVFTSGBW@*2_P<O4B
MP>1DWYJ<U)FU\")H^F7:I=RE-%)>=%>G4I\6: 1?<8OPO&.$4\JRP6?+A+%M
MY5IY?X][I(0H'HDOSVHU/-1= 2%N]LEZ#'S&P.?+!3[6I;,\@\C)=7?CEE%&
M/A^3E..L9&X@$N+#H=Q-/VE>)=8&QXS)"/L6&5UI;")WTL5V3*C?/*>ZJ-_(
MZ\2CK_;V( 7,IV)OV_#A;P*>VG6#=MJ!X5*2(X8?F8A2%1.X#+>7.&O5Q_:'
MA!417(+$H2HRC9P/IO6DU_GI8XA$_SVPKT+BKGCHJ#\6.["Y_G=&9V5S)C?)
MU>#>D3_C_V*$LXWFY3-O#D?71!-6Y) 9C0?#]X)][I8+,J9.O[X$8> +K_NC
MYAE!':=U!.2,\N(%/3SY)4L_HAMBAP^XC!NS+1CNXW:V>U46\[269A"L1U::
M!_%F:6):Y\9A:=NF=DWI3#%#Y-JQ_!=$$X I+[ /3474_IQTRG-N/@NZOF?&
M!6T(R!^,03J,?K.]<#S+*NS?]&=)*?\RP].C=F S=V )PP-,\JGN-ATR4:OV
M.#>YJ=1MN=]Y'@]UUP=0@S"U[<'>Y=PJ)@H-5R)-J#P.?470%RM/G543,5XW
M2@EF?@_-]Q/^'H\N6@@Q9<J4)3H/O>RT7_78 $G(>8+>LFX\'A2P#Z-N@E+U
M)"BC($')=8ZA-GWX?3[PDF)^!IPZ6=*&<V)3WEIK'8>*!<FRQ 9-HG$X/LT4
M&^U@D8DC(4&^'L<U%>V9,6K\\FA-$OKODW8)7ZWR"ZJ;]X5%):V"L!/+IMY
MS0'I%376VL_8&WVA+!$_;GU:N8NZ/#__GO+O@2!.6]2,$#SKRR3WWQR.*^@N
MRXY]J$R)2DFQH%H0)H>FH_&ZTIS?JID*0S01+2DV9M:?C"*OCD0QZ<PF&-PK
MU=DK2?I,DTH+:50\=$S-60I&)$3M+#RW]8<JA@E_TQ5VI,-%'/=P96;EM<^$
MZ0GK83EA<DWA+-O'-TC5%G_'#,+$C5ZP:R:^J&+.XT2\TZ#L)X@_C*;LB#6<
MFPF:8_+C,X?0W1N1OX/(WY.C$?E[QT_#<"HPRU0PW#0QTSH<-P^WN<[T,G=4
M381_ &?.] ^VG&WCA_L*V5 #]7#^X&2+/O>B0Q/4O9,9-.>I]89Z(UE5BC,R
MZV7@PNDQ*Z%C8N<JF'+3<F_(H@U/51)N,-_["9;.T[H[#Q!'WKP=]^AJ\VX-
M><Q(!E^B+VI++QXU#;B7.(J59KE<PTAVZUQ+.XWB@D/CYB"=NUT=X5S7ZA<\
M4_V1G[B@Z#"M&=;4BFS,^94_7T.W9[B7&!3C<QFN#Y$=MA^=(5&JF\76'N1<
M>$F(X4\-1H\>0!.<Z/02W<P5N )FI,>G7UD(SDE?^\]C. OLU"8";"*IZQ1C
M\H7F)F\W1D^Y,7J$Y-^T%3T%N]B,Q6,M**.6^J]@!D;(?#9_V8Y"3AG*5CI[
M.K\PXR:"F7D]BQO\8P?P$-M]Z&F18ZY;I9>KK%AK&CK%MJP=8&P(#@9G,/6$
M-$/L@AC5JH'1;A@@VGQ VR3Y*%\7WI@A++TSWZCHVF<N)"@]5/Y,R?9=O7 =
M3>^\R>8I\J?E%@3@J U]!3#"FL::XJ=#5FK%T(]NCD$.B8#GPO/!":%+W0MY
M[,/8TSDL;< >SL4E@5<3+0<2F\>32V;%YC-A:/>"5 2XG<8H3(A9'37@W<9@
MC06M6^@=:2O_SQ-L_ (E&A-D/:BZR;U2F[0?7'+)?2'P-&[69@#H:H_9'(MC
M@S.&K!UE)/^ :_I5/5-S<4.-[UXO#?U5//0WY%K&*LZ2M14FPHW-1Y38.O)F
M!?]DL6.=W"0WT*7Y99%9U4@4!JLZ<%.+,G"AU#3)9:8!!?/DY"915N0($,1G
MB'O*+6W?K)W\IL5YU^!I3+8ARE%:AFR6.R!$.["$+<C9U2"3MYV=?K- ;"CZ
MH&]Z62-ZNZT>8]67D;IF$K-,JN"A[@QE[/5Z:?:$>:9@4'$5Q@D0;-THI3/*
MVE:]8JR!_%?#1,6NM,.I/%,@G*Q=8PX2=;(90QM8-ER3IGB(C",3(', OUDY
M^ZE#J81B9#V5RE(RN^1<J:74G200%-4V%(4_H')DU;2%!I>KT"KAW_]IX)=4
M9GV>I%G#T(BJ<&NX2JGQ#*<RFN^"(H;]G]G4:OO>]EC@349AM,)(UJ*;CE(]
MZ2CDX=/S-.?HH*,+&?[NOVX/-<%,M(2[ICY#Z4Q/+\-A>*81TINQ$-#/3C3'
M_BTFH.@TN&_*H^&;)4.])WJ#+DZ]."MH?'MPY./_5:^3Z')%FY#]G)P(XSJO
M9!QF.:15OPWX9]YIW'WRM]2V*41Z9UHVPLZGS7M4##_U2;?K8?BI%6P>^-/\
MLKH[Z!PQVLLM'.WHN<GX-27V@9(%$2-D?"R\-O4CZA++A; [RLS_8G(-G.%B
M'J$_K!A00;U8_8 K>5,SN>*AY%H&0OZ;7KW<&@24AFAX#%E8/[R SUS$/2<)
M1W)=Y! RT8E*ZR:1,$>79A83=<U6O:GDOK/KZWYO,+#DS%B1^\.A@T\%$7^2
MU0O<D6[W);LI,AO>X4R40RSZPNJ:)PB[ KXK[@98DHI=(VE^9N'"+.-M-?[N
M.K'7_;&\/US>/Q[+^W>(V,M-@O$JD>/$M"WA#JKK6IMI$R&%[81GPJ-?L2JN
MW" ,GT=YD#B<H87)%.$%/+K"XIDAFBRQ! \F!Z_MS144H*>Y*_7=2139H96<
M=1T(?VP9/.BRP"J/N(3P*_BS2V%;3XG3V(1U"\M(>:MNPT9O+-F,)9O/*-G@
M %HJ?)NL2#^@^OI&L/XJB!C'KFD<)>>.2PXH-LS,:I7V8^9E1OP?.$,7U1CX
MOJNT3K)1DD9)"F^^U.4%N--J&Z:^43;^6K)!70A>>4"R!(:LBUJ(3&X@*%T0
M1F!:]Z [.2-B:@]]U8-K:2EVR=&Z5<:N8+<0"\CNNOBNJM=M+U:8Q*P,V F1
MAV7*U1C\E52ZN[[SF-RVR6T$9\TP8)*-SB#>N$S2#$524:DKB3#BGRYHG!]F
MIWC((((16Y!-]SG7!^A*R#QIQHQ1HH\0;1\=(WF1@OGN!CO*E-&3S"V99GJ:
MQ9JH*<W_W93&,Y#D]P[L]0XLH0-&&"QG]6:_D:A0-!P&K%2)PDJ]+;1SNV)3
M3XLESWP,KL'@$VG>:U\\%F;R;HEV(&B(;2V!PW6OED <B2Q9@N$,AD;WM8V2
MJLEEC"I>KT/+9Q<68\*;2]TNEV#';N((!YI%4A=723FKPM3]<*NTY;_F2DLS
M8?@!1TX\W&DM_0M4Z*/A[A;ZL.D,1]N?X?:A-%\R\=O@T\91G7PTQ8>^@J*=
M4='*JL![*6AX=I/7AW]SZ:S;S;)]F[L^-6@ 6]_JMJ2/*3ZSA+?]P]#AX"I=
MH?^45@NLX%W1X<BIC&/Q%MCO X<;O\H JKT-W<\#:.Y]LC;P1+,$[KSF/F0L
MUN))Q*^4::5GYJC0_%PS4U[:FB92%D8" E"6\R:?BD%S:S#T!U@7$K*T!MNP
M],Q;"8^<MYJ\F$Z3BBZ$ '^S3RK8)\2V8+815<N!VQ>JV!DHB^3\I-B4S$!!
M3KG6),@N1B:4Z3387,;BYX4!P<CC,KN<5A?8HY03%L)#QC.> B>PXEZ2RL4;
M(ZUOL=(E^V]&RX+#M]171?F1+GW1P-YDA.N"!8&YR6A?R?]SI7>#OYC0EJAO
MS?:P$Z6$4Q)XJW>^=@WAJ[=YT0U">_K>ZS<8V[6VF?'AC12?!5R+>5M!?K43
M<SN"\DHHM'T1N?4FQ#L@(E9U1TYUJ[(1%_Q-4LV2_Z#D1&W)68(1(4/2%1V&
M.E2&1</R>#*,&)<"%A?7X^,ZC;]*/-?$SXYK2=',J2RM-:V1:F/<><1\V&BD
MV*$4=@V3S[%?%\ 0!03Z=YR_#)9[#!$_A4;AP8BS&,99G(PXBSM^&C#HZ/+4
M3%&SJ)6'B$^BJQ+_FB-53TGT/:+P2&>^+@^C?Z:4:\!__@R?.U\D7-?'7SQ+
MUDE^&/[-T243^X_0_F-NK+NF0W6:93;:Z/\,U?XE6>#U9*/_[Q0C:]7IVFN&
M< 0W$=L 7+3? 2 !S_G94^4"J*X%B5H6Y# :CNA<1DG:.TZ7.3R\W1MFN&H_
MH'T,Q4J=IXIQ0""ML[!([RDL&!4WI()']W:"+I'2>>U>9JOGN]O.4BM4@*]E
M>G26KJ?(@U"S+9?49E2M4!_@*8(3-Z)JQJKEI\\>=EAO97I)&.[,X.IY.D6]
MA2)I&D_,?&S/[UUA IA[[]A<V.PV:L8E9W,18KU$$$\(2^LJ;80OITLFPJ%,
MD;W\B,@8Y7<+^;7$3389&53AP_*[-P8O^/V-V3Y)UF4-JD/=!WH[)(LL2D<G
MS Y2H/WWH[T*U+V@" YN,I WDH&\"BXCB(/]\>2,)R>\N?X]D7.#"IN$F(L'
MS+(C=77Y+7DAA5>!8[0QNJH^39%G03K?I6-3-7.V* AKJ>#&4_&>ZP+NJ7A*
MB.E#(H2S\76$-GN4XU&.A^28*F738J6#H-636EOTZ1 45LT$_6ONU@H=E2BL
MW:-OA)[+$.TW4^+ZN'K.1@IM$IL4CG*7/CNPJ7>W\ 7>8XRB/XI^2_1-J9HR
M2&4QU3/BI#>-DPL0[4R2Y(:1S))S$=,ZYM@-:R<WS>8>81H*GW7W33H&[E/K
MJ>E:G&B/.Z-@M\?>:I3846*O=]>-CVXPL!U_FUE?J Y3SB@[1BK9(_28I[-F
MFJ)73:"BXHI+2$'7$W7P#CC@RO1CK;RHD]9#UN(6@XA]Y44170+P+:*(;F_S
M)P02PK8O@40T!A+CF=YPIJ?I;"#^EG-E#55(@TDFJPI.#^;$=2Z4/=*)CLY:
MG=)\/_J&QD]6^P':R#]UZFMR7_T4C<T?XQG89-?$22+)#J@<T>OWC0,S&)>:
M#%RN+V!UF-/W ^HV%4>]7@G LW,A@M].M&'F5F+_KN&<'1M(O@ARX>&(7!A&
M+MP;D0MW_#3\IH5/9E:L:AZ?V](C2J *4:4YC0(O"XVP(Q*H8BF/APF](2YL
M03Q@)&I)K6Q1W%3?T;W@ GF4,1Z,H65#9 :R!DM,,)9.1YO_R3?W,G?J4\J<
MF [$#(N#B5 ?#B%ID#?^,M57?BMBPYV)), ]7Z$Q*,*Y:UA VFMIMR$-7FMX
MT:LR+<IHP+EPH!GO6I/U0*IT#"7'(Q7>'/%/%7+:*,D^^EC>4E^@04!XL$SH
M\)"Y\[1<"IA,1-Z<%3<#(FY- V+B7M-GTAD7@>B;F]U_^-3TI*],;B5+KL:#
M,!Z$\.:^%*M0BGODEB).AG3B[ PC^9)PM$<IK,?Z)H8J9X8^V^;S17&;+RI3
MR.5C9K[+HY#32YU+P(O?J=9P4H@;O%U8IB%3GM$I]0H\1;C0> C&0W#-(;!S
M?3A80#G,B_R ?^J57P8BW$2'S[G?^\"Z-I.A+L@Q$S@*;9_0BF+DF*#(4652
M')K./?A[#$]]0<U#W"5++@&X/CPD$0?H+N&MUKZ2%I@\=K@*8Q7&SZ:<.T_I
MG%#D,-7I)7\#=6NE'!5M6O)5^+MT@G@=/'>;\3S<DB .BQ#H2OGH:@'')].3
MC%@25@4\C26UZ7I?(49">>[0//(&T3)*E'P_36S3^"VZMEFC5]MVS^*6+/V_
MKK? F1<FU[%'7$IXBIJZD5$A[N]#V,FTZ [T_#[U'>BQ]7<W\D6[T*J [%=]
MT[GG/%P]F*C(XPU<33 9X$A@AI.!F1=F3JOE2O [015W@G[]41C?KM=XE$F_
MK:Y?2!2V=K$QNZ:_CD&!G]=CEPH]3]A@AP=C2+QOT+-&W<O<D^?W6/0<C+0*
M/%X+"E';])GYM4=*\#F:+'?1::OKSS.\!D;FF@<'#_?=/I+]AI :V\:3N<7)
M9+>V"IW&:AA6^V.T=[S/(IGG#89E2=6R#7(L].]ZVA!8A/,?PI@S<V';WLF^
M7$6!M&.Z_!*'J.9-U19_3)2C0PXG)A%(?+)$7Q(N<F\_PD-0KX-5P!_N[PL"
MDK(UR46I34Z_PEE#=.S\H>DQ10J@BN 7$<_1ID2)^^8/=APOKO[!/NQ8+:<O
MNH +<?+_!V(GL'^@!](<I49[#_>]V0X3G>MYBBOREQZ'>LHZX)CQ\98[4AM8
MLL-9XU<PPYES3A_+"!@N?@;(\A"B:&'J WZ4A%M>!!3D1%K):Y)]94'H<"L&
M/%WA*N8RO#@*U-@[NK[CE6O]P;I<I@HL^97V\KN'%R1\7O,$YP#KWBY/>8-Y
MNKIU>%UL>/-@;DP[?>-#\NF\I94_PYX..H7C,C3(-W!@J//HN9Z4#2(NCX_B
MZ.3HY"3N7-=-&,2_Y"!Q/:N-Y3TT.1A>6 H^/M-+TH M9#TAHG_*JD88MF;N
MWD_HU@]NG6SJZQK4+S.DY=$(P1F&X-P?(3@[+NPMEY*5Q>A*MJ<X]MDD1>PF
MD?!O\#@KM $(3":G"0T/.((61>G2@\YZ.H\-OAG:TNL\2L]K5/KW:9.MV)_"
MH9!-:7HD9WK)R5U3?*9,2)'K&C7[*K$W=Z-;\.;F#]1_P,"-#<OM&DG5-M[&
M1NV1NVA^W"<0JIEGBQ/D.I-Y8W'6,R*++2ST>IZT=\'0)9H-Q.BS[2449'MA
M4ZNXWPGR^XX0RX)K.Z#9B56-4>R%L O@; >S6?0TJS+EJ9GBVK,PV)=8':J7
M-6\'D=4:IZ1_ZDW?TLJT^NAU2H%?G_[A^#[SI&Y*V[\J]).84M[\:N9-B3>F
M&7IF2:TI.EXP+GL^XM?&2M5G#2Q $NY,SRY 0U4?4WA!L>.PL[43++-4"\[U
MB(L.6D!?)G2Z_::F/:,3(__$C3U#H^SUR)Z1%6<2/)EQRK9PY;D6<I@K@VEK
MW+N7-S%]@DOI$QSE<)3#KAR:(:S5(EV!AU1?:9T'J94YX46,?4\PAW?!VA%Y
M\I.\DX8D\!6Y$;85NC-OV4\T%I56\DF\!Z4QT,'@60134VD;Q7<4WZ[X,E"$
MTX5P84%V@%]>)1E&%C2P@9@O?$%O#X*^N6QM_]9['<KMDAU?\#6QH,M#CO)^
M9^5]553B ]!H=U#-#4T0N 31Y[<8. .U#'^OIE@;<?JYFV3_R5%<A+<P+4U)
ME*7+%,=G,R279[%JN'/64,"'8,1I4BWZUS+B!4>1[AEK2JQ7KC(85.0,LCLM
M9BR(!'$U(MP;;,5A5<@CR0C.Q:RA*@Q/E.?+*KY1?\[#(_PRWR5<0F=Q=LU5
MD=MO4TDSG312]>K,,G+CF::+%+;"C'G%#(HKO3)!S>]P!O^PKA9-6"X+KF9:
MQN"TG#9+GGED./&XZN(AY6%C,IU<FIR@F:JTB\"_7<^_4A[-KW.ZG!7$9_DT
M74$,-^:J1BWY688_2_./-CX;L/:(9[9Y8E]G<;268#Z>OE6F1)HSAE2CI&V9
M$; 2AZ(T3W_7LY:MMM9'IYETP-//UCWL]PI'"1PEL".!X#!QK2=T7Y)^GP_"
M^R:;877/'Z!3ZE42@M.B59+2GUQ*%%LQ(*2Y2L ;2HB_85%<Y>3;49 S2^I$
M4@BT G(8@VOB5Q&,-Z-_I7DRG39VE@[^RE\3+9%ZPV?1P#3VOG[T\9",AZ1[
M2) 7:=DLJ?@DTYDN-2/E)2Q!%6RT;BQPS0,6UC$R'T5L\\TIU&R6BI(^#"+H
M#]/'F/%38T8+=!@";I3%$M-NODM/&)A4N 7E'477OZ,=V(\=6,(-,96/1TSE
M,*;RP8BIO..GH:.@GOJ=8ZTQ2]2 TF&7Z=-O_GSW#:AXNFA:5PZKOB=4]!7)
M4FW_H'I [/O<UW&R;[H0##NQ-!5T>SG6AHVU\V?;IA4 ]'QD#W*$JROP4!!E
M:49-8^957Z9%4V5K^&6&W"/<%I!TO/KV!+ V$Y7I@_>>HDTN97+:JJ_3(;*=
M#K:P/B8<1^?ORW"/&&+CI/=40<2,T3?6.-*\T:Y[@R@?2'(7.C^ J+BD65G\
M+:87)J<&A/@"0:P&>>MA;D$E&!V J-]4EH&])7U+*<S,75J*.]RPHM^EA[CO
M:P1 I4F[ZVB*?74%QO!=!/ (Y!O/R4:.GF*@M"[Q>#J-FM4,!+W:8*5&&1ME
MK%TBKS1Q7R+6*2/#'T#M^H1HS.B,@M2Y^<"PRU" +'2"_K)(=4\#4 O-"?98
MSZB!9J)M%VJ/!^O[[SN9--H!AJ&7AB_PE-D&OS:WT-V*6#?R[_11#)/S9ZA&
M^VAX* \G0\?PLYVQ?7E!5)."@*Z:%>)\*M?^W9D>_K:';!+1-LR; DO.D"]E
ME98)]D(7Y E/L,)*""+$V56]A)51A9G!Z'523A?1R='10^9?D6O1&._H*6K&
M>:IGZAT_ZRES?R4YTP7BX<//_7QX>AC--'8*H.-[!AXS/.:4<4:G'B4@)B!_
M3LJ#EQGLS:]Y2@2U]3J6/1W3BC:1@HT:1M&U7QVF4W ,#(WJTU$83X7XKUH:
M-L'2KQWS>Y9<&2*XE?:&DEEB.";3(>Z=92*SI*0A=&B(I2K*"Q!'QI)AN5%$
MNRBY5:\C?S1A@R<%$JYN<#HFH:U7*#$& ^!; CO2SS\TO3=<)FMC5>!:0L%G
M!M&8052&?@]KPGXJ)*8>4P%]D^FB^*[]]>[WA,S<W=KC'>HKV/IL0VTV3<EP
ME5J(R6DIKA/2T:WAI.F<>GJ\%2I>(47*9G;//'KP/4V]*DH=V%7".5X63/.'
M'-)5D->*F8A,>)FP9[9&>"^!&!<B*?0U%%2C\R)FDD#=J RW6%3D(?02OWFA
M<UT2?P1VA7;\ ^GVE;NCTJ.6Y8H?S;^8K*3G>O9)AC4LOC"BP)&NDQ@.2NWF
M^E%A%'8T-Q>D5R1U?2;  &>).@/"J\,7;YURXMM[(N_ULLFE>S>PJJ-+LI5+
M4GK[IX)L0,B]TC=(H)\U*N;QJTPF(^Y'3[)!@%BM#\J14DNM:S.-J>V31R]S
M3H!QCVOX_GW(=<4T:QU2=T<AVF)%:UU,&@CDD+FK$H\-86R"+S [S(1Z#I;P
M?L@MZ=LWJS?X(?]:I_9FM<TG8VUSN+;Y<*QMW@V9EYA9>$9&R[2%9:)!.>2$
M"_>6-)<S*C'!U)IP8B9558!7)/!>%S>#;UQ,:F;JDIUGTK%\;7D_PNHI_'4L
M1XZ9RT]/@2O4J#PYWFOIXFG'<_!92LN]ZL4<F(+,N1&=0X^ HR>22R9E6C'K
MNB'KD6&4&- A$+F96A:?0*S'2LTHIC<24PA*DZQ>MR0U]B;(+Z1?-Z252::"
M%[\H$-2;$-L_9O,25-P)#N@E\4@:=-T+!7J[66J)[=TRL$V>D?(8**]*_6\X
M"5,]D-3@),0(/1^%O"/DKD4A2Q/I$T^7JP*SXM0KX?=7($':9<$9ET 9^ZQT
MG+(T'6N<7*<P,#P(:>[)LYHF*!:2(#/SY<M1.8]RVR^W^5JQ_+'72KULE&_O
MRV1TW.91H$:!"F^.3'%YI2MD44=P&T,_\Y;.X@($CP-"-3?# CQ1.&)50N>@
M\(0IDHHY6F;[D-N)364MH&BO5C3LFYXS@!QAPJ)IULF$=B!]9:[7;G"2UN,H
MKU&^>VXNU*N5P;5Q-2K-_]V4KOQ]F1998NA>>[7HN8;3P:Q,H$9W$O>Q \F:
MW^! ,$(V6_.P<>M;*9=EX4B!M4E-8\N$C0V\J_]Z$"UQ^B6"P)#N)$M2'@DK
MC:;)Q052Y]?:5F5E#@*Y9IFMS8:%!)_R5YD,D+TM-QS9]TOWK XC>!C"5?#0
M=-1 4ZQ6GT.0$YW"#8A2#I^'QSV85E^!X[J'3/H>\^3P@?J:#XI?X@>!*R6P
M]Q22+0UQ/66_B-56*RI?KLITB41C=I'X4,(-C,44''SAJCWRC(RRDK$[\OR'
M.Y!*_<9YW( D>LSF]C7K!'E<&M)\DSRNR35P<N!*DS@;<NX>[T5.P)B\'?V(
MKY0PV#I=0,[U&A8XNUA*:G8P?1 D"B*3*%!^HL#"A/R4,%+=97;,=%).4G34
M/6A3@MQ=CD2>>KVF< CKGZ(7Q15VC/"@TYQY*^KDH[C^]HRISAGK=?&]C?)&
M^J*+Q=SRL5<K;]W-4-U34S#WDL'"B \8+1@^,=7?BQ5$(IL8 6/8N1ROA&7,
M"B&*S!V U?U>Z-HENP%7"V&0'=H#?*8+')G-8"N)C&BR%.V[/WG54!7Y(^$V
M8!\J/R-JA[^%E&BQ0#EI#(U=H:)]@[LD:<9^Q*1@*C;8)#USFR";Z:9AX9I'
M1J51_0VU"!EY5#U!>:!_^F)S^H!-+W2* S]&>^D^X^A /)NL%LQSFA,7B!FD
M47K9!8PGZK1NR$T0#]=3P9S$,".6[;#E/UB3F((8G9X--VE7-?82'+&!*B"=
MUL1ON$=C'N=TH ,N'/%O]HD]9YYFWC)[LA^M1[]N73(/;D*KL79).75+U\,F
M9-XB&T/  4=09.:G:;9[A*'4>,_*U<8=+=BXT"/VF53O9K%A-3(W;QL9MD(H
M@OQ^9H5F *70%2FX,747NP?'FA"._J,-3$'J.'K+-2=1>0BU&^E2)=PF/6K$
M42-^88U('YT-:$2RQ@N0&=WF^G+>6BLKJ[;Q'J,![[%]!GA4ISNWE2OK&FR"
M5<!5S CJI#;>KC+TK/8CZ&[UE6@G>I%D\[A'A<N(3W=R>3OP,',.8T'([@K^
M@RHBF2(Q%%@# M'C8,]$M;^*6K#ON_#LERDEJ@D Y&ZY4;E$7>4"-@;;QD9E
M,2J+;U=EP<&B_466^&95EFLTV"CEHY3WUEJV*[6,Y;I1A+HW=_4BXD8E;<1C
M>*YP2L,*DR<UQ7S29A9.9 RF&8_%NB]((W?O:&RU&&ZU>#2V6MSQT_#VNEX"
MU:I!)3@=(6JJ,">,)=E6VT"S$C(Y*:=RNK6O?Y;*S:SB*J]5 ;YM,KQ:N>1Y
M>.-N4!>FKE*;50HU)G.UT5-L7>"(%:6,*HA[)KA#F&*65'X[82Z\6BZ1_^,.
MO.O11[C3/D)=J"G.#B[*E$O#4LNP&8J>DHJMN\#!*E$8/^J,3A:SI,&IRJAO
MW S^LQ-_VUW@<HL:EJCL#3>5B);)3(^^[BC'W9NGN>J4WG"JTQ8EPMB70]LW
MG%Y*3W2[*A@(96PY_&T"<Z#$>+WG_,5$]G9!:@3I(J^0$J7>[HA95&[^;,QY
M%=,1T\5<T9^-<6>6C<I\LM)Y2AP@N9WM?I:8"0QM4VSO:4QWI;IY8;I;^YL2
M<,^;#!R5FGK2\]H+EOC]>LWLAHJEWS>)P_2/:I==C'O C+58^K$T.\SY W_"
M&A.S]]#L5?R %)=^S:F@?UZ3WT$%:.QT(Y2$QYO;^G9EJ^RFZSZOG<8?0,$Y
MS.&LH-0MP=OP&Y7VG^*OU6)/-S_[?=J >1@A:EM3822Y,AQ<?A,QBI66S=3=
MG"Z="N=/<X%AFP8[YGW!.[BK.^>_"\"A&WF7<_=L=^JEQ%Z340DDS2E-QR<>
M%S=+EJ"J*N[#F[6^VRG1;]'1NE<(11^E:^S\6KSR#)/;,E&PVN<'+G+PRQ!\
MQ$JP(L4HQ7L[[% [X64.#YI:-\/@B$*G?MC@872ZZ<TY"I_6.VOUUM+*%NF$
MM!A()RAJU#EE\#@T#S)@);DVP-P&Y.@+VGJSI&'4:%'O@Y8!/ RP!2,#VK!G
MX,F::D^E]YT"0PT=FJ(.ZV35]LO\5XI2@?Q4NB^/P',T\C79042 M]YU0+L.
MTB%'DWW(I3B):;??O*FN]1]82G;1*Q#)_>O9[U>83N$0=;3?FR'FGC?M-&FH
M_,D2#N+'<Z::(V0OEV:=8TE3<1%YP1>G;)?1W$&'"8JSWPTC=> .Z&UMPCD[
M?Y6Q&$EXH-MPD8V]^DV>8>O*GIPUIH>?FT?F8HM[)#3!;(S]30))V[]A6W_B
MPU@G2<4$DA/PH/2E=LZ[;>E784M_4QD,R,V?G)2;,/?+MPGID91EBNG,IA8D
M&-%&9L2T 7K[(^Y3MB987['BU"<.M@!SD*T=HT:VWO^),2;H$S%J!K.S!'8K
MEFE5^91G,]=&QO<DWP>DG/N*<.#&!2I&PLPDF6GT^0G?RMY]O@G"\_#B($ES
MG2*+X67J00H[V_(-(AISQ]M5A6<T#RYZ:>9-1>^R!%7B+:O#G; ))CPY1\<S
M>KOB>39(8;IW<G3\ &16/J%Z/W'T8#\:;8F_A)=Y](\&#C[N38R6(YD5*W*Q
M%EIMW&W8R]CPBN)/] ?3?<<S-B."\TA$Z$:P'Q_QG([#Z->5@.;T[TB.[%,8
MNDNJ<%71=3+@K>J8+T&5*/@L?CXO0.U)WKNI,0U(^!_.'Z$79V]\^%>7C2 /
M/$FF'R_* O;I8%ID1?DCONE:8T@!1HUFW\$&7I1,8;WF#IS*:^VP;P,= D$]
M$Y<Q6""7"#XY.KDG;S94>-Y;A4_P;\#R$QS1&_"D: 5H-_C^I5YBUL][U1"G
M8M,*0I_/F9#7:_OT1<*(B;EBWZ.0A2?A)=M%L=44PYN9XA0T".J%'<T%H5(Y
M19 '6DLTT/!YO!/1BIL_DJN!<0H3.4]P<@F([F629LR%@0:1+C=OZ@;NRWON
MKTXVB")RU9=:IP,YPW/O=0U8_E(3[_7U[0A@3S,)J'<OFTC_<YOCFR%*CD=$
MR3"BY/&(*+E#GM>@8K[E]>RLM?S@JT,&[+/38L8B]JA3<%R>Z2G3UI\\CNG[
M#)MQ5S*QO>UP8GV/H !_4+0=1VLL'UDS1[)>Q<HW *UIA#33PA)7"(\$S;V%
MJ#W!;" :T9),3&'O!6:#,V_\NU(+)W5:XFBYHJSI">G9J0F"R"F07*$LED7-
MC'95,R72"6-S9&3"871*OWNN)V6#MOJ8=N=^#/\X.KX7/WK\*.X8\BMT\K#[
ML[R43@>(4QN*^/O,XPX(S0XL <XV;Y\ZM3X&;MTO*&:N;IB2@)M!QGE#,MM^
M 4EPA4V;CT4-D%_L*"E$#BB!NY?N*WC#1T?X_T=F9()M94//LNIX;1M\36F&
MH9PWN6DS\GY(4J:X.)P%&D>,1\#<<FP2$'!PB34%.\W))YLFU8)A-+JAW))Y
M/(0CV-$.X*^!I8NV\YT]?S':X"^*;Z4VNHUM.!PXY31\@LI2&PX-I@KAQO@T
MIOF1(S+Q5>'IG,(_KXOI1\4Q%_+0S\,4>K^:B\WVU%@;*OE95\DZO,^J1 54
M</T?%1-5#Y+?HV*22?-&%;1'*NDAH5;_/B?=B%H['*1'9C=ZHF\@L['),GKX
M%0O<5H-(%BZ,]6A_6@8"(F%+&B'XE(,%GVN_)ZO7J'*P8=&J=="X8CA+*U#0
M,@?^EM3-H-SOAMH[];J/O-'KZ=^_=-AD8U>OWPF;A"G <R%5.WK[M?LVX^YE
M[%@8VPH>$!F%D)B8337<#$)FP5?Y@^2<V)CZE#!IV+(@*D71M^;,T1 +$KT8
M,;.P]UAP@&=/5RE5$C'K3U^)W=$17@;-0S#<*LP'76M6GY:8$SJ 4S_T#=Z8
M>9(B%*G\",]VB8&7=-D7YBR1(HH=K@P709W<6'>?+N <9KHU$L.J&'F'2PW;
M3._7- -Q[<.L(P%_)B/>*9(7^X1;W@;5N.".I49B-L9BI_!^2"$<JBAE7QOF
MZ9E JQ8^8=*=/"\I^)-Y&Z)=<XVN&.[3O"NP06[.4R[6*^1IP@T2;E%O5%-B
M=:%'M+#N8DQ9XD\I][,)WT(UG-S'2'KG]=89^0A490O=,S40-=!!I2Y'WU&Z
M3$K,F9&-+?4%K\X>N]B^HLS68:6-&B**U'$'GDM/]?'1B:%?9]-%[#<H=.83
M]Y "0Z3!?L3"<MI*A<.7L&AN@QGJ;6['+*'2 -E3.,(*(]89GIR91856"&BI
MK62&]R#1ARTQ\AO;]=\_,4\8/2UF.GBV^T=/3OT_CA*\28([L<5IEJF6 ,#^
MHU=C9R]YL74J4X8(F#2UK<8M4\5,EZ1 +1-4+#.)4/?C=>&_L9T0Z5M5 [2J
M$$7F^4X4G+=N)!/W-&EF*8/V$0<:^1 ]'UJX>KW2UO[%X@<J%UIX)IW)I/AS
M7:L2WG+/W46($^C0713@>-)\.@@^&KC^OAE'U3*UR&2BG*4ZI-&5A*/MQESF
M_:!?BZD#869A=A2""W E:*;GNBQY&I0_02OP6WH.EL*#Y?,[<NM.A!T ,AQ1
MB L8P"21S-"K<-M8C2XQXT(QNE&N%[6+TP\]3Z+G8HB?X?1L'T%F\ J&J'4/
MA%_28;%"L284F)0_1"A;;&$6/V+%'S0@SET,YBT21L5[!';F>+WSM,3ALCE/
M3$7/1[YKSA6/C6=. H4SX:_=E#V?XG12:9,A0&D+_"UV0^F:A4E4.)FD#*+H
M0CZ<#P_YV=1USR:@$\)LSAG!Y^'+Z@6\G(,E2-/"U&1K-X7.H,>)?Z6RC1=N
MI^GK7+_]274G8O"*M=3=B'@$]K&AVIQT-!LC[BF&RACSJ@W'A=MAA0_]$-H;
M\UYPVRIN-5"R7ZB$I117ZYR7Z$;0\3[/O0PJ/74QMU$]7;^"$(I",5U2/LHK
M3",$QSL:$N>8O5>!%/SU%,K@.FY8,CL92V;#);,G8\GLKIV+H=P3^QU;A6]!
MT8<4O\4F>.Y=*TDKP!AV?/(BQUP[C1R'Q\0_RQ7V.PGA6"%NOV2V*#8S<?3^
M_%>3QB5?6AL(OXPPIIXD1C+C9Z0F)<Z57<JF)&U+[]M(S\9POQZ>'WJQ&_I_
M_$QD5V3J], FF.'3&+"*:0;'-Y=>PH'XCK)VDAV'#3RP.ZB"'>20H).@HH'V
MO:OQAU:3X>$,_=&1=5QZTUBUZ<+-UMQV#INBQ(TQQDVDI!1F)$[_< -F8C/]
MXB-W(RQ^:,]],2C:(=&2]TDM&)I8WO%S+&"VM(A/ZCWF\='W?SWC.)3($:$Y
M1 7 2SK-E9_6'(RO)MH##$U\,G[_% G7XU6)"6J>)YZ!L)=%GD[QQ8BH6N&E
M7 Q"CTQJ4^2N)=US(V'BA7IBZ<>W<R_%2<$X,V)2/(ZY2$ZD.L&\QK.F>" H
M-X6Y[</H-,P)^P?-;1;'H/-20,W4[D3/(;%]X,S#%>)N!256F.2%]TTEP59\
MF^LZ*&&Y$)[2$?@5.@YV3Y=Z"B<CK98=\D],0WF7&L^-G)L/H'>JN2Z33A+T
M+:H\19IFLJ:0@*,L$ ^*-I'20Q-"<18TL\E,>X^&R40VO77 7*?U0GYM3'$N
M'1!D$9&[N\VYRCK96&4TI!7%$!/N4ZSM0V6WF#W<]3?MPF7416?D%5"7N7OG
M+Z5@?:G90_)";#[=$I-:1DYMK^*GD5OCQ*A?PIN4F\SG(&P8=<+I!PV)@:@4
M8_WDA.0O%CISP_%,3)S8A(<-1KVE=K2Z=58PX*9X'5=1:]&]> T57L.&LENG
M<+@)!NZ2"_E\A UVTLOJK[0+T)9< X;N5 *CIOV^)!#H9;?J;O8AIGJ4\#FX
MIY>-I*C>HC-LDK*;_B!:9OD2SZ'_A K_SIR['3A]+WGZ@#U6W7,TTTG-YD]C
M6IE;0RM1RK'T7H='TV6(6E?Q/'-/X$5$U)YQ. 1F+GFKI+I.OO>]S)770]52
M$:("6!(W'FSU)0ZV+-1\VX_PO'WAEJF+!FZ;XEOE9FJ"&*U58J9M4'0T%8<>
M+\/FA[INQ;]P1W*""_E/@PVP]')@*]):ZG15X*S)ZRAR3O6U]4[K$6/5T3O6
M?GY%K1-UM8[RM4Z.;8'F=;)FZ+XIUDJ^/!@&9331\FW7*=A1SIB\U0>T22*5
M5N*4W:_X9GHL^FP]ALBLSH%5O8:OVM[R80K4(>5H%1)W$Y>"B;)[Z/;MRO;9
M>OI]%IM,YM[50I.G)2\"D0_R2O?;>]J*A3LO-MQS]<7W?%=LQ[?VV?Y98(9>
MO:?,D.>GG?U.,5,[R&EGFRP"2&1 ?  \?@27M$JNDAD0CH.BS62&MU+!,(5U
MSXE+7*Q=FY$R]#,"JYPU^"'4T_17IP_\FNPJ21D[%8;-RH;-HL1L>8OQ6Z7&
M<3I1^"B\W,/HMT_;M5515:B84:;3?,JY,_0:BZL<#,@B79D;]23]P@*U-2R7
MA65RF&I,"AF&$*JX>GF!O]Z)^%)%D'MC$62P"'+O:"R"W+5S,6 IGAG%X5F)
M7T1_*9,_&]!T#@4$6IL@^J05VQK)%28"*J9NJLTY8V$VLU,-X?NS>\F%@ K\
MYCJ6'\RM8X0.3/P@P[8(5.D2? K)^"0F0\1/T\)*F)OCFDTRM@!-G#+8I7]E
M9@LCLX58O7%6U.\RZ-DS2\K5_SEE/X=EA,LD0XLRHMVN35<*"C?(6[4#;'Z+
M(DXE3BFL=/A+_L')&+R49 4Q7);^(1F@0.J(\2/#/*,E4@Q=)!L:&)O?Q;/T
M ^$X,T[DD ONNI(8M).69X_:P4GQ#KEVDVA@4\P&Y&MEJ)T9J)PS< _<)PJ:
M9KC3%+[XN&/^-<U7JUT'!>&]\-&]L[>AA8(.E@M*E'&GJ.OHFLMZOF0WKJ%+
MR#5:9925*9>&WNC:^)%[Z>6^&D2P>7,U#2@FR%D(LYN'K^>L=Q,&U+TKOMSW
M,(DE/S!A$7F&-+[Y"@-P%#!R"_LJ0!B\81Q-+UL4#W'?$5@HE,-8T.FD=?R_
M5PT$J9>,Q"I712FI8 Y0;61JL#RMTB>9AK5,Z1#_W^01D-';U\!8":<VLTMI
M,Q-2/[\[@A^+R<8IV%2MV9SAR7',X"RB.+DI1$P1[XU4HD"A.S'UJ<4X9'"R
MSQ$J%G)1XY'A4WRH\-NU,!^R8-TT'WP8M;/I2:M.,I<:EK,7N+%9%G !QJJ[
M&_AR[=U#=1#J "\"2KSN#H-JZRNT!T*,I*\ND2SH,+=IU&ME S\NC@>=B.Y8
M@DW!;B_SH/)ANQ]N#ZT4#S;>_/5BH>URRDM=7L@L.! "#$7ZS!1W7E5)QB\<
MS4G!I'G8G)P2O17_MM>Z>;X7Z2UJ8I+S[?E@TE:96 >-.UI:@]UB&5R7\PAY
MEE\$(J?^P@>:P+(4S*1YQ!)\J0J>N6'+'>HN?V%X0Y^U6C1D?U>AQP//_0X)
M42Y>$M##752F&<@Q5*UCZ"4Z8K*L-R\LT6MK&Q?KY\)[:):<T'-#/*E5GA,(
MW!5.8F'5/FT1&60> 99)W[C)$6+QO:C%;/1\7VY:A3>M?(N5[!L-K?Q<C\V0
M"KR@/[V>5$878DT$C$Z8Q'$V+H##YZYC3.3'F'/XITEV.G]DLB]]R_Z-$1A!
M ^))-=M^V[:-I6]PL8!VBR7-WR&VV"GFU:S5Y$2JDQQW>- UTR6/7+P6*UXQ
MK,D<F7#0,[[8Z7Y(".L\'[$+H2;W<.I".@M>8S%CC%M1>HGJ>)OU\5D97.)M
MZ>]OR3-G('>'(YW'=W]_ZU%SW&/RB6,B2%LD,W6?4%('U$9DD8J'4<]W3LQW
MHGM;?^?>QJ_ 1UCI%4M%- 8>(7^'C/]'LA)/%ZF>1V>6J/<M$_52\1#/.O:@
MN\\]MT-RS.=0O_#?/NCI(@>OX@*91^7/(X\&+>$-%DN+D"G9H5@=:;\A.T[1
MT<=>7YU; N()U;>X-:;THT+PY!"XAR]O NM+4HK[7%?V8?2;#FE'B00VS:E7
MBXA+#2UYQ;3&9*;F(47,8?2BN,*T V'>F&>/20'+(#-E9BD8)CY>.&*L,"-Q
MT<B-&'J<2'##'^*QO@@@UKA[JFPR&GV *OI*8^6MLI>W].@5=XIMWH)6/W53
MX;Y=IF7=2"FYUGG%WI3L/Q%>I&1_X7?$.2]I07&7W',9FV&>&)_L93X#>>"6
MH3/PG8KE6A(B5#V&U9C*8CCU@I^H3<]#3G'$?';H>ZR%K;"VGD3"HL&O%ZM/
MB![#9,9U6_/5;1<G_6_9=-F;WJRT<G\LK0R75H['TLJ7$77ZGR1*9__]7?+_
M'QT?H9@F?__:*_KY[,W9\Y=/7YZ^BM[^]N;L_?F+E^^BM\^C=^]?OGGZ\AW\
M^OS%Z?NS%V]?/8,_JM,WSZ+7IV].?SE[??;FPZV>V5M1%#T$;5X?(QD*3 98
M&!%U1\O(0(POF6,)F:K)&[(E<R5VL\-^%3*6G3QDRC*P'3_>UC-^RWEI<"PW
MCTS[3DYN_X2TWMEE_#0XFVOHFR?]7_VJ ]3,8OY.O;6,Q*,8%O-NA*BPF>F9
M_!EN\#$'"7+C*(3?I2U@^&W'V\7-S#0JPV>F#>ALJI\B;Z-HAMDGO(J;;/XV
MG_W[MU[3K4C ACEZ7U4H>V>UQ0/S6#JS&>W[^*I#HO\\JFE[3?3MQ>Y+KL"+
M$4,AHW7T#/XA0!XIP</KY>T+2=M.!/^";236^QF6VH7&NRAJ".&T3*E"^*S@
MJUO1NLT2F^Q GBP->M9\B^&/5(>_+&R]-Z4,,4>7$+R7'62+K<UA&01,C!"3
M.[N#HT&N7%YT&4?<O8N4!YY/Y"J7)KAV4#\[ NS7=ID GQY+H.!UQ4Q%X6ZL
MR.#9(@V<_A*_#,\[_:&(SJ?I.82^T^A5/3M$3RIZGS19]!LL6.<375Y$YS4$
MN#6\0GKN4_B'SJ+3R_0RCAX^>73\Y/BAQ.M> /P5W=I/*+W=2/=)H(G!?K*J
MX)":?P7*CH_Q-H]TG5KD *VK&:\+>$617&E$!N!ELAEY_"]$M <<G)8W_2.'
M!D.6/KQZGWJ&W4$-]-_?G7S7IR[M._N4IWEC6#K_-BE_^+M=.O_$Z^=__^R=
M,ODL';6]X_W>9Q,QL,NYCP%SWW96S<H^-?Y[T/?:M!_7/WMO\/;%[ L(Q3OI
M&3=;^92P-7LG^_SZ>WSNF_F5_&Q]1[.\F.R='-V/3^X]CD\>/-CO"GIW+/._
M3J.7+Z-W;^+HU8=GA_02]N[M;_L&!B^[Y8<):O/=WQ\\B$^>W-M>?+:ZWU==
M\.'1PRTO_/WGO]??6.5^TD-\S5W8\.G=?&V?>NFO?"K;FW7,&-#NDG!N@:^J
MZ!,S;+(@A^9'QJRE.0C+6^O @D?US$(I#/4(9N'!4(F7\Z-52P,&JG>%-Q*
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MA*_0=/H*9Y#SK,CO@RY21:+VMZ_10]K7U#F*V>V(&;7"?0M!^[G5B$K3,-*
M*3 @AW(LD&63.7;%\[.G9. NX'(E==/RW SXA+3I$HGV-5VZPJR<ZNI0M7E%
MF+D+.4L*.S]0&,:R=3"D"@=\>C_*D**'1]$L67=G5+G.8B(51[*H64""/2?"
MKN6JJ0VQLXQX1:(=N9K,H3)4\]P3;!^&R.1-"TWW#M%U=T!*<.&:I/L<1GV=
MUI.U[;1F#@2?JZQ8+IN<:* -6R41>C%MN3_SRCU-T'ZM>8\4,T9_F1YL7/YP
M _8=TWJWO(P;\GT]&/F^AOF^3D:^K]$7V"5?X.0;^0(? LMCM72I'1?&<7ST
MY&'\\-&C#N^7,$DB+TI >-VB SMA.K X6F5-U;E(GY$G-LFD1!+J&UE\=:W%
MC[T9AY]@EK<S_.KS#'\4&/Y;LXEW]Z1OSOEL9CGZZC1JS).P,P1:_SIEEO-Y
M0YSLR)=,_M>_BO+C99K!"SV=7:859J]^R8I)DL71JW?$\>8^\>K=X?#GHY<O
MX2NOGK:_@[])F7/^%XX8P"*7M3"_A1<_I:E]UK><Z:F0Q^+I@2? \[5,9CI<
M.-S"<NJ$+:6O\3GQO+TFRN@X>ET>PB_+C]%I?J&SXC!"/3AI*IP>X AY<%VT
M7<='QR?1^:J$2\S1!D>GESIO0)F\QL$829KCO>+HS3^BHT='3TZVX( :C^UM
M&&CJAMW"GKXT@>N]^T===DMDL!;#!#9JU933!=C&Z,F3AYV(E4;;](QJ^:_C
MAT_<?!4:-H-[S\,=4!BY$QIM2M5[LY.C[L)XDDZIE3>AMR?\/70WL,?#W(*B
M.EJQG3=L;.8_DIS,]SVRWH\YODPB3H"CU8=WAC;+/*P*'O9PT%Z-DG_'7-,'
MW\@U-8=2G3RXR9GL?O93SR3W_ 9G4FU[)J-MSB3=X!/.I-KV3$;M,[G9E>P<
M37O@QC/U9<_4PV]]IK[LX8D'#^3#'GL:7-(S&P_B^_#Q32>2VV8_S4I>=R*5
MO<%G6$E<S=MI72!)WO$1_>[)34[I_9.3\93NS"E]M(NG=/LS^N;E>?3H47QR
M_SC:HW&BOZ=+$-ML'?W7R5'\^-'#??\$]]WKWF-[,W6=0G@0/[Q_M(U*^ P;
MK0*-@'VN08_KUU$,G?O8V;%;Z >;!3MF4OR'GZLA3HX>C1IB9S3$XQMI"!MF
M]HGH\:/MCH7J<5W/A!4];-2,(]=]A:D*UU(11PXGC:+GX1^'S]"]CANNMCY"
M'^P(P2\:<X8[,AQS_C4&CPY7#B<XC?LIC>[$\G'TSJ:<U5N+ )BLH]?)OT$0
MSCUF:YS7?:M3\79E,V]4"_M0*&1RQD$7F9Y=H#7E6::(YL$9C&DUS8JJ55GG
M6<PQ3[F@S^/LC/RB<H +@[' ?Y_F.0[K?:]715G'//F9QF%--!SXO*"Q6#3O
M/*]5.*?5+S'8][W 1*8,WE[2B_<HS7%<MBU0)!42M9=:1VN=E+<X]'Y7A.&:
MD_5/1D2\1RUU^R<FD-1[1X=<K-^1G;O1,7I3J(X@5E&65J3[!89",T[)A@@0
MA:"A50=Z I*;=D<568LU2^=S3;,*:=8XRGEP/9IU1(=RX>C;>^C:=^ P?(O!
MJ=>>B??(-SR+7HQF9'OY/R6ILR'#(U,W9U5/,T]/[OGR6/(F]TMF'#WF>:E8
M[V:G"^=[X6G"X9IVZ@2;B%_S%$_9>0VNV"T*]2X!L3[/!5CH2JN\X9&TQB>V
M@TX3Z0"@O<[-% 5_"%9+S0AJ+D<,);RDODLQDH_P!]WKJ/_'WILVQVTD?\+O
MZU,@O']MD!$0S4/487D<04N4S7ED24O2XYU7&V WFL0(W>  :-*<3__D696%
MHTEY=% B-V+_8S6[@3JRLO+XY2\Y 9J"58#(ICGA"NCUC?;E9HDB,R#($A@$
M)W7UGD:B9LFB0E3HK14+5C@J'+=%T5BC&P_9"WAM795N#V$MW*3X"]L*7_-Q
M^R/W()L)+VR9BS7;:^Z>JI6+:#UX9W**_847!"T &9<_+K)VB: $;'R;G\)_
M*"0V]\#;)F^E9R*>O&+!+:%8._-HDLSL;M3XCM7P9;4LL2-QLRQ; EDGP5"7
M>9#3CT#>AE")+3G'GZF3[1<7AFN'\8$@V,?W(-AQ$.S./0CV4YV*:=0&=WOK
M\[3!/=Q_O7>\_S)YMW=X_,_D^'#OS='>B^.#MV^./LTE\YFO")KC/O4-)]V]
MYUN@?^$[]!9<E7@CLI%/XD"1)KAX+NNB;?.%R\.JF<;QY#)CVE,9B3D6]1=8
MB3E2.T0\:A[I//DHXF3EER%XS::I&1Y>B(BM2R8P;UBJ^LKVD0^MBA?5 A&U
M>2MY(?C=C+!_,$"L?X%GFWY^CF+*#0;+V *8$=1P0<'I#7!8+_,+G! :ZCG^
M;)*# M4'D?D>O<^.:9Y=88O!LIB3,T6-=DRI#1;@4"P</ 4S3S0=N/**O@3V
M2%XP CC#JIWE.;QDAR/IDGK"N#?8*;*[: 7!4G;RY9=#\M#9?$>-"7L5RK29
M6L6,"8!FF2THJ")6C#R:GD9]$5$6YPN0S20/NSF'H5,1$.BH&G<RR>:(E^2(
M9L4K_"=,H'7:"[+!Q>/E1AD))MX%S0&6)BZN]B75("9@O2UP%1CC&1RI?(%K
MQ5!7/@'PU!Q.5(&KC8C2DVJQ;/*&5P-#G(('Y8_I^^?9%6T.;<8\S[F^C8JM
M8.%X,"V<7&RK[6-,:"_"D*\[4Y2;O2 @/49XRRLG/^IW%Y!GETU%#V]UE/[=
M.)T5[]L +9,G*$7;F\]?H! O&CH5#Q.C6'%0H(TNX!>-V^OHB]XS22BWMYYS
M 5K.W9VG>3.I"\GXP S B%Z6YYSMX<HQ%A@L9*//S'$PPA?OLO.['-O9(%D'
M+8C;XPV=VD'G\78-4S]PUEH\<7!O91Y?TLO]$C?J6]FESWB)WHH+\X@"(WA8
M\#_.(ZWI3K'V)!\&, S$VJAX!3[.5992+[0IG DZ2MI(5H1:=6*WSS <48SH
M\(OM-8&7BUR)6)R;PWV==2\@4D_ZY'D..@&OYLF_E_!WGB"6G[#+"2]6E[.%
MV3;91*[ /_3XGO!<92CG989OH#L-C[@<M>W-[1U>A<3G$A_NPQOAZCI8H'6*
MNN(=_GA#-<4!7Z1<^@/OI/1CWEYB(FO)R\-Y[\Z]5-4N"Q<35A/PM0D[E:J?
M3@4V&2CN9 TS;_E,"YHIQ)_!Q;G4_':"4S*J9]V@8%2'8Q$"_/ZR*,M0Z>SJ
M?(XK;%/>^-YG4GZ4S5I,SN,^Z@@+*N6Y4XH%[I<YK@^8B5_$5/_"D<&A3<"(
M8 D&!HC$E =T5R1B> AO%UB& \>$<QW;I( CBQ5/[8L*"]A9V7E)8FO$KV8*
MF@&M<@SEP<ED0_4:AR09<D@,]IN_ZDN)V%SP,-%!9\G=P%FB"R'G,DG3?M/>
M &!%D47S:.-G;]/\K.5);R_P0LDO'R8H3M@+^T0BG9TU00D3E4N4!NH<9*5U
MB,#]6R1OP "EI,26W0FNP8*M^)^MC=UD#CJPH.;HX142N%SDD_#^@DRR MTO
MN#1/P/G!B>:()W 5Z^$W63/-_IV\R,Z+%KZ%I5C8T)Q4JEQ/..#MG<WTR>-G
MQ&4 OY2T!5Q<8=M#7@0M\F<;.SL/U$^S99?T4[@7Z'W./H'<IE"L"K<931UL
M<?!5)NC>X%40)CPK2OH0X1#^YL699BW9SNSM\2U""1;^ 9CTX1F*[W"_'[T[
M?LM\4.CLJ3%0+4XK'/7$;BX[)4.OJ?,9WLD5^$H7>4E\#W61MS@?6+D3N7YH
MX<HK$+Y3V)%L4J#(Y>W959G-,5/DSINBK"97)Q+83MZD;QY.X9CC5]KZZKS-
M, W$%CF>B_T]/ DJ4N45[=^JE81Y7CM+USG6?W7E%4%#*YR2-"T7Q;^7>6])
M9LMVB1Y><S4YRZ?@&$X>4NVS0W6",;_FHZS\3OH(7%-<2[ BID7UYQ6N;#8_
M/\MY8=/DX*0ZS72)_S_YF+U2FH]?]8[$/K*K1,XA+]70B(/]]N[%,2T+N]UV
MN!M\,\!;_KY<Y+R3KG\F+GF@1JQ1W(EZ9#%=3BB-T2ZG5TE^D97+C%WF96U?
M!99GGG&1)WFN)Z!JVRMZ+*P." 4JC^9J,:VK.04XW-[R%"X4D:ZN;&0#4]8Y
MFE?!;DROFO>H38LL3;)H1%KE'<0AF5<EJ'>P\78>\@[BSL'3SXI%!1N$H]5M
M\7J4!P@F(/C0S6Q92M)'=$)824*?P+CK_&%;H\:$(=057C=P_;2@?16%E>-=
MD4U\%&IP%5&SP5#XHMK?.\"GR:*FF-!"I<_*Z.]5DY^?)<?9/ !@?@69@AO^
M]P5<9'4C$:^_Y_6RR<I\SJ= IQ%(:#1V@Q %U&1X04Q@0$WNQ.H.6PD'9$(5
MMKAE\+.398W*!IZ* B.7"VP>QM9R$0-8$\3<BK?NOTEN?S8_69;FZLO@GIG0
MDEU4)9;FP@%!O^8")G.'S.]1X_-=55[5Q7^JQ1<W/CMV^9>V0:^2G:V^">J\
M">H7+HD-KHXYZK^V<8V=>+.@.AF*C2/[(+B]"_N:FYF*R9BM& F$NN<K;,7[
M,_33WT$3^T#\SS5L8//%9?@6K$SD1.R.G:4L*?.V9? 3?. /SL"BIFA*P 68
M@0?1L#$7?>OO8#RVR3_@$4NL@7AK;2(N(-@9="?='WE9+ND('&7(7Q$?X>@=
MOS+)"U]8@V/L94?2A*_#!!'?9/*HCXL%#3PJ^R07WH%QNEIM@F63[#[A(!T[
M/VTU>8__/IH41V!&3Y(WR[;.)OF2:F1@*/F_$1^.BQP5>V7)HV</:+'A[B;4
M">JCR[,J\*\AVJ28%K!TJ1M]/+O4\ ,F\?"K2&RPQ[\Q$RRO"]O;8%=EL'%@
M#:+_7'OSZG^V@S,9):TT*80_<_'/.+#)*TJ["LHP+RYTL0:V!@T1H\0T]329
MX/]Z)AX)E?K8+A=:95,4=8I7.0I2:I8+\X15S0;J956_)_>%G4K/+!1^ZPTA
M!O!W7H*XH[@J[]'39^G.SJ:8WZ]@@ZI+,?^<EZ99O/I=&1Z0-J9E9,X^%!(T
M[&!UR<8+!N^,KQ_\%BT56JIHEEY@P+2\TNCU%$O@1V2$EK2_+#EA$CN3W=T:
M]-/E5]=*NW=17#?ZL&IUNF<S'1&<Z>@,XVPJR3:8PQC9R,)+Q.$(H_@M)!_#
M3JE?XEU9G*[D"AHRT0?&IC\RZ4QM18Y?X# /."R+]@P6>99KT6"ZN;FY,3Q;
M]!?]:<I @, 3@1N!RTE@2SC!V%%J8MG+J:+ZSRU^QW&D80=G7I#MGI.MSIIB
M07XIA^K!32DJ2GO2,,@)X+QZB/;WDN2T]7&2W&73"\H5#J;'K=[^,)$!>28G
MNJVJ]^CB4F3)AZUZ=XC3F\)')=%O5E6__>A)^FAK%T1&\DDAQC4FFH.?Z_-V
M'F^FV\^>C$'"T2.C>,($]=!9=B%:(3L]13Q%BQF2<BE"\_0IL:&K.'..9U\F
MRMY@0#++N'4=IN0+PI&9+%E]>CHY5&9:QZ?2Y,M;\3VZ E&D4.4>MAC/G%K1
M<#9);5#6)6<5(C\$[[R>VB\DQ1Q\WX+5#P$HG-XW,@Q"6K)B^4BH&"&\@C4I
MP(+VNO9$$_L^Y@N..[_8[BY_HO)##L4<M..5C4Y?_V@?M8XK0$%+Y+IY^"#Z
MH;,_3)D'L *!#@\K%JO'2>E#UO=PQR^J&F\;;WS X[<VMAZA.3(DQ[?3O5B)
M,'URCS =1Y@^ND>8?@J!C-&E6]N?!UWZ<O_HQ>'!.\23)F]?)4>_[AWN)R_V
MWAT<[[W^'(E5,Y0O4.XVM#]X \Z\E6X@3\X:KJ_;Z8:GE%DSR(D7G*Z4J,MZ
MG*,BK6V0':+>X8C!&*82"FU:NELSI$D09O:L:2JX@V@4]F5[\AW_-@*H+><P
M]T+P:].*P'9@&6&%,1I&)Q1F/@>7_=-7('R1^ ;#IJDH3AQ-L6AH]7$AFD!X
M+_OU36"I1V(X8 ?4 ZM!6%%<@H.FSO*R2'3)R'K@=2F($!C\NH<[NT^W'N\^
MW 8+:EGK*L;U,Q*$4*$D.ZD" ^XTXUH8S.*7V27F3>Y@^)ZD$N]6!HJ5&7.1
M!I+ANP;50SG*ENT96)/_P7!5E,RG0%'3TA(]V44G%/]_<'W8GV!26<T\FXA#
M%\E'R&:B5 !7J)AB6PNBN69K&"02O8>L8!6\J!8/87?RAC!@=TU$WZ&/?$[>
M4"W<!W=/+GN</8Q9=^"-P^HPSP>FY07*;CITH)([[RSAMRE"K- 09#JST8)O
M_"8UNJ)+G(32(.SY<-N9JGS,M-F0UPSD Q[2RMK5OJK$7I\I?%9BNH]A#K+,
M14,68EU,",A<HS5Y5IP4;50HBYCZMEY*J"LJ5=' C^_ZDTE8U@>[*@UIF;@-
M3DTH.RAH4V=3"18%ZAGX7%L$D4+N\2C#^%"U*O*.WLZV!TZ+*^O]U,1>N,05
MNXKM"ID!-;[1MD6MD$WQ\RQNV+1#.J&"8$H=T"\U44#9 [*8%2&<>CX2O#12
MKNIM]"67F33%X;=]P\?[=:%E4J#:9LN:J[#%F9ED9?FM'_>!R!L<8C?/WH.,
M,,8&X]D8<X3_31D>3@M#39U:.O)X9R0S^ <EO"(>G%YO)9!Y<.#@[).*Z376
M$G.&69X<MZF(GD<G5XZ3UC=1\?FL^!-35@5"KHXZOR/&*:R&R*XZ&0 LF[NB
M"25-Q?3\-(FS8DY')*^_8>G?+R4'9??_&Q;XWP<NH>$H<C)'O)X8Z72+M$F9
M!TJQM9UU,:7A!%0(($32-&+\2]:>KMMPM$]DPG_.XA9FEQ65$M:8Z@U!=?@*
M@@08>EKGDB,)$,C@N;Z&ZV[WR>ZSAUO/GCT;B-+(=S1Z JYM('BCPI_>RY.U
M@KJYK*<NJN\1]BG*I2HF =>!W+Q<CCG<'Z>G9!#0'Q]B42*EOQJIE_5.87BN
M^D$I3G8!/\#<?Y. \]U@I6-*C%8+38S(;=A6J)Y#&B=^7%NTH4\-0JSKH00#
MN%8M9Y6X@%'K9$*=I*&T$>V34C@A]Z<&XPX/\Z%#9")L7##J62-U"K L] I*
MNOC6/_[W] $(W<"2%8TD3#O/H._3FT(BBI=M9(9AC*1G1^8E.I^>3A?"]N;V
M)G&(4,$0I1I7K>/0;!<(XECD0[.CFB6>A4B-_BU5FD]^" (B2D[,W7@#?4:.
M1-/G-K'1$BM['JDN(IYP?HWYAJ!CN91KNBP)$,$'-G76I,T7B-!&OV%I9N$?
MCK)>Y'4OIQL?;[J,"&\PX992+"QJV>47;&C6:DS7^1RK<AWME*P4VLUHNGHQ
M,ZQ-7J\]WGT0'R^Q=;E%XM!:TJU[@T5W WTY\3N#46%5S-_FK?LAF+T/R^@]
MO<_HC6?T=N\S>E_Y:7C%KEG*0P'MP?]AU0Q_HK0$+EL(10$I)W3]BV:>-,6\
M*+.:"1["QW)U4D!60$(O<_"_T>KAOE\M*F8FY\I1,2MP3NPS!NZ!NB7(,=-\
MHKIU(^B&-=#)3X+&95!#LTY^> =7Z&<QI(,Q)5%/N9J']"E?-B$%=^?U:(2?
M0N/6[T)@Q)=K,I]4.(2+#,F(4RGVQI)I,I$0XX8)4^LG4RUZL5B2@YQ-6HWJ
MP/@7:!HI_-"7FQBCE:)/W8<ZV%VP?]"M0$H6MB6R1? Z-K0,W8"8Y"$OC868
ME'1MRV^14W8.TYA3I8XT3V:>CNA]YPA5:UN&2\)T(D9HC_R3U!A7XH/]06BL
M(4/ I!]]*GG0&C./%%N*GNEQL.YEL-I?5;4/U!B,OQJ\WHAEJV*N)R=L6Q.X
M1)1_P[!L'#'QBD$ ]M@VMK:?O]APO'SO:LST37R&>FS:8J+61(.-8WV%(=/M
MS8>O[M !E?KZ1<OEN;I5MRO_,KAT?SGH,11QD N&3'<.4$]Z:S(:EX ?8Z4R
M<K/7N;!_H,>DQ#I8Y,<X5(4Q&J<3+Z7&4[.SD@I>$.L[,.Z66HT*SSTA.#56
M*K-6&/("\(>=XT^XU3!+4G_5<+AQ6N4<S6./:LE\4BT&X]XC^^\T-VP4<'0X
M* BGOA7"JT7'==9QTUI*V@"[^-:9Y<.*W!M?CHWNR."$<)FDARZQ;SJ$A3.D
M7I,"'044!1MNCWQ__,:%S%?QDH)#"W;GR@*LHBGO6/UY".9OG^7Q1R[!\4F)
M=F0F\;,%G2,\5Q@ %R-O-5T["5]=X=T1#,.BUL YVIO^3&)1SD;R^W"T,/5C
M0 W2UL4)GW7'G:7YH/&160'+%<B5F+X](]6GU6R8P=-<F A)YY)T(X@PM:+8
M&+DLFIPQ.CY?UAF/C?O;<67#DP^8M2G'T-SP&FER,UZF8:7VZ<[[[1/S=V/Q
M*T<"Q[K9+C?G7M!&%<9!^>$IUH.S20M76T8KG&?U@LK,,'"F_WTJ'AFL^46N
MY2A<\D,Q=>KWD4K,":M<Y-ZBNZ+$8!=^.[_D!'.VG-(H,'2,@0UZ\,RCXBDN
M->?*]KXY'WJUYX._T4P5Y@@<F=%-\2=7NC3"ARBSMT^RZT69VDM1)?IY[D59
M4KIR!/"RDA1=#9.JBXQCK11SF\ :M$Y/!-W0OJJ".2]J"<UZ/P '9UYJ3E Q
M&[O/U;R@U_5R'O[T-,Z4X-,J)5AU5O'U#YLQR>L%3^X\N[(U0WX,=-'CSN,?
M8>\IYHG,@,WL2FD;R*GG>A%*[<,MG],;JA.0[4RT'^FC*_$ D^GR$X*B;M$!
MWGZZL;/+K?MBBQ07SESAJ1-J,%K:S)LWEO02"33J'$X2>5$4WFV:O W66!"C
MOWKI.;[T.C?=,8;FR<:@%-)E#J_C_>1/\652*!8.3:K*G*D7PHU'#'HXH',B
M26$ZUB!Q5>TB729=7/KSR0P 4MH6X!&,GJH_1A'7X02XH'@)S//R2<3Q"["F
M7V-#:IF64OQ]4JOQ=G9F&$'L"U<_IX#:$H%&"FMVDA>Z\L2(BC)B"#XBM5";
M8_)%<FUZ=52+X18L1'B23YM LH)<*MU2M]I42-6NDKK&*[[WB%UH$ L5<1YV
ML!V5 /P);?@7($SN;D&8/ETZZ=E].FD\G?3X/IWTU9P&5>?'V9\9!QL_JT+_
M$K,].#K<VW]]D!SO_=_DQ=LW1P<O]P_WJ*%"LO?F9?++VW_L'[[Y;?_-L7MW
M^/:7P[W?CCXGB_(MD(F;U,45Q%X4%\=QT)3<JM(7%14+\AG:[$^N\69EX(&[
M!CX\W(DOB=]+Q :^AT T!$PG^M?7>9E?H*W:K[83(V%HA B:GA!QH %-$_>=
M+X9:^&M:L)EDL$[H:QAY9@($I,1<XN M(;YQBXMFLFR('@(6TE?1+V#/<!@E
M0L>5 4TZO362A (7W50;_ N<<W*IB=P)<UA<Y761L_%QCI$"]E'8DYR BWW"
M38T:I5WWP\)WBXE-3@OY)LA*?<Y_QZ  L@%@,-CT/;6S622PP4U@MHQGBB44
M1! TI=(;3,>>4?,D2;"UV7LT56"RW*V)\>VSO!%22!K@E'BWB6^^D1[%9QE*
M+C=0PWR=PN.\V'G.F?N$[WA]JRRG;I"0/C)>,)<0)5:-PMIGY553-+K<O</-
M'. (;JNZIQQ!DPWL3Z%>\M"A=[9;L<J(T+)(;)>:<(DX- )MQ)"(A]0-*YR"
MN44*3/V >0U3X^-A?6,,P\+/7?1S[X9F-?:H#G!3+4,@Y#::UVE25A/DR-'.
M9+[E'CP4A_>O)3QBR@[('1)'-35^D<Q1P(N \9$<>=7K5>RW;8N,P#'D4E+'
M,%P]E(/P9/7V$ICXA00!2XT3+&J]%I]OFUF4?:[!9]_A9W33\4VXX1F<3^F2
M!4$G%B$J+W(C [RRGBD=>SR;K0\^9]0$.QXJ#4QS,?K<SOW'1*Z^ZY^&RSR1
M&*/ X5)3R,+(\!1_4,RH*"/'T!LB;#4VK0KQAV2M6,>O(-,-KH>,=QK$\CD>
MZ+6B6'<<QI4&?U3>9?F;T!HX4<Y&IA/B!O?F67?P^./]L[_ Z+=9J\.\R9'@
M+$U>YA=Y69T3[RVN:6!SGZ!5N5A4%YEGBJ7J]<447@!W!Z53=I\\>O1PZ]G3
M1[<B,G4+%,J/S3EF5<+K'LZR>5%>_;#ZA0+-8'X O^B\QK5L%B<[PWZAK79:
M9W.M0N)LRWD^*68%)I TY:*5L[Y%$B$0D!$1DRK^3!X<[$5=G0C53P%HNF^Y
M#=7NI@<)PL-0^7BM!G8JDD?AG4+7>S]_ZR?BWRU&J5%CF.:E/KPM5CU.WCN^
M^0,DA$/B1))\F=5@-VTD>UXIDM4@X75T5_C+/FP(4Z0PG?X!OEF<%U2UB>0)
M5^<H]*#(?96+U&C5U556HHGN_*,HS0.FM\G^]:*3L$+(L]P(^(LYO#PYG>PD
M6N:$>:GP1X1_(7YW@\/G,3=$\8PF&3A_S/>\6BZ2V9+L2EE]F+Q-Q-?Y*=ED
MLMH-+W<C.$.=<!+?@H2QKZ7SC=O9 &E H=A@J?!KXFLAM-X%98N7G IJ$6J
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MV4FCU4ST;7Y0B@K#)/SI3]$H]*ZX0Z;E^(Y1=:4W*+P=@] ;Y4A5D)9H2QC
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MX,W*AB/7:@%.B6"29NKKHFML_]#6F85X&15%AA%<Y]7I@CJ!-FT%+IJZ[.D
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MH3%F[7L1[D]L.1M1]$H?9!O13?,Y=@?V?<="570WV,F3*>KX3L7B%DJVT\V
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M:2,3'6-7P.R04K("/93!,91A3^A4OO]9$4#E]^\\ET2H([X964/*84\4V+
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M!,<T(EH)LC82>7,"[>%VNHK:D:!<ZPGA:NU:!=_C0%#4PUT?B3-DR+])GUR
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M XQOH01L'P2+]3O4KTV#)G2#4KFU7M!#<>).U'$D6)QJ6PTB">>0X7/&L(1
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M3I?L*47KO4%&*93\SW,F^88?BC&&/OY9MC@E.N.3?)'#2J"?"3XPS."LH+B
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M>Y'HO22<UKDB)P\YO0/:[YU &OGM1Y/BZ#RK)\GK=KK1M;&_-MDD.+?,%(5
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M@QFE@SUC_[0B6H^%X041K72E@'_58Y'VPC7"\II943>MZ!T$'U +<]I@\^;
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M^7')XCOA9 5SC5_5KOP0#(9P^G)W-E?ZN+IM+70S%#:_=N0B1A&C[_"7<:_
MMM^+FG([_6<+6W_F=I]+;%XWB6IV< /":Q>_LMN1UY63 K&)V-SM6>!.*:K.
M!=X%N'<T^<U"\$7>G\.W70('A#(G_DW,A+@O<!L:? Z7]SKQ0P04-AA=#;6Z
M65#ESDIS",S+!*825%SBQS&_S6:3 .!-;&OY-'-]Z 6^&GYYH##QN-3=*&@"
M G?"\X45"^ ]8SQEP)?.8'?;^F1I>K445Y?IE^5=&TQ#SK&0["AX9B.[^MYT
ML+%R<T^\T1:K_.6'0+_Z.E7P=4AR--77DK2ZJ:=D,GDTB@G<Q"(97(O=BFX^
M5@C*&T\)RY:TEFXXP@F":)?.DMTZ Z94KW*1![" Z)L.0MY$,.C!P%(A5W>S
M6[/05[GP6^^!;J@ JV#O I?.7TMZF!NL35@PP.:K)8\S;,^2)O[ULLZBR.'.
M@>,:8H0+GG;J#\6+WJX)?8U,7"A:KKS2___)2.+?.P=<Y0U])3UXK.&'!4%<
M+>-./MV-T;P:?]X*"GP#F']+BUR95[E:#P'$T,T_>0;L^E9"O 8E!>^Y  #]
M(2T,EA4+H<(07L*7J9CFTHN/Y@YSMFT0+1R*SP@7?%O8Y%G16?6#D BZDG[W
MUZ124.DL],T+,5$X\6S=^1,6O#2GRK-E,U@'M+&/%"=U/(%P<"!Q&P.)=P<2
M-S"0^/V)5IUL@H;_^*W_V)?^-?PN7??NI=O!_8W4N[D90"^EWITT@)#B;[WC
M=582XFSW(QFGNL%*J7M% D;]ZX*R*VV$_G)+&8_/_K9<V5VE9OU277=696*B
M6Q[!:;W>TU>SR.KR'.*ZO(A;&(P'7O+9;?4'CYX[5P>B*W^&RB$HT,,#HF<A
M3'BNNP4_JBP\I-=X?3UTV;=T_-R3MZ8S6H5#S[W*]YNO7&7$%4)AD(Y?+)D;
M<% RE54"YA2RO= PS5*9UXN%&=,3E,+$*RP'^PCU'&P(40XO2YE8GL;@/^SX
M3_Z7:$R?8->JON_"("XXW1S5UA?!1L+;>0<MR[^5#=[F]T_FD/."DS>^P\(W
M(8AOID_T(!LO>A-+A5=KZ<6S*MK:S,'S1XPIT[>4R-G"V. >9)/UVX)=2]"_
MG?559>H,\[10#>*%3!S=+X;D(<[QTHZ\B&JVZ^'MA.[3W(_#M$#;@P@L7B*@
M4MF6"<9BN#HNG<&5-%Q"[A3H)<[:7WAA00@^54!O86J'MS\\J(2BA-E*_@-!
M3UI_^F#*O[Q<.42]>K*>LPY4%4/H<7Y8:^P6HEJ!TQ2H]E:EXE"QQU50,C2)
M\%3IP%W'J<^[I/D"TW(V2B'#>SC1 UBMHV+,GN$P\[ZQXO8P[KQP<@I0KZ:,
M5T99HE.WGXBOZ[+4 \:UG"DFP)(3:O5<23UG9?85UI?!^KFQJC _6,D^3Q3Z
MDC6ZY!X_#5:ZO5>7<Q6$'81W0^6PUU"F"-\TJ!SH9RR4-A)2@J8'O+PWKV#F
M1$\Q("VKF0.%S\O.BU=*<ZJ[OM6W%O ;/EX*:^VZ*LTH5+ @=K\]>[!;_%[!
M*\VY8Y, .B ;N!U3DOY:*M3^M2'7!#:)64[NFLR)3 I=EQC4-K69"@IA[I;7
M)H)*0_B5_LRBK'E-4>8281@+Q??SDJ)!5N;VS MLR;]9+^0Y!(Y@J?Z:PI,J
M^=DEE:K7#9%UQ5.F+O'#'31F[4+YTJGN4!')\E196V^>+Q#B-W :*4XA7/<T
M& >L=VX4>@FB:_I+52[?^N3E":81NQG*?#T@6;7@):N:7H\:*F_F>J@W(;0H
M#T^E6?Y_)2BAZ W&+%M]'II1B+\O*KW@#Q(<R.P8]Y+<_ .MX!]HJNY %O05
MA3(P8)1V"-S(G"]P@GLI(2ID?;# >G9NEIAFZA^680742ZL)E?7=T-58S42F
M3P?Z7_A=?E_W""4/&F9R9F0 8R6T"=L,#EPH,T#50-;^C]>1A)0:+SDO>+_Y
M&NAT(6;@U<2HP@#/\,P>QD#^8YR?0^RTVF'+CJSIOU:F/LAN*+$!N&1]E?[O
ME\<[CF&^F,(*QYKB*M+&]+8-D*"JJ-\<E.ZWYU"4YH2X3#/RZ\"&I/[%9Z<=
MZ,?IH!]GMQ^GB7Z<?86T6;&?SX#.J,K:VU5]WGE=M-5PVKM^V>]'JLKI^)'>
MJ!\>Z5U*L,[!_4W__Z3Q$#Q2O?OK0>].&HU[X_ZW_KU?[63'\L^7L'FAW>AZ
M,'KH/5X7[L8W5V>QHC,BSN!^W'\<?"M<#^]'P[O!#>6IFY,R&1(NWE)ZH\+P
M5OK]^WU?JLFL+%'M+-9U1B3Z?M_[?C.@#'46JSDCPC!MXHS6$V,I[\V:NJ;3
MG-AZ2?J-&,\$0KCHP(KIE+?3I@(C9[O8=)*,JH[\(8.$*+Z!NP.]@G5^V++E
M)OM+K28D<,1L*<7!B%FC=]I1=UGN[=%W*X(_8N]75.G'OU]?]_NWMYEO)37C
M9C:9_ES\^_3?LEQA:[L.U4)DTQFM%9.Z#1Q,#UZ#;[X-2O>D%+DM5R5JDI=K
M4GI4>7F[VO6%P_L )$?N>:;PKL:!]P._GK)LZ<[RJA0-V;7?M35?V&1&3 =\
MQNR/<8"_JVAU!@Q11TY 3HCDA%H<3KAFEX[L'J7_UQ*RP#[>D*FNZNY/@@._
MP>8"IT$KSFD0&^ZG(-S;/'"RC3Y/WJC'X@W%F4FWAO7B",X*[8 5*C*R K+"
M0:S08&N[MUSB^#EK R]<(LP?(9,@Q"6",T:E$G!&M;J3<,?)-GJW9V:# XY[
M^QUL_$$7W71^TI"'J'Z&8;TPKLNX_;XMO^O^&V^_XT(Q%XSC]>;)YH8S=!GO
MNW".E=2Q:EWRAKLRV=K#%X>%U74AE)M?72,^#$>#5=)()F1->MP>Q;%^FFZ,
M,?N:'9>)8S5)2W&P?"S9TW=>" \MF5A&$G;<LPL4:/#IS\7F)ACW=(S;FEO*
M^_7[TN1%M6IR2:1=._7XVU2KKMW-'9,F?K,C/JM:12S"Q&TSN-_Y>6ZR+;NU
M1: OP^6^EQUB&2#OG2^/O!&(1Y!:^ZE516HAM?#\P?,G#27Z]#SRW4^.$XI1
MA".92&*M)R#!\B#93@LE8<QFN.(1<H<"9JO( G';]]&-7ZH.LOT=Q=2<,V2]
MY [/2-[+M]Z0U9F2YH7"T1>"^X+[DDL!U1N-^I")A@+JS &'^X+[DD<!A1K4
MA0 .]P7W)8\"ZOK[XV/_?BQQ3>HS2JJS1Q[N"^[+,2155-Z9_33Y6)7KI6JM
M7:HV&C_MS.EN-*-SNC=J=Y7EJPIOB.D[YJ"PCM\F,XD85)P9FQJK'PG9(:NN
M [M\@WZ WH>C>I>]45H?4@]-:U=KG4WDG&1ME8VU)2R6](_]:^I\2#G<5__Q
MV;3,6]MKE<%*M/YP'R$-0Z5,KQ%5GRN&\W.Q7"M*O-SBST7]A_O97,[+FN66
MO6\4)5.9T\'UJ>V4ITO#^ RH[)D:_*>_@B.5(Y3YZ!?IZZ"]&QMIZ6A%%D6L
M_W@NUUJ-:JW8K9;D=N7KI_7Y==^B>*JTV'M[@R!+!V2UDX&L7NQ6JJ5.O8$H
M.WN4U4^&LD:Q6RLU6G7A0)9$-?HC=DI^5CK0(W%<6U?]C%F-+*! "%J$[YC]
M,>593G27$=2,AX81-QQ'SK6A.(X^U8G6<]XE!IK%;CVV##@V-1!)F2DHZ2.I
M19$D(Y)RB*1D2DCZ2&H7NTU!D'1</\T)]9*QK6@\*\PF*J'TF1ADTR>#:LG%
MB("$+A7>&X9AZG$%IWC<WJ'G1DT,;K\,T)0=HI;U'^69KE$A\UGB_Z5#JVY9
M]L(P8\ZCC&02G[<3^A@2\'9-+G9;+3%X^[S<"JS\(K];X4V?G- YCL?XI;)Z
MLF.<@<KC]X-9O5+LMBNQ7=9X0 B$FF2>A$2HJ5)3K]-!U.00-<G4BD2HJ16[
ME5KL2UAQ]8IW>@CV%=DYNN8Q,)_I );]*G!>=!;I>"==\MO9D5F)F\-F(K#R
MX^-:CRN$ZO3HBN^FC%$8ZYAD0H@F@>@^CTDE'8\)XB/'^!!$ISI8A#5 A+6%
M%F&"N6TJ";4G3%TZ>Z,I]D!HP2(QD!AHI6=WT*"-C@INGFUTSU_8<QP2,Y:H
MUH0PYV;\  .TPQ"FB9,_#H=I"SS:I68[=B@NXA1QFE)HQR$X;1>[]5*C(K;;
M$WT&Z#- RPB)@<1 8N3+9Y#1B7(_O"][-6K8M+!.#3(22C4D!A(C1T>,>$'I
M ]-5S"=]8O#$,@7LRI)DDMRFN]>1<T[EZEUAB;LG6+SH>*:8OUJ6]J(;1CQ_
M!227E>KQJUR@[#UN?ED5\\M$(9,@3LAT&+TN Z.W*F>0;"9TVCB$F#DN-+/W
MFWVHUIR^Z]7/0P/B2XK+*OVYFS'BN3GX-UL-HCS(\.#W$>8,3"H2+%57W)@!
MC75(0NM@,GD>49/LRC41:B )K8%):'E$3?* Z7>CIE;L-CIGD(0FHA\A((NO
M94QU4S$I=0SN5<AMI9H&,ONI% MF6-Q;ILJC'FY]1!T0_E"O4_VBCB>%(,Z$
M&CH31"&3( =Z&CS>*'9;M<LM/W?2Y/('VUK0!;X&70/ C;  32#J'L$? </9
M,?XRC^'L/MH?#,5T>Z;6]\$>3U!!:#O&M2->,W.R),1KBQZLL75GQ"OB-:DV
MF!"O;6JNQ[Y/PD!W#'1'VT_D6"LD!A(#B7$67@9,CL_[DE';3=V;L')['N+M
M[!2[S5(U_IT&VF6(U*1^A'<AM0&UY&MB%RM#G J&TV3^@_?AM (25>[$+H6.
MG@/T'*!])+)]A,1 8B Q!/4<U$7U&]0%\!JD/8<3+C=2JZ2#2IJUG!@DDP[A
M!\U!8%?!(>ILM=CME-J=ZGO5V?HIS2X$99:@3.85. 24T "F7JI7$96(RN/Z
M  Y!99VB4BXUY7>;_AF@TM?8/KG0;ZG[5=.?NP7ZOZ^?X*>OB_ PGZ6*3"FV
M=Y OTERQGW0Z5_BJO#Y]3VE+;P4+?\*"3G<\(P5(A&4IL92RDFFY]/N*323Z
M0IVB\LE6#*JFV:YD325W1MB'MCX'S#+OF.(2+93NXKCT Y8*<Y6;73@RT8H1
M[_Q;N2S=ZL30/DL/RA,5+R/RUY*8*J'O;U:^2/]4C"7\+)7+WI-,9O*'Z3_^
ME/A 9==:T"]7@1V]3WP6;<)G;WDXBUN+-$'F&+'6&J77AZ<E1\Q*AA/EMAS>
M!G\#ODCCUP5=>L]6)KKZ1;JG HYOTKT%NU$-/_3)?XKM$^QRL$.[=FQB$^7/
M\H10J4K?NV";'YYN,V*ZL+/A/0J1=X6>G8.'YPOK6-$T180)BOV4S\U)=W0]
M&#WT'J\+=^,;*F$FW6RES!8O32)X*<'RKH?WH^'=X*8W[M\41F/ZGV_]^_%(
M&MY*MX/[WOWUH'<G/0Q'@_%@>'_4Y2=2;P)8Z;LGR YT*C$,PU,K?B[*1?8[
M?4#U?U]7SU3+,)2%0QG7_^F+]*)K[@P6*'_@^55Q%EN,Y0;:=O'$N/PXCGO]
MM!/([S9X*7<O!$0/T-5(PJ%[=H8"$C[]N=C<!.V>B\6MN:6\A[\O35[;K":7
M1-])$>>T3=UJ<>W-1Z3=#5')?$)L/JM:17P"QO6N[Q:K:X[O+.7):4+:LK^E
MW;?>"$!GN 41''9Z^5F5JYNEE0Y&3(9R$ZD:EZI5I"I2]014Q2,2C\CS,C&^
MF\I2TUVB"<][N2"M2!*UEQ/"GIE0/2T2A4'?O>62W.Q:P+^5+9_E*67SZ,8O
M2.?.K*6CF-IF);ISXF8,WA9J]J$S3>#IXNHO>/7"RYJ[0>^7P=U@/.B/I-X]
ME^;]__T^&/\+Y<^98!!7?[FK%U[^H*YS5GC#U5_NZH67-5Z'3RFD\V"+SW-!
M'Z[^<E>?0=9EO$K/0;!@H_DAU<2%L:UH/-!JH;Q"7.,N-YL?K/CAJ,Y;;Y36
MARQ=V9DNK9(N_79E!7FC=3YDF/^3+%62(;%G:JRR_(,'QK'%/AXM%PM#)W;,
M]*!&L5LI5>NQ2XH>AS2(.>$S(5/$7+/8;<?O?HJ($QEQE5*ETSDUY8Y5."BN
MPI'BZAA[\4X3O'>EXVL;:"6]8_9Y*9>2E;)PS4N'^?([GKQN439O8 /+/$(G
MQ3/_7=!I%[O5"C8Z%Q0ZE4Z<P'>QSNM4?04)EO6'8MN*F=^FCVWDC5.=R)XD
M]1!TIRL3W=#=UW@2M0,Z=PME:BYQD^PX3H*;ILSJP%0;L:L3(7"R!4ZUU*JU
M<G<<)S.?,7(!V2*M@5!&(3&0&.*?&"E?]J:XT#NB./R"U_!UJQV[*T)*)+;C
MR5'SB'T=X^OI=(S'YB(YQH=8%B83A+Y]J<?T]38KQ6Y=[ 8CB-;LT5K=9=.>
M58L9-'4%GCTJ]$@,) 82([^F+O:6S?N2+U7]._XUZL%V2K78K94J\6]0T51!
MK*9E6!^*5>@I4RG5VFA7(UC7IU(O51I-D4" IC6:UFA (#&0&$B,O)G6J9Z-
MO'03FTYO/'X<_/)]W/OEKB^-AUY5)^FWX=U-_Y$U?!G_UI>NA]\>>O?_RFT=
MA,W\+V0Q85@,B8'$0&((:*ZD>N*,9HK- Y=49:&[BB$IIB8M;#+7E_.\GBK(
M0*=UKS)0/7 ,Q7-6U8O=1KO4[K0QQ2"':$GFX#P<+0V&ED;\TB.(EFS1 M3I
MQ.FV(M;A++!E^$@<8C_SDWIJ6W/) :XI3Q2':%#F 5HJ2ZZMF [GA-PFER)_
MG?;L]H VG#*QS/#UP.$5\]ZI2=F_5*WC29Y'["0[R1-CIP674YVVC-@1$SN-
M4@6(D[-C_;17A'FO]H",<=H#^7TY^VW&K!V4I'D$3+)3^'V Z2!@A :,1YR<
M';T"6]2WEDWH>[COF\78J:_<@C84QI(VUV;QW#YCKLK"D.[_4&>*^41N].F4
M ,R(,S3'*Z#%DL\MF9I&'71XYA%'*1G5Z>"H@C@2&$>,-#D[XP4K@SP..<'9
MG%YT=R91K)>!*6W+,.CPD@ZG*W'0+#]K=CKB\<X*V_;_6E(#:^!A*9X KA:[
MK0J6TLLC8I(=Y.]&3(U:?XT.(D9,Q##2Y.S(%K>05D]5E_,E56B)QJ:DD:FN
MZJXP.6.8?WPQ:7(?C^H<<!7=)%I?L4U*S;7K48?.GKYRWXE0+W:;S5*]'OM0
M.'Y:WT^(5Z'QFM0)D0BO#8;75JV)>$6\!GAMUDJ-YB[E*6L$Y#?  '.0S][&
MP,PC) 820S!B"&& X^&!+'(Z)SCW9O9<U]8G2Q>:NXVMX8M);&<X?5"@;%$\
M#V<3XG[E3FSS *6L0!!*9EFF!:$6E&:3:WBS+2B$/'=5SLYIP>ZV[]=OL=FT
M=MUDHX\<?3AYKM%)L1Z"NG]C&B^1J 7-8TO-=NQK=JQ]F&/ [NN0TL .*1>/
MC]P" #T,Z&'(@VZ/'E$D!A)#,&*<4Y6RL>4J!IL-8>XB8=0D-'6/JQG^0PBE
M\.@>]'A&;0>\:*U6[,HJ:+1<.#33\,S'@F9;/M#[CM \?VCN\_BC.9U+M1O-
MZ3,W&I 82 PDQN68T\:JJQ@K_'V0>5T7P+A.>PXG7&ZD=D8'E31K.3'(Z33$
M77,0WJSNF=JA;?/:E6*W4VIWWGUS7#^E'8,0S1*BJ02^O0.BU6*W4B_5JXA1
MQ"B=1$4N->6&.*3W-:5/+)JS^U73G[N%0N'K)_CAZR(\"C7\9;HK>\?X(LT5
M^TFG4X6ORNG-=>%/+:69K>_K?Y:.JT]?DVAI,U)05-6:T^=?H6:-:;F@IMF$
MJFHL[._)5@RJ$=FN9$TE=T9X+* ^!S'%'#J01B]-=5,Q59U^U7'I!ZP<\U5N
M=N'K)*#;I'NT61<CWOFW<EFZU8FA?98>E"?*M".J'4/9+?K^9O6+]$_%6,+/
M4KGL/<DD$7^8_N-/B0]4=JT%_7(5^,_[Q.?))GSVEF^NN+5($TX;(]9:HS3I
M\+3DB%G)(*=OR^%M\#?@BS1^7="E]VQZ<JE?I'MZM/%-NK=@-VKAAS[Y3[%]
M@ET.=FC7CDULHOQ9GA!ZGM+W+MCFAZ?;C)@N[&QXCT+D77'^SL'#\X5UK&@J
M@-S*A@525IPFW='U8/30>[PNW(UOKO9.G?VC,!UG^F]9K@(W*MUC"J0M?IM$
M\%N"M5\/[T?#N\%-;]R_*8S&]#_?^O=CUK;QX7%X.QA+PT?I;C@:2;W[&VDX
M_JW_R'HY/O9_Z]^/!O_LLS\>6^0=%Y#L^*?BQC \)>3GHEQDO],'5/_W=8U)
MM0Q#63B4Z_V?OD@ONN;.8('R!Q[,&6>QQ5C.FC1],L?QC9\VT"#[NX!]ZV4O
M?R$@F8" AI;I%E! PJ<_%YN;H-USGQ8QY53W<*3_8!.<TV=FCD0H<#7IZ\3^
MQ.?]^](D4DTN)055Q$(ND/#5@/!Q-REE:O^+*#:;5A_HO"+S#5')?$)LOHA:
M17QZQ_6FHX!& 9V 3T\OH*MRM28\-R)5#Z=JG.Z&2%6D*IZ<>'+FAAM%,FV^
MF\I2TUVJYXK.DKD@K4B"MI<3PEZ&K#TM0(4!Y;WE;O9Z$G?7 K:N;+E03RFR
M1S=>21+)G5E+1S$U^D?R0R5T#@MB\Z;5DC*WEML-,2^5_?,:,YJC6/#0(2CP
M=''U%[QZ<7)3@@NW1O-#@BU[),_$7))=4MZ_U$LRQ-ORRANE]2%U':M=K75V
M*5F9KJWR(9.(-F^TSH<,XROEA"7K&0#CA536BMU*J=.*'5%YG,W?J[I?.*KV
M%7GJI%/D"8F:6U'1RDY4U$%4U.JQ4YTS0Q5V,#AW.R9B]IBYA\1 8B Q<F]T
MIKC2:\MQV62LJ?1D69H#_L]=MPTBW#1BS:@SK2:ZOR5;,OL64#Z<CJC"&C-M
ML &*:[4I4(T>[,%V#(#NLY0K,M9#OGB I"?!DIG=!TNP9K%;>W_6,W80%%)/
M1_O[S*T,) 82 XEQ0?;WK[;E.&PV"]N:ZBX>+&?,/D>T<!F.'AB$XNF'K6*W
M!950L -<5DC9:VM6TK$UD4X"<70RB^]@CFZ#STJN"L+3:.'A02PLVZ)1@<1
M8@A&C#.U\!Z)0Q1;G;$)0=U@C3P3PUI ;3F)_%@0T]F*_,W-:5.1%62H4]E\
M/K)ZIG:SPE2?0RJ>SMBA5F"[(H;&B-@Y"#O-$V.G(X.]46_5$3TY1$_2(.#$
MZ*E U^FV7!,#/>?4L8!=$@?:QERQ_R0N'3&O*@;R^FFU# 8GRNC??" =Q.;5
M8K?6B1U&A4?$D=W,570SYX).M3S0Z4P-]E^)26ROYP^<H(HVUTW=<6W%U9_)
M+I/='^D\8Z0KE8DPZ[W4\,)CWAYSR--3OK<&]H..^AIH]/5.;'L0XV(1N$G=
M&*D MPX->6NU#@(7@9O9[7X:P&U X^"&+#9PS\FU,EP0()/YQ!M"6DYN+VXN
MUNP21./B@3UW%$&WMC4/<-6C SUOM;=SZ&KH&/M$01.4KT[\A#6TX 6"4C(=
M*&THM8K=>JE=$<0SCU#*4"M)&TKM8K==JK8%D4IGZJ^ZYET/H<Y:I?6%W_SP
MXJ'6E.DH]&'Z$V^.R)I7JRH4%85VAY8M*:[7R;HDF03S#RY6<B2\)0+ #:<K
M 3*<]AS'4G7%9;='OUNZZ?Z34GEIT]]] -Y:]G<'KI08 +\1=V9I!XJ83K';
MB6T X5$E$."2:3TG EQ3EJEZA!%3>01<,MWH9("K0)BE("+NG)PYMZS7,_&J
ML%/U:+.D/2H_YR0:CEE?R(/2@*$HCN^V"8U[(5OK%-&3FZ6$+@$I>Z,MZGF(
MMK@,.J7'T<E.^W=P=*W8;97:M=@U=X0LKB.PGR-\7E]D$ [>"HM_*YR*'@'%
MOF*5^6K*]6*WW1*H3"%B5'R,)G.\'([11K';B5]J!#&*&$U)>SL H^S^7*Z(
M';QX3MZ7.[_NU810TA+/ R.YRH_\9D.CU29*4,TO#%1CY<>!OM86"Z.I".)M
M1?"<)(SFO>!I%[N-4JN!X,DC>-(*G'DO>#H@>1JMMAC@$<>%E%>F0&7BS,L5
M(3&0&$B,<S=3QV"/\@9)9G24 -XYH*\LSW<._(J3XMQ+/;NFK];-):6K%_]M
MF?%\:!4H"!4[:P#=O#F&[MYHB@:V3;IX@ ABEJ<GVR (\WPO!]!D1Y/] @P3
M) 82 XEQ]B:[Y7K5NR#ET28S>O)#X:Z(<@V[#NRZ )9[VG,XX7(C]4DZJ*19
MRXE!3JS8[IJ(P#;[=1C8VS'*;U\W5:KLHCM^L'($9$YGBR%>,\=KLKOUY'BM
M'7BWCGB];+PF[;:<%*]U=IW?$5F^BN,P2'6E/=>U]<G252C@V*1<ZS,Z%-!L
M0AL6B8'$.'^'0NH'"B_=P&8SLPRJW[!R2NZ,2%[E)3Q=SIB',JL!&74W%=9E
MQM;0ID!7[%<.R-\X%H?3!\6&YCOT:?<UWF56@_7>:<MBQ)HBYDX2Y9XQYIH8
M')]?S*5953)#S+4.-,+%58E2L[=3UX[N+;,,6+$MP_ +8^N@F!#'Q?(,&$YT
M\$P$5M@BW(+KDHLR0X@7!CX;Q)-6D#[V;G\A1L?E",Y[PR>;&#Z) -D'D%:.
M 7+B.)-SN?##^)%+O]],R_.4HO[2P9 2A/ )'%GI0;@J8Y0)0O@$?K$4(5S!
MP),3!9[\HCBZ&C2&DQ;$]MJP*"'J2J[EM5O9<9F(L2KG[&7'\ @D!A)#,&*<
M4_)+4%9Q:EMSR0INV 31(=%Q<>DJ<SNL,E</U)B9BM57;),2T0&H/Q";]>4)
M=&-Y73>F?V<ZF+.N)$/S#?FJ_>Z:Q&CG719H.R* ME;LUIM7\:.V$+27#=J*
M+ )JZU XXZJ-_HC,5<$;W5BZ1$./!-I=8MI=2 PD!A(#/1+HD4 ].:\>"4_)
M2D%1;J!/ F&;E4\B/=@VT2N!L,W,*Y$>;EOY\4M\8G9Z]ZNF/W<+A<+73_##
MUT5XE,]21:;4W#O&%VFNV$\ZG2I\54Y"X$DPW<GFQ!?^/%.:YOHF_V?IN/KT
M-<'<QS-24%25NS8H0273<NGWF5?$9)E+3[9B4!70=GT_"$MGTN> 8Q:_K5 $
M2E/68DZG7W5<^L&<JH[.56YVX<A$*T:\\V_ELG2K$T/[+#TH3U3DC,A?2V*J
MA+Z_6?LB_5,QEO"S5"Y[3S)ARA^F__A3X@.576M!OUP%+O0^\3FS"9^]%8-?
MW%JD"7+(B+76*)LA/"TY8E8R'#6WY? V^!OP11J_+NC2>[8RT=4OTCT5>GR3
M[BW8C7KXH4_^4VR?8)>#'=JU8Q.;*'^6>9^]SQ39L/GAZ38CI@L[&]ZC$'E7
MZ-DY>'B^L(X530607ID*K,1GZ:0[NAZ,'GJ/UX6[\<T52-R=4V?_*.R8F_Y;
MAH;D7S\IW6.*H"U&FT0P6H*U7P_O1\.[P4UOW+\IC,;T/]_Z]^.1-+R5KG_K
MW?_:'TF#>ZG_O]\'XW])'V_ZMX/KP?BGO9MTVG/SUK+A3"DX^@]I3A^=.1(Q
M-7J>_+XTB5232U)5KM8$7L#JX-\Y07ZMH!+#\)0FII/![_0!U?]]73-5+<-0
M%@Z53_Y/7Z0777-GL$#Y T]YBK/88BS'69K^L>/<4ZR]Z(6 &(')&UH6B<O!
MYE!BP*=446\6]\PHZD",<0*_=\(1)=[V7V$=E@*WM< S2))<$;*XAOA,,'RN
MF?;GOJEQKR%0FKX;+Z<7ILQY\G5B?^+S5)6%[BH&^X!:Q!K_86&3N;Z<"RI'
MD:I;\WTD#K&?0W2%VS=.2^8-*T\4A_C$55[!?<%_<6W%=+@K[*#R+4CN4Y+[
M#\6F=#NLX Y2[)04&X?Y+.#2%]V=2:9EECDSAM( ^0?OJJR$A#XEH:G%3X<W
M0R?LTK:)J;Z&Y*W!0B+X![8GN9' .2%P3U67\Z4!MP(K(FMDJJNZBU3,"Q59
MUR D5U[(=>^?D5ZC)SPG\TY1SH !2;D_3RCRH3OD2#"LU07"X??1C5?$5')G
MUM)13$TL*2)2NHI_1=/YD*APAJ&8*O?D*Z[TNV(N%?M5JOAW89%[[X^<9."W
M [B"45*-]?G'_C4U/V09CU5+5,.&UVB.5YH&"IRV#ZE-<YS=WRL1\PRK. O+
M%EOUS+#5@<I=E?AAJ BMG$.KD16T:JPH7*6#T+H4:"4K3'@(M"H46O&K#2*P
M<@ZL9.4"#P%6M=BM=UH(K+,!UL?]R&JGC*RW.YS6:L5NLU9J-$\LOGY"@&4@
MN3J92:XZA56I7L=#46QH[>M04&VGTZ$ 29MOJ9&9]5]KB"HTSJS?!98(>>=
M6*\%B8'$0&(@,9 82 PD!A(#B8'$0&*(3PR1HHU27"GOWLNF\Q&*XVZZD2\!
M@7M]>)UT?'@H*8Y+IYJ,=,H%G2I(IUS0J8ITR@6=:D@G4>B47AQ#5;R>L+4F
M--1LQX\L/6)L X+I(#")UYVUUD(PY11,R2*LC@(FR*>(G4N!2!($2;)X0.J
M5.K43H^E<^I[,7"<)7<P65.O[9)76PE2"REU%D1E)89U\YF2"BKPP!^4Z50W
M=,7=+ "!3+8^T'YI74G$9*PD%J/?(V%U':XMQXW%2G69LE*[?0)&NECK8Z^5
M6$<K,1=T:B"=<D&G)M(I%W1J(9UR0:>4(N613B(IG\G\3@F4SPHJGR(Q-UZA
M"T.GU)@[F?<F 6]7!>+M,XT)&BE&X+"9ZZ9E0T,!OY(<^&:<Y<31-5VQ-^N2
M70(+[1-U=8Q"R0>=, HE'W3"*!1AZ)2>79 L'W9@JC91'')#^'_',WJN/LVN
M9XKY1)R!.7PQH=.EO@@N?P;FR#^P=.*,9XI[8]U;=#;.TG ')EPB#:?7_-8H
MGA)2*W8KC9H82LAEH&^OE, 8J'S0"6\AA*&3*%X>$:1Y':5Y;M&7+!Q)!/0U
M(.BD5:LC_G*(OV1N,!'@YX7UQJZ1)ZY'[;1U8I@W,PAQ<DIL&B;AD4WL;^3'
M@I@.V2RBCORV/M ;\:?OB6AR%K;Z^IE1:#AEOF?GGKC#*?ND[Y'EL+)_]5:Q
M6V^</%#P,N"SUZC D)E\T E#9O)!)PR9R0>=,&0F'W3"Z =AZ'3BG+ICJ*%M
M5$.%8/,&WOP+0Z?3YJ@=@\L[0G#YF88[0>S96GX:[PD?M(./WN4,^P-Z;WNK
MUU]V1;0/FXG(&6X][3]+GG/HW%HVXU9&_ =.^WAYHPT96D#$9<\=S1*SHAWB
M5@S<5@7 ;87B-G8H+>(VQ[C=J[JF% R) #E7@*04A8D .5> I!2 AP Y5X"D
M%/F' ,DQ0$0).4Q'=ZX6NY5:!97G"P#N7LF64O@! B3' !$DG# =P5837[#E
M-TH0[V32' @OR) 82 PD!A(#B8'$0&(@,9 82 PDAOC$$">4*L&Z?E$,Q52)
MI+C2[TN3EXRJR26I*E=K,=T%]5-XF>B@DF8M)P9)U5'QCT/\2[OF<%S'>2>1
M?ZG_UU)W7^-YD>K%;J-=:G?>'5Y2/Z7[\YQ@>;CO\R38K"7S?1Z"S0;%9JE:
M1V@B-.-!,UF,Z2'0; (T*YW8?9$0FA<.S61AI(= LU7LMBJQ6^,@,"\<F+7,
M@ DI<)W8]4L0F&</S/TY7;5DY2>WD?EV_E:C4^PVFZ5ZO2,*2C?3-Q&@XDC.
M1E:2LRE3R5F2.TU14(FR4W!H)FM+? @TH85'J=E&?1.A&<^UF1DRJ_0L+[5:
M(GN/_-N%3ZPI:O>KIC]W"_"_KY_@QZ^+\#B?I8I,*;9WE"_27+&?=#I9^*J<
MA(B38,+^3QL+6/CS36FRZYL-$9+Z]#7!"L8S4E!4U9K3YU\I8273<NGWH:\I
M?2&TR7BR%4-:*#:K_>?.".^=H<\!L2RB%#J>2%/=5$Q5IU]U7/H!B]"\RLTN
M9$HT7W)L#?.W<EFZU8FA?98>E"<J;T;DKR4Q54*';-:_2/]4C"7\+)7+WI-,
MDO*'Z3_^+/G89==:T"]7@4&]3WRF;<)G;P4*%[?6;8(0,F(M/[Q>E0!@@DFP
M:<D1LY+AG+DMA[?!WX OTOAU09?>LY6)KGZ1[JG$XYMT;\%N-,(/??*?8OL$
MNQSLT*X=F]A$^;,\(53,TO<NV.:'I]N,F"[L;'B/0A1? 6KGX.'YPCI6-#TN
MZ'+%(0G$\NAZ,'KH/5X7[L8W5R"=LY5%6^PUB6"O!,N['MZ/AG>#F]ZX?U,8
MC>E_OO7OQR-I>"M=_]:[_[4_D@;W4O]_OP_&_Y(^WO1O!]>#\4]'W8=D"[JU
M;#A<"H[^0YK31V>.1$R-'BQP%^_?PU<%7L!*#]@Y0::_4'%H&)X6]7-1+K+?
MZ0.J__NZ,JI:AJ$L'"J5_)^^2"^ZYLY@@?('GJX39['%6!$::1:RX7(_BX@6
M_X1A+W\A(#U@08:VFF<&J4"40/#IS\5J<Y.*>[)Q(N:<ZB;V7-?6)TN&/395
MUY((,Q"D&1V-V(ZOUUUS)?" _=Z1+K.UI"PQ<!*"%W?/Z+S6?O()7/3FQXVS
M0RF>*JY.+\19]N/7B?V)SU-5%KJK&.P#:J9K_(>%3>;Z<IYS^8W4WYKO(W&(
M_1RB_]2VYISFH0I_'@B\,G_L%]=63(?[\S;[-" L<@^+/Q2;TM=%RIX=9<=A
MO@VX_D5W9Y)IF67.W'!A8%.;D&X4_\#O:8R .#M W%HV?;D9T@"6MDU,]34D
MYPT%\,(_L+T3 X%P9D#HJ>IROF1-YE=@T,A45_5=I7V1VKFE]M@"+1_)>F9D
MO??/<"[*\1R_&,ISA@Y(S_VPPI,9W4X9PA4">H7!Z_?1#9NA;DKNS%HZBJF)
M+Y7$R49>7=5U/B3/3&8S@>QDQ5PJ]JM4\>]$(^GACYQDX+=C]X)1,LD]]D9K
M?L@R2C19><Y#8O%J+,NX48]=KNXXN[]7<N895G$6EBVVDO7[/@1;=0B.K\6O
MA(C0RCFT,BN.T&P<F.6+T,HWM.J9U39H0@)Y(W::&0(KY\#*K#)!LW50EBT"
M2WA@[<^2K:>=4/-VEFRS7>PVY5*G=6*4[<J-18"E*;DRJP_0[!2[[5(%;43!
MH;6WRT+SL"X+X<2R7?_NZL2 Y,^W9,DL?;XEBRI8L#]";*;(BA..F%F&1621
M&$@,) 82 XF!Q$!B(#&0&$@,)$:>B2%21%***QV8JC7G84D?#<MQ-EW-EX#
MO7Z^5CK=5%%2')E.;:13+NC403KE@4[TK4BG/-"I@G02A4[IQ3HTDH5G/=C6
M5'?OJ#H7KAPTMNXM,Y2I-/!SE.+=+54@1+ 5/Y+KB/$/"*:#P)0L).LH8*HB
MF(0Y0:IX@HA"I_28/EE=]*/P?$T4GL]O,$+_QT*W%49M:\H+![&96(NH^D#(
M,>L#[0__2Q:E,S!5FR@.N2'\O^,9A<W3K/^#V*KND.'4K_1S2#A/O=B-W0D#
MQ:](XK>>3/XF0-/;4<VMQFE@A8K7AN)50\4K%W2J(YUR0:<&TBD7=#HP=![I
M="(ZX=5G/NB$5Y_YH%,NKC[/-,[EVG)<[BJ9A@LN![66H[<ZP^)1WMO>KA>5
M%=0/F\FAS-!*Z7YY1WFJK#8) 9($(.DY[Y*Y6WH:M'QB_>YN+9L5ZF?2X8$+
MAYC^[6:QVVPTWMN$$8&;(^#NE6PI160@0,X5("E=N") SA4@*3F&$2#G"I"4
M/-((D!P#)#7E.6%\6#K*<PN5YTL![E[)EM(=#@(DQP!)3;*)X!5HBR_8\AL/
M=['W##E)FD5B(#&0&$@,) 82 XF!Q$!B(#&0&$@,D2S8=(.6$JS+:Q'&VH,M
M39[859/W-@C;=!?43^%EHH-*FK6<&"23!F('S>&XCO/,*L:W.EY;L=B-""*0
M<3KWYSG!\G#?YVFP6<\*FVT9VI)UVK%[1R$T+QR:F=7#;U<.;&N&T+QP:":[
M,3H$FM6#VJ(A,"\<F)EUL&W7#FJKAL \>V"^45TJ[?ZW;Q<P:$-=C&:I58M=
MQ>#8*-W5H T!>GK)F5D3W7:CV*V5Y!K*SO.&YM[XM91RVQ$:N81&:E(K,\]B
MNRF^T/*]^Y]8%;KN5TU_[A;H_[Y^@I^^+L+#?)8J,B78WD&^2'/%?M+I7.&K
M<A(:3H+Y3E8;MO"GF-($U_<7@A+UZ:OW87 M4;E*QJ;C&2DHJFK-Z?.OE,"2
M:;GT^XI-)/I"G6+SR58,::'8+N10NS/"/K3U.2"7178J+M&DJ6XJIJK3KSHN
M_8!%2E[E>VLV('G<-:@$=K48,<[?RF7I5B>&]EEZ4)ZH-!J1OY;$5 D=$VK?
M_%,QEO"S5"Y[3S(YRQ^F__C3Y(.776M!OUP%]O4^\5FZ"9^]%<9;W%JX"2+*
MB+7^[04'DV#3DB-F)0,-;\OA;? WX(LT?EW0I?=L9:*K7Z1[*@_Y)MU;L!O-
M\$.?_*?8/L$N!SNT:\<F-E'^+$\(%<+TO0NV^>'I-B.F"SL;WJ,0R5>(VCEX
M>+ZPCA5-CXRZ7/!(XJ-WTAU=#T8/O<?KPMWXYNH4TGN#OR81_)5@>=?#^]'P
M;G#3&_=O"J,Q_<^W_OUX) UOI>O?>O>_]D?2X%[J_^_WP?A?TE&7GVP=MY8-
M1TWAE2BV1*A UZ0;HI+YA-A2K>+?C8LY_3=8@BDSE/$,PU.I?B[*1?8[?4#U
M?U_73%7+,)2%0X60_],7R>_A*\L?N.T19Y7%6.$2VZ$0,0JUI"U*=L>1^"<'
M>_D+ :$ ,S>T56Q&!@DXE!+PZ<_%:G.37'MR8"+FG.HFANLVLZFZED2862#-
MZ&C$=GPM[IJK? ?L]XXDE:TE98F!DQ"\N'M&Y[7VDT_@HC<_;G0;BNOW >CT
MTIHE%WZ=V)_X/%5EH;N*P3Z@UK?&?UC89*XOYSD7U$C]K?D^$H?8SR'Z3VUK
MSFD>*E7G@<"K5\=^<6W%=+B[;K/V/\(B][#P:[PC9<^-LN,PWP9<_Z*[,\FT
MS#)G[E"C%?Z![K=;04"<&R!N+9N^W QI $O;)J;Z&I+SA@)XX1_8WHF!0#@S
M(/14=3E?&G"3L@*#1J:ZJN^J48O4SBVUQQ9H^4C6,R/KO7^&<U&.Y_C%4)XS
M=$!Z[G 5GLSH7SH&+FMU@8#Y?73#9JB;DCNSEHYB:N*+'W&R>E>W;)T/R3-\
MV4P@RU<QEXK]*E7VYOCZ(R<9^.T8O&"43')XO=&:'[(,J<LNA:+E9>M6X@;5
M'6?W]TK./,,JSL*RQ5;:21"[L=6&;-M:#:%U*=#*+G^A<V"V+$(KW]"JRUE!
MJR,?E.V*P,HYL))5%#\$6)6#LE416,(#ZXV^VM7,LTT[U6*W*9<ZK1.C;%>.
M*0(L3<F56>)5IU;LMDL5M!$%A];>;,\#.^3R.>WZ=U<N*!(^WS(ELW)'G;JH
M(@4[#,1F"JS\B<1 8B QD!A(#"0&$@.)@<1 8B QD!C882 BO"[A2@>F:LUY
M0-)'PW*<32?S)2!PKX>OG4X]-Y041Z93!^F4!SJU9:13+NA403KE@DY5I),H
M=$HORJ&9K W!@VU-=?>.JG/A*D!CZ]XR0\E( S\-*=[=4J/8K98:G6K<NZ4C
M1CX@F X"4[*X]Z. J8E@$N8$J>$)(@J=TF-Z 7F^)0K/YS<8H?^#V*KN$"C=
M]Q)='0;99'V@_4?C>^*4G86MOG[V23&<^F5ZXG%!N]BMG8 #+E:D[CWZZGCT
MY8).#:13+NB44O,3I-.1Z71@V#+2Z41TPLLG8>B4GL[Y'M,LF<[909U3')[&
MBTIAZ)0:3V?-TBU9%H:ESS0PYMIR7#89:QHNPAS47X[>Z@SK3'EO>[NT5%;<
M=MA,Q//KK-R?/0VZ]+#.9;>6S6JS,^(_<-K'9%'(3&^_MZN>5V K*]HA;L7
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MW>2__00A@I8[([:?4^!  7JB/RL3@R!,$_@-TRWHP\DU,/W_#H%F0[_\_V-
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M;Y9Q?"_)W-I1HO%82GS\%WFY]R\$F! 6:F@[XAJ.8P50RL&G/Q>;Q90F'W4
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M-R)+[$@OEDW9AG*&5TF%E44(\,2*:$-QAE51C#7E@Z7^DQ_$5J&7X(+JTN1
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M3R;Y)2BDP!22$QOK($'6! ^V%CE$7SBC:D-L[81ZM$1J+8/8=^07B42$0(9
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ML&-50TY51?EV>^$'@PN 3V3T-H>K]TS@ILDG<@?LQH%T9R TI(;_6[^Z7V.
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M+'1*I J1J[)< 8:DY,IXAL>] <$]SS5JTRE1R-Q47Q2;$F,V@V_JC^15M9^
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M4[;7^.;?"[ LW:J.V+WY![W*WV\OX_#TXDX'['R\(#?_^ZT_^C.E*7P97ZJ
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M_W&Z,$$C3<&:"L)B! \<S/K.JP(7;5?+71RI5GJCBFFMYF>XEER>T3XL\!]
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MB6DVW)65/=ZP$?A'171'('H3HJ5J3$3CDHY;S7@]*BO7JBBL:[+ \T8\2Q$
M>6?8SM07/\*7.GB)^GV1S>KL+] KH!B3>S45.'6B%%!C^KHE;2 !-TR=Y!R2
M/;VEN*_;._PJB_#KEO!K381?0TCL%%S]6OT= %E]?B2*9O^]#,<R)W\OJSAU
M"BP;^?)?\T?N">WEB]=J[]91YY#F.F%&$%K_8U@VS@*D)OE=&8^5-_+?RC/<
MXG\42P7/UEP9#4 2>[=4KY.O5,?)K<^ES[@4"I"C3"NIO&Q$M0N<P4N:]8XL
M5>6*,Q(VK'GV*)B  WXD_U^G)5_4+IIR36Z@WYX"(&Z5G]Y[&DU9;C0VO&=U
M_->*&-S_S?3M<F(\[\C?IJ<8=P5*V?\4EIAV@T+,I$@WBLJGBF#,'..I]S?P
MO[L1>;CYO3\<W3S<7)?NOWW^TK\BO:NKP;<[-G[DMO_P->&X:Q[23(?DI,?=
M$:]=' 9::_1I"7_(B_3!.[A633JQ#1-=A4+'Y ^#T4J"CBWH-+6WT@^P@'6L
M@0S+U)$4,W6I&J?C[F"NZLYJ/"2#S8Y#2E2PTLJ<369F:S?U=^I4+BVFJMN[
M[B\$*TW\GI85<*UG'OCF3NPSL*".C\-W:8HL:>J)@G>E_B2?5<.:J&C46NS#
MO(R?=<JY$XVQ&0#+V4K>&'ROVX;7_;.#7-,);XAQDXJ\O(U/=O:M'&1WV'*A
M22#\IQD6P'>R#!3Q78DEUAB/48491A58(;!_]Y -/BTEK"3+'4/@;.6BK+YL
MPV']1]29F_L>K4O>]L/'*/.MH]@KP8J379@$+K3$R?)JRX'9?<#0PB0&9P->
M2+OSZ\0I\B<S135QDQ NF-(T@B7O)GRTY/0-6UN?YR>1P.0$.QKZ H^%-RXT
MCC,D%P, S%HYK))+0<DBB)>Q(RFK[KXTMH-75YS:R:4D\>:@E8:X^1/TC.4-
MK>C?/@S]I!L<"!]\HB]=M'P0TUN71T^KIE4Q/N[ZN@"6[:%C54.P\[ /0 07
MJ0*FR>\&0@=^-@&X99AOSJTP'ZT([P#3E$)YFPG_,0Y? 2X'L<U:'ZS%,V\.
M5D(VJTZ6.,!69\-Y#^* ;>'%YIF%9?$Y\QBP(Y+;1^*=H+0\0;":_TE!X8]S
M'!B73Q8FGU,"HI@Z?1]+9J\0G:T>>:$!=O=]"-N24(#RKC)>IFOQZ_/6S!)J
M&ISAA6"9&HLQSJ!G7<;*V%@$;K]L>U[2XU98?/56='I?I5BJ'6BSIFR"8FEE
M73G?V[CV=1RIB"/$'A5GWO83"&:4PS8S;G%$$,ZA"4SZYQA8KI'<*NI+4X,/
MS^?;7=@,;?\&:$81S]@NYXC@92L.0 L(SYDTH^)4&6?]A?V6E<#* 5\R(?99
ML9S=G(Z]*603DTT6#2<Z)%QN_EAS;&=Q^&O#A(,E7UR2 1@S*]_B2\?I3S1:
MD)%<8\>U^5<?%R:3EDL>T5IBIK%U2<!49BSFS@'S[TO'@@YS6?*Q;'3C'W7%
MFT^I#]B^;>0D[HR^QWX>D-+,$[$^>#8#JQ()]KF:""IGCR%?L*[Z*D_8N]U1
M+H[@];7C\6G]K"7 .R4K4YO1*>N:L[PVW)*FO%J> :;,YW 5%F4U%YHC3N'.
MN!?3W?[$'.YE&R];8.+NT;SR9DEYCV1W.R/IL-$%0]&_8'V'2X(#9)7"D&5Y
MUJ#;(,>@" +>L/R_=4B$R^Q7UL"HNY.-T9+E2,57(9488[:J""=>@/F)2$8S
MP,17E[@J?'VBK.4SH,C]I@32Y<SDRZ1=WX @RMV/5+QG3/EJ%G!H#)QR!U^#
M@ZST@%I,$_D(O82V"C8]F7SL%=S)77F+K4G\5FRG!+^5XQRHW*SFAHMI:&QN
MFN\&IFNP,^O%[3STX>&5!EBNM(26.]&. =T=]!+U=60,0,4KNIVD3I,J/L01
M7\Y"SQ4)Y@V#T.$CI0U2<I];^[?$(E =V:D;N%?AR7W]V?/IP,^:SB),A^K0
MW6/=R=.%LY9$08.5]Q";JO7#VL@4RXTKZRRU@V$J?G;FZX?=(Y08UW/5..5:
M $F+'>62#!&MOO-ZUZ$_%7@0FY2(8AK 8-FH#+$OFN+>>91$ ?O3'8_.CC+U
M1H.[GG6HT\'UM@-*9K$N#^ 8R.[#E_IR#H[ 1)VCXEGPX9Q3ON)]!DH)5T<!
MYA# :"!,61_ZTE"HE!1D8W!>%&OU%<@7&,UP@AP!XSS\\-_18=)4^N+(5I^H
MP,%-*MK-?D$Z=LW!DB_VD@(WY2BQ7Q.)_2V)_;I([&<=^+]"BW2"835F&GSE
M+G.N8OT;1Q0E=@06 G !P6TD'CM@<UX7.OR<;;BGFO$*]E=)<7^M@-Y@;H[K
M[&-<!G67$S?U[*V-MB$W0D'Z!MYDF*N.3.#7W'DI\:>S4;1P&NIX#PK<Z[WT
MP8F96\YZ0:Z+X+E^5<1>CB:<IX!7XU$!,Q8>_U[^@&-^^ @OE-K,G8(/:F\E
M=\4GTY+68OPO=S(7 R,HJ)^ ONFCHRQXV,6]E$^WA"-B:E!N]RJ:,\:8Q=UP
M=O!2=X!N+D6*W%>(K?R@.H].O3X9&N4F@V/1PGO8.DK?^1RE&'XX1A@51\DQ
MV[1D8<R0[8T+VJCA#T#;1?<K]B"F$"U\[)EJNW@MFIX<=[^H0-%3#$4@J-WA
MU0_4 @Q.:$HRA_U?DMJ7DI?M]5I0\<?5QK8FU!S43D5N5G!+;'!)R+:JDK >
MD>]\F/)O:M<W&=YE2*X3?OM5[6X:(N>\6EY]\\871=HHTFR_VQ1*3"E$N3U(
M'RY5MD;LP3)?L-RD$Z<'93'!H!2N56)Y1N0$'!4UX=/JO;"Y;?#O>@%^QQ5&
MR\:BE*_N7>!R77!3EXG"TC(S%^;[LF2 EZ5%!0,F/\]DNDE()[J J0854] L
M!H)#:$(?B*$3G.RZ3#TP<QZTB@9F/@X6PFPBR,<WPWF"?Y>F-X+#E?R[Q+8;
MR\'QGEB:8BHXL6,]4\'B,J48*8K8 X;WI/Q$V&;WL*D]'GQ:%X\N K_CJ#><
M5:/J-)SFHY%0266+SL-M&<[@+&3%G7,W]DM_T@F;INC/$JW$%=;B]$P,^!-]
M7M6$:OW ,-A89:(H+''F&60\@(X)SCGG8RSK< [G)=1\[^"WY\FP0";46&C.
MS!^?#-%<U8\Q0@M0A$%"U;:H-N/C(%,4&"H/N>#R6\VI$BD]J8]/@.=')RC+
ML /'\(Q6UTAQP<-"3#P\0GWA82_R8RWF;O#29CM874N'P\C=$W&J[)6*7'$_
MX+9E8T'M1])9-^,ZX?."HEH\?X!/!US?FTXQN.LP/;=YD' P(L=\XS #*'?B
MR[F%2XC/[C4<CRTT),HECQ?\*ZW0=LBD2N9R.>'!5?]F)TMR8'B!SK!P:P6#
MISBX#T.\:%91R^.M9?Q0]RTV1KL(I!,O@7JA(),KOE('=Q@GM[<6EG-GQ_%@
M!6XHV1:.V;<N)TL\:NV&I?T9G]4"C56)Y]E/01MI*?(,G==<^8((.V!8\N0@
M?L21<2Z,O(BQJF,  ;.-#&>^H"^?C3AUCH,7XN;?"P\A>+4C2Q* *_+AIR&@
M<4%OA=N<SOG1*<;Q<8]., ' S :'^F;:\\P+NU,%S?4?E ]4!48'KC#?7+./
MYV(<:1Q6#E*"GVAO&%OF3U9-YP8ND?JH9:G27/D<?R=EA GA*;WB.W7R*V[!
MZA2,?&6RJ62@%#!95K(4'AE%<H/\'+XR!'VE4R%^13?7!-5+N:'J$5HL3L&Y
MWQ7F7XYHW^7^E[N_6K^2_QD,1^1V\'#S0'[O??[<^]/M8.H-^S?PTUV>_MI;
MXKGZ.T^]1>6-J$:P36FM/2GN?A@_S/:%5X)6VQ[&S/9W.ANSOBIO1')>R>?9
M9]1T&RT4UR-?>9$QB*P;4P<%R2'])USED?RN&6-%*U;HT^TDP%6GRP':ZSMC
M'!^$A8CD:K53M CO?IG0NLB$;LF$-D0F= _B7>E#;*78A^@O9\WG%$?_"0.#
M%9?C%+%W<CEF\7XP[(_Z@[OPP_GP^K#0Z(4?MZ']M9LZ[0);S/W?]BLX'R.S
MIX5PL4L$['3KM+=VR&+,V-MH**X8E%&/7D;FW&+X<-24'1:./K9JVR>CC-#S
MW@?W0ZN#[0[(Z-T['L#H\)5BZ3'"1YL>=I_F*DZW&.V1CE'NNND=_MZ:5#D8
M'J&/7YUM(RCG.)0C)T\Y?)!L6L128*A(I\="^84W!I *3H4I2/5OPVM>#&PL
M+$6?6GFBR&YO.+S!N=O\2,G)X2W_#'MP>M\^ ";[O?P\8'+U[>$!QZ]P>ODH
M@/,<%J S'\?OY6J](M?:%;G1^+ N^H-9SNJEQ(/;;BD4SL7"@8VK,L(;7QTN
MOE8_M7NVX=J7.AN^5-]XE.#G\4([7G'8Z?F#?XEX;!-E(^9[M^ST"6Q'OHBV
MTF>Y'AG1T].G^,?-LK+*V^M3V[*'L V45ZLT6O6U=3ZG!^3&T8!<*W>;E79K
M?6_GP4".(Q*<F'U$.;!^C@=JV:;*6B.GE.5OMPJY!"S,*)\,(\2HY]E&Q-FR
M\O#),+%PXOF:0]:ZTA3+4F<JG?:L@VBO#K2WOE^U")",QZ_)0[(!JF<W"Z?'
MMP>K\O4CC4QLR#/IA ((QAJU! <GIHQY'PZ#\,,2P-%(K%GNMEIY9=:+[$@]
MKHH:L"(IK_EH2>CITWDS)]A*D<09=!TZWYO$<?%L;7U[9!&@%D\AQ8):N]R5
M*YWJ;C,]A^IG0]"KK^.<)<-\6[W"'D&R;=_8Q^/<XP&- [Z[C0CWO^U^8<!M
M[][O2>D+%I<DU*ALT0%YVUQ?*'SN*%K3U <!($$%?J#P+KB56?C#9*,N7**L
M;TY][OIHA$?'40=)?WT?8;/KJJ$" K[$&A(U&E/2;'I09GY4S[)H1 >]4P4'
MO=*0=D<[!(*2"(CNCR"IW.U4VO)N*_8 ! EM);15FMIJ_=UW@[N+?9*0@F1R
M=Q@A- 0%Y"(@W]=M17]4G2&?U,8YVAFDU:2MQ6AYB;O%#2JXH.6F"HO#C9X4
M_7?#F.+X]&BVBXS&94O*;73>7]=^8=')A?KSXDF=3BE\A/]Y@5VL%TT6'N E
M[$4)YV-<R)UWSIK"G3T5/+Z/S:"\K9DZ:V/39IM67G">;BC. 7E?!\8Q)BK.
M_HK&*[5RM]');XP_(J>TCL IB:J4 -,L^Z69@LD@X[O>2SI3GE7M[>.NUI>U
M'MAVA<AU&F@6/3X5I9Q?NS-T9Z2CM\AF'U>[#E*JEMNZCR/;ZGORTL84UKV)
MHS6<B3VH?.9\RH7/=BM&4@MC9GM_^:12)BFRLTLE]YJBVSU]>N,22C1.;H R
MW6UU"GPE%MB,B2\PL#MR.OA*Q[(0D8M"'B9%?1BI'3'?&NW@!YR/E(RGU9;V
MZ3YF:0LKX:N=W66T E.)Z;/#,-46:DRHL=-08Z*PY)"K'E"WL-:ME;.:DGWD
M7P>]XDJSNK^J.C^LQ--/D;'2KE:K6$'2D9II5I $9T:>UC[GM77$?*\Y6Z*I
MLPUUC[APTEFY%VVER>DNO]YOKEQ#S)7;,E>N*>;*Y97,Q3PY,4_N=.;))181
MB&Z7)S[I)^2!8?)ZMX+8.;\ML[$^A<6*G#Q6PF:CQ9U E>O;KI69'9GLX@$K
M:0"%#2G+KTC9-3PL,]1^Z?<^][^ PK\9DM[=-;GYWV_]T9_)Q/^B,LG.(%@F
MSTUGHI@ E@LLM\K?1W$)E?J?)N@.JVQS)XXU0Z<?\9$E<^4M,*]DY;O11DUM
M&BPFK2GEG$VPBA?]9!#LZ5-67G;O ')DL!\/%_.YIE(S8AA. F!5I$Y'3 W+
M#N9RXC!/(?6R_L*542P. Q\J/:5:RBFLK/C/Z9YT22(:"=0  )U:7HLZLV*C
M@T!7!] U\CD^I?N=[2<[O"1;:C\5ERL<;#HP^*(Z2TZC8;6!8W%:M?PVY:3>
M?GT8W)KE;JVQ6Y,<77UL='J_4,7";:?.K=,(*VU\=^>TBXT286>&'Y<HHXWS
M:;/U.;(H=<Y>B!R&K7:D>9BG6B&6HQ*J7!VF>&7)>XC^<Y HR<C_?85)!]NK
MI<;^A3U"^F>-*ZF*D8A66DU)0O8+V;_MA?ZQ.QD%Y 5J4P[]%\+O.Q6%$G'\
M07OC^ .A@E/HS3G(!Y,P$9/2_-N\SL;*D5#,U6&R'G_'RRU(;S1ZZ'_^-NI]
M_G)#1@.G"H/\,?AR??/ ZC-'?]R0J\'7^][=GP<K:23RW$$\5X?)Q/8:/F&G
MP$29JS8.DM&G9&[29W7QG&O63G5?#P#DGL,@FL26R]U&N]*(T%MY>CF+_:%5
MX]"JQQTFE;5P?* 6-5\HF9G&,['PVA=CT.]3S']CTPRQ346W^%4.S_MUBLLX
M#H &,T83##;W'#01+9\Z4$9%:N=VQ%&*;!0;=KC)JE*+O84E20LQ?@Z\N+QP
M4 Y7:C(&Z)PC QP&L%8R ,M:E=P:)H5_$NXG3MZXZM 4!E23BX)#N4:>%I=K
M/"EX\W/RI.B/]%J=S2B"B%H#?;0$4C3JP&QFYQP+21*&8R<).&;BS(Q\)AAY
M5>TG @>^0,B:AJ9A<S3V0P.')34LLW@\QNKM;MA4W;X#BTA4(%=!UL8N,"HB
M-QT,,2D)B.4D2M^;3!;/"TWA*X)GZD1-8![F^47JWZ>J/6U%U>GT1C%U $K
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M@[3^\IWC\IU6H"K<R>5;+[)0P_)=X/+U5^HSO0\&EC55'63SYI,9,H_J[N/
MG(3LR0V2R)RPT V<?=-'XC+BDYV]9K[SB3X$W\0TO]$LJPG(Y2YW,:F<AGL%
M_::;$P+JQMOM;E-'U VRNL5*/!;%\*'KF+#^'A$/>ZXU<+U]!#WRW9?3^@:S
MNO,_XYP^RRDM96Q2%^-=A$17/O+=G>L@W0 ;4.V[CNW#=[4]R,J'_3N;I';
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ML:3]?0C@5HIC9D93'UXS9AWSVOO/B('@A&H;'3?"S#!?.%Q@Z]&-25H[V&L
M_J\%PA^-C6C";+C^QO@+LF:X6,!WD\B\F;@>V 8NK-@1GE%SQ"SGSP3<2A9&
MLM)0KB*:#W GRG/S (?F^LE]ZH@3=+1]7;_N.^C_=JGN<HYC+M<#E8ELZ )R
M!6<@ :7ON1$LD)&J'#A6;  R&)O\(VQ$Q?5+"->1%4ZY98;\K@%Z].83>J<F
MLT"O2+G*?355=0$78MB+0]P+V%<P6LR;G_;(\A^9H>3R^OY&J1CBE)5@8[-W
M1@KMU$Q(G^' '(8C%<=4*(%S_%;WHD/2\V; 9W!-MAN<ZX]L$D0N6DXF]26+
MU,BO/]ZKX1IBM%^MR+'^-$7S,E2A/UBL?L$_34>KSJ=+&LN-,:PQ208>6(T!
M*AW\3/[X]MN=^B6\36AG/GCXOZ"#GT>N/3)("\.6A):+Y_LO\^.,%_5U(<16
M*3#(:L%&9#[I%S+K=;3MBI(((Y@X;-I:L7E\J_ *(B<^3K>UP[\GM@%^]O<$
MY+>'B]0[YNH!E((0CR[_<\= 3 HC%>9-C\Q/:EMP1S6)X3H#MUU_2T8?*R5&
MWZ(;3QP-(2#?7/\'"!)CXA*#O_G:3+RID4Q /3N\J1+^XN[AP_]]CS]7<GW!
MQWUDWJ47&8DZSFC^8$!-..@&N+ J-FZ8Y\&;<"#T,1.GRS%0?>>.)HJ8!0-A
MA_#A(?RO23;$$==3=]H >[UYH\D_EMX<LL-TH<3VP; ,?KG"O438-T+!TD.C
MZ7@ MXPTL+Y]E[?3T<84YH;U\S7=6FJ-^UQZ>YDU-D86BE3(&*AO%TPHEC'4
M.F@A>@DMI25-QZS5F*ZP9SW3&_D5^,Z\ =LL,/_&+ _,$;!OE6*B#Z1J^@UV
MS8#M%0;!<J]X#SK+A_^+,?C,*_0/]#<Y<Z=AZ._ _T;3@/%5A#];&,8#(S(B
MP_9K D(FS>H(;$3[2+??^9?^N)=6.IW=X)&A:<E1FGQ]\._Z:&E[#/D<;2_D
M-%ZLO#Y4B=P;.4-,6HW3.;5#0NQ);2A3&J]S$'E/W(CHR] = 6/BGWZQIB;_
M;3_CHUS3$RS/^ ACRFS*!J)&OV8B107!UAH+Y);,)?3:7,*<7$*_S25LGUR@
MS0RTF8%&JHE?0 IB]V/#NQ++-]_ R7R0BJ$\SL/7=VL))9$UXDAF]*17S1QM
M1C862L;*&8,ZLP6#3&1O39%"@Y<BWNB*8$S6D7%VK-H*(FR8'+EH)O!PCW17
M<$/15D7DGPTF,?C],D6(,0!ZV.R3I*6,%D3$&&WI,(E!$([,N:XB'R(ZBC 7
MR[:3<<*;.#MLZ-INK"+4/]TQ_-V;&O-#2*M0FDD$=0R.$G-NK!"Y8*L%CI#+
M]*1S?#S+/HS)&,N$U4@\FD3(<!<H<I-;O-EX[HN+YEYG9'46O/K,L<O* 9-N
MD(EN4%90,-V!87-'%2;B2H;LB8&$BE!89&&JPOQ;\(PIG Y)>#93I2>=*-[N
ML DCCD#PS@S\OB@$0YFGV*6)R@F_#Z,:)GC9TJO83Q&/DUD(6#'7?V(1*#P*
M];N1>K8]!:WD>>EYXJ'%=';TZ0!>A<<G#BBV[3&4>N&NLER^##NR/)*>C;55
MX".C28L,%>4<< X#<$_1U84?HP\,L@K#%!/$V$QL^13V13!BC%]/8D.-3\7,
MM+51<R%Q?PQP&/ WFX4^3W04^=GP> 3:B?@/0NVFL+PH+?QC$6NTK3 D4)XU
M!F$!742I0\^*(BHXYRN ^@%+^W@ TTM;6L(CK-@<4_1&',,(#"7/T19\@'L@
M5GON5-01G=1P)I<,CNR^\;3YQ+I==V+](UPWOBOT 0C2%V;A+1"]:S;9MO&M
M5@[5+*O0.E+0[1VC#5VA!/7XEY4V7,L'SMMY\9;>:B\YW"&T1J'<5=R<JB4M
M54YJW=]O?"X5S>*:MWI3HC-'8B08YCZ38['0_@#+UN-@@J]!S,RN58PA:,5K
M[6W3UG[')8QK4V4HH1&,%E 84!(6#$LM$R+$:(C^$4&Y/GV_A\=T9-KBKRX\
M3DNN?%)&W[TR^L!#NA(9#9X->1X%$:^^0.-.#B!]R#-'&N&7<GF9-^Z0MQ]D
M;UM!;D:0KZ,H@ V,=UZ,KWT3_1GP1L"U"3GJ)",LY#*Z*4F5ZP\]RH_,"/7U
MO=F[T&7ZEAPY@HO!Y^F2D/C^'1R$V/P'?)B$3)=NKH@C\G"L5!M/6U%M1E2_
M,QXQ^F:%\>ZKW>M9F3O194Z?S=1, ZJZA!VUUF$SH@3;L>/B<XO99-\2@:AK
M?GEBI (N6M^Q0B?BE=OJ!J_P@_<!_$^*[+N^?Z\A#UHY:T+.P'[:*T%+#;KO
M#-'C<R4.!&@N1IEBY7H&::O9K(UC6?HMEF4.EN6DQ;*T6)86R])B6785R[)$
M.6T&#_&!L.S1K9_:8-]@WVUP632,Q**BVK1GT/+/UFMLSXY/]Z+&=J4XO@3K
M],K!.HN?<'_[^]?;3[<?KK\^F-<?/MS]\?7A]NOOYC?0-*#V[G>CZ+:65.3Q
MT?E\X'1:&F2E_L-$")@YLIZ8,6#,1Z"&YS*'PGA8/D%E@++\KR@/C+ 1R_-$
MCSVJ\HK0QG"P[,;#VD:JEGRF]#3^S*D+H%YE<9<NG']OP;3OAM_X+ 07GS*=
MTU!HM<KYJD_+'&ODHVLA524%V&NZ1+0A&(N>:%LB8]-%\CV;/,[Z0!K8?F,2
MG4'NU2'#O0,- +C""5C_ J]4_1&5J"#47B9J+P-V=6*%/"Z'>BYT"'%#:0AT
MV"E>7.CJ3@I<VLWIJ-IWM+_6CO8VM:,SI7R%)3UJ?TVUOXAPA(6*8BPZ=Z."
MN\;U'==6UTTCF[LD"*B)?3Y9:Y_[F]YGRN0PC]DQ+T<56ICP:9,P&")8-"1,
MI>G"8".3,R"0<DY\6RIK06EICAGX&KN[P6OLS,G&=J90HZ*[I@PY Y0ING94
M'0F6'M7<\^\0 C2M+/89UM_&R@/D 6DXV,?'QV\[IO &G[%">:,'M1%+\2.8
M?:$[X7N9<]JFGX)0883MJ>VQ)?Q#0;JTZN,SMF3_HK4EFX3GIT!PVH:=MQ:U
M.H\:Q'=3.BJWRCDLB0$6_8+CJU40(/GJ.R<)G\$X!/V6/71W\D4/+!QGRP3.
M#JZ0H0#KB/-;^<(4EPX#4K=#M*3GN^9+,DKL]+A58J7 Z;4A9 L*ZG=>I34H
MX1F_N+YCLRFUN9@L :M30C3"2L-[H&KM)5"&YAL=/OGV"/Y.WZ0:CY19 ZQ'
M>^0RY%E :]#($9"!?1]$&$$$9P ]!B*^0)ZR (S/T"5-$+(X"?TH+91Q_:?
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M/VJ,'2L$$UV'=Y48N[X[3L8=W@-VDL2"W%\QY#T1XM#&=Y,*5MS[V*-%(YO
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MXH!XE\:6%]%&:DV1W_G)^- )XD/QA>RM\HV%^#;K45-U8.'<A?H]09JN5'V
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M*^X:GFMDB0JW(4-B1#-*!@A Q&0\9H@\3^,9XHQ\SU;HB/0!553((U%\@&2
MMLHA"D(:CL]<RF7HP_()W!5;Q#Q4=8QZ'[^..4CBF=G2F ,O\\W?8!ROX@3W
MZD9S=5\ZG&MG3[ Z&FX<U7 0Y5&!?\%N.\0:GSXS&,!8N6#"<R?6-']+NKZ)
M[ Q$ !HD2+])^6</E(:'WP[@@?'(#1WX<1A/-UZJLIW35C=\K'>\^Z=M.]YK
MO[D D00)NVSS'NMVQ+9NA%BO18AMJIRJ4&SGU%.]$HFNG=!B,_"OXMW$I)0
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MCL[J/F*8/85M<G8D<+1#\="Z 6[]S;1L MU(<HR'QV$#& TEQ;D_CP.Q7-\
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M*Q:QMNJT>"400>30L^!FY.%ONBHRJ)_LI5"*MS44O*P<6L;O(;548A7Y55-
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M#=SR_:AJW,Z3B<VJ K&SG%#'4JXQ[)1A\0U.(Q7J0\P_1[PN0O1_D6S5])6
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M*Z$F+X:NF-11WOT4$C!#'TO<CU$<6K04GNLS;->+HWH2V'S^0)KI&UAT\VL
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MCE$V!FW46:FK.H"B7^(0$"BI#^.%JML:@%SUL=_.D=9;;G@2N%76!0C<A/"
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MC 0/"P9$R83) BI7A^'(WQ(/L:HF+R!J]+77JX:5S']RP\ G (IJKRSX^?S
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MTXX$[Y5K/5DN=0(N*Y7?9HAH?C%C4?F@.PRC0^R<]B[3T<**1N#MX?_<P.;
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M4@CZHGNL'X82C-*G@,+ 7!.EMXZ.!<4\_,<0SIH'ZN3>]>"@T2P"'CS&1?U
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MG+S+$K43TC:JVL5PODHUT$DABTKUI7\EDE'95SFM[*NT*U_#F5PO&]C\F;P
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MBI6J;_M/*_5/W0^+>,7JF[U2Y(T(P5D-_N0.PQQ:P/-&(6E8>]@"GI?9MIT
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MP3@'D>NX5CB%/;+=^XD5VN;7!(9FLX3.4 0OMX\Z>%_"$QQZ#3[/HH-_9#[
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MWB NE<.ZQGC/E/%24EMAR%9D=IP/(*?P/@-K>0OD6E8,Z15AN;CU<:I\,_$
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M&HG7^.P8[F!5?Z/(*L;2:DL0O3X3)$YLA@RYXKFRA]D)!PN?Q#@.Y_["H%N
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M]LI4?4G]G1@'1)B?-LYSKVSAOQP^^EV-^M#UQ0FC;$DC>3OL0]^;_I*?!2;
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MX<;;ZT1'/8K9_Z+R?4KG;A1J,'M):66'GG[:A)Z.*[:#X:3C8:-_9QHS!&I
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MZ;LO3'G)+%E1L2B8VT_8A.,G?65Y-^5?BO7"=V1P0WI@=J%;GM[X*<LW^DQ
M=Q ES<^RBM6Z)BRZ]2(9W+" 2TB/_>1(>JV@PM'N_'0[N?F,+TLQZ=AB[!6@
MXWJ<4,X>(Z3^\$HOA^AH(.[,0X79H1%++($,X^^%UJL<PL[_A[US,<)>E)\9
MQ=SIYR4S3%W36$8!V*++@5Q\/G-A]848N"D\#2%4RK!'98AG;>)%TD,<RFXK
M-(J>HJ3\R\HPB$QJ<Q3,$_.+*DM.5)*<+)@:]W$;HJU\D/'_-R*<E@ZZ(82>
M./C0.QOU&TEBM*EJT$]LW2-6/%VP:=<5[Y^-NHFPE-6*9[;BO8.L.-QF.YU^
MM>3Y+/EYMG+TA0?6(P@9P-!*% OSEU8WMNA.5' LY$G!^,Y<7BCJ^Z>HJ06>
M])0DLI;K2+S!KM#(E/1!TRU)T:;J"M=:DA?@+UHF&"5S:BA/\$%%DVYUBTFM
MSO3CIT!4UHU;Y1&X"D ?<PTL5C6SAZN9W=8GZH0QDIG)MS#1OGW--J/(7DEF
MN^<V:GF@]%+$%^Z9">9C^B+)V@Q.+@<#;%.GIHDV;$%G[<"'M@V^E3DKVBZ\
MUCSW8PMTK,T\D&K!LQGSCC%$Q8SNP7Z .T;!ES0V>"=6>Z!*J,F$VLE)J'NI
M6BK152XW6,,T/UB#[^*Q?N'X/^S]FY/\N+/3'@D@#.&HI<2O\2;<>[UV)&Z!
M:6RNP(W/TJ7O[%UR$SB2D[LAZG%Q09PI!IO">\R/!P8U;"^+2[,Z!X<HE.2:
MLN]^P2=\#\Q,OJ6X!V8YV^+? [.<[6G? Q]>=,,Z!UDLI"=QK&7HT18K'9'Y
MS<]U/\+/2NSC M<_.E))T"CGJ\52U=\9L[V(6%=#[,O3K \[A<PREWC5F^GJ
M;W)?=O"LAKWHUAO5HB=:]'34][DO>NMLU.\DJOE+<;FNVC96@RE V\;,<'.Z
M:2%U"%%RGS_))N5MW^/06^30RR.Y62N>VP)R)#'><2G&,V%M,&']81X]/HYL
M_?;@@.RT@)VS42=Y&\$37+_\?8F=UJ\+CF-R6KYL@O*G%),O";QJ%HCPP__D
M5)3\S;B0)O^1QC.5&75)7QG2EQ>%S:6K'VRZLI17)DWF<V7*#,H]\[_QQIV*
MK-I_JTN**5DOL.POV"D5Q "'.O[\I,O&#']PHNKP Q?Y/]A\;O[W?PU:S;Z
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MK%T->+M["I3Y57<62R_Z=0-V/+DUMN%5; KVC?!:$9\,OZ1/,(%"QY)6'02
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M7>BX'[2*[%KEA7*</4%?\8@1S'EJ'<GT2IXNSHL<.1E='!5^&@R8B]/N#=3
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MLX1:)O'4+8=$)=V(W$Z8R\2ET(;]%C:X:+#@73;S1$U D1Q<"/OU(CV OJO
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MVNB/9T^L4$A$,4%(</+<OAS6-\T"BYH$):)9N,[)\;1^1'6ET\FE&3OM+W-
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M6 #KX@DN,>$W0HF6X %,!;(6Q[!991;BU)WHE5=ZV W3W,(Q'Y:/.;-E8-V
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M' &C2)!AQIG)5\ H[OZ1@D3G(;K94_XX!AHT-A;PB:;(+(,/SK/]UFMZPVE
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M1M%T%>L-FR0N8+@&G8RI%6_=PCC4Y*TT.&W3)G2">T.*IQ.M=3V298EH'&0
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M4]QL4XBQ6;>L:<JE+7R,I\Z7U2G>9FYFT<5^NIZ!V%>P4<22Q!_":GTJN-@
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MCF,<YRJ<'[]-PR,+[^&!X TOU\*%#=WJF-E_R;-?LRR8I]QKQB#_IF5AVZ+
MFELCCW\F93>Y_! FV.!%)$Q1,P+"Q8VPT ;6+5LT5<]MQHI A5\(DH#ERJA
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M!RI@*:A/Y8.#C8 :&4B" =^KUD<=JK4.5"LJU28X8UG.4&,=(;(LEP+(-#8
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M;*)_D75R?=['OMT)][>B=B>>H/=^B62)U.30.']@+-35*3:2HK8XHAGQ6)K
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M\=PF/RAS"T?)&0SB_,$<%<X*?H2R,-I__)>Q:_ZX!8^6:O78O*AI "7F)IB
M>!XL%/?)GK*LD8&X17B$\T(49S9I-*W:KOE-*4].!F?98JNAFD]!=(QEHHM/
M]%^P71Z \JS7G +GUWZR@R^>=+ZWR_LY^2*+IR10!E'H(-R6@LSX%:SN@R7L
M[A/M6DC ,X;RXPWY *@V=>/.65N+CV2PV,ST/,_JYB!$JG'67+$I=;[$GB\*
MOV<^=K3,6V2I'5B L.DF/K?:'%.A($VB+A[.[S7"];]A>.K+%>B^A*J[P(>"
MI<8EGU.M'LS^<86LS82;I7J^H+5V:BK:*8XMV3E'ETMT )P8+5UH.C41;M*?
M-L2MJ&1&+W.\NT6\9@/@LC$B&'57H)U?V>*#'3@XDR8A%]R!X[\,975<<]%4
MF=Q?2J656H9$_$MD]Z2<T$YAW]7XVHU28A+G#0BM4MQ_HB9R^7I34YUK4:)$
ML]9U/UWAL2 H!Z0<KI:3H'3)@.F(>T&<6[!]SN %]0!J=[:PQZ-3'KWG([XU
M.],=4])!X&":+QC(&A$Y6_JPA'/OS/2=G4F&G+]3W@41% \D\*S3'FS7T7^B
MHRV;.269='R^H-4_R7E)I;T!RTK^R7W"LU> 7F*:"-A[=>::6%'Y[J9!4Q<$
M %L "XM(S#AT[2IJYV&_ 1QI*;KTVA759X_C4LGBO?MDL2:+]^YFLOBFR/D7
M',@/Y4#VP0LVN"Q\^ZQ@SQE1F:.]7;&K_#$X<TH]\[ \L7"OPIC,/,47V/N3
MS3K&#ZJA98[/F0,B91,P&-T9#0,'G6\/<_,CB]&YI".QDQQJ\$[;OK?1532C
MJ:V&T((JA!^M'7^E\JZP>6")3[@[IZD7"F;9O5TW'Q_=CZ!;<\&A]G:]TQMU
MN[>.%((/0G&62H0_XM^G53%+7=9:C0EI0"N=PH*6]XR)=2D+,H7X2<P\<YML
MYJL$8IZX0(P(Z5T/O%"%V)40%(*X)LFF+8LL?@(WA/OAA+;:IP4%$#96D%G4
M.V_.X<! +#PYBA-L(>FZE!N)MX_9;*F00?:[>C@Q[,.5+Z34JTW:U_"ER=3<
M/Q'.:X)#3YIB5J!=Z*[05)/\C7E$L=8S^.=2TTW"1H5[%O&J99,Y]"9'#DP)
MQ2-DTS)5%,K2DDHPJ35AJ/;8%\]GH3/>5+XQ3U.44GG3?^2(#E-7G(WE>U>\
MO:7 %7\CW?7((4A<'1_/M[;X;D2"2:QTO:(#(37M;)Q Z;6.#6-##F0^B_'P
M>#4,Q!S*T>TU3A:D1H,P%BZZQ4=-E%*,"T&R]4F:O,*(GA#*U\G[?%UP.&%L
M!D]AN^[1Z]CA25%E0_PN@7W10F3)2;Y9\;FGL2H*=S6>KF(XZ'M;7_+BBZTE
M3'910<F8[2>I1>%E+ZL$H5FFRD,?[&T:%\VD67)H=K)$LB8N"VS;#U7=319P
M@ >=[Z^*2AD^</U5/YK^JD9I#@=*V_;!JS-L?*=:E,I-RX A*Y8HHWS<ZW3+
M/1I-+XG<;$11B3D?.(C7'L-('*'O=+JI:S9#"VX/Z5N,A(0NG<\9!WN(CH%U
M16$9$Z$()-,]FB532VM;[WK5MB5:!K"5@ZSNXR#SM<:-H6S6$GW7L=R ^^4!
M&&;#5GH%2*AL$Q\ X^D8NSKBA$CE9.R&'$(^D4"@9\6)EWJ2E["0MM#8IP41
M2^/J%/!\G),U3=5$F>_1Z$L.^!"-HL%JXDOS"6PG>$R$:AWU*,HJ9NGJ@[(1
MUR4C,EGB5H]23S0G2:#FOVASB([TI'"V^M862&TMO\47H@;IZ[@"*TI\F^!:
MG4_SHEVFP>MBG[R11&_A&7+3OI@9K1O]("H5#*%/ 2FK[DF:8=V702H@4&H7
M;=:0ZL[10!JA]ECJ:B$V"=I,0ELA9\##7="UYW#HM%SI+B&0MQ11<R)!])ZR
M /@%N5IPMH>NUCPK%ES5(L,(IE_? +QO_PJQG(="SX*JS9XZVCBY&1!Z?MI;
MPA7*-+PJ]B%K)#F$OO5[3.L/[SK=L$D0MJ1QRX[]8:OIAI;,QU==_T4Y3V4:
MTBY&=MH#Q K/W1ZP) D_:4##"[^HBT!W]<^A)6 ]&G32X>=3!I>B$K)=)^<_
M4?V?FQ&*+2\6\?;$_=L2M$LI0I=\%KT7S5FJ#4^/W=FH:\-LG%PMY4(6CD"X
M?P.D[I&Q=M! A+D!R]9GJ24Z]43?.;54AZH/ECA;-Q5S=?4KE0,NO101=6L0
MO'?GKC&O?8"]YPM:2[SOY]WD.N;.\QI?H-.O;^ZP3S.W8!'/4'N?4I:--L?5
MYP)'@_@MB@@2V$%4J+P3*Q?Q48O:]2\O%^>BP(K:OS&NSI;IH$-E4?SOII@%
MH3S9YLRT:U[3Y>0RV\/*D85ROC%H 9M-3PJ82]@^W,T!+9S-8MT<T-1D32<#
M0H>)MO9H"U(S$_@G:D4+O8BYLXK&&#G&PAD.X(R3.N]6GQW7/,:\66C+%&N7
M.S,]J[ -B#@#9<:N457W*VUL>DK$'ASII+$?8YQ#=+;:OMJLU#8#.:W6CG^K
M45[I8K'@9D I]=[2;)W4?]+UI.3=<3C#LD^PH-;3G>N&@GW3",%GC.!2V:_]
M^^R79K_V[W3VZ_N,?CUL-<.@OI1HEFMW(HI#UF [IK'Z%;!;I]8ES(F6PG4W
M02(:'^*!<\@]D_I/,;:\UL8-'-CAXFU6PN);J]UG^P8JBH:(1.$E#*[-QJP.
M\/F,1Y["&<0D&+Y9A>_Z-!PL*JX'A$-4S'BR$FR/ZNR36I7*K!<U%K6Z6IG4
M?3>P-.JJ9A./",0R06^P:4S4>\PX+3Y ]3RA_O#F5D'OM7+V8^58]Z*8I^-&
M\8&Z27Y>R2IP@*R:DYV.;F-?U,X[<#&';U]8M<X9P]R<%"LV,-!\)!_!3Z.$
M]WAZ79S=)2J8/* %&?J\03@N?_G%!=%3BO?X:J-;<VY^@6Y!_F'TU3K)]V]%
MG>IGS]%3,TG8G# ,^_>%6[IR#X*A\Q8M!6 =9VEW6;HWI6=A-3RY*/A-=X:-
M0,B;1I23ZA^#/D3W7=)BA;8&<:9E,/H,5,9Q8&ESASH;/$S)B\0["OF+RP2N
MLJGT2/2T3L:^=YDRBJ^4U#]3Y[!-6],?N$R4-D@>C#R^:^G$Z[6(TIB7QV!6
MT)+)59=Z1P?+#6"<ZP Q",<3:"+LWH"S@3D>FA8,GO@F@)=((KIYH0/3'@-&
MPK:/EY./'#*\=/8QA*>0$E<=[SF"G \$+E23<)]S\O07.?G,W2T^G?I_QNK_
M&^G>I[L[SVZ<9J'63F!&B<SVI-A==ML3!-8N^ZT$T,5ZPU%6^=&%Z>^DG?T6
M9H[<];9,_I'7QWG]XP=,)VSA-U0JQCA)P7:1?Z-(>.><;@O/GEALGJ0V#V]#
M.AV=7>YER\G60Y\V=\ ,2W7)/:3*:;'*%JIWZM#6@N\*U)94K]:;PKP@0RDT
MZ\KQJ>>@Z]NS50H2@K,Y/%9'!<AEWX&:43!C%[+U]KW.O01Y"7HDD$O*GEN>
MDPW2;#I&$]GURQR9V#%<1X8*6B:,26)F5&E.S*DMS'Q@?KJ0\*LPB ?4DYE-
MRF,VK]X(':RA0@\2:0%HYU(YY'&(ZI?"'$YR4$KN))^OTV1>9QLX_?/E)/_/
M?]BS!,L'G.F3"M3/^CPEY.E\ Y, #C;X8ILI D!KJA>"N\\+^(1$;;81NC<.
M5V94BD=YPCELD,BY].FAANTD5+YQGW'**W0:2'!/.&_9@M(H+@+OHQS,*,HK
MD8O5XF=P.SOPP+37AZ//.U"#L$P$X[^LB-<?]C><4&#,AD]W"--L*CXNN70-
MQT)Q.E#]E/_>4&*,^4GMVF8S+$3+L1:*FY4(%3(2Y*\VZKA/D%P(A (3 V"B
M(&O^2M(&-+/Z??ART6%%3>@N#^0X8-N)@C4J"G'VBQ=YB3X[DKEZB:=YK>K6
M%20^[8ATA[G<,TXZ#\@^,) '+Z@@NW,VH3-TH+'U3/F ^E!76-/$?V\:^0<&
MPL&]5C<"/\)0Z%2;PR.\MZ1^->O*H44NEEO.]F3%8E/3VX$WSW(S16>(1XD[
MS#0_I*?FS841''<A+S1%T+!D.WAKQ@$3*(N4S%E5_[%:9--<'SR6))+*K3!2
M@=B0%8:VL9G3K+6%(G4@D\-'=1_<$O[V2YHF?O'\ZL0+2& F"M;E:WQ845*]
M46 EXF.FZ(=RO\LZL0M(AZ4@(T"MFE9X5*HC3Z8 %(?5TB12_Q*1@W.>I ?7
M%7['72M@:* M.7VO#^$\<\J(?3B4"O"[-J 84UHDC)]I^R-0A:N*BK3(>"88
MP$D(2DGB#4L=;=U>1_DXX"Q9AYH+7I<D'@;K@Y\,9IWE>"I-I4 584&HC8S^
MAN$>%Q-M*>C^(BT4OD6U@G^L-Z7Q72]T@(VT<S8J%G?RB)<X9M@D&T9#?9:\
M2._.4SD6P\IJ5MM.^H<#Y@O@4'!0CDB\GC@.7ZM\.6A;I!FCV;&VJ(VF6%.!
M(ET<K43XO[9WG56;R3J5\*$=J[*!\]$81BB+QF#M.JU7;C:@WA"V)9^1_W1<
M53-4;>N3GA)R]9_ -LJX6&%2E,JX:^;K=IFIGS6&2R7_'MXG_S3Y]_ ^^?>M
MY/LJ-35/J:;F%>4RAH.^9$;B<QEWO>;F*<;GW\Q!V4>!]UF!<8YBD=NH*IL>
M7'K-#/H./)W&YTKL3E5U8JO;PMR:1$T9\DV1"?"]CIEV0NH4F:3D@@X,DK+U
MF=KQQ4D[B[;6DY3 ,AU'Z<B_Q26A^9BL)5"4HZ>P$/FH&.F)%"-QW^MBW@U=
M[1Y:#'T/:B/\3K@R_IP2Q%'?8^]"]I5+^% "UF(6!AW?W>ME[5M>CL-"BM#M
M(\<G_,C/"W<\X@LRCVE"/)8DABC+FQ^#=<#@38NJM4GD"2*@0,<W$C^!URW6
M#%>FV^-^^9+[=\Q 2*,<5X5951:".AUA/%TJ_;@#5+0(+#+1C?:XK#>Y]GT&
MP_ ;#?4O3E3OJ+]F<4N8O&E7[%YS<0L&BF.H@:8:T)KG7>4ZJAG M!/QX/&,
M&1;(AS;"6;N2IR#\$R'C59FUJ)EA<<+F*IG"GBF%MJ+E6>1PKQIG!/81OK*$
M/T!QX8UA#ILY..Q5?6ZB)EJ'.3>(:!U&@.86-FJ_">Y1!'3\7F=]'C46$4Z3
MGH/-6$%=U7S#0:L@[J(J.&-6$2CJ<]5^&NP)D-BV!NLW'#I.^7AP7Z!Q;I.H
M7L6:?D;6](=-L\K+1NL#A2^0.X5][,HMBJ5C(LVIY:(3B=NB&1MZ(MI*LTVM
M$&R;+>>^@TQYEEKMV*JE/J=L!*?8_6\DZ'A&O?'R!WT]A.#LH'C>HIUL%=R!
MZ\_5>K_4@[P$(-*XUL>+:JKA\\L%J]CJZ&F<S+\8#CI^@E^9D"*(/];)<"B'
M>2TPKD/H0+0,MT1CEGB*XX% 4YDR4H;. @JOE^)CK?2/X4#F'+,GX.X+R$%8
MJB2-&0 @[(I>)0MU"[RW:VYO\^@^;*-AFT=W,VSS'4CRDYWG?+JX&J#A &'$
M[S$K4'#]A[2X9:A?9O6![6@:@6@[[/8X)6XU:8NY@]B)C(Y5:D%3%6VPRY:/
M,N]"XL;WO\"+M^P&5,E+<?)Q<E9M%@3PAC<_*2:%\"LX"PEKA!;G#M1+N0NI
ML,61:--(NLMI42VT ! [H<.$\Y %/\DY<Y]EL$MTR)E#O/ T6QC0I?V1^19<
M63I*9 G\,OT;;MG,9*&%OMF[76P*,,JO%5@P!$42UU=CDR&:+-.\9-;YRZR7
MBV8D7PBV)/]#4-Z?X1I3 [E+Q:"^7$+$)/+ 4".7++A"YT5K[7O4,UDI+;UF
MW- \Z9LL'6R$>[R4HTR8Z!Y/6:$L'8>\W=3MO&^+(JSP;1O5UA,QUWKTX>"R
M= 97V].7"\B9K<R5\,%6MILP+@$ON#+3]8NDQ/MYSR9IT:=<O!G8?%;!=HU@
M(T4*9N#Z@7U[-X\MG^MSYV@XV";-2;\P.SGNJZ+OF\(M4N_83RXG]MN/G.X-
M<)=,U2<[>[MTPK];$^7 [XZ!CX_UHP[5D>/^+Z>.H=R?0DI=I]WAF4/8=,_L
MK,%"@<&^XR ,S5H3X*@D'1->5[C>=-HT-!)!<(&<5PLD,?R""'.ORE(B^R[E
M7AO#AK:J$D4X'U)#,74'F[@)'FO_3^<N:Y);V35T[S7./71E_H3A@J5C]@ =
M@D-3"6.S$'AMF=C>'J7Y,F"!__8"[WMJV1Y:<8^M+^NI=3G_Y>C]UNXJ.-:X
MXY;$"9_N</\0_WUW6Y-?7L!V>_ON[?_W\?"W-[^^>8V7OWOY_R;O?C]Z\^[M
M!VX&]\N+'=^-Q'<B^6J]V/X<%?3#BRBLU%+ 0:KM*3-]('LEQ9G6E<'@)&^K
M4JH5X2M;(-2$.).(H/0X+W.":W;MF* />9CV&PZT5,%M.J-.PCB,U#W-M6Z_
M^SK3L+@*-:D/?F)%)UOG"(X]EAXKS<YP$.0SQ+(R6G1Z+O01=+9.M>^-=ZDZ
M!A5.ON,LL!HF?$_\IR-GU9^YN.QI5BQVDK\S@1A9@G,7[:*4IRO?ZI2'X+;/
MR.!'_)B!]HT9[H;G!TO".:79^KD9R3:+VZ1J%!JQG4'Y:\J?RQ [G^^$#+O>
MUS,I!PE$,RR4=6\:'9ED=9>5+">1_.(0?ZF(HK8C^OB[HY$,8; >[%W4-JJH
MC)0-Y6:YWW=5-T(% C]:%)H$A.FQ"4 /5^=4$<SZQD%R%<-:V09+^*4L2&O)
MMU41?^6#Z!N:603@ +7_D@NUAX/?'(21S(S7<(M"IA]GK%^WL5FV1?=Y7E0+
M%N@@/ST[J8:#@(>$BD9 9@@MJ4OZL:0PQH<UX3%;P>?L4Z;@:,RQ!\AUHWFC
MN^0STL&HKY98;/<)G$"?I% >,M]BSVS$QIX!4K'1+H5I<$ZT>",HU4X>[3X_
MM!5AC/2EAW-RS3\'25"\;:BT/$$L!<,V/3>^ 7;5G_'@_6<[>VA 4)849/RU
M2R,349+W(]H]V;)^00XKBT4T0'6@+:>3W-G*+Y-&?H:FE'Q&5Q]JE7IGU9WV
M'8'GGQ-">RHM92P]0<-*FM5GLB#*GN@%0P)ODB:*S@5EA2VAB:DP6,V:;AQ;
MYDPX@73?"WN/"0G0N&BPZ,P(4 &<J&*Y6<:7Q6"'PC(XX$;O.K3)6VLVRY4J
MA:!PDP\#/DRJ%;OS%$8".02K3 \-<I-<8#,V5 B)S7,95FAV4!W#\_9V<(H?
M[(TFX]'C\>AT/'KEKOFX\P%$LZ9N-F [O/<&EAZE/AEWO&%(]9^[JW5S?<-]
M?:ELUN/[;)9FLQ[?9[.N*,V7\_[_^>;5T=__ZP<\ #XC%/#UO/\?7L1^OWS#
M)_*SJX0%WKQ]^?KMT9O_?OV9,8%+=5V_[*3=R)C LZTQ@6Z_+PH(Z(.BP(!I
M*8@&0$^((+5!!*X;ODH4(?EJ002J9+MB%"&Y_B!"% YX=LDH0NSMAT&$6^L7
M/A._T/A_G(7J$60VIOND/#+_E'?SM;K^41J&\BSQ]YE$%BA,8,LQ33HU)BOH
M-JX;)/[HX_ )7%.0(A>GT,&X.#F516IAO>-%$]2JM+V!;>!^%_-SZ).8O))J
M-@VSOKV9-O:T:;!4C6C?9$3,X]9\,&P1;WH1B\@S\)3NAF^H4GYUS[!7<GK\
M0L3-GX#>PTR,ZX**ML*XUUN\3%O8)FYWT>E&*A9!-3IY?VX_&DD)SS;Q^(:#
MBUR^WLFX@L.77,+?(]WS=1V^Q/I['<Y<>*K0$O7[=W=L%SWDNCF-:%"05N.!
MH0"9F*W.96@UM%@UR^J2,A8%KK6B9&^WLQ.=?R(2[,Q !G)NN=9S183Q)5Y@
MII'6C"HF$XA>C0$4=TP$'L6*E$ >*@3;=>8D*A-P^?((4Q1V%C27N1,T5H:V
M8B3M;>/U#)NI]0_R8I. );'5%=SU>%G[3CTA?U+_^7['Q.<QB<__!>=BNKN[
M2^*3_ LKS7P^PI_*V?$QIK7678'64;\YB/_H66)_AD2MR24H:@A3>?E0;/NL
MW1Z%E&C30]9_DB$HW$TH,R"'D28(5O"[QB'SK'DL/E%7MBWMDD5M%L!=Y F*
M"*J,>%(TIV:J):8(OYS!]%.UG[-LT-:<YF3!>Z,&J2\:?+<PE3(#KQ6WZ4@7
M==SBGK451K"R0?+3!;4[%WLX<&%UQ:9V+A,]89OO[<\CNK1[-9I6)9/,)I@E
MP71:FN7>V>0I;#YO#B7UJ^/R%7KK.J<J*9#Y_AP<;Q_/G.G4+U,/\NG&;0OT
M"4&G:\&N<:,"2R]ZGH AYXYB! &86#<>GTL7%!&8)EM@)A3@N5/TI$:7*H3-
MM=SQG<=I7)5E[B/L=][EP@B"D+YPY1#"@]WA$:D+7(Y.B56FZ,8SQG)=.Z5I
M/-Z*7EJ9L 7FBWF4-X8?EII ^J7K-ZBQY3TVPR"AC5/YW9<&)=SX6GYJL(7/
MQ3-KP&"";-/F+[SPBCJ(G [[,\^5#4+EPCI:1^4.:+VS8\X)2Q0#"E_*;/GJ
MURU:W8S/8 !HR^[ Z\(DX;N$'7SJ' OW<F[=3NJ13VJYE=B<MMU9%^ST3X$-
MW+0S7#O2EG1\DZ/[P9O)&B%B\_ZB;J6AT07W3#INB<[!%O]T.+@(2O0,"4Y'
MPJ0>^?J7<.>YFJ T;OU>MUMOCJN.+'#;>^]#"3ERXW"\C*?V Y9#>HXW&#VV
MG;BE4KC77M[V^#LBS;M7*)5[<I]<U.3BD_ODX@42]0TU,_,:_<XP(0K1A,I.
M*N4R%U/KQ-1?%/ID_A0Z,[,%%O)F=.4R!^N6K")?IA$%7!6WJ,<KUO7>$76C
M2\3%\K^Y\O1#-I&ZHV@1[\^SM*/@*6:!;O="X$Z$AF"A@VF>*52W<LR[4<!!
M>F#X^D\47ZO->06V<B*W4S\H[I.2^K/Q7'[;='13"<NL-(2B_%SF.?C8'KGM
M:HLH)2+(6"W00V^?4POUGGLQUW*SSC.3T=6?DGQSP&J[\9YV]#WW]+]""H16
MZGI3,S>*7V8,8FPR_@U[(51EG_M4Z?2NA96>1U')7YW0'$7<F)YKJ#=PS6V?
M\D63.Y^I.V3=%W!04I3A@*VTJ-GW-A&_4H5<%T\GUI1V!8N8"MB1H4JN).N!
M<<O&LE=K+P3\E>F5\,XD52[1"<&EO"AB()T0+.L;VMT4/K%M0+[BK B4/+,D
M5"-#)(.,ZU+YJ6^ROS_*Q[A\YE7&?<VCMP1I[L86W75  Z[S.YSA=81=)L3(
M5J#!(2R?A&&\J<)'#RZ*!CN=6].W(WEM%$HK&]0.A,AC.ZLQ6[&AOF=,J?C4
M8($RC?W:/F0:\>WQP3SX>Y0IXA?K3 O?;-Z<R+BG3D(YY$. 1D(E_D+>3@@<
M')L8[(V;.^V1&H\GK(R05LP:K)4?-2?NG;'M&LT4SEN%+=EK>B8\OV@8]0/+
MZ(]Q,Q)]=/]L406_N;&'[?/)Z_>]6:?^@-&=VWF,\7E+]&^TZ9QJ),I @WJ&
MOU85=ZTRSH+I:*)5\]MBF,L-=AK$_8KK@*QS\Y QJ>!N[12[*<"@FV$5*/47
MT%2?#T=2&Z3^4?;4]+> #C9RU[.#=X:#0Q7"WN?I_BVX.=/,C,2P_9,)G"%S
M0!4V-687F*.TTD;0E-^?51S#"5@2-:7E%B'SJ:=^&8]JV-VQNN7&CIY2QWKN
M,$>Z;WOV4]Q??E;X5PW:N==$0<(%90VK$=\,*ZQKF9'D,+H0[7&LZP^F.\3.
M4#&$:8K4+S$W C]_JQ''SZ^".-[;W4\._WGX_M4]R-A[V<^W@HQIREP;TZ^!
M*_97&/1C#Z[X*T**?5TREN=],TAQ>VT^ U+\_*Y BI\+I/BHSJ9_L!VOA!&7
ME?XD%GXCW%T5VK@A-".'1B;!7NV%W/.$.T>:'V%)UCZ9S.C.:7 2+6]#_I.:
M4K!IMBK6L#V.J=DQOF R\DV[<!@OY8J_X14T!2+!IIG7."5OG#(\T6CV_##\
M4RMZI_K<V;U=#WZG%[WABWJ>S<FE=76<\XR0U;QUX&D2/NBHAL7/\X[7VDG:
MWU^HG40G]50R"(6+4KBU)*5':UU#,81$*KY$=:GK=%G5=:?<DDLEWI[>)]XT
M\?;T/O%V4Q-OS[6\8*%M54$ED IE'_J#UWB'G@[LM^PL)-; I)A$LK!P!EVV
M-<@$ZI<.O2JTCL?@C)4,3,,P)JA:1^M$_ I9G4<':,>].@-?J3$NYP61*B;Y
M(N:K>G-T&,5V.L;LSO]BS;>@QD_\KL8C;J$4\ 4[ACO"B_VAI-,>'D4?T._4
MKX(&J:2BN73 @0(==Z5EZYI4Y:9A"#A\[D(+$0"0$CUP!4; 8,SJT^(8VV.7
M;I]VR:6K=\_4^1X<F"!K3Q^)2A^2&GZRR+-F#5O:Y1H4'9^C;2]&DP;<?>*6
M\8[\B#.J))EUEA6QP9R?%A7,E,XVDTIW<C;"W(5;@&*\PT&X4.3YXVT9(6J:
M&>/H:52>_"WM,PE'TW';*M06;IF;X-".PEJ8\L$6&^=N'-*JV!YV5P?JO-SE
MKD@X.7M.N7/U:Z3=C:...YWV:D2+ Z8HR-7Z0.F1^*]D>P8*A3OK$.X1;6#B
MH(KJ(PF-.9,*J,!@Q=LW!(XSO2!M-R<*]#9UEB^*9"K[<)*KBKN0DYZ]9?)U
M[ .H'PZ& Y$YAR*F,T9?E\=@/LQ<[UZ8L1$'_U 3U-7FF O,J)O[&+6,;-\*
M'CG5S$2C85J'T85#.7H)Z1#31U?T$B,$U6)!. R/1;3J@K?%@O6\'KOA*=1Y
M"::;SET_3I(*+RG*VXB7L-O:&IIJ)R0%"6H0MOK#+<UW"[;NE;8KERZ1CF?T
M$ZU'@N5L=UV3/4)-AJF>X<!)8AQ2]U7=7K-L[?[45X:%C]M/O4U IHVB<UT#
MKY.,&U3G7$SCNW0[,'[4AB.BTXUUL=-"<9ZP96P%5CD/Q(T5AV(H??VH))JA
M-^HQE9##!U10F:/-/5D4S8E_#["DI9,[X:4]#WW1<$V.S@9<@C<):H5=<HC/
MC>>[B*J*:R&WK%8RVKI:8V&59GZRUHSUUKQ70K[+N2XNMVA$(]OWZWPUBLI8
MHU17VJX(VO1?<TDZH.SG8?1862A]H:N&AT-_IJL*FQOK*:YR@X=>/N.2E !(
M0B4FG' ,[JF(AIDV.G-U+X@=:ZK%1I$^$=[S-O4J^@*MMZ^]B< 5\LZ*K? )
MSM"47>XZ$^*]/C\-#1GRF 1EU>XMV6>.2<?VN*;(N^0=3?SHD;8TU1!-H'.X
M[O ,X98U(IT>[HY94_@QHN6&B?G 2A3SS@S+!,NC$8W#Z$#/OO.&B5,>+FB;
M+0S[1CAPTAT/=Q\@:)33QJEBU92DPW"B9JQ%BB8L":.**0K&3G.I?+-[)_%;
M1RO":4;H.;+Z# .57VX!4]O?C+35-<PF(P-=XR@:3BUQX_!]QFF@4 R7H"_K
MZUKBKIF*!M!64EZAK*5N#F8%#\NJG#F"!!^%]S3 %ZC'Y*MK1T8P7U8])G=&
M.W[&""X5FG]V'YK7T/RSNQF:__:R?95(UF/O_<71O;OM^ST.?;_(%:(R'RYE
ME&+8;<BZSH!]ZBKPJ; A0*])4\=6U!T.6PF[NT-.'D]'[DPZ4I&?('&R,ELZ
MVTJ?'\!CJ J$\O:(3U3\ZR0O\WGAV*;5D7*5_^1N-L7:];-Q#3_;]F&<F7BO
MKNK?)2F@;"DV1-3N"XQ_MOME>6*[SO".H3QW+8HH-='VUK2_XC)?M[H%2666
MK56G.YBHN(9/8(8>HMNNBTP(ZYX,09@L-^/>20[)\FRWE>J9O-0NL$;2%E3&
M0Q9/5ZI,Q,] $?O"#_K+D\Q@2=$>G_Y15F>+?'9,!I[SJ]' Q1L$+=C90<6>
ME60S>]]TG7U"MH=-##4/7 S7$#24XQ]%7DU/3_U(^&FXA@+#E$W+*^8G,S)B
MN=HL&NS)*7SB%XP(Q(4!H.ZENZ?X1_$1!)#)V_5JO;5Z%I#I+/0SGR'2=>])
M$_H..5<>BWHWEMG'T:^#D,\WR._278I"J/>>B9:I' YH+K?(ZX]^\++(NK8X
M//866!D6)8L+4:;=)L/U"PZT_=X#K;<K"\K2*8F_1_,%VY)4TF9AVB6IRY()
M?K+>H./,S-WD-&*>0T7/!OFBQDP*62X)\G:,0";B]9 Q]"BT $V8(',@#8JJ
M1=JH*7'B575[5U4*+VD_F0Y8M %0Y+@&)R)QNX:)L3.BSC!(>P.^< #8"D(0
MG8.GTRQ'DO2,>\Z[Q$J=8&-(:@%&4P,;4T][U7:4MMMZKK;Z9X7,)SP_JOC5
MLNDX=14)%S=U<$_RL-).&)L,C(T7'SPEYR:76$1?[V=SE+ N#8M@02-.J6")
M+^?#P\11U2:)CIXPT6</)'UQY]3+V2$H%?WOQ"X<UOX1WQ!AG9>$^N\(%NGK
MD,3=JSM2=P]WDE<;WR!NJ^$4KKP]17F)2+RH]>)BH6W@4M<"CE*.PJ$T1=*J
M->(N^<[FK,7#5$[;T$/8WEGS L/"@W34%Z!&0M@O;[)Q[*,NL\/1HQ21X^MB
MT1D#[9VK[B88=,2F08D[%OFD;@I]$V%6*-441MP(1=C6Q4%H#YNRA"-"C=57
MN"<'EB[D)3*_P9Z!";'GCP%#F<-Q4M6E[Q9\'C&X?8CK"QQ1K-W\\#HA-">C
MHB\DTD'G!M9=S"#S-IR2CX[F+GR]-_UF7CAMJ1$]SQ%9S2C@/:-S]3RV_2<5
M=GN46?/%$D;W$H/"!#4K&'Z@\!;H!JMI2$\U$J##^8F<"C4:T26@.U!>0,L3
MCZCU"DZZ,]"QX*)M.+JD)ZM-<B[<_NJ<C* \*M739%[4RS!"W!J@;XLK)[1U
MILTQ$-$4=7I.NN#!D]VBZWG"Q_AB$3J]<R$U1A>\X_VZUH1]3XFB1Z+3;O[J
M@\'NK.,$CS]=C]&N*F7_@P,NDQD4>K3[DZH=%"'=OO51<7,.K$=8,0AF1D=L
MPA/)L7[O.B_R6>O$49(V$NG+G#=16(G: /5%D;:'BNZ-$%K3QSO)QU4E"4P*
MZ9 66*U[CG8Z1U6MM3D()WF@\U"/HX=$IYU05Y*ISYHA6"U4+X3<\!T%8\P'
M[?*I9G]F^92=F]EF0<28.6>IQ"XF/^2X@D-ZGN%](K58H,J4-M-ALI;ME@XO
MU,<F++#+'K(F-GJ;Y.MK):.>WR>C-!GU_#X9=?.344]\,JH+;JX$V)[!]\*B
M5-%!K!9[@P^NHC[6B*RDVF,)@E6&ZVM+ "T<ZJ4<$W] #P?LV-/K]_1;9WNQ
M;[P=KF@7?^MV3[1O.K[<'36@#7 T&)R L127W#)'"[EJBG_ V*^/&'</C>&)
MTVF-]Y)D&X>R2WY=0CU?-@7F SJN8*4;@.0=;(J+JT=1S3D6WI4^^.R5D\K9
M"X((7V'EG$AJX0XX:B=5U2 HS+,@+LZINS/,[#0DUS",V(5PU62>QLU'#F1L
MYZY)= /W;>9JK,PY(1L:J#YRZ)9IRY($^XW]SEN0_KZ*]F6:S'^R;SH<Z!)]
M]+:EJ." J;Z+)WQ;OCM$*E^D!R4Z1!$:O/ZTJ-<;YXD84]HVNK "%C12)N?8
M4S2JU2QVK7CC4;SC3.?#VMA4>T&/M)_Z9P6P.H>'\[%C ?9&*&6"E95E7$MH
M2-PP5:%-E7O54D1G3),B:#D^M>R8.^C9^"1D-,&"V'"X@K)]? X'QDX/XE6*
MJ(N;0+@-S:T=-!'1@JWK</DN+JC41HUR1O(6[-3/]C&IA_D1GD81AZ?)J% H
MK9,%H(O1M+=.1DI:=;4%T=&F2/#\9+6]L).+P1,P6'J)M,,(PH29I-,,/0#N
MY^5F<9S%T)G,]5W0@*K)LWQ3W^WF2,Y^)#FP3>?9$E-7C)K@9: )I9!_T\:M
MI-O%!F,$3$/AEY3-GQKK>TFK.4J/X> BD4HN+U':"**8@JC44D.R;EJ9@X-0
MC6*XD@AW);O7DV?6>+H'F0<!MTM:U#T/&*F:/"/3KA5*Z?K1.'6529;7UT6I
M5ZNJN!I3#'%Z:*DTK<YL$Z:)9!7"G(U._TA+6K8P-<)SQX;1Y9*K[\3D"@HE
M3/"&$BV< 2Y9T8NX,=@9:2> 7VM$B[)>08(A!,IT\+7&J<C,SY)DU6A-??H+
MA)=O0&*'2H X8D"DT=9(.4.F73DKN-EL,W6)<D(9P)"HP69%E%?>KC[)P5X_
MT=W!-G\A'=?YR.Y(P!S@7KA7I:A*'T:JE!6)6_L(GZ &8!N9P.:KPZY%.(5+
M[^/AP&,);] "W6J"O[W=JS#\,4CTUE/\Q3L&)^H"VK.H5_7>;HOXS+#^>:SM
MY6C_KDR*A:?-UVT1[OG\MG%B8<+W3^3SPUGOY/-#VV@+H1_\[L]D].L2KV\6
M0P$%@+Y8)7V&.$ 2%V9[ TML68([&(-/7?%6,3*#'(@ZFGTD_#J2?Q?,D_Z-
M<03M:M&]?F9"$N"N(@1W4I65=M9 QMSP3:X.B-?)<M"%+#Y36P;?&\U[G]*W
M="B&:&D?/ XG\$MF3,/(&FS<EK8?#CAO'P>"=.-MBQO3\] *33NZ5X>(#NS+
M4:L=V(8<8F./( [0,;4<.")CU"-,K@ZR?#/OJ+;_I9*R"0VI*U,"!]F<]F9G
M(AZ9-8YH?$1F12M+<>*NR/DEO#.'?#+[BR1L42$M"SG"YW0N=711N<2+)E=\
M3]Y!H?@2& !K4)M"NW):.+R >]D(E;ZM$9B O";$ ^C,T#QQ;T*'D=(H'/>$
M4-UV*?]6"A6^_^C<-3,X[N_>9^8E,[^_>S<S\S>;P7'7&33[.ZX7=(A:]8HQ
M[+#%9V57)R<E,6FB@\J6$$VSY@25"JC,25;^D4Q/<FQ$+"A6.IB):VV)!@08
MV9RMJR)+2="C5ANZ(C-%*E.C+6WM&R=3(LY_'Z)R-7Z(]U9^#&K]4W-=A.8E
M*ZZZ:(V+[!R;=ZR:O#W0>S;^K^ZL[UW%67__^L/1^S<OCU[#Q7\_A+]NL\O^
MPXLVS"0CN7^?H_4[7?N=P:G-X2!71C>7 O2ERQ=C\8/NB_!E^SEQ(M%90$(J
M(FZ&!]/[6-LVRU0W?*M".7R^1S$'?.6HL$@OL4)JPMU.Q=K($MNVN*G<2V+2
M[7?M*L:+"U<[P/]LXA4A\8B_N^*TKT*.IPVB<"7S&%K%\1 V7R4%8@?L6&1Y
MK&'W-Q.I6!O^%'P1GI6V*W@*G@_2J;;GRRU.$[HDL<R4V!A03RG4?*A(=L I
M[%@%@UOO2*<RU4H?-]@3[\ %+>S:O27DC#2Y'HE 38GBT15DJ)R%8/H+)I+R
M$B'8_J=;VUX!U#GW5_A]4T]/,M=;5:BF=7GJQ?( KHQQ?Z)_+A0"[O%*1%1J
M-D1]LTTA"GM]+B/@[0[&>32PLI).4\29];[6G:HAK(7$4FPQ)=:Z&SU-IF[;
ME3:^]>95&D=%G=)R00,M2278C1T8YMOA;[1O8/YRDR!254QTI[ Z$QAX2?)=
M^DQ@P[ L$W2EI%<O!=\=<1Z=%#-GNJY\H3W_AH.V,!B.5FX?Q76)5#<@]4!4
M1+!"@@;J27N^PI5R\$H3<J1&4/CIW(6OL64Q!E1$.#D,/1\.9GDS517DPF'2
MZ4O$;RK5!^>V%ZP;47RNU>9E\5>E/-+UC#7G'D?9QJY^D>2J[PBE4)6$V.B$
M%ZZ2D/\Q(%-TY3;^E%3(H))HA?G[]L(8%(HP EMB N$/$V.AT^3HHD/IL,@P
MSE4L<=FD($PSOQFMF6U"'<QP7$%==NL:BG85:XI&-S9W;$V[=1N*"7YB7J-!
M1 IC"N88O$XF),RI;6#:3K"G'89$-4&$& 6T-#\SI4@HU\]SI8K-K>OJ#@=O
MC@Z5\KYS3$9+<HFE4L L"IAH6J^4LOH-,OY0Q9MKX%:0I='P-B"?#<LOJ2\Q
M-7Y%*9'(G?OIBII#PD-2H5U;3B) @(>V8Q,4Q]I6G:U/-,D37YE>H$ M RS5
M];<C[7A;YXM7L-?.?=:"Y1@F#L2?4O_!+V/6^I?HGE&;2NFEV03%:,$XVJ>M
MR "<DQI$4/61,?VC 3 L\N.<D& Q0Z"5=<^QE,%4+%<D4*+K2%1]Q;*,LY2<
M&>8,;#UHL(.<4BLQ0(^/.*V*F8/"(ITTLTV*\$WMK% !,+QB4YE5<U6E)BQL
MN)F06JDZ$]9Q^2,[)B7L\ #M&^ YCS9'STRCEHL;O&YG4THC5!'E6/0E5!VT
M%!E+F#QSW=)CBO]VB"LGV436&L_Z(ELU>0MQ[!.WL,?P=(+9<9X#^:YYE_?*
MA@ER+5#U?EE2> H<#?]C1R[I\T0Q!/HR&;ZTQZ#K8 _;M@+J4P8Y-YL9^(S,
MFJN#[W=$20ZCN@B7(;'<8!8OULLB<#<LNJND _;NTP&:#MB[3P?<O'2 \TZX
M\<FO53W/"[!U\@,T?U?B<K?:.DG9.7H3ZNF)?;>5(;_H9A##@[DH-Q@#BOO:
MV[J(*+<@> C'R*.>LB@W-1QSA]8!26I ^P;0S2Z&E,Y3SI  AMA/F/_%>1]7
M6A1#$(NLRR*W+9V78A8;6]FY)MK"T!R1WL?1]<(A3IF:@MW(O.3(A0Q/S2_V
M9S ]/*%IPK6/G$RRE!F9S^@5-(;U.3."H4SQL"$^BDE/P9P04H' EI13Z:Y.
MX!#;SI.=?68GY.8GH]-Q$-0(#5,]X^(:"7(0RPK>MJ8(AA0'MJR+3B?SCIQC
M;N]SHY!W9[ XS4FQDK $4RSU[ EK'@@JK&H:# E)7)G"L&235'I?9W)WR']7
MQ%5">AQ6"J%H>]A0(W16:85IJU3K7"26>=&H"4_N^+SCY9<U3PX7B[ OF@3U
M GX8C[.([]41T@L;I9%'0EW$&Y#@=2I_Z.C2V&M40E@/6P+?=9'5"$Z'[9G9
M_F%=Y<DV,&#B+/QU!=.%$'.U>V/Z)Q@L-M9PQ#+L.X&7R%&.U$^JTBL1*AYU
M3 ]6J?$]A9I0A:INTS!,IXJ4%]664O9)KH5*KWQY;:]D?^ZA-EP9S%+/G:B'
MTV;"12;(9,]!$G101N*2"G&^%3M>(AHT*"7N#@)N49G\(ZNQ(.&Q'AC3; $_
M :>86M29+$/KNZ!]G1-^<FSDP<.!GDJ,!\+#H!0MCV\YN@%Z[G9GHO>_)!.=
M?'S[YNA6IZ,[$>1E\O[#1XQ@N,C"%$FI*&J0)>5F.6&R+UNG59!%L5[DS+(C
M@6&FZPHA; ZTV<I^,%[C@U.ZJ29<9T4SK7-C(D901I,RHB1,CK34NA>SXV,L
MK03%]FM6U+C=_P#3AUS"D+&,PW&"&G?AZI$D6E%5=/1QBJG=D9R3ID^,<8V/
M2-;V2U/Y1R=M[B^EX7 !2%>C#.-H9_<O2L=_+(MU7T[>!TBN(SF/H[O6?#S>
M,,C 7T!@_A52\-V)8X/KOVH*/EJ/STK#\\P0@80IWFBE2@GY76M9F\XN&%_%
MJH!;.3O"EZSE94,_O5.%"/N2#7_M^$%,-OQM91%HD?-IH,42O2-2TSA=C:OE
M\ LBG:[G0+S[N>^MWI LY,@_&SD5X^N)'^X^"CD*,2H+%PN704].G_+Y;);[
M6H!O;\'\J6O/.633GK.1?3$<O"</UW,IM8EOU4-#A^*,/7+OFXF#+.O<?2;1
M1F9\BEY//HXQ[57[YI]  85F/C@L>#"V@>A=#2VNG6OP^UA?CL)](%N&%"XY
M-98FRW^G&6O,?P2'F?:NEI3+TLPT16O 1AE=D*RE[*]_DG03[[EWHRF7Q?EX
M)WEE@0.$)U9)Y&R16$M8"<__;,9\5C>];S;-2@XM<DB*3(U,NBL2CL#\] +,
M"6T-;[!E[J8AX$$+_\LI!@US;0OL4L., Z;H%WRC#A>:?L4I>FGK!AOM*;X@
M-(FLL4IB'YNT9M>Q$]IKJLQ0G!@"%#41NR,;YRJIF/W[5(RF8O;O4S$W-A6S
M+^%8L8)X((]VGQ]Z/)+#CET^;.<#[AK HRA;RV<QUGS@5(#?C" +(<<XB?HU
M>=Y#/UQOX<T\<1$WIVCC+CQ[E'=-FHJ'X'4@Q=$,7/<S1A+9CU&P4E =(=!$
MX\"&4"LZ7TQ 0#%8MAU)!P8Y=*M:_3/A;7>27ROL$I7!V^9IQY19(&AF)T$H
M;DQ&R:TD8U@%7T#UH!UAQG9T$2,*>![#0[%V,;Q%A$G(DGGQB;")=?[ PF":
MZ0DX=S?"9+_=0<>'5PDZOCOZ^^OW$F]\)_]X\,OAA]>O[AZ#A9L_I5T+X4QB
MQ9&:"D@=O,JT8!_>/K(#1PZ\S7!$C900%JR=9.@ #0T'>WL2%0(WV1GQH=%,
M/W\P(8M5R*/(10]22PY0CAJ!>@:=.XM^@ZE_BAQJG5Q5NP18ZALJH9'M:0!P
M')3+VH!::\*H(A)SG:+9-5,\*@RO($6]!--Z0YZ##W(N.4!*O[@!FN)/%;O]
M3K$C-+#T/Z9)QC!F/BUX,4U>&\&)@;>1L7:FDXVP RON3\RR*+^4Y"VU +>>
M=T->EBQ]JAV7*8XJ*3K;!Y./)[ICVA4%9X<+<>?N4+DH'D[<:!3LII'$N:ZS
MS%LN!1D+GH\!@2FY4-JY43(D0H2?_<#H.\W1$FJT9ZH#8DR3##ZI:!3>-_NX
M\V$GF><SHJ0IF,4,L<U=5@3%0N&<+_PQ&H2#D<[OCNV%AVR*:1EN6[&%*!+B
M5%.OW34E6U1EBSF-\NG$MP:/7&K5U[FO4"1R!7"?XEB^R6'H;J,(V@3>)]/.
M"KY<6$"O:K]VO(!FA3%.CM$ VBR^99N>+F$\E9DWE2E99(J:EVKT8]L!-;X!
M8O1]&U\[TJ.ATP#;?[KSC+[?>W05&^SUK[^^?GF4O/L59N']T>&;M\G+OQ^^
M_=OM+D7NWOB/)+OQ-^;RNMNMJFDV]A"*+]0LCA&,(HZ-Z!PX=/R??(2"<G(A
M 8K.PIG,S)MA:RB. @213[B &E)K5'=D($M8G(4)(PQS.977A5KJ>5PRJG-N
M\A;<%*V,!5:X42&%8\@VJ6YC%FB/&0%#X6_Y6<5_^+<T2S!NY(V']PN2S>&E
M878Y WNT/L[K(&.%CC6/6+XDB(_[$*8M*Y&Z#<X'O@!M<SM#<(MEMCC.EFZ^
M%L4?4C/G.>[M' GL5<G%-=W)I.-\1WA^51]GI;ZR]RZP%%1# L'"8"AA>H+$
MO 9:QF+>K$!35/,Y_V5(05VWL(+ 4N0:$%$6"UL;F<;]_VHBWTUC9C V?);9
M'\1]ZLU5<H7FXJ64C2&]XXR2+3*1.(B/>U]48TJ%+Y,\+G(CNF"/ZTB#9IQ\
M=]<A6\+S%-=!*349#_A?7I\*TB1#3KQ,Z9K(>&@\4Q),A^L<M^6.!'7A][![
M6-,R< NY1Y3;=?5G]@[.K,$?GO+ON@MUX9]3Z?NFN#CI!X4/T:92MD29:T0C
MUN#.(>N#T:1"=>'>6 EJ830-6G*5H'1[D# LXQ9B0%A ,K':6LTW=C??@VUV
M"L)+J#^WGQ1'GBF.G 27@.0!.0W;:>?<4M&!,*0.B<Q/LZD;266/3K%3=836
MD!]IV52V5O>[@IW8"3."M:TVBQF3!*)TYM=8:_.9I],-.B/WJ2DQDL'S["/]
ML=NAF\7:=6/QBJ/->Q@"C!\YV %5..<4Y]BN:X2(7 [K;-)HQ3RC08-*5H_%
MJ#9*?<K*,*/\(OB3B]Q7E ;-3B*$NW% X":H7[D$%9QP0Q*IL)!.!'1KWFX2
ML? -;<&V__ ^G:CIQ(=W,YWX7<HV*<R'F#E$6@&G#D/PR,052VFM;.0B( )^
M6A<K&X.L7)5-A23'DH5LN2(FV:=0($;N\Y=QMQA#-N>/0Z>%#</._8'H#\1'
M$DFVAK(YN2YQ]GDGB# R]NPBBZ6TZ!,,?7)J$:5G[(5ICB4F8."!'S)3HQ)M
MS<4&R[)OTRGS):OUN)7')_J"[D2^0V3Z//[LXO(XF_(69D3:D/@\H6:(6<>#
M/4\[E.+Z#NL4;E1%3FN!CV&9[7(#R7BA<6W $T0W@)M:B(CV>8@<?KC 171T
M ]W%EW*58+B;0$%Q3QQ#[.Q R'!*N_HDYF2QTY-:<.UL,W6 ,4E\!,F05>Y[
MX59-XV=4+K9$U%V]LR*T>T>KR(Z7]RE^01(HSMHS7B ["JO:3(CDP:,_U<Q,
M)F/&@@K;=YX9/+#42"Z^QACS][VMGZ@2YJWG'66C</OZZP5-3/M9<X0HQ[$>
M,1U%)X4%5R]Z+; 0Y1"5#78V3["),7[D+0C*7FTY&7C]#XKQ_?@A6[#-(ON2
ML5AQWP8,(&6N=5#&?%MH.(&V61=$ YCY2G&*@32M2 ;%Q>@>]D0N731O3..X
MZ.9J>$4W%X$#A=1(."_S)>14[&J0W7&<DJ&OJ'9]X$2=7?.S5%^^=QR.9[W_
M+3C(: M(^>D=7X#G#%M.4&MN:$+IS]%#@C90DV$,Y1PD%)C[LO!OTA/]A:%<
M=_CW0** L#C3DUS2\:;GFI*YP$(*&9)0%I%=P<N3(:2,AWQAO%HB5W[$!QQ-
M5!I!/:/"Y8ED9<[QZ-4B1X*G A: 'T<1BAF2#BXV';/!X<.7'+<&"X5Y]E^?
M2ND)1M=,@"Z850*%4TU>44\W2Y2HJ2D7[,#PT<T[H\/2GB-X0*0W+VRZ BKD
M '>MV\)MOJ\@@,BDCHMLTV 2QO(AX.0+D0;/A_&&?,(YK!'7Z"$/(+=$>=B5
MC)/CI@V.-1DI^"N<0%VOE8SB!X9I%Z,TPXP+/*3TEA[(376<K8/S3%OZ."N1
M(]>KZLSKH^[>"W'F.[0H.PA(&B4^E#FSE%_<Z@=+66 _HC5ET):M/ ?:8RX*
M%WI.F>D:IAE[GR%0R6LP]$<CF="VR -9S!I/'LLNP%>F?KW9"5(JA_M(,0+!
MBDBCG:UAVG//65;&$0HVN!#(L63X&YM?TI6J;9+S2<3I!2(<0Y"<S2\HX-GL
M W=X4CI!M%F+R.9"_K^6JHK+:S_X$;WT(PIWH6P4MOLNY!OT-J(MB65=X7_B
MGIN8QU(NCD]@/[EV9J^[I\AWZ#Z@5/\:'N"F,U=+]>[LI2:5Y(17BSHI9=$Y
MU04(EW<),RN;]H[8.)N.<S9MM<1/\V,>C8?=WM5P](C1E(P1:N#.SJ/)[+GJ
M_F()XT.Q7YR']8+!F/*"CGA-R@9EJ\/!2#O9Q!%&R^>B#2A<H0'8O6O>P(I<
ME%1@!UIV'+CEW+!:<;$H]6+XT#$95C7:;1]-!QF^,K=BHYUZ-MKXQT0O @>_
MLW1SS,=3/SDT2J<G5<'$A V:I]0]]'S%UG8P7:G)QT9?79CA:B=A/1 -;TA1
M&A!"!9&.&3-,%C:WF&9:]'E[%8/I]-)F0DD=,YK2:;DX-POO\'ON9*5:0_AA
M 2/Q%7ICAS?M5%98,2'1#S;_KJ2(Q9E">E L>.F<[#]';"^JAZ3$:<]Z>&YC
M7_$IIJJU3)EGHQAWABN<?(3  L>Z9E/B#ESN^B=>3CE(CF []5R'6:^QLO"]
M?;&K>0W?N'';>QA(C/S="M@E'?&Z8AW'>.@6N*R.^!EV,]Z1@<M^'7QU-S$;
MA\_RE.^=45:'/8"C>^,2U71BK)P3I8>&.&>\0-2HQ[5.WK*-4D.NZ@"O]B R
M3,*?*?WD0O:(ORU%Z&.=HW-T/W',WM_(_O@:M!)7'\"E,M^/[C/?FOE^=)_Y
M_B:2_24.X_Y.\MZ9(G3VZ3',#KXK,*CS'O,YSFFA2A]A69?7Q@A/8V .':#C
MZW/2O]?L]%.[ N"T2Q2#CQ(3E*%6"IH>=-Z%*]7QSHDO$#(FHH$_^BNEQRD%
MP7R,8))[@"/%\VLAG5"?V'<VB1,B,>>4++S)7^JY+]RH+ON#E]D,HUJH*H(\
M AK,IN0_QMS $V/"?=;0=%$UOG%%IW$4CE<FOTDNG'PJOFK/OK=T:"[U-MBZ
M;V$8G4Q'#6\(I!((DW@_1N&CVJ^N552>25Y&W&-]2YE<XTI^<Y5UL_;M?L>^
MC46<'-P6%!@=JDN*<!PM$V"E1*:#[*;K@!3BET)BT)!XIBBW&)SM%-F)UL)6
M=#Y()B- #_--)IL&0_!PH@A0V"$,,H\9;NW.+_+N+@H0TMY%& Z66BI=G4V'
M]'0H[MDH%_+J=*(\D&]Z. @\D 9T!#?63I:@]BIV ^)V$PI9'7&K'?RH*-=U
M ;[:-!E)D+-9@2TUTVBFARNL"4[-+@A9E@\^3!%3"\NSK&;Y0F>5YYU',=Y)
M?G[SXDU)G8D61?;SCV]>I$$B@'RL /+N@VAAJ)_'K&Q)DL4+IC[*&SA?+;Q/
MJX^&SHKWM7-:N?_D=:5IH=.N<MI@_5@NV !R>(\0,J*%DI]QQEY6.9,"R<PN
M%LP^31NA^PO*=)N043C&@X3[NG]S]7BSM/1#HZ5=D,,%6GSZP\F07RQP<!"/
MGB:P2[CM2E5[*OW9A2F)"Q3.G0[N&Q_D86>IOYO8GR30+30NLC\:IT_,GHR1
M0KQW4)LNLG-?6$ A.$=_;?1(.RHIOXA2^3X$"Y>7%KX4QZFU^9 9Q/_?WK?V
MM)%UZ7Y'XC^4YDA'<.30G7MZ,FK) 9/X'6(SMDDZ'PN[@'K;N)#+)F%^_5GW
MO795V9CNI#L=D&;>#F!7[>NZ/NM9%29T[G-$&<])=CFSNC_NQ46V XA'', I
M2.XREM7<+.(<Z7*$T,Z4E$ YPFFOZC -*VK27M9 APL_>U(@#6*WM*I.,2/Y
M.+^RW!Y/IF$N\PP;YFB'L4<TJV232;W6B*H_ RLZ+.J,0A]KA_'2W'Y<FQ0:
MZ.JQH:=49QT#8;@9E38H11OG/#TWWI&T!LXIL2'$' MPKK!*;H9:$Q-"[MB=
M9=X&&Q?(+R1!U6Q6$G]^68RKZ!UI!N(.STT ME3?1EETMCS^UTID&CY)SQ=Y
M58Z+*\=I$7VN(: JWPJKCFT4;UGV!XBDB,%GZ\4@[Q:(NKBGL^V"E!MX!Q6O
MBE!'@HEN7K<F&[G.],KZNA"?B?HA;)%AHTUITX>"<7EY:09?E"?U>_NPG[R?
MS_>2CVPJ;V^1K:R&NP!Y\,*LP!%9<Z X&9,'J&/B<@[$718I'8;%EPQ4-7^.
M!>9DF7%V\<K:Z2K\PMJ$!QB'<J%6NJ*92)"O[-)9%220R-\*OE:SU?/L')/'
M ?&&</!0[6ZH2>>&SM528W F:]#3>?$[ARDG&4R:,T3G*\OZPO->$UI.=:-A
MU9A(U:V"O#.?44=-&EQ0+,,PO/9X$>LO-W3L)LO8KML37^Y2.Q=>.Q516BJX
MNN<IN'Z(;L,*<P=(]=2VE6";C4\A5E$88(7O33OTYYWOVTSAS7UO+)!>[WSW
M"BX6D1:T0L',O#+1!@=*)_JU,OC&=RZ "(W>"-TZ2HG" +2)@']6;-_Y[YJP
MAH68+IF#D%NFW!"!6;,33!BXR!/>E7V016EA"TD#X3&PUGQS!7F*U)G>K&9\
M;&Q/$SS3O/2^47B(W0I)RS9&7KD<F%<#R9:;2V'\E5@)RXB:@WLSUB_U#^5=
M?:NRW></R4M-7CY_2%[^\TRL%R#M&0PG/ /BB>09JPW"1OLX=AT/[9$/K60F
M9DZ@\\,H_1632E8T'DLL-&M.0X<Q25=I9VWI]?<90WEL8Z43+I<@E#4?,O N
MD;C,YY#$UV6CBC2)&"=--7X&.4IAB?^K^RL1LX.>M*@MQU]3<#)3YJWQG!N4
M3T,T$+&TM!C=A;T-\94X2L[S$JB.*7.X237&QM1[M019:1I/!EKEB^,E%D];
MRZB:UR1%5!]^K(P6#I<J^F!UI9C< J,$4??T@H^)56H4U8;J8B-AI.*:ZH'A
MZ^;:[G[===G>JD'R'4T+PQ^S$&JO%'JJ)5*%Y<.&"SM-O3LH[K"!JD6ILY.7
MS]581NNE@,^,2>U/P)Y 8G^,V5 CTDQN51P&<+@N]QB#?_-7D-#J/!3/58L]
M]K:WXI2)@2H76#Q@,;MT1:'@=&KXJWGC7X?2-?68(\'SLIJCP97'=V$IJX+;
MI/BDD8#+==72U+3ZV*6_G4WO"4:.ZY<U7X6+9,O9\*!<(F3@VYKO9^Q7@M*C
MZW-9B.MI43S9%7CTXG,FWHD%N[2;//L"'LW;6+/VU2VMO:?/-U5(]-'O2B>]
MO"V,@^**A&Z\<8ZB7&L 0_2QF),'7G4CQ!O?Y4:,L$\-).08KX7SLI3#+&3E
M3:C=:BR[GGKFPU5A-' D!G1RE-\ 9^C0SP^GQ)^25]1BU<#&MV0^RUM9*ERQ
MSF*3PJG9I+J-1">PP3Y&H7 \E.-I2M1E*$YRZ8&742#2LJUTY.C,>\/*X6$L
M#5<RIZMR]&NH0G [&]4T[?YYO9@L&""_L5YLQ3'_;Z,E6UP&V9!Q$N  ?D%K
MZ5I8 P&OA\\OYUSY&JI!*X>+4CY_-^;WNW,N?ME+NF>8P%@#I(_4YBK$OTN!
M6-ICI]S=)'V8A@ '60)-92!V&4/,K.4"9JWH)-(O:)O!VH%OP4]Z.PAB'@)'
MI4_:27J)/D,V-"; %/CO<T_1/?AI=>++\H98US"+4D.:\FIM\JSM+?EX<K:<
ML3W&.4A?!DX%#X3$HC9?MP40.ZF+]FD'MVR,,G3')]$DP,Y!:3PH>'O3>EDD
MA:8*?0;)275LJAU9?<@=)Z[5T;+9%8"BLP-@E&>[0L929K"^U _,GS8"L* A
M8%2AXFU@Z) -V&HUYV)E09 A' 4,5C_*DH1<4>\9!#G[06+?4$ ^E.J;Y\V9
MDZ:B/PLLBJ2\# T=>3:7XEOPZL<9AJ9ETF:QX0:%)N*<-$%)NJYF,^1U737)
MP@IZ6I4 @\>@1"O#AK\G1-?D"W>(^X:%(K=R8CWAF^ /.?ZBTE"HY<\S+ZW-
M&_5NE(T&L4+$H62:P$62T$#HKCF38ZYZT?(T\R!P8_!NE-\)+O@WR3W_$ZA;
M-HH)OWB("6M,^,7]C E_WYWA@HG&_4$'Q#NMZ>2SQ+=^[7P99U?4" *L!)"6
MY?0F$$:0TFCPI':XQ]EN*Y8R#CAAIG*%?59"?:<WZ#DH8R1UA[EF]JE*#6F#
M8,42U- 5MF)'1 $8$M[(']UBB)'EG$%Q40L'@M\0<T[X$E/-Q]\.=3HIQ1U9
MI<:<AH$#4R$#,<:N$B+SO3Q;%-@B?6.=961 41-O'R_S77MXR6L:B9@6JD/W
M\7:+O1*834A2#&>L=ME"R4F4K,782CQ=9#'G7M]*1'3S;? N][2-R&T]W)[?
MI7](K]][-!JT>\/#SJ#]IGO4'7W"9B+<OPT4W<G@0_<#K$CRIM/K'';WN^W!
MI_O76N0Y%IU1 $KBYJOZ7K($RI43):KIHSL (HU-/=>W#%M;Y5S/)!(,<3!X
MG\%'&BNW4,09B0F1S4,\23&O<QJ98*?H435HOR86U8K_"$.Y$AX*%Z$*^07Y
ME\6H/+5GW,=S9DODZ-.KGZIHA5@AO-C>VMD/"%<:6+?6,WPWT49>PSCRP!9U
M,(%;,?C=5Z$Y^AJ)_CN$A]2<A1Z=-AT-$MJ2L8\RSM,Y>2+L=E&P+)U@/0M!
MO^AG/%:EX'XL#%8!S.SI:FMF3&L% YL[G1503E-PR&$>D^5<<7;3_"PC3&/L
M,+2XFD+.E/,BD+D$@3)+>&.>,D%==IY.:^&+J.QJ>\L.'KJPC#IB/6Z[[S49
M-9^G#G.+S)L2CM)0OQ>'?9E":SQG8V227Q=S+$QQA'&T*.;67J:8")[A46D)
M:Q?[@:Y/8DL@@O25")<;0]K"KZ6O:7E5+$L)M>+'G,:FOBO2&ESTL1!,<;\Q
M["*N<$95UF*1<&B50Q7R[^9'G4JW'JXE<Z*G&40W6U*Z>9)<%_G$!;]Q+YC6
M1S(RX9'SP 39^'1^/UM\L-MVCO"@GN73S.)Y43_<Y/,<_S5+-%AD8-IP;VY:
MU$$O( #ML'AL;R.LS*((U"-0TN 2-:BEG -1-6(,XQA9G0*Y*>PT@8V\2-C3
M22[8$[_@(K?@Z9=TJ?AFJ" IC"^(0VC%7 DZ:5HR8KRHTI,! SLA8H6W<0RJ
MHTDS2!J]);QY>/WQNL)_6YR;9[*BZP)SO=*,PK8"([YH^?I07M@7:9F2E?$Y
M6%ATJ1":$B?G5BT=G&B\HX%>)6 +1$DTY_IH(/56UW&>($ACB>U50R8K:;*W
MMY GNQ+D]ADEGT2B<KQ:KTQ:;A5\ 69"'2(7& K"DUE6% 4W9/9WEVO9&E?"
MRF:3L_0RAZ-VF:&C@9 1(4UESB>9]>5]B?*8;?>DF4.]WE5<C@5W.(^YU1&H
MDW1G:*UAXF)(CF/_RNHP3SGAW+*]GE.?ZVDV.>?*.+Q!626D"<//Z%J1"+BX
MN<(_C;F6[D_9CU*>6>^_[:^OE[FJ6"FK$MM<9!L?+N<XGA;)I>9E"$9SU/W4
MY+:O\Q2KQ$G"8)RP,2+"2.V>>W9BGX(*+;>WI@5S$RT"DMVHX2H%";#;9^EU
M3<#RADD@YJHH0?^404V8L7>M,/[P$E;WE A7*%;%SYG[@VUG'3?TLI@OL 1L
MY3&^[?S>M_U^QKG5.H=!N$=P57SNPU2*&=*B(60+&]D4ZQ(A\G]4]O% G+7K
M^D-8KD#SJS6/3A7ICNNM:W3B5M%H]/%&+VK =?0!%L4NX?$TR52)_''&!]^/
M1GR!1UH'(K%)LRQ#DH_LIU2S8AB]@RG=$"W)U:(!_M^*I:* ?5:]E%9&+<A3
M[-REM.4K%,Q&:QR<H,]1[52JN)6;U3YV!&N-3T<@.Y.JD)V+XC-:":VH% ,M
MOVE^K20I82FM($XWI*'A<G IA+TY$R@J_%974=?%-E^<CK"N]\Y8>2YXN=M(
MPT4YKZG2342<D!<G!*QSD]C,V!M?&LNLWY-%OTL>\.5#'E#S@"\?\H!WRP/^
MV/F(%W?)1^SW>P?=4;??&R8GQ_U>TAT.3]J]_0XF)8;OVH/.\'7RMO^A,^AA
M4N)XT/_0'>*G-2?Q7]3T^^37>Y.:>"%=SX\P]$K!,S 4T(#CE&Z4'E1R0H&B
MY+7(>!UT&F*?380A+B@RMA<+GHFJ#"H-Q58@R=B:BBDC]'NN4K-DY@?$^D];
M"4>$<"XH,1 !@V73E3R&-BVQ=*\5&*SMADIV&J4W=&'BA&JV9HV\P>W"\=M;
MXAZY#F'ZU8D5L-]Q2Y@R*:JNN<Z+N(@YWH/5]<#K-J&RZ P_HS6O%&\'%!5N
M!H4.L<=-L.4OXAWE#D2X$Q0I"'W&YW@A?@>3L;P!__625X%-;.>(7G+B>D:$
M5#FU-L962L&M@%WES:@F1!0BS8V6XB)[FB2M[[H"]L &3G.E>#M/_=_PR7*2
M^QYIRJ,DZ975I\<L<JF8EN*FQJ*:,J3AN+ X/BGN82VKX:]WB^:<#;;U*[-I
MS<6AB/SF+])UEKSA;1ZE=G_@4P9/%/)H:^(2;TQ5%OR9C6%!D,\4ZA[7Z(1F
M:8ZN12OE<"!TJHLY3+:8W* $0>_$/Y^Q?;B$$JJN@UPQTY)A)@^C;;+P,.*S
MY33( 0H]:QLP7_(B>3 )ORRBN52%5\B:39B2?E;,'E4$-CU=!W<%IB91)#4>
M.QF.)G(E*#\'5S 3]D_?NRDJ*(CYIR@,'_Q)'K,0 $6- IGSTWG8=!+*?.&;
M0!+IBLY)LUDH=$F^GV+9%F\IB]YT?('CG6 HK0F_&D-.$P=&U=EY#@_"3C+=
MAGQ1^R4*9L!S%^"7(QH/5Y49'8IBSJVRKN88OZ<H248-'\=95>$VR/I8_EKX
MR" [,="=:@$)!;ZXJ>P[1UPVPD"[K&P17L E)OQP&$<L#*VNU3'%RD=<O)&+
M<M5/G7 <^(SBV @[N+2W1'V7^.V4V#4*IXQBC*X)9^;/&D=$,5Q*230FTZ!8
M&RX&T]K%D[XGSK#9F]S.\-CB#]M;;S% 3,1'O(9L>L80DC@U7R41C$I -.&Z
M<Z<R)I&$JZI*VNC.3!G6UQ9R,,?%Z;JD:LCMW&8U*<;+2.F$3V/\3H0E9OAF
M<*N%.(@R\3."0P03*)T45PT5#PW)USB]'*Z>D"S6OW+?CB'#6>F0;6\=:P.A
MD6N#]SHY1,S').'V<;4^FR9FN T<E[JCN(G*+ZRZ_#1@+U XC%F-H!A>3DLT
M!4IJ[6ETW%67H<H:L^)$QN4$&M-[^NQQ?/A0.XN,=S0(A?(%;6^Y;LR^7$CK
M1GQOT54M/M?VV*O%:+FP1&UOU1K"55M+]QG#?:6Z,B3V26U3L-NR'M2QB+0@
M6\6+BX8V1TYQ:":,'18>B:/D:AR8-<E63K_&OJ-\6!1+$$/$JEV;%G&9CE@!
M7*,6_"&TG?_-Y E^24A="=ICY<R2-1,3:,-:4LLFXDY5ARML^*A*FGRPN%1:
M.F(R>"%FCH@K:3'Y7L4@D<HMD5UCKB5=XVF:7Y9<C0ER9,(X[HB[#_<DS<O4
M$II<6VM![AJ-PIK2-;C'*VO7DK^N= UTZYK:-:>8:+ N,72[K<:K(Y;:90HZ
M=%[I<N-%2Z!LOT/!V0OAJOTSU63QH.V@-A>$?>TBJV1MC=7VUK<HLKHG>OPN
MN957#[D5S:V\>LBM?'\U5F:3/B.;]"!=I&"2SO/K= P?Q1_9+@7C1<W00)+I
ME%3$*".AXQ#IH22ZJDXCN"%;S(D=DMA,G_ 3FCQB*,21BQJ10R/\<Z;,_)[3
M$P6FF$@@Q&>E%.HC>Y@@@J*/R^Q(;@=*C-!EUJU$W%I6&[XMR[KFJ@^?NS3F
M6/F$M?)9J:S3_.6@_2\C0NY(%6@2XR;$4SPGJT#;0_-FM;T<@-4YE(SA(-/H
MAHS:LA+7F5PSV(UKBU6[.K8+;0KBF[G>M@QA:DUL"<XWJMM&9(Q>[L8)$C+J
MXW<$P%X3W C'YT]WX%):0R)BN*8<X]ZZ@Q6#HX8@:3GR)CV1? ;+9%H03!(^
M."_224Q'[HAQ9><RJX&@72L$],E(4"4-;XA=ZJ?)5IJP9^*/4.W,*#NHG3JZ
MEG=A%./8PM<G2Q&?PRU.J12MN#9^2P,(N_$$Y(M;=ZXI";<D0KO+2S3%B';5
M(%CD@L.7F:Q[5E*T6%QW.+0.SD265&VHG!QB@D'C)K!G4_&F74PB<-]+WMRX
MN=?K6%L!0C/^?59\)F2C;(WBO#2VX(>3N_[K\.<:RRWB;$CNX8/T%4)F9^W?
M2S@1J%IIRRM8+O<R2O15U_U^F):FCI]KI/(B/\VEXF>&;6#0&8$KTN>KEAP5
ML(RLF:N5 @TX\%MAX,9\?%%P"R<&W.OWR#,60@GMMY[9F.3ZBR*LBGS7:^ R
M2V=2;"=>%R_UXZ<[OUM_XHXF5#$WUE@B@XUS?@_M+&IL@,8T5:MYS*20L- 6
M%$MVPPF:J@LUGF?@R#5SC,L[6PH8 *F=NMR?4QCR)^&HJ=D#L")1VGNS];AO
MM^$%W8;]:?H9FXB@@:I>*!_]=J"%W(E-I/-Y499&O7BFU7'C+,,P#'&KA\1_
M!H>AN,S'%H_R#C!8'TN2[GQH)(1TG4UO!,M[K8@'HX^9KR9_85%NGX/S5<^4
M.J"S9:EW?3MA31+ @XKE%?OU]:C.(F"N+5Y7T?;UY)NE4NOI954//I=XFD7/
MIEP!<9A5XF]5]O=6]=5FO3BS,K\\16(SQ1GD5J.!4X#[*K'G2CM3OJ<TA>VM
MSRD905?@-V=51$.-@N [N%T_-JSNY5U@=>VW@T[G?:<W2@:=M^T!+D8R:O^&
M:+J#[G#_J-U]WQG<O[K^EPB>ZU9H+B3N7NAE;'&+@A"2K !XJI'=B*?1XP:$
M'\YAN^(B'>%RS'QK>)$; ^/+3HZI 4VK5D)%AB<)%C)"T+MS9;@3PFV)B5R,
MQ]0(8QQ3\K%4O$I#E-7BJ%6O18CV=,H$UT)402"1*R7/D8X))E-YH/HK&@&O
MKN&<FBR3_^6Z/E5<\D7Z)=.4AB7AK-^9?/[WG/RE0')6D96,PT&Q2I$2]/W2
M_'N07G\E.=!+2>J#2-C>.NH*$8B8!4='*"J2_7YOV/F?DTYOOS-,3GH'G4'2
M[GU*VL?'1]U]DK1'[8_)QW?=_7?)^S;\8= ==I+#0?]],GK72=X.VB!]D%H$
MOT3T(DE_0'_J_-89[..'X>>=[J%[Y.[VUH?.<$32ZEUGT.D?MN@;P_81?1ID
MUW%_2'AA?32#A/EUG8,$O\6#A8\CF!A^1\#B-2^E5^A[^;';6S1D?GL;'O/^
M&%\**W_R!CXW.N&?]A&J?'34Y@$-DN/V)Q*ZW5YRU.V<!&85_",M#0ZYCW-+
MVOOT+?@HK'2OPS]][([>T3L/^R"X^S"@[:V=;F__Z(1$./ZY?S*"A[_OCOBM
M^$"2[/"O WC4^^.3HV%_\$G',L0QPQ:UA\FPO]]M'R7#SO[)@'A?!K!<[2-\
M(^PW?)YV]<VGL'^=CNX9/IC6)1XO[1*.:A<W D[.&WA ?]#KT&B.VUU05OVC
MSM&GRF-;]'?_'OYZ%[;N?:][^,F_M)5T1T-:^>Y!%XY99PC; U]O'Q["N6V/
M9.[XC='@9&B/YT>^ZQ_1W]XG<%+>'W6&\.FW[6YO.*(/V:[8-<"UYZ.%ZX9+
MXW96_G3<Z<'"?6KA>HQ@"8;T%QS];^VP,/W>7M)IPT-TDJ26A\FHSP.D@SIJ
M_S?]BF8+"X6KV:*7#$Z.8--A_SJCT1%I<SAQ1W#^X20$!0_OI0.UO36$4W'4
M'L1_:P_@W6_Y1SI=<F"2]@F<)3H'MQU!N>3=(5Z:0?\#7*DWT0;]M=+SR:N]
MQ]^ "_<NK]XHB_7+0Q9+LUB_/&2QOL/3;,8 0ZMZ_>TM$@P''[K['2DG<1(:
M[S_\:0C7GZ15;WARI#(ET2^"ZN%?@4P\!HF"'R7!7+4H0#4..OL=(AMKJ78F
M!0R23/2\J&/6H*;9][SH20[Z\+!>?\1:NL."$]X-[^J*/(<A\,!CQ=9C ?^^
M/0()#FJ2I1PKC4'G/:@($*FLO/![E8?"P-S3[HG]:"?F63 ?1X-.>X3J)9P8
MW1O4<:BZG:)VQ@R9@J#R^I\Z@UW81]I%4XFDN\*6!NT,OZ_O+SQK>ZMS>$@G
M[EU[%*Q.V=#_.6D?H5EA*O"X/1AU]T]07^+9!%4'+C$]_.2H0YKNZ!.-LE_]
MJ$VXA1]GGKR1V1';6ZL^3J847Q,X,^VW'35A1Y^..V;!_)&U4],+WMCKAZ6J
M&FNFV=^WX7=HKLB9#XL%=YS&"W?\4(9[?#* N]B!"\*A!+*@8.0?WW7(CB4+
MF;[\L1WL<!0#\"-:1["C!W!,^K8'P9E8N0FV:'B@8%!6^"=S'9X<PYWM''3"
M D:V-CZ-7P<VOMC9!_A/'$J7K>;]/DQL +_"\]0_.E$CGB=C1E0L&/!HH8,$
MXQRBL0M6Z;^<F!N ?.L.Z'NT2+&WM!>;TG_J>@0#%W__QEY-PED^\<DY&?T!
M+KK;!=OT[2T[&&[X>CA7GF8< )PV65=Y"TOD_1/ZA*Q)\[7LAL/A1K6]I<9W
M_#+Q#LA 9G>F9VL!B_45Q0Z,9="!<S'BH?@;X$??JRX.WREP5>Q%\AFY;*C\
MNN";>#-\U=KNX<*B\!N@?PD'=@A/.>A4K&[U16"C-IVM[<%J&46N2W* UP(>
MS%[\QRXL/DP '.23#EWESF]==GGHB4X$]$_ V[(CQG\:T:4^-!>\%9SMV*47
MGW^3!2*!_\=E)>[YN_:'!MW2?W/4?=OV$89>>W0RZ.!VTI,^T-'FA=0+9$:(
MSEQ/\6K5L5J8ZJSV:2UIE/"TX;OP(Q[4GK_?:(^U3X:P)'0Y8LD'?P3Q\+[#
M5[;A VSL#&/99OXI_6Z_.X!+/1RUR7:3?1UTA_]=M8-B"6?K<KM:9Y-RA)YT
M.SGH@$GVOMNSP IYV<>#C@0]=G2]/H(#"W<*/W+2DQ]V3:\Z+[<+"@PEO[N<
M:J'*#.(UV4!';6XH["7=PW!)AK@NT6E9^;)P+\'"X/, HT:S&X7+P0?4@773
M6N3N_3)-[X O??KS@V<NGOG3GQ\\\^\67_K2R'\\- )3W<O3,I_D@BPT9%TU
MC=]A$-E\U]HW"O:<,8+<CXR[[V67:ZI0<VZ ZK@M&ZL#&OO<<*9%ZATD1;,^
MCQ.*_CUF+EFY!)1%VV -=N2;$;,6EX41._0N8G=\XJBAP!:+DF4^C3U] GHF
M8E;0DJJH>Q0#66 %*+'52J@@;*HHBM)^D2,"CEF*+[)TBKA._/@58VZHF\Z\
MF$[YMV>(;,P0K*=/R;YPB2U]1U-K##&0QII"R9=^>:08T7R!\%6'&'5)0T.O
MN2953%8<4+"SB5ME0E=,>?%\\G%G#*/.! W22@)$^*,[,?U T>'APLCD;0>Y
MC!"A2/# N\A-?16$3#G.>49LK+4N=_ZDT,9B@Z#0?;1<(D@K9Z(SJ^JFN[1B
ML!4VMZ83;YE.[HA$9ZR.>ZZ-K*$C6H2/69>IQK]KMEI._>OM+>*):*2[Q3-/
M-:_%9[U/ANDF4!<FE1$<)NGM*ID$43'H(C(AO$!,&'$^S\[P!&"V_1KU,>;E
M TY&&(NM!EC)].Z^&Z^1"R/?C621##G4&D=L%XP0:*($P"G(<!4MOX9@Y4\,
MF?;O>I>%BF]#52]KJZ-KA7O&BBZET6_QN79&FKI,2J&AKW9"N)[>7-C-G&L4
M:\VFTSD3(=#I8OZ,.:&4B^FUMN,%#3E#AL-5/(OWQ& U)?^"ZQ*M]"]L(7RI
MBGM$&DLB1H"UO5I,;ZP,U]KH*&0TFR4[CW_>32;I#>S+V4(PG P,F7ER#7WO
M63XOL<B-2#/*Q)#.3F\[^HU\AD(6:^)!RRV(1S";,Z@L*O]L"6.#G&S"CU*%
MHI6+2/D"P^+H;"B=9 6)&GC1?6> 0&,I%:F+\+=05RN0U6*)38ZX8B66M4*Q
M#XLX+:Y4+C/HD1I!$H'$>%F&ZN<9W+]%GKKZ"JFNI%7E$DM?VALN8+7<HH+O
MQV<$]9KIXKC1,/;<#PB[TPI]@7M]N9><,+J2EKR.(A)\>AVO<Q.5]6 9KM2>
M^IFR<.)7$7DOL\Z+,7"%FT6"#:?&\*-@W7DM43$OU0R[+[61)@I>[I$^L,ZZ
MN"V/?WZ2](K9(X5.";NV48A9W0#U(M6VB&PRU/E:CM,Y0;!C%X(D?X,)S;?0
M;.@8/:;UTXLLT!2[@_U3U7I)E3R,7HEM1$3LJ"L1@%]L+R%YD95]".ZT2D8D
MY"U-%>MQU:U6*N-RB@;M(^+,6)<(=K><WK]#]TK(IEV/CM_)6DVRJ2P:"U-=
MPE=/=TYW \)YHKTX<=<F#14%:CA909N"$WTY"V\HG/QT80SAU6_,Z;]EE1S.
MX(S$CA<L.AX2VW35":31!%JQ(I2*)R4[1BSHU8VA*6U5*F>>1D6U9'FA7;*Q
MUXF)9/NB'=&3O2$6APIQS  5.+)X<07:'FQVCI.)X:JS-?>UXO(ZNL.8EHO!
M\S#>,I??>/6%+Q [#KU6M3=I)N1MHW4I$XOXG'1^,L))=D;6O0CX@/__+@C=
M?VRT^*N[H,4'W;?O,'T"_\=X2L3,=0:ODP]]2M-@+N"@^Z%[T.D=#.\?:OP5
MHL:E=5A#0XS'>\_J=E6EYR4AREV_[J8ZKVH9EABU8Z2ETHB4B%+RP)J(=NBU
M$>/H3@6ZC:9XJ1::@-41 4VO[*AC>$RM*-F+*]B,/LTP5E5J$4Z!!9(T%^+T
MI$I%B2$(9[B2+XT% X^:5X-C'@O^51:,C(3ZBH46;N*U^A>OG!&9))Z/<'5C
M<>G$I 9$A==&W/"H>5$\K> =_/D%J)\8YT6Y^9OZC6L4H@EK49ZN51.5_$46
M:7!9PN(S>'#E17Y5>:85&5@ 4&MC6XEU&[#X3[U=C*L]%B>P/DH*E6#L;I(3
M;2+=@*@1#K9CI:I0"X VTBSYA]IA6+G[4:-6]I-]J*DYTKV[M[W5B[K(QCUC
MSVCH/ TB/$!CE<UUD%'S5'\1:KCRV1_L>@Y6%[<]5\W=T/5\M[:4&/*G1\F)
MQ0$'HTQ. YTUJH-V1E$<@XCN#7S(:D0JDFOU=8WWL$%@4AA<6AW[!L?5WL;2
M)_+O-TZ^MXSIXX>,J69,'S]D3+_;C.DKK&NJ15#24.@<>*HEA'[IJO.BD*+U
M"-PTH1+H\F.R9H[RX1BN"_J@*OC%(AU?L$+SJK>)T-3DU'P*<FKO<<W@6*\G
M38UX$MRZIQZQXE;H5.M-BS:FMT0Q7B4Q96/ :(<J"C3.0-T3<6Q'^&DEZ4_M
M.F''5J=V6L*;SB>7F:;9AHG#98D&Q:,L>$SI'S>VK;2^_ ZVXL=VVW^Y6R]W
MA*H..L-.3W!Q;SXI]NY']M+_X]<WTE$Y8GDH8Z (&)UP54B^-+MC*3$X_ZZL
M+RO9T?.0V59I:^7*E4P&B'5C\4K/SM(<N9SPMR ^2<R65O-]MEP@L1$GDI&@
M 3ZE].?<\_NB,J32LZIK4UC4-:<WE#Q!PE2DMU^9#79D$]:56T5N<.RBQ$_+
M<V%CT3=R9Q$HI1&)4/60,.0'+Q%2U\9\.GA!HXAN@W$"&PU#.E.:&[FHS5R=
MZA#Z;&*ZIW;D&.\=,^$/>@Z>P].QSD9$YMCR=\H,INRUSO/R]PHUZ-<3F?2_
M7"ZVB?1\M**R;#,!&DLGE*.;2X&_18"*[?GDYSM+4,3D$PR:HJ _LN"LFNNX
M8+T"X0+G;!(+$W\K0$&VM]J^Y7W49=ZEY8W.-B'_BTQL3&(KL[ETE+!4?-12
MWFX:W2 PCIEI1RBFC-^<TAIPNRA*<:I_2(2OKX$L<1U44J(:'&:3A$MRS))D
M+BWB*]8T*XG+Y2S3_C0T#@;:,7N.9U,.?0TT?F2+U)(74,L ;+?(4JF8,T)0
M5_DS=SN2-6F>'W<<63G+(E$D1M8<P^)5U>W5M:SR)ZX;@>BNP.](MKTU(0?Y
M2)GI1OW0_'9>G/("5C*;,1?ZG/ 0.@*$QHR)UHR845@;<^N(,XN&\8<X..W(
MR)'4Z!R<HBK3= .[9F']M67<NWNKN-%TJR-]FX9. H+B8BXRV-[)DC0XSJLH
MC67&E$ZKP?DK.4KU8N\%O&]>+,\O]!>O/*5ZLR=(QH'80MZ0$?/A<TJP$^-=
MAZ.*$*#%W6Y4BO><-A+^\YE";01)4L=/KK1"1]!QMA9U]=RPVS/XT;4&=X>&
MV;'"T2G)&=I\T+AP5=Q5PZWWE%D-M* R!XYF<A*:[(YKIF&_2"<;W#T0<#/L
MD1U8^?PT=M;/8U>.7#8+]_TOYK3Y^0_[:O]44P-,B">/]Z@)Y>86QW%GT.T?
M) <G@T"L(66K2*+S1LMV#O:LP^7]L$-"YT2\@2I?HX[;0<S6V*L5]9B*4F )
M(@C(FRR=NY16A\0RQL4.J+R![ZU\S_H&+E:TW3&R0*+UW$L.N4G<1""6W*:!
M4!D@T_0Q>#]Y3J6+$\J[*-O#\;Q8C9@)Q+8(]JA:PJ^I%PT# %<T"Y3GKP-&
MDK0&:P8[WA7+A?*?_E-DQC\TOO/DR9U(_-YW>@=:B\UE\$=8<XK41R0R[I&O
M8NOW6**CTL.)0P5T0:DU;$TPX"4KEW UL#.(*<=6<EE,,$B*>O4R\Y<OY%/!
M99D7J52H"$NXTFU/;R1H0-]FST?-O48\HFN68G;&:<ZDP^P)P>^BA@ A;1&&
M9')1TZDX?A0\;-9%K'\V,J'VER(D,J"EQY*TO"24!M-.*Z!+HQ=H64:FV#P\
ME^V?2&;!>K!(8M+3+!(N!D0@4SW[@L$M1&-;1C:2K']_J/E[2\(^>4C":A+V
MR4,2]GM-PH*,?L*(XC4LG#N5K!][QH1+JY9<HJ'"3A73F+OV=RW)XFJ!&@M6
MWZ*5V[9AH_0564N'L"H9<4)=4$!PH722>H;:^'?_D^H,\]EX3K$-I6A/O^27
M2_2>SS$F ;)XME0F> -!N<:O8I95@P@PBJ[1-0^I4;: _I,=P;%@@=95%G/&
M-N/=!=JR]QA6BRK]>*F)9YKD_C3EN(FVTLA@BW.IRM($\HKAL&+AVCK.%Z[0
M#6X3=7?NMC.\1'7&;0J/+:>A5XK/:])0I:TXH:9XZJ%3LX<@&7J04PJPM?D5
M,9?#:"3(N9B#I0XF_PDK,'2Y [-^[8Q8@4:-*AM34S[C+2M!>$4WZ5:LT^TQ
M =+GFBA:_2%6=?O/8/3!@@/NK6PBR*O!C0EMF;4/=A@6#R3:D!#H<L%*:1GI
M@'GP_9S;M*FM(RZ+F!GUM:&CPKD[_&7EY&UO\=&3LB8;(S\AG+[(6Q2S(AI_
MM;UC0[<9G."*@[^]M2H *"92\ 7#F$(;Q"6>J\S<T+!EZX:(&RDM2QGZ84\F
M/"-G^R_YO-P3X\D4SM/(*1"Y$$J(-_,2JAY!2'1(FA#-!K7 ?>?K\$'+E<#=
MW="+^/MWZI_M<:/=NM+K?O)R[Q7]_<G3.SG>1'/;/KI__O53]J]SD' N$$74
M(2*XR5>EQIG8KL)U[.2[MX/_#%P.<:PMHG#X^P_^7[JN8!,/"2X DJ$2K@N!
MP95V5C4TF$[+HH(1]+I#C"C3CRV-CQ:SC,*AVO^M%@PEZ(,V)E85=%U@.FR<
ME@OM+HSH\0([[Q(;PF66,002:^6P0AU#KRZ@$!O9!O9GI2>Z](\82,E7MH^V
MMU892+M-%E+TB48K0U:=NZIP@'DSPVE[Z\Z6DV'<#4"C3@.FX7(N?%]EMJ#^
MPS$I=M"[(& 91S[(Z7+12KA,LQ4BU7#X%TN80:^8\4-R;,3NO]A@L]W%1FMJ
M<+;62%LY66^CU>_ +79:@RV\WE!S;ZV_[+Y)03#4'O_\9'M+T[[S+/19@2-A
MH&NI+E581/62=4=M$A\:86C%!GRULN,7Y"MV]Q=D)[R JTT:[_*W\FY:@3*&
M_)M0$_<='(1_MAUX6^;EV9T*8HG:T9,Q]A,DBT1^2.1A[(VP"\5K;*5!T+%G
M/__2MGSMR:^2N[TG-N,SM!DK?10)[\+ ,O2=\H;&B50^"%I9>;%$"I2Q7I!(
M6;F\DM;S@C>3@H):W:SPIBRG*3:<6\++F" .:_(0)']))%O82['4H,$5YH;R
M+U',P/6HC8&I*T<=21]!V/-S$>XVS;%TV/H,5ZLI[*WU.)X*)GX6"Z9SK'";
M@:%^ZT :O@U;<X4][(K9],8EBU59^K[-H?/COY?SO)SD8Q]OQ$4'-3_6=3:<
MFW&>Z8IK3&?ABH31 (U'%TIA23;2(,/X-(5=.&@N?F[U&.GIMXU- @?FS'@^
M@\JJQ^:VCRY'G3YKX0<^2Z"M&EG")$1!*7X7,E\!L);PI@YU#.*1$G@PG\4\
M2Q><[C/8)1O/<4!4PZ :-\4(Q?ER*A!SK0_%^#H'(&?L;#3-=VU$31#1.B'U
M*;X#1?>]Y?6>/N3U-*_W]"&O]]WF]9YA#(-C0Y%UC7\0$4DZI2JYFS0+MDI&
MX]\)U),9=>P>+@A[>YC!6:9"$V5(_0$$A_X_/OP.6_[D.:S\XZ2+S6%9B2)P
M?.9U<=1G=E;4XQ]GV1RE<(1D;2@P14,V8G82L$;-&FJDZE2+@/)FCK<S4#*M
MJ[^G:3X)I:W&);O&4@3-'8I[;;J$J[^:9WB>"$DS@7%0?23^@J Y8)E^S> [
MU^:\W*PRY]GS;]#PZ<^<K2=L!#6N,=N:49K#=;MOI&EM:+:\ZGQ5TRADDS"[
MM-'!S858ZCKCVJ_9)*46HWRH@S7BOB#,73>N]!4;4",!1K"-.*G3,JI>MH=<
M:9\:5)2B#DPRQI[#?)N$VW^?S<^S^4_#=)JUG+D8UX-$V>E*PLA9OW* R;\)
M+:?S&9]U<78XMKAF7>]RBZ+);72+8"P/UZAZC9[&==NN I'V$!;2D5Q:_0^N
ML&X)\J-E/*-H[QHRC%7&5+R168E\NGEYD1%!*-8M7K);0R&K'6K"#B/)#9BX
MZXUTZZ.[ZE0AK"<YDU($1+Y@92:[2G I+I'ODPLHL<)EGIYA4D X$,RIU>?I
MW'Y2.KO*]"9%)D$R;%[,A43"%TWI)[LB-NG0-7C]Q-D/W^5E)B7GYTNAQ$EV
M29N1"K*#ZEC+!2^[[%G%80)I@!P+7(C&^EG6)DS=KI;6Q=)%NCS-SY&7%E^,
MAV)1;K1Q*U5V39+H)6:G4^=ME,+*R+R]%:;)'R(10W/0":41U[5(-7>H>1S1
M*_#08(?J*#XDP"UAL(Y#'FA:.+1LL V>MI+51\G5P[EJ1,8<C=,EVAZ^I!?4
MSE*8$"86?D8WFHH<4<8A%7),&UD7LM[TPD@5L:5=5K?=LUY[R9Y>%_E$[#EM
MT&VD93I6LG%L8BO'^AK[\:EIA>''2$<[>82(?XP9M"K1+;[.<)-P@1&N0&J*
MIPB..TA(Q&KQ.: CEL%I*2[SL99 5FODZX"LL"**1;[."Z6=7 E@JPNAPT+@
MSK2 J=RY2;$\Y5;HE0,29TXK=X)N%LM=MG"5T"PFS$2A=Q82"**3N>G#K1*4
M>=!=H6M$L8&9 ]BU)>YIK3&!*[!,K3"QI?2^;-90%XNOR%K[SU;"SQI#T8'T
M+-Q)%1VM)OW3BC=)D]I&@FU:1P_O*M/*4C]P>2)H/09$4X5*B.>$ZDRVMB5
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MD^Q^#^)U??,LKZ+ZQOH54$L#!!0    ( &F!6UAY=MQ((@,  ",1   ?
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MB03*S2";!C3VJ<RU/LG!FV4$B[ UXS<C;JIN%0,>I))IAFH0/@?G(5@2OJ"
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M!_;+7(K?@=Z!WAQ0S7SDR+]ZF(\C/P%02P,$%     @ :8%;6&<%,MA!"P
MVRX  !X   !E83 R,# S.3%E>#4M,5]S8VES<&%R8VQT9"YH=&WM6FUOVS@2
M_F[ _X%GX(HMX+RV::^)&R!OW<U=N@WB[!;[Z4!+M,VN+&E)RJX/]^/OF2$E
M2[+3:_?6;1>]%DALB9P9SCSSR@Q^N']]<]KM#'ZX.KO$;T'_!O?7]S=7IX,]
M_QMO]\+KP?F;RU_$\/Z7FZN7O7&6NF-QL)\[<:]GRHH?U4+<93.9]OV#OA@J
MH\<];/3_![>?NO=$S*29Z/18T-+]$^'4>[<C$SW!(Z,G4]<['9R?7KV?ZI%V
MXFCW8+!W#LEO3[? +U*I4Z9W^B@=V?SD?V>RX[*<&54/1IESV2P\V\1Z</WZ
M>S&\NWC94^^/=@[^N;]_H'??Y9.>.+NY?]GK;?OHT'5Y^JVI.9CUE1J90IJE
M.'S>%X?[AT^WQ.Y=89T>+_\XLWZ8RS#2PUR:2-RX>'=+S!(UA@(/]\6=+!+Q
M5B:)2D?*3,30&:4<*&4+9<39ML]ZKQ)Q-M=S\>S%\X,7!\^VS>_:&JF2/XGW
M?Y#)G3H.?.!F/[5!\]/I%MWO,_O#C8PU:,@T%M_C\(F:J?1XNTS#0YW&BH@>
M_FWWR5'N/L^!6[SW=X]TVCM]J\14SI60D5.QD%9X)&L1945JX44N$PT,](7$
MNUDNTZ7(S$2F^E\J[G8*D#7"395(Y,**;,R?ATXZ15\\5?$=/7R4Q+\5&>'K
MPM,A2#TR_/!Q7^@4]--414YGJ5AH-V528YWH=")&2_YV44HPACA&3;1U1M*&
M;L<23YC2"6Q_E9F9>+5ST.9\5]OBI:0==4%6G(<J*HQV)5:NWD=3F4Y8AIFV
MEBBTJ ^O+NJDNIV\,+:0$ G:O"L2)9X>'(G<9+,BF4A2_$I]-6YGD:,#'KQX
M\J1/II&0,<;B-K?&CJ8RC4IP1N@-C+&KVS'*2O /:H2!6:MV*HV:9@D)H0D?
M>JS!"*:@59N5M2Z&IS5<T6KH$R<I<LAQ++[34,E1_\G3Y_VC%T^!HEBGE&Y9
M"D ZS03@)N8R*52;RYMR,;.QS=,NICJ:PA668J0$3%/@#&-H63CX"JN ?C<A
MU.UXU8@-\HNZW20=/8VQ^^JW0KNEN"T,D&"5.)L@MVU2R5D\EVFDUF5E(+4Q
M<WM66]%G4^7D!7.5+!MP7).S+V)&T=]EZNN6 U^W])E/#3GD$55Q\\POXC7?
M:?U8'!WU#U\\$2T5=SM!DZ2#5,@Q>6)PZP?E 4\XL066 FS&F=FT\I&Q=%HK
MM#%JGD5R!'!&Y%B.%0J>>5!SMY,5IBU<W7&@P T!IJ3T2FVPPV.6=%P8;#,B
M5C8R>O3?@+^MVNFKS1'7C8@,32D"(]P--N'DH=[+F4Z5AW2&*AHF2L WGV8N
MB[*<0A/L[S_U46J8$&#P,"/5+S3<J!9X8'8RMH7F[5@RWS[PQJ'C Y9A7_9!
MP$TU>.8ZI07X*)V3T=2G.*!8^;;MQ .?*$K(%"6*4Y>T-HNT)QY0'J*%1W8!
ML*)@6!).U'@,Q:QY?J!6Q]I)MP-N8 <,9DE!U*M$.<JDB>E+K W(9<:V*9[3
MBG9 K:="?VZV!YG(97 Y$%8*/ILCU\SI\'!U3@FJ"GMA^\H1+44\!"U:R[EB
MQ6?=EWA5GCFRG$Q6F\.>9@#LETD\O+UKY.U58B&:# OA36\)#XCH3OZ*PVRH
M#VR!DZ\)?A(BV_RQ7^!)1IG),T/Q"XI&ZH%4LHS?%E$WSJ*"/]?$T"G$]$]]
M2&5Z <81: 5X0Y.&(]B*"(Z:%Z-$1_B$M5!2(#SV#Y2Q;4-*A-Q%*,MB$HQM
MIN8RJ 9'5]92#"0LBY&TP#?%5_8^#WG+&)!CE/1(\HY>N^FNJ*J]Q&8(!S&<
M+D4R,]KCWJNI%&M[<GR)(/9%PR<KUD=)Z8-94&RW@UA3S$+HG*BT0!Q-H58.
M0TDB+.A+5[#W<'6M)O"S2.8RHAHDK.(E>)[#;E"Z7RH+_(1?UA>N@&F+$=S9
M<;!%^4[FKH=N(@ W@[UFM)T"<GC9!/?#1(6GN0KV]420CK69^6C,28**=AUU
M.V6**.NC]AD:"::"+ (: :R2HP7TNHKAQVY:"DZIQ7*Y4:3LQT'N;J?59GAQ
MI.-=,&+AO,/,E*+JNG)A#M*5\+6J>LW)F1J+R!&:XK..5WHS+"G!@PJX"!F'
M(A9]:>R!O9&%<J,0>'S9@K4(:AP'JXJQ3$:^&L0)D \0D3A24;?VC?ECB8VR
M[%O!0Z*"@%D8)]0IP&:-K!)2)FCZ-+5L99Y%5B0Q7D<JH&TFW^M9,?-((*_5
M#@[4@L*JG""T ]UHJ)&(:$E:S$:0$!O:=2_CITZ%:IQJ.TG*53MQAL%7H-%I
MA'AL'P9+JQ[H=BKT\%F]%^ S9S-2P\,RTIEK,C'ZYE(G##Q*%)7B5E5\R>T;
MPV3%\R\[.^*55DE\+&[E!#7,4/U6*.@(_,7.3K@H&5Q>_UP*5Y_H'QQN&.D_
MHV<C&%J9ZMEY(J-?Q<$N.@N!8E3'$*%UW!2A'V#]F%.OSQ$_ZJ*AKO OP9WY
M[D&5&[0Z@I?\NC-25$0?BYQ-42?Z; -1TGY=CW^$6NKBU;"Q1^#P>/A3NXA.
M-]T?K-\U'7Z6NZ:O-#B<<[PN<K0[OOD8O:.6D^HVGHP"HI,,90A7E11TRT(I
MM+\4LU>M<[LGX_3'(T(*[;G15,'[1%=OYRC'-+>NHC::MZO;,U\T@D"D^K6L
MT-I$)Z":4"+_^.X*?C&SC5S+R2B,O_S8"9D67ZC;$C+02S-D"NI,$CU7IIRA
M>I7P+&BAD?E&ZRFH;(9#C>=K-AQ:LNRD"3^ <DHUZ[H-&;.<EM_(19]+JZJ]
M['; A@H!K@]7O5+9()52A7Z@46>$,RTWM]%K.=WWQ=C8]R"I:)7CRZK9KU1=
M*8G8;3C7AA&%UX&?'E2E$)I%8'O5TK?!M?X,/66PRQS8CVF(PN/%/NJQA(I9
MJ;V=TBS= 39);50O5%/*!V<1/)OYR!D>ZBMRE$\28<LER9>,,*\5>2N;FN9N
MU)SYZBWV[5P%H'-I2L6V[G9\S[:@V0>Y)JI@M"76LN^6@4C:$C?E)1&_Y2CP
MKC#:QIJG.KOBOC6^2S0$J<DQXXX/KN 8C31DT&FP67V?GJ'3\8/&\EH@!6(I
M7(S4,DOC!K4@,R#@Z7YC1>A;;OEMF+NO+MVZ'?;NFD4:0]1R\0/71+7&R2CH
MGHK9<L#K@9;G2G(06;4!:)683)A_WM#4H]MY[>U4OT0)"ZYH4A$I.8+ ?E)P
MH><Z$3?:/]*JVA7@B^C,^:7@F14G0#31;M-LLC;Z%]=IMS,!:<Z7VI8*Z]>0
M3W!62"[L/#ZKAKQ,H36PIVG#)/,A/DQMQ&*:V94)0-PH&LY5UX/#,/-\CDTA
MSS6N_GRX-479ZJ,L*!+9".+#JXO&O2/+ZJG#1:YQ2G&T_Z*VNIH+WU7$Q'#G
M'W4B]<O?ID#?F/\T@E:B>";%5B3UD)YD90>ZK^.HQ3'0QTUMHT3JF8^)(_#S
MVJ;Z)Y[3!<DR*V@_3ZWZ(M(F*F8(5/ G?%5S/Y*C:ZRY2K+<3^08?B'TC4Q6
M3*:^&B#O(V]*F8<?T%:"?= '5B1EXOBNS]^ 4(C-8BBG.?\-,;4*TE\#)N[/
MSF^NQ,75S<WP]NSB^L?O7_;V>_S]]NSRLOS^R=(M=.RFM'3_KU7#'65)(G.+
M'K+\U.-V;G!_5S*8TX0TDDEY$O2&O;+EN[\L5P7BSXCV>L=4'O#^\L&=3]L[
MJ[IC\.K-C_?UX^Y85,O^S+W3GZD0=8@J2P*@L?W!'JT_96;X<??[SO-I9_C@
MZL\E1&N&,FK/4'Z7>O?LGGBMM$-A]6]J(\0;OG^Q7UK+'RG^QXN^QUYW^N<N
MGS]N4G=X(MYP_6*/H1?K_C^XV_+@[O-.QM:@MD=_G.[_6IW^J/T_4$L#!!0
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MQ[&SWCTZX6/RF.CRM<ZD5%.;8)YY6WM;[2.W:UN=>TTR4 ]63<\ND&BS?J9
M\CR'(N+&V<L2<H+,BD;=G$&$2O3TC6FBA]CIHHR5FALS%]C)6O5/<_7"HS_4
M%)19:V3M;*PYA5IV1JW2/ODY 9(N-H!4\VBR<X]6G- 54E#%VQV-51(O1!A!
M6K?2@<FK8G8<O\8KWVH7.C.:AWUN4X[<-S'@C+UN- \I?UO1\/@<J=NL=ZU#
M/KOAA!;KE+'C7WQF04)EZG+?:,H97YMEAD*1_WN#,Z\, JM)K*,0.9%X,A_
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M=DVY(LQLU79/K@_M2 ,(TAF -7) PDS2;?=,Z3',1-UV3['S.TIF* 88A2,
M9M:U8#+]GBG3AYE[W.Z9^B!AYA^W>W+.?!J%B1^F!.F(0&&?!S509/#T&37,
MO.IVSY11P\RM;O=,&37,_.IVSW0;&&:.=;MGRC!AYEFW^Z:,'V:N=;MO2K=@
MYENW^Z;>2)@YU^V^*4>!F7?=[IMR%)BYU^V^BJ/,%S&:$:Y,%F27H1O-:[>"
M?HS(PS")HR"@XH0)BA&NT9=Y%*+$B9]XPDZ< "NDS7Z[=P(G=,D/;HP\/]F*
MV&PFDXCS7&*<HF)C[2-*1A/VI%AB/&=;>.A^JZ9001>&+9X_HMCU,2G[V8EC
M)TR>5<RM5<Z!*Q2MW"9YYK!&RX 65DL K<2(%U%\.5\X?DS_(A6$2Y3]<AD.
M,8YH@-BS-L6VW=M4%(D3X":-W9E#>U#]Q'MR06K]S0E2-)X1,--9.3DCY-;9
M5"29O2 ON@AY^"*.YIQ^. R]8@"&19>DPKS$7+GUN-I6-N&,<XL6SE/6+Z\0
M44CIS#OH!I'AEG62PJ+>.+XW"BM%GR /&"EN$3NX*9JHWA]N$0NU'4<W,5KZ
M44JO72<R0&X 8UE$C5+J.7>S*$Y(N\Y/\^[X-CI\';;8GMXB%_F+),J*C%=%
MZ#3"?-&@C80&>K'HUVF2.@&;),\?B:T)IV3.',4>,3?Q4T8Z,8)-IC1%$,_M
M_G1&6B_%B-E6TIS1-/3_1-YG/YF=1C$IOXA"4MWTY>;![<?!ID+)1LDTW_B+
MPC>RJ!! EKL%" 7U7FQYN+6(/+P2DGSF8S>(<!J3,9+OZI)B!(R31/'3&#TF
M)T'D?BU$]I+X?5(\W%#BC473Q2I39ZYS6((U0&DJ[,XG8WCBNZ3L^9(NF<Y2
MZJ$:SQ Q>V3N)__.K#HL<;<40<102E4-73=*Z5[8])?4F[+5Y#G!-B>,!].@
M!3(ZY@NV/?8)(^\R)!QHX133PFII=9>0][/"4(?$2\LLZ9BG#IZ-J1 O[C3U
MDO<S4C)VTWMT6?<<KE")#1E]Y\H/65D,P.5;Q2/T8:[\(?[:'X*=T%O_@/TP
M^P,A#$\U&PD@Z8"&]4'2^,;0A23V)HX(QN2)U''^+?59A.!'E,#K!5*@PA4Z
MOQ DE2HA:MKX?%K'9"%/<9 _"0ZOG&,Q]-BJKO1H7?XT)<P^3$#8JMU+)6G"
M\_DBB)X0.B$\<>(GI6K@#0$55O&6CK @I)&@@U(:&NM@'X\FA*]@\E!,6$!T
M<FVP0J6>(>S&_B(KN29U-U'@NT\7$9M6'/K$?7(#5&)I(.3?'+UHKE?5>$H8
M+?FW1[V9DZ*A,:Q>L:T,8NY:JYE8&NSG?]R1+P29NX?NGSLAR!ZB0+SQ,+E%
M=+)SL\P8$?:!V$!CU+*9457;FCWF/R*///V$LP4VI27)TS5*9I&7@%K5/H=<
MND.(_.#1'\?1Y?#.?AM&9SL)9$147/%132_$G)\R7SL>1^N?RAZ(\SB.8O -
MMK%<D@Y6(KZ?,)JDP94_H20XW[H?AF'J!+>T.G#F?#/HLDGKSITA+PUH#$,1
MLC":D&%[23II./7O<P/ J"\P9]M&R/7ZQ1E*'#^@?KE)%,_S+$Y1FIQD&P-T
MER;;L;UQ8DJ=(7>4;6317!6+/C&.G1 38:F;\U^BS;0%DC1<N0XG]'(UX(=5
M=5Y>'^NY !?(&PFPNP:!M)C>&+J82)=Z83VJ+/1XMWJ &SR:L(5-L)[8BRWA
MU03/2.5)X+A?L3N+BLX%U2X9P]<S3FPWV:,NN30AJU(6)E".HP/1"D: I:NJ
M<D7KZ9C=XLW&$G7O-.-%X0BO@5GD;!EZ'EN,.T&IEB1*\EJBO):(U0+57&PL
MA'""V*!&2$9C*_@Z0X7T.KII208<_1]=@"^=@"XN <Z6IIA%0V6ULPQP!-2Q
M2<\+K=Z%U&5YJ%3&*HUQ:6N)A4$NUXT L1?J(A9.3&R/K%D>:K_4@"M6LK0P
MI+ZK"52XX5%FM@61NT8.?9)%,F<T-RFK%T!GUD4L/L:U04 (P$Z^A1B[C/4!
M-22V%$!VRDL2/P*P<VC %<^ TL*0U*T)5&<&',>.A_(P$7AKK2HZX<Q6>0UJ
MUQ2"%'=(3A%(W5 *3QA&O/*F5.QX7@V('JB J.7J$SF<S]"$-)%'4PFQ\_7D
M^4W@A&_2>:XCR^8Q9 "'L![B+42&-+KUL6H-B/RTS/ID5#D 'NH"TABZ=CC)
MB/W_)O9=HMGKR$/9B;KL\0?J948>C(8P1JWK_"T5I7L*GQ$]0X>\X1+%SA05
M"2KHQRI;<< [RVZDDLPA[ ,G#J9;4>SH;7G/"NK,J0U:&MJ@K@32!&H$5TP"
MUVSD%BU1F+*@&'IOX_H!P"%ACEIWVA"QD7,G#HF2Z4'[_'#RVV-4,AG$/81N
M*Q0EAA[8.4 "4\@@N&4@#7(%0%FG'A6QVG<H.T\(57%2H*)UGJ 0)-TI(9J>
MALN&-2[FOFCMK8TF=#=P50:>CG<AS[,U%Z1.LRM)--ST9[M.)K8#H<_RK&#\
MY2T+#:=3(LIR0I5RBEW[271*)LDOH-,[Z$D@S?>URB&6;<I 3F73P"KLE*N
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MW9B+49D7)1. D9^!)B8PF7)%$\&\2:?W\(7L_;BTN I0 ,\<PU3N.Y5"-.8
MR=I)#-YC7=L[I'+#GB[QK,@AL%<H'TAED5'S@8)8+?PV4HAGJ-8HS Q0OM<M
MQ(RR$R2>*=@5,/]\O/OTZJ\_/ZN&M?J"7EUHS^>+Z9<U>KBVEKUS<G'^H?7]
M8;RF^OE"?6[J?Y@-<P3^>#X_^[$Z56_-YM=NMS7ZT%BLKCI?F@MM1+[T%UIS
M?C5%B^]7/WI-W;(,\^NG,6ZB(>DU*;CN*J][D][ZZFNW-Q]^?@,?/W7!9Z5Y
MVUBTE\O7R\?&^6C]B!_NK--^Y_[]QQMU^%YO+5]J@^OAFDQ:ZH>?+^^0_A%_
M__"EM5"6/;UG7+WJ*%/KNOG^\</YKW>?>Y/^\ZS= L^31V7\\WS61N;K-V?H
M>:2>OSQ?G-$+Z^D9#+\N3U_]JMPL/EKFE_'/'K[K]Z_4TU>?9R]GRF+:F;\Q
MU>7M_RX^W*U4VE+;OYJK5FMZ_7/Z[J]:9S3D-4'3C#6GQ%Q&&KW#3%C +FOK
MLH\PY!@A.=4J/.M>ZC;TMA)GYME*6_MNN:4NNI@, >NL"G6P4VQICCH>28ZD
MW]OX-6"D\]43;JU(:\\Q,2&U_RQ[]3DU,.G)36*+\<:A] P4>F7+*U[BO:U8
M()(740JA-]6AY&+&-(<&:$^!B [0-:0&IHH^F$BKRI4-W3]C="?FHH"[VTX<
M]\KOSPT%$O[78+*KY;17RBEA6I2VU6,:NAGU5FQM'H]TS^(X7YN5-%:#..1/
M!0L9EB$*#A[CS[L%O"=RC$. ;JO?=>QK$K2/'C'YP7+KCF) 4RFOOF!NH 4&
MKVN@$G[.E5'C_K2E;S>!9=1<S8ZP.FXPEP5&YZ\I"#M@(KN1O\/CU+1Q]H#=
M6C:23"89MDKYUH/92T*>#IPCBU#XBEA5S%[\Z*J4(Y=N, &JBCU#$.?E]JUV
MY^,J$Y,$\"JP!2XG*(GH$M9M.(S5R"A.G@;3_X5'B:%%=*$W^WM5^,*TO7?Y
M0/F%*9FW)1+"*>1FB(2M<^G[,.GH%NUS5_12:9[.)9BW1]Y />H>9W1EQ68T
M(7UQEK8JXXG"X.1\I95/0M#U#YE$ E5W"U'R&[#RHZU @I?.SH)OTRJ LF*O
M!R0"%7AM%,.U]_:$:IE1'-@J1IIB;2B6K@+*(3@;"_<646=,YL#_[LVVV54@
M^:3H%AC/"+:F,R<V#$@P>1)NS&1MO8)Y4@S!.;4I+LF8,<W= A&^OV'_Q7$R
M(VT!4.6O3>;Q"$5P=8 K@EM4_O<B5<]PTB*L7MJ>P5A2TR+:0RPL[7!]7E7R
M]3 XJ?-UQZ]OSA/>*U ;($^IFW7"4!C91!4SF@@V=P$O6C'%)KK,.ZH :#;$
M/J7\C+U]?JG4E1P!@@HF+#'\)=)KP9=0]R7=K !1(7=D Z/<NUS1**HY1<U$
M9HB*BUBS<5-=Y\ @BT/,9/AQ%?<\*!T"G1]Y'N-[ A806_0>$.B_>RZ>,:1M
M]FA=9WH%1A<D34.>O<=DF'AB3S3';*+9(4"#IEW1@"_\)9W@)6CH* =4<C45
M4JG;M0B?(]Y4#7977-F$P*V_2Q$(L9ND(RRGE.,=<'G5&RQ#FZ6RSL:TC,WX
MCZY!&3'TQ"U4;X*3<+Q%*"58:#;#]?^ G.U*FS.RT^O>WT EUR+2:C^@%5?Y
M;XJ9.P8/S4C>W4@,2':>GU9SL6O/J>H7_;.Z'K5(4JV2_(5W/=0?R+LJ.5)G
M0+-T@/W+Y@K2MI_L!8.Q?3HJS^IF6*NE>9M0X=DB6<:T79"DR[3Q*$;V[@&+
M\N]<:TQ.VYOL+^W*7O YR>E7,E6&=+?@Y1YIQ=4K6%(]CI,HK<DJI+YSRSR$
M;)QN]NV" 7K/''JI6P*NR(S.E0=.?MMNSIR.8H)':,XTHBS]EY_$;E;<@'R+
M##*RYV8C>EZ<PQ5+Z:./_5%N)3NM'*NF71V(?'*)HW]S_GB=Q05L]HFV1Y@_
M@J2S;-]#^>H?.1>:]YKL.V][*O%M#E$8I*0,4=R$OEDF7'W%;O-U>0ED9GH]
MC+52<_(]J9)F?,GY\"DI*G$KRTO8";E[AX7N+K'DGZO9#;L&*.."K4A^CLS8
M/@C6UIB*Q\I*1I^$ "JP6Q/#MW<@B#59K%>R04FSOB!#1T-04''BR[.Y0OL]
M 88"M?#=L,-'=;]XR6L J3@2:3#Z1>%E!1;[<N3F(FW^<!)Z/W>,[8]'EF'H
M,+".=D#K288F6ZT=5246$ P(<2T=WU.R=SQ2T;57,,??^8*K4WM@;<9/I8PI
M#E0%(GUJ;K/J7WQ=(LR)O6UP@;PL&K?]OP%02P,$%     @ :8%;6-PX'LOX
M8P  H4X& !8   !S<')C>2TR,#(S,#8S,%]D968N>&UL[;UI<^-&TB#\?7]%
M;^^7]XTG>OJP/1Y/S.P&14D]LJ6F5F*[/;.Q,0$111)C$*!Q2"W_^JW"0>*H
M(ZM0!R SPA'N5JLJ$YE969E9>?SM?WW=A:\>49(&<?3WU^__].[U*Q2M8C^(
M-G]__?G^S>Q^?G7U^G_]SU>O_MO?_ON;-Z\^H@@E7H;\5P_/K^;Q;G^_"EXM
M$R]*UW&R>_7_9;O__]6;5]LLV__U[=NGIZ<_K?#OI*L@06F<)RN4DA^\>O,&
M;UAO.4\0V?"OKY8Y>G6)'EY]^/[5^Q_^^N[/?_WP_M7GY?S5AW<?OBV7_+>_
MA4'TZX.7HE<8[RC]^^L&I*\/2?BG.-F\_?#NW3=OZU]\7?[F7[^2'[1^_^F;
MXK??__###V^+?SW\:AK0?A%O^_[M+S?7]ZLMVGEO@BC-O&A% *3!7]/BA]?Q
MRLL*2@KQ>L7\#?*W-_6OO2$_>O/^PYMOWO_I:^H?4,2_XV<',,T-OGM;_N-K
M0J]7K_Z6Q"&Z0^M7Q2?^-7O>H[^_3H/=/B28%S_;)FB-?[9/5L\8W(=OWOWY
MFW<$V/\H?O3OY-_S.$KC,/ )F\Z\D'SU_1:A[/4KLOGGNZL#(EFR_THX_);\
MPUOFNK<E^_5C=X5E=X?N,_SG'8JD$.PN+7'4A>3]UDO0-@Y]?-0N?LN#['F)
MM_D0)]^(<.2L+% T0,6YEVXOP_A)AGR'-1@I32B5NB8485'_FF:&!9LH6 <K
M+\IFJU6<1QE6B;?X:U<!2H4\XR[6*OU7T2-*,R*Q031+TW@58&Z(\*,OTBE.
M5Q%6CIO@(41X?[&FZ/ZZ/B%J?NIE$&$=%'AA 43(1=Y2O<)67*#>BEP=J1?5
MNC)]"K+M'0K)\;KUD@P@>/"-=#+[0)PK?"<F.:&8$%/J&GUL_^(EF!1B- Z_
M]U;?=5EJ:1'DZK=T\F'F^P%A/2$J,<<*6R2+LRVZPI=:&J]ODW@=9'%R':="
MRLAMIH]S#=UY\4BDPL\3K#TQW#NTCY-"DZ(DB'T))2S82"</2E#>.D.)/,K\
MQ5KO#>H5]6/N;XJ3>)%F >8X(DH$:[Q\MR]4RN<48<\ HW:;H+V7%"(1K_'?
M#Z?Y8#^IW9%:$="KHXF!(S2(R.]HO][QJ4N$ZN3XBUKA+S!MDXH_Z1U:H>#1
M>PB%!@9KF48M2[5AB+@<_R$-HO(O2'QSRFZG5[BN$?;UA#A6OZ5376$EOL?*
MYAE_*+F0]N0[/XGM-=8RC?S%IHR/;KUG(C<0NZ?QRQJQ: ER!4!*^.LU^B[(
M"_S;\3-"9]COP1?P=> ]!&$ L0XY*W7*U-+[BM(X*AUJ(>=:OZR1<]@Y)3<*
M%LS&=\[CW2XH#_,\]((=.>#7 8J$I)/<32<YBP# &3[YV'9_)L":1CXH>L!<
MK/6JN$/X!LH+G3F/TRQ>US\0X<A>J._0$",5FU$%.6:^6--V?ET?(HL]B9]B
M4;I'&Y"=U%^@]^KI!RC.GHL_"4T.SDJM\L\+IBQ!UP-D"S,AAX,I 4.4MU0O
MVSL1%RAZM$5:[PYH  .&L.QV>FE,BW' \.:LU$GM.OH!0ZKSVUHOCRJR#<*C
M];N:E:%,T .&K<J66@/[V">%8=KX3;W*L/!+X0JP^>L:+UZZ2PI#B[_8?$"?
M[8@.N%>$FVJTQAD.(PQ[_F*MU&\YDN [IK?$7 RF J0@MNV56F.>3+\2J-!%
MZPV\Q;)\(J!!"=A"G^IB.D@P9$7+=8I"QW&"(4A?I!.MGA,%/#^,91H5(\DF
M\?,0Q>M++TA^]L(<%0'MHV)>0F).T&WTOB$P@?;=!/4/H.QEZBO:C[SXO!Q^
MTM5)$I\CL:D1N:K-]@-=)3^ L5ZS3CZ *[3 W-L'F1=*8MI?:@K)JS3-D8]Y
MN<@SD@9&\N4&( [;SM3'R'LH\"]3V%OC4_(!C7.T3Q Q>C'T()U[X2HOO'^,
MV'V6>,%FBZV.B-SH0;IX+%Y?/Z=HG>,CNI8]+QI@:0V?'1 [^'?P;SDN,:1R
MV_Z>Q(EIKS.$'<_M@^/*W<6^*?%.DRWQSLA)Y?EZ<,2YNU@A>=]J&4!WVF8F
MB-]W9>$X4]8:(333IU4\D*TM3!!5P@"4$1&970VIQYYE^#G%ALM9Z*U^Q;^$
M(:6+VYNAUB9[3U/VT#E:X_O9)T^^2?"0DWO\-O0BV0/!W\802WI6HX1(4=8:
M.<$@:U<";^!^=IRK)Z]A\A6RBY5-2WR+3+;;)%CA?[N)?23K+.@#:80B%U_W
M*$I1>IZC+#[&R4BM$/YY815+?C!X1R/:NZ8R]EX*V"4QTX^$!\A7C6WP=C-C
M_7]!Q/- _@R['-X&77Q%R2I($9$*E%:'O\)&5B!E=S8B=_PH)_QK!/N8D#%Y
M)UE".ZIL;D8"/^6[!Y14 E'D2F&(AXQ><ISSK,KH;4:$)?DW"(H)[M*#R!+6
M*GV]*>M'D",!QUNTD1DA:S[$#/X$R&8F1*9Z",/:YR?T?.-%6*L2SF-93>,H
MDK888-OI%:BJ*N\<95X0"A]:.K]MOM*A3OX"X@?:0V_]'.7!'H@L=ZW6#/Q6
M7 *,'765[NPV9NF> A$9.^A./(!EJ@'QE]Y/HV#0LM> :/.6ZA61VHT"(M;]
M=8WY_$4Z&Q"-]B_K-*2AU7+R&A.VG\X"3%X9'930D#V,:WQVBM:0NT"\JU;5
M5I8M 1%N_[+Y##0@6H+5^K1!JQX&JNMI:_2A)%?[ L19;5.="H^7P@55<I ]
M="B)\WA5W(4S+'Z8;MESPY<7(<E=>SSH7K*"(LAH75-WGB$]:[XKT/8##)BT
M%GKCH[67A]GK5Q68)KJ'/;"'_A8O>5O]SMO^\DJH#>,:[[P@4D:U7&V6L%N\
M1;+*']"; V Y?&D;-.PK(P0N"/-FATA\1I*ZK:6' V4"2R\,Y7 C"PX8^>3-
MIPBW76/8+:S0UPQ%/O)KO,ABV;Y)!P9A4&&\:NT?DMY3<5)O'WH/*/S[ZV"=
MI&_6>1C^^U 8OSB^'=[&:8'L[ $;VUAM]6F6UI].-BJ^/_.^QE&\>WY+%-2;
M=]^\^?#-VP( ^8WCG]ZLXN3?QU\I:"N)S.$(*7SM/$\2HO,*A\WZY]&A-[_G
M*"BSI/UE6*YJ/"L1DST?U>IU$N]4!2"+ <2,$Q\E?W_]#B\J#M%?5V&,K\*_
MO\:.&QK&/2_=XNN*_(]86X]>6%9*VF(?'7QY^;AA'E>>.]QB$ _"+E7=LL7>
M$?:4=N?83\(21:RW-,7N'_)GJ2LN2B'5^OQQ\U>.V!77W[.Y/DC!%ED_QYPV
MBV>4 ;^^BD?/1B8!*XY]8'),C6%%TE,%U 7#6/ GPS F 2N&?:.9876*:V"1
M24V8CLT5"<ZT*%5QXUL#5DD3(S>VY'1.2X=8%5>^TWQ&/L71RJFEST3 M4&A
M;NVS:6K*EN@\"::%IEUNO>AC'/M/ ?'(K>D_$29N#Z!(WKMZ44A7<SY<XX'A
MJO'T8/4JH\&?%@,9-!2?1%6V%3)RQ++7,M>FM<A&XZAK1L]#$4$-F?OU@Q5)
M.2]"__6KE346LC&8$/<X9#1D]G?Q<V;*N'8 Y!C5)YO8$5!CD&6VC(,9ZN8D
M6,\-]<L:[\BN OXT%";+.!Y9A;I/F9E%/ PKVN+:/)03QL6/[_/]/@Q08N_P
MP; 9P<, 1_C;7 72U^!C00N#"OUCGU\7C.TB,8H@BQI'>_04>@J#=&Z5%5GC
M^FQ;X?;@3XMU3"H:<@IJ_$B.7:MOM.5KL@M_DESK4]&01]#'SZ%=,U%>4=C$
M=@R&.FXN+5$^%B\A*LTS2+4[>PVPKI0F!X71>.C@\\BCI]CFE.%AF>=;UDO,
MLK(%0]'H(RY_]H]RI-YBO2RK0KWHN4;]79NWS"1BQ<VG=@B'45+X\F>-K2:Y
MZOA:M,C2 T?_K%O7%MGTMPG:!?G.FG9M ;7OR&L0YVYV6).( #=>C5=W*$7)
M(UJ49?8/C1((>Q<C#X<7P$DNB0$/@&J,=>;1TUWYR7-1P;<?>B0OOJZV7K1!
MY\%ZC;"IM4+I(BHJD\*J8,CV 15B]#)X+<$!<0!]P/-]B?Y5E&'8J3W7DP;;
MM:TK?2@HC_==<NKU4YJX9A[I&'?A)5$0;6Q>I!W COW*@4SKT]%<N@Q->RR>
MHD)MW'J)S7P+ "H3/XT08INZ74G@@G1RC$/\[YM:&=B- M'@N_4[!S*4251#
MD?1Z,K?5$_E"C)N:=J8BK16JI.#??HR5"MQ!FIHAKG6I"LG&_]O;=C'SL3A<
M?Y%SV;GB$,1Z+>N^YNF;C>?MCV$PC%C9WI C06LO?2CX4ZTN!.@M"K.T_DD1
M'2PDA0- (1>BMUO5S\T,JJV>F]J%V3MFYY<B+.8%D5 6"?JV-;X?L%1=A,5O
MX1-2-D'4K7W(88HC$EO!=UEY9KX&%M]9Z> -1;&HW2.X/&P):.>%E4$Y4UY2
M">.FI3PMW0\WA_X31JZ%7@,2QA,X5U1IZK\FEKEBCR:<?[]SQA9#]W6_BXU>
MSOS[G;G:JML$/09QGH;/Q6'V+1\<!GB7&9,T!=)-^J?33'A^5.,^18-IB^&>
M$IY])L!L PIE( $<Y9L_S1;K>\]J\X(&3"?>H2PC6D0RE\G_,2$=N8M^Y-9X
MT80Y"5ZTB&0N$9^$=C#VI)7,.3Z&85R4/56S&*P^(;&Q<!//E-=B7$J:"J@4
MIQ7#O/&27Q'IM6B;=TP$IL$V-OW$*4V*ZJ_L@HYASOP=)@H)[&3!([+-.!$>
MTU"3(F**TYC4;6ZBG,ETB4N,^F%^PVR%X=N-:XHQ<?%^(,M* #TK9GZOV30O
M9]>LCP@LUL<R?"Q:/\;XLW_&7Y G^._E9 #D7\9),8:I]C2R;>S;T[KZ4)Z(
MGM;(HTJ,_J);LY=)F:B,<UL3A3;4*9ST#ITJ=OR@^5174(A38T\5MX".W_5N
MTZCVOW6'/HZ']HR,1$-+[ZN#N_$(>QH:CTJUFD7Z4T++TXB!5*93V;H]Q\JS
MNHKCR&9;'P RDS!0862MV<J-M@QX]$K0E@2W'VW?3338TSA]5*K5;.(%8N3+
M7-HI ))U+(S%8[UZ^%]<TU=3E*0$1N%D&SX]/PE(?]7=G:6=\*7MR"-ELAEZ
M/SE>AY#S8L6BF-C9DZ%E?1)UM_)L._FTR["3^)GXV$1-GCN)464>:#GHQ%&8
M10_N;A,[H6>*%ZC1Q$-3B22*:LQN4I 2@H[3]]5D1YT=!A^'69_B6C1D\7*9
M;S%4E<A)@9Z6.:6A<^:EP:HY)-I,P?E@,&/VFW11LC[D!IYK"N3J8J$FDM:.
M,QL#9\Z +MEOGVH.J4UT_S@/PCQ#OODCK '0B&-6^HA9GV+=[W05;DX/,0\'
M5^T(]!V ]CGFTAOBYINN+BE0V9:?57[C$F_Q(4Z^>:V>4'-LLC(OBMW2JZC<
MNW=J; [08^(R('6(N;NH4L765QZ+6BR5M2B)0>>A6D35X<4O@YX"3O4O,LPV
M41)SJH@Y5<2<*F(,5\0T.V19/C04T&[#O.):&!JUS#5 87:\LLPH,29CYQN
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MKL^0)(KN@CF#18634B7)IG'XOT41YIF7DCX2Q=219J.)0?4?5;]B,L&B /+
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MZZ8 4N;Q2WE[ZT-&=;#WJ%35R6IW+"GE"CCBNXR7%;Z+"M]%@:_*+0G8U=4
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MNA1H+U>9^,88!22A^%7)J<_8'S&C[#@"Y]A(IMC*[JIL@W!F]UB[QG@XN#I
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M"Y?8_":20;"5TTW\3:;&"Q%-A#FN"G,"L).#TK3P@S#4\P#+ /[=]!))G@W
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MID#R]S"86P$<B.WJ'#<'ZG"IK+5T6P#QO+AYSUO3IU7YV]K+E%'-G9@M(<0
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M45VL97DAVL5AA,F0.FO1"%(_;\&)./A#5Q'^E)S8>*EJ?6_YY9P=>VZ60$1
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M,"U?+I)H3>3@R!);Z\#<=A>T6>37QQAXCF@KIW"8J%\LG ^K=MDWVUIVHE!
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M2S)4J!A<XR7>/.$0C3B"\/]+0IV:^IISYL>$"=[3&B<8$'7]*0C<;]YZ;?S
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M-&>07)JS%A5MOP;A[Y[_G(:H%[2$HO.A&8[I5--&C$39+LF\?1T])Y]IU[\
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MG?1UWHNDK_-C2/HZAR1]G7?95.]<.[/EO!>9+>?'D-ER#LEL.>^RJ=ZY=@+
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M@BOK+5@A%L6'&#W8II^'M;#4=$WLL^$GY6QXXXJP%=MS5:E/.UUYS3/ND^\
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M#$!=6@::75J$\/3KMP]Z4+]]<!SUVP>@^NV#5O7;)\OE;I,4+2O6+5+M^M
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M/,M6<HB$Z96FW3X09.S5?&W 3-.=;4OB5#C/R3N#$$,SF*[B==()3ZE--OM
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M[6@[^1XP4821LYZO\OJM]*9'[:EGGRSBSOS[,%AY\3RDOY_Y,2&:1\TL5B*
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M1\)@KFQ>4N[,[JNG$<E4-R_;$5WO=6VK86ENK5J:6X"E6<TQ3%PQRW40I7G
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M[UOLUQ+"A:PNSC"NPPN+BQXW,8U.94/L\I-#V9R-U7WHEWD,_%V4EO!(V_@
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MZ*CQ? 4-\0D7C_DDJK_3D!TU=!^2W<>6WY7R[Z95?FS6F[;=A(WF8YL9;K"
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MGH3J^>Z4)R4,*JUZ.'[8<-!]5Z(Q3@BM@[0([Z-GZN1VO,XS!X9?-^UQ&D3
M34UU1:?2W</_G>5L-6;%9&?N9_GW]2P/)N"EI[R"X4/'WTZM+]X_P>41;XLD
M6U8K?(<W>4$+[N,BR>,)VW_:V@Y/B$D &C2/8(LAMAI]T=RLA]B"H1TV.XF!
MM&&#)4&G'EFV7[0]U::O[Z/GDAV(>Y?D4$[3G85BND3O=B:WVOV7/(OB7[<E
M?(!]V+%1J 3 N7M<!8E"?,GPM\UXA)D 1XL*PV.\6G8W3'9#R4,8XW;7\M,2
M9++N1Q>B=-K+Y6^^GLOXLC%4*KU1%*?_A(O=FJV"KFE%J\FEB$T^8VV+6*WI
MSA]A!=<^1#"4&WD2D^U$<7CS.NL"]/K=N3PG-UL"^DJ]M0(H6+('^=BU#\\>
MLZ7-/VI[ ._Z%=\/C,Q!?2U9EY[<_R'RKCG)]T'MJ2KN)QR5D\YLR42' CK\
MNJH.'QT8F@:JIKI0V4Z.XEX8;7MT*2:[*\$J_;XQRT/1^/0\4+!^'QYM?<.A
M_36(<YT(9@#-3CVK M"N+%AGVF!JYSPR_?*VAXOI:DXU?4.@5-D63=DR* RR
MX6N]09L4',@@<KA>-(B&FY8,-16TP=$UH;A.](WPE2@_\WP]Y=V^>KZ[4TH)
M@ZH>#8R'-NELAN8\<E\\9HP=0N$7+=833Q[9HK;GC7X-MR7)=* 8G2T)$Y$J
M^B;MDQ*$@&C.CW$"3#HUZ#.-"Z)$Q;?1"TW]$:H038G:&Z_GTG%O#)7N:<Y;
MN@#B*Z!.+:RP<N:MF2I$+*TH-=EM;_(9V]/*;DUWEYH57'L00+D-%Z00:LX[
M>ZKMW:D2YW.:M$VKWDM9>SXG([:TX-H#+M9)1H?>+)A9"E"]DS!3F(6J=AI<
M4BF=^(/';%$M1D,VF5!@_R>] 6?B.($_1BE-:N4.0B5'FM$HHL.)M@#C?_!Z
MC,MQD/! @ZN/34&S"W!\OH8^;#>+\R6!:DDDA/;@5+'@8851Q&>BB$Z%#1'5
MD]$3S/:Y,[1HR;@R3@8_.P/@HJ[R#WEQO=Y$20$_W2Q:)_IUZUU7;YEF&5JJ
M.FD68LJV&,"(ZL5^\'DA62*NXJ@EY7QLP%K2N.@5EP4F)P3[2<G/3-AK]?XK
M4#G/B?F4E&@=Q1AM-\#<$C_1HHGE.DI37/#193.\)!LYAKLM7V+HR/@#@LU=
MP,)D]K+(GZL5_.OCEUOTG*0IBO$&9S%9/6<=?(9#6]!BO(ZRV.<YH*.N1&C&
MF;%O5=1"0CX6T,JGR.?DVE#K*PWQZ7!4CT=K3%0RRK&6/[P)]:8> Z1#4?:"
MRH@5_^7-+<F_+O/UFG#\OLKGOZ''%SKO:Q;CXKE((#UELRW*+;@!JYS\C<A@
M\S[E#7K$"Q!,F$)$;3NO%2A8,RG+ID#Q;1K-Z13T 4*D&]XIE18>)F!L\)PO
MGY>8@^;YTI>R1B-7$A;Z/'-NR=HKHOO=%LE<?7DTXK+APXG D/%PT !+X>U=
MBN91.@?5DK.6BE5W.%P\$9KGY"C.7G[P&ZF44T##. FE?#)N7#MKE+*\UZA6
MIZ?YY85*-U/H8HY)GV5;*,E3ZP[*W=)JPW2&H%WYO =[T$NH+,5OSZ'P<3+S
MZN@WS\1$S2^)A0UF:FPFZ8]L+LJ?J3Z#YO5TOY>$'*4A!W2H>SAK+J(R*6\6
MMV3U>MS-0O($6<>;&)?S(MF(EP+N%!6(6/]OFJ>?I\G\!9%3-EMB2)8J* 0L
MTMC"4*\C>_'MU6(QI9>,\3:4]F&&7N!EDF6$2UQ&+W/FLI U1F\/P,=Z5KTS
MWY#;O_1Y#,KPD/!#B:T7VN?9MAPQ!UN2PV!^)/JD<PNSA+Q]A-Q?,BT$=WB.
MDR>LO&$N!((2&X0-]GO.#('7TKB+H7O%Z:)(XB7^E$>97HCO5WE1O06_='VV
MDX/C>97,5V!HX&]@_;%[_9%8%%$2DU.%F**TZQK!+WU!OV^3^6_IRQM4;LFD
MJ 0S-2(_/);X]RU8E6E.KI;B+;CQR;^C[ =TGI8YF"XI6;E\AB_"[\$Y\DC!
M1@!W"X]?QO<(*>&ZE-3.M]=E5*ZHSVV-8_"M_4SL][B(GJ/43(^;D_G4Z&>3
MO!)=C<N0_&-X!\2(Z^S+];V*&S"-6NO-1($;X"(F<]%\6Q0XF[_XU:U',+3A
MD4 2]XQ*HV1=WF17T3I:JF.1;!BD4,5LH&?+O0>VA-HRO'PH48TY=;.MB+V0
MQ=!O52AZ>HO))\D"2ZU39=.,HL=4O2;*VT69EZ4I#-O.\+Q/C/&7,=&.=AYL
MU4OF5"PI6#>TY3V4M>6_/F=&)H[)QC^O6%V5+UBIB/!9__6G'V<'I\1&91R%
M>#]=EK*>#:G-5Z(\4.=FQ0ODO4$9%L/1[MD]A1X2SD\GZROD&YJ)08%7."MI
M55E(OCNOJB)YW%802'C(OQ#"Y5E%EB.3E]<$^$*3:-#32L3%ZP3%2%@>5-,L
MS]X*7R##V"?*'] O=WB!B_^#+B7K_(2^J"9ZS(J=2$ZY'$WFBY?K0@08Q%YW
M5K3,A /"K[;:AWN$%RUJ7@[MG+4^S[,F5@CJ6'/?Z.W%_NYL%FLCCRQRV*PW
M\(OX89$1UC+&69#+O9G/(N4?HGF2DGM@Q%^%YG0T6O#A8.%'",!C]RRQN6D*
M Z2CH,=MF62XI"D+\[S8Y#3C@-GD1-,BYP;^5OV KBM$[/C\F04E'_.BR*E!
MWTR'R''T&P9M#:WS#+^@_ D2(C)$YN,,DB!XK1AP,2=KFMJPHI47R)@"1YM-
M^@(KLD FA1)'\Q4;2[#)6)P=EO8L8Q)>2 1*R3$O1VX7FBR^PU#,DM#[_"E*
M4K@GKHB=-N)$8JN@>AF:55#4"Z&H7@F!R9?Y]Y/:(3W*0B.BN3=N&9 $[1O8
M3MJ D7"@,TY" )O."F)'-3@H6='#TA.QRW%J\YU",WZ&%/9$X'*<P@/4/&@N
M5Z#)$VC F<03WI5TKL<RK^:&C_;LN)$A,"2X&DT?%\05_@VGGY(YT5QQHP!=
MM0%F-0/(/)2RB2QCG.J&0FS:.S?TF,DX8T(++SNC@>%F<=X$]V]I;/]#7ESF
M64G^#979XR:"7[Y^+@$2/SR:.^!%!G8BG$Q$]L )+UZ<,<C;'"71 _65:/E+
M(B?,#_495ZL\!L/@(LWGO^U9KF@*?;>P3Y,U7[($ZM%5UV1L 2(X7#[)R ?6
MS);M?ZKK<033AM5JY9TYUA1OCQKM*S#/7K8G2TB0\L[-_FPY?YFG^/TWJ+8
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M8=BG5_JR,*"6GQ.)H6/N!*IZ\2TT )L%IT0^JP-57EDX%K32H^S!IU?#8\2
M&V9=]&C/0OF/VS+)<%DR9W)KB"R*:-X6;":[L1[XAMZ)CY@. Q.!J#S$3,%0
MJCDF-C8MO8>JZ#><P2:FWP+[A&BT:XS!QBA_0/V &E6DF&6RJKW"JV0)SXC;
MDV%)[!WZ(CGC+XR!PFVOSY_0*G_&3[AX@U[R+3'"RAS2+,%8XDL52?D;#%]'
MO_'D2[ID$&>_J0 JQ,^3_!F9--1M7)\!33%RJB;3'P@_:UL9LDE*ZKAJ?@F
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MH!##I(?K;ORX=32!O\:[670Z(B2Z1/_Z 1_10^DD),SR&4I1HB*+HHS@[3"
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MBWJ=(;XD_*U=%/[0+.O/'S&-#$.F[D).=[[PNO(VK]2UC-0,K4N-MT,],FD
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MG_%V]FYV^.[D\-T/W\KX3T:+N+O ](  F23<KR<-?:^#-ZONA<&,/ZUH&%#
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M\%!$,0;7&M2@)ORGU=(?<OKK^^UFDR8\:T-&>#H*]DT8C4R,<)'O!PLR.-L
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MR*BZMSV,\^H_[((\/$-E*/DQYJ_@Q7L*9=V[W=1Y/B\D5S'_@SQ18?R*JS^
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MO3B]3^Q?;3N9]6Z2-IR>F[D['!9*-]O63;=DB&HGWD]_+#XD2GR(4O<4M<
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M0)EL%&F2"=KPUH(!O4#!3?T!0%JB_ Y@=;[? _+2T; USPL1+4)<[HO[] G
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MW."<'[*\8#J"[S.M/Y4%K;/JY0YB9P/!5J*?1%RG[#7$./)^Y*!ZDR?5/7F
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M;);0%K$^C.ZR?+LJA--"H[UYKX2F)@)T@J@VT8TT_1(CG_D9LM?U,/N)<H_
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MKP[;2./](V?<&_X/;Y3?O3D5=E=,)'?D+F5_WI$0A&#STQQ'6TC>;;V8;*/
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ME<F?<!URV\MY, ^Z\;Z:4<#^?5,J(K<1-]GZV.'T@:Q7DA7Y%B\GJCL]Y<_
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M&:E''HO1.JOG>AZ%]VP!1E^V6_'GE#(-=14F:9RY'9-DCN%$+X<!++'77&>
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M,M*H:0 2'J4<5O:XA/!LAQV$,3LDJM<YFP4/L,9IQRMZ&2VW)$=I$7.DQ$T
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M)C7E-.=T&_G81]4$3^RPEH&(J4^U$:/LMLUV<,AKZ>\#)A T$^D9%SY&D?]
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M/E\Z>.$V6]$5E,[,J7[:3^KU05ITQ(,?E6(,6C1=)\0DMO$=UR,!B0MQ;(Q
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M"[V\02#1$_/1#HFP^[6%Q%J33(=$AAX!38I8#OZ86@*%X!2<_@^I]M<85$L
M!(YT@DP41_.NAY 0I<-"=2I-WECE)J8K&FX^13X)*OU6BG8KNIP&PYT:D^&$
MPS;LJ\USF#_WE=#-EB$VNR>QMR$7CR1>T83P7=3J 0:?=#OKXAC[-G2 );K;
MZT7FPNZ_)?<DS$0BTCQ*TFA=_L T$GVT9PI(SDWRYKKFLRM*6LQRXBSJQ#%O
MW*<+%]TD5;"P'BC6IM*D8L>\++P<7#SS+1R'YC1D]ZZJ"@&#,*N4.A OL@,
MV,&5PH+ZBCU <$<X]<D./Y!=+)EF]+9?R)3[MNR9V6_3KSVK?E!TMF_:_#A8
M:AR)U1DP/XU4@#VS,?D@QCNRJ?<\'YZ$V(+M_.+1PP9:("LG&:@TM@L$U&I4
M (->0[U@\*M\0,(EJD [637-NTE'_#KV?H)W1!L)RRULL1.2.Q%"N<%TS[DZ
MU[B;R)-[."S\P.A8BQ2M>;^N0UE3?B:L#9 LP0(SU   #?PA:757;K8DNA32
MVX>-E9QO$'H+VEH-*1@)EEUE,2=4A%P_0QTUW,$ >*2)LZNBMNAHJCK-SGW]
MPJB3L\)6N#O:!OJ)[+Z1V#F7BF7Q+5B9K,K)7U*J<BL_ S&SILPM=I\V$.?&
M&*"B!-J?I0?,E]LXRC9;D1(YCW8,Q2T)$WK/=L,,&.+L! S'%,76M7SIUX^8
M!>Z9V\I[,8?D+O7BM&DQ&YA$YXPL8,M&?#2F]A/#&-ND!HY;F[?:YU%&DO!$
MJB-65^$GFD9S1I*_ZZ9^:\'"NLU.P$)-XDU<Z?_K[<34_O,0+LL<+(3P1U/5
M?Q'Z(PJ5I%ZXH;R.BU/$<KRD!MM:T$0.=5#GA 90GD_ <UP?:! X.[%=.* D
MKIJQM7[@.@EKVX8"-8')XM76$YT%!6*:4MGZ;&QAGE[>M#>.//F)L#6YDN=4
M"_W9+HI3FHB_%IFQ[J+__:A@F5Q6#J,.J0TLK ^Y,(1DPR>,#Q2'#H7AT'KJ
MT<53%8 >XMHU;!R;-77+SI//92[M&T/S1FOVL[F= P,/OO)D ]W:AC6 CGH;
MM+XL4+=87!_ZEG22I;&J( 8> ZZ)[$N@^PR[[_W9Z51:!/ &]?("]5V]0)U2
MXDYS.9B'*<V>PIL:&6:!J+Y&>?<YY6U=8WB35):3GPP4E'SHE#-%I5@>]<2K
MB\;[R6:U,Z8!.T5[N,JX"F>,;"V,9#&"N-BFEK57/ C[/D;W) Y%GE26;J-8
M*!)-/2K_%B=<H$%[Q5:MU9 ..#5E*ZFB61S:(>K 8S)GJHN6Y@$?*[QN; ;K
M;?1Y&CH=9$;1K!)\JM&"M(A&$U'(ZUX4.G#Y7L2CBQTHMX*%Z&IO!/79,;:;
M:-8T/M LGK-E:,HS>\1EI#W%NOD9LC75$]]L[])FWP%M8G_U8MY0)BFQU2WK
M;7^'%:W2);ADI]@U;=?$8U".:#N[REH+8YNH/;SK(AFR$R+; JI)\CROJCZ"
M%U+P6P,IB%(&RVG3EB-%2J5TS"DLL^J 2N7XY-8":?S(K(8$?%8M ;4$0K%]
MV!6D"]7 %-%? OK<:P(9.YND5[*JUZPVKU''8"W9;R5%3[5J(],9QW5#W+_9
M:B.$HN4-#W(CU*1-<U31*+?D^ VXL2S^&S#TB-29W:2BN9-S3^)O4=VMG)+\
M&UTE%AZ'S3NAKU+>IOF>^LRLF?'F12M.Y0VI-J"4MG$]<1]S"%X8+Y(#C(;Z
MV0$S :/E;S5EN-+#ML3]YRA@-.?N-J;8&* V\ONU1W1,>&$O&F)#@&YI\LME
M3'C2,F$,2&^]%%7S&"$W:?5CQ@[<LLM&-V2!H6B%+,'U_=MW']R9=5#$<)P]
M:\(#9P3R W.M<3:VM&@A,WH;N->\T:'X@,">I5R[O-)\$<ZWW-^Y"BM%-><D
MIO>,Z/<N8_=ZZ$Q<?^@2O1"/WTVB6?>1'$+<Y]Z>IEXP/.1;A68<[94" 5[$
M>6N&%O/;N]5#3AN<?32A\5P02/2RG"Z!.;;8T.&CQ;:H\,$-:1PEW+5AJF"V
MWP=T59:KUO[IEIFKS%H5,2N7H5Q3_% \3^C)K6MK8U8@BL]-3.YIE"7!TQW'
MR7<<YU4LC]O ?^"1J@N%BL 60\"3.":PV\9U/="17Y\SSI_B<DB*1._$88A%
MB0#6(XB)G5 _ VJ:XL9JZW@MLI2=Y]"GX0:)V54,QGJP0:RND=1F$K5#)^4J
M23+BLTU4-F/7<<E7F"E7,'9FM $#3U"=R?DJ[S2QDW^+G=0!90$7>@45D/M<
M,C2\<-7P;JY"9JMPJX7MM-(G<+9>TX "^F&: 4=W]$RX:TI(E%*1J@@NHWD4
M)EF0>JU:V.[9R]+O<?NHF3"N@Q96ISW:.Y)W6Q*L;PJ_(M-NNP\%BV)1G/@0
MMDAGZ_UD\'78[+UE<B%.CE]*2IB_7XRA ^C,]\5,=BYZAZ%F:<2[@7)+..(2
MN*9,,'B\_F@/FEF#TL66T;)8;%$LMA"+&9N&9JM [R40X5INAP'9]<C@'"T#
M0\XACM H/PIJV!["H&/)=:/[L^ \K)QW?+XK@Z+)=90'3B7)XQT]][M@(+D2
M6'HL[]7?252D?#4E5N?1SJ-A_O]#65Z#A=>[7T.H.QE5)XFL-YAN'<Y&#.Z^
M)0%_22@ZT$I3\SLJ;KI@H'6PUR1Q#P4P^C(+4_>L4A$ 8H?J:Z0),IIL4.[9
MGH,-+)9G?Z$K+[A+,Y\"3X3\6QQS0YL#B@W;:U8 H?XMV62!F(A9MLXQ4DV]
M8$9_ _03PF(>'XQ#"6'[Y%W?;F*R&G!:="#A#%W3YI$&*6SFT^DKL2W94>8W
M<.&Y9&8B%R6^ Y@VZP8R:M;T$:#@RN^=<H7;YB1)A/G.\#JG3&C8;R67!'AR
M- "-W?S2H47!I)]<VF!G64)#PCVO>Q)$>[X)HQNH'\ZX[3(-.A3L^8-K"VVQ
M7M,5^<0\H)3PSA7DEF=-#3$7(!#'S380;0H&?G#-P/RY,XJ%ZR5V$?JEO!GQ
M#P!P](8?A#BED^J\;_)7$@29J&,K9]J;11#ZP(R>6_V$*'ED(ZIFZ$H-=*$F
M%MA1[[MDA:W.5M])U!CG^0BM4T/%JVL;/\ZR.;NQP-*+F"^)S0*)3BYA]Y__
M2$)V'W#/9N;O:,A=45%@YUJ,^O!X_H]@/7+4RRB+CV*.4TVJ$P=I,O>"52:>
M.ACA[M@N>3DY)\Z9E]!D<4]B1K\O"6%4N:;K:ML\L]R3ZNI7E=47X4RZ^K*Z
MNG$NBIU5X5'1.[H)*7.]/.9MK591Q@<H;VZB@*XH:0NP!<YH$L8U6@9VJD,<
M6[I@/.2['DUVBM6#*Y[XG)\-S,%T\\ 3A?;\$F(^8?IT$W@B!,,+8O;.:V8U
MT4$2.B2MV9AAI,DQQ-+:>;3;9>&Q=O0S21^B^)<#@HY+;371P1$JTZ/8$ I-
MBEN<7&8L&ON,P4*4!>GZ$V>^G*;H'=WR^#X6K^6K(_F0=EBM("AR#WS1E'\;
M!?[5;A]']P1C=FH7#KA-%8;PNY.R.#E/E: 6;\WDMJ7*846T*J%1V( 5RMOH
M%S%( %P?]-JBR.U2F@= PJ7.R<A0@I]%:1KM%FL!V3'=96OC=R?O88&48!C)
MTD>4EM$>AX&MA=$MH1[FM2EENXSY.[DX<&*6YN:)T9/HL3?Z8EWB<\_,KKBZ
M']ZV.%':8;KYC!96^@[L%^E3EA4N8?1.*O<;5/=[W.QB74S99:B&F1>(+?#$
MMD!WHMZ !7#Z&R!+TA"&($^UK716%]/HX_B)T6ZVXT3D[552=N=1IL/S'7RE
MZ?8J],F:AC2M4,69X6 )W>]22NTSW6*E&41ZI9$(3=4F__;9VV%2@5#0T?*P
M78=Y&W,OV1[2+\R2+S@(XQR*VL<F%93L^\LHOMKMB,\;6?&3Y\?>@Q=HHM(!
M /MQ7$9846_4L6<,XTJ-SU7X^>IN,"-R*-/C1K%[W( %1V\1_L4+W76"K2R)
MW+M+Q3,Y>0;<S?4IM,ZU.*_C"'D6^D!5?H!CWKJS!6'0](YY%G,NEU#9)7\5
M+F,O3&CJ3IP[<$!N,ZAB5T/&NXB(,K?^B-LE3X-E^_D81;[3R=N55;%O%DTV
M-DAE+ST 6DY7"-%GHJL>&A_A]U7M(GASAQ9O!;>7@BC#++RDY):L"+WGMT-Y
M19C=$ J@QO=%'[P!#]SYD&N?D6WI/1Y!N],R2@3PFV1JLK&N@-0$Q:Z $=O!
M8'%K873=9L39-OTL5Z*8FWXW,=E[]- RR[75UUP>U^ S8JZ*D+BS/L56"M30
M3JYD?6QCT/S\RH@Y(#!9-U[<FBZ'>8'1FA?:'3K6"]OE[8 FQ95!A,LJ8&/[
MI1>@<<L*#H6&LR2)> 2;)%[H'_\AH6'^%R()>W=2#V"RGPX'J+]X*FQ:,7XD
MJES7"[)0%9#N$3GV#SF9I"(6P=R1C<#>:8)L;5&<EF<.-$_]ZJH3NL+Q0<9C
M"=5QDEYC6?P$2YD8R^G?E>CZ'"70P95B);G;.*SJA6Q+09Z/\(EX2<86GZ4'
MM)?;.,HVV]QRC'8,ORWS"^@]R7O?N S%#L04J4F:(XND%0,>RE>[<[[,K+AS
MP.RN^D=H#:$<LKM))W,SJ#ER%<*M?*9B/LG]DA'AB)4FYSH 8'6I=LC$+O(9
M7 P?<H:&9,,3F 8'3 ?KD>:8J-'?$,]=WBSSUCQPU!Y\Y39V5&:>>Y6D\\\D
M'?;L50*=U8$:AXWZX(&/MF+7+9GJI([>+JPL9=#.>LBBT$"/M>7PXSF:HEOT
MR;8@1#:B-B_M<$XM(#85!F*+FY=&)J/I=M#7R 2O;8TP=)0[<MW71 <9].+>
M06U.M,B-4L75Z,!BTKF_]3%^E!?.+!4=<"9-O_2B^<Y[T7R*V+_^3+9T%3CO
M2");>XI'NH>:%B=X3=]8M>=-.G_CF4<)-.Q0^V2B+)3&O.JT0*ED.",;&H8T
MW)QY 1^!PU'29(OT4XP+1B928BR3=&]X[T<W6;S:>D(K LC<_&I,%&[M""OM
M5L;J9H@?+,@(6@8BRI4PMX'ZEH:YM>G]F3P(@TPW'GG\?23/4$78RD8L%L$;
M-N:@R3Y*O$"W1= IFV[THX)U$:LX":.C@3FI>,*$\'JV6F6[O(=#M;<#T![J
M@S+)@*S40.JE%T9MNE*J()=Z)PRL03-ZTEEU0!0TL&MCF2O4RBY&H%.UL,$P
M[P",!Q-W="=4VRSL/:-CYE,O"6Q:CL8'5(GEQSA*DGJ7JDOVP=-AV\>DBI.?
MVT%(X@Q -#G/PWAATWC^TW]__?K5__WZZ>??_;__^_?5/GO\1_B[#_Y_?KK?
M_.,I_'*>/7S\*?[PT]_>__O+\BD)?KI?_>=M\-?T37I'_OJ?GW[\Y?'=ZCI]
M^\_+R_=W?WMS_W@V_\?;>_\N_L?5O?]V=[8)[_]]]LO'MT&6[=-__KR,WH:W
M\<>W"3F_]'[_<?WQZ>R?EQ]WMW__ _WZ\R7YN_?V^LW][.'A]P]?W_QT]_0U
M^O(I>W<UO_G+YXO5[5^"]P^_]1?GMT_Q^OWJ;[_^]E,8?([^_;=_O+_W'CX&
M'_=GOYM[F^S\[5^^_NVG__7I[Q_75__9SMZ3_ZR_>LM??]K.PO3W?_@Q_,_=
MZJ??_G3_8_(A^_8?<OO/AW>_^U_>Q?WG+/W'\M>/T:>KJ[/5N]_]??O;K7>_
MF>_^D/[]\>OYFZ]?OT1Q%/[ES?E?_OKVXY=H]N?_]VI^=_OZM5635%=9]H)Y
M3G&[?IJAC$2HH+4D\8Z& JO%&N2I]P 9X;7W5L$:*0TLON4CUY36.C9:+RRM
M0;=672J':E1B6@/5FWK:)I9V^O[@A0QZU Q8LZ6P3KG!ZVJ>X(AJ/CNE-R]1
M&"X_%O*_7FH[(=GHMHX\I(#SI7SS.RO?M"EDMA0Y4M/E(Y>:_:&9>\B[N#W0
M(' FW%TX3$Y4I&Z%)KWQ'["CHKL]\ 7[\!E6^9QMAK7I@3[SL('V84]?$N+/
MDG-"=L1OOU.X.[9JA)#*H)T=X@Y6V*RG/(&*=U@KV:/DG[>$-&D^W1K&9>SY
MY,9[$EV\AE4NUD 9!R+D4, 6_FRUBC.B:.;7%5*K?87K*W<2M BAU3>)7O\B
M4&:'H]HF[B!=D?C7NVR_#RA;SIFJ B&%7T;9RW93<N/T<59@.RZIZ!*'"8I"
MKPP,[C&-V&"ZV-QA (&-_M(%3#O-I9O P*5C$F M:T9-$CW<!RYB8,$:KP@-
ME%M8:%2]617"*:KK!HK*2]]#QRRV<[9!C0U? N/?56#<GH394-@6JM8,Y7<;
MQ2FS6W<7NWT0/1%R1D*RIHR1W&GR H<ZIQ<3G-O&WGW<. _]E$<>!>1<!)XI
MIUL,Q1J46W-ZG'&UONKS8FV#HBA9<C*75M,%D'XZJ=M8RA\Y1>R6P[E,E*OW
M#_1"__"3:^I]HP%-:1&5?FL^:K"QRDR^BGGF' S\ (]I[J5D(\:%M5>58G_*
MME(:N""/Y#3C>W-HIP;)T:/NMX2A0E<I\<48TE#\A^=&WWL!:8W?/J%4]"*"
MW-5&_P#5Q:"?P):SE;6%X&-T3^)0=&G)4F9X"YG6U&'R;]$;P\&8I"  >GK'
M=S\HSL*Q4PZ+<YU?5VFC?!4VMJ"=O=T! N6F-&90-S5L6:.#9ODU=Y'.=E&<
MTL1Q2I4>-L@9^3;,)#VJ8U08S]D2-!6-\84ZT3VO[>_P,P/,626A L90QJ]>
M''M,;938/FDRH_W=E)DAH0*NTA0E=Q6DG>G'UL+H0VUM:,,V.>VW1#0>PX'!
M9NGBSR Z("=JP>S?32X<5^JE2OXS[V,6>*M?V"^QWTT6-Y^.:3>F\3B-9?8[
MXW <##I099[3>^HSPOZ#DJ-D]:!6_P99ZHUHSX6^L7-;X0[0F*C'/>$AF)^C
M@!$-8#U(/IPJ&V0TP+"J;VGRRV5,>!8]801,;_7'K$D_Q76!C-DA)P-.:_,O
M3-_'@>C\XB<W,5WI,D3RX52/AXP&&*;UQ2.)5\SO%2C<D/ANRW:MK:UDWV(G
M) [06%)26+2(31S0PS9H>!X%@1<G)6JZ\0$=2!/5:EI$LF?ENC5RS\F:ACP@
M%:8Q_9:)GGB!%QYJGPR-6A588SNV%^ @=["9FE64$#GS"%7K8ZLY73;6_4 E
M->V]"KH]).*0S[T]3;W@D'YA=C"JH(P/@Q0(M!%VQM-S"U@'ANIV35-]C6PI
M=5%7-,U6;1K#@3L>F 9:^<-MXK!3I!(!K+ARCW36]8V:?%AI""K<%EF:I%[H
M,\,#B;=5#% .ZP#.UJAGT<UW>)-<)4E&?+:'REXLWBXY^)D2O/&-HPW8D@[,
MUT,Z(\7BR'<9E)==)Z<DYTC:FU^%JY@_"IV3_+]7(;Z:A."$;98/$PT0]3&B
MJ66,A,]@(^N,*]G2!U^$T+B1 @AN+,*$@7U4P0FS=F UG%$C2&NPS"FKU0DP
M(X$CG>]F&<V81Y]D =N/MBF@^AP]1<&$0VIB6 O$VK."'':Q4MI!D^-P/TG-
M([:J.1*8N0D/7C+W@E7>0%Q$MM,MJ0>W\WDG=,7^[5/DDV!8>ZL6!E];&"S[
M,+"7U3!D\0$E2.7[<YD.,.-/ BO.Z@T1\I8OFWSDV#KT9Z!XC>QEQH(H-2+2
M4#[AQ@//2;**Z3X? -#.<<"4+ /4QO9Z;EVZ3-B%7I!30UJ6N#$:*=-%[KDK
M,3..8>2U'_-.%C$SUKPX/P-F63@2$,]4HW23S9KC:)RY8Y*Q\UQYU2 ,BMO8
MGYAB+7D'WPD\%2-UB#C5Y)ZR$^YY1M)([.7,$]5G._YSL=#0MI&5)9:*)8R]
M/ ALZ-FY9;1FXL>+U\_)/0DB,3>M7/'M.]WLW3XP^!%, PZ)7-Y> EG-YM&O
M\"<AB;V H37S=S2D'/.4WA-@:^M>,)-E7#^!<!H?M[?SK;D=;0.C'Q*N,V#(
M.BT2633H,88 KJ-8XJ=4RJ@,NQJ5\"^E\(</ NR!"W?%%6+!K9$-X;KV[.GX
M*S?>D^CI\>#%_@&E69)D.X'.+?]FL2[#6U]:N6/=[SHGQ&(DX_7TI.+P-'1*
MMJ T>[2YJW:$"U#NY  1[$I:7)E3<<=BP!%/S9F7V9T<#>R<(&Q5-Z+2/[GE
MU-[7-\!QXC.9=9W"TZV/'H4QE;+3< .CEK$K2*OK?';#F"*3>ZAB*SSJ.,F"
MT,V6;_B>.=0;4@OY)D554$&:@;D470LM:@N9ITP8K '6O!Y#X3T0Q?HWV,\%
MYIS@QZ"Q?Q13O\QW:B9+Y6AK,J4'"(97)Y6M:E&7:L.6D]Y!+S0=XE23I@KN
M5V'[.CQ>EKHO.O87Q@J(*OE^"N*:>TD6"B1JF8HYZM+$"[VJS#H '/>D]\S*
MMHK27%];F HTW9Y2O451[L[AQU.3HG;;^@\YE,PL7A-J2P@&+# NA@^A%%;_
M$UT9M<MRZ\N.RAZS3U1;^1?@()+G%UDDO(<%98N>9S&S(OY!O%B3U;U@1F=6
M]6^\8,?O$:)Z'7AUB9TE9G4N,:HS.(Q8!8-_<GG>NKVX9@W4 ,=U3&>M?],%
M*_Y@I4H)UW75YN&)G-?QL/TTM"U$Y8.]@K8A1G)2_7.Q0S&V-UUN"5MJL6;_
M!5RD@Y88E6X>1JPR0H$U+%);=JO[Z!;>]V_??:A+P0E+2TZ%_ZA$S &[2CFT
M5,'D\%GGEMR3,"-\OAZ?PW'\@5DN=/GU+ >W.( #OH/TPS$_M 4H9X>L7 _C
M4&CSHSG3K" 13EIS97B,0/K.<SDDJ[HFTO.S(=MJU$(>N_LQCI+D)H[6U-U(
MI>J:T^)<C5HV8_X.KY*9[U,.S0NNPG44[P3H-$JW^:S::)WO+XJOV5Z/@UM-
MDYRERRVC9;'<HEAN(98SSA0P6P5Z;$"D:XT(AA->DPS.T3)(J72(XW5S[/)X
MR'=$#3OU<M"QY$K1_5DPORD#,_OF*F3JD]PQS@@?(KGFOR72:!ZI_LS(+AA(
MMQ^6'LLG3W82%:G'A!*K\VCG\>I:_O]#65Z#A?6&HB74G8RJDZ3B>H G"6Z$
M 79+1#ET64CVB?!0DV[8M1,&TO'2)G$/!3#Z6+:2YT'L4'V-$LK69H-RSQ9'
M%0/#,QO>(B"*GW@#.3[LT^AP]((9O0[J)P12ADVETOPF)BOV3W3E!7=IYE,P
MD_HA882D #S2( 5*KY'Y +;(O\6QVK59H=BPU58@^M3?DATOY.=']Y*9B?P@
M<Z1A;.@&,NJ#T4< :RDI$*YPVYPDB3#?>9L,RHXL^ZWDD@ /B :@L9M?.K3
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M.K@S G[S$JZ5GMKI5<@RU<0-*5+N4I1:[+#;J>/D6K^8+5+8?S\ 1;?Z$E%
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MOU)]\3*6;LDMV4=Q>G@E,^NY>DZ351 E6<R]EN92^2/<LK44</S=L#7@[ZI
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M9C%?<V-I<W!A<F-L=&0N:'1M4$L! A0#%     @ :8%;6*:3#BK_!@  ESX
M !\              ( !4+\% &5A,#(P,#,Y,65X+69E95]S8VES<&%R8VQT
M9"YH=&U02P$"% ,4    " !I@5M8A;S[+,P5  !%@P  (
M@ &,Q@4 96$P,C P,SDQ97@Q,"TR,E]S8VES<&%R8VQT9"YH=&U02P$"% ,4
M    " !I@5M8<]W /+VM  #HT0, 'P              @ &6W 4 96$P,C P
M,SDQ97@Q,"TW7W-C:7-P87)C;'1D+FAT;5!+ 0(4 Q0    ( &F!6UBG%,"L
M-@(  +@.   ?              "  9"*!@!E83 R,# S.3%E>#(Q+3%?<V-I
M<W!A<F-L=&0N:'1M4$L! A0#%     @ :8%;6'EVW$@B P  (Q$  !\
M         ( ! XT& &5A,#(P,#,Y,65X,C,M,5]S8VES<&%R8VQT9"YH=&U0
M2P$"% ,4    " !I@5M89P4RV$$+  #;+@  '@              @ %BD 8
M96$P,C P,SDQ97@U+3%?<V-I<W!A<F-L=&0N:'1M4$L! A0#%     @ :8%;
M6*#5&CH1"   [ @   T              ( !WYL& &EM86=E7S P,2YJ<&=0
M2P$"% ,4    " !I@5M85'JC9XX&   5!P  #0              @ $;I 8
M:6UA9V5?,# R+FIP9U!+ 0(4 Q0    ( &F!6U@Z]PJ!Q#$  $O! @ 2
M          "  =2J!@!S<')C>2TR,#(S,#8S,"YX<V102P$"% ,4    " !I
M@5M8B,]6;\,-  #&J   %@              @ '(W 8 <W!R8WDM,C R,S V
M,S!?8V%L+GAM;%!+ 0(4 Q0    ( &F!6UC<.![+^&,  *%.!@ 6
M      "  ;_J!@!S<')C>2TR,#(S,#8S,%]D968N>&UL4$L! A0#%     @
M:8%;6!-.@ JI%0$ R>0- !8              ( !ZTX' '-P<F-Y+3(P,C,P
M-C,P7VQA8BYX;6Q02P$"% ,4    " !I@5M8BB7^WXYF  !QK@8 %@
M        @ '(9 @ <W!R8WDM,C R,S V,S!?<')E+GAM;%!+!08     #@ .
+ -X#  "*RP@    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>ea0200391-f1_scisparcltd_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sprcy="http://trpx.com/20230630"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sprcy-20230630.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:TotalEquityHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:TotalEquityHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:TotalEquityHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:TotalEquityHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:TotalEquityHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:TotalEquityHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:TotalEquityHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:TotalEquityHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:TotalEquityHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:TotalEquityHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:TotalEquityHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-18</endDate>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-03-10</startDate>
            <endDate>2022-03-10</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-10</startDate>
            <endDate>2022-03-10</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-31</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AutoMaxSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AutoMaxSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-11-17</startDate>
            <endDate>2022-11-17</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2023-08-18</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-02</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-01</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-22</instant>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">sprcy:March2021FinancingRoundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">sprcy:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">sprcy:June2022FinancingRoundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">sprcy:June2022WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-01</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">sprcy:June2022WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-01</instant>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WellutionOperatingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WellutionOperatingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WellutionOperatingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2023-02-23</instant>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:NewCoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-23</instant>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-02-23</startDate>
            <endDate>2023-02-23</endDate>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">sprcy:CapitalPointWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">sprcy:SCISPARCLTDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-14</instant>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">sprcy:SCISPARCLTDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-18</endDate>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-18</instant>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-11</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2017-03-15</startDate>
            <endDate>2017-03-27</endDate>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:EveroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-15</startDate>
            <endDate>2020-05-15</endDate>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:EveroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-15</instant>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2020-05-15</startDate>
            <endDate>2020-05-15</endDate>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:CapitalPointMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-15</instant>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:CapitalPointMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-15</startDate>
            <endDate>2020-05-15</endDate>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:CapitalPointWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:EveroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2020-11-29</instant>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2020-11-16</startDate>
            <endDate>2020-11-29</endDate>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-11-17</instant>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2020-09-01</instant>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-01</endDate>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:LeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2020-01-15</instant>
        </period>
    </context>
    <context id="c239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2020-04-17</instant>
        </period>
    </context>
    <context id="c240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2020-09-08</startDate>
            <endDate>2020-09-08</endDate>
        </period>
    </context>
    <context id="c241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2020-03-19</startDate>
            <endDate>2020-03-19</endDate>
        </period>
    </context>
    <context id="c242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2020-03-19</instant>
        </period>
    </context>
    <context id="c243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:ADSsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-19</instant>
        </period>
    </context>
    <context id="c244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sprcy:PrivatePlacementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-19</startDate>
            <endDate>2020-03-19</endDate>
        </period>
    </context>
    <context id="c245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-23</endDate>
        </period>
    </context>
    <context id="c246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2019-11-02</startDate>
            <endDate>2019-11-13</endDate>
        </period>
    </context>
    <context id="c247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-04-11</endDate>
        </period>
    </context>
    <context id="c248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2021-12-02</startDate>
            <endDate>2021-12-02</endDate>
        </period>
    </context>
    <context id="c249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-07-27</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2020-08-02</startDate>
            <endDate>2020-08-11</endDate>
        </period>
    </context>
    <context id="c251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-17</endDate>
        </period>
    </context>
    <context id="c252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-17</endDate>
        </period>
    </context>
    <context id="c253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-17</endDate>
        </period>
    </context>
    <context id="c254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-16</endDate>
        </period>
    </context>
    <context id="c255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-16</endDate>
        </period>
    </context>
    <context id="c256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="c257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">sprcy:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="c258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-02</endDate>
        </period>
    </context>
    <context id="c259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-02</endDate>
        </period>
    </context>
    <context id="c260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-09-15</startDate>
            <endDate>2022-09-15</endDate>
        </period>
    </context>
    <context id="c261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:AgreementTypeAxis">sprcy:AprilTwoThousandTwentyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-20</startDate>
            <endDate>2020-04-01</endDate>
        </period>
    </context>
    <context id="c262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2020-11-02</startDate>
            <endDate>2020-11-20</endDate>
        </period>
    </context>
    <context id="c263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">sprcy:November2020FinancingRoundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-20</instant>
        </period>
    </context>
    <context id="c264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2020-11-30</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="c266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2021-07-21</startDate>
            <endDate>2021-07-21</endDate>
        </period>
    </context>
    <context id="c267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-08-02</startDate>
            <endDate>2022-08-02</endDate>
        </period>
    </context>
    <context id="c268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="c269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2021-03-04</startDate>
            <endDate>2021-03-04</endDate>
        </period>
    </context>
    <context id="c270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">sprcy:March2021FinancingRoundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">sprcy:March2021FinancingRoundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="c276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-05-02</startDate>
            <endDate>2023-06-01</endDate>
        </period>
    </context>
    <context id="c279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2019-11-13</instant>
        </period>
    </context>
    <context id="c280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2021-04-21</instant>
        </period>
    </context>
    <context id="c281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-12</endDate>
        </period>
    </context>
    <context id="c282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2019-03-12</instant>
        </period>
    </context>
    <context id="c283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-10</endDate>
        </period>
    </context>
    <context id="c284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-01-03</instant>
        </period>
    </context>
    <context id="c286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-10</endDate>
        </period>
    </context>
    <context id="c287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">sprcy:OrdinaryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2019-09-11</startDate>
            <endDate>2019-10-10</endDate>
        </period>
    </context>
    <context id="c294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-01-04</startDate>
            <endDate>2022-02-02</endDate>
        </period>
    </context>
    <context id="c295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2021-12-04</startDate>
            <endDate>2022-01-03</endDate>
        </period>
    </context>
    <context id="c296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WellutionOperatingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WellutionOperatingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ImpairmentOfInvestmentInAssociateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ImpairmentOfInvestmentInAssociateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ImpairmentOfInvestmentInAssociateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:GroupsShareOfLossesOfCompanyAccountedForAtEquityNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:GroupsShareOfLossesOfCompanyAccountedForAtEquityNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:GroupsShareOfLossesOfCompanyAccountedForAtEquityNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">sprcy:ADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">sprcy:ADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">sprcy:ADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">sprcy:OrdinaryShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-17</endDate>
        </period>
    </context>
    <context id="c344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-22</startDate>
            <endDate>2023-03-22</endDate>
        </period>
    </context>
    <context id="c351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">sprcy:SCISPARCLTDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="ils">
        <measure>iso4217:ILS</measure>
    </unit>
    <unit id="ilsPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-37506">F-1</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-37507">SCISPARC LTD.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-37508">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c1" id="ixv-37509">20 Raul Wallenberg Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c1" id="ixv-37510">Tower A</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-89">Puglisi &amp; Associates</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c1" id="ixv-37511">Tel Aviv</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c1" id="ixv-37512">6971916</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c1" id="ixv-37513">IL</dei:EntityAddressCountry>
    <dei:EntityAddressAddressLine2 contextRef="c0" id="ixv-37514">Suite 204</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-37515">Newark</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0" id="ixv-37516">DE</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-37517">19711</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c1" id="ixv-37518">(+972)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c1" id="ixv-37519">(3) 610-3100</dei:LocalPhoneNumber>
    <dei:CityAreaCode contextRef="c0" id="ixv-37520">(302)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0" id="ixv-37521">738-6680</dei:LocalPhoneNumber>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-37522">false</dei:EntityEmergingGrowthCompany>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-37523" unitRef="usd">2081000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-37524" unitRef="usd">12945000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c4" decimals="-3" id="ixv-37525" unitRef="usd">3574000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c2" decimals="-3" id="ixv-37526" unitRef="usd">44000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c3" decimals="-3" id="ixv-37527" unitRef="usd">40000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c4" decimals="-3" id="ixv-37528" unitRef="usd">60000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:CurrentTradeReceivables contextRef="c2" decimals="-3" id="ixv-37529" unitRef="usd">43000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c4" decimals="-3" id="ixv-37530" unitRef="usd">77000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="c2" decimals="-3" id="ixv-37531" unitRef="usd">815000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="c3" decimals="-3" id="ixv-37532" unitRef="usd">699000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="c4" decimals="-3" id="ixv-37533" unitRef="usd">131000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:Inventories contextRef="c2" decimals="-3" id="ixv-37534" unitRef="usd">660000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c4" decimals="-3" id="ixv-37535" unitRef="usd">668000</ifrs-full:Inventories>
    <ifrs-full:CurrentAssets contextRef="c2" decimals="-3" id="ixv-37536" unitRef="usd">3643000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c3" decimals="-3" id="ixv-37537" unitRef="usd">13684000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c4" decimals="-3" id="ixv-37538" unitRef="usd">4510000</ifrs-full:CurrentAssets>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c2" decimals="-3" id="ixv-37539" unitRef="usd">4474000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c4" decimals="-3" id="ixv-37540" unitRef="usd">4717000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:InvestmentsInAssociates contextRef="c2" decimals="-3" id="ixv-37541" unitRef="usd">893000</ifrs-full:InvestmentsInAssociates>
    <ifrs-full:InvestmentsInAssociates contextRef="c3" decimals="-3" id="ixv-37542" unitRef="usd">659000</ifrs-full:InvestmentsInAssociates>
    <ifrs-full:InvestmentsInAssociates contextRef="c4" decimals="-3" id="ixv-37543" unitRef="usd">591000</ifrs-full:InvestmentsInAssociates>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c2" decimals="-3" id="ixv-37544" unitRef="usd">849000</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c4" decimals="-3" id="ixv-37545" unitRef="usd">730000</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c2" decimals="-3" id="ixv-37546" unitRef="usd">33000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c3" decimals="-3" id="ixv-37547" unitRef="usd">79000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c4" decimals="-3" id="ixv-37548" unitRef="usd">57000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:NoncurrentAssets contextRef="c2" decimals="-3" id="ixv-37549" unitRef="usd">6249000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c3" decimals="-3" id="ixv-37550" unitRef="usd">738000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c4" decimals="-3" id="ixv-37551" unitRef="usd">6095000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets contextRef="c2" decimals="-3" id="ixv-37552" unitRef="usd">9892000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c3" decimals="-3" id="ixv-37553" unitRef="usd">14422000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c4" decimals="-3" id="ixv-37554" unitRef="usd">10605000</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c2" decimals="-3" id="ixv-37555" unitRef="usd">1247000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c3" decimals="-3" id="ixv-37556" unitRef="usd">874000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c2" decimals="-3" id="ixv-37557" unitRef="usd">153000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c3" decimals="-3" id="ixv-37558" unitRef="usd">214000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:CurrentWarrantLiability contextRef="c2" decimals="-3" id="ixv-37559" unitRef="usd">1714000</ifrs-full:CurrentWarrantLiability>
    <ifrs-full:CurrentWarrantLiability contextRef="c3" decimals="-3" id="ixv-37560" unitRef="usd">10252000</ifrs-full:CurrentWarrantLiability>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c3" decimals="-3" id="ixv-37561" unitRef="usd">45000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c2" decimals="-3" id="ixv-37562" unitRef="usd">3114000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c3" decimals="-3" id="ixv-37563" unitRef="usd">11385000</ifrs-full:CurrentLiabilities>
    <ifrs-full:SharePremium contextRef="c2" decimals="-3" id="ixv-37564" unitRef="usd">58898000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium contextRef="c3" decimals="-3" id="ixv-37565" unitRef="usd">58547000</ifrs-full:SharePremium>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c2" decimals="-3" id="ixv-37566" unitRef="usd">5248000</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c3" decimals="-3" id="ixv-37567" unitRef="usd">4980000</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:WarrantLiability contextRef="c2" decimals="-3" id="ixv-37568" unitRef="usd">5190000</ifrs-full:WarrantLiability>
    <ifrs-full:WarrantLiability contextRef="c3" decimals="-3" id="ixv-37569" unitRef="usd">5190000</ifrs-full:WarrantLiability>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation contextRef="c2" decimals="-3" id="ixv-37570" unitRef="usd">497000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation contextRef="c3" decimals="-3" id="ixv-37571" unitRef="usd">497000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:OtherEquityInterest contextRef="c2" decimals="-3" id="ixv-37572" unitRef="usd">712000</ifrs-full:OtherEquityInterest>
    <ifrs-full:OtherEquityInterest contextRef="c3" decimals="-3" id="ixv-37573" unitRef="usd">559000</ifrs-full:OtherEquityInterest>
    <ifrs-full:RetainedEarnings contextRef="c2" decimals="-3" id="ixv-37574" unitRef="usd">-66449000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="c3" decimals="-3" id="ixv-37575" unitRef="usd">-66736000</ifrs-full:RetainedEarnings>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c2" decimals="-3" id="ixv-37576" unitRef="usd">4096000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c3" decimals="-3" id="ixv-37577" unitRef="usd">3037000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:NoncontrollingInterests contextRef="c2" decimals="-3" id="ixv-37578" unitRef="usd">2682000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:Equity contextRef="c2" decimals="-3" id="ixv-37579" unitRef="usd">6778000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c3" decimals="-3" id="ixv-37580" unitRef="usd">3037000</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities contextRef="c2" decimals="-3" id="ixv-37581" unitRef="usd">9892000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c3" decimals="-3" id="ixv-37582" unitRef="usd">14422000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:Revenue contextRef="c0" decimals="-3" id="ixv-37583" unitRef="usd">1972000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c7" decimals="-3" id="ixv-37584" unitRef="usd">1347000</ifrs-full:Revenue>
    <ifrs-full:CostOfSales contextRef="c0" decimals="-3" id="ixv-37585" unitRef="usd">1267000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c7" decimals="-3" id="ixv-37586" unitRef="usd">322000</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit contextRef="c0" decimals="-3" id="ixv-37587" unitRef="usd">705000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="c7" decimals="-3" id="ixv-37588" unitRef="usd">1025000</ifrs-full:GrossProfit>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-37589" unitRef="usd">781000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c6" decimals="-3" id="ixv-37590" unitRef="usd">1474000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c7" decimals="-3" id="ixv-37591" unitRef="usd">2803000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c0" decimals="-3" id="ixv-37592" unitRef="usd">397000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-37593" unitRef="usd">2494000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c6" decimals="-3" id="ixv-37594" unitRef="usd">3339000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c7" decimals="-3" id="ixv-37595" unitRef="usd">6509000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c0" decimals="-3" id="ixv-37596" unitRef="usd">-2967000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c6" decimals="-3" id="ixv-37597" unitRef="usd">-4813000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c7" decimals="-3" id="ixv-37598" unitRef="usd">-8287000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c0" decimals="-3" id="ixv-37599" unitRef="usd">-99000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c6" decimals="-3" id="ixv-37600" unitRef="usd">-41000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c7" decimals="-3" id="ixv-37601" unitRef="usd">-109000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:FinanceIncome contextRef="c0" decimals="-3" id="ixv-37602" unitRef="usd">1024000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c7" decimals="-3" id="ixv-37603" unitRef="usd">7832000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts contextRef="c0" decimals="-3" id="ixv-37604" unitRef="usd">877000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c6" decimals="-3" id="ixv-37605" unitRef="usd">905000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c7" decimals="-3" id="ixv-37606" unitRef="usd">2014000</ifrs-full:FinanceCosts>
    <ifrs-full:ProfitLossBeforeTax contextRef="c0" decimals="-3" id="ixv-37607" unitRef="usd">-2919000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c6" decimals="-3" id="ixv-37608" unitRef="usd">-5759000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c7" decimals="-3" id="ixv-37609" unitRef="usd">-2578000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c0" decimals="-3" id="ixv-37610" unitRef="usd">13000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c7" decimals="-3" id="ixv-37611" unitRef="usd">14000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ComprehensiveIncome contextRef="c0" decimals="-3" id="ixv-37612" unitRef="usd">-2932000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c6" decimals="-3" id="ixv-37613" unitRef="usd">-5759000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c7" decimals="-3" id="ixv-37614" unitRef="usd">-2592000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity contextRef="c0" decimals="-3" id="ixv-37615" unitRef="usd">2880000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity contextRef="c6" decimals="-3" id="ixv-37616" unitRef="usd">5759000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity contextRef="c7" decimals="-3" id="ixv-37617" unitRef="usd">2592000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="c0" decimals="-3" id="ixv-37618" unitRef="usd">52000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c0" decimals="-3" id="ixv-37619" unitRef="usd">2932000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c6" decimals="-3" id="ixv-37620" unitRef="usd">5759000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c7" decimals="-3" id="ixv-37621" unitRef="usd">2592000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c8"
      decimals="2"
      id="ixv-37622"
      unitRef="usdPershares">10.85</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c9"
      decimals="2"
      id="ixv-37623"
      unitRef="usdPershares">46.8</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c10"
      decimals="2"
      id="ixv-37624"
      unitRef="usdPershares">14.82</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c8"
      decimals="2"
      id="ixv-37625"
      unitRef="usdPershares">10.85</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c9"
      decimals="2"
      id="ixv-37626"
      unitRef="usdPershares">46.8</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c10"
      decimals="2"
      id="ixv-37627"
      unitRef="usdPershares">14.82</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:Equity contextRef="c13" decimals="-3" id="ixv-37628" unitRef="usd">58592000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c14" decimals="-3" id="ixv-37629" unitRef="usd">5180000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c15" decimals="-3" id="ixv-37630" unitRef="usd">5190000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c16" decimals="-3" id="ixv-37631" unitRef="usd">559000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c17" decimals="-3" id="ixv-37632" unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c18" decimals="-3" id="ixv-37633" unitRef="usd">-63569000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c19" decimals="-3" id="ixv-37634" unitRef="usd">6449000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c4" decimals="-3" id="ixv-37635" unitRef="usd">6449000</ifrs-full:Equity>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c26" decimals="-3" id="ixv-37636" unitRef="usd">2880000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c27" decimals="-3" id="ixv-37637" unitRef="usd">2880000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c28" decimals="-3" id="ixv-37638" unitRef="usd">52000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c0" decimals="-3" id="ixv-37639" unitRef="usd">2932000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ShareIssueRelatedCost contextRef="c21" decimals="-3" id="ixv-37640" unitRef="usd">288000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="c27" decimals="-3" id="ixv-37641" unitRef="usd">288000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="c0" decimals="-3" id="ixv-37642" unitRef="usd">288000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="c24" decimals="-3" id="ixv-37643" unitRef="usd">153000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="c27" decimals="-3" id="ixv-37644" unitRef="usd">153000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="c28" decimals="-3" id="ixv-37645" unitRef="usd">2734000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="c0" decimals="-3" id="ixv-37646" unitRef="usd">2887000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <sprcy:IssueOfSharesNetOfIssueExpenses contextRef="c21" decimals="-3" id="ixv-37647" unitRef="usd">-45000</sprcy:IssueOfSharesNetOfIssueExpenses>
    <sprcy:IssueOfSharesNetOfIssueExpenses contextRef="c27" decimals="-3" id="ixv-37648" unitRef="usd">-45000</sprcy:IssueOfSharesNetOfIssueExpenses>
    <sprcy:IssueOfSharesNetOfIssueExpenses contextRef="c0" decimals="-3" id="ixv-37649" unitRef="usd">-45000</sprcy:IssueOfSharesNetOfIssueExpenses>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c21" decimals="-3" id="ixv-37650" unitRef="usd">63000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c22" decimals="-3" id="ixv-37651" unitRef="usd">68000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c27" decimals="-3" id="ixv-37652" unitRef="usd">131000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c0" decimals="-3" id="ixv-37653" unitRef="usd">131000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:Equity contextRef="c29" decimals="-3" id="ixv-37654" unitRef="usd">58898000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c30" decimals="-3" id="ixv-37655" unitRef="usd">5248000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c31" decimals="-3" id="ixv-37656" unitRef="usd">5190000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c32" decimals="-3" id="ixv-37657" unitRef="usd">712000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c33" decimals="-3" id="ixv-37658" unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c34" decimals="-3" id="ixv-37659" unitRef="usd">-66449000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c35" decimals="-3" id="ixv-37660" unitRef="usd">4096000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c36" decimals="-3" id="ixv-37661" unitRef="usd">2682000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c2" decimals="-3" id="ixv-37662" unitRef="usd">6778000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c37" decimals="-3" id="ixv-37663" unitRef="usd">58541000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c38" decimals="-3" id="ixv-37664" unitRef="usd">4331000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c39" decimals="-3" id="ixv-37665" unitRef="usd">5190000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c40" decimals="-3" id="ixv-37666" unitRef="usd">559000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c41" decimals="-3" id="ixv-37667" unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c42" decimals="-3" id="ixv-37668" unitRef="usd">-60977000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c43" decimals="-3" id="ixv-37669" unitRef="usd">8141000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c5" decimals="-3" id="ixv-37670" unitRef="usd">8141000</ifrs-full:Equity>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c50" decimals="-3" id="ixv-37671" unitRef="usd">5759000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c51" decimals="-3" id="ixv-37672" unitRef="usd">5759000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c6" decimals="-3" id="ixv-37673" unitRef="usd">5759000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c45" decimals="-3" id="ixv-37674" unitRef="usd">6000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c46" decimals="-3" id="ixv-37675" unitRef="usd">-6000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c46" decimals="-3" id="ixv-37676" unitRef="usd">655000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c51" decimals="-3" id="ixv-37677" unitRef="usd">655000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c6" decimals="-3" id="ixv-37678" unitRef="usd">655000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:Equity contextRef="c53" decimals="-3" id="ixv-37679" unitRef="usd">58547000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c54" decimals="-3" id="ixv-37680" unitRef="usd">4980000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c55" decimals="-3" id="ixv-37681" unitRef="usd">5190000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c56" decimals="-3" id="ixv-37682" unitRef="usd">559000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c57" decimals="-3" id="ixv-37683" unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c58" decimals="-3" id="ixv-37684" unitRef="usd">-66736000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c59" decimals="-3" id="ixv-37685" unitRef="usd">3037000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c3" decimals="-3" id="ixv-37686" unitRef="usd">3037000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c37" decimals="-3" id="ixv-37687" unitRef="usd">58541000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c38" decimals="-3" id="ixv-37688" unitRef="usd">4331000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c39" decimals="-3" id="ixv-37689" unitRef="usd">5190000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c40" decimals="-3" id="ixv-37690" unitRef="usd">559000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c41" decimals="-3" id="ixv-37691" unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c42" decimals="-3" id="ixv-37692" unitRef="usd">-60977000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c43" decimals="-3" id="ixv-37693" unitRef="usd">8141000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c5" decimals="-3" id="ixv-37694" unitRef="usd">8141000</ifrs-full:Equity>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c66" decimals="-3" id="ixv-37695" unitRef="usd">2592000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c67" decimals="-3" id="ixv-37696" unitRef="usd">2592000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c7" decimals="-3" id="ixv-37697" unitRef="usd">2592000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <sprcy:ExerciseOfWarrants contextRef="c61" decimals="-3" id="ixv-37698" unitRef="usd">3000</sprcy:ExerciseOfWarrants>
    <sprcy:ExerciseOfWarrants contextRef="c67" decimals="-3" id="ixv-37699" unitRef="usd">3000</sprcy:ExerciseOfWarrants>
    <sprcy:ExerciseOfWarrants contextRef="c7" decimals="-3" id="ixv-37700" unitRef="usd">3000</sprcy:ExerciseOfWarrants>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c61" decimals="-3" id="ixv-37701" unitRef="usd">48000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c62" decimals="-3" id="ixv-37702" unitRef="usd">849000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c67" decimals="-3" id="ixv-37703" unitRef="usd">897000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c7" decimals="-3" id="ixv-37704" unitRef="usd">897000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:Equity contextRef="c13" decimals="-3" id="ixv-37705" unitRef="usd">58592000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c14" decimals="-3" id="ixv-37706" unitRef="usd">5180000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c15" decimals="-3" id="ixv-37707" unitRef="usd">5190000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c16" decimals="-3" id="ixv-37708" unitRef="usd">559000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c17" decimals="-3" id="ixv-37709" unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c18" decimals="-3" id="ixv-37710" unitRef="usd">-63569000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c19" decimals="-3" id="ixv-37711" unitRef="usd">6449000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c69" decimals="-3" id="ixv-37712" unitRef="usd">6449000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-37713" unitRef="usd">-2932000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c6" decimals="-3" id="ixv-37714" unitRef="usd">-5759000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c7" decimals="-3" id="ixv-37715" unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c0" decimals="-3" id="ixv-37716" unitRef="usd">267000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c6" decimals="-3" id="ixv-37717" unitRef="usd">21000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c7" decimals="-3" id="ixv-37718" unitRef="usd">187000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c0" decimals="-3" id="ixv-37719" unitRef="usd">131000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c6" decimals="-3" id="ixv-37720" unitRef="usd">655000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c7" decimals="-3" id="ixv-37721" unitRef="usd">897000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="c0" decimals="-3" id="ixv-37722" unitRef="usd">1023000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="c6" decimals="-3" id="ixv-37723" unitRef="usd">-913000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="c7" decimals="-3" id="ixv-37724" unitRef="usd">6585000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="c0" decimals="-3" id="ixv-37725" unitRef="usd">98000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="c6" decimals="-3" id="ixv-37726" unitRef="usd">41000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="c7" decimals="-3" id="ixv-37727" unitRef="usd">109000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <sprcy:AdjustmentsForImpairmentOfInvestmentInAssociate contextRef="c0" decimals="-3" id="ixv-37728" unitRef="usd">855000</sprcy:AdjustmentsForImpairmentOfInvestmentInAssociate>
    <sprcy:AdjustmentsForImpairmentOfInvestmentInAssociate contextRef="c7" decimals="-3" id="ixv-37729" unitRef="usd">770000</sprcy:AdjustmentsForImpairmentOfInvestmentInAssociate>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="c0" decimals="-3" id="ixv-37730" unitRef="usd">328000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="c6" decimals="-3" id="ixv-37731" unitRef="usd">1630000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="c7" decimals="-3" id="ixv-37732" unitRef="usd">-4622000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables contextRef="c0" decimals="-3" id="ixv-37733" unitRef="usd">-684000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables contextRef="c6" decimals="-3" id="ixv-37734" unitRef="usd">2205000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables contextRef="c7" decimals="-3" id="ixv-37735" unitRef="usd">3000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c0" decimals="-3" id="ixv-37736" unitRef="usd">48000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c6" decimals="-3" id="ixv-37737" unitRef="usd">-324000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c0" decimals="-3" id="ixv-37738" unitRef="usd">-40000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c6" decimals="-3" id="ixv-37739" unitRef="usd">60000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c7" decimals="-3" id="ixv-37740" unitRef="usd">39000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c0" decimals="-3" id="ixv-37741" unitRef="usd">39000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c7" decimals="-3" id="ixv-37742" unitRef="usd">-77000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c0" decimals="-3" id="ixv-37743" unitRef="usd">8000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c7" decimals="-3" id="ixv-37744" unitRef="usd">-668000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital contextRef="c0" decimals="-3" id="ixv-37745" unitRef="usd">-629000</ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital>
    <ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital contextRef="c6" decimals="-3" id="ixv-37746" unitRef="usd">1941000</ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital>
    <ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital contextRef="c7" decimals="-3" id="ixv-37747" unitRef="usd">-703000</ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-37748" unitRef="usd">-3233000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c6" decimals="-3" id="ixv-37749" unitRef="usd">-2188000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c7" decimals="-3" id="ixv-37750" unitRef="usd">-7917000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents contextRef="c0" decimals="-3" id="ixv-37751" unitRef="usd">16000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents contextRef="c6" decimals="-3" id="ixv-37752" unitRef="usd">-8000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents contextRef="c7" decimals="-3" id="ixv-37753" unitRef="usd">-15000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c7" decimals="-3" id="ixv-37754" unitRef="usd">8000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments contextRef="c0" decimals="-3" id="ixv-37755" unitRef="usd">-400000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments contextRef="c6" decimals="-3" id="ixv-37756" unitRef="usd">-700000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments contextRef="c7" decimals="-3" id="ixv-37757" unitRef="usd">-700000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments>
    <sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c0" decimals="-3" id="ixv-37758" unitRef="usd">-687000</sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss>
    <sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c7" decimals="-3" id="ixv-37759" unitRef="usd">-1500000</sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c7" decimals="-3" id="ixv-37760" unitRef="usd">4861000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c0" decimals="-3" id="ixv-37761" unitRef="usd">-1071000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c6" decimals="-3" id="ixv-37762" unitRef="usd">-708000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c7" decimals="-3" id="ixv-37763" unitRef="usd">-7084000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses contextRef="c0" decimals="-3" id="ixv-37764" unitRef="usd">50000</sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses>
    <sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses contextRef="c6" decimals="-3" id="ixv-37765" unitRef="usd">-9005000</sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses>
    <sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses contextRef="c7" decimals="-3" id="ixv-37766" unitRef="usd">-9005000</sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses>
    <sprcy:RepaymentOfLeaseLiabilities contextRef="c0" decimals="-3" id="ixv-37767" unitRef="usd">26000</sprcy:RepaymentOfLeaseLiabilities>
    <sprcy:RepaymentOfLeaseLiabilities contextRef="c6" decimals="-3" id="ixv-37768" unitRef="usd">39000</sprcy:RepaymentOfLeaseLiabilities>
    <sprcy:RepaymentOfLeaseLiabilities contextRef="c7" decimals="-3" id="ixv-37769" unitRef="usd">70000</sprcy:RepaymentOfLeaseLiabilities>
    <sprcy:InterestPaidOnLeaseLiability contextRef="c7" decimals="-3" id="ixv-37770" unitRef="usd">-8000</sprcy:InterestPaidOnLeaseLiability>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c0" decimals="-3" id="ixv-37771" unitRef="usd">2887000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromExerciseOfOptions contextRef="c7" decimals="-3" id="ixv-37772" unitRef="usd">2770000</ifrs-full:ProceedsFromExerciseOfOptions>
    <sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod contextRef="c7" decimals="-3" id="ixv-37773" unitRef="usd">3000</sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c0" decimals="-3" id="ixv-37774" unitRef="usd">2811000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c6" decimals="-3" id="ixv-37775" unitRef="usd">8966000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c7" decimals="-3" id="ixv-37776" unitRef="usd">11700000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c0" decimals="-3" id="ixv-37777" unitRef="usd">-1493000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c6" decimals="-3" id="ixv-37778" unitRef="usd">6070000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c7" decimals="-3" id="ixv-37779" unitRef="usd">-3301000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c4" decimals="-3" id="ixv-37780" unitRef="usd">3574000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c5" decimals="-3" id="ixv-37781" unitRef="usd">6875000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c5" decimals="-3" id="ixv-37782" unitRef="usd">6875000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-37783" unitRef="usd">2081000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-37784" unitRef="usd">12945000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c4" decimals="-3" id="ixv-37785" unitRef="usd">3574000</ifrs-full:CashAndCashEquivalents>
    <sprcy:MutualShareExchangeOfOrdinarySharessee contextRef="c0" decimals="-3" id="ixv-37786" unitRef="usd">288000</sprcy:MutualShareExchangeOfOrdinarySharessee>
    <sprcy:DisclosureOfGeneralExplanatoryTextBlock contextRef="c0" id="ixv-21871">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
1:- GENERAL&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;SciSparc
    Ltd. (formerly known as Therapix Biosciences Ltd.) (&#x201c;SciSparc&#x201d; or the &#x201c;Company&#x201d; or the &#x201c;Group&#x201d;),
    a pharmaceutical company, was incorporated in Israel and commenced its operations on August 23, 2004. Until March 2014, SciSparc
    and its subsidiaries at the time were mainly engaged in developing several innovative immunotherapy products and SciSparc&#x2019;s
    own patents in the immunotherapy field. In August 2015, the Company decided to adopt a different business strategy and began focusing
    on developing a portfolio of approved drugs based on cannabinoid molecules. With this focus, the Company is currently engaged in
    development programs based on &#x394;9-tetrahydrocannabinol (&#x201c;THC&#x201d;) and/or non-psychoactive cannabidiol for the treatment
    of Tourette syndrome, Alzheimer&#x2019;s disease and agitation, pain, autism spectrum disorder and Status Epilepticus. The headquarters
    of the Company are located in Tel Aviv, Israel.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
    September 30, 2022, the Company announced the closing of the acquisition of Wellution&lt;sup&gt;TM&lt;/sup&gt;, a top seller Amazon.com Marketplace
    account (the &#x201c;Brand&#x201d;), American food supplements and cosmetics brand and trademark (the &#x201c;Acquisition&#x201d;). In
    connection with the Acquisition, the Company incorporated a new wholly owned Delaware subsidiary, SciSparc Nutraceuticals Inc. (&#x201c;SciSparc
    US&#x201d;), to hold the new assets.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The Company&#x2019;s ordinary shares are listed on Nasdaq and are trading under the symbol &#x201c;SPRC&#x201d;.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As of June 30, 2023, the Company had three private subsidiaries, including a company incorporated under the laws of Israel: Evero Health Ltd (&#x201c;Evero&#x201d;); an inactive company incorporated under the laws of Israel: Brain Bright Ltd (&#x201c;Brain Bright&#x201d;); and a company incorporated under the laws of the State of Delaware: Scisparc US (together with Evero and Brain Bright, the &#x201c;Subsidiaries&#x201d;).&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On August 18, 2023, the Company convened a general meeting of its shareholders, whereby the shareholders approved, inter alia, a reverse split of the Company&#x2019;s share capital up to a ratio of 30:1 (the &#x201c;Reverse Split&#x201d;). Following the implementation of the reverse split, the Company&#x2019;s authorized share capital will not be adjusted under the Company&#x2019;s articles of association, as currently in effect (the &#x201c;Articles&#x201d;), which as of the date hereof consists of 75,000,000 Ordinary Shares, no par value.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
September 14, 2023, the Company&#x2019;s Board resolved that the final ratio for the Reverse Split will be 26:1, which became effective
on September 28, 2023.&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Consequently,
all share numbers, share prices, and exercise prices have been retroactively adjusted in these interim consolidated financial statements
for all periods presented.&lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These interim consolidated
    financial statements should be read in conjunction with the Company&#x2019;s annual financial statements for the year ended December
    31, 2022, and accompanying notes, that were approved on April 27, 2023, and signed on May 1, 2023 (the &#x201c;2022 Annual Consolidated
    Financial Statements&#x201d;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The Company incurred a net loss of $2,932 and had negative cash flows from operating activities of $3,233 for the six month period ended June 30, 2023. As of June 30, 2023, the Company had an accumulated deficit of $66,449 as a result of recurring operating losses. At June 30, 2023, the Company&#x2019;s cash and cash equivalents position is not sufficient to fund the Company&#x2019;s planned operations for at least a year beyond the date of the filing date of the consolidated financial statements.. The Company&#x2019;s pharmaceuticals operations are dependent on its ability to raise additional funds from existing and/or new investors. This dependency will continue until the Group will be able to completely finance its operations by generating revenue from its pharmaceutical products. These abovementioned factors raise substantial doubt about the Group&#x2019;s ability to continue as a going concern.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The Company intends to finance operating costs over the next twelve months through a combination of actions that may include existing cash on hand, reducing operating expenses and issuing equity and/or debt securities.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The interim consolidated financial statements for the period ended June 30, 2023, do not include any adjustments to the carrying amounts and classifications of assets and liabilities that might result should the Group be unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The interim consolidated financial statements
    of the Company for the six-month period ended on June&#160;30, 2023, were approved for issuance on October 2, 2023 (the &#x201c;Approval
    Date&#x201d;). In connection with the preparation of the interim consolidated financial statements and in accordance with authoritative
    guidance for subsequent events, the Company evaluated subsequent events after the consolidated statements of financial position date
    of June 30, 2023, through September 27, 2023, the date on which the unaudited interim consolidated financial statements were available
    to be issued.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfGeneralExplanatoryTextBlock>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c105"
      decimals="0"
      id="ixv-37787"
      unitRef="shares">75000000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:GainsLossesOnNetMonetaryPosition contextRef="c0" decimals="-3" id="ixv-37788" unitRef="usd">2932000</ifrs-full:GainsLossesOnNetMonetaryPosition>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-37789" unitRef="usd">-3233000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <sprcy:RetainedEarning contextRef="c2" decimals="-3" id="ixv-37790" unitRef="usd">66449000</sprcy:RetainedEarning>
    <ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory contextRef="c0" id="ixv-22000">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
2:- SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Unaudited
Interim Financial Information&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company&#x2019;s unaudited condensed consolidated financial statements have been prepared in accordance with International Accounting
Standard (&#x201c;IAS&#x201d;) 34, &#x201c;Interim Financial Reporting&#x201d;. The significant accounting policies adopted in the preparation
of the interim consolidated financial statements are consistent with those followed in the preparation of the 2022 Annual Consolidated
Financial Statements. Accordingly, these condensed consolidated financial statements should be read in conjunction with the 2022 Annual
Consolidated Financial Statements. The results for any interim period are not necessarily indicative of results for any future period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
unaudited condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the
opinion of the Company&#x2019;s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments
that are necessary to present fairly the Company&#x2019;s financial position and results of operations for the interim periods presented.
The results for the six month period ended June 30, 2023, are not necessarily indicative of the results for the year ending December&#160;31,
2023, or for any future period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of June 30, 2023, there have been no material changes in the Company&#x2019;s significant accounting policies from those that were disclosed
in the 2022 Annual Consolidated Financial Statements.&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="c0" id="ixv-22006">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Unaudited
Interim Financial Information&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company&#x2019;s unaudited condensed consolidated financial statements have been prepared in accordance with International Accounting
Standard (&#x201c;IAS&#x201d;) 34, &#x201c;Interim Financial Reporting&#x201d;. The significant accounting policies adopted in the preparation
of the interim consolidated financial statements are consistent with those followed in the preparation of the 2022 Annual Consolidated
Financial Statements. Accordingly, these condensed consolidated financial statements should be read in conjunction with the 2022 Annual
Consolidated Financial Statements. The results for any interim period are not necessarily indicative of results for any future period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
unaudited condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the
opinion of the Company&#x2019;s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments
that are necessary to present fairly the Company&#x2019;s financial position and results of operations for the interim periods presented.
The results for the six month period ended June 30, 2023, are not necessarily indicative of the results for the year ending December&#160;31,
2023, or for any future period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of June 30, 2023, there have been no material changes in the Company&#x2019;s significant accounting policies from those that were disclosed
in the 2022 Annual Consolidated Financial Statements.&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory contextRef="c0" id="ixv-22055">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
3:- INVESTMENT IN ASSOCIATE&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
March 10, 2022, the Company entered into a Founders and Investment Agreement with Dr. Alon Silberman, or the MitoCareX Agreement. Pursuant
to the MitoCareX Agreement, the Company invested an initial amount of $700, and agreed to invest over the next&#160;two years, an additional
$1,000, subject to the achievement of certain pre-determined milestones as agreed upon in the MitoCareX Agreement, for up to a&#160;50.01%
ownership in MitoCareX Bio Ltd. (&#x201c;MitoCareX&#x201d;). MitoCareX is focused on the discovery and development of potential drugs for
cancers and other life-threatening conditions. The MitoCareX Agreement also contains customary representations, warranties, covenants,
and indemnification provisions. On March 31, 2022, the closing conditions were met, and the Company paid the initial investment amount
of $700&#160;to MitoCareX. As of December 31, 2022, the Company owns&#160;31.48% of the outstanding shares of MitoCareX.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
February 17, 2023, MitoCareX achieved its first milestone pursuant to the MitoCareX Agreement. The first milestone refers to the establishment
of MitoCareX&#x2019;s cloud-based computing infrastructure that is expected to allow its future expansion into machine learning system.
The system is harnessed to investigating mitochondrial carriers that are crucial for cell viability. As a result of MitoCareX meeting
this milestone, the Company will invest an additional $400&#160;in MitoCareX and increase its share ownership in MitoCareX Bio from&#160;31.48%
to&#160;41.92%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
table below summarizes the fair value of the investment in MitoCareX:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at January
    1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-220; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 88%; font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Investment
    date March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;700&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Equity
    losses from investment in MitoCareX&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(109&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at December
    31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;591&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Investment date March
    31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;400&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Equity
    losses from investment in MitoCareX&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(98&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance
    at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;893&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
the six months ended June 30, 2023, and 2022, the Company recorded equity losses from the investment in MitoCareX in the amount of $98
and $41, respectively.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory>
    <sprcy:InvestedInitialAmount
      contextRef="c106"
      decimals="-3"
      id="ixv-37791"
      unitRef="usd">700000</sprcy:InvestedInitialAmount>
    <sprcy:AdditionalAgreedInvest
      contextRef="c106"
      decimals="-3"
      id="ixv-37792"
      unitRef="usd">1000000</sprcy:AdditionalAgreedInvest>
    <sprcy:OwnershipAgreement
      contextRef="c107"
      decimals="4"
      id="ixv-37793"
      unitRef="pure">0.5001</sprcy:OwnershipAgreement>
    <sprcy:InitialInvestment
      contextRef="c108"
      decimals="-3"
      id="ixv-37794"
      unitRef="usd">700000</sprcy:InitialInvestment>
    <sprcy:OutstandingSharesPercentage contextRef="c7" decimals="4" id="ixv-37795" unitRef="pure">0.3148</sprcy:OutstandingSharesPercentage>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="c109"
      decimals="-3"
      id="ixv-37796"
      unitRef="usd">400000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c110"
      decimals="4"
      id="ixv-37797"
      unitRef="pure">0.3148</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c111"
      decimals="4"
      id="ixv-37798"
      unitRef="pure">0.4192</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory contextRef="c0" id="ixv-22070">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
table below summarizes the fair value of the investment in MitoCareX:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at January
    1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-220; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 88%; font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Investment
    date March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;700&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Equity
    losses from investment in MitoCareX&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(109&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at December
    31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;591&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Investment date March
    31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;400&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Equity
    losses from investment in MitoCareX&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(98&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance
    at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;893&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfEffectOfChangeOfInvestmentEntityStatusOnFinancialStatementsExplanatory>
    <sprcy:InvestmentDate contextRef="c7" decimals="-3" id="ixv-37799" unitRef="usd">700000</sprcy:InvestmentDate>
    <sprcy:EquityLossesFromInvestmentInMitoCareX contextRef="c7" decimals="-3" id="ixv-37800" unitRef="usd">-109000</sprcy:EquityLossesFromInvestmentInMitoCareX>
    <ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="c4" decimals="-3" id="ixv-37801" unitRef="usd">591000</ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <sprcy:InvestmentDate contextRef="c0" decimals="-3" id="ixv-37802" unitRef="usd">400000</sprcy:InvestmentDate>
    <sprcy:EquityLossesFromInvestmentInMitoCareX contextRef="c0" decimals="-3" id="ixv-37803" unitRef="usd">-98000</sprcy:EquityLossesFromInvestmentInMitoCareX>
    <ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="c2" decimals="-3" id="ixv-37804" unitRef="usd">893000</ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <sprcy:EquityLossesInvestment contextRef="c0" decimals="-3" id="ixv-37805" unitRef="usd">98000</sprcy:EquityLossesInvestment>
    <sprcy:EquityLossesInvestment
      contextRef="c112"
      decimals="-3"
      id="ixv-37806"
      unitRef="usd">41000</sprcy:EquityLossesInvestment>
    <ifrs-full:DisclosureOfIntangibleAssetsExplanatory contextRef="c0" id="ixv-22218">&lt;p style="text-align: justify; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4:- INTANGIBLE ASSET&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
September 30, 2022, the Company announced the closing of the Acquisition. In connection with the Acquisition, the Company incorporated
a new wholly owned Delaware subsidiary, SciSparc US, to hold the new assets. The definitive agreement for the acquisition of the Brand
was entered into with Merhavit M.R.M Holding and Management Ltd (&#x201c;M.R.M&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;At
the closing, the Company paid a base cash payment of $4,540 and in 12 months following the closing agreed to pay an additional deferred
cash payment equal to a multiple of 3 times the amount by which the Brand&#x2019;s EBITDA exceeds $1,120 during the 12-month period following
the closing of the Acquisition. The Company paid an additional $321 as purchase costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
addition, the Company issued to M.R.M $15,000 worth of warrants to purchase ordinary shares of the Company at an exercise price of $7.00
per share (with a cashless exercise mechanism) and with an exercise period of five years from the closing of the Acquisition (the &#x201c;September
2022 Warrants&#x201d;). The September 2022 Warrants will become exercisable upon the earlier of (i) an achievement of $100,000 of gross
sales by the Brand in the aggregate or (ii) if the price of our Ordinary Shares closes at $10.00 or above.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company reviewed the transaction and deemed it to be the purchase of assets for accounting purposes under generally accepted accounting
principles and not as a business combination. The Company reviewed the guidance under IFRS 3 for the transaction and determined that
the fair value of the gross assets acquired was concentrated in a single identifiable asset, a brand. Accordingly, the Company treated
the transaction as an asset acquisition. On the closing date of the Acquisition, the Company fully recognized the acquisition amount
total of $4,861 as an intangible asset, to be amortized over a period of 10 years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
table below summarizes the fair value of the intangible asset:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at January
    1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-221; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 88%; font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Purchase
    date September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,861&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Depreciation
    of intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(144&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at December
    31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,717&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Depreciation
    of intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(243&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance
    at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,474&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
the year ended December 31, 2022, the Company recognized depreciation expenses in respect to intangible asset in the amount of $144.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
estimated fair values of the tangible and intangible assets in respect of the Acquisition of&#160;the Wellution&#x2122; brand are provisional
and are based on information that was available as of the Acquisition date to estimate the fair value of these amounts. The Group&#x2019;s
management believes the information provides a reasonable basis for estimating the fair values of these amounts but is waiting for additional
information necessary to finalize those fair values. Therefore, provisional measurements of fair value that appear are subject to change.
The Group expects to finalize the tangible and intangible assets valuation and complete the Acquisition accounting as soon as practicable
but no later than the measurement period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
the six months ended June 30, 2023, and 2022, the Company recorded depreciation expenses with respect to intangible asset in the amount
of $243 and $ &lt;span style="-sec-ix-hidden: hidden-fact-222"&gt;nil&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfIntangibleAssetsExplanatory>
    <sprcy:CashPayment contextRef="c0" decimals="-3" id="ixv-37807" unitRef="usd">4540000</sprcy:CashPayment>
    <ifrs-full:AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount contextRef="c2" decimals="-3" id="ixv-37808" unitRef="usd">1120000</ifrs-full:AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount>
    <sprcy:PurchaseCosts contextRef="c0" decimals="-3" id="ixv-37809" unitRef="usd">321000</sprcy:PurchaseCosts>
    <sprcy:WarrantsToPurchase contextRef="c0" decimals="-3" id="ixv-37810" unitRef="usd">15000000</sprcy:WarrantsToPurchase>
    <sprcy:ExercisePrice1
      contextRef="c0"
      decimals="2"
      id="ixv-37811"
      unitRef="usdPershares">7</sprcy:ExercisePrice1>
    <sprcy:ExercisePeriod contextRef="c0" id="ixv-37812">P5Y</sprcy:ExercisePeriod>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="c113"
      decimals="-3"
      id="ixv-37813"
      unitRef="usd">100000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <sprcy:PricePerShare
      contextRef="c113"
      decimals="2"
      id="ixv-37814"
      unitRef="usdPershares">10</sprcy:PricePerShare>
    <sprcy:AmountTotal contextRef="c0" decimals="-3" id="ixv-37815" unitRef="usd">4861000</sprcy:AmountTotal>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="c0" id="ixv-37816">P10Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <sprcy:ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock contextRef="c0" id="ixv-22241">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
table below summarizes the fair value of the intangible asset:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at January
    1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-221; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 88%; font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Purchase
    date September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,861&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Depreciation
    of intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(144&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at December
    31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,717&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Depreciation
    of intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(243&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance
    at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,474&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock>
    <sprcy:PurchaseOfAssets contextRef="c7" decimals="-3" id="ixv-37817" unitRef="usd">4861000</sprcy:PurchaseOfAssets>
    <ifrs-full:DepreciationAndAmortisationExpense contextRef="c7" decimals="-3" id="ixv-37818" unitRef="usd">144000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c4" decimals="-3" id="ixv-37819" unitRef="usd">4717000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:DepreciationAndAmortisationExpense contextRef="c0" decimals="-3" id="ixv-37820" unitRef="usd">243000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c2" decimals="-3" id="ixv-37821" unitRef="usd">4474000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c7" decimals="-3" id="ixv-37822" unitRef="usd">144000</ifrs-full:ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c0" decimals="-3" id="ixv-37823" unitRef="usd">243000</ifrs-full:ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory contextRef="c0" id="ixv-22387">&lt;p style="text-align: justify; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5:- INVESTMENT IN FINANCIAL ASSETS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
June 25, 2023, the Company entered into a Share Purchase Agreement (the &#x201c;Agreement&#x201d;) with AutoMax Motors Ltd. (&#x201c;AutoMax&#x201d;),
an Israeli company traded on the Tel Aviv Stock Exchange (&#x201c;TASE&#x201d;) and the leading parallel importer and distributor of vehicles
in Israel, pursuant to which, at the closing and upon the terms and conditions set forth in the Agreement, the Company will invest NIS
2,500,000 in cash, in exchange for ordinary shares, NIS 0.05 par value, of AutoMax (the &#x201c;AutoMax Shares&#x201d;) based on a price
per share of NIS 0.5. As of June 30, 2023, the listed share price of AutoMax on the TASE was NIS 0.41, and the Company has recorded a
loss in its statements of comprehensive loss of $133 on its investment. &#160;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory>
    <ifrs-full:Cash contextRef="c2" decimals="0" id="ixv-37824" unitRef="ils">2500000</ifrs-full:Cash>
    <ifrs-full:ParValuePerShare
      contextRef="c114"
      decimals="2"
      id="ixv-37825"
      unitRef="ilsPershares">0.05</ifrs-full:ParValuePerShare>
    <ifrs-full:ParValuePerShare
      contextRef="c115"
      decimals="1"
      id="ixv-37826"
      unitRef="ilsPershares">0.5</ifrs-full:ParValuePerShare>
    <sprcy:ExerciseOfPricePerShare
      contextRef="c116"
      decimals="2"
      id="ixv-37827"
      unitRef="ilsPershares">0.41</sprcy:ExerciseOfPricePerShare>
    <ifrs-full:OtherComprehensiveIncome contextRef="c0" decimals="-3" id="ixv-37828" unitRef="usd">133000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory contextRef="c0" id="ixv-22399">&lt;p style="text-align: justify; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6:- TRANSACTIONS AND BALANCES WITH RELATED PARTIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Mr. Oz Adler, the Company&#x2019;s Chief Executive Officer and Chief Financial Officer, is the chairman of the board of directors of&#160;Jeffs&#x2019;&#160;Brands Ltd. (&#x201c;Jeffs&#x2019; Brands&#x201d;) (see Note 11).&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On March 7, 2022, the Company entered into the Cooperation Agreement with Clearmind Medicine Inc. (&#x201c;Clearmind&#x201d;), a company in which Dr. Adi Zuloff-Shani, the Company&#x2019;s Chief Technologies Officer, Mr. Weiss, the Company&#x2019;s President, and Mr. Adler, the Company&#x2019;s Chief Executive Officer and Chief Financial Officer, serve as officers and directors.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
the year ended December 31, 2022, the Company recognized expenses in respect of the Cooperation Agreement with Clearmind in the amount
of $208, and the balance owed to Clearmind as of December 31, 2022, was $55.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
November 17, 2022, the Company invested $1,500 thousand in Clearmind in connection with its initial public offering on the Nasdaq Capital
Market, in exchange for 230,769 common shares of Clearmind, representing 9.33% of the outstanding share capital of Clearmind.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Mr. Amitai Weiss, our chairman of the board of directors, is the chairman of the board of directors of&#160;AutoMax (see Note 5).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <sprcy:CooperationAgreementWithClearmindAmount contextRef="c7" decimals="-3" id="ixv-37829" unitRef="usd">208000</sprcy:CooperationAgreementWithClearmindAmount>
    <sprcy:BalanceOwedToClearmind contextRef="c7" decimals="-3" id="ixv-37830" unitRef="usd">55000</sprcy:BalanceOwedToClearmind>
    <sprcy:InvestedAmount
      contextRef="c117"
      decimals="-3"
      id="ixv-37831"
      unitRef="usd">1500000</sprcy:InvestedAmount>
    <sprcy:ExchangeCommonShares
      contextRef="c117"
      decimals="0"
      id="ixv-37832"
      unitRef="shares">230769</sprcy:ExchangeCommonShares>
    <sprcy:ClearmindOutstandingShareCapitalPercentage
      contextRef="c117"
      decimals="4"
      id="ixv-37833"
      unitRef="pure">0.0933</sprcy:ClearmindOutstandingShareCapitalPercentage>
    <ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory contextRef="c0" id="ixv-22445">&lt;p style="text-align: justify; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
7:- FINANCIAL INSTRUMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Calibri, Helvetica, Sans-Serif; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Classification
of financial assets and financial liabilities:&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
financial assets and financial liabilities in the consolidated statements of financial position are classified by groups of financial
instruments pursuant to IFRS 9, &#x201c;&lt;i&gt;Financial Instruments&lt;/i&gt;&#x201d;:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unaudited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Audited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Note&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD
    in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 52%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash
    and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,081&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,945&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,574&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;43&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-223; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;60&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Government authorities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;77&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other
    receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;715&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;622&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;86&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Investments in financial
    assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;849&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-224; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;730&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,778&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,644&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,495&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-style: italic; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Credit from others&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-225; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-226; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;102&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants liability&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,714&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,252&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,737&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease
    liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-227; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;27&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total financial and
    lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,714&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,297&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,866&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory>
    <ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory contextRef="c0" id="ixv-22456">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
financial assets and financial liabilities in the consolidated statements of financial position are classified by groups of financial
instruments pursuant to IFRS 9, &#x201c;&lt;i&gt;Financial Instruments&lt;/i&gt;&#x201d;:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unaudited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Audited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Note&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD
    in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 52%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash
    and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,081&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,945&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,574&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;43&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-223; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;60&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Government authorities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;77&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other
    receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;715&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;622&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;86&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Investments in financial
    assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;849&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-224; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;730&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,778&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,644&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,495&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-style: italic; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Credit from others&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-225; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-226; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;102&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants liability&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,714&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,252&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,737&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease
    liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-227; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;27&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total financial and
    lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,714&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,297&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,866&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-37834" unitRef="usd">2081000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-37835" unitRef="usd">12945000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c4" decimals="-3" id="ixv-37836" unitRef="usd">3574000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:TradeReceivables contextRef="c2" decimals="-3" id="ixv-37837" unitRef="usd">43000</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables contextRef="c4" decimals="-3" id="ixv-37838" unitRef="usd">60000</ifrs-full:TradeReceivables>
    <sprcy:GovernmentAuthorities contextRef="c2" decimals="-3" id="ixv-37839" unitRef="usd">100000</sprcy:GovernmentAuthorities>
    <sprcy:GovernmentAuthorities contextRef="c3" decimals="-3" id="ixv-37840" unitRef="usd">77000</sprcy:GovernmentAuthorities>
    <sprcy:GovernmentAuthorities contextRef="c4" decimals="-3" id="ixv-37841" unitRef="usd">45000</sprcy:GovernmentAuthorities>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="c2" decimals="-3" id="ixv-37842" unitRef="usd">715000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="c3" decimals="-3" id="ixv-37843" unitRef="usd">622000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="c4" decimals="-3" id="ixv-37844" unitRef="usd">86000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:FinancialAssets contextRef="c2" decimals="-3" id="ixv-37845" unitRef="usd">849000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c4" decimals="-3" id="ixv-37846" unitRef="usd">730000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialLiabilitiesAtAmortisedCost contextRef="c2" decimals="-3" id="ixv-37847" unitRef="usd">3778000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
    <ifrs-full:FinancialLiabilitiesAtAmortisedCost contextRef="c3" decimals="-3" id="ixv-37848" unitRef="usd">13644000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
    <ifrs-full:FinancialLiabilitiesAtAmortisedCost contextRef="c4" decimals="-3" id="ixv-37849" unitRef="usd">4495000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
    <sprcy:CreditFromOthers contextRef="c4" decimals="-3" id="ixv-37850" unitRef="usd">102000</sprcy:CreditFromOthers>
    <sprcy:WarrantsLiability contextRef="c2" decimals="-3" id="ixv-37851" unitRef="usd">1714000</sprcy:WarrantsLiability>
    <sprcy:WarrantsLiability contextRef="c3" decimals="-3" id="ixv-37852" unitRef="usd">10252000</sprcy:WarrantsLiability>
    <sprcy:WarrantsLiability contextRef="c4" decimals="-3" id="ixv-37853" unitRef="usd">2737000</sprcy:WarrantsLiability>
    <ifrs-full:LeaseLiabilities contextRef="c3" decimals="-3" id="ixv-37854" unitRef="usd">45000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c4" decimals="-3" id="ixv-37855" unitRef="usd">27000</ifrs-full:LeaseLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c2" decimals="-3" id="ixv-37856" unitRef="usd">1714000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c3" decimals="-3" id="ixv-37857" unitRef="usd">10297000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c4" decimals="-3" id="ixv-37858" unitRef="usd">2866000</ifrs-full:FinancialLiabilities>
    <sprcy:WarrantTextBlock contextRef="c0" id="ixv-23051">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
8:- WARRANTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
June 1, 2022, the Company completed a private offering with an investor for gross proceeds of $10,210 (the &#x201c;June 2022 Private Placement&#x201d;),
providing for the issuance of an aggregate of 136,388 units and pre-funded units, as follows: (a) 12,884 units at a price of $74.88 per
unit, each consisting of (i) one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#x201c;June
2022 Warrants&#x201d;), and (b) 123,504 pre-funded units at a price of $73.294 per unit, each consisting of (i) one pre-funded warrant
to purchase one ordinary share and (ii) two June 2022 Warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
June 2022 Warrants have an exercise price of $68.38 per ordinary share. The June 2022 Warrants were exercisable upon issuance and will
expire seven years from the date of issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;General
Overview of Valuation Approaches used in the Valuation:&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair
value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants
at the measurement date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Economic
methodology:&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
June 2022 Warrants&#x2019; fair value was calculated using the Black&#x2013;Scholes option pricing model, which takes into account the
parameters as disclosed below for each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting
date with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,&lt;br/&gt;
    2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30,&lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dividend
    yield (%)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected
    volatility (%)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;72&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;72&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free
    interest rate (%)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.97&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.97&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Underlying share
    price ($)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19.656&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14.274&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise price ($)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;68.38&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;68.38&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants fair value
    ($)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,396&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,373&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
June 2022 Warrants are classified as current warrant liability in the Company&#x2019;s balance sheet, as they are exercisable at any given
time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
the six months ended June 30, 2023, and 2022, the Company recorded finance income from the change in fair value of the June 2022 Warrants
in the amount of $1,023 and $&lt;span style="-sec-ix-hidden: hidden-fact-228"&gt;nil&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</sprcy:WarrantTextBlock>
    <sprcy:GrossProceed
      contextRef="c118"
      decimals="-3"
      id="ixv-37859"
      unitRef="usd">10210000</sprcy:GrossProceed>
    <sprcy:IssuanceOfAggregateShares
      contextRef="c119"
      decimals="0"
      id="ixv-37860"
      unitRef="shares">136388</sprcy:IssuanceOfAggregateShares>
    <sprcy:WarrantsDescription contextRef="c118" id="ixv-37861">(a) 12,884 units at a price of $74.88 per
unit, each consisting of (i) one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#x201c;June
2022 Warrants&#x201d;), and (b) 123,504 pre-funded units at a price of $73.294 per unit, each consisting of (i) one pre-funded warrant
to purchase one ordinary share and (ii) two June 2022 Warrants.</sprcy:WarrantsDescription>
    <sprcy:ExerciseOfPricePerShare
      contextRef="c120"
      decimals="2"
      id="ixv-37862"
      unitRef="usdPershares">68.38</sprcy:ExerciseOfPricePerShare>
    <sprcy:WarrantExpiryPeriod contextRef="c7" id="ixv-37863">P7Y</sprcy:WarrantExpiryPeriod>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory contextRef="c0" id="ixv-23082">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
June 2022 Warrants&#x2019; fair value was calculated using the Black&#x2013;Scholes option pricing model, which takes into account the
parameters as disclosed below for each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting
date with the following assumptions:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,&lt;br/&gt;
    2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30,&lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dividend
    yield (%)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected
    volatility (%)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;72&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;72&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free
    interest rate (%)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.97&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.97&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Underlying share
    price ($)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19.656&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14.274&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise price ($)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;68.38&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;68.38&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants fair value
    ($)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,396&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,373&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c121"
      decimals="2"
      id="ixv-37864"
      unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c122"
      decimals="2"
      id="ixv-37865"
      unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c121"
      decimals="2"
      id="ixv-37866"
      unitRef="pure">0.72</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c122"
      decimals="2"
      id="ixv-37867"
      unitRef="pure">0.72</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c121"
      decimals="4"
      id="ixv-37868"
      unitRef="pure">0.0397</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c122"
      decimals="4"
      id="ixv-37869"
      unitRef="pure">0.0397</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c121"
      decimals="3"
      id="ixv-37870"
      unitRef="usdPershares">19.656</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c122"
      decimals="3"
      id="ixv-37871"
      unitRef="usdPershares">14.274</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c121"
      decimals="2"
      id="ixv-37872"
      unitRef="usdPershares">68.38</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c122"
      decimals="2"
      id="ixv-37873"
      unitRef="usdPershares">68.38</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:LossesOnChangeInFairValueOfDerivatives
      contextRef="c121"
      decimals="-3"
      id="ixv-37874"
      unitRef="usd">2396000</ifrs-full:LossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:LossesOnChangeInFairValueOfDerivatives
      contextRef="c122"
      decimals="-3"
      id="ixv-37875"
      unitRef="usd">1373000</ifrs-full:LossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:WarrantReserve contextRef="c2" decimals="-3" id="ixv-37876" unitRef="usd">1023000</ifrs-full:WarrantReserve>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="c0" id="ixv-23256">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
9:- EQUITY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Reverse
Share Splits&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
August 18, 2023, the Company convened a general meeting of its shareholders, whereby the shareholders approved, inter alia, a reverse
split of the Company&#x2019;s share capital up to a ratio of 30:1. Following the implementation of the Reverse Split, the Company&#x2019;s
authorized share capital will not be adjusted under the Company&#x2019;s Articles, which as of the date hereof consists of 75,000,000
Ordinary Shares, &lt;span style="-sec-ix-hidden: hidden-fact-229"&gt;no&lt;/span&gt; par value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
September 14, 2023, the Company&#x2019;s Board resolved that the final ratio for the Reverse Split will be 26:1, which became effective
on September 28, 2023.&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Composition of share capital as of June 30, 2023, June 30, 2022, and December 31, 2022:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued
    and&lt;br/&gt; outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued
    and&lt;br/&gt; outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued
    and&lt;br/&gt; outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 28%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Ordinary
    Shares of no par value each&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;75,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;282,782&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;75,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;261,494&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25,714,286&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;135,644&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Changes in share capital:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Issued
and outstanding share capital:&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of &lt;br/&gt; ordinary&lt;br/&gt; shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance
    at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;261,494&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issuance
    of share capital &#x2013; in respect of investment in affiliate (Note 6e)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,858&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares
    issued to consultants (Note 6e)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,134&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issuance
    of share capital &#x2013; in respect of shelf prospectus (Note 6e)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;296&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance
    at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;282,782&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rights attached to shares:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Voting
rights at shareholders meetings, right to dividends, rights upon liquidation of the Company and right to nominate the directors in the
Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Capital management in the
    Company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company&#x2019;s capital management objectives are to preserve the Company&#x2019;s ability to ensure business continuity thereby creating
a return for the shareholders, investors and other interested parties. The Company is not under any minimal equity requirements nor is
it required to attain a certain level of capital return.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additional issuance of
    ordinary shares:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
August 2, 2022, the Company issued a consultant 923 ordinary shares in respect of services rendered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
November 1, 2022, the Company issued a consultant 1,423 ordinary shares in respect of services rendered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
March 22, 2023, the Company issued 13,858 ordinary shares in respect of the stock purchase&lt;span style="text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;agreement
entered into by and among Jeffs&#x2019; Brands and Jeffs&#x2019; Brands Holdings Inc. (&#x201c;NewCo&#x201d;) (see also note 8a)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
May 31, 2023, the Company issued 7,134 ordinary shares to consultants in respect of services rendered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;March 2021 Financing Round&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
March 4, 2021, the Company completed a private offering with several accredited and institutional investors for gross proceeds of $8,150,
providing for the issuance of an aggregate of 44,331 units, as follows: (a) 35,242 units at a price of $183,82 per unit, consisting of
(i) one ordinary share of the Company, and (ii) a Series A Warrant to purchase an equal number of units purchased (the &#x201c;2021 Series
A Warrants&#x201d;) and a Series B Warrant (the &#x201c;2021 Series B Warrants&#x201d; and, collectively with the 2021 Series A Warrants,
the March 2021 Warrants) to purchase half the number of units, and (b) 9,089 pre-funded units at a price of $183.794 per unit, consisting
of (i) one pre-funded warrant to purchase one ordinary share and (ii) one 2021 Series A Warrant and one 2021 Series B Warrant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Series A Warrants have an exercise price of&#160;$183.82&#160;per ordinary share and the Series B Warrants have an exercise price of&#160;$275.60&#160;per
ordinary share). Both were exercisable upon issuance and will expire five years from the date of issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
March 2021 Warrants are classified as issued warrants in the Company&#x2019;s equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
the year ended December 31, 2021, the Company issued 4,929 ordinary shares in respect of the exercise of 385 2021 Series A Warrants and
the exercise of 4,544 of pre-funded warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
the year ended December 31, 2022, the Company issued 3,846 ordinary shares in respect of the exercise of 3,846 pre-funded warrants. During
the six months ended June 30, 2023, there were no exercises of 2021 Series A Warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;g.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;June 2022 Financing Round
    (see also note 8)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
June 1, 2022, the Company completed the June 2022 Private Placement with an investor for gross proceeds of $10,210, providing for the
issuance of an aggregate of 136,388 units and pre-funded units, as follows: (a) 12,884 units at a price of $74.88 per unit, each consisting
of (i) one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#x201c;June 2022 Warrants&#x201d;),
and (b) 123,504 pre-funded units at a price of $73.294 per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary
share and (ii) two June 2022 Warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
June 2022 Warrants have an exercise price of&#160;$68.38&#160;per ordinary share. The June 2022 Warrants were exercisable upon issuance
and will expire seven years from the date of issuance.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
June 2022 Warrants are classified as current warrant liability in the Company&#x2019;s balance sheet, as they are exercisable at any given
time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
the year ended December 31, 2022, the Company issued 123,504 ordinary shares in respect of the exercise of 123,504 pre-funded warrants.
During the six months ended June 30, 2023, there were no exercises of June 2022 Warrants.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <sprcy:StockIssuedDuringPeriodReverseStockSplits
      contextRef="c105"
      decimals="0"
      id="ixv-37877"
      unitRef="shares">75000000</sprcy:StockIssuedDuringPeriodReverseStockSplits>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="c0" id="ixv-23284">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Composition of share capital as of June 30, 2023, June 30, 2022, and December 31, 2022:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued
    and&lt;br/&gt; outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued
    and&lt;br/&gt; outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued
    and&lt;br/&gt; outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 28%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Ordinary
    Shares of no par value each&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;75,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;282,782&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;75,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;261,494&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25,714,286&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;135,644&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c137"
      decimals="INF"
      id="ixv-37878"
      unitRef="shares">75000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c137"
      decimals="INF"
      id="ixv-37879"
      unitRef="shares">282782</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c138"
      decimals="INF"
      id="ixv-37880"
      unitRef="shares">75000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c138"
      decimals="INF"
      id="ixv-37881"
      unitRef="shares">261494</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c139"
      decimals="INF"
      id="ixv-37882"
      unitRef="shares">25714286</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c139"
      decimals="INF"
      id="ixv-37883"
      unitRef="shares">135644</ifrs-full:NumberOfSharesOutstanding>
    <sprcy:DisclosureOfIssuedAndOutstandingShareCapital contextRef="c0" id="ixv-23426">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Issued
and outstanding share capital:&lt;/i&gt;&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of &lt;br/&gt; ordinary&lt;br/&gt; shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance
    at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;261,494&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issuance
    of share capital &#x2013; in respect of investment in affiliate (Note 6e)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,858&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares
    issued to consultants (Note 6e)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,134&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issuance
    of share capital &#x2013; in respect of shelf prospectus (Note 6e)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;296&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance
    at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;282,782&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</sprcy:DisclosureOfIssuedAndOutstandingShareCapital>
    <sprcy:NumberOfSharesIssued1
      contextRef="c4"
      decimals="INF"
      id="ixv-37884"
      unitRef="shares">261494</sprcy:NumberOfSharesIssued1>
    <sprcy:IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate
      contextRef="c0"
      decimals="INF"
      id="ixv-37885"
      unitRef="shares">13858</sprcy:IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate>
    <sprcy:SharesIssuedToConsultants
      contextRef="c0"
      decimals="INF"
      id="ixv-37886"
      unitRef="shares">7134</sprcy:SharesIssuedToConsultants>
    <sprcy:IssuanceOfShareCapitalInRespectOfShelfProspectus
      contextRef="c0"
      decimals="INF"
      id="ixv-37887"
      unitRef="shares">296</sprcy:IssuanceOfShareCapitalInRespectOfShelfProspectus>
    <sprcy:NumberOfSharesIssued1
      contextRef="c2"
      decimals="INF"
      id="ixv-37888"
      unitRef="shares">282782</sprcy:NumberOfSharesIssued1>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c124"
      decimals="0"
      id="ixv-37889"
      unitRef="shares">923</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c125"
      decimals="0"
      id="ixv-37890"
      unitRef="shares">1423</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c126"
      decimals="0"
      id="ixv-37891"
      unitRef="shares">13858</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c127"
      decimals="0"
      id="ixv-37892"
      unitRef="shares">7134</ifrs-full:NumberOfSharesIssued>
    <sprcy:DescriptionOfPrivateOffering contextRef="c128" id="ixv-37893">the Company completed a private offering with several accredited and institutional investors for gross proceeds of $8,150,
providing for the issuance of an aggregate of 44,331 units, as follows: (a) 35,242 units at a price of $183,82 per unit, consisting of
(i) one ordinary share of the Company, and (ii) a Series A Warrant to purchase an equal number of units purchased (the &#x201c;2021 Series
A Warrants&#x201d;) and a Series B Warrant (the &#x201c;2021 Series B Warrants&#x201d; and, collectively with the 2021 Series A Warrants,
the March 2021 Warrants) to purchase half the number of units, and (b) 9,089 pre-funded units at a price of $183.794 per unit, consisting
of (i) one pre-funded warrant to purchase one ordinary share and (ii) one 2021 Series A Warrant and one 2021 Series B Warrant.</sprcy:DescriptionOfPrivateOffering>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c129"
      decimals="-1"
      id="ixv-37894"
      unitRef="usdPershares">183820</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c130"
      decimals="-1"
      id="ixv-37895"
      unitRef="usdPershares">275600</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <sprcy:DateOfIssuance contextRef="c2" id="ixv-37896">P5Y</sprcy:DateOfIssuance>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c131"
      decimals="0"
      id="ixv-37897"
      unitRef="shares">4929</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:WarrantsAndExercise
      contextRef="c131"
      decimals="0"
      id="ixv-37898"
      unitRef="shares">385</sprcy:WarrantsAndExercise>
    <sprcy:ExerciseOfPrefundedWarrants
      contextRef="c132"
      decimals="0"
      id="ixv-37899"
      unitRef="shares">4544</sprcy:ExerciseOfPrefundedWarrants>
    <sprcy:IssuanceOfShares
      contextRef="c120"
      decimals="0"
      id="ixv-37900"
      unitRef="shares">3846</sprcy:IssuanceOfShares>
    <sprcy:ExerciseOfPrefundedWarrants
      contextRef="c133"
      decimals="0"
      id="ixv-37901"
      unitRef="shares">3846</sprcy:ExerciseOfPrefundedWarrants>
    <sprcy:DescriptionOfPrivateOffering contextRef="c134" id="ixv-37902">the Company completed the June 2022 Private Placement with an investor for gross proceeds of $10,210, providing for the
issuance of an aggregate of 136,388 units and pre-funded units, as follows: (a) 12,884 units at a price of $74.88 per unit, each consisting
of (i) one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#x201c;June 2022 Warrants&#x201d;),
and (b) 123,504 pre-funded units at a price of $73.294 per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary
share and (ii) two June 2022 Warrants.</sprcy:DescriptionOfPrivateOffering>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c135"
      decimals="2"
      id="ixv-37903"
      unitRef="usdPershares">68.38</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <sprcy:DateOfIssuance contextRef="c136" id="ixv-37904">P7Y</sprcy:DateOfIssuance>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c4"
      decimals="0"
      id="ixv-37905"
      unitRef="shares">123504</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <sprcy:WarrantsAndExercise
      contextRef="c7"
      decimals="0"
      id="ixv-37906"
      unitRef="shares">123504</sprcy:WarrantsAndExercise>
    <ifrs-full:DisclosureOfAdditionalInformationExplanatory contextRef="c0" id="ixv-23752">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
10:- ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Six
    months ended&lt;br/&gt; June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    Ended&lt;br/&gt; December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unaudited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Audited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD
    in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; font-style: italic; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;a.
    Research and development expenses:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Wages
    and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;202&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;243&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;436&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based
    payment&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;23&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;224&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;264&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Clinical
    studies&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;145&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;106&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;369&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Regulatory,
    professional and other expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;366&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;373&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;750&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
    and preclinical studies&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;410&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;703&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Chemistry
    and formulations&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-230; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;118&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;281&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;781&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,474&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,803&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; font-style: italic; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;b.
    General and administrative expenses:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Wages
    and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;217&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;245&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;437&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based
    payment&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;431&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;633&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Professional
    and directors&#x2019; fees&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,366&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,292&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,499&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Business
    development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;38&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;161&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Office
    maintenance, rent and other expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;48&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;63&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;224&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Investor
    relations and business expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;310&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,193&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,486&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Wellution
    operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;366&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-231; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;907&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Regulatory
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;104&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;113&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;162&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,494&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,339&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,509&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfAdditionalInformationExplanatory>
    <sprcy:DisclosureOfInformationToTheItemsOfProfitOrLoss contextRef="c0" id="ixv-23759">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%; margin-left: auto; margin-right: auto;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Six
    months ended&lt;br/&gt; June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    Ended&lt;br/&gt; December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unaudited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Audited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;USD
    in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; font-style: italic; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;a.
    Research and development expenses:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Wages
    and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;202&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;243&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;436&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based
    payment&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;23&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;224&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;264&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Clinical
    studies&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;145&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;106&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;369&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Regulatory,
    professional and other expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;366&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;373&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;750&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
    and preclinical studies&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;410&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;703&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Chemistry
    and formulations&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-230; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;118&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;281&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;781&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,474&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,803&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; font-style: italic; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;b.
    General and administrative expenses:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Wages
    and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;217&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;245&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;437&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based
    payment&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;431&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;633&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Professional
    and directors&#x2019; fees&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,366&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,292&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,499&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Business
    development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;38&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;161&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Office
    maintenance, rent and other expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;48&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;63&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;224&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Investor
    relations and business expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;310&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,193&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,486&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Wellution
    operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;366&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-231; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;907&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Regulatory
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;104&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;113&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;162&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,494&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,339&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,509&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfInformationToTheItemsOfProfitOrLoss>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c140"
      decimals="-3"
      id="ixv-37907"
      unitRef="usd">202000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c141"
      decimals="-3"
      id="ixv-37908"
      unitRef="usd">243000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c142"
      decimals="-3"
      id="ixv-37909"
      unitRef="usd">436000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c143"
      decimals="-3"
      id="ixv-37910"
      unitRef="usd">23000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c144"
      decimals="-3"
      id="ixv-37911"
      unitRef="usd">224000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c145"
      decimals="-3"
      id="ixv-37912"
      unitRef="usd">264000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c146"
      decimals="-3"
      id="ixv-37913"
      unitRef="usd">145000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c147"
      decimals="-3"
      id="ixv-37914"
      unitRef="usd">106000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c148"
      decimals="-3"
      id="ixv-37915"
      unitRef="usd">369000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c149"
      decimals="-3"
      id="ixv-37916"
      unitRef="usd">366000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c150"
      decimals="-3"
      id="ixv-37917"
      unitRef="usd">373000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c151"
      decimals="-3"
      id="ixv-37918"
      unitRef="usd">750000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c152"
      decimals="-3"
      id="ixv-37919"
      unitRef="usd">45000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c153"
      decimals="-3"
      id="ixv-37920"
      unitRef="usd">410000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c154"
      decimals="-3"
      id="ixv-37921"
      unitRef="usd">703000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c156"
      decimals="-3"
      id="ixv-37922"
      unitRef="usd">118000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c157"
      decimals="-3"
      id="ixv-37923"
      unitRef="usd">281000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-37924" unitRef="usd">781000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c6" decimals="-3" id="ixv-37925" unitRef="usd">1474000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c7" decimals="-3" id="ixv-37926" unitRef="usd">2803000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c140"
      decimals="-3"
      id="ixv-37927"
      unitRef="usd">217000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c141"
      decimals="-3"
      id="ixv-37928"
      unitRef="usd">245000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c142"
      decimals="-3"
      id="ixv-37929"
      unitRef="usd">437000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c143"
      decimals="-3"
      id="ixv-37930"
      unitRef="usd">45000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c144"
      decimals="-3"
      id="ixv-37931"
      unitRef="usd">431000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c145"
      decimals="-3"
      id="ixv-37932"
      unitRef="usd">633000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c158"
      decimals="-3"
      id="ixv-37933"
      unitRef="usd">1366000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c159"
      decimals="-3"
      id="ixv-37934"
      unitRef="usd">1292000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c160"
      decimals="-3"
      id="ixv-37935"
      unitRef="usd">2499000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c161"
      decimals="-3"
      id="ixv-37936"
      unitRef="usd">38000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c162"
      decimals="-3"
      id="ixv-37937"
      unitRef="usd">2000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c163"
      decimals="-3"
      id="ixv-37938"
      unitRef="usd">161000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c164"
      decimals="-3"
      id="ixv-37939"
      unitRef="usd">48000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c165"
      decimals="-3"
      id="ixv-37940"
      unitRef="usd">63000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c166"
      decimals="-3"
      id="ixv-37941"
      unitRef="usd">224000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c167"
      decimals="-3"
      id="ixv-37942"
      unitRef="usd">310000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c168"
      decimals="-3"
      id="ixv-37943"
      unitRef="usd">1193000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c169"
      decimals="-3"
      id="ixv-37944"
      unitRef="usd">1486000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c170"
      decimals="-3"
      id="ixv-37945"
      unitRef="usd">366000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c172"
      decimals="-3"
      id="ixv-37946"
      unitRef="usd">907000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c173"
      decimals="-3"
      id="ixv-37947"
      unitRef="usd">104000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c174"
      decimals="-3"
      id="ixv-37948"
      unitRef="usd">113000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c175"
      decimals="-3"
      id="ixv-37949"
      unitRef="usd">162000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-37950" unitRef="usd">2494000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c6" decimals="-3" id="ixv-37951" unitRef="usd">3339000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c7" decimals="-3" id="ixv-37952" unitRef="usd">6509000</ifrs-full:GeneralAndAdministrativeExpense>
    <sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock contextRef="c0" id="ixv-24462">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
11:- SIGNIFICANT EVENTS DURING THE REPORTING PERIOD &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 48px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On February 23, 2023, the Company entered into an agreement with Jeffs&#x2019; Brands and NewCo, a newly-formed wholly owned subsidiary of Jeffs&#x2019; Brands, pursuant to which, at the closing and upon the terms and conditions set forth in the Agreement, NewCo Inc. acquired from the Company a number of shares of stock equal to approximately a 49% interest in the Company&#x2019;s wholly owned subsidiary, SciSparc US which owns Wellution&lt;sup&gt;TM&lt;/sup&gt;&#160;, for $2,500 in cash, and additional deferred cash payments of approximately $489,330 accounting for price adjustments related to inventory and working capital, which is to be paid in five equal monthly installments beginning in May 2023 (the &#x201c;Price Adjustment&#x201d;). As collateral for the payment in full of the Price Adjustment, SciSparc held back such number of shares of common stock of SciSparc US, equal to the outstanding due amount of the Price Adjustment (the &#x201c;Holdback Shares&#x201d;). Following the closing of the transaction on March 22, 2023, which included an equity conversion of financing amounts previously provided to SciSparc US. by the Company for working capital, and the release of the Holdback Shares upon the payment in full of the Price Adjustment the Company will hold approximately 51% of the share capital of SciSparc US.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pursuant to the agreement, at the closing of the transaction, Jeffs&#x2019; Brands and SciSparc US. entered into a consulting agreement, pursuant to which Jeffs&#x2019; Brands will provide management services to SciSparc US for the WellutionTM brand for a monthly fee of $20 and Jeffs&#x2019; Brands will receive a one-time signing bonus in the amount of $51. The consulting agreement is for an undefined period of time and may be terminated by either party with 30 days advance notice.&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In addition, in connection with the closing of the transaction, the Company and Jeffs&#x2019; Brands, engaged in a mutual share exchange in the amount of $288,238 of ordinary shares from each of the Company and Jeffs&#x2019; Brands. The number of shares in the share exchange was calculated based on the average closing price of the relevant company&#x2019;s shares for 30 consecutive trading days ending on the third trading day immediately prior to the closing. Accordingly, the Company acquired 247,415 ordinary shares of Jeffs&#x2019; Brands and Jeffs&#x2019; Brands acquired 13,858 ordinary shares of the Company having an aggregate value of $288,238, which was adjusted from $300,000 according to the 4.99% ownership limit included in the definitive agreements.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On May 2, 2023, Capital Point Ltd. (&#x201c;Capital Point&#x201d;) filed with the Tel Aviv-Jaffa District Court (the &#x201c;Court&#x201d;) a suit against the Company, case number 2050-05-23 (the &#x201c;Suit&#x201d;). The Suit names the Company as the sole defendant and includes allegations of breaches of contract by the Company under the Israeli Contracts Law, 1973, unjust enrichment under the Israeli Unjust Enrichment Law, 1979 and breaches of the Company under the Israeli Torts Ordinance, 1968.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The Suit challenges a certain warrant issued by the Company to Capital Point (the &#x201c;Capital Point Warrant&#x201d;) to purchase $340,000 of ordinary shares of the Company (the &#x201c;Warrant Shares&#x201d;). The Capital Point Warrant was exercisable for 12 months from May 15, 2021, to May 15, 2022 and was issued in connection with the joint venture transaction, entered on May 15, 2020, by and between the Company, Capital Point and Evero Health Ltd., a majority owned subsidiary of the Company, as further described in the Company&#x2019;s Report on Form 6-K, filed on May 19, 2020. The Suit claims that the Company unlawfully refused to accept the Capital Point Warrant exercise notice as of November 4, 2021 and accordingly the Company did not issue to Capital Point the Warrant Shares.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The Suit claims damages in the amount of NIS 10,000,000 (approximately $2.75 million), which accounts for, as of the date of the filing of the Suit, the agreed compensation according to Section 2(d)(i) of the Capital Point Warrant, an injunction order for the Company to issue the Warrant Shares to Capital Point, return of any unlawful profits received by the Company and punitive damages.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As of the Approval Date, the Company cannot predict the likelihood of success of the Suit.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock>
    <sprcy:InterestPercentgae
      contextRef="c176"
      decimals="2"
      id="ixv-37953"
      unitRef="pure">0.49</sprcy:InterestPercentgae>
    <ifrs-full:Cash
      contextRef="c177"
      decimals="-3"
      id="ixv-37954"
      unitRef="usd">2500000</ifrs-full:Cash>
    <sprcy:DeferredCashPayments
      contextRef="c176"
      decimals="-3"
      id="ixv-37955"
      unitRef="usd">489330000</sprcy:DeferredCashPayments>
    <sprcy:ShareCapitalPercentage
      contextRef="c178"
      decimals="2"
      id="ixv-37956"
      unitRef="pure">0.51</sprcy:ShareCapitalPercentage>
    <sprcy:FeeExpenses contextRef="c0" decimals="-3" id="ixv-37957" unitRef="usd">20000</sprcy:FeeExpenses>
    <sprcy:BonusAmountReceived contextRef="c0" decimals="-3" id="ixv-37958" unitRef="usd">51000</sprcy:BonusAmountReceived>
    <sprcy:MutualShareExchangeAmount contextRef="c0" decimals="-3" id="ixv-37959" unitRef="usd">288238000</sprcy:MutualShareExchangeAmount>
    <sprcy:OrdinarySharesAcquired
      contextRef="c0"
      decimals="0"
      id="ixv-37960"
      unitRef="shares">247415</sprcy:OrdinarySharesAcquired>
    <sprcy:OrdinarySharesAcquired
      contextRef="c179"
      decimals="0"
      id="ixv-37961"
      unitRef="shares">13858</sprcy:OrdinarySharesAcquired>
    <sprcy:AggregateValue contextRef="c0" decimals="-3" id="ixv-37962" unitRef="usd">288238000</sprcy:AggregateValue>
    <sprcy:AdjustedAmountOfAggregateValue
      contextRef="c179"
      decimals="-3"
      id="ixv-37963"
      unitRef="usd">300000000</sprcy:AdjustedAmountOfAggregateValue>
    <sprcy:OwnershipPercentage contextRef="c0" decimals="4" id="ixv-37964" unitRef="pure">0.0499</sprcy:OwnershipPercentage>
    <sprcy:WarrantsToPurchase
      contextRef="c180"
      decimals="-3"
      id="ixv-37965"
      unitRef="usd">340000000</sprcy:WarrantsToPurchase>
    <sprcy:ClaimsOnDamages contextRef="c0" decimals="0" id="ixv-37966" unitRef="ils">10000000</sprcy:ClaimsOnDamages>
    <sprcy:ClaimsOnDamages contextRef="c0" decimals="-4" id="ixv-37967" unitRef="usd">2750000</sprcy:ClaimsOnDamages>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="c0" id="ixv-24548">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
12:- EVENTS AFTER THE REPORTING PERIOD &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;a.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On August 1, 2023, the Company issued a consultant 807 ordinary shares in respect of services rendered.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;b.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; background-color: white"&gt;On August 14, 2023, the Company closed an underwritten public offering (the &#x201c;Public Offering&#x201d;) of 212,500 ordinary shares, at a purchase price of $5.20 per ordinary share and pre-funded warrants to purchase up to 37,500 ordinary shares at a purchase price of $5.174 per pre-funded warrant, for aggregate gross proceeds of approximately $1.3 million, pursuant to an underwriting agreement between the Company and Aegis Capital Corp (&#x201c;Aegis&#x201d;), the underwriter in the Public Offering, dated August 10, 2023. Pursuant to the terms of the underwriting agreement, the Company also granted the underwriter a 45-day option to purchase up to an additional 37,500 ordinary shares solely to cover over-allotments, if any, at the share price of the Public Offering less underwriting discounts and commissions.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; background-color: white"&gt;The pre-funded warrants were exercisable immediately upon issuance and have an exercise price of $0.026 per share. Following the offering and &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;as of the Approval Date, the Company issued 25,000 ordinary shares in respect of the exercise of 25,000 pre-funded warrants.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On August 18, 2023, the Company convened a general meeting of its shareholders, whereby the shareholders approved, inter alia, a reverse split of the Company&#x2019;s share capital up to a ratio of 30:1. Following the implementation of the Reverse Split, the Company&#x2019;s authorized share capital will not be adjusted under the Company&#x2019;s Articles, which as of the date hereof consists of 75,000,000 Ordinary Shares, &lt;span style="-sec-ix-hidden: hidden-fact-232"&gt;no&lt;/span&gt; par value.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On September 14, 2023, the Company&#x2019;s Board resolved that the final ratio for the Reverse Split will be 26:1, which became effective on September 28, 2023.&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt; &lt;td style="font-size: 10pt; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On October 11, 2023, the Company entered into a private placement transaction (the &#x201c;Private Placement&#x201d;), pursuant to a Securities Purchase Agreement (the &#x201c;Agreement&#x201d;) and a Registration Rights Agreement (the &#x201c;Registration Rights Agreement&#x201d;) with an institutional investor (the &#x201c;Purchaser&#x201d;) for aggregate gross proceeds of approximately $5 million (representing a 30% original issue discount to the aggregate purchase price of approximately $7.18 million), before deducting fees to the placement agent and other expenses payable by the Company in connection with the Private Placement. The Company intends to use the net proceeds from the Private Placement for general corporate purposes, including working capital. Aegis, acted as the exclusive placement agent for the Private Placement.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
part of the Private Placement, the Company issued units (the &#x201c;Units&#x201d;), at a purchase price of $3.72 per Unit, consisting
of 1,930,108 pre-funded ordinary share purchase warrants (the &#x201c;Pre-Funded Warrant&#x201d;) to purchase up to 1,930,108 ordinary
shares of the Company, no par value per share (the &#x201c;Ordinary Shares&#x201d;), and an additional accompanying Pre-Funded Warrant
to purchase up to 1,930,108 Ordinary Shares. The Pre-Funded Warrants are immediately exercisable upon issuance and have a term of five
years from issuance at an exercise price of $0.001 per Ordinary Share.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <sprcy:DescriptionOfPublicOffering contextRef="c181" id="ixv-37968">the Company closed an underwritten public offering (the &#x201c;Public Offering&#x201d;) of 212,500 ordinary shares, at a purchase price of $5.20 per ordinary share and pre-funded warrants to purchase up to 37,500 ordinary shares at a purchase price of $5.174 per pre-funded warrant, for aggregate gross proceeds of approximately $1.3 million, pursuant to an underwriting agreement between the Company and Aegis Capital Corp (&#x201c;Aegis&#x201d;), the underwriter in the Public Offering, dated August 10, 2023. Pursuant to the terms of the underwriting agreement, the Company also granted the underwriter a 45-day option to purchase up to an additional 37,500 ordinary shares solely to cover over-allotments, if any, at the share price of the Public Offering less underwriting discounts and commissions.</sprcy:DescriptionOfPublicOffering>
    <sprcy:ExerciseOfWarrants contextRef="c181" decimals="0" id="ixv-37969" unitRef="usd">26.000</sprcy:ExerciseOfWarrants>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c182"
      decimals="0"
      id="ixv-37970"
      unitRef="shares">25000</ifrs-full:NumberOfSharesIssued>
    <sprcy:ExerciseOfPrefundedWarrants
      contextRef="c183"
      decimals="0"
      id="ixv-37971"
      unitRef="shares">25000</sprcy:ExerciseOfPrefundedWarrants>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c184"
      decimals="0"
      id="ixv-37972"
      unitRef="shares">75000000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:AggregateGrossProceeds
      contextRef="c186"
      decimals="-6"
      id="ixv-37973"
      unitRef="usd">5000000</sprcy:AggregateGrossProceeds>
    <sprcy:PercentageOfAggregatePurchasePrice
      contextRef="c186"
      decimals="2"
      id="ixv-37974"
      unitRef="pure">0.30</sprcy:PercentageOfAggregatePurchasePrice>
    <sprcy:AggregatePurchasePrice
      contextRef="c186"
      decimals="-4"
      id="ixv-37975"
      unitRef="usd">7180000</sprcy:AggregatePurchasePrice>
    <sprcy:PurchasePricePerShare
      contextRef="c186"
      decimals="2"
      id="ixv-37976"
      unitRef="usdPershares">3.72</sprcy:PurchasePricePerShare>
    <sprcy:PrefundedOrdinaryShare
      contextRef="c186"
      decimals="0"
      id="ixv-37977"
      unitRef="shares">1930108</sprcy:PrefundedOrdinaryShare>
    <sprcy:OrdinarySharesAcquired
      contextRef="c186"
      decimals="0"
      id="ixv-37978"
      unitRef="shares">1930108</sprcy:OrdinarySharesAcquired>
    <sprcy:PurchaseOrdinaryShares
      contextRef="c186"
      decimals="0"
      id="ixv-37979"
      unitRef="shares">1930108</sprcy:PurchaseOrdinaryShares>
    <sprcy:TermOfIssuance contextRef="c186" id="ixv-37980">P5Y</sprcy:TermOfIssuance>
    <sprcy:ExercisePricePerShare
      contextRef="c186"
      decimals="3"
      id="ixv-37981"
      unitRef="usdPershares">0.001</sprcy:ExercisePricePerShare>
    <ifrs-full:CashAndCashEquivalents contextRef="c4" decimals="-3" id="ixv-37982" unitRef="usd">3574000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c5" decimals="-3" id="ixv-37983" unitRef="usd">6875000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c4" decimals="-3" id="ixv-37984" unitRef="usd">60000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c5" decimals="-3" id="ixv-37985" unitRef="usd">45000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:CurrentTradeReceivables contextRef="c4" decimals="-3" id="ixv-37986" unitRef="usd">77000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="c4" decimals="-3" id="ixv-37987" unitRef="usd">131000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="c5" decimals="-3" id="ixv-37988" unitRef="usd">2904000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:Inventories contextRef="c4" decimals="-3" id="ixv-37989" unitRef="usd">668000</ifrs-full:Inventories>
    <ifrs-full:CurrentAssets contextRef="c4" decimals="-3" id="ixv-37990" unitRef="usd">4510000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c5" decimals="-3" id="ixv-37991" unitRef="usd">9824000</ifrs-full:CurrentAssets>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c4" decimals="-3" id="ixv-37992" unitRef="usd">4717000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:InvestmentsInAssociates contextRef="c4" decimals="-3" id="ixv-37993" unitRef="usd">591000</ifrs-full:InvestmentsInAssociates>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c4" decimals="-3" id="ixv-37994" unitRef="usd">730000</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c4" decimals="-3" id="ixv-37995" unitRef="usd">57000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c5" decimals="-3" id="ixv-37996" unitRef="usd">92000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:NoncurrentAssets contextRef="c4" decimals="-3" id="ixv-37997" unitRef="usd">6095000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c5" decimals="-3" id="ixv-37998" unitRef="usd">92000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets contextRef="c4" decimals="-3" id="ixv-37999" unitRef="usd">10605000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c5" decimals="-3" id="ixv-38000" unitRef="usd">9916000</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c4" decimals="-3" id="ixv-38001" unitRef="usd">1199000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c5" decimals="-3" id="ixv-38002" unitRef="usd">1199000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c4" decimals="-3" id="ixv-38003" unitRef="usd">193000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c5" decimals="-3" id="ixv-38004" unitRef="usd">154000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:CurrentWarrantLiability contextRef="c4" decimals="-3" id="ixv-38005" unitRef="usd">2737000</ifrs-full:CurrentWarrantLiability>
    <ifrs-full:CurrentWarrantLiability contextRef="c5" decimals="-3" id="ixv-38006" unitRef="usd">359000</ifrs-full:CurrentWarrantLiability>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c4" decimals="-3" id="ixv-38007" unitRef="usd">27000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c5" decimals="-3" id="ixv-38008" unitRef="usd">45000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c4" decimals="-3" id="ixv-38009" unitRef="usd">4156000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c5" decimals="-3" id="ixv-38010" unitRef="usd">1757000</ifrs-full:CurrentLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c5" decimals="-3" id="ixv-38011" unitRef="usd">18000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:SharePremium contextRef="c4" decimals="-3" id="ixv-38012" unitRef="usd">58592000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium contextRef="c5" decimals="-3" id="ixv-38013" unitRef="usd">58541000</ifrs-full:SharePremium>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c4" decimals="-3" id="ixv-38014" unitRef="usd">5180000</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c5" decimals="-3" id="ixv-38015" unitRef="usd">4331000</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:WarrantLiability contextRef="c4" decimals="-3" id="ixv-38016" unitRef="usd">5190000</ifrs-full:WarrantLiability>
    <ifrs-full:WarrantLiability contextRef="c5" decimals="-3" id="ixv-38017" unitRef="usd">5190000</ifrs-full:WarrantLiability>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation contextRef="c4" decimals="-3" id="ixv-38018" unitRef="usd">497000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation contextRef="c5" decimals="-3" id="ixv-38019" unitRef="usd">497000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:OtherEquityInterest contextRef="c4" decimals="-3" id="ixv-38020" unitRef="usd">559000</ifrs-full:OtherEquityInterest>
    <ifrs-full:OtherEquityInterest contextRef="c5" decimals="-3" id="ixv-38021" unitRef="usd">559000</ifrs-full:OtherEquityInterest>
    <ifrs-full:RetainedEarnings contextRef="c4" decimals="-3" id="ixv-38022" unitRef="usd">-63569000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="c5" decimals="-3" id="ixv-38023" unitRef="usd">-60977000</ifrs-full:RetainedEarnings>
    <ifrs-full:Equity contextRef="c4" decimals="-3" id="ixv-38024" unitRef="usd">6449000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c5" decimals="-3" id="ixv-38025" unitRef="usd">8141000</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities contextRef="c4" decimals="-3" id="ixv-38026" unitRef="usd">10605000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c5" decimals="-3" id="ixv-38027" unitRef="usd">9916000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:Revenue contextRef="c7" decimals="-3" id="ixv-38028" unitRef="usd">1347000</ifrs-full:Revenue>
    <ifrs-full:CostOfSales contextRef="c7" decimals="-3" id="ixv-38029" unitRef="usd">322000</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit contextRef="c7" decimals="-3" id="ixv-38030" unitRef="usd">1025000</ifrs-full:GrossProfit>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c7" decimals="-3" id="ixv-38031" unitRef="usd">2803000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c11" decimals="-3" id="ixv-38032" unitRef="usd">1990000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c12" decimals="-3" id="ixv-38033" unitRef="usd">649000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c7" decimals="-3" id="ixv-38034" unitRef="usd">6509000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c11" decimals="-3" id="ixv-38035" unitRef="usd">3778000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c12" decimals="-3" id="ixv-38036" unitRef="usd">1902000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c7" decimals="-3" id="ixv-38037" unitRef="usd">-8287000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c11" decimals="-3" id="ixv-38038" unitRef="usd">-5768000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c12" decimals="-3" id="ixv-38039" unitRef="usd">-3293000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c7" decimals="-3" id="ixv-38040" unitRef="usd">-109000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c12" decimals="-3" id="ixv-38041" unitRef="usd">-742000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:FinanceIncome contextRef="c7" decimals="-3" id="ixv-38042" unitRef="usd">7832000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c12" decimals="-3" id="ixv-38043" unitRef="usd">630000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts contextRef="c7" decimals="-3" id="ixv-38044" unitRef="usd">2014000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c11" decimals="-3" id="ixv-38045" unitRef="usd">21000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c12" decimals="-3" id="ixv-38046" unitRef="usd">872000</ifrs-full:FinanceCosts>
    <ifrs-full:ProfitLossBeforeTax contextRef="c7" decimals="-3" id="ixv-38047" unitRef="usd">-2578000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c11" decimals="-3" id="ixv-38048" unitRef="usd">-5789000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c12" decimals="-3" id="ixv-38049" unitRef="usd">-3535000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c7" decimals="-3" id="ixv-38050" unitRef="usd">14000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ComprehensiveIncome contextRef="c7" decimals="-3" id="ixv-38051" unitRef="usd">-2592000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c11" decimals="-3" id="ixv-38052" unitRef="usd">-5789000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c12" decimals="-3" id="ixv-38053" unitRef="usd">-3535000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity contextRef="c7" decimals="-3" id="ixv-38054" unitRef="usd">2592000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity contextRef="c11" decimals="-3" id="ixv-38055" unitRef="usd">5789000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity contextRef="c12" decimals="-3" id="ixv-38056" unitRef="usd">3482000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity>
    <sprcy:ComprehensiveIncomeAttributableToNoncontrollingInterest contextRef="c12" decimals="-3" id="ixv-38057" unitRef="usd">53000</sprcy:ComprehensiveIncomeAttributableToNoncontrollingInterest>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c7" decimals="-3" id="ixv-38058" unitRef="usd">2592000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c11" decimals="-3" id="ixv-38059" unitRef="usd">5789000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c12" decimals="-3" id="ixv-38060" unitRef="usd">3535000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c7"
      decimals="2"
      id="ixv-38061"
      unitRef="usdPershares">0.57</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c11"
      decimals="2"
      id="ixv-38062"
      unitRef="usdPershares">2.83</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c12"
      decimals="2"
      id="ixv-38063"
      unitRef="usdPershares">0.1</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c7"
      decimals="2"
      id="ixv-38064"
      unitRef="usdPershares">0.57</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c11"
      decimals="2"
      id="ixv-38065"
      unitRef="usdPershares">2.83</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c12"
      decimals="2"
      id="ixv-38066"
      unitRef="usdPershares">0.11</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:Equity contextRef="c70" decimals="-3" id="ixv-38067" unitRef="usd">45636000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c71" decimals="-3" id="ixv-38068" unitRef="usd">4862000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c72" decimals="-3" id="ixv-38069" unitRef="usd">464000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c73" decimals="-3" id="ixv-38070" unitRef="usd">261000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c74" decimals="-3" id="ixv-38071" unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c75" decimals="-3" id="ixv-38072" unitRef="usd">-51706000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c76" decimals="-3" id="ixv-38073" unitRef="usd">14000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c78" decimals="-3" id="ixv-38074" unitRef="usd">14000</ifrs-full:Equity>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c84" decimals="-3" id="ixv-38075" unitRef="usd">3482000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c85" decimals="-3" id="ixv-38076" unitRef="usd">3482000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c86" decimals="-3" id="ixv-38077" unitRef="usd">53000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c87" decimals="-3" id="ixv-38078" unitRef="usd">3535000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c81" decimals="-3" id="ixv-38079" unitRef="usd">-464000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c85" decimals="-3" id="ixv-38080" unitRef="usd">-464000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c12" decimals="-3" id="ixv-38081" unitRef="usd">-464000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c79" decimals="-3" id="ix_0_fact" unitRef="usd">2763000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c81" decimals="-3" id="ix_1_fact" unitRef="usd">2207000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c85" decimals="-3" id="ix_2_fact" unitRef="usd">4970000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c12" decimals="-3" id="ix_3_fact" unitRef="usd">4970000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="c79" decimals="-3" id="ixv-38086" unitRef="usd">3000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="c85" decimals="-3" id="ixv-38087" unitRef="usd">3000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="c12" decimals="-3" id="ixv-38088" unitRef="usd">3000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests contextRef="c82" decimals="-3" id="ixv-38089" unitRef="usd">298000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests contextRef="c85" decimals="-3" id="ixv-38090" unitRef="usd">298000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests contextRef="c86" decimals="-3" id="ixv-38091" unitRef="usd">53000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests contextRef="c12" decimals="-3" id="ixv-38092" unitRef="usd">351000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c79" decimals="-3" id="ixv-38093" unitRef="usd">638000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c80" decimals="-3" id="ixv-38094" unitRef="usd">-638000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c80" decimals="-3" id="ixv-38095" unitRef="usd">91000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c85" decimals="-3" id="ixv-38096" unitRef="usd">91000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c12" decimals="-3" id="ixv-38097" unitRef="usd">91000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:Equity contextRef="c88" decimals="-3" id="ixv-38098" unitRef="usd">49040000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c89" decimals="-3" id="ixv-38099" unitRef="usd">4315000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c90" decimals="-3" id="ixv-38100" unitRef="usd">2207000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c91" decimals="-3" id="ixv-38101" unitRef="usd">559000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c92" decimals="-3" id="ixv-38102" unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c93" decimals="-3" id="ixv-38103" unitRef="usd">-55188000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c94" decimals="-3" id="ixv-38104" unitRef="usd">1430000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c96" decimals="-3" id="ixv-38105" unitRef="usd">1430000</ifrs-full:Equity>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c102"
      decimals="-3"
      id="ixv-38106"
      unitRef="usd">5789000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c103"
      decimals="-3"
      id="ixv-38107"
      unitRef="usd">5789000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c11" decimals="-3" id="ixv-38108" unitRef="usd">5789000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <sprcy:ExerciseOfWarrants contextRef="c97" decimals="-3" id="ix_8_fact" unitRef="usd">6110000</sprcy:ExerciseOfWarrants>
    <sprcy:ExerciseOfWarrants contextRef="c99" decimals="-3" id="ix_9_fact" unitRef="usd">-1352000</sprcy:ExerciseOfWarrants>
    <sprcy:ExerciseOfWarrants
      contextRef="c103"
      decimals="-3"
      id="ix_10_fact"
      unitRef="usd">4758000</sprcy:ExerciseOfWarrants>
    <sprcy:ExerciseOfWarrants
      contextRef="c11"
      decimals="-3"
      id="ix_11_fact"
      unitRef="usd">4758000</sprcy:ExerciseOfWarrants>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c97" decimals="-3" id="ix_4_fact" unitRef="usd">3364000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c99" decimals="-3" id="ix_5_fact" unitRef="usd">4335000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c103"
      decimals="-3"
      id="ix_6_fact"
      unitRef="usd">7699000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c11" decimals="-3" id="ix_7_fact" unitRef="usd">7699000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c97" decimals="-3" id="ixv-38117" unitRef="usd">27000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c98" decimals="-3" id="ixv-38118" unitRef="usd">-27000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c98" decimals="-3" id="ixv-38119" unitRef="usd">43000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c103"
      decimals="-3"
      id="ixv-38120"
      unitRef="usd">43000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c11" decimals="-3" id="ixv-38121" unitRef="usd">43000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:Equity contextRef="c37" decimals="-3" id="ixv-38122" unitRef="usd">58541000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c38" decimals="-3" id="ixv-38123" unitRef="usd">4331000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c39" decimals="-3" id="ixv-38124" unitRef="usd">5190000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c40" decimals="-3" id="ixv-38125" unitRef="usd">559000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c41" decimals="-3" id="ixv-38126" unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c42" decimals="-3" id="ixv-38127" unitRef="usd">-60977000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c43" decimals="-3" id="ixv-38128" unitRef="usd">8141000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c5" decimals="-3" id="ixv-38129" unitRef="usd">8141000</ifrs-full:Equity>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c66" decimals="-3" id="ixv-38130" unitRef="usd">2592000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c67" decimals="-3" id="ixv-38131" unitRef="usd">2592000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c7" decimals="-3" id="ixv-38132" unitRef="usd">2592000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <sprcy:ExerciseOfWarrants contextRef="c61" decimals="-3" id="ixv-38133" unitRef="usd">3000</sprcy:ExerciseOfWarrants>
    <sprcy:ExerciseOfWarrants contextRef="c67" decimals="-3" id="ixv-38134" unitRef="usd">3000</sprcy:ExerciseOfWarrants>
    <sprcy:ExerciseOfWarrants contextRef="c7" decimals="-3" id="ixv-38135" unitRef="usd">3000</sprcy:ExerciseOfWarrants>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c61" decimals="-3" id="ixv-38136" unitRef="usd">48000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c62" decimals="-3" id="ixv-38137" unitRef="usd">849000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c67" decimals="-3" id="ixv-38138" unitRef="usd">897000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c7" decimals="-3" id="ixv-38139" unitRef="usd">897000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:Equity contextRef="c13" decimals="-3" id="ixv-38140" unitRef="usd">58592000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c14" decimals="-3" id="ixv-38141" unitRef="usd">5180000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c15" decimals="-3" id="ixv-38142" unitRef="usd">5190000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c16" decimals="-3" id="ixv-38143" unitRef="usd">559000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c17" decimals="-3" id="ixv-38144" unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c18" decimals="-3" id="ixv-38145" unitRef="usd">-63569000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c19" decimals="-3" id="ixv-38146" unitRef="usd">6449000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c4" decimals="-3" id="ixv-38147" unitRef="usd">6449000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c7" decimals="-3" id="ixv-38148" unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c11" decimals="-3" id="ixv-38149" unitRef="usd">-5789000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c12" decimals="-3" id="ixv-38150" unitRef="usd">-3535000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c7" decimals="-3" id="ixv-38151" unitRef="usd">187000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c11" decimals="-3" id="ixv-38152" unitRef="usd">33000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c12" decimals="-3" id="ixv-38153" unitRef="usd">164000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c7" decimals="-3" id="ixv-38154" unitRef="usd">897000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c11" decimals="-3" id="ixv-38155" unitRef="usd">43000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c12" decimals="-3" id="ixv-38156" unitRef="usd">91000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="c7" decimals="-3" id="ixv-38157" unitRef="usd">6585000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="c11" decimals="-3" id="ixv-38158" unitRef="usd">-9000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="c12" decimals="-3" id="ixv-38159" unitRef="usd">476000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="c7" decimals="-3" id="ixv-38160" unitRef="usd">109000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="c12" decimals="-3" id="ixv-38161" unitRef="usd">795000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <sprcy:AdjustmentsForImpairmentOfInvestmentInAssociate contextRef="c7" decimals="-3" id="ixv-38162" unitRef="usd">770000</sprcy:AdjustmentsForImpairmentOfInvestmentInAssociate>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="c7" decimals="-3" id="ixv-38163" unitRef="usd">-4622000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="c11" decimals="-3" id="ixv-38164" unitRef="usd">85000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="c12" decimals="-3" id="ixv-38165" unitRef="usd">574000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables contextRef="c7" decimals="-3" id="ixv-38166" unitRef="usd">3000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables contextRef="c11" decimals="-3" id="ixv-38167" unitRef="usd">170000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables contextRef="c12" decimals="-3" id="ixv-38168" unitRef="usd">-519000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c11" decimals="-3" id="ixv-38169" unitRef="usd">353000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c12" decimals="-3" id="ixv-38170" unitRef="usd">-752000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c7" decimals="-3" id="ixv-38171" unitRef="usd">39000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c11" decimals="-3" id="ixv-38172" unitRef="usd">120000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c12" decimals="-3" id="ixv-38173" unitRef="usd">-75000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c7" decimals="-3" id="ixv-38174" unitRef="usd">-77000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c7" decimals="-3" id="ixv-38175" unitRef="usd">-668000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital contextRef="c7" decimals="-3" id="ixv-38176" unitRef="usd">-703000</ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital>
    <ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital contextRef="c11" decimals="-3" id="ixv-38177" unitRef="usd">643000</ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital>
    <ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital contextRef="c12" decimals="-3" id="ixv-38178" unitRef="usd">-1346000</ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c7" decimals="-3" id="ixv-38179" unitRef="usd">-7917000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c11" decimals="-3" id="ixv-38180" unitRef="usd">-5061000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c12" decimals="-3" id="ixv-38181" unitRef="usd">-4307000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents contextRef="c7" decimals="-3" id="ixv-38182" unitRef="usd">-15000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents contextRef="c11" decimals="-3" id="ixv-38183" unitRef="usd">-35000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents contextRef="c12" decimals="-3" id="ixv-38184" unitRef="usd">24000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c7" decimals="-3" id="ixv-38185" unitRef="usd">8000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c11" decimals="-3" id="ixv-38186" unitRef="usd">35000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments contextRef="c7" decimals="-3" id="ixv-38187" unitRef="usd">-700000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments>
    <sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c7" decimals="-3" id="ixv-38188" unitRef="usd">-1500000</sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c7" decimals="-3" id="ixv-38189" unitRef="usd">4861000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c7" decimals="-3" id="ixv-38190" unitRef="usd">-7084000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c11" decimals="-3" id="ixv-38191" unitRef="usd">-70000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c12" decimals="-3" id="ixv-38192" unitRef="usd">24000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses contextRef="c7" decimals="-3" id="ixv-38193" unitRef="usd">-9005000</sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses>
    <sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses contextRef="c11" decimals="-3" id="ixv-38194" unitRef="usd">-7699000</sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses>
    <sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses contextRef="c12" decimals="-3" id="ixv-38195" unitRef="usd">-2650000</sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses>
    <ifrs-full:ProceedsFromExerciseOfOptions contextRef="c7" decimals="-3" id="ixv-38196" unitRef="usd">2770000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfOptions contextRef="c11" decimals="-3" id="ixv-38197" unitRef="usd">2568000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfOptions contextRef="c12" decimals="-3" id="ixv-38198" unitRef="usd">2376000</ifrs-full:ProceedsFromExerciseOfOptions>
    <sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod contextRef="c7" decimals="-3" id="ixv-38199" unitRef="usd">3000</sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod>
    <sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod contextRef="c12" decimals="-3" id="ixv-38200" unitRef="usd">116000</sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod>
    <sprcy:InterestPaidOnLeaseLiability contextRef="c7" decimals="-3" id="ixv-38201" unitRef="usd">-8000</sprcy:InterestPaidOnLeaseLiability>
    <sprcy:InterestPaidOnLeaseLiability contextRef="c12" decimals="-3" id="ixv-38202" unitRef="usd">-7000</sprcy:InterestPaidOnLeaseLiability>
    <sprcy:RepaymentOfLeaseLiabilities contextRef="c7" decimals="-3" id="ixv-38203" unitRef="usd">70000</sprcy:RepaymentOfLeaseLiabilities>
    <sprcy:RepaymentOfLeaseLiabilities contextRef="c11" decimals="-3" id="ixv-38204" unitRef="usd">19000</sprcy:RepaymentOfLeaseLiabilities>
    <sprcy:RepaymentOfLeaseLiabilities contextRef="c12" decimals="-3" id="ixv-38205" unitRef="usd">26000</sprcy:RepaymentOfLeaseLiabilities>
    <sprcy:RepaymentOfShorttermCredit contextRef="c11" decimals="-3" id="ixv-38206" unitRef="usd">188000</sprcy:RepaymentOfShorttermCredit>
    <sprcy:RepaymentOfShorttermCredit contextRef="c12" decimals="-3" id="ixv-38207" unitRef="usd">1410000</sprcy:RepaymentOfShorttermCredit>
    <sprcy:ReceiptofShortTermCreditFromOthers contextRef="c12" decimals="-3" id="ixv-38208" unitRef="usd">1660000</sprcy:ReceiptofShortTermCreditFromOthers>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c7" decimals="-3" id="ixv-38209" unitRef="usd">11700000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c11" decimals="-3" id="ixv-38210" unitRef="usd">10060000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c12" decimals="-3" id="ixv-38211" unitRef="usd">5359000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c7" decimals="-3" id="ixv-38212" unitRef="usd">-3301000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c11" decimals="-3" id="ixv-38213" unitRef="usd">4929000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c12" decimals="-3" id="ixv-38214" unitRef="usd">1076000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c5" decimals="-3" id="ixv-38215" unitRef="usd">6875000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c96" decimals="-3" id="ixv-38216" unitRef="usd">1946000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c78" decimals="-3" id="ixv-38217" unitRef="usd">870000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c4" decimals="-3" id="ixv-38218" unitRef="usd">3574000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c5" decimals="-3" id="ixv-38219" unitRef="usd">6875000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c96" decimals="-3" id="ixv-38220" unitRef="usd">1946000</ifrs-full:CashAndCashEquivalents>
    <sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability contextRef="c11" decimals="-3" id="ixv-38221" unitRef="usd">78000</sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability>
    <sprcy:RegistrationOfWarrants contextRef="c11" decimals="-3" id="ixv-38222" unitRef="usd">2480000</sprcy:RegistrationOfWarrants>
    <sprcy:UnpaidIssueExpenses contextRef="c11" decimals="-3" id="ixv-38223" unitRef="usd">290000</sprcy:UnpaidIssueExpenses>
    <sprcy:DisclosureOfGeneralExplanatoryTextBlock contextRef="c7" id="ixv-28399">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 1:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;GENERAL&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) (&#x201c;SciSparc&#x201d;
or the &#x201c;Company&#x201d; or the &#x201c;Group&#x201d;), a pharmaceutical company, was incorporated in Israel and commenced its operations
on August 23, 2004. Until March 2014, SciSparc and its subsidiaries at the time (the &#x201c;Group&#x201d;) were mainly engaged in developing
several innovative immunotherapy products and SciSparc&#x2019;s own patents in the immunotherapy field. In August 2015, the Company decided
to adopt a different business strategy and began focusing on developing a&#160;portfolio of approved drugs based on cannabinoid molecules.
With this focus, the Company is currently engaged in the following development programs based on &#x394;9-tetrahydrocannabinol (&#x201c;THC&#x201d;)
and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer&#x2019;s disease&#160;and agitation, pain, autism
spectrum disorder and Status Epilepticus. The headquarters of the Company are located in Tel Aviv, Israel.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company was previously a dual-listed
company, whereby it listed (a) its ordinary shares, no par value each (&#x201c;ordinary shares&#x201d;), on the Tel-Aviv Stock Exchange
(&#x201c;TASE&#x201d;) from December 26, 2005 until its delisting on August 7, 2018, and (b) its American Depository Shares (&#x201c;ADSs&#x201d;)
on the Nasdaq Capital Market (&#x201c;Nasdaq&#x201d;) following its initial public offering (&#x201c;IPO&#x201d;) on March 27, 2017, at which
time it raised $13,700, until its suspension from listing, and subsequent delisting, from Nasdaq on July 2, 2020 and September 21, 2020,
respectively. Following the delisting of the ADSs from Nasdaq, the Company&#x2019;s ADSs were listed on the Pink Sheets and then subsequently
upgraded to the OTCQB on December 8, 2020. On August 26, 2021, the Company&#x2019;s ADSs were mandatorily cancelled and were exchanged
for ordinary shares at a one-for-one ratio.&#160;On December 22, 2021, the Company&#x2019;s ordinary shares were re-listed on Nasdaq and
began trading under the symbol &#x201c;SPRC&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;As of December 31, 2022, the Company
had three private subsidiaries, including a company incorporated under the laws of Israel: Evero Health Ltd (&#x201c;Evero&#x201d;); an
inactive company incorporated under the laws of Israel: Brain Bright Ltd (&#x201c;Brain Bright&#x201d;); and a company incorporated under
the laws of the State of Delaware: Scisparc Nutraceuticals Inc. (&#x201c;Scisparc US&#x201d; and together with Evero and Brain Bright, the
&#x201c;Subsidiaries&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The consolidated financial statements
of the Company for the year ended December&#160;31, 2022, were approved on April 27, 2023, and signed on May 1, 2023 (the &#x201c;Approval
Date&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Group incurred operating losses since its incorporation and expects
to continue to incur operating losses for the foreseeable future. As of December 31, 2022, the Group had an accumulated deficit of approximately
$64,009 as a result of recurring operating losses.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;A&lt;span style="background-color: white"&gt;s
of the Approval Date, the Group has started recognizing revenues from sales. However, its pharmaceuticals operations are dependent on
its ability to raise additional funds from existing and/or new investors. This dependency will continue until the Group will be able to
completely finance its operations by generating revenue from its products. These abovementioned factors raise substantial doubt about
the Group&#x2019;s ability to continue as a going concern. The financial statements do not include any adjustments to the carrying amounts
and classifications of assets and liabilities that might result should the Group be unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Definitions and Meanings:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Group&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;SciSparc Ltd. (formerly Therapix Biosciences Ltd.) and its Subsidiaries, as detailed in Note 1a.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Subsidiaries&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Companies that are controlled by the Company, as defined in IFRS 10, &#x201c;&lt;i&gt;Consolidated Financial Statements&lt;/i&gt;&#x201d;, and whose accounts are consolidated with those of the Company (if active).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Associates&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;An entity over which the Company has significant influence, as defined in IAS 28, &#x201c;&lt;i&gt;Investment in Associates and Joint Ventures&lt;/i&gt;&#x201d; and is not a Subsidiary.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Related Parties&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;As defined in IAS 24, &#x201c;&lt;i&gt;Related Party Disclosures&lt;/i&gt;&#x201d;. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;IAS&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;International Accounting Standards issued by the International Accounting Standards Board (&#x201c;IASB&#x201d;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;IFRS&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;International Financial Reporting Standards issued by the IASB.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfGeneralExplanatoryTextBlock>
    <sprcy:ProceedsFromIssuanceIPO
      contextRef="c187"
      decimals="-3"
      id="ixv-38224"
      unitRef="usd">13700000</sprcy:ProceedsFromIssuanceIPO>
    <sprcy:RetainedEarning contextRef="c4" decimals="-3" id="ixv-38225" unitRef="usd">64009000</sprcy:RetainedEarning>
    <ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory contextRef="c7" id="ixv-28605">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 2:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The following accounting policies have
been applied consistently in the financial statements for all periods presented, unless otherwise stated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Basis of presentation of the financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;These financial statements have been
prepared in accordance with IFRS, as issued by the IASB.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s financial statements
have been prepared on a cost basis, unless otherwise indicated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company has elected to present
the profit or loss items using the function of expense method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial statements are presented
in USD and all values are rounded to the nearest thousand (&#x2019;000), except when otherwise indicated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The operating cycle:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The operating cycle of the Company
is one year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Consolidated financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The consolidated financial statements
comprise the financial statements of companies that are controlled by the Company (Subsidiaries). Control of a company is achieved when
the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those
returns through its power over the investee. Potential voting rights are considered when assessing whether an entity has control over
the other entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such
control ceases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial statements of the Company
and of the Subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform
accounting policies by all companies in the Group. Significant intra-Group balances and transactions and gains or losses resulting from
intra-Group transactions are eliminated in full in the consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Non-controlling interests in subsidiaries
represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in
equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive
income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they
result in a negative balance of non-controlling interests in the consolidated statement of financial position.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 72px"&gt;&lt;/td&gt;&lt;td style="width: 48px; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Functional currency and foreign currency:&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;The functional currency of the Company, which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions is the U.S. Dollar (&#x201c;USD&#x201d; or &#x201c;$&#x201d;), since it&#x2019;s the primary currency of the economic environment in which the Company operates. The consolidated financial statements are also presented in USD since the Company believes that preparing the consolidated financial statements in USD provides more relevant information to the users of the consolidated financial statements.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Acquisition of a single asset company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Upon the acquisition
of a single asset company, the Group evaluates whether it is the acquisition of a business or of an asset. To be considered a business,
the acquisition must include, at a minimum, an input and a substantive process that together can significantly contribute to the creation
of outputs. The acquisition is accounted for as a business combination if the single asset company is a business. If it is not a business,
the acquisition is accounted for as the acquisition of assets and liabilities. In such an acquisition, the cost of the acquisition includes
transaction costs which are allocated to the identifiable acquired assets and liabilities proportionally based on their fair value on
the acquisition date. In such case, goodwill and deferred taxes in respect of the temporary differences existing as of the acquisition
date are not recognized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted deposits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;A restricted deposit is cash invested
in a short-term deposit (between three months and one year) or in a long-term deposit (with a maturity of more than one year from the
date of investment). Restricted deposits are designated to secure the Company&#x2019;s office facilities lease agreements and its credit
cards.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 72px"&gt;&lt;/td&gt;&lt;td style="width: 48px"&gt;g.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Investment in joint arrangements:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Joint arrangements
are arrangements in which the Company has joint control. Joint control is the contractually agreed sharing of control of an arrangement,
which exists only when decisions about the relevant activities require the unanimous consent of the parties sharing control.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 1.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;1.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Joint ventures:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"&gt;In joint ventures
the parties that have joint control of the arrangement have rights to the net assets of the arrangement. A joint venture is accounted
for at equity&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 1.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;2.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Joint operations:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"&gt;In joint operations
the parties that have joint control of the arrangement have rights to the assets and obligations for the liabilities relating to the arrangement.
The Company recognizes in relation to its interest its share of the assets, liabilities, revenues and expenses of the joint operation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"&gt;The acquisition
of interests in a joint operation which represents a business, as defined in IFRS 3, is accounted for using the acquisition method, including
the measurement of the identifiable assets and liabilities at fair value, the recognition of deferred taxes arising from this measurement,
the accounting treatment of the related transaction costs and the recognition of goodwill or bargain purchase gains. This applies to the
acquisition of the initial interest and additional interests in a joint operation that represents a business.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 72px"&gt;&lt;/td&gt;&lt;td style="width: 48px"&gt;h.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Investments in associates:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"&gt;&lt;span style="text-transform: uppercase"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Associates are companies in which the Group has significant
influence over the financial and operating policies without having control. The investment in an associate is accounted for using the
equity method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 72px"&gt;&lt;/td&gt;&lt;td style="width: 48px"&gt;i.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Investments accounted for using the equity method:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"&gt;&lt;span style="text-transform: uppercase"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The Group&#x2019;s investments
in associates and joint ventures are accounted for using the equity method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Under the equity
method, the investment in the associate or in the joint venture is presented at cost with the addition of post-acquisition changes in
the Group&#x2019;s share of net assets, including other comprehensive income of the associate or the joint venture. Gains and losses resulting
from transactions between the Group and the associate or the joint venture are eliminated to the extent of the interest in the associate
or in the joint venture. The cost of the investment includes transaction costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Goodwill relating
to the acquisition of an associate or a joint venture is presented as part of the investment in the associate or the joint venture, measured
at cost and not systematically amortized. Goodwill is evaluated for impairment as part of the investment in the associate or in the joint
venture as a whole.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The financial statements
of the Company and of the associate or joint venture are prepared as of the same dates and periods. The accounting policies applied in
the financial statements of the associate or the joint venture are uniform and consistent with the policies applied in the financial statements
of the Group.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Upon the acquisition
of an associate or a joint venture achieved in stages when the former investment in the acquiree was accounted for pursuant to the provisions
of IFRS 9, the Group applies the principles of IFRS 3 regarding business combinations achieved in stages. Consequently, equity interests
in the acquiree that had been held by the Group prior to achieving significant influence or joint control are measured at fair value on
the acquisition date and are included in the acquisition consideration while recognizing a gain or loss resulting from the fair value
measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The equity method
is applied until the loss of significant influence in the associate or loss of joint control in the joint venture or classification as
investment held for sale.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;j.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Property and equipment, net:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Property and equipment are measured
at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment
grants and excluding day-to-day servicing expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Mainly %&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Lab equipment&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 9%"&gt;6-50&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;33&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Computers&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;33-50&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;33&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office furniture and equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;20-33&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;25&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;see below&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-233"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including the extension option held by a company and intended to be exercised)
and the expected life of the improvement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The useful life, depreciation method
and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting
estimate. Depreciation of an asset ceases at the earlier of: the date that the asset is classified as held for sale and the date that
the asset is derecognized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;k.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Separately acquired intangible assets
are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination
are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized
development costs, are recognized in profit or loss when incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Intangible assets with a finite useful
life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired.
The amortization period and the amortization method for an intangible asset are reviewed at least at each year end.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;l.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Impairment of non-financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company evaluates the need to record
an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.
If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount. The
recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future cash
flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset that
does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses are
recognized in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;m.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Financial assets are measured upon
initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except
for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company classifies and measures
debt instruments in the financial statements based on the following criteria:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company&#x2019;s business model for managing financial assets; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The contractual cash flow terms of the financial asset.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Debt instruments are measured at amortized cost when:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;The Company&#x2019;s business model
is to hold the financial assets in order to collect their contractual cash flows, and the contractual terms of the financial assets give
rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial
recognition, the instruments in this category are measured according to their terms at amortized cost using the effective interest rate
method, less any provision for impairment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;On the date of initial recognition,
the Company may irrevocably designate a debt instrument as measured at fair value through profit or loss if doing so eliminates or significantly
reduces a measurement or recognition inconsistency, such as when a related financial liability is also measured at fair value through
profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Debt instruments are measured at fair value through profit or loss when:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;A financial asset which is a debt instrument
does not meet the criteria for measurement at amortized cost or at fair value through other comprehensive income. After initial recognition,
the financial asset is measured at fair value and gains or losses from fair value adjustments are recognized in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;c)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Equity instruments and other financial assets held for trading:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Investments in equity instruments do
not meet the above criteria and accordingly are measured at fair value through profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Other financial assets held for trading
such as derivatives, including embedded derivatives separated from the host contract, are measured at fair value through profit or loss
unless they are designated as effective hedging instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Dividends from investments in equity
instruments are recognized in profit or loss when the right to receive the dividends is established.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Derecognition of financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A financial asset is derecognized only
when:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The contractual rights to the cash flows from the financial asset have expired;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company has transferred substantially all the risks and rewards deriving from the contractual rights to receive cash flows from the financial asset or has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset; or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company has retained its contractual rights to receive cash flows from the financial asset but has assumed a contractual obligation to pay the cash flows in full without material delay to a third party.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial liabilities measured at amortized cost:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Financial liabilities are initially
recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;After initial recognition, the Company
measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair
value through profit or loss such as derivatives.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial liabilities measured at fair value through profit or loss:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;At initial recognition, the Company
measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;After initial recognition, changes
in fair value are recognized in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Derecognition of financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A financial liability is derecognized
only when it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires. A financial
liability is extinguished when the debtor discharges the liability by paying in cash, other financial assets, goods or services, or is
legally released from the liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Offsetting financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Financial assets and financial liabilities
are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off the
recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously.
The right of set-off must be legally enforceable not only during the ordinary course of business of the parties to the contract but also
in the event of bankruptcy or insolvency of one of the parties. In order for the right of set-off to be currently available, it must not
be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events that
will cause the right to expire.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;6.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Compound financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Convertible debentures which contain
both an equity/derivative component and a liability component are separated into two components. This separation is performed by first
determining the liability component based on the fair value of an equivalent non-convertible liability. The value of the conversion component
is determined to be the residual amount. Directly attributable transaction costs are apportioned between the equity component and the
liability component based on the allocation of proceeds to the equity and liability components.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;7.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Issue of a unit of securities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The issue of a unit of securities involves
the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following order: financial
derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for financial liabilities
that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual amount. Issue costs
are allocated to each component pro rata to the amounts determined for each component in the unit.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;n.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Research and development expenditures:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Research expenditures are recognized
in profit or loss when incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The conditions enabling capitalization
of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss when
incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;o.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Finance income and expenses:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Finance income and expenses comprise
interest income on amounts invested and exchange rate gains and losses. Interest income is recognized as it accrues using the effective
interest method. Finance income and expenses derive also from changes in the fair value of financial liabilities measured at fair value
through profit or loss. Borrowing costs are recognized in profit or loss using the effective interest method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;p.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Fair value measurement:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Fair value measurement is based on the assumption that the transaction will take place in the asset&#x2019;s or the liability&#x2019;s
principal market, or in the absence of a principal market, in the most advantageous market.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The fair value of an asset or a liability
is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants
act in their economic best interest.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Fair value measurement of a non-financial
asset takes into account a market participant&#x2019;s ability to generate economic benefits by using the asset in its highest and best
use or by selling it to another market participant that would use the asset in its highest and best use.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company uses valuation techniques
that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant
observable inputs and minimizing the use of unobservable inputs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;All assets and liabilities measured
at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level
input that is significant to the entire fair value measurement:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Inputs other than quoted prices included within Level 1 that are observable directly or indirectly.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;q.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Taxes on income:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Current or deferred taxes are recognized
in profit or loss, except to the extent that they relate to items which are recognized in other comprehensive income or equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Current taxes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A current tax liability is measured
using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required
in connection with the tax liability in respect of previous years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Deferred taxes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are computed in respect
of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are measured at the
tax rate that is expected to apply when the asset is realized, or the liability is settled, based on tax laws that have been enacted or
substantively enacted by the reporting date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred tax assets are reviewed at
each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and temporary
differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred tax asset
is recognized to the extent that their utilization is probable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Taxes that would apply in the event
of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of the
investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution
of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends
does not involve an additional tax liability or since it is the Company&#x2019;s policy not to initiate distribution of dividends from
a subsidiary that would trigger an additional tax liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Taxes on income that relate to distributions
of an equity instrument and to transaction costs of an equity transaction are accounted for pursuant to IAS 12, &#x201c;&lt;i&gt;Income Taxes&lt;/i&gt;&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are offset if there
is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same
taxpayer and the same taxation authority.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;r.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Share-based payment transactions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s employees and other
service providers may receive remuneration in the form of share-based payments (&#x201c;Equity-settled transactions&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Equity-settled transactions:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The cost of equity-settled transactions
with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable
option pricing model (&#x201c;OPM&#x201d;). As for service providers, the cost of the transactions is measured at the fair value of the
goods or services received as consideration for equity instruments granted.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The cost of equity-settled transactions
is recognized in profit or loss together with a corresponding increase in equity during the period in which the performance and/or service
conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award (the &#x201c;Vesting Period&#x201d;).
The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects
the extent to which the Vesting Period has expired and the Company&#x2019;s best estimate of the number of equity instruments that will
ultimately vest.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;No expense is recognized for awards
that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective
of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;If the Company modifies the conditions
on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value
of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;If a grant of an equity instrument
is cancelled, it is accounted for as if it had vested on the cancellation date and any expense not yet recognized for the grant is recognized
immediately. However, if a new grant replaces the cancelled grant and is identified as a replacement grant on the grant date, the cancelled
and new grants are accounted for as a modification of the original grant, as described above.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;s.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Earnings (loss) per share:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Earnings (loss) per share are calculated
by dividing the income (loss) attributable to equity holders of the Company by the weighted number of ordinary shares outstanding during
the period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Basic loss per ordinary share includes
only ordinary shares that were outstanding during the period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Potential ordinary shares are included
in the computation of diluted loss per ordinary share when their conversion increases loss per ordinary share from continuing operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; font-size: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;t.&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Employee benefit liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;The Company has several employee-benefit
plans:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Short-term employee benefits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;Short-term employee benefits are benefits
that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render
the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions
and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and a
reliable estimate of the amount can be made.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Post-employment benefits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;The plans are normally financed by contributions
to insurance companies and classified as defined contribution plans or as defined benefit plans.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;The Company has defined contribution
plans to its employees according to the specific laws per country.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;u.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Provisions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;A provision in accordance with IAS 37,
&#x201c;&lt;i&gt;Provisions, Contingent Liabilities and Contingent Assets&lt;/i&gt;&#x201d;, is recognized when the Company has a present obligation
(legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required
to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects part or all of
the expense to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when
the reimbursement is virtually certain. The expense is recognized in the statement of profit or loss net of any reimbursement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;Following are the types of provisions
included in the financial statements:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&lt;i&gt;Legal claims:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;A provision for claims is recognized
when the Company has a present legal or constructive obligation as a result of a past event, it is more likely than not that an outflow
of resources embodying economic benefits will be required by the Company to settle the obligation and a reliable estimate can be made
of the amount of the obligation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;v.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Leases:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;The Company elected to apply the provisions
of IFRS 16, &#x201c;&lt;i&gt;Leases&lt;/i&gt;&#x201d; (&#x201c;IFRS 16&#x201d;) using the modified retrospective method (without restatement of comparative
data).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;The accounting policy for leases applied
effective from January 1, 2019, is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;The Company accounts for a contract as
a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company as a lessee:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;For leases in which the Company is the
lessee, the Company recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases whose
term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Company has elected
to recognize lease payments as an expense in profit or loss on a straight-line basis over the lease term (see Note 9). In measuring the
lease liability, the Company has elected to apply the practical expedient in IFRS 16 and separates the lease components from the non-lease
components (such as management and maintenance services, etc.) included in a single contract.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;On the commencement date, the lease
liability includes all unpaid lease payments discounted at the interest rate implicit in the lease, if that rate can be readily determined,
or otherwise using the Company&#x2019;s incremental borrowing rate. After the commencement date, the Company measures the lease liability
using the effective interest rate method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;On the commencement date, the right-of-use
asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and
initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful
life and the lease term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;The Company tests for impairment of
the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36, &#x201c;&lt;i&gt;Impairment of Assets&lt;/i&gt;&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Lease extension and termination options:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;A non-cancelable lease term includes
both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised, and
the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;In the event of any change in the expected
exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Company remeasures the lease
liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total change
is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized
in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Lease modifications:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;If a lease modification does not reduce
the scope of the lease and does not result in a separate lease, the Company remeasures the lease liability based on the modified lease
terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the
right-of-use asset.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;If a lease modification reduces the
scope of the lease, the Company recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use
asset and the lease liability. The Company subsequently remeasures the carrying amount of the lease liability according to the revised
lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment to
the right-of-use asset.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 72px"&gt;&lt;/td&gt;&lt;td style="width: 48px; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;w.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendment
to IAS 1, &#x201c;Presentation of Financial Statements&#x201d;:&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"&gt;In January 2020, the IASB issued
an amendment to IAS 1, &#x201c;Presentation of Financial Statements&#x201d; regarding the criteria for determining the classification of liabilities
as current or non-current (&#x201c;the Original Amendment&#x201d;). In October 2022, the IASB issued a subsequent amendment (&#x201c;the Subsequent
Amendment&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"&gt;According to the Subsequent Amendment:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"&gt;Only covenants with which an entity
must comply on or before the reporting date will affect a liability&#x2019;s classification as current or non-current.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"&gt;An entity should provide disclosure
when a liability arising from a loan agreement is classified as non-current and the entity&#x2019;s right to defer settlement is contingent on
compliance with future covenants within twelve months from the reporting date. This disclosure is required to include information about
the covenants and the related liabilities. The disclosures must include information about the nature of the future covenants and when
compliance is applicable, as well as the carrying amount of the related liabilities. The purpose of this information is to allow users
to understand the nature of the future covenants and to assess the risk that a liability classified as non-current could become repayable
within twelve months. Furthermore, if facts and circumstances indicate that an entity may have difficulty in complying with such covenants,
those facts and circumstances should be disclosed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"&gt;According to the Original Amendment,
the conversion option of a liability affects the classification of the entire liability as current or non-current unless the conversion
component is an equity instrument.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"&gt;The Original Amendment and Subsequent
Amendment are both effective for annual periods beginning on or after January 1, 2024, and must be applied retrospectively. Early application
is permitted.&lt;/p&gt;

&lt;p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"&gt;The Company is evaluating the
effects of the Amendments on its financial statements.&lt;/p&gt;

&lt;p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 72px"&gt;&lt;/td&gt;&lt;td style="width: 48px; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;x.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendment
to IAS 8, &#x201c;Accounting Policies, Changes to Accounting Estimates and Errors&#x201d;:&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -10.1pt"&gt;&#160;&lt;/p&gt;

&lt;p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in"&gt;In February 2021, the IASB issued an amendment to IAS 8,
&#x201c;Accounting Policies, Changes to Accounting Estimates and Errors&#x201d; (&#x201c;the Amendment&#x201d;), in which it introduces a new
definition of &#x201c;accounting estimates&#x201d;.&lt;/p&gt;

&lt;p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"&gt;Accounting estimates are defined as
&#x201c;monetary amounts in financial statements that are subject to measurement uncertainty&#x201d;. The Amendment clarifies the distinction
between changes in accounting estimates and changes in accounting policies and the correction of errors.&lt;/p&gt;

&lt;p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"&gt;The Amendment is to be applied prospectively
for annual reporting periods beginning on or after January 1, 2023 and is applicable to changes in accounting policies and changes in
accounting estimates that occur on or after the start of that period. Early application is permitted.&lt;/p&gt;</ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory>
    <sprcy:BasisOfPresentationOfFinancialStatements contextRef="c7" id="ixv-28617">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Basis of presentation of the financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;These financial statements have been
prepared in accordance with IFRS, as issued by the IASB.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s financial statements
have been prepared on a cost basis, unless otherwise indicated.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company has elected to present
the profit or loss items using the function of expense method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial statements are presented
in USD and all values are rounded to the nearest thousand (&#x2019;000), except when otherwise indicated.&lt;/p&gt;</sprcy:BasisOfPresentationOfFinancialStatements>
    <sprcy:DescriptionOfAccountingPolicyForoperatingcycleExplanatory contextRef="c7" id="ixv-28638">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The operating cycle:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The operating cycle of the Company
is one year.&lt;/p&gt;</sprcy:DescriptionOfAccountingPolicyForoperatingcycleExplanatory>
    <sprcy:OperatingTerm contextRef="c7" id="ixv-38226">P1Y</sprcy:OperatingTerm>
    <sprcy:DescriptionOfAccountingPolicyForConsolidatedfinancialstatements contextRef="c7" id="ixv-28650">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Consolidated financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The consolidated financial statements
comprise the financial statements of companies that are controlled by the Company (Subsidiaries). Control of a company is achieved when
the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those
returns through its power over the investee. Potential voting rights are considered when assessing whether an entity has control over
the other entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such
control ceases.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial statements of the Company
and of the Subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform
accounting policies by all companies in the Group. Significant intra-Group balances and transactions and gains or losses resulting from
intra-Group transactions are eliminated in full in the consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Non-controlling interests in subsidiaries
represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in
equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive
income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they
result in a negative balance of non-controlling interests in the consolidated statement of financial position.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</sprcy:DescriptionOfAccountingPolicyForConsolidatedfinancialstatements>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="c7" id="ixv-28708">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 72px"&gt;&lt;/td&gt;&lt;td style="width: 48px; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Functional currency and foreign currency:&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;The functional currency of the Company, which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions is the U.S. Dollar (&#x201c;USD&#x201d; or &#x201c;$&#x201d;), since it&#x2019;s the primary currency of the economic environment in which the Company operates. The consolidated financial statements are also presented in USD since the Company believes that preparing the consolidated financial statements in USD provides more relevant information to the users of the consolidated financial statements.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <sprcy:DescriptionOfAcquisitionOfASingleAssetCompany contextRef="c7" id="ixv-28719">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Acquisition of a single asset company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Upon the acquisition
of a single asset company, the Group evaluates whether it is the acquisition of a business or of an asset. To be considered a business,
the acquisition must include, at a minimum, an input and a substantive process that together can significantly contribute to the creation
of outputs. The acquisition is accounted for as a business combination if the single asset company is a business. If it is not a business,
the acquisition is accounted for as the acquisition of assets and liabilities. In such an acquisition, the cost of the acquisition includes
transaction costs which are allocated to the identifiable acquired assets and liabilities proportionally based on their fair value on
the acquisition date. In such case, goodwill and deferred taxes in respect of the temporary differences existing as of the acquisition
date are not recognized.&lt;/p&gt;</sprcy:DescriptionOfAcquisitionOfASingleAssetCompany>
    <sprcy:DescriptionOfAccountingPolicyForRestrictedDeposit contextRef="c7" id="ixv-28731">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted deposits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;A restricted deposit is cash invested
in a short-term deposit (between three months and one year) or in a long-term deposit (with a maturity of more than one year from the
date of investment). Restricted deposits are designated to secure the Company&#x2019;s office facilities lease agreements and its credit
cards.&lt;/p&gt;</sprcy:DescriptionOfAccountingPolicyForRestrictedDeposit>
    <ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory contextRef="c7" id="ixv-28743">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 72px"&gt;&lt;/td&gt;&lt;td style="width: 48px"&gt;g.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Investment in joint arrangements:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Joint arrangements
are arrangements in which the Company has joint control. Joint control is the contractually agreed sharing of control of an arrangement,
which exists only when decisions about the relevant activities require the unanimous consent of the parties sharing control.&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 1.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;1.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Joint ventures:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"&gt;In joint ventures
the parties that have joint control of the arrangement have rights to the net assets of the arrangement. A joint venture is accounted
for at equity&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 1.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;2.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Joint operations:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"&gt;In joint operations
the parties that have joint control of the arrangement have rights to the assets and obligations for the liabilities relating to the arrangement.
The Company recognizes in relation to its interest its share of the assets, liabilities, revenues and expenses of the joint operation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"&gt;The acquisition
of interests in a joint operation which represents a business, as defined in IFRS 3, is accounted for using the acquisition method, including
the measurement of the identifiable assets and liabilities at fair value, the recognition of deferred taxes arising from this measurement,
the accounting treatment of the related transaction costs and the recognition of goodwill or bargain purchase gains. This applies to the
acquisition of the initial interest and additional interests in a joint operation that represents a business.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociates contextRef="c7" id="ixv-28818">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 72px"&gt;&lt;/td&gt;&lt;td style="width: 48px"&gt;h.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Investments in associates:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Associates are companies in which the Group has significant
influence over the financial and operating policies without having control. The investment in an associate is accounted for using the
equity method.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociates>
    <sprcy:DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock contextRef="c7" id="ixv-28829">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 72px"&gt;&lt;/td&gt;&lt;td style="width: 48px"&gt;i.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Investments accounted for using the equity method:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The Group&#x2019;s investments
in associates and joint ventures are accounted for using the equity method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Under the equity
method, the investment in the associate or in the joint venture is presented at cost with the addition of post-acquisition changes in
the Group&#x2019;s share of net assets, including other comprehensive income of the associate or the joint venture. Gains and losses resulting
from transactions between the Group and the associate or the joint venture are eliminated to the extent of the interest in the associate
or in the joint venture. The cost of the investment includes transaction costs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Goodwill relating
to the acquisition of an associate or a joint venture is presented as part of the investment in the associate or the joint venture, measured
at cost and not systematically amortized. Goodwill is evaluated for impairment as part of the investment in the associate or in the joint
venture as a whole.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The financial statements
of the Company and of the associate or joint venture are prepared as of the same dates and periods. The accounting policies applied in
the financial statements of the associate or the joint venture are uniform and consistent with the policies applied in the financial statements
of the Group.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Upon the acquisition
of an associate or a joint venture achieved in stages when the former investment in the acquiree was accounted for pursuant to the provisions
of IFRS 9, the Group applies the principles of IFRS 3 regarding business combinations achieved in stages. Consequently, equity interests
in the acquiree that had been held by the Group prior to achieving significant influence or joint control are measured at fair value on
the acquisition date and are included in the acquisition consideration while recognizing a gain or loss resulting from the fair value
measurement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The equity method
is applied until the loss of significant influence in the associate or loss of joint control in the joint venture or classification as
investment held for sale.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</sprcy:DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory contextRef="c7" id="ixv-28897">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;j.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Property and equipment, net:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Property and equipment are measured
at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment
grants and excluding day-to-day servicing expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Mainly %&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Lab equipment&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 9%"&gt;6-50&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;33&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Computers&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;33-50&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;33&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office furniture and equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;20-33&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;25&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;see below&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-233"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including the extension option held by a company and intended to be exercised)
and the expected life of the improvement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The useful life, depreciation method
and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting
estimate. Depreciation of an asset ceases at the earlier of: the date that the asset is classified as held for sale and the date that
the asset is derecognized.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <sprcy:DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory contextRef="c7" id="ixv-38227">Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Mainly %&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Lab equipment&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 9%"&gt;6-50&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;33&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Computers&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;33-50&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;33&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office furniture and equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;20-33&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;25&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;see below&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-233"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory>
    <sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment
      contextRef="c188"
      decimals="2"
      id="ixv-38228"
      unitRef="pure">0.06</sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment>
    <sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment
      contextRef="c189"
      decimals="2"
      id="ixv-38229"
      unitRef="pure">0.50</sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment>
    <sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly
      contextRef="c190"
      decimals="2"
      id="ixv-38230"
      unitRef="pure">0.33</sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly>
    <sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment
      contextRef="c191"
      decimals="2"
      id="ixv-38231"
      unitRef="pure">0.33</sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment>
    <sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment
      contextRef="c192"
      decimals="2"
      id="ixv-38232"
      unitRef="pure">0.50</sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment>
    <sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly
      contextRef="c193"
      decimals="2"
      id="ixv-38233"
      unitRef="pure">0.33</sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly>
    <sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment
      contextRef="c194"
      decimals="2"
      id="ixv-38234"
      unitRef="pure">0.20</sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment>
    <sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment
      contextRef="c195"
      decimals="2"
      id="ixv-38235"
      unitRef="pure">0.33</sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment>
    <sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly
      contextRef="c196"
      decimals="2"
      id="ixv-38236"
      unitRef="pure">0.25</sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly>
    <ifrs-full:DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife contextRef="c197" id="ixv-38237">see below</ifrs-full:DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife>
    <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory contextRef="c7" id="ixv-28963">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;k.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Separately acquired intangible assets
are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination
are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized
development costs, are recognized in profit or loss when incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Intangible assets with a finite useful
life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired.
The amortization period and the amortization method for an intangible asset are reviewed at least at each year end.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory contextRef="c7" id="ixv-28978">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;l.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Impairment of non-financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company evaluates the need to record
an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.
If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount. The
recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future cash
flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset that
does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses are
recognized in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory contextRef="c7" id="ixv-29032">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;m.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Financial assets are measured upon
initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except
for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company classifies and measures
debt instruments in the financial statements based on the following criteria:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company&#x2019;s business model for managing financial assets; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The contractual cash flow terms of the financial asset.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Debt instruments are measured at amortized cost when:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;The Company&#x2019;s business model
is to hold the financial assets in order to collect their contractual cash flows, and the contractual terms of the financial assets give
rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial
recognition, the instruments in this category are measured according to their terms at amortized cost using the effective interest rate
method, less any provision for impairment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;On the date of initial recognition,
the Company may irrevocably designate a debt instrument as measured at fair value through profit or loss if doing so eliminates or significantly
reduces a measurement or recognition inconsistency, such as when a related financial liability is also measured at fair value through
profit or loss.&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Debt instruments are measured at fair value through profit or loss when:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;A financial asset which is a debt instrument
does not meet the criteria for measurement at amortized cost or at fair value through other comprehensive income. After initial recognition,
the financial asset is measured at fair value and gains or losses from fair value adjustments are recognized in profit or loss.&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;c)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Equity instruments and other financial assets held for trading:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Investments in equity instruments do
not meet the above criteria and accordingly are measured at fair value through profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Other financial assets held for trading
such as derivatives, including embedded derivatives separated from the host contract, are measured at fair value through profit or loss
unless they are designated as effective hedging instruments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Dividends from investments in equity
instruments are recognized in profit or loss when the right to receive the dividends is established.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Derecognition of financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A financial asset is derecognized only
when:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The contractual rights to the cash flows from the financial asset have expired;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company has transferred substantially all the risks and rewards deriving from the contractual rights to receive cash flows from the financial asset or has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset; or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company has retained its contractual rights to receive cash flows from the financial asset but has assumed a contractual obligation to pay the cash flows in full without material delay to a third party.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial liabilities measured at amortized cost:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Financial liabilities are initially
recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;After initial recognition, the Company
measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair
value through profit or loss such as derivatives.&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial liabilities measured at fair value through profit or loss:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;At initial recognition, the Company
measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;After initial recognition, changes
in fair value are recognized in profit or loss.&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Derecognition of financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A financial liability is derecognized
only when it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires. A financial
liability is extinguished when the debtor discharges the liability by paying in cash, other financial assets, goods or services, or is
legally released from the liability.&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Offsetting financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Financial assets and financial liabilities
are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off the
recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously.
The right of set-off must be legally enforceable not only during the ordinary course of business of the parties to the contract but also
in the event of bankruptcy or insolvency of one of the parties. In order for the right of set-off to be currently available, it must not
be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events that
will cause the right to expire.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;6.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Compound financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Convertible debentures which contain
both an equity/derivative component and a liability component are separated into two components. This separation is performed by first
determining the liability component based on the fair value of an equivalent non-convertible liability. The value of the conversion component
is determined to be the residual amount. Directly attributable transaction costs are apportioned between the equity component and the
liability component based on the allocation of proceeds to the equity and liability components.&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;7.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Issue of a unit of securities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The issue of a unit of securities involves
the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following order: financial
derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for financial liabilities
that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual amount. Issue costs
are allocated to each component pro rata to the amounts determined for each component in the unit.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory contextRef="c7" id="ixv-29349">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;n.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Research and development expenditures:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Research expenditures are recognized
in profit or loss when incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The conditions enabling capitalization
of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss when
incurred.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory contextRef="c7" id="ixv-29364">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;o.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Finance income and expenses:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Finance income and expenses comprise
interest income on amounts invested and exchange rate gains and losses. Interest income is recognized as it accrues using the effective
interest method. Finance income and expenses derive also from changes in the fair value of financial liabilities measured at fair value
through profit or loss. Borrowing costs are recognized in profit or loss using the effective interest method.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory contextRef="c7" id="ixv-29376">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;p.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Fair value measurement:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Fair value measurement is based on the assumption that the transaction will take place in the asset&#x2019;s or the liability&#x2019;s
principal market, or in the absence of a principal market, in the most advantageous market.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The fair value of an asset or a liability
is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants
act in their economic best interest.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Fair value measurement of a non-financial
asset takes into account a market participant&#x2019;s ability to generate economic benefits by using the asset in its highest and best
use or by selling it to another market participant that would use the asset in its highest and best use.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company uses valuation techniques
that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant
observable inputs and minimizing the use of unobservable inputs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;All assets and liabilities measured
at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level
input that is significant to the entire fair value measurement:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Inputs other than quoted prices included within Level 1 that are observable directly or indirectly.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory contextRef="c7" id="ixv-29487">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;q.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Taxes on income:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Current or deferred taxes are recognized
in profit or loss, except to the extent that they relate to items which are recognized in other comprehensive income or equity.&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Current taxes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A current tax liability is measured
using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required
in connection with the tax liability in respect of previous years.&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Deferred taxes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are computed in respect
of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are measured at the
tax rate that is expected to apply when the asset is realized, or the liability is settled, based on tax laws that have been enacted or
substantively enacted by the reporting date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred tax assets are reviewed at
each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and temporary
differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred tax asset
is recognized to the extent that their utilization is probable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Taxes that would apply in the event
of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of the
investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution
of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends
does not involve an additional tax liability or since it is the Company&#x2019;s policy not to initiate distribution of dividends from
a subsidiary that would trigger an additional tax liability.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Taxes on income that relate to distributions
of an equity instrument and to transaction costs of an equity transaction are accounted for pursuant to IAS 12, &#x201c;&lt;i&gt;Income Taxes&lt;/i&gt;&#x201d;.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are offset if there
is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same
taxpayer and the same taxation authority.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory contextRef="c7" id="ixv-29581">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;r.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Share-based payment transactions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s employees and other
service providers may receive remuneration in the form of share-based payments (&#x201c;Equity-settled transactions&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Equity-settled transactions:&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The cost of equity-settled transactions
with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable
option pricing model (&#x201c;OPM&#x201d;). As for service providers, the cost of the transactions is measured at the fair value of the
goods or services received as consideration for equity instruments granted.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The cost of equity-settled transactions
is recognized in profit or loss together with a corresponding increase in equity during the period in which the performance and/or service
conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award (the &#x201c;Vesting Period&#x201d;).
The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects
the extent to which the Vesting Period has expired and the Company&#x2019;s best estimate of the number of equity instruments that will
ultimately vest.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;No expense is recognized for awards
that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective
of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;If the Company modifies the conditions
on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value
of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;If a grant of an equity instrument
is cancelled, it is accounted for as if it had vested on the cancellation date and any expense not yet recognized for the grant is recognized
immediately. However, if a new grant replaces the cancelled grant and is identified as a replacement grant on the grant date, the cancelled
and new grants are accounted for as a modification of the original grant, as described above.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory contextRef="c7" id="ixv-29612">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;s.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Earnings (loss) per share:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Earnings (loss) per share are calculated
by dividing the income (loss) attributable to equity holders of the Company by the weighted number of ordinary shares outstanding during
the period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Basic loss per ordinary share includes
only ordinary shares that were outstanding during the period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Potential ordinary shares are included
in the computation of diluted loss per ordinary share when their conversion increases loss per ordinary share from continuing operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory contextRef="c7" id="ixv-29672">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; font-size: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;t.&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Employee benefit liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;The Company has several employee-benefit
plans:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Short-term employee benefits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;Short-term employee benefits are benefits
that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render
the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions
and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and a
reliable estimate of the amount can be made.&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Post-employment benefits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;The plans are normally financed by contributions
to insurance companies and classified as defined contribution plans or as defined benefit plans.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;The Company has defined contribution
plans to its employees according to the specific laws per country.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory contextRef="c7" id="ixv-29711">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;u.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Provisions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;A provision in accordance with IAS 37,
&#x201c;&lt;i&gt;Provisions, Contingent Liabilities and Contingent Assets&lt;/i&gt;&#x201d;, is recognized when the Company has a present obligation
(legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required
to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects part or all of
the expense to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when
the reimbursement is virtually certain. The expense is recognized in the statement of profit or loss net of any reimbursement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;Following are the types of provisions
included in the financial statements:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&lt;i&gt;Legal claims:&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;A provision for claims is recognized
when the Company has a present legal or constructive obligation as a result of a past event, it is more likely than not that an outflow
of resources embodying economic benefits will be required by the Company to settle the obligation and a reliable estimate can be made
of the amount of the obligation.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory contextRef="c7" id="ixv-29734">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;v.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Leases:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;The Company elected to apply the provisions
of IFRS 16, &#x201c;&lt;i&gt;Leases&lt;/i&gt;&#x201d; (&#x201c;IFRS 16&#x201d;) using the modified retrospective method (without restatement of comparative
data).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;The accounting policy for leases applied
effective from January 1, 2019, is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;The Company accounts for a contract as
a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company as a lessee:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;For leases in which the Company is the
lessee, the Company recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases whose
term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Company has elected
to recognize lease payments as an expense in profit or loss on a straight-line basis over the lease term (see Note 9). In measuring the
lease liability, the Company has elected to apply the practical expedient in IFRS 16 and separates the lease components from the non-lease
components (such as management and maintenance services, etc.) included in a single contract.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;On the commencement date, the lease
liability includes all unpaid lease payments discounted at the interest rate implicit in the lease, if that rate can be readily determined,
or otherwise using the Company&#x2019;s incremental borrowing rate. After the commencement date, the Company measures the lease liability
using the effective interest rate method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;On the commencement date, the right-of-use
asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and
initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful
life and the lease term.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;The Company tests for impairment of
the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36, &#x201c;&lt;i&gt;Impairment of Assets&lt;/i&gt;&#x201d;.&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Lease extension and termination options:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;A non-cancelable lease term includes
both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised, and
the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;In the event of any change in the expected
exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Company remeasures the lease
liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total change
is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized
in profit or loss.&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Lease modifications:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;If a lease modification does not reduce
the scope of the lease and does not result in a separate lease, the Company remeasures the lease liability based on the modified lease
terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the
right-of-use asset.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;If a lease modification reduces the
scope of the lease, the Company recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use
asset and the lease liability. The Company subsequently remeasures the carrying amount of the lease liability according to the revised
lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment to
the right-of-use asset.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <sprcy:DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements contextRef="c7" id="ixv-29901">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 72px"&gt;&lt;/td&gt;&lt;td style="width: 48px; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;w.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendment
to IAS 1, &#x201c;Presentation of Financial Statements&#x201d;:&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"&gt;In January 2020, the IASB issued
an amendment to IAS 1, &#x201c;Presentation of Financial Statements&#x201d; regarding the criteria for determining the classification of liabilities
as current or non-current (&#x201c;the Original Amendment&#x201d;). In October 2022, the IASB issued a subsequent amendment (&#x201c;the Subsequent
Amendment&#x201d;).&lt;/p&gt;&lt;p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"&gt;According to the Subsequent Amendment:&lt;/p&gt;&lt;p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"&gt;Only covenants with which an entity
must comply on or before the reporting date will affect a liability&#x2019;s classification as current or non-current.&lt;/p&gt;&lt;p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"&gt;An entity should provide disclosure
when a liability arising from a loan agreement is classified as non-current and the entity&#x2019;s right to defer settlement is contingent on
compliance with future covenants within twelve months from the reporting date. This disclosure is required to include information about
the covenants and the related liabilities. The disclosures must include information about the nature of the future covenants and when
compliance is applicable, as well as the carrying amount of the related liabilities. The purpose of this information is to allow users
to understand the nature of the future covenants and to assess the risk that a liability classified as non-current could become repayable
within twelve months. Furthermore, if facts and circumstances indicate that an entity may have difficulty in complying with such covenants,
those facts and circumstances should be disclosed.&lt;/p&gt;&lt;p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"&gt;According to the Original Amendment,
the conversion option of a liability affects the classification of the entire liability as current or non-current unless the conversion
component is an equity instrument.&lt;/p&gt;&lt;p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"&gt;The Original Amendment and Subsequent
Amendment are both effective for annual periods beginning on or after January 1, 2024, and must be applied retrospectively. Early application
is permitted.&lt;/p&gt;&lt;p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"&gt;The Company is evaluating the
effects of the Amendments on its financial statements.&lt;/p&gt;</sprcy:DescriptionOfAmendmentToIAS1PresentationOfFinancialStatements>
    <sprcy:DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors contextRef="c7" id="ixv-29931">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 72px"&gt;&lt;/td&gt;&lt;td style="width: 48px; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;x.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendment
to IAS 8, &#x201c;Accounting Policies, Changes to Accounting Estimates and Errors&#x201d;:&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in"&gt;In February 2021, the IASB issued an amendment to IAS 8,
&#x201c;Accounting Policies, Changes to Accounting Estimates and Errors&#x201d; (&#x201c;the Amendment&#x201d;), in which it introduces a new
definition of &#x201c;accounting estimates&#x201d;.&lt;/p&gt;&lt;p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"&gt;Accounting estimates are defined as
&#x201c;monetary amounts in financial statements that are subject to measurement uncertainty&#x201d;. The Amendment clarifies the distinction
between changes in accounting estimates and changes in accounting policies and the correction of errors.&lt;/p&gt;&lt;p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"&gt;The Amendment is to be applied prospectively
for annual reporting periods beginning on or after January 1, 2023 and is applicable to changes in accounting policies and changes in
accounting estimates that occur on or after the start of that period. Early application is permitted.&lt;/p&gt;</sprcy:DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors>
    <sprcy:SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock contextRef="c7" id="ixv-29980">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 3:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify"&gt;In the process of applying the significant
accounting policies, the Company has made the following judgments which have the most significant effect on the amounts recognized in
the financial statements:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Judgments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Discount rate for a lease liability:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;When a company in the Group is unable
to readily determine the discount rate implicit in a lease in order to measure the lease liability, such company uses an incremental borrowing
rate. That rate represents the rate of interest that the Company would have to pay to borrow over a similar term and with similar security,
the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment. When there are no
financing transactions that can serve as a basis, said company determines the incremental borrowing rate based on its credit risk, the
lease term and other economic variables deriving from the lease contract&#x2019;s conditions and restrictions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Effective control:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;The Company assesses whether it controls
a company in which it holds less than the majority of the voting rights by, among others, reference to the size of its holding of voting
rights relative to the size and dispersion of holdings of the other vote holders including voting patterns at previous shareholders&#x2019;
meetings.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Determining the fair value of share-based payment transactions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;The fair value of share-based payment
transactions is determined upon initial recognition by an acceptable OPM. The inputs to the model include share price, exercise price
and assumptions regarding expected volatility, expected life of share option, risk-free interest and expected dividend yield.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Estimates and assumptions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;The preparation of the financial statements
requires management to make estimates and assumptions that have an effect on the application of the accounting policies and on the reported
amounts of assets, liabilities, revenues and expenses. Changes in accounting estimates are reported in the period of the change in estimate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;The key assumptions made in the financial
statements concerning uncertainties at the reporting date and the critical estimates computed by the Company that may result in a material
adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Legal claims:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;In estimating the likelihood of outcome
of legal claims filed or threatened to commence against the Company and/or its Subsidiaries and/or affiliates, the Company relies on its
management&#x2019;s best knowledge and estimations and where applicable, on the opinion of their legal counsels. These estimates are based,
among others, on management&#x2019;s familiarity of and proximity to the circumstances, and also on the legal counsels&#x2019; best professional
judgment, taking into account the stage of proceedings and legal precedents in respect of the different issues. Since the outcome of the
claims might be determined in courts and/or other quasi-judicial tribunals, the results could differ from these estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Lease extension and/or termination options:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;In evaluating whether it is reasonably
certain that a company of the Group will exercise an option to extend a lease or not exercise an option to terminate a lease, the Company
considers all relevant facts and circumstances that create an economic incentive for the Company to exercise the option to extend or not
exercise the option to terminate such as: significant amounts invested in leasehold improvements, the significance of the underlying asset
to the Company&#x2019;s operation and whether it is a specialized asset, the company&#x2019;s past experience with similar leases, etc.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;After the commencement date, the Company
reassesses the term of the lease upon the occurrence of a significant event or a significant change in circumstances that affects whether
the company is reasonably certain to exercise an option or not exercise an option previously included in the determination of the lease
term, such as significant leasehold improvements that had not been anticipated on the lease commencement date, sublease of the underlying
asset for a period that exceeds the end of the previously determined lease period, etc.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Fair value of financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;When the fair values of financial assets
and financial liabilities recorded in the statement of financial position cannot be derived from active markets, their fair value is determined
using a variety of valuation techniques that include the use of valuation models. The inputs to these models are taken from observable
markets where possible, but where this is not feasible, estimation is required in establishing fair values. The models are tested for
validity by calibrating to prices from any observable current market transactions in the same instrument when available.&lt;/p&gt;</sprcy:SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock>
    <ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory contextRef="c7" id="ixv-30128">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 4:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;CASH&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Cash for immediate withdrawal - in USD&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,443&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,590&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Cash for immediate withdrawal - in NIS&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;131&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;285&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,574&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,875&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory>
    <sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock contextRef="c7" id="ixv-30139">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Cash for immediate withdrawal - in USD&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,443&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,590&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Cash for immediate withdrawal - in NIS&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;131&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;285&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,574&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,875&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock>
    <sprcy:CashForImmediateWithdrawal contextRef="c4" decimals="-3" id="ixv-38238" unitRef="usd">3443000</sprcy:CashForImmediateWithdrawal>
    <sprcy:CashForImmediateWithdrawal contextRef="c5" decimals="-3" id="ixv-38239" unitRef="usd">6590000</sprcy:CashForImmediateWithdrawal>
    <sprcy:CashForImmediateWithdrawalInNIS contextRef="c4" decimals="-3" id="ixv-38240" unitRef="usd">131000</sprcy:CashForImmediateWithdrawalInNIS>
    <sprcy:CashForImmediateWithdrawalInNIS contextRef="c5" decimals="-3" id="ixv-38241" unitRef="usd">285000</sprcy:CashForImmediateWithdrawalInNIS>
    <ifrs-full:CashOnHand contextRef="c4" decimals="-3" id="ixv-38242" unitRef="usd">3574000</ifrs-full:CashOnHand>
    <ifrs-full:CashOnHand contextRef="c5" decimals="-3" id="ixv-38243" unitRef="usd">6875000</ifrs-full:CashOnHand>
    <ifrs-full:DisclosureOfInventoriesExplanatory contextRef="c7" id="ixv-30225">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify; font-size: 10pt; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 5:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;INVENTORY&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Goods in transit&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;198&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-234"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;470&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-235"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;668&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-236"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfInventoriesExplanatory>
    <ifrs-full:DisclosureOfInvestmentEntitiesExplanatory contextRef="c7" id="ixv-30235">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Goods in transit&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;198&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-234"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;470&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-235"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;668&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-236"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfInvestmentEntitiesExplanatory>
    <ifrs-full:CurrentInventoriesInTransit contextRef="c4" decimals="-3" id="ixv-38244" unitRef="usd">198000</ifrs-full:CurrentInventoriesInTransit>
    <ifrs-full:FinishedGoods contextRef="c4" decimals="-3" id="ixv-38245" unitRef="usd">470000</ifrs-full:FinishedGoods>
    <sprcy:InventoriesNet contextRef="c4" decimals="-3" id="ixv-38246" unitRef="usd">668000</sprcy:InventoriesNet>
    <ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory contextRef="c7" id="ixv-30296">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 6:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;OTHER ACCOUNTS RECEIVABLE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Government authorities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;45&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;52&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,504&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;40&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;348&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;131&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,904&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory>
    <sprcy:DisclourseOfAccountsReceivablesTableTextBlock contextRef="c7" id="ixv-30307">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Government authorities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;45&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;52&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,504&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;40&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;348&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;131&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,904&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclourseOfAccountsReceivablesTableTextBlock>
    <ifrs-full:ValueAddedTaxReceivables contextRef="c4" decimals="-3" id="ixv-38247" unitRef="usd">45000</ifrs-full:ValueAddedTaxReceivables>
    <ifrs-full:ValueAddedTaxReceivables contextRef="c5" decimals="-3" id="ixv-38248" unitRef="usd">52000</ifrs-full:ValueAddedTaxReceivables>
    <ifrs-full:OtherReceivables contextRef="c4" decimals="-3" id="ixv-38249" unitRef="usd">46000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables contextRef="c5" decimals="-3" id="ixv-38250" unitRef="usd">2504000</ifrs-full:OtherReceivables>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c4" decimals="-3" id="ixv-38251" unitRef="usd">40000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c5" decimals="-3" id="ixv-38252" unitRef="usd">348000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:OtherCurrentReceivables contextRef="c4" decimals="-3" id="ixv-38253" unitRef="usd">131000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="c5" decimals="-3" id="ixv-38254" unitRef="usd">2904000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:DisclosureOfInvestmentPropertyExplanatory contextRef="c7" id="ixv-30376">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 7:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;INVESTMENT IN ASSOCIATES AND INVESTMENTS IN INVESTEES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Sale of Orimmune Bio Ltd.:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;On June 22, 2016, the Company entered
into a share transfer agreement (the &#x201c;Transfer Agreement&#x201d;) with its then wholly owned subsidiary, Orimmune Bio Ltd. (&#x201c;Orimmune&#x201d;)
and Karma Link Ltd. (the &#x201c;Buyer&#x201d;), whereby the Company would sell its interests in Orimmune to the Buyer, and also use its
best efforts to transfer to and assign Orimmune its rights in the Anti-CD3 technology.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;On December 13, 2018, an additional amendment
to the Transfer Agreement was signed (the &#x201c;Second Amendment&#x201d;) between the parties, under which it was agreed that Orimmune
will be assigned certain rights in intellectual property (&#x201c;IP&#x201d;) related to the licensed technology owned by the Company subject
to certain conditions precedent which were still not met as of December 31, 2022. As of the Approval Date, the conditions precedent have
not yet been completed and the assignment of the IP related to the licensed technology owned by us has not yet been transferred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Coeruleus - Joint Venture Transaction&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;On May 15, 2020, the Company entered into a series of transactions (together, the &#x201c;Joint Venture Transaction&#x201d;), including a definitive share transfer agreement with Capital Point Ltd. (&#x201c;Capital Point&#x201d;), an Israeli holding company traded on the TASE, and Evero, pursuant to which Capital Point sold to Evero 5,952,469 ordinary shares, NIS 0.01 par value each, of Coeruleus Ltd. (the &#x201c;Purchased Coeruleus Shares&#x201d; and &#x201c;Coeruleus,&#x201d; respectively), an Israeli company and a subsidiary of Capital Point (owns approximately 46%), engaged in, among others, developing innovative medications based on the active generic substance flumazenil, including a sublingual spray to reduce the side effects of hypnotic sleep medication, and a sublingual spray to improve function and quality of life in patients with hepatic encephalopathy. The Purchased Coeruleus Shares represented approximately 35% of the issued and outstanding share capital of Coeruleus. In consideration thereof, Evero issued and sold to Capital Point 176,470 ordinary shares, NIS 1.00 par value each, constituting 15% of the issued and outstanding share capital of Evero, which was valued at $351, based on apportionment of the fair market value of the Company as reflected on Nasdaq as of May 15, 2020. Following the transaction, Capital Point held approximately 11% of Coeruleus&#x2019; issued and outstanding share capital. The transaction costs of $51 were also capitalized as part of the investment in associate.&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;As part of the Joint Venture Transaction,
the Company transferred to Evero its SCI-110 sleep technology, to be fully owned by Evero, under the terms and conditions of an asset
purchase agreement. In addition, the Company issued to Capital Point a warrant (the &#x201c;Capital Point Warrant&#x201d;) to purchase $340
of ordinary shares of the Company. Pursuant to the terms of the Capital Point Warrant, the exercise price per ordinary share is equal
to the closing price of the Company&#x2019;s ordinary shares on the trading day on which the notice of exercise was actually received by
the Company and shall be paid by transferring to the Company a duly executed share transfer deed for 9,577 ordinary shares of Evero. The
Capital Point Warrant is exercisable for twelve months starting from May 15, 2021, until May 15, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On November 29, 2020, the shareholders
of Coeruleus approved an investment from its shareholders of approximately $30. The Company did not participate in this investment in
Coeruleus and therefore, as of the completion of such financing, the Company held less than 1% of the issued and outstanding shares of
Coeruleus. As of December 31, 2022, the fair value of the Company&#x2019;s investment in Coeruleus is $nil.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;MitocareX - Joint Venture Transaction&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;On March 10, 2022, the Company entered into a Founders and Investment Agreement with Dr. Alon Silberman, or the MitoCareX Agreement. Pursuant to the MitoCareX Agreement, the Company invested an initial amount of $700, and agreed to invest over the next two years, an additional $1,000, subject to the achievement of certain pre-determined milestones as agreed upon in the MitoCareX Agreement, for up to a 50.01% ownership in MitoCareX Bio Ltd. (&#x201c;MitoCareX&#x201d;). MitoCareX is focused on the discovery and development of potential drugs for cancers and other life-threatening conditions. The MitoCareX Agreement also contains customary representations, warranties, covenants, and indemnification provisions. On March 31, 2022, the closing conditions were met, and the Company paid the initial investment amount of $700 to MitoCareX. As of December 31, 2022, the Company owns 31.48% of the outstanding shares of MitocareX.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;On February 17, 2023, MitoCareX achieved its first milestone pursuant to the MitoCare X Agreement. The first milestone refers to the establishment of MitoCareX&#x2019;s cloud-based computing infrastructure that is expected to allow its future expansion into machine learning system. The system is harnessed to investigating mitochondrial carriers that are crucial for cell viability. As a result of MitoCareX meeting this milestone, the Company will invest an additional $400 in MitoCareX and increase its share ownership in MitoCareX Bio from 31.48% to 41.92%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;During the year ended December 31, 2022, the Company recorded equity losses from the investment in MitoCareX in the amount of $109.&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The table below summarizes the fair value of the
investment in MitoCareX:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-237"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 88%"&gt;Investment date March 31, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;700&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Equity losses from investment in MitoCareX&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(109&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;591&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfInvestmentPropertyExplanatory>
    <sprcy:ConversionOfOrdinaryShares
      contextRef="c199"
      decimals="0"
      id="ixv-38255"
      unitRef="shares">5952469</sprcy:ConversionOfOrdinaryShares>
    <sprcy:OrdinarySharesPerValue
      contextRef="c200"
      decimals="2"
      id="ixv-38256"
      unitRef="ilsPershares">0.01</sprcy:OrdinarySharesPerValue>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c201"
      decimals="2"
      id="ixv-38257"
      unitRef="pure">0.46</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <sprcy:PercentageOfSharesIssuedAndOutstandingShareCapital
      contextRef="c201"
      decimals="2"
      id="ixv-38258"
      unitRef="pure">0.35</sprcy:PercentageOfSharesIssuedAndOutstandingShareCapital>
    <sprcy:ConversionOfOrdinaryShares
      contextRef="c201"
      decimals="0"
      id="ixv-38259"
      unitRef="shares">176470</sprcy:ConversionOfOrdinaryShares>
    <sprcy:OrdinarySharesPerValue
      contextRef="c202"
      decimals="2"
      id="ixv-38260"
      unitRef="ilsPershares">1</sprcy:OrdinarySharesPerValue>
    <sprcy:PercentageOfSharesIssuedAndOutstandingShareCapital
      contextRef="c199"
      decimals="2"
      id="ixv-38261"
      unitRef="pure">0.15</sprcy:PercentageOfSharesIssuedAndOutstandingShareCapital>
    <sprcy:FairMarketValue
      contextRef="c201"
      decimals="-3"
      id="ixv-38262"
      unitRef="usd">351000</sprcy:FairMarketValue>
    <sprcy:PercentageOfSharesIssuedAndOutstandingShareCapital
      contextRef="c203"
      decimals="2"
      id="ixv-38263"
      unitRef="pure">0.11</sprcy:PercentageOfSharesIssuedAndOutstandingShareCapital>
    <ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination
      contextRef="c201"
      decimals="-3"
      id="ixv-38264"
      unitRef="usd">51000</ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination>
    <sprcy:PurchaseOfOrdinaryShares
      contextRef="c204"
      decimals="-3"
      id="ixv-38265"
      unitRef="usd">340000</sprcy:PurchaseOfOrdinaryShares>
    <sprcy:ConversionOfOrdinaryShares
      contextRef="c205"
      decimals="0"
      id="ixv-38266"
      unitRef="shares">9577</sprcy:ConversionOfOrdinaryShares>
    <sprcy:ShareholdersAmount
      contextRef="c206"
      decimals="-3"
      id="ixv-38267"
      unitRef="usd">30000</sprcy:ShareholdersAmount>
    <sprcy:IssuedAndOutstandingSharesPercentage
      contextRef="c207"
      decimals="2"
      id="ixv-38268"
      unitRef="pure">0.01</sprcy:IssuedAndOutstandingSharesPercentage>
    <ifrs-full:AdjustmentsForAmountsTransferredToInitialCarryingAmountOfHedgedItems
      contextRef="c106"
      decimals="-3"
      id="ixv-38269"
      unitRef="usd">700000</ifrs-full:AdjustmentsForAmountsTransferredToInitialCarryingAmountOfHedgedItems>
    <sprcy:InvestedInitialAmounts contextRef="c106" id="ixv-38270">P2Y</sprcy:InvestedInitialAmounts>
    <sprcy:PreDeterminedValue
      contextRef="c106"
      decimals="-3"
      id="ixv-38271"
      unitRef="usd">1000000</sprcy:PreDeterminedValue>
    <sprcy:OwnershipPercentage
      contextRef="c106"
      decimals="4"
      id="ixv-38272"
      unitRef="pure">0.5001</sprcy:OwnershipPercentage>
    <sprcy:InitialInvestmentAmount
      contextRef="c108"
      decimals="-3"
      id="ixv-38273"
      unitRef="usd">700000</sprcy:InitialInvestmentAmount>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStocks contextRef="c7" decimals="4" id="ixv-38274" unitRef="pure">0.3148</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStocks>
    <sprcy:InitialInvestmentAmount
      contextRef="c208"
      decimals="-3"
      id="ixv-38275"
      unitRef="usd">400000</sprcy:InitialInvestmentAmount>
    <sprcy:OwnershipPercentage
      contextRef="c209"
      decimals="4"
      id="ixv-38276"
      unitRef="pure">0.3148</sprcy:OwnershipPercentage>
    <sprcy:OwnershipPercentage
      contextRef="c210"
      decimals="4"
      id="ixv-38277"
      unitRef="pure">0.4192</sprcy:OwnershipPercentage>
    <sprcy:InitialInvestmentAmount contextRef="c7" decimals="-3" id="ixv-38278" unitRef="usd">109000</sprcy:InitialInvestmentAmount>
    <sprcy:DisclosureOfFairValueMeasurementOfAssetstable contextRef="c7" id="ixv-38279">The table below summarizes the fair value of the
investment in MitoCareX:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-237"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 88%"&gt;Investment date March 31, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;700&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Equity losses from investment in MitoCareX&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(109&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;591&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfFairValueMeasurementOfAssetstable>
    <sprcy:InvestmentDate contextRef="c7" decimals="-3" id="ixv-38280" unitRef="usd">700000</sprcy:InvestmentDate>
    <sprcy:EquityLossesFromInvestment contextRef="c7" decimals="-3" id="ixv-38281" unitRef="usd">109000</sprcy:EquityLossesFromInvestment>
    <ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="c4" decimals="-3" id="ixv-38282" unitRef="usd">591000</ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory contextRef="c7" id="ixv-30518">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 8:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;INVESTMENT IN FINANCIAL ASSETS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;On November 17, 2022, the Company invested
$1,500 in the initial public offering of Clearmind Medicine Inc. (&#x201c;Clearmind&#x201d;) and received 230,769 common shares of Clearmind,
resulting in the Company holding 9.33% of share capital of Clearmind. Clearmind is a psychedelic pharmaceutical biotech company focused
on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including
alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as
regulated medicines, foods or supplements. Shares of Clearmind are listed for trading on Nasdaq and the Canadian Securities Exchange under
the symbol &#x201c;CMND&#x201d; and the Frankfurt Stock Exchange under the symbol &#x201c;CWY.&#x201d; &#160; As of December 31, 2022, the
listed share price of Clearmind on Nasdaq was $3.16, and the Company has recorded a loss in its statements of comprehensive loss of $771
on its investment. &#160;&lt;/p&gt;</ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory>
    <sprcy:InvestmentAmount
      contextRef="c117"
      decimals="-3"
      id="ixv-38283"
      unitRef="usd">1500000</sprcy:InvestmentAmount>
    <ifrs-full:NumberOfSharesIssuedButNotFullyPaid
      contextRef="c211"
      decimals="0"
      id="ixv-38284"
      unitRef="shares">230769</ifrs-full:NumberOfSharesIssuedButNotFullyPaid>
    <sprcy:ShareCapitalPercentage
      contextRef="c117"
      decimals="4"
      id="ixv-38285"
      unitRef="pure">0.0933</sprcy:ShareCapitalPercentage>
    <sprcy:SharePricePerShare
      contextRef="c7"
      decimals="2"
      id="ixv-38286"
      unitRef="usdPershares">3.16</sprcy:SharePricePerShare>
    <sprcy:ComprehensiveLoss contextRef="c7" decimals="-3" id="ixv-38287" unitRef="usd">771000</sprcy:ComprehensiveLoss>
    <ifrs-full:DisclosureOfLeasesExplanatory contextRef="c7" id="ixv-30532">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 9:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;LEASES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify"&gt;On September 1, 2020, the Company entered
into a one-year lease agreement (&#x201c;the 2020 Lease&#x201d;) with a third party for an area of approximately 100 square meters for the
Company&#x2019;s offices in the district of Tel Aviv, Israel. The yearly lease fee was set at approximately $44, linked to the NIS. The
lease expired on August 31, 2021. The Company did not exercise its option to extend the lease until August 31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify"&gt;On July 1, 2021, the Company entered
into a two-year joint lease agreement (&#x201c;the 2021 Lease&#x201d;) with a third party and for a total area of approximately 240 square
meters, whereby the Company occupies approximately 120 square meters for the Company&#x2019;s offices, in the district of Tel Aviv, Israel.
The Company and the third party have an option to extend for an additional three-year term. The yearly lease fee was set at approximately
$40, linked to the NIS.&lt;/p&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
    <sprcy:SquareMeters
      contextRef="c212"
      decimals="0"
      id="ixv-38288"
      unitRef="pure">100</sprcy:SquareMeters>
    <sprcy:LeaseFee
      contextRef="c212"
      decimals="-3"
      id="ixv-38289"
      unitRef="usd">44000</sprcy:LeaseFee>
    <sprcy:ExpireTerm contextRef="c213" id="ixv-38290">2021-08-31</sprcy:ExpireTerm>
    <sprcy:SquareMeters
      contextRef="c214"
      decimals="0"
      id="ixv-38291"
      unitRef="pure">240</sprcy:SquareMeters>
    <sprcy:SquareMeters
      contextRef="c215"
      decimals="0"
      id="ixv-38292"
      unitRef="pure">120</sprcy:SquareMeters>
    <sprcy:LeaseFee
      contextRef="c214"
      decimals="-3"
      id="ixv-38293"
      unitRef="usd">40000</sprcy:LeaseFee>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory contextRef="c7" id="ixv-30579">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 10:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;PROPERTY AND EQUIPMENT, NET&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Assets owned and used by the Company&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Right-of-&lt;br/&gt; use assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Computers&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Lab&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Office&lt;br/&gt; furniture&lt;br/&gt; and&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Leasehold&lt;br/&gt; office&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; font-style: italic"&gt;Cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%; text-indent: -9pt; padding-left: 9pt"&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-238"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;29&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;78&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;114&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Purchases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-239"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-240"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-241"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;78&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;122&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Balance at January&#160;1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-242"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-243"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;43&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-244"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;59&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;65&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Depreciated cost at December 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-245"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;30&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;19&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;57&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Balance at January 1, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-246"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;New leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-247"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-248"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-249"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Purchases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-250"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-251"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Disposals&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(19&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(12&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(23&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-252"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(54&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-253"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;29&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;78&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;114&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Balance at January&#160;1, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-254"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Depreciation of leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-255"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-256"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-257"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-258"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-259"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Disposals&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(19&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(12&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(23&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-260"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(54&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-261"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Depreciated cost at December 31, 2021&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-262"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;58&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;92&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Depreciation expenses for the years
ended December 31, 2022, 2021 and 2020 amounted to $43, $32 and $7, respectively.&lt;/p&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory contextRef="c7" id="ixv-30589">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Assets owned and used by the Company&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Right-of-&lt;br/&gt; use assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Computers&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Lab&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Office&lt;br/&gt; furniture&lt;br/&gt; and&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Leasehold&lt;br/&gt; office&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; font-style: italic"&gt;Cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%; text-indent: -9pt; padding-left: 9pt"&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-238"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;29&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;78&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;114&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Purchases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-239"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-240"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-241"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;78&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;122&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Balance at January&#160;1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-242"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-243"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;43&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-244"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;59&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;65&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Depreciated cost at December 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-245"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;30&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;19&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;57&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Balance at January 1, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-246"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;New leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-247"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-248"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-249"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Purchases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-250"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-251"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Disposals&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(19&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(12&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(23&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-252"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(54&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-253"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;29&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;78&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;114&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Balance at January&#160;1, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-254"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Depreciation of leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-255"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-256"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-257"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-258"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-259"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Disposals&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(19&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(12&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(23&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-260"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(54&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-261"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Depreciated cost at December 31, 2021&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-262"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;58&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;92&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <sprcy:BeginningBalanceCost
      contextRef="c216"
      decimals="-3"
      id="ixv-38294"
      unitRef="usd">7000</sprcy:BeginningBalanceCost>
    <sprcy:BeginningBalanceCost
      contextRef="c218"
      decimals="-3"
      id="ixv-38295"
      unitRef="usd">29000</sprcy:BeginningBalanceCost>
    <sprcy:BeginningBalanceCost
      contextRef="c219"
      decimals="-3"
      id="ixv-38296"
      unitRef="usd">78000</sprcy:BeginningBalanceCost>
    <sprcy:BeginningBalanceCost
      contextRef="c220"
      decimals="-3"
      id="ixv-38297"
      unitRef="usd">114000</sprcy:BeginningBalanceCost>
    <sprcy:PurchasesOfCost
      contextRef="c221"
      decimals="-3"
      id="ixv-38298"
      unitRef="usd">4000</sprcy:PurchasesOfCost>
    <sprcy:PurchasesOfCost
      contextRef="c223"
      decimals="-3"
      id="ixv-38299"
      unitRef="usd">4000</sprcy:PurchasesOfCost>
    <sprcy:PurchasesOfCost
      contextRef="c224"
      decimals="-3"
      id="ixv-38300"
      unitRef="usd">8000</sprcy:PurchasesOfCost>
    <sprcy:BeginningBalanceCost
      contextRef="c221"
      decimals="-3"
      id="ixv-38301"
      unitRef="usd">11000</sprcy:BeginningBalanceCost>
    <sprcy:BeginningBalanceCost
      contextRef="c223"
      decimals="-3"
      id="ixv-38302"
      unitRef="usd">33000</sprcy:BeginningBalanceCost>
    <sprcy:BeginningBalanceCost
      contextRef="c198"
      decimals="-3"
      id="ixv-38303"
      unitRef="usd">78000</sprcy:BeginningBalanceCost>
    <sprcy:BeginningBalanceCost
      contextRef="c224"
      decimals="-3"
      id="ixv-38304"
      unitRef="usd">122000</sprcy:BeginningBalanceCost>
    <sprcy:PropertyPlantAndEquipmentCost
      contextRef="c216"
      decimals="-3"
      id="ixv-38305"
      unitRef="usd">1000</sprcy:PropertyPlantAndEquipmentCost>
    <sprcy:PropertyPlantAndEquipmentCost
      contextRef="c218"
      decimals="-3"
      id="ixv-38306"
      unitRef="usd">1000</sprcy:PropertyPlantAndEquipmentCost>
    <sprcy:PropertyPlantAndEquipmentCost
      contextRef="c219"
      decimals="-3"
      id="ixv-38307"
      unitRef="usd">20000</sprcy:PropertyPlantAndEquipmentCost>
    <sprcy:PropertyPlantAndEquipmentCost
      contextRef="c220"
      decimals="-3"
      id="ixv-38308"
      unitRef="usd">22000</sprcy:PropertyPlantAndEquipmentCost>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c193"
      decimals="-3"
      id="ixv-38309"
      unitRef="usd">2000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c226"
      decimals="-3"
      id="ixv-38310"
      unitRef="usd">2000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c197"
      decimals="-3"
      id="ixv-38311"
      unitRef="usd">39000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c227"
      decimals="-3"
      id="ixv-38312"
      unitRef="usd">43000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <sprcy:PropertyPlantAndEquipmentCost
      contextRef="c221"
      decimals="-3"
      id="ixv-38313"
      unitRef="usd">3000</sprcy:PropertyPlantAndEquipmentCost>
    <sprcy:PropertyPlantAndEquipmentCost
      contextRef="c223"
      decimals="-3"
      id="ixv-38314"
      unitRef="usd">3000</sprcy:PropertyPlantAndEquipmentCost>
    <sprcy:PropertyPlantAndEquipmentCost
      contextRef="c198"
      decimals="-3"
      id="ixv-38315"
      unitRef="usd">59000</sprcy:PropertyPlantAndEquipmentCost>
    <sprcy:PropertyPlantAndEquipmentCost
      contextRef="c224"
      decimals="-3"
      id="ixv-38316"
      unitRef="usd">65000</sprcy:PropertyPlantAndEquipmentCost>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated
      contextRef="c221"
      decimals="-3"
      id="ixv-38317"
      unitRef="usd">8000</ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated
      contextRef="c223"
      decimals="-3"
      id="ixv-38318"
      unitRef="usd">30000</ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated
      contextRef="c198"
      decimals="-3"
      id="ixv-38319"
      unitRef="usd">19000</ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated
      contextRef="c224"
      decimals="-3"
      id="ixv-38320"
      unitRef="usd">57000</ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated>
    <sprcy:BeginningBalanceCost
      contextRef="c228"
      decimals="-3"
      id="ixv-38321"
      unitRef="usd">20000</sprcy:BeginningBalanceCost>
    <sprcy:BeginningBalanceCost
      contextRef="c229"
      decimals="-3"
      id="ixv-38322"
      unitRef="usd">12000</sprcy:BeginningBalanceCost>
    <sprcy:BeginningBalanceCost
      contextRef="c230"
      decimals="-3"
      id="ixv-38323"
      unitRef="usd">23000</sprcy:BeginningBalanceCost>
    <sprcy:BeginningBalanceCost
      contextRef="c232"
      decimals="-3"
      id="ixv-38324"
      unitRef="usd">55000</sprcy:BeginningBalanceCost>
    <sprcy:NewLeases
      contextRef="c219"
      decimals="-3"
      id="ixv-38325"
      unitRef="usd">78000</sprcy:NewLeases>
    <sprcy:NewLeases
      contextRef="c220"
      decimals="-3"
      id="ixv-38326"
      unitRef="usd">78000</sprcy:NewLeases>
    <sprcy:PurchasesOfCost
      contextRef="c216"
      decimals="-3"
      id="ixv-38327"
      unitRef="usd">6000</sprcy:PurchasesOfCost>
    <sprcy:PurchasesOfCost
      contextRef="c218"
      decimals="-3"
      id="ixv-38328"
      unitRef="usd">29000</sprcy:PurchasesOfCost>
    <sprcy:PurchasesOfCost
      contextRef="c220"
      decimals="-3"
      id="ixv-38329"
      unitRef="usd">35000</sprcy:PurchasesOfCost>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="c233"
      decimals="-3"
      id="ixv-38330"
      unitRef="usd">19000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="c234"
      decimals="-3"
      id="ixv-38331"
      unitRef="usd">12000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="c235"
      decimals="-3"
      id="ixv-38332"
      unitRef="usd">23000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="c237"
      decimals="-3"
      id="ixv-38333"
      unitRef="usd">54000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <sprcy:BeginningBalanceCost
      contextRef="c216"
      decimals="-3"
      id="ixv-38334"
      unitRef="usd">7000</sprcy:BeginningBalanceCost>
    <sprcy:BeginningBalanceCost
      contextRef="c218"
      decimals="-3"
      id="ixv-38335"
      unitRef="usd">29000</sprcy:BeginningBalanceCost>
    <sprcy:BeginningBalanceCost
      contextRef="c219"
      decimals="-3"
      id="ixv-38336"
      unitRef="usd">78000</sprcy:BeginningBalanceCost>
    <sprcy:BeginningBalanceCost
      contextRef="c220"
      decimals="-3"
      id="ixv-38337"
      unitRef="usd">114000</sprcy:BeginningBalanceCost>
    <sprcy:PropertyPlantAndEquipmentCost
      contextRef="c228"
      decimals="-3"
      id="ixv-38338"
      unitRef="usd">19000</sprcy:PropertyPlantAndEquipmentCost>
    <sprcy:PropertyPlantAndEquipmentCost
      contextRef="c229"
      decimals="-3"
      id="ixv-38339"
      unitRef="usd">12000</sprcy:PropertyPlantAndEquipmentCost>
    <sprcy:PropertyPlantAndEquipmentCost
      contextRef="c230"
      decimals="-3"
      id="ixv-38340"
      unitRef="usd">13000</sprcy:PropertyPlantAndEquipmentCost>
    <sprcy:PropertyPlantAndEquipmentCost
      contextRef="c232"
      decimals="-3"
      id="ixv-38341"
      unitRef="usd">44000</sprcy:PropertyPlantAndEquipmentCost>
    <sprcy:AccumulatedTerminationOfLeases
      contextRef="c236"
      decimals="-3"
      id="ixv-38342"
      unitRef="usd">20000</sprcy:AccumulatedTerminationOfLeases>
    <sprcy:AccumulatedTerminationOfLeases
      contextRef="c237"
      decimals="-3"
      id="ixv-38343"
      unitRef="usd">20000</sprcy:AccumulatedTerminationOfLeases>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c233"
      decimals="-3"
      id="ixv-38344"
      unitRef="usd">1000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c235"
      decimals="-3"
      id="ixv-38345"
      unitRef="usd">11000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c237"
      decimals="-3"
      id="ixv-38346"
      unitRef="usd">12000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="c233"
      decimals="-3"
      id="ixv-38347"
      unitRef="usd">19000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="c234"
      decimals="-3"
      id="ixv-38348"
      unitRef="usd">12000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="c235"
      decimals="-3"
      id="ixv-38349"
      unitRef="usd">23000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="c237"
      decimals="-3"
      id="ixv-38350"
      unitRef="usd">54000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <sprcy:PropertyPlantAndEquipmentCost
      contextRef="c216"
      decimals="-3"
      id="ixv-38351"
      unitRef="usd">1000</sprcy:PropertyPlantAndEquipmentCost>
    <sprcy:PropertyPlantAndEquipmentCost
      contextRef="c219"
      decimals="-3"
      id="ixv-38352"
      unitRef="usd">20000</sprcy:PropertyPlantAndEquipmentCost>
    <sprcy:PropertyPlantAndEquipmentCost
      contextRef="c220"
      decimals="-3"
      id="ixv-38353"
      unitRef="usd">22000</sprcy:PropertyPlantAndEquipmentCost>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated
      contextRef="c216"
      decimals="-3"
      id="ixv-38354"
      unitRef="usd">6000</ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated
      contextRef="c218"
      decimals="-3"
      id="ixv-38355"
      unitRef="usd">28000</ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated
      contextRef="c219"
      decimals="-3"
      id="ixv-38356"
      unitRef="usd">58000</ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated
      contextRef="c220"
      decimals="-3"
      id="ixv-38357"
      unitRef="usd">92000</ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated>
    <ifrs-full:DepreciationExpense contextRef="c7" decimals="-3" id="ixv-38358" unitRef="usd">43000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c11" decimals="-3" id="ixv-38359" unitRef="usd">32000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c12" decimals="-3" id="ixv-38360" unitRef="usd">7000</ifrs-full:DepreciationExpense>
    <ifrs-full:DisclosureOfIntangibleAssetsExplanatory contextRef="c7" id="ixv-31309">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 11:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;INTANGIBLE ASSET&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify"&gt;On September 30, 2022, the Company announced
the closing of the acquisition of Wellution&lt;sup&gt;TM&lt;/sup&gt;, a top seller Amazon.com Marketplace account (the &#x201c;Brand&#x201d;), American
food supplements and cosmetics brand and trademark (the &#x201c;Acquisition&#x201d;). In connection with the Acquisition, the Company incorporated
a new wholly owned Delaware subsidiary, SciSparc Nutraceuticals Inc., to hold the new assets. The definitive agreement for the acquisition
of the Brand was entered into with Merhavit M.R.M Holding and Management Ltd (&#x201c;M.R.M&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;At the closing, the Company paid a
base cash payment of $4,540 and in 12 months following the closing agreed to pay an additional deferred cash payment equal to a multiple
of 3 times the amount by which the Brand&#x2019;s EBITDA exceeds $1,120 during the 12-month period following the closing of the Acquisition.
The Company paid an additional $321 as purchase costs.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In addition, the Company issued to
M.R.M $15,000 worth of warrants to purchase ordinary shares of the Company at an exercise price of $7.00 per share (with a cashless exercise
mechanism) and with an exercise period of five years from the closing of the Acquisition (the &#x201c;September 2022 Warrants&#x201d;).
The September 2022 Warrants will become exercisable upon the earlier of (i) an achievement of $100 million of gross sales by the Brand
in the aggregate or (ii) if the price of our Ordinary Shares closes at $10.00 or above.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company reviewed the transaction
and deemed it to be the purchase of assets for accounting purposes under generally accepted accounting principles and not as a business
combination. The Company reviewed the guidance under IFRS 3 for the transaction and determined that the fair value of the gross assets
acquired was concentrated in a single identifiable asset, a brand. Accordingly, the Company treated the transaction as an asset acquisition.
On the closing date of the acquisition, the Company fully recognized the acquisition amount total of $4,861 as an intangible asset, to
be amortized over a period of 10 years.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"&gt;The table below
summarizes the fair value of the intangible asset:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-263"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 88%"&gt;Purchase date September 30, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Depreciation of intangible asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(144&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,717&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;During the year ended December 31,
2022, the Company recognized depreciation expenses in respect to intangible asset in the amount of $144.&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The estimated fair values of the tangible
and intangible assets in respect of the acquisition of&#160;the Wellution&#x2122; brand are provisional and are based on information that
was available as of the acquisition date to estimate the fair value of these amounts. The Group&#x2019;s management believes the information
provides a reasonable basis for estimating the fair values of these amounts but is waiting for additional information necessary to finalize
those fair values. Therefore, provisional measurements of fair value that appear are subject to change. The Group expects to finalize
the tangible and intangible assets valuation and complete the acquisition accounting as soon as practicable but no later than the measurement
period.&lt;/p&gt;</ifrs-full:DisclosureOfIntangibleAssetsExplanatory>
    <sprcy:CashPayment contextRef="c7" decimals="-3" id="ixv-38361" unitRef="usd">4540000</sprcy:CashPayment>
    <ifrs-full:AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount contextRef="c4" decimals="-3" id="ixv-38362" unitRef="usd">1120000</ifrs-full:AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount>
    <sprcy:PurchaseCosts contextRef="c7" decimals="-3" id="ixv-38363" unitRef="usd">321000</sprcy:PurchaseCosts>
    <sprcy:WarrantsToPurchase contextRef="c7" decimals="-3" id="ixv-38364" unitRef="usd">15000000</sprcy:WarrantsToPurchase>
    <sprcy:ExercisePrice1
      contextRef="c7"
      decimals="2"
      id="ixv-38365"
      unitRef="usdPershares">7</sprcy:ExercisePrice1>
    <sprcy:ExercisePeriod contextRef="c7" id="ixv-38366">P5Y</sprcy:ExercisePeriod>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c7" decimals="-6" id="ixv-38367" unitRef="usd">100000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <sprcy:pricePerShare
      contextRef="c7"
      decimals="2"
      id="ixv-38368"
      unitRef="usdPershares">10</sprcy:pricePerShare>
    <sprcy:AmountTotal contextRef="c7" decimals="-3" id="ixv-38369" unitRef="usd">4861000</sprcy:AmountTotal>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="c7" id="ixv-38370">P10Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <sprcy:ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock contextRef="c7" id="ixv-38371">The table below
summarizes the fair value of the intangible asset:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-263"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 88%"&gt;Purchase date September 30, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Depreciation of intangible asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(144&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,717&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:ScheduleOfFairValueOfTheIntangibleAssetTableTextBlock>
    <sprcy:PurchaseofAssets contextRef="c7" decimals="-3" id="ixv-38372" unitRef="usd">4861000</sprcy:PurchaseofAssets>
    <ifrs-full:IntangibleAssetFairValueUsedAsDeemedCost contextRef="c4" decimals="-3" id="ixv-38373" unitRef="usd">144000</ifrs-full:IntangibleAssetFairValueUsedAsDeemedCost>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c4" decimals="-3" id="ixv-38374" unitRef="usd">4717000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c7" decimals="-3" id="ixv-38375" unitRef="usd">144000</ifrs-full:ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory contextRef="c7" id="ixv-31412">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 12:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;TRADE PAYABLES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 78%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;901&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;758&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Open debts&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;298&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;441&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,199&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,199&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <sprcy:DisclosureOfTradePayables contextRef="c7" id="ixv-31422">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 78%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;901&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;758&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Open debts&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;298&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;441&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,199&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,199&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfTradePayables>
    <sprcy:AccruedExpenses contextRef="c4" decimals="-3" id="ixv-38376" unitRef="usd">901000</sprcy:AccruedExpenses>
    <sprcy:AccruedExpenses contextRef="c5" decimals="-3" id="ixv-38377" unitRef="usd">758000</sprcy:AccruedExpenses>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c4" decimals="-3" id="ixv-38378" unitRef="usd">298000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c5" decimals="-3" id="ixv-38379" unitRef="usd">441000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c4" decimals="-3" id="ixv-38380" unitRef="usd">1199000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c5" decimals="-3" id="ixv-38381" unitRef="usd">1199000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <sprcy:DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent contextRef="c7" id="ixv-31526">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 13:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;OTHER ACCOUNTS PAYABLE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Employees and payroll accruals&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;102&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;45&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Accrued vacation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Other payables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;71&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;193&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;154&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrent>
    <sprcy:ScheduleOfOtherAccountsPayable contextRef="c7" id="ixv-31536">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Employees and payroll accruals&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;102&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;45&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Accrued vacation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Other payables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;71&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;193&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;154&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:ScheduleOfOtherAccountsPayable>
    <ifrs-full:ShorttermEmployeeBenefitsAccruals contextRef="c4" decimals="-3" id="ixv-38382" unitRef="usd">102000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
    <ifrs-full:ShorttermEmployeeBenefitsAccruals contextRef="c5" decimals="-3" id="ixv-38383" unitRef="usd">45000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
    <ifrs-full:Accruals contextRef="c4" decimals="-3" id="ixv-38384" unitRef="usd">77000</ifrs-full:Accruals>
    <ifrs-full:Accruals contextRef="c5" decimals="-3" id="ixv-38385" unitRef="usd">38000</ifrs-full:Accruals>
    <ifrs-full:OtherPayables contextRef="c4" decimals="-3" id="ixv-38386" unitRef="usd">14000</ifrs-full:OtherPayables>
    <ifrs-full:OtherPayables contextRef="c5" decimals="-3" id="ixv-38387" unitRef="usd">71000</ifrs-full:OtherPayables>
    <sprcy:TradeAndOtherPayable contextRef="c4" decimals="-3" id="ixv-38388" unitRef="usd">193000</sprcy:TradeAndOtherPayable>
    <sprcy:TradeAndOtherPayable contextRef="c5" decimals="-3" id="ixv-38389" unitRef="usd">154000</sprcy:TradeAndOtherPayable>
    <ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory contextRef="c7" id="ixv-31604">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 14:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;FINANCIAL INSTRUMENTS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Classification of financial assets and financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;The financial assets and financial liabilities
in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9, &#x201c;&lt;i&gt;Financial
Instruments&lt;/i&gt;&#x201d; (&#x201c;IFRS 9&#x201d;):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic"&gt;Financial assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Cash and restricted deposits&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,634&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,920&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Government authorities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other receivables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;46&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,504&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Investments in financial assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;591&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-264"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total financial assets at amortized cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,316&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,476&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;Financial liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Credit from others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrants liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,737&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;359&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total financial and lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,866&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;422&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;USD in thousands (except share data)&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 14:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;FINANCIAL INSTRUMENTS (CONT.)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px"&gt;b&lt;span style="font-size: 10pt"&gt;.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Bridge Loan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;On January 15, 2020, the Company entered
into a bridge loan agreement (the &#x201c;Bridge Loan&#x201d;) with a third party, in which the third party lent to the Company $50 (the
&#x201c;Bridge Loan Amount&#x201d;). On April 17, 2020, the Bridge Loan Amount was fully repaid by the Company, including interest in the
amount of $2. Accordingly, the Bridge Loan was terminated with no further effect.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px"&gt;c&lt;span style="font-size: 10pt"&gt;.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Line of Credit&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;On September 8, 2020, the Company entered
into a certain credit agreement (the &#x201c;Credit Facility&#x201d;), with M.R.M. Merchavit Holdings and Management Ltd. (the &#x201c;Lender&#x201d;),
whereby the Lender agreed to extend a line of credit to the Company in the aggregate amount of $200, or the Credit Amount. According to
the terms of the Credit Facility, $100 of the Credit Amount (the &#x201c;Loan Amount&#x201d;), was immediately drawn on the date of the
Credit Facility, and the remaining $100 was available be drawn on an as-needed basis. The Loan Amount was due upon the earlier of one
year from September 8, 2020 or at such time that the Company raised $1,500. The Lender was entitled to a transaction and interest fee
of $5 (plus VAT) that was offset from the Credit Facility for the immediately drawn $100 and 5% from any additional withdrawal amount
from the Credit Facility. On November 24, 2020, the Loan Amount was fully repaid by the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px"&gt;d&lt;span style="font-size: 10pt"&gt;.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Dekel&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;On March 19, 2020, the Company entered
into a securities purchase agreement with Dekel Pharmaceutical Ltd. (&#x201c;Dekel&#x201d;) pursuant to which Dekel agreed to invest in
the Company through a private placement transaction (the &#x201c;Private Placement&#x201d;). At the time of the Private Placement, Dekel
was considered as a related party to the Company; however, it is no longer a related party to the Company. In connection with the Private
Placement, Dekel received convertible promissory notes (the &#x201c;Notes&#x201d;), with an aggregate original principal amount of approximately
$350, at an aggregate purchase price of $315 to be paid in several tranches spread across a twelve-month period. In addition, the Company
issued a warrant to purchase up to 314,285 ordinary shares of the Company (the &#x201c;Private Placement Warrant&#x201d;) and 40,000 ordinary
shares. The initial tranche of the Private Placement was for a principal amount of $220 at a purchase price of $198. The Notes are unsecured,
have a maturity date of March 23, 2021, bear interest at a rate of 12% per annum, and may be converted, at the election of the holder,
into ordinary shares at an initial conversion price of $0.35 per ordinary share (the &#x201c;Fixed Conversion Price&#x201d;), subject to
adjustments. After the six-month anniversary of the issuance of the Notes, the conversion price shall be equal to the lower of the Fixed
Conversion Price or 70% of the lowest trading price of the ordinary shares as reported on Nasdaq or any exchange upon which the ordinary
shares of the Company are traded at such time, for the 20 prior trading days including the day upon which a notice of conversion is received
by the Company or its transfer agent. The Private Placement Warrant is exercisable at any time on or after the actual closing date and
on or prior to the close of business on the five-year anniversary of the date of issuance, at an initial exercise price of $0.35 per ordinary
share, subject to adjustment. On November 8, 2020, the Notes were terminated and the initial tranche was fully repaid by the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&lt;i&gt;General Overview of Valuation Approaches
used in the Valuation:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;Fair value is the price that would be
received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&lt;i&gt;Economic methodology:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;The warrants&#x2019; fair value was calculated
using the Black&#x2013;Scholes OPM, which takes into account the parameters as disclosed below for each period valuated, in which a valuation
was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;23,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;148&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.87&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Underlying Share Price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.756&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants fair value ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;e&lt;span style="font-size: 10pt"&gt;.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial risk factors:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;The Company&#x2019;s activities expose
it to various financial risks such as market risks (foreign currency risk and interest risk), credit risk and liquidity risk. The Company&#x2019;s
comprehensive risk management plan focuses on activities that reduce to a minimum any possible adverse effects on the Company&#x2019;s
financial performance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;Risk management is performed by management
in accordance with the policies approved by the Company&#x2019;s board of directors (the &#x201c;Board&#x201d;). The Board establishes written
principles for the overall risk management activities as well as specific policies with respect to certain exposures to risks such as
exchange rate risk, credit risk and the investments of surplus funds.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Market risks:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;&lt;i&gt;Foreign currency risk:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;The Company is exposed to exchange rate
risk resulting from the exposure to different currencies, mainly from transactions in NIS. Exchange rate risk arises from recognized liabilities
that are denominated in a foreign currency other than the functional currency.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Credit risks:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;All cash and restricted deposits related
to the Company are held in two banks in Israel which are considered financially solid.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Liquidity risk:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;The Company monitors the risk of a shortage
of funds on a regular basis and acts to raise funds to satisfy its liabilities. As of December 31, 2022, the Company expects to settle
all of its financial liabilities in less than one year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;The carrying amounts of cash and restricted
deposits, and all other financial assets and liabilities approximate their fair value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;Refer to Note 1c for more information.&lt;/p&gt;</ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory>
    <sprcy:DisclosureOfFinancialAssetsAndFinancialLiabilities contextRef="c7" id="ixv-31623">The financial assets and financial liabilities
in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9, &#x201c;&lt;i&gt;Financial
Instruments&lt;/i&gt;&#x201d; (&#x201c;IFRS 9&#x201d;):&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic"&gt;Financial assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Cash and restricted deposits&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,634&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,920&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Government authorities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other receivables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;46&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,504&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Investments in financial assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;591&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-264"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total financial assets at amortized cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,316&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,476&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;Financial liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Credit from others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrants liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,737&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;359&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total financial and lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,866&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;422&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</sprcy:DisclosureOfFinancialAssetsAndFinancialLiabilities>
    <ifrs-full:RestrictedCashAndCashEquivalents contextRef="c4" decimals="-3" id="ixv-38390" unitRef="usd">3634000</ifrs-full:RestrictedCashAndCashEquivalents>
    <ifrs-full:RestrictedCashAndCashEquivalents contextRef="c5" decimals="-3" id="ixv-38391" unitRef="usd">6920000</ifrs-full:RestrictedCashAndCashEquivalents>
    <sprcy:GovernmentAuthorities contextRef="c4" decimals="-3" id="ixv-38392" unitRef="usd">45000</sprcy:GovernmentAuthorities>
    <sprcy:GovernmentAuthorities contextRef="c5" decimals="-3" id="ixv-38393" unitRef="usd">52000</sprcy:GovernmentAuthorities>
    <ifrs-full:OtherReceivables contextRef="c4" decimals="-3" id="ixv-38394" unitRef="usd">46000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables contextRef="c5" decimals="-3" id="ixv-38395" unitRef="usd">2504000</ifrs-full:OtherReceivables>
    <sprcy:InvestmentsInFinancialAssets contextRef="c4" decimals="-3" id="ixv-38396" unitRef="usd">591000</sprcy:InvestmentsInFinancialAssets>
    <ifrs-full:CurrentFinancialAssetsAtAmortisedCost contextRef="c4" decimals="-3" id="ixv-38397" unitRef="usd">4316000</ifrs-full:CurrentFinancialAssetsAtAmortisedCost>
    <ifrs-full:CurrentFinancialAssetsAtAmortisedCost contextRef="c5" decimals="-3" id="ixv-38398" unitRef="usd">9476000</ifrs-full:CurrentFinancialAssetsAtAmortisedCost>
    <sprcy:CreditsFromOthers contextRef="c4" decimals="-3" id="ixv-38399" unitRef="usd">102000</sprcy:CreditsFromOthers>
    <sprcy:CreditsFromOthers contextRef="c5" decimals="-3" id="ixv-38400" unitRef="usd">45000</sprcy:CreditsFromOthers>
    <sprcy:WarrantsLiability contextRef="c4" decimals="-3" id="ixv-38401" unitRef="usd">2737000</sprcy:WarrantsLiability>
    <sprcy:WarrantsLiability contextRef="c5" decimals="-3" id="ixv-38402" unitRef="usd">359000</sprcy:WarrantsLiability>
    <ifrs-full:LeaseLiabilities contextRef="c4" decimals="-3" id="ixv-38403" unitRef="usd">27000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c5" decimals="-3" id="ixv-38404" unitRef="usd">18000</ifrs-full:LeaseLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c4" decimals="-3" id="ixv-38405" unitRef="usd">2866000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c5" decimals="-3" id="ixv-38406" unitRef="usd">422000</ifrs-full:FinancialLiabilities>
    <sprcy:BridgeLoanAmount
      contextRef="c238"
      decimals="-3"
      id="ixv-38407"
      unitRef="usd">50000</sprcy:BridgeLoanAmount>
    <ifrs-full:InterestPayable
      contextRef="c239"
      decimals="-3"
      id="ixv-38408"
      unitRef="usd">2000</ifrs-full:InterestPayable>
    <sprcy:AggregateAmountOrCreditAmount
      contextRef="c240"
      decimals="-3"
      id="ixv-38409"
      unitRef="usd">200000</sprcy:AggregateAmountOrCreditAmount>
    <sprcy:CreditFacilityAmount
      contextRef="c240"
      decimals="-3"
      id="ixv-38410"
      unitRef="usd">100000</sprcy:CreditFacilityAmount>
    <sprcy:CreditFacilityAndRemainingAvailableDrawnAmount
      contextRef="c240"
      decimals="-3"
      id="ixv-38411"
      unitRef="usd">100000</sprcy:CreditFacilityAndRemainingAvailableDrawnAmount>
    <sprcy:LoanAmountDueTerm contextRef="c240" id="ixv-38412">P1Y</sprcy:LoanAmountDueTerm>
    <sprcy:LoanAmountRaised
      contextRef="c240"
      decimals="-3"
      id="ixv-38413"
      unitRef="usd">1500000</sprcy:LoanAmountRaised>
    <ifrs-full:DisclosureOfCompoundFinancialInstrumentsWithMultipleEmbeddedDerivativesExplanatory contextRef="c240" id="ixv-38414">The Lender was entitled to a transaction and interest fee
of $5 (plus VAT) that was offset from the Credit Facility for the immediately drawn $100 and 5% from any additional withdrawal amount
from the Credit Facility. On November 24, 2020, the Loan Amount was fully repaid by the Company.</ifrs-full:DisclosureOfCompoundFinancialInstrumentsWithMultipleEmbeddedDerivativesExplanatory>
    <ifrs-full:CashOutflowForLeases
      contextRef="c241"
      decimals="-3"
      id="ixv-38415"
      unitRef="usd">350000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash
      contextRef="c242"
      decimals="-3"
      id="ixv-38416"
      unitRef="usd">315000</ifrs-full:PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c242"
      decimals="0"
      id="ixv-38417"
      unitRef="shares">314285</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c243"
      decimals="0"
      id="ixv-38418"
      unitRef="shares">40000</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:CashOutflowForLeases
      contextRef="c244"
      decimals="-3"
      id="ixv-38419"
      unitRef="usd">220000</ifrs-full:CashOutflowForLeases>
    <sprcy:PurchasePrice
      contextRef="c244"
      decimals="-3"
      id="ixv-38420"
      unitRef="usd">198000</sprcy:PurchasePrice>
    <sprcy:MaturityDate contextRef="c241" id="ixv-38421">2021-03-23</sprcy:MaturityDate>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c242"
      decimals="2"
      id="ixv-38422"
      unitRef="pure">0.12</ifrs-full:BorrowingsInterestRate>
    <sprcy:InitialConversionPrice
      contextRef="c242"
      decimals="2"
      id="ixv-38423"
      unitRef="usdPershares">0.35</sprcy:InitialConversionPrice>
    <sprcy:ConversionPrice
      contextRef="c241"
      decimals="2"
      id="ixv-38424"
      unitRef="pure">0.70</sprcy:ConversionPrice>
    <sprcy:OrdinaryShareExercisePrice
      contextRef="c241"
      decimals="2"
      id="ixv-38425"
      unitRef="usdPershares">0.35</sprcy:OrdinaryShareExercisePrice>
    <sprcy:ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock contextRef="c7" id="ixv-38426">The warrants&#x2019; fair value was calculated
using the Black&#x2013;Scholes OPM, which takes into account the parameters as disclosed below for each period valuated, in which a valuation
was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;23,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;148&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.87&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Underlying Share Price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.756&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants fair value ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock>
    <sprcy:DividendYield contextRef="c7" decimals="2" id="ixv-38427" unitRef="pure">0</sprcy:DividendYield>
    <sprcy:DividendYield contextRef="c11" decimals="2" id="ixv-38428" unitRef="pure">0</sprcy:DividendYield>
    <sprcy:DividendYield
      contextRef="c245"
      decimals="2"
      id="ixv-38429"
      unitRef="pure">0</sprcy:DividendYield>
    <sprcy:ExpectedVolatility contextRef="c7" decimals="2" id="ixv-38430" unitRef="pure">0.72</sprcy:ExpectedVolatility>
    <sprcy:ExpectedVolatility contextRef="c11" decimals="2" id="ixv-38431" unitRef="pure">1.48</sprcy:ExpectedVolatility>
    <sprcy:ExpectedVolatility
      contextRef="c245"
      decimals="4"
      id="ixv-38432"
      unitRef="pure">1.2201</sprcy:ExpectedVolatility>
    <sprcy:RiskFreeInterestRate contextRef="c7" decimals="4" id="ixv-38433" unitRef="pure">0.04</sprcy:RiskFreeInterestRate>
    <sprcy:RiskFreeInterestRate contextRef="c11" decimals="4" id="ixv-38434" unitRef="pure">0.0087</sprcy:RiskFreeInterestRate>
    <sprcy:RiskFreeInterestRate
      contextRef="c245"
      decimals="4"
      id="ixv-38435"
      unitRef="pure">0.0038</sprcy:RiskFreeInterestRate>
    <sprcy:UnderlyingAdsPrice
      contextRef="c7"
      decimals="3"
      id="ixv-38436"
      unitRef="usdPershares">0.756</sprcy:UnderlyingAdsPrice>
    <sprcy:UnderlyingAdsPrice
      contextRef="c11"
      decimals="2"
      id="ixv-38437"
      unitRef="usdPershares">6.23</sprcy:UnderlyingAdsPrice>
    <sprcy:UnderlyingAdsPrice
      contextRef="c245"
      decimals="2"
      id="ixv-38438"
      unitRef="usdPershares">0.43</sprcy:UnderlyingAdsPrice>
    <sprcy:ExercisePricePerShare
      contextRef="c7"
      decimals="2"
      id="ixv-38439"
      unitRef="usdPershares">24.5</sprcy:ExercisePricePerShare>
    <sprcy:ExercisePricePerShare
      contextRef="c11"
      decimals="2"
      id="ixv-38440"
      unitRef="usdPershares">24.5</sprcy:ExercisePricePerShare>
    <sprcy:ExercisePricePerShare
      contextRef="c245"
      decimals="2"
      id="ixv-38441"
      unitRef="usdPershares">24.5</sprcy:ExercisePricePerShare>
    <sprcy:WarrantsFairValueinDollarsPerShares
      contextRef="c7"
      decimals="0"
      id="ixv-38442"
      unitRef="usdPershares">0</sprcy:WarrantsFairValueinDollarsPerShares>
    <sprcy:WarrantsFairValueinDollarsPerShares
      contextRef="c11"
      decimals="2"
      id="ixv-38443"
      unitRef="usdPershares">4.15</sprcy:WarrantsFairValueinDollarsPerShares>
    <sprcy:WarrantsFairValueinDollarsPerShares
      contextRef="c245"
      decimals="2"
      id="ixv-38444"
      unitRef="usdPershares">0.36</sprcy:WarrantsFairValueinDollarsPerShares>
    <ifrs-full:DisclosureOfEmployeeBenefitsExplanatory contextRef="c7" id="ixv-32105">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 15:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;EMPLOYEE BENEFIT LIABILITIES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify"&gt;Employee benefits consist of short-term
benefits and post-employment benefits.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify"&gt;&lt;i&gt;Post-employment benefits:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify"&gt;According to the labor laws and the Israeli
Severance Pay Law, 1963 (the &#x201c;Severance Pay Law&#x201d;), the Company is required to pay compensation to an employee upon dismissal
or retirement or to make current contributions in defined contribution plans pursuant to Section 14 of the Severance Pay Law, as specified
below. The Company&#x2019;s liability is accounted for as a post-employment benefit. The computation of the Company&#x2019;s employee benefit
liability is made in accordance with a valid employment contract based on the employee&#x2019;s salary and employment term which establish
the entitlement to receive the compensation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify"&gt;The post-employment benefits are normally
financed by contributions classified as defined benefit plans or as defined contribution plans as detailed below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify"&gt;&lt;i&gt;Defined contribution plans:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify"&gt;Section 14 of the Severance Pay Law applies
to a substantial part of the compensation payments, pursuant to which the fixed contributions paid by the Company into pension funds and/or
policies of insurance companies release the Company from any additional liability to employees for whom said contributions were made.
These contributions and contributions for compensation represent defined contribution plans.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Expenses in respect of defined contribution plans&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;115&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;98&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;52&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfEmployeeBenefitsExplanatory>
    <sprcy:DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory contextRef="c7" id="ixv-38445">These contributions and contributions for compensation represent defined contribution plans.&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Expenses in respect of defined contribution plans&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;115&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;98&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;52&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c7" decimals="-3" id="ixv-38446" unitRef="usd">115000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c11" decimals="-3" id="ixv-38447" unitRef="usd">98000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c12" decimals="-3" id="ixv-38448" unitRef="usd">52000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="c7" id="ixv-32164">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 16:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;TAXES ON INCOME&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Tax rates applicable to the Company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;The Israeli statutory corporate tax rate
and real capital gains tax rate were 23% in 2022, 2021, and 2020.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Tax assessments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The assessments of the Company are
deemed final through the 2016 tax year.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Carryforward tax losses and other temporary differences:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;The Company has accumulated tax losses
since its inception.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;As of December 31, 2022, the Company&#x2019;s
net carryforward tax losses are estimated to grow to approximately $58,000.&lt;/p&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <ifrs-full:ApplicableTaxRate contextRef="c7" decimals="2" id="ixv-38449" unitRef="pure">0.23</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate contextRef="c11" decimals="2" id="ixv-38450" unitRef="pure">0.23</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate contextRef="c12" decimals="2" id="ixv-38451" unitRef="pure">0.23</ifrs-full:ApplicableTaxRate>
    <sprcy:OperatingLossCarryforwardsTaxAmount contextRef="c4" decimals="-3" id="ixv-38452" unitRef="usd">58000000</sprcy:OperatingLossCarryforwardsTaxAmount>
    <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory contextRef="c7" id="ixv-32234">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; font-size: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 17:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; font-size: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;License Agreement with Dekel Pharmaceuticals Ltd.:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;In May 2015, the Company entered into
an exclusive, irrevocable, worldwide license agreement with Dekel for certain technology and one granted U.S. patent related to compositions
and methods for treating inflammatory disorders (the &#x201c;Dekel License Agreement&#x201d;). The Dekel License Agreement became effective
in August 2015.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;Pursuant to the Dekel License Agreement,
the Company is obligated to pay Dekel fees based on specific milestones and royalties upon commercialization. The milestone payments include:
(i) $25 upon the successful completion of preclinical trials (which milestone was met in November 2016; this milestone was paid in cash
in March 2017); (ii) $75 upon the successful completion of a Phase I/IIa trial; and (iii) $75 upon the earlier of generating net revenues
of at least $200 from the commercialization of the technology or the approval of the U.S. Food and Drug Administration or the European
Medicines Agency, of a drug based on the licensed assets. In each case, and subject to the Company&#x2019;s discretion, the respective
milestone payments are payable in cash or equity based on a price per ordinary share of NIS 0.5. The royalty payments are 8% for commercialization
and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of any patents maturing from this application would
likely be 2029.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;On July 14, 2019, an amendment to the
Dekel License Agreement was signed (the &#x201c;Amendment&#x201d;), which encompasses the Company and Dekel&#x2019;s original intention to
exclude certain consumer packaged goods (meaning, inter alia, food, beverage, cosmetics, pet products and hemp based products, which are
sources of nutrients or other substances which may have a nutritional effect) from the scope of the licensed products and the field of
activity of the Company described in the Dekel License Agreement. The parties agreed to amend the Dekel License Agreement to reflect the
foregoing clarification, as well as certain additional less material matters as discussed in the Amendment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;The Amendment also prescribes for a specific
development plan under the Dekel License Agreement requiring the Company to invest in the licensed technology (as defined under the License
Agreement) formulation development and maintenance a total annual investment to be capped at $350. The Amendment also included a non-compete
and non-solicitation obligation by Dekel and Dr. Ascher Shmulewitz, the Company&#x2019;s former Executive Chairman of the Board and former
interim Chief Executive Officer, towards the Company&#x2019;s field of activity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;On November 13, 2019, an additional milestone
under the Dekel License Agreement, in the amount of $75, was reached upon the successful completion of a Phase IIa clinical trial. The
Company paid the milestone amount on April 13, 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;License Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (&#x201c;Yissum&#x201d;):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;On July 29, 2018, the Company entered
into an exclusive, worldwide, sublicensable, royalty-bearing license with Yissum for a license to make commercial use of the licensed
technology, in order to develop, obtain regulatory approvals, manufacture, market, distribute or sell products, all within the field and
the territory only, as determined in the agreement (the &#x201c;Yissum License Agreement&#x201d;). According to the Yissum License Agreement,
the Company shall pay Yissum royalties at the rates of future net sales, subject to the royalty reductions as described in the Yissum
License Agreement. The Company is also obligated to pay sublicense fees out of the sublicense consideration. All right, title and interest
in and to the Yissum License Agreement shall vest solely in Yissum, and the Company shall hold and make use of the rights granted. All
rights in the development results shall be solely owned by the Company, except to the extent that an employee of Yissum, including the
researcher, is considered an inventor of a patentable invention arising from the development results, in which case such invention and
all patent applications and/or patents claiming such invention shall be owned jointly by the Company and Yissum, as appropriate, and Yissum&#x2019;s
share in such joint patents shall be automatically included in the Yissum License Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Agreement with Hannover Medical School:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;On April 11, 2017, the Company entered
into an investigator-initiated study contract with Hannover Medical School (&#x201c;MHH&#x201d;) to conduct during 2018 a phase IIb clinical
trial titled &#x201c;A Randomized, Double-Blind, Placebo controlled study to Evaluate the Safety, Tolerability and Efficacy of Up to Twice
Daily Oral SCI-110 in Treating Adults with Tourette Syndrome&#x201d; in treating approximately 20 Tourette syndrome subjects aged 18 to
65. Upon the execution of the agreement the Company paid the first installment in the amount of $122 out of a total estimated amount of
approximately $776. Due to regulatory and strategic reasons, the Company decided to change the study design from investigator-initiated
to an industry sponsored trial. During October 2017, a discussion was carried out between the Company and MHH and the latter was informed
about this change and a termination letter stating the above was sent to MHH on November 19, 2017. MHH has acknowledged that part of the
first instalment that was paid by the Company, in accordance with the initial agreement, will be used to set-off amounts owed under a
new agreement or will be paid back to the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;On August 13, 2018, the Company entered
into an agreement with MHH to conduct a clinical investigation and laboratory services for a randomized, double-blind, placebo-controlled
proof of concept study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating adults with Tourette syndrome,
which agreement was subsequently updated on December 2, 2021, in an estimated amount of $1,385.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Agreement with Yale University:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 27, 2022, the Company entered into an agreement with Yale University to conduct a clinical investigation and laboratory services for a randomized, double-blind, placebo-controlled, cross over study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating adults with Tourette syndrome in treating approximately 10 Tourette syndrome subjects aged 18 to 65. The total estimated amount of the agreement is approximately $370.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;e&lt;span style="font-size: 10pt"&gt;.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 23, 2020, the Company submitted to the Tel Aviv-Jaffa District Court (the &#x201c;Court&#x201d;) a petition pursuant to the Israeli Insolvency and Economic Rehabilitation Law, 2018, to commence proceedings for the economic rehabilitation of the Company (the &#x201c;Petition&#x201d;). In the Petition submitted to the Court, the Company stated that it is insolvent (as determined by the cash flow test) and unable to pay its debts to the Company&#x2019;s creditors.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 6, 2020, L.I.A. Pure Capital Ltd. (&#x201c;Pure Capital&#x201d;) filed with the Court a demand, requesting an order to have the results of the Company&#x2019;s annual general meeting held on August 4, 2020, declared invalid, mainly due to the Company&#x2019;s reliance on discretionary voting of the depositary bank for the Company&#x2019;s then outstanding ADSs. The Court asked for the Company and directors&#x2019; response by no later than August 13, 2020, which was subsequently extended.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 11, 2020, Pure Capital proposed to deposit $1,500 with the Company&#x2019;s temporary trustee nominated by the Court to cover and pay all of the Company&#x2019;s debts, without derogating from any other creditor&#x2019;s rights towards the Company (the &#x201c;Pure Capital Proposal&#x201d;). The Pure Capital Proposal was made subject to the replacement of the Company&#x2019;s Board as of the date of the Pure Capital Proposal (the &#x201c;Prior Board&#x201d;) with Pure Capital&#x2019;s designated nominees that were voted upon at the adjourned annual general meeting of the Company&#x2019;s shareholders on August 4, 2020 (as discussed below). The Court&#160;issued an order on August 14, 2020 (the &#x201c;Order&#x201d;), approving the Pure Capital Proposal and settlement agreement submitted to the Court by the parties thereto.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with the terms of the Order and following the deposit by Pure Capital, the Prior Board was replaced with: Itschak Shrem (chairman), Amity Weiss (also appointed to act as the Company&#x2019;s Chief Executive Officer), Moshe Revach, Lior Amit, Lior Vider and Liat Sidi. Following the issuance of the Order, a related case that was filed by Pure Capital with the Court was withdrawn as well.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 15, 2020, Mr. Lior Amit tendered his resignation from the Board and on March 13, 2022, Mr. Moshe Revach tendered his resignation from the Board and then later re-joined the Board in September 2022.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
    <sprcy:DekelLicenseAgreementDescription contextRef="c7" id="ixv-38453">(i) $25 upon the successful completion of preclinical trials (which milestone was met in November 2016; this milestone was paid in cash
in March 2017); (ii) $75 upon the successful completion of a Phase I/IIa trial; and (iii) $75 upon the earlier of generating net revenues
of at least $200 from the commercialization of the technology or the approval of the U.S. Food and Drug Administration or the European
Medicines Agency, of a drug based on the licensed assets. In each case, and subject to the Company&#x2019;s discretion, the respective
milestone payments are payable in cash or equity based on a price per ordinary share of NIS 0.5. The royalty payments are 8% for commercialization
and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of any patents maturing from this application would
likely be 2029.</sprcy:DekelLicenseAgreementDescription>
    <sprcy:AnnualInvestment contextRef="c7" decimals="-3" id="ixv-38454" unitRef="usd">350000</sprcy:AnnualInvestment>
    <sprcy:AdditionalMilestoneAmount
      contextRef="c246"
      decimals="-3"
      id="ixv-38455"
      unitRef="usd">75000</sprcy:AdditionalMilestoneAmount>
    <sprcy:InstallmentAmount
      contextRef="c247"
      decimals="-3"
      id="ixv-38456"
      unitRef="usd">122000</sprcy:InstallmentAmount>
    <sprcy:TotalAgreementEstimatingAmount
      contextRef="c247"
      decimals="-3"
      id="ixv-38457"
      unitRef="usd">776000</sprcy:TotalAgreementEstimatingAmount>
    <sprcy:TotalAgreementEstimatingAmount
      contextRef="c248"
      decimals="-3"
      id="ixv-38458"
      unitRef="usd">1385000</sprcy:TotalAgreementEstimatingAmount>
    <sprcy:TotalAgreementEstimatingAmount
      contextRef="c249"
      decimals="-3"
      id="ixv-38459"
      unitRef="usd">370000</sprcy:TotalAgreementEstimatingAmount>
    <sprcy:CapitalProposedToDeposit
      contextRef="c250"
      decimals="-3"
      id="ixv-38460"
      unitRef="usd">1500000</sprcy:CapitalProposedToDeposit>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="c7" id="ixv-32397">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 18:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;EQUITY&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Composition of share capital:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt;
2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and&lt;br/&gt;
outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and&lt;br/&gt;
outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; padding-bottom: 4pt"&gt;Ordinary shares&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;75,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;6,798,840&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;25,714,285&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;3,091,740&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&lt;i&gt;Reverse Share Splits&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;On September 17, 2020, the Company convened
a special general meeting of its shareholders, whereby the shareholders approved, inter alia, (i) an increase to the Company&#x2019;s share
capital from 500,000,000 ordinary shares to 750,000,000 ordinary shares; and (ii) a reverse split of the Company&#x2019;s share capital
up to a ratio of 20:1 (the &#x201c;Reverse Split&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;On October 16, 2020, the Company convened
a special general meeting of its shareholders, whereby the shareholders approved an increase to the Company&#x2019;s share capital from
750,000,000 ordinary shares to 1,800,000,000 ordinary shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;On October 1, 2020, the Company&#x2019;s
Board resolved that the final ratio for the Reverse Split will be 20:1, which went effective on October 16, 2020.&#160;Concurrently with
the Reverse Split, a change to the ratio of its ADSs to its ordinary shares was effective pursuant to which each ADS representing 40 ordinary
shares changed to each ADS representing 140 ordinary shares. This resulted in a reverse split on the Company&#x2019;s American Depositary
Receipt program.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;On March 2, 2021, the Company convened
a special general meeting of its shareholders, whereby the shareholders approved to eliminate the par value of the ordinary shares and
an increase to the Company&#x2019;s share capital from 1,800,000,000 ordinary shares to 3,600,000,000 ordinary shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&#160;On July 19, 2021, the Company&#x2019;s
Board resolved that the final ratio for the Second Reverse Split will be 140:1, which went effective on August 9, 2021.&#160;Concurrently
with the Second Reverse Split, a change to the ratio of its ADSs to its Ordinary Shares was effective pursuant to which each ADS representing
140 ordinary shares changed to each ADS representing 1 ordinary share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;Consequently, all share numbers, share
prices, and exercise prices have been retroactively adjusted in these consolidated financial statements for all periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;On September 15, 2022, the Company convened
an annual general meeting of its shareholders, whereby the shareholders approved to increase to the Company&#x2019;s share capital to 75,000,000
ordinary shares with no par value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Changes in share capital:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&lt;i&gt;Issued and outstanding share capital:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Number of&lt;br/&gt; ordinary&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;shares&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-indent: -9pt; padding-left: 9pt"&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,091,740&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Issuance of share capital &#x2013; June 2022 Financing Round (Note 18h)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;335,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Exercise of pre-funded warrants (Note 18g)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise of pre-funded warrants (Note 18h)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,211,100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Share issued to a consultant (Note 18f)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;61,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,798,840&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Rights attached to shares:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;Voting rights at the shareholders meeting,
right to dividends, rights upon liquidation of the Company and right to nominate the directors in the Company.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Capital management in the Company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;The Company&#x2019;s capital management
objectives are to preserve the Company&#x2019;s ability to ensure business continuity thereby creating a return for the shareholders, investors
and other interested parties. The Company is not under any minimal equity requirements nor is it required to attain a certain level of
capital return.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financing Rounds: (Cont.)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;April 2020 Financing Round&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;On April 1, 2020, the Company entered
into a definitive securities purchase agreement (the &#x201c;April 2020 Purchase Agreement&#x201d;) with institutional investors to purchase
of 4,166,168 units, each consisting of (i) one pre-funded warrant to purchase one ordinary share and (ii) one Series B warrant to purchase
one ordinary share, at a purchase price of $0.2999 per unit. The Series B warrants have an exercise price of $0.43 per ordinary share,
are exercisable upon issuance and expire five years from the date of issuance. The offering resulted in gross proceeds to the Company
of approximately $1,250. The closing of the sale of the securities took place on April 3, 2020. After the closing of the April 2020 Purchase
Agreement and until the Approval Date, all pre-funded warrants were exercised. In addition, 4,166,168 of the Series B warrants were exercised
pursuant to a cashless exercise mechanism as described in the April 2020 Purchase Agreement for no further consideration to the Company.
As of the Approval Date, all Series B warrants were exercised.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;The Series B warrants are classified
as a financial liability that will be measured at fair value, through profit or loss, as of the issuance date and on any following financial
reporting date (accordingly, issue expenses related to the Series B warrants will be recorded through profit or loss). No consideration
will be left to attribute to the pre-funded warrants, which is an equity instrument.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;The valuation of the conversion component
of the Series B warrants was set at fair value, as required in IFRS 9, and in accordance with IFRS 13, and was categorized as Level 3
by the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;November 2020 Financing Round&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;On November 20, 2020, the Company completed
an offering for gross proceeds of $4,200 by way of the issuance of an aggregate of 835,447 units, each consisting of (i) one ordinary
share and (ii) two warrants to purchase one ordinary share each, at a purchase price of&#160;$5.02&#160;per unit (&#x201c;November 2020
Warrants&#x201d;). The November 2020 Warrants have an exercise price of&#160;$5.02&#160;per ordinary share, will be exercisable upon issuance
and will expire five years from the date of issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;The November 2020 Warrants are classified
as issued warrants in the Company&#x2019;s equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;During the year ended December 31,
2021, the Company issued 1,004,494 ordinary shares in respect of the exercise of 1,004,494 November 2020 Warrants. During the year ended
December 31, 2022, there were no exercises of November 2020 Warrants.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Additional issuance of ordinary shares:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;On July 21, 2021, the Company issued
a consultant 6,000 ordinary shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On August 2, 2022, the Company issued
a consultant 24,000 ordinary shares in respect of services rendered.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On November 1, 2022, the Company issued
a consultant 37,000 ordinary shares in respect of services rendered.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;g.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;March 2021 Financing Round&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;On March 4, 2021, the Company completed
a private offering with several accredited and institutional investors for gross proceeds of $8,150, providing for the issuance of an
aggregate of 1,152,628 units, as follows: (a) 916,316 units at a price of $7.07 per unit, consisting of (i) one ordinary share of the
Company, and (ii) a Series A Warrant to purchase an equal number of units purchased (the &#x201c;2021 Series A Warrants&#x201d;) and a Series
B Warrant (the &#x201c;2021 Series B Warrants&#x201d; and, collectively with the 2021 Series A Warrants, the March 2021 Warrants) to purchase
half the number of units, and (b) 236,312 pre-funded units at a price of $7.069 per unit, consisting of (i) one pre-funded warrant to
purchase one ordinary share and (ii) one 2021 Series A Warrant and one 2021 Series B Warrant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;The Series A Warrants have an exercise
price of&#160;$7.07&#160;per ordinary share and the Series B Warrants have an exercise price of&#160;$10.60&#160;per ordinary share).
Both were exercisable upon issuance and will expire five years from the date of issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;The March 2021 Warrants are classified
as issued warrants in the Company&#x2019;s equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;During the year ended December 31, 2021,
the Company issued 128,156 ordinary shares in respect of the exercise of 10,000 2021 Series A Warrants and the exercise of 118,156 of
pre-funded warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;During the year ended December 31, 2022,
the Company issued 100,000 ordinary shares in respect of the exercise of 100,000 pre-funded warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;h.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;June 2022 Financing Round&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;On June 1, 2022, the Company completed
a private offering with an investor for gross proceeds of $10,210 (the &#x201c;June 2022 Private Placement&#x201d;), providing for the issuance
of an aggregate of 3,546,100 units and pre-funded units, as follows: (a) 335,000 units at a price of $2.88 per unit, each consisting of
(i) one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#x201c;June 2022 Warrants&#x201d;),
and (b) 3,211,100 pre-funded units at a price of $2.819 per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary
share and (ii) two June 2022 Warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;The June 2022 Warrants have an exercise
price of&#160;$2.63&#160;per ordinary share. The June 2022 Warrants were exercisable upon issuance and will expire seven years from the
date of issuance.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&lt;i&gt;General Overview of Valuation Approaches
used in the Valuation:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;Fair value is the price that would be
received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&lt;i&gt;Economic methodology:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;The June 2022 Warrants&#x2019; fair value
was calculated using the Black&#x2013;Scholes option pricing model, which takes into account the parameters as disclosed below for each
period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 1,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Dividend yield (%)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Underlying share price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.756&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-265"&gt;2,87&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Exercise price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.63&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.63&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Warrants fair value ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,396&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,209&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;The June 2022 Warrants are classified
as current warrant liability in the Company&#x2019;s balance sheet, as they are exercisable at any given time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;During the year ended December 31, 2022,
the Company issued 3,211,100 ordinary shares in respect of the exercise of 3,211,100 pre-funded warrants.&lt;/p&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="c7" id="ixv-32413">&lt;span style="font-size: 10pt"&gt;Composition of share capital:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt;
2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and&lt;br/&gt;
outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and&lt;br/&gt;
outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; padding-bottom: 4pt"&gt;Ordinary shares&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;75,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;6,798,840&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;25,714,285&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;3,091,740&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c4"
      decimals="INF"
      id="ixv-38461"
      unitRef="shares">75000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c4"
      decimals="INF"
      id="ixv-38462"
      unitRef="shares">6798840</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c5"
      decimals="INF"
      id="ixv-38463"
      unitRef="shares">25714285</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c5"
      decimals="INF"
      id="ixv-38464"
      unitRef="shares">3091740</ifrs-full:NumberOfSharesOutstanding>
    <sprcy:DescriptionOfReverseShareSplit contextRef="c251" id="ixv-38465">the Company convened
a special general meeting of its shareholders, whereby the shareholders approved, inter alia, (i) an increase to the Company&#x2019;s share
capital from 500,000,000 ordinary shares to 750,000,000 ordinary shares; and (ii) a reverse split of the Company&#x2019;s share capital
up to a ratio of 20:1 (the &#x201c;Reverse Split&#x201d;).</sprcy:DescriptionOfReverseShareSplit>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c252"
      decimals="0"
      id="ixv-38466"
      unitRef="shares">500000000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c253"
      decimals="0"
      id="ixv-38467"
      unitRef="shares">750000000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c254"
      decimals="0"
      id="ixv-38468"
      unitRef="shares">750000000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c255"
      decimals="0"
      id="ixv-38469"
      unitRef="shares">1800000000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c256"
      decimals="0"
      id="ixv-38470"
      unitRef="shares">40</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c257"
      decimals="0"
      id="ixv-38471"
      unitRef="shares">140</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c258"
      decimals="0"
      id="ixv-38472"
      unitRef="shares">1800000000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c259"
      decimals="0"
      id="ixv-38473"
      unitRef="shares">3600000000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c260"
      decimals="0"
      id="ixv-38474"
      unitRef="shares">75000000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:DisclosureOfIssuedAndOutstandingShareCapital contextRef="c7" id="ixv-32546">&lt;i&gt;Issued and outstanding share capital:&lt;/i&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Number of&lt;br/&gt; ordinary&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;shares&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-indent: -9pt; padding-left: 9pt"&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,091,740&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Issuance of share capital &#x2013; June 2022 Financing Round (Note 18h)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;335,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Exercise of pre-funded warrants (Note 18g)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise of pre-funded warrants (Note 18h)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,211,100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Share issued to a consultant (Note 18f)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;61,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,798,840&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</sprcy:DisclosureOfIssuedAndOutstandingShareCapital>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c5"
      decimals="INF"
      id="ixv-38475"
      unitRef="shares">3091740</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="c7"
      decimals="INF"
      id="ixv-38476"
      unitRef="shares">335000</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <sprcy:ExerciseOfPrefundedWarrantsOne
      contextRef="c7"
      decimals="INF"
      id="ixv-38477"
      unitRef="shares">100000</sprcy:ExerciseOfPrefundedWarrantsOne>
    <sprcy:ExerciseOfPrefundedWarrants
      contextRef="c7"
      decimals="INF"
      id="ixv-38478"
      unitRef="shares">3211100</sprcy:ExerciseOfPrefundedWarrants>
    <sprcy:ShareIssuedToAConsultant
      contextRef="c7"
      decimals="INF"
      id="ixv-38479"
      unitRef="shares">61000</sprcy:ShareIssuedToAConsultant>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c4"
      decimals="INF"
      id="ixv-38480"
      unitRef="shares">6798840</ifrs-full:NumberOfSharesIssued>
    <sprcy:PurchaseAgreementsDescription contextRef="c261" id="ixv-38481">the Company entered
into a definitive securities purchase agreement (the &#x201c;April 2020 Purchase Agreement&#x201d;) with institutional investors to purchase
of 4,166,168 units, each consisting of (i) one pre-funded warrant to purchase one ordinary share and (ii) one Series B warrant to purchase
one ordinary share, at a purchase price of $0.2999 per unit. The Series B warrants have an exercise price of $0.43 per ordinary share,
are exercisable upon issuance and expire five years from the date of issuance. The offering resulted in gross proceeds to the Company
of approximately $1,250. The closing of the sale of the securities took place on April 3, 2020. After the closing of the April 2020 Purchase
Agreement and until the Approval Date, all pre-funded warrants were exercised. In addition, 4,166,168 of the Series B warrants were exercised
pursuant to a cashless exercise mechanism as described in the April 2020 Purchase Agreement for no further consideration to the Company.
As of the Approval Date, all Series B warrants were exercised.</sprcy:PurchaseAgreementsDescription>
    <sprcy:GrossProceeds
      contextRef="c262"
      decimals="-3"
      id="ixv-38482"
      unitRef="usd">4200000</sprcy:GrossProceeds>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c263"
      decimals="0"
      id="ixv-38483"
      unitRef="shares">835447</ifrs-full:NumberOfSharesIssued>
    <sprcy:PurchaseAgreementsDescription contextRef="c262" id="ixv-38484">(i) one ordinary
share and (ii) two warrants to purchase one ordinary share each, at a purchase price of&#160;$5.02&#160;per unit (&#x201c;November 2020
Warrants&#x201d;). The November 2020 Warrants have an exercise price of&#160;$5.02&#160;per ordinary share, will be exercisable upon issuance
and will expire five years from the date of issuance.</sprcy:PurchaseAgreementsDescription>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c264"
      decimals="0"
      id="ixv-38485"
      unitRef="shares">1004494</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares
      contextRef="c265"
      decimals="0"
      id="ixv-38486"
      unitRef="shares">1004494</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c266"
      decimals="0"
      id="ixv-38487"
      unitRef="shares">6000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c267"
      decimals="0"
      id="ixv-38488"
      unitRef="shares">24000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c268"
      decimals="0"
      id="ixv-38489"
      unitRef="shares">37000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:DescriptionOfPrivateOffering contextRef="c269" id="ixv-38490">the Company completed
a private offering with several accredited and institutional investors for gross proceeds of $8,150, providing for the issuance of an
aggregate of 1,152,628 units, as follows: (a) 916,316 units at a price of $7.07 per unit, consisting of (i) one ordinary share of the
Company, and (ii) a Series A Warrant to purchase an equal number of units purchased (the &#x201c;2021 Series A Warrants&#x201d;) and a Series
B Warrant (the &#x201c;2021 Series B Warrants&#x201d; and, collectively with the 2021 Series A Warrants, the March 2021 Warrants) to purchase
half the number of units, and (b) 236,312 pre-funded units at a price of $7.069 per unit, consisting of (i) one pre-funded warrant to
purchase one ordinary share and (ii) one 2021 Series A Warrant and one 2021 Series B Warrant.</sprcy:DescriptionOfPrivateOffering>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c270"
      decimals="2"
      id="ixv-38491"
      unitRef="usdPershares">7.07</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c271"
      decimals="2"
      id="ixv-38492"
      unitRef="usdPershares">10.6</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <sprcy:DateOfIssuance contextRef="c5" id="ixv-38493">P5Y</sprcy:DateOfIssuance>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c272"
      decimals="0"
      id="ixv-38494"
      unitRef="shares">128156</ifrs-full:NumberOfSharesIssued>
    <sprcy:WarrantsAndExercise
      contextRef="c11"
      decimals="0"
      id="ixv-38495"
      unitRef="shares">10000</sprcy:WarrantsAndExercise>
    <sprcy:WarrantsAndExercise
      contextRef="c270"
      decimals="0"
      id="ixv-38496"
      unitRef="shares">118156</sprcy:WarrantsAndExercise>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c273"
      decimals="0"
      id="ixv-38497"
      unitRef="shares">100000</ifrs-full:NumberOfSharesIssued>
    <sprcy:WarrantsAndExercise
      contextRef="c274"
      decimals="0"
      id="ixv-38498"
      unitRef="shares">100000</sprcy:WarrantsAndExercise>
    <sprcy:DescriptionOfPrivateOffering contextRef="c118" id="ixv-38499">the Company completed
a private offering with an investor for gross proceeds of $10,210 (the &#x201c;June 2022 Private Placement&#x201d;), providing for the issuance
of an aggregate of 3,546,100 units and pre-funded units, as follows: (a) 335,000 units at a price of $2.88 per unit, each consisting of
(i) one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#x201c;June 2022 Warrants&#x201d;),
and (b) 3,211,100 pre-funded units at a price of $2.819 per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary
share and (ii) two June 2022 Warrants.</sprcy:DescriptionOfPrivateOffering>
    <sprcy:GrossProceeds
      contextRef="c118"
      decimals="-3"
      id="ixv-38500"
      unitRef="usd">10210000</sprcy:GrossProceeds>
    <sprcy:IssuanceOfAggregateShares
      contextRef="c275"
      decimals="0"
      id="ixv-38501"
      unitRef="shares">3546100</sprcy:IssuanceOfAggregateShares>
    <sprcy:WarrantsExercisePrice contextRef="c3" decimals="-1" id="ixv-38502" unitRef="pure">2630</sprcy:WarrantsExercisePrice>
    <ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory contextRef="c7" id="ixv-38503">The June 2022 Warrants&#x2019; fair value
was calculated using the Black&#x2013;Scholes option pricing model, which takes into account the parameters as disclosed below for each
period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 1,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Dividend yield (%)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Underlying share price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.756&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-265"&gt;2,87&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Exercise price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.63&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.63&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Warrants fair value ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,396&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,209&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c7" decimals="2" id="ixv-38504" unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c278"
      decimals="2"
      id="ixv-38505"
      unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c7" decimals="2" id="ixv-38506" unitRef="pure">0.72</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c278"
      decimals="2"
      id="ixv-38507"
      unitRef="pure">0.72</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c7" decimals="4" id="ixv-38508" unitRef="pure">0.0397</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c278"
      decimals="4"
      id="ixv-38509"
      unitRef="pure">0.0274</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <sprcy:UnderlyingOrdinarySharePrice
      contextRef="c7"
      decimals="3"
      id="ixv-38510"
      unitRef="usdPershares">0.756</sprcy:UnderlyingOrdinarySharePrice>
    <sprcy:ExercisePrice
      contextRef="c7"
      decimals="2"
      id="ixv-38511"
      unitRef="usdPershares">2.63</sprcy:ExercisePrice>
    <sprcy:ExercisePrice
      contextRef="c278"
      decimals="2"
      id="ixv-38512"
      unitRef="usdPershares">2.63</sprcy:ExercisePrice>
    <sprcy:WarrantsFairValueinDollarsPerShare
      contextRef="c7"
      decimals="0"
      id="ixv-38513"
      unitRef="usdPershares">2396</sprcy:WarrantsFairValueinDollarsPerShare>
    <sprcy:WarrantsFairValueinDollarsPerShare
      contextRef="c278"
      decimals="0"
      id="ixv-38514"
      unitRef="usdPershares">10209</sprcy:WarrantsFairValueinDollarsPerShare>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c276"
      decimals="0"
      id="ixv-38515"
      unitRef="shares">3211100</ifrs-full:NumberOfSharesIssued>
    <sprcy:WarrantsAndExercise
      contextRef="c277"
      decimals="0"
      id="ixv-38516"
      unitRef="shares">3211100</sprcy:WarrantsAndExercise>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="c7" id="ixv-32963">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 19:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;SHARE-BASED PAYMENT TRANSACTIONS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The cost of share-based payment recognized in the financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;The expenses due to share-based compensation
for the years ended December 31, 2022, 2021 and 2020, recognized in the financial statements in respect of the share option plan of the
Company is shown in the following table, detailed by departments:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;264&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;27&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;69&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;General and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;633&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;897&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;43&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;91&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The 2005 and 2015 ESOP of the Company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify"&gt;During 2005, the Board adopted the 2005
Employees Share Option Plan (the &#x201c;2005 ESOP&#x201d;). Ten years later the Board adopted a new plan - the 2015 Employees Share Option
Plan (the &#x201c;2015 ESOP&#x201d;). Under both the 2005 ESOP and 2015 ESOP, the Company may grant its employees and other service providers
options to purchase the Company&#x2019;s ordinary shares (&#x201c;Share Options&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify"&gt;On November 13, 2019, the Board reserved
an additional number of 6,788 Share Options for the purposes of the 2015 ESOP, bringing the amount of Share Options reserved under the
2015 ESOP to 15,714.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"&gt;On April 21, 2021, the Board reserved
an additional number of 338,929&#160;Share Options for the purposes of the 2015 ESOP, bringing the amount of Share Options reserved under
the 2015 ESOP to 357,143, out of which a total of 161,114 were still available for grant as of December 31, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On March 12, 2019, the Board approved and granted 1,171 ordinary shares under the 2015 ESOP to a new consultant of the Company. The exercise price was set at $420.00 per share Option.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;&lt;i&gt;The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Dividend yield (%)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.61&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Expected life of share options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;The fair value of the Share Options
was set at $224 per Share Option.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On October 10, 2019 (the &#x201c;2019 Grant Date&#x201d;), the Board approved the grant of 72 Share Options under the 2015 ESOP to directors, officers and employees, some of which required the approval of the general meeting of the Company&#x2019;s shareholders (the &#x201c;2019 General Meeting&#x201d;), which occurred on January 15, 2020. Following the resignation of some directors and employees on December 31, 2019, 15 Share Options (were not granted. Out of the 57 Share Options that were granted, 10 Share Options didn&#x2019;t require the General Meeting&#x2019;s approval. The date of commencement for all Share Options granted, the date on which the vesting started, was the 2019 Grant Date. The exercise price was set at $210.00 per Share Option.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;According to IFRS 2, &#x201c;&lt;i&gt;Share-based
Payment&lt;/i&gt;&#x201d;, the fair value of the Share Options was estimated using the Black-Scholes OPM, in which the fair value estimation
for the Share Options which required the 2019 General Meeting&#x2019;s approval was calculated based on parameters as of December 31, 2019.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;&lt;i&gt;Based on the above-mentioned, hereinafter
are the parameters used in order to estimate the fair value of the Share Options using the Black-Scholes OPM:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt;
2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;October&#160;10,&lt;br/&gt;
2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Underlying ordinary share price&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;78.12&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;154&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected life of Share Options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;The fair value of the Share Options
approved on October 10, 2019 by the Board, and on January 15, 2020 at the General Meeting (valuated as of December 31, 2019) was set at
$114.1 and $51.1, per Share Option, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On January 3, 2022 (the &#x201c;2022 Grant Date&#x201d;), the Board approved the grant of 178,140 Share Options under the 2015 ESOP to directors, officers, employees and consultants, some of which required the approval of the general meeting of the Company&#x2019;s shareholders (the &#x201c;2022 General Meeting&#x201d;), which occurred on February 10, 2022. The date of commencement for all Share Options granted, the date on which the vesting started, was the 2022 Grant Date. The exercise price was set at $6.50 per Share Option.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;&lt;i&gt;The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;February&#160;2,&lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January 3,&lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Underlying ordinary share price&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.99&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.73&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;134&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected life of Share Options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;The fair value of the Share Options
granted on January 3, 2022, was set at $6.09 per Share Option, and the fair value of the Share Options granted on February 10, 2022, was
set at $4.41 per Share Option.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 120px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During the year ended December 31, 2022, the Company granted consultants Restricted Share Units (&#x201c;RSUs&#x201d;) in respect of services rendered. The RSU&#x2019;s were granted at a discount rate of 25% to share price quoted on the date of each grant. The total fair value of the RSU&#x2019;s granted to consultants was $70. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 120px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During the year ended December 31, 2022, the Company issued consultants 61,000 ordinary shares in respect of services rendered. The ordinary were granted at a discount rate of 25% to share price quoted on the date of each grant. The total fair value of the RSU&#x2019;s granted to consultants was $48. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 126pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Movement during the year:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 120px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The following table lists the number of Share Options, the weighted average exercise prices of share options and changes in directors (and former directors), officers, employees and consultants share options during the years ended on December 31, 2022, and 2021:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt;
Share&lt;br/&gt;
Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt;
average&lt;br/&gt;
exercise&lt;br/&gt;
price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the beginning of the year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,431&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.95&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options granted during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;178,140&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the end of the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;183,571&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.39&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options exercisable at the end of the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;107,679&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;2021:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the beginning of the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,643&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.41&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options granted during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-266"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-267"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options forfeited during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(212&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Share Options expired during the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-268"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-269"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,431&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.95&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Share Options exercisable at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,416&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.28&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;No Share Options were granted during 2021.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 120px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The weighted average remaining contractual life of the Share Options outstanding was 5.03 years and 6.35 years as of December 31, 2022, and 2021, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 120px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The range of exercise prices of Share Options outstanding at the end of the year was $6.5 - $844 (inclusive) as of December 31, 2022, and $210 - $955 (inclusive) as of December 31, 2021.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <sprcy:DisclosureOfExpenseRecognizedExplanatoryTableTextBlock contextRef="c7" id="ixv-38517">The expenses due to share-based compensation
for the years ended December 31, 2022, 2021 and 2020, recognized in the financial statements in respect of the share option plan of the
Company is shown in the following table, detailed by departments:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;264&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;27&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;69&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;General and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;633&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;897&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;43&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;91&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfExpenseRecognizedExplanatoryTableTextBlock>
    <sprcy:ResearchAndDevelopmentExpenses01 contextRef="c7" decimals="-3" id="ixv-38518" unitRef="usd">264000</sprcy:ResearchAndDevelopmentExpenses01>
    <sprcy:ResearchAndDevelopmentExpenses01 contextRef="c11" decimals="-3" id="ixv-38519" unitRef="usd">27000</sprcy:ResearchAndDevelopmentExpenses01>
    <sprcy:ResearchAndDevelopmentExpenses01 contextRef="c12" decimals="-3" id="ixv-38520" unitRef="usd">69000</sprcy:ResearchAndDevelopmentExpenses01>
    <sprcy:GeneralAndAdministrativeExpenses contextRef="c7" decimals="-3" id="ixv-38521" unitRef="usd">633000</sprcy:GeneralAndAdministrativeExpenses>
    <sprcy:GeneralAndAdministrativeExpenses contextRef="c11" decimals="-3" id="ixv-38522" unitRef="usd">16000</sprcy:GeneralAndAdministrativeExpenses>
    <sprcy:GeneralAndAdministrativeExpenses contextRef="c12" decimals="-3" id="ixv-38523" unitRef="usd">22000</sprcy:GeneralAndAdministrativeExpenses>
    <sprcy:ExpensesDueToSharebasedCompensation contextRef="c7" decimals="-3" id="ixv-38524" unitRef="usd">897000</sprcy:ExpensesDueToSharebasedCompensation>
    <sprcy:ExpensesDueToSharebasedCompensation contextRef="c11" decimals="-3" id="ixv-38525" unitRef="usd">43000</sprcy:ExpensesDueToSharebasedCompensation>
    <sprcy:ExpensesDueToSharebasedCompensation contextRef="c12" decimals="-3" id="ixv-38526" unitRef="usd">91000</sprcy:ExpensesDueToSharebasedCompensation>
    <ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares
      contextRef="c279"
      decimals="0"
      id="ixv-38527"
      unitRef="shares">6788</ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares>
    <sprcy:ShareOptionsReserved
      contextRef="c279"
      decimals="0"
      id="ixv-38528"
      unitRef="shares">15714</sprcy:ShareOptionsReserved>
    <ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares
      contextRef="c280"
      decimals="0"
      id="ixv-38529"
      unitRef="shares">338929</ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares>
    <sprcy:ShareOptionsReserved
      contextRef="c280"
      decimals="0"
      id="ixv-38530"
      unitRef="shares">357143</sprcy:ShareOptionsReserved>
    <sprcy:NumberOfSharesOptionGrantedInSharebasedPaymentArrangement
      contextRef="c7"
      decimals="0"
      id="ixv-38531"
      unitRef="shares">161114</sprcy:NumberOfSharesOptionGrantedInSharebasedPaymentArrangement>
    <sprcy:OrdinaryShares
      contextRef="c281"
      decimals="0"
      id="ixv-38532"
      unitRef="shares">1171</sprcy:OrdinaryShares>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c282"
      decimals="2"
      id="ixv-38533"
      unitRef="usdPershares">420</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <sprcy:DescriptionOfOptionPricingModelShareOptionGranted contextRef="c7" id="ixv-33134">&lt;i&gt;The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:&lt;/i&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Dividend yield (%)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.61&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Expected life of share options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;i&gt;Based on the above-mentioned, hereinafter
are the parameters used in order to estimate the fair value of the Share Options using the Black-Scholes OPM:&lt;/i&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt;
2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;October&#160;10,&lt;br/&gt;
2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Underlying ordinary share price&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;78.12&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;154&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected life of Share Options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;i&gt;The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:&lt;/i&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;February&#160;2,&lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January 3,&lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Underlying ordinary share price&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.99&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.73&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;134&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected life of Share Options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DescriptionOfOptionPricingModelShareOptionGranted>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed contextRef="c7" decimals="2" id="ixv-38534" unitRef="pure">0</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate contextRef="c7" decimals="2" id="ixv-38535" unitRef="pure">0.76</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate contextRef="c7" decimals="4" id="ixv-38536" unitRef="pure">0.0261</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate>
    <sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1 contextRef="c7" id="ixv-38537">P10Y</sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1>
    <sprcy:FairValueOption contextRef="c11" decimals="-3" id="ixv-38538" unitRef="usd">224000</sprcy:FairValueOption>
    <sprcy:StockOptionDescription contextRef="c283" id="ixv-38539">the Board approved the grant of 72 Share Options under the 2015 ESOP to directors, officers and employees, some of which required the approval of the general meeting of the Company&#x2019;s shareholders (the &#x201c;2019 General Meeting&#x201d;), which occurred on January 15, 2020. Following the resignation of some directors and employees on December 31, 2019, 15 Share Options (were not granted. Out of the 57 Share Options that were granted, 10 Share Options didn&#x2019;t require the General Meeting&#x2019;s approval. The date of commencement for all Share Options granted, the date on which the vesting started, was the 2019 Grant Date. The exercise price was set at $210.00 per Share Option.</sprcy:StockOptionDescription>
    <sprcy:UnderlyingOrdinarySharePrices
      contextRef="c292"
      decimals="2"
      id="ixv-38540"
      unitRef="usdPershares">78.12</sprcy:UnderlyingOrdinarySharePrices>
    <sprcy:UnderlyingOrdinarySharePrices
      contextRef="c293"
      decimals="0"
      id="ixv-38541"
      unitRef="usdPershares">154</sprcy:UnderlyingOrdinarySharePrices>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed
      contextRef="c292"
      decimals="2"
      id="ixv-38542"
      unitRef="pure">0</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed
      contextRef="c293"
      decimals="2"
      id="ixv-38543"
      unitRef="pure">0</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate
      contextRef="c292"
      decimals="2"
      id="ixv-38544"
      unitRef="pure">0.73</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate
      contextRef="c293"
      decimals="2"
      id="ixv-38545"
      unitRef="pure">0.70</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate
      contextRef="c292"
      decimals="4"
      id="ixv-38546"
      unitRef="pure">0.0191</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate
      contextRef="c293"
      decimals="4"
      id="ixv-38547"
      unitRef="pure">0.0167</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate>
    <sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1 contextRef="c292" id="ixv-38548">P9Y9M10D</sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1>
    <sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1 contextRef="c293" id="ixv-38549">P10Y</sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1>
    <sprcy:FairValueDescription contextRef="c284" id="ixv-38550">The fair value of the Share Options
approved on October 10, 2019 by the Board, and on January 15, 2020 at the General Meeting (valuated as of December 31, 2019) was set at
$114.1 and $51.1, per Share Option, respectively.</sprcy:FairValueDescription>
    <sprcy:ShareOptionsReserved
      contextRef="c285"
      decimals="0"
      id="ixv-38551"
      unitRef="shares">178140</sprcy:ShareOptionsReserved>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c4"
      decimals="2"
      id="ixv-38552"
      unitRef="usdPershares">6.5</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <sprcy:UnderlyingOrdinarySharePrices
      contextRef="c294"
      decimals="2"
      id="ixv-38553"
      unitRef="usdPershares">4.99</sprcy:UnderlyingOrdinarySharePrices>
    <sprcy:UnderlyingOrdinarySharePrices
      contextRef="c295"
      decimals="2"
      id="ixv-38554"
      unitRef="usdPershares">6.73</sprcy:UnderlyingOrdinarySharePrices>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed
      contextRef="c294"
      decimals="2"
      id="ixv-38555"
      unitRef="pure">0</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed
      contextRef="c295"
      decimals="2"
      id="ixv-38556"
      unitRef="pure">0</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate
      contextRef="c294"
      decimals="2"
      id="ixv-38557"
      unitRef="pure">1.33</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate
      contextRef="c295"
      decimals="2"
      id="ixv-38558"
      unitRef="pure">1.34</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate
      contextRef="c294"
      decimals="4"
      id="ixv-38559"
      unitRef="pure">0.02</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate
      contextRef="c295"
      decimals="4"
      id="ixv-38560"
      unitRef="pure">0.0146</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate>
    <sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1 contextRef="c294" id="ixv-38561">P6Y</sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1>
    <sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1 contextRef="c295" id="ixv-38562">P6Y</sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1>
    <sprcy:FairValueDescription contextRef="c286" id="ixv-38563">The fair value of the Share Options
granted on January 3, 2022, was set at $6.09 per Share Option, and the fair value of the Share Options granted on February 10, 2022, was
set at $4.41 per Share Option</sprcy:FairValueDescription>
    <sprcy:RSUGrantedDiscountRate contextRef="c7" decimals="2" id="ixv-38564" unitRef="pure">0.25</sprcy:RSUGrantedDiscountRate>
    <sprcy:FairValueOfTheRSUsGranted contextRef="c7" decimals="-3" id="ixv-38565" unitRef="usd">70000</sprcy:FairValueOfTheRSUsGranted>
    <sprcy:OrdinarySharesIssued
      contextRef="c7"
      decimals="0"
      id="ixv-38566"
      unitRef="shares">61000</sprcy:OrdinarySharesIssued>
    <sprcy:OrdinaryGrantedDiscountRate contextRef="c7" decimals="2" id="ixv-38567" unitRef="pure">0.25</sprcy:OrdinaryGrantedDiscountRate>
    <sprcy:FairValueOfTheRSUsGranted
      contextRef="c287"
      decimals="-3"
      id="ixv-38568"
      unitRef="usd">48000</sprcy:FairValueOfTheRSUsGranted>
    <sprcy:DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock contextRef="c7" id="ixv-33439">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The following table lists the number of Share Options, the weighted average exercise prices of share options and changes in directors (and former directors), officers, employees and consultants share options during the years ended on December 31, 2022, and 2021:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt;
Share&lt;br/&gt;
Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt;
average&lt;br/&gt;
exercise&lt;br/&gt;
price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the beginning of the year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,431&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.95&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options granted during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;178,140&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the end of the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;183,571&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.39&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options exercisable at the end of the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;107,679&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;2021:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the beginning of the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,643&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.41&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options granted during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-266"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-267"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options forfeited during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(212&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Share Options expired during the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-268"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-269"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,431&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.95&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Share Options exercisable at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,416&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.28&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock>
    <sprcy:NumberOfOutstandingShareOption
      contextRef="c5"
      decimals="0"
      id="ixv-38569"
      unitRef="shares">5431</sprcy:NumberOfOutstandingShareOption>
    <sprcy:WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement
      contextRef="c5"
      decimals="2"
      id="ixv-38570"
      unitRef="usdPershares">2.95</sprcy:WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement>
    <sprcy:NumberOfShareOptionGranted
      contextRef="c4"
      decimals="0"
      id="ixv-38571"
      unitRef="shares">178140</sprcy:NumberOfShareOptionGranted>
    <sprcy:WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement
      contextRef="c7"
      decimals="2"
      id="ixv-38572"
      unitRef="usdPershares">6.5</sprcy:WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement>
    <sprcy:NumberOfOutstandingShareOption
      contextRef="c4"
      decimals="0"
      id="ixv-38573"
      unitRef="shares">183571</sprcy:NumberOfOutstandingShareOption>
    <sprcy:WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement
      contextRef="c4"
      decimals="2"
      id="ixv-38574"
      unitRef="usdPershares">6.39</sprcy:WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement>
    <sprcy:NumberOfShareOptionsShareOptionsExercisableAtTheEndOfTheYear
      contextRef="c4"
      decimals="0"
      id="ixv-38575"
      unitRef="shares">107679</sprcy:NumberOfShareOptionsShareOptionsExercisableAtTheEndOfTheYear>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c4"
      decimals="2"
      id="ixv-38576"
      unitRef="usdPershares">6.3</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <sprcy:NumberOfOutstandingShareOption
      contextRef="c96"
      decimals="0"
      id="ixv-38577"
      unitRef="shares">5643</sprcy:NumberOfOutstandingShareOption>
    <sprcy:WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement
      contextRef="c96"
      decimals="2"
      id="ixv-38578"
      unitRef="usdPershares">2.41</sprcy:WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement>
    <sprcy:NumberOfShareOptionForfeitedInSharebasedPaymentArrangement
      contextRef="c11"
      decimals="0"
      id="ixv-38579"
      unitRef="shares">-212</sprcy:NumberOfShareOptionForfeitedInSharebasedPaymentArrangement>
    <sprcy:WeightedAverageExercisePriceOfShareOptionForfeitedInSharebasedPaymentArrangement
      contextRef="c11"
      decimals="2"
      id="ixv-38580"
      unitRef="usdPershares">2.5</sprcy:WeightedAverageExercisePriceOfShareOptionForfeitedInSharebasedPaymentArrangement>
    <sprcy:NumberOfOutstandingShareOption
      contextRef="c5"
      decimals="0"
      id="ixv-38581"
      unitRef="shares">5431</sprcy:NumberOfOutstandingShareOption>
    <sprcy:WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement
      contextRef="c5"
      decimals="2"
      id="ixv-38582"
      unitRef="usdPershares">2.95</sprcy:WeightedAverageExercisePriceOfShareOptionOutstandingInSharebasedPaymentArrangement>
    <sprcy:NumberOfShareOptionsShareOptionsExercisableAtTheEndOfTheYear
      contextRef="c5"
      decimals="0"
      id="ixv-38583"
      unitRef="shares">4416</sprcy:NumberOfShareOptionsShareOptionsExercisableAtTheEndOfTheYear>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c5"
      decimals="2"
      id="ixv-38584"
      unitRef="usdPershares">3.28</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <sprcy:WeightedAverageRemainingContractualLifesOfOutstandingShareOption contextRef="c7" id="ixv-38585">P5Y10D</sprcy:WeightedAverageRemainingContractualLifesOfOutstandingShareOption>
    <sprcy:WeightedAverageRemainingContractualLifesOfOutstandingShareOption contextRef="c11" id="ixv-38586">P6Y4M6D</sprcy:WeightedAverageRemainingContractualLifesOfOutstandingShareOption>
    <sprcy:ShareOptionsOutstandingParValue
      contextRef="c288"
      decimals="1"
      id="ixv-38587"
      unitRef="usdPershares">6.5</sprcy:ShareOptionsOutstandingParValue>
    <sprcy:ShareOptionsOutstandingParValue
      contextRef="c289"
      decimals="0"
      id="ixv-38588"
      unitRef="usdPershares">844</sprcy:ShareOptionsOutstandingParValue>
    <sprcy:ShareOptionsOutstandingParValue
      contextRef="c290"
      decimals="0"
      id="ixv-38589"
      unitRef="usdPershares">210</sprcy:ShareOptionsOutstandingParValue>
    <sprcy:ShareOptionsOutstandingParValue
      contextRef="c291"
      decimals="0"
      id="ixv-38590"
      unitRef="usdPershares">955</sprcy:ShareOptionsOutstandingParValue>
    <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory contextRef="c7" id="ixv-33672">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;20:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;REVENUES AND COST OF REVENUES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Our revenues consist of revenue derived
from sales on Amazon. The following table discloses the breakdown of our revenues, cost of sales and gross profit for the periods set
forth below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Revenues&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,347&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-270"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Cost of goods sold&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;322&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-271"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Gross profit&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,025&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-272"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
    <sprcy:ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock contextRef="c7" id="ixv-38591">Our revenues consist of revenue derived
from sales on Amazon. The following table discloses the breakdown of our revenues, cost of sales and gross profit for the periods set
forth below:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Revenues&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,347&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-270"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Cost of goods sold&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;322&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-271"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Gross profit&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,025&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-272"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock>
    <ifrs-full:Revenue contextRef="c7" decimals="-3" id="ixv-38592" unitRef="usd">1347000</ifrs-full:Revenue>
    <ifrs-full:CostOfSales contextRef="c7" decimals="-3" id="ixv-38593" unitRef="usd">322000</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit contextRef="c7" decimals="-3" id="ixv-38594" unitRef="usd">1025000</ifrs-full:GrossProfit>
    <ifrs-full:DisclosureOfAdditionalInformationExplanatory contextRef="c7" id="ixv-33745">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;21:- &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 5%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-decoration: underline; width: 57%; font-style: italic; text-align: left"&gt;Research and development expenses:&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Wages and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;436&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;357&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;322&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Share-based payment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;264&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Regulatory, professional and other expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;934&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;119&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Research and preclinical studies&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;703&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;139&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Clinical studies&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;369&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;172&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-273"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left"&gt;Chemistry and formulations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;281&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;335&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-274"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,803&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,990&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;649&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-decoration: underline; font-style: italic; text-align: left"&gt;General and administrative expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Wages and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;437&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;256&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;237&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Share-based payment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;633&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Professional and directors&#x2019; fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,499&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,417&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,283&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Business development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;161&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Regulatory expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;162&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Office maintenance, rent and other expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;224&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;135&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;182&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Wellution operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;907&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-275"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-276"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left"&gt;Investor relations and business expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,486&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;784&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;General and administrative expenses:&lt;/span&gt;&lt;/i&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,509&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,778&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,902&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-decoration: underline; font-style: italic; text-align: left"&gt;Other expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left"&gt;Impairment of company accounted for at equity&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-277"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-278"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;742&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left"&gt;Group&#x2019;s share of losses of company accounted for at equity, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;109&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-279"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-280"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;109&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-281"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;742&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-decoration: underline; font-style: italic; text-align: left"&gt;Finance income:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Net change in fair value of financial liabilities designated at fair value through profit or loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,832&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-282"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(630&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(7,832&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-283"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(630&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-style: italic; text-align: left"&gt;Finance expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Issuance expenses related to warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,204&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;835&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Exchange rate differences, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Losses from remeasurement of investment in financial assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;770&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-284"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-285"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Finance expense in respect of leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left"&gt;Finance expenses from interest and commissions&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,014&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;872&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfAdditionalInformationExplanatory>
    <sprcy:DisclosureOfInformationToTheItemsOfProfitOrLoss contextRef="c7" id="ixv-33755">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 5%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-decoration: underline; width: 57%; font-style: italic; text-align: left"&gt;Research and development expenses:&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Wages and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;436&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;357&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;322&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Share-based payment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;264&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Regulatory, professional and other expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;934&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;119&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Research and preclinical studies&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;703&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;139&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Clinical studies&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;369&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;172&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-273"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left"&gt;Chemistry and formulations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;281&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;335&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-274"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,803&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,990&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;649&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-decoration: underline; font-style: italic; text-align: left"&gt;General and administrative expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Wages and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;437&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;256&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;237&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Share-based payment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;633&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Professional and directors&#x2019; fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,499&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,417&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,283&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Business development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;161&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Regulatory expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;162&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Office maintenance, rent and other expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;224&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;135&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;182&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Wellution operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;907&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-275"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-276"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left"&gt;Investor relations and business expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,486&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;784&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;General and administrative expenses:&lt;/span&gt;&lt;/i&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,509&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,778&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,902&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-decoration: underline; font-style: italic; text-align: left"&gt;Other expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left"&gt;Impairment of company accounted for at equity&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-277"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-278"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;742&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left"&gt;Group&#x2019;s share of losses of company accounted for at equity, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;109&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-279"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-280"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;109&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-281"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;742&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-decoration: underline; font-style: italic; text-align: left"&gt;Finance income:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Net change in fair value of financial liabilities designated at fair value through profit or loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,832&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-282"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(630&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(7,832&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-283"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(630&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-style: italic; text-align: left"&gt;Finance expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Issuance expenses related to warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,204&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;835&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Exchange rate differences, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Losses from remeasurement of investment in financial assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;770&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-284"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-285"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Finance expense in respect of leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left"&gt;Finance expenses from interest and commissions&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,014&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;872&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfInformationToTheItemsOfProfitOrLoss>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c142"
      decimals="-3"
      id="ixv-38595"
      unitRef="usd">436000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c296"
      decimals="-3"
      id="ixv-38596"
      unitRef="usd">357000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c297"
      decimals="-3"
      id="ixv-38597"
      unitRef="usd">322000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c145"
      decimals="-3"
      id="ixv-38598"
      unitRef="usd">264000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c298"
      decimals="-3"
      id="ixv-38599"
      unitRef="usd">27000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c299"
      decimals="-3"
      id="ixv-38600"
      unitRef="usd">69000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c151"
      decimals="-3"
      id="ixv-38601"
      unitRef="usd">750000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c300"
      decimals="-3"
      id="ixv-38602"
      unitRef="usd">934000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c301"
      decimals="-3"
      id="ixv-38603"
      unitRef="usd">119000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c154"
      decimals="-3"
      id="ixv-38604"
      unitRef="usd">703000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c302"
      decimals="-3"
      id="ixv-38605"
      unitRef="usd">165000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c303"
      decimals="-3"
      id="ixv-38606"
      unitRef="usd">139000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c148"
      decimals="-3"
      id="ixv-38607"
      unitRef="usd">369000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c304"
      decimals="-3"
      id="ixv-38608"
      unitRef="usd">172000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c157"
      decimals="-3"
      id="ixv-38609"
      unitRef="usd">281000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c306"
      decimals="-3"
      id="ixv-38610"
      unitRef="usd">335000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1 contextRef="c7" decimals="-3" id="ixv-38611" unitRef="usd">2803000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1 contextRef="c11" decimals="-3" id="ixv-38612" unitRef="usd">1990000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1 contextRef="c12" decimals="-3" id="ixv-38613" unitRef="usd">649000</sprcy:ResearchAndDevelopmentExpenses1>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c142"
      decimals="-3"
      id="ixv-38614"
      unitRef="usd">437000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c296"
      decimals="-3"
      id="ixv-38615"
      unitRef="usd">256000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c297"
      decimals="-3"
      id="ixv-38616"
      unitRef="usd">237000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c145"
      decimals="-3"
      id="ixv-38617"
      unitRef="usd">633000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c298"
      decimals="-3"
      id="ixv-38618"
      unitRef="usd">16000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c299"
      decimals="-3"
      id="ixv-38619"
      unitRef="usd">22000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c160"
      decimals="-3"
      id="ixv-38620"
      unitRef="usd">2499000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c308"
      decimals="-3"
      id="ixv-38621"
      unitRef="usd">2417000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c309"
      decimals="-3"
      id="ixv-38622"
      unitRef="usd">1283000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c163"
      decimals="-3"
      id="ixv-38623"
      unitRef="usd">161000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c310"
      decimals="-3"
      id="ixv-38624"
      unitRef="usd">5000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c311"
      decimals="-3"
      id="ixv-38625"
      unitRef="usd">58000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c175"
      decimals="-3"
      id="ixv-38626"
      unitRef="usd">162000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c312"
      decimals="-3"
      id="ixv-38627"
      unitRef="usd">165000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c313"
      decimals="-3"
      id="ixv-38628"
      unitRef="usd">98000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c166"
      decimals="-3"
      id="ixv-38629"
      unitRef="usd">224000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c314"
      decimals="-3"
      id="ixv-38630"
      unitRef="usd">135000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c315"
      decimals="-3"
      id="ixv-38631"
      unitRef="usd">182000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c172"
      decimals="-3"
      id="ixv-38632"
      unitRef="usd">907000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c169"
      decimals="-3"
      id="ixv-38633"
      unitRef="usd">1486000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c318"
      decimals="-3"
      id="ixv-38634"
      unitRef="usd">784000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c319"
      decimals="-3"
      id="ixv-38635"
      unitRef="usd">22000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c7" decimals="-3" id="ixv-38636" unitRef="usd">6509000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c11" decimals="-3" id="ixv-38637" unitRef="usd">3778000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c12" decimals="-3" id="ixv-38638" unitRef="usd">1902000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="c322"
      decimals="-3"
      id="ixv-38639"
      unitRef="usd">-742000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="c323"
      decimals="-3"
      id="ixv-38640"
      unitRef="usd">-109000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c7" decimals="-3" id="ixv-38641" unitRef="usd">-109000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c12" decimals="-3" id="ixv-38642" unitRef="usd">-742000</ifrs-full:OtherOperatingIncomeExpense>
    <sprcy:FinanceIncomeFromConvertibleLoan contextRef="c7" decimals="-3" id="ixv-38643" unitRef="usd">-7832000</sprcy:FinanceIncomeFromConvertibleLoan>
    <sprcy:FinanceIncomeFromConvertibleLoan contextRef="c12" decimals="-3" id="ixv-38644" unitRef="usd">-630000</sprcy:FinanceIncomeFromConvertibleLoan>
    <ifrs-full:FinanceIncomeCost contextRef="c7" decimals="-3" id="ixv-38645" unitRef="usd">7832000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost contextRef="c12" decimals="-3" id="ixv-38646" unitRef="usd">630000</ifrs-full:FinanceIncomeCost>
    <sprcy:IssueExpensesRelatedToIssuanceOfWarrants contextRef="c7" decimals="-3" id="ixv-38647" unitRef="usd">1204000</sprcy:IssueExpensesRelatedToIssuanceOfWarrants>
    <sprcy:IssueExpensesRelatedToIssuanceOfWarrants contextRef="c11" decimals="-3" id="ixv-38648" unitRef="usd">6000</sprcy:IssueExpensesRelatedToIssuanceOfWarrants>
    <sprcy:IssueExpensesRelatedToIssuanceOfWarrants contextRef="c12" decimals="-3" id="ixv-38649" unitRef="usd">835000</sprcy:IssueExpensesRelatedToIssuanceOfWarrants>
    <sprcy:FinanceExpensesFromExchangeRateDifferences contextRef="c7" decimals="-3" id="ixv-38650" unitRef="usd">4000</sprcy:FinanceExpensesFromExchangeRateDifferences>
    <sprcy:FinanceExpensesFromExchangeRateDifferences contextRef="c11" decimals="-3" id="ixv-38651" unitRef="usd">3000</sprcy:FinanceExpensesFromExchangeRateDifferences>
    <sprcy:FinanceExpensesFromExchangeRateDifferences contextRef="c12" decimals="-3" id="ixv-38652" unitRef="usd">12000</sprcy:FinanceExpensesFromExchangeRateDifferences>
    <ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c7" decimals="-3" id="ixv-38653" unitRef="usd">770000</ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss>
    <sprcy:InterestExpenseInRespectOfLeases contextRef="c7" decimals="-3" id="ixv-38654" unitRef="usd">15000</sprcy:InterestExpenseInRespectOfLeases>
    <sprcy:InterestExpenseInRespectOfLeases contextRef="c11" decimals="-3" id="ixv-38655" unitRef="usd">4000</sprcy:InterestExpenseInRespectOfLeases>
    <sprcy:InterestExpenseInRespectOfLeases contextRef="c12" decimals="-3" id="ixv-38656" unitRef="usd">7000</sprcy:InterestExpenseInRespectOfLeases>
    <sprcy:FinanceExpensesFromInterestAndCommissions contextRef="c7" decimals="-3" id="ixv-38657" unitRef="usd">21000</sprcy:FinanceExpensesFromInterestAndCommissions>
    <sprcy:FinanceExpensesFromInterestAndCommissions contextRef="c11" decimals="-3" id="ixv-38658" unitRef="usd">8000</sprcy:FinanceExpensesFromInterestAndCommissions>
    <sprcy:FinanceExpensesFromInterestAndCommissions contextRef="c12" decimals="-3" id="ixv-38659" unitRef="usd">18000</sprcy:FinanceExpensesFromInterestAndCommissions>
    <ifrs-full:InsuranceFinanceIncomeExpenses contextRef="c7" decimals="-3" id="ixv-38660" unitRef="usd">2014000</ifrs-full:InsuranceFinanceIncomeExpenses>
    <ifrs-full:InsuranceFinanceIncomeExpenses contextRef="c11" decimals="-3" id="ixv-38661" unitRef="usd">21000</ifrs-full:InsuranceFinanceIncomeExpenses>
    <ifrs-full:InsuranceFinanceIncomeExpenses contextRef="c12" decimals="-3" id="ixv-38662" unitRef="usd">872000</ifrs-full:InsuranceFinanceIncomeExpenses>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory contextRef="c7" id="ixv-34492">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 22:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;LOSS PER SHARE/ADS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Details of the number of shares and loss used in the computation of loss per share:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year ended December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amounts used in the computation of basic and diluted&#160;loss&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt;
number of&lt;br/&gt;
shares (*)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Loss&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt;
number of&lt;br/&gt;
shares (*)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Loss&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt;
number of&lt;br/&gt;
shares (*)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Loss&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;In&lt;br/&gt;
thousands&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;USD&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;In&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;thousands&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;USD&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;In&lt;br/&gt;
thousands&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;USD&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Continuing operations:&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 28%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic loss per share&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,575&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,592&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,049&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5,789&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;258&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3,482&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effect of potential dilutive ordinary shares&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(468&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Diluted loss per share&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,575&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,592&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,049&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5,789&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;265&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3,950&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The computation of diluted loss per share did not include the following convertible securities since their inclusion would decrease the loss per share (anti-dilutive effect):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Share Options to employees, officers, directors and consultants; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Non-marketable warrants to investors.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <sprcy:DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory contextRef="c7" id="ixv-34508">&lt;span style="font-size: 10pt"&gt;Details of the number of shares and loss used in the computation of loss per share:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year ended December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amounts used in the computation of basic and diluted&#160;loss&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt;
number of&lt;br/&gt;
shares (*)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Loss&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt;
number of&lt;br/&gt;
shares (*)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Loss&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt;
number of&lt;br/&gt;
shares (*)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Loss&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;In&lt;br/&gt;
thousands&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;USD&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;In&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;thousands&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;USD&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;In&lt;br/&gt;
thousands&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;USD&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Continuing operations:&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 28%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic loss per share&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,575&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,592&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,049&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5,789&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;258&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3,482&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effect of potential dilutive ordinary shares&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(468&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Diluted loss per share&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,575&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,592&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,049&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5,789&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;265&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3,950&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory>
    <ifrs-full:WeightedAverageShares
      contextRef="c326"
      decimals="INF"
      id="ixv-38663"
      unitRef="shares">4575</ifrs-full:WeightedAverageShares>
    <ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity
      contextRef="c326"
      decimals="-3"
      id="ixv-38664"
      unitRef="usd">-2592000</ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:WeightedAverageShares
      contextRef="c327"
      decimals="INF"
      id="ixv-38665"
      unitRef="shares">2049</ifrs-full:WeightedAverageShares>
    <ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity
      contextRef="c327"
      decimals="-3"
      id="ixv-38666"
      unitRef="usd">-5789000</ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:WeightedAverageShares
      contextRef="c328"
      decimals="INF"
      id="ixv-38667"
      unitRef="shares">258</ifrs-full:WeightedAverageShares>
    <ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity
      contextRef="c328"
      decimals="-3"
      id="ixv-38668"
      unitRef="usd">-3482000</ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:WeightedAverageShares
      contextRef="c329"
      decimals="INF"
      id="ixv-38669"
      unitRef="shares">7</ifrs-full:WeightedAverageShares>
    <ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity
      contextRef="c329"
      decimals="-3"
      id="ixv-38670"
      unitRef="usd">-468000</ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:WeightedAverageShares
      contextRef="c330"
      decimals="INF"
      id="ixv-38671"
      unitRef="shares">4575</ifrs-full:WeightedAverageShares>
    <ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity
      contextRef="c330"
      decimals="-3"
      id="ixv-38672"
      unitRef="usd">-2592000</ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:WeightedAverageShares
      contextRef="c331"
      decimals="INF"
      id="ixv-38673"
      unitRef="shares">2049</ifrs-full:WeightedAverageShares>
    <ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity
      contextRef="c331"
      decimals="-3"
      id="ixv-38674"
      unitRef="usd">-5789000</ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:WeightedAverageShares
      contextRef="c332"
      decimals="INF"
      id="ixv-38675"
      unitRef="shares">265</ifrs-full:WeightedAverageShares>
    <ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity
      contextRef="c332"
      decimals="-3"
      id="ixv-38676"
      unitRef="usd">-3950000</ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory contextRef="c7" id="ixv-34873">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;23:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;OPERATING SEGMENTS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company applies the principles
of IFRS 8,&#160;&#x201c;&lt;i&gt;Operating Segments&lt;/i&gt;&#x201d;&lt;i&gt;&#160;&lt;/i&gt;(&#x201c;IFRS 8&#x201d;), regarding operating segments. The segment
reporting is based on internal management reports of the Company&#x2019;s management, which are regularly reviewed by the chief operating
decision maker to make decisions about resources to be allocated and assess performance. According to the principles of IFRS 8, the Company&#x2019;s
management determined that as of December 31, 2022, the Company has two reportable segments &#x2013; (1) development of drugs based on
cannabinoid molecules to be approved by an official regulatory authority (the Company&#x2019;s operation); and (2) online sales of a various
range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial
creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended December&#160;31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Drug Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Online Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;External&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-286"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,347&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,347&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Inter-segment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-287"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-288"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-289"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-style: italic"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-290"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,347&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,347&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt"&gt;Segment loss (gain)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,405&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(118&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,287&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Company&#x2019;s share of losses of company accounted for at equity, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;109&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance expense (income), net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,818&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Tax expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;Loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,592&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug&lt;br/&gt;
Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online&lt;br/&gt;
Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-indent: -9pt; padding-left: 9pt"&gt;External&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-291"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-292"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-293"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Inter-segment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-294"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-295"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-296"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-297"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-298"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-299"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Segment loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,768&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-300"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,768&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Finance expense (income), net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;Loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,789&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug&lt;br/&gt;
Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online&lt;br/&gt;
Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-indent: -9pt; padding-left: 9pt"&gt;External&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-301"&gt;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-302"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-303"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Inter-segment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-304"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-305"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-306"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-307"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-308"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-309"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Segment loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,293&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-310"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,293&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Finance expense (income), net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;242&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;Loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,535&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of December&#160;31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Drug&lt;br/&gt; Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Online&lt;br/&gt; Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Segment Assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,664&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;941&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,605&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Segment Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;135&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,156&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December&#160;31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug&lt;br/&gt;
Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online&lt;br/&gt;
Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Segment Assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,916&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-311"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,916&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Segment Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,775&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-312"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,775&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
    <ifrs-full:DisclosureOfOperatingSegmentsExplanatory contextRef="c7" id="ixv-34887">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended December&#160;31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Drug Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Online Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;External&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-286"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,347&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,347&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Inter-segment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-287"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-288"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-289"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-style: italic"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-290"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,347&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,347&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt"&gt;Segment loss (gain)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,405&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(118&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,287&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Company&#x2019;s share of losses of company accounted for at equity, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;109&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance expense (income), net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,818&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Tax expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;Loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,592&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug&lt;br/&gt;
Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online&lt;br/&gt;
Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-indent: -9pt; padding-left: 9pt"&gt;External&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-291"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-292"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-293"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Inter-segment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-294"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-295"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-296"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-297"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-298"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-299"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Segment loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,768&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-300"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,768&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Finance expense (income), net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;Loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,789&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug&lt;br/&gt;
Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online&lt;br/&gt;
Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-indent: -9pt; padding-left: 9pt"&gt;External&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-301"&gt;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-302"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-303"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Inter-segment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-304"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-305"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-306"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-307"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-308"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-309"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Segment loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,293&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-310"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,293&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Finance expense (income), net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;242&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;Loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,535&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of December&#160;31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Drug&lt;br/&gt; Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Online&lt;br/&gt; Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Segment Assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,664&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;941&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,605&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Segment Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;135&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,156&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December&#160;31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug&lt;br/&gt;
Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online&lt;br/&gt;
Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Segment Assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,916&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-311"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,916&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Segment Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,775&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-312"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,775&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfOperatingSegmentsExplanatory>
    <sprcy:ExternalRevenues
      contextRef="c334"
      decimals="-3"
      id="ixv-38677"
      unitRef="usd">1347000</sprcy:ExternalRevenues>
    <sprcy:ExternalRevenues contextRef="c7" decimals="-3" id="ixv-38678" unitRef="usd">1347000</sprcy:ExternalRevenues>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="c334"
      decimals="-3"
      id="ixv-38679"
      unitRef="usd">1347000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c7" decimals="-3" id="ixv-38680" unitRef="usd">1347000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c333"
      decimals="-3"
      id="ixv-38681"
      unitRef="usd">8405000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c334"
      decimals="-3"
      id="ixv-38682"
      unitRef="usd">-118000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome contextRef="c7" decimals="-3" id="ixv-38683" unitRef="usd">8287000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet contextRef="c7" decimals="-3" id="ixv-38684" unitRef="usd">109000</sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet>
    <ifrs-full:InterestRevenueExpense contextRef="c7" decimals="-3" id="ixv-38685" unitRef="usd">-5818000</ifrs-full:InterestRevenueExpense>
    <sprcy:TaxExpense contextRef="c7" decimals="-3" id="ixv-38686" unitRef="usd">14000</sprcy:TaxExpense>
    <ifrs-full:ProfitLoss contextRef="c7" decimals="-3" id="ixv-38687" unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c335"
      decimals="-3"
      id="ixv-38688"
      unitRef="usd">5768000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome contextRef="c11" decimals="-3" id="ixv-38689" unitRef="usd">5768000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:InterestRevenueExpense contextRef="c11" decimals="-3" id="ixv-38690" unitRef="usd">21000</ifrs-full:InterestRevenueExpense>
    <ifrs-full:ProfitLoss contextRef="c11" decimals="-3" id="ixv-38691" unitRef="usd">-5789000</ifrs-full:ProfitLoss>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c337"
      decimals="-3"
      id="ixv-38692"
      unitRef="usd">3293000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome contextRef="c12" decimals="-3" id="ixv-38693" unitRef="usd">3293000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:InterestRevenueExpense contextRef="c12" decimals="-3" id="ixv-38694" unitRef="usd">242000</ifrs-full:InterestRevenueExpense>
    <ifrs-full:ProfitLoss contextRef="c12" decimals="-3" id="ixv-38695" unitRef="usd">-3535000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherAssets
      contextRef="c339"
      decimals="-3"
      id="ixv-38696"
      unitRef="usd">9664000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets
      contextRef="c340"
      decimals="-3"
      id="ixv-38697"
      unitRef="usd">941000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets contextRef="c4" decimals="-3" id="ixv-38698" unitRef="usd">10605000</ifrs-full:OtherAssets>
    <ifrs-full:OtherLiabilities
      contextRef="c339"
      decimals="-3"
      id="ixv-38699"
      unitRef="usd">4021000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="c340"
      decimals="-3"
      id="ixv-38700"
      unitRef="usd">135000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities contextRef="c4" decimals="-3" id="ixv-38701" unitRef="usd">4156000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherAssets
      contextRef="c341"
      decimals="-3"
      id="ixv-38702"
      unitRef="usd">9916000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets contextRef="c5" decimals="-3" id="ixv-38703" unitRef="usd">9916000</ifrs-full:OtherAssets>
    <ifrs-full:OtherLiabilities
      contextRef="c341"
      decimals="-3"
      id="ixv-38704"
      unitRef="usd">1775000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities contextRef="c5" decimals="-3" id="ixv-38705" unitRef="usd">1775000</ifrs-full:OtherLiabilities>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory contextRef="c7" id="ixv-35542">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;24:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;TRANSACTIONS AND BALANCES WITH RELATED PARTIES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Balances with related parties:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt;
2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Key&lt;br/&gt;
management&lt;br/&gt;
personnel&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Other&lt;br/&gt;
related&lt;br/&gt;
parties&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Key&lt;br/&gt;
management&lt;br/&gt;
personnel&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Other&lt;br/&gt;
related&lt;br/&gt;
parties&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Current liabilities&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;70&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;55&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;447&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transactions with related parties (not including amounts described in Note 24c):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;208&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-313"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-314"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Benefits to key management personnel (including directors):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Short-term benefits&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;1,940&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;962&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;746&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Cost of share-based payment&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;779&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;43&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;91&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Mr. Oz Adler, our Chief Executive Officer and Chief Financial Officer, is the chairman of the board of directors of&#160;Jeffs&#x2019;&#160;Brands.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 7, 2022, we entered into the Cooperation Agreement with Clearmind, a company in which Dr. Adi Zuloff-Shani, our Chief Technologies Officer, Mr. Weiss, our President, and Mr. Adler, our Chief Executive Officer and Chief Financial Officer serve as officers and directors.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2022, the Company recognized expenses in respect of the Cooperation Agreement with Clearmind in the amount of $208, and the balance owed to Clearmind as of December 31, 2022, was $55.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 17, 2022, we invested $1.5 million
in Clearmind in connection with its initial public offering on the Nasdaq Capital Market, in exchange for 230,769 common shares of Clearmind,
representing 9.33% of the outstanding share capital of Clearmind (see also note 8).&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <sprcy:DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory contextRef="c7" id="ixv-35558">&lt;span style="font-size: 10pt"&gt;Balances with related parties:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;208&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-313"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-314"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory>
    <sprcy:DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory contextRef="c7" id="ixv-35561">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt;
2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Key&lt;br/&gt;
management&lt;br/&gt;
personnel&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Other&lt;br/&gt;
related&lt;br/&gt;
parties&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Key&lt;br/&gt;
management&lt;br/&gt;
personnel&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Other&lt;br/&gt;
related&lt;br/&gt;
parties&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Current liabilities&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;70&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;55&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;447&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</sprcy:DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory>
    <ifrs-full:CurrentLiabilities
      contextRef="c344"
      decimals="-3"
      id="ixv-38706"
      unitRef="usd">70000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="c345"
      decimals="-3"
      id="ixv-38707"
      unitRef="usd">55000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="c346"
      decimals="-3"
      id="ixv-38708"
      unitRef="usd">447000</ifrs-full:CurrentLiabilities>
    <sprcy:ResearchAndDevelopmentExpenses contextRef="c7" decimals="-3" id="ixv-38709" unitRef="usd">208000</sprcy:ResearchAndDevelopmentExpenses>
    <ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory contextRef="c7" id="ixv-35663">&lt;span style="font-size: 10pt"&gt;Benefits to key management personnel (including directors):&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Short-term benefits&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;1,940&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;962&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;746&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Cost of share-based payment&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;779&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;43&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;91&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c7" decimals="-3" id="ixv-38710" unitRef="usd">1940000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c11" decimals="-3" id="ixv-38711" unitRef="usd">962000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c12" decimals="-3" id="ixv-38712" unitRef="usd">746000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c7" decimals="-3" id="ixv-38713" unitRef="usd">779000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c11" decimals="-3" id="ixv-38714" unitRef="usd">43000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c12" decimals="-3" id="ixv-38715" unitRef="usd">91000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <sprcy:CooperationAgreementWithClearmindAmount contextRef="c7" decimals="-3" id="ixv-38716" unitRef="usd">208000</sprcy:CooperationAgreementWithClearmindAmount>
    <sprcy:BalanceOwedToClearmind contextRef="c7" decimals="-3" id="ixv-38717" unitRef="usd">55000</sprcy:BalanceOwedToClearmind>
    <sprcy:InvestedAmountInClearmind
      contextRef="c343"
      decimals="-5"
      id="ixv-38718"
      unitRef="usd">1500000</sprcy:InvestedAmountInClearmind>
    <sprcy:ExchangeCommonSharesOfClearmind
      contextRef="c343"
      decimals="0"
      id="ixv-38719"
      unitRef="shares">230769</sprcy:ExchangeCommonSharesOfClearmind>
    <sprcy:ClearmindOutstandingShareCapitalPercentage
      contextRef="c343"
      decimals="4"
      id="ixv-38720"
      unitRef="pure">0.0933</sprcy:ClearmindOutstandingShareCapitalPercentage>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="c7" id="ixv-35776">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;25:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;EVENTS AFTER THE REPORTING DATE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;On
February 23, 2023, the Company signed an agreement with Jeffs&#x2019; Brands Holdings (&#x201c;NewCo&#x201d;) Inc. a recently newly-formed
wholly owned subsidiary of Jeffs&#x2019; Brands and Jeffs&#x2019; Brands, pursuant to which, at the closing and upon the terms and conditions
set forth in the Agreement, NewCo Inc. will acquire from the Company a number of shares of stock equal to approximately a 49% interest
in the Company&#x2019;s wholly owned subsidiary, SciSparc Nutraceuticals Inc., which owns Wellution&lt;sup&gt;TM&lt;/sup&gt;&#160;, for $2,500 in cash,
and additional deferred cash payments of approximately $489,330 accounting for price adjustments related to inventory and working capital,
which will be paid in five equal monthly installments beginning in May 2023 (the &#x201c;Price Adjusment&#x201d;). As collateral for the
payment in full of the Price Adjustment, SciSparc will hold back such number of shares of common stock of SciSparc Nutraceuticals, equal
to the outstanding due amount of the Price Adjustment (the &#x201c;Holdback Shares&#x201d;). Following the closing of the transaction on
March 22, 2023, which included an equity conversion of financing amounts previously provided to SciSparc Nutraceuticals Inc. by the Company
for working capital, and the release of the Holdback Shares upon the payment in full of the Price Adjustment the Company will hold approximately
51% of SciSparc Nutraceuticals Inc.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;Pursuant
to the agreement, at the closing of the transaction, Jeffs&#x2019; Brands and SciSparc Nutraceuticals Inc. entered into a consulting agreement,
pursuant to which Jeffs&#x2019; Brands will provide management services to SciSparc Nutraceuticals Inc. for the Wellution&lt;sup&gt;TM&lt;/sup&gt;
brand for a monthly fee of $20 and Jeffs&#x2019; Brands will receive a one-time signing bonus in the amount of $51. The consulting agreement
is for an undefined period of time and may be terminated by either party with 30 days advance notice.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;In
addition, in connection with the closing of the transaction, the Company and Jeffs&#x2019; Brands, engaged in a mutual share exchange in
the amount of $288,238 of ordinary shares from each of us and Jeffs&#x2019; Brands. The number of shares in the share exchange was calculated
based on the average closing price of the relevant company&#x2019;s shares for 30 consecutive trading days ending on the third trading
day immediately prior to the closing. Accordingly, the Company acquired 247,415 ordinary shares of Jeffs&#x2019; Brands and Jeffs&#x2019;
Brands acquired 360,297 ordinary shares of us having an aggregate value of $288,238, which was adjusted from $300,000 according to the
4.99% ownership limit included in the definitive agreements.&lt;/p&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <sprcy:PercentageOfStockEqual
      contextRef="c347"
      decimals="2"
      id="ixv-38721"
      unitRef="pure">0.49</sprcy:PercentageOfStockEqual>
    <ifrs-full:Cash
      contextRef="c348"
      decimals="-3"
      id="ixv-38722"
      unitRef="usd">2500000</ifrs-full:Cash>
    <sprcy:AdditionalAgreedInvest
      contextRef="c347"
      decimals="-3"
      id="ixv-38723"
      unitRef="usd">489330000</sprcy:AdditionalAgreedInvest>
    <sprcy:OwnershipAgreement
      contextRef="c349"
      decimals="2"
      id="ixv-38724"
      unitRef="pure">0.05</sprcy:OwnershipAgreement>
    <sprcy:PercentageOfWorkingCapital
      contextRef="c350"
      decimals="2"
      id="ixv-38725"
      unitRef="pure">0.51</sprcy:PercentageOfWorkingCapital>
    <sprcy:MonthlyFee contextRef="c7" decimals="-3" id="ixv-38726" unitRef="usd">20000</sprcy:MonthlyFee>
    <sprcy:BonusAmount contextRef="c7" decimals="-3" id="ixv-38727" unitRef="usd">51000</sprcy:BonusAmount>
    <ifrs-full:IssuedCapitalOrdinaryShares contextRef="c4" decimals="-3" id="ixv-38728" unitRef="usd">288238000</ifrs-full:IssuedCapitalOrdinaryShares>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c351"
      decimals="0"
      id="ixv-38729"
      unitRef="shares">247415</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c352"
      decimals="0"
      id="ixv-38730"
      unitRef="shares">360297</ifrs-full:NumberOfSharesIssued>
    <sprcy:AggregateValue contextRef="c7" decimals="-3" id="ixv-38731" unitRef="usd">288238000</sprcy:AggregateValue>
    <sprcy:AdjustedAmountOfAggregateValue contextRef="c7" decimals="-3" id="ixv-38732" unitRef="usd">300000000</sprcy:AdjustedAmountOfAggregateValue>
    <ifrs-full:ProportionOfOwnershipInterestInJointOperation contextRef="c7" decimals="4" id="ixv-38733" unitRef="pure">0.0499</ifrs-full:ProportionOfOwnershipInterestInJointOperation>
    <ifrs-full:CurrentTradeReceivables
      contextRef="c3"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Inventories
      contextRef="c3"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherNoncurrentFinancialAssets
      contextRef="c3"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="c2"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:NoncontrollingInterests
      contextRef="c3"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="c5"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:InvestmentsInAssociates
      contextRef="c5"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="c4"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Revenue
      contextRef="c6"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CostOfSales
      contextRef="c6"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:GrossProfit
      contextRef="c6"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c6"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c7"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="c6"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c6"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
      contextRef="c6"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
      contextRef="c7"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Revenue
      contextRef="c11"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Revenue
      contextRef="c12"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:GrossProfit
      contextRef="c11"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:GrossProfit
      contextRef="c12"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="c11"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="c11"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c11"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c12"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ComprehensiveIncomeAttributableToNoncontrollingInterest
      contextRef="c7"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ComprehensiveIncomeAttributableToNoncontrollingInterest
      contextRef="c11"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c20"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c21"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c22"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c23"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c24"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c25"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c22"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c23"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c24"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c25"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c26"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c28"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
      contextRef="c21"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
      contextRef="c22"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
      contextRef="c23"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
      contextRef="c25"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
      contextRef="c26"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfSharesNetOfIssueExpenses
      contextRef="c22"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfSharesNetOfIssueExpenses
      contextRef="c23"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfSharesNetOfIssueExpenses
      contextRef="c24"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfSharesNetOfIssueExpenses
      contextRef="c25"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfSharesNetOfIssueExpenses
      contextRef="c26"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfSharesNetOfIssueExpenses
      contextRef="c28"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c23"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c24"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c25"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c26"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c28"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c44"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c45"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c46"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c47"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c48"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c49"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c52"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c47"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c48"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c49"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c50"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c51"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c52"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c6"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c45"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c47"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c48"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c49"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c50"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c52"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c60"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c44"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c61"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c62"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c63"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c64"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c65"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c68"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c62"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c63"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c64"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c65"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c66"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c68"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c63"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c64"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c65"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c66"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c68"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c20"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c77"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c79"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c80"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c81"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c82"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c83"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c80"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c82"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c83"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c84"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c86"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
      contextRef="c80"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
      contextRef="c81"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
      contextRef="c82"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
      contextRef="c83"
      id="hidden-fact-110"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
      contextRef="c84"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
      contextRef="c86"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c79"
      id="hidden-fact-113"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c80"
      id="hidden-fact-114"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c81"
      id="hidden-fact-115"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c83"
      id="hidden-fact-116"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c84"
      id="hidden-fact-117"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c81"
      id="hidden-fact-118"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c82"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c83"
      id="hidden-fact-120"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c84"
      id="hidden-fact-121"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c85"
      id="hidden-fact-122"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c86"
      id="hidden-fact-123"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c12"
      id="hidden-fact-124"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c79"
      id="hidden-fact-125"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c81"
      id="hidden-fact-126"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c82"
      id="hidden-fact-127"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c83"
      id="hidden-fact-128"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c84"
      id="hidden-fact-129"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c86"
      id="hidden-fact-130"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c95"
      id="hidden-fact-131"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c97"
      id="hidden-fact-132"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c98"
      id="hidden-fact-133"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c99"
      id="hidden-fact-134"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c100"
      id="hidden-fact-135"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c101"
      id="hidden-fact-136"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c104"
      id="hidden-fact-137"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c98"
      id="hidden-fact-138"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c100"
      id="hidden-fact-139"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c101"
      id="hidden-fact-140"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c102"
      id="hidden-fact-141"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c104"
      id="hidden-fact-142"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c98"
      id="hidden-fact-143"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c100"
      id="hidden-fact-144"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c101"
      id="hidden-fact-145"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c102"
      id="hidden-fact-146"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c104"
      id="hidden-fact-147"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c99"
      id="hidden-fact-148"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c100"
      id="hidden-fact-149"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c101"
      id="hidden-fact-150"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c102"
      id="hidden-fact-151"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c103"
      id="hidden-fact-152"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c104"
      id="hidden-fact-153"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c11"
      id="hidden-fact-154"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c97"
      id="hidden-fact-155"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c99"
      id="hidden-fact-156"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c100"
      id="hidden-fact-157"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c101"
      id="hidden-fact-158"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c102"
      id="hidden-fact-159"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c104"
      id="hidden-fact-160"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c44"
      id="hidden-fact-161"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c61"
      id="hidden-fact-162"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c62"
      id="hidden-fact-163"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c63"
      id="hidden-fact-164"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c64"
      id="hidden-fact-165"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c65"
      id="hidden-fact-166"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c68"
      id="hidden-fact-167"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c62"
      id="hidden-fact-168"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c63"
      id="hidden-fact-169"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c64"
      id="hidden-fact-170"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c65"
      id="hidden-fact-171"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c66"
      id="hidden-fact-172"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c68"
      id="hidden-fact-173"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c63"
      id="hidden-fact-174"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c64"
      id="hidden-fact-175"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c65"
      id="hidden-fact-176"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c66"
      id="hidden-fact-177"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c68"
      id="hidden-fact-178"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c20"
      id="hidden-fact-179"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:AdjustmentsForImpairmentOfInvestmentInAssociate
      contextRef="c6"
      id="hidden-fact-180"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="c7"
      id="hidden-fact-181"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable
      contextRef="c6"
      id="hidden-fact-182"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="c6"
      id="hidden-fact-183"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="c0"
      id="hidden-fact-184"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="c6"
      id="hidden-fact-185"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="c6"
      id="hidden-fact-186"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="c0"
      id="hidden-fact-187"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="c6"
      id="hidden-fact-188"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:InterestPaidOnLeaseLiability
      contextRef="c0"
      id="hidden-fact-189"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:InterestPaidOnLeaseLiability
      contextRef="c6"
      id="hidden-fact-190"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="c6"
      id="hidden-fact-191"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="c7"
      id="hidden-fact-192"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="c0"
      id="hidden-fact-193"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="c6"
      id="hidden-fact-194"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod
      contextRef="c0"
      id="hidden-fact-195"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod
      contextRef="c6"
      id="hidden-fact-196"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:MutualShareExchangeOfOrdinarySharessee
      contextRef="c6"
      id="hidden-fact-197"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:MutualShareExchangeOfOrdinarySharessee
      contextRef="c7"
      id="hidden-fact-198"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets
      contextRef="c11"
      id="hidden-fact-199"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:AdjustmentsForImpairmentOfInvestmentInAssociate
      contextRef="c11"
      id="hidden-fact-200"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:AdjustmentsForImpairmentOfInvestmentInAssociate
      contextRef="c12"
      id="hidden-fact-201"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="c12"
      id="hidden-fact-202"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments
      contextRef="c11"
      id="hidden-fact-203"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments
      contextRef="c12"
      id="hidden-fact-204"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="c11"
      id="hidden-fact-205"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="c12"
      id="hidden-fact-206"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="c11"
      id="hidden-fact-207"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="c12"
      id="hidden-fact-208"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod
      contextRef="c11"
      id="hidden-fact-209"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:InterestPaidOnLeaseLiability
      contextRef="c11"
      id="hidden-fact-210"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:RepaymentOfShorttermCredit
      contextRef="c7"
      id="hidden-fact-211"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ReceiptofShortTermCreditFromOthers
      contextRef="c7"
      id="hidden-fact-212"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ReceiptofShortTermCreditFromOthers
      contextRef="c11"
      id="hidden-fact-213"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability
      contextRef="c7"
      id="hidden-fact-214"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability
      contextRef="c12"
      id="hidden-fact-215"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:RegistrationOfWarrants
      contextRef="c7"
      id="hidden-fact-216"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:RegistrationOfWarrants
      contextRef="c12"
      id="hidden-fact-217"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:UnpaidIssueExpenses
      contextRef="c7"
      id="hidden-fact-218"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:UnpaidIssueExpenses
      contextRef="c12"
      id="hidden-fact-219"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="c5"
      id="hidden-fact-220"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="c5"
      id="hidden-fact-221"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill
      contextRef="c6"
      id="hidden-fact-222"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:TradeReceivables
      contextRef="c3"
      id="hidden-fact-223"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinancialAssets
      contextRef="c3"
      id="hidden-fact-224"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CreditFromOthers
      contextRef="c2"
      id="hidden-fact-225"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CreditFromOthers
      contextRef="c3"
      id="hidden-fact-226"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:LeaseLiabilities
      contextRef="c2"
      id="hidden-fact-227"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="c3"
      id="hidden-fact-228"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:NoParValuePerShare
      contextRef="c123"
      id="hidden-fact-229"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c155"
      id="hidden-fact-230"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c171"
      id="hidden-fact-231"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ParValuePerShare
      contextRef="c185"
      id="hidden-fact-232"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <sprcy:LeaseholdImprovements
      contextRef="c198"
      id="hidden-fact-233"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CurrentInventoriesInTransit
      contextRef="c5"
      id="hidden-fact-234"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinishedGoods
      contextRef="c5"
      id="hidden-fact-235"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:InventoriesNet
      contextRef="c5"
      id="hidden-fact-236"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="c5"
      id="hidden-fact-237"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:BeginningBalanceCost
      contextRef="c217"
      id="hidden-fact-238"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PurchasesOfCost
      contextRef="c222"
      id="hidden-fact-239"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PurchasesOfCost
      contextRef="c198"
      id="hidden-fact-240"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:BeginningBalanceCost
      contextRef="c222"
      id="hidden-fact-241"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PropertyPlantAndEquipmentCost
      contextRef="c217"
      id="hidden-fact-242"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c225"
      id="hidden-fact-243"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PropertyPlantAndEquipmentCost
      contextRef="c222"
      id="hidden-fact-244"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated
      contextRef="c222"
      id="hidden-fact-245"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:BeginningBalanceCost
      contextRef="c231"
      id="hidden-fact-246"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:NewLeases
      contextRef="c216"
      id="hidden-fact-247"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:NewLeases
      contextRef="c217"
      id="hidden-fact-248"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:NewLeases
      contextRef="c218"
      id="hidden-fact-249"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PurchasesOfCost
      contextRef="c217"
      id="hidden-fact-250"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PurchasesOfCost
      contextRef="c219"
      id="hidden-fact-251"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="c236"
      id="hidden-fact-252"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:BeginningBalanceCost
      contextRef="c217"
      id="hidden-fact-253"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PropertyPlantAndEquipmentCost
      contextRef="c231"
      id="hidden-fact-254"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:AccumulatedTerminationOfLeases
      contextRef="c233"
      id="hidden-fact-255"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:AccumulatedTerminationOfLeases
      contextRef="c234"
      id="hidden-fact-256"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:AccumulatedTerminationOfLeases
      contextRef="c235"
      id="hidden-fact-257"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c234"
      id="hidden-fact-258"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c236"
      id="hidden-fact-259"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="c236"
      id="hidden-fact-260"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PropertyPlantAndEquipmentCost
      contextRef="c217"
      id="hidden-fact-261"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated
      contextRef="c217"
      id="hidden-fact-262"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="c5"
      id="hidden-fact-263"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:InvestmentsInFinancialAssets
      contextRef="c5"
      id="hidden-fact-264"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:UnderlyingOrdinarySharePrice
      contextRef="c278"
      decimals="0"
      id="hidden-fact-265"
      unitRef="usdPershares">287</sprcy:UnderlyingOrdinarySharePrice>
    <sprcy:NumberOfShareOptionGranted
      contextRef="c5"
      id="hidden-fact-266"
      unitRef="shares"
      xsi:nil="true"/>
    <sprcy:WeightedAverageExercisePriceOfShareOptionGrantedInSharebasedPaymentArrangement
      contextRef="c11"
      id="hidden-fact-267"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <sprcy:ShareadsOptionsExpiredDuringYear
      contextRef="c11"
      id="hidden-fact-268"
      unitRef="shares"
      xsi:nil="true"/>
    <sprcy:ShareadsOptionsExpiredDuringYearWeightedAverageExercisePrice
      contextRef="c11"
      id="hidden-fact-269"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrs-full:Revenue
      contextRef="c11"
      id="hidden-fact-270"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CostOfSales
      contextRef="c11"
      id="hidden-fact-271"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:GrossProfit
      contextRef="c11"
      id="hidden-fact-272"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c305"
      id="hidden-fact-273"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c307"
      id="hidden-fact-274"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c316"
      id="hidden-fact-275"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c317"
      id="hidden-fact-276"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="c320"
      id="hidden-fact-277"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="c321"
      id="hidden-fact-278"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="c324"
      id="hidden-fact-279"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="c325"
      id="hidden-fact-280"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="c11"
      id="hidden-fact-281"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:FinanceIncomeFromConvertibleLoan
      contextRef="c11"
      id="hidden-fact-282"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncomeCost
      contextRef="c11"
      id="hidden-fact-283"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="c11"
      id="hidden-fact-284"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="c12"
      id="hidden-fact-285"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExternalRevenues
      contextRef="c333"
      id="hidden-fact-286"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:Intersegment
      contextRef="c333"
      id="hidden-fact-287"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:Intersegment
      contextRef="c334"
      id="hidden-fact-288"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:Intersegment
      contextRef="c7"
      id="hidden-fact-289"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="c333"
      id="hidden-fact-290"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExternalRevenues
      contextRef="c335"
      id="hidden-fact-291"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExternalRevenues
      contextRef="c336"
      id="hidden-fact-292"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExternalRevenues
      contextRef="c11"
      id="hidden-fact-293"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:Intersegment
      contextRef="c335"
      id="hidden-fact-294"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:Intersegment
      contextRef="c336"
      id="hidden-fact-295"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:Intersegment
      contextRef="c11"
      id="hidden-fact-296"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="c335"
      id="hidden-fact-297"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="c336"
      id="hidden-fact-298"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="c11"
      id="hidden-fact-299"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c336"
      id="hidden-fact-300"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExternalRevenues
      contextRef="c337"
      id="hidden-fact-301"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExternalRevenues
      contextRef="c338"
      id="hidden-fact-302"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExternalRevenues
      contextRef="c12"
      id="hidden-fact-303"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:Intersegment
      contextRef="c337"
      id="hidden-fact-304"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:Intersegment
      contextRef="c338"
      id="hidden-fact-305"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:Intersegment
      contextRef="c12"
      id="hidden-fact-306"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="c337"
      id="hidden-fact-307"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="c338"
      id="hidden-fact-308"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="c12"
      id="hidden-fact-309"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c338"
      id="hidden-fact-310"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherAssets
      contextRef="c342"
      id="hidden-fact-311"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherLiabilities
      contextRef="c342"
      id="hidden-fact-312"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ResearchAndDevelopmentExpenses
      contextRef="c11"
      id="hidden-fact-313"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ResearchAndDevelopmentExpenses
      contextRef="c12"
      id="hidden-fact-314"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0" id="ixv-39051">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-39052">0001611746</dei:EntityCentralIndexKey>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#hidden-fact-106"
          xlink:label="hidden-fact-106"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-104"
          xlink:label="hidden-fact-104"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-102"
          xlink:label="hidden-fact-102"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-103"
          xlink:label="hidden-fact-103"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-105"
          xlink:label="hidden-fact-105"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">Net of issue expenses of $784</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-106"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-104"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-102"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-103"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-105"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-146"
          xlink:label="hidden-fact-146"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-145"
          xlink:label="hidden-fact-145"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-144"
          xlink:label="hidden-fact-144"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-147"
          xlink:label="hidden-fact-147"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-143"
          xlink:label="hidden-fact-143"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">Net of issue expenses of $449</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-146"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-145"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-144"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-147"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-143"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-142"
          xlink:label="hidden-fact-142"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_9_fact"
          xlink:label="ix_9_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-139"
          xlink:label="hidden-fact-139"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_10_fact"
          xlink:label="ix_10_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-140"
          xlink:label="hidden-fact-140"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-141"
          xlink:label="hidden-fact-141"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_11_fact"
          xlink:label="ix_11_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-138"
          xlink:label="hidden-fact-138"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">Net of issue expenses of $358</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-142"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_9_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-139"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_10_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-140"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-141"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_11_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-138"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
